[
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT05838625",
        "orgStudyIdInfo": { "id": "CT-155-R-001" },
        "organization": {
          "fullName": "Click Therapeutics, Inc.",
          "class": "INDUSTRY"
        },
        "briefTitle": "Study of Two Digital Therapeutics for the Treatment of Experiential Negative Symptoms of Schizophrenia",
        "officialTitle": "A Randomized, Multicenter, 16-week Study to Evaluate the Efficacy and Safety of Two Prescription Digital Therapeutics As an Adjunct to Standard-of-Care Antipsychotic Therapy in Adult and Late Adolescent Participants with Experiential Negative Symptoms of Schizophrenia",
        "acronym": "CONVOKE"
      },
      "statusModule": {
        "statusVerifiedDate": "2025-01",
        "overallStatus": "ACTIVE_NOT_RECRUITING",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2023-03-31", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2025-06-18",
          "type": "ESTIMATED"
        },
        "completionDateStruct": { "date": "2025-07-18", "type": "ESTIMATED" },
        "studyFirstSubmitDate": "2023-04-20",
        "studyFirstSubmitQcDate": "2023-04-20",
        "studyFirstPostDateStruct": { "date": "2023-05-01", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2025-01-22",
        "lastUpdatePostDateStruct": { "date": "2025-01-23", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": {
          "name": "Click Therapeutics, Inc.",
          "class": "INDUSTRY"
        },
        "collaborators": [
          { "name": "Boehringer Ingelheim", "class": "INDUSTRY" }
        ]
      },
      "oversightModule": {
        "oversightHasDmc": true,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": true,
        "isUnapprovedDevice": true,
        "isUsExport": false
      },
      "descriptionModule": {
        "briefSummary": "This study evaluates the efficacy of two prescription digital therapeutics (PDT) in addition to standard of care (SOC) therapy for the treatment of experiential negative symptoms of schizophrenia in late adolescents and adults.",
        "detailedDescription": "The purpose of the proposed study is to evaluate the efficacy and safety of two prescription digital therapeutics as an adjunct treatment to SOC in participants 18 years of age or older diagnosed with experiential negative symptoms of schizophrenia."
      },
      "conditionsModule": {
        "conditions": ["Schizophrenia"],
        "keywords": [
          "Prescription digital therapeutic (PDT)",
          "Software as a Medical Device (SaMD)",
          "Smartphone app",
          "Schizophrenia",
          "Negative Symptoms"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["PHASE3"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": {
            "masking": "DOUBLE",
            "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]
          }
        },
        "enrollmentInfo": { "count": 432, "type": "ESTIMATED" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "Digital Therapeutic A",
            "type": "EXPERIMENTAL",
            "description": "Evaluate the efficacy and safety of digital therapeutic A as an adjunct treatment to SOC in participants with experiential negative symptoms of schizophrenia.",
            "interventionNames": ["Device: Digital Therapeutic"]
          },
          {
            "label": "Digital Therapeutic B",
            "type": "EXPERIMENTAL",
            "description": "Evaluate the efficacy and safety of digital therapeutic B as an adjunct treatment to SOC in participants with experiential negative symptoms of schizophrenia.",
            "interventionNames": ["Device: Digital Therapeutic"]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "Digital Therapeutic",
            "description": "A prescription digital therapeutic in the form of a smartphone app.",
            "armGroupLabels": ["Digital Therapeutic A", "Digital Therapeutic B"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Experiential negative symptoms",
            "description": "Change from baseline to Week 16 in experiential negative symptoms, as assessed by Clinical Assessment Interview for Negative Symptoms, Motivation and Pleasure Scale (CAINS-MAP)",
            "timeFrame": "Baseline to Week 16"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Motivation and pleasure symptoms",
            "description": "Change from baseline in motivation and pleasure symptoms at Week 8, as assessed by CAINS-MAP",
            "timeFrame": "Baseline to Week 8"
          },
          {
            "measure": "Expressive negative symptoms",
            "description": "Change from baseline in expressive negative symptoms at Weeks 8 and 16, as assessed by the Clinical Assessment Interview for Negative Symptoms, Expressivity Scale (CAINS-EXP)",
            "timeFrame": "Baseline to Weeks 8 and 16"
          },
          {
            "measure": "Positive symptoms",
            "description": "Change from baseline in positive symptoms at Weeks 8 and 16, as assessed by the Positive and Negative Syndrome Scale (PANSS)",
            "timeFrame": "Baseline to Weeks 8 and 16"
          },
          {
            "measure": "Social functioning",
            "description": "Change from baseline in social functioning at Weeks 8 and 16, as assessed by the Personal and Social Performance Scale (PSP)",
            "timeFrame": "Baseline to Weeks 8 and 16"
          },
          {
            "measure": "Self-reported defeatist beliefs",
            "description": "Change from baseline in self-reported defeatist beliefs at Weeks 8 and 16, as assessed by the Defeatist Beliefs Subscale of the Dysfunctional Attitudes Scale (DAS)",
            "timeFrame": "Baseline to Weeks 8 and 16"
          },
          {
            "measure": "Patient global impression of improvement",
            "description": "Patient Global Impression of Improvement Scale (PGI-I) at Weeks 8 and 16",
            "timeFrame": "Weeks 8 and 16"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\nA participant will be eligible for entry into the study if all of the following criteria are met:\n\n1. Has a primary diagnosis of schizophrenia.\n2. Is on a stable dose of antipsychotic medication(s).\n3. Has obtained an average score of ≥2 (moderate to severe) in at least two of the three CAINS-MAP domains (Social, Work, or Recreational).\n\nExclusion Criteria:\n\nA participant will not be eligible for study entry if any of the following criteria are met:\n\n1. Is currently treated with more than two antipsychotic medications (including more than two dosage forms).\n2. Meets DSM-5, for diagnoses not under investigation.\n3. Has participated in a CT-155 clinical study.",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "Shaheen Lakhan, MD, PhD, FAAN",
            "affiliation": "Click Therapeutics",
            "role": "STUDY_DIRECTOR"
          }
        ],
        "locations": [
          {
            "facility": "Investigational center",
            "city": "Chandler",
            "state": "Arizona",
            "zip": "85226",
            "country": "United States",
            "geoPoint": { "lat": 33.30616, "lon": -111.84125 }
          },
          {
            "facility": "Investigational center",
            "city": "Phoenix",
            "state": "Arizona",
            "zip": "85012",
            "country": "United States",
            "geoPoint": { "lat": 33.44838, "lon": -112.07404 }
          },
          {
            "facility": "Investigational center",
            "city": "Anaheim",
            "state": "California",
            "zip": "92805",
            "country": "United States",
            "geoPoint": { "lat": 33.83529, "lon": -117.9145 }
          },
          {
            "facility": "Investigational center",
            "city": "Culver City",
            "state": "California",
            "zip": "90230",
            "country": "United States",
            "geoPoint": { "lat": 34.02112, "lon": -118.39647 }
          },
          {
            "facility": "Investigational center",
            "city": "Garden Grove",
            "state": "California",
            "zip": "92845",
            "country": "United States",
            "geoPoint": { "lat": 33.77391, "lon": -117.94145 }
          },
          {
            "facility": "Investigational center",
            "city": "La Habra",
            "state": "California",
            "zip": "90631",
            "country": "United States",
            "geoPoint": { "lat": 33.93196, "lon": -117.94617 }
          },
          {
            "facility": "Investigational center",
            "city": "Long Beach",
            "state": "California",
            "zip": "90807",
            "country": "United States",
            "geoPoint": { "lat": 33.76696, "lon": -118.18923 }
          },
          {
            "facility": "Investigational center",
            "city": "Los Angeles",
            "state": "California",
            "zip": "90025",
            "country": "United States",
            "geoPoint": { "lat": 34.05223, "lon": -118.24368 }
          },
          {
            "facility": "Investigational center",
            "city": "Newport Beach",
            "state": "California",
            "zip": "92660",
            "country": "United States",
            "geoPoint": { "lat": 33.61891, "lon": -117.92895 }
          },
          {
            "facility": "Investigational center",
            "city": "Oceanside",
            "state": "California",
            "zip": "92056",
            "country": "United States",
            "geoPoint": { "lat": 33.19587, "lon": -117.37948 }
          },
          {
            "facility": "Investigational center",
            "city": "Orange",
            "state": "California",
            "zip": "92868",
            "country": "United States",
            "geoPoint": { "lat": 33.78779, "lon": -117.85311 }
          },
          {
            "facility": "Investigational center",
            "city": "San Bernardino",
            "state": "California",
            "zip": "92408",
            "country": "United States",
            "geoPoint": { "lat": 34.10834, "lon": -117.28977 }
          },
          {
            "facility": "Investigational center",
            "city": "Torrance",
            "state": "California",
            "zip": "90504",
            "country": "United States",
            "geoPoint": { "lat": 33.83585, "lon": -118.34063 }
          },
          {
            "facility": "Investigational center",
            "city": "Cromwell",
            "state": "Connecticut",
            "zip": "06416",
            "country": "United States",
            "geoPoint": { "lat": 41.5951, "lon": -72.64537 }
          },
          {
            "facility": "Investigational center",
            "city": "Hartford",
            "state": "Connecticut",
            "zip": "06116",
            "country": "United States",
            "geoPoint": { "lat": 41.76371, "lon": -72.68509 }
          },
          {
            "facility": "Investigational center",
            "city": "Hialeah",
            "state": "Florida",
            "zip": "33016",
            "country": "United States",
            "geoPoint": { "lat": 25.8576, "lon": -80.27811 }
          },
          {
            "facility": "Investigational center",
            "city": "Largo",
            "state": "Florida",
            "zip": "33777",
            "country": "United States",
            "geoPoint": { "lat": 27.90979, "lon": -82.78842 }
          },
          {
            "facility": "Investigational center",
            "city": "Miami Lakes",
            "state": "Florida",
            "zip": "33014",
            "country": "United States",
            "geoPoint": { "lat": 25.90871, "lon": -80.30866 }
          },
          {
            "facility": "Investigational center",
            "city": "Miami",
            "state": "Florida",
            "zip": "33156",
            "country": "United States",
            "geoPoint": { "lat": 25.77427, "lon": -80.19366 }
          },
          {
            "facility": "Investigational center",
            "city": "Orlando",
            "state": "Florida",
            "zip": "32803",
            "country": "United States",
            "geoPoint": { "lat": 28.53834, "lon": -81.37924 }
          },
          {
            "facility": "Investigational center",
            "city": "West Palm Beach",
            "state": "Florida",
            "zip": "33407",
            "country": "United States",
            "geoPoint": { "lat": 26.71534, "lon": -80.05337 }
          },
          {
            "facility": "Investigational center",
            "city": "Atlanta",
            "state": "Georgia",
            "zip": "30338",
            "country": "United States",
            "geoPoint": { "lat": 33.749, "lon": -84.38798 }
          },
          {
            "facility": "Investigational center",
            "city": "Augusta",
            "state": "Georgia",
            "zip": "30912",
            "country": "United States",
            "geoPoint": { "lat": 33.47097, "lon": -81.97484 }
          },
          {
            "facility": "Investigational center",
            "city": "Chicago",
            "state": "Illinois",
            "zip": "60611",
            "country": "United States",
            "geoPoint": { "lat": 41.85003, "lon": -87.65005 }
          },
          {
            "facility": "Investigational center",
            "city": "Springfield",
            "state": "Illinois",
            "zip": "77030",
            "country": "United States",
            "geoPoint": { "lat": 39.80172, "lon": -89.64371 }
          },
          {
            "facility": "Investigational center",
            "city": "Warrenville",
            "state": "Illinois",
            "zip": "60555",
            "country": "United States",
            "geoPoint": { "lat": 41.81781, "lon": -88.1734 }
          },
          {
            "facility": "Investigational center",
            "city": "Marrero",
            "state": "Louisiana",
            "zip": "70072",
            "country": "United States",
            "geoPoint": { "lat": 29.89937, "lon": -90.10035 }
          },
          {
            "facility": "Investigational center",
            "city": "Baltimore",
            "state": "Maryland",
            "zip": "21204",
            "country": "United States",
            "geoPoint": { "lat": 39.29038, "lon": -76.61219 }
          },
          {
            "facility": "Investigational center",
            "city": "Boston",
            "state": "Massachusetts",
            "zip": "02131",
            "country": "United States",
            "geoPoint": { "lat": 42.35843, "lon": -71.05977 }
          },
          {
            "facility": "Investigational center",
            "city": "Flowood",
            "state": "Mississippi",
            "zip": "39232",
            "country": "United States",
            "geoPoint": { "lat": 32.30959, "lon": -90.13898 }
          },
          {
            "facility": "Investigational center",
            "city": "St. Louis",
            "state": "Missouri",
            "zip": "63141",
            "country": "United States",
            "geoPoint": { "lat": 38.62727, "lon": -90.19789 }
          },
          {
            "facility": "Investigational center",
            "city": "Omaha",
            "state": "Nebraska",
            "zip": "68144",
            "country": "United States",
            "geoPoint": { "lat": 41.25626, "lon": -95.94043 }
          },
          {
            "facility": "Investigational center",
            "city": "Las Vegas",
            "state": "Nevada",
            "zip": "89124",
            "country": "United States",
            "geoPoint": { "lat": 36.17497, "lon": -115.13722 }
          },
          {
            "facility": "Investigational center",
            "city": "Marlton",
            "state": "New Jersey",
            "zip": "08054",
            "country": "United States",
            "geoPoint": { "lat": 39.89122, "lon": -74.92183 }
          },
          {
            "facility": "Investigational center",
            "city": "Cedarhurst",
            "state": "New York",
            "zip": "11516",
            "country": "United States",
            "geoPoint": { "lat": 40.62288, "lon": -73.7243 }
          },
          {
            "facility": "Investigational center",
            "city": "Glen Oaks",
            "state": "New York",
            "zip": "11004",
            "country": "United States",
            "geoPoint": { "lat": 40.74705, "lon": -73.71152 }
          },
          {
            "facility": "Click Therapeutics",
            "city": "New York",
            "state": "New York",
            "zip": "10013",
            "country": "United States",
            "geoPoint": { "lat": 40.71427, "lon": -74.00597 }
          },
          {
            "facility": "Investigational center",
            "city": "New York",
            "state": "New York",
            "zip": "10027",
            "country": "United States",
            "geoPoint": { "lat": 40.71427, "lon": -74.00597 }
          },
          {
            "facility": "Investigational center",
            "city": "Rochester",
            "state": "New York",
            "zip": "14623",
            "country": "United States",
            "geoPoint": { "lat": 43.15478, "lon": -77.61556 }
          },
          {
            "facility": "Investigational center",
            "city": "Charlotte",
            "state": "North Carolina",
            "zip": "27608",
            "country": "United States",
            "geoPoint": { "lat": 35.22709, "lon": -80.84313 }
          },
          {
            "facility": "Investigational center",
            "city": "Beachwood",
            "state": "Ohio",
            "zip": "44122",
            "country": "United States",
            "geoPoint": { "lat": 41.4645, "lon": -81.50873 }
          },
          {
            "facility": "Investigational center",
            "city": "Cincinatti",
            "state": "Ohio",
            "zip": "45267",
            "country": "United States",
            "geoPoint": { "lat": 39.12713, "lon": -84.51435 }
          },
          {
            "facility": "Investigational center",
            "city": "Columbus",
            "state": "Ohio",
            "zip": "43210",
            "country": "United States",
            "geoPoint": { "lat": 39.96118, "lon": -82.99879 }
          },
          {
            "facility": "Investigational center",
            "city": "Oklahoma City",
            "state": "Oklahoma",
            "zip": "73116",
            "country": "United States",
            "geoPoint": { "lat": 35.46756, "lon": -97.51643 }
          },
          {
            "facility": "Investigational center",
            "city": "State College",
            "state": "Pennsylvania",
            "zip": "16801",
            "country": "United States",
            "geoPoint": { "lat": 40.79339, "lon": -77.86 }
          },
          {
            "facility": "Investigational center",
            "city": "Charleston",
            "state": "South Carolina",
            "zip": "29425",
            "country": "United States",
            "geoPoint": { "lat": 32.77657, "lon": -79.93092 }
          },
          {
            "facility": "Investigational center",
            "city": "Austin",
            "state": "Texas",
            "zip": "78752",
            "country": "United States",
            "geoPoint": { "lat": 30.26715, "lon": -97.74306 }
          },
          {
            "facility": "Investigational center",
            "city": "Forth Worth",
            "state": "Texas",
            "zip": "76104",
            "country": "United States",
            "geoPoint": { "lat": 32.72541, "lon": -97.32085 }
          },
          {
            "facility": "Investigational center",
            "city": "Houston",
            "state": "Texas",
            "zip": "77030",
            "country": "United States",
            "geoPoint": { "lat": 29.76328, "lon": -95.36327 }
          },
          {
            "facility": "Investigational center",
            "city": "Irving",
            "state": "Texas",
            "zip": "75062",
            "country": "United States",
            "geoPoint": { "lat": 32.81402, "lon": -96.94889 }
          },
          {
            "facility": "Investigational center",
            "city": "Mesquite",
            "state": "Texas",
            "zip": "75149",
            "country": "United States",
            "geoPoint": { "lat": 32.7668, "lon": -96.59916 }
          },
          {
            "facility": "Investigational center",
            "city": "Plano",
            "state": "Texas",
            "zip": "75093",
            "country": "United States",
            "geoPoint": { "lat": 33.01984, "lon": -96.69889 }
          },
          {
            "facility": "Investigational center",
            "city": "Salt Lake City",
            "state": "Utah",
            "zip": "84105",
            "country": "United States",
            "geoPoint": { "lat": 40.76078, "lon": -111.89105 }
          },
          {
            "facility": "Investigational center",
            "city": "St. George",
            "state": "Utah",
            "zip": "84770",
            "country": "United States",
            "geoPoint": { "lat": 37.10415, "lon": -113.58412 }
          }
        ]
      }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [{ "id": "D012559", "term": "Schizophrenia" }],
        "ancestors": [
          {
            "id": "D019967",
            "term": "Schizophrenia Spectrum and Other Psychotic Disorders"
          },
          { "id": "D001523", "term": "Mental Disorders" }
        ],
        "browseLeaves": [
          {
            "id": "M15376",
            "name": "Schizophrenia",
            "asFound": "Schizophrenia",
            "relevance": "HIGH"
          },
          { "id": "M14473", "name": "Psychotic Disorders", "relevance": "LOW" },
          { "id": "M4815", "name": "Mental Disorders", "relevance": "LOW" },
          {
            "id": "M21838",
            "name": "Schizophrenia Spectrum and Other Psychotic Disorders",
            "relevance": "LOW"
          }
        ],
        "browseBranches": [
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" },
          { "abbrev": "All", "name": "All Conditions" }
        ]
      },
      "interventionBrowseModule": {
        "browseLeaves": [
          { "id": "M6263", "name": "Coal Tar", "relevance": "LOW" },
          { "id": "M16904", "name": "Antipsychotic Agents", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "Derm", "name": "Dermatologic Agents" },
          { "abbrev": "All", "name": "All Drugs and Chemicals" },
          { "abbrev": "CNSDep", "name": "Central Nervous System Depressants" },
          { "abbrev": "PsychDr", "name": "Psychotropic Drugs" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT06791122",
        "orgStudyIdInfo": { "id": "1471-0002" },
        "organization": {
          "fullName": "Boehringer Ingelheim",
          "class": "INDUSTRY"
        },
        "briefTitle": "A Prospective Cohort Study to Assess Clinical Effectiveness of an Investigational Digital Therapeutic (CT-155) in Patients With Experiential Negative Symptoms of Schizophrenia",
        "officialTitle": "A Multicenter, Pragmatic Study to Evaluate Clinical Effectiveness, Engagement With the Study App, Healthcare Resource Utilization, and Safety of an Investigational Digital Therapeutic (CT-155) in Patients With Experiential Negative Symptoms of Schizophrenia"
      },
      "statusModule": {
        "statusVerifiedDate": "2025-04",
        "overallStatus": "RECRUITING",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2025-01-23", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2026-06-08",
          "type": "ESTIMATED"
        },
        "completionDateStruct": { "date": "2027-02-15", "type": "ESTIMATED" },
        "studyFirstSubmitDate": "2025-01-20",
        "studyFirstSubmitQcDate": "2025-01-20",
        "studyFirstPostDateStruct": { "date": "2025-01-24", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2025-04-25",
        "lastUpdatePostDateStruct": { "date": "2025-04-27", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": { "name": "Boehringer Ingelheim", "class": "INDUSTRY" }
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": true,
        "isUnapprovedDevice": true,
        "isUsExport": false
      },
      "descriptionModule": {
        "briefSummary": "This study is open to people aged 18 years or older with schizophrenia. People can join the study if they are willing to use a smartphone app called CT-155. This app is being developed to help people with schizophrenia manage their negative symptoms.\n\nThe purpose of this study is to gather new information on CT-155. Researchers want to see how well it works, how well participants use the study app, and how it affects the use of health care services.\n\nParticipants use the app for 16 weeks. They may continue using it for another 16 weeks. During the study, participants continue with their normal treatment for schizophrenia. Participants are in the study for about a year. During this time, they visit the study site every 2 months.\n\nDuring this study, doctors regularly check participants' schizophrenia symptoms and overall quality of life. Researchers may also compare the healthcare data of study participants with a similar group of people with schizophrenia who are not part of the study. The doctors also regularly check participants' health and take note of any unwanted effects."
      },
      "conditionsModule": { "conditions": ["Schizophrenia"] },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "NA",
          "interventionModel": "SINGLE_GROUP",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": { "masking": "NONE" }
        },
        "enrollmentInfo": { "count": 250, "type": "ESTIMATED" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "CT-155 treatment arm",
            "type": "EXPERIMENTAL",
            "interventionNames": ["Device: Digital therapeutic (CT-155)"]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "Digital therapeutic (CT-155)",
            "description": "Digital therapeutic (CT-155) - in the form of a smartphone app",
            "armGroupLabels": ["CT-155 treatment arm"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "To assess the change from Baseline to Week 16 in negative symptoms severity, as assessed by the CGI-SCH negative symptoms item 2 among patients with schizophrenia using the investigational CT-155 Digital Therapeutic (DTx)",
            "description": "The Clinical Global Impression - Schizophrenia (CGI-SCH) contains 2 categories: severity of illness and degree of change.\n\nThe severity of illness category evaluates the situation during the week prior to the assessment, while the degree of change category evaluates the change from the previous evaluation.\n\nEach category contains 5 different ratings (positive, negative, depressive, cognitive and global) that are evaluated using a seven-point ordinal scale (1 \\[Normal, not ill\\] - 7 \\[Among the most severely ill\\]) with higher ratings indicating more severe illness (severity of illness) or worsening of symptoms (degree of change).",
            "timeFrame": "up to 16 weeks"
          },
          {
            "measure": "To assess the change from Baseline to Week 16 in experiential negative symptoms (ENS), as assessed by the Motivation and Pleasure Scale Self-Report (MAP-SR) among patients with schizophrenia using the investigational CT-155 DTx",
            "description": "The MAP-SR is an 15-item self-report version of the Clinical Assessment Interview for Negative Symptoms Motivation and Pleasure subscale.\n\nSix items evaluate consummatory and anticipatory pleasure related to social and recreational or work domains; 3 items evaluate feelings and motivations to be around family, romantic partners, and friends; 6 items evaluate motivation and effort to engage in activities.\n\nAll items are rated on a 5-point Likert scale (0 \\[not at all\\] - 4 \\[extreme pleasure\\]) with lower scores representing greater pathology.",
            "timeFrame": "up to 16 weeks"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria\n\n1. Has a primary diagnosis of schizophrenia using the diagnostic criteria for schizophrenia as defined in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5 TR), and/or International Classification of Disease-10 (ICD-10) diagnosis code consistent with a schizophrenia diagnosis.\n2. Has a Clinical Global Impression - Schizophrenia (CGI-SCH) negative symptoms score (item #2) ≥ 4 (moderately ill) at Screening.\n3. 18 years of age or older at the time of informed consent.\n4. Is willing and able to use CT-155 in English language regularly, to provide written informed consent to participate in the study and to be compliant with study-related assessments and activities.\n5. Has outpatient treatment status at the time of screening, with no inpatient treatment for schizophrenia within 12 weeks prior to Screening.\n6. Is on an antipsychotic medication(s) for at least 12 weeks prior to study entry.\n7. Is the sole user of an iPhone with an iPhone operating system (iOS) 16+ or a smartphone with an Android operating system (OS) 12+ with a United States telephone number, and is willing to download and use the specified digital mobile application required by the protocol.\n8. Is willing and able to receive SMS text messages and push notifications on their smartphone.\n\nFurther inclusion criteria apply.\n\nExclusion Criteria\n\n1. Has a score of ≥3 (mildly ill) for CGI-SCH positive symptoms (item #1) at Screening.\n2. Has active substance use disorder of any severity in the last 3 months, other than caffeine and nicotine. Patients are excluded if they fulfill criteria for moderate or severe substance use disorder for cannabis. Only mild substance use disorder for cannabis is allowed if considered by investigator to not impact ability of the patient to participate in the study.\n3. Has suicidal ideation or behavior, as assessed by the Columbia Suicide Severity Rating Scale (C-SSRS):\n\n   * Patients with a \"yes\" response to either Items #4 or #5 on the C-SSRS Suicidal Ideation Item within the last 3 months (12 weeks) prior to screening, or at Screening.\n   * Patients with a \"yes\" response on the C-SSRS Suicidal Behavior Items within the last 6 months (26 weeks) prior to screening or at Screening.\n4. Patients who, in the opinion of the investigator, present a risk of suicide.\n5. Is currently enrolled or has participated in the last 3 months (12 weeks) in a mental health related clinical study (interventional or observational).\n6. Has participated in previous studies of CT-155 or CT-156.",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "centralContacts": [
          {
            "name": "Boehringer Ingelheim",
            "role": "CONTACT",
            "phone": "1-800-243-0127",
            "email": "clintriage.rdg@boehringer-ingelheim.com"
          }
        ],
        "locations": [
          {
            "facility": "Sun Valley Behavioral Med Center",
            "status": "RECRUITING",
            "city": "Imperial",
            "state": "California",
            "zip": "92251",
            "country": "United States",
            "contacts": [
              {
                "name": "Boehringer Ingelheim",
                "role": "CONTACT",
                "phone": "833-602-2368",
                "email": "unitedstates@bitrialsupport.com"
              }
            ],
            "geoPoint": { "lat": 32.84755, "lon": -115.56944 }
          },
          {
            "facility": "North County Clinical Research",
            "status": "RECRUITING",
            "city": "Oceanside",
            "state": "California",
            "zip": "92054",
            "country": "United States",
            "contacts": [
              {
                "name": "Boehringer Ingelheim",
                "role": "CONTACT",
                "phone": "833-602-2368",
                "email": "unitedstates@bitrialsupport.com"
              }
            ],
            "geoPoint": { "lat": 33.19587, "lon": -117.37948 }
          },
          {
            "facility": "NRC Research",
            "status": "RECRUITING",
            "city": "Orange",
            "state": "California",
            "zip": "92868",
            "country": "United States",
            "contacts": [
              {
                "name": "Boehringer Ingelheim",
                "role": "CONTACT",
                "phone": "833-602-2368",
                "email": "unitedstates@bitrialsupport.com"
              }
            ],
            "geoPoint": { "lat": 33.78779, "lon": -117.85311 }
          },
          {
            "facility": "Stanford University School of Medicine",
            "status": "RECRUITING",
            "city": "Stanford",
            "state": "California",
            "zip": "94304",
            "country": "United States",
            "contacts": [
              {
                "name": "Boehringer Ingelheim",
                "role": "CONTACT",
                "phone": "833-602-2368",
                "email": "unitedstates@bitrialsupport.com"
              }
            ],
            "geoPoint": { "lat": 37.42411, "lon": -122.16608 }
          },
          {
            "facility": "CT Clinical Research",
            "status": "RECRUITING",
            "city": "Cromwell",
            "state": "Connecticut",
            "zip": "06416",
            "country": "United States",
            "contacts": [
              {
                "name": "Boehringer Ingelheim",
                "role": "CONTACT",
                "phone": "833-602-2368",
                "email": "unitedstates@bitrialsupport.com"
              }
            ],
            "geoPoint": { "lat": 41.5951, "lon": -72.64537 }
          },
          {
            "facility": "New Life Medical Research Center, Inc",
            "status": "RECRUITING",
            "city": "Hialeah",
            "state": "Florida",
            "zip": "33012",
            "country": "United States",
            "contacts": [
              {
                "name": "Boehringer Ingelheim",
                "role": "CONTACT",
                "phone": "833-602-2368",
                "email": "unitedstates@bitrialsupport.com"
              }
            ],
            "geoPoint": { "lat": 25.8576, "lon": -80.27811 }
          },
          {
            "facility": "Health Synergy Clinical Research, LLC",
            "status": "RECRUITING",
            "city": "West Palm Beach",
            "state": "Florida",
            "zip": "33407",
            "country": "United States",
            "contacts": [
              {
                "name": "Boehringer Ingelheim",
                "role": "CONTACT",
                "phone": "833-602-2368",
                "email": "unitedstates@bitrialsupport.com"
              }
            ],
            "geoPoint": { "lat": 26.71534, "lon": -80.05337 }
          },
          {
            "facility": "CenExel Center for Behavioral Health",
            "status": "RECRUITING",
            "city": "Gaithersburg",
            "state": "Maryland",
            "zip": "20877",
            "country": "United States",
            "contacts": [
              {
                "name": "Boehringer Ingelheim",
                "role": "CONTACT",
                "phone": "833-602-2368",
                "email": "unitedstates@bitrialsupport.com"
              }
            ],
            "geoPoint": { "lat": 39.14344, "lon": -77.20137 }
          },
          {
            "facility": "Boston Neurobehavioral Associates",
            "status": "RECRUITING",
            "city": "Brookline",
            "state": "Massachusetts",
            "zip": "02446",
            "country": "United States",
            "contacts": [
              {
                "name": "Boehringer Ingelheim",
                "role": "CONTACT",
                "phone": "833-602-2368",
                "email": "unitedstates@bitrialsupport.com"
              }
            ],
            "geoPoint": { "lat": 42.33176, "lon": -71.12116 }
          },
          {
            "facility": "Western Michigan University",
            "status": "RECRUITING",
            "city": "Kalamazoo",
            "state": "Michigan",
            "zip": "49008",
            "country": "United States",
            "contacts": [
              {
                "name": "Boehringer Ingelheim",
                "role": "CONTACT",
                "phone": "833-602-2368",
                "email": "unitedstates@bitrialsupport.com"
              }
            ],
            "geoPoint": { "lat": 42.29171, "lon": -85.58723 }
          },
          {
            "facility": "Midwest Research Group",
            "status": "RECRUITING",
            "city": "Saint Charles",
            "state": "Missouri",
            "zip": "63304",
            "country": "United States",
            "contacts": [
              {
                "name": "Boehringer Ingelheim",
                "role": "CONTACT",
                "phone": "833-602-2368",
                "email": "unitedstates@bitrialsupport.com"
              }
            ],
            "geoPoint": { "lat": 38.78394, "lon": -90.48123 }
          },
          {
            "facility": "Creighton University",
            "status": "RECRUITING",
            "city": "Omaha",
            "state": "Nebraska",
            "zip": "68124",
            "country": "United States",
            "contacts": [
              {
                "name": "Boehringer Ingelheim",
                "role": "CONTACT",
                "phone": "833-602-2368",
                "email": "unitedstates@bitrialsupport.com"
              }
            ],
            "geoPoint": { "lat": 41.25626, "lon": -95.94043 }
          },
          {
            "facility": "Neurobehavioral Research",
            "status": "RECRUITING",
            "city": "Cedarhurst",
            "state": "New York",
            "zip": "11516",
            "country": "United States",
            "contacts": [
              {
                "name": "Boehringer Ingelheim",
                "role": "CONTACT",
                "phone": "833-602-2368",
                "email": "unitedstates@bitrialsupport.com"
              }
            ],
            "geoPoint": { "lat": 40.62288, "lon": -73.7243 }
          },
          {
            "facility": "Richmond Behavioral Associates ERG Clinical Research - New York PLLC",
            "status": "RECRUITING",
            "city": "Staten Island",
            "state": "New York",
            "zip": "10314",
            "country": "United States",
            "contacts": [
              {
                "name": "Boehringer Ingelheim",
                "role": "CONTACT",
                "phone": "833-602-2368",
                "email": "unitedstates@bitrialsupport.com"
              }
            ],
            "geoPoint": { "lat": 40.56233, "lon": -74.13986 }
          },
          {
            "facility": "Oklahoma Clinical Research Center/Rivus Institute",
            "status": "RECRUITING",
            "city": "Oklahoma City",
            "state": "Oklahoma",
            "zip": "73112",
            "country": "United States",
            "contacts": [
              {
                "name": "Boehringer Ingelheim",
                "role": "CONTACT",
                "phone": "833-602-2368",
                "email": "unitedstates@bitrialsupport.com"
              }
            ],
            "geoPoint": { "lat": 35.46756, "lon": -97.51643 }
          },
          {
            "facility": "Axon Psychiatry",
            "status": "RECRUITING",
            "city": "Philadelphia",
            "state": "Pennsylvania",
            "zip": "19129",
            "country": "United States",
            "contacts": [
              {
                "name": "Boehringer Ingelheim",
                "role": "CONTACT",
                "phone": "833-602-2368",
                "email": "unitedstates@bitrialsupport.com"
              }
            ],
            "geoPoint": { "lat": 39.95233, "lon": -75.16379 }
          },
          {
            "facility": "Psychiatric Consultants, PC",
            "status": "RECRUITING",
            "city": "Franklin",
            "state": "Tennessee",
            "zip": "37067",
            "country": "United States",
            "contacts": [
              {
                "name": "Boehringer Ingelheim",
                "role": "CONTACT",
                "phone": "833-602-2368",
                "email": "unitedstates@bitrialsupport.com"
              }
            ],
            "geoPoint": { "lat": 35.92506, "lon": -86.86889 }
          },
          {
            "facility": "Beaumont Psychiatric Clinic",
            "status": "RECRUITING",
            "city": "Beaumont",
            "state": "Texas",
            "zip": "77706",
            "country": "United States",
            "contacts": [
              {
                "name": "Boehringer Ingelheim",
                "role": "CONTACT",
                "phone": "833-602-2368",
                "email": "unitedstates@bitrialsupport.com"
              }
            ],
            "geoPoint": { "lat": 30.08605, "lon": -94.10185 }
          },
          {
            "facility": "Red Oak Psychiatry Associates, PA",
            "status": "RECRUITING",
            "city": "Houston",
            "state": "Texas",
            "zip": "77090",
            "country": "United States",
            "contacts": [
              {
                "name": "Boehringer Ingelheim",
                "role": "CONTACT",
                "phone": "833-602-2368",
                "email": "unitedstates@bitrialsupport.com"
              }
            ],
            "geoPoint": { "lat": 29.76328, "lon": -95.36327 }
          },
          {
            "facility": "SMS Clinical research",
            "status": "RECRUITING",
            "city": "Mesquite",
            "state": "Texas",
            "zip": "75149",
            "country": "United States",
            "contacts": [
              {
                "name": "Boehringer Ingelheim",
                "role": "CONTACT",
                "phone": "833-602-2368",
                "email": "unitedstates@bitrialsupport.com"
              }
            ],
            "geoPoint": { "lat": 32.7668, "lon": -96.59916 }
          }
        ]
      },
      "referencesModule": {
        "seeAlsoLinks": [
          { "label": "Related Info", "url": "https://www.mystudywindow.com" }
        ]
      },
      "ipdSharingStatementModule": {
        "ipdSharing": "YES",
        "description": "Once the criteria in section \"Time Frame\" are fulfilled, researchers can use the following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed \"Document Sharing Agreement\".\n\nFurthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.",
        "infoTypes": ["STUDY_PROTOCOL", "SAP", "CSR"],
        "timeFrame": "One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.",
        "accessCriteria": "For study documents - upon signing of a \"Document Sharing Agreement\". For study data - 1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.",
        "url": "https://www.mystudywindow.com/msw/datasharing"
      }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [{ "id": "D012559", "term": "Schizophrenia" }],
        "ancestors": [
          {
            "id": "D019967",
            "term": "Schizophrenia Spectrum and Other Psychotic Disorders"
          },
          { "id": "D001523", "term": "Mental Disorders" }
        ],
        "browseLeaves": [
          {
            "id": "M15376",
            "name": "Schizophrenia",
            "asFound": "Schizophrenia",
            "relevance": "HIGH"
          },
          { "id": "M14473", "name": "Psychotic Disorders", "relevance": "LOW" },
          { "id": "M4815", "name": "Mental Disorders", "relevance": "LOW" },
          {
            "id": "M21838",
            "name": "Schizophrenia Spectrum and Other Psychotic Disorders",
            "relevance": "LOW"
          }
        ],
        "browseBranches": [
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" },
          { "abbrev": "All", "name": "All Conditions" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT06230445",
        "orgStudyIdInfo": { "id": "A2023-002" },
        "organization": {
          "fullName": "Sun Yat-sen University",
          "class": "OTHER"
        },
        "briefTitle": "Effects of Digital Therapeutic in Whole Process Management of Lung Cancer",
        "officialTitle": "A Phase 3, Randomized, Open-label Trial of Digital Therapeutic vs Regular Follow-up in Whole Process Management of Lung Cancer"
      },
      "statusModule": {
        "statusVerifiedDate": "2024-02",
        "overallStatus": "RECRUITING",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2023-06-01", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2026-03-01",
          "type": "ESTIMATED"
        },
        "completionDateStruct": { "date": "2028-09-01", "type": "ESTIMATED" },
        "studyFirstSubmitDate": "2023-08-31",
        "studyFirstSubmitQcDate": "2024-01-27",
        "studyFirstPostDateStruct": { "date": "2024-01-30", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2024-02-23",
        "lastUpdatePostDateStruct": { "date": "2024-02-26", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": {
          "type": "PRINCIPAL_INVESTIGATOR",
          "investigatorFullName": "Hao Long",
          "investigatorTitle": "Prof.",
          "investigatorAffiliation": "Sun Yat-sen University"
        },
        "leadSponsor": { "name": "Sun Yat-sen University", "class": "OTHER" }
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": false
      },
      "descriptionModule": {
        "briefSummary": "This trial will randomize patients into two groups, the treatment group will use the digital therapeutic application named 'UHealth' for the whole process management and the control group will use regular follow-up. The trial aims to look into the difference between quality of life, anxiety/depression index, emergency treatment times, hospital admission rate, treatment compliance, OS, DFS and follow-up cost."
      },
      "conditionsModule": {
        "conditions": [
          "Application of Digital Therapeutic in Lung Cancer Whole Process Management"
        ],
        "keywords": [
          "Digital therapeutic",
          "Whole process management",
          "Lung cancer",
          "Patient follow-up"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["PHASE3"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "primaryPurpose": "HEALTH_SERVICES_RESEARCH",
          "maskingInfo": { "masking": "NONE" }
        },
        "enrollmentInfo": { "count": 900, "type": "ESTIMATED" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "UHealth digital therapeutic group",
            "type": "EXPERIMENTAL",
            "description": "The patients in this group will use UHealth application to monitor their symptoms and give medical advisement through digital methods.",
            "interventionNames": ["Other: UHealth digital therapeutic"]
          },
          {
            "label": "Regular follow-up group",
            "type": "NO_INTERVENTION",
            "description": "The patients in this group will use paper-based follow-up to monitor their symptoms and give medical advisement in outpatient clinic."
          }
        ],
        "interventions": [
          {
            "type": "OTHER",
            "name": "UHealth digital therapeutic",
            "description": "UHealth digital therapeutic is an application that patients can report their symptoms. If the contents that patients fill in reach the threshold, UHealth application will automatic report to doctor and the doctor will give medical advisement through UHealth digital therapeutic application.",
            "armGroupLabels": ["UHealth digital therapeutic group"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "The quality of life after 6 months follow-up",
            "description": "The evaluation of quality of life is based on FACT questionnaire (Version 4.0)",
            "timeFrame": "From enrollment to 6 months after follow-up"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "The score of anxiety/depression after 6 months follow-up",
            "description": "The evaluation of anxiety/depression is based on HADS questionnaire",
            "timeFrame": "From enrollment to 6 months after follow-up"
          },
          {
            "measure": "The physical fitness score at the time of tumor progression",
            "description": "The physical fitness score at the time of tumor progression",
            "timeFrame": "From enrollment to the time of tumor progression (up to 72 months)"
          },
          {
            "measure": "The frequency of emergency treatment",
            "description": "The frequency of emergency treatment",
            "timeFrame": "24 months after enrollment"
          },
          {
            "measure": "The frequency of rehospitalization",
            "description": "The frequency of rehospitalization",
            "timeFrame": "24 months after enrollment"
          },
          {
            "measure": "The compliance of follow-up",
            "description": "The evaluation of follow-up compliance is based on the frequency of drop out",
            "timeFrame": "24 months after enrollment"
          },
          {
            "measure": "Disease-free survival",
            "timeFrame": "24 months after enrollment"
          },
          {
            "measure": "Overall survival",
            "timeFrame": "24 months after enrollment"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients with histologically or cytologically confirmed lung cancer;\n* Patients have received surgery, neoadjuvant therapy, adjuvant therapy, radiotherapy or other chemotherapy, such as cytotoxic chemotherapy, targeted therapy and immunotherapy;\n* ECOG (Performance status) 0-1;\n* Patients aged \\> 18 years and \\< 70 years;\n* The patients themselves or their family members are familiar with mobile and internet;\n\nExclusion Criteria:\n\n* Patients have disease progression in the screening period;\n* Patients with symptomatic brain metastasis;\n* Patients with dementia, schizophrenia or other psychological diseases that may affect the cognitive behavior;\n* Other medical, mental or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or understand the patient information;\n* Women who are pregnant or in the period of breastfeeding.",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "maximumAge": "70 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "centralContacts": [
          {
            "name": "Hao Long, MD",
            "role": "CONTACT",
            "phone": "+86-13802770989",
            "email": "longhao@sysucc.org.cn"
          }
        ],
        "locations": [
          {
            "facility": "Sun Yat-sen University Cancer Center",
            "status": "RECRUITING",
            "city": "Guangzhou",
            "state": "Guangdong",
            "zip": "510060",
            "country": "China",
            "contacts": [
              {
                "name": "Hao Long, MD",
                "role": "CONTACT",
                "phone": "+86-13802770989",
                "email": "longhao@sysucc.org.cn"
              }
            ],
            "geoPoint": { "lat": 23.11667, "lon": 113.25 }
          }
        ]
      },
      "referencesModule": {
        "references": [
          {
            "pmid": "26644527",
            "type": "BACKGROUND",
            "citation": "Basch E, Deal AM, Kris MG, Scher HI, Hudis CA, Sabbatini P, Rogak L, Bennett AV, Dueck AC, Atkinson TM, Chou JF, Dulko D, Sit L, Barz A, Novotny P, Fruscione M, Sloan JA, Schrag D. Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial. J Clin Oncol. 2016 Feb 20;34(6):557-65. doi: 10.1200/JCO.2015.63.0830. Epub 2015 Dec 7. Erratum In: J Clin Oncol. 2016 Jun 20;34(18):2198. doi: 10.1200/JCO.2016.68.4555. J Clin Oncol. 2019 Feb 20;37(6):528. doi: 10.1200/JCO.19.00057."
          },
          {
            "pmid": "28586821",
            "type": "BACKGROUND",
            "citation": "Basch E, Deal AM, Dueck AC, Scher HI, Kris MG, Hudis C, Schrag D. Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment. JAMA. 2017 Jul 11;318(2):197-198. doi: 10.1001/jama.2017.7156."
          },
          {
            "pmid": "34995100",
            "type": "RESULT",
            "citation": "Dai W, Feng W, Zhang Y, Wang XS, Liu Y, Pompili C, Xu W, Xie S, Wang Y, Liao J, Wei X, Xiang R, Hu B, Tian B, Yang X, Wang X, Xiao P, Lai Q, Wang X, Cao B, Wang Q, Liu F, Liu X, Xie T, Yang X, Zhuang X, Wu Z, Che G, Li Q, Shi Q. Patient-Reported Outcome-Based Symptom Management Versus Usual Care After Lung Cancer Surgery: A Multicenter Randomized Controlled Trial. J Clin Oncol. 2022 Mar 20;40(9):988-996. doi: 10.1200/JCO.21.01344. Epub 2022 Jan 7."
          }
        ]
      },
      "ipdSharingStatementModule": {
        "ipdSharing": "UNDECIDED",
        "description": "The participant data will be encrypted and masked before uploading."
      }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [{ "id": "D008175", "term": "Lung Neoplasms" }],
        "ancestors": [
          { "id": "D012142", "term": "Respiratory Tract Neoplasms" },
          { "id": "D013899", "term": "Thoracic Neoplasms" },
          { "id": "D009371", "term": "Neoplasms by Site" },
          { "id": "D009369", "term": "Neoplasms" },
          { "id": "D008171", "term": "Lung Diseases" },
          { "id": "D012140", "term": "Respiratory Tract Diseases" }
        ],
        "browseLeaves": [
          {
            "id": "M11172",
            "name": "Lung Neoplasms",
            "asFound": "Lung Cancer",
            "relevance": "HIGH"
          },
          {
            "id": "M14979",
            "name": "Respiratory Tract Neoplasms",
            "relevance": "LOW"
          },
          { "id": "M16658", "name": "Thoracic Neoplasms", "relevance": "LOW" },
          { "id": "M11168", "name": "Lung Diseases", "relevance": "LOW" },
          {
            "id": "M14977",
            "name": "Respiratory Tract Diseases",
            "relevance": "LOW"
          }
        ],
        "browseBranches": [
          { "abbrev": "BC04", "name": "Neoplasms" },
          {
            "abbrev": "BC08",
            "name": "Respiratory Tract (Lung and Bronchial) Diseases"
          },
          { "abbrev": "All", "name": "All Conditions" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT06004388",
        "orgStudyIdInfo": { "id": "CT-132-R-002" },
        "organization": {
          "fullName": "Click Therapeutics, Inc.",
          "class": "INDUSTRY"
        },
        "briefTitle": "Study of Two Digital Therapeutics for the Prevention of Episodic Migraine Receiving CGRP Therapy (ReMMiD-C)",
        "officialTitle": "A Randomized, Double-Blind, Parallel-Group, Virtual Study to Evaluate the Efficacy and Safety of Two Prescription Digital Therapeutics for the Prevention of Episodic Migraine in Late Adolescents and Adults Currently Receiving Calcitonin Gene-Related Peptide (CGRP) Inhibitor Therapy"
      },
      "statusModule": {
        "statusVerifiedDate": "2024-03",
        "overallStatus": "COMPLETED",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2023-07-21", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2024-05-21",
          "type": "ACTUAL"
        },
        "completionDateStruct": { "date": "2024-06-05", "type": "ACTUAL" },
        "studyFirstSubmitDate": "2023-07-26",
        "studyFirstSubmitQcDate": "2023-08-15",
        "studyFirstPostDateStruct": { "date": "2023-08-22", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2024-12-13",
        "lastUpdatePostDateStruct": { "date": "2024-12-18", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": {
          "name": "Click Therapeutics, Inc.",
          "class": "INDUSTRY"
        }
      },
      "oversightModule": {
        "oversightHasDmc": true,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": true,
        "isUnapprovedDevice": true,
        "isUsExport": false
      },
      "descriptionModule": {
        "briefSummary": "Randomized study of two digital therapeutics for the prevention of episodic migraine in patients currently receiving Calcitonin Gene-Related Peptide (CGRP) Inhibitor Therapy",
        "detailedDescription": "The purpose of this randomized trial is to evaluate the efficacy and safety of two prescription mobile applications that provide an interactive, software-based intervention for the preventative treatment of episodic migraine in late adolescents and adults who are receiving Calcitonin Gene-Related Peptide (CGRP) Inhibitor Therapy."
      },
      "conditionsModule": {
        "conditions": [
          "Migraine",
          "Episodic Migraine",
          "Headache",
          "Headache, Migraine"
        ],
        "keywords": [
          "Prescription digital therapeutic (PDT)",
          "Software as a Medical Device (SaMD)",
          "Smartphone app",
          "CGRP",
          "Calcitonin Gene-Related Peptide Inhibitor Therapy"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["PHASE3"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": {
            "masking": "DOUBLE",
            "maskingDescription": "Double-blind",
            "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]
          }
        },
        "enrollmentInfo": { "count": 110, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "ReMMiD-C Therapeutic Arm A",
            "type": "EXPERIMENTAL",
            "description": "Mobile application A (ReMMiD-C Digital Therapeutic) as a software-based intervention for the preventive treatment of episodic migraine in late adolescents and adults receiving Calcitonin Gene-Related Peptide (CGRP) Inhibitor Therapy.",
            "interventionNames": ["Device: Click Digital Therapeutic"]
          },
          {
            "label": "ReMMiD-C Therapeutic Arm B",
            "type": "EXPERIMENTAL",
            "description": "Mobile application B as a software-based intervention for the preventive treatment of episodic migraine in late adolescents and adults receiving Calcitonin Gene-Related Peptide (CGRP) Inhibitor Therapy.",
            "interventionNames": ["Device: Click Digital Therapeutic"]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "Click Digital Therapeutic",
            "description": "Evaluate the efficacy and safety of prescription mobile applications that provide an interactive, software-based intervention for the preventative treatment of episodic migraine in late adults and adolescents receiving Calcitonin Gene-Related Peptide (CGRP) Inhibitor Therapy",
            "armGroupLabels": [
              "ReMMiD-C Therapeutic Arm A",
              "ReMMiD-C Therapeutic Arm B"
            ]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Change in Monthly Migraine Days (MMDs)",
            "description": "Change from baseline in the number of Monthly Migraine Days (MMDs) at Week 12",
            "timeFrame": "Baseline to Week 12"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Proportion of Patients with Decrease in MMDs",
            "description": "Proportion of participants who have at least a 50% reduction from baseline in the mean number of MMDs at Week 12",
            "timeFrame": "Baseline to Week 12"
          },
          {
            "measure": "Change in MMDs at Weeks 4 and 8",
            "description": "Change from baseline in the number of MMDs recorded over the previous 28 days at Week 4 and Week 8",
            "timeFrame": "Baseline to Weeks 4 and 8"
          },
          {
            "measure": "Change in Mean MMDs",
            "description": "Reduction from baseline in the mean number of MMDs over 12 weeks",
            "timeFrame": "Baseline to Week 12"
          },
          {
            "measure": "Change in Average Headache Severity",
            "description": "Change in the average severity of headache from the run-in period to Weeks 9-12",
            "timeFrame": "Run-in to Weeks 9-12"
          },
          {
            "measure": "Change in Migraine Questionnaire",
            "description": "Change from baseline in the Migraine-Specific Quality-of-Life Questionnaire v2.1 (MSQ) at Week 4, Week 8, and Week 12",
            "timeFrame": "Baseline to Weeks 4, 8 and 12"
          },
          {
            "measure": "Change in Migraine Disability Assessment (MIDAS)",
            "description": "Change from baseline in the Migraine Disability Assessment (MIDAS) at Week 4, Week 8, and Week 12",
            "timeFrame": "Baseline to Weeks 4, 8, and 12"
          },
          {
            "measure": "Change in Migraine Medication Use (frequency)",
            "description": "Change in the use (frequency) of acute migraine medications from the run-in period to Weeks 9-12",
            "timeFrame": "Run-in to Weeks 9-12"
          },
          {
            "measure": "Change in Migraine Medication Use (dose)",
            "description": "Change in the use (dose) of acute migraine medications from the run-in period to Weeks 9-12",
            "timeFrame": "Run-in to Weeks 9-12"
          },
          {
            "measure": "Change in Migraine Medication Use (medication type)",
            "description": "Change in the use (type) of acute migraine medications from the run-in period to Weeks 9-12",
            "timeFrame": "Run-in to Weeks 9-12"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* A participant will be eligible for entry into the study if all of the following criteria are met per participant self-report:\n* Willing and able to provide written informed consent to participate in the study, attend study visits, and comply with study-related requirements and assessments.\n* Lives in the United States.\n* Adult or late adolescent, ≥ 18 years of age at the time of informed consent.\n* Able to read and understand the English informed consent form.\n* The following will be investigator-reviewed: Participant has at least a 1-year history of migraine (with or without aura) consistent with a diagnosis according to the International Classification of Headache Disorders (ICHD), 3rd Edition:\n\n  i. Age of onset of migraines prior to 50 years of age\n\nii. Migraine attacks, on average, lasting 4-72 hours if untreated\n\niii. Per participant report, 4 or more migraine days per month within the last 3 months prior to the Screening Visit (a month is defined as 28 days)\n\niv. Four to fourteen migraine days during the run-in period\n\n* Is currently managing migraines with at least 1 prescription CGRP inhibitor therapy for the preventive or acute treatment of episodic or chronic migraine during the 3 months prior to screening.\n* Is the sole user of an iPhone with an iPhone operating system (iOS) 14 or later or a smartphone with an Android operating system (OS) 11 or later, and is willing to download and use the specified eDiary and Study App required by the protocol.\n* Is willing and able to receive SMS text messages and push messages on their smartphone.\n* Is the owner of, and has regular access to, an email address.\n* Has regular access to the Internet via cellular data plan and/or wifi.\n* Understands the use of and interest in the eDiary and the Study App during the screening period and the baseline visit (Day 1).\n\nExclusion Criteria:\n\n* A participant will not be eligible for study entry if any of the following criteria are met per participant self-report:\n* History of basilar migraine or hemiplegic migraine.\n* Active chronic pain syndromes, such as fibromyalgia, chronic pelvic pain, or complex regional pain syndrome (CRPS).\n* Other pain syndromes (including trigeminal neuralgia), psychiatric conditions (such as current major depressive episode, bipolar disorder, major depressive disorder, schizophrenia), dementia, or significant neurological disorders (other than migraine) that, in the Investigator's opinion, might interfere with study assessments.\n* History of, treatment for, or evidence of, alcohol or drug abuse within the past 12 months (48 weeks) or having met DSM-5 criteria for any significant substance use disorder within the past 12 months (48 weeks) from the date of the screening visit.\n* History of use of analgesics (e.g., nonsteroidal anti-inflammatory drugs \\[NSAIDs\\] or acetaminophen, including opioids) or butalbital on ≥ 15 days per month during the 3 months (12 weeks) prior to the Screening Visit or during the run-in period.\n* Post-traumatic headache, persistent post-traumatic headache, or post-concussion syndrome.\n* Other significant acute or chronic medical condition(s) that, in the opinion of the Investigator, may confound the interpretation of findings to inform PDT development.\n* Failure to adhere with or inability to complete eDiary inputs and onboarding activities during the run-in period. Participants who are not adherent during the run-in period are not eligible for study entry.\n* Previous enrollment in any digital therapeutics pilot or pivotal study for a migraine indication.\n* Participation in any other investigational clinical study",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "Shaheen Lakhan",
            "affiliation": "Click Therapeutics",
            "role": "STUDY_DIRECTOR"
          }
        ],
        "locations": [
          {
            "facility": "Click Therapeutics",
            "city": "New York",
            "state": "New York",
            "zip": "10013",
            "country": "United States",
            "geoPoint": { "lat": 40.71427, "lon": -74.00597 }
          }
        ]
      }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [
          { "id": "D008881", "term": "Migraine Disorders" },
          { "id": "D006261", "term": "Headache" }
        ],
        "ancestors": [
          { "id": "D051270", "term": "Headache Disorders, Primary" },
          { "id": "D020773", "term": "Headache Disorders" },
          { "id": "D001927", "term": "Brain Diseases" },
          { "id": "D002493", "term": "Central Nervous System Diseases" },
          { "id": "D009422", "term": "Nervous System Diseases" },
          { "id": "D010146", "term": "Pain" },
          { "id": "D009461", "term": "Neurologic Manifestations" }
        ],
        "browseLeaves": [
          {
            "id": "M11852",
            "name": "Migraine Disorders",
            "asFound": "Migraine",
            "relevance": "HIGH"
          },
          {
            "id": "M9351",
            "name": "Headache",
            "asFound": "Headache",
            "relevance": "HIGH"
          },
          { "id": "M22529", "name": "Headache Disorders", "relevance": "LOW" },
          {
            "id": "M26657",
            "name": "Headache Disorders, Primary",
            "relevance": "LOW"
          },
          { "id": "M5204", "name": "Brain Diseases", "relevance": "LOW" },
          {
            "id": "M5742",
            "name": "Central Nervous System Diseases",
            "relevance": "LOW"
          },
          { "id": "M13066", "name": "Pain", "relevance": "LOW" },
          {
            "id": "M12404",
            "name": "Neurologic Manifestations",
            "relevance": "LOW"
          }
        ],
        "browseBranches": [
          { "abbrev": "BC10", "name": "Nervous System Diseases" },
          { "abbrev": "All", "name": "All Conditions" },
          { "abbrev": "BC23", "name": "Symptoms and General Pathology" }
        ]
      },
      "interventionBrowseModule": {
        "browseLeaves": [
          { "id": "M6263", "name": "Coal Tar", "relevance": "LOW" },
          { "id": "M5379", "name": "Calcitonin", "relevance": "LOW" },
          { "id": "M260622", "name": "Salmon calcitonin", "relevance": "LOW" },
          {
            "id": "M18305",
            "name": "Calcitonin Gene-Related Peptide",
            "relevance": "LOW"
          },
          { "id": "M254422", "name": "Katacalcin", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "Derm", "name": "Dermatologic Agents" },
          { "abbrev": "All", "name": "All Drugs and Chemicals" },
          { "abbrev": "BDCA", "name": "Bone Density Conservation Agents" },
          { "abbrev": "VaDiAg", "name": "Vasodilator Agents" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT05375500",
        "orgStudyIdInfo": { "id": "1" },
        "organization": { "fullName": "Karuna Labs Inc.", "class": "INDUSTRY" },
        "briefTitle": "Embodiment in Virtual Reality as a Telemedicine Digital Therapeutic for the Treatment of Chronic Shoulder Pain",
        "officialTitle": "Embodiment in Virtual Reality as a Telemedicine Digital Therapeutic for the Treatment of Chronic Shoulder Pain"
      },
      "statusModule": {
        "statusVerifiedDate": "2022-05",
        "overallStatus": "COMPLETED",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2020-01-01", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2021-05-27",
          "type": "ACTUAL"
        },
        "completionDateStruct": { "date": "2021-09-10", "type": "ACTUAL" },
        "studyFirstSubmitDate": "2022-03-28",
        "studyFirstSubmitQcDate": "2022-05-10",
        "studyFirstPostDateStruct": { "date": "2022-05-16", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2022-05-10",
        "lastUpdatePostDateStruct": { "date": "2022-05-16", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": { "name": "Karuna Labs Inc.", "class": "INDUSTRY" }
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": true,
        "isUsExport": false
      },
      "descriptionModule": {
        "briefSummary": "Chronic shoulder pain is a common musculoskeletal pain condition that can have a profound impact on a sufferer's life and a large socioeconomic healthcare burden to society. The aim of this study was to determine the feasibility of delivering telemedicine enabled functional shoulder rehabilitation for chronic shoulder pain patients using immersive virtual reality. Ten chronic shoulder pain patients were recruited from local pain clinics. Patients engaged in three sessions of virtual embodiment training per week over the course of eight weeks. Rehabilitation sessions were delivered on an Oculus Quest head-mounted display and hand controllers. Rehabilitation exercises (virtual embodiment training) leverage techniques from graded motor imagery, such as visual mirror feedback and augmentation of the virtual avatar's movements. Eight pain assessments were administered prior to the first session, and at weeks four and eight to get an indication of the effect that telemedicine delivered virtual embodiment training has on symptoms of chronic shoulder pain.",
        "detailedDescription": "This study protocol was conducted in accordance with the ethical standards of the Declaration of Helsinki and approved by ADVARRA, an independent institutional review board. Ten chronic shoulder pain patients (7 Female, 3 Male, mean age = 48.44 years) provided written informed consent prior to participating in the study. Eight patients presented with chronic pain of the left shoulder and two presented with right chronic shoulder pain. Patients were recruited from a local pain clinic. Patients were excluded if they reported a history of motion sickness, a history of seizures, or cognitive impairments. A total of twenty-one patients were assessed for eligibility. Two patients were excluded prior to participation for a history of vertigo or motion sickness, and one was excluded due to color blindness. Four patients declined to participate prior to beginning treatment. Four patients were excluded due to impending surgeries scheduled that would prevent them from completing the study protocol (see Figure 1 consort diagram).\n\nPatients who volunteered to participate in the study were shipped an Oculus Quest six-degrees-of-freedom wireless head mounted VR display (HMD) and hand controllers. Patients were assigned a health coach to assist with the use of the VR hardware. The health coach met with the patients via a HIPAA compliant telehealth video chat platform. Patients were instructed on safe use of the VR headset and hand controllers and instructed on how to create the safe play guardian of the Oculus Quest VR system and how to connect the HMD to a home wi-fi. After the patients confirmed that they were comfortable using the Oculus Quest, they were advised to complete three sessions of functional rehabilitation in VR exercises per week over the course of eight weeks. All function rehabilitation exercises were self-administered by each patient. The coach conducted telehealth video chat sessions with each patient once per week and administered a structured curriculum that included pain neuroscience education, goal setting, instructions for pacing and grading, and flare-up management.\n\nFunctional rehabilitation exercises were delivered through KarunaHOME (Karuna Labs, Inc, San Francisco, CA). KarunaHOME is a virtual reality software delivered on the oculus quest to provide rehabilitation exercises in patient's homes. KarunaHOME Virtual Embodiment Training™ consists of five functional rehabilitation exercises designed on the principles of graded exposure and mirror therapy.\n\nEach session of functional rehabilitation began with a calibration exercise that measured shoulder range of motion for flexion, scaption, and abduction (Figure 2). The calibration exercise progressed through shoulder flexion, shoulder scaption, and shoulder abduction one at a time, on each side. The patient was instructed in VR to perform three repetitions within a comfortable range. The calibration exercise was a measurement of a patient's comfortable range of motion for flexion, scaption, and abduction and was used to set the limits of subsequent exercises so that patient did not move beyond their comfortable range during that day's session. The second exercise was a functional movement exercise that promoted shoulder flexion, scaption, and abduction while engaged in a reach and grasp task. Patients reached for an orb in the form of a floating lotus flower positioned in front of the patient in the virtual environment. Patients grasped the orb by moving the hand controller, which corresponded to movement of the virtual avatar's arm, and then pulled the trigger of the Oculus Quest hand controller using the index finger to toss the orb into a pond by producing either an overhand or underhand throwing motion and releasing the trigger. The second exercise also incorporated a mirror visual feedback (MVF) manipulation where the avatar's contralateral limb moved relative to the patient's movement. For example, if the patient moved their right arm, they would see embodied avatar's left arm moving. MVF was used for half the duration of each exercise. The third exercise was a reach and grasp exercise where patients reached to grasp colorful flowers by moving the hand controller to position the virtual avatar's arm in front of their embodied virtual avatar. The goal of this exercise was to match flowers of the same color in sets of three or more. The patient reached up for a flower to remove it and then the flowers above will fall into place. The exercise required patients to reach a maximum height by continuing to remove flowers. The fourth exercise was a painting exercise designed to promote complex dynamic shoulder motion. The goal of this exercise was to connect numbered dots by using the hand controller to move the virtual avatar's arm in a dynamic pattern to recreate different shapes in the sky using a virtual paintbrush. The first few shapes were directly in front of the patient and were simple movements such as a circle, triangle, heart. The shapes became progressively more difficult, requiring greater shoulder range of motion for reaching above and to the side, and progressed to more complex shapes to connect. The final exercise was a simulated activity of daily living in the form of a bow and arrow experience. Movements were designed to mimic motions that are included in activities of daily living such as putting on a seatbelt or shampooing hair. There were three distinct exercises within the bow and arrow activity. In all exercises, the patient moved the hand controller to move the virtual avatar's upper extremity limbs in a position that was necessary to complete the task. The first exercise required patients to reach the affected arm across body (horizontal adduction) to the quiver on the opposite hip to grasp an arrow and then bring the arrow to the bow (shoulder flexion) and pull back (scapular retraction) and shoot towards a target. The second exercise required patients to reach with affected arm over and behind the opposite shoulder to the quiver to get an arrow and then bring the arrow to the bow (shoulder flexion) and pull back (scapular retraction) and shoot. The third exercise required patients to reach over the affected shoulder (shoulder flexion, abduction, and internal and external rotation). Each session progressed from the first exercise to the last exercise with one minute of a guided breathing exercise in between each exercise. Patients completed three sessions per week over the course of eight weeks.\n\nTelehealth-based pain education and behavioral health coaching was administered once per week. The first session was ninety minutes in duration and consisted of a general introduction, a tutorial on safely using the VR hardware in the home, and general introductions to Virtual Embodiment Training. Sessions two through eight were sixty minutes in duration with each session addressing topics that could be applied in the virtual embodiment exercises as well as activities of daily living. Each session included discussions of goals to work towards, including goals within virtual embodiment exercises. Sessions also contained pain neuroscience education, instruction on graded exposure, and behavioral exercises designed to help patients cope with their chronic pain and manage stress with relaxation, awareness of emotions and pain-related thoughts, mindfulness and gratitude-based exercises.Patients were encouraged to apply what they learned in the behavioral coaching sessions in exercised performed in VR.\n\nThe primary objective of this study was to assess the feasibility of a home-based functional rehabilitation program delivered in VR combined with telehealth-based education and coaching. The secondary objective was to determine appropriate outcome measures for an eventual larger scale randomized controlled trial. To assess the potential effectiveness of VR telehealth delivered functional rehabilitation, a battery of pain assessments were administered at three timepoints (pre, mid, and post), prior to beginning the eight week protocol, at the midpoint (week 4), and after completing the eight week protocol. The Disability of the Arm, Shoulder, and Hand (DASH) questionnaire was used to assess shoulder disability. The SF-36 was used to assess was administered to assess quality of life. The Pain Catastrophizing Scale (PCS) was used to assess psychological aspects of pain. The Fear Avoidance Beliefs Questionnaire (FABQ) physical activity subscale was used to assess fear of movement due to chronic pain. The Upper Extremity Functional Index (UEFI) was used to assess shoulder function. The Tampa Scale of Kinesiophobia (TSK) was used to assess fear of movement. The Pain Self-Efficacy Questionnaire (PSEQ) was used to assess patient confidence. The Yellow Flag Risk Form (YFRF) was used to assess chronic pain mechanisms. Since this was a feasibility study, additional measures were assessed to determine appropriate outcome measures for an eventual larger randomized controlled trial."
      },
      "conditionsModule": {
        "conditions": ["Chronic Pain", "Low Back Pain", "Shoulder Pain"]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "NA",
          "interventionModel": "SINGLE_GROUP",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": { "masking": "NONE" }
        },
        "enrollmentInfo": { "count": 10, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "Digital Therapeutic Arm",
            "type": "EXPERIMENTAL",
            "description": "measure the treatment effects of digital therapeutic intervention",
            "interventionNames": ["Device: telemedicine digital therapeutic"]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "telemedicine digital therapeutic",
            "description": "digital therapeutics intervention for chronic pain utilizing coaching and virtual reality application",
            "armGroupLabels": ["Digital Therapeutic Arm"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Disabilities of the Arm, Shoulder and Hand",
            "description": "30-item questionnaire that evaluates disability performing upper extremity activities. This questionnaire is a self- report questionnaire that patients can rate difficulty and interference with daily life on a 5 point Likert scale.",
            "timeFrame": "1-2 months"
          },
          {
            "measure": "Upper Extremity Functional Index",
            "description": "The Upper Extremity Functional Index (UEFI) is a patient reported outcome measure used to assess the functional impairment in individuals with musculoskeletal upper limb dysfunction. The original UEFI consists of 20 questions on a 5- point rating scale assessing level of difficulty in performing activities of daily living using the upper extremities including household and work activities, hobbies, lifting a bag of groceries, washing your scalp, pushing up on your hands, driving etc.",
            "timeFrame": "1-2 months"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Pain Catastrophizing Scale",
            "description": "A total PCS score of 30 represents clinically relevant level of catastrophizing. A total PCS score of 30 corresponds to the 75th percentile of the distribution of PCS scores in clinic samples of chronic pain patients.",
            "timeFrame": "1-2 months"
          },
          {
            "measure": "Fear Avoidance Beliefs",
            "description": "The Fear-Avoidance Beliefs Questionnaire (FABQ) is a patient reported questionnaire which measures a patient\\&#39;s fear avoidance beliefs about physical activity and work due to pain and resulting disability",
            "timeFrame": "1-2 months"
          },
          {
            "measure": "Pain Self-efficacy",
            "description": "The Pain Self-Efficacy Questionnaire (PSEQ) is a 10-item questionnaire, developed to assess the confidence people with ongoing pain have in performing activities while in pain.",
            "timeFrame": "1-2 months"
          },
          {
            "measure": "Yellow Flag Risk",
            "description": "A 17 question questionnaire that predicts and screens risk of pain disability and factors preventing recovery. Patterns suggest pain mechanism; Measures functional outcome from low, moderate, or high risk groups",
            "timeFrame": "1-2 months"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* 18 years of age or older\n* Able to wear a VR HMD (head-mounted display)\n* Able to attend visits with the frequency outlined in the protocol\n\nExclusion Criteria:\n\n* Individuals who have a cognitive impairment\n* Susceptibility to motion sickness or simulator-sickness\n* History of susceptibility to seizures per subject's reporting\n* Pain due to skin infections\n* Pain due to blood clots",
        "healthyVolunteers": true,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "James Petros, MD",
            "affiliation": "Chief Medical Officer",
            "role": "PRINCIPAL_INVESTIGATOR"
          }
        ],
        "locations": [
          {
            "facility": "Allied Pain & Spine Institute",
            "city": "Los Gatos",
            "state": "California",
            "zip": "95032",
            "country": "United States",
            "geoPoint": { "lat": 37.22661, "lon": -121.97468 }
          }
        ]
      },
      "ipdSharingStatementModule": { "ipdSharing": "NO" }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [
          { "id": "D020069", "term": "Shoulder Pain" },
          { "id": "D017116", "term": "Low Back Pain" },
          { "id": "D059350", "term": "Chronic Pain" }
        ],
        "ancestors": [
          { "id": "D001416", "term": "Back Pain" },
          { "id": "D010146", "term": "Pain" },
          { "id": "D009461", "term": "Neurologic Manifestations" },
          { "id": "D018771", "term": "Arthralgia" },
          { "id": "D007592", "term": "Joint Diseases" },
          { "id": "D009140", "term": "Musculoskeletal Diseases" }
        ],
        "browseLeaves": [
          { "id": "M13066", "name": "Pain", "relevance": "LOW" },
          {
            "id": "M29442",
            "name": "Chronic Pain",
            "asFound": "Chronic Pain",
            "relevance": "HIGH"
          },
          { "id": "M4714", "name": "Back Pain", "relevance": "LOW" },
          {
            "id": "M19433",
            "name": "Low Back Pain",
            "asFound": "Low Back Pain",
            "relevance": "HIGH"
          },
          {
            "id": "M21907",
            "name": "Shoulder Pain",
            "asFound": "Shoulder Pain",
            "relevance": "HIGH"
          },
          {
            "id": "M12404",
            "name": "Neurologic Manifestations",
            "relevance": "LOW"
          },
          { "id": "M20833", "name": "Arthralgia", "relevance": "LOW" },
          { "id": "M10621", "name": "Joint Diseases", "relevance": "LOW" },
          {
            "id": "M12097",
            "name": "Musculoskeletal Diseases",
            "relevance": "LOW"
          },
          {
            "id": "T1303",
            "name": "Chronic Graft Versus Host Disease",
            "relevance": "LOW"
          }
        ],
        "browseBranches": [
          { "abbrev": "BC23", "name": "Symptoms and General Pathology" },
          { "abbrev": "All", "name": "All Conditions" },
          { "abbrev": "BC05", "name": "Musculoskeletal Diseases" },
          { "abbrev": "BC10", "name": "Nervous System Diseases" },
          { "abbrev": "Rare", "name": "Rare Diseases" }
        ]
      },
      "interventionBrowseModule": {
        "browseLeaves": [
          { "id": "M6263", "name": "Coal Tar", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "Derm", "name": "Dermatologic Agents" },
          { "abbrev": "All", "name": "All Drugs and Chemicals" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT04770285",
        "orgStudyIdInfo": { "id": "345-201-00002" },
        "organization": {
          "fullName": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
          "class": "INDUSTRY"
        },
        "briefTitle": "Trial to Evaluate the Effectiveness of a Digital Therapeutics in Adults Diagnosed With Major Depressive Disorder",
        "officialTitle": "A Multi-center, Randomized, Controlled Trial to Evaluate the Effectiveness of a Digital Therapeutic (CT-152) as Adjunctive Therapy in Adult Subjects Diagnosed With Major Depressive Disorder",
        "acronym": "MIRAI"
      },
      "statusModule": {
        "statusVerifiedDate": "2024-09",
        "overallStatus": "COMPLETED",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2021-02-25", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2022-10-26",
          "type": "ACTUAL"
        },
        "completionDateStruct": { "date": "2022-10-26", "type": "ACTUAL" },
        "studyFirstSubmitDate": "2021-02-19",
        "studyFirstSubmitQcDate": "2021-02-22",
        "studyFirstPostDateStruct": { "date": "2021-02-25", "type": "ACTUAL" },
        "resultsFirstSubmitDate": "2024-09-23",
        "resultsFirstSubmitQcDate": "2024-09-23",
        "resultsFirstPostDateStruct": {
          "date": "2024-10-16",
          "type": "ACTUAL"
        },
        "dispFirstSubmitDate": "2023-10-26",
        "dispFirstPostDateStruct": { "date": "2024-05-07", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2024-09-23",
        "lastUpdatePostDateStruct": { "date": "2024-10-16", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": {
          "name": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
          "class": "INDUSTRY"
        },
        "collaborators": [
          { "name": "Click Therapeutics, Inc.", "class": "INDUSTRY" }
        ]
      },
      "oversightModule": {
        "oversightHasDmc": true,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": true,
        "isUnapprovedDevice": true
      },
      "descriptionModule": {
        "briefSummary": "This study compares the effectiveness of 2 digital therapeutics in adult participants diagnosed with major depressive disorder (MDD) who are on antidepressant therapy (ADT) monotherapy for the treatment of depression.",
        "detailedDescription": "This is a pivotal, 13-week, multi-center, randomized, controlled trial to evaluate the effectiveness and safety of two digital therapeutics in adult participants diagnosed with MDD who are on antidepressant therapy (ADT) monotherapy for the treatment of depression.\n\nThe trial consists of a 3-week screening period, a 6-week treatment period, and a 4-week extension. Trial visits will be conducted remotely either by video visit or telephone. The screening visit may be performed in person at the discretion of the investigator. Eligible participants will be randomized to 1 of 2 digital therapeutics within a mobile application that will reside on the participant's personal iPhone or smartphone.\n\nThe trial population will include male and female participants between 22 and 64 years of age with a primary diagnosis of major depressive disorder (MDD) who are on an ADT for the treatment of depression. This trial will analyze data gathered from approximately 360 participants in the United States. An interim analysis will be conducted when a targeted sample of the first 180 participants has completed week 6 or discontinued the trial prior to week 6."
      },
      "conditionsModule": { "conditions": ["Major Depressive Disorder"] },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": {
            "masking": "QUADRUPLE",
            "whoMasked": [
              "PARTICIPANT",
              "CARE_PROVIDER",
              "INVESTIGATOR",
              "OUTCOMES_ASSESSOR"
            ]
          }
        },
        "enrollmentInfo": { "count": 386, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "Digital Therapeutic A - CT-152",
            "type": "OTHER",
            "description": "Participants received digital treatment session by using the CT-152 mobile application (app) from Day 1 up to Week 6 of the treatment period. Each treatment session consisted of Emotional Faces Memory Task (EFMT) exercises and a psychotherapy lesson. From Week 7 up to Week 10 participants continued using the CT-152 app with optional psychotherapy lesson but did not receive any new EFMT exercises during this period. Participants continued receiving brief SMS messages during Weeks 7 to 10 as a reminder of the previously completed CT-152 treatment courses.",
            "interventionNames": ["Device: CT-152 - Digital Therapeutic"]
          },
          {
            "label": "Digital Therapeutic B - Sham",
            "type": "OTHER",
            "description": "Participants received digital treatment session by using a sham mobile app from Day 1 up to Week 6 of the treatment period. Each treatment session consisted of a Shape and Memory Task (SMT) exercise only. From Week 7 up to Week 10 participants continued using the sham app but did not receive any new SMT exercises during this period. Participants continued receiving brief SMS messages during Weeks 7 to 10 as a reminder of the previously completed sham treatment courses.",
            "interventionNames": ["Device: Sham"]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "CT-152 - Digital Therapeutic",
            "description": "CT-152 mobile app was used by the participants as per the schedule specified in the respective arm.",
            "armGroupLabels": ["Digital Therapeutic A - CT-152"]
          },
          {
            "type": "DEVICE",
            "name": "Sham",
            "description": "Sham mobile app was used by the participants as per the schedule specified in the respective arm.",
            "armGroupLabels": ["Digital Therapeutic B - Sham"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Change From Baseline to Week 6 in the MADRS Total Score",
            "description": "The MADRS is used to assess depressive symptom severity. It consists of 10 items (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts and suicidal thoughts), each rated from 0 to 6 with zero being the \"best\" rating and 6 being the \"worst\" rating. The MADRS total score is the sum of ratings for all 10 items. The total score ranges from 0 to 60. A higher score on the MADRS represents a more severe level of depression. A negative change from baseline indicates improvement. Least square (LS) mean was estimated using Mixed Model Repeated Measures (MMRM) method.",
            "timeFrame": "Baseline (Day 1) to Week 6"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Change From Baseline to Week 6 in the GAD-7 Total Score",
            "description": "The GAD-7 is self-reported questionnaire designed to assess anxiety in participants. The scale contains 7 items (anxiety symptoms) and each item was rated by the participants from 0 (not at all) to 3 (nearly every day) based on how much they were bothered by each symptom. The total score ranges from 0 to 21. A higher score on the GAD-7 represents greater anxiety symptomatology. A negative change from baseline indicates improvement. LS mean was estimated using MMRM method.",
            "timeFrame": "Baseline (Day 1) to Week 6"
          }
        ],
        "otherOutcomes": [
          {
            "measure": "Change From Baseline to Weeks 2 and 4 in the MADRS Total Score",
            "description": "The MADRS is used to assess depressive symptom severity. It consists of 10 items (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts and suicidal thoughts), each rated from 0 to 6 with zero being the \"best\" rating and 6 being the \"worst\" rating. The MADRS total score is the sum of ratings for all 10 items. The total score ranges from 0 to 60. A higher score on the MADRS represents a more severe level of depression. A negative change from baseline indicates improvement. LS mean was estimated using MMRM method.",
            "timeFrame": "Baseline (Day 1) to Weeks 2 and 4"
          },
          {
            "measure": "Change From Baseline to Weeks 2 and 4 in the GAD-7 Total Score",
            "description": "The GAD-7 is self-reported questionnaire designed to assess anxiety in participants. The scale contains 7 items (anxiety symptoms) and each item was rated by the participants from 0 (not at all) to 3 (nearly every day) based on how much they were bothered by each symptom. The total score ranges from 0 to 21. A higher score on the GAD-7 represents greater anxiety symptomatology. A negative change from baseline indicates improvement. LS mean was estimated using MMRM method.",
            "timeFrame": "Baseline (Day 1) to Weeks 2 and 4"
          },
          {
            "measure": "MADRS Response Rate at Weeks 2, 4, and 6",
            "description": "The MADRS is used to assess depressive symptom severity. It consists of 10 items (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts and suicidal thoughts), each rated from 0 to 6 with zero being the \"best\" rating and 6 being the \"worst\" rating. The MADRS total score is the sum of ratings for all 10 items. The total score ranges from 0 to 60. A higher score on the MADRS represents a more severe level of depression. MADRS Response Rate was defined as the percentage of participants who achieved a reduction in the MADRS total score by 50% or more from baseline.",
            "timeFrame": "Baseline (Day 1), Weeks 2, 4 and 6"
          },
          {
            "measure": "Change From Baseline to Weeks 2, 4 and 6 in the Clinical Global Impression - Severity of Illness (CGI-S) Score",
            "description": "The CGI-S is a standardized, clinician-administered global rating scale that measures disease severity on a 7-point Likert scale To perform this assessment, the investigator (or designee) answered the following question: \"Considering your total clinical experience with this particular population, how mentally ill (as related to agitation) is the participant at this time?\" Response choices are 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill subjects. The score 0 (not assessed) will be set to missing. LS mean was estimated using MMRM method.",
            "timeFrame": "Baseline (Day 1) to Weeks 2, 4 and 6"
          },
          {
            "measure": "Change From Baseline to Week 6 in the World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0) Total Score",
            "description": "The WHODAS 2.0 is a 36-item self-assessment scale to measure a participant's function and disability across 6 domains of life: cognition (understanding \\& communicating), mobility (moving \\& getting around), self-care (hygiene, dressing, eating, staying alone), getting along (interacting with others), life activities (domestic responsibilities, leisure, work \\& school), \\& participation (community \\& society). Each item is rated from 0 (none) to 4 (extreme or cannot do). The total score of the 36 items is converted into a metric ranging from 0 (no-disability) to 100 (full- disability) by dividing the total score by the maximum possible value of the total score, which is 144 for 36 items and multiplying by 100. LS Mean was estimated using ANCOVA method.",
            "timeFrame": "Baseline (Day 1) to Week 6"
          },
          {
            "measure": "Change From Screening to Weeks 4 and 6 in the PHQ-9 Total Score.",
            "description": "The PHQ-9 is a standardized, self-administered rating scale that assesses the severity of depressive symptoms. The scale consists of 9 items, representing the 9 criteria upon which the diagnosis of DSM-IV depressive disorders is based. Each item is rated from 0 (not at all) to 3 (nearly every day). The total score ranges from 0 to 27. A higher score on the PHQ-9 represents a higher severity of depressive symptoms. LS mean was estimated using MMRM method.",
            "timeFrame": "Screening to Weeks 4 and 6"
          },
          {
            "measure": "MADRS Partial Response at Weeks 2, 4 and 6",
            "description": "The MADRS is used to assess depressive symptom severity. It consists of 10 items (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts and suicidal thoughts), each rated from 0 to 6 with zero being the \"best\" rating and 6 being the \"worst\" rating. The MADRS total score is the sum of ratings for all 10 items. The total score ranges from 0 to 60. A higher score on the MADRS represents a more severe level of depression. MADRS partial response was defined as the percentage of participants who achieved a reduction in the MADRS total score by 30% or more and less than 50% from baseline.",
            "timeFrame": "Baseline (Day 1), Weeks 2, 4 and 6"
          },
          {
            "measure": "MADRS Response Rate at Weeks 8 and 10",
            "description": "The MADRS is used to assess depressive symptom severity. It consists of 10 items (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts and suicidal thoughts), each rated from 0 to 6 with zero being the \"best\" rating and 6 being the \"worst\" rating. The MADRS total score is the sum of ratings for all 10 items. The total score ranges from 0 to 60. A higher score on the MADRS represents a more severe level of depression. MADRS Response Rate (full or partial) was defined as the percentage of participants who achieved a reduction in the MADRS total score by 30% or more from baseline.",
            "timeFrame": "Baseline (Day 1), Weeks 8 and 10"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Key Inclusion Criteria:\n\n* Participants with a current primary diagnosis of MDD.\n* Participants with a Hamilton Rating Scale for Depression, 17-item (HAM-D17) score ≥ 18\n* Participants who are receiving treatment with an adequate dose and duration of an ADT and who are willing to maintain that same treatment regimen for the duration of this trial.\n* Participants who are the only users of an iPhone or an Android smartphone, and agree to download and use the digital mobile application as required by the protocol.\n\nKey Exclusion Criteria:\n\n* Participants with an inadequate response to \\> 1 adequate trial of ADT for the current episode.\n* Participants who are receiving or have received psychotherapy within 90 days prior to screening.\n* Participants who are currently using a computer, web, or smartphone software-based application for mental health or depression.\n* Participants with a history of schizophrenia, schizoaffective disorder, other psychotic disorder, or Bipolar I/II disorder, or current posttraumatic stress disorder, panic disorder, obsessive-compulsive disorder, or personality disorder\n* General Anxiety Disorder/social anxiety can be present as long as they are not the main disorder requiring treatment.",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "22 Years",
        "maximumAge": "64 Years",
        "stdAges": ["ADULT"]
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "facility": "For additional information regarding sites, contact 844-687-8522",
            "city": "Dallas",
            "state": "Texas",
            "zip": "75231",
            "country": "United States",
            "geoPoint": { "lat": 32.78306, "lon": -96.80667 }
          }
        ]
      },
      "ipdSharingStatementModule": {
        "ipdSharing": "YES",
        "description": "Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.",
        "infoTypes": ["STUDY_PROTOCOL", "SAP", "CSR"],
        "timeFrame": "Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.",
        "accessCriteria": "Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/",
        "url": "https://clinical-trials.otsuka.com"
      }
    },
    "resultsSection": {
      "participantFlowModule": {
        "preAssignmentDetails": "Participants with major depressive disorder were enrolled and randomized in a 1:1 ratio to 1 of the 2 digital mobile applications (CT-152 or sham) on Day 1.",
        "recruitmentDetails": "Participants were enrolled at 37 investigative sites in the United States from 25 February 2021 to 26 October 2022.",
        "groups": [
          {
            "id": "FG000",
            "title": "Digital Therapeutic A - CT-152",
            "description": "Participants received digital treatment session by using the CT-152 mobile application (app) from Day 1 up to Week 6 of the treatment period. Each treatment session consisted of Emotional Faces Memory Task (EFMT) exercises and a psychotherapy lesson. From Week 7 up to Week 10 participants continued using the CT-152 app with optional psychotherapy lesson but did not receive any new EFMT exercises during this period. Participants continued receiving brief SMS messages during Weeks 7 to 10 as a reminder of the previously completed CT-152 treatment courses."
          },
          {
            "id": "FG001",
            "title": "Digital Therapeutic B - Sham",
            "description": "Participants received digital treatment session by using a sham mobile app from Day 1 up to Week 6 of the treatment period. Each treatment session consisted of a Shape and Memory Task (SMT) exercise only. From Week 7 up to Week 10 participants continued using the sham app but did not receive any new SMT exercises during this period. Participants continued receiving brief SMS messages during Weeks 7 to 10 as a reminder of the previously completed sham treatment courses."
          }
        ],
        "periods": [
          {
            "title": "Overall Study",
            "milestones": [
              {
                "type": "STARTED",
                "achievements": [
                  { "groupId": "FG000", "numSubjects": "194" },
                  { "groupId": "FG001", "numSubjects": "192" }
                ]
              },
              {
                "type": "Full Analysis Set (FAS)",
                "comment": "FAS included all randomized participants who received at least 1 occurrence of either CT-152 or sham use and had baseline and at least 1 postbaseline assessment of Montgomery-Asberg Depression Rating Scale (MADRS) total score.",
                "achievements": [
                  { "groupId": "FG000", "numSubjects": "177" },
                  { "groupId": "FG001", "numSubjects": "177" }
                ]
              },
              {
                "type": "COMPLETED",
                "achievements": [
                  { "groupId": "FG000", "numSubjects": "165" },
                  { "groupId": "FG001", "numSubjects": "164" }
                ]
              },
              {
                "type": "NOT COMPLETED",
                "achievements": [
                  { "groupId": "FG000", "numSubjects": "29" },
                  { "groupId": "FG001", "numSubjects": "28" }
                ]
              }
            ],
            "dropWithdraws": [
              {
                "type": "Non-Compliance With Study Treatment",
                "reasons": [
                  { "groupId": "FG000", "numSubjects": "3" },
                  { "groupId": "FG001", "numSubjects": "3" }
                ]
              },
              {
                "type": "Lack of Efficacy",
                "reasons": [
                  { "groupId": "FG000", "numSubjects": "0" },
                  { "groupId": "FG001", "numSubjects": "1" }
                ]
              },
              {
                "type": "Lost to Follow-up",
                "reasons": [
                  { "groupId": "FG000", "numSubjects": "11" },
                  { "groupId": "FG001", "numSubjects": "8" }
                ]
              },
              {
                "type": "Protocol Deviation",
                "reasons": [
                  { "groupId": "FG000", "numSubjects": "6" },
                  { "groupId": "FG001", "numSubjects": "6" }
                ]
              },
              {
                "type": "Technical Problem",
                "reasons": [
                  { "groupId": "FG000", "numSubjects": "0" },
                  { "groupId": "FG001", "numSubjects": "1" }
                ]
              },
              {
                "type": "Withdrawal by Subject",
                "reasons": [
                  { "groupId": "FG000", "numSubjects": "9" },
                  { "groupId": "FG001", "numSubjects": "8" }
                ]
              },
              {
                "type": "Reason Not Specified",
                "reasons": [
                  { "groupId": "FG000", "numSubjects": "0" },
                  { "groupId": "FG001", "numSubjects": "1" }
                ]
              }
            ]
          }
        ]
      },
      "baselineCharacteristicsModule": {
        "populationDescription": "Randomized sample included all participants allocated based on the randomization process and recorded in the database.",
        "groups": [
          {
            "id": "BG000",
            "title": "Digital Therapeutic A - CT-152",
            "description": "Participants received digital treatment session by using the CT-152 mobile app from Day 1 up to Week 6 of the treatment period. Each treatment session consisted of EFMT exercises and a psychotherapy lesson. From Week 7 up to Week 10 participants continued using the CT-152 app with optional psychotherapy lesson but did not receive any new EFMT exercises during this period. Participants continued receiving brief SMS messages during Weeks 7 to 10 as a reminder of the previously completed CT-152 treatment courses."
          },
          {
            "id": "BG001",
            "title": "Digital Therapeutic B - Sham",
            "description": "Participants received digital treatment session by using a sham mobile app from Day 1 up to Week 6 of the treatment period. Each treatment session consisted of a SMT exercise only. From Week 7 up to Week 10 participants continued using the sham app but did not receive any new SMT exercises during this period. Participants continued receiving brief SMS messages during Weeks 7 to 10 as a reminder of the previously completed sham treatment courses."
          },
          {
            "id": "BG002",
            "title": "Total",
            "description": "Total of all reporting groups"
          }
        ],
        "denoms": [
          {
            "units": "Participants",
            "counts": [
              { "groupId": "BG000", "value": "194" },
              { "groupId": "BG001", "value": "192" },
              { "groupId": "BG002", "value": "386" }
            ]
          }
        ],
        "measures": [
          {
            "title": "Age, Continuous",
            "paramType": "MEAN",
            "dispersionType": "STANDARD_DEVIATION",
            "unitOfMeasure": "years",
            "classes": [
              {
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "BG000", "value": "194" },
                      { "groupId": "BG001", "value": "192" },
                      { "groupId": "BG002", "value": "386" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "BG000", "value": "43.0", "spread": "12.1" },
                      { "groupId": "BG001", "value": "42.2", "spread": "12.1" },
                      { "groupId": "BG002", "value": "42.6", "spread": "12.1" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Sex: Female, Male",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "BG000", "value": "194" },
                      { "groupId": "BG001", "value": "192" },
                      { "groupId": "BG002", "value": "386" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "title": "Female",
                    "measurements": [
                      { "groupId": "BG000", "value": "165" },
                      { "groupId": "BG001", "value": "167" },
                      { "groupId": "BG002", "value": "332" }
                    ]
                  },
                  {
                    "title": "Male",
                    "measurements": [
                      { "groupId": "BG000", "value": "29" },
                      { "groupId": "BG001", "value": "25" },
                      { "groupId": "BG002", "value": "54" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Ethnicity (NIH/OMB)",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "BG000", "value": "194" },
                      { "groupId": "BG001", "value": "192" },
                      { "groupId": "BG002", "value": "386" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "title": "Hispanic or Latino",
                    "measurements": [
                      { "groupId": "BG000", "value": "20" },
                      { "groupId": "BG001", "value": "16" },
                      { "groupId": "BG002", "value": "36" }
                    ]
                  },
                  {
                    "title": "Not Hispanic or Latino",
                    "measurements": [
                      { "groupId": "BG000", "value": "173" },
                      { "groupId": "BG001", "value": "174" },
                      { "groupId": "BG002", "value": "347" }
                    ]
                  },
                  {
                    "title": "Unknown or Not Reported",
                    "measurements": [
                      { "groupId": "BG000", "value": "1" },
                      { "groupId": "BG001", "value": "2" },
                      { "groupId": "BG002", "value": "3" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Race/Ethnicity, Customized",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "title": "White",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "BG000", "value": "194" },
                      { "groupId": "BG001", "value": "192" },
                      { "groupId": "BG002", "value": "386" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "BG000", "value": "141" },
                      { "groupId": "BG001", "value": "160" },
                      { "groupId": "BG002", "value": "301" }
                    ]
                  }
                ]
              },
              {
                "title": "Black or African American",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "BG000", "value": "194" },
                      { "groupId": "BG001", "value": "192" },
                      { "groupId": "BG002", "value": "386" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "BG000", "value": "36" },
                      { "groupId": "BG001", "value": "25" },
                      { "groupId": "BG002", "value": "61" }
                    ]
                  }
                ]
              },
              {
                "title": "American Indian or Alaska Native",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "BG000", "value": "194" },
                      { "groupId": "BG001", "value": "192" },
                      { "groupId": "BG002", "value": "386" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "BG000", "value": "5" },
                      { "groupId": "BG001", "value": "1" },
                      { "groupId": "BG002", "value": "6" }
                    ]
                  }
                ]
              },
              {
                "title": "Asian",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "BG000", "value": "194" },
                      { "groupId": "BG001", "value": "192" },
                      { "groupId": "BG002", "value": "386" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "BG000", "value": "5" },
                      { "groupId": "BG001", "value": "4" },
                      { "groupId": "BG002", "value": "9" }
                    ]
                  }
                ]
              },
              {
                "title": "Other",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "BG000", "value": "194" },
                      { "groupId": "BG001", "value": "192" },
                      { "groupId": "BG002", "value": "386" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "BG000", "value": "7" },
                      { "groupId": "BG001", "value": "2" },
                      { "groupId": "BG002", "value": "9" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "MADRS Total Score",
            "description": "The MADRS is used to assess depressive symptom severity. It consists of 10 items (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts and suicidal thoughts), each rated from 0 to 6 with zero being the \"best\" rating and 6 being the \"worst\" rating. The MADRS total score is the sum of ratings for all 10 items. The total score ranges from 0 to 60. A higher score on the MADRS represents a more severe level of depression.",
            "populationDescription": "Number analyzed is the number of participants with data available for analysis at the specified timepoint.",
            "paramType": "MEAN",
            "dispersionType": "STANDARD_DEVIATION",
            "unitOfMeasure": "score on a scale",
            "classes": [
              {
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "BG000", "value": "189" },
                      { "groupId": "BG001", "value": "186" },
                      { "groupId": "BG002", "value": "375" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "BG000", "value": "28.4", "spread": "6.0" },
                      { "groupId": "BG001", "value": "28.4", "spread": "6.0" },
                      { "groupId": "BG002", "value": "28.4", "spread": "6.0" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Generalized Anxiety Disorder-7 (GAD-7) Total Score",
            "description": "The GAD-7 is self-reported questionnaire designed to assess anxiety in participants. The scale contains 7 items (anxiety symptoms) and each item was rated by the participants from 0 (not at all) to 3 (nearly every day) based on how much they were bothered by each symptom. The total score ranges from 0 to 21. A higher score on the GAD-7 represents greater anxiety symptomatology.",
            "populationDescription": "Number analyzed is the number of participants with data available for analysis at the specified timepoint.",
            "paramType": "MEAN",
            "dispersionType": "STANDARD_DEVIATION",
            "unitOfMeasure": "score on a scale",
            "classes": [
              {
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "BG000", "value": "185" },
                      { "groupId": "BG001", "value": "184" },
                      { "groupId": "BG002", "value": "369" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "BG000", "value": "9.5", "spread": "4.5" },
                      { "groupId": "BG001", "value": "9.7", "spread": "4.8" },
                      { "groupId": "BG002", "value": "9.6", "spread": "4.7" }
                    ]
                  }
                ]
              }
            ]
          }
        ]
      },
      "outcomeMeasuresModule": {
        "outcomeMeasures": [
          {
            "type": "PRIMARY",
            "title": "Change From Baseline to Week 6 in the MADRS Total Score",
            "description": "The MADRS is used to assess depressive symptom severity. It consists of 10 items (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts and suicidal thoughts), each rated from 0 to 6 with zero being the \"best\" rating and 6 being the \"worst\" rating. The MADRS total score is the sum of ratings for all 10 items. The total score ranges from 0 to 60. A higher score on the MADRS represents a more severe level of depression. A negative change from baseline indicates improvement. Least square (LS) mean was estimated using Mixed Model Repeated Measures (MMRM) method.",
            "populationDescription": "FAS included all randomized participants who received at least 1 occurrence of either CT-152 or sham use and had baseline and at least 1 postbaseline assessment of MADRS total score. Overall number of participants analyzed is the number of participants with data available for analysis.",
            "reportingStatus": "POSTED",
            "paramType": "LEAST_SQUARES_MEAN",
            "dispersionType": "Standard Error",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "Baseline (Day 1) to Week 6",
            "groups": [
              {
                "id": "OG000",
                "title": "Digital Therapeutic A - CT-152",
                "description": "Participants received digital treatment session by using the CT-152 mobile app from Day 1 up to Week 6 of the treatment period. Each treatment session consisted of EFMT exercises and a psychotherapy lesson. From Week 7 up to Week 10 participants continued using the CT-152 app with optional psychotherapy lesson but did not receive any new EFMT exercises during this period. Participants continued receiving brief SMS messages during Weeks 7 to 10 as a reminder of the previously completed CT-152 treatment courses."
              },
              {
                "id": "OG001",
                "title": "Digital Therapeutic B - Sham",
                "description": "Participants received digital treatment session by using a sham mobile app from Day 1 up to Week 6 of the treatment period. Each treatment session consisted of a SMT exercise only. From Week 7 up to Week 10 participants continued using the sham app but did not receive any new SMT exercises during this period. Participants continued receiving brief SMS messages during Weeks 7 to 10 as a reminder of the previously completed sham treatment courses."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "176" },
                  { "groupId": "OG001", "value": "176" }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-9.03",
                        "spread": "0.73"
                      },
                      { "groupId": "OG001", "value": "-7.25", "spread": "0.73" }
                    ]
                  }
                ]
              }
            ],
            "analyses": [
              {
                "groupIds": ["OG000", "OG001"],
                "nonInferiorityType": "SUPERIORITY",
                "pValue": "0.0568",
                "statisticalMethod": "MMRM",
                "statisticalComment": "p-value was calculated by MMRM method with model terms: Treatment, trial center, visit, treatment by visit, and baseline by visit interaction.",
                "paramType": "Treatment Difference",
                "paramValue": "-1.78",
                "ciPctValue": "95",
                "ciNumSides": "TWO_SIDED",
                "ciLowerLimit": "-3.60",
                "ciUpperLimit": "0.05"
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Change From Baseline to Week 6 in the GAD-7 Total Score",
            "description": "The GAD-7 is self-reported questionnaire designed to assess anxiety in participants. The scale contains 7 items (anxiety symptoms) and each item was rated by the participants from 0 (not at all) to 3 (nearly every day) based on how much they were bothered by each symptom. The total score ranges from 0 to 21. A higher score on the GAD-7 represents greater anxiety symptomatology. A negative change from baseline indicates improvement. LS mean was estimated using MMRM method.",
            "populationDescription": "FAS included all randomized participants who received at least 1 occurrence of either CT-152 or sham use and had baseline and at least 1 postbaseline assessment of MADRS total score. Overall number of participants analyzed is the number of participants with data available for analysis.",
            "reportingStatus": "POSTED",
            "paramType": "LEAST_SQUARES_MEAN",
            "dispersionType": "Standard Error",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "Baseline (Day 1) to Week 6",
            "groups": [
              {
                "id": "OG000",
                "title": "Digital Therapeutic A - CT-152",
                "description": "Participants received digital treatment session by using the CT-152 mobile app from Day 1 up to Week 6 of the treatment period. Each treatment session consisted of EFMT exercises and a psychotherapy lesson. From Week 7 up to Week 10 participants continued using the CT-152 app with optional psychotherapy lesson but did not receive any new EFMT exercises during this period. Participants continued receiving brief SMS messages during Weeks 7 to 10 as a reminder of the previously completed CT-152 treatment courses."
              },
              {
                "id": "OG001",
                "title": "Digital Therapeutic B - Sham",
                "description": "Participants received digital treatment session by using a sham mobile app from Day 1 up to Week 6 of the treatment period. Each treatment session consisted of a SMT exercise only. From Week 7 up to Week 10 participants continued using the sham app but did not receive any new SMT exercises during this period. Participants continued receiving brief SMS messages during Weeks 7 to 10 as a reminder of the previously completed sham treatment courses."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "167" },
                  { "groupId": "OG001", "value": "167" }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-3.41",
                        "spread": "0.34"
                      },
                      { "groupId": "OG001", "value": "-2.64", "spread": "0.34" }
                    ]
                  }
                ]
              }
            ],
            "analyses": [
              {
                "groupIds": ["OG000", "OG001"],
                "nonInferiorityType": "SUPERIORITY",
                "pValue": "0.0705",
                "statisticalMethod": "MMRM",
                "statisticalComment": "p-value was calculated by MMRM method with model terms: Treatment, trial center, visit, treatment by visit, and baseline by visit interaction.",
                "paramType": "Treatment Difference",
                "paramValue": "-0.77",
                "ciPctValue": "95",
                "ciNumSides": "TWO_SIDED",
                "ciLowerLimit": "-1.61",
                "ciUpperLimit": "0.07"
              }
            ]
          },
          {
            "type": "OTHER_PRE_SPECIFIED",
            "title": "Change From Baseline to Weeks 2 and 4 in the MADRS Total Score",
            "description": "The MADRS is used to assess depressive symptom severity. It consists of 10 items (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts and suicidal thoughts), each rated from 0 to 6 with zero being the \"best\" rating and 6 being the \"worst\" rating. The MADRS total score is the sum of ratings for all 10 items. The total score ranges from 0 to 60. A higher score on the MADRS represents a more severe level of depression. A negative change from baseline indicates improvement. LS mean was estimated using MMRM method.",
            "populationDescription": "FAS included all randomized participants who received at least 1 occurrence of either CT-152 or sham use and had baseline and at least 1 postbaseline assessment of MADRS total score. Overall number of participants analyzed is the number of participants with data available for analysis. Number analyzed is the number of participants with data available for analysis at the specified timepoints.",
            "reportingStatus": "POSTED",
            "paramType": "LEAST_SQUARES_MEAN",
            "dispersionType": "Standard Error",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "Baseline (Day 1) to Weeks 2 and 4",
            "groups": [
              {
                "id": "OG000",
                "title": "Digital Therapeutic A - CT-152",
                "description": "Participants received digital treatment session by using the CT-152 mobile app from Day 1 up to Week 6 of the treatment period. Each treatment session consisted of EFMT exercises and a psychotherapy lesson. From Week 7 up to Week 10 participants continued using the CT-152 app with optional psychotherapy lesson but did not receive any new EFMT exercises during this period. Participants continued receiving brief SMS messages during Weeks 7 to 10 as a reminder of the previously completed CT-152 treatment courses."
              },
              {
                "id": "OG001",
                "title": "Digital Therapeutic B - Sham",
                "description": "Participants received digital treatment session by using a sham mobile app from Day 1 up to Week 6 of the treatment period. Each treatment session consisted of a SMT exercise only. From Week 7 up to Week 10 participants continued using the sham app but did not receive any new SMT exercises during this period. Participants continued receiving brief SMS messages during Weeks 7 to 10 as a reminder of the previously completed sham treatment courses."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "176" },
                  { "groupId": "OG001", "value": "176" }
                ]
              }
            ],
            "classes": [
              {
                "title": "Week 2",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "175" },
                      { "groupId": "OG001", "value": "171" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-3.85",
                        "spread": "0.58"
                      },
                      { "groupId": "OG001", "value": "-3.23", "spread": "0.59" }
                    ]
                  }
                ]
              },
              {
                "title": "Week 4",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "165" },
                      { "groupId": "OG001", "value": "166" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-6.62",
                        "spread": "0.67"
                      },
                      { "groupId": "OG001", "value": "-5.16", "spread": "0.67" }
                    ]
                  }
                ]
              }
            ],
            "analyses": [
              {
                "groupIds": ["OG000", "OG001"],
                "groupDescription": "Week 2",
                "nonInferiorityType": "SUPERIORITY",
                "pValue": "0.3687",
                "pValueComment": "p-value was calculated by MMRM method with model terms: Treatment, trial center, visit, treatment by visit, and baseline by visit interaction.",
                "statisticalMethod": "MMRM",
                "paramType": "Treatment Difference",
                "paramValue": "-0.62",
                "ciPctValue": "95",
                "ciNumSides": "TWO_SIDED",
                "ciLowerLimit": "-1.99",
                "ciUpperLimit": "0.74"
              },
              {
                "groupIds": ["OG000", "OG001"],
                "groupDescription": "Week 4",
                "nonInferiorityType": "SUPERIORITY",
                "pValue": "0.0828",
                "pValueComment": "p-value was calculated by MMRM method with model terms: Treatment, trial center, visit, treatment by visit, and baseline by visit interaction.",
                "statisticalMethod": "MMRM",
                "paramType": "Treatment Difference",
                "paramValue": "-1.45",
                "ciPctValue": "95",
                "ciNumSides": "TWO_SIDED",
                "ciLowerLimit": "-3.10",
                "ciUpperLimit": "0.19"
              }
            ]
          },
          {
            "type": "OTHER_PRE_SPECIFIED",
            "title": "Change From Baseline to Weeks 2 and 4 in the GAD-7 Total Score",
            "description": "The GAD-7 is self-reported questionnaire designed to assess anxiety in participants. The scale contains 7 items (anxiety symptoms) and each item was rated by the participants from 0 (not at all) to 3 (nearly every day) based on how much they were bothered by each symptom. The total score ranges from 0 to 21. A higher score on the GAD-7 represents greater anxiety symptomatology. A negative change from baseline indicates improvement. LS mean was estimated using MMRM method.",
            "populationDescription": "FAS included all randomized participants who received at least 1 occurrence of either CT-152 or sham use and had baseline and at least 1 postbaseline assessment of MADRS total score. Overall number of participants analyzed is the number of participants with data available for analysis. Number analyzed is the number of participants with data available for analysis at the specified timepoints.",
            "reportingStatus": "POSTED",
            "paramType": "LEAST_SQUARES_MEAN",
            "dispersionType": "Standard Error",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "Baseline (Day 1) to Weeks 2 and 4",
            "groups": [
              {
                "id": "OG000",
                "title": "Digital Therapeutic A - CT-152",
                "description": "Participants received digital treatment session by using the CT-152 mobile app from Day 1 up to Week 6 of the treatment period. Each treatment session consisted of EFMT exercises and a psychotherapy lesson. From Week 7 up to Week 10 participants continued using the CT-152 app with optional psychotherapy lesson but did not receive any new EFMT exercises during this period. Participants continued receiving brief SMS messages during Weeks 7 to 10 as a reminder of the previously completed CT-152 treatment courses."
              },
              {
                "id": "OG001",
                "title": "Digital Therapeutic B - Sham",
                "description": "Participants received digital treatment session by using a sham mobile app from Day 1 up to Week 6 of the treatment period. Each treatment session consisted of a SMT exercise only. From Week 7 up to Week 10 participants continued using the sham app but did not receive any new SMT exercises during this period. Participants continued receiving brief SMS messages during Weeks 7 to 10 as a reminder of the previously completed sham treatment courses."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "167" },
                  { "groupId": "OG001", "value": "167" }
                ]
              }
            ],
            "classes": [
              {
                "title": "Week 2",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "161" },
                      { "groupId": "OG001", "value": "161" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-1.22",
                        "spread": "0.30"
                      },
                      { "groupId": "OG001", "value": "-0.88", "spread": "0.30" }
                    ]
                  }
                ]
              },
              {
                "title": "Week 4",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "157" },
                      { "groupId": "OG001", "value": "153" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-2.22",
                        "spread": "0.33"
                      },
                      { "groupId": "OG001", "value": "-1.93", "spread": "0.33" }
                    ]
                  }
                ]
              }
            ],
            "analyses": [
              {
                "groupIds": ["OG000", "OG001"],
                "groupDescription": "Week 2",
                "nonInferiorityType": "SUPERIORITY",
                "pValue": "0.3549",
                "pValueComment": "p-value was calculated by MMRM method with model terms: Treatment, trial center, visit, treatment by visit, and baseline by visit interaction.",
                "statisticalMethod": "MMRM",
                "paramType": "Treatment Difference",
                "paramValue": "-0.34",
                "ciPctValue": "95",
                "ciNumSides": "TWO_SIDED",
                "ciLowerLimit": "-1.06",
                "ciUpperLimit": "0.38"
              },
              {
                "groupIds": ["OG000", "OG001"],
                "groupDescription": "Week 4",
                "nonInferiorityType": "SUPERIORITY",
                "pValue": "0.4948",
                "pValueComment": "p-value was calculated by MMRM method with model terms: Treatment, trial center, visit, treatment by visit, and baseline by visit interaction.",
                "statisticalMethod": "MMRM",
                "paramType": "Treatment Difference",
                "paramValue": "-0.28",
                "ciPctValue": "95",
                "ciNumSides": "TWO_SIDED",
                "ciLowerLimit": "-1.09",
                "ciUpperLimit": "0.53"
              }
            ]
          },
          {
            "type": "OTHER_PRE_SPECIFIED",
            "title": "MADRS Response Rate at Weeks 2, 4, and 6",
            "description": "The MADRS is used to assess depressive symptom severity. It consists of 10 items (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts and suicidal thoughts), each rated from 0 to 6 with zero being the \"best\" rating and 6 being the \"worst\" rating. The MADRS total score is the sum of ratings for all 10 items. The total score ranges from 0 to 60. A higher score on the MADRS represents a more severe level of depression. MADRS Response Rate was defined as the percentage of participants who achieved a reduction in the MADRS total score by 50% or more from baseline.",
            "populationDescription": "FAS included all randomized participants who received at least 1 occurrence of either CT-152 or sham use and had baseline and at least 1 postbaseline assessment of MADRS total score. Overall number of participants analyzed is the number of participants with data available for analysis. Number analyzed is the number of participants with data available for analysis at the specified timepoints.",
            "reportingStatus": "POSTED",
            "paramType": "NUMBER",
            "unitOfMeasure": "percentage of participants",
            "timeFrame": "Baseline (Day 1), Weeks 2, 4 and 6",
            "groups": [
              {
                "id": "OG000",
                "title": "Digital Therapeutic A - CT-152",
                "description": "Participants received digital treatment session by using the CT-152 mobile app from Day 1 up to Week 6 of the treatment period. Each treatment session consisted of EFMT exercises and a psychotherapy lesson. From Week 7 up to Week 10 participants continued using the CT-152 app with optional psychotherapy lesson but did not receive any new EFMT exercises during this period. Participants continued receiving brief SMS messages during Weeks 7 to 10 as a reminder of the previously completed CT-152 treatment courses."
              },
              {
                "id": "OG001",
                "title": "Digital Therapeutic B - Sham",
                "description": "Participants received digital treatment session by using a sham mobile app from Day 1 up to Week 6 of the treatment period. Each treatment session consisted of a SMT exercise only. From Week 7 up to Week 10 participants continued using the sham app but did not receive any new SMT exercises during this period. Participants continued receiving brief SMS messages during Weeks 7 to 10 as a reminder of the previously completed sham treatment courses."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "176" },
                  { "groupId": "OG001", "value": "176" }
                ]
              }
            ],
            "classes": [
              {
                "title": "Week 2",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "175" },
                      { "groupId": "OG001", "value": "171" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "10.86" },
                      { "groupId": "OG001", "value": "5.85" }
                    ]
                  }
                ]
              },
              {
                "title": "Week 4",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "176" },
                      { "groupId": "OG001", "value": "176" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "18.18" },
                      { "groupId": "OG001", "value": "13.64" }
                    ]
                  }
                ]
              },
              {
                "title": "Week 6",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "176" },
                      { "groupId": "OG001", "value": "176" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "28.41" },
                      { "groupId": "OG001", "value": "20.45" }
                    ]
                  }
                ]
              }
            ],
            "analyses": [
              {
                "groupIds": ["OG000", "OG001"],
                "groupDescription": "Week 2",
                "nonInferiorityType": "SUPERIORITY",
                "pValue": "0.1420",
                "pValueComment": "p-value was calculated by Cochran-Mantel-Haenzsel general association test controlling for study center.",
                "statisticalMethod": "Cochran-Mantel-Haenszel",
                "paramType": "Ratio of Response Rate",
                "paramValue": "1.68",
                "ciPctValue": "95",
                "ciNumSides": "TWO_SIDED",
                "ciLowerLimit": "0.84",
                "ciUpperLimit": "3.34"
              },
              {
                "groupIds": ["OG000", "OG001"],
                "groupDescription": "Week 4",
                "nonInferiorityType": "SUPERIORITY",
                "pValue": "0.2939",
                "pValueComment": "p-value was calculated by Cochran-Mantel-Haenzsel general association test controlling for study center.",
                "statisticalMethod": "Cochran-Mantel-Haenszel",
                "paramType": "Ratio of Response Rate",
                "paramValue": "1.31",
                "ciPctValue": "95",
                "ciNumSides": "TWO_SIDED",
                "ciLowerLimit": "0.79",
                "ciUpperLimit": "2.16"
              },
              {
                "groupIds": ["OG000", "OG001"],
                "groupDescription": "Week 6",
                "nonInferiorityType": "SUPERIORITY",
                "pValue": "0.0884",
                "pValueComment": "p-value was calculated by Cochran-Mantel-Haenzsel general association test controlling for study center.",
                "statisticalMethod": "Cochran-Mantel-Haenszel",
                "paramType": "Ratio of Response Rate",
                "paramValue": "1.38",
                "ciPctValue": "95",
                "ciNumSides": "TWO_SIDED",
                "ciLowerLimit": "0.96",
                "ciUpperLimit": "1.99"
              }
            ]
          },
          {
            "type": "OTHER_PRE_SPECIFIED",
            "title": "Change From Baseline to Weeks 2, 4 and 6 in the Clinical Global Impression - Severity of Illness (CGI-S) Score",
            "description": "The CGI-S is a standardized, clinician-administered global rating scale that measures disease severity on a 7-point Likert scale To perform this assessment, the investigator (or designee) answered the following question: \"Considering your total clinical experience with this particular population, how mentally ill (as related to agitation) is the participant at this time?\" Response choices are 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill subjects. The score 0 (not assessed) will be set to missing. LS mean was estimated using MMRM method.",
            "populationDescription": "FAS included all randomized participants who received at least 1 occurrence of either CT-152 or sham use and had baseline and at least 1 postbaseline assessment of MADRS total score. Overall number of participants analyzed is the number of participants with data available for analysis. Number analyzed is the number of participants with data available for analysis at the specified timepoints.",
            "reportingStatus": "POSTED",
            "paramType": "LEAST_SQUARES_MEAN",
            "dispersionType": "Standard Error",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "Baseline (Day 1) to Weeks 2, 4 and 6",
            "groups": [
              {
                "id": "OG000",
                "title": "Digital Therapeutic A - CT-152",
                "description": "Participants received digital treatment session by using the CT-152 mobile app from Day 1 up to Week 6 of the treatment period. Each treatment session consisted of EFMT exercises and a psychotherapy lesson. From Week 7 up to Week 10 participants continued using the CT-152 app with optional psychotherapy lesson but did not receive any new EFMT exercises during this period. Participants continued receiving brief SMS messages during Weeks 7 to 10 as a reminder of the previously completed CT-152 treatment courses."
              },
              {
                "id": "OG001",
                "title": "Digital Therapeutic B - Sham",
                "description": "Participants received digital treatment session by using a sham mobile app from Day 1 up to Week 6 of the treatment period. Each treatment session consisted of a SMT exercise only. From Week 7 up to Week 10 participants continued using the sham app but did not receive any new SMT exercises during this period. Participants continued receiving brief SMS messages during Weeks 7 to 10 as a reminder of the previously completed sham treatment courses."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "175" },
                  { "groupId": "OG001", "value": "172" }
                ]
              }
            ],
            "classes": [
              {
                "title": "Week 2",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "175" },
                      { "groupId": "OG001", "value": "172" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-0.54",
                        "spread": "0.06"
                      },
                      { "groupId": "OG001", "value": "-0.34", "spread": "0.06" }
                    ]
                  }
                ]
              },
              {
                "title": "Week 4",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "166" },
                      { "groupId": "OG001", "value": "166" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-0.84",
                        "spread": "0.07"
                      },
                      { "groupId": "OG001", "value": "-0.52", "spread": "0.07" }
                    ]
                  }
                ]
              },
              {
                "title": "Week 6",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "160" },
                      { "groupId": "OG001", "value": "155" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-1.06",
                        "spread": "0.08"
                      },
                      { "groupId": "OG001", "value": "-0.80", "spread": "0.08" }
                    ]
                  }
                ]
              }
            ],
            "analyses": [
              {
                "groupIds": ["OG000", "OG001"],
                "groupDescription": "Week 2",
                "nonInferiorityType": "SUPERIORITY",
                "pValue": "0.0039",
                "pValueComment": "p-value was calculated by MMRM method with model terms: Treatment, trial center, visit, treatment by visit, and baseline by visit interaction.",
                "statisticalMethod": "MMRM",
                "paramType": "Treatment Difference",
                "paramValue": "-0.19",
                "ciPctValue": "95",
                "ciNumSides": "TWO_SIDED",
                "ciLowerLimit": "-0.32",
                "ciUpperLimit": "-0.06"
              },
              {
                "groupIds": ["OG000", "OG001"],
                "groupDescription": "Week 4",
                "nonInferiorityType": "SUPERIORITY",
                "pValue": "0.0003",
                "pValueComment": "p-value was calculated by MMRM method with model terms: Treatment, trial center, visit, treatment by visit, and baseline by visit interaction.",
                "statisticalMethod": "MMRM",
                "paramType": "Treatment Difference",
                "paramValue": "-0.32",
                "ciPctValue": "95",
                "ciNumSides": "TWO_SIDED",
                "ciLowerLimit": "-0.50",
                "ciUpperLimit": "-0.15"
              },
              {
                "groupIds": ["OG000", "OG001"],
                "groupDescription": "Week 6",
                "nonInferiorityType": "SUPERIORITY",
                "pValue": "0.0098",
                "pValueComment": "p-value was calculated by MMRM method with model terms: Treatment, trial center, visit, treatment by visit, and baseline by visit interaction.",
                "statisticalMethod": "MMRM",
                "paramType": "Treatment Difference",
                "paramValue": "-0.26",
                "ciPctValue": "95",
                "ciNumSides": "TWO_SIDED",
                "ciLowerLimit": "-0.46",
                "ciUpperLimit": "-0.06"
              }
            ]
          },
          {
            "type": "OTHER_PRE_SPECIFIED",
            "title": "Change From Baseline to Week 6 in the World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0) Total Score",
            "description": "The WHODAS 2.0 is a 36-item self-assessment scale to measure a participant's function and disability across 6 domains of life: cognition (understanding \\& communicating), mobility (moving \\& getting around), self-care (hygiene, dressing, eating, staying alone), getting along (interacting with others), life activities (domestic responsibilities, leisure, work \\& school), \\& participation (community \\& society). Each item is rated from 0 (none) to 4 (extreme or cannot do). The total score of the 36 items is converted into a metric ranging from 0 (no-disability) to 100 (full- disability) by dividing the total score by the maximum possible value of the total score, which is 144 for 36 items and multiplying by 100. LS Mean was estimated using ANCOVA method.",
            "populationDescription": "FAS included all randomized participants who received at least 1 occurrence of either CT-152 or sham use and had baseline and at least 1 postbaseline assessment of MADRS total score. Overall number of participants analyzed is the number of participants with data available for analysis.",
            "reportingStatus": "POSTED",
            "paramType": "LEAST_SQUARES_MEAN",
            "dispersionType": "Standard Error",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "Baseline (Day 1) to Week 6",
            "groups": [
              {
                "id": "OG000",
                "title": "Digital Therapeutic A - CT-152",
                "description": "Participants received digital treatment session by using the CT-152 mobile app from Day 1 up to Week 6 of the treatment period. Each treatment session consisted of EFMT exercises and a psychotherapy lesson. From Week 7 up to Week 10 participants continued using the CT-152 app with optional psychotherapy lesson but did not receive any new EFMT exercises during this period. Participants continued receiving brief SMS messages during Weeks 7 to 10 as a reminder of the previously completed CT-152 treatment courses."
              },
              {
                "id": "OG001",
                "title": "Digital Therapeutic B - Sham",
                "description": "Participants received digital treatment session by using a sham mobile app from Day 1 up to Week 6 of the treatment period. Each treatment session consisted of a SMT exercise only. From Week 7 up to Week 10 participants continued using the sham app but did not receive any new SMT exercises during this period. Participants continued receiving brief SMS messages during Weeks 7 to 10 as a reminder of the previously completed sham treatment courses."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "157" },
                  { "groupId": "OG001", "value": "155" }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-5.58",
                        "spread": "1.15"
                      },
                      { "groupId": "OG001", "value": "-4.56", "spread": "1.18" }
                    ]
                  }
                ]
              }
            ],
            "analyses": [
              {
                "groupIds": ["OG000", "OG001"],
                "nonInferiorityType": "SUPERIORITY",
                "pValue": "0.4463",
                "pValueComment": "p-value was calculated by ANCOVA model, with treatment and study center as main effects and baseline value as covariate.",
                "statisticalMethod": "ANCOVA",
                "paramType": "Treatment Difference",
                "paramValue": "-1.02",
                "ciPctValue": "95",
                "ciNumSides": "TWO_SIDED",
                "ciLowerLimit": "-3.66",
                "ciUpperLimit": "1.61"
              }
            ]
          },
          {
            "type": "OTHER_PRE_SPECIFIED",
            "title": "Change From Screening to Weeks 4 and 6 in the PHQ-9 Total Score.",
            "description": "The PHQ-9 is a standardized, self-administered rating scale that assesses the severity of depressive symptoms. The scale consists of 9 items, representing the 9 criteria upon which the diagnosis of DSM-IV depressive disorders is based. Each item is rated from 0 (not at all) to 3 (nearly every day). The total score ranges from 0 to 27. A higher score on the PHQ-9 represents a higher severity of depressive symptoms. LS mean was estimated using MMRM method.",
            "populationDescription": "FAS included all randomized participants who received at least 1 occurrence of either CT-152 or sham use and had baseline and at least 1 postbaseline assessment of MADRS total score. Overall number of participants analyzed is the number of participants with data available for analysis. Number analyzed is the number of participants with data available for analysis at the specified timepoints.",
            "reportingStatus": "POSTED",
            "paramType": "LEAST_SQUARES_MEAN",
            "dispersionType": "Standard Error",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "Screening to Weeks 4 and 6",
            "groups": [
              {
                "id": "OG000",
                "title": "Digital Therapeutic A - CT-152",
                "description": "Participants received digital treatment session by using the CT-152 mobile app from Day 1 up to Week 6 of the treatment period. Each treatment session consisted of EFMT exercises and a psychotherapy lesson. From Week 7 up to Week 10 participants continued using the CT-152 app with optional psychotherapy lesson but did not receive any new EFMT exercises during this period. Participants continued receiving brief SMS messages during Weeks 7 to 10 as a reminder of the previously completed CT-152 treatment courses."
              },
              {
                "id": "OG001",
                "title": "Digital Therapeutic B - Sham",
                "description": "Participants received digital treatment session by using a sham mobile app from Day 1 up to Week 6 of the treatment period. Each treatment session consisted of a SMT exercise only. From Week 7 up to Week 10 participants continued using the sham app but did not receive any new SMT exercises during this period. Participants continued receiving brief SMS messages during Weeks 7 to 10 as a reminder of the previously completed sham treatment courses."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "160" },
                  { "groupId": "OG001", "value": "157" }
                ]
              }
            ],
            "classes": [
              {
                "title": "Week 4",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "160" },
                      { "groupId": "OG001", "value": "157" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-5.14",
                        "spread": "0.43"
                      },
                      { "groupId": "OG001", "value": "-3.85", "spread": "0.45" }
                    ]
                  }
                ]
              },
              {
                "title": "Week 6",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "153" },
                      { "groupId": "OG001", "value": "152" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-6.68",
                        "spread": "0.45"
                      },
                      { "groupId": "OG001", "value": "-5.10", "spread": "0.46" }
                    ]
                  }
                ]
              }
            ],
            "analyses": [
              {
                "groupIds": ["OG000", "OG001"],
                "groupDescription": "Week 4",
                "nonInferiorityType": "SUPERIORITY",
                "pValue": "0.0102",
                "pValueComment": "p-value was calculated by MMRM method with model terms: Treatment, trial center, visit, treatment by visit, and baseline by visit interaction.",
                "statisticalMethod": "MMRM",
                "paramType": "Treatment Difference",
                "paramValue": "-1.29",
                "ciPctValue": "95",
                "ciNumSides": "TWO_SIDED",
                "ciLowerLimit": "-2.28",
                "ciUpperLimit": "-0.31"
              },
              {
                "groupIds": ["OG000", "OG001"],
                "groupDescription": "Week 6",
                "nonInferiorityType": "SUPERIORITY",
                "pValue": "0.0029",
                "pValueComment": "p-value was calculated by MMRM method with model terms: Treatment, trial center, visit, treatment by visit, and baseline by visit interaction.",
                "statisticalMethod": "MMRM",
                "paramType": "Treatment Difference",
                "paramValue": "-1.58",
                "ciPctValue": "95",
                "ciNumSides": "TWO_SIDED",
                "ciLowerLimit": "-2.62",
                "ciUpperLimit": "-0.54"
              }
            ]
          },
          {
            "type": "OTHER_PRE_SPECIFIED",
            "title": "MADRS Partial Response at Weeks 2, 4 and 6",
            "description": "The MADRS is used to assess depressive symptom severity. It consists of 10 items (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts and suicidal thoughts), each rated from 0 to 6 with zero being the \"best\" rating and 6 being the \"worst\" rating. The MADRS total score is the sum of ratings for all 10 items. The total score ranges from 0 to 60. A higher score on the MADRS represents a more severe level of depression. MADRS partial response was defined as the percentage of participants who achieved a reduction in the MADRS total score by 30% or more and less than 50% from baseline.",
            "populationDescription": "FAS included all randomized participants who received at least 1 occurrence of either CT-152 or sham use and had baseline and at least 1 postbaseline assessment of MADRS total score. Overall number of participants analyzed is the number of participants with data available for analysis. Number analyzed is the number of participants with data available for analysis at the specified timepoints.",
            "reportingStatus": "POSTED",
            "paramType": "NUMBER",
            "unitOfMeasure": "percentage of participants",
            "timeFrame": "Baseline (Day 1), Weeks 2, 4 and 6",
            "groups": [
              {
                "id": "OG000",
                "title": "Digital Therapeutic A - CT-152",
                "description": "Participants received digital treatment session by using the CT-152 mobile app from Day 1 up to Week 6 of the treatment period. Each treatment session consisted of EFMT exercises and a psychotherapy lesson. From Week 7 up to Week 10 participants continued using the CT-152 app with optional psychotherapy lesson but did not receive any new EFMT exercises during this period. Participants continued receiving brief SMS messages during Weeks 7 to 10 as a reminder of the previously completed CT-152 treatment courses."
              },
              {
                "id": "OG001",
                "title": "Digital Therapeutic B - Sham",
                "description": "Participants received digital treatment session by using a sham mobile app from Day 1 up to Week 6 of the treatment period. Each treatment session consisted of a SMT exercise only. From Week 7 up to Week 10 participants continued using the sham app but did not receive any new SMT exercises during this period. Participants continued receiving brief SMS messages during Weeks 7 to 10 as a reminder of the previously completed sham treatment courses."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "176" },
                  { "groupId": "OG001", "value": "176" }
                ]
              }
            ],
            "classes": [
              {
                "title": "Week 2",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "175" },
                      { "groupId": "OG001", "value": "171" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "13.14" },
                      { "groupId": "OG001", "value": "11.11" }
                    ]
                  }
                ]
              },
              {
                "title": "Week 4",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "176" },
                      { "groupId": "OG001", "value": "176" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "19.32" },
                      { "groupId": "OG001", "value": "16.48" }
                    ]
                  }
                ]
              },
              {
                "title": "Week 6",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "176" },
                      { "groupId": "OG001", "value": "176" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "19.89" },
                      { "groupId": "OG001", "value": "17.05" }
                    ]
                  }
                ]
              }
            ],
            "analyses": [
              {
                "groupIds": ["OG000", "OG001"],
                "groupDescription": "Week 2",
                "nonInferiorityType": "SUPERIORITY",
                "pValue": "0.5757",
                "pValueComment": "p-value was calculated by Cochran-Mantel-Haenzsel general association test controlling for study center.",
                "statisticalMethod": "Cochran-Mantel-Haenszel",
                "paramType": "Ratio of Response Rate",
                "paramValue": "1.18",
                "ciPctValue": "95",
                "ciNumSides": "TWO_SIDED",
                "ciLowerLimit": "0.65",
                "ciUpperLimit": "2.16"
              },
              {
                "groupIds": ["OG000", "OG001"],
                "groupDescription": "Week 4",
                "nonInferiorityType": "SUPERIORITY",
                "pValue": "0.5102",
                "pValueComment": "p-value was calculated by Cochran-Mantel-Haenzsel general association test controlling for study center.",
                "statisticalMethod": "Cochran-Mantel-Haenszel",
                "paramType": "Ratio of Response Rate",
                "paramValue": "1.16",
                "ciPctValue": "95",
                "ciNumSides": "TWO_SIDED",
                "ciLowerLimit": "0.75",
                "ciUpperLimit": "1.78"
              },
              {
                "groupIds": ["OG000", "OG001"],
                "groupDescription": "Week 6",
                "nonInferiorityType": "SUPERIORITY",
                "pValue": "0.5342",
                "pValueComment": "p-value was calculated by Cochran-Mantel-Haenzsel general association test controlling for study center.",
                "statisticalMethod": "Cochran-Mantel-Haenszel",
                "paramType": "Ratio of Response Rate",
                "paramValue": "1.15",
                "ciPctValue": "95",
                "ciNumSides": "TWO_SIDED",
                "ciLowerLimit": "0.74",
                "ciUpperLimit": "1.79"
              }
            ]
          },
          {
            "type": "OTHER_PRE_SPECIFIED",
            "title": "MADRS Response Rate at Weeks 8 and 10",
            "description": "The MADRS is used to assess depressive symptom severity. It consists of 10 items (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts and suicidal thoughts), each rated from 0 to 6 with zero being the \"best\" rating and 6 being the \"worst\" rating. The MADRS total score is the sum of ratings for all 10 items. The total score ranges from 0 to 60. A higher score on the MADRS represents a more severe level of depression. MADRS Response Rate (full or partial) was defined as the percentage of participants who achieved a reduction in the MADRS total score by 30% or more from baseline.",
            "populationDescription": "FAS included all randomized participants who received at least 1 occurrence of either CT-152 or sham use and had baseline and at least 1 postbaseline assessment of MADRS total score. Overall number of participants analyzed is the number of participants with data available for analysis. Number analyzed is the number of participants with data available for analysis at the specified timepoints.",
            "reportingStatus": "POSTED",
            "paramType": "NUMBER",
            "unitOfMeasure": "percentage of participants",
            "timeFrame": "Baseline (Day 1), Weeks 8 and 10",
            "groups": [
              {
                "id": "OG000",
                "title": "Digital Therapeutic A - CT-152",
                "description": "Participants received digital treatment session by using the CT-152 mobile app from Day 1 up to Week 6 of the treatment period. Each treatment session consisted of EFMT exercises and a psychotherapy lesson. From Week 7 up to Week 10 participants continued using the CT-152 app with optional psychotherapy lesson but did not receive any new EFMT exercises during this period. Participants continued receiving brief SMS messages during Weeks 7 to 10 as a reminder of the previously completed CT-152 treatment courses."
              },
              {
                "id": "OG001",
                "title": "Digital Therapeutic B - Sham",
                "description": "Participants received digital treatment session by using a sham mobile app from Day 1 up to Week 6 of the treatment period. Each treatment session consisted of a SMT exercise only. From Week 7 up to Week 10 participants continued using the sham app but did not receive any new SMT exercises during this period. Participants continued receiving brief SMS messages during Weeks 7 to 10 as a reminder of the previously completed sham treatment courses."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "168" },
                  { "groupId": "OG001", "value": "160" }
                ]
              }
            ],
            "classes": [
              {
                "title": "Week 8",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "164" },
                      { "groupId": "OG001", "value": "155" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "54.88" },
                      { "groupId": "OG001", "value": "54.84" }
                    ]
                  }
                ]
              },
              {
                "title": "Week 10",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "168" },
                      { "groupId": "OG001", "value": "160" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "60.71" },
                      { "groupId": "OG001", "value": "57.50" }
                    ]
                  }
                ]
              }
            ],
            "analyses": [
              {
                "groupIds": ["OG000", "OG001"],
                "groupDescription": "Week 8",
                "nonInferiorityType": "SUPERIORITY",
                "paramType": "Ratio of Response Rate",
                "paramValue": "1.00",
                "ciPctValue": "95",
                "ciNumSides": "TWO_SIDED",
                "ciLowerLimit": "0.82",
                "ciUpperLimit": "1.22"
              },
              {
                "groupIds": ["OG000", "OG001"],
                "groupDescription": "Week 10",
                "nonInferiorityType": "SUPERIORITY",
                "paramType": "Ratio of Response Rate",
                "paramValue": "1.05",
                "ciPctValue": "95",
                "ciNumSides": "TWO_SIDED",
                "ciLowerLimit": "0.88",
                "ciUpperLimit": "1.25"
              }
            ]
          }
        ]
      },
      "adverseEventsModule": {
        "frequencyThreshold": "5",
        "timeFrame": "From the signing of the informed consent up to end of study (up to Week 10)",
        "description": "Safety sample included all randomized participants who received at least 1 occurrence of either CT-152 or sham use.",
        "eventGroups": [
          {
            "id": "EG000",
            "title": "Digital Therapeutic A - CT-152",
            "description": "Participants received digital treatment session by using the CT-152 mobile app from Day 1 up to Week 6 of the treatment period. Each treatment session consisted of EFMT exercises and a psychotherapy lesson. From Week 7 up to Week 10 participants continued using the CT-152 app with optional psychotherapy lesson but did not receive any new EFMT exercises during this period. Participants continued receiving brief SMS messages during Weeks 7 to 10 as a reminder of the previously completed CT-152 treatment courses.",
            "deathsNumAffected": 0,
            "deathsNumAtRisk": 187,
            "seriousNumAffected": 1,
            "seriousNumAtRisk": 187,
            "otherNumAffected": 3,
            "otherNumAtRisk": 187
          },
          {
            "id": "EG001",
            "title": "Digital Therapeutic B - Sham",
            "description": "Participants received digital treatment session by using a sham mobile app from Day 1 up to Week 6 of the treatment period. Each treatment session consisted of a SMT exercise only. From Week 7 up to Week 10 participants continued using the sham app but did not receive any new SMT exercises during this period. Participants continued receiving brief SMS messages during Weeks 7 to 10 as a reminder of the previously completed sham treatment courses.",
            "deathsNumAffected": 0,
            "deathsNumAtRisk": 186,
            "seriousNumAffected": 0,
            "seriousNumAtRisk": 186,
            "otherNumAffected": 10,
            "otherNumAtRisk": 186
          }
        ],
        "seriousEvents": [
          {
            "term": "Transient Ischaemic Attack",
            "organSystem": "Nervous system disorders",
            "sourceVocabulary": "MedDRA (25.1)",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              { "groupId": "EG000", "numAffected": 1, "numAtRisk": 187 },
              { "groupId": "EG001", "numAffected": 0, "numAtRisk": 186 }
            ]
          }
        ],
        "otherEvents": [
          {
            "term": "Upper Respiratory Tract Infection",
            "organSystem": "Infections and infestations",
            "sourceVocabulary": "MedDRA (25.1)",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              { "groupId": "EG000", "numAffected": 3, "numAtRisk": 187 },
              { "groupId": "EG001", "numAffected": 10, "numAtRisk": 186 }
            ]
          }
        ]
      },
      "moreInfoModule": {
        "certainAgreement": {
          "piSponsorEmployee": false,
          "restrictiveAgreement": true
        },
        "pointOfContact": {
          "title": "Global Clinical Development",
          "organization": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
          "email": "clinicaltransparency@otsuka-us.com",
          "phone": "1-609-524-6788"
        }
      }
    },
    "documentSection": {
      "largeDocumentModule": {
        "largeDocs": [
          {
            "typeAbbrev": "Prot",
            "hasProtocol": true,
            "hasSap": false,
            "hasIcf": false,
            "label": "Study Protocol",
            "date": "2021-11-03",
            "uploadDate": "2024-09-19T10:12",
            "filename": "Prot_000.pdf",
            "size": 10218578
          },
          {
            "typeAbbrev": "SAP",
            "hasProtocol": false,
            "hasSap": true,
            "hasIcf": false,
            "label": "Statistical Analysis Plan",
            "date": "2022-11-16",
            "uploadDate": "2024-09-19T10:09",
            "filename": "SAP_001.pdf",
            "size": 6506223
          }
        ]
      }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [
          { "id": "D003866", "term": "Depressive Disorder" },
          { "id": "D003863", "term": "Depression" },
          { "id": "D003865", "term": "Depressive Disorder, Major" }
        ],
        "ancestors": [
          { "id": "D019964", "term": "Mood Disorders" },
          { "id": "D001523", "term": "Mental Disorders" },
          { "id": "D001526", "term": "Behavioral Symptoms" }
        ],
        "browseLeaves": [
          {
            "id": "M7061",
            "name": "Depressive Disorder",
            "asFound": "Depressive Disorder",
            "relevance": "HIGH"
          },
          {
            "id": "M7060",
            "name": "Depressive Disorder, Major",
            "asFound": "Major Depressive Disorder",
            "relevance": "HIGH"
          },
          {
            "id": "M7058",
            "name": "Depression",
            "asFound": "Depressive Disorder",
            "relevance": "HIGH"
          },
          { "id": "M21835", "name": "Mood Disorders", "relevance": "LOW" },
          { "id": "M14473", "name": "Psychotic Disorders", "relevance": "LOW" },
          { "id": "M4815", "name": "Mental Disorders", "relevance": "LOW" },
          { "id": "M4818", "name": "Behavioral Symptoms", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" },
          { "abbrev": "All", "name": "All Conditions" }
        ]
      },
      "interventionBrowseModule": {
        "browseLeaves": [
          { "id": "M6263", "name": "Coal Tar", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "Derm", "name": "Dermatologic Agents" },
          { "abbrev": "All", "name": "All Drugs and Chemicals" }
        ]
      }
    },
    "hasResults": true
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT06868446",
        "orgStudyIdInfo": { "id": "2024-Oui-002" },
        "secondaryIdInfos": [
          {
            "id": "R44MH136888",
            "type": "NIH",
            "link": "https://reporter.nih.gov/quickSearch/R44MH136888"
          }
        ],
        "organization": {
          "fullName": "Oui Therapeutics, Inc.",
          "class": "INDUSTRY"
        },
        "briefTitle": "Feasibility of a Digital Therapeutic for Adults with Posttraumatic Stress Disorder (PTSD)",
        "officialTitle": "Dosage, Feasibility, Acceptability and Usability of OTX-601"
      },
      "statusModule": {
        "statusVerifiedDate": "2025-03",
        "overallStatus": "NOT_YET_RECRUITING",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2025-03-31", "type": "ESTIMATED" },
        "primaryCompletionDateStruct": {
          "date": "2026-07",
          "type": "ESTIMATED"
        },
        "completionDateStruct": { "date": "2026-07", "type": "ESTIMATED" },
        "studyFirstSubmitDate": "2025-03-05",
        "studyFirstSubmitQcDate": "2025-03-05",
        "studyFirstPostDateStruct": { "date": "2025-03-11", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2025-03-05",
        "lastUpdatePostDateStruct": { "date": "2025-03-11", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": {
          "name": "Oui Therapeutics, Inc.",
          "class": "INDUSTRY"
        },
        "collaborators": [
          {
            "name": "National Institute of Mental Health (NIMH)",
            "class": "NIH"
          },
          { "name": "Florida State University", "class": "OTHER" }
        ]
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": false,
        "isUsExport": false
      },
      "descriptionModule": {
        "briefSummary": "This study is exploring the efficacy of a digital therapeutic app in reducing symptoms of posttraumatic stress disorder (PTSD) in adults.",
        "detailedDescription": "The purpose of this study is to conduct a randomized controlled trial to evaluate the usability and feasibility as well as the safety and effectiveness of OTX-601 (version 1) + TAU compared to OTX-601 (version 2) + TAU in reducing PTSD symptoms from baseline to 7 weeks."
      },
      "conditionsModule": {
        "conditions": ["PTSD", "Post Traumatic Stress Disorder"],
        "keywords": ["PTSD"]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["PHASE1"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "primaryPurpose": "DEVICE_FEASIBILITY",
          "maskingInfo": { "masking": "SINGLE", "whoMasked": ["PARTICIPANT"] }
        },
        "enrollmentInfo": { "count": 40, "type": "ESTIMATED" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "OTX-601 Version 1",
            "type": "EXPERIMENTAL",
            "interventionNames": ["Device: Digital Therapeutic (Version 1)"]
          },
          {
            "label": "OTX-601 Version 2",
            "type": "EXPERIMENTAL",
            "description": "Increased dose",
            "interventionNames": ["Device: Digital Therapeutic (Version 2)"]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "Digital Therapeutic (Version 1)",
            "description": "Prescription digital therapeutic designed to overcome existing barriers and deliver evidence-based treatment for PTSD",
            "armGroupLabels": ["OTX-601 Version 1"]
          },
          {
            "type": "DEVICE",
            "name": "Digital Therapeutic (Version 2)",
            "description": "Prescription digital therapeutic (increased dose) designed to overcome existing barriers and deliver evidence-based treatment for PTSD",
            "armGroupLabels": ["OTX-601 Version 2"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "PTSD Checklist for DSM-V (PCL-5)",
            "description": "Change in PTSD symptoms will be ascertained with the PTSD Checklist for DSM-V (PCL-5). The PCL-5 total score ranges from 0 to 80, with higher scores indicating more severe symptoms.",
            "timeFrame": "Baseline, week 1, week 2, week 3, and week 7"
          },
          {
            "measure": "System Usability Scale (SUS)",
            "description": "App usability will be ascertained with the System Usability Scale (SUS). The SUS provides a score from 0 to 100. An average SUS score equal to or greater than 68 is considered usable.",
            "timeFrame": "week 1, week 2, and week 3"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Anxiety Sensitivity Index 3 (ASI-3)",
            "description": "Change in anxiety sensitivity level will be ascertained with the Anxiety Sensitivity Index 3 (ASI-3). The ASI-3 total score ranges from 0 to 72 with a higher score indicating greater anxiety sensitivity.",
            "timeFrame": "Baseline, week 1, week 2, week 3 and week 7"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\nThe primary inclusion criteria for this study will be a PTSD diagnosis, ASI-3 scores above 24, PCL scores above 30, and understanding and speaking English. The only software/hardware requirements are that participants have access to a smartphone that is connected to the internet.\n\nExclusion Criteria:\n\n1) Score of 24 or lower on the ASI-3, 2) score of 30 and below on the PCL-5, 3) no PTSD diagnosis, 4) active psychosis, 5) Acutely intoxication during study baseline, 6) enrolled in another treatment research study, 8) If applicable, medical illness that would prevent the completion of interoceptive exposure exercises.",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "centralContacts": [
          {
            "name": "Brian Keenaghan",
            "role": "CONTACT",
            "phone": "(203) 200-0482",
            "email": "brian@ouitherapeutics.com"
          }
        ],
        "overallOfficials": [
          {
            "name": "Patricia Simon, PhD",
            "affiliation": "Oui Therapeutics, Inc.",
            "role": "PRINCIPAL_INVESTIGATOR"
          }
        ]
      }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [
          { "id": "D040921", "term": "Stress Disorders, Traumatic" },
          { "id": "D013313", "term": "Stress Disorders, Post-Traumatic" }
        ],
        "ancestors": [
          {
            "id": "D000068099",
            "term": "Trauma and Stressor Related Disorders"
          },
          { "id": "D001523", "term": "Mental Disorders" }
        ],
        "browseLeaves": [
          {
            "id": "M16103",
            "name": "Stress Disorders, Post-Traumatic",
            "asFound": "Post Traumatic Stress Disorder",
            "relevance": "HIGH"
          },
          {
            "id": "M24916",
            "name": "Stress Disorders, Traumatic",
            "asFound": "Stress Disorder",
            "relevance": "HIGH"
          },
          { "id": "M17685", "name": "Wounds and Injuries", "relevance": "LOW" },
          {
            "id": "M222",
            "name": "Trauma and Stressor Related Disorders",
            "relevance": "LOW"
          },
          { "id": "M14473", "name": "Psychotic Disorders", "relevance": "LOW" },
          { "id": "M4815", "name": "Mental Disorders", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" },
          { "abbrev": "All", "name": "All Conditions" },
          { "abbrev": "BC26", "name": "Wounds and Injuries" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT05853900",
        "orgStudyIdInfo": { "id": "CT-132-R-001" },
        "organization": {
          "fullName": "Click Therapeutics, Inc.",
          "class": "INDUSTRY"
        },
        "briefTitle": "Study of Two Digital Therapeutics for the Prevention of Episodic Migraine",
        "officialTitle": "A Randomized Double-blind, Parallel-Group, Virtual Study to Evaluate the Efficacy and Safety of Two Digital Therapeutics in Late Adolescents and Adults for the Prevention of Episodic Migraine",
        "acronym": "ReMMi-D"
      },
      "statusModule": {
        "statusVerifiedDate": "2025-04",
        "overallStatus": "COMPLETED",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2023-03-28", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2024-05-07",
          "type": "ACTUAL"
        },
        "completionDateStruct": { "date": "2024-05-07", "type": "ACTUAL" },
        "studyFirstSubmitDate": "2023-04-18",
        "studyFirstSubmitQcDate": "2023-05-02",
        "studyFirstPostDateStruct": { "date": "2023-05-11", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2025-04-25",
        "lastUpdatePostDateStruct": { "date": "2025-04-29", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": {
          "name": "Click Therapeutics, Inc.",
          "class": "INDUSTRY"
        }
      },
      "oversightModule": {
        "oversightHasDmc": true,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": true,
        "isUnapprovedDevice": true,
        "isUsExport": false
      },
      "descriptionModule": {
        "briefSummary": "Randomized study of two digital therapeutics for the prevention of episodic migraine",
        "detailedDescription": "The purpose of this randomized ReMMi-D trial is to evaluate the efficacy and safety of two prescription mobile applications that provide an interactive, software-based intervention for the preventative treatment of episodic migraine in late adolescents and adults."
      },
      "conditionsModule": {
        "conditions": [
          "Migraine",
          "Episodic Migraine",
          "Headache",
          "Headache, Migraine"
        ],
        "keywords": [
          "Prescription digital therapeutic (PDT)",
          "Software as a Medical Device (SaMD)",
          "Smartphone app"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["PHASE3"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": {
            "masking": "DOUBLE",
            "maskingDescription": "Double-blind",
            "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]
          }
        },
        "enrollmentInfo": { "count": 558, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "Arm A",
            "type": "EXPERIMENTAL",
            "description": "Mobile application A as a software-based intervention for the preventive treatment of episodic migraine in late adolescents and adults.",
            "interventionNames": ["Device: ReMMi-D Digital Therapeutic"]
          },
          {
            "label": "Arm B",
            "type": "EXPERIMENTAL",
            "description": "Mobile application B is an investigational digital therapeutic that is being studied for the preventative treatment of episodic migraine.",
            "interventionNames": ["Device: ReMMi-D Digital Therapeutic"]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "ReMMi-D Digital Therapeutic",
            "description": "Evaluate the efficacy and safety of prescription mobile applications that provide an interactive, software-based intervention for the preventative treatment of episodic migraine in late adults and adolescents.",
            "armGroupLabels": ["Arm A", "Arm B"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Change in MMD (monthly migraine days)",
            "description": "Change from baseline in the number of Monthly Migraine Days (MMD) at Week 12 of intervention",
            "timeFrame": "Baseline to Week 12"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Proportion of Patients with Decrease in MMD",
            "description": "Proportion of participants who have at least a 50% reduction from baseline in the mean number of MMD at Week 12",
            "timeFrame": "Baseline to Week 12"
          },
          {
            "measure": "Decrease in MMD",
            "description": "Change from baseline in the number of MMD recorded over the previous 28 days at Week 4 and Week 8",
            "timeFrame": "Baseline to Weeks 4 and 8"
          },
          {
            "measure": "Decrease in MMD",
            "description": "Change from baseline in the mean number of MMD over 12 weeks",
            "timeFrame": "Baseline to Week 12"
          },
          {
            "measure": "Change in average headache severity",
            "description": "Change in the average severity of headache from the run-in period to Weeks 9-12 assessed by Likert-type scale of 1-3 in severity",
            "timeFrame": "Run-in to Weeks 9-12"
          },
          {
            "measure": "Change in MSQ",
            "description": "Change from baseline in the Migraine-Specific Quality-of-Life Questionnaire v2.1 (MSQ) at Week 4, Week 8, and Week 12",
            "timeFrame": "Baseline to Weeks 4, 8 and 12"
          },
          {
            "measure": "Change in MIDAS",
            "description": "Change from baseline in the Migraine Disability Assessment (MIDAS) at Week 4, Week 8, and Week 12",
            "timeFrame": "Baseline to Weeks 4, 8, and 12"
          },
          {
            "measure": "Change in frequency of Migraine Medications",
            "description": "Change in the frequency used of acute migraine medications from the run-in period to Weeks 9-12",
            "timeFrame": "Run-in to Weeks 9-12"
          },
          {
            "measure": "Change in dose of Migraine Medications",
            "description": "Change in the dose of acute migraine medications from the run-in period to Weeks 9-12",
            "timeFrame": "Run-in to Weeks 9-12"
          },
          {
            "measure": "Change in type of Migraine Medications",
            "description": "Change in the type of acute migraine medications from the run-in period to Weeks 9-12",
            "timeFrame": "Run-in to Weeks 9-12"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* A participant will be eligible for entry into the study if all of the following criteria are met:\n\n  1. Willing and able to provide written informed consent to participate in the study, attend study visits, and comply with study-related requirements and assessments.\n  2. Lives in the United States.\n  3. Adult or late adolescent, 18 years of age or older at the time of informed consent.\n  4. Fluent in written and spoken English, confirmed by ability to read and understand the informed consent form.\n  5. The following will be physician-reviewed: Participant has at least a 1-year history of migraine (with or without aura) consistent with a diagnosis according to the International Classification of Headache Disorders, 3rd Edition.\n\n     1. Age of onset of migraines prior to 50 years of age\n     2. Migraine attacks, on average, lasting 4-72 hours if untreated\n     3. Per participant report, 4-14 migraine days per month within the last 3 months prior to the Screening Visit (a month is defined as 28 days)\n     4. Four to fourteen migraine days during the run-in period\n  6. Is currently managing migraines with ≥1 prescription acute treatment and/or prescription first or second-line preventive medications, as assessed by a physician.\n  7. Is the sole user of an iPhone with an iPhone operating system (iOS) 14 or later or a smartphone with an Android operating system (OS) 11 or later and is willing to download and use the Study App required by the protocol.\n  8. Is willing and able to receive SMS text messages and push messages on their smartphone.\n  9. Is the owner of, and has regular access to, an email address.\n  10. Has regular access to the Internet via cellular data plan and/or wifi.\n\nExclusion Criteria:\n\n* A participant will not be eligible for study entry if any of the following criteria are met:\n\n  1. History of basilar migraine or hemiplegic migraine.\n  2. Active chronic pain syndromes, such as fibromyalgia, chronic pelvic pain, or complex regional pain syndrome (CRPS).\n  3. Other pain syndromes (including trigeminal neuralgia), psychiatric conditions (such as major depressive episode, bipolar disorder, major depressive disorder, schizophrenia), dementia, or significant neurological disorders (other than migraine) that, in the Investigator's opinion, might interfere with study assessments.\n  4. History of, treatment for, or evidence of, alcohol or drug abuse within the past 12 months (48 weeks) or having met DSM-V criteria for any significant substance use disorder within the past 12 months (48 weeks) from the date of the screening visit.\n  5. History of use of analgesics (e.g., nonsteroidal anti-inflammatory drugs \\[NSAIDs\\] or acetaminophen, including opioids) or butalbital on ≥ 15 days per month during the 3 months (12 weeks) prior to the Screening Visit or during the run-in period.\n  6. Currently taking a prescription anti-calcitonin gene-related peptide (CGRP) for either episodic or chronic migraine.\n  7. Post-traumatic headache, persistent post-traumatic headache, or post-concussion syndrome.\n  8. Other significant episodic or chronic medical condition(s) that in the opinion of the Investigator, may confound the interpretation of findings to inform PDT development.\n  9. Failure to adhere with or inability to complete Study App inputs and onboarding activities during the run-in period. Participants who are not adherent during the run-in period are not eligible for study entry.\n  10. Previous enrollment in any digital therapeutics pilot or pivotal study for a migraine indication.\n  11. Participation in any other investigational clinical study while participating in this clinical study.",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "Parth Shah",
            "affiliation": "ObvioHealth",
            "role": "PRINCIPAL_INVESTIGATOR"
          }
        ],
        "locations": [
          {
            "facility": "Click Therapeutics",
            "city": "New York",
            "state": "New York",
            "zip": "10013",
            "country": "United States",
            "geoPoint": { "lat": 40.71427, "lon": -74.00597 }
          }
        ]
      },
      "ipdSharingStatementModule": { "ipdSharing": "NO" }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [
          { "id": "D008881", "term": "Migraine Disorders" },
          { "id": "D006261", "term": "Headache" }
        ],
        "ancestors": [
          { "id": "D051270", "term": "Headache Disorders, Primary" },
          { "id": "D020773", "term": "Headache Disorders" },
          { "id": "D001927", "term": "Brain Diseases" },
          { "id": "D002493", "term": "Central Nervous System Diseases" },
          { "id": "D009422", "term": "Nervous System Diseases" },
          { "id": "D010146", "term": "Pain" },
          { "id": "D009461", "term": "Neurologic Manifestations" }
        ],
        "browseLeaves": [
          {
            "id": "M11852",
            "name": "Migraine Disorders",
            "asFound": "Migraine",
            "relevance": "HIGH"
          },
          {
            "id": "M9351",
            "name": "Headache",
            "asFound": "Headache",
            "relevance": "HIGH"
          },
          { "id": "M22529", "name": "Headache Disorders", "relevance": "LOW" },
          {
            "id": "M26657",
            "name": "Headache Disorders, Primary",
            "relevance": "LOW"
          },
          { "id": "M5204", "name": "Brain Diseases", "relevance": "LOW" },
          {
            "id": "M5742",
            "name": "Central Nervous System Diseases",
            "relevance": "LOW"
          },
          { "id": "M13066", "name": "Pain", "relevance": "LOW" },
          {
            "id": "M12404",
            "name": "Neurologic Manifestations",
            "relevance": "LOW"
          }
        ],
        "browseBranches": [
          { "abbrev": "BC10", "name": "Nervous System Diseases" },
          { "abbrev": "All", "name": "All Conditions" },
          { "abbrev": "BC23", "name": "Symptoms and General Pathology" }
        ]
      },
      "interventionBrowseModule": {
        "browseLeaves": [
          { "id": "M6263", "name": "Coal Tar", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "Derm", "name": "Dermatologic Agents" },
          { "abbrev": "All", "name": "All Drugs and Chemicals" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT06651385",
        "orgStudyIdInfo": { "id": "STUDY00002796" },
        "organization": {
          "fullName": "University of Vermont",
          "class": "OTHER"
        },
        "briefTitle": "Pilot of Exercise and Asthma Control",
        "officialTitle": "Pilot of Exercise and Asthma Control",
        "acronym": "PEAC"
      },
      "statusModule": {
        "statusVerifiedDate": "2024-10",
        "overallStatus": "ACTIVE_NOT_RECRUITING",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2024-10-01", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2026-09",
          "type": "ESTIMATED"
        },
        "completionDateStruct": { "date": "2026-09", "type": "ESTIMATED" },
        "studyFirstSubmitDate": "2024-10-17",
        "studyFirstSubmitQcDate": "2024-10-17",
        "studyFirstPostDateStruct": { "date": "2024-10-21", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2024-10-22",
        "lastUpdatePostDateStruct": { "date": "2024-10-26", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": {
          "type": "PRINCIPAL_INVESTIGATOR",
          "investigatorFullName": "Kate M Huether",
          "investigatorTitle": "Principal Investigator",
          "investigatorAffiliation": "University of Vermont"
        },
        "leadSponsor": { "name": "University of Vermont", "class": "OTHER" }
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": false,
        "isUsExport": false
      },
      "descriptionModule": {
        "briefSummary": "This will be a pilot, single arm, un-blinded study of a remote digital therapeutic exercise program in adults with obesity and poorly controlled asthma. Participants will be recruited from the University of Vermont Medical Center adult Pulmonary Clinic, Internal Medicine Clinic, and from the greater community via flyers and referrals, as needed. The primary outcome of interest will be the feasibility and acceptability of a remote digital therapeutic exercise program using a mobile application, called Vitala. Vitala is a FDA Registered, HIPAA Compliant CE-marked MDR class 1 medical device developed by doctors and physiotherapists. It is a mobile application tool that enables health care providers to prescribe and monitor diagnosis-specific exercise prescriptions that allows patients to remotely access their tailored therapeutic exercise program. URL: Medical exercise and digital rehabilitation - Vitala\n\nFeasibility and acceptability will be defined as ≥60% of subjects enrolled in the exercise program completing, on average, ≥50% (≥75 minutes/ week) of the digital exercise program during their 12-week period, respectively. The secondary outcome of interest will be the efficacy of a remote digital therapeutic exercise program in participants with obesity and poorly controlled asthma by comparing asthma symptoms before, during, and at the end of the intervention. Efficacy will be defined as ≥30% of subjects who achieving a minimal clinically important difference in Asthma Control Test scores (defined as increase of ≥3 points\\[31\\]).\n\nThe Investigators plan to enroll participants on a rolling basis. Prospective participants will be contacted by phone, mail, or e-mail to establish interest and eligibility in the study. Once confirmed interested and eligible to participate in the study, they will be scheduled for eConsent and enrollment in the study (V0). Participants will receive a tailored exercise prescription unique to their individual needs, space, and available equipment and will be encouraged to complete 150 minutes of activity per week via their customized exercise program through the Vitala platform remotely for 12 weeks. Participants will be contacted when the program has been made available to them for program start, which will also be guided based on the participant's availability and preferred program start date (P0). During the 12 week exercise program, participants will have 3 remote contacts/visits (RC, V1, and 2), approximately every 4 - 6 weeks, over the 12 week intervention period including a final remote visit (V2) after completion of the program to assess adherence to the program, asthma control, and asthma-related quality of life."
      },
      "conditionsModule": {
        "conditions": ["Asthma", "Obesity"],
        "keywords": ["Exercise"]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "NA",
          "interventionModel": "SINGLE_GROUP",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": { "masking": "NONE" }
        },
        "enrollmentInfo": { "count": 20, "type": "ESTIMATED" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "Remote digital therapeutic exercise program",
            "type": "EXPERIMENTAL",
            "interventionNames": [
              "Other: Remote digital therapeutic exercise program"
            ]
          }
        ],
        "interventions": [
          {
            "type": "OTHER",
            "name": "Remote digital therapeutic exercise program",
            "description": "Participants will be introduced to the digital therapeutic exercise program during Screening and Consent (Visit 0, V0). Participants will be provided with an orientation to the Vitala platform and assistance will be offered in the download and access to the application, as needed. The study team will ensure access has been obtained via the health care professionals' dashboard on the Vitala app. Information obtained in the assessments outlined above will inform the tailored exercise prescription to meet the participant's needs. Participants will be encouraged to complete a total of 150 minutes of remote exercise sessions each week for 12 weeks via the Vitala platform. Participants will receive daily notifications to remind them to complete their assigned daily exercises.",
            "armGroupLabels": ["Remote digital therapeutic exercise program"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "The primary objective of this study is to determine the feasibility and acceptability of a remote digital therapeutic exercise program in people with obesity and poorly controlled asthma.",
            "description": "Successful feasibility will be defined as ≥60% of subjects enrolled in the exercise program completing, on average, ≥50% (≥75 minutes/ week) of the digital exercise program during their 12-week period.",
            "timeFrame": "12 weeks"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* Physician diagnosis of asthma on regular prescribed controller therapy for 3 months prior to enrollment (per EMR or self-report)\n* Age: ≥18 years of age\n* Obese: BMI ≥30 kg/m2\n* Poorly controlled asthma (defined as one or more of the following criteria:\n* Asthma Control Test Score ≤19, or\n* Use of rescue inhaler on average \\>2 uses/week for preceding month, or\n* Nocturnal asthma awakening on average ≥1 times/week in preceding month, or\n* ED/hospital visit or prednisone course for asthma in past six months\n* Ability and willingness to provide informed consent\n* Internet access on a mobile smart phone to access the digital exercise program\n\nExclusion Criteria:\n\n* Any condition that precludes participation in regular exercise as judged by the investigator and/or study physician\n* Pregnancy (by self-report)\n* Active participation in another exercise or weight loss program, or within 30 days prior to enrollment\n* Current use of prescription weight loss medication, or within 30 days or 5- half lives, whichever is longer, prior to enrollment.\n* Failing to meet criteria on the PAR-Q+ screening questionnaire for safe exercise \\[32, 33\\]",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "facility": "University of Vermont Medical Center",
            "city": "Burlington",
            "state": "Vermont",
            "zip": "05401",
            "country": "United States",
            "geoPoint": { "lat": 44.47588, "lon": -73.21207 }
          }
        ]
      },
      "ipdSharingStatementModule": {
        "ipdSharing": "NO",
        "description": "This is a pilot study to examine the feasibility of an exercise program in subjects with poorly controlled asthma and obesity. The data may be used for future research by the local study team only for projects examining the impact of exercise on asthma control."
      }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [{ "id": "D001249", "term": "Asthma" }],
        "ancestors": [
          { "id": "D001982", "term": "Bronchial Diseases" },
          { "id": "D012140", "term": "Respiratory Tract Diseases" },
          { "id": "D008173", "term": "Lung Diseases, Obstructive" },
          { "id": "D008171", "term": "Lung Diseases" },
          { "id": "D012130", "term": "Respiratory Hypersensitivity" },
          { "id": "D006969", "term": "Hypersensitivity, Immediate" },
          { "id": "D006967", "term": "Hypersensitivity" },
          { "id": "D007154", "term": "Immune System Diseases" }
        ],
        "browseLeaves": [
          { "id": "M12701", "name": "Obesity", "relevance": "LOW" },
          {
            "id": "M4556",
            "name": "Asthma",
            "asFound": "Asthma",
            "relevance": "HIGH"
          },
          { "id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW" },
          {
            "id": "M14977",
            "name": "Respiratory Tract Diseases",
            "relevance": "LOW"
          },
          { "id": "M11168", "name": "Lung Diseases", "relevance": "LOW" },
          {
            "id": "M11170",
            "name": "Lung Diseases, Obstructive",
            "relevance": "LOW"
          },
          { "id": "M10018", "name": "Hypersensitivity", "relevance": "LOW" },
          {
            "id": "M14967",
            "name": "Respiratory Hypersensitivity",
            "relevance": "LOW"
          },
          {
            "id": "M10020",
            "name": "Hypersensitivity, Immediate",
            "relevance": "LOW"
          },
          {
            "id": "M10200",
            "name": "Immune System Diseases",
            "relevance": "LOW"
          }
        ],
        "browseBranches": [
          { "abbrev": "BC18", "name": "Nutritional and Metabolic Diseases" },
          { "abbrev": "BC23", "name": "Symptoms and General Pathology" },
          { "abbrev": "All", "name": "All Conditions" },
          {
            "abbrev": "BC08",
            "name": "Respiratory Tract (Lung and Bronchial) Diseases"
          },
          { "abbrev": "BC20", "name": "Immune System Diseases" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT06609317",
        "orgStudyIdInfo": { "id": "007382" },
        "organization": {
          "fullName": "University of South Florida",
          "class": "OTHER"
        },
        "briefTitle": "Postpartum pElvic Assisted Recovery With Leva",
        "officialTitle": "Feasibility of Pelvic Floor Muscle Training With a Digital Therapeutic Motion-based Device (Leva Device) in a Postpartum Population",
        "acronym": "PEARL"
      },
      "statusModule": {
        "statusVerifiedDate": "2024-09",
        "overallStatus": "NOT_YET_RECRUITING",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2024-10-15", "type": "ESTIMATED" },
        "primaryCompletionDateStruct": {
          "date": "2025-06-15",
          "type": "ESTIMATED"
        },
        "completionDateStruct": { "date": "2025-06-15", "type": "ESTIMATED" },
        "studyFirstSubmitDate": "2024-09-20",
        "studyFirstSubmitQcDate": "2024-09-20",
        "studyFirstPostDateStruct": { "date": "2024-09-24", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2024-09-20",
        "lastUpdatePostDateStruct": { "date": "2024-09-24", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": {
          "name": "University of South Florida",
          "class": "OTHER"
        }
      },
      "oversightModule": {
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": false,
        "isUsExport": false
      },
      "descriptionModule": {
        "briefSummary": "The goal of this prospective cohort study is to evaluate the feasibility of postpartum pelvic floor muscle training using an FDA-cleared digital therapeutic motion-based device.\n\nIn addition to assessing feasibility, investigators also will evaluate bladder and bowel function, pelvic organ prolapse symptoms, and vaginal and perineal pain in the immediate postpartum period and at 3 and 6 months postpartum. Investigators also will assess sexual function at 3 and 6 months postpartum.\n\nParticipants will use the motion-based device for postpartum pelvic floor muscle training and will complete electronically administered surveys at 3 and 6 months postpartum."
      },
      "conditionsModule": {
        "conditions": ["Postpartum Pelvic Floor Function and Symptoms"],
        "keywords": [
          "postpartum pelvic muscle training",
          "postpartum pelvic floor",
          "postpartum pelvic floor physical therapy",
          "postpartum urinary incontinence",
          "postpartum bowel incontinence",
          "postpartum pelvic floor recovery"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "NA",
          "interventionModel": "SINGLE_GROUP",
          "primaryPurpose": "DEVICE_FEASIBILITY",
          "maskingInfo": { "masking": "NONE" }
        },
        "enrollmentInfo": { "count": 25, "type": "ESTIMATED" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "Device Arm",
            "type": "EXPERIMENTAL",
            "description": "Participants in this arm will use a digital therapeutic motion-based device for postpartum pelvic floor muscle training",
            "interventionNames": [
              "Device: Digital therapeutic motion-based device"
            ]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "Digital therapeutic motion-based device",
            "description": "This intervention includes use of a digital therapeutic motion-based device for pelvic floor muscle training",
            "armGroupLabels": ["Device Arm"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Feasibility",
            "description": "Feasibility will be assessed using participant reported discomfort with device use, ease of device use, net promotor score, patient satisfaction, and free text feedback on the device.",
            "timeFrame": "From enrollment to 6 months postpartum"
          },
          {
            "measure": "Perineal Pain",
            "description": "Participants will complete validated surveys assessing perineal pain at baseline, 3 months postpartum, and 6 months postpartum.",
            "timeFrame": "From enrollment to 6 months postpartum"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Bladder function",
            "description": "Participants will complete validated surveys assessing bladder function at baseline, 3 months postpartum, and 6 months postpartum.",
            "timeFrame": "From enrollment to 6 months postpartum"
          },
          {
            "measure": "Bowel Function",
            "description": "Participants will complete validated surveys assessing bowel function at baseline, 3 months postpartum, and 6 months postpartum.",
            "timeFrame": "From enrollment to 6 months postpartum"
          },
          {
            "measure": "Pelvic Organ Prolapse",
            "description": "Participants will complete validated surveys assessing pelvic organ prolapse symptoms at baseline, 3 months postpartum, and 6 months postpartum.",
            "timeFrame": "From enrollment to 6 months postpartum"
          },
          {
            "measure": "Vaginal pain",
            "description": "Participants will complete validated surveys assessing vaginal pain at baseline, 3 months postpartum, and 6 months postpartum.",
            "timeFrame": "From enrollment to 6 months postpartum"
          },
          {
            "measure": "Sexual function",
            "description": "Participants will complete validated surveys assessing sexual function at 3 months postpartum and 6 months postpartum.",
            "timeFrame": "From enrollment to 6 months postpartum"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* Spontaneous vaginal delivery within the last 4-8 weeks\n* Age ≥ 18 years\n* Ambulatory\n* Willing and able to consent to participate.\n* English speaking\n* Owns a smartphone\n\nExclusion Criteria:\n\n* Operative or cesarean delivery\n* Obstetric delivery at less than 20 weeks gestation\n* Third- or fourth-degree perineal laceration\n* Episiotomy\n* Multiples",
        "healthyVolunteers": false,
        "sex": "FEMALE",
        "minimumAge": "18 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "centralContacts": [
          {
            "name": "Katie Propst, MD",
            "role": "CONTACT",
            "phone": "813-259-0655",
            "email": "katiepropst@usf.edu"
          },
          {
            "name": "Katilin Tibbets",
            "role": "CONTACT",
            "email": "ktibbetts1@usf.edu"
          }
        ]
      },
      "ipdSharingStatementModule": { "ipdSharing": "NO" }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "browseLeaves": [
          { "id": "M8381", "name": "Fecal Incontinence", "relevance": "LOW" },
          {
            "id": "M17299",
            "name": "Urinary Incontinence",
            "relevance": "LOW"
          },
          { "id": "M7936", "name": "Enuresis", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "BC06", "name": "Digestive System Diseases" },
          { "abbrev": "All", "name": "All Conditions" },
          {
            "abbrev": "BXS",
            "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
          },
          { "abbrev": "BC23", "name": "Symptoms and General Pathology" },
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT06058104",
        "orgStudyIdInfo": { "id": "60181-Stanford" },
        "organization": { "fullName": "Stanford University", "class": "OTHER" },
        "briefTitle": "Evaluating Efficacy of a Digital Game Therapeutic for Children With Autism",
        "officialTitle": "Evaluating Efficacy of a Digital Game Based Therapeutic for Improving Socialization Outcomes in Autistic Children, A Randomized Clinical Trial."
      },
      "statusModule": {
        "statusVerifiedDate": "2024-08",
        "overallStatus": "NOT_YET_RECRUITING",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2025-01", "type": "ESTIMATED" },
        "primaryCompletionDateStruct": {
          "date": "2025-12",
          "type": "ESTIMATED"
        },
        "completionDateStruct": { "date": "2026-05", "type": "ESTIMATED" },
        "studyFirstSubmitDate": "2023-09-15",
        "studyFirstSubmitQcDate": "2023-09-21",
        "studyFirstPostDateStruct": { "date": "2023-09-28", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2024-08-29",
        "lastUpdatePostDateStruct": { "date": "2024-09-03", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": {
          "type": "PRINCIPAL_INVESTIGATOR",
          "investigatorFullName": "Dennis Paul Wall",
          "investigatorTitle": "Professor",
          "investigatorAffiliation": "Stanford University"
        },
        "leadSponsor": { "name": "Stanford University", "class": "OTHER" }
      },
      "oversightModule": {
        "oversightHasDmc": true,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": false
      },
      "descriptionModule": {
        "briefSummary": "The following study aims to assess the efficacy of the game-based digital therapeutic, GuessWhat, in improving adaptive socialization skills in children with Autism Spectrum Disorder (ASD). GuessWhat is a mobile application (available for free for iOS and Android) which contains a suite of games: pro-social charades, emotion guessing, and quiz. Participant families will use their personal smartphones to download the app and play it with their child according to a predetermined regimen.",
        "detailedDescription": "The following study aims to understand the efficacy of the digital therapeutic, GuessWhat, in improving socialization outcomes in children with Autism Spectrum Disorder (ASD) after regular use over 8 weeks. We will use a cross-over, waitlist control design to examine outcomes after 8 weeks. GuessWhat is a mobile application (available for free for iOS and Android) which contains a suite of games: pro-social charades, emotion guessing, and quiz. Participant families will use their personal smartphones to download the app and play it with their child according to a predetermined regimen. The study will enroll parents who are at least 18 years old and have a child between 3 and 12 years old with a formal ASD diagnosis. Parents will be asked to complete two clinical outcome measure questionnaires immediately prior to and up to 1 week after playing GuessWhat with their child 3 times per week for 8 weeks."
      },
      "conditionsModule": {
        "conditions": ["Autism", "Autism Spectrum Disorder"],
        "keywords": ["digital", "mobile health", "autism", "pediatrics"]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "CROSSOVER",
          "interventionModelDescription": "We will use block randomization stratified by sex to assign participants to the group where they will use the treatment immediately for 8 weeks or the cross over waitlist control, where they will be able to use the treatment after 8 weeks.",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": {
            "masking": "SINGLE",
            "maskingDescription": "The parent will know whether their child is receiving the treatment or not as they administer the treatment.",
            "whoMasked": ["INVESTIGATOR"]
          }
        },
        "enrollmentInfo": { "count": 1000, "type": "ESTIMATED" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "Charades-based mobile digital therapeutic",
            "type": "EXPERIMENTAL",
            "description": "The mobile app is a charades style game and app that engages parent and child in fluid social interaction where the parent must guess what the child is acting out based on the prompt shown on the phone screen. Participants will use their own personal phone to download the study app. Parents are asked to play with their child for 15 minutes 3-4 times per week for 8 weeks.",
            "interventionNames": [
              "Device: Charades based mobile digital therapeutic"
            ]
          },
          {
            "label": "Treatment as Usual",
            "type": "NO_INTERVENTION",
            "description": "Participants in control group will continue their Applied Behavior Analysis therapy as usual for 8 weeks, and then will be able to cross-over to the treatment condition at week 8."
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "Charades based mobile digital therapeutic",
            "description": "The mobile app is a charades style game and app that engages parent and child in fluid social interaction where the parent must guess what the child is acting out based on the prompt shown on the phone screen. Participants will use their own personal phone to download the study app. Parents are asked to play with their child 15 minutes 3-4 times per week for 8 weeks.",
            "armGroupLabels": ["Charades-based mobile digital therapeutic"],
            "otherNames": ["GuessWhat"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Change in parent reported socialization based on the Vineland Adaptive Behavior Scales 3rd Edition (VABS-3) Parent/Caregiver Socialization Subscale, from baseline to week 8",
            "description": "Vineland Adaptive Behavior Scales, 3rd edition (VABS-3) Socialization subscale of the Parent/Caregiver Comprehensive form will be administered online to the parents. Scores from the socialization domain of the VABS-III reflects one's functioning in social situations. The socialization subscale is up to 112 items depending on age and development, where raw scores are converted to Intellectual Quotient-type standard scores--v-scale scores (M=15, SD=3) where scores range from 1 to 24, and factor in age equivalents, growth scale values, and higher scores indicate better adaptive functioning.",
            "timeFrame": "Baseline (Week 0), Week 8"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Change in Parental Stress Scale - from baseline to week 8",
            "description": "The Parental Stress Scale is an 18-item parent report scale that evaluates the extent of parent stress. Scores range from 18-90, where higher scores indicate a higher level of Parental stress.",
            "timeFrame": "Baseline (Week 0), Week 8"
          },
          {
            "measure": "Change in Emotion Recognition from baseline to week 8",
            "description": "Study team will use an image based emotion recognition task where participants will select the emotion that corresponds to an emotional facial image in the form of a GIF (Graphics Interchange Format) image. Participants will select 1 of 8 available Ekman emotion labels for 16 facial emotional image stimuli presented in random order. Correct responses will be measured against a predetermined majority rules consensus of the emotional content of the GIFs.",
            "timeFrame": "Baseline (Week 0), Week 8"
          }
        ],
        "otherOutcomes": [
          {
            "measure": "mobile autism risk assessment score at baseline",
            "description": "Study team will use a level 2 screening tool that has been validated in several studies and that uses a brief parent/caregiver questionnaire with a 2 minute home video to generate a classification score that indicates severity of the autism phenotype (ranging from no autistic symptoms to severe autism) as well as confidence in the classification.",
            "timeFrame": "baseline (week 0)"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n1. Parent who is at least 18 years old of child with autism.\n2. Child with autism is between 3 and 12 years old at time of baseline data collection.\n3. A professional diagnosis of Autism that is able to be confirmed by negative score on a machine learning based algorithm using items from Mobile Autism Risk Assessment and video based classifier or by a copy of diagnostic report.\n\nExclusion Criteria:\n\n1. Parent is unable to read the app in the offered languages (English, Spanish, Portuguese)\n2. Parent does not have an Android or iOS smartphone compatible with GuessWhat App.\n3. Child has additional psychiatric or neurologic diagnoses including genetic syndromes or epilepsy in addition to autism.",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "3 Years",
        "maximumAge": "12 Years",
        "stdAges": ["CHILD"]
      },
      "contactsLocationsModule": {
        "centralContacts": [
          {
            "name": "Kaiti Dunlap, MRes",
            "role": "CONTACT",
            "phone": "650-497-9214",
            "email": "kdunlap2@stanford.edu"
          }
        ],
        "overallOfficials": [
          {
            "name": "Dennis P Wall, PhD",
            "affiliation": "Stanford University",
            "role": "PRINCIPAL_INVESTIGATOR"
          }
        ],
        "locations": [
          {
            "facility": "Stanford University",
            "city": "Stanford",
            "state": "California",
            "zip": "94305",
            "country": "United States",
            "geoPoint": { "lat": 37.42411, "lon": -122.16608 }
          }
        ]
      },
      "ipdSharingStatementModule": {
        "ipdSharing": "YES",
        "infoTypes": ["STUDY_PROTOCOL", "SAP", "ICF"]
      }
    },
    "documentSection": {
      "largeDocumentModule": {
        "largeDocs": [
          {
            "typeAbbrev": "Prot_SAP",
            "hasProtocol": true,
            "hasSap": true,
            "hasIcf": false,
            "label": "Study Protocol and Statistical Analysis Plan",
            "date": "2023-09-21",
            "uploadDate": "2023-09-21T11:13",
            "filename": "Prot_SAP_000.pdf",
            "size": 649414
          }
        ]
      }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [
          { "id": "D001321", "term": "Autistic Disorder" },
          { "id": "D000067877", "term": "Autism Spectrum Disorder" }
        ],
        "ancestors": [
          { "id": "D002659", "term": "Child Development Disorders, Pervasive" },
          { "id": "D065886", "term": "Neurodevelopmental Disorders" },
          { "id": "D001523", "term": "Mental Disorders" }
        ],
        "browseLeaves": [
          {
            "id": "M4623",
            "name": "Autistic Disorder",
            "asFound": "Autism",
            "relevance": "HIGH"
          },
          {
            "id": "M206",
            "name": "Autism Spectrum Disorder",
            "asFound": "Autism Spectrum Disorder",
            "relevance": "HIGH"
          },
          {
            "id": "M5903",
            "name": "Child Development Disorders, Pervasive",
            "relevance": "LOW"
          },
          {
            "id": "M5902",
            "name": "Developmental Disabilities",
            "relevance": "LOW"
          },
          {
            "id": "M30644",
            "name": "Neurodevelopmental Disorders",
            "relevance": "LOW"
          },
          { "id": "M14473", "name": "Psychotic Disorders", "relevance": "LOW" },
          { "id": "M4815", "name": "Mental Disorders", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" },
          { "abbrev": "All", "name": "All Conditions" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT04616482",
        "orgStudyIdInfo": { "id": "H19-00316" },
        "organization": {
          "fullName": "University of British Columbia",
          "class": "OTHER"
        },
        "briefTitle": "Therapeutic Nutrition With Technology in Primary Care",
        "officialTitle": "Supporting and Enabling Physicians to Deliver Personalized Therapeutic Nutrition Using an Online Technology Platform"
      },
      "statusModule": {
        "statusVerifiedDate": "2020-10",
        "overallStatus": "UNKNOWN",
        "lastKnownStatus": "RECRUITING",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2020-09-15", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2021-09-15",
          "type": "ESTIMATED"
        },
        "completionDateStruct": { "date": "2021-09-30", "type": "ESTIMATED" },
        "studyFirstSubmitDate": "2020-10-08",
        "studyFirstSubmitQcDate": "2020-10-29",
        "studyFirstPostDateStruct": { "date": "2020-11-05", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2020-10-29",
        "lastUpdatePostDateStruct": { "date": "2020-11-05", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": {
          "type": "PRINCIPAL_INVESTIGATOR",
          "investigatorFullName": "Jonathan Little",
          "investigatorTitle": "Associate Professor",
          "investigatorAffiliation": "University of British Columbia"
        },
        "leadSponsor": {
          "name": "University of British Columbia",
          "class": "OTHER"
        }
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": false
      },
      "descriptionModule": {
        "briefSummary": "Low-carbohydrate diets (less than approximately 130 grams per day) are emerging as an efficacious treatment option with several studies supporting weight loss and remission of type 2 diabetes. Many physicians are now implementing this strategy but the time it takes to educate patients on nutrition is a barrier. The research team is working with physicians to develop a solution whereby the nutrition education and intervention is delivered via mobile/online technology (i.e., an app). This study will test whether it is feasible and efficacious for physicians to recommend this app to their patients with obesity and type 2 diabetes to help them lose weight and improve their condition.",
        "detailedDescription": "The study is a non-experimental feasibility study to explore the acceptability, practicality and demand for the use of a 12-week, personalized, online program to teach and coach patients about therapeutic carbohydrate restriction for individuals with obesity and/or at risk for type 2 diabetes/with type 2 diabetes. The program is intended to enhance the usual clinical care provided for patients with these conditions and will allow for physicians to monitor patient progress through the program. Both physician and patient perspectives will be explored."
      },
      "conditionsModule": { "conditions": ["Diet Modification"] },
      "designModule": {
        "studyType": "OBSERVATIONAL",
        "patientRegistry": false,
        "designInfo": {
          "observationalModel": "COHORT",
          "timePerspective": "PROSPECTIVE"
        },
        "enrollmentInfo": { "count": 100, "type": "ESTIMATED" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "Digital therapeutic carbohydrate restriction (TCR) program",
            "description": "The intervention involves 12 weeks of online/app-based behaviour change coaching. Each week the participant focuses on a different aspect of healthy eating habits designed to cut sugar and refined carbohydrates while encouraging and providing resources for lower-carbohydrate food options. Education is done through short videos and information sheets. Participants set goals and complete worksheets/tasks based on their individual goals.",
            "interventionNames": [
              "Behavioral: Digital therapeutic carbohydrate restriction (TCR) program"
            ]
          }
        ],
        "interventions": [
          {
            "type": "BEHAVIORAL",
            "name": "Digital therapeutic carbohydrate restriction (TCR) program",
            "description": "A 12-week, personalized, online program to teach and coach patients about therapeutic carbohydrate restriction as for obesity and/or T2D (or risk of T2D). The program is intended to enhance the usual clinical care provided for patients.",
            "armGroupLabels": [
              "Digital therapeutic carbohydrate restriction (TCR) program"
            ]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "The percentage of eligible patients who receive prescriptions to access the online TCR program",
            "description": "Assessed through the number of voucher cards handed-out over physician documentation of eligible patient visits over the study period.",
            "timeFrame": "through study completion, an average of 9 months"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Present descriptive characteristics of patients who get prescriptions to access the online TCR program",
            "description": "Assessed through program intake collected through the online program (e.g. age, sex, weight, HbA1c, chronic condition, health goals)",
            "timeFrame": "through study completion, an average of 9 months"
          },
          {
            "measure": "The percentage of patients who receive a prescription for TCR program that sign up and start",
            "description": "Assessed through the number of voucher cards redeemed on the online program over the number of voucher cards handed-out by physicians.",
            "timeFrame": "through study completion, an average of 9 months"
          },
          {
            "measure": "Program drop-out as assessed by the number of patients who sign up for and start the TCR program and the number of patients who complete the full program.",
            "description": "Assessed through the number of patients enrolled in the program and the number of patients who complete the program through program tracking.",
            "timeFrame": "Pre-program (month 0) to post-program (6 months)"
          },
          {
            "measure": "Program impact assessed through changes in weight from pre-program to post-program.",
            "description": "For patients who complete the program, the change in weight from program sign-up to program completion.",
            "timeFrame": "Pre-program (month 0) to post-program (6 months)"
          },
          {
            "measure": "Program impact assessed through change in HbA1c from pre-program to post-program.",
            "description": "For patients who complete the program, the change in HbA1c from program sign-up to program completion.",
            "timeFrame": "Pre-program (month 0) to post-program (6 months)"
          },
          {
            "measure": "Program impact assessed through changes in medications from pre-program to post-program.",
            "description": "For patients who complete the program, the change in medications from program sign-up to program completion.",
            "timeFrame": "Pre-program (month 0) to post-program (6 months)"
          }
        ],
        "otherOutcomes": [
          {
            "measure": "Qualitative patient feedback on program acceptability",
            "description": "Qualitative semi-structured interviews with patients collecting program feedback on their experiences in the program, specifically asking about the acceptability of the program. Acceptability will be assessed through the audio-recorded responses to semi-structured interview questions, subsequently transcribed and coded using content analysis.",
            "timeFrame": "Post-program (6 months)"
          },
          {
            "measure": "Qualitative patient feedback on program practicality",
            "description": "Qualitative semi-structured interviews with patients collecting program feedback on their experiences in the program, specifically asking about the practicality of the program. Practicality will be assessed through the audio-recorded responses to semi-structured interview questions, subsequently transcribed and coded using content analysis.",
            "timeFrame": "Post-program (6 months)"
          },
          {
            "measure": "Qualitative patient feedback on program satisfaction",
            "description": "Qualitative semi-structured interviews with patients collecting program feedback on their experiences in the program, specifically asking about their satisfaction of the program. Satisfaction will be assessed through the audio-recorded responses to semi-structured interview questions, subsequently transcribed and coded using content analysis.",
            "timeFrame": "Post-program (6 months)"
          },
          {
            "measure": "Qualitative physician feedback on program acceptability",
            "description": "Qualitative semi-structured interviews with physicians collecting feedback on their experiences in the program, specifically asking about the acceptability of the program within their daily physician practice. Acceptability will be assessed through the audio-recorded responses to semi-structured interview questions, subsequently transcribed and coded using content analysis.",
            "timeFrame": "through study completion, an average of 9 months"
          },
          {
            "measure": "Qualitative physician feedback on program practicality",
            "description": "Qualitative semi-structured interviews with physicians collecting feedback on their experiences in the program, specifically asking about the practicality of the program within their daily physician practice. Practicality will be assessed through the audio-recorded responses to semi-structured interview questions, subsequently transcribed and coded using content analysis.",
            "timeFrame": "through study completion, an average of 9 months"
          },
          {
            "measure": "Qualitative physician feedback on program satisfaction",
            "description": "Qualitative semi-structured interviews with physicians collecting feedback on their experiences in the program, specifically asking about the satisfaction of the program within their daily physician practice. Satisfaction will be assessed through the audio-recorded responses to semi-structured interview questions, subsequently transcribed and coded using content analysis.",
            "timeFrame": "through study completion, an average of 9 months"
          },
          {
            "measure": "Characteristics of individuals who drop-out of program",
            "description": "Provide descriptive statistics (e.g. age, sex, weight, HbA1c, chronic condition, health goals) of individuals who drop-out after enrolling in the program and prior to program completion.",
            "timeFrame": "through study completion, an average of 9 months"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* Overweight or obese (BMI \\>25 kg/m2)\n* At risk for T2D as deemed by physician\n* Diagnosed with T2D\n* Able to read and speak English (in order to communicate with the technology platform/app\n* Over the age of 18\n\nExclusion Criteria:\n\n* Unable to read or speak English (due to the app being provided in English)\n* Unable to access a computer or mobile phone that has access to the internet.\n* Currently compliant with a very low carbohydrate ketogenic diet or very low calorie commercial weight loss program\n* Planning to change doctors in the next 12 months.",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"],
        "studyPopulation": "Individuals with obesity, at risk for type 2 diabetes or diagnosed with type 2 diabetes interested in therapeutic carbohydrate restriction for management of their condition.",
        "samplingMethod": "NON_PROBABILITY_SAMPLE"
      },
      "contactsLocationsModule": {
        "centralContacts": [
          {
            "name": "Jonathon Little, PhD",
            "role": "CONTACT",
            "phone": "(250) 807-9876",
            "email": "jonathan.little@ubc.ca"
          },
          {
            "name": "Tineke Dineen, MSc",
            "role": "CONTACT",
            "phone": "403-470-9754",
            "email": "tineke.dineen@ubc.ca"
          }
        ],
        "overallOfficials": [
          {
            "name": "Jonathon Little, PhD",
            "affiliation": "The University of British Columbia, Okanagan Campus",
            "role": "PRINCIPAL_INVESTIGATOR"
          }
        ],
        "locations": [
          {
            "facility": "University of British Columbia Okanagan",
            "status": "RECRUITING",
            "city": "Kelowna",
            "state": "British Columbia",
            "zip": "V1V 3G1",
            "country": "Canada",
            "contacts": [
              {
                "name": "Jonathan Little, PhD",
                "role": "CONTACT",
                "phone": "2508079876",
                "email": "jonathan.little@ubc.ca"
              },
              {
                "role": "CONTACT",
                "phone": "2508079876",
                "email": "jonathan.little@ubc.ca"
              }
            ],
            "geoPoint": { "lat": 49.88307, "lon": -119.48568 }
          }
        ]
      },
      "ipdSharingStatementModule": { "ipdSharing": "NO" }
    },
    "derivedSection": { "miscInfoModule": { "versionHolder": "2025-05-07" } },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT05016050",
        "orgStudyIdInfo": { "id": "HPY-HPDT-DA-013-RWE-01" },
        "organization": { "fullName": "Happify Inc.", "class": "INDUSTRY" },
        "briefTitle": "Digital Therapeutic for Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD)",
        "officialTitle": "A Real-World Evidence, Single-Arm, Open-Label Study Evaluating the Safety and Efficacy of HPDT-DA-013 Digital Therapeutic in the Treatment of Major Depressive Disorder(MDD)and Generalized Anxiety Disorder(GAD)"
      },
      "statusModule": {
        "statusVerifiedDate": "2023-05",
        "overallStatus": "COMPLETED",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2021-08-09", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2023-03-16",
          "type": "ACTUAL"
        },
        "completionDateStruct": { "date": "2023-04-14", "type": "ACTUAL" },
        "studyFirstSubmitDate": "2021-08-16",
        "studyFirstSubmitQcDate": "2021-08-19",
        "studyFirstPostDateStruct": { "date": "2021-08-23", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2023-05-31",
        "lastUpdatePostDateStruct": { "date": "2023-06-01", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": { "name": "Happify Inc.", "class": "INDUSTRY" }
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": true,
        "isUnapprovedDevice": true,
        "isUsExport": true
      },
      "descriptionModule": {
        "briefSummary": "Participants with Major Depressive Disorder (MDD) or Generalized Anxiety Disorder (GAD) will use a prescribed digital therapeutic for 8-10 weeks, and will complete depression and anxiety measures during this time. After the treatment period, participants will be followed monthly for 12 months.",
        "detailedDescription": "This study aims to assess the safety and efficacy of HPDT-DA-013 digital therapeutic in adults ages 22 years and older with MDD or GAD. Participants access HPDT-DA-013 on their smart device or computer and complete treatment over a period of 8-10 weeks. During the treatment period, participants complete PHQ-9 and GAD-7 assessments, as well as safety and medication use questionnaires. After 8-10 weeks, participants will complete end-of-treatment assessments, and access to HPDT-DA-013 will be removed. Participants are then followed for a period of 12 months."
      },
      "conditionsModule": {
        "conditions": [
          "Major Depressive Disorder",
          "Generalized Anxiety Disorder"
        ],
        "keywords": ["depression", "anxiety"]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "NA",
          "interventionModel": "SINGLE_GROUP",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": { "masking": "NONE" }
        },
        "enrollmentInfo": { "count": 367, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "Digital therapeutic",
            "type": "EXPERIMENTAL",
            "description": "Use HPDT-DA-013 digital therapeutic for a period of 8-10 weeks.",
            "interventionNames": ["Device: HPDT-DA-013"]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "HPDT-DA-013",
            "description": "Digital program with therapeutic interventions based on Cognitive Behavioral Therapy (CBT).",
            "armGroupLabels": ["Digital therapeutic"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Patient Health Questionnaire-9 (PHQ-9)",
            "description": "A 9-item self-report measure to assess symptoms of depression",
            "timeFrame": "baseline to end of treatment (8-10 weeks)"
          },
          {
            "measure": "Generalized Anxiety Disorder-7 (GAD-7)",
            "description": "A 7-item self-report measure to assess symptoms of anxiety",
            "timeFrame": "baseline to end of treatment (8-10 weeks)"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "PHQ-9",
            "description": "A 9-item self-report measure to assess symptoms of depression",
            "timeFrame": "Through study completion, average of 14 months"
          },
          {
            "measure": "GAD-7",
            "description": "A 7-item self-report measure to assess symptoms of anxiety",
            "timeFrame": "Through study completion, average of 14 months"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n1. Adults 22 years or older at the time of screening\n2. Meets DSM-5 diagnostic criteria for Major Depressive Disorder or Generalized Anxiety Disorder\n3. Access to and willingness to use computer equipment/smartphone compatible with the product platform over a functional network for the study duration\n4. Currently residing in the United States\n\nKey Exclusion Criteria:\n\n1. Risk of suicide or has attempted suicide within 24 months of the screening visit\n2. Moderate to severe substance use disorder\n3. Current co-morbid psychiatric diagnosis including PTSD, Schizophrenia, Bipolar Disorder I or II, or Borderline Personality Disorder\n4. Currently pregnant or planning to become pregnant during the treatment period\n\nNote: Other protocol-defined inclusion/exclusion criteria applied.",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "22 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "Roger Vilardaga, Ph.D.",
            "affiliation": "Duke University",
            "role": "PRINCIPAL_INVESTIGATOR"
          }
        ],
        "locations": [
          {
            "facility": "Happify Health (Remote)",
            "city": "New York",
            "state": "New York",
            "zip": "10003",
            "country": "United States",
            "geoPoint": { "lat": 40.71427, "lon": -74.00597 }
          }
        ]
      },
      "ipdSharingStatementModule": { "ipdSharing": "NO" }
    },
    "derivedSection": {
      "miscInfoModule": {
        "versionHolder": "2025-05-07",
        "submissionTracking": {
          "estimatedResultsFirstSubmitDate": "2024-11-22",
          "submissionInfos": [
            {
              "releaseDate": "2024-11-22",
              "resetDate": "2024-12-17",
              "mcpReleaseN": 6
            }
          ]
        }
      },
      "conditionBrowseModule": {
        "meshes": [
          { "id": "D001008", "term": "Anxiety Disorders" },
          { "id": "D003866", "term": "Depressive Disorder" },
          { "id": "D003863", "term": "Depression" },
          { "id": "D003865", "term": "Depressive Disorder, Major" }
        ],
        "ancestors": [
          { "id": "D001523", "term": "Mental Disorders" },
          { "id": "D019964", "term": "Mood Disorders" },
          { "id": "D001526", "term": "Behavioral Symptoms" }
        ],
        "browseLeaves": [
          {
            "id": "M4324",
            "name": "Anxiety Disorders",
            "asFound": "Anxiety Disorder",
            "relevance": "HIGH"
          },
          {
            "id": "M7061",
            "name": "Depressive Disorder",
            "asFound": "Depressive Disorder",
            "relevance": "HIGH"
          },
          {
            "id": "M7060",
            "name": "Depressive Disorder, Major",
            "asFound": "Major Depressive Disorder",
            "relevance": "HIGH"
          },
          {
            "id": "M7058",
            "name": "Depression",
            "asFound": "Depressive Disorder",
            "relevance": "HIGH"
          },
          { "id": "M14473", "name": "Psychotic Disorders", "relevance": "LOW" },
          { "id": "M4815", "name": "Mental Disorders", "relevance": "LOW" },
          { "id": "M21835", "name": "Mood Disorders", "relevance": "LOW" },
          { "id": "M4818", "name": "Behavioral Symptoms", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" },
          { "abbrev": "All", "name": "All Conditions" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT05647226",
        "orgStudyIdInfo": { "id": "312269" },
        "organization": {
          "fullName": "Habitual Health Ltd",
          "class": "INDUSTRY"
        },
        "briefTitle": "Digital Diabetes Remission Trial",
        "officialTitle": "Exploring the Use of Digital Therapeutics Alongside a Remote Intensive Lifestyle Programme on Inducing Weight Loss and Diabetes Remission in Patients With Type 2 Diabetes Versus Standard of Care (DIGEST)",
        "acronym": "DIGEST"
      },
      "statusModule": {
        "statusVerifiedDate": "2022-12",
        "overallStatus": "UNKNOWN",
        "lastKnownStatus": "ENROLLING_BY_INVITATION",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2022-01-09", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2023-10",
          "type": "ESTIMATED"
        },
        "completionDateStruct": { "date": "2024-01", "type": "ESTIMATED" },
        "studyFirstSubmitDate": "2022-11-30",
        "studyFirstSubmitQcDate": "2022-12-09",
        "studyFirstPostDateStruct": { "date": "2022-12-12", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2022-12-09",
        "lastUpdatePostDateStruct": { "date": "2022-12-12", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": { "name": "Habitual Health Ltd", "class": "INDUSTRY" },
        "collaborators": [{ "name": "Lindus Health", "class": "INDUSTRY" }]
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": false
      },
      "descriptionModule": {
        "briefSummary": "This is a multicentre, open-label Randomised Controlled Trial run in the United Kingdom. The main aims are to assess whether the Habitual Remission Programme (digital therapeutics + 12-week 800kcal/day low-energy diet, delivered remotely) is more likely to lead to weight loss and remission in adults with type 2 diabetes, when compared to standard of care.",
        "detailedDescription": "Participants will be randomly allocated to the Habitual Programme or standard care as delivered by the National Health Service (NHS). They will take a home blood test for HbA1c at baseline, 3 months and 6 months, and complete online fortnightly surveys to record their weight, waist circumference, blood pressure, side-effects and any changes in medication, for 6 months. These measurements will be taken at 6 months and 12 months after finishing the intervention for those allocated to the intervention.\n\nParticipants will be recruited from General Practitioner (GP) surgeries in England, managed by Lindus Health. Research Nurses at Lindus Health will complete screening and informed consent procedures."
      },
      "conditionsModule": { "conditions": ["Diabetes Mellitus, Type 2"] },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "interventionModelDescription": "A multicentre, open-label, parallel design, randomised controlled trial.",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": {
            "masking": "SINGLE",
            "maskingDescription": "Due to the nature of the lifestyle programme, participants, clinicians and data collectors will not be able to be masked, however allocation will be concealed from the statistician in charge of performing the analysis.",
            "whoMasked": ["OUTCOMES_ASSESSOR"]
          }
        },
        "enrollmentInfo": { "count": 100, "type": "ESTIMATED" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "Intervention arm",
            "type": "EXPERIMENTAL",
            "description": "Intervention participants will be given an initial 12-week low energy-diet (LED) and will have continual use of an intensive behaviour education programme delivered through an app.",
            "interventionNames": [
              "Combination Product: Digital therapeutic and intensive lifestyle programme"
            ]
          },
          {
            "label": "Standard of care arm",
            "type": "OTHER",
            "description": "All participants in the control arm will receive standard care provided by the National Health Service.",
            "interventionNames": ["Other: Standard of care"]
          }
        ],
        "interventions": [
          {
            "type": "COMBINATION_PRODUCT",
            "name": "Digital therapeutic and intensive lifestyle programme",
            "description": "Initial 12-week LED and behaviour education app.",
            "armGroupLabels": ["Intervention arm"]
          },
          {
            "type": "OTHER",
            "name": "Standard of care",
            "description": "Standard of care.",
            "armGroupLabels": ["Standard of care arm"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Weight loss of ≥15kg",
            "description": "Number of participants that achieved ≥15kg",
            "timeFrame": "6-months"
          },
          {
            "measure": "HbA1C <6.5% (48mmol/mol)",
            "description": "Number of participants who have achieved HbA1C \\<6.5% (48mmol/mol) after at least 2-months of all glucose-lowering medication.",
            "timeFrame": "6-months"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Glycaemic Control",
            "description": "Changes in HbA1C from baseline to mid and endpoints.",
            "timeFrame": "3-months- 6-months"
          },
          {
            "measure": "Weight control",
            "description": "Changes in weight from baseline to mid and endpoints.",
            "timeFrame": "3-months- 6-months"
          },
          {
            "measure": "Systolic blood pressure (SBP)",
            "description": "Changes in SBP from baseline to mid and endpoints.",
            "timeFrame": "3-months- 6-months"
          },
          {
            "measure": "Diastolic blood pressure (DBP)",
            "description": "Changes in DBP from baseline to mid and endpoints.",
            "timeFrame": "3-months- 6-months"
          },
          {
            "measure": "Medication use",
            "description": "Medication use reported by the participant.",
            "timeFrame": "Baseline, 3-months and 6-months"
          },
          {
            "measure": "Weight loss ≥10kg",
            "description": "Number of participants that achieved ≥10kg",
            "timeFrame": "6-months"
          },
          {
            "measure": "Safety of Intervention",
            "description": "Monitoring the number of Adverse Events (AEs), Severe Adverse Events (SAEs) and (S)AE's that constitute Major Adverse Cardiovascular Events and Major Adverse Diabetes Events",
            "timeFrame": "Baseline- 6-months"
          },
          {
            "measure": "HbA1C <6.5% (48mmol/mol)",
            "description": "Number of participants with an HbA1C \\<6.5% (48mmol/mol) after a 6-month follow up",
            "timeFrame": "12-months (6-months after completing the trial)."
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* Able and willing to give consent for the study prior to participation\n* Be aged between 18-75 years, with type 2 Diabetes Mellitus of duration \\<6years.\n* Has access to a smartphone or computer\n* Has a Body Mass Index (BMI) of ≥28 kg/m2\n* HbA1C between 86 mmol/mol (10%) ≥ 48mmol/mol (6.5%), within the previous 12-months\n\nExclusion Criteria\n\n* Is currently using Insulin\n* Weight of change \\>5% in the past 3-months\n* Has a history of are known to be suffering with alcohol/substance abuse\n* Has cancer or is knowingly under investigation for cancer\n* Has had a myocardial infarction within the previous 6-months\n* Has severe or unstable heart failure e.g., New York Heart Association (NYHA) grade IV\n* Has porphyria\n* Has learning difficulties\n* Is currently on treatment with anti-obesity drugs\n* Has had bariatric surgery\n* Has been diagnosed with an eating disorder or purging\n* Is pregnant or less than 4-months postpartum or considering pregnancy in the next 2-years\n* Is currently breastfeeding\n* Has required hospitalisation for depression or taking antipsychotic drug\n* Has a history of illnesses that could interfere with the interpretation of the study (e.g. HIV, Cushing syndrome, chronic kidney disease, chronic liver disease, hyperthyroidism, hereditary fructose intolerance, depression or antipsychotic drug use within the past 2 years)\n* Currently talking Glucagon-like peptide-1 receptor agonists (GLP-1 RAs)\n* Has pancreatitis\n* Currently taking part in a Clinical Trial of an Investigative Medicinal Product (CTIMP) trial for antidiabetic medication\n* Abnormal diabetic foot review (QOF codes for diabetic foot at moderate risk, at high risk, at increased risk, ulcerated).",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "maximumAge": "75 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "Carol Le Roux, Professor",
            "affiliation": "Principal Investigator",
            "role": "PRINCIPAL_INVESTIGATOR"
          }
        ],
        "locations": [
          {
            "facility": "Lindus Health Ltd",
            "city": "London",
            "zip": "SE1 3ER",
            "country": "United Kingdom",
            "geoPoint": { "lat": 51.50853, "lon": -0.12574 }
          }
        ]
      },
      "referencesModule": {
        "references": [
          {
            "pmid": "29221645",
            "type": "BACKGROUND",
            "citation": "Lean ME, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, Peters C, Zhyzhneuskaya S, Al-Mrabeh A, Hollingsworth KG, Rodrigues AM, Rehackova L, Adamson AJ, Sniehotta FF, Mathers JC, Ross HM, McIlvenna Y, Stefanetti R, Trenell M, Welsh P, Kean S, Ford I, McConnachie A, Sattar N, Taylor R. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet. 2018 Feb 10;391(10120):541-551. doi: 10.1016/S0140-6736(17)33102-1. Epub 2017 Dec 5."
          },
          {
            "pmid": "30852132",
            "type": "BACKGROUND",
            "citation": "Lean MEJ, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, Peters C, Zhyzhneuskaya S, Al-Mrabeh A, Hollingsworth KG, Rodrigues AM, Rehackova L, Adamson AJ, Sniehotta FF, Mathers JC, Ross HM, McIlvenna Y, Welsh P, Kean S, Ford I, McConnachie A, Messow CM, Sattar N, Taylor R. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. Lancet Diabetes Endocrinol. 2019 May;7(5):344-355. doi: 10.1016/S2213-8587(19)30068-3. Epub 2019 Mar 6."
          }
        ],
        "seeAlsoLinks": [
          {
            "label": "Habitual Health Ltd (Sponsor)",
            "url": "https://www.tryhabitual.com/"
          }
        ]
      },
      "ipdSharingStatementModule": {
        "ipdSharing": "NO",
        "description": "Data will be entered into a validated Electronic Data Capture (EDC) platform. Direct access to the EDC platform will be granted to authorised representatives from the Sponsor, Lindus Health and the regulatory authorities to allow trial-related monitoring, audits and inspections."
      }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [
          { "id": "D003920", "term": "Diabetes Mellitus" },
          { "id": "D003924", "term": "Diabetes Mellitus, Type 2" }
        ],
        "ancestors": [
          { "id": "D044882", "term": "Glucose Metabolism Disorders" },
          { "id": "D008659", "term": "Metabolic Diseases" },
          { "id": "D004700", "term": "Endocrine System Diseases" }
        ],
        "browseLeaves": [
          { "id": "M18102", "name": "Weight Loss", "relevance": "LOW" },
          {
            "id": "M7115",
            "name": "Diabetes Mellitus",
            "asFound": "Diabetes",
            "relevance": "HIGH"
          },
          {
            "id": "M7119",
            "name": "Diabetes Mellitus, Type 2",
            "asFound": "Diabetes Mellitus, Type 2",
            "relevance": "HIGH"
          },
          { "id": "M5114", "name": "Body Weight", "relevance": "LOW" },
          { "id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW" },
          {
            "id": "M25403",
            "name": "Glucose Metabolism Disorders",
            "relevance": "LOW"
          },
          {
            "id": "M7862",
            "name": "Endocrine System Diseases",
            "relevance": "LOW"
          }
        ],
        "browseBranches": [
          { "abbrev": "BC23", "name": "Symptoms and General Pathology" },
          { "abbrev": "All", "name": "All Conditions" },
          { "abbrev": "BC18", "name": "Nutritional and Metabolic Diseases" },
          { "abbrev": "BC19", "name": "Gland and Hormone Related Diseases" }
        ]
      },
      "interventionBrowseModule": {
        "browseLeaves": [
          { "id": "M6263", "name": "Coal Tar", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "Derm", "name": "Dermatologic Agents" },
          { "abbrev": "All", "name": "All Drugs and Chemicals" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT04574193",
        "orgStudyIdInfo": {
          "id": "2R44MD008848-02",
          "type": "NIH",
          "link": "https://reporter.nih.gov/quickSearch/2R44MD008848-02"
        },
        "organization": { "fullName": "COG Analytics", "class": "OTHER" },
        "briefTitle": "Continuing Care App for Probationers and Parolees",
        "officialTitle": "Continuing Care App for Probationers and Parolees With Substance Use Disorders"
      },
      "statusModule": {
        "statusVerifiedDate": "2023-10",
        "overallStatus": "COMPLETED",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2021-03-08", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2023-02-28",
          "type": "ACTUAL"
        },
        "completionDateStruct": { "date": "2023-02-28", "type": "ACTUAL" },
        "studyFirstSubmitDate": "2020-09-14",
        "studyFirstSubmitQcDate": "2020-09-29",
        "studyFirstPostDateStruct": { "date": "2020-10-05", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2023-10-04",
        "lastUpdatePostDateStruct": { "date": "2023-10-06", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": {
          "type": "PRINCIPAL_INVESTIGATOR",
          "investigatorFullName": "Steven Carswell",
          "investigatorTitle": "Principal Investigator",
          "investigatorAffiliation": "COG Analytics"
        },
        "leadSponsor": { "name": "COG Analytics", "class": "OTHER" },
        "collaborators": [
          { "name": "Friends Research Institute, Inc.", "class": "OTHER" }
        ]
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": false
      },
      "descriptionModule": {
        "briefSummary": "This project extends successful Phase I work that developed a Continuing Care mobile application (app) for probationers and parolees with SUDs who are at elevated risk of relapse, re-arrest, and incarceration. This Phase II STTR project will finalize app development and evaluate its efficacy in a randomized controlled trial. The project has high public health significance due to its potential to provide an accessible recovery support tool for individuals on probation or parole that could improve their substance use disorder treatment outcomes.",
        "detailedDescription": "Substance use disorders (SUDs) continue to be one of the most serious public health problems in the US. Studies have consistently documented a substantially higher prevalence of SUDs among adults under criminal justice supervision in the community (i.e., probation or parole) as compared to the general population. There is growing recognition that addiction is a chronic health condition, and individuals with SUDs typically cycle through multiple periods of treatment, abstinence, and relapse over several years to achieve and maintain recovery. Studies show that continuing care interventions can provide ongoing support or extend primary treatment gains with respect to reducing substance use, relapse, and criminal activity. Recent diffusion of Internet and smartphone technologies among disadvantaged populations now offers unprecedented opportunities for increasing access to quality continuing care interventions as well as chronic disease self-management tools. Probationers and parolees at high risk for drug abuse relapse and involvement in health compromising behaviors are an important population that stands to benefit from continuing care technologies. However, to date, no such technologies exist that are specifically tailored to meet the unique needs of this high-risk population.\n\nBuilding on our team's extensive experience in the fields of criminology and substance use, we propose to complete the development of a Continuing Care mobile application (app) and conduct a randomized controlled trial to assess efficacy among clients on probation or parole who are enrolled in outpatient substance use treatment. The app is designed to meet the recovery and personal support needs of probationers and parolees with SUDs who are at elevated risk of relapse, re-arrest, and incarceration. It is guided by the principles of the transtheoretical model of behavior change and app content is derived from the Your Own Reintegration System (YOURS) program, an empirically-supported16 intervention that focuses on substance use recovery, reducing criminal thinking and behavior, and managing and building support systems. If proven to be efficacious, the app could be deployed across the national network of outpatient treatment providers, and be highly significant in its direct impact on public health."
      },
      "conditionsModule": { "conditions": ["Substance Use Disorders"] },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "interventionModelDescription": "The evaluation will involve a two-group RCT in which 100 men and women on probation or parole, who are currently receiving outpatient substance use treatment at THC, will be randomly assigned to one of two conditions: (1) Continuing Care app (CC app; n=50): Participants will receive the CC app, in addition to usual care at the treatment program (12-weeks of weekly group cognitive behavioral therapy), or (2) Treatment As Usual (TAU; n=50): Participants will only receive 12-weeks of weekly group cognitive behavioral therapy.",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": { "masking": "NONE" }
        },
        "enrollmentInfo": { "count": 100, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "Continuing Care App",
            "type": "EXPERIMENTAL",
            "description": "Participants will receive the Continuing Care app, in addition to usual care at the treatment program (12-weeks of weekly group cognitive behavioral therapy).",
            "interventionNames": [
              "Device: digital therapeutic for substance use disorders"
            ]
          },
          {
            "label": "Treatment As Usual",
            "type": "ACTIVE_COMPARATOR",
            "description": "Participants will only receive 12-weeks of weekly group cognitive behavioral therapy.",
            "interventionNames": ["Other: Treatment As Usual"]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "digital therapeutic for substance use disorders",
            "description": "The Continuing Care application (app) is a HIPAA-compliant, mobile-friendly, software program designed to meet the recovery and personal support needs of probationers and parolees with SUDs who are at elevated risk of relapse, re-arrest, and incarceration.",
            "armGroupLabels": ["Continuing Care App"]
          },
          {
            "type": "OTHER",
            "name": "Treatment As Usual",
            "description": "12-weeks of weekly group cognitive behavioral therapy",
            "armGroupLabels": ["Treatment As Usual"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Weeks Retained in Substance Use Treatment",
            "description": "Number of weeks retained in treatment based on a review of clinical records",
            "timeFrame": "up to 12 weeks"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Completion of Substance Use Treatment",
            "description": "Treatment completed (yes or no) based on a review of clinical records",
            "timeFrame": "up to 12 weeks"
          },
          {
            "measure": "Days of Substance Use",
            "description": "Number of days of drug use based on self-report drug use and urine drug screen results",
            "timeFrame": "up to 18 weeks"
          },
          {
            "measure": "Days of Criminal Activity; Re-arrest; Incarceration",
            "description": "Number of crime days; re-arrest (yes or not); incarceration (yes or no) based on self-report information and public court record databases",
            "timeFrame": "up to 18 weeks"
          }
        ],
        "otherOutcomes": [
          {
            "measure": "Rating of App Satisfaction",
            "description": "Rating of client satisfaction using the app based on self-report information",
            "timeFrame": "up to 12 weeks"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* Age 18 or older\n* Currently on community supervision (probation or parole) or justice-involvement in the past 12 months\n* Currently a client receiving outpatient substance use treatment\n* Willing to receive supplemental treatment services through a mobile app\n* Willing to provide informed consent and complete research assessments\n\nExclusion Criteria:\n\n* Severe psychiatric problems (e.g., untreated psychosis, untreated bipolar disorder)\n* Suicidality within the past 6-months, as determined by clinical staff, which could make participation in a novel treatment hazardous",
        "healthyVolunteers": true,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "maximumAge": "90 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "Steven B Carswell, Ph.D.",
            "affiliation": "COG Analytics",
            "role": "PRINCIPAL_INVESTIGATOR"
          }
        ],
        "locations": [
          {
            "facility": "REACH Health Services",
            "city": "Baltimore",
            "state": "Maryland",
            "zip": "21218",
            "country": "United States",
            "geoPoint": { "lat": 39.29038, "lon": -76.61219 }
          }
        ]
      },
      "ipdSharingStatementModule": {
        "ipdSharing": "NO",
        "description": "COG Analytics (COG) and Friends Research Institute (FRI) are committed to the open and timely dissemination of research outcomes. Investigators in the proposed study recognize that promising new methods, technologies, strategies and computer software may arise during the course of this research. The investigators are aware of, and agree to abide by, the principles for sharing research resources as described by the National Institutes of Health (NIH) in \"Principles and Guidelines for Recipients of NIH Research Grants and Contracts on Obtaining and Disseminating Biomedical Research Resources.\""
      }
    },
    "annotationSection": {
      "annotationModule": {
        "unpostedAnnotation": {
          "unpostedResponsibleParty": "Steven Carswell, Principal Investigator, COG Analytics",
          "unpostedEvents": [
            { "type": "RELEASE", "date": "2024-05-29" },
            { "type": "RESET", "date": "2024-06-24" },
            { "type": "RELEASE", "date": "2024-08-29" },
            { "type": "RESET", "date": "2024-09-22" }
          ]
        }
      }
    },
    "derivedSection": {
      "miscInfoModule": {
        "versionHolder": "2025-05-07",
        "submissionTracking": {
          "estimatedResultsFirstSubmitDate": "2024-05-29",
          "submissionInfos": [
            { "releaseDate": "2024-05-29", "resetDate": "2024-06-24" },
            { "releaseDate": "2024-08-29", "resetDate": "2024-09-22" }
          ]
        }
      },
      "conditionBrowseModule": {
        "meshes": [{ "id": "D019966", "term": "Substance-Related Disorders" }],
        "ancestors": [
          { "id": "D064419", "term": "Chemically-Induced Disorders" },
          { "id": "D001523", "term": "Mental Disorders" }
        ],
        "browseLeaves": [
          {
            "id": "M21837",
            "name": "Substance-Related Disorders",
            "asFound": "Substance Use Disorders",
            "relevance": "HIGH"
          },
          {
            "id": "M30302",
            "name": "Chemically-Induced Disorders",
            "relevance": "LOW"
          },
          { "id": "M14473", "name": "Psychotic Disorders", "relevance": "LOW" },
          { "id": "M4815", "name": "Mental Disorders", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "BC25", "name": "Substance Related Disorders" },
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" },
          { "abbrev": "All", "name": "All Conditions" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT04857008",
        "orgStudyIdInfo": { "id": "BNT001 VA Pilot Study_3_4_2021" },
        "organization": {
          "fullName": "Blue Note Therapeutics",
          "class": "INDUSTRY"
        },
        "briefTitle": "BNT001 Digital Therapeutic Feasibility Pilot Study",
        "officialTitle": "Phase II Pilot Study Evaluating the Feasibility of Delivery and Evaluation of BNT001, a Digital Cognitive-Behavioral Stress Management (CBSM) Software Application for Treatment of Anxiety and Depressive Symptoms in Veterans With Cancer"
      },
      "statusModule": {
        "statusVerifiedDate": "2022-10",
        "overallStatus": "TERMINATED",
        "whyStopped": "recruitment challenges",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2021-10-08", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2022-08-05",
          "type": "ACTUAL"
        },
        "completionDateStruct": { "date": "2022-08-05", "type": "ACTUAL" },
        "studyFirstSubmitDate": "2021-04-20",
        "studyFirstSubmitQcDate": "2021-04-22",
        "studyFirstPostDateStruct": { "date": "2021-04-23", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2022-10-18",
        "lastUpdatePostDateStruct": { "date": "2022-10-20", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": {
          "name": "Blue Note Therapeutics",
          "class": "INDUSTRY"
        },
        "collaborators": [
          { "name": "Durham VA Health Care System", "class": "FED" }
        ]
      },
      "oversightModule": {
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": false
      },
      "descriptionModule": {
        "briefSummary": "This single arm phase II trial focused on cancer patients and cancer survivors in the Veterans Health Administration will gather data on feasibility, acceptability, ease of clinical implementation, and preliminary efficacy of BNT001, a prescription digital software application. BNT001 delivers a 10-session digitally administered version of a published manualized therapy for stress management in adult cancer patients that has established efficacy in improving quality of life and mood.",
        "detailedDescription": "This pilot will study specific implementation barriers and facilitators, procedures that are necessary to ensure adherence to utilization of the digital program, as well as any potential safety issues associated with recruiting and offering an intervention to cancer patients with moderate anxiety or mild depressive symptoms. Data relating to patient experience, adherence, satisfaction and pre-post intervention outcomes will also be tracked.\n\nThe study will run in two distinct phases to first assess the process of clinical implementation by prescribing oncology clinicians, and in a second more expanded phase, further assess the clinical implementation and impact on enrolled patients.\n\nStudy Phase 1: We aim to identify promoters and barriers to the clinical implementation of BNT001, a software application that delivers a 10-session digitally administered version of a published manualized therapy for stress management in adult cancer patients that has established efficacy in improving quality of life and mood.\n\nStudy Phase 2: We aim to further identify promoters and barriers to provider clinical implementation of BNT001, assess patient acceptability and feasibility including patient adherence to BNT's 10-sessions, and obtain preliminary data on BNT001's impact on cancer-related distress."
      },
      "conditionsModule": { "conditions": ["Cancer"] },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "NA",
          "interventionModel": "SINGLE_GROUP",
          "primaryPurpose": "HEALTH_SERVICES_RESEARCH",
          "maskingInfo": { "masking": "NONE" }
        },
        "enrollmentInfo": { "count": 17, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "BNT001",
            "type": "EXPERIMENTAL",
            "description": "BNT001 is a commercially-available, prescription-only, software / medical device in the form of a digital application (digital app) for use on the participant's mobile device which delivers 10-sessions on cognitive behavioral therapy for cancer patients.",
            "interventionNames": ["Device: BNT001"]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "BNT001",
            "description": "BNT001 is a commercially-available, prescription-only, software / medical device in the form of a digital application (digital app) for use on the participant's mobile device which delivers 10-sessions on cognitive behavioral therapy for cancer patients.",
            "armGroupLabels": ["BNT001"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Identification of promoters and barriers to clinical implementation",
            "description": "Identification of promoters and barriers to clinical implementation of BNT001, a software application that delivers a 10-session, cancer-specific, behavioral intervention called Cognitive-Behavioral Stress Management (CBSM), to adult patients currently undergoing cancer treatment.",
            "timeFrame": "Baseline to 4 weeks"
          },
          {
            "measure": "To measure changes in pre and post cancer-related distress in patient participants.",
            "description": "Patient participants symptoms will be assessed with the Veterans Symptom Assessment Screen (VSAS). The VSAS is a clinical patient reported outcomes tool to document cancer-related symptoms to improve quality of life that has been adopted across VA hematology-oncology sites. The VSAS is comprised of 13 symptoms, rated on a 0 to 10 scale.",
            "timeFrame": "Baseline to 12 weeks"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Patient completion rates",
            "description": "To measure patient completion rates via the BNT001's underlying device data capture system.",
            "timeFrame": "Baseline to 12 weeks"
          },
          {
            "measure": "Patient feasibility and acceptability",
            "description": "To measure patient feasibility and acceptability via a midpoint and post-completion questionnaire.",
            "timeFrame": "Baseline to 12 weeks"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* Diagnosis or history of invasive cancer (excluding non-melanoma skin cancer).\n* Patients showing mild to moderate anxiety or depression on the Veteran System Assessment Screen (VSAS), with anxiety or depression scored as 1-6 on a 0-10 scale.\n* Fluent in English.\n* Has access to iOS or Android smartphone, or tablet and capable of receiving text messages.\n* Has an e-mail address.\n\nExclusion Criteria:\n\n* Endorses thoughts of self-harm, history of suicidality.\n* Currently participating in investigative behavioral intervention trial for treatment of anxiety or depression.\n* Participant is unable to complete training, has cognitive deficits, major psychiatric conditions, psycho-social conditions; lack of access to reliable internet and accessible device; other social conditions that would interfere with adherence to self directed care, such that in investigator's opinion the participant would be unable to complete the study.\n* Recently completed use of Blue Note Therapeutics COVID Cancer Care Program or other Blue Note Therapeutics sponsored study.",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "17 Years",
        "maximumAge": "75 Years",
        "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "Daphne Friedman, MD",
            "affiliation": "Durham Veterans Administration Health Care System",
            "role": "PRINCIPAL_INVESTIGATOR"
          }
        ],
        "locations": [
          {
            "facility": "Durham Veterans Administration",
            "city": "Durham",
            "state": "North Carolina",
            "zip": "27705",
            "country": "United States",
            "geoPoint": { "lat": 35.99403, "lon": -78.89862 }
          }
        ]
      },
      "ipdSharingStatementModule": { "ipdSharing": "NO" }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "browseLeaves": [
          { "id": "M4324", "name": "Anxiety Disorders", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" },
          { "abbrev": "All", "name": "All Conditions" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT03694327",
        "orgStudyIdInfo": { "id": "CT-101-002" },
        "organization": { "fullName": "My Digital Study", "class": "INDUSTRY" },
        "briefTitle": "Innovative Digital Therapeutic for Smoking Cessation",
        "officialTitle": "Clinical Trial of an Innovative Digital Therapeutic for Smoking Cessation With Biochemical Verification"
      },
      "statusModule": {
        "statusVerifiedDate": "2022-05",
        "overallStatus": "COMPLETED",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2018-10-24", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2019-03-14",
          "type": "ACTUAL"
        },
        "completionDateStruct": { "date": "2019-03-14", "type": "ACTUAL" },
        "studyFirstSubmitDate": "2018-09-12",
        "studyFirstSubmitQcDate": "2018-10-01",
        "studyFirstPostDateStruct": { "date": "2018-10-03", "type": "ACTUAL" },
        "resultsFirstSubmitDate": "2022-03-10",
        "resultsFirstSubmitQcDate": "2022-05-12",
        "resultsFirstPostDateStruct": {
          "date": "2022-06-06",
          "type": "ACTUAL"
        },
        "dispFirstSubmitDate": "2020-03-10",
        "dispFirstSubmitQcDate": "2022-05-12",
        "dispFirstPostDateStruct": { "date": "2022-06-06", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2022-05-12",
        "lastUpdatePostDateStruct": { "date": "2022-06-06", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": { "name": "My Digital Study", "class": "INDUSTRY" }
      },
      "oversightModule": {
        "oversightHasDmc": true,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": true,
        "isUnapprovedDevice": true
      },
      "descriptionModule": {
        "briefSummary": "This study is comparing the efficacy of two smoking cessation apps.",
        "detailedDescription": "Given that tobacco smoking is the leading cause of preventable death in the US, the development of effective cessation programs is critical; mobile phone applications represent a novel, accessible platform for helping smokers quit. This research project seeks to compare the efficacy of two smoking cessation apps. In a blinded, randomized, controlled study, current smokers motivated to quit will use a smoking cessation app for 8 weeks."
      },
      "conditionsModule": {
        "conditions": [
          "Smoking Cessation",
          "Nicotine Addiction",
          "Drug Addiction",
          "Drug Dependence",
          "Tobacco Dependence",
          "Tobacco Use Disorder",
          "Substance Use Disorder",
          "Tobacco Smoking"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": {
            "masking": "DOUBLE",
            "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]
          }
        },
        "enrollmentInfo": { "count": 158, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "Treatment A Mobile Application",
            "type": "EXPERIMENTAL",
            "description": "Treatment A Digital Intervention: Smartphone application designed to assist with smoking cessation.",
            "interventionNames": ["Device: CT-101-M"]
          },
          {
            "label": "Treatment B Mobile Application",
            "type": "ACTIVE_COMPARATOR",
            "description": "Treatment B Digital Intervention: Smartphone application designed to assist with smoking cessation.",
            "interventionNames": ["Device: QuitGuide"]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "CT-101-M",
            "description": "Mobile Application",
            "armGroupLabels": ["Treatment A Mobile Application"]
          },
          {
            "type": "DEVICE",
            "name": "QuitGuide",
            "description": "Mobile Application",
            "armGroupLabels": ["Treatment B Mobile Application"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "30-Day Sustained Abstinence From Smoking",
            "description": "Self-reported abstinence from smoking was assessed in the 8-Week Outcome Survey.",
            "timeFrame": "Upon completion of 8-week period"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Feasibility of Biochemical Verification of Smoking Cessation",
            "description": "Confirmation with the remote CO assessment was conducted to assess concordance between self-report and remote CO assessment results. Abstinence as per the CO assessment was defined as an iCO reading of fewer than 7ppm exhaled CO.",
            "timeFrame": "Upon completion of 8-week period"
          },
          {
            "measure": "NRT and Smoking Cessation Pharmacotherapy Use",
            "description": "Self-reported NRT and smoking cessation pharmacotherapy use will be acquired via the outcome survey. Cessation rates will be compared between those using/not using pharmacotherapy.",
            "timeFrame": "Upon completion of 8-week period"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* Male or female age 18 to 65\n* Fluent in written and spoken English (confirmed by ability to read and comprehend Informed Consent Form)\n* Lives in the United States\n* Smokes at least 5 cigarettes daily\n* Is interested in quitting in the next 30 days\n* The participant owns and has access to an iPhone with iOS 9 or greater capabilities, or an Android with OS 7 or greater capabilities\n* The participant is willing and able to receive SMS text messages on their smartphone\n* The participant is willing and able to receive email messages.\n* Ability to confirm download of installed treatment arm app via telephone on randomization date.\n* One half of the study sample will be recruited from the general population of smokers via social media advertisements\n* One half of the study sample will be recruited via mail form a Magellan Behavioral Health value-based care network\n\nExclusion Criteria:\n\n* Prior use of Treatment A Digital Intervention or Treatment B Digital Intervention\n* Current use of pharmacotherapy for smoking cessation or nicotine replacement therapy (NRT)",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "maximumAge": "65 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "Brian M Iacoviello, PhD",
            "affiliation": "My Digital Study",
            "role": "PRINCIPAL_INVESTIGATOR"
          }
        ],
        "locations": [
          {
            "facility": "My Digital Study",
            "city": "New York",
            "state": "New York",
            "zip": "10013",
            "country": "United States",
            "geoPoint": { "lat": 40.71427, "lon": -74.00597 }
          }
        ]
      }
    },
    "resultsSection": {
      "participantFlowModule": {
        "groups": [
          {
            "id": "FG000",
            "title": "Treatment A Mobile Application",
            "description": "Treatment A Digital Intervention: Smartphone application designed to assist with smoking cessation.\n\nCT-101-M (Mobile Application): A reduced-functionality minimal viable product (MVP) version of Clickotine (CT-101)."
          },
          {
            "id": "FG001",
            "title": "Treatment B Mobile Application",
            "description": "Treatment B Digital Intervention: Smartphone application designed to assist with smoking cessation.\n\nQuitGuide: Mobile Application"
          }
        ],
        "periods": [
          {
            "title": "Overall Study",
            "milestones": [
              {
                "type": "STARTED",
                "achievements": [
                  { "groupId": "FG000", "numSubjects": "79" },
                  { "groupId": "FG001", "numSubjects": "79" }
                ]
              },
              {
                "type": "COMPLETED",
                "achievements": [
                  { "groupId": "FG000", "numSubjects": "66" },
                  { "groupId": "FG001", "numSubjects": "56" }
                ]
              },
              {
                "type": "NOT COMPLETED",
                "achievements": [
                  { "groupId": "FG000", "numSubjects": "13" },
                  { "groupId": "FG001", "numSubjects": "23" }
                ]
              }
            ],
            "dropWithdraws": [
              {
                "type": "Lost to Follow-up",
                "reasons": [
                  { "groupId": "FG000", "numSubjects": "13" },
                  { "groupId": "FG001", "numSubjects": "23" }
                ]
              }
            ]
          }
        ]
      },
      "baselineCharacteristicsModule": {
        "populationDescription": "The population enrolled was US only, male or female, ages 18 to 65, and smoke at least 5 cigarettes per day with an interest in quitting smoking within the next 30 days. Participants enrolled had not used Clickotine or QuitGuide; and were not using an NRT at the time of enrollment.",
        "groups": [
          {
            "id": "BG000",
            "title": "Treatment A Mobile Application (CT-101-M)",
            "description": "Treatment A Digital Intervention: Smartphone application designed to assist with smoking cessation.\n\nCT-101-M (Mobile Application): A reduced-functionality minimal viable product (MVP) version of Clickotine (CT-101)."
          },
          {
            "id": "BG001",
            "title": "Treatment B Mobile Application (QuitGuide)",
            "description": "Treatment B Digital Intervention: Smartphone application designed to assist with smoking cessation.\n\nQuitGuide: Mobile Application"
          },
          {
            "id": "BG002",
            "title": "Total",
            "description": "Total of all reporting groups"
          }
        ],
        "denoms": [
          {
            "units": "Participants",
            "counts": [
              { "groupId": "BG000", "value": "79" },
              { "groupId": "BG001", "value": "79" },
              { "groupId": "BG002", "value": "158" }
            ]
          }
        ],
        "measures": [
          {
            "title": "Age, Customized",
            "description": "Measured via Self-Report in the Baseline Survey.",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "title": "18-39 years",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "BG000", "value": "60" },
                      { "groupId": "BG001", "value": "59" },
                      { "groupId": "BG002", "value": "119" }
                    ]
                  }
                ]
              },
              {
                "title": "40-59 years",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "BG000", "value": "18" },
                      { "groupId": "BG001", "value": "19" },
                      { "groupId": "BG002", "value": "37" }
                    ]
                  }
                ]
              },
              {
                "title": "60+ years",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "BG000", "value": "1" },
                      { "groupId": "BG001", "value": "1" },
                      { "groupId": "BG002", "value": "2" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Sex: Female, Male",
            "description": "Measured via Self-Report in the Baseline Survey.",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "Female",
                    "measurements": [
                      { "groupId": "BG000", "value": "52" },
                      { "groupId": "BG001", "value": "55" },
                      { "groupId": "BG002", "value": "107" }
                    ]
                  },
                  {
                    "title": "Male",
                    "measurements": [
                      { "groupId": "BG000", "value": "27" },
                      { "groupId": "BG001", "value": "24" },
                      { "groupId": "BG002", "value": "51" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Race/Ethnicity, Customized",
            "description": "Measured via Self-Report in the Baseline Survey.",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "title": "White",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "BG000", "value": "59" },
                      { "groupId": "BG001", "value": "65" },
                      { "groupId": "BG002", "value": "124" }
                    ]
                  }
                ]
              },
              {
                "title": "All Other Races",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "BG000", "value": "20" },
                      { "groupId": "BG001", "value": "14" },
                      { "groupId": "BG002", "value": "34" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Region of Enrollment",
            "description": "Measured via Self-Report in the Baseline Survey.",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "title": "United States",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "BG000", "value": "79" },
                      { "groupId": "BG001", "value": "79" },
                      { "groupId": "BG002", "value": "158" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Family Size, Categorical",
            "description": "Measured via Self-Report in the Baseline Survey.",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "0-2",
                    "measurements": [
                      { "groupId": "BG000", "value": "31" },
                      { "groupId": "BG001", "value": "32" },
                      { "groupId": "BG002", "value": "63" }
                    ]
                  },
                  {
                    "title": "3-5",
                    "measurements": [
                      { "groupId": "BG000", "value": "47" },
                      { "groupId": "BG001", "value": "40" },
                      { "groupId": "BG002", "value": "87" }
                    ]
                  },
                  {
                    "title": "6+",
                    "measurements": [
                      { "groupId": "BG000", "value": "1" },
                      { "groupId": "BG001", "value": "7" },
                      { "groupId": "BG002", "value": "8" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Education, Categorical",
            "description": "Measured via Self-Report in the Baseline Survey.",
            "paramType": "NUMBER",
            "unitOfMeasure": "participants",
            "classes": [
              {
                "title": "< HS or GED",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "BG000", "value": "17" },
                      { "groupId": "BG001", "value": "12" },
                      { "groupId": "BG002", "value": "29" }
                    ]
                  }
                ]
              },
              {
                "title": "High School",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "BG000", "value": "10" },
                      { "groupId": "BG001", "value": "13" },
                      { "groupId": "BG002", "value": "23" }
                    ]
                  }
                ]
              },
              {
                "title": "> High School",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "BG000", "value": "52" },
                      { "groupId": "BG001", "value": "54" },
                      { "groupId": "BG002", "value": "106" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Income Range, Categorical",
            "description": "Measured via Self-Report in the Baseline Survey.",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "Less than $20,000",
                    "measurements": [
                      { "groupId": "BG000", "value": "16" },
                      { "groupId": "BG001", "value": "21" },
                      { "groupId": "BG002", "value": "37" }
                    ]
                  },
                  {
                    "title": "$20,000 to $55,000",
                    "measurements": [
                      { "groupId": "BG000", "value": "38" },
                      { "groupId": "BG001", "value": "38" },
                      { "groupId": "BG002", "value": "76" }
                    ]
                  },
                  {
                    "title": "$55,000 to $100,000",
                    "measurements": [
                      { "groupId": "BG000", "value": "15" },
                      { "groupId": "BG001", "value": "13" },
                      { "groupId": "BG002", "value": "28" }
                    ]
                  },
                  {
                    "title": "Over $100,000",
                    "measurements": [
                      { "groupId": "BG000", "value": "10" },
                      { "groupId": "BG001", "value": "7" },
                      { "groupId": "BG002", "value": "17" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Internet Frequency, Categorical",
            "description": "Measured via Self-Report in the Baseline Survey.",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "A few times per day",
                    "measurements": [
                      { "groupId": "BG000", "value": "3" },
                      { "groupId": "BG001", "value": "1" },
                      { "groupId": "BG002", "value": "4" }
                    ]
                  },
                  {
                    "title": "At least once per day but less than several times",
                    "measurements": [
                      { "groupId": "BG000", "value": "3" },
                      { "groupId": "BG001", "value": "4" },
                      { "groupId": "BG002", "value": "7" }
                    ]
                  },
                  {
                    "title": "At least several times per day",
                    "measurements": [
                      { "groupId": "BG000", "value": "32" },
                      { "groupId": "BG001", "value": "33" },
                      { "groupId": "BG002", "value": "65" }
                    ]
                  },
                  {
                    "title": "Several times per day",
                    "measurements": [
                      { "groupId": "BG000", "value": "41" },
                      { "groupId": "BG001", "value": "41" },
                      { "groupId": "BG002", "value": "82" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Fagerstrom Test for Nicotine Dependence",
            "description": "The Fagerstrom Test for Nicotine Dependence is a standard instrument for assessing the intensity of physical addiction to nicotine. The test was designed to provide an ordinal measure of nicotine dependence related to cigarette smoking. In scoring the Fagerstrom Nicotine Dependency Test, yes/no items are scored from 0 to 1 and multiple-choice items are scored from 0 to 3. The items are added to yield a total score of 0-10. The higher total Fagerstrom score indicates a more intense/ higher dependency to nicotine (Heatherton, et. al, 1991)",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "0-3",
                    "measurements": [
                      { "groupId": "BG000", "value": "21" },
                      { "groupId": "BG001", "value": "19" },
                      { "groupId": "BG002", "value": "40" }
                    ]
                  },
                  {
                    "title": "4-7",
                    "measurements": [
                      { "groupId": "BG000", "value": "48" },
                      { "groupId": "BG001", "value": "52" },
                      { "groupId": "BG002", "value": "100" }
                    ]
                  },
                  {
                    "title": "8+",
                    "measurements": [
                      { "groupId": "BG000", "value": "10" },
                      { "groupId": "BG001", "value": "8" },
                      { "groupId": "BG002", "value": "18" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Money Spent on Cigarettes (Per Month)",
            "description": "Measured via Self-Report in the Baseline Survey.",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "Less than $15",
                    "measurements": [
                      { "groupId": "BG000", "value": "4" },
                      { "groupId": "BG001", "value": "9" },
                      { "groupId": "BG002", "value": "13" }
                    ]
                  },
                  {
                    "title": "$16 to $30",
                    "measurements": [
                      { "groupId": "BG000", "value": "27" },
                      { "groupId": "BG001", "value": "23" },
                      { "groupId": "BG002", "value": "50" }
                    ]
                  },
                  {
                    "title": "$31 to $50",
                    "measurements": [
                      { "groupId": "BG000", "value": "33" },
                      { "groupId": "BG001", "value": "33" },
                      { "groupId": "BG002", "value": "66" }
                    ]
                  },
                  {
                    "title": "More than $50",
                    "measurements": [
                      { "groupId": "BG000", "value": "15" },
                      { "groupId": "BG001", "value": "14" },
                      { "groupId": "BG002", "value": "29" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Quit Duration",
            "description": "Participants longest prior quit attempt was measured via self-report in the Baseline Survey.",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "Less than a week",
                    "measurements": [
                      { "groupId": "BG000", "value": "13" },
                      { "groupId": "BG001", "value": "19" },
                      { "groupId": "BG002", "value": "32" }
                    ]
                  },
                  {
                    "title": "1 week to 1 month",
                    "measurements": [
                      { "groupId": "BG000", "value": "18" },
                      { "groupId": "BG001", "value": "17" },
                      { "groupId": "BG002", "value": "35" }
                    ]
                  },
                  {
                    "title": "1 month to 6 months",
                    "measurements": [
                      { "groupId": "BG000", "value": "23" },
                      { "groupId": "BG001", "value": "22" },
                      { "groupId": "BG002", "value": "45" }
                    ]
                  },
                  {
                    "title": "6 months to 1 year",
                    "measurements": [
                      { "groupId": "BG000", "value": "15" },
                      { "groupId": "BG001", "value": "13" },
                      { "groupId": "BG002", "value": "28" }
                    ]
                  },
                  {
                    "title": "More than 1 year",
                    "measurements": [
                      { "groupId": "BG000", "value": "7" },
                      { "groupId": "BG001", "value": "6" },
                      { "groupId": "BG002", "value": "13" }
                    ]
                  },
                  {
                    "title": "N/A",
                    "measurements": [
                      { "groupId": "BG000", "value": "3" },
                      { "groupId": "BG001", "value": "2" },
                      { "groupId": "BG002", "value": "5" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Prior Quit Attempts",
            "description": "Participants prior quit attempts were measured via self-report in the Baseline Survey.",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "0",
                    "measurements": [
                      { "groupId": "BG000", "value": "5" },
                      { "groupId": "BG001", "value": "5" },
                      { "groupId": "BG002", "value": "10" }
                    ]
                  },
                  {
                    "title": "1",
                    "measurements": [
                      { "groupId": "BG000", "value": "12" },
                      { "groupId": "BG001", "value": "19" },
                      { "groupId": "BG002", "value": "31" }
                    ]
                  },
                  {
                    "title": "2",
                    "measurements": [
                      { "groupId": "BG000", "value": "16" },
                      { "groupId": "BG001", "value": "20" },
                      { "groupId": "BG002", "value": "36" }
                    ]
                  },
                  {
                    "title": "3",
                    "measurements": [
                      { "groupId": "BG000", "value": "17" },
                      { "groupId": "BG001", "value": "11" },
                      { "groupId": "BG002", "value": "28" }
                    ]
                  },
                  {
                    "title": "4",
                    "measurements": [
                      { "groupId": "BG000", "value": "6" },
                      { "groupId": "BG001", "value": "12" },
                      { "groupId": "BG002", "value": "18" }
                    ]
                  },
                  {
                    "title": "5",
                    "measurements": [
                      { "groupId": "BG000", "value": "12" },
                      { "groupId": "BG001", "value": "4" },
                      { "groupId": "BG002", "value": "16" }
                    ]
                  },
                  {
                    "title": "N/A",
                    "measurements": [
                      { "groupId": "BG000", "value": "11" },
                      { "groupId": "BG001", "value": "8" },
                      { "groupId": "BG002", "value": "19" }
                    ]
                  }
                ]
              }
            ]
          }
        ]
      },
      "outcomeMeasuresModule": {
        "outcomeMeasures": [
          {
            "type": "PRIMARY",
            "title": "30-Day Sustained Abstinence From Smoking",
            "description": "Self-reported abstinence from smoking was assessed in the 8-Week Outcome Survey.",
            "populationDescription": "The study population was randomized 1:1 across Treatment A (CT-101-M) and Treatment B (QuitGuide). The population enrolled was US only, male or female, ages 18 to 65, and smoke at least 5 cigarettes per day with an interest in quitting smoking within the next 30 days. Participants enrolled had not used Clickotine or QuitGuide; and were not using an NRT at the time of enrollment",
            "reportingStatus": "POSTED",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "timeFrame": "Upon completion of 8-week period",
            "groups": [
              {
                "id": "OG000",
                "title": "Treatment A Mobile Application (CT-101-M)",
                "description": "Treatment A Digital Intervention: Smartphone application designed to assist with smoking cessation.\n\nCT-101-M (Mobile Application): A reduced-functionality minimal viable product (MVP) version of Clickotine (CT-101)."
              },
              {
                "id": "OG001",
                "title": "Treatment B Mobile Application (QuitGuide)",
                "description": "Treatment B Digital Intervention: Smartphone application designed to assist with smoking cessation.\n\nQuitGuide: Mobile Application"
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "79" },
                  { "groupId": "OG001", "value": "79" }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "title": "Reported Smoking in the Last 30 Days",
                    "measurements": [
                      { "groupId": "OG000", "value": "69" },
                      { "groupId": "OG001", "value": "66" }
                    ]
                  },
                  {
                    "title": "Reported Not Smoking in the Last 30 Days",
                    "measurements": [
                      { "groupId": "OG000", "value": "10" },
                      { "groupId": "OG001", "value": "13" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Feasibility of Biochemical Verification of Smoking Cessation",
            "description": "Confirmation with the remote CO assessment was conducted to assess concordance between self-report and remote CO assessment results. Abstinence as per the CO assessment was defined as an iCO reading of fewer than 7ppm exhaled CO.",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "PPM",
            "timeFrame": "Upon completion of 8-week period",
            "groups": [
              {
                "id": "OG000",
                "title": "Treatment A Mobile Application (CT-101-M)",
                "description": "Treatment A Digital Intervention: Smartphone application designed to assist with smoking cessation.\n\nCT-101-M (Mobile Application): A reduced-functionality minimal viable product (MVP) version of Clickotine (CT-101)."
              },
              {
                "id": "OG001",
                "title": "Treatment B Mobile Application (QuitGuide)",
                "description": "Treatment B Digital Intervention: Smartphone application designed to assist with smoking cessation.\n\nQuitGuide: Mobile Application"
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "47" },
                  { "groupId": "OG001", "value": "46" }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "9.766",
                        "spread": "11.099"
                      },
                      {
                        "groupId": "OG001",
                        "value": "8.609",
                        "spread": "9.448"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "NRT and Smoking Cessation Pharmacotherapy Use",
            "description": "Self-reported NRT and smoking cessation pharmacotherapy use will be acquired via the outcome survey. Cessation rates will be compared between those using/not using pharmacotherapy.",
            "reportingStatus": "POSTED",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "timeFrame": "Upon completion of 8-week period",
            "groups": [
              {
                "id": "OG000",
                "title": "Treatment A Mobile Application (CT-101-M)",
                "description": "Treatment A Digital Intervention: Smartphone application designed to assist with smoking cessation.\n\nCT-101-M (Mobile Application): A reduced-functionality minimal viable product (MVP) version of Clickotine (CT-101)."
              },
              {
                "id": "OG001",
                "title": "Treatment B Mobile Application (QuitGuide)",
                "description": "Treatment B Digital Intervention: Smartphone application designed to assist with smoking cessation.\n\nQuitGuide: Mobile Application"
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "79" },
                  { "groupId": "OG001", "value": "79" }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "title": "Used NRT (or other pharmaceutical quit aids)",
                    "measurements": [
                      { "groupId": "OG000", "value": "10" },
                      { "groupId": "OG001", "value": "15" }
                    ]
                  },
                  {
                    "title": "Did not Use NRT (or other pharmaceutical quit aids)",
                    "measurements": [
                      { "groupId": "OG000", "value": "56" },
                      { "groupId": "OG001", "value": "41" }
                    ]
                  },
                  {
                    "title": "Not Reported",
                    "measurements": [
                      { "groupId": "OG000", "value": "13" },
                      { "groupId": "OG001", "value": "23" }
                    ]
                  }
                ]
              }
            ]
          }
        ]
      },
      "adverseEventsModule": {
        "frequencyThreshold": "0",
        "timeFrame": "AE collection occurred 8 weeks after participant began treatment.",
        "description": "Adverse event and serious adverse event definitions used are the same as clinilcaltrials.gov.\n\nMethod of collection: Participants were instructed to contact the study coordinator via a study-specific e-mail and phone number in the event they experienced any adverse event during their participation in the study.",
        "eventGroups": [
          {
            "id": "EG000",
            "title": "Treatment A Mobile Application (CT-101-M)",
            "description": "Treatment A Digital Intervention: Smartphone application designed to assist with smoking cessation.\n\nCT-101-M (Mobile Application): A reduced-functionality minimal viable product (MVP) version of Clickotine (CT-101).",
            "deathsNumAffected": 0,
            "deathsNumAtRisk": 79,
            "seriousNumAffected": 0,
            "seriousNumAtRisk": 79,
            "otherNumAffected": 11,
            "otherNumAtRisk": 79
          },
          {
            "id": "EG001",
            "title": "Treatment B Mobile Application (QuitGuide)",
            "description": "Treatment B Digital Intervention: Smartphone application designed to assist with smoking cessation.\n\nQuitGuide: Mobile Application",
            "deathsNumAffected": 0,
            "deathsNumAtRisk": 79,
            "seriousNumAffected": 1,
            "seriousNumAtRisk": 79,
            "otherNumAffected": 5,
            "otherNumAtRisk": 79
          }
        ],
        "seriousEvents": [
          {
            "term": "Diabetic Ketoacidosis",
            "organSystem": "Endocrine disorders",
            "sourceVocabulary": "MedDRA",
            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 79
              },
              {
                "groupId": "EG001",
                "numEvents": 1,
                "numAffected": 1,
                "numAtRisk": 79
              }
            ]
          }
        ],
        "otherEvents": [
          {
            "term": "Miscarriage",
            "organSystem": "Pregnancy, puerperium and perinatal conditions",
            "sourceVocabulary": "MedDRA",
            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 1,
                "numAffected": 1,
                "numAtRisk": 79
              },
              {
                "groupId": "EG001",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 79
              }
            ]
          },
          {
            "term": "Upper Respiratory Tract Infection Viral NOS",
            "organSystem": "Respiratory, thoracic and mediastinal disorders",
            "sourceVocabulary": "MedDRA",
            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 3,
                "numAffected": 3,
                "numAtRisk": 79
              },
              {
                "groupId": "EG001",
                "numEvents": 1,
                "numAffected": 1,
                "numAtRisk": 79
              }
            ]
          },
          {
            "term": "Concussion with no loss of consciousness",
            "organSystem": "General disorders",
            "sourceVocabulary": "MedDRA",
            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 1,
                "numAffected": 1,
                "numAtRisk": 79
              },
              {
                "groupId": "EG001",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 79
              }
            ]
          },
          {
            "term": "Fractured Coccyx",
            "organSystem": "Musculoskeletal and connective tissue disorders",
            "sourceVocabulary": "MedDRA",
            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 1,
                "numAffected": 1,
                "numAtRisk": 79
              },
              {
                "groupId": "EG001",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 79
              }
            ]
          },
          {
            "term": "Borderline Personality",
            "organSystem": "Psychiatric disorders",
            "sourceVocabulary": "MedDRA",
            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 1,
                "numAffected": 1,
                "numAtRisk": 79
              },
              {
                "groupId": "EG001",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 79
              }
            ]
          },
          {
            "term": "Acute Gastroenteritis",
            "organSystem": "Gastrointestinal disorders",
            "sourceVocabulary": "MedDRA",
            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 1,
                "numAffected": 1,
                "numAtRisk": 79
              },
              {
                "groupId": "EG001",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 79
              }
            ]
          },
          {
            "term": "Acute Bronchitis",
            "organSystem": "Respiratory, thoracic and mediastinal disorders",
            "sourceVocabulary": "MedDRA",
            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 1,
                "numAffected": 1,
                "numAtRisk": 79
              },
              {
                "groupId": "EG001",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 79
              }
            ]
          },
          {
            "term": "Knee Osteoarthritis",
            "organSystem": "Musculoskeletal and connective tissue disorders",
            "sourceVocabulary": "MedDRA",
            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 79
              },
              {
                "groupId": "EG001",
                "numEvents": 1,
                "numAffected": 1,
                "numAtRisk": 79
              }
            ]
          },
          {
            "term": "Acute Upper Respiratory Tract Infection",
            "organSystem": "Respiratory, thoracic and mediastinal disorders",
            "sourceVocabulary": "MedDRA",
            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 2,
                "numAffected": 2,
                "numAtRisk": 79
              },
              {
                "groupId": "EG001",
                "numEvents": 2,
                "numAffected": 2,
                "numAtRisk": 79
              }
            ]
          },
          {
            "term": "Influenza",
            "organSystem": "Infections and infestations",
            "sourceVocabulary": "MedDRA",
            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 79
              },
              {
                "groupId": "EG001",
                "numEvents": 1,
                "numAffected": 1,
                "numAtRisk": 79
              }
            ]
          }
        ]
      },
      "moreInfoModule": {
        "certainAgreement": { "piSponsorEmployee": true },
        "pointOfContact": {
          "title": "Alankar Gupta, VP, Medical Affairs & Clinical Development",
          "organization": "MyDigitalStudy",
          "email": "agupta@clicktherapeutics.com",
          "phone": "862-485-9279"
        }
      }
    },
    "documentSection": {
      "largeDocumentModule": {
        "largeDocs": [
          {
            "typeAbbrev": "Prot",
            "hasProtocol": true,
            "hasSap": false,
            "hasIcf": false,
            "label": "Study Protocol",
            "date": "2022-03-10",
            "uploadDate": "2022-03-10T16:26",
            "filename": "Prot_000.pdf",
            "size": 1820837
          },
          {
            "typeAbbrev": "SAP",
            "hasProtocol": false,
            "hasSap": true,
            "hasIcf": false,
            "label": "Statistical Analysis Plan",
            "date": "2022-03-10",
            "uploadDate": "2022-03-10T16:31",
            "filename": "SAP_001.pdf",
            "size": 301819
          }
        ]
      }
    },
    "derivedSection": {
      "miscInfoModule": {
        "versionHolder": "2025-05-07",
        "submissionTracking": {
          "firstMcpInfo": {
            "postDateStruct": { "date": "2022-04-06", "type": "ACTUAL" }
          }
        }
      },
      "conditionBrowseModule": {
        "meshes": [
          { "id": "D019966", "term": "Substance-Related Disorders" },
          { "id": "D014029", "term": "Tobacco Use Disorder" },
          { "id": "D016739", "term": "Behavior, Addictive" }
        ],
        "ancestors": [
          { "id": "D003192", "term": "Compulsive Behavior" },
          { "id": "D007175", "term": "Impulsive Behavior" },
          { "id": "D064419", "term": "Chemically-Induced Disorders" },
          { "id": "D001523", "term": "Mental Disorders" }
        ],
        "browseLeaves": [
          {
            "id": "M16785",
            "name": "Tobacco Use Disorder",
            "asFound": "Tobacco Use Disorder",
            "relevance": "HIGH"
          },
          {
            "id": "M19100",
            "name": "Behavior, Addictive",
            "asFound": "Addiction",
            "relevance": "HIGH"
          },
          {
            "id": "M21837",
            "name": "Substance-Related Disorders",
            "asFound": "Substance Use Disorders",
            "relevance": "HIGH"
          },
          { "id": "M6418", "name": "Compulsive Behavior", "relevance": "LOW" },
          { "id": "M10220", "name": "Impulsive Behavior", "relevance": "LOW" },
          {
            "id": "M30302",
            "name": "Chemically-Induced Disorders",
            "relevance": "LOW"
          },
          { "id": "M14473", "name": "Psychotic Disorders", "relevance": "LOW" },
          { "id": "M4815", "name": "Mental Disorders", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "BC25", "name": "Substance Related Disorders" },
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" },
          { "abbrev": "All", "name": "All Conditions" }
        ]
      }
    },
    "hasResults": true
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT06000007",
        "orgStudyIdInfo": { "id": "STUDY00016340" },
        "secondaryIdInfos": [
          {
            "id": "1R44AT011593-01",
            "type": "NIH",
            "link": "https://reporter.nih.gov/quickSearch/1R44AT011593-01"
          }
        ],
        "organization": {
          "fullName": "University of Washington",
          "class": "OTHER"
        },
        "briefTitle": "Digital Therapeutic for Chronic Pain Feasibility Study",
        "officialTitle": "Development and Implementation of a Behavioral Digital Therapeutic Designed to Support, Educate, Screen and Remotely Monitor Patients with Chronic Pain"
      },
      "statusModule": {
        "statusVerifiedDate": "2024-08",
        "overallStatus": "COMPLETED",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2023-08-25", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2024-07-30",
          "type": "ACTUAL"
        },
        "completionDateStruct": { "date": "2024-07-30", "type": "ACTUAL" },
        "studyFirstSubmitDate": "2023-08-10",
        "studyFirstSubmitQcDate": "2023-08-10",
        "studyFirstPostDateStruct": { "date": "2023-08-21", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2024-10-18",
        "lastUpdatePostDateStruct": { "date": "2024-10-22", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": {
          "type": "PRINCIPAL_INVESTIGATOR",
          "investigatorFullName": "Kari Stephens",
          "investigatorTitle": "Professor of Family Medicine",
          "investigatorAffiliation": "University of Washington"
        },
        "leadSponsor": { "name": "University of Washington", "class": "OTHER" },
        "collaborators": [
          {
            "name": "National Center for Complementary and Integrative Health (NCCIH)",
            "class": "NIH"
          }
        ]
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": true,
        "isUnapprovedDevice": true,
        "isUsExport": false
      },
      "descriptionModule": {
        "briefSummary": "The investigators will conduct a 2-arm randomized control feasibility study to evaluate: 1) the feasibility of using the mobile app and an optional activity tracker, 2) the feasibility of conducting a 2-arm trial, and 3) estimate the effect size for planning for a larger efficacy trial based on our primary outcomes. The intervention arm will test a mobile app that aims to help people reduce pain interference who have chronic pain, as well as mental health issues with depression and anxiety. Participants in the intervention arm will also have the option to sense health data with a tracker that integrates with the app, which will inform the feasibility of this feature.",
        "detailedDescription": "This study will evaluate the existing 2Morrow Chronic Pain Self-Management Program, in the form of a mobile app, as a digital therapeutic for improving patients' pain self management and function who suffer from chronic pain. Specifically, the investigators will conduct a 2-arm randomized control feasibility study to evaluate: 1) the feasibility of using the mobile app and an optional activity tracker, 2) the feasibility of conducting a 2-arm trial, and 3) estimate the effect size for planning for a larger efficacy trial based on our primary outcomes. The intervention arm will test a mobile app that aims to help people reduce pain interference who have chronic pain, as well as mental health issues with depression and anxiety. Participants in the intervention arm will also have the option to sense health data with a tracker that integrates with the app, which will inform the feasibility of this feature."
      },
      "conditionsModule": {
        "conditions": ["Chronic Pain"],
        "keywords": [
          "chronic pain",
          "primary care",
          "digital therapeutic",
          "mobile app",
          "pain function",
          "pain interference",
          "psychotherapy"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["PHASE3"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "interventionModelDescription": "Randomized control feasibility study with two arms: intervention arm vs. control arm",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": { "masking": "NONE" }
        },
        "enrollmentInfo": { "count": 108, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "Treatment as usual",
            "type": "ACTIVE_COMPARATOR",
            "description": "Treatment as usual arm entails the patients continuing to receive care from their primary care provider and any specialists they choose to get involved in their care.",
            "interventionNames": ["Other: Treatment as usual"]
          },
          {
            "label": "Intervention arm",
            "type": "ACTIVE_COMPARATOR",
            "description": "Intervention arm includes access to the digital therapeutic mobile app in addition to treatment as usual",
            "interventionNames": [
              "Device: 2Morrow Chronic Pain Self-Management Program - digital therapeutic mobile app"
            ]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "2Morrow Chronic Pain Self-Management Program - digital therapeutic mobile app",
            "description": "2Morrow Chronic Pain Self-Management Program is delivered via a mobile app that engaged patients in evidenced based psychotherapy for chronic pain, including Acceptance and Commitment Therapy and Cognitive Behavioral Therapy based activities, to improve a patient's pain self management. The mobile app also offers the ability to track activities, screen for other problems, support for communicating with medical providers, and access a coach via texting.",
            "armGroupLabels": ["Intervention arm"]
          },
          {
            "type": "OTHER",
            "name": "Treatment as usual",
            "description": "Treatment as usual entails continuing with treatment for chronic pain with the patient's primary care provider and any potential specialists they choose to engage with.",
            "armGroupLabels": ["Treatment as usual"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "PROMIS Pain Interference Scale - Short Form 6b",
            "description": "Brief survey of patient's perceived pain interference in their ability to function; scores are normed on a T-score with 50 as the mean, 10 as the standard deviation, and higher scores are worse",
            "timeFrame": "will be measured at baseline, 1 month, 3 months, and 6 months after enrollment (and start of intervention in the intervention arm)"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Patient Health Questionnaire 9 (PHQ-9)",
            "description": "depression symptom measure; scores range from 0 to 27; higher scores are worse",
            "timeFrame": "will be measured at baseline, 1 month, 3 months, and 6 months after enrollment (and start of intervention in the intervention arm)"
          },
          {
            "measure": "Generalized Anxiety Disorder 7 (GAD-7)",
            "description": "anxiety symptom measure; scores range from 0-21; higher scores are worse",
            "timeFrame": "will be measured at baseline, 1 month, 3 months, and 6 months after enrollment (and start of intervention in the intervention arm)"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* \\>=18 years old\n* at least one ICD pain related diagnosis noted in the electronic health record (EHR)\n* at least 2 visits in a primary care clinic with at least one in the last 12 months\n* willing to use a mobile app in English\n* T-score for the PROMIS brief pain inventory of \\>= 55\n* access to a smartphone\n* willing to download and use a mobile app daily\n\nExclusion Criteria:\n\n* current cancer related diagnosis (to exclude cancer related chronic pain)\n* plans for surgery in next 3 months\n* pregnant\n* currently receiving hospice care",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "Kari A Stephens, Ph.D.",
            "affiliation": "University of Washington",
            "role": "PRINCIPAL_INVESTIGATOR"
          }
        ],
        "locations": [
          {
            "facility": "University of Washington Primary Care",
            "city": "Seattle",
            "state": "Washington",
            "zip": "98116",
            "country": "United States",
            "geoPoint": { "lat": 47.60621, "lon": -122.33207 }
          }
        ]
      },
      "referencesModule": {
        "references": [
          {
            "type": "BACKGROUND",
            "citation": "Stephens, K. A., Ma, K., Keiser, B., Prado, M., Zhang, Y., West, I., Hsu, C., Anastas, T., Zbikowski, S., Waters, D., & Masterson, J. (2024, August). Improving chronic pain through use of a digital behavioral health app. Abstract and poster presented at the American Psychological Association Annual Convention, Seattle, WA."
          }
        ]
      },
      "ipdSharingStatementModule": {
        "ipdSharing": "YES",
        "description": "Data will be made upon request after evaluation for appropriateness by principal investigator as an appropriate research request by individuals seeking to do further research. All data will be de-identified to protect participant privacy.",
        "infoTypes": ["STUDY_PROTOCOL", "SAP"],
        "timeFrame": "Sharing will occur after the publication of the final outcomes of the study are published and will be available for up to 7 years post completion of data collection.",
        "accessCriteria": "The requestor must provide acceptable research justification and appropriate permissions from their institutional to use the data requested for specific and detailed research purposes."
      }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [{ "id": "D059350", "term": "Chronic Pain" }],
        "ancestors": [
          { "id": "D010146", "term": "Pain" },
          { "id": "D009461", "term": "Neurologic Manifestations" }
        ],
        "browseLeaves": [
          { "id": "M13066", "name": "Pain", "relevance": "LOW" },
          {
            "id": "M29442",
            "name": "Chronic Pain",
            "asFound": "Chronic Pain",
            "relevance": "HIGH"
          },
          {
            "id": "M12404",
            "name": "Neurologic Manifestations",
            "relevance": "LOW"
          },
          {
            "id": "T1303",
            "name": "Chronic Graft Versus Host Disease",
            "asFound": "Chronic",
            "relevance": "HIGH"
          }
        ],
        "browseBranches": [
          { "abbrev": "BC23", "name": "Symptoms and General Pathology" },
          { "abbrev": "All", "name": "All Conditions" },
          { "abbrev": "BC10", "name": "Nervous System Diseases" },
          { "abbrev": "Rare", "name": "Rare Diseases" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT05801965",
        "orgStudyIdInfo": { "id": "SKH-ONC-99-003" },
        "organization": { "fullName": "Sidekick Health", "class": "INDUSTRY" },
        "briefTitle": "A Digital Therapeutic Solution for Cancer Patients",
        "officialTitle": "Sidekick Health Digital Therapeutic Solution for Cancer Patients: A Feasibility Randomized Controlled Trial"
      },
      "statusModule": {
        "statusVerifiedDate": "2024-03",
        "overallStatus": "ACTIVE_NOT_RECRUITING",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2023-04-06", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2024-03-30",
          "type": "ESTIMATED"
        },
        "completionDateStruct": { "date": "2024-09-01", "type": "ESTIMATED" },
        "studyFirstSubmitDate": "2023-03-24",
        "studyFirstSubmitQcDate": "2023-03-24",
        "studyFirstPostDateStruct": { "date": "2023-04-06", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2024-03-20",
        "lastUpdatePostDateStruct": { "date": "2024-03-21", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": { "name": "Sidekick Health", "class": "INDUSTRY" },
        "collaborators": [
          { "name": "Landspitali University Hospital", "class": "OTHER" },
          { "name": "Ljósið Cancer Rehabilitation Center", "class": "UNKNOWN" }
        ]
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": false
      },
      "descriptionModule": {
        "briefSummary": "This is a randomized, controlled trial to assess the feasibility of Sidekick Health's digital programs for cancer patients. Participants will be treated with standard of care (SoC) in combination with the digital programs, or SoC only.\n\nWe will compare the effect of the digital programs in addition to SoC to SoC only, on the cancer-related quality of life (QoL), cancer-related fatigue, and side-effect management.",
        "detailedDescription": "In line with the growing need to support cancer patients with lifestyle modifications, education and disease management, Sidekick Health developed 14-week digital programs addressing the specific needs of patients with cancers. In this study, the effect of adding the Sidekick's digital program to the standard of care (SoC) treatment for cancer patients will be assessed, with focus on prostate cancer, colorectal cancer and lung cancer. The digital programs investigated are a general oncology program (SK-411), or specific programs tailored for patients diagnosed with prostate cancer (PC-SK-451), colorectal cancer (CRC-SK-441), or lung cancer (LC-SK-431).\n\nThe study will be a single center feasibility study with an intervention group and a comparison group recruiting 84 cancer patients in active cancer treatment from Landspítali University Hospital. Patients will be randomized to receive either the SoC treatment alone or SoC with the addition of the digital program. Active cancer treatment is defined as chemotherapy, hormonal therapy, targeted therapy, immunotherapy, or radiation therapy according to standard treatment guidelines."
      },
      "conditionsModule": {
        "conditions": [
          "Cancer",
          "Prostate Cancer",
          "Colorectal Cancer",
          "Lung Cancer"
        ],
        "keywords": [
          "cancer",
          "digital solution",
          "lifestyle change",
          "prostate cancer",
          "quality of life",
          "digital intervention",
          "side effects",
          "medication adherence",
          "physical activity",
          "colorectal cancer",
          "lung cancer"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "interventionModelDescription": "Single-center prospective randomized open label pilot study",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": { "masking": "NONE" }
        },
        "enrollmentInfo": { "count": 48, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "Digital intervention group",
            "type": "EXPERIMENTAL",
            "description": "Participants will be instructed to download Sidekick Health app and receive a code to access the 14-week digital intervention in addition to standard of care, as is defined for the control arm.\n\nBeyond this, all participants in the interventional arm will also receive standard of care as defined for the control arm.",
            "interventionNames": [
              "Device: A digital solution for patients with Cancer",
              "Other: Standard of care for patients with Cancer"
            ]
          },
          {
            "label": "Standard of care - control group",
            "type": "ACTIVE_COMPARATOR",
            "description": "Participants in the control arm will receive standard of care treatment. Standard of care includes medical treatment at Landspitali University Hospital, and optional cancer rehabilitation at the Ljósið Cancer Rehabilitation Center.",
            "interventionNames": [
              "Other: Standard of care for patients with Cancer"
            ]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "A digital solution for patients with Cancer",
            "description": "A digital program that provides holistic lifestyle intervention as well as disease education.",
            "armGroupLabels": ["Digital intervention group"],
            "otherNames": [
              "SK-411 - General Oncology Program; PC-SK-451 Prostate Cancer program; CRC-SK-441; Colorectal Cancer Program LC-SK-431; Lung Cancer Program"
            ]
          },
          {
            "type": "OTHER",
            "name": "Standard of care for patients with Cancer",
            "description": "Standard of care includes medical treatment at Landspitali University Hospital, and optional cancer rehabilitation at the Ljósið Cancer Rehabilitation Center.",
            "armGroupLabels": [
              "Digital intervention group",
              "Standard of care - control group"
            ]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Cancer-specific Quality of Life",
            "description": "Difference in change in total score of the 30-item European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30) between the intervention and control groups.\n\nThe EORTC-QLQ-C30 is a 30-item questionnaire. It is composed of 28 questions with a Likert scale of 4 options where 1 represents \"not at all\" to 4 \"very much\", and 2 questions with a Likert scale of 7 options where 1 represents \"very poor\" to 7 \"excellent\". Scores on the QLQ-C30 range from 30 to 126, with a lower score representing a higher quality of life.",
            "timeFrame": "Baseline, 14 , 26, and 38 weeks after inclusion in the study"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Cancer-related fatigue derived from the general cancer questionnaire subscale",
            "description": "Difference in change in fatigue related subscale (questions 10, 12 and 18) of the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30) between the intervention and control groups.\n\nThe fatigue subscale consists of questions 10, 12, and 18 of EORTC-QLQ-C30. These 3 questions are scored on a Likert scale of 4 options where 1 represents \"not at all\" to 4 \"very much\". Scores on the fatigue subscale range from 3 to 12, with a low score representing a low level of fatigue.",
            "timeFrame": "Baseline, 14 , 26, and 38 weeks after inclusion in the study"
          },
          {
            "measure": "Cancer-related fatigue",
            "description": "Difference in change in the total score on the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Fatigue Module (EORTC-QLQ-FA12) between the intervention and control groups.\n\nThis 12-item questionnaire assesses physical-, cognitive- and emotional fatigue, the questionnaire is composed of 12 questions with a Likert scale of 4 options where 1 represents \"not at all\" to 4 \"very much\". Scores on the EORTC-QLQ-FA12 range from 12 to 48, with a lower score representing less fatigue.",
            "timeFrame": "Baseline, 14 , 26, and 38 weeks after inclusion in the study"
          },
          {
            "measure": "Health-related quality of life of prostate cancer patients",
            "description": "Difference in change in the scores on the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire for Prostate Cancer (EORTC-QLQ-PR25) between the prostate cancer patients in the intervention and control groups.\n\nThe EORTC QLQ-PR25 questionnaire assesses symptoms related to prostate cancer, its treatment, and aspects of life related to this type of cancer. It consists of 25 questions with a Likert scale of 4 options where 1 represents \"not at all,\" to 4 \"very.\" The questions included in the questionnaire are grouped into symptom scales (questions 1 to 19) and functional scales (questions 20-25).\n\nFor the EORTC QLQ-PR25 questionnaire, a higher score on the symptomatic scales means a greater severity of symptoms, while a higher score on question 20-22 and a lower score on questions 23-25 of the functional scales means a higher level of functioning.",
            "timeFrame": "Baseline, 14 , 26, and 38 weeks after inclusion in the study"
          },
          {
            "measure": "Health-related quality of life of lung cancer patients",
            "description": "Difference in change in the total score on the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire for Lung Cancer (EORTC-QLQ-LC13) between the lung cancer patients in the intervention and control groups.\n\nThe EORTC-QLQ-LC13 is a 13-item questionnaire. It is composed of 13 questions with a Likert scale of 4 options where 1 represents \"not at all\" to 4 \"very much\". Scores on the EORTC-QLQ-LC13 range from 13 to 52, with a lower score representing a higher quality of life.",
            "timeFrame": "Baseline, 14 , 26, and 38 weeks after inclusion in the study"
          },
          {
            "measure": "Health-related quality of life of colorectal cancer patients",
            "description": "Difference in change in the total score on the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire for Colorectal Cancer (EORTC-QLQ-CR29) between the colorectal cancer patients in the intervention and control groups.\n\nThe EORTC-QLQ-CR29 is a 29-item questionnaire. It is composed of 29 questions with a Likert scale of 4 options where 1 represents \"not at all\" to 4 \"very much\", with some of these questions specific for people with or without a stoma bag, and two specific questions for each sex. Scores on the EORTC-QLQ-CR29 range from 25 to 104 with a lower score (on all but one of the two specific questions for each sex) representing a higher quality of life.",
            "timeFrame": "Baseline, 14 , 26, and 38 weeks after inclusion in the study"
          },
          {
            "measure": "Depression, anxiety, and stress levels",
            "description": "Difference in change in the total score of the 21-item Depression, Anxiety and Stress Scale (DASS21) questionnaire between the intervention and control group.\n\nEach question has a Likert scale of 4 options where 0 represents \"did not apply to me\" to 3 \"applied to me very much\". The scores on the subscales range from 0 to 63, and low scores indicate a better mental health status.",
            "timeFrame": "Baseline and 14 weeks after inclusion in the study"
          },
          {
            "measure": "Cancer- and treatment-specific side effects",
            "description": "Evaluate the difference in cancer- and treatment-specific side effects in the intervention group between baseline and end of intervention.\n\nSide effects are measured through in-app patient reported outcomes (PROs): patients evaluate their symptoms, grading them on a scale of 1 to 10, where low scores indicate the mildest symptoms and high scores indicate the most severe symptoms.",
            "timeFrame": "Baseline and 14 weeks after inclusion in the study"
          },
          {
            "measure": "Sleep, energy, and stress levels",
            "description": "Evaluate the difference in sleep, energy, and stress levels in the intervention group between base line and end of intervention.\n\nSleep, energy, and stress levels are measured through in-app patient reported outcomes (PROs). Patients score their sleep, energy, and stress levels, grading them on a scale of 1 to 10. Low scores indicate poor sleep quality, low energy levels, and low stress levels. High scores indicate good sleep quality, high energy levels, and stress levels.",
            "timeFrame": "Baseline and 14 weeks after inclusion in the study"
          },
          {
            "measure": "Self-assessed health-related quality of life for health economic evaluation",
            "description": "Difference in change in total score of the self-assessed EuroQuol Five Dimension - Five Level (EQ-5D-5L) health questionnaire between the intervention and control groups EQ-E5-5L scores range from -0.530 to 1, with higher scores indicating a better health status. A score of 1 indicates full health.",
            "timeFrame": "Baseline, 14 , 26, and 38 weeks after inclusion in the study"
          },
          {
            "measure": "Patients' disease related self-efficacy",
            "description": "Difference in change in a 6-item Self-Efficacy for Managing Chronic Disease questionnaire (SEMCD) score between the intervention and control groups.\n\nThe SEMCD covers several domains that are common across many chronic diseases, such as symptom control, role function, emotional functioning, and communicating with physicians.\n\nThe SEMCD questionnaire is composed of 6 questions with Likert scales of 10 options where 1 represents \"not at all confident\" to 10 \"totally confident\". Scores on the SEMCD range from 6 to 60, with a higher score representing a higher self-efficacy.",
            "timeFrame": "Baseline and 14 weeks after inclusion in the study"
          },
          {
            "measure": "User satisfaction in intervention group",
            "description": "Scores in the mHealth App Usability Questionnaire (MAUQ) of the intervention group.\n\nThe MAUQ is an 18-item questionnaire. It is composed of questions with Likert scales of 7 options where 1 represents \"strongly disagree\" to 7 \"strongly agree\". Scores on the MAUQ range from 18 to 126, with a higher score representing a higher usability.",
            "timeFrame": "14 weeks"
          },
          {
            "measure": "User retention",
            "description": "Percentage of participants that will complete the digital intervention (DTx) program. Where \"complete\" is defined as finishing 75% of program.",
            "timeFrame": "14 weeks"
          },
          {
            "measure": "User engagement",
            "description": "Percentage of participants that are active in the digital intervention (DTx) program. Where \"active\" is defined as visiting the app at least once per week.",
            "timeFrame": "14 weeks"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* Adults (at least 18 years of age) diagnosed with cancer\n* Has started active cancer treatment (chemotherapy, hormonal therapy, targeted therapy, immunotherapy, radiotherapy) during the study\n* Cancer diagnosis (all stages), with a focus on prostate cancer, lung cancer, or colorectal cancer\n* Understands verbal and written Icelandic or English\n* Owning a smartphone compatible with the Sidekick Health app and capable of using it.\n* Capacity to give informed consent\n* Willing to comply with all scheduled visits, study interventions, and procedures\n\nExclusion Criteria:\n\n* Pregnancy\n* Surgeries in the last 4 weeks prior to participation in the study\n* Surgeries planned during the 14-weeks intervention\n* Not able to comply with study intervention or scheduled measures and visits, as assessed by oncologist\n* Current breast cancer diagnosis",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "facility": "Landspitali University Hospital",
            "city": "Reykjavik",
            "zip": "101",
            "country": "Iceland",
            "geoPoint": { "lat": 64.13548, "lon": -21.89541 }
          },
          {
            "facility": "Ljósið Cancer Rehabilitation Center",
            "city": "Reykjavik",
            "zip": "104",
            "country": "Iceland",
            "geoPoint": { "lat": 64.13548, "lon": -21.89541 }
          }
        ]
      },
      "ipdSharingStatementModule": {
        "ipdSharing": "NO",
        "description": "Anonymized Individual Participant Data may be shared with other researchers for relevant research purposes following complementary ethical review and approval from the Ethical Review Board."
      }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [
          { "id": "D011471", "term": "Prostatic Neoplasms" },
          { "id": "D015179", "term": "Colorectal Neoplasms" }
        ],
        "ancestors": [
          { "id": "D009371", "term": "Neoplasms by Site" },
          { "id": "D009369", "term": "Neoplasms" },
          { "id": "D005834", "term": "Genital Neoplasms, Male" },
          { "id": "D014565", "term": "Urogenital Neoplasms" },
          { "id": "D005832", "term": "Genital Diseases, Male" },
          { "id": "D000091662", "term": "Genital Diseases" },
          { "id": "D000091642", "term": "Urogenital Diseases" },
          { "id": "D011469", "term": "Prostatic Diseases" },
          { "id": "D052801", "term": "Male Urogenital Diseases" },
          { "id": "D007414", "term": "Intestinal Neoplasms" },
          { "id": "D005770", "term": "Gastrointestinal Neoplasms" },
          { "id": "D004067", "term": "Digestive System Neoplasms" },
          { "id": "D004066", "term": "Digestive System Diseases" },
          { "id": "D005767", "term": "Gastrointestinal Diseases" },
          { "id": "D003108", "term": "Colonic Diseases" },
          { "id": "D007410", "term": "Intestinal Diseases" },
          { "id": "D012002", "term": "Rectal Diseases" }
        ],
        "browseLeaves": [
          { "id": "M11172", "name": "Lung Neoplasms", "relevance": "LOW" },
          {
            "id": "M14335",
            "name": "Prostatic Neoplasms",
            "asFound": "Prostate Cancer",
            "relevance": "HIGH"
          },
          {
            "id": "M17890",
            "name": "Colorectal Neoplasms",
            "asFound": "Colorectal Cancer",
            "relevance": "HIGH"
          },
          {
            "id": "M8946",
            "name": "Genital Neoplasms, Male",
            "relevance": "LOW"
          },
          {
            "id": "M17315",
            "name": "Urogenital Neoplasms",
            "relevance": "LOW"
          },
          { "id": "M2876", "name": "Genital Diseases", "relevance": "LOW" },
          {
            "id": "M8944",
            "name": "Genital Diseases, Male",
            "relevance": "LOW"
          },
          { "id": "M2875", "name": "Urogenital Diseases", "relevance": "LOW" },
          { "id": "M14333", "name": "Prostatic Diseases", "relevance": "LOW" },
          {
            "id": "M27095",
            "name": "Male Urogenital Diseases",
            "relevance": "LOW"
          },
          {
            "id": "M10448",
            "name": "Intestinal Neoplasms",
            "relevance": "LOW"
          },
          {
            "id": "M8886",
            "name": "Gastrointestinal Neoplasms",
            "relevance": "LOW"
          },
          {
            "id": "M7256",
            "name": "Digestive System Neoplasms",
            "relevance": "LOW"
          },
          {
            "id": "M8883",
            "name": "Gastrointestinal Diseases",
            "relevance": "LOW"
          },
          {
            "id": "M7255",
            "name": "Digestive System Diseases",
            "relevance": "LOW"
          },
          { "id": "M6336", "name": "Colonic Diseases", "relevance": "LOW" },
          { "id": "M10444", "name": "Intestinal Diseases", "relevance": "LOW" },
          { "id": "M14844", "name": "Rectal Diseases", "relevance": "LOW" },
          { "id": "T6034", "name": "Quality of Life", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "BC04", "name": "Neoplasms" },
          {
            "abbrev": "BC08",
            "name": "Respiratory Tract (Lung and Bronchial) Diseases"
          },
          { "abbrev": "All", "name": "All Conditions" },
          {
            "abbrev": "BXS",
            "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
          },
          { "abbrev": "BC06", "name": "Digestive System Diseases" },
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" }
        ]
      },
      "interventionBrowseModule": {
        "browseLeaves": [
          {
            "id": "M21860",
            "name": "Pharmaceutical Solutions",
            "relevance": "LOW"
          }
        ],
        "browseBranches": [
          { "abbrev": "PhSol", "name": "Pharmaceutical Solutions" },
          { "abbrev": "All", "name": "All Drugs and Chemicals" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT04573296",
        "orgStudyIdInfo": { "id": "0001" },
        "organization": { "fullName": "Vitadio s.r.o.", "class": "INDUSTRY" },
        "briefTitle": "Impact of Digital Therapeutic on Metabolic Parameters",
        "officialTitle": "Impact of Digital Therapeutic Intervention on Metabolic Parameters in Obese Adults With Insulin Resistance, Prediabetes and Type 2 Diabetes as Compared to Conventional Intensive Obesity Management Programme"
      },
      "statusModule": {
        "statusVerifiedDate": "2023-08",
        "overallStatus": "COMPLETED",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2020-02-26", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2022-11-30",
          "type": "ACTUAL"
        },
        "completionDateStruct": { "date": "2022-11-30", "type": "ACTUAL" },
        "studyFirstSubmitDate": "2020-09-29",
        "studyFirstSubmitQcDate": "2020-10-01",
        "studyFirstPostDateStruct": { "date": "2020-10-05", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2023-08-30",
        "lastUpdatePostDateStruct": { "date": "2023-08-31", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": { "name": "Vitadio s.r.o.", "class": "INDUSTRY" },
        "collaborators": [
          { "name": "University Hospital Olomouc", "class": "OTHER" }
        ]
      },
      "oversightModule": {
        "oversightHasDmc": true,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": false
      },
      "descriptionModule": {
        "briefSummary": "The purpose of this prospective randomized controlled study is to evaluate the impact of a six-month digitally administered behavioral change program on body weight, glycemic control and other metabolic parameters in obese adults with insulin resistance, prediabetes or type 2 diabetes as compared to conventional high-intensity lifestyle intervention program administered at a specialized department of a university hospital.",
        "detailedDescription": "In this prospective randomized clinical study, obese adults with insulin resistance, prediabetes or diabetes mellitus type 2, patients of the Department of Exercise Medicine and Cardiovascular Rehabilitation at the University Hospital Olomouc, are randomized to receive either Vitadio or a conventional 6-month high-intensity lifestyle intervention program at the clinic.\n\nVitadio is a mobile application delivering behavioral change program focused on lifestyle change and self-management. The program aims for strengthening patients autonomy with the goal to promote weight loss and improve metabolic health. The program includes personalized education, adaptive daily tasks and weekly goals, automated motivational and educational messaging, monitoring tools, recipes, peer-support group and one-on-one remote coaching. Personalization of the intervention is achieved by analyzing participant's interactions with the application.\n\nThe conventional therapy consists of 5 face-to-face nutrition/lifestyle education sessions (at baseline, at 1st, 2nd and 3rd month, and at month 6). Participants in the control group can use an online diary tool for recording meals with an option to receive remote feedback on their diet from the educator. In addition, all participants undergo a regular medical assessment at the clinic (baseline, month 3, month 6).\n\nThe aim of the study is to assess feasibility and efficacy of digitally administered intervention by comparing evolution of weight, physical fitness, laboratory measures of metabolic health, blood pressure and other outcomes."
      },
      "conditionsModule": {
        "conditions": [
          "Insulin Resistance",
          "Prediabetic State",
          "Diabetes Mellitus, Type 2",
          "Obesity"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "interventionModelDescription": "This prospective randomized controlled study evaluates efficacy of lifestyle intervention using digital application Vitadio as compared to conventional high-intensity lifestyle intervention program administered at a specialized clinic at a University hospital.",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": { "masking": "NONE" }
        },
        "enrollmentInfo": { "count": 100, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "Participants using Vitadio",
            "type": "EXPERIMENTAL",
            "description": "Participants in the intervention arm undergo a 6-month digitally administered behavioral change program Vitadio focused on lifestyle change and self-management. The program aims for strengthening patients autonomy with the goal to promote weight loss and improve metabolic health. The program includes personalized education, adaptive daily tasks and weekly goals, automated motivational and educational messaging, monitoring tools, recipes, peer-support group and one-on-one remote coaching. In addition, they undergo regular face-to-face medical assessment.",
            "interventionNames": ["Device: Vitadio"]
          },
          {
            "label": "Participants assigned to conventional high-intensity lifestyle intervention program",
            "type": "ACTIVE_COMPARATOR",
            "description": "Participants in the control group undergo a 6-month high-intensity lifestyle intervention program consisting of of 5 face-to-face nutrition/lifestyle education sessions. Participants can use an online diary tool for recording meals with an option to receive remote feedback on their diet from the educator. In addition, they undergo regular face-to-face medical assessment.",
            "interventionNames": [
              "Behavioral: Conventional high-intensity lifestyle intervention program"
            ]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "Vitadio",
            "description": "A 6-month digitally administered behavioral change program Vitadio focus on lifestyle change and self-management. The program aims for strengthening patients autonomy with the goal to promote weight loss and improve metabolic health. The program includes personalized education, adaptive daily tasks and weekly goals, automated motivational and educational messaging, monitoring tools, recipes, peer-support group and remote coaching.",
            "armGroupLabels": ["Participants using Vitadio"]
          },
          {
            "type": "BEHAVIORAL",
            "name": "Conventional high-intensity lifestyle intervention program",
            "description": "A 6-month high-intensity lifestyle intervention program consisting of 5 face-to-face nutrition/lifestyle education sessions. Participants can use an online diary tool for recording meals with an option to receive remote feedback on their diet from the educator.",
            "armGroupLabels": [
              "Participants assigned to conventional high-intensity lifestyle intervention program"
            ]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Change in body weight",
            "description": "comparison of baseline and end program body weight",
            "timeFrame": "baseline, three months, six months"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "change in waist circumference",
            "description": "comparison of baseline, three-month and end-program waist circumference between groups",
            "timeFrame": "baseline, three months, six months"
          },
          {
            "measure": "change in body mass index (BMI)",
            "description": "comparison of baseline, three-month and end-program body mass index (BMI) between groups",
            "timeFrame": "baseline, three months, six months"
          },
          {
            "measure": "change in haemoglobin A1c",
            "description": "comparison of baseline, three-month and end-program haemoglobin A1c values between groups",
            "timeFrame": "baseline, three months, six months"
          },
          {
            "measure": "change in adherence to lifestyle intervention",
            "description": "comparison of baseline, three-month and end-program adherence to healthy lifestyle assigned both by subjective (adapted questionnaire) and objective (program usage frequency, attrition) measures between groups",
            "timeFrame": "baseline, three months, six months"
          },
          {
            "measure": "change in blood glucose",
            "description": "comparison of baseline, three-month and end-program blood glucose values between groups",
            "timeFrame": "baseline, three months, six months"
          },
          {
            "measure": "change in insulin resistance",
            "description": "comparison of baseline, three-month and end-program insulin resistance quantified by HOMA-IR between groups",
            "timeFrame": "baseline, three months, six months"
          },
          {
            "measure": "change in blood pressure",
            "description": "comparison of baseline, three-month and end-program blood pressure between groups",
            "timeFrame": "baseline, three months, six months"
          },
          {
            "measure": "change in body composition",
            "description": "comparison of baseline, three-month and end-program body composition assessed with the InBody bioelectrical impedance analysis device between groups",
            "timeFrame": "baseline, three months, six months"
          },
          {
            "measure": "change in resting metabolic rate (RMR)",
            "description": "comparison of baseline, three-month and end-program resting metabolic rate assessed by indirect calorimetry between groups",
            "timeFrame": "baseline, three months, six months"
          },
          {
            "measure": "change in cardiorespiratory fitness",
            "description": "comparison of baseline, three-month and end-program cardiorespiratory fitness assessed by spiroergometry between groups",
            "timeFrame": "baseline, three months, six months"
          },
          {
            "measure": "change in lipid parameters (total cholesterol, LDL-cholesterol, HDL-cholesterol and triglycerides)",
            "description": "comparison of baseline, three-month and end-program levels of total cholesterol, LDL-cholesterol, HDL-cholesterol and triglycerides between groups",
            "timeFrame": "baseline, three months, six months"
          },
          {
            "measure": "change in fasting insulin levels",
            "description": "comparison of baseline, three-month and end-program fasting insulin levels between groups",
            "timeFrame": "baseline, three months, six months"
          },
          {
            "measure": "change in liver function tests",
            "description": "comparison of baseline, three-month and end-program standard liver panel (ALT, AST, GGT, ALP) values between groups",
            "timeFrame": "baseline, three months, six months"
          }
        ],
        "otherOutcomes": [
          {
            "measure": "Vitadio usability for HCPs",
            "description": "The healthcare professionals' (HCPs) user experience from interacting with Vitadio Health, assessed with the User Experience Questionnaire (UEQ)",
            "timeFrame": "six months"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* obesity with body mass index (BMI) above 30 kg/m\\^2\n* insulin resistance or prediabetes or type 2 diabetes mellitus\n* acess to device with internet access (notebook, smartphone, tablet)\n* willingness and ability to comply with all scheduled visits, laboratory tests, lifestyle considerations and other study procedures\n\nExclusion Criteria:\n\n* pregnancy\n* steroid treatment\n* type 2 diabetes mellitus on insulin therapy\n* severe renal and/or hepatic impairment\n* any impairments including mental and psychological or conditions which, in the opinion of the investigator, would seriously compromise the integrity of the study\n* inability to understand, consent to, or comply with the study protocol for any reason, including inability to read or comprehend Czech language\n* inability to comply with study procedures",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "maximumAge": "65 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "Katarína Moravcová, MD",
            "affiliation": "University Hospital Olomouc",
            "role": "PRINCIPAL_INVESTIGATOR"
          }
        ],
        "locations": [
          {
            "facility": "University Hospital Olomouc",
            "city": "Olomouc",
            "zip": "779 00",
            "country": "Czechia",
            "geoPoint": { "lat": 49.59552, "lon": 17.25175 }
          }
        ]
      }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [
          { "id": "D009765", "term": "Obesity" },
          { "id": "D003924", "term": "Diabetes Mellitus, Type 2" },
          { "id": "D007333", "term": "Insulin Resistance" },
          { "id": "D011236", "term": "Prediabetic State" }
        ],
        "ancestors": [
          { "id": "D050177", "term": "Overweight" },
          { "id": "D044343", "term": "Overnutrition" },
          { "id": "D009748", "term": "Nutrition Disorders" },
          { "id": "D001835", "term": "Body Weight" },
          { "id": "D003920", "term": "Diabetes Mellitus" },
          { "id": "D044882", "term": "Glucose Metabolism Disorders" },
          { "id": "D008659", "term": "Metabolic Diseases" },
          { "id": "D004700", "term": "Endocrine System Diseases" },
          { "id": "D006946", "term": "Hyperinsulinism" }
        ],
        "browseLeaves": [
          {
            "id": "M12701",
            "name": "Obesity",
            "asFound": "Obesity",
            "relevance": "HIGH"
          },
          {
            "id": "M10370",
            "name": "Insulin Resistance",
            "asFound": "Insulin Resistance",
            "relevance": "HIGH"
          },
          { "id": "M7115", "name": "Diabetes Mellitus", "relevance": "LOW" },
          {
            "id": "M7119",
            "name": "Diabetes Mellitus, Type 2",
            "asFound": "Diabetes Mellitus, Type 2",
            "relevance": "HIGH"
          },
          { "id": "M20295", "name": "Glucose Intolerance", "relevance": "LOW" },
          {
            "id": "M14117",
            "name": "Prediabetic State",
            "asFound": "Prediabetic State",
            "relevance": "HIGH"
          },
          { "id": "M26186", "name": "Overweight", "relevance": "LOW" },
          { "id": "M25307", "name": "Overnutrition", "relevance": "LOW" },
          { "id": "M12684", "name": "Nutrition Disorders", "relevance": "LOW" },
          { "id": "M5114", "name": "Body Weight", "relevance": "LOW" },
          { "id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW" },
          {
            "id": "M25403",
            "name": "Glucose Metabolism Disorders",
            "relevance": "LOW"
          },
          {
            "id": "M7862",
            "name": "Endocrine System Diseases",
            "relevance": "LOW"
          },
          { "id": "M9997", "name": "Hyperinsulinism", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "BC18", "name": "Nutritional and Metabolic Diseases" },
          { "abbrev": "BC23", "name": "Symptoms and General Pathology" },
          { "abbrev": "All", "name": "All Conditions" },
          { "abbrev": "BC19", "name": "Gland and Hormone Related Diseases" }
        ]
      },
      "interventionBrowseModule": {
        "browseLeaves": [
          { "id": "M10365", "name": "Insulin", "relevance": "LOW" },
          {
            "id": "M173166",
            "name": "Insulin, Globin Zinc",
            "relevance": "LOW"
          }
        ],
        "browseBranches": [
          { "abbrev": "Hypo", "name": "Hypoglycemic Agents" },
          { "abbrev": "All", "name": "All Drugs and Chemicals" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT04542642",
        "orgStudyIdInfo": { "id": "PEAR-008-101" },
        "secondaryIdInfos": [
          {
            "id": "R44DA042652",
            "type": "NIH",
            "link": "https://reporter.nih.gov/quickSearch/R44DA042652"
          }
        ],
        "organization": {
          "fullName": "Pear Therapeutics, Inc.",
          "class": "INDUSTRY"
        },
        "briefTitle": "A Remote, Decentralized Opioid Use Disorder Study to Evaluate Patient Engagement With a Game-Based Digital Therapeutic",
        "officialTitle": "A Randomized, Controlled, Open-Label, Decentralized Study, to Evaluate Patient Engagement With PEAR-008, a Game-Based Digital Therapeutic for the Treatment of Opioid Use Disorder"
      },
      "statusModule": {
        "statusVerifiedDate": "2022-12",
        "overallStatus": "COMPLETED",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2021-05-19", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2022-11-16",
          "type": "ACTUAL"
        },
        "completionDateStruct": { "date": "2022-11-23", "type": "ACTUAL" },
        "studyFirstSubmitDate": "2020-08-27",
        "studyFirstSubmitQcDate": "2020-09-02",
        "studyFirstPostDateStruct": { "date": "2020-09-09", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2022-12-13",
        "lastUpdatePostDateStruct": { "date": "2022-12-14", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": {
          "name": "Pear Therapeutics, Inc.",
          "class": "INDUSTRY"
        },
        "collaborators": [
          {
            "name": "Addiction Research and Education Foundation (AREF)",
            "class": "UNKNOWN"
          },
          {
            "name": "Research Foundation for Mental Hygiene, Inc.",
            "class": "OTHER"
          },
          { "name": "National Institute on Drug Abuse (NIDA)", "class": "NIH" }
        ]
      },
      "oversightModule": {
        "oversightHasDmc": true,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": true,
        "isUnapprovedDevice": true,
        "isUsExport": false
      },
      "descriptionModule": {
        "briefSummary": "The purpose of this study is to evaluate how patients use and engage with a game-based mobile application that is designed to treat opioid use disorder.",
        "detailedDescription": "This is a randomized, controlled, open-label, decentralized study to evaluate patient engagement with PEAR-008, a game-based digital therapeutic for the treatment of opioid use disorder.\n\nPEAR-008 is a new version of reSET-O, an FDA-authorized mobile application treatment (available by prescription only) for opioid use disorder. The study will examine if changing the application's delivery format and enhancing clinical content affects how patients use and interact with the intervention.\n\nProspective participants will complete a short screening assessment and if eligible complete informed consent procedures at the beginning of the Baseline visit. Qualifying participants will attend weekly virtual study visits during the 8-week treatment period.\n\nIn addition to weekly assessments, additional assessments will be administered at week 4 and week 8. Participants will be asked to complete a follow-up assessment 4 weeks after completing treatment."
      },
      "conditionsModule": {
        "conditions": ["Opioid-use Disorder"],
        "keywords": ["digital therapeutic"]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "interventionModelDescription": "Participants will be randomly assigned to receive either the game-based treatment (PEAR-008) or the original, FDA-authorized treatment (reSET-O).",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": {
            "masking": "SINGLE",
            "maskingDescription": "Independent Outcomes Assessor will conduct data analysis and be blinded to intervention assignments.",
            "whoMasked": ["OUTCOMES_ASSESSOR"]
          }
        },
        "enrollmentInfo": { "count": 52, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "reSET-O",
            "type": "ACTIVE_COMPARATOR",
            "description": "Prescription Digital therapeutic",
            "interventionNames": ["Device: reSET-O"]
          },
          {
            "label": "PEAR-008",
            "type": "EXPERIMENTAL",
            "description": "Investigational Digital Therapeutic",
            "interventionNames": ["Device: PEAR-008"]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "reSET-O",
            "description": "reSET-O is an FDA-authorized mobile application treatment for opioid use disorder.",
            "armGroupLabels": ["reSET-O"]
          },
          {
            "type": "DEVICE",
            "name": "PEAR-008",
            "description": "PEAR-008 is a new, game-based version of reSET-O, a mobile application treatment for opioid use disorder.",
            "armGroupLabels": ["PEAR-008"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Evaluate Participant Engagement Data",
            "description": "Evaluate the number of active sessions per week between PEAR-008 and reSET-O",
            "timeFrame": "From Week 1 to Week 8 (End of Treatment)"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Evaluate Treatment Retention Based on Drop-Out Rates",
            "description": "Evaluate if PEAR-008 increases retention in treatment compared to reSET-O by comparing drop-out rates",
            "timeFrame": "Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7, Week 8 (End of Treatment), Week 12 (Follow-up)"
          },
          {
            "measure": "Evaluate Illicit Drug Abstinence",
            "description": "Evaluate if PEAR-008 increases abstinence compared to reSET-O, as measured by saliva drug screens, urine drug screens and self-reporting",
            "timeFrame": "Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7, Week 8 (End of Treatment), Week 12 (Follow-up)"
          },
          {
            "measure": "Evaluate Digital Therapeutic Use Patterns Based on Usage Data",
            "description": "Evaluate participants' digital therapeutic use patterns based on usage data collected, comparing PEAR-008 to reSET-O",
            "timeFrame": "From Week 1 to Week 8 (End of Treatment)"
          },
          {
            "measure": "Assess Effect on Depressive Symptoms",
            "description": "Assess the effect of PEAR-008 and reSET-O on depressive symptoms using the eight-item Patient Health Questionnaire (PHQ-8) scores from Baseline to End of Treatment and Follow-up. The PHQ's total score ranges from 0 (not clinically significant) to 24 (clinically significant)",
            "timeFrame": "Baseline, Week 4, Week 8 (End of Treatment), Week 12 (Follow-up)"
          },
          {
            "measure": "Assess Effect on Anxiety Symptoms",
            "description": "Assess the effect of PEAR-008 and reSET-O on anxiety symptoms using the Generalized Anxiety Disorder-7's (GAD-7) scores from Baseline to End of Treatment and Follow-up. The GAD-7's total score ranges from 0 (not clinically significant) to 21 (clinically significant)",
            "timeFrame": "Baseline, Week 4, Week 8 (End of Treatment), Week 12 (Follow-up)"
          },
          {
            "measure": "Assess Effect on Recovery Capital",
            "description": "Assess the effect of PEAR-008 and reSET-O on recovery capital using the ten-item Brief Assessment of Recovery Capital (BARC-10) scores from Baseline to End of Treatment and Follow-up. The BARC-10's total score ranges from 10 to 60",
            "timeFrame": "Baseline, Week 4, Week 8 (End of Treatment), Week 12 (Follow-up)"
          },
          {
            "measure": "Describe Participant Satisfaction Surveys",
            "description": "Summarize participant satisfaction surveys and evaluate if PEAR-008 increases participant satisfaction in treatment compared to reSET-O through descriptive statistics",
            "timeFrame": "Baseline, Week 4, Week 8 (End of Treatment), Week 12 (Follow-up)"
          },
          {
            "measure": "Describe Participant Satisfaction Interviews",
            "description": "Summarize participant satisfaction interviews and evaluate if PEAR-008 increases participant satisfaction in treatment compared to reSET-O through descriptive statistics",
            "timeFrame": "Week 12 (Follow-up)"
          },
          {
            "measure": "Assess Coronavirus Disease (COVID-19) Impact",
            "description": "Assess the impact of the COVID-19 pandemic on participants using the five-item Council on American-Islamic Relations (CAIR) Pandemic Impact Questionnaire (C-PIQ) scores from Baseline to End of Treatment and Follow-up. The C-PIQ's total score ranges from 0 to 20",
            "timeFrame": "Baseline, Week 4, Week 8 (End of Treatment), Week 12 (Follow-up)"
          },
          {
            "measure": "Assess Coronavirus Disease (COVID-19) Impact on Stress",
            "description": "Assess the effect of the COVID-19 pandemic on depressive symptoms using the COPE: Coronavirus Perinatal Experiences - Impact Survey (COPE-IS) (MODIFIED) scores from Baseline to End of Treatment and Follow-up. Participants will be asked how they are coping with stress during COVID-19 from a list of responses. There is no scoring for this measure",
            "timeFrame": "Baseline, Week 4, Week 8 (End of Treatment), Week 12 (Follow-up)"
          },
          {
            "measure": "Assess Effect on Resilience",
            "description": "Assess the effect of PEAR-008 and reSET-O on resilience using the 10-item Connor-Davidson Resilience Scale 10 (CD-RISC-10) scores from Baseline to End of Treatment and Follow-up. The CD-RISC-10 is a 10-item self-rating scale using a 5-point Likert scale ranging from \"not true at all\" to \"true nearly all of the time\"",
            "timeFrame": "Baseline, Week 4, Week 8 (End of Treatment), Week 12 (Follow-up)"
          }
        ],
        "otherOutcomes": [
          {
            "measure": "Evaluate Engagement and Efficacy Relationship",
            "description": "Evaluate the correlation between engagement (daily and weekly participant use patterns of PEAR-008 and reSET-O) and treatment outcomes (abstinence and retention in treatment)",
            "timeFrame": "From Week 1 to Week 8 (End of Treatment), Week 12 (Follow-up)"
          },
          {
            "measure": "Change in Skill Acquisition",
            "description": "Assess the effect of PEAR-008 and reSET-O on changes in skill acquisition using the Cognitive-Behavioral Therapy Skills Questionnaire (CBTSQ) from Baseline to End of Treatment. The CBTSQ measures two factors: Behavioral Activation (BA) and Cognitive Restructuring (CR). BA factor scores range from 0 to 35, and higher scores indicate greater use of BA skills. CR factor scores range from 0 to 45, and higher scores indicate greater use of CR skills",
            "timeFrame": "Baseline, Week 4, Week 8 (End of Treatment), Week 12 (Follow-up)"
          },
          {
            "measure": "Medication Adherence Rates",
            "description": "Assess the effect of PEAR-008 and reSET-O on medication adherence rates using findings from saliva drug screens and urine drug screens",
            "timeFrame": "Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7, Week 8 (End of Treatment), Week 12 (Follow-up)"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* Provide informed consent prior to any study specific assessments being performed\n* Between 18 and 60 years old, inclusively\n* Proficient in English language\n* Within the first 120 days of starting buprenorphine treatment\n* Receiving buprenorphine pharmacotherapy under the care of a licensed healthcare provider and willing to provide the provider or practice name\n* Capable of using common software applications on a mobile device (smartphone)\n* Access to an internet-enabled smartphone for the duration of the study, meeting minimal operations systems (OS) requirements\n* Interest in using a digital therapeutic for Opioid-use Disorder\n* No prior history of reSET-O use\n* Has not participated in user testing of PEAR-008 or any investigational drug trials within the past 30 days of enrollment\n\nExclusion Criteria:\n\n* On methadone or naltrexone pharmacotherapy\n* Unable to use English to participate in the consent process, interventions, or assessments\n* Inability to comply with study procedures",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "maximumAge": "60 Years",
        "stdAges": ["ADULT"]
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "Aimee Campbell, PhD",
            "affiliation": "Columbia University",
            "role": "STUDY_DIRECTOR"
          },
          {
            "name": "Lisa Chiodo, PhD",
            "affiliation": "Addiction Research and Education Foundation",
            "role": "STUDY_DIRECTOR"
          }
        ],
        "locations": [
          {
            "facility": "The Substance and Treatment Research Service (STARS) at Columbia University Irving Medical Center and the New York State Psychiatric Institute",
            "city": "New York",
            "state": "New York",
            "zip": "10019",
            "country": "United States",
            "geoPoint": { "lat": 40.71427, "lon": -74.00597 }
          },
          {
            "facility": "Addiction Research and Education Foundation",
            "city": "Gig Harbor",
            "state": "Washington",
            "zip": "98335",
            "country": "United States",
            "geoPoint": { "lat": 47.32926, "lon": -122.58013 }
          }
        ]
      },
      "referencesModule": {
        "references": [
          {
            "pmid": "35080499",
            "type": "DERIVED",
            "citation": "Luderer H, Chiodo L, Wilson A, Brezing C, Martinez S, Xiong X, Gerwien R, Imbert B, Deeg M, Maricich Y, Campbell A. Patient Engagement With a Game-Based Digital Therapeutic for the Treatment of Opioid Use Disorder: Protocol for a Randomized Controlled Open-Label, Decentralized Trial. JMIR Res Protoc. 2022 Jan 26;11(1):e32759. doi: 10.2196/32759."
          }
        ]
      },
      "ipdSharingStatementModule": { "ipdSharing": "NO" }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [
          { "id": "D009293", "term": "Opioid-Related Disorders" },
          { "id": "D019966", "term": "Substance-Related Disorders" }
        ],
        "ancestors": [
          { "id": "D000079524", "term": "Narcotic-Related Disorders" },
          { "id": "D064419", "term": "Chemically-Induced Disorders" },
          { "id": "D001523", "term": "Mental Disorders" }
        ],
        "browseLeaves": [
          {
            "id": "M12244",
            "name": "Opioid-Related Disorders",
            "asFound": "Opioid Use Disorder",
            "relevance": "HIGH"
          },
          {
            "id": "M21837",
            "name": "Substance-Related Disorders",
            "asFound": "Opioid Use Disorder",
            "relevance": "HIGH"
          },
          {
            "id": "M2057",
            "name": "Narcotic-Related Disorders",
            "relevance": "LOW"
          },
          {
            "id": "M30302",
            "name": "Chemically-Induced Disorders",
            "relevance": "LOW"
          },
          { "id": "M14473", "name": "Psychotic Disorders", "relevance": "LOW" },
          { "id": "M4815", "name": "Mental Disorders", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "BC25", "name": "Substance Related Disorders" },
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" },
          { "abbrev": "All", "name": "All Conditions" }
        ]
      },
      "interventionBrowseModule": {
        "browseLeaves": [
          { "id": "M4033", "name": "Analgesics, Opioid", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "Analg", "name": "Analgesics" },
          { "abbrev": "CNSDep", "name": "Central Nervous System Depressants" },
          { "abbrev": "All", "name": "All Drugs and Chemicals" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT04326231",
        "orgStudyIdInfo": { "id": "PRO-003" },
        "organization": { "fullName": "Cognoa, Inc.", "class": "INDUSTRY" },
        "briefTitle": "Cognoa Autism Spectrum Disorder (ASD) Digital Therapeutic Engagement and Usability Study",
        "officialTitle": "Cognoa ASD Digital Therapeutic Engagement and Usability Study"
      },
      "statusModule": {
        "statusVerifiedDate": "2023-08",
        "overallStatus": "TERMINATED",
        "whyStopped": "COVID and the Study was withdrawn (limited recruitment within study timeline)",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2020-03-17", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2020-07-31",
          "type": "ACTUAL"
        },
        "completionDateStruct": { "date": "2020-07-31", "type": "ACTUAL" },
        "studyFirstSubmitDate": "2020-03-23",
        "studyFirstSubmitQcDate": "2020-03-26",
        "studyFirstPostDateStruct": { "date": "2020-03-30", "type": "ACTUAL" },
        "resultsFirstSubmitDate": "2021-10-27",
        "resultsFirstSubmitQcDate": "2023-08-28",
        "resultsFirstPostDateStruct": {
          "date": "2023-09-21",
          "type": "ACTUAL"
        },
        "lastUpdateSubmitDate": "2023-08-28",
        "lastUpdatePostDateStruct": { "date": "2023-09-21", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": { "name": "Cognoa, Inc.", "class": "INDUSTRY" }
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": true,
        "isUnapprovedDevice": true,
        "isUsExport": false
      },
      "descriptionModule": {
        "briefSummary": "Cognoa will measure usability, engagement with the device, and changes in parent-reported socialization during a 4-week period of intervention at home with the Cognoa ASD therapeutic device.",
        "detailedDescription": "Parents who consent will be given access to the study device through its caregiver and child-facing smartphone app that provides therapeutic content. In order to access the study device app, parents will be provided access to two other apps. The first is Testflight. TestFlight is an online service for over-the-air installation and testing of mobile applications, currently owned by Apple Inc.that allows users to test iOS apps before they are released to the App Store. Parents will also be provided access to the Cognoa for Child Development app in order to create an account as a means to gain access to the study device app. The parents will only be able to engage with the study device app once they have created an account in the Cognoa for Child for Development app"
      },
      "conditionsModule": { "conditions": ["Autism Spectrum Disorder"] },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "NA",
          "interventionModel": "SINGLE_GROUP",
          "primaryPurpose": "BASIC_SCIENCE",
          "maskingInfo": { "masking": "NONE" }
        },
        "enrollmentInfo": { "count": 10, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "Cognoa ASD Therapeutic Device",
            "type": "EXPERIMENTAL",
            "description": "Usability assessment of Cognoa ASD Therapeutic Device",
            "interventionNames": [
              "Device: Usability assessment of Cognoa ASD Therapeutic Device"
            ]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "Usability assessment of Cognoa ASD Therapeutic Device",
            "description": "Usability assessment of Cognoa ASD Therapeutic Device",
            "armGroupLabels": ["Cognoa ASD Therapeutic Device"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Vineland Adaptive Behavior Scales, Third Edition",
            "description": "Change was calculated on an average from all relevant time points used in the calculation in the Time Frame ( baseline assessment, 4 weeks of intervention 4-6 times a week, weekly surveys of usability, final assessment); These measures were not completed due to COVID\n\nChange in scores on the Vineland-3 domain level caregiver report social skills and relationships, measures of usability.\n\nQualitative descriptors: scores of 1 to 17 may be considered Average, 18 to 20 Elevated, and 21 to 24 Clinically Significant\n\nCaregivers partially completed their scores on the Vineland Adaptive Behavior Scales, Third Edition, This was due to COVID and not being able to complete the study.\n\n0 Caregivers had their scores analyzed as they were unable to complete the study due to COVID, this study was terminated.",
            "timeFrame": "Enrollment, baseline assessment, 4 weeks of intervention 4-6 times a week, weekly surveys of usability, final assessment; These measures were not completed due to COVID"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* Functional English language capability in the home environment.\n* Parent, Guardian, or legal authorized representative (LAR) must be able to read, understand and sign the Informed Consent Form (ICF)\n* Female or Male, \\> 3 to \\< 9 years of age and parent/caregiver\n* Diagnosis of Autism Spectrum Disorder, within the last 12 months\n* Parent, Guardian, or legal authorized representative (LAR) must have smartphone capabilities for downloading Testflight software; test versions of the Cognoa for Child development app; and test versions of the Cognoa Digital Therapeutic app (iOS 12.0 and up and Apple iPhone 8 and higher)\n\nExclusion Criteria:\n\n* Participants with any other medical, behavioral, or developmental condition that in the opinion of the investigator may confound study data/assessments.\n* Participants with planned extensive travel (more than 1 week) during the course of the 4 week intervention time period.\n* Participants with deafness or blindness.\n* Participants with known physical impairments affecting their ability to use their hands.\n* Participants with active diagnosis of epilepsy and uncontrolled seizures.\n* Participants whose age on the date of enrollment is outside the target age range",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "3 Years",
        "maximumAge": "8 Years",
        "stdAges": ["CHILD"]
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "Kelley Abrams, PhD",
            "affiliation": "Cognoa, Inc.",
            "role": "PRINCIPAL_INVESTIGATOR"
          }
        ],
        "locations": [
          {
            "facility": "Cognoa",
            "city": "Palo Alto",
            "state": "California",
            "zip": "94306",
            "country": "United States",
            "geoPoint": { "lat": 37.44188, "lon": -122.14302 }
          }
        ]
      }
    },
    "resultsSection": {
      "participantFlowModule": {
        "preAssignmentDetails": "The protocol enrollment number represents Child/Caregiver enrollment in the study.",
        "recruitmentDetails": "Withdrawn (limited recruitment within study timeline)",
        "groups": [
          {
            "id": "FG000",
            "title": "Cognoa ASD Therapeutic Device",
            "description": "Usability assessment of Cognoa ASD Therapeutic Device\n\nUsability assessment of Cognoa ASD Therapeutic Device: Usability assessment of Cognoa ASD Therapeutic Device"
          }
        ],
        "periods": [
          {
            "title": "Overall Study",
            "milestones": [
              {
                "type": "STARTED",
                "comment": "10 subjects represents Child/Caregiver pair",
                "achievements": [
                  {
                    "groupId": "FG000",
                    "comment": "Child/Caregiver pair",
                    "numSubjects": "10"
                  }
                ]
              },
              {
                "type": "COMPLETED",
                "comment": "10 subjects represents Child/Caregiver pair",
                "achievements": [
                  {
                    "groupId": "FG000",
                    "comment": "COVID Withdrawn",
                    "numSubjects": "0"
                  }
                ]
              },
              {
                "type": "NOT COMPLETED",
                "achievements": [{ "groupId": "FG000", "numSubjects": "10" }]
              }
            ],
            "dropWithdraws": [
              {
                "type": "COVID Withdrawn (limited recruitment within study timeline)",
                "reasons": [{ "groupId": "FG000", "numSubjects": "10" }]
              }
            ]
          }
        ]
      },
      "baselineCharacteristicsModule": {
        "populationDescription": "Up to 30 caregivers and children diagnosed with ASD ages \\> 3 to \\< 9 years of age will be recruited from across the U.S.\n\nBaseline data was only collected for children. This study was terminated data was not collected.\n\nZero participants completed the study due to COVID.",
        "groups": [
          {
            "id": "BG000",
            "title": "Cognoa ASD Therapeutic Device",
            "description": "Usability assessment of Cognoa ASD Therapeutic Device Usability assessment of Cognoa ASD Therapeutic Device: Usability assessment of Cognoa ASD Therapeutic Device"
          }
        ],
        "denoms": [
          {
            "units": "Participants",
            "counts": [{ "groupId": "BG000", "value": "0" }]
          }
        ],
        "measures": [
          {
            "title": "Age, Categorical",
            "description": "Study was terminated and data was not collected.",
            "calculatePct": false,
            "classes": [
              {
                "categories": [
                  { "title": "<=18 years" },
                  { "title": "Between 18 and 65 years" },
                  { "title": ">=65 years" }
                ]
              }
            ]
          },
          {
            "title": "Sex: Female, Male",
            "description": "Study was terminated and data was not collected.",
            "classes": [
              { "categories": [{ "title": "Female" }, { "title": "Male" }] }
            ]
          },
          {
            "title": "Race and Ethnicity Not Collected",
            "populationDescription": "Race and Ethnicity were not collected from any participant."
          },
          {
            "title": "Region of Enrollment",
            "description": "Study was terminated and data was not collected.",
            "unitOfMeasure": "participants",
            "classes": [{ "title": "United States" }]
          }
        ]
      },
      "outcomeMeasuresModule": {
        "outcomeMeasures": [
          {
            "type": "PRIMARY",
            "title": "Vineland Adaptive Behavior Scales, Third Edition",
            "description": "Change was calculated on an average from all relevant time points used in the calculation in the Time Frame ( baseline assessment, 4 weeks of intervention 4-6 times a week, weekly surveys of usability, final assessment); These measures were not completed due to COVID\n\nChange in scores on the Vineland-3 domain level caregiver report social skills and relationships, measures of usability.\n\nQualitative descriptors: scores of 1 to 17 may be considered Average, 18 to 20 Elevated, and 21 to 24 Clinically Significant\n\nCaregivers partially completed their scores on the Vineland Adaptive Behavior Scales, Third Edition, This was due to COVID and not being able to complete the study.\n\n0 Caregivers had their scores analyzed as they were unable to complete the study due to COVID, this study was terminated.",
            "populationDescription": "0 Caregivers completed their scores on the Vineland Adaptive Behavior Scales, Third Edition, This was due to COVID and not being able to complete the study. This study was terminated. Data were not collected due to early termination of the study.",
            "reportingStatus": "POSTED",
            "timeFrame": "Enrollment, baseline assessment, 4 weeks of intervention 4-6 times a week, weekly surveys of usability, final assessment; These measures were not completed due to COVID",
            "groups": [
              {
                "id": "OG000",
                "title": "Caregivers",
                "description": "Caregivers and female and male participants between the ages \\>3 years and \\< 9 years of age on date of enrollment from a general population diagnosed with ASD"
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [{ "groupId": "OG000", "value": "0" }]
              }
            ]
          }
        ]
      },
      "adverseEventsModule": {
        "frequencyThreshold": "0",
        "timeFrame": "This study was terminated. no adverse events were not collected due to early termination of the study.",
        "description": "This study was terminated. no adverse events were not collected due to early termination of the study.",
        "eventGroups": [
          {
            "id": "EG000",
            "title": "Primary",
            "description": "Usability of Cognoa ASD Therapeutic Device\n\nZero subjects completed the study due to COVID.",
            "deathsNumAffected": 0,
            "deathsNumAtRisk": 0,
            "seriousNumAffected": 0,
            "seriousNumAtRisk": 0,
            "otherNumAffected": 0,
            "otherNumAtRisk": 0
          }
        ]
      },
      "moreInfoModule": {
        "certainAgreement": { "piSponsorEmployee": true },
        "pointOfContact": {
          "title": "Senior Director of Clinical Research",
          "organization": "Cognoa",
          "email": "minda.seal@cognoa.com",
          "phone": "4082076659"
        }
      }
    },
    "documentSection": {
      "largeDocumentModule": {
        "noSap": true,
        "largeDocs": [
          {
            "typeAbbrev": "Prot",
            "hasProtocol": true,
            "hasSap": false,
            "hasIcf": false,
            "label": "Study Protocol",
            "date": "2020-05-03",
            "uploadDate": "2021-10-22T10:56",
            "filename": "Prot_000.pdf",
            "size": 433915
          }
        ]
      }
    },
    "derivedSection": {
      "miscInfoModule": {
        "versionHolder": "2025-05-07",
        "submissionTracking": {
          "firstMcpInfo": {
            "postDateStruct": { "date": "2021-11-24", "type": "ACTUAL" }
          }
        }
      },
      "conditionBrowseModule": {
        "meshes": [{ "id": "D000067877", "term": "Autism Spectrum Disorder" }],
        "ancestors": [
          { "id": "D002659", "term": "Child Development Disorders, Pervasive" },
          { "id": "D065886", "term": "Neurodevelopmental Disorders" },
          { "id": "D001523", "term": "Mental Disorders" }
        ],
        "browseLeaves": [
          { "id": "M4623", "name": "Autistic Disorder", "relevance": "LOW" },
          {
            "id": "M206",
            "name": "Autism Spectrum Disorder",
            "asFound": "Autism Spectrum Disorder",
            "relevance": "HIGH"
          },
          {
            "id": "M5903",
            "name": "Child Development Disorders, Pervasive",
            "relevance": "LOW"
          },
          {
            "id": "M5902",
            "name": "Developmental Disabilities",
            "relevance": "LOW"
          },
          {
            "id": "M30644",
            "name": "Neurodevelopmental Disorders",
            "relevance": "LOW"
          },
          { "id": "M14473", "name": "Psychotic Disorders", "relevance": "LOW" },
          { "id": "M4815", "name": "Mental Disorders", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" },
          { "abbrev": "All", "name": "All Conditions" }
        ]
      }
    },
    "hasResults": true
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT04909229",
        "orgStudyIdInfo": { "id": "2000029050" },
        "organization": { "fullName": "Yale University", "class": "OTHER" },
        "briefTitle": "Prescription Digital Therapeutic for the Treatment of Insomnia",
        "officialTitle": "Randomized Controlled Trial Examining Real-World Effectiveness of a Prescription Digital Therapeutic for the Treatment of Insomnia",
        "acronym": "SLEEP-I"
      },
      "statusModule": {
        "statusVerifiedDate": "2024-09",
        "overallStatus": "COMPLETED",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2021-12-20", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2023-03-03",
          "type": "ACTUAL"
        },
        "completionDateStruct": { "date": "2024-03-01", "type": "ACTUAL" },
        "studyFirstSubmitDate": "2021-05-23",
        "studyFirstSubmitQcDate": "2021-05-24",
        "studyFirstPostDateStruct": { "date": "2021-06-01", "type": "ACTUAL" },
        "resultsFirstSubmitDate": "2024-02-23",
        "resultsFirstSubmitQcDate": "2024-03-27",
        "resultsFirstPostDateStruct": {
          "date": "2024-03-29",
          "type": "ACTUAL"
        },
        "lastUpdateSubmitDate": "2024-09-18",
        "lastUpdatePostDateStruct": { "date": "2024-10-09", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": { "name": "Yale University", "class": "OTHER" },
        "collaborators": [
          { "name": "Mayo Clinic", "class": "OTHER" },
          {
            "name": "National Evaluation System for health Technology Coordinating Center",
            "class": "OTHER"
          },
          { "name": "Pear Therapeutics, Inc.", "class": "INDUSTRY" }
        ]
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": true,
        "isUsExport": false
      },
      "descriptionModule": {
        "briefSummary": "This will be a prospective multi-center controlled trial of 100 patients conducted to assess the real-world effectiveness of a mobile-delivered, prescription digital therapeutic (PDT) device delivering Cognitive Behavioral Therapy for Insomnia using a novel patient-centered data-sharing platform with linkage to Fitbit for 61 weeks",
        "detailedDescription": "This is a multi-center, randomized, controlled trial to assess the real-world effectiveness of a mobile-delivered, prescription digital therapeutic (PDT) device delivering Cognitive Behavioral Therapy for Insomnia (i.e., Somryst, herein called PEAR-003b) using a novel patient-centered data sharing platform (called Hugo), with linkage to Fitbit (Inspire 2), among 100 patients with chronic insomnia. Half of the patients with insomnia will receive the PEAR-003b digital therapeutic with linkage to the Hugo platform and Fitbit (Inspire 2) and half of the patients with insomnia will not receive the PDT but will receive a Fitbit and be enrolled in the Hugo platform. The treatment duration will be 9 weeks with a 21-, 35-, and 61-week follow-up. All patients will be evaluated at baseline, as well as prompted to complete additional assessments at weeks 9, 21, 35, and 61. The PEAR-003b intervention will deliver CBT-I via mobile devices as 6 treatment core modules over 9 weeks. Additionally, the Hugo platform will be used to collect patient-generated engagement data, healthcare utilization outcomes, and patient activity/clinical outcomes. These real-world data points and trends collected as part of this pilot investigation will help inform a future larger healthcare effectiveness and outcomes research study."
      },
      "conditionsModule": {
        "conditions": ["Insomnia Chronic"],
        "keywords": ["insomnia", "CBT-I"]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": { "masking": "NONE" }
        },
        "enrollmentInfo": { "count": 100, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "PEAR-003b PDT Intervention",
            "type": "EXPERIMENTAL",
            "description": "Participants will receive the PEAR-003b digital therapeutic, a Fitbit, and materials on sleep hygiene and healthy sleep tips. Using the Hugo platform, patient-generated engagement data, healthcare utilization, and patient activity/clinical outcomes for patients with insomnia will also be collected.",
            "interventionNames": [
              "Device: PEAR-003b PDT Intervention",
              "Device: Fitbit",
              "Behavioral: Sleep education materials"
            ]
          },
          {
            "label": "Control Arm",
            "type": "PLACEBO_COMPARATOR",
            "description": "Participants will receive a Fitbit, and materials on sleep hygiene and healthy sleep tips. Using the Hugo platform, patient-generated engagement data, healthcare utilization, and patient activity/clinical outcomes for patients with insomnia will also be collected.",
            "interventionNames": [
              "Device: Fitbit",
              "Behavioral: Sleep education materials"
            ]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "PEAR-003b PDT Intervention",
            "description": "The PEAR-003b digital therapeutic delivers CBT-I via mobile devices as 6 treatment core modules over 9 weeks.",
            "armGroupLabels": ["PEAR-003b PDT Intervention"]
          },
          {
            "type": "DEVICE",
            "name": "Fitbit",
            "description": "Patients will receive a Fitbit and receive standard of care",
            "armGroupLabels": ["Control Arm", "PEAR-003b PDT Intervention"]
          },
          {
            "type": "BEHAVIORAL",
            "name": "Sleep education materials",
            "description": "Patients will receive sleep hygiene and healthy sleep tips.",
            "armGroupLabels": ["Control Arm", "PEAR-003b PDT Intervention"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Change in Insomnia Severity",
            "description": "Insomnia will be measured by the Insomnia Severity Index (ISI) score. Participants rate the severity of sleep problems (e.g. problems with sleep onset, sleep maintenance, and early morning awakening), interference with daytime functioning, how noticeable the impairment is to others, distress or concern caused by the sleep problem(s), as well as satisfaction with the current sleep pattern on a 5-point Likert scale. The ISI's total score ranges from 0 (not clinically significant) to 28 (clinically significant)",
            "timeFrame": "From baseline to 9 weeks post randomization"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Change in Insomnia Severity",
            "description": "Insomnia will be measured by the Insomnia Severity Index (ISI) score. Participants rate the severity of sleep problems (e.g. problems with sleep onset, sleep maintenance, and early morning awakening), interference with daytime functioning, how noticeable the impairment is to others, distress or concern caused by the sleep problem(s), as well as satisfaction with the current sleep pattern on a 5-point Likert scale. The ISI's total score ranges from 0 (not clinically significant) to 28 (clinically significant)",
            "timeFrame": "From baseline to 21 weeks post-randomization"
          },
          {
            "measure": "Change in Insomnia Severity",
            "description": "Insomnia will be measured by the Insomnia Severity Index (ISI) score. Participants rate the severity of sleep problems (e.g. problems with sleep onset, sleep maintenance, and early morning awakening), interference with daytime functioning, how noticeable the impairment is to others, distress or concern caused by the sleep problem(s), as well as satisfaction with the current sleep pattern on a 5-point Likert scale. The ISI's total score ranges from 0 (not clinically significant) to 28 (clinically significant)",
            "timeFrame": "From baseline to 35 weeks post-randomization"
          },
          {
            "measure": "Change in Insomnia Severity",
            "description": "Insomnia will be measured by the Insomnia Severity Index (ISI) score. Participants rate the severity of sleep problems (e.g. problems with sleep onset, sleep maintenance, and early morning awakening), interference with daytime functioning, how noticeable the impairment is to others, distress or concern caused by the sleep problem(s), as well as satisfaction with the current sleep pattern on a 5-point Likert scale. The ISI's total score ranges from 0 (not clinically significant) to 28 (clinically significant)",
            "timeFrame": "From baseline to 61 weeks post-randomization"
          },
          {
            "measure": "Change in Depressive Symptoms",
            "description": "Depressive symptoms will be measured by the Patient Health Questionnaire (PHQ-8. The PHQ-8 is an 8 item 0 to 3 scale questionnaire. Total score ranges from 0 (not clinically significant) to 24 (clinically significant)",
            "timeFrame": "From baseline to 9 weeks post-randomization"
          },
          {
            "measure": "Change in Depressive Symptoms",
            "description": "Depressive symptoms will be measured by the Patient Health Questionnaire (PHQ-8. The PHQ-8 is an 8 item 0 to 3 scale questionnaire. Total score ranges from 0 (not clinically significant) to 24 (clinically significant)",
            "timeFrame": "From baseline to 21 weeks post-randomization"
          },
          {
            "measure": "Change in Depressive Symptoms",
            "description": "Depressive symptoms will be measured by the Patient Health Questionnaire (PHQ-8. The PHQ-8 is an 8 item 0 to 3 scale questionnaire. Total score ranges from 0 (not clinically significant) to 24 (clinically significant)",
            "timeFrame": "From baseline to 35 weeks post-randomization"
          },
          {
            "measure": "Change in Depressive Symptoms",
            "description": "Depressive symptoms will be measured by the Patient Health Questionnaire (PHQ-8. The PHQ-8 is an 8 item 0 to 3 scale questionnaire. Total score ranges from 0 (not clinically significant) to 24 (clinically significant)",
            "timeFrame": "From baseline to 61 weeks post-randomization"
          },
          {
            "measure": "Change in Anxiety",
            "description": "The General Anxiety Disorder-7 (GAD-7) is a widely used diagnostic self-report scale that screens, diagnoses, and assesses the severity of anxiety disorder. The GAD-7 is a 7-item 0 to 3 (0 = Not at all, 3 = Nearly every day) scale that measures the degree of severity of anxiety over the last 2 weeks with a total score ranging from 0 to 21, with a higher score indicating a more severe anxiety.",
            "timeFrame": "From baseline to 9 weeks post-randomization"
          },
          {
            "measure": "Change in Anxiety",
            "description": "The General Anxiety Disorder-7 (GAD-7) is a widely used diagnostic self-report scale that screens, diagnoses, and assesses the severity of anxiety disorder. The GAD-7 is a 7-item 0 to 3 (0 = Not at all, 3 = Nearly every day) scale that measures the degree of severity of anxiety over the last 2 weeks with a total score ranging from 0 to 21, with a higher score indicating a more severe anxiety.",
            "timeFrame": "From baseline to 21 weeks post-randomization"
          },
          {
            "measure": "Change in Anxiety",
            "description": "The General Anxiety Disorder-7 (GAD-7) is a widely used diagnostic self-report scale that screens, diagnoses, and assesses the severity of anxiety disorder. The GAD-7 is a 7-item 0 to 3 (0 = Not at all, 3 = Nearly every day) scale that measures the degree of severity of anxiety over the last 2 weeks with a total score ranging from 0 to 21, with a higher score indicating a more severe anxiety.",
            "timeFrame": "From baseline to 35 weeks post-randomization"
          },
          {
            "measure": "Change in Anxiety",
            "description": "The General Anxiety Disorder-7 (GAD-7) is a widely used diagnostic self-report scale that screens, diagnoses, and assesses the severity of anxiety disorder. The GAD-7 is a 7-item 0 to 3 (0 = Not at all, 3 = Nearly every day) scale that measures the degree of severity of anxiety over the last 2 weeks with a total score ranging from 0 to 21, with a higher score indicating a more severe anxiety.",
            "timeFrame": "From baseline to 61 weeks post-randomization"
          },
          {
            "measure": "Change in Stress",
            "description": "The Perceived Stress Scale (PSS) is a widely used self-reported 10-item questionnaire that assesses how stressful participants believe their life is. Scores range from 0 - 40 with higher scores pointing to more perceived stress.",
            "timeFrame": "From baseline to 9 weeks post-randomization"
          },
          {
            "measure": "Change in Stress",
            "description": "The Perceived Stress Scale (PSS) is a widely used self-reported 10-item questionnaire that assesses how stressful participants believe their life is. Scores range from 0 - 40 with higher scores pointing to more perceived stress.",
            "timeFrame": "From baseline to 21 weeks post-randomization"
          },
          {
            "measure": "Change in Stress",
            "description": "The Perceived Stress Scale (PSS) is a widely used self-reported 10-item questionnaire that assesses how stressful participants believe their life is. Scores range from 0 - 40 with higher scores pointing to more perceived stress.",
            "timeFrame": "From baseline to 35 weeks post-randomization"
          },
          {
            "measure": "Change in Stress",
            "description": "The Perceived Stress Scale (PSS) is a widely used self-reported 10-item questionnaire that assesses how stressful participants believe their life is. Scores range from 0 - 40 with higher scores pointing to more perceived stress.",
            "timeFrame": "From baseline to 61 weeks post-randomization"
          },
          {
            "measure": "Change in Quality of Life (PCS)",
            "description": "Change in quality of life as measured in the Short Form 12 (SF-12). The physical health component (PCS) score ranges from 0-100 with higher scores representing better self-reported physical health.",
            "timeFrame": "From baseline to 9 weeks post-randomization"
          },
          {
            "measure": "Change in Quality of Life (PCS)",
            "description": "Change in quality of life as measured in the Short Form 12 (SF-12). The physical health component (PCS) score ranges from 0-100 with higher scores representing better self-reported physical health.",
            "timeFrame": "From baseline to 21 weeks post-randomization"
          },
          {
            "measure": "Change in Quality of Life (PCS)",
            "description": "Change in quality of life as measured in the Short Form 12 (SF-12). The physical health component (PCS) score ranges from 0-100 with higher scores representing better self-reported physical health.",
            "timeFrame": "From baseline to 35 weeks post-randomization"
          },
          {
            "measure": "Change in Quality of Life (PCS)",
            "description": "Change in quality of life as measured in the Short Form 12 (SF-12). The physical health component (PCS) score ranges from 0-100 with higher scores representing better self-reported physical health.",
            "timeFrame": "From baseline to 61 weeks post-randomization"
          },
          {
            "measure": "Change in Daytime Sleepiness",
            "description": "Daytime sleepiness is measured by the Epworth Sleepiness Scale (ESS) The ESS total score ranges from 0 (not clinically significant) to 24 (clinically significant)",
            "timeFrame": "From baseline to 9 weeks post-randomization"
          },
          {
            "measure": "Change in Daytime Sleepiness",
            "description": "Daytime sleepiness is measured by the Epworth Sleepiness Scale (ESS) The ESS total score ranges from 0 (not clinically significant) to 24 (clinically significant)",
            "timeFrame": "From baseline to 21 weeks post-randomization"
          },
          {
            "measure": "Change in Daytime Sleepiness",
            "description": "Daytime sleepiness is measured by the Epworth Sleepiness Scale (ESS) The ESS total score ranges from 0 (not clinically significant) to 24 (clinically significant)",
            "timeFrame": "From baseline to 35 weeks post-randomization"
          },
          {
            "measure": "Change in Daytime Sleepiness",
            "description": "Daytime sleepiness is measured by the Epworth Sleepiness Scale (ESS) The ESS total score ranges from 0 (not clinically significant) to 24 (clinically significant)",
            "timeFrame": "From baseline to 61 weeks post-randomization"
          },
          {
            "measure": "Healthcare Utilization",
            "description": "Healthcare utilization will be reported as the number of outpatient visits with a primary care clinician or specialty care clinician.",
            "timeFrame": "From baseline to 9 weeks post-randomization"
          },
          {
            "measure": "Healthcare Utilization",
            "description": "Healthcare utilization will be reported as the number of outpatient visits with a primary care clinician or specialty care clinician.",
            "timeFrame": "From baseline to 21 weeks post-randomization"
          },
          {
            "measure": "Healthcare Utilization",
            "description": "Healthcare utilization will be reported as the number of outpatient visits with a primary care clinician or specialty care clinician.",
            "timeFrame": "From baseline to 35 weeks post-randomization"
          },
          {
            "measure": "Healthcare Utilization",
            "description": "Healthcare utilization will be reported as the number of outpatient visits with a primary care clinician or specialty care clinician.",
            "timeFrame": "From baseline to 61 weeks post-randomization"
          },
          {
            "measure": "Medication Utilization",
            "description": "Medication utilization will be reported as the number of medication refills for sleep and/or psychotropic medications.",
            "timeFrame": "From baseline to 9 weeks post-randomization"
          },
          {
            "measure": "Medication Utilization",
            "description": "Medication utilization will be reported as the number of medication refills for sleep and/or psychotropic medications.",
            "timeFrame": "From baseline to 21 weeks post-randomization"
          },
          {
            "measure": "Medication Utilization",
            "description": "Medication utilization will be reported as the number of medication refills for sleep and/or psychotropic medications.",
            "timeFrame": "From baseline to 35 weeks post-randomization"
          },
          {
            "measure": "Medication Utilization",
            "description": "Medication utilization will be reported as the number of medication refills for sleep and/or psychotropic medications.",
            "timeFrame": "From baseline to 61 weeks post-randomization"
          },
          {
            "measure": "Change in Sleep Efficiency",
            "description": "Change in sleep efficiency, calculated as time spent sleeping divided by time spent in bed. This data is acquired from sleep diaries filled out by patient. (range 0-100%)",
            "timeFrame": "From baseline to 9 weeks post-randomization"
          },
          {
            "measure": "Change in Sleep Efficiency",
            "description": "Change in sleep efficiency, calculated as time spent sleeping divided by time spent in bed. This data is acquired from sleep diaries filled out by patient. (range 0-100%)",
            "timeFrame": "From baseline to 21 weeks post-randomization"
          },
          {
            "measure": "Change in Sleep Efficiency",
            "description": "Change in sleep efficiency, calculated as time spent sleeping divided by time spent in bed. This data is acquired from sleep diaries filled out by patient. (range 0-100%)",
            "timeFrame": "From baseline to 35 weeks post-randomization"
          },
          {
            "measure": "Change in Sleep Efficiency",
            "description": "Change in sleep efficiency, calculated as time spent sleeping divided by time spent in bed. This data is acquired from sleep diaries filled out by patient. (range 0-100%)",
            "timeFrame": "From baseline to 61 weeks post-randomization"
          },
          {
            "measure": "Change in Sleep Onset Latency",
            "description": "Sleep-onset latency (SOL; min), is based on the participants sleep diary and how many minutes it took the participants to fall asleep.",
            "timeFrame": "From baseline to 9 weeks post-randomization"
          },
          {
            "measure": "Change in Sleep Onset Latency",
            "description": "Sleep-onset latency (SOL; min), is based on the participants sleep diary and how many minutes it took the participants to fall asleep.",
            "timeFrame": "From baseline to 21 weeks post-randomization"
          },
          {
            "measure": "Change in Sleep Onset Latency",
            "description": "Sleep-onset latency (SOL; min), is based on the participants sleep diary and how many minutes it took the participants to fall asleep.",
            "timeFrame": "From baseline to 35 weeks post-randomization"
          },
          {
            "measure": "Change in Sleep Onset Latency",
            "description": "Sleep-onset latency (SOL; min), is based on the participants sleep diary and how many minutes it took the participants to fall asleep.",
            "timeFrame": "From baseline to 61 weeks post-randomization"
          },
          {
            "measure": "Change in Health Utility Score",
            "description": "Change in health utility score will be generated by applying the Short Form-6D algorithm to Short Form-12 responses. Utility values for SF-6D health states can fall between 0.30 and 1.0, where 1.0 represents full health and 0 represents death.",
            "timeFrame": "From baseline to 9 weeks post-randomization"
          },
          {
            "measure": "Change in Health Utility Score",
            "description": "Change in health utility score will be generated by applying the Short Form-6D algorithm to Short Form-12 responses. Utility values for SF-6D health states can fall between 0.30 and 1.0, where 1.0 represents full health and 0 represents death.",
            "timeFrame": "From baseline to 21 weeks post-randomization"
          },
          {
            "measure": "Change in Health Utility Score",
            "description": "Change in health utility score will be generated by applying the Short Form-6D algorithm to Short Form-12 responses. Utility values for SF-6D health states can fall between 0.30 and 1.0, where 1.0 represents full health and 0 represents death.",
            "timeFrame": "From baseline to 35 weeks post-randomization"
          },
          {
            "measure": "Change in Health Utility Score",
            "description": "Change in health utility score will be generated by applying the Short Form-6D algorithm to Short Form-12 responses. Utility values for SF-6D health states can fall between 0.30 and 1.0, where 1.0 represents full health and 0 represents death.",
            "timeFrame": "From baseline to 61 weeks post-randomization"
          },
          {
            "measure": "Change in Quality of Life (MCS)",
            "description": "Change in quality of life as measured in the Short Form 12 (SF-12). The mental health component (MCS) score ranges from 0-100 with higher scores representing better self-reported mental health.",
            "timeFrame": "From baseline to 9 weeks post-randomization"
          },
          {
            "measure": "Change in Quality of Life (MCS)",
            "description": "Change in quality of life as measured in the Short Form 12 (SF-12). The mental health component (MCS) score ranges from 0-100 with higher scores representing better self-reported mental health.",
            "timeFrame": "From baseline to 21 weeks post-randomization"
          },
          {
            "measure": "Change in Quality of Life (MCS)",
            "description": "Change in quality of life as measured in the Short Form 12 (SF-12). The mental health component (MCS) score ranges from 0-100 with higher scores representing better self-reported mental health.",
            "timeFrame": "From baseline to 35 weeks post-randomization"
          },
          {
            "measure": "Change in Quality of Life (MCS)",
            "description": "Change in quality of life as measured in the Short Form 12 (SF-12). The mental health component (MCS) score ranges from 0-100 with higher scores representing better self-reported mental health.",
            "timeFrame": "From baseline to 61 weeks post-randomization"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* • Age between 22-64 years\n\n  * English-speaking (both reading and writing in English required)\n  * Diagnosis of chronic insomnia\n  * Participant is willing and able to give consent and participate in study\n  * Participant has an email account or is willing to create one and a smartphone able to download the necessary applications\n  * Participant is willing and able to use the PDT, the Hugo data sharing platform and the syncable devices (e.g. Fitbit)\n  * Participant has primary care at YNHH or Mayo Clinic\n\nExclusion Criteria:\n\n* Pregnancy\n* Shift work or family/other commitments that interfere with establishment of regular night-time sleep patterns, and if wake/sleep time is outside the ranges of 4:00h - 10:00h (wake time) and 20:00h - 02:00h (bed time)\n* Absence of a reliable internet access and smartphone\n* A reported diagnosis of psychosis, schizophrenia or bipolar disorder, or any medical disorders contraindicated with sleep restriction\n* Current involvement in a non-medication treatment program for insomnia (participants are still eligible if they are taking traditional sleep medications)\n* Those with untreated co-existing sleep conditions (e.g. sleep apnea)\n* Those who have failed CBT for insomnia in the past",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "22 Years",
        "maximumAge": "64 Years",
        "stdAges": ["ADULT"]
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "facility": "Yale-New Haven Hospital",
            "city": "New Haven",
            "state": "Connecticut",
            "zip": "06510",
            "country": "United States",
            "geoPoint": { "lat": 41.30815, "lon": -72.92816 }
          },
          {
            "facility": "Mayo Clinic",
            "city": "Rochester",
            "state": "Minnesota",
            "zip": "55905",
            "country": "United States",
            "geoPoint": { "lat": 44.02163, "lon": -92.4699 }
          }
        ]
      },
      "referencesModule": {
        "references": [
          {
            "pmid": "35940841",
            "type": "DERIVED",
            "citation": "Dreyer RP, Berkowitz A, Yaggi HK, Schneeberg L, Shah ND, Emanuel L, Kolla B, Jeffery MM, Deeg M, Ervin K, Thorndike F, Ross JS. PreScription DigitaL ThErapEutic for Patients with Insomnia (SLEEP-I): a protocol for a pragmatic randomised controlled trial. BMJ Open. 2022 Aug 8;12(8):e062041. doi: 10.1136/bmjopen-2022-062041."
          }
        ]
      },
      "ipdSharingStatementModule": {
        "ipdSharing": "YES",
        "description": "Once the study has been completed, IPD will be shared in a way which will protect patient confidentiality using a data sharing platform for research purposes",
        "infoTypes": ["STUDY_PROTOCOL", "SAP", "ICF", "CSR", "ANALYTIC_CODE"],
        "timeFrame": "Data will become available once the study has been completed"
      }
    },
    "resultsSection": {
      "participantFlowModule": {
        "groups": [
          {
            "id": "FG000",
            "title": "PEAR-003b PDT Intervention",
            "description": "Participants will receive the PEAR-003b digital therapeutic, a Fitbit, and materials on sleep hygiene and healthy sleep tips. Using the Hugo platform, patient-generated engagement data, healthcare utilization, and patient activity/clinical outcomes for patients with insomnia will also be collected.\n\nPEAR-003b PDT Intervention: The PEAR-003b digital therapeutic delivers CBT-I via mobile devices as 6 treatment core modules over 9 weeks.\n\nFitbit: Patients will receive a Fitbit and receive standard of care\n\nSleep education materials: Patients will receive sleep hygiene and healthy sleep tips."
          },
          {
            "id": "FG001",
            "title": "Control Arm",
            "description": "Participants will receive a Fitbit, and materials on sleep hygiene and healthy sleep tips. Using the Hugo platform, patient-generated engagement data, healthcare utilization, and patient activity/clinical outcomes for patients with insomnia will also be collected.\n\nFitbit: Patients will receive a Fitbit and receive standard of care\n\nSleep education materials: Patients will receive sleep hygiene and healthy sleep tips."
          }
        ],
        "periods": [
          {
            "title": "Overall Study",
            "milestones": [
              {
                "type": "STARTED",
                "achievements": [
                  { "groupId": "FG000", "numSubjects": "50" },
                  { "groupId": "FG001", "numSubjects": "50" }
                ]
              },
              {
                "type": "COMPLETED",
                "achievements": [
                  { "groupId": "FG000", "numSubjects": "47" },
                  { "groupId": "FG001", "numSubjects": "49" }
                ]
              },
              {
                "type": "NOT COMPLETED",
                "achievements": [
                  { "groupId": "FG000", "numSubjects": "3" },
                  { "groupId": "FG001", "numSubjects": "1" }
                ]
              }
            ]
          }
        ]
      },
      "baselineCharacteristicsModule": {
        "populationDescription": "The Participant Flow number differs from the Overall Number of Baseline Participants because two enrolled participants did not complete their baseline survey.",
        "groups": [
          {
            "id": "BG000",
            "title": "PEAR-003b PDT Intervention",
            "description": "Participants will receive the PEAR-003b digital therapeutic, a Fitbit, and materials on sleep hygiene and healthy sleep tips. Using the Hugo platform, patient-generated engagement data, healthcare utilization, and patient activity/clinical outcomes for patients with insomnia will also be collected.\n\nPEAR-003b PDT Intervention: The PEAR-003b digital therapeutic delivers CBT-I via mobile devices as 6 treatment core modules over 9 weeks.\n\nFitbit: Patients will receive a Fitbit and receive standard of care\n\nSleep education materials: Patients will receive sleep hygiene and healthy sleep tips."
          },
          {
            "id": "BG001",
            "title": "Control Arm",
            "description": "Participants will receive a Fitbit, and materials on sleep hygiene and healthy sleep tips. Using the Hugo platform, patient-generated engagement data, healthcare utilization, and patient activity/clinical outcomes for patients with insomnia will also be collected.\n\nFitbit: Patients will receive a Fitbit and receive standard of care\n\nSleep education materials: Patients will receive sleep hygiene and healthy sleep tips."
          },
          {
            "id": "BG002",
            "title": "Total",
            "description": "Total of all reporting groups"
          }
        ],
        "denoms": [
          {
            "units": "Participants",
            "counts": [
              { "groupId": "BG000", "value": "48" },
              { "groupId": "BG001", "value": "50" },
              { "groupId": "BG002", "value": "98" }
            ]
          }
        ],
        "measures": [
          {
            "title": "Age, Continuous",
            "populationDescription": "1 enrolled participant did not answer this survey question",
            "paramType": "MEAN",
            "dispersionType": "STANDARD_DEVIATION",
            "unitOfMeasure": "years",
            "classes": [
              {
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "BG000", "value": "47" },
                      { "groupId": "BG001", "value": "50" },
                      { "groupId": "BG002", "value": "97" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "46.3",
                        "spread": "12.09"
                      },
                      {
                        "groupId": "BG001",
                        "value": "43.9",
                        "spread": "12.69"
                      },
                      { "groupId": "BG002", "value": "45.1", "spread": "12.40" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Sex/Gender, Customized",
            "paramType": "NUMBER",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "title": "Female",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "BG000", "value": "48" },
                      { "groupId": "BG001", "value": "50" },
                      { "groupId": "BG002", "value": "98" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "BG000", "value": "35" },
                      { "groupId": "BG001", "value": "34" },
                      { "groupId": "BG002", "value": "69" }
                    ]
                  }
                ]
              },
              {
                "title": "Male",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "BG000", "value": "48" },
                      { "groupId": "BG001", "value": "50" },
                      { "groupId": "BG002", "value": "98" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "BG000", "value": "13" },
                      { "groupId": "BG001", "value": "14" },
                      { "groupId": "BG002", "value": "27" }
                    ]
                  }
                ]
              },
              {
                "title": "Non-binary/third gender",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "BG000", "value": "48" },
                      { "groupId": "BG001", "value": "50" },
                      { "groupId": "BG002", "value": "98" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "BG000", "value": "0" },
                      { "groupId": "BG001", "value": "2" },
                      { "groupId": "BG002", "value": "2" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Ethnicity (NIH/OMB)",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "BG000", "value": "48" },
                      { "groupId": "BG001", "value": "50" },
                      { "groupId": "BG002", "value": "98" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "title": "Hispanic or Latino",
                    "measurements": [
                      { "groupId": "BG000", "value": "3" },
                      { "groupId": "BG001", "value": "3" },
                      { "groupId": "BG002", "value": "6" }
                    ]
                  },
                  {
                    "title": "Not Hispanic or Latino",
                    "measurements": [
                      { "groupId": "BG000", "value": "44" },
                      { "groupId": "BG001", "value": "45" },
                      { "groupId": "BG002", "value": "89" }
                    ]
                  },
                  {
                    "title": "Unknown or Not Reported",
                    "measurements": [
                      { "groupId": "BG000", "value": "1" },
                      { "groupId": "BG001", "value": "2" },
                      { "groupId": "BG002", "value": "3" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Race (NIH/OMB)",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "BG000", "value": "48" },
                      { "groupId": "BG001", "value": "50" },
                      { "groupId": "BG002", "value": "98" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "title": "American Indian or Alaska Native",
                    "measurements": [
                      { "groupId": "BG000", "value": "0" },
                      { "groupId": "BG001", "value": "0" },
                      { "groupId": "BG002", "value": "0" }
                    ]
                  },
                  {
                    "title": "Asian",
                    "measurements": [
                      { "groupId": "BG000", "value": "3" },
                      { "groupId": "BG001", "value": "0" },
                      { "groupId": "BG002", "value": "3" }
                    ]
                  },
                  {
                    "title": "Native Hawaiian or Other Pacific Islander",
                    "measurements": [
                      { "groupId": "BG000", "value": "0" },
                      { "groupId": "BG001", "value": "0" },
                      { "groupId": "BG002", "value": "0" }
                    ]
                  },
                  {
                    "title": "Black or African American",
                    "measurements": [
                      { "groupId": "BG000", "value": "1" },
                      { "groupId": "BG001", "value": "2" },
                      { "groupId": "BG002", "value": "3" }
                    ]
                  },
                  {
                    "title": "White",
                    "measurements": [
                      { "groupId": "BG000", "value": "43" },
                      { "groupId": "BG001", "value": "43" },
                      { "groupId": "BG002", "value": "86" }
                    ]
                  },
                  {
                    "title": "More than one race",
                    "measurements": [
                      { "groupId": "BG000", "value": "1" },
                      { "groupId": "BG001", "value": "3" },
                      { "groupId": "BG002", "value": "4" }
                    ]
                  },
                  {
                    "title": "Unknown or Not Reported",
                    "measurements": [
                      { "groupId": "BG000", "value": "0" },
                      { "groupId": "BG001", "value": "2" },
                      { "groupId": "BG002", "value": "2" }
                    ]
                  }
                ]
              }
            ]
          }
        ]
      },
      "outcomeMeasuresModule": {
        "outcomeMeasures": [
          {
            "type": "PRIMARY",
            "title": "Change in Insomnia Severity",
            "description": "Insomnia will be measured by the Insomnia Severity Index (ISI) score. Participants rate the severity of sleep problems (e.g. problems with sleep onset, sleep maintenance, and early morning awakening), interference with daytime functioning, how noticeable the impairment is to others, distress or concern caused by the sleep problem(s), as well as satisfaction with the current sleep pattern on a 5-point Likert scale. The ISI's total score ranges from 0 (not clinically significant) to 28 (clinically significant)",
            "populationDescription": "Primary outcome measure was erased from study surveys and therefore not collected.",
            "reportingStatus": "POSTED",
            "timeFrame": "From baseline to 9 weeks post randomization",
            "groups": [
              {
                "id": "OG000",
                "title": "PEAR-003b PDT Intervention",
                "description": "Participants will receive the PEAR-003b digital therapeutic, a Fitbit, and materials on sleep hygiene and healthy sleep tips. Using the Hugo platform, patient-generated engagement data, healthcare utilization, and patient activity/clinical outcomes for patients with insomnia will also be collected.\n\nPEAR-003b PDT Intervention: The PEAR-003b digital therapeutic delivers CBT-I via mobile devices as 6 treatment core modules over 9 weeks.\n\nFitbit: Patients will receive a Fitbit and receive standard of care\n\nSleep education materials: Patients will receive sleep hygiene and healthy sleep tips."
              },
              {
                "id": "OG001",
                "title": "Control Arm",
                "description": "Participants will receive a Fitbit, and materials on sleep hygiene and healthy sleep tips. Using the Hugo platform, patient-generated engagement data, healthcare utilization, and patient activity/clinical outcomes for patients with insomnia will also be collected.\n\nFitbit: Patients will receive a Fitbit and receive standard of care\n\nSleep education materials: Patients will receive sleep hygiene and healthy sleep tips."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "0" },
                  { "groupId": "OG001", "value": "0" }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Change in Insomnia Severity",
            "description": "Insomnia will be measured by the Insomnia Severity Index (ISI) score. Participants rate the severity of sleep problems (e.g. problems with sleep onset, sleep maintenance, and early morning awakening), interference with daytime functioning, how noticeable the impairment is to others, distress or concern caused by the sleep problem(s), as well as satisfaction with the current sleep pattern on a 5-point Likert scale. The ISI's total score ranges from 0 (not clinically significant) to 28 (clinically significant)",
            "populationDescription": "Primary outcome measure was erased from study surveys and therefore not collected.",
            "reportingStatus": "POSTED",
            "timeFrame": "From baseline to 21 weeks post-randomization",
            "groups": [
              {
                "id": "OG000",
                "title": "PEAR-003b PDT Intervention",
                "description": "Participants will receive the PEAR-003b digital therapeutic, a Fitbit, and materials on sleep hygiene and healthy sleep tips. Using the Hugo platform, patient-generated engagement data, healthcare utilization, and patient activity/clinical outcomes for patients with insomnia will also be collected.\n\nPEAR-003b PDT Intervention: The PEAR-003b digital therapeutic delivers CBT-I via mobile devices as 6 treatment core modules over 9 weeks.\n\nFitbit: Patients will receive a Fitbit and receive standard of care\n\nSleep education materials: Patients will receive sleep hygiene and healthy sleep tips."
              },
              {
                "id": "OG001",
                "title": "Control Arm",
                "description": "Participants will receive a Fitbit, and materials on sleep hygiene and healthy sleep tips. Using the Hugo platform, patient-generated engagement data, healthcare utilization, and patient activity/clinical outcomes for patients with insomnia will also be collected.\n\nFitbit: Patients will receive a Fitbit and receive standard of care\n\nSleep education materials: Patients will receive sleep hygiene and healthy sleep tips."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "0" },
                  { "groupId": "OG001", "value": "0" }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Change in Insomnia Severity",
            "description": "Insomnia will be measured by the Insomnia Severity Index (ISI) score. Participants rate the severity of sleep problems (e.g. problems with sleep onset, sleep maintenance, and early morning awakening), interference with daytime functioning, how noticeable the impairment is to others, distress or concern caused by the sleep problem(s), as well as satisfaction with the current sleep pattern on a 5-point Likert scale. The ISI's total score ranges from 0 (not clinically significant) to 28 (clinically significant)",
            "populationDescription": "Primary outcome measure was erased from study surveys and therefore not collected.",
            "reportingStatus": "POSTED",
            "timeFrame": "From baseline to 35 weeks post-randomization",
            "groups": [
              {
                "id": "OG000",
                "title": "PEAR-003b PDT Intervention",
                "description": "Participants will receive the PEAR-003b digital therapeutic, a Fitbit, and materials on sleep hygiene and healthy sleep tips. Using the Hugo platform, patient-generated engagement data, healthcare utilization, and patient activity/clinical outcomes for patients with insomnia will also be collected.\n\nPEAR-003b PDT Intervention: The PEAR-003b digital therapeutic delivers CBT-I via mobile devices as 6 treatment core modules over 9 weeks.\n\nFitbit: Patients will receive a Fitbit and receive standard of care\n\nSleep education materials: Patients will receive sleep hygiene and healthy sleep tips."
              },
              {
                "id": "OG001",
                "title": "Control Arm",
                "description": "Participants will receive a Fitbit, and materials on sleep hygiene and healthy sleep tips. Using the Hugo platform, patient-generated engagement data, healthcare utilization, and patient activity/clinical outcomes for patients with insomnia will also be collected.\n\nFitbit: Patients will receive a Fitbit and receive standard of care\n\nSleep education materials: Patients will receive sleep hygiene and healthy sleep tips."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "0" },
                  { "groupId": "OG001", "value": "0" }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Change in Insomnia Severity",
            "description": "Insomnia will be measured by the Insomnia Severity Index (ISI) score. Participants rate the severity of sleep problems (e.g. problems with sleep onset, sleep maintenance, and early morning awakening), interference with daytime functioning, how noticeable the impairment is to others, distress or concern caused by the sleep problem(s), as well as satisfaction with the current sleep pattern on a 5-point Likert scale. The ISI's total score ranges from 0 (not clinically significant) to 28 (clinically significant)",
            "populationDescription": "Primary outcome measure was erased from study surveys and therefore not collected.",
            "reportingStatus": "POSTED",
            "timeFrame": "From baseline to 61 weeks post-randomization",
            "groups": [
              {
                "id": "OG000",
                "title": "PEAR-003b PDT Intervention",
                "description": "Participants will receive the PEAR-003b digital therapeutic, a Fitbit, and materials on sleep hygiene and healthy sleep tips. Using the Hugo platform, patient-generated engagement data, healthcare utilization, and patient activity/clinical outcomes for patients with insomnia will also be collected.\n\nPEAR-003b PDT Intervention: The PEAR-003b digital therapeutic delivers CBT-I via mobile devices as 6 treatment core modules over 9 weeks.\n\nFitbit: Patients will receive a Fitbit and receive standard of care\n\nSleep education materials: Patients will receive sleep hygiene and healthy sleep tips."
              },
              {
                "id": "OG001",
                "title": "Control Arm",
                "description": "Participants will receive a Fitbit, and materials on sleep hygiene and healthy sleep tips. Using the Hugo platform, patient-generated engagement data, healthcare utilization, and patient activity/clinical outcomes for patients with insomnia will also be collected.\n\nFitbit: Patients will receive a Fitbit and receive standard of care\n\nSleep education materials: Patients will receive sleep hygiene and healthy sleep tips."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "0" },
                  { "groupId": "OG001", "value": "0" }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Change in Depressive Symptoms",
            "description": "Depressive symptoms will be measured by the Patient Health Questionnaire (PHQ-8. The PHQ-8 is an 8 item 0 to 3 scale questionnaire. Total score ranges from 0 (not clinically significant) to 24 (clinically significant)",
            "reportingStatus": "POSTED",
            "paramType": "MEDIAN",
            "dispersionType": "Inter-Quartile Range",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "From baseline to 9 weeks post-randomization",
            "groups": [
              {
                "id": "OG000",
                "title": "PEAR-003b PDT Intervention",
                "description": "Participants will receive the PEAR-003b digital therapeutic, a Fitbit, and materials on sleep hygiene and healthy sleep tips. Using the Hugo platform, patient-generated engagement data, healthcare utilization, and patient activity/clinical outcomes for patients with insomnia will also be collected.\n\nPEAR-003b PDT Intervention: The PEAR-003b digital therapeutic delivers CBT-I via mobile devices as 6 treatment core modules over 9 weeks.\n\nFitbit: Patients will receive a Fitbit and receive standard of care\n\nSleep education materials: Patients will receive sleep hygiene and healthy sleep tips."
              },
              {
                "id": "OG001",
                "title": "Control Arm",
                "description": "Participants will receive a Fitbit, and materials on sleep hygiene and healthy sleep tips. Using the Hugo platform, patient-generated engagement data, healthcare utilization, and patient activity/clinical outcomes for patients with insomnia will also be collected.\n\nFitbit: Patients will receive a Fitbit and receive standard of care\n\nSleep education materials: Patients will receive sleep hygiene and healthy sleep tips."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "27" },
                  { "groupId": "OG001", "value": "30" }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-2.0",
                        "lowerLimit": "-4.0",
                        "upperLimit": "0.0"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-1.5",
                        "lowerLimit": "-5.0",
                        "upperLimit": "1.0"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Change in Depressive Symptoms",
            "description": "Depressive symptoms will be measured by the Patient Health Questionnaire (PHQ-8. The PHQ-8 is an 8 item 0 to 3 scale questionnaire. Total score ranges from 0 (not clinically significant) to 24 (clinically significant)",
            "reportingStatus": "POSTED",
            "paramType": "MEDIAN",
            "dispersionType": "Inter-Quartile Range",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "From baseline to 21 weeks post-randomization",
            "groups": [
              {
                "id": "OG000",
                "title": "PEAR-003b PDT Intervention",
                "description": "Participants will receive the PEAR-003b digital therapeutic, a Fitbit, and materials on sleep hygiene and healthy sleep tips. Using the Hugo platform, patient-generated engagement data, healthcare utilization, and patient activity/clinical outcomes for patients with insomnia will also be collected.\n\nPEAR-003b PDT Intervention: The PEAR-003b digital therapeutic delivers CBT-I via mobile devices as 6 treatment core modules over 9 weeks.\n\nFitbit: Patients will receive a Fitbit and receive standard of care\n\nSleep education materials: Patients will receive sleep hygiene and healthy sleep tips."
              },
              {
                "id": "OG001",
                "title": "Control Arm",
                "description": "Participants will receive a Fitbit, and materials on sleep hygiene and healthy sleep tips. Using the Hugo platform, patient-generated engagement data, healthcare utilization, and patient activity/clinical outcomes for patients with insomnia will also be collected.\n\nFitbit: Patients will receive a Fitbit and receive standard of care\n\nSleep education materials: Patients will receive sleep hygiene and healthy sleep tips."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "20" },
                  { "groupId": "OG001", "value": "30" }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-2.0",
                        "lowerLimit": "-5.0",
                        "upperLimit": "1.0"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-2.0",
                        "lowerLimit": "-5.0",
                        "upperLimit": "1.0"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Change in Depressive Symptoms",
            "description": "Depressive symptoms will be measured by the Patient Health Questionnaire (PHQ-8. The PHQ-8 is an 8 item 0 to 3 scale questionnaire. Total score ranges from 0 (not clinically significant) to 24 (clinically significant)",
            "reportingStatus": "POSTED",
            "paramType": "MEDIAN",
            "dispersionType": "Inter-Quartile Range",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "From baseline to 35 weeks post-randomization",
            "groups": [
              {
                "id": "OG000",
                "title": "PEAR-003b PDT Intervention",
                "description": "Participants will receive the PEAR-003b digital therapeutic, a Fitbit, and materials on sleep hygiene and healthy sleep tips. Using the Hugo platform, patient-generated engagement data, healthcare utilization, and patient activity/clinical outcomes for patients with insomnia will also be collected.\n\nPEAR-003b PDT Intervention: The PEAR-003b digital therapeutic delivers CBT-I via mobile devices as 6 treatment core modules over 9 weeks.\n\nFitbit: Patients will receive a Fitbit and receive standard of care\n\nSleep education materials: Patients will receive sleep hygiene and healthy sleep tips."
              },
              {
                "id": "OG001",
                "title": "Control Arm",
                "description": "Participants will receive a Fitbit, and materials on sleep hygiene and healthy sleep tips. Using the Hugo platform, patient-generated engagement data, healthcare utilization, and patient activity/clinical outcomes for patients with insomnia will also be collected.\n\nFitbit: Patients will receive a Fitbit and receive standard of care\n\nSleep education materials: Patients will receive sleep hygiene and healthy sleep tips."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "22" },
                  { "groupId": "OG001", "value": "21" }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-2.0",
                        "lowerLimit": "-4.0",
                        "upperLimit": "1.0"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-4.0",
                        "lowerLimit": "-8.0",
                        "upperLimit": "-1.0"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Change in Depressive Symptoms",
            "description": "Depressive symptoms will be measured by the Patient Health Questionnaire (PHQ-8. The PHQ-8 is an 8 item 0 to 3 scale questionnaire. Total score ranges from 0 (not clinically significant) to 24 (clinically significant)",
            "reportingStatus": "POSTED",
            "paramType": "MEDIAN",
            "dispersionType": "Inter-Quartile Range",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "From baseline to 61 weeks post-randomization",
            "groups": [
              {
                "id": "OG000",
                "title": "PEAR-003b PDT Intervention",
                "description": "Participants will receive the PEAR-003b digital therapeutic, a Fitbit, and materials on sleep hygiene and healthy sleep tips. Using the Hugo platform, patient-generated engagement data, healthcare utilization, and patient activity/clinical outcomes for patients with insomnia will also be collected.\n\nPEAR-003b PDT Intervention: The PEAR-003b digital therapeutic delivers CBT-I via mobile devices as 6 treatment core modules over 9 weeks.\n\nFitbit: Patients will receive a Fitbit and receive standard of care\n\nSleep education materials: Patients will receive sleep hygiene and healthy sleep tips."
              },
              {
                "id": "OG001",
                "title": "Control Arm",
                "description": "Participants will receive a Fitbit, and materials on sleep hygiene and healthy sleep tips. Using the Hugo platform, patient-generated engagement data, healthcare utilization, and patient activity/clinical outcomes for patients with insomnia will also be collected.\n\nFitbit: Patients will receive a Fitbit and receive standard of care\n\nSleep education materials: Patients will receive sleep hygiene and healthy sleep tips."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "23" },
                  { "groupId": "OG001", "value": "21" }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-2.0",
                        "lowerLimit": "-8.0",
                        "upperLimit": "0.0"
                      },
                      {
                        "groupId": "OG001",
                        "value": "0.0",
                        "lowerLimit": "-4.0",
                        "upperLimit": "1.0"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Change in Anxiety",
            "description": "The General Anxiety Disorder-7 (GAD-7) is a widely used diagnostic self-report scale that screens, diagnoses, and assesses the severity of anxiety disorder. The GAD-7 is a 7-item 0 to 3 (0 = Not at all, 3 = Nearly every day) scale that measures the degree of severity of anxiety over the last 2 weeks with a total score ranging from 0 to 21, with a higher score indicating a more severe anxiety.",
            "reportingStatus": "POSTED",
            "paramType": "MEDIAN",
            "dispersionType": "Inter-Quartile Range",
            "unitOfMeasure": "units on a scale",
            "timeFrame": "From baseline to 9 weeks post-randomization",
            "groups": [
              {
                "id": "OG000",
                "title": "PEAR-003b PDT Intervention",
                "description": "Participants will receive the PEAR-003b digital therapeutic, a Fitbit, and materials on sleep hygiene and healthy sleep tips. Using the Hugo platform, patient-generated engagement data, healthcare utilization, and patient activity/clinical outcomes for patients with insomnia will also be collected.\n\nPEAR-003b PDT Intervention: The PEAR-003b digital therapeutic delivers CBT-I via mobile devices as 6 treatment core modules over 9 weeks.\n\nFitbit: Patients will receive a Fitbit and receive standard of care\n\nSleep education materials: Patients will receive sleep hygiene and healthy sleep tips."
              },
              {
                "id": "OG001",
                "title": "Control Arm",
                "description": "Participants will receive a Fitbit, and materials on sleep hygiene and healthy sleep tips. Using the Hugo platform, patient-generated engagement data, healthcare utilization, and patient activity/clinical outcomes for patients with insomnia will also be collected.\n\nFitbit: Patients will receive a Fitbit and receive standard of care\n\nSleep education materials: Patients will receive sleep hygiene and healthy sleep tips."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "27" },
                  { "groupId": "OG001", "value": "30" }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-2.0",
                        "lowerLimit": "-5.0",
                        "upperLimit": "1.0"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-1.0",
                        "lowerLimit": "-2.0",
                        "upperLimit": "1.0"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Change in Anxiety",
            "description": "The General Anxiety Disorder-7 (GAD-7) is a widely used diagnostic self-report scale that screens, diagnoses, and assesses the severity of anxiety disorder. The GAD-7 is a 7-item 0 to 3 (0 = Not at all, 3 = Nearly every day) scale that measures the degree of severity of anxiety over the last 2 weeks with a total score ranging from 0 to 21, with a higher score indicating a more severe anxiety.",
            "reportingStatus": "POSTED",
            "paramType": "MEDIAN",
            "dispersionType": "Inter-Quartile Range",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "From baseline to 21 weeks post-randomization",
            "groups": [
              {
                "id": "OG000",
                "title": "PEAR-003b PDT Intervention",
                "description": "Participants will receive the PEAR-003b digital therapeutic, a Fitbit, and materials on sleep hygiene and healthy sleep tips. Using the Hugo platform, patient-generated engagement data, healthcare utilization, and patient activity/clinical outcomes for patients with insomnia will also be collected.\n\nPEAR-003b PDT Intervention: The PEAR-003b digital therapeutic delivers CBT-I via mobile devices as 6 treatment core modules over 9 weeks.\n\nFitbit: Patients will receive a Fitbit and receive standard of care\n\nSleep education materials: Patients will receive sleep hygiene and healthy sleep tips."
              },
              {
                "id": "OG001",
                "title": "Control Arm",
                "description": "Participants will receive a Fitbit, and materials on sleep hygiene and healthy sleep tips. Using the Hugo platform, patient-generated engagement data, healthcare utilization, and patient activity/clinical outcomes for patients with insomnia will also be collected.\n\nFitbit: Patients will receive a Fitbit and receive standard of care\n\nSleep education materials: Patients will receive sleep hygiene and healthy sleep tips."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "20" },
                  { "groupId": "OG001", "value": "30" }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-1.0",
                        "lowerLimit": "-3.0",
                        "upperLimit": "2.0"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-1.0",
                        "lowerLimit": "-3.0",
                        "upperLimit": "1.0"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Change in Anxiety",
            "description": "The General Anxiety Disorder-7 (GAD-7) is a widely used diagnostic self-report scale that screens, diagnoses, and assesses the severity of anxiety disorder. The GAD-7 is a 7-item 0 to 3 (0 = Not at all, 3 = Nearly every day) scale that measures the degree of severity of anxiety over the last 2 weeks with a total score ranging from 0 to 21, with a higher score indicating a more severe anxiety.",
            "reportingStatus": "POSTED",
            "paramType": "MEDIAN",
            "dispersionType": "Inter-Quartile Range",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "From baseline to 35 weeks post-randomization",
            "groups": [
              {
                "id": "OG000",
                "title": "PEAR-003b PDT Intervention",
                "description": "Participants will receive the PEAR-003b digital therapeutic, a Fitbit, and materials on sleep hygiene and healthy sleep tips. Using the Hugo platform, patient-generated engagement data, healthcare utilization, and patient activity/clinical outcomes for patients with insomnia will also be collected.\n\nPEAR-003b PDT Intervention: The PEAR-003b digital therapeutic delivers CBT-I via mobile devices as 6 treatment core modules over 9 weeks.\n\nFitbit: Patients will receive a Fitbit and receive standard of care\n\nSleep education materials: Patients will receive sleep hygiene and healthy sleep tips."
              },
              {
                "id": "OG001",
                "title": "Control Arm",
                "description": "Participants will receive a Fitbit, and materials on sleep hygiene and healthy sleep tips. Using the Hugo platform, patient-generated engagement data, healthcare utilization, and patient activity/clinical outcomes for patients with insomnia will also be collected.\n\nFitbit: Patients will receive a Fitbit and receive standard of care\n\nSleep education materials: Patients will receive sleep hygiene and healthy sleep tips."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "22" },
                  { "groupId": "OG001", "value": "21" }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-1.0",
                        "lowerLimit": "-3.0",
                        "upperLimit": "2.0"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-1.0",
                        "lowerLimit": "-4.0",
                        "upperLimit": "0.0"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Change in Anxiety",
            "description": "The General Anxiety Disorder-7 (GAD-7) is a widely used diagnostic self-report scale that screens, diagnoses, and assesses the severity of anxiety disorder. The GAD-7 is a 7-item 0 to 3 (0 = Not at all, 3 = Nearly every day) scale that measures the degree of severity of anxiety over the last 2 weeks with a total score ranging from 0 to 21, with a higher score indicating a more severe anxiety.",
            "reportingStatus": "POSTED",
            "paramType": "MEDIAN",
            "dispersionType": "Inter-Quartile Range",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "From baseline to 61 weeks post-randomization",
            "groups": [
              {
                "id": "OG000",
                "title": "PEAR-003b PDT Intervention",
                "description": "Participants will receive the PEAR-003b digital therapeutic, a Fitbit, and materials on sleep hygiene and healthy sleep tips. Using the Hugo platform, patient-generated engagement data, healthcare utilization, and patient activity/clinical outcomes for patients with insomnia will also be collected.\n\nPEAR-003b PDT Intervention: The PEAR-003b digital therapeutic delivers CBT-I via mobile devices as 6 treatment core modules over 9 weeks.\n\nFitbit: Patients will receive a Fitbit and receive standard of care\n\nSleep education materials: Patients will receive sleep hygiene and healthy sleep tips."
              },
              {
                "id": "OG001",
                "title": "Control Arm",
                "description": "Participants will receive a Fitbit, and materials on sleep hygiene and healthy sleep tips. Using the Hugo platform, patient-generated engagement data, healthcare utilization, and patient activity/clinical outcomes for patients with insomnia will also be collected.\n\nFitbit: Patients will receive a Fitbit and receive standard of care\n\nSleep education materials: Patients will receive sleep hygiene and healthy sleep tips."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "23" },
                  { "groupId": "OG001", "value": "21" }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-2.0",
                        "lowerLimit": "-5.0",
                        "upperLimit": "1.0"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-1.0",
                        "lowerLimit": "-3.0",
                        "upperLimit": "0.0"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Change in Stress",
            "description": "The Perceived Stress Scale (PSS) is a widely used self-reported 10-item questionnaire that assesses how stressful participants believe their life is. Scores range from 0 - 40 with higher scores pointing to more perceived stress.",
            "reportingStatus": "POSTED",
            "paramType": "MEDIAN",
            "dispersionType": "Inter-Quartile Range",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "From baseline to 9 weeks post-randomization",
            "groups": [
              {
                "id": "OG000",
                "title": "PEAR-003b PDT Intervention",
                "description": "Participants will receive the PEAR-003b digital therapeutic, a Fitbit, and materials on sleep hygiene and healthy sleep tips. Using the Hugo platform, patient-generated engagement data, healthcare utilization, and patient activity/clinical outcomes for patients with insomnia will also be collected.\n\nPEAR-003b PDT Intervention: The PEAR-003b digital therapeutic delivers CBT-I via mobile devices as 6 treatment core modules over 9 weeks.\n\nFitbit: Patients will receive a Fitbit and receive standard of care\n\nSleep education materials: Patients will receive sleep hygiene and healthy sleep tips."
              },
              {
                "id": "OG001",
                "title": "Control Arm",
                "description": "Participants will receive a Fitbit, and materials on sleep hygiene and healthy sleep tips. Using the Hugo platform, patient-generated engagement data, healthcare utilization, and patient activity/clinical outcomes for patients with insomnia will also be collected.\n\nFitbit: Patients will receive a Fitbit and receive standard of care\n\nSleep education materials: Patients will receive sleep hygiene and healthy sleep tips."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "27" },
                  { "groupId": "OG001", "value": "30" }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-1.0",
                        "lowerLimit": "-3.0",
                        "upperLimit": "2.0"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-0.5",
                        "lowerLimit": "-3.0",
                        "upperLimit": "2.0"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Change in Stress",
            "description": "The Perceived Stress Scale (PSS) is a widely used self-reported 10-item questionnaire that assesses how stressful participants believe their life is. Scores range from 0 - 40 with higher scores pointing to more perceived stress.",
            "reportingStatus": "POSTED",
            "paramType": "MEDIAN",
            "dispersionType": "Inter-Quartile Range",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "From baseline to 21 weeks post-randomization",
            "groups": [
              {
                "id": "OG000",
                "title": "PEAR-003b PDT Intervention",
                "description": "Participants will receive the PEAR-003b digital therapeutic, a Fitbit, and materials on sleep hygiene and healthy sleep tips. Using the Hugo platform, patient-generated engagement data, healthcare utilization, and patient activity/clinical outcomes for patients with insomnia will also be collected.\n\nPEAR-003b PDT Intervention: The PEAR-003b digital therapeutic delivers CBT-I via mobile devices as 6 treatment core modules over 9 weeks.\n\nFitbit: Patients will receive a Fitbit and receive standard of care\n\nSleep education materials: Patients will receive sleep hygiene and healthy sleep tips."
              },
              {
                "id": "OG001",
                "title": "Control Arm",
                "description": "Participants will receive a Fitbit, and materials on sleep hygiene and healthy sleep tips. Using the Hugo platform, patient-generated engagement data, healthcare utilization, and patient activity/clinical outcomes for patients with insomnia will also be collected.\n\nFitbit: Patients will receive a Fitbit and receive standard of care\n\nSleep education materials: Patients will receive sleep hygiene and healthy sleep tips."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "30" },
                  { "groupId": "OG001", "value": "20" }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "0.0",
                        "lowerLimit": "-2.0",
                        "upperLimit": "3.0"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-1.5",
                        "lowerLimit": "-4.0",
                        "upperLimit": "1.0"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Change in Stress",
            "description": "The Perceived Stress Scale (PSS) is a widely used self-reported 10-item questionnaire that assesses how stressful participants believe their life is. Scores range from 0 - 40 with higher scores pointing to more perceived stress.",
            "reportingStatus": "POSTED",
            "paramType": "MEDIAN",
            "dispersionType": "Inter-Quartile Range",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "From baseline to 35 weeks post-randomization",
            "groups": [
              {
                "id": "OG000",
                "title": "PEAR-003b PDT Intervention",
                "description": "Participants will receive the PEAR-003b digital therapeutic, a Fitbit, and materials on sleep hygiene and healthy sleep tips. Using the Hugo platform, patient-generated engagement data, healthcare utilization, and patient activity/clinical outcomes for patients with insomnia will also be collected.\n\nPEAR-003b PDT Intervention: The PEAR-003b digital therapeutic delivers CBT-I via mobile devices as 6 treatment core modules over 9 weeks.\n\nFitbit: Patients will receive a Fitbit and receive standard of care\n\nSleep education materials: Patients will receive sleep hygiene and healthy sleep tips."
              },
              {
                "id": "OG001",
                "title": "Control Arm",
                "description": "Participants will receive a Fitbit, and materials on sleep hygiene and healthy sleep tips. Using the Hugo platform, patient-generated engagement data, healthcare utilization, and patient activity/clinical outcomes for patients with insomnia will also be collected.\n\nFitbit: Patients will receive a Fitbit and receive standard of care\n\nSleep education materials: Patients will receive sleep hygiene and healthy sleep tips."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "22" },
                  { "groupId": "OG001", "value": "21" }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-1.0",
                        "lowerLimit": "-3.0",
                        "upperLimit": "1.0"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-3.0",
                        "lowerLimit": "-4.0",
                        "upperLimit": "0.0"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Change in Stress",
            "description": "The Perceived Stress Scale (PSS) is a widely used self-reported 10-item questionnaire that assesses how stressful participants believe their life is. Scores range from 0 - 40 with higher scores pointing to more perceived stress.",
            "reportingStatus": "POSTED",
            "paramType": "MEDIAN",
            "dispersionType": "Inter-Quartile Range",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "From baseline to 61 weeks post-randomization",
            "groups": [
              {
                "id": "OG000",
                "title": "PEAR-003b PDT Intervention",
                "description": "Participants will receive the PEAR-003b digital therapeutic, a Fitbit, and materials on sleep hygiene and healthy sleep tips. Using the Hugo platform, patient-generated engagement data, healthcare utilization, and patient activity/clinical outcomes for patients with insomnia will also be collected.\n\nPEAR-003b PDT Intervention: The PEAR-003b digital therapeutic delivers CBT-I via mobile devices as 6 treatment core modules over 9 weeks.\n\nFitbit: Patients will receive a Fitbit and receive standard of care\n\nSleep education materials: Patients will receive sleep hygiene and healthy sleep tips."
              },
              {
                "id": "OG001",
                "title": "Control Arm",
                "description": "Participants will receive a Fitbit, and materials on sleep hygiene and healthy sleep tips. Using the Hugo platform, patient-generated engagement data, healthcare utilization, and patient activity/clinical outcomes for patients with insomnia will also be collected.\n\nFitbit: Patients will receive a Fitbit and receive standard of care\n\nSleep education materials: Patients will receive sleep hygiene and healthy sleep tips."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "23" },
                  { "groupId": "OG001", "value": "21" }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "0.0",
                        "lowerLimit": "-3.0",
                        "upperLimit": "3.0"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-1.0",
                        "lowerLimit": "-4.0",
                        "upperLimit": "1.0"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Change in Quality of Life (PCS)",
            "description": "Change in quality of life as measured in the Short Form 12 (SF-12). The physical health component (PCS) score ranges from 0-100 with higher scores representing better self-reported physical health.",
            "reportingStatus": "POSTED",
            "paramType": "MEDIAN",
            "dispersionType": "Inter-Quartile Range",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "From baseline to 9 weeks post-randomization",
            "groups": [
              {
                "id": "OG000",
                "title": "PEAR-003b PDT Intervention",
                "description": "Participants will receive the PEAR-003b digital therapeutic, a Fitbit, and materials on sleep hygiene and healthy sleep tips. Using the Hugo platform, patient-generated engagement data, healthcare utilization, and patient activity/clinical outcomes for patients with insomnia will also be collected.\n\nPEAR-003b PDT Intervention: The PEAR-003b digital therapeutic delivers CBT-I via mobile devices as 6 treatment core modules over 9 weeks.\n\nFitbit: Patients will receive a Fitbit and receive standard of care\n\nSleep education materials: Patients will receive sleep hygiene and healthy sleep tips."
              },
              {
                "id": "OG001",
                "title": "Control Arm",
                "description": "Participants will receive a Fitbit, and materials on sleep hygiene and healthy sleep tips. Using the Hugo platform, patient-generated engagement data, healthcare utilization, and patient activity/clinical outcomes for patients with insomnia will also be collected.\n\nFitbit: Patients will receive a Fitbit and receive standard of care\n\nSleep education materials: Patients will receive sleep hygiene and healthy sleep tips."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "27" },
                  { "groupId": "OG001", "value": "30" }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-3.0",
                        "lowerLimit": "-6.5",
                        "upperLimit": "0.3"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-1.1",
                        "lowerLimit": "-5.3",
                        "upperLimit": "1.0"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Change in Quality of Life (PCS)",
            "description": "Change in quality of life as measured in the Short Form 12 (SF-12). The physical health component (PCS) score ranges from 0-100 with higher scores representing better self-reported physical health.",
            "reportingStatus": "POSTED",
            "paramType": "MEDIAN",
            "dispersionType": "Inter-Quartile Range",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "From baseline to 21 weeks post-randomization",
            "groups": [
              {
                "id": "OG000",
                "title": "PEAR-003b PDT Intervention",
                "description": "Participants will receive the PEAR-003b digital therapeutic, a Fitbit, and materials on sleep hygiene and healthy sleep tips. Using the Hugo platform, patient-generated engagement data, healthcare utilization, and patient activity/clinical outcomes for patients with insomnia will also be collected.\n\nPEAR-003b PDT Intervention: The PEAR-003b digital therapeutic delivers CBT-I via mobile devices as 6 treatment core modules over 9 weeks.\n\nFitbit: Patients will receive a Fitbit and receive standard of care\n\nSleep education materials: Patients will receive sleep hygiene and healthy sleep tips."
              },
              {
                "id": "OG001",
                "title": "Control Arm",
                "description": "Participants will receive a Fitbit, and materials on sleep hygiene and healthy sleep tips. Using the Hugo platform, patient-generated engagement data, healthcare utilization, and patient activity/clinical outcomes for patients with insomnia will also be collected.\n\nFitbit: Patients will receive a Fitbit and receive standard of care\n\nSleep education materials: Patients will receive sleep hygiene and healthy sleep tips."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "20" },
                  { "groupId": "OG001", "value": "30" }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "0.5",
                        "lowerLimit": "-4.3",
                        "upperLimit": "4.8"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-2.6",
                        "lowerLimit": "-7.2",
                        "upperLimit": "1.4"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Change in Quality of Life (PCS)",
            "description": "Change in quality of life as measured in the Short Form 12 (SF-12). The physical health component (PCS) score ranges from 0-100 with higher scores representing better self-reported physical health.",
            "reportingStatus": "POSTED",
            "paramType": "MEDIAN",
            "dispersionType": "Inter-Quartile Range",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "From baseline to 35 weeks post-randomization",
            "groups": [
              {
                "id": "OG000",
                "title": "PEAR-003b PDT Intervention",
                "description": "Participants will receive the PEAR-003b digital therapeutic, a Fitbit, and materials on sleep hygiene and healthy sleep tips. Using the Hugo platform, patient-generated engagement data, healthcare utilization, and patient activity/clinical outcomes for patients with insomnia will also be collected.\n\nPEAR-003b PDT Intervention: The PEAR-003b digital therapeutic delivers CBT-I via mobile devices as 6 treatment core modules over 9 weeks.\n\nFitbit: Patients will receive a Fitbit and receive standard of care\n\nSleep education materials: Patients will receive sleep hygiene and healthy sleep tips."
              },
              {
                "id": "OG001",
                "title": "Control Arm",
                "description": "Participants will receive a Fitbit, and materials on sleep hygiene and healthy sleep tips. Using the Hugo platform, patient-generated engagement data, healthcare utilization, and patient activity/clinical outcomes for patients with insomnia will also be collected.\n\nFitbit: Patients will receive a Fitbit and receive standard of care\n\nSleep education materials: Patients will receive sleep hygiene and healthy sleep tips."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "22" },
                  { "groupId": "OG001", "value": "21" }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-1.2",
                        "lowerLimit": "-7.6",
                        "upperLimit": "3.5"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-2.4",
                        "lowerLimit": "-9.4",
                        "upperLimit": "0.1"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Change in Quality of Life (PCS)",
            "description": "Change in quality of life as measured in the Short Form 12 (SF-12). The physical health component (PCS) score ranges from 0-100 with higher scores representing better self-reported physical health.",
            "reportingStatus": "POSTED",
            "paramType": "MEDIAN",
            "dispersionType": "Inter-Quartile Range",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "From baseline to 61 weeks post-randomization",
            "groups": [
              {
                "id": "OG000",
                "title": "PEAR-003b PDT Intervention",
                "description": "Participants will receive the PEAR-003b digital therapeutic, a Fitbit, and materials on sleep hygiene and healthy sleep tips. Using the Hugo platform, patient-generated engagement data, healthcare utilization, and patient activity/clinical outcomes for patients with insomnia will also be collected.\n\nPEAR-003b PDT Intervention: The PEAR-003b digital therapeutic delivers CBT-I via mobile devices as 6 treatment core modules over 9 weeks.\n\nFitbit: Patients will receive a Fitbit and receive standard of care\n\nSleep education materials: Patients will receive sleep hygiene and healthy sleep tips."
              },
              {
                "id": "OG001",
                "title": "Control Arm",
                "description": "Participants will receive a Fitbit, and materials on sleep hygiene and healthy sleep tips. Using the Hugo platform, patient-generated engagement data, healthcare utilization, and patient activity/clinical outcomes for patients with insomnia will also be collected.\n\nFitbit: Patients will receive a Fitbit and receive standard of care\n\nSleep education materials: Patients will receive sleep hygiene and healthy sleep tips."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "23" },
                  { "groupId": "OG001", "value": "21" }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-1.0",
                        "lowerLimit": "-5.0",
                        "upperLimit": "3.8"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-4.1",
                        "lowerLimit": "-8.3",
                        "upperLimit": "0.4"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Change in Daytime Sleepiness",
            "description": "Daytime sleepiness is measured by the Epworth Sleepiness Scale (ESS) The ESS total score ranges from 0 (not clinically significant) to 24 (clinically significant)",
            "reportingStatus": "POSTED",
            "paramType": "MEDIAN",
            "dispersionType": "Inter-Quartile Range",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "From baseline to 9 weeks post-randomization",
            "groups": [
              {
                "id": "OG000",
                "title": "PEAR-003b PDT Intervention",
                "description": "Participants will receive the PEAR-003b digital therapeutic, a Fitbit, and materials on sleep hygiene and healthy sleep tips. Using the Hugo platform, patient-generated engagement data, healthcare utilization, and patient activity/clinical outcomes for patients with insomnia will also be collected.\n\nPEAR-003b PDT Intervention: The PEAR-003b digital therapeutic delivers CBT-I via mobile devices as 6 treatment core modules over 9 weeks.\n\nFitbit: Patients will receive a Fitbit and receive standard of care\n\nSleep education materials: Patients will receive sleep hygiene and healthy sleep tips."
              },
              {
                "id": "OG001",
                "title": "Control Arm",
                "description": "Participants will receive a Fitbit, and materials on sleep hygiene and healthy sleep tips. Using the Hugo platform, patient-generated engagement data, healthcare utilization, and patient activity/clinical outcomes for patients with insomnia will also be collected.\n\nFitbit: Patients will receive a Fitbit and receive standard of care\n\nSleep education materials: Patients will receive sleep hygiene and healthy sleep tips."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "27" },
                  { "groupId": "OG001", "value": "30" }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-2.0",
                        "lowerLimit": "-4.0",
                        "upperLimit": "0.0"
                      },
                      {
                        "groupId": "OG001",
                        "value": "0.0",
                        "lowerLimit": "-3.0",
                        "upperLimit": "1.0"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Change in Daytime Sleepiness",
            "description": "Daytime sleepiness is measured by the Epworth Sleepiness Scale (ESS) The ESS total score ranges from 0 (not clinically significant) to 24 (clinically significant)",
            "reportingStatus": "POSTED",
            "paramType": "MEDIAN",
            "dispersionType": "Inter-Quartile Range",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "From baseline to 21 weeks post-randomization",
            "groups": [
              {
                "id": "OG000",
                "title": "PEAR-003b PDT Intervention",
                "description": "Participants will receive the PEAR-003b digital therapeutic, a Fitbit, and materials on sleep hygiene and healthy sleep tips. Using the Hugo platform, patient-generated engagement data, healthcare utilization, and patient activity/clinical outcomes for patients with insomnia will also be collected.\n\nPEAR-003b PDT Intervention: The PEAR-003b digital therapeutic delivers CBT-I via mobile devices as 6 treatment core modules over 9 weeks.\n\nFitbit: Patients will receive a Fitbit and receive standard of care\n\nSleep education materials: Patients will receive sleep hygiene and healthy sleep tips."
              },
              {
                "id": "OG001",
                "title": "Control Arm",
                "description": "Participants will receive a Fitbit, and materials on sleep hygiene and healthy sleep tips. Using the Hugo platform, patient-generated engagement data, healthcare utilization, and patient activity/clinical outcomes for patients with insomnia will also be collected.\n\nFitbit: Patients will receive a Fitbit and receive standard of care\n\nSleep education materials: Patients will receive sleep hygiene and healthy sleep tips."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "20" },
                  { "groupId": "OG001", "value": "30" }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-2.0",
                        "lowerLimit": "-3.0",
                        "upperLimit": "-0.5"
                      },
                      {
                        "groupId": "OG001",
                        "value": "0.0",
                        "lowerLimit": "-2.0",
                        "upperLimit": "1.0"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Change in Daytime Sleepiness",
            "description": "Daytime sleepiness is measured by the Epworth Sleepiness Scale (ESS) The ESS total score ranges from 0 (not clinically significant) to 24 (clinically significant)",
            "reportingStatus": "POSTED",
            "paramType": "MEDIAN",
            "dispersionType": "Inter-Quartile Range",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "From baseline to 35 weeks post-randomization",
            "groups": [
              {
                "id": "OG000",
                "title": "PEAR-003b PDT Intervention",
                "description": "Participants will receive the PEAR-003b digital therapeutic, a Fitbit, and materials on sleep hygiene and healthy sleep tips. Using the Hugo platform, patient-generated engagement data, healthcare utilization, and patient activity/clinical outcomes for patients with insomnia will also be collected.\n\nPEAR-003b PDT Intervention: The PEAR-003b digital therapeutic delivers CBT-I via mobile devices as 6 treatment core modules over 9 weeks.\n\nFitbit: Patients will receive a Fitbit and receive standard of care\n\nSleep education materials: Patients will receive sleep hygiene and healthy sleep tips."
              },
              {
                "id": "OG001",
                "title": "Control Arm",
                "description": "Participants will receive a Fitbit, and materials on sleep hygiene and healthy sleep tips. Using the Hugo platform, patient-generated engagement data, healthcare utilization, and patient activity/clinical outcomes for patients with insomnia will also be collected.\n\nFitbit: Patients will receive a Fitbit and receive standard of care\n\nSleep education materials: Patients will receive sleep hygiene and healthy sleep tips."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "22" },
                  { "groupId": "OG001", "value": "21" }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "0.0",
                        "lowerLimit": "-3.0",
                        "upperLimit": "1.0"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-2.0",
                        "lowerLimit": "-4.0",
                        "upperLimit": "1.0"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Change in Daytime Sleepiness",
            "description": "Daytime sleepiness is measured by the Epworth Sleepiness Scale (ESS) The ESS total score ranges from 0 (not clinically significant) to 24 (clinically significant)",
            "reportingStatus": "POSTED",
            "paramType": "MEDIAN",
            "dispersionType": "Inter-Quartile Range",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "From baseline to 61 weeks post-randomization",
            "groups": [
              {
                "id": "OG000",
                "title": "PEAR-003b PDT Intervention",
                "description": "Participants will receive the PEAR-003b digital therapeutic, a Fitbit, and materials on sleep hygiene and healthy sleep tips. Using the Hugo platform, patient-generated engagement data, healthcare utilization, and patient activity/clinical outcomes for patients with insomnia will also be collected.\n\nPEAR-003b PDT Intervention: The PEAR-003b digital therapeutic delivers CBT-I via mobile devices as 6 treatment core modules over 9 weeks.\n\nFitbit: Patients will receive a Fitbit and receive standard of care\n\nSleep education materials: Patients will receive sleep hygiene and healthy sleep tips."
              },
              {
                "id": "OG001",
                "title": "Control Arm",
                "description": "Participants will receive a Fitbit, and materials on sleep hygiene and healthy sleep tips. Using the Hugo platform, patient-generated engagement data, healthcare utilization, and patient activity/clinical outcomes for patients with insomnia will also be collected.\n\nFitbit: Patients will receive a Fitbit and receive standard of care\n\nSleep education materials: Patients will receive sleep hygiene and healthy sleep tips."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "23" },
                  { "groupId": "OG001", "value": "21" }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-1.0",
                        "lowerLimit": "-3.0",
                        "upperLimit": "0.0"
                      },
                      {
                        "groupId": "OG001",
                        "value": "0.0",
                        "lowerLimit": "-2.0",
                        "upperLimit": "1.0"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Healthcare Utilization",
            "description": "Healthcare utilization will be reported as the number of outpatient visits with a primary care clinician or specialty care clinician.",
            "reportingStatus": "NOT_POSTED",
            "timeFrame": "From baseline to 9 weeks post-randomization",
            "denomUnitsSelected": "Participants"
          },
          {
            "type": "SECONDARY",
            "title": "Healthcare Utilization",
            "description": "Healthcare utilization will be reported as the number of outpatient visits with a primary care clinician or specialty care clinician.",
            "reportingStatus": "NOT_POSTED",
            "timeFrame": "From baseline to 21 weeks post-randomization",
            "denomUnitsSelected": "Participants"
          },
          {
            "type": "SECONDARY",
            "title": "Healthcare Utilization",
            "description": "Healthcare utilization will be reported as the number of outpatient visits with a primary care clinician or specialty care clinician.",
            "reportingStatus": "NOT_POSTED",
            "timeFrame": "From baseline to 35 weeks post-randomization",
            "denomUnitsSelected": "Participants"
          },
          {
            "type": "SECONDARY",
            "title": "Healthcare Utilization",
            "description": "Healthcare utilization will be reported as the number of outpatient visits with a primary care clinician or specialty care clinician.",
            "reportingStatus": "NOT_POSTED",
            "timeFrame": "From baseline to 61 weeks post-randomization",
            "denomUnitsSelected": "Participants"
          },
          {
            "type": "SECONDARY",
            "title": "Medication Utilization",
            "description": "Medication utilization will be reported as the number of medication refills for sleep and/or psychotropic medications.",
            "reportingStatus": "NOT_POSTED",
            "timeFrame": "From baseline to 9 weeks post-randomization",
            "denomUnitsSelected": "Participants"
          },
          {
            "type": "SECONDARY",
            "title": "Medication Utilization",
            "description": "Medication utilization will be reported as the number of medication refills for sleep and/or psychotropic medications.",
            "reportingStatus": "NOT_POSTED",
            "timeFrame": "From baseline to 21 weeks post-randomization",
            "denomUnitsSelected": "Participants"
          },
          {
            "type": "SECONDARY",
            "title": "Medication Utilization",
            "description": "Medication utilization will be reported as the number of medication refills for sleep and/or psychotropic medications.",
            "reportingStatus": "NOT_POSTED",
            "timeFrame": "From baseline to 35 weeks post-randomization",
            "denomUnitsSelected": "Participants"
          },
          {
            "type": "SECONDARY",
            "title": "Medication Utilization",
            "description": "Medication utilization will be reported as the number of medication refills for sleep and/or psychotropic medications.",
            "reportingStatus": "NOT_POSTED",
            "timeFrame": "From baseline to 61 weeks post-randomization",
            "denomUnitsSelected": "Participants"
          },
          {
            "type": "SECONDARY",
            "title": "Change in Sleep Efficiency",
            "description": "Change in sleep efficiency, calculated as time spent sleeping divided by time spent in bed. This data is acquired from sleep diaries filled out by patient. (range 0-100%)",
            "reportingStatus": "NOT_POSTED",
            "timeFrame": "From baseline to 9 weeks post-randomization",
            "denomUnitsSelected": "Participants"
          },
          {
            "type": "SECONDARY",
            "title": "Change in Sleep Efficiency",
            "description": "Change in sleep efficiency, calculated as time spent sleeping divided by time spent in bed. This data is acquired from sleep diaries filled out by patient. (range 0-100%)",
            "reportingStatus": "NOT_POSTED",
            "timeFrame": "From baseline to 21 weeks post-randomization",
            "denomUnitsSelected": "Participants"
          },
          {
            "type": "SECONDARY",
            "title": "Change in Sleep Efficiency",
            "description": "Change in sleep efficiency, calculated as time spent sleeping divided by time spent in bed. This data is acquired from sleep diaries filled out by patient. (range 0-100%)",
            "reportingStatus": "NOT_POSTED",
            "timeFrame": "From baseline to 35 weeks post-randomization",
            "denomUnitsSelected": "Participants"
          },
          {
            "type": "SECONDARY",
            "title": "Change in Sleep Efficiency",
            "description": "Change in sleep efficiency, calculated as time spent sleeping divided by time spent in bed. This data is acquired from sleep diaries filled out by patient. (range 0-100%)",
            "reportingStatus": "NOT_POSTED",
            "timeFrame": "From baseline to 61 weeks post-randomization",
            "denomUnitsSelected": "Participants"
          },
          {
            "type": "SECONDARY",
            "title": "Change in Sleep Onset Latency",
            "description": "Sleep-onset latency (SOL; min), is based on the participants sleep diary and how many minutes it took the participants to fall asleep.",
            "reportingStatus": "NOT_POSTED",
            "timeFrame": "From baseline to 9 weeks post-randomization",
            "denomUnitsSelected": "Participants"
          },
          {
            "type": "SECONDARY",
            "title": "Change in Sleep Onset Latency",
            "description": "Sleep-onset latency (SOL; min), is based on the participants sleep diary and how many minutes it took the participants to fall asleep.",
            "reportingStatus": "NOT_POSTED",
            "timeFrame": "From baseline to 21 weeks post-randomization",
            "denomUnitsSelected": "Participants"
          },
          {
            "type": "SECONDARY",
            "title": "Change in Sleep Onset Latency",
            "description": "Sleep-onset latency (SOL; min), is based on the participants sleep diary and how many minutes it took the participants to fall asleep.",
            "reportingStatus": "NOT_POSTED",
            "timeFrame": "From baseline to 35 weeks post-randomization",
            "denomUnitsSelected": "Participants"
          },
          {
            "type": "SECONDARY",
            "title": "Change in Sleep Onset Latency",
            "description": "Sleep-onset latency (SOL; min), is based on the participants sleep diary and how many minutes it took the participants to fall asleep.",
            "reportingStatus": "NOT_POSTED",
            "timeFrame": "From baseline to 61 weeks post-randomization",
            "denomUnitsSelected": "Participants"
          },
          {
            "type": "SECONDARY",
            "title": "Change in Health Utility Score",
            "description": "Change in health utility score will be generated by applying the Short Form-6D algorithm to Short Form-12 responses. Utility values for SF-6D health states can fall between 0.30 and 1.0, where 1.0 represents full health and 0 represents death.",
            "reportingStatus": "NOT_POSTED",
            "timeFrame": "From baseline to 9 weeks post-randomization",
            "denomUnitsSelected": "Participants"
          },
          {
            "type": "SECONDARY",
            "title": "Change in Health Utility Score",
            "description": "Change in health utility score will be generated by applying the Short Form-6D algorithm to Short Form-12 responses. Utility values for SF-6D health states can fall between 0.30 and 1.0, where 1.0 represents full health and 0 represents death.",
            "reportingStatus": "NOT_POSTED",
            "timeFrame": "From baseline to 21 weeks post-randomization",
            "denomUnitsSelected": "Participants"
          },
          {
            "type": "SECONDARY",
            "title": "Change in Health Utility Score",
            "description": "Change in health utility score will be generated by applying the Short Form-6D algorithm to Short Form-12 responses. Utility values for SF-6D health states can fall between 0.30 and 1.0, where 1.0 represents full health and 0 represents death.",
            "reportingStatus": "NOT_POSTED",
            "timeFrame": "From baseline to 35 weeks post-randomization",
            "denomUnitsSelected": "Participants"
          },
          {
            "type": "SECONDARY",
            "title": "Change in Health Utility Score",
            "description": "Change in health utility score will be generated by applying the Short Form-6D algorithm to Short Form-12 responses. Utility values for SF-6D health states can fall between 0.30 and 1.0, where 1.0 represents full health and 0 represents death.",
            "reportingStatus": "NOT_POSTED",
            "timeFrame": "From baseline to 61 weeks post-randomization",
            "denomUnitsSelected": "Participants"
          },
          {
            "type": "SECONDARY",
            "title": "Change in Quality of Life (MCS)",
            "description": "Change in quality of life as measured in the Short Form 12 (SF-12). The mental health component (MCS) score ranges from 0-100 with higher scores representing better self-reported mental health.",
            "reportingStatus": "POSTED",
            "paramType": "MEDIAN",
            "dispersionType": "Inter-Quartile Range",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "From baseline to 9 weeks post-randomization",
            "groups": [
              {
                "id": "OG000",
                "title": "PEAR-003b PDT Intervention",
                "description": "Participants will receive the PEAR-003b digital therapeutic, a Fitbit, and materials on sleep hygiene and healthy sleep tips. Using the Hugo platform, patient-generated engagement data, healthcare utilization, and patient activity/clinical outcomes for patients with insomnia will also be collected.\n\nPEAR-003b PDT Intervention: The PEAR-003b digital therapeutic delivers CBT-I via mobile devices as 6 treatment core modules over 9 weeks.\n\nFitbit: Patients will receive a Fitbit and receive standard of care\n\nSleep education materials: Patients will receive sleep hygiene and healthy sleep tips."
              },
              {
                "id": "OG001",
                "title": "Control Arm",
                "description": "Participants will receive a Fitbit, and materials on sleep hygiene and healthy sleep tips. Using the Hugo platform, patient-generated engagement data, healthcare utilization, and patient activity/clinical outcomes for patients with insomnia will also be collected.\n\nFitbit: Patients will receive a Fitbit and receive standard of care\n\nSleep education materials: Patients will receive sleep hygiene and healthy sleep tips."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "27" },
                  { "groupId": "OG001", "value": "30" }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "2.2",
                        "lowerLimit": "-0.4",
                        "upperLimit": "8.1"
                      },
                      {
                        "groupId": "OG001",
                        "value": "3.0",
                        "lowerLimit": "-1.2",
                        "upperLimit": "6.8"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Change in Quality of Life (MCS)",
            "description": "Change in quality of life as measured in the Short Form 12 (SF-12). The mental health component (MCS) score ranges from 0-100 with higher scores representing better self-reported mental health.",
            "reportingStatus": "POSTED",
            "paramType": "MEDIAN",
            "dispersionType": "Inter-Quartile Range",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "From baseline to 21 weeks post-randomization",
            "groups": [
              {
                "id": "OG000",
                "title": "PEAR-003b PDT Intervention",
                "description": "Participants will receive the PEAR-003b digital therapeutic, a Fitbit, and materials on sleep hygiene and healthy sleep tips. Using the Hugo platform, patient-generated engagement data, healthcare utilization, and patient activity/clinical outcomes for patients with insomnia will also be collected.\n\nPEAR-003b PDT Intervention: The PEAR-003b digital therapeutic delivers CBT-I via mobile devices as 6 treatment core modules over 9 weeks.\n\nFitbit: Patients will receive a Fitbit and receive standard of care\n\nSleep education materials: Patients will receive sleep hygiene and healthy sleep tips."
              },
              {
                "id": "OG001",
                "title": "Control Arm",
                "description": "Participants will receive a Fitbit, and materials on sleep hygiene and healthy sleep tips. Using the Hugo platform, patient-generated engagement data, healthcare utilization, and patient activity/clinical outcomes for patients with insomnia will also be collected.\n\nFitbit: Patients will receive a Fitbit and receive standard of care\n\nSleep education materials: Patients will receive sleep hygiene and healthy sleep tips."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "20" },
                  { "groupId": "OG001", "value": "30" }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "1.7",
                        "lowerLimit": "-5.2",
                        "upperLimit": "12.3"
                      },
                      {
                        "groupId": "OG001",
                        "value": "2.0",
                        "lowerLimit": "-1.6",
                        "upperLimit": "7.7"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Change in Quality of Life (MCS)",
            "description": "Change in quality of life as measured in the Short Form 12 (SF-12). The mental health component (MCS) score ranges from 0-100 with higher scores representing better self-reported mental health.",
            "reportingStatus": "POSTED",
            "paramType": "MEDIAN",
            "dispersionType": "Inter-Quartile Range",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "From baseline to 35 weeks post-randomization",
            "groups": [
              {
                "id": "OG000",
                "title": "PEAR-003b PDT Intervention",
                "description": "Participants will receive the PEAR-003b digital therapeutic, a Fitbit, and materials on sleep hygiene and healthy sleep tips. Using the Hugo platform, patient-generated engagement data, healthcare utilization, and patient activity/clinical outcomes for patients with insomnia will also be collected.\n\nPEAR-003b PDT Intervention: The PEAR-003b digital therapeutic delivers CBT-I via mobile devices as 6 treatment core modules over 9 weeks.\n\nFitbit: Patients will receive a Fitbit and receive standard of care\n\nSleep education materials: Patients will receive sleep hygiene and healthy sleep tips."
              },
              {
                "id": "OG001",
                "title": "Control Arm",
                "description": "Participants will receive a Fitbit, and materials on sleep hygiene and healthy sleep tips. Using the Hugo platform, patient-generated engagement data, healthcare utilization, and patient activity/clinical outcomes for patients with insomnia will also be collected.\n\nFitbit: Patients will receive a Fitbit and receive standard of care\n\nSleep education materials: Patients will receive sleep hygiene and healthy sleep tips."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "22" },
                  { "groupId": "OG001", "value": "21" }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "3.2",
                        "lowerLimit": "-5.4",
                        "upperLimit": "6.4"
                      },
                      {
                        "groupId": "OG001",
                        "value": "5.7",
                        "lowerLimit": "-1.0",
                        "upperLimit": "9.9"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Change in Quality of Life (MCS)",
            "description": "Change in quality of life as measured in the Short Form 12 (SF-12). The mental health component (MCS) score ranges from 0-100 with higher scores representing better self-reported mental health.",
            "reportingStatus": "POSTED",
            "paramType": "MEDIAN",
            "dispersionType": "Inter-Quartile Range",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "From baseline to 61 weeks post-randomization",
            "groups": [
              {
                "id": "OG000",
                "title": "PEAR-003b PDT Intervention",
                "description": "Participants will receive the PEAR-003b digital therapeutic, a Fitbit, and materials on sleep hygiene and healthy sleep tips. Using the Hugo platform, patient-generated engagement data, healthcare utilization, and patient activity/clinical outcomes for patients with insomnia will also be collected.\n\nPEAR-003b PDT Intervention: The PEAR-003b digital therapeutic delivers CBT-I via mobile devices as 6 treatment core modules over 9 weeks.\n\nFitbit: Patients will receive a Fitbit and receive standard of care\n\nSleep education materials: Patients will receive sleep hygiene and healthy sleep tips."
              },
              {
                "id": "OG001",
                "title": "Control Arm",
                "description": "Participants will receive a Fitbit, and materials on sleep hygiene and healthy sleep tips. Using the Hugo platform, patient-generated engagement data, healthcare utilization, and patient activity/clinical outcomes for patients with insomnia will also be collected.\n\nFitbit: Patients will receive a Fitbit and receive standard of care\n\nSleep education materials: Patients will receive sleep hygiene and healthy sleep tips."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "23" },
                  { "groupId": "OG001", "value": "21" }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "1.9",
                        "lowerLimit": "-2.9",
                        "upperLimit": "6.7"
                      },
                      {
                        "groupId": "OG001",
                        "value": "2.2",
                        "lowerLimit": "-2.5",
                        "upperLimit": "10.8"
                      }
                    ]
                  }
                ]
              }
            ]
          }
        ]
      },
      "adverseEventsModule": {
        "frequencyThreshold": "5",
        "timeFrame": "up to 61 weeks post-randomization",
        "eventGroups": [
          {
            "id": "EG000",
            "title": "PEAR-003b PDT Intervention",
            "description": "Participants will receive the PEAR-003b digital therapeutic, a Fitbit, and materials on sleep hygiene and healthy sleep tips. Using the Hugo platform, patient-generated engagement data, healthcare utilization, and patient activity/clinical outcomes for patients with insomnia will also be collected.\n\nPEAR-003b PDT Intervention: The PEAR-003b digital therapeutic delivers CBT-I via mobile devices as 6 treatment core modules over 9 weeks.\n\nFitbit: Patients will receive a Fitbit and receive standard of care\n\nSleep education materials: Patients will receive sleep hygiene and healthy sleep tips.",
            "deathsNumAffected": 0,
            "deathsNumAtRisk": 50,
            "seriousNumAffected": 0,
            "seriousNumAtRisk": 50,
            "otherNumAffected": 0,
            "otherNumAtRisk": 50
          },
          {
            "id": "EG001",
            "title": "Control Arm",
            "description": "Participants will receive a Fitbit, and materials on sleep hygiene and healthy sleep tips. Using the Hugo platform, patient-generated engagement data, healthcare utilization, and patient activity/clinical outcomes for patients with insomnia will also be collected.\n\nFitbit: Patients will receive a Fitbit and receive standard of care\n\nSleep education materials: Patients will receive sleep hygiene and healthy sleep tips.",
            "deathsNumAffected": 0,
            "deathsNumAtRisk": 50,
            "seriousNumAffected": 0,
            "seriousNumAtRisk": 50,
            "otherNumAffected": 0,
            "otherNumAtRisk": 50
          }
        ]
      },
      "moreInfoModule": {
        "certainAgreement": {
          "piSponsorEmployee": false,
          "restrictiveAgreement": false
        },
        "pointOfContact": {
          "title": "Joseph Ross, MD, MHS",
          "organization": "Yale University",
          "email": "joseph.ross@yale.edu",
          "phone": "203-785-2987"
        }
      }
    },
    "documentSection": {
      "largeDocumentModule": {
        "largeDocs": [
          {
            "typeAbbrev": "Prot_SAP",
            "hasProtocol": true,
            "hasSap": true,
            "hasIcf": false,
            "label": "Study Protocol and Statistical Analysis Plan",
            "date": "2021-12-19",
            "uploadDate": "2024-02-15T12:16",
            "filename": "Prot_SAP_000.pdf",
            "size": 547442
          },
          {
            "typeAbbrev": "ICF",
            "hasProtocol": false,
            "hasSap": false,
            "hasIcf": true,
            "label": "Informed Consent Form",
            "date": "2022-10-07",
            "uploadDate": "2024-02-15T15:23",
            "filename": "ICF_001.pdf",
            "size": 883886
          }
        ]
      }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [
          {
            "id": "D007319",
            "term": "Sleep Initiation and Maintenance Disorders"
          }
        ],
        "ancestors": [
          { "id": "D020919", "term": "Sleep Disorders, Intrinsic" },
          { "id": "D020920", "term": "Dyssomnias" },
          { "id": "D012893", "term": "Sleep Wake Disorders" },
          { "id": "D009422", "term": "Nervous System Diseases" },
          { "id": "D001523", "term": "Mental Disorders" }
        ],
        "browseLeaves": [
          {
            "id": "M10356",
            "name": "Sleep Initiation and Maintenance Disorders",
            "asFound": "Insomnia",
            "relevance": "HIGH"
          },
          { "id": "M22242", "name": "Parasomnias", "relevance": "LOW" },
          {
            "id": "M22654",
            "name": "Sleep Disorders, Intrinsic",
            "relevance": "LOW"
          },
          { "id": "M22655", "name": "Dyssomnias", "relevance": "LOW" },
          {
            "id": "M15696",
            "name": "Sleep Wake Disorders",
            "relevance": "LOW"
          },
          { "id": "M14473", "name": "Psychotic Disorders", "relevance": "LOW" },
          { "id": "M4815", "name": "Mental Disorders", "relevance": "LOW" },
          {
            "id": "T1303",
            "name": "Chronic Graft Versus Host Disease",
            "relevance": "LOW"
          }
        ],
        "browseBranches": [
          { "abbrev": "BC10", "name": "Nervous System Diseases" },
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" },
          { "abbrev": "All", "name": "All Conditions" },
          { "abbrev": "BC23", "name": "Symptoms and General Pathology" },
          { "abbrev": "Rare", "name": "Rare Diseases" }
        ]
      }
    },
    "hasResults": true
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT05412966",
        "orgStudyIdInfo": { "id": "PEAR-002-101" },
        "secondaryIdInfos": [
          {
            "id": "R44DA049493",
            "type": "NIH",
            "link": "https://reporter.nih.gov/quickSearch/R44DA049493"
          }
        ],
        "organization": {
          "fullName": "Pear Therapeutics, Inc.",
          "class": "INDUSTRY"
        },
        "briefTitle": "Feasibility Study of Novel Prescription Digital Therapeutic Supporting Unobserved Buprenorphine Initiation & Adherence",
        "officialTitle": "A Feasibility Study of PEAR-002b, a Novel Prescription Digital Therapeutic to Support Unobserved Buprenorphine Initiation and Adherence in Opioid Use Disorder Outpatients"
      },
      "statusModule": {
        "statusVerifiedDate": "2023-01",
        "overallStatus": "COMPLETED",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2022-11-04", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2022-11-23",
          "type": "ACTUAL"
        },
        "completionDateStruct": { "date": "2022-12-16", "type": "ACTUAL" },
        "studyFirstSubmitDate": "2022-05-19",
        "studyFirstSubmitQcDate": "2022-06-07",
        "studyFirstPostDateStruct": { "date": "2022-06-09", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2023-01-05",
        "lastUpdatePostDateStruct": { "date": "2023-01-09", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": {
          "name": "Pear Therapeutics, Inc.",
          "class": "INDUSTRY"
        },
        "collaborators": [
          { "name": "Kaiser Foundation Research Institute", "class": "OTHER" },
          { "name": "Whitman-Walker Institute, Inc.", "class": "OTHER_GOV" },
          { "name": "National Institute on Drug Abuse (NIDA)", "class": "NIH" },
          { "name": "Hassman Research Institute, LLC", "class": "UNKNOWN" }
        ]
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": true,
        "isUnapprovedDevice": true,
        "isUsExport": false
      },
      "descriptionModule": {
        "briefSummary": "The purpose of this study is to assess feasibility of an at-home digital therapy designed to support buprenorphine initiation and adherence.",
        "detailedDescription": "The purpose of this study is to develop and evaluate the acceptability of a novel feature for use with the prescription digital therapeutic reSET-O.\n\nThis feature aims to improve the quality of treatment for opioid use disorder (OUD) patients starting buprenorphine initiation at home by providing new digital content and withdrawal symptom assessment to support them during this process.\n\nThis study will evaluate the acceptability of this new feature and assess success of at-home buprenorphine initiation."
      },
      "conditionsModule": {
        "conditions": ["Opioid Use Disorder"],
        "keywords": ["digital therapeutic"]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "NA",
          "interventionModel": "SINGLE_GROUP",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": { "masking": "NONE" }
        },
        "enrollmentInfo": { "count": 7, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "PEAR-002B / reSET-O",
            "type": "EXPERIMENTAL",
            "description": "Digital Therapeutic",
            "interventionNames": ["Device: PEAR-002B", "Device: reSET-O"]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "PEAR-002B",
            "description": "PEAR-002B is a novel prescription digital therapeutic to support unobserved buprenorphine initiation and adherence in Opioid Use Disorder",
            "armGroupLabels": ["PEAR-002B / reSET-O"]
          },
          {
            "type": "DEVICE",
            "name": "reSET-O",
            "description": "reSET-O is an FDA-authorized mobile application treatment for opioid use disorder.",
            "armGroupLabels": ["PEAR-002B / reSET-O"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "PEAR-002B User Satisfaction Surveys",
            "description": "Satisfaction survey questions will be rated on a 5-point Likert scale ranging from \"not at all satisfied\" to \"very satisfied\". Descriptive statistics will be calculated for quantitative and ordinal endpoints",
            "timeFrame": "Week 1"
          },
          {
            "measure": "PEAR-002B Qualitative User Experience Interviews",
            "description": "Qualitative user experience interviews will be coded and analyzed using grounded theory methodology to identify common themes",
            "timeFrame": "Week 1"
          },
          {
            "measure": "Buprenorphine Initiation Success",
            "description": "Buprenorphine initiation success will be measured as the proportion of participants attending the post-buprenorphine initiation visit",
            "timeFrame": "Week 1"
          },
          {
            "measure": "Medication Adherence Rates",
            "description": "Buprenorphine adherence rates as measured by proportion of total urine samples testing positive for buprenorphine or norbuprenorphine",
            "timeFrame": "From Week 1 to Week 4"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "PEAR-002B Engagement Data",
            "description": "PEAR-002B engagement rates as measured by participant use patterns data",
            "timeFrame": "From Baseline to Week 1"
          },
          {
            "measure": "reSET-O Qualitative User Experience Interviews",
            "description": "Qualitative user experience interviews will be coded and analyzed using grounded theory methodology to identify common themes",
            "timeFrame": "Week 4"
          },
          {
            "measure": "reSET-O User Satisfaction Surveys",
            "description": "Satisfaction survey questions will be rated on a 5-point Likert scale ranging from \"not at all satisfied\" to \"very satisfied\". Descriptive statistics will be calculated for quantitative and ordinal endpoints",
            "timeFrame": "Week 4"
          }
        ],
        "otherOutcomes": [
          {
            "measure": "Abstinence From Illicit Opioids",
            "description": "Abstinence from illicit opioid use as measured by urine immunoassay to detect the presence/absence of opioids.",
            "timeFrame": "From Baseline to Week4"
          },
          {
            "measure": "Treatment Retention",
            "description": "Treatment retention measured as time to drop out (last face to face contact with a patient) and analyzed using the Kaplan Meier method",
            "timeFrame": "From Baseline to Week 4"
          },
          {
            "measure": "Device Wearing Time",
            "description": "Device wearing time as measured by EmbracePlus wearable device data",
            "timeFrame": "From Baseline to Week 4"
          },
          {
            "measure": "Physiological Biomarker Data",
            "description": "Physiological data (e.g., heart rate) as measured by EmbracePlus wearable device",
            "timeFrame": "From Baseline to Week 4"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n1. Provide written informed consent prior to any study specific assessments being performed\n2. Male or female ≥18 years of age, inclusive\n3. English proficiency to meaningfully participate in consent process, assessment and intervention\n4. Meets clinical sites criteria for buprenorphine initiation (e.g. current opioid use)\n5. Currently receiving buprenorphine outpatient treatment for OUD (Part 1) or wishing to start buprenorphine treatment\n6. Capable of using common software applications on an internet-enabled mobile device (smart phone or tablet)\n7. Interested in testing or using PEAR-002b\n8. No prior history of reSET-O use\n9. Has not participated in any other investigational drug trials within the past 30 days (or within 5 half-lives of study drug, whichever is longer) of enrollment\n10. Is considered appropriate for participation by their clinician\n\nExclusion Criteria:\n\n1. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) diagnosis of OUD and on methadone or naltrexone pharmacotherapy\n2. DSM-5 diagnosis of OUD and already on buprenorphine\n3. Planning to move out of the geographic area within 2 months\n4. Unable to use English to participate in the consent process, the interventions, or assessments\n5. Inability to comply with study procedures, due to severe medical conditions or otherwise\n6. Currently receiving inpatient treatment for OUD\n7. Women who are pregnant",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "Michael Hassman",
            "affiliation": "Hassman Research Institute, LLC",
            "role": "STUDY_DIRECTOR"
          }
        ],
        "locations": [
          {
            "facility": "Hassman Research Institute, LLC",
            "city": "Berlin",
            "state": "New Jersey",
            "zip": "08009",
            "country": "United States",
            "geoPoint": { "lat": 39.79123, "lon": -74.92905 }
          }
        ]
      }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [{ "id": "D009293", "term": "Opioid-Related Disorders" }],
        "ancestors": [
          { "id": "D000079524", "term": "Narcotic-Related Disorders" },
          { "id": "D019966", "term": "Substance-Related Disorders" },
          { "id": "D064419", "term": "Chemically-Induced Disorders" },
          { "id": "D001523", "term": "Mental Disorders" }
        ],
        "browseLeaves": [
          {
            "id": "M12244",
            "name": "Opioid-Related Disorders",
            "asFound": "Opioid Use Disorder",
            "relevance": "HIGH"
          },
          {
            "id": "M2057",
            "name": "Narcotic-Related Disorders",
            "relevance": "LOW"
          },
          {
            "id": "M21837",
            "name": "Substance-Related Disorders",
            "relevance": "LOW"
          },
          {
            "id": "M30302",
            "name": "Chemically-Induced Disorders",
            "relevance": "LOW"
          },
          { "id": "M14473", "name": "Psychotic Disorders", "relevance": "LOW" },
          { "id": "M4815", "name": "Mental Disorders", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "BC25", "name": "Substance Related Disorders" },
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" },
          { "abbrev": "All", "name": "All Conditions" }
        ]
      },
      "interventionBrowseModule": {
        "browseLeaves": [
          { "id": "M5317", "name": "Buprenorphine", "relevance": "LOW" },
          { "id": "M4033", "name": "Analgesics, Opioid", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "Analg", "name": "Analgesics" },
          { "abbrev": "CNSDep", "name": "Central Nervous System Depressants" },
          { "abbrev": "NarcAntag", "name": "Narcotic Antagonists" },
          { "abbrev": "All", "name": "All Drugs and Chemicals" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT06352177",
        "orgStudyIdInfo": { "id": "protocol-1" },
        "organization": {
          "fullName": "Milton S. Hershey Medical Center",
          "class": "OTHER"
        },
        "briefTitle": "Digital Therapeutic Lifestyle Intervention Program for Patients with MASLD",
        "officialTitle": "Efficacy of a Novel Digital Therapeutic Lifestyle Intervention Program for Patients with MASLD",
        "acronym": "ENLIGHTEN"
      },
      "statusModule": {
        "statusVerifiedDate": "2024-10",
        "overallStatus": "NOT_YET_RECRUITING",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2025-09-01", "type": "ESTIMATED" },
        "primaryCompletionDateStruct": {
          "date": "2030-01-01",
          "type": "ESTIMATED"
        },
        "completionDateStruct": { "date": "2030-04-01", "type": "ESTIMATED" },
        "studyFirstSubmitDate": "2024-02-08",
        "studyFirstSubmitQcDate": "2024-04-01",
        "studyFirstPostDateStruct": { "date": "2024-04-08", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2024-10-22",
        "lastUpdatePostDateStruct": { "date": "2024-10-24", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": {
          "type": "PRINCIPAL_INVESTIGATOR",
          "investigatorFullName": "Jonathan Stine",
          "investigatorTitle": "Fatty Liver Program Director, Penn State Health",
          "investigatorAffiliation": "Milton S. Hershey Medical Center"
        },
        "leadSponsor": {
          "name": "Milton S. Hershey Medical Center",
          "class": "OTHER"
        }
      },
      "oversightModule": {
        "oversightHasDmc": true,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": false,
        "isUsExport": false
      },
      "descriptionModule": {
        "briefSummary": "The ENLIGHTEN study that will evaluate the efficacy of a novel DTx lifestyle intervention in participants with non-cirrhotic MASH. People who have MASH, the progressive subtype of MASLD, have the highest risk for liver disease progression and poor outcomes, including cirrhosis and hepatocellular carcinoma, and greater overall mortality. Thus, these participants are expected to experience the greatest benefit from treatment.\n\nThis is a randomized, controlled trial comparing DTx lifestyle intervention in participants with non-cirrhotic MASH to standard clinical care. The study includes a screening period (up to 2 wks.) followed by randomization, 52-wk treatment period and 12-wk follow-up period (total duration up to 64 wks.)."
      },
      "conditionsModule": {
        "conditions": [
          "NASH",
          "NASH - Nonalcoholic Steatohepatitis",
          "Liver Diseases"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "interventionModelDescription": "2:1 randomization",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": { "masking": "NONE" }
        },
        "enrollmentInfo": { "count": 120, "type": "ESTIMATED" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "Standard of Care",
            "type": "NO_INTERVENTION",
            "description": "Participants in this group will receive counseling about best MASLD clinical practices in accordance with AASLD and ACSM practice guidelines Because in-office hepatology counseling for lifestyle intervention occurs every 12-24 wks,standard counseling will occur at each in-person visit. Mediterranean-informed, hypocaloric dietary counseling will be provided by a study investigator, with specific instructions to limit carbohydrates and saturated fat and enrich dietary intake with high fiber and unsaturated fats. Physical activity goals of 150 min/wk. of moderate intensity of 75 min/wk. of vigorous intensity activity will be suggested. To reinforce this education and promote self-monitoring, participants in this group will also receive a digital scale and fitness activity tracker."
          },
          {
            "label": "Intervention",
            "type": "EXPERIMENTAL",
            "description": "This commercially available program (Noom Weight) promotes clinically significant body weight loss and behavior change in multiple populations including our pilot study in individuals with MASLD. The program is delivered through a smartphone application and includes self-monitoring and feedback features for diet, physical activity, and body weight, as well as digital access to a 1:1 behavior change coach, a support group facilitated by a health coach, and a curriculum delivered via daily articles focused on nutrition, physical activity, and sustainable behavioral change.",
            "interventionNames": ["Other: Noom Weight Application"]
          }
        ],
        "interventions": [
          {
            "type": "OTHER",
            "name": "Noom Weight Application",
            "description": "This commercially available program (Noom Weight) promotes clinically significant body weight loss and behavior change in multiple populations. The program is delivered through a smartphone application and includes self-monitoring and feedback features for diet, physical activity, and body weight, as well as digital access to a 1:1 behavior change coach, a support group facilitated by a health coach, and a curriculum delivered via daily articles focused on nutrition, physical activity, and sustainable behavioral change.",
            "armGroupLabels": ["Intervention"],
            "otherNames": ["NW"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Clinically significant liver fat loss",
            "description": "Proportion of participants achieving \\>30% relative reduction in MRI-PDFF after Wk. 16.",
            "timeFrame": "16 weeks"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Sustained clinically significant body weight loss",
            "description": "Proportion of participants achieving \\>5% body weight loss after Wk. 16.",
            "timeFrame": "16 weeks"
          },
          {
            "measure": "Sustained clinically significant body weight loss",
            "description": "Proportion of participants achieving \\>5% body weight loss after Wk. 52",
            "timeFrame": "52 weeks"
          },
          {
            "measure": "Liver fat and liver stiffness using imaging analysis",
            "description": "• VCTE will assess change in liver fat and stiffness at Wks. 16",
            "timeFrame": "16 weeks"
          },
          {
            "measure": "Liver fat and liver stiffness using imaging analysis",
            "description": "• MRI-PDFF will assess change in liver fat at Wks. 16",
            "timeFrame": "16 weeks"
          },
          {
            "measure": "Liver fat and liver stiffness using imaging analysis",
            "description": "• MRE will assess change in liver stiffness at Wks. 16",
            "timeFrame": "16 weeks"
          },
          {
            "measure": "Liver fat and liver stiffness using imaging analysis",
            "description": "VCTE will assess change in liver fat and stiffness at Wks. 52.",
            "timeFrame": "52 weeks"
          },
          {
            "measure": "Liver fat and liver stiffness using imaging analysis",
            "description": "• MRI-PDFF will assess change in liver fat at Wks. 52.",
            "timeFrame": "52 weeks"
          },
          {
            "measure": "Liver fat and liver stiffness using imaging analysis",
            "description": "• MRE will assess change in liver stiffness at Wks. 52",
            "timeFrame": "52 weeks"
          },
          {
            "measure": "Clinically meaningful improvement in liver fat and stiffness",
            "description": "• Proportion of participants with \\>26% relative reduction in VCTE-measured liver stiffness (kPA) after Wks. 16",
            "timeFrame": "16 weeks"
          },
          {
            "measure": "Clinically meaningful improvement in liver fat and stiffness",
            "description": "• Proportion of participants with \\>30% relative reduction in MRI-PDFF after Wk. 16",
            "timeFrame": "16 weeks"
          },
          {
            "measure": "Clinically meaningful improvement in liver fat and stiffness",
            "description": "• Proportion of participants with \\>15% decrease in MRE-measured liver stiffness (kPA) after Wks. 16",
            "timeFrame": "16 weeks"
          },
          {
            "measure": "Clinically meaningful improvement in liver fat and stiffness",
            "description": "• Proportion of participants with \\>26% relative reduction in VCTE-measured liver stiffness (kPA) after Wks. 52",
            "timeFrame": "52 weeks"
          },
          {
            "measure": "Clinically meaningful improvement in liver fat and stiffness",
            "description": "• Proportion of participants with \\>30% relative reduction in MRI-PDFF after Wk. 52",
            "timeFrame": "52 weeks"
          },
          {
            "measure": "Clinically meaningful improvement in liver fat and stiffness",
            "description": "• Proportion of participants with \\>15% decrease in MRE-measured liver stiffness (kPA) after Wks. 52",
            "timeFrame": "52 weeks"
          },
          {
            "measure": "Circulating biomarkers of hepatic injury",
            "description": "• Change in ALT after Wks. 16",
            "timeFrame": "16 Weeks"
          },
          {
            "measure": "Circulating biomarkers of hepatic injury",
            "description": "• Proportion of participants with \\>17 IU/L decrease in ALT after Wks. 16",
            "timeFrame": "16 Weeks"
          },
          {
            "measure": "Circulating biomarkers of hepatic injury",
            "description": "• Change in AST after Wks. 16",
            "timeFrame": "16 Weeks"
          },
          {
            "measure": "Circulating biomarkers of hepatic injury",
            "description": "• Change in CK-18 after Wks. 16",
            "timeFrame": "16 Weeks"
          },
          {
            "measure": "Circulating biomarkers of hepatic injury",
            "description": "• Change in GGT after Wks. 16",
            "timeFrame": "16 Weeks"
          },
          {
            "measure": "Circulating biomarkers of hepatic injury",
            "description": "• Change in NASH Fibrotic Index after Wks. 16",
            "timeFrame": "16 Weeks"
          },
          {
            "measure": "Circulating biomarkers of hepatic injury",
            "description": "• Proportion of participants with \\>17 IU/L decrease in ALT after Wks. 16.",
            "timeFrame": "16 Weeks"
          },
          {
            "measure": "Circulating biomarkers of hepatic injury",
            "description": "• Change in ALT after Wks. 52",
            "timeFrame": "52 weeks"
          },
          {
            "measure": "Circulating biomarkers of hepatic injury",
            "description": "• Change in AST after Wks. 52",
            "timeFrame": "52 weeks"
          },
          {
            "measure": "Circulating biomarkers of hepatic injury",
            "description": "• Change in CK-18 after Wks. 52",
            "timeFrame": "52 weeks"
          },
          {
            "measure": "Circulating biomarkers of hepatic injury",
            "description": "• Change in GGT after Wks. 48.",
            "timeFrame": "52 weeks"
          },
          {
            "measure": "Circulating biomarkers of hepatic injury",
            "description": "• Change in NASH Fibrotic Index after Wks. 52.",
            "timeFrame": "52 weeks"
          },
          {
            "measure": "Circulating biomarkers of hepatic injury",
            "description": "• Proportion of participants with \\>17 IU/L decrease in ALT after Wks. 52",
            "timeFrame": "52 weeks"
          },
          {
            "measure": "Circulating biomarkers of liver fibrosis and fibrogenesis",
            "description": "• Change in Enhanced Liver Fibrosis (ELF) score after Wks. 16",
            "timeFrame": "16 Weeks"
          },
          {
            "measure": "Circulating biomarkers of liver fibrosis and fibrogenesis",
            "description": "• Change in Fibrosis-4 index (FIB-4) after Wks. 16",
            "timeFrame": "16 Weeks"
          },
          {
            "measure": "Circulating biomarkers of liver fibrosis and fibrogenesis",
            "description": "• Change in PRO-C3 after Wks. 16",
            "timeFrame": "16 Weeks"
          },
          {
            "measure": "Circulating biomarkers of liver fibrosis and fibrogenesis",
            "description": "• Change in Enhanced Liver Fibrosis (ELF) score after Wks. 52",
            "timeFrame": "52 weeks"
          },
          {
            "measure": "Circulating biomarkers of liver fibrosis and fibrogenesis",
            "description": "• Change in Fibrosis-4 index (FIB-4) after Wks. 52",
            "timeFrame": "52 weeks"
          },
          {
            "measure": "Circulating biomarkers of liver fibrosis and fibrogenesis",
            "description": "• Change in PRO-C3 after Wks. 52",
            "timeFrame": "52 weeks"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n1. Age 18-75 years at the time of signing informed consent\n2. MASH defined by any of the following within 12-months prior to SV (V1):\n\n   1. Liver biopsy with definitive MASH with NAS \\>4 with \\>1 in each component (i.e., steatosis, lobular inflammation, ballooning) or;\n   2. Imaging study (e.g., ultrasound) with hepatic steatosis and one of the following:\n\n   i) FIB-4 \\>1.3 or; ii) ELF test \\>7.7 or; iii) VCTE measured liver stiffness \\>8kPa or FAST score \\>0.35 or; iv) MRE measured liver stiffness \\>2.55kPa or MAST score \\>0.165\n3. Possession of a smartphone (iPhone6s or newer with iOS version 15.6 or above; Android device with Android version 6 or above)\n4. If participants are on GLP1-RA or other regulatory agency approved anti-obesity medication (e.g., orlistat, buproprion/naltrexone, phentermine-topiramate, phentermine, loreaserin), the medication dose must be stable (no change in dose) for the 3 mos. before SV.\n5. Stable body weight for 3 mos. before screening visit defined as \\<5% weight loss or weight gain\n\nExclusion Criteria:\n\n1. Recent (within 3 mos. of SV) participation in lifestyle intervention program or use of supplements marked for weight loss or appetite.\n2. Plans to undergo bariatric surgery or initiate anti-obesity medication.\n3. History of cirrhosis and/or hepatic decompensation (e.g., ascites, encephalopathy, variceal bleeding)\n4. Liver disease of other etiologies (e.g., viral hepatitis), including liver transplantation\n5. History of excessive alcohol consumption defined by self-report (men \\>30g/d or women \\>20g/d), AUDIT-C \\>4 or PETH \\> 20ug/L\n6. History of malignancy within last 5 yrs., excluding successful treatment of non-melanoma skin cancer\n7. Participant in any clinical trial or use of drugs under investigation for treatment of MASH within 3 mos. of SV\n8. History of type 1 diabetes or uncontrolled type 2 diabetes (A1c \\>9.5% or changes in diabetes medication doses within 3 mos. of SV)\n9. Recent (within 3 mos. of SV) initiation or change in dose of medications used to treat MASH (e.g., vitamin E, pioglitazone)\n10. Recent (within 3 mos. of SV) use of drugs associated with the development of steatotic liver disease (e.g., methotrexate, tamoxifen)\n11. Known or suspected history of drug abuse within the last 2 years prior to SV at the discretion of study investigator\n12. Vulnerable participants (e.g., protected adults under guardianship or committed to an institution by governmental or judicial order)\n13. Participants who cannot communicate with the study investigators or use digital technology reliably\n14. Severe medical comorbidities that may hinder study participation at the discretion of study investigator\n15. Current pregnancy or plans to become pregnant during the study period",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "maximumAge": "75 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "centralContacts": [
          {
            "name": "Breianna Hummer-Bair, MS",
            "role": "CONTACT",
            "phone": "717-531-0003",
            "phoneExt": "320222",
            "email": "bhummer@pennstatehealth.psu.edu"
          }
        ]
      },
      "ipdSharingStatementModule": {
        "ipdSharing": "YES",
        "description": "For this project, we anticipate data from 120 participants enrolled into the ENLIGHTEN study. There will be ten data collection points over the study duration. We will collect demographic, clinical, quality of life and outcomes information. Data will be converted to SAS and csv formats for analysis and sharing. To protect research participant personal identifying information (PII) and protected health information (PHI), all data will be de-identified prior to receipt by the repository and sharing in accordance with guidance provided for Limited Data Sets and Data Use Agreements section of NIH HIPAA Privacy Rule summary.",
        "infoTypes": ["STUDY_PROTOCOL", "SAP", "ICF", "CSR", "ANALYTIC_CODE"],
        "timeFrame": "We agree to deposit all data into the repository as soon as possible but no later than within one year of the completion of the funded project period for the parent award or upon acceptance of the main outcome data for publication. The data shared will be archived and available on the platform for request by researchers for a minimum of 10 years after contribution. Data will be made accessible no later than the time of our associated publication or the end of the grant period (whichever comes first).",
        "accessCriteria": "We will make the data available via the Vivli platform. Vivli is a non-profit clinical research data sharing platform that has been created to meet the needs of researchers who use and produce clinical research data worldwide. Using the Vivli platform, researchers can share or access anonymized data using a managed access process. To access anonymized individual patient-level data (IPD) arising from this project, users complete the Vivli data request form and sign the Vivli Data Use Agreement, which limits subsequent use to the terms of the approved proposal and requires that users maintain data security, and refrain from any attempts to re-identify research participants or engage in unauthorized uses of the data. Vivli will then make the data available via secure download. Researchers have a requirement to publish their findings as part of the Data Use Agreement and once the project is complete, must confirm that the original data and documents have been destroyed.",
        "url": "https://vivli.org/"
      }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [
          { "id": "D008107", "term": "Liver Diseases" },
          { "id": "D005234", "term": "Fatty Liver" },
          { "id": "D065626", "term": "Non-alcoholic Fatty Liver Disease" }
        ],
        "ancestors": [{ "id": "D004066", "term": "Digestive System Diseases" }],
        "browseLeaves": [
          {
            "id": "M11107",
            "name": "Liver Diseases",
            "asFound": "Liver Disease",
            "relevance": "HIGH"
          },
          {
            "id": "M8375",
            "name": "Fatty Liver",
            "asFound": "Steatohepatitis",
            "relevance": "HIGH"
          },
          {
            "id": "M30540",
            "name": "Non-alcoholic Fatty Liver Disease",
            "asFound": "Nonalcoholic Steatohepatitis",
            "relevance": "HIGH"
          },
          {
            "id": "M8883",
            "name": "Gastrointestinal Diseases",
            "relevance": "LOW"
          },
          {
            "id": "M7255",
            "name": "Digestive System Diseases",
            "relevance": "LOW"
          },
          { "id": "T5868", "name": "Visceral Steatosis", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "BC06", "name": "Digestive System Diseases" },
          { "abbrev": "All", "name": "All Conditions" },
          { "abbrev": "Rare", "name": "Rare Diseases" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT06909500",
        "orgStudyIdInfo": { "id": "RG1125194" },
        "secondaryIdInfos": [
          {
            "id": "NCI-2025-01611",
            "type": "REGISTRY",
            "domain": "CTRP (Clinical Trial Reporting Program)"
          },
          {
            "id": "UH3DA057032",
            "type": "NIH",
            "link": "https://reporter.nih.gov/quickSearch/UH3DA057032"
          }
        ],
        "organization": {
          "fullName": "Fred Hutchinson Cancer Center",
          "class": "OTHER"
        },
        "briefTitle": "A Digital Intervention (ACT on Vaping App) for Vaping Cessation in Young Adult E-Cigarette Users",
        "officialTitle": "ACT on Vaping: Digital Therapeutic for Young Adult Vaping Cessation"
      },
      "statusModule": {
        "statusVerifiedDate": "2025-04",
        "overallStatus": "NOT_YET_RECRUITING",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2025-09-01", "type": "ESTIMATED" },
        "primaryCompletionDateStruct": {
          "date": "2027-05-01",
          "type": "ESTIMATED"
        },
        "completionDateStruct": { "date": "2027-05-01", "type": "ESTIMATED" },
        "studyFirstSubmitDate": "2025-03-27",
        "studyFirstSubmitQcDate": "2025-03-27",
        "studyFirstPostDateStruct": { "date": "2025-04-03", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2025-04-02",
        "lastUpdatePostDateStruct": { "date": "2025-04-04", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": {
          "name": "Fred Hutchinson Cancer Center",
          "class": "OTHER"
        },
        "collaborators": [
          { "name": "National Institute on Drug Abuse (NIDA)", "class": "NIH" }
        ]
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": false
      },
      "descriptionModule": {
        "briefSummary": "This clinical trial evaluates a smartphone application (app) called Acceptance and Commitment Therapy (ACT) on Vaping for helping young adults quit using electronic cigarettes (e-cigarettes). E-cigarettes pose numerous risks, particularly to youth and young adults. Addressing the high prevalence of e-cigarette use by young adults requires effective and accessible treatments to support current users to quit. Research shows this group prefers and benefits from newer methods of treatment delivery such as digital interventions. ACT on Vaping is a digital therapeutic intended to deliver behavioral therapy to young adults who vape to motivate and support abstinence from all nicotine and tobacco products. The app contains sessions that promote awareness of cues that trigger tobacco use and teach skills for responding to these triggers in a way that is tailored for the participant's readiness to quit. Receiving access to the ACT on Vaping app may be effective in helping young adults quit vaping.",
        "detailedDescription": "OUTLINE: Participants are randomized to 1 of 2 arms.\n\nARM I: Participants use the ACT on Vaping app (Version A) and receive a text messaging program to motivate and support quitting. Participants also receive incentivized text message check-ins at 2 weeks, 2 months, and 4 months to assess their vaping status.\n\nARM II: Participants use the ACT on Vaping app (Version B) and receive incentivized text message check-ins at 2 weeks, 2 months, and 4 months to assess their vaping status.\n\nAfter completion of study intervention, participants are followed up at 3 and 6 months."
      },
      "conditionsModule": {
        "conditions": ["Nicotine Dependence", "Tobacco-Related Carcinoma"]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "primaryPurpose": "PREVENTION",
          "maskingInfo": {
            "masking": "DOUBLE",
            "maskingDescription": "The control app will also be called ACT on Vaping in participant-facing materials, for blinding purposes; Any outcome evaluator who has direct contact with participants will remain blinded to treatment group assignment.",
            "whoMasked": ["PARTICIPANT", "OUTCOMES_ASSESSOR"]
          }
        },
        "enrollmentInfo": { "count": 1372, "type": "ESTIMATED" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "Arm I (ACT on Vaping app (Version A) + incentivized texts + intervention texts)",
            "type": "EXPERIMENTAL",
            "description": "Participants receive access to the ACT on Vaping app utilizing Acceptance and Commitment Therapy. Participants also receive text message intervention content, as well as incentivized text message check-ins at 2 weeks, 2 months, and 4 months to assess changes in vaping on study.",
            "interventionNames": [
              "Behavioral: Smartphone app",
              "Other: Text Message",
              "Other: Survey Administration"
            ]
          },
          {
            "label": "Arm II (ACT on Vaping app (Version B) + incentivized texts)",
            "type": "SHAM_COMPARATOR",
            "description": "Participants receive access to the ACT on Vaping app including health education content. Participants receive incentivized text message check-ins at 2 weeks, 2 months, and 4 months to assess changes in vaping on study.",
            "interventionNames": [
              "Behavioral: Smartphone app",
              "Other: Text Message",
              "Other: Survey Administration"
            ]
          }
        ],
        "interventions": [
          {
            "type": "BEHAVIORAL",
            "name": "Smartphone app",
            "description": "Receive access to the ACT on Vaping app",
            "armGroupLabels": [
              "Arm I (ACT on Vaping app (Version A) + incentivized texts + intervention texts)"
            ],
            "otherNames": ["ACT on Vaping (Version A)"]
          },
          {
            "type": "BEHAVIORAL",
            "name": "Smartphone app",
            "description": "Receive access to the ACT on Vaping app",
            "armGroupLabels": [
              "Arm II (ACT on Vaping app (Version B) + incentivized texts)"
            ],
            "otherNames": ["ACT on Vaping (Version B)"]
          },
          {
            "type": "OTHER",
            "name": "Text Message",
            "description": "Receive incentivized text messages to access vaping status",
            "armGroupLabels": [
              "Arm I (ACT on Vaping app (Version A) + incentivized texts + intervention texts)",
              "Arm II (ACT on Vaping app (Version B) + incentivized texts)"
            ],
            "otherNames": ["SMS Text"]
          },
          {
            "type": "OTHER",
            "name": "Text Message",
            "description": "Receive intervention text messages",
            "armGroupLabels": [
              "Arm I (ACT on Vaping app (Version A) + incentivized texts + intervention texts)"
            ],
            "otherNames": ["SMS Text"]
          },
          {
            "type": "OTHER",
            "name": "Survey Administration",
            "description": "Ancillary studies",
            "armGroupLabels": [
              "Arm I (ACT on Vaping app (Version A) + incentivized texts + intervention texts)",
              "Arm II (ACT on Vaping app (Version B) + incentivized texts)"
            ]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Cotinine-confirmed 7-day point prevalence abstinence from all nicotine and tobacco",
            "description": "Biochemically confirmed 7-day abstinence from all nicotine and tobacco (excluding FDA-approved pharmacotherapies).",
            "timeFrame": "At 6 months post-randomization"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Self-reported 7-day point prevalence abstinence from all nicotine and tobacco",
            "description": "Proportion of participants self-reporting 7-day abstinence from all nicotine and tobacco (excluding FDA-approved pharmacotherapies).",
            "timeFrame": "At 6 months post-randomization"
          },
          {
            "measure": "Self-reported 7-day point prevalence abstinence from all nicotine and tobacco",
            "description": "Proportion of participants self-reporting 7-day abstinence from all nicotine and tobacco (excluding FDA-approved pharmacotherapies).",
            "timeFrame": "At 3 months post-randomization"
          },
          {
            "measure": "Cotinine-confirmed 7-day point prevalence abstinence from all nicotine and tobacco",
            "description": "Biochemically-confirmed 7-day abstinence from all nicotine and tobacco (excluding FDA-approved pharmacotherapies).",
            "timeFrame": "3 At 3 months post-randomization"
          },
          {
            "measure": "Self-reported 30-day point prevalence abstinence from all nicotine and tobacco",
            "description": "Proportion of participants self-reporting 30-day abstinence from all nicotine and tobacco (including FDA-approved pharmacotherapies).",
            "timeFrame": "At 3 months post-randomization"
          },
          {
            "measure": "Self-reported 30-day point prevalence abstinence from all nicotine and tobacco",
            "description": "Proportion of participants self-reporting 30-day abstinence from all nicotine and tobacco (including FDA-approved pharmacotherapies).",
            "timeFrame": "At 6 months post-randomization"
          },
          {
            "measure": "Self-reported 7-day point prevalence abstinence from vaping",
            "description": "Proportion of participants self-reporting 7-day abstinence from vaping.",
            "timeFrame": "At 3 months post-randomization"
          },
          {
            "measure": "Self-reported 30-day point prevalence abstinence from vaping",
            "description": "Proportion of participants self-reporting 30-day abstinence from vaping.",
            "timeFrame": "At 3 months post-randomization"
          },
          {
            "measure": "Self-reported 7-day point prevalence abstinence from vaping",
            "description": "Proportion of participants self-reporting 7-day abstinence from vaping.",
            "timeFrame": "At 6 months post-randomization"
          },
          {
            "measure": "Self-reported 30-day point prevalence abstinence from vaping",
            "description": "Proportion of participants self-reporting 30-day abstinence from vaping.",
            "timeFrame": "At 6 months post-randomization"
          },
          {
            "measure": "Number of 24-hour quit attempts",
            "description": "Number of times between baseline and 3-month follow-up that participant stopped using all nicotine and tobacco (excluding FDA-approved pharmacotherapies) for 24 hours or longer.",
            "timeFrame": "Baseline to 3 months post-randomization"
          },
          {
            "measure": "Prolonged self-reported abstinence from all nicotine and tobacco for 90 days",
            "description": "Proportion of participants self-reporting no nicotine or tobacco use (excluding FDA-approved pharmacotherapies) for 90 days prior to 6-month follow-up.",
            "timeFrame": "At 6 months post-randomization"
          },
          {
            "measure": "Change in readiness to quit using electronic cigarettes (e-cigarettes) on the Contemplation Ladder",
            "description": "Self-reported motivation to quit smoking e-cigarettes (Contemplation Ladder), rated 1-10. Higher scores indicate greater motivation to quit \\[i.e., high (\\>5) vs. low (5 or less)\\].",
            "timeFrame": "Baseline to 3 months post-randomization"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* Age 18-30\n* Age of majority (to provide informed consent) in current state/territory of residence\n* Current weekly user of e-cigarette product(s) for the last 30 days\n* Has a smartphone; either an Android (running version 12 or higher) or iPhone (running iOS version 17 or higher, iPhone 11 or more recent)\n* Experience downloading and using one or more apps on their smartphone\n* Have a mobile data plan and/or access to WiFi to support the use of the ACT on Vaping app\n* Has access to text messaging\n* Has an email address\n* United States (US) resident, with a US mailing address\n* Willing to complete all study procedures\n* Comfortable reading and writing in English\n\nExclusion Criteria:\n\n* Currently using other tobacco cessation treatments at the time of screening, including pharmacotherapy or behavioral support (note: use of these treatment is allowable during trial participation)\n* Member of the same household as another research participant\n* Currently in prison\n* Google voice number as sole phone number, due to its association with fraudulent study entry attempts\n* Is ineligible per fraud prevention protocol\n* Employees/family of investigator or study center",
        "healthyVolunteers": true,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "maximumAge": "30 Years",
        "stdAges": ["ADULT"]
      },
      "contactsLocationsModule": {
        "centralContacts": [
          {
            "name": "Jaimee Heffner, PhD",
            "role": "CONTACT",
            "phone": "206-667-7314",
            "email": "jheffner@fredhutch.org"
          }
        ],
        "overallOfficials": [
          {
            "name": "Jaimee Heffner, PhD",
            "affiliation": "Fred Hutch/University of Washington Cancer Consortium",
            "role": "PRINCIPAL_INVESTIGATOR"
          }
        ],
        "locations": [
          {
            "facility": "Fred Hutch/University of Washington Cancer Consortium",
            "city": "Seattle",
            "state": "Washington",
            "zip": "98109",
            "country": "United States",
            "contacts": [
              {
                "name": "Jaimee Heffner, PhD",
                "role": "CONTACT",
                "phone": "206-667-7314",
                "email": "jheffner@fredhutch.org"
              },
              {
                "name": "Jaimee Heffner, PhD",
                "role": "PRINCIPAL_INVESTIGATOR"
              }
            ],
            "geoPoint": { "lat": 47.60621, "lon": -122.33207 }
          }
        ]
      },
      "ipdSharingStatementModule": {
        "ipdSharing": "YES",
        "description": "We plan to preserve \\& share the following scientific data:\n\n* Survey Data: De-identified individual \\& aggregate survey data (including raw and recoded data) necessary to replicate main outcomes will be shared\n* App utilization data: Individual level, de-identified aggregate data necessary to replicate main outcomes will be shared\n\nDocumentation made publicly available to the research community will also include PDFs of the following:\n\n* Survey instruments with proprietary measures redacted\n* A description of the data collection methods\n* Copies of study consent forms \\& other relevant documentation of IRB approval \\& limitations on data sharing or usage\n* Survey codebook\n* Methods used to code or summarize open-text survey responses\n* Steps taken to remove direct \\& indirect identifiers in the data\n* Description of the software \\& analytical methods used in survey data analyses\n* Code used in data analyses",
        "infoTypes": ["STUDY_PROTOCOL", "SAP", "ICF", "ANALYTIC_CODE"],
        "timeFrame": "Final data submission and release of data used in publications will occur at the time of publication. Other shared data will be made available at or before the end of the project period. We will follow the data retention plan of the final selected repository, but at a minimum, we intend to ensure that data is available for a period of not less than 5 years after the end of this trial.",
        "accessCriteria": "All data sharing will be done in compliance with NIH data sharing policies, applicable laws and regulations, and in accordance with guidance from journal publishers. At this time, we plan to share scientific data and meta-data in NCI's Cancer Data Service (CDS). CDS allows open and controlled access to data to ensure access is provided to qualified researchers, data access is tracked, and users understand how to cite and credit use of the data. Data will only be shared for non-profit, non-commercial and non-proprietary purposes to qualified researchers or as allowed by CDS. Based on the nature of the data, which is not sensitive, we anticipate making it publicly available (as opposed to controlled access) but will follow final recommendations from the IRB as to whether access should be controlled.",
        "url": "https://dataservice.datacommons.cancer.gov/#/home"
      }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [{ "id": "D014029", "term": "Tobacco Use Disorder" }],
        "ancestors": [
          { "id": "D019966", "term": "Substance-Related Disorders" },
          { "id": "D064419", "term": "Chemically-Induced Disorders" },
          { "id": "D001523", "term": "Mental Disorders" }
        ],
        "browseLeaves": [
          { "id": "M5534", "name": "Carcinoma", "relevance": "LOW" },
          {
            "id": "M16785",
            "name": "Tobacco Use Disorder",
            "asFound": "Nicotine Dependence",
            "relevance": "HIGH"
          },
          {
            "id": "M21837",
            "name": "Substance-Related Disorders",
            "relevance": "LOW"
          },
          {
            "id": "M30302",
            "name": "Chemically-Induced Disorders",
            "relevance": "LOW"
          },
          { "id": "M14473", "name": "Psychotic Disorders", "relevance": "LOW" },
          { "id": "M4815", "name": "Mental Disorders", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "BC04", "name": "Neoplasms" },
          { "abbrev": "All", "name": "All Conditions" },
          { "abbrev": "BC25", "name": "Substance Related Disorders" },
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT05486611",
        "orgStudyIdInfo": { "id": "W-GenZD-004" },
        "organization": { "fullName": "Woebot Health", "class": "INDUSTRY" },
        "briefTitle": "Digital Therapeutic vs Educational App for Depression Among Adolescents",
        "officialTitle": "A Randomized Controlled Trial of a Digital Therapeutic (WB002) and Educational App (ED002) for Depression Among Adolescents"
      },
      "statusModule": {
        "statusVerifiedDate": "2022-12",
        "overallStatus": "TERMINATED",
        "whyStopped": "Terminated due to difficulty enrolling patients in the proposed time frame",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2022-08-09", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2022-10-06",
          "type": "ACTUAL"
        },
        "completionDateStruct": { "date": "2022-11-02", "type": "ACTUAL" },
        "studyFirstSubmitDate": "2022-08-01",
        "studyFirstSubmitQcDate": "2022-08-01",
        "studyFirstPostDateStruct": { "date": "2022-08-03", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2022-12-01",
        "lastUpdatePostDateStruct": { "date": "2022-12-05", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": { "name": "Woebot Health", "class": "INDUSTRY" }
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": false
      },
      "descriptionModule": {
        "briefSummary": "The primary aim of this study is to investigate the difference in depression symptoms at 4-weeks across two types of programs for addressing depressive symptoms, including Woebot (WB002) and Digital Education (ED002). The secondary aim of this study is to investigate the difference in anxiety symptoms at 4-weeks across the two programs. The tertiary aim of this study is to evaluate the feasibility, acceptability, and satisfaction of each program."
      },
      "conditionsModule": {
        "conditions": ["Depression"],
        "keywords": [
          "Mental Health",
          "Adolescent",
          "Digital Therapeutic",
          "Chatbot",
          "Mental Health App"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": { "masking": "SINGLE", "whoMasked": ["PARTICIPANT"] }
        },
        "enrollmentInfo": { "count": 6, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "W-GenZD Mobile Application Group",
            "type": "EXPERIMENTAL",
            "description": "Participants assigned to the W-GenZD mobile application group will be asked to download and use the W-GenZD mobile application that will provide information and tools through a chatbot (a computer program designed to communicate with users). Participants will be invited to use the mobile application as often as they like during the 4-week treatment period - we will encourage 5 to 10 minutes of daily use.",
            "interventionNames": ["Device: W-GenZD Mobile Application"]
          },
          {
            "label": "Digital Education Application Group",
            "type": "SHAM_COMPARATOR",
            "description": "Participants assigned to the Digital Education mobile app group will be given instructions on how to download and access the application that will provide general health information. A new article will be provided to the participant at a rate of once per week across the 4 weeks (4 articles total) and they will receive a weekly notification when a new article is available. Each article will be available for one week from release date. We expect a target dosage of roughly 30 minutes per week (120 min), which would make it comparable to Woebot (about 5 min per day X 28 days = 140 min).",
            "interventionNames": [
              "Device: Digital Education Application (W-EdZD)"
            ]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "W-GenZD Mobile Application",
            "description": "W-GenZD is a mobile application program that delivers evidence-based therapy for the symptoms of mild-moderate depression and anxiety in adolescents in brief \"conversations\" with a fully automated relational agent called Woebot. It is a brief, self-guided 4 week-intervention that draws from cognitive behavioral therapy (CBT), interpersonal psychotherapy for adolescents (IPT-A), and elements of dialectical behavior therapy (DBT), depending on the presenting situation, to help the adolescent develop emotion regulation skills in the context of their everyday life. In this way, the mobile application is designed to be targeted, relevant, and integrated into the lived experience of adolescents, capable of delivering the appropriate technique for the problem at hand, at the time of need.",
            "armGroupLabels": ["W-GenZD Mobile Application Group"]
          },
          {
            "type": "DEVICE",
            "name": "Digital Education Application (W-EdZD)",
            "description": "Digital Education will be available to the participant via the 'Quest GenZ' smartphone application but will be devoid of active elements included in WB002. We will source this material from kidshealth.org, which is supported by Nemours Children's Health. We have received permission to use their content.\n\nThe materials are written at an 8th grade reading level and will include general health (e.g., food plate guide, caffeine, online safety, study skills) articles. A new article will be provided to the participant at a rate of once per week across the 4 weeks (4 articles total) and they will receive a weekly notification when a new article is available. Each article will be available for one week from release date.",
            "armGroupLabels": ["Digital Education Application Group"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Patient Health Questionnaire for Teens (PHQ-A)",
            "description": "Measure of depression severity. An 8-item abbreviated version of the PHQ-9 used to assess mood and anxiety symptoms respectively. The PHQ-8 excludes an item assessing suicidality. Total score between 0-27, where higher scores indicate greater levels of depression.",
            "timeFrame": "Change from Screening to Mid-treatment at 2 weeks; Change from Screening to Post-treatment at 4 weeks; Change from Screening to Follow-up at 6 and 8 weeks"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "General Anxiety Disorder Questionnaire (GAD-7)",
            "description": "Measure of anxiety. A 7-item brief self-report measure used to assess the frequency and severity of anxious thoughts and behaviors over the past 2 weeks. Total score between 0-21, where higher scores indicate greater levels of anxiety.",
            "timeFrame": "Change from Baseline to Mid-treatment at 2 weeks; Change from Baseline to Post-treatment at 4 weeks; Change from Baseline to Follow-up at 6 and 8 weeks"
          },
          {
            "measure": "Children's Depression Rating Scale-Revised (CDRS-R)",
            "description": "Measure of depression. The CDRS-R is a brief rating scale based on a semi-structured interview with the child. Designed for 6- to 12-year-olds, it has been successfully used with adolescents. Seventeen symptom areas are assessed during the interview with a 5- to 7-point rating scale: Impaired Schoolwork, Difficulty Having Fun, Social Withdrawal, Appetite Disturbance, Sleep Disturbance, Excessive Fatigue, Physical Complaints, Irritability, Excessive Guilt, Low Self-Esteem, Depressed Feelings, Morbid Ideation, Suicidal Ideation, Excessive Weeping, Depressed Facial Affect, Listless Speech, and Hypoactivity. Total scores range from 17- 113. A score of ≥40 is indicative of depression, whereas a score ≤28 is often used to define remission (minimal or no symptoms).",
            "timeFrame": "Change from Baseline to Post-treatment at 4 weeks"
          },
          {
            "measure": "PROMIS Pediatric Global Health (PGH-7)",
            "description": "Measure of global health. A 7-item self-report measure of a child's global health developed for children and adolescents in the 8-17 age range. Items assess general, physical, mental, and social health, with response options on a 5-point likert scale. Total score ranges from 1-35, where higher scores indicate better health.",
            "timeFrame": "Change from Baseline to Post-treatment at 4 weeks; Change from Baseline to Follow-up at 8 weeks"
          },
          {
            "measure": "Client Satisfaction Questionnaire (CSQ-8)",
            "description": "An 8-item measure used to assess client's satisfaction with treatment on a 4-point scale (1 = \"very dissatisfied\" to 4 = \"very satisfied\"). Example questions include, \"How would you rate the quality of service you received\"? and \"Did you get the kind of service you wanted?\" Total sums range from 8-32, with high scores indicating greater satisfaction with the W-GenZD mobile application or the W-EdZD mobile application.",
            "timeFrame": "Post-treatment at 4 weeks"
          },
          {
            "measure": "Usage Rating Profile - Intervention (URPI)-Feasibility",
            "description": "Measure of feasibility. A 6-item subscale that inquires about factors that impact treatment usage (i.e., intervention quality). Responses range from 1 = \"slightly disagree\" to 6 = \"strongly agree\". Scores are averages, with greater scores indicating greater intervention feasibility.",
            "timeFrame": "Post-treatment at 4 weeks"
          },
          {
            "measure": "Usage Rating Profile - Intervention (URPI)-Acceptability",
            "description": "Measure of acceptability. A 6-item subscale that inquires about intervention acceptability. Responses range from 1 = \"slightly disagree\" to 6 = \"strongly agree\". Scores are averages, with greater scores indicating greater intervention acceptability.",
            "timeFrame": "Post-treatment at 4 weeks"
          },
          {
            "measure": "Working Alliance Inventory - Short Revised (WAI-SR)",
            "description": "Measure of working alliance. A measure of therapeutic alliance that assesses three key aspects of the therapeutic alliance: (a) agreement on the tasks of therapy, (b) agreement on the goals of therapy and (c) development of an affective bond. Scores range from 5-20, with higher scores indicating greater alliance. The present study utilized the validated 12-item Short-Revised version (WAI-SR) with minor changes to language, replacing \"therapist\" with \"Woebot\" for participants randomized to the W-GenZD treatment arm.",
            "timeFrame": "Day 4; Change from Day 4 to Post-treatment at 4 weeks"
          },
          {
            "measure": "Alexithymia Questionnaire for Children (AQC)",
            "description": "Measure of the alexithymia construct. A self-report questionnaire based on the original Toronto Alexithymia Scale (TAS-20), revised with language oriented toward children and adolescents. A total of 20 items comprises the AQC, with responses on a 3-point Likert-scale (ranging from 0 = not true to 2 = often true). The AQC measures 3 core factors including difficulty identifying feelings (7 items), difficulty describing feelings (5 items), and externally-oriented thinking (8 items). Higher total scores correspond to an elevated presence of the factor. Emotional awareness can be measured using the 12 items that make up the difficulty identifying feelings and difficulty describing feelings factors, so we will be administering these subscales.",
            "timeFrame": "Change from Baseline to Day 4; Change from Baseline to Post-treatment at 4 weeks"
          },
          {
            "measure": "Cognitive Flexibility Inventory (CFI)",
            "description": "Measure of cognitive flexibility. A 20-item assessment designed to measure three aspects of cognitive flexibility: the tendency to perceive difficult situations as controllable; the ability to perceive multiple alternative explanations for life occurrences and human behavior; and the ability to generate multiple alternative solutions to difficult situations. Total scores range from 7-140, with Alternatives scale ranging from 7-91 and Control scale from 7-49. There are currently no established cutoff scores for high, moderate, and low flexibility across the scales, though higher scores indicate greater flexibility.",
            "timeFrame": "Change from Baseline to Post-treatment at 4 weeks"
          },
          {
            "measure": "CAR, RELAX, ALONE, FORGET, FRIENDS, TROUBLE (CRAFFT)",
            "description": "Measure of substance use. A validated 9-item screening tool designed to identify substance use past 12 months, substance-related risk, and substance use disorder in adolescents aged 12-21. Total CRAFFT scores range from 0-6, where a score of 0 indicates low risk level, a score \\<2 is medium risk, and a score \\>= 2 is deemed high risk.",
            "timeFrame": "Baseline"
          },
          {
            "measure": "Woebot Reflection Questionnaire (WRQ)",
            "description": "Measure of user perceptions on three domains: symptoms, abilities, and quality of life. The 17-item measure assesses user perceptions on symptoms, abilities, and quality of life over the past 2 weeks. The Symptoms domain consists of 4-items asking the user to rate the severity of symptoms related to their mood, such as sadness, stress, irritability, and negative thoughts. The 7-item Abilities domain assesses how well users were able to copy, complete, or navigate responsibilities, activities, or emotions. The Quality of Life domain is 6-items and assesses the frequency of users experienced physical and social wellbeing. All responses are presented with Likert responses. This measure has not undergone psychometric testing and will be used in this study to evaluate its preliminary validity and sensitivity to change against more validated measures.",
            "timeFrame": "Change from Baseline to Post-treatment at 4 weeks; Change from Baseline to Follow-up at 8 weeks"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n1. Be 13-17.5 years of age\n2. Be a U.S. Resident\n3. Able to read and write in English\n4. If currently on medication: regular, stable dose of antidepressant medications (e.g., escitalopram/Lexapro, fluoxetine/Prozac) for at least 60 days at screening\n5. If currently receiving psychotherapy: must be in therapy for at least 4 weeks at screening\n6. Own or have regular access to a smartphone (operating systems: Android 6 or later and iOS 13 or later) that can receive SMS messages, and has reliable Wi-Fi access or sufficient data to engage with study app\n7. Available and committed to engage with the program for a 8-week duration and complete assessments\n8. Participants must be able to understand and willing to provide informed assent and to comply with all study procedures and restrictions\n9. Willingness to provide parent/guardian contact information to provide eConsent and participate in clinical interviews\n\nExclusion Criteria:\n\n1. PHQ-A score less than 10\n2. Lifetime diagnosis of a psychotic disorder (including schizophrenia or schizoaffective disorder)\n3. Lifetime diagnosis of bipolar disorder\n4. Lifetime diagnosis of autism spectrum disorder or pervasive developmental disorder (e.g., Asperger syndrome, Rett's syndrome, or pervasive developmental disorder not otherwise specified)\n5. Current (past year) diagnosis of a substance use disorder\n6. Suicide attempt or suicidal ideation with plan and intent within the past 12 months\n7. Previous Woebot application use\n8. Enrollment of more than one member of the same household",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "13 Years",
        "maximumAge": "17 Years",
        "stdAges": ["CHILD"]
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "Athena Robinson, PhD",
            "affiliation": "Woebot Health",
            "role": "PRINCIPAL_INVESTIGATOR"
          }
        ],
        "locations": [
          {
            "facility": "Woebot Health",
            "city": "San Francisco",
            "state": "California",
            "zip": "94105",
            "country": "United States",
            "geoPoint": { "lat": 37.77493, "lon": -122.41942 }
          }
        ]
      }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [
          { "id": "D003863", "term": "Depression" },
          { "id": "D003866", "term": "Depressive Disorder" }
        ],
        "ancestors": [
          { "id": "D001526", "term": "Behavioral Symptoms" },
          { "id": "D019964", "term": "Mood Disorders" },
          { "id": "D001523", "term": "Mental Disorders" }
        ],
        "browseLeaves": [
          {
            "id": "M7061",
            "name": "Depressive Disorder",
            "asFound": "Depression",
            "relevance": "HIGH"
          },
          {
            "id": "M7058",
            "name": "Depression",
            "asFound": "Depression",
            "relevance": "HIGH"
          },
          { "id": "M4818", "name": "Behavioral Symptoms", "relevance": "LOW" },
          { "id": "M21835", "name": "Mood Disorders", "relevance": "LOW" },
          { "id": "M14473", "name": "Psychotic Disorders", "relevance": "LOW" },
          { "id": "M4815", "name": "Mental Disorders", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" },
          { "abbrev": "All", "name": "All Conditions" }
        ]
      },
      "interventionBrowseModule": {
        "browseLeaves": [
          { "id": "M5373", "name": "Caffeine", "relevance": "LOW" },
          { "id": "T370", "name": "Caffeine", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "CNSSti", "name": "Central Nervous System Stimulants" },
          { "abbrev": "All", "name": "All Drugs and Chemicals" },
          { "abbrev": "Ot", "name": "Other Dietary Supplements" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT05897242",
        "orgStudyIdInfo": { "id": "RG1122763" },
        "secondaryIdInfos": [
          {
            "id": "NCI-2022-10010",
            "type": "REGISTRY",
            "domain": "CTRP (Clinical Trial Reporting Program)"
          },
          {
            "id": "UG3DA057032",
            "type": "NIH",
            "link": "https://reporter.nih.gov/quickSearch/UG3DA057032"
          }
        ],
        "organization": {
          "fullName": "Fred Hutchinson Cancer Center",
          "class": "OTHER"
        },
        "briefTitle": "A Smartphone Application (ACT on Vaping) for Vaping Cessation in Young Adults",
        "officialTitle": "ACT on Vaping: Digital Therapeutic for Young Adult Vaping Cessation"
      },
      "statusModule": {
        "statusVerifiedDate": "2024-05",
        "overallStatus": "COMPLETED",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2024-01-04", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2024-04-26",
          "type": "ACTUAL"
        },
        "completionDateStruct": { "date": "2024-04-26", "type": "ACTUAL" },
        "studyFirstSubmitDate": "2023-05-31",
        "studyFirstSubmitQcDate": "2023-05-31",
        "studyFirstPostDateStruct": { "date": "2023-06-09", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2024-05-21",
        "lastUpdatePostDateStruct": { "date": "2024-05-23", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": {
          "name": "Fred Hutchinson Cancer Center",
          "class": "OTHER"
        },
        "collaborators": [
          { "name": "National Institute on Drug Abuse (NIDA)", "class": "NIH" }
        ]
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": false
      },
      "descriptionModule": {
        "briefSummary": "Almost one in ten young adults report current e-cigarette use, putting them at risk of developing nicotine addiction and long-term health effects of exposure to inhaled toxicants. Despite the need for effective treatments to help these young users quit, very few treatments targeting any type of tobacco use among young adults have been evaluated, particularly for young adults who vape and have unique treatment needs. To address these needs, this trial will evaluate a digital program for young adult e-cigarette users at all stages of readiness to quit called ACT on Vaping.",
        "detailedDescription": "OUTLINE:\n\nParticipants are randomized to 1 of 2 arms.\n\nARM I: Participants use the ACT on Vaping smartphone app and text messaging program and receive incentivized text messages assessing their vaping status.\n\nARM II: Participants receive incentivized text messages check-ins assessing their vaping status."
      },
      "conditionsModule": {
        "conditions": [
          "Nicotine Dependence",
          "Nicotine Addiction",
          "Nicotine Use Disorder",
          "Nicotine Vaping",
          "Vaping"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "primaryPurpose": "PREVENTION",
          "maskingInfo": {
            "masking": "SINGLE",
            "maskingDescription": "Any outcome evaluator who has direct contact with participants will be blinded to treatment assignment.",
            "whoMasked": ["OUTCOMES_ASSESSOR"]
          }
        },
        "enrollmentInfo": { "count": 61, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "Arm I (Act on Vaping app)",
            "type": "EXPERIMENTAL",
            "description": "Participants receive supportive messages and use the ACT on Vaping smartphone app. They also receive incentivized text message check-ins assessing their vaping status.",
            "interventionNames": [
              "Behavioral: Smartphone app",
              "Other: Text Message",
              "Other: Survey Administration"
            ]
          },
          {
            "label": "Arm II (Incentivized text message check-ins)",
            "type": "ACTIVE_COMPARATOR",
            "description": "Participants receive incentivized text messages check-ins assessing their vaping status.",
            "interventionNames": [
              "Other: Text Message",
              "Other: Survey Administration"
            ]
          }
        ],
        "interventions": [
          {
            "type": "BEHAVIORAL",
            "name": "Smartphone app",
            "description": "Use ACT on Vaping smartphone app",
            "armGroupLabels": ["Arm I (Act on Vaping app)"],
            "otherNames": ["ACT on Vaping"]
          },
          {
            "type": "OTHER",
            "name": "Text Message",
            "description": "Receive text messages",
            "armGroupLabels": [
              "Arm I (Act on Vaping app)",
              "Arm II (Incentivized text message check-ins)"
            ],
            "otherNames": ["SMS Text"]
          },
          {
            "type": "OTHER",
            "name": "Survey Administration",
            "description": "Ancillary studies",
            "armGroupLabels": [
              "Arm I (Act on Vaping app)",
              "Arm II (Incentivized text message check-ins)"
            ]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Overall treatment satisfaction rating",
            "description": "Will calculate descriptive statistics (e.g., means, proportions) for the ACT on Vaping treatment group to assess treatment satisfaction (i.e., mean level of overall satisfaction with ACT on Vaping, with 3.5 on a 5-point scale being the \"go\" criterion).",
            "timeFrame": "At 3 months"
          },
          {
            "measure": "Change in readiness to quit",
            "description": "Will evaluate differences of Contemplation Ladder scores.",
            "timeFrame": "From baseline to 3 months post-randomization"
          },
          {
            "measure": "Self-reported 24-hour quit attempt",
            "description": "Will evaluate differences descriptively.",
            "timeFrame": "At 3 months post-randomization"
          },
          {
            "measure": "Cotinine-confirmed 30-day point prevalence abstinence from all nicotine and tobacco",
            "description": "Will evaluate differences descriptively.",
            "timeFrame": "At 3 months post-randomization"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* Age 18-30.\n* Current weekly user of e-cigarette product(s).\n* Owns an Android phone or iPhone.\n* Has an email address.\n* United States (US) resident, with a US mailing address.\n* Willing to complete all study procedures.\n\nExclusion Criteria:\n\n* Currently using other tobacco cessation treatments at the time of screening, including pharmacotherapy or behavioral support (note: use of these treatments is allowable during trial participation).\n* Member of the same household as another research participant.",
        "healthyVolunteers": true,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "maximumAge": "30 Years",
        "stdAges": ["ADULT"]
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "Jaimee Heffner",
            "affiliation": "Fred Hutch/University of Washington Cancer Consortium",
            "role": "PRINCIPAL_INVESTIGATOR"
          }
        ],
        "locations": [
          {
            "facility": "Fred Hutch/University of Washington Cancer Consortium",
            "city": "Seattle",
            "state": "Washington",
            "zip": "98109",
            "country": "United States",
            "geoPoint": { "lat": 47.60621, "lon": -122.33207 }
          }
        ]
      },
      "ipdSharingStatementModule": { "ipdSharing": "NO" }
    },
    "documentSection": {
      "largeDocumentModule": {
        "largeDocs": [
          {
            "typeAbbrev": "ICF",
            "hasProtocol": false,
            "hasSap": false,
            "hasIcf": true,
            "label": "Informed Consent Form",
            "date": "2023-12-20",
            "uploadDate": "2024-03-21T15:16",
            "filename": "ICF_000.pdf",
            "size": 3862444
          }
        ]
      }
    },
    "annotationSection": {
      "annotationModule": {
        "unpostedAnnotation": {
          "unpostedResponsibleParty": "Jaimee Heffner, Associate Professor, Fred Hutchinson Cancer Center",
          "unpostedEvents": [
            { "type": "RELEASE", "date": "2025-04-22" },
            { "type": "RESET", "date": "2025-05-06" }
          ]
        }
      }
    },
    "derivedSection": {
      "miscInfoModule": {
        "versionHolder": "2025-05-07",
        "submissionTracking": {
          "estimatedResultsFirstSubmitDate": "2025-04-22",
          "submissionInfos": [
            { "releaseDate": "2025-04-22", "resetDate": "2025-05-06" }
          ]
        }
      },
      "conditionBrowseModule": {
        "meshes": [{ "id": "D014029", "term": "Tobacco Use Disorder" }],
        "ancestors": [
          { "id": "D019966", "term": "Substance-Related Disorders" },
          { "id": "D064419", "term": "Chemically-Induced Disorders" },
          { "id": "D001523", "term": "Mental Disorders" }
        ],
        "browseLeaves": [
          { "id": "M19100", "name": "Behavior, Addictive", "relevance": "LOW" },
          {
            "id": "M16785",
            "name": "Tobacco Use Disorder",
            "asFound": "Nicotine Use Disorder",
            "relevance": "HIGH"
          },
          {
            "id": "M21837",
            "name": "Substance-Related Disorders",
            "relevance": "LOW"
          },
          {
            "id": "M30302",
            "name": "Chemically-Induced Disorders",
            "relevance": "LOW"
          },
          { "id": "M14473", "name": "Psychotic Disorders", "relevance": "LOW" },
          { "id": "M4815", "name": "Mental Disorders", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" },
          { "abbrev": "All", "name": "All Conditions" },
          { "abbrev": "BC25", "name": "Substance Related Disorders" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT05648786",
        "orgStudyIdInfo": {
          "id": "2R44DA047150",
          "type": "NIH",
          "link": "https://reporter.nih.gov/quickSearch/2R44DA047150"
        },
        "secondaryIdInfos": [
          {
            "id": "2R44DA047150",
            "type": "NIH",
            "link": "https://reporter.nih.gov/quickSearch/2R44DA047150"
          }
        ],
        "organization": {
          "fullName": "Square2 Systems, Inc.",
          "class": "INDUSTRY"
        },
        "briefTitle": "Socializing a Science-Based Digital Therapeutic for Substance Use Disorders",
        "officialTitle": "Socializing a Science-Based Digital Therapeutic for Substance Use Disorders"
      },
      "statusModule": {
        "statusVerifiedDate": "2024-11",
        "overallStatus": "ACTIVE_NOT_RECRUITING",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2022-11-09", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2024-12-31",
          "type": "ESTIMATED"
        },
        "completionDateStruct": { "date": "2024-12-31", "type": "ESTIMATED" },
        "studyFirstSubmitDate": "2022-12-05",
        "studyFirstSubmitQcDate": "2022-12-05",
        "studyFirstPostDateStruct": { "date": "2022-12-13", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2025-01-02",
        "lastUpdatePostDateStruct": { "date": "2025-01-06", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": {
          "type": "PRINCIPAL_INVESTIGATOR",
          "investigatorFullName": "Grabinski",
          "investigatorTitle": "Principal Investigator",
          "investigatorAffiliation": "Square2 Systems, Inc."
        },
        "leadSponsor": { "name": "Square2 Systems, Inc.", "class": "INDUSTRY" },
        "collaborators": [
          { "name": "National Institute on Drug Abuse (NIDA)", "class": "NIH" }
        ]
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": false,
        "isUsExport": false
      },
      "descriptionModule": {
        "briefSummary": "The purpose of this study is to evaluate the effectiveness of an intervention delivered on a smartphone. This study examines whether this intervention might improve treatment outcomes for people with substance use disorders. The intervention, called Laddr®, is a smartphone application (\"app\") that provides information and skills that can help people stop using substances. The social version of Laddr® being tested in this study has new features that allow people in treatment for substance use disorders to include a support person in their treatment journey, including a friend, family member, or other acquaintance. This research study will compare the effectiveness of Laddr® in combination with standard outpatient substance use treatment to standard treatment only for substance use disorders.",
        "detailedDescription": "Digital therapeutics, or software used to prevent, treat, or manage a medical disorder or disease, are redefining the future of healthcare by providing on-demand access to state-of-the-science care. Digital therapeutics have been developed to treat a wide range of disorders, including substance use disorders (SUD). Developed by the study Principal Investigator (PI) and Co-Investigator (Co-I), Laddr® is a unique mobile platform integrating science-based therapeutic processes to address a wide range of behavioral problems, including SUD.\n\nThe current project expands Laddr® to allow users to engage a support network of their choosing in their journey of behavioral change. Individuals can share data from Laddr about their successes and challenges, and their support network can offer anytime/anywhere social support. Social support will be embedded within a strongly science-based digital therapeutic process - thus providing support persons with a clear framework in which to offer support. Research has shown that engaging a support network of non-substance users (e.g., family members, friends) in one's SUD treatment can greatly enhance treatment outcomes - and is aligned with the \"community reinforcement\" tenet of the CRA treatment model. Interventions that leverage social support networks can help keep individuals engaged in treatment, reinforce their successes, and help them troubleshoot challenges.\n\nThis pragmatic, randomized controlled trial aims to evaluate the effectiveness of the social version of Laddr® in improving SUD treatment outcomes. Adults entering outpatient SUD treatment at the Farnum Center in Manchester, New Hampshire (NH) will be offered the opportunity to be randomized to 12 weeks of standard treatment (treatment as usual \\[TAU\\] arm), or standard treatment plus the social version of Laddr® (Laddr® arm). The primary study outcome is retention in SUD treatment (time to treatment dropout), and the investigators hypothesize that participants receiving Laddr® will be retained in treatment for a longer duration. Secondary outcomes include participant substance use (self-report and urine toxicology), stages of change, coping skills, recovery capital, and treatment acceptability."
      },
      "conditionsModule": {
        "conditions": [
          "Substance Use Disorders",
          "Substance-Related Disorders"
        ],
        "keywords": [
          "Digital therapeutic",
          "Smartphone",
          "Social support",
          "Randomized controlled trial"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": { "masking": "NONE" }
        },
        "enrollmentInfo": { "count": 189, "type": "ESTIMATED" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "Standard outpatient treatment plus Laddr®",
            "type": "EXPERIMENTAL",
            "description": "Laddr® is a smartphone application integrating science-based, therapeutic processes to address a wide range of behavioral problems in the context of a single mobile platform. Laddr includes tools for activating behavior change, solving problems and overcoming obstacles to effective behavior change; teaching skills and providing guidance on the execution of behavior change; and maintaining the end user's motivation to change. It enables longitudinal assessment of individuals' behavior and health status in naturalistic contexts, offers science-based self-regulation behavior change tools of relevance to an array of populations, and enables ongoing monitoring of health behavior. This study evaluates the effectiveness of new features to Laddr®. These new features are designed to be used with a support person, which could include a friend, family member, or acquaintance.\n\nIn addition to Laddr®, participants will receive standard outpatient substance use disorder treatment.",
            "interventionNames": [
              "Behavioral: Laddr® plus Behavioral- Group and individual counseling"
            ]
          },
          {
            "label": "Standard outpatient treatment",
            "type": "ACTIVE_COMPARATOR",
            "description": "The active control condition consists of standard outpatient treatment for substance use disorders. Outpatient treatment will include a range of services, including group counseling, individual counseling, medication treatment, and other recovery support services.",
            "interventionNames": [
              "Behavioral: Behavioral- Group and individual counseling"
            ]
          }
        ],
        "interventions": [
          {
            "type": "BEHAVIORAL",
            "name": "Laddr® plus Behavioral- Group and individual counseling",
            "description": "Smartphone application utilizing the Community Reinforcement Approach (CRA) to facilitate social support in substance use treatment.\n\nOutpatient treatment will include a range of services, including group counseling, individual counseling, medication treatment, and other recovery support services.",
            "armGroupLabels": ["Standard outpatient treatment plus Laddr®"]
          },
          {
            "type": "BEHAVIORAL",
            "name": "Behavioral- Group and individual counseling",
            "description": "The active control condition consists of standard outpatient treatment for substance use disorders. Outpatient treatment will include a range of services, including group counseling, individual counseling, medication treatment, and other recovery support services.",
            "armGroupLabels": ["Standard outpatient treatment"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Retention in treatment Retention in treatment Retention in treatment Retention in treatment Retention in treatment",
            "description": "Time between randomization and dropout from standard outpatient treatment",
            "timeFrame": "16 weeks"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Substance use composite measure (Timeline Follow-Back and Urine Toxicology)",
            "description": "Abstinence from substance use. Each half-week of treatment will be categorized as abstinent if the toxicology screen is negative and the self-report indicates no drug use/heavy drinking days. If self-report is missing but the urine screen is positive, the half-week will be scored as not abstinent.",
            "timeFrame": "16 weeks"
          },
          {
            "measure": "Stages of Change Readiness and Treatment Eagerness Scale (SOCRATES)",
            "description": "Motivation to change substance use. SOCRATES scores are calculated for three domains of change readiness, Recognition (Range: 7-35), Ambivalence (Range: 4-20), and Taking Steps (Range: 8-40), with higher scores indicating higher levels of change readiness.",
            "timeFrame": "16 weeks"
          },
          {
            "measure": "Coping Strategies Scale (CSS)",
            "description": "Assessment of strategies to refuse drugs, solve problems, avoid high risk situations, cope with cravings, manage emotions, and develop assertiveness. The CSS total score is calculated by taking the mean of all items and will range from 1-4 points, with higher scores indicating more frequent use of coping strategies.",
            "timeFrame": "16 weeks"
          },
          {
            "measure": "Assessment of Recovery Capital (ARC)",
            "description": "Assessment of resources to help in recovery. This 50 item assessment is scored by assigning one point for each \"Yes\" response. Total scores range from 0-50 with higher scores indicating higher recovery capital.",
            "timeFrame": "16 weeks"
          },
          {
            "measure": "Treatment acceptability",
            "description": "Acceptability of the treatment model will be assessed among both patients in SUD treatment (for both treatment conditions) and support persons in the Laddr condition. Acceptability will be comprised of both utility and satisfaction with each treatment model across five indicators (0-10 point scales) asking how useful (not at all to very), how much new information (none to a great deal), how easy to understand (very easy to very difficult; reverse coded), how interesting (not at all to very), and how satisfied (not at all to very) they were with the treatment condition to which they were exposed.",
            "timeFrame": "16 weeks"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* In first 30 days of new outpatient treatment episode at the Farnum Center\n* 18 years of age or older\n* Ability to provide informed consent\n* Has access to a functioning smartphone\n* Able to identify a support person who can participate in the study with them\n* Available to participate for the full duration of the study.\n\nExclusion Criteria:\n\n* Inability to understand or read English.",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "facility": "Farnum Center",
            "city": "Manchester",
            "state": "New Hampshire",
            "zip": "03103",
            "country": "United States",
            "geoPoint": { "lat": 42.99564, "lon": -71.45479 }
          }
        ]
      },
      "ipdSharingStatementModule": { "ipdSharing": "NO" }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [{ "id": "D019966", "term": "Substance-Related Disorders" }],
        "ancestors": [
          { "id": "D064419", "term": "Chemically-Induced Disorders" },
          { "id": "D001523", "term": "Mental Disorders" }
        ],
        "browseLeaves": [
          {
            "id": "M21837",
            "name": "Substance-Related Disorders",
            "asFound": "Substance Use Disorders",
            "relevance": "HIGH"
          },
          {
            "id": "M30302",
            "name": "Chemically-Induced Disorders",
            "relevance": "LOW"
          },
          { "id": "M14473", "name": "Psychotic Disorders", "relevance": "LOW" },
          { "id": "M4815", "name": "Mental Disorders", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "BC25", "name": "Substance Related Disorders" },
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" },
          { "abbrev": "All", "name": "All Conditions" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT05227898",
        "orgStudyIdInfo": { "id": "PROT004" },
        "organization": {
          "fullName": "Blue Note Therapeutics",
          "class": "INDUSTRY"
        },
        "briefTitle": "Virtual Trial to Compare Two Digital Therapeutics as Interventions for Physical and Mental Health in People With Cancer",
        "officialTitle": "Two-arm, Double-blind, Randomized Controlled Trial to Compare Efficacy of Two Digital Software Medical Devices as Interventions for Physical and Mental Health in Patients With Stage I-III Cancer",
        "acronym": "RESTORE"
      },
      "statusModule": {
        "statusVerifiedDate": "2022-10",
        "overallStatus": "UNKNOWN",
        "lastKnownStatus": "ACTIVE_NOT_RECRUITING",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2022-03-10", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2022-12-02",
          "type": "ESTIMATED"
        },
        "completionDateStruct": { "date": "2022-12-15", "type": "ESTIMATED" },
        "studyFirstSubmitDate": "2022-01-06",
        "studyFirstSubmitQcDate": "2022-01-22",
        "studyFirstPostDateStruct": { "date": "2022-02-08", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2022-10-18",
        "lastUpdatePostDateStruct": { "date": "2022-10-25", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": {
          "name": "Blue Note Therapeutics",
          "class": "INDUSTRY"
        },
        "collaborators": [{ "name": "Curebase Inc.", "class": "INDUSTRY" }]
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": true,
        "isUnapprovedDevice": true,
        "isUsExport": false
      },
      "descriptionModule": {
        "briefSummary": "This is a 2-arm randomized controlled study comparing how effective two therapeutic digital software devices are at improving anxiety and other indicators of psychological and physical health in patients with cancer. The study will be completely virtual, meaning participants can take part completely from home without visiting a clinic or study site.\n\nThe digital software devices, called called attune™ and cerena™, are designed to be used for approximately 12 weeks alongside oncology usual care regimens (medical, psychosocial). The study will enroll at least 352 stage I-III cancer patients with elevated anxiety symptoms who are currently receiving systemic treatment (radiation, chemotherapy, immunotherapy), have received systemic treatment within the last 6 months, or who have an established treatment plan that includes systemic treatment."
      },
      "conditionsModule": {
        "conditions": ["Cancer"],
        "keywords": [
          "Breast Cancer",
          "Colon/Rectal Cancer",
          "Endometrial Cancer",
          "Lymphoma",
          "Leukemia",
          "Lung Cancer",
          "Ovarian Cancer",
          "Pancreatic Cancer",
          "Prostate Cancer",
          "Thyroid Cancer"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": {
            "masking": "DOUBLE",
            "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]
          }
        },
        "enrollmentInfo": { "count": 352, "type": "ESTIMATED" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "Attune™",
            "type": "ACTIVE_COMPARATOR",
            "description": "Attune™ is a completely digital therapeutic intervention.",
            "interventionNames": ["Device: Device: Attune™"]
          },
          {
            "label": "Cerena™",
            "type": "ACTIVE_COMPARATOR",
            "description": "Cerena™ is a completely digital therapeutic intervention.",
            "interventionNames": ["Device: Device: Cerena™"]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "Device: Attune™",
            "description": "People enrolled in the study use the app to complete ten informational sessions, each approximately 60-minute in length. The app also include guided exercises and other interactive opportunities.",
            "armGroupLabels": ["Attune™"]
          },
          {
            "type": "DEVICE",
            "name": "Device: Cerena™",
            "description": "People enrolled in the study use the app to complete ten informational sessions, each approximately 60-minute in length. The app also include guided exercises and other interactive opportunities.",
            "armGroupLabels": ["Cerena™"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Symptoms of anxiety",
            "description": "The PROMIS-Anxiety (PROMIS-A) is a validated PRO consisting of 8 questions measuring anxiety symptoms. The change in PROMIS-A score over time will be assessed (reduction indicates reduced anxiety).",
            "timeFrame": "Baseline up to week 12"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Symptoms of depression",
            "description": "The PROMIS-Depression (PROMIS-D) is a validated PRO consisting of 8 questions measuring depression symptoms. The change in PROMIS-D score over time will be assessed (decrease indicates reduced depression).",
            "timeFrame": "Baseline up to week 12"
          },
          {
            "measure": "Symptoms of emotional distress",
            "description": "Change in PROMIS Emotional Distress; a composite of PROMIS-Anxiety and PROMIS-Depression over time (decrease indicates reduced emotional distress).",
            "timeFrame": "Baseline up to week 12"
          },
          {
            "measure": "Positive and negative affect",
            "description": "The Positive and Negative Affect Schedule Short Form (PANAS-SF) measures positive and negative affect. Change in PANAS-SF scores over time will be assessed (increase in Positive Affect Scale indicates increase in positive emotions and expression; decrease in Negative Affect Scale indicates decrease in negative emotions and expression).",
            "timeFrame": "Baseline up to week 12"
          },
          {
            "measure": "Cancer-related symptoms of anxiety (thought intrusions)",
            "description": "The Impact of Events Scale-Revised (IES-R) is used to assess subjective distress caused by a stressful life event. The change in the IES-R Intrusion subscale mean score over time will be assessed (decrease in Intrusion score indicates reduced intrusive symptoms related to a specific stressor).",
            "timeFrame": "Baseline up to week 12"
          },
          {
            "measure": "Wellbeing and quality of life",
            "description": "The Functional Assessment of Cancer Therapy - General (FACT-G) is designed to measure four domains of HRQOL in cancer patients: Physical, social, emotional, and functional well-being. The change in FACT-G scores over time will be assessed (a reduction in the FACT-G total score, derived from the subscale scores, indicates an increased health-related quality of life).",
            "timeFrame": "Baseline up to Week 12"
          },
          {
            "measure": "Global Improvement-Likert Scale",
            "description": "The Global Improvement-Likert Scale uses a Likert scale to assess participant self-perception of the level of improvement of their overall well-being, symptoms of anxiety, and symptoms of depression since they began the study.",
            "timeFrame": "Baseline up to Week 12"
          },
          {
            "measure": "Symptom-related distress",
            "description": "The Rotterdam Symptom Checklist (RSCL) is measures health-related quality of life of cancer patients. This study uses the same Likert scale and a subset of the symptoms (\"eye strain\" and \"headache\") that are part of the Rotterdam Symptom Checklist with the addition of the symptom \"finger cramping\" to monitor for all potential device adverse effects.",
            "timeFrame": "Baseline up to week 12"
          },
          {
            "measure": "Perceived stress",
            "description": "The Perceived Stress Scale (PSS) measures how different situations affect feelings and perceived stress. The change in PSS scores over time will be assessed (higher PSS scores indicate higher perceived stress).",
            "timeFrame": "Baseline up to Week 12"
          },
          {
            "measure": "Level of stress management skill and coping skill efficacy (PAM)",
            "description": "The Patient Activation Measure (PAM) is used to assess the knowledge, skills, and confidence to manage one's health. The change in PAM scores over time will be assessed (higher PAM scores indicate higher patient activation).",
            "timeFrame": "Baseline up to Week 12"
          },
          {
            "measure": "Level of stress management skill and coping skill efficacy (MOCS Part A)",
            "description": "The Measure of Current Status (MOCS) Part A measures self-perceived status for using coping skills. The change in MOCS Part A scores over time will be assessed (increase indicates greater confidence in skill use ability).",
            "timeFrame": "Baseline up to Week 12"
          },
          {
            "measure": "Non-specific (social) intervention effects",
            "description": "The Measure of Current Status (MOCS) Part B assesses non-specific intervention effects - feelings of normalcy vs. alienation, sense of cohesiveness with other patients, perceptions of care from persons around them, and a sense of being better off than other cancer patients. The change in MOCS Part B scores over time will be assessed (increase indicates greater non-specific intervention effects).",
            "timeFrame": "Baseline up to Week 12"
          },
          {
            "measure": "Benefit Finding",
            "description": "The Benefit Finding Scale (BFS) assesses the perception that positive contributions were made to one's life by the experience of being diagnosed with and treated for cancer. The change in BFS scores over time will be assessed",
            "timeFrame": "Baseline up to Week 12"
          },
          {
            "measure": "Safety of each digital product",
            "description": "Self-reported device related adverse events; 3-item Distress Assessment and Response Tool (DART) self-reported to monitor suicidality.",
            "timeFrame": "Baseline up to Week 12"
          },
          {
            "measure": "Usability of each digital product",
            "description": "mHealth App Usability Questionnaire (MAUQ) mean scores will be measured at end of study (higher scores indicate higher ease of use / easier to use applications).",
            "timeFrame": "Week 12"
          },
          {
            "measure": "Acceptability of each digital product",
            "description": "Net promoter score (NPS), an index ranging from -100 to 100 that measures willingness to recommend the digital products, will be measured at end of study.",
            "timeFrame": "Week 12"
          }
        ],
        "otherOutcomes": [
          {
            "measure": "Healthcare utilization",
            "description": "Incidence of ER visits, hospitalization, 30-day readmission rates, and average LOS for hospitalization",
            "timeFrame": "Baseline up to Week 12"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* Stage I-III cancer diagnosis\n* Currently in active systemic treatment of chemotherapy, radiation or immunotherapy, have completed systemic treatment within the past 6 months, or have a treatment plan including planned systemic treatment.\n* Are experiencing at least moderate anxiety\n* 18 years of age or older\n* Are fluent in English\n* Have access to a smartphone (a mobile phone that performs many of the functions of a computer, typically having a touchscreen interface, internet access, and an operating system capable of running downloaded applications) or tablet that runs iOS or Android software, with cellular data service or wifi access.\n* Willing to download software onto smartphone or tablet from Apple store or Android store\n\nExclusion Criteria:\n\n* Systemic treatment plan includes only endocrine therapy.\n* Treatment plan includes stem cell/bone marrow transplant.\n* Currently participating in any other investigative CBT trial for treatment of anxiety or depression.\n* Participant is unable to complete training, has cognitive deficits, more severe psychiatric conditions, lack of access to internet accessible device or psycho-social conditions (e.g., other social conditions, that would interfere with adherence to self-directed care), such that in investigator's opinion the participant would be unable to complete the study\n* Recently completed use of Blue Note Therapeutics Covid Cancer Care Program or other Blue Note Therapeutics device or Blue Note Therapeutics-sponsored study\n* Are experiencing severe levels of depression OR indicate suicidal risk (measured by surveys during screening for the study)\n* Are experiencing anxiety below the required level (measured by a survey during screening for the study)\n* Cancer diagnosis is melanoma, multiple myeloma, unstaged cancer.",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "Dianne M Shumay",
            "affiliation": "Blue Note Therapeutics",
            "role": "PRINCIPAL_INVESTIGATOR"
          }
        ],
        "locations": [
          {
            "facility": "Www.Restoreclinicaltrial.Com",
            "city": "San Francisco",
            "state": "California",
            "zip": "94104",
            "country": "United States",
            "geoPoint": { "lat": 37.77493, "lon": -122.41942 }
          }
        ]
      }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "browseLeaves": [
          { "id": "M5220", "name": "Breast Neoplasms", "relevance": "LOW" },
          { "id": "M11172", "name": "Lung Neoplasms", "relevance": "LOW" },
          { "id": "M16723", "name": "Thyroid Neoplasms", "relevance": "LOW" },
          { "id": "M16718", "name": "Thyroid Diseases", "relevance": "LOW" },
          { "id": "M14335", "name": "Prostatic Neoplasms", "relevance": "LOW" },
          { "id": "M11220", "name": "Lymphoma", "relevance": "LOW" },
          {
            "id": "M13110",
            "name": "Pancreatic Neoplasms",
            "relevance": "LOW"
          },
          { "id": "M10945", "name": "Leukemia", "relevance": "LOW" },
          { "id": "M12974", "name": "Ovarian Neoplasms", "relevance": "LOW" },
          {
            "id": "M1704",
            "name": "Carcinoma, Ovarian Epithelial",
            "relevance": "LOW"
          },
          { "id": "T4387", "name": "Pancreatic Cancer", "relevance": "LOW" },
          { "id": "T4352", "name": "Ovarian Cancer", "relevance": "LOW" },
          { "id": "T3543", "name": "Lymphosarcoma", "relevance": "LOW" },
          {
            "id": "T4354",
            "name": "Ovarian Epithelial Cancer",
            "relevance": "LOW"
          }
        ],
        "browseBranches": [
          { "abbrev": "BC04", "name": "Neoplasms" },
          { "abbrev": "BC17", "name": "Skin and Connective Tissue Diseases" },
          { "abbrev": "All", "name": "All Conditions" },
          {
            "abbrev": "BC08",
            "name": "Respiratory Tract (Lung and Bronchial) Diseases"
          },
          { "abbrev": "BC19", "name": "Gland and Hormone Related Diseases" },
          {
            "abbrev": "BXS",
            "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
          },
          { "abbrev": "BC15", "name": "Blood and Lymph Conditions" },
          { "abbrev": "BC20", "name": "Immune System Diseases" },
          { "abbrev": "BC06", "name": "Digestive System Diseases" },
          { "abbrev": "Rare", "name": "Rare Diseases" }
        ]
      },
      "interventionBrowseModule": {
        "browseLeaves": [
          { "id": "M6263", "name": "Coal Tar", "relevance": "LOW" },
          { "id": "T120", "name": "Cola", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "Derm", "name": "Dermatologic Agents" },
          { "abbrev": "All", "name": "All Drugs and Chemicals" },
          { "abbrev": "HB", "name": "Herbal and Botanical" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT03369626",
        "orgStudyIdInfo": { "id": "dmstudyv4" },
        "organization": { "fullName": "FareWell", "class": "INDUSTRY" },
        "briefTitle": "Effectiveness of a Digital Therapeutic on Type 2 Diabetes",
        "officialTitle": "Effectiveness of a Digital Therapeutic in a Geographically Distributed Population With Type 2 Diabetes"
      },
      "statusModule": {
        "statusVerifiedDate": "2019-08",
        "overallStatus": "COMPLETED",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2017-07-26", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2018-01-31",
          "type": "ACTUAL"
        },
        "completionDateStruct": { "date": "2018-02-28", "type": "ACTUAL" },
        "studyFirstSubmitDate": "2017-12-06",
        "studyFirstSubmitQcDate": "2017-12-08",
        "studyFirstPostDateStruct": { "date": "2017-12-12", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2019-08-19",
        "lastUpdatePostDateStruct": { "date": "2019-08-21", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": { "name": "FareWell", "class": "INDUSTRY" }
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": false
      },
      "descriptionModule": {
        "briefSummary": "A clinical study evaluating a three month digitally delivered lifestyle change program in adults with Type 2 Diabetes. The FareWell Program (the \"Program\") aims to reduce well-established biomarkers of cardiometabolic diseases, weight, and medications. The current study is designed to evaluate to what degree adults with Type 2 Diabetes engaged with the Program can improve glycemic control and/or decrease medication needs.",
        "detailedDescription": "The Program aims to reduce well-established biomarkers of cardiometabolic diseases, weight, and medications. It includes meal planning tools, smart shopping lists, recipes curated by a physician, dietitian and chef educator, daily self-monitoring features with personalized weekly goals, bi-weekly live one-on-one health coaching and support from an online member community, and an educational curriculum. Subjects in the Program may receive support from other members of a Care Team (lifestyle medicine physician, chef educator, registered dietitian and/or psychologist/psychiatrist) as needed. The Care Team does not provide medical advice, nor replace traditional medical care. Instead, the Care Team encourages behavior change by providing support and sharing its expertise.\n\nStudy participants will have access to the Program for a twelve week period and will be asked to complete short health surveys at baseline and at the end of the study."
      },
      "conditionsModule": { "conditions": ["Type2 Diabetes"] },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "NA",
          "interventionModel": "SINGLE_GROUP",
          "interventionModelDescription": "evaluation of pre/post measures of a single group",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": { "masking": "NONE" }
        },
        "enrollmentInfo": { "count": 118, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "FareWell Program",
            "type": "OTHER",
            "description": "All participants receive the FareWell Program intervention in this evaluation study",
            "interventionNames": ["Behavioral: FareWell Program"]
          }
        ],
        "interventions": [
          {
            "type": "BEHAVIORAL",
            "name": "FareWell Program",
            "description": "The FareWell Program is a digitally delivered lifestyle management curriculum, which includes meal planning tools, daily self monitoring, personalized goal setting and bi-weekly live one-on-one health coaching.",
            "armGroupLabels": ["FareWell Program"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Level of engagement with the assigned mobile app",
            "description": "How do participants interact with the digital program (e.g. feature use, coaching calls completed, targets tracked, targets met)",
            "timeFrame": "12 weeks"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Change in self-reported Hemoglobin A1c",
            "description": "Comparison of baseline and end program self reported Hemoglobin A1c",
            "timeFrame": "12 weeks"
          },
          {
            "measure": "Change in self-reported diabetes medication type or dose",
            "description": "Comparison of diabetes medications reported at baseline to any changes reported at the end of the study or mid-study",
            "timeFrame": "12 weeks"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* diagnosis of type 2 diabetes\n\nExclusion Criteria:\n\n* Inability to understand, consent to, or comply with the study protocol for any reason, including inability to read or comprehend English.\n* Does not have a smartphone (either an iPhone or Android phone)",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "Mark Berman, MD",
            "affiliation": "FareWell",
            "role": "PRINCIPAL_INVESTIGATOR"
          }
        ],
        "locations": [
          {
            "facility": "FareWell LLC",
            "city": "San Francisco",
            "state": "California",
            "zip": "94108",
            "country": "United States",
            "geoPoint": { "lat": 37.77493, "lon": -122.41942 }
          }
        ]
      },
      "ipdSharingStatementModule": { "ipdSharing": "UNDECIDED" }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [
          { "id": "D003920", "term": "Diabetes Mellitus" },
          { "id": "D003924", "term": "Diabetes Mellitus, Type 2" }
        ],
        "ancestors": [
          { "id": "D044882", "term": "Glucose Metabolism Disorders" },
          { "id": "D008659", "term": "Metabolic Diseases" },
          { "id": "D004700", "term": "Endocrine System Diseases" }
        ],
        "browseLeaves": [
          {
            "id": "M7115",
            "name": "Diabetes Mellitus",
            "asFound": "Diabetes",
            "relevance": "HIGH"
          },
          {
            "id": "M7119",
            "name": "Diabetes Mellitus, Type 2",
            "asFound": "Type 2 Diabetes",
            "relevance": "HIGH"
          },
          { "id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW" },
          {
            "id": "M25403",
            "name": "Glucose Metabolism Disorders",
            "relevance": "LOW"
          },
          {
            "id": "M7862",
            "name": "Endocrine System Diseases",
            "relevance": "LOW"
          }
        ],
        "browseBranches": [
          { "abbrev": "BC18", "name": "Nutritional and Metabolic Diseases" },
          { "abbrev": "BC19", "name": "Gland and Hormone Related Diseases" },
          { "abbrev": "All", "name": "All Conditions" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT06318962",
        "orgStudyIdInfo": { "id": "UMemphis" },
        "secondaryIdInfos": [
          {
            "id": "SPC-1000007404 GR127268",
            "type": "OTHER",
            "domain": "Department of Defense"
          }
        ],
        "organization": {
          "fullName": "University of Memphis",
          "class": "OTHER"
        },
        "briefTitle": "Examining the Efficacy of a Digital Therapeutic to Prevent Suicidal Behaviors",
        "officialTitle": "Examining the Efficacy of a Digital Therapeutic to Prevent Suicidal Behaviors"
      },
      "statusModule": {
        "statusVerifiedDate": "2024-03",
        "overallStatus": "RECRUITING",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2024-02-07", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2027-08-01",
          "type": "ESTIMATED"
        },
        "completionDateStruct": { "date": "2027-08-01", "type": "ESTIMATED" },
        "studyFirstSubmitDate": "2024-02-26",
        "studyFirstSubmitQcDate": "2024-03-11",
        "studyFirstPostDateStruct": { "date": "2024-03-19", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2024-03-11",
        "lastUpdatePostDateStruct": { "date": "2024-03-19", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": { "name": "University of Memphis", "class": "OTHER" }
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": false
      },
      "descriptionModule": {
        "briefSummary": "The primary aim of the project is to test the efficacy of BCBT delivered via a digital platform (i.e., smartphone) to Servicemembers with recent suicidal ideation and/or suicide attempts presenting to primary care clinics. Given existing challenges of scaling empirically-supported treatments/interventions for suicidality with fidelity, this project could lead to markedly expanded access to BCBT, along with improving our understanding about what intervention strategies are most effective and how they can be delivered with meaningful fidelity. Aviva, the digital version of BCBT, was developed for use with patients across the full spectrum of healthcare settings, including primary care. Aviva is not an emergency alert system, rather a digital platform for delivery of the full scope of BCBT treatment components. An open-label single group Phase I clinical trial has demonstrated the safety, tolerability, feasibility, fidelity, and potential efficacy of Aviva, with participants completing modules over 8 weeks, and follow-up assessments at weeks 1, 4, and 8. Subsequent refinements included the addition of technical features that would allow patients to revisit and/or repeat previously completed modules, along with integration of more characters for delivering video vignettes and greater opportunities for skills practice and treatment engagement. These modifications have further enhanced Aviva safety, tolerability, and fidelity, consistent with the original BCBT protocol. Not only is it hypothesized that Aviva will result in significantly larger reductions in severity of suicidal ideation than participants randomized to the control condition, but also that greater app engagement will be negatively correlated with severity of suicidal thinking. Moderators and mediators (i.e. suicidal beliefs, wish to live, impulsive decision-making) of intervention effects will also be examined. The study will be conducted at the primary care clinics at Fort Carson, with a goal of enrolling 720 patients across a two-year timeframe. Participants will be identified using each clinic's existing suicide risk assessment methods, including the PHQ-9 suicide risk item and a score of 1 or higher on the CSSRS Screener (Recent). Participants will be randomly assigned to one of two treatment conditions, Aviva or control (i.e., development of a safety plan consistent with local procedures and policies, along with referral for standard mental health care and suicide risk management in accordance with local policies and procedures). In an effort to address potential performance bias specific to smartphone use, participants in the control condition will download the Suicide Safety Plan app to their smartphones. Those in the Aviva condition will also complete weekly check-ins with Project 2 research clinicians to review treatment adherence, identify and respond to any logistical/operational problems, and respond to any unexpected emergencies and/or participant safety concerns. Participants will have up to five data points: baseline, 3, 6, 9, and 12 months. All data available from all participants and all time points will be included in the analyses, consistent with the intent-to-treat principle. Across our two previous clinical trials and our in-progress RCT, attrition during the first 12 months postbaseline was \\&lt;30% and we anticipate similar rates in this trial.",
        "detailedDescription": "See Attached Documents"
      },
      "conditionsModule": {
        "conditions": [
          "Suicidal Behaviors",
          "Suicide Ideation",
          "Depression/Anxiety"
        ],
        "keywords": [
          "BCBT",
          "Suicide Ideation",
          "Suicide Attempts",
          "Depression and Anxiety"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": { "masking": "SINGLE", "whoMasked": ["PARTICIPANT"] }
        },
        "enrollmentInfo": { "count": 400, "type": "ESTIMATED" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "Digital Therapeutic",
            "type": "EXPERIMENTAL",
            "description": "BCBT Delivery via digital app",
            "interventionNames": ["Behavioral: Aviva"]
          },
          { "label": "Treatment as Usual", "type": "NO_INTERVENTION" }
        ],
        "interventions": [
          {
            "type": "BEHAVIORAL",
            "name": "Aviva",
            "description": "Digital phone app for BCBT",
            "armGroupLabels": ["Digital Therapeutic"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Self Injurious Thoughts and Behaviors Interview Revised",
            "description": "Suicide Attempts, self-injury and suicidal ideation",
            "timeFrame": "At intake, 3 months, 6 months, 9 months and 12 months"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Beck Scale for Suicide Ideation",
            "description": "Suicidal ideation",
            "timeFrame": "At intake, 3 months, 6 months, 9 months and 12 months"
          },
          {
            "measure": "Beck Hopelessness Scale",
            "description": "Hopelessness",
            "timeFrame": "At intake, 3 months, 6 months, 9 months and 12 months"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* at least 18 years old\n* suicidal ideation within the past week and/or a suicide attempt within the past 30 days\n* ability to complete the informed consent process\n* ownership of either an Apple iPhone iOS 11 or higher or an Android smartphone OS 8.1 or higher\n\nExclusion Criteria:\n\n* an inability to complete informed consent procedures (e.g., acute intoxication, altered consciousness)\n* experiencing active psychosis or mania requiring hospitalization; (3) and inability to use a smartphone.",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "centralContacts": [
          {
            "name": "Michael Rudd, Ph.D.",
            "role": "CONTACT",
            "phone": "901-456-0580",
            "email": "mdrudd@memphis.edu"
          },
          {
            "name": "Michelle Wine, Ph.D.",
            "role": "CONTACT",
            "phone": "719-526-7461",
            "email": "michelle.d.wine@health.mil"
          }
        ],
        "locations": [
          {
            "facility": "Fort Carson",
            "status": "RECRUITING",
            "city": "Colorado Springs",
            "state": "Colorado",
            "zip": "80829",
            "country": "United States",
            "contacts": [
              {
                "name": "Michelle Wine Chief Psychologist, Ph.D.",
                "role": "CONTACT",
                "phone": "719-526-7461",
                "email": "michelle.d.wine.civ@health.mil"
              },
              {
                "name": "Michelle Wine, Ph.D.",
                "role": "PRINCIPAL_INVESTIGATOR"
              }
            ],
            "geoPoint": { "lat": 38.83388, "lon": -104.82136 }
          }
        ]
      },
      "referencesModule": {
        "references": [
          {
            "type": "RESULT",
            "citation": "Bryan C.J., Rudd M.D. Guilford Press; 2018. Brief cognitive-behavioral therapy for suicide prevention."
          },
          {
            "pmid": "25677353",
            "type": "RESULT",
            "citation": "Rudd MD, Bryan CJ, Wertenberger EG, Peterson AL, Young-McCaughan S, Mintz J, Williams SR, Arne KA, Breitbach J, Delano K, Wilkinson E, Bruce TO. Brief cognitive-behavioral therapy effects on post-treatment suicide attempts in a military sample: results of a randomized clinical trial with 2-year follow-up. Am J Psychiatry. 2015 May;172(5):441-9. doi: 10.1176/appi.ajp.2014.14070843. Epub 2015 Feb 13."
          },
          {
            "pmid": "34602808",
            "type": "RESULT",
            "citation": "Rojas SM, Gold SD, Bryan CJ, Pruitt LD, Felker BL, Reger MA. Brief Cognitive-Behavioral Therapy for Suicide Prevention (BCBT-SP) via Video Telehealth: A Case Example During the COVID-19 Outbreak. Cogn Behav Pract. 2022 May;29(2):446-453. doi: 10.1016/j.cbpra.2020.12.001. Epub 2021 Feb 4."
          }
        ]
      },
      "ipdSharingStatementModule": { "ipdSharing": "NO" }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [
          { "id": "D003863", "term": "Depression" },
          { "id": "D013405", "term": "Suicide" }
        ],
        "ancestors": [
          { "id": "D001526", "term": "Behavioral Symptoms" },
          { "id": "D016728", "term": "Self-Injurious Behavior" }
        ],
        "browseLeaves": [
          { "id": "M4324", "name": "Anxiety Disorders", "relevance": "LOW" },
          { "id": "M7061", "name": "Depressive Disorder", "relevance": "LOW" },
          {
            "id": "M7058",
            "name": "Depression",
            "asFound": "Depression",
            "relevance": "HIGH"
          },
          {
            "id": "M16191",
            "name": "Suicide",
            "asFound": "Suicide",
            "relevance": "HIGH"
          },
          { "id": "M16192", "name": "Suicide, Attempted", "relevance": "LOW" },
          { "id": "M4818", "name": "Behavioral Symptoms", "relevance": "LOW" },
          {
            "id": "M19089",
            "name": "Self-Injurious Behavior",
            "relevance": "LOW"
          }
        ],
        "browseBranches": [
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" },
          { "abbrev": "All", "name": "All Conditions" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT05005351",
        "orgStudyIdInfo": { "id": "Swing-004" },
        "organization": {
          "fullName": "Swing Therapeutics, Inc.",
          "class": "OTHER"
        },
        "briefTitle": "\"SMART-FM\": Smart-Phone Based Digital Therapeutic for Management of Fibromyalgia",
        "officialTitle": "\"SMART-FM\": Smart-Phone Based Digital Therapeutic for Management of Fibromyalgia",
        "acronym": "SMART-FM"
      },
      "statusModule": {
        "statusVerifiedDate": "2022-02",
        "overallStatus": "COMPLETED",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2020-10-28", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2021-07-09",
          "type": "ACTUAL"
        },
        "completionDateStruct": { "date": "2021-07-09", "type": "ACTUAL" },
        "studyFirstSubmitDate": "2021-08-10",
        "studyFirstSubmitQcDate": "2021-08-10",
        "studyFirstPostDateStruct": { "date": "2021-08-13", "type": "ACTUAL" },
        "resultsFirstSubmitDate": "2023-07-12",
        "resultsFirstSubmitQcDate": "2023-07-12",
        "resultsFirstPostDateStruct": {
          "date": "2023-08-01",
          "type": "ACTUAL"
        },
        "lastUpdateSubmitDate": "2023-07-12",
        "lastUpdatePostDateStruct": { "date": "2023-08-01", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": { "name": "Swing Therapeutics, Inc.", "class": "OTHER" }
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": true,
        "isUnapprovedDevice": true,
        "isUsExport": false
      },
      "descriptionModule": {
        "briefSummary": "This is a non-significant risk, multi-center, randomized, active-controlled study to compare the effectiveness of two digital therapies in the management of fibromyalgia over 12 weeks. The primary endpoint is mean change from baseline to Week 12 in the weekly revised Fibromyalgia Impact Questionnaire (FIQ-R) total score."
      },
      "conditionsModule": { "conditions": ["Fibromyalgia"] },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["PHASE2"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": { "masking": "NONE" }
        },
        "enrollmentInfo": { "count": 67, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "Digital Acceptance and Commitment Therapy (ACT)",
            "type": "ACTIVE_COMPARATOR",
            "interventionNames": ["Device: Digital ACT"]
          },
          {
            "label": "Digital Symptom Tracker",
            "type": "ACTIVE_COMPARATOR",
            "interventionNames": ["Device: Digital Symptom Tracker"]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "Digital ACT",
            "description": "Participants in Digital ACT arm complete daily ACT lessons and activities and continue their non-pharmacological and pharmacological treatment as usual.",
            "armGroupLabels": [
              "Digital Acceptance and Commitment Therapy (ACT)"
            ]
          },
          {
            "type": "DEVICE",
            "name": "Digital Symptom Tracker",
            "description": "Participants in the Digital Symptom Tracker arm complete daily symptom and function tracking, have access to digital fibromyalgia and health education, and continue their non-pharmacological and pharmacological treatment as usual.",
            "armGroupLabels": ["Digital Symptom Tracker"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Revised Fibromyalgia Impact Questionnaire (FIQ-R) Total Score",
            "description": "FIQ-R total score ranges between 0-100 with a reduction in score indicating reduced fibromyalgia severity.",
            "timeFrame": "Baseline to Week 12"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Key Secondary Endpoint of This Clinical Trial - Rate of Patient's Global Impression of Change (PGIC) Responders at Week 12 - Any Improvement",
            "description": "PGIC scores included are: Very much improved, much improved, minimally improved, no change, minimally worse, much worse, very much worse",
            "timeFrame": "Week 12"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Key Inclusion Criteria:\n\n1. Subject is 22 to 75 years of age, inclusive\n2. Subject has a diagnosis of primary FM as defined by the 2016 American College of Rheumatology Preliminary Diagnostic Criteria for FM, which requires satisfaction of the following criteria:\n\n   1. Widespread pain index (WPI) ≥7 and symptom severity (SS) scale score ≥5, OR WPI 4-6 and SS scale score ≥9;\n   2. Symptoms have been present at a similar level for at least 3 months;\n   3. Pain must be present in at least 4 out of 5 body regions\n3. Subject with ongoing treatments should be on stable therapy for 30 days prior to screening appointment.\n4. Subject is capable of reading and understanding English and has provided written informed consent to participate.\n\nKey Exclusion Criteria:\n\n1. Lifetime history of bipolar disorder as assessed by the MINI.\n2. Current, untreated, major depressive episode and/or anxiety disorders as assessed by the MINI.\n3. Subject has a BDI-II total score \\> 25 at either the Screening appointment or Baseline appointment.\n4. The subject is at increased risk of suicide on the basis of the investigator's judgment, a response \\> 1 to BDI item #9, or the results of the Columbia-Suicide Severity Rating Scale (\"C-SSRS\") conducted at Screening or Baseline (i.e., any suicidal behavior during the preceding year or C-SSRS Type 3, 4, or 5 suicidal ideation during the preceding year).\n5. Subject has any other disease or medical condition that, in the opinion of the Investigator or Sponsor, could endanger the subject, interfere with the evaluation of the study device's efficacy or safety, or compromise the subject's ability to comply with/complete the study.",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "22 Years",
        "maximumAge": "75 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "Michael Gendreau, MD",
            "affiliation": "Consulting Chief Medical Officer",
            "role": "STUDY_DIRECTOR"
          }
        ],
        "locations": [
          {
            "facility": "Excell Research, Inc.",
            "city": "Oceanside",
            "state": "California",
            "zip": "92056",
            "country": "United States",
            "geoPoint": { "lat": 33.19587, "lon": -117.37948 }
          },
          {
            "facility": "Superior Research LLC",
            "city": "Sacramento",
            "state": "California",
            "zip": "95831",
            "country": "United States",
            "geoPoint": { "lat": 38.58157, "lon": -121.4944 }
          },
          {
            "facility": "Clinical Neuroscience Solutions, Inc.",
            "city": "Orlando",
            "state": "Florida",
            "zip": "32801",
            "country": "United States",
            "geoPoint": { "lat": 28.53834, "lon": -81.37924 }
          },
          {
            "facility": "Upstate Clinical Research Associates LLC",
            "city": "Williamsville",
            "state": "New York",
            "zip": "14221",
            "country": "United States",
            "geoPoint": { "lat": 42.96395, "lon": -78.73781 }
          },
          {
            "facility": "University of Cincinnati Physicians Company, LLC",
            "city": "Cincinnati",
            "state": "Ohio",
            "zip": "45219",
            "country": "United States",
            "geoPoint": { "lat": 39.12713, "lon": -84.51435 }
          },
          {
            "facility": "Neuro-Behavioral Clinical Research, Inc.",
            "city": "North Canton",
            "state": "Ohio",
            "zip": "44720",
            "country": "United States",
            "geoPoint": { "lat": 40.87589, "lon": -81.40234 }
          },
          {
            "facility": "Lehigh Center for Clinical Research",
            "city": "Allentown",
            "state": "Pennsylvania",
            "zip": "18104",
            "country": "United States",
            "geoPoint": { "lat": 40.60843, "lon": -75.49018 }
          }
        ]
      },
      "referencesModule": {
        "references": [
          {
            "pmid": "37382794",
            "type": "RESULT",
            "citation": "Catella S, Gendreau RM, Kraus AC, Vega N, Rosenbluth MJ, Soefje S, Malhotra S, Luciano JV, McCracken LM, Williams DA, Arnold LM. Self-guided digital acceptance and commitment therapy for fibromyalgia management: results of a randomized, active-controlled, phase II pilot clinical trial. J Behav Med. 2024 Feb;47(1):27-42. doi: 10.1007/s10865-023-00429-3. Epub 2023 Jun 29."
          }
        ],
        "seeAlsoLinks": [
          {
            "label": "Swing Therapeutics Website",
            "url": "https://www.swingtherapeutics.com/"
          }
        ]
      },
      "ipdSharingStatementModule": { "ipdSharing": "NO" }
    },
    "resultsSection": {
      "participantFlowModule": {
        "groups": [
          {
            "id": "FG000",
            "title": "Digital Acceptance and Commitment Therapy (ACT) Arm",
            "description": "Digital ACT: Participants in Digital ACT complete daily ACT lessons and activities and continue their non-pharmacological and pharmacological treatment as usual."
          },
          {
            "id": "FG001",
            "title": "Digital Symptom Tracker Arm",
            "description": "Digital Symptom Tracker: Participants in the Digital Symptom Tracker arm complete daily symptom and function tracking, have access to digital fibromyalgia and health education, and continue their non-pharmacological and pharmacological treatment as usual."
          }
        ],
        "periods": [
          {
            "title": "Overall Study",
            "milestones": [
              {
                "type": "STARTED",
                "achievements": [
                  { "groupId": "FG000", "numSubjects": "39" },
                  { "groupId": "FG001", "numSubjects": "28" }
                ]
              },
              {
                "type": "COMPLETED",
                "achievements": [
                  { "groupId": "FG000", "numSubjects": "37" },
                  { "groupId": "FG001", "numSubjects": "27" }
                ]
              },
              {
                "type": "NOT COMPLETED",
                "achievements": [
                  { "groupId": "FG000", "numSubjects": "2" },
                  { "groupId": "FG001", "numSubjects": "1" }
                ]
              }
            ]
          }
        ]
      },
      "baselineCharacteristicsModule": {
        "groups": [
          {
            "id": "BG000",
            "title": "Digital Acceptance and Commitment Therapy (ACT)",
            "description": "Digital ACT: Participants in Digital ACT complete daily ACT lessons and activities and continue their non-pharmacological and pharmacological treatment as usual."
          },
          {
            "id": "BG001",
            "title": "Digital Symptom Tracker Arm",
            "description": "Digital Symptom Tracker: Participants in the Digital Symptom Tracker arm complete daily symptom and function tracking, have access to digital fibromyalgia and health education, and continue their non-pharmacological and pharmacological treatment as usual."
          },
          {
            "id": "BG002",
            "title": "Total",
            "description": "Total of all reporting groups"
          }
        ],
        "denoms": [
          {
            "units": "Participants",
            "counts": [
              { "groupId": "BG000", "value": "39" },
              { "groupId": "BG001", "value": "28" },
              { "groupId": "BG002", "value": "67" }
            ]
          }
        ],
        "measures": [
          {
            "title": "Age, Continuous",
            "paramType": "MEAN",
            "dispersionType": "STANDARD_DEVIATION",
            "unitOfMeasure": "Years",
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "BG000", "value": "52.2", "spread": "10.5" },
                      { "groupId": "BG001", "value": "53.6", "spread": "10.1" },
                      { "groupId": "BG002", "value": "52.8", "spread": "10.3" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Sex: Female, Male",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "Female",
                    "measurements": [
                      { "groupId": "BG000", "value": "38" },
                      { "groupId": "BG001", "value": "28" },
                      { "groupId": "BG002", "value": "66" }
                    ]
                  },
                  {
                    "title": "Male",
                    "measurements": [
                      { "groupId": "BG000", "value": "1" },
                      { "groupId": "BG001", "value": "0" },
                      { "groupId": "BG002", "value": "1" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Ethnicity (NIH/OMB)",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "Hispanic or Latino",
                    "measurements": [
                      { "groupId": "BG000", "value": "7" },
                      { "groupId": "BG001", "value": "4" },
                      { "groupId": "BG002", "value": "11" }
                    ]
                  },
                  {
                    "title": "Not Hispanic or Latino",
                    "measurements": [
                      { "groupId": "BG000", "value": "32" },
                      { "groupId": "BG001", "value": "24" },
                      { "groupId": "BG002", "value": "56" }
                    ]
                  },
                  {
                    "title": "Unknown or Not Reported",
                    "measurements": [
                      { "groupId": "BG000", "value": "0" },
                      { "groupId": "BG001", "value": "0" },
                      { "groupId": "BG002", "value": "0" }
                    ]
                  }
                ]
              }
            ]
          }
        ]
      },
      "outcomeMeasuresModule": {
        "outcomeMeasures": [
          {
            "type": "PRIMARY",
            "title": "Revised Fibromyalgia Impact Questionnaire (FIQ-R) Total Score",
            "description": "FIQ-R total score ranges between 0-100 with a reduction in score indicating reduced fibromyalgia severity.",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Error",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "Baseline to Week 12",
            "groups": [
              {
                "id": "OG000",
                "title": "Digital Acceptance and Commitment Therapy (ACT) Arm",
                "description": "Digital ACT: Participants in Digital ACT complete daily ACT lessons and activities and continue their non-pharmacological and pharmacological treatment as usual."
              },
              {
                "id": "OG001",
                "title": "Digital Symptom Tracker Arm",
                "description": "Digital Symptom Tracker: Participants in the Digital Symptom Tracker arm complete daily symptom and function tracking, have access to digital fibromyalgia and health education, and continue their non-pharmacological and pharmacological treatment as usual."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "39" },
                  { "groupId": "OG001", "value": "28" }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "-8.7", "spread": "2.0" },
                      { "groupId": "OG001", "value": "-3.0", "spread": "2.4" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Key Secondary Endpoint of This Clinical Trial - Rate of Patient's Global Impression of Change (PGIC) Responders at Week 12 - Any Improvement",
            "description": "PGIC scores included are: Very much improved, much improved, minimally improved, no change, minimally worse, much worse, very much worse",
            "reportingStatus": "POSTED",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "timeFrame": "Week 12",
            "groups": [
              {
                "id": "OG000",
                "title": "Digital Acceptance and Commitment Therapy (ACT) Arm",
                "description": "Digital ACT: Participants in Digital ACT complete daily ACT lessons and activities and continue their non-pharmacological and pharmacological treatment as usual."
              },
              {
                "id": "OG001",
                "title": "Digital Symptom Tracker Arm",
                "description": "Digital Symptom Tracker: Participants in the Digital Symptom Tracker arm complete daily symptom and function tracking, have access to digital fibromyalgia and health education, and continue their non-pharmacological and pharmacological treatment as usual."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "37" },
                  { "groupId": "OG001", "value": "27" }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "27" },
                      { "groupId": "OG001", "value": "6" }
                    ]
                  }
                ]
              }
            ]
          }
        ]
      },
      "adverseEventsModule": {
        "frequencyThreshold": "2",
        "timeFrame": "12 weeks",
        "eventGroups": [
          {
            "id": "EG000",
            "title": "Digital Acceptance and Commitment Therapy (ACT) Arm",
            "description": "Digital ACT: Participants in Digital ACT complete daily ACT lessons and activities and continue their non-pharmacological and pharmacological treatment as usual.",
            "deathsNumAffected": 0,
            "deathsNumAtRisk": 39,
            "seriousNumAffected": 0,
            "seriousNumAtRisk": 39,
            "otherNumAffected": 7,
            "otherNumAtRisk": 39
          },
          {
            "id": "EG001",
            "title": "Digital Symptom Tracker Arm",
            "description": "Digital Symptom Tracker: Participants in the Digital Symptom Tracker arm complete daily symptom and function tracking, have access to digital fibromyalgia and health education, and continue their non-pharmacological and pharmacological treatment as usual.",
            "deathsNumAffected": 0,
            "deathsNumAtRisk": 28,
            "seriousNumAffected": 0,
            "seriousNumAtRisk": 28,
            "otherNumAffected": 3,
            "otherNumAtRisk": 28
          }
        ],
        "otherEvents": [
          {
            "term": "COVID-19",
            "organSystem": "Infections and infestations",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              { "groupId": "EG000", "numAffected": 0, "numAtRisk": 39 },
              { "groupId": "EG001", "numAffected": 2, "numAtRisk": 28 }
            ]
          },
          {
            "term": "Sinus infection",
            "organSystem": "Infections and infestations",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              { "groupId": "EG000", "numAffected": 0, "numAtRisk": 39 },
              { "groupId": "EG001", "numAffected": 1, "numAtRisk": 28 }
            ]
          },
          {
            "term": "Urinary Tract Infection",
            "organSystem": "Infections and infestations",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              { "groupId": "EG000", "numAffected": 0, "numAtRisk": 39 },
              { "groupId": "EG001", "numAffected": 1, "numAtRisk": 28 }
            ]
          },
          {
            "term": "Cellulitis in Face",
            "organSystem": "Infections and infestations",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              { "groupId": "EG000", "numAffected": 0, "numAtRisk": 39 },
              { "groupId": "EG001", "numAffected": 1, "numAtRisk": 28 }
            ]
          },
          {
            "term": "Post COVID-19 Vaccination Syndrome",
            "organSystem": "Infections and infestations",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              { "groupId": "EG000", "numAffected": 1, "numAtRisk": 39 },
              { "groupId": "EG001", "numAffected": 0, "numAtRisk": 28 }
            ]
          },
          {
            "term": "Anxiety",
            "organSystem": "Psychiatric disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              { "groupId": "EG000", "numAffected": 1, "numAtRisk": 39 },
              { "groupId": "EG001", "numAffected": 0, "numAtRisk": 28 }
            ]
          },
          {
            "term": "Fever",
            "organSystem": "General disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              { "groupId": "EG000", "numAffected": 1, "numAtRisk": 39 },
              { "groupId": "EG001", "numAffected": 0, "numAtRisk": 28 }
            ]
          },
          {
            "term": "Broken Foot",
            "organSystem": "Injury, poisoning and procedural complications",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              { "groupId": "EG000", "numAffected": 1, "numAtRisk": 39 },
              { "groupId": "EG001", "numAffected": 0, "numAtRisk": 28 }
            ]
          },
          {
            "term": "Worsening Anemia",
            "organSystem": "Blood and lymphatic system disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              { "groupId": "EG000", "numAffected": 1, "numAtRisk": 39 },
              { "groupId": "EG001", "numAffected": 0, "numAtRisk": 28 }
            ]
          },
          {
            "term": "Vertigo",
            "organSystem": "Ear and labyrinth disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              { "groupId": "EG000", "numAffected": 1, "numAtRisk": 39 },
              { "groupId": "EG001", "numAffected": 0, "numAtRisk": 28 }
            ]
          },
          {
            "term": "Exacerbation of Gastroparesis",
            "organSystem": "Gastrointestinal disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              { "groupId": "EG000", "numAffected": 1, "numAtRisk": 39 },
              { "groupId": "EG001", "numAffected": 0, "numAtRisk": 28 }
            ]
          },
          {
            "term": "Headache",
            "organSystem": "Nervous system disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              { "groupId": "EG000", "numAffected": 1, "numAtRisk": 39 },
              { "groupId": "EG001", "numAffected": 0, "numAtRisk": 28 }
            ]
          },
          {
            "term": "Exacerbation of Fibromyalgia Pain",
            "organSystem": "Musculoskeletal and connective tissue disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              { "groupId": "EG000", "numAffected": 1, "numAtRisk": 39 },
              { "groupId": "EG001", "numAffected": 0, "numAtRisk": 28 }
            ]
          },
          {
            "term": "Left Side Rib Contusions",
            "organSystem": "Injury, poisoning and procedural complications",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              { "groupId": "EG000", "numAffected": 1, "numAtRisk": 39 },
              { "groupId": "EG001", "numAffected": 0, "numAtRisk": 28 }
            ]
          }
        ]
      },
      "moreInfoModule": {
        "certainAgreement": {
          "piSponsorEmployee": false,
          "restrictiveAgreement": false
        },
        "pointOfContact": {
          "title": "Clinical Project Manager",
          "organization": "Swing Therapeutics, Inc.",
          "email": "research@swingtherapeutics.com",
          "phone": "1 (415) 662-0415"
        }
      }
    },
    "documentSection": {
      "largeDocumentModule": {
        "noSap": true,
        "largeDocs": [
          {
            "typeAbbrev": "Prot",
            "hasProtocol": true,
            "hasSap": false,
            "hasIcf": false,
            "label": "Study Protocol",
            "date": "2021-01-10",
            "uploadDate": "2023-07-12T18:31",
            "filename": "Prot_000.pdf",
            "size": 192727
          }
        ]
      }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [
          { "id": "D005356", "term": "Fibromyalgia" },
          { "id": "D009209", "term": "Myofascial Pain Syndromes" }
        ],
        "ancestors": [
          { "id": "D009135", "term": "Muscular Diseases" },
          { "id": "D009140", "term": "Musculoskeletal Diseases" },
          { "id": "D012216", "term": "Rheumatic Diseases" },
          { "id": "D009468", "term": "Neuromuscular Diseases" },
          { "id": "D009422", "term": "Nervous System Diseases" }
        ],
        "browseLeaves": [
          {
            "id": "M8486",
            "name": "Fibromyalgia",
            "asFound": "Fibromyalgia",
            "relevance": "HIGH"
          },
          {
            "id": "M12161",
            "name": "Myofascial Pain Syndromes",
            "asFound": "Fibromyalgia",
            "relevance": "HIGH"
          },
          { "id": "M13066", "name": "Pain", "relevance": "LOW" },
          { "id": "M16355", "name": "Syndrome", "relevance": "LOW" },
          { "id": "M12092", "name": "Muscular Diseases", "relevance": "LOW" },
          {
            "id": "M12097",
            "name": "Musculoskeletal Diseases",
            "relevance": "LOW"
          },
          { "id": "M15045", "name": "Rheumatic Diseases", "relevance": "LOW" },
          { "id": "M6323", "name": "Collagen Diseases", "relevance": "LOW" },
          {
            "id": "M12411",
            "name": "Neuromuscular Diseases",
            "relevance": "LOW"
          }
        ],
        "browseBranches": [
          { "abbrev": "BC05", "name": "Musculoskeletal Diseases" },
          { "abbrev": "BC10", "name": "Nervous System Diseases" },
          { "abbrev": "All", "name": "All Conditions" },
          { "abbrev": "BC23", "name": "Symptoms and General Pathology" },
          { "abbrev": "BC17", "name": "Skin and Connective Tissue Diseases" }
        ]
      }
    },
    "hasResults": true
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT05668819",
        "orgStudyIdInfo": { "id": "TH001_1001" },
        "organization": {
          "fullName": "Tesu Saglik Teknolojileri A.S.",
          "class": "INDUSTRY"
        },
        "briefTitle": "Efficacy and Safety of Digital Therapeutic in Adults With Prediabetes",
        "officialTitle": "Open-Label, Randomized, Controlled, Parallel Group Study Evaluating Efficacy and Safety of Digital Therapeutic (TH-001) for the Treatment of Prediabetes in Adults"
      },
      "statusModule": {
        "statusVerifiedDate": "2025-01",
        "overallStatus": "COMPLETED",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2023-02-07", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2024-12-24",
          "type": "ACTUAL"
        },
        "completionDateStruct": { "date": "2024-12-24", "type": "ACTUAL" },
        "studyFirstSubmitDate": "2022-12-17",
        "studyFirstSubmitQcDate": "2022-12-24",
        "studyFirstPostDateStruct": { "date": "2022-12-30", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2025-01-08",
        "lastUpdatePostDateStruct": { "date": "2025-01-10", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": {
          "name": "Tesu Saglik Teknolojileri A.S.",
          "class": "INDUSTRY"
        }
      },
      "oversightModule": {
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": false
      },
      "descriptionModule": {
        "briefSummary": "The study aims to evaluate the efficacy and safety of a digital therapeutic (TH-001) for adult individuals with prediabetes."
      },
      "conditionsModule": {
        "conditions": ["PreDiabetes"],
        "keywords": [
          "Prediabetic State",
          "Digital Therapeutic",
          "Mobile Health",
          "Digital Health",
          "Mobile Apps",
          "Lifestyle Modification",
          "mHealth"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "interventionModelDescription": "Open-Label, Randomized, Controlled",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": { "masking": "NONE" }
        },
        "enrollmentInfo": { "count": 68, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "TH-001",
            "type": "EXPERIMENTAL",
            "interventionNames": ["Device: TH-001"]
          },
          { "label": "Control", "type": "NO_INTERVENTION" }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "TH-001",
            "description": "TH001 is a software program intended to treat adults with prediabetes.",
            "armGroupLabels": ["TH-001"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Change in HbA1c",
            "description": "The difference in the mean change from baseline in HbA1c (%) at Day 90 between groups.",
            "timeFrame": "90 days"
          },
          {
            "measure": "Change in FPG",
            "description": "The difference in the mean change from baseline in FPG (mg/dL) at Day 90 between groups.",
            "timeFrame": "90 days"
          },
          {
            "measure": "Change in PPG",
            "description": "The difference in the mean change from baseline in 2-hour 75 g OGTT (mg/dL) at Day 90 between groups.",
            "timeFrame": "90 days"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Change in weight",
            "description": "The difference in the mean change from baseline in weight (kg) at Day 90 between groups.",
            "timeFrame": "90 days"
          },
          {
            "measure": "Change in BMI",
            "description": "The difference in the mean change from baseline in BMI (kg/m\\^2) at Day 90 between groups.",
            "timeFrame": "90 days"
          },
          {
            "measure": "Change in WC",
            "description": "The difference in the mean change from baseline in Waist Circumference (centimeters) at Day 90 between groups.",
            "timeFrame": "90 days"
          },
          {
            "measure": "Change in WHR",
            "description": "The difference in the mean change from baseline in waist-to-hip ratio (WHR) (waist circumference and hip circumference measured in centimeters) at Day 90 between groups.",
            "timeFrame": "90 days"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* Being diagnosed with prediabetes according to the ADA Prediabetes Diagnostic Criteria (the presence of at least one of the following criteria is sufficient for diagnosis: FBG 100 - 125 mg/dL, OGTT 2 hour BG: 140 - 199 mg/dL, HbA1c: 5.7% - 6.4)\n* Not using medication for the treatment of prediabetes, and if so, taking a break for at least two weeks\n* Having a smartphone with an iOS or Android operating system\n* Being able to use a mobile application\n\nExclusion Criteria:\n\n* Being diagnosed with diabetes mellitus\n* Having a disease that can cause prediabetes\n* Taking medication that may cause prediabetes",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "Ramazan Cakmak, MD",
            "affiliation": "Istinye University Health Practice and Research Center Gaziosmanpasa Hospital",
            "role": "PRINCIPAL_INVESTIGATOR"
          }
        ],
        "locations": [
          {
            "facility": "Istinye University Health Practice and Research Center Gaziosmanpasa Hospital",
            "city": "Istanbul",
            "country": "Turkey",
            "geoPoint": { "lat": 41.01384, "lon": 28.94966 }
          }
        ]
      },
      "ipdSharingStatementModule": { "ipdSharing": "NO" }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [
          { "id": "D011236", "term": "Prediabetic State" },
          { "id": "D018149", "term": "Glucose Intolerance" }
        ],
        "ancestors": [
          { "id": "D003920", "term": "Diabetes Mellitus" },
          { "id": "D044882", "term": "Glucose Metabolism Disorders" },
          { "id": "D008659", "term": "Metabolic Diseases" },
          { "id": "D004700", "term": "Endocrine System Diseases" },
          { "id": "D006943", "term": "Hyperglycemia" }
        ],
        "browseLeaves": [
          {
            "id": "M20295",
            "name": "Glucose Intolerance",
            "asFound": "Prediabetes",
            "relevance": "HIGH"
          },
          {
            "id": "M14117",
            "name": "Prediabetic State",
            "asFound": "Prediabetes",
            "relevance": "HIGH"
          },
          { "id": "M7115", "name": "Diabetes Mellitus", "relevance": "LOW" },
          { "id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW" },
          {
            "id": "M25403",
            "name": "Glucose Metabolism Disorders",
            "relevance": "LOW"
          },
          {
            "id": "M7862",
            "name": "Endocrine System Diseases",
            "relevance": "LOW"
          },
          { "id": "M9994", "name": "Hyperglycemia", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "BC18", "name": "Nutritional and Metabolic Diseases" },
          { "abbrev": "All", "name": "All Conditions" },
          { "abbrev": "BC19", "name": "Gland and Hormone Related Diseases" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT04664634",
        "orgStudyIdInfo": { "id": "STU00212981" },
        "organization": {
          "fullName": "Northwestern University",
          "class": "OTHER"
        },
        "briefTitle": "A Digital Therapeutic Platform for Swallowing and Drooling Problems in Parkinson's",
        "officialTitle": "A Digital Therapeutic Platform for Swallowing and Drooling Problems in Parkinson's"
      },
      "statusModule": {
        "statusVerifiedDate": "2024-04",
        "overallStatus": "RECRUITING",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2025-04-01", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2025-05-31",
          "type": "ESTIMATED"
        },
        "completionDateStruct": { "date": "2025-05-31", "type": "ESTIMATED" },
        "studyFirstSubmitDate": "2020-12-06",
        "studyFirstSubmitQcDate": "2020-12-06",
        "studyFirstPostDateStruct": { "date": "2020-12-11", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2025-04-11",
        "lastUpdatePostDateStruct": { "date": "2025-04-16", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": {
          "type": "PRINCIPAL_INVESTIGATOR",
          "investigatorFullName": "Shuai (Steve) Xu",
          "investigatorTitle": "Principal Investigator",
          "investigatorAffiliation": "Northwestern University"
        },
        "leadSponsor": { "name": "Northwestern University", "class": "OTHER" }
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": false,
        "isUsExport": false
      },
      "descriptionModule": {
        "briefSummary": "The purpose of this study is the development and early-stage validation of a wearable sensor for dysphagia in patients with PD.",
        "detailedDescription": "The project goal is the development and early stage validation of a wearable sensor for dysphagia in patients with PD. The first phase of the program involves engineering goals relating to increasing the battery life of this sensor to 48 hours between charges and reducing the overall form factor size. The second phase of the program is to conduct focus groups with PD patients to assess sensor usability, set up burden, and design feedback. The third phase of the study will assess the feasibility of the sensor to detect and cue swallowing in a small cohort of PD patients."
      },
      "conditionsModule": { "conditions": ["Dysphagia", "Parkinson Disease"] },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["PHASE3"],
        "designInfo": {
          "allocation": "NON_RANDOMIZED",
          "interventionModel": "SINGLE_GROUP",
          "primaryPurpose": "DIAGNOSTIC",
          "maskingInfo": { "masking": "NONE" }
        },
        "enrollmentInfo": { "count": 60, "type": "ESTIMATED" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "Single Arm",
            "type": "EXPERIMENTAL",
            "description": "The Aria sensor is a wearable patch that continuously monitors physiological signals and provides vibratory haptic cues to increase swallow frequency. The intervention consists of using the sensor over a 3-week period, with active haptic cueing during Week 2 only.",
            "interventionNames": ["Device: Aria Sensor"]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "Aria Sensor",
            "description": "The Aria sensor is a wearable patch that continuously monitors physiological signals and provides vibratory haptic cues to increase swallow frequency. The intervention consists of using the sensor over a 3-week period, with active haptic cueing during Week 2 only.",
            "armGroupLabels": ["Single Arm"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Percent agreement with Gold Standard",
            "description": "Percent agreement between experimental sensor Gold standard (GS) respiratory inductance plethysmography (RIP) with Inductotrace System®, Ambulatory Monitoring)",
            "timeFrame": "1 year"
          },
          {
            "measure": "Change in mean swallow frequency during haptic cueing week",
            "description": "This outcome measures the change in the average number of swallows per hour during the intervention week (Week 2, with haptic cueing) compared to baseline (Week 1, no cueing). Swallows will be manually labeled from sensor audio recordings by at least three independent annotators.",
            "timeFrame": "Week 1 to Week 2"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Change in algorithm-detected swallow frequency during haptic cueing week",
            "description": "This outcome measures the change in the mean swallow frequency as automatically detected by the Aria sensor's AI algorithm, comparing Week 2 (intervention) to Week 1 (baseline). Performance will be benchmarked against manually annotated swallows.",
            "timeFrame": "Week 1 to Week 2"
          },
          {
            "measure": "Change in Sialorrhea Clinical Scale for Parkinson's Disease (SCS-PD) score",
            "description": "Assesses the effect of the intervention on drooling symptoms using the Sialorrhea Clinical Scale for PD. Participants complete this validated questionnaire at baseline, during, and after the intervention.",
            "timeFrame": "Baseline to Week 3"
          },
          {
            "measure": "Change in ROMP-Swallowing Subscale score",
            "description": "Assesses changes in self-reported swallowing function using the Swallowing Subscale of the Radboud Oral Motor Inventory for Parkinson's Disease (ROMP). The ROMP is a validated, PD-specific measure.",
            "timeFrame": "Baseline to Week 3"
          },
          {
            "measure": "Change in participant adherence to haptic cueing",
            "description": "Evaluates adherence to the intervention by quantifying the percentage of haptic cues that are followed by a swallow within 5 seconds during Week 2. Cue-swallow pairings are based on algorithmic and manual labeling.",
            "timeFrame": "Week 2"
          }
        ],
        "otherOutcomes": [
          {
            "measure": "Change in Modified Barium Swallow Impairment Profile (MBSImP)",
            "description": "Subsample of participants will undergo video fluoroscopy to evaluate swallowing function. The MBSImP scores will assess changes in swallow physiology pre- and post-intervention.",
            "timeFrame": "Baseline to Week 3"
          },
          {
            "measure": "Change in Penetration-Aspiration Scale Score",
            "description": "Assesses airway protection during swallowing via penetration-aspiration scale scores from videofluoroscopic studies in a subsample of participants.",
            "timeFrame": "Baseline to Week 3"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion criteria. Age ≥22. English speaking. Diagnosis of idiopathic Parkinson's disease of any Hoehn and Yahr stage (I-V), determined by a neurologist.\n\nMild to moderate sialorrhea defined as a score of ≥ 11\\* on the Radboud Oral Motor Inventory for Parkinson's Disease (ROMP)-Saliva (C) subscale Subjects must be in the \"on\" phase of their medication during all study assessments. The \"on\" phase is defined as the period when the participant's medication is at peak effectiveness, minimizing motor fluctuations and enabling optimal motor function.\n\nStudy Exclusion Criteria. History of aspiration pneumonia within the past 12 months. Unable to swallow saliva without a maneuver. Actively receiving treatment for swallowing disorders or sialorrhea. Current alcohol/drug abuse. Diagnosed with neurological disorders other than PD. End stage dementia. History of head and neck cancer or surgery. Unable to demonstrate competency with the user-friendly sensor platform technology.\n\nKnown allergy to contrast material used during MBSS. Known allergy to sensor adhesive. Indwelling tracheostomy tube. Nasogastric (NG) feeding tube. Currently pregnant.",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "22 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "centralContacts": [
          {
            "name": "Kate Davidson",
            "role": "CONTACT",
            "phone": "(803) 413-2435",
            "email": "kate.humphries@northwestern.edu"
          },
          {
            "name": "Ankita M Bhutada",
            "role": "CONTACT",
            "email": "ankita.bhutada@northwestern.edu"
          }
        ],
        "locations": [
          {
            "facility": "Northwestern University",
            "status": "RECRUITING",
            "city": "Evanston",
            "state": "Illinois",
            "zip": "60208",
            "country": "United States",
            "contacts": [{ "name": "Kate Davidson", "role": "CONTACT" }],
            "geoPoint": { "lat": 42.04114, "lon": -87.69006 }
          }
        ]
      }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [
          { "id": "D012798", "term": "Sialorrhea" },
          { "id": "D010300", "term": "Parkinson Disease" }
        ],
        "ancestors": [
          { "id": "D020734", "term": "Parkinsonian Disorders" },
          { "id": "D001480", "term": "Basal Ganglia Diseases" },
          { "id": "D001927", "term": "Brain Diseases" },
          { "id": "D002493", "term": "Central Nervous System Diseases" },
          { "id": "D009422", "term": "Nervous System Diseases" },
          { "id": "D009069", "term": "Movement Disorders" },
          { "id": "D000080874", "term": "Synucleinopathies" },
          { "id": "D019636", "term": "Neurodegenerative Diseases" },
          { "id": "D012466", "term": "Salivary Gland Diseases" },
          { "id": "D009059", "term": "Mouth Diseases" },
          { "id": "D009057", "term": "Stomatognathic Diseases" }
        ],
        "browseLeaves": [
          {
            "id": "M13213",
            "name": "Parkinson Disease",
            "asFound": "Parkinson's",
            "relevance": "HIGH"
          },
          {
            "id": "M6882",
            "name": "Deglutition Disorders",
            "relevance": "LOW"
          },
          {
            "id": "M15604",
            "name": "Sialorrhea",
            "asFound": "Drooling",
            "relevance": "HIGH"
          },
          {
            "id": "M22494",
            "name": "Parkinsonian Disorders",
            "relevance": "LOW"
          },
          { "id": "M25603", "name": "Ganglion Cysts", "relevance": "LOW" },
          { "id": "M16358", "name": "Synovial Cyst", "relevance": "LOW" },
          {
            "id": "M4774",
            "name": "Basal Ganglia Diseases",
            "relevance": "LOW"
          },
          { "id": "M5204", "name": "Brain Diseases", "relevance": "LOW" },
          {
            "id": "M5742",
            "name": "Central Nervous System Diseases",
            "relevance": "LOW"
          },
          { "id": "M12029", "name": "Movement Disorders", "relevance": "LOW" },
          { "id": "M2217", "name": "Synucleinopathies", "relevance": "LOW" },
          {
            "id": "M21558",
            "name": "Neurodegenerative Diseases",
            "relevance": "LOW"
          },
          {
            "id": "M15285",
            "name": "Salivary Gland Diseases",
            "relevance": "LOW"
          },
          { "id": "M12019", "name": "Mouth Diseases", "relevance": "LOW" },
          {
            "id": "M12017",
            "name": "Stomatognathic Diseases",
            "relevance": "LOW"
          }
        ],
        "browseBranches": [
          { "abbrev": "BC10", "name": "Nervous System Diseases" },
          { "abbrev": "All", "name": "All Conditions" },
          { "abbrev": "BC06", "name": "Digestive System Diseases" },
          { "abbrev": "BC09", "name": "Ear, Nose, and Throat Diseases" },
          { "abbrev": "BC07", "name": "Mouth and Tooth Diseases" },
          { "abbrev": "BC04", "name": "Neoplasms" },
          { "abbrev": "BC17", "name": "Skin and Connective Tissue Diseases" },
          { "abbrev": "BC18", "name": "Nutritional and Metabolic Diseases" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT05461599",
        "orgStudyIdInfo": { "id": "LMX-003" },
        "organization": {
          "fullName": "Limbix Health, Inc.",
          "class": "INDUSTRY"
        },
        "briefTitle": "Digital Therapeutic for Adolescent Depressive Symptoms in Cardiology and Gastroenterology",
        "officialTitle": "Feasibility and Acceptability of a Digital Therapeutic for Adolescent Depressive Symptoms in Cardiology and Gastroenterology"
      },
      "statusModule": {
        "statusVerifiedDate": "2023-05",
        "overallStatus": "TERMINATED",
        "whyStopped": "Enrollment too low",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2022-08-25", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2023-05-16",
          "type": "ACTUAL"
        },
        "completionDateStruct": { "date": "2023-05-16", "type": "ACTUAL" },
        "studyFirstSubmitDate": "2022-04-29",
        "studyFirstSubmitQcDate": "2022-07-13",
        "studyFirstPostDateStruct": { "date": "2022-07-18", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2023-05-18",
        "lastUpdatePostDateStruct": { "date": "2023-05-19", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": { "name": "Limbix Health, Inc.", "class": "INDUSTRY" },
        "collaborators": [
          { "name": "Children's Hospital Los Angeles", "class": "OTHER" }
        ]
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": true
      },
      "descriptionModule": {
        "briefSummary": "The primary aim of this pilot study is to assess the feasibility, acceptability, and preliminary evidence of efficacy of a self-guided, cognitive behavioral therapy (CBT)-based mobile app intervention (SparkRx) for symptoms of depression among adolescents being treated in specialty medical care settings at Children's Hospital of Los Angeles (CHLA).",
        "detailedDescription": "Self-report assessments will be collected at pre, post and 1-month follow up time points. Weekly PHQ-8 assessments will also be collected during the 5-week intervention as well as at pre, post and 1- month follow up time points.\n\nStudy aims involve evaluating:\n\n* Feasibility of recruiting and enrolling adolescents with elevated symptoms of depression from the Cardiology and Gastroenterology programs at CHLA.\n* Retention, program adherence, completion, and withdrawal rates.\n* Safety of the intervention, including reported adverse and serious adverse events\n* Perceived utility, usability, and enjoyment of the SparkRx app by adolescents\n* Clinically significant changes in pre- to -post treatment depressive symptoms and persistence of such gains at 1 month follow up."
      },
      "conditionsModule": {
        "conditions": [
          "Depressive Symptoms",
          "Major Depressive Disorder",
          "Depression",
          "Cardiology",
          "Gastrointestinal Diseases",
          "Depressive Disorder",
          "Depressive Episode",
          "Adolescent Behavior",
          "Adolescent - Emotional Problem"
        ],
        "keywords": ["Depression", "Mental Health", "Adolescent Depression"]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "NA",
          "interventionModel": "SINGLE_GROUP",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": { "masking": "NONE" }
        },
        "enrollmentInfo": { "count": 2, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "SparkRx Mobile App",
            "type": "OTHER",
            "description": "The 5-week SparkRx app is divided into 5 levels intended to be completed weekly. A character called 'Limbot' is used as a guide. Limbot encourages the user in completing the behavioral activation program and provides personal examples of how they have undertaken behavioral activation therapy. Participants are instructed to complete a weekly Patient Health Questionnaire (PHQ)-8 assessment and Participant Symptom Check (PSC) questionnaire in the mobile app. Tasks in the mobile app progress in a linear fashion-- i.e., each task must be completed to progress to the next task. Certain on-demand resources can be accessed in the app at any time, including crisis resources. Text entries that match a database of concerning words/phrases will trigger an automated pop-up suggesting participants visit the in-app crisis resources if they need additional support.",
            "interventionNames": ["Device: SparkRx Mobile App"]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "SparkRx Mobile App",
            "description": "The SparkRx app will be fully self-guided and completed by participants at home. It is designed to be completed over 5 weeks but users may progress through the app at their own pace. The app progresses linearly, i.e., a task must be completed before a participant can progress to the next task. Content for a given week is not expected to take more than 60 minutes to complete.",
            "armGroupLabels": ["SparkRx Mobile App"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Feasibility of intervention - Eligibility",
            "description": "Percent of potential participants eligible to participate",
            "timeFrame": "Screening"
          },
          {
            "measure": "Feasibility of intervention - Participant willingness",
            "description": "Percent of eligible participants willing to participate",
            "timeFrame": "Screening"
          },
          {
            "measure": "Feasibility of intervention - Adherence",
            "description": "Adherence to program: percent of enrolled participants completing all modules by post-treatment",
            "timeFrame": "5 weeks"
          },
          {
            "measure": "Participant satisfaction with the SparkRx app",
            "description": "Acceptability of intervention. Measured by the User Experience (UXR) questionnaire. Includes questions from the UMUX-Lite; a two-item questionnaire that assesses the usability of the mobile application. Questions have seven response options from Strongly agree to Strongly disagree. Includes questions from the HaTs questionnaire; an open-ended questionnaire that assesses respondents' experiences with the product and provides options for feedback.",
            "timeFrame": "5 weeks"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Change in depressive symptoms",
            "description": "Measured by the Patient Health Questionnaire (PHQ-8). Score range of 0 to 24 with higher scores indicating worse outcome.\n\n* Clinically significant improvement: reduction in assessment score \\>= 5\n* Treatment response: 50% reduction in symptoms from pre to post-intervention\n* Remission is defined as a score \\< 5",
            "timeFrame": "Change from screening to post-intervention (5 weeks)"
          },
          {
            "measure": "Change in participant-reported health-related quality of life",
            "description": "Measured by the Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q).A 15-item self-administered questionnaire that captures life satisfaction over the past week. Score range of 14 to 84 with a higher score indicating better outcome.",
            "timeFrame": "Change from screening to post-intervention (5 weeks)"
          },
          {
            "measure": "Change in legal-guardian reported health-related quality of life",
            "description": "Measured by the Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q).A 15-item self-administered questionnaire that captures life satisfaction over the past week. Score range of 14 to 84 with a higher score indicating better outcome.",
            "timeFrame": "Change from screening to post-intervention (5 weeks)"
          },
          {
            "measure": "Change in participant-rated anxiety symptoms",
            "description": "Measured by the Generalized Anxiety Disorder scale (GAD-7).The GAD-7 is a brief 7-item assessment for generalized anxiety disorder with satisfactory sensitivity and specificity. Score range of 0 to 21 with a higher score indicating worse outcome.",
            "timeFrame": "Change from screening to post-intervention (5 weeks)"
          },
          {
            "measure": "Change in legal guardian-reported depressive symptoms",
            "description": "Measured by the Patient Health Questionnaire (PHQ-8). Score range of 0 to 24 with higher scores indicating worse outcome.\n\n* Clinically significant improvement: reduction in assessment score \\>= 5\n* Treatment response: 50% reduction in symptoms from pre to post-intervention\n* Remission is defined as a score \\< 5",
            "timeFrame": "Change from screening to post-intervention (5 weeks)"
          },
          {
            "measure": "Average treatment related usability rating",
            "description": "Measured by the System Usability Scale (SUS). The SUS consists of a 10 item questionnaire with five response options for respondents; from Strongly agree to Strongly disagree. Score range of 0 to 100 with a higher score indicating a better outcome.",
            "timeFrame": "5 weeks"
          },
          {
            "measure": "Average treatment related engagement rating",
            "description": "Measured by the User Engagement Scale (UES-SF).A statistically reliable measure of self-reported user engagement. The form has 12 items and uses a 5 point Likert scale. Score range of 1-5 with a higher score indicating a better outcome.",
            "timeFrame": "5 weeks"
          },
          {
            "measure": "Average treatment related program adherence",
            "description": "Measured by mobile app analytics",
            "timeFrame": "5 weeks"
          },
          {
            "measure": "Average treatment related program engagement",
            "description": "Measured by mobile app analytics",
            "timeFrame": "5 weeks"
          }
        ],
        "otherOutcomes": [
          {
            "measure": "Health care utilization",
            "description": "Measured by the Healthcare Utilization Questionnaire. A two-item questionnaire that asks whether participants' have used healthcare resources in the past week.",
            "timeFrame": "5 weeks"
          },
          {
            "measure": "Treatment related changes by physical symptom severity",
            "description": "Measured by the Functional Disability Inventory a fifteen-item questionnaire that measures functional disability and evaluates the impact of illness on the respondents' physical and psychosocial functioning in everyday social roles. Each question is rated on a 5-point scale from 0(No Trouble) to 4 (Impossible). Score range is 0 to 60 with higher scores indicating a worse outcome.",
            "timeFrame": "5 weeks"
          },
          {
            "measure": "Treatment related perceptions of participants' experiences in general with SparkRx",
            "description": "Measured by the User Experience (UXR) questionnaire. Includes questions from the Usability Metric for User Experience-Lite; a two-item questionnaire that assesses the usability of the mobile application. Questions have seven response options from Strongly agree to Strongly disagree. Includes questions from the Happiness Tracking Surveys; an open-ended questionnaire that assesses respondents' experiences with the product and provides options for feedback.",
            "timeFrame": "5 weeks"
          },
          {
            "measure": "Caregiver burden",
            "description": "Measured by the work absenteeism questionnaire, containing qualitative and quantitative questions about caregiving responsibilities and related impacts on employment. Higher scores are equal to more time missed from work.",
            "timeFrame": "5 weeks"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* 13-22 years of age at time of enrollment\n* Moderate-severe self-reported symptoms of depression at baseline (PHQ-8 \\>=5)\n* Under the care of a US-based healthcare provider and willing and able to provide the name and contact information of the provider during consent\n* English fluency or proficiency and literacy of adolescent and consenting legal guardian, if required\n* Access to an eligible mobile device (capable of installing the app) and regular internet access\n* Willing to provide informed e-consent/assent and have legal guardian willing to provide informed e consent (if required)\n\nExclusion Criteria:\n\n* Change in concurrent treatment (medication, and/or psychotherapy) for depression 30 days prior to study enrollment\n* Suicide attempt within the past year\n* Active suicide ideation with intent\n* Previously participated in user testing or clinical testing of the Spark app\n* Any condition, comorbidity, or event that, in the opinion of the investigator, will prevent the participant from adhering to the protocol or benefitting from the treatment (e.g., unable to perform informed assent or consent, treatment resistance as determined by investigator) or will prevent investigators from being able to ensure safety (e.g., will be leaving the country during study time period)",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "13 Years",
        "maximumAge": "22 Years",
        "stdAges": ["CHILD", "ADULT"]
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "Aarthi Padmanabhan, PhD",
            "affiliation": "Limbix Health",
            "role": "PRINCIPAL_INVESTIGATOR"
          }
        ],
        "locations": [
          {
            "facility": "Limbix Health Inc.",
            "city": "San Francisco",
            "state": "California",
            "zip": "94104",
            "country": "United States",
            "geoPoint": { "lat": 37.77493, "lon": -122.41942 }
          }
        ]
      },
      "ipdSharingStatementModule": { "ipdSharing": "NO" }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [
          { "id": "D005767", "term": "Gastrointestinal Diseases" },
          { "id": "D004066", "term": "Digestive System Diseases" },
          { "id": "D003863", "term": "Depression" },
          { "id": "D003866", "term": "Depressive Disorder" },
          { "id": "D003865", "term": "Depressive Disorder, Major" }
        ],
        "ancestors": [
          { "id": "D001526", "term": "Behavioral Symptoms" },
          { "id": "D019964", "term": "Mood Disorders" },
          { "id": "D001523", "term": "Mental Disorders" }
        ],
        "browseLeaves": [
          {
            "id": "M8883",
            "name": "Gastrointestinal Diseases",
            "asFound": "Gastrointestinal Diseases",
            "relevance": "HIGH"
          },
          {
            "id": "M7255",
            "name": "Digestive System Diseases",
            "asFound": "Gastrointestinal Diseases",
            "relevance": "HIGH"
          },
          {
            "id": "M7061",
            "name": "Depressive Disorder",
            "asFound": "Depressive Disorder",
            "relevance": "HIGH"
          },
          {
            "id": "M7060",
            "name": "Depressive Disorder, Major",
            "asFound": "Major Depressive Disorder",
            "relevance": "HIGH"
          },
          {
            "id": "M7058",
            "name": "Depression",
            "asFound": "Depressive Symptoms",
            "relevance": "HIGH"
          },
          { "id": "M4818", "name": "Behavioral Symptoms", "relevance": "LOW" },
          { "id": "M21835", "name": "Mood Disorders", "relevance": "LOW" },
          { "id": "M14473", "name": "Psychotic Disorders", "relevance": "LOW" },
          { "id": "M4815", "name": "Mental Disorders", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "BC06", "name": "Digestive System Diseases" },
          { "abbrev": "All", "name": "All Conditions" },
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT06667843",
        "orgStudyIdInfo": { "id": "774938" },
        "organization": {
          "fullName": "Norwegian University of Science and Technology",
          "class": "OTHER"
        },
        "briefTitle": "Smart Nutrition, Healthier Communities",
        "officialTitle": "Smart Nutrition, Healthier Communities: a Digital Therapeutic Strategy for Early Obesity Intervention"
      },
      "statusModule": {
        "statusVerifiedDate": "2024-09",
        "overallStatus": "RECRUITING",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2024-09-23", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2024-12-31",
          "type": "ESTIMATED"
        },
        "completionDateStruct": { "date": "2025-10-01", "type": "ESTIMATED" },
        "studyFirstSubmitDate": "2024-10-15",
        "studyFirstSubmitQcDate": "2024-10-30",
        "studyFirstPostDateStruct": { "date": "2024-10-31", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2024-10-30",
        "lastUpdatePostDateStruct": { "date": "2024-10-31", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": {
          "name": "Norwegian University of Science and Technology",
          "class": "OTHER"
        },
        "collaborators": [
          { "name": "Stjørdal Municipally", "class": "UNKNOWN" },
          { "name": "Lifeness AS", "class": "UNKNOWN" },
          { "name": "National patient organization (LFO)", "class": "UNKNOWN" }
        ]
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": false,
        "isUsExport": false
      },
      "descriptionModule": {
        "briefSummary": "The project investigates the effect of the health app Lifeness as a digital therapeutic (DTx) and follow-up tool in a municipal setting at a regional Healthy Lives Center in central Norway (Frisklivssentralen Værnesregionen), targeting early intervention for overweight and obesity."
      },
      "conditionsModule": { "conditions": ["Obesity and Overweight"] },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "interventionModelDescription": "RCT",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": { "masking": "NONE" }
        },
        "enrollmentInfo": { "count": 40, "type": "ESTIMATED" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "Intervention",
            "type": "EXPERIMENTAL",
            "description": "Standard follow-up at respective Healthy Lives Center with the addition of a digital therapeutic app with a full lifestyle program, including daily logging, tasks, articles and general information and possibility for digital communication with their healthcare provider.",
            "interventionNames": [
              "Behavioral: Lifestyle Management",
              "Device: Intervention"
            ]
          },
          {
            "label": "Control",
            "type": "EXPERIMENTAL",
            "description": "Standard follow-up at respective Healthy Lives Center, including daily logging in the digital therapeutic app.",
            "interventionNames": [
              "Behavioral: Lifestyle Management",
              "Device: Control"
            ]
          }
        ],
        "interventions": [
          {
            "type": "BEHAVIORAL",
            "name": "Lifestyle Management",
            "description": "Behavioral intervention for lifestyle change",
            "armGroupLabels": ["Control", "Intervention"]
          },
          {
            "type": "DEVICE",
            "name": "Intervention",
            "description": "Full access to DTx function in the app, and digital follow up/communication with helthcare professionals at the Healthy Lives Center",
            "armGroupLabels": ["Intervention"]
          },
          {
            "type": "DEVICE",
            "name": "Control",
            "description": "Basic access to the app (daily logging functions). No digital follow up or communication with healthcare professionals at the Healthy Lives Center.",
            "armGroupLabels": ["Control"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Body weight",
            "description": "Body weight, and weight circumference, will be measured with standard proceduress (medically approved digital Seca scale (kg), and standard measuring band (cm)) wearing light clothing at baseline and after 12 weeks.",
            "timeFrame": "12 weeks"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Eating behavior and hedonic appetite",
            "description": "Validated quistionaires assessing hedonic appetite and eating behavior will be measured at baseline and after 12 weeks: Dutch Eating Behavior Questionnaire (DEBQ), Three Factor Eating Questonnaire (TFEQ), and the Power of Food Scale (PFS).",
            "timeFrame": "12 weeks"
          },
          {
            "measure": "Weight related quality of life",
            "description": "A validated quistionaire assessing weight-related quality of life (IWQOL-Lite) will be handed out at baseline and after 12 weeks",
            "timeFrame": "12 weeks"
          }
        ],
        "otherOutcomes": [
          {
            "measure": "Feasability",
            "description": "Engagement in the app will be evaluated by monitoring the participants check-in streaks and progress in the DTx programme during the intervention. Usability and feasbility for both study participants and healthcare professionals will be evaluted through a standardized validation form at the end of the 12 week intervention.",
            "timeFrame": "12 weeks"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* BMI ≤27kg/m2 or obesity measured by waist circumference, current weight stability, motivated to lifestyle change using mobile apps, access to smartphone with 5G. Living in the municipallies covered by the Værnes region of central Norway.\n\nExclusion Criteria:\n\n* previous bariatric surgery, use of anti-obesity drugs, pregnancy, current or present cancer diagnosis,substance abuse or psychiatric diagnosis (such as eating disorders), or other conditions that can hinder physical activity.",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "maximumAge": "65 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "centralContacts": [
          {
            "name": "Marthe Isaksen Aukan, Ph.D",
            "role": "CONTACT",
            "phone": "+47 92804568",
            "email": "marthe.i.aukan@ntnu.no"
          }
        ],
        "locations": [
          {
            "facility": "Frisklivssentralen Værnesregionen",
            "status": "RECRUITING",
            "city": "Stjørdal",
            "state": "Trøndelag",
            "zip": "7500",
            "country": "Norway",
            "contacts": [
              {
                "name": "Tone Melan, Nurse",
                "role": "CONTACT",
                "phone": "+47 918 71 292",
                "email": "Tone.Iren.Melan@stjordal.kommune.no"
              }
            ],
            "geoPoint": { "lat": 63.46803, "lon": 10.91776 }
          },
          {
            "facility": "Norwegian University of Science and Technology",
            "status": "RECRUITING",
            "city": "Trondheim",
            "state": "Trøndelag",
            "zip": "7030",
            "country": "Norway",
            "geoPoint": { "lat": 63.43049, "lon": 10.39506 }
          }
        ]
      },
      "ipdSharingStatementModule": {
        "ipdSharing": "YES",
        "description": "Collected data at baseline and w12 (anthropometrics, BMI, eating behavior and quality of life) can be shared upon request"
      }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [
          { "id": "D009765", "term": "Obesity" },
          { "id": "D050177", "term": "Overweight" }
        ],
        "ancestors": [
          { "id": "D044343", "term": "Overnutrition" },
          { "id": "D009748", "term": "Nutrition Disorders" },
          { "id": "D001835", "term": "Body Weight" }
        ],
        "browseLeaves": [
          {
            "id": "M12701",
            "name": "Obesity",
            "asFound": "Obesity",
            "relevance": "HIGH"
          },
          {
            "id": "M26186",
            "name": "Overweight",
            "asFound": "Overweight",
            "relevance": "HIGH"
          },
          { "id": "M25307", "name": "Overnutrition", "relevance": "LOW" },
          { "id": "M12684", "name": "Nutrition Disorders", "relevance": "LOW" },
          { "id": "M5114", "name": "Body Weight", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "BC18", "name": "Nutritional and Metabolic Diseases" },
          { "abbrev": "BC23", "name": "Symptoms and General Pathology" },
          { "abbrev": "All", "name": "All Conditions" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT04325464",
        "orgStudyIdInfo": { "id": "PEAR-003-101" },
        "secondaryIdInfos": [
          {
            "id": "DREAM Study",
            "type": "OTHER",
            "domain": "Pear Therapeutics"
          }
        ],
        "organization": {
          "fullName": "Pear Therapeutics, Inc.",
          "class": "INDUSTRY"
        },
        "briefTitle": "A Remote, 9-week Insomnia Treatment Trial to Collect Real World Data for a Digital Therapeutic",
        "officialTitle": "Open-label, 9-week Treatment, De-centralized Trial to Collect Real World Evidence for a Digital Therapeutic (DT) Delivering Cognitive Behavioral Therapy for Insomnia (CBT-I) for Participants With Chronic Insomnia",
        "acronym": "DREAM"
      },
      "statusModule": {
        "statusVerifiedDate": "2023-01",
        "overallStatus": "UNKNOWN",
        "lastKnownStatus": "ACTIVE_NOT_RECRUITING",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2020-02-18", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2022-10-21",
          "type": "ACTUAL"
        },
        "completionDateStruct": { "date": "2024-10-31", "type": "ESTIMATED" },
        "studyFirstSubmitDate": "2020-02-20",
        "studyFirstSubmitQcDate": "2020-03-26",
        "studyFirstPostDateStruct": { "date": "2020-03-27", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2023-01-31",
        "lastUpdatePostDateStruct": { "date": "2023-02-01", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": {
          "name": "Pear Therapeutics, Inc.",
          "class": "INDUSTRY"
        }
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": true,
        "isUnapprovedDevice": true,
        "isUsExport": false
      },
      "descriptionModule": {
        "briefSummary": "The purpose of the study is to collect data in a real-world environment, for a digital therapeutic that delivers CBT-I through a decentralized clinical trial, open to participants with chronic insomnia.",
        "detailedDescription": "This is an open-access, open-label, decentralized clinical trial to collect real-world evidence for PEAR-003A, a digital therapeutic delivering CBT-I.\n\nPotential participants will answer an online prescreening questionnaire to determine eligibility. Qualifying participants will proceed to complete 6 weekly modules through their personal mobile phone or tablet in nine weeks. A series of the assessment and questionnaires will be administered at set points during the study. Participants will be asked to complete a follow-up module about 26 weeks, and at Days 243 (6-month), 428 (12-month), 610 (18-month) and 793 (24-month) after completing treatment.\n\nA subset of approximately 34 participants may be asked to partake in a optional user experience sub study. The participant will be asked to provide study feedback by either completing a five-day diary or an interview."
      },
      "conditionsModule": {
        "conditions": ["Chronic Insomnia"],
        "keywords": ["Digital Therapeutic", "CBT-I", "Chronic Insomnia"]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "NA",
          "interventionModel": "SINGLE_GROUP",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": { "masking": "NONE" }
        },
        "enrollmentInfo": { "count": 1590, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "PEAR-003A",
            "type": "EXPERIMENTAL",
            "description": "Digital Therapeutic",
            "interventionNames": ["Device: PEAR-003A"]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "PEAR-003A",
            "description": "PEAR-003A delivers CBT-I through a decentralized clinical trial open to participants with chronic insomnia",
            "armGroupLabels": ["PEAR-003A"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Change in Insomnia Severity Index (ISI)",
            "description": "Change in the Insomnia Severity Index's (ISI) total score from Baseline to End of Treatment and Follow-up. The ISI's total score ranges from 0 (not clinically significant) to 28 (clinically significant)",
            "timeFrame": "From Baseline to Day 63 (End of Treatment) and Days 243, 428, 610, 793 (Follow-up)"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Evaluate PEAR-003A Engagement Data",
            "description": "Evaluate PEAR-003A engagement rates",
            "timeFrame": "Baseline, Day 63, Day 243, Day 428, Day 610, Day 793"
          },
          {
            "measure": "Evaluate PEAR-003A Adherence Data",
            "description": "Evaluate PEAR-003A adherence rates",
            "timeFrame": "Baseline, Day 63, Day 243, Day 428, Day 610, Day 793"
          },
          {
            "measure": "Examine change in depression symptoms",
            "description": "Change in the eight-item Patient Health Questionnaire (PHQ-8) scores from Baseline to End of Treatment and Follow-up. The PHQ's total score ranges from 0 (not clinically significant) to 24 (clinically significant)",
            "timeFrame": "Baseline, Day 63, Day 243, Day 428, Day 610, Day 793"
          },
          {
            "measure": "Examine change in anxiety symptoms",
            "description": "Change in the Generalized Anxiety Disorder-7's (GAD-7) scores from Baseline to End of Treatment and Follow-up. The GAD-7's total score ranges from 0 (not clinically significant) to 21 (clinically significant)",
            "timeFrame": "Baseline, Day 63, Day 243, Day 428, Day 610, Day 793"
          }
        ],
        "otherOutcomes": [
          {
            "measure": "Examine treatment responders' data",
            "description": "Treatment responders are those whose ISI decreased by more than 7 points. Responders ISI score will be evaluated at the end of treatment and follow-up.",
            "timeFrame": "Baseline, Day 63, Day 243, Day 428, Day 610, Day 793"
          },
          {
            "measure": "Examine Insomnia Remission",
            "description": "Subjects in treatment remission are those whose ISI score is 8 or less. Subjects in treatment remission ISI scores will be evaluated at end of treatment and follow-up",
            "timeFrame": "Day 63, Day 243, Day 428, Day 610, Day 793"
          },
          {
            "measure": "Describe user experience surveys",
            "description": "Summarize user experience surveys through descriptive statistics",
            "timeFrame": "Baseline, Day 63"
          },
          {
            "measure": "Describe user experience diary data",
            "description": "Summarize qualitative diary data through descriptive statistics",
            "timeFrame": "Baseline, Day 63"
          },
          {
            "measure": "Describe user experience interviews",
            "description": "Summarize user experience interviews through descriptive statistics",
            "timeFrame": "Baseline, Day 63"
          },
          {
            "measure": "To determine if there is a change in daytime sleepiness",
            "description": "Change in Epworth Sleepiness Scale from baseline to end of treatment and follow-up. The ESS total score ranges from 0 (not clinically significant) to 24 (clinically significant)",
            "timeFrame": "Baseline, Day 63, Day 243, Day 428, Day 610, Day 793"
          },
          {
            "measure": "To determine change in quality of life",
            "description": "Change in quality of life as measured in The Short Form 12 (SF-12). The SF-12 summary scores range from 0-100 with higher scores representing better self-reported health",
            "timeFrame": "Baseline, Day 63, Day 243, Day 428, Day 610, Day 793"
          },
          {
            "measure": "To determine change in work attendance and productivity",
            "description": "Change in presenteeism/absenteeism work questions based on a survey. Subject answers Yes/No questions of whether continuously employed during the time period. If not, they can enter number of days employed or missed. Survey also contains a question regarding rating of productivity in %.",
            "timeFrame": "Baseline, Day 63, Day 243, Day 428, Day 610, Day 793"
          },
          {
            "measure": "To evaluate potential changes in healthcare utilization and costs identified in claims",
            "description": "Change in tokenized health claims from a specified period (up to 24 months) prior to intervention and a similar period after intervention",
            "timeFrame": "Matched period"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n1. Provide electronic informed consent prior to any study specific assessments being performed\n2. Between 22 and 75 years old, inclusively\n3. Insomnia as defined by an ISI score of 8 or above\n4. Insomnia symptoms for at least 3 months\n5. \\< or = 6.5 hours of sleep per night\n6. Access to a mobile device\n7. Resident of the United States and currently living in the United States for the duration of the trial.\n\nExclusion Criteria:\n\n1. Presence of an active and/or progressive physical illness (e.g., congestive-heart failure, chronic obstructive pulmonary disease, acute pain), neurological disorder (e.g., epilepsy) or neurological degenerative diseases (e.g., dementia, multiple sclerosis)\n2. Unstable medication regimen (change to schedule or dosage within the past 3 months)\n3. Diagnosis of a psychotic disorder or bipolar disorder or medical condition contraindicated by sleep restriction\n4. Have family or work schedules that prevent them from having normal sleep schedules defined as bedtime between 8:00 pm and 2:00 am and/or waking times between 4:00 am and 10:00 am.\n5. Individuals who need to be alert or cautious to avoid serious accidents in their job or daily life. Examples include: Long-haul truck drivers, Long-distance bus drivers, Air traffic controllers, Operators of heavy machinery, some assembly line jobs.\n6. Pregnant or planning to become pregnant during the course of the trial.\n7. Other untreated sleep disorders as self-reported by the participant (e.g., obstructive sleep apnea, periodic leg movements, parasomnias)\n8. Participated in an investigational research study in the past 30 days",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "22 Years",
        "maximumAge": "75 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "Abby Doctolero",
            "affiliation": "Pear Therapeutics, Inc.",
            "role": "STUDY_DIRECTOR"
          }
        ],
        "locations": [
          {
            "facility": "Pear Therapeutics, Inc.",
            "city": "Boston",
            "state": "Massachusetts",
            "zip": "02109",
            "country": "United States",
            "geoPoint": { "lat": 42.35843, "lon": -71.05977 }
          }
        ]
      },
      "referencesModule": {
        "references": [
          {
            "pmid": "33682430",
            "type": "DERIVED",
            "citation": "Thorndike FP, Berry RB, Gerwien R, Braun S, Maricich YA. Protocol for Digital Real-world Evidence trial for Adults with insomnia treated via Mobile (DREAM): an open-label trial of a prescription digital therapeutic for treating patients with chronic insomnia. J Comp Eff Res. 2021 May;10(7):569-581. doi: 10.2217/cer-2021-0004. Epub 2021 Mar 8."
          }
        ]
      },
      "ipdSharingStatementModule": { "ipdSharing": "NO" }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [
          {
            "id": "D007319",
            "term": "Sleep Initiation and Maintenance Disorders"
          }
        ],
        "ancestors": [
          { "id": "D020919", "term": "Sleep Disorders, Intrinsic" },
          { "id": "D020920", "term": "Dyssomnias" },
          { "id": "D012893", "term": "Sleep Wake Disorders" },
          { "id": "D009422", "term": "Nervous System Diseases" },
          { "id": "D001523", "term": "Mental Disorders" }
        ],
        "browseLeaves": [
          {
            "id": "M10356",
            "name": "Sleep Initiation and Maintenance Disorders",
            "asFound": "Chronic Insomnia",
            "relevance": "HIGH"
          },
          { "id": "M22242", "name": "Parasomnias", "relevance": "LOW" },
          {
            "id": "M22654",
            "name": "Sleep Disorders, Intrinsic",
            "relevance": "LOW"
          },
          { "id": "M22655", "name": "Dyssomnias", "relevance": "LOW" },
          {
            "id": "M15696",
            "name": "Sleep Wake Disorders",
            "relevance": "LOW"
          },
          { "id": "M14473", "name": "Psychotic Disorders", "relevance": "LOW" },
          { "id": "M4815", "name": "Mental Disorders", "relevance": "LOW" },
          {
            "id": "T1303",
            "name": "Chronic Graft Versus Host Disease",
            "relevance": "LOW"
          }
        ],
        "browseBranches": [
          { "abbrev": "BC10", "name": "Nervous System Diseases" },
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" },
          { "abbrev": "All", "name": "All Conditions" },
          { "abbrev": "BC23", "name": "Symptoms and General Pathology" },
          { "abbrev": "Rare", "name": "Rare Diseases" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT05034276",
        "orgStudyIdInfo": { "id": "IRB_00141495" },
        "secondaryIdInfos": [
          {
            "id": "R44DA053848",
            "type": "NIH",
            "link": "https://reporter.nih.gov/quickSearch/R44DA053848"
          }
        ],
        "organization": { "fullName": "University of Utah", "class": "OTHER" },
        "briefTitle": "Digital Therapeutic Development of Virtual Cognitive-Affective Training for Opioid Use Disorder",
        "officialTitle": "Digital Therapeutic Development of Virtual Cognitive-Affective Training for Opioid Use Disorder"
      },
      "statusModule": {
        "statusVerifiedDate": "2023-07",
        "overallStatus": "COMPLETED",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2021-10-04", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2022-04-01",
          "type": "ACTUAL"
        },
        "completionDateStruct": { "date": "2022-07-22", "type": "ACTUAL" },
        "studyFirstSubmitDate": "2021-09-01",
        "studyFirstSubmitQcDate": "2021-09-01",
        "studyFirstPostDateStruct": { "date": "2021-09-05", "type": "ACTUAL" },
        "resultsFirstSubmitDate": "2023-07-14",
        "resultsFirstSubmitQcDate": "2023-07-18",
        "resultsFirstPostDateStruct": {
          "date": "2023-07-20",
          "type": "ACTUAL"
        },
        "lastUpdateSubmitDate": "2023-07-18",
        "lastUpdatePostDateStruct": { "date": "2023-07-20", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": {
          "type": "PRINCIPAL_INVESTIGATOR",
          "investigatorFullName": "Eric Garland",
          "investigatorTitle": "Distinguished Professor",
          "investigatorAffiliation": "University of Utah"
        },
        "leadSponsor": { "name": "University of Utah", "class": "OTHER" },
        "collaborators": [
          { "name": "BehaVR LLC", "class": "INDUSTRY" },
          { "name": "National Institute on Drug Abuse (NIDA)", "class": "NIH" }
        ]
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": false
      },
      "descriptionModule": {
        "briefSummary": "This is a Phase 1 trial that aims to establish the safety of MORE-VR, as well as to collect feasibility, usability, and engagement data, for patients receiving medications for opioid use disorder (mOUD)."
      },
      "conditionsModule": { "conditions": ["Opioid-use Disorder"] },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "NA",
          "interventionModel": "SINGLE_GROUP",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": { "masking": "NONE" }
        },
        "enrollmentInfo": { "count": 34, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "MORE-VR",
            "type": "EXPERIMENTAL",
            "description": "Mindfulness-Oriented Recovery Enhancement deployed over virtual reality.",
            "interventionNames": ["Other: MORE-VR"]
          }
        ],
        "interventions": [
          {
            "type": "OTHER",
            "name": "MORE-VR",
            "description": "Mindfulness-Oriented Recovery Enhancement therapy delivered over virtual reality.",
            "armGroupLabels": ["MORE-VR"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Number of Participants With Adverse Events and/or Serious Adverse Events",
            "description": "Number of participants who reported adverse events and serious adverse events.",
            "timeFrame": "Baseline through week 8"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Engagement",
            "description": "Net Promoter Score (NPS) is a engagement and satisfaction measurement taken from asking participants how likely they were to recommend the MORE-VR intervention to others on a scale of 0-10. Net Promoter Score (NPS) is calculated by subtracting the percentage of customers who answer the NPS question with a 6 or lower (known as 'detractors') from the percentage of customers who answer with a 9 or 10 (known as 'promoters'). The summary Net Promoter Score is reflected as a percentage.",
            "timeFrame": "Baseline through week 8"
          },
          {
            "measure": "Numeric Rating Scale of State Craving",
            "description": "Craving measured on a 0 to 10 numeric rating scale, with 0 indicating no craving and 10 indicating extreme craving.",
            "timeFrame": "Baseline through week 8"
          },
          {
            "measure": "Numeric Rating Scale of State Positive Affect",
            "description": "Positive affect measured on a 0 to 10 numeric rating scale, with 0 indicating no positive affect and 10 indicating very high positive affect.",
            "timeFrame": "Baseline through week 8"
          }
        ],
        "otherOutcomes": [
          {
            "measure": "Desire for Drugs",
            "description": "Desires for Drugs Questionnaire",
            "timeFrame": "Baseline, week 8"
          },
          {
            "measure": "Trait Positive and Negative Affect",
            "description": "Positive and Negative Affect Schedule",
            "timeFrame": "Baseline, week 8"
          },
          {
            "measure": "Coping Self-efficacy",
            "description": "Drug Taking Confidence Questionnaire",
            "timeFrame": "Baseline, week 8"
          },
          {
            "measure": "Cue-elicited Heart Rate",
            "description": "Heart rate during cue exposure minus baseline heart rate",
            "timeFrame": "Baseline through week 8"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* Age 18 or older\n* DSM-5 opioid use disorder diagnosis\n* treated with medications for opioid use disorder (MOUD)\n\nExclusion Criteria:\n\n* Mindfulness intervention experience (MBSR, MBRP)\n* Active psychosis or high risk of suicidality\n* Cognitive impairment (per self-report or report by clinician)\n* Unwilling or unable to remain in MOUD treatment for duration of study",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "maximumAge": "75 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "facility": "Center on Mindfulness and Integrative Health Intervention Development",
            "city": "Salt Lake City",
            "state": "Utah",
            "zip": "84112",
            "country": "United States",
            "geoPoint": { "lat": 40.76078, "lon": -111.89105 }
          }
        ]
      },
      "ipdSharingStatementModule": { "ipdSharing": "UNDECIDED" }
    },
    "resultsSection": {
      "participantFlowModule": {
        "preAssignmentDetails": "34 participants were enrolled but only 28 participants started the intervention and attended the first treatment session. The other 6 participants were lost-to-follow up prior to initiation of the study intervention. This type of dropout is common among patients with opioid use disorder.",
        "groups": [
          {
            "id": "FG000",
            "title": "MORE-VR",
            "description": "Mindfulness-Oriented Recovery Enhancement deployed over virtual reality.\n\nMORE-VR: Mindfulness-Oriented Recovery Enhancement therapy delivered over virtual reality."
          }
        ],
        "periods": [
          {
            "title": "Overall Study",
            "milestones": [
              {
                "type": "STARTED",
                "achievements": [{ "groupId": "FG000", "numSubjects": "28" }]
              },
              {
                "type": "COMPLETED",
                "achievements": [{ "groupId": "FG000", "numSubjects": "23" }]
              },
              {
                "type": "NOT COMPLETED",
                "achievements": [{ "groupId": "FG000", "numSubjects": "5" }]
              }
            ]
          }
        ]
      },
      "baselineCharacteristicsModule": {
        "groups": [
          {
            "id": "BG000",
            "title": "MORE-VR",
            "description": "Mindfulness-Oriented Recovery Enhancement deployed over virtual reality.\n\nMORE-VR: Mindfulness-Oriented Recovery Enhancement therapy delivered over virtual reality."
          }
        ],
        "denoms": [
          {
            "units": "Participants",
            "counts": [{ "groupId": "BG000", "value": "28" }]
          }
        ],
        "measures": [
          {
            "title": "Age, Continuous",
            "paramType": "MEAN",
            "dispersionType": "STANDARD_DEVIATION",
            "unitOfMeasure": "years",
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "BG000", "value": "38.5", "spread": "9.7" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Sex: Female, Male",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "Female",
                    "measurements": [{ "groupId": "BG000", "value": "6" }]
                  },
                  {
                    "title": "Male",
                    "measurements": [{ "groupId": "BG000", "value": "22" }]
                  }
                ]
              }
            ]
          },
          {
            "title": "Race (NIH/OMB)",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "American Indian or Alaska Native",
                    "measurements": [{ "groupId": "BG000", "value": "0" }]
                  },
                  {
                    "title": "Asian",
                    "measurements": [{ "groupId": "BG000", "value": "1" }]
                  },
                  {
                    "title": "Native Hawaiian or Other Pacific Islander",
                    "measurements": [{ "groupId": "BG000", "value": "1" }]
                  },
                  {
                    "title": "Black or African American",
                    "measurements": [{ "groupId": "BG000", "value": "0" }]
                  },
                  {
                    "title": "White",
                    "measurements": [{ "groupId": "BG000", "value": "26" }]
                  },
                  {
                    "title": "More than one race",
                    "measurements": [{ "groupId": "BG000", "value": "0" }]
                  },
                  {
                    "title": "Unknown or Not Reported",
                    "measurements": [{ "groupId": "BG000", "value": "0" }]
                  }
                ]
              }
            ]
          },
          {
            "title": "Region of Enrollment",
            "paramType": "NUMBER",
            "unitOfMeasure": "participants",
            "classes": [
              {
                "title": "United States",
                "categories": [
                  { "measurements": [{ "groupId": "BG000", "value": "28" }] }
                ]
              }
            ]
          }
        ]
      },
      "outcomeMeasuresModule": {
        "outcomeMeasures": [
          {
            "type": "PRIMARY",
            "title": "Number of Participants With Adverse Events and/or Serious Adverse Events",
            "description": "Number of participants who reported adverse events and serious adverse events.",
            "reportingStatus": "POSTED",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "timeFrame": "Baseline through week 8",
            "groups": [
              {
                "id": "OG000",
                "title": "MORE-VR",
                "description": "Mindfulness-Oriented Recovery Enhancement deployed over virtual reality.\n\nMORE-VR: Mindfulness-Oriented Recovery Enhancement therapy delivered over virtual reality."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [{ "groupId": "OG000", "value": "28" }]
              }
            ],
            "classes": [
              {
                "categories": [
                  { "measurements": [{ "groupId": "OG000", "value": "2" }] }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Engagement",
            "description": "Net Promoter Score (NPS) is a engagement and satisfaction measurement taken from asking participants how likely they were to recommend the MORE-VR intervention to others on a scale of 0-10. Net Promoter Score (NPS) is calculated by subtracting the percentage of customers who answer the NPS question with a 6 or lower (known as 'detractors') from the percentage of customers who answer with a 9 or 10 (known as 'promoters'). The summary Net Promoter Score is reflected as a percentage.",
            "reportingStatus": "POSTED",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "timeFrame": "Baseline through week 8",
            "groups": [
              {
                "id": "OG000",
                "title": "MORE-VR",
                "description": "Mindfulness-Oriented Recovery Enhancement deployed over virtual reality.\n\nMORE-VR: Mindfulness-Oriented Recovery Enhancement therapy delivered over virtual reality."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [{ "groupId": "OG000", "value": "28" }]
              }
            ],
            "classes": [
              {
                "categories": [
                  { "measurements": [{ "groupId": "OG000", "value": "20" }] }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Numeric Rating Scale of State Craving",
            "description": "Craving measured on a 0 to 10 numeric rating scale, with 0 indicating no craving and 10 indicating extreme craving.",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Error",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "Baseline through week 8",
            "groups": [
              {
                "id": "OG000",
                "title": "MORE-VR",
                "description": "Mindfulness-Oriented Recovery Enhancement deployed over virtual reality.\n\nMORE-VR: Mindfulness-Oriented Recovery Enhancement therapy delivered over virtual reality."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [{ "groupId": "OG000", "value": "28" }]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "1.22", "spread": ".23" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Numeric Rating Scale of State Positive Affect",
            "description": "Positive affect measured on a 0 to 10 numeric rating scale, with 0 indicating no positive affect and 10 indicating very high positive affect.",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Error",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "Baseline through week 8",
            "groups": [
              {
                "id": "OG000",
                "title": "MORE-VR",
                "description": "Mindfulness-Oriented Recovery Enhancement deployed over virtual reality.\n\nMORE-VR: Mindfulness-Oriented Recovery Enhancement therapy delivered over virtual reality."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [{ "groupId": "OG000", "value": "28" }]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "1.23", "spread": ".17" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "OTHER_PRE_SPECIFIED",
            "title": "Desire for Drugs",
            "description": "Desires for Drugs Questionnaire",
            "reportingStatus": "NOT_POSTED",
            "timeFrame": "Baseline, week 8",
            "denomUnitsSelected": "Participants"
          },
          {
            "type": "OTHER_PRE_SPECIFIED",
            "title": "Trait Positive and Negative Affect",
            "description": "Positive and Negative Affect Schedule",
            "reportingStatus": "NOT_POSTED",
            "timeFrame": "Baseline, week 8",
            "denomUnitsSelected": "Participants"
          },
          {
            "type": "OTHER_PRE_SPECIFIED",
            "title": "Coping Self-efficacy",
            "description": "Drug Taking Confidence Questionnaire",
            "reportingStatus": "NOT_POSTED",
            "timeFrame": "Baseline, week 8",
            "denomUnitsSelected": "Participants"
          },
          {
            "type": "OTHER_PRE_SPECIFIED",
            "title": "Cue-elicited Heart Rate",
            "description": "Heart rate during cue exposure minus baseline heart rate",
            "reportingStatus": "NOT_POSTED",
            "timeFrame": "Baseline through week 8",
            "denomUnitsSelected": "Participants"
          }
        ]
      },
      "adverseEventsModule": {
        "frequencyThreshold": "0",
        "timeFrame": "3 months",
        "eventGroups": [
          {
            "id": "EG000",
            "title": "MORE-VR",
            "description": "Mindfulness-Oriented Recovery Enhancement deployed over virtual reality.\n\nMORE-VR: Mindfulness-Oriented Recovery Enhancement therapy delivered over virtual reality.",
            "deathsNumAffected": 0,
            "deathsNumAtRisk": 28,
            "seriousNumAffected": 0,
            "seriousNumAtRisk": 28,
            "otherNumAffected": 2,
            "otherNumAtRisk": 28
          }
        ],
        "otherEvents": [
          {
            "term": "Nausea",
            "organSystem": "Gastrointestinal disorders",
            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 1,
                "numAffected": 1,
                "numAtRisk": 28
              }
            ]
          },
          {
            "term": "Panic attack",
            "organSystem": "Psychiatric disorders",
            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 1,
                "numAffected": 1,
                "numAtRisk": 28
              }
            ]
          }
        ]
      },
      "moreInfoModule": {
        "limitationsAndCaveats": {
          "description": "This study was nonrandomized and cannot determine the efficacy of the intervention."
        },
        "certainAgreement": {
          "piSponsorEmployee": false,
          "restrictiveAgreement": false
        },
        "pointOfContact": {
          "title": "Eric Garland",
          "organization": "University of Utah",
          "email": "eric.garland@socwk.utah.edu",
          "phone": "801-581-3826"
        }
      }
    },
    "documentSection": {
      "largeDocumentModule": {
        "largeDocs": [
          {
            "typeAbbrev": "Prot_SAP",
            "hasProtocol": true,
            "hasSap": true,
            "hasIcf": false,
            "label": "Study Protocol and Statistical Analysis Plan",
            "date": "2021-03-09",
            "uploadDate": "2023-07-18T14:57",
            "filename": "Prot_SAP_000.pdf",
            "size": 734139
          }
        ]
      }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [
          { "id": "D009293", "term": "Opioid-Related Disorders" },
          { "id": "D019966", "term": "Substance-Related Disorders" }
        ],
        "ancestors": [
          { "id": "D000079524", "term": "Narcotic-Related Disorders" },
          { "id": "D064419", "term": "Chemically-Induced Disorders" },
          { "id": "D001523", "term": "Mental Disorders" }
        ],
        "browseLeaves": [
          {
            "id": "M12244",
            "name": "Opioid-Related Disorders",
            "asFound": "Opioid Use Disorder",
            "relevance": "HIGH"
          },
          {
            "id": "M21837",
            "name": "Substance-Related Disorders",
            "asFound": "Opioid Use Disorder",
            "relevance": "HIGH"
          },
          {
            "id": "M2057",
            "name": "Narcotic-Related Disorders",
            "relevance": "LOW"
          },
          {
            "id": "M30302",
            "name": "Chemically-Induced Disorders",
            "relevance": "LOW"
          },
          { "id": "M14473", "name": "Psychotic Disorders", "relevance": "LOW" },
          { "id": "M4815", "name": "Mental Disorders", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "BC25", "name": "Substance Related Disorders" },
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" },
          { "abbrev": "All", "name": "All Conditions" }
        ]
      },
      "interventionBrowseModule": {
        "browseLeaves": [
          { "id": "M4033", "name": "Analgesics, Opioid", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "Analg", "name": "Analgesics" },
          { "abbrev": "CNSDep", "name": "Central Nervous System Depressants" },
          { "abbrev": "All", "name": "All Drugs and Chemicals" }
        ]
      }
    },
    "hasResults": true
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT04857515",
        "orgStudyIdInfo": { "id": "CT-101-CLS-001" },
        "organization": {
          "fullName": "Click Therapeutics, Inc.",
          "class": "INDUSTRY"
        },
        "briefTitle": "Clinical Learning Study for a Mobile Smoking Cessation Program",
        "officialTitle": "An Exploratory, Observational, Open-label, Remote Study of Clickotine: A Digital Therapeutic"
      },
      "statusModule": {
        "statusVerifiedDate": "2021-08",
        "overallStatus": "COMPLETED",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2021-03-12", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2021-06-28",
          "type": "ACTUAL"
        },
        "completionDateStruct": { "date": "2021-06-28", "type": "ACTUAL" },
        "studyFirstSubmitDate": "2021-04-01",
        "studyFirstSubmitQcDate": "2021-04-20",
        "studyFirstPostDateStruct": { "date": "2021-04-23", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2021-08-11",
        "lastUpdatePostDateStruct": { "date": "2021-08-17", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": {
          "name": "Click Therapeutics, Inc.",
          "class": "INDUSTRY"
        }
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": true,
        "isUnapprovedDevice": true,
        "isUsExport": false
      },
      "descriptionModule": {
        "briefSummary": "The purpose of this study are to obtain learnings regarding the Digital Therapeutic (DTx) experience of Clickotine, including acceptability and preference of the overall program and specific DTx components, as well as to obtain learnings related to adult participants' use of the DTx for smoking cessation."
      },
      "conditionsModule": {
        "conditions": [
          "Smoking Cessation",
          "Smoking Behaviors",
          "Smoking Reduction",
          "Smoking, Cigarette",
          "Smoking",
          "Nicotine Dependence"
        ],
        "keywords": [
          "Smoking Cessation",
          "Smoking Cessation Program",
          "Smoking Cessation Digital Therapeutic"
        ]
      },
      "designModule": {
        "studyType": "OBSERVATIONAL",
        "patientRegistry": false,
        "designInfo": {
          "observationalModel": "COHORT",
          "timePerspective": "PROSPECTIVE"
        },
        "enrollmentInfo": { "count": 78, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "Cigarette Smokers",
            "description": "Adult cigarette smokers who only smoke combustible cigarettes",
            "interventionNames": ["Device: Clickotine®"]
          },
          {
            "label": "Dual-Users",
            "description": "Adult smokers who smoke both combustible cigarettes and vape",
            "interventionNames": ["Device: Clickotine®"]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "Clickotine®",
            "description": "Clickotine is a DTx that contains behavior modification techniques that include controlled breathing, social engagement, personalized messaging, medication access and adherence, digital diversions, and financial incentives.",
            "armGroupLabels": ["Cigarette Smokers", "Dual-Users"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "The main outcome of the Clickotine Learning Study is to determine acceptability of the digital intervention (DTx).",
            "description": "General acceptability of the DTx will be evaluated via surveys for all participants",
            "timeFrame": "4 Months"
          },
          {
            "measure": "The main outcome of the Clickotine Learning Study is to determine engagement with the digital intervention (DTx).",
            "description": "Engagement with the digital intervention will be measured via app use for all participants",
            "timeFrame": "4 Months"
          },
          {
            "measure": "The main outcome of the Clickotine Learning Study is to evaluate attitudes and beliefs regarding the digital intervention.",
            "description": "Attitudes and beliefs regarding the digital intervention will be evaluated by interview for selected participants",
            "timeFrame": "4 Months"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "The secondary outcome of the Clickotine Learning Study is to measure engagement levels with the digital intervention for cigarette smokers as compared to dual-users",
            "description": "These engagement levels will be measured via app use.",
            "timeFrame": "4 Months"
          },
          {
            "measure": "The secondary outcome of the Clickotine Learning Study is to determine acceptability of the digital intervention for cigarette users as compared to dual-users",
            "description": "Acceptability of the digital intervention will be evaluated via survey",
            "timeFrame": "4 Months"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* Signed informed consent.\n* Age 18 and older.\n* For cigarette smokers: Smokes at least 5 cigarettes a day. For dual-users: Smokes cigarettes AND uses e-cigarettes, with the following additional criteria:\n\n  * Smokes at least 5 cigarettes a day\n  * Vaping sessions, when they occur, must be for at least 10 minutes (15 puffs)\n* Fluent in written and spoken English (confirmed by ability to read and comprehend the informed consent form)\n* Lives in the United States.\n* Is the solo user of an iPhone with iPhone operating system (iOS)13 or greater capabilities or a smart phone with an Android operating system (OS) 9 or greater capabilities.\n* Has an active email address.\n* Willing and able to receive SMS text messages on their smartphone and email messages.\n* Have access to internet connection during the study duration.\n* Able to confirm download of installed DTx on baseline date.\n* Willing and able to comply with study protocol and assessments.\n* Is willing and able to self-identify sessions of cigarette smoking (1 or more consecutive cigarettes) or vaping (approximately 15 puffs or around 10 minutes in duration) and log those sessions.\n* Self-reported comfort with and ability to use smartphone apps/programs.\n\nExclusion Criteria:\n\n* Prior use of Clickotine.\n* Currently using a software app for smoking cessation.\n* Lifetime diagnosis of schizophrenia, psychotic disorder, or pervasive developmental disorders, as per participant self-report.\n* Any unstable medical illnesses including hepatic, renal, gastroenterological, respiratory, cardiovascular, endocrine, neurologic (including history of severe head injury with loss of consciousness), immunologic, or hematologic disease, as per participant self-report.\n* Other significant medical condition that, in the opinion of the Investigator or study sponsor, may cofound the interpretation of device efficacy, safety, and tolerability.\n* Current use of tobacco-containing products other than cigarettes or e-cigarettes (e.g. snuff, chewing tobacco, cigars, or pipes).\n* Does not have or is unwilling to create a PayPal account",
        "healthyVolunteers": true,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"],
        "studyPopulation": "Age: 18+ US Resident Fluent in english",
        "samplingMethod": "NON_PROBABILITY_SAMPLE"
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "facility": "Click Therapeutics",
            "city": "New York",
            "state": "New York",
            "zip": "10013",
            "country": "United States",
            "geoPoint": { "lat": 40.71427, "lon": -74.00597 }
          }
        ]
      }
    },
    "annotationSection": {
      "annotationModule": {
        "unpostedAnnotation": {
          "unpostedResponsibleParty": "Click Therapeutics, Inc.",
          "unpostedEvents": [
            { "type": "RELEASE", "date": "2022-06-25" },
            { "type": "RESET", "date": "2023-04-28" }
          ]
        }
      }
    },
    "derivedSection": {
      "miscInfoModule": {
        "versionHolder": "2025-05-07",
        "submissionTracking": {
          "estimatedResultsFirstSubmitDate": "2022-06-25",
          "submissionInfos": [
            { "releaseDate": "2022-06-25", "resetDate": "2023-04-28" }
          ]
        }
      },
      "conditionBrowseModule": {
        "meshes": [{ "id": "D014029", "term": "Tobacco Use Disorder" }],
        "ancestors": [
          { "id": "D019966", "term": "Substance-Related Disorders" },
          { "id": "D064419", "term": "Chemically-Induced Disorders" },
          { "id": "D001523", "term": "Mental Disorders" }
        ],
        "browseLeaves": [
          {
            "id": "M16785",
            "name": "Tobacco Use Disorder",
            "asFound": "Nicotine Dependence",
            "relevance": "HIGH"
          },
          {
            "id": "M21837",
            "name": "Substance-Related Disorders",
            "relevance": "LOW"
          },
          {
            "id": "M30302",
            "name": "Chemically-Induced Disorders",
            "relevance": "LOW"
          },
          { "id": "M14473", "name": "Psychotic Disorders", "relevance": "LOW" },
          { "id": "M4815", "name": "Mental Disorders", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "BC25", "name": "Substance Related Disorders" },
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" },
          { "abbrev": "All", "name": "All Conditions" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT03908762",
        "orgStudyIdInfo": { "id": "00142758" },
        "organization": { "fullName": "Amalgam Rx, Inc.", "class": "INDUSTRY" },
        "briefTitle": "mHealth Titration and Management",
        "officialTitle": "Use of a Digital Therapeutic and Connected Devices to Support Insulin Titration"
      },
      "statusModule": {
        "statusVerifiedDate": "2019-04",
        "overallStatus": "UNKNOWN",
        "lastKnownStatus": "RECRUITING",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2019-01-01", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2019-12",
          "type": "ESTIMATED"
        },
        "completionDateStruct": { "date": "2020-03", "type": "ESTIMATED" },
        "studyFirstSubmitDate": "2019-04-08",
        "studyFirstSubmitQcDate": "2019-04-08",
        "studyFirstPostDateStruct": { "date": "2019-04-09", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2019-04-08",
        "lastUpdatePostDateStruct": { "date": "2019-04-09", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": { "name": "Amalgam Rx, Inc.", "class": "INDUSTRY" },
        "collaborators": [
          {
            "name": "Kansas City Area Life Sciences Institute, Inc.",
            "class": "OTHER"
          },
          { "name": "University of Kansas", "class": "OTHER" },
          { "name": "LifeScan", "class": "INDUSTRY" }
        ]
      },
      "oversightModule": {
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": true,
        "isUsExport": false
      },
      "descriptionModule": {
        "briefSummary": "The principal objective of this application is to improve glycemic control of diabetic patients treated with basal insulin through use of an innovative, FDA-cleared smartphone-based insulin titration application connected to Bluetooth enabled glucose meters. iSage Rx (isageapp.com) allows providers to prescribe basal insulin treatment plans to patients and manages basal insulin doses utilizing clinically proven algorithms. In this pilot study, we hypothesize that this user-friendly application and seamless data capture will improve glycemic control (achieve HgbA1c \\<7%) and reduce the frequency and severity of hypoglycemia. Exploratory measures will include healthcare resource utilization and patient and provider satisfaction. The basal insulin titration algorithms used in iSage have had thousands of user-years' experience in FDA-mandated, closely supervised clinical trials, both for long-acting insulins (e.g., Lantus, Levemir) that have been available for a long time and for the newer ultra-long-acting ones (e.g., Tresiba, Toujeo). However, the effectiveness of iSage with a connected glucose meter has not been studied in a \"real world\" clinical environment. Broad use of such an application and connected devices will, we believe, prove to be cost-effective, favor early and appropriate prescription of insulin, reduce provider effort, shorten time to achieve glycemic goals, and simplify the transition to basal insulin therapy."
      },
      "conditionsModule": {
        "conditions": ["Diabetes Mellitus, Type 2", "Diabetic Complication"]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": { "masking": "NONE" }
        },
        "enrollmentInfo": { "count": 40, "type": "ESTIMATED" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "iSage",
            "type": "EXPERIMENTAL",
            "description": "The provider will choose a treatment algorithm embedded within the app and set the parameters to make insulin dose adjustments no less frequently than every 7 days. The app is downloaded by the patient while in the examination room, and the patient is instructed to perform daily fasting glucose fingerstick measurements and follow the app's recommendations for insulin adjustment. Data on telephone or visit contact with a healthcare provider will be collected via the EMR. Hypoglycemic events (defined as blood glucose \\<70 mg/dl, measured or perceived) are recorded in the iSage application as well as patient report. Providers are asked to review the patients transmitted blood sugar logs as necessary, and those reviews are recorded. Return visits are managed by the HCP and will be logged as resource utilization.",
            "interventionNames": ["Device: iSage App with connected glucometer"]
          },
          {
            "label": "Conventional Management",
            "type": "ACTIVE_COMPARATOR",
            "description": "Our clinic uses a modified treat-to-target algorithm which is summarized on a 3 x 5 refrigerator magnet. In the case of glargine or detemir (Basaglar, Lantus, Levemir) adjustments of 1 unit of insulin/day are made until the fasting blood sugars (2 of 3 consecutive values) are 80-130 mg/dl. In the instance of Toujeo or Tresiba, adjustments of 2 units are made every 5 days. Volunteers will have meters downloaded (or interviewed where necessary) to obtain data on fasting blood sugar and episodes of hypoglycemia (perceived or measured \\<70 mg/dl). The PCP is free to request glucose logs and set return appointments as needed to manage the patient.",
            "interventionNames": ["Behavioral: Magnet"]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "iSage App with connected glucometer",
            "description": "Providers prescribe an insulin dosing plan to patients and provide them with a connected glucometer. The patient's plan is administered through a mobile application. In addition, patients receive education and guidance on insulin administration.",
            "armGroupLabels": ["iSage"]
          },
          {
            "type": "BEHAVIORAL",
            "name": "Magnet",
            "description": "Patients are given a refrigerator magnet with an insulin titration algorithm and are asked to follow the instructions on the magnet.",
            "armGroupLabels": ["Conventional Management"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Change in A1C",
            "description": "Mean and Median Change from Baseline",
            "timeFrame": "3 Months"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "A1C in Target",
            "description": "Percentage of patients with an A1C \\< 7",
            "timeFrame": "Baseline to 3 months"
          },
          {
            "measure": "Rate of Hypoglycemia",
            "description": "Percentage of glucose readings \\<70",
            "timeFrame": "Baseline to 3 months"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* T2DM (WHO criteria) treated with basal insulin (glargine, detemir, degludec)\n* HgbA1c 8 or above\n* GFR \\>60 ml/min within the last 12 months\n* English speaking, informed consent\n* Has an Android or iOS based compatible smartphone (iOS 9.0 or above; Android 4.4 or above)\n* Currently performs at least 3 fasting fingerstick glucose measurements/week\n* Have a PCP within the KU Health System\n\nExclusion Criteria:\n\n* Diagnosis of hypoglycemic unawareness within 6 months of enrollment\n* Diagnosis of hyperglycemic hyperosmolar non-ketotic coma (HONK) or diabetic ketoacidosis (DKA) within 6 months of enrollment\n* Recent (within the last 6 months)/current use of non-topical steroids\n* Insulin requirements in excess of 1U/kg per day\n* Use of pioglitazone or another thiazolidinedione (TZD)\n* In the opinion of the provider, HgbA1c goals should adjusted above 7% due to infirmity, unstable cardiovascular disease, etc.",
        "healthyVolunteers": true,
        "sex": "ALL",
        "minimumAge": "21 Years",
        "maximumAge": "100 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "facility": "Cray Diabetes Self-Management Center",
            "status": "RECRUITING",
            "city": "Kansas City",
            "state": "Kansas",
            "zip": "66160",
            "country": "United States",
            "contacts": [
              {
                "name": "Teri Lavenbarg",
                "role": "CONTACT",
                "phone": "913-588-6022",
                "email": "tlavenbarg@kumc.edu"
              },
              { "name": "David Robbins", "role": "PRINCIPAL_INVESTIGATOR" },
              { "name": "Kristin Grdinovac", "role": "SUB_INVESTIGATOR" }
            ],
            "geoPoint": { "lat": 39.11417, "lon": -94.62746 }
          }
        ]
      }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [
          { "id": "D003924", "term": "Diabetes Mellitus, Type 2" },
          { "id": "D048909", "term": "Diabetes Complications" }
        ],
        "ancestors": [
          { "id": "D003920", "term": "Diabetes Mellitus" },
          { "id": "D044882", "term": "Glucose Metabolism Disorders" },
          { "id": "D008659", "term": "Metabolic Diseases" },
          { "id": "D004700", "term": "Endocrine System Diseases" }
        ],
        "browseLeaves": [
          { "id": "M7115", "name": "Diabetes Mellitus", "relevance": "LOW" },
          {
            "id": "M7119",
            "name": "Diabetes Mellitus, Type 2",
            "asFound": "Diabetes Mellitus, Type 2",
            "relevance": "HIGH"
          },
          {
            "id": "M26004",
            "name": "Diabetes Complications",
            "asFound": "Diabetic Complications",
            "relevance": "HIGH"
          },
          { "id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW" },
          {
            "id": "M25403",
            "name": "Glucose Metabolism Disorders",
            "relevance": "LOW"
          },
          {
            "id": "M7862",
            "name": "Endocrine System Diseases",
            "relevance": "LOW"
          }
        ],
        "browseBranches": [
          { "abbrev": "BC18", "name": "Nutritional and Metabolic Diseases" },
          { "abbrev": "BC19", "name": "Gland and Hormone Related Diseases" },
          { "abbrev": "All", "name": "All Conditions" }
        ]
      },
      "interventionBrowseModule": {
        "browseLeaves": [
          { "id": "M10365", "name": "Insulin", "relevance": "LOW" },
          {
            "id": "M173166",
            "name": "Insulin, Globin Zinc",
            "relevance": "LOW"
          },
          { "id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW" },
          { "id": "M347", "name": "Insulin Glargine", "relevance": "LOW" },
          { "id": "M349", "name": "Insulin Detemir", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "Hypo", "name": "Hypoglycemic Agents" },
          { "abbrev": "All", "name": "All Drugs and Chemicals" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT05551195",
        "orgStudyIdInfo": { "id": "WB001-001" },
        "organization": { "fullName": "Woebot Health", "class": "INDUSTRY" },
        "briefTitle": "[Study Evaluating the Efficacy and Safety of a Digital Therapeutic as an Adjunct to TAU in Postpartum Depression]",
        "officialTitle": "A Multicenter, Randomized, Double-Blind, Controlled Study Evaluating the Efficacy and Safety of a Digital Therapeutic as an Adjunct to Treatment as Usual Among Women With Mild to Moderate Postpartum Depression"
      },
      "statusModule": {
        "statusVerifiedDate": "2025-01",
        "overallStatus": "TERMINATED",
        "whyStopped": "Internal company decision",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2022-11-16", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2023-05-10",
          "type": "ACTUAL"
        },
        "completionDateStruct": { "date": "2023-05-10", "type": "ACTUAL" },
        "studyFirstSubmitDate": "2022-09-19",
        "studyFirstSubmitQcDate": "2022-09-19",
        "studyFirstPostDateStruct": { "date": "2022-09-22", "type": "ACTUAL" },
        "resultsFirstSubmitDate": "2024-10-22",
        "resultsFirstSubmitQcDate": "2025-02-21",
        "resultsFirstPostDateStruct": {
          "date": "2025-02-24",
          "type": "ACTUAL"
        },
        "lastUpdateSubmitDate": "2025-02-21",
        "lastUpdatePostDateStruct": { "date": "2025-02-24", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": { "name": "Woebot Health", "class": "INDUSTRY" },
        "collaborators": [{ "name": "Iqvia Pty Ltd", "class": "INDUSTRY" }]
      },
      "oversightModule": {
        "oversightHasDmc": true,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": true,
        "isUnapprovedDevice": true,
        "isUsExport": false
      },
      "descriptionModule": {
        "briefSummary": "This study evaluates the efficacy of two digital therapeutics, WB001 and ED001, on depressive symptoms among women diagnosed with postpartum depression.",
        "detailedDescription": "This randomized, double-blind, controlled trial evaluates the efficacy and safety of 8 weeks of treatment of two digital therapeutics in a population of women with mild to moderate postpartum depression. Patients will be referred by an obstetrician, pediatrician, or other healthcare professional, or by other digital and site based recruitment methods and, if interested, will complete the pre-screening process. Those confirmed as eligible will be scheduled to attend a screening/baseline onsite visit. Eligible participants will be randomized to one of the two groups and will receive instructions on downloading and using the smartphone application to which they were randomized. Participants will use the app as instructed and will attend telehealth visits to complete assessments for the primary and safety endpoints at Weeks 4 and 8 (EOT)."
      },
      "conditionsModule": {
        "conditions": ["Postpartum Depression"],
        "keywords": [
          "Postpartum Depression",
          "PPD",
          "Postpartum Depression Treatment",
          "PPD Treatment",
          "Smartphone application",
          "Digital therapeutic"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "interventionModelDescription": "1:1 randomization",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": {
            "masking": "TRIPLE",
            "whoMasked": ["PARTICIPANT", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]
          }
        },
        "enrollmentInfo": { "count": 7, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "WB001 with adjunctive Treatment as Usual",
            "type": "OTHER",
            "description": "Participants randomized to the WB001 + TAU group will be asked to download and use the study application.",
            "interventionNames": ["Device: WB001"]
          },
          {
            "label": "Educational Control (ED001) with adjunctive Treatment as Usual",
            "type": "OTHER",
            "description": "Participants randomized to the ED001 + TAU group will be asked to download and use the study application.",
            "interventionNames": ["Device: ED001"]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "WB001",
            "description": "WB001 is a digital therapeutic for postpartum depression.",
            "armGroupLabels": ["WB001 with adjunctive Treatment as Usual"]
          },
          {
            "type": "DEVICE",
            "name": "ED001",
            "description": "ED001 is a digital therapeutic for postpartum depression.",
            "armGroupLabels": [
              "Educational Control (ED001) with adjunctive Treatment as Usual"
            ]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Hamilton Rating Scale for Depression (HAM-D)",
            "description": "Measure of depression. This is a 6-item questionnaire, where total scores range from 0 to 22, with higher scores indicating greater severity of depression.",
            "timeFrame": "Change from Baseline to Post-treatment at Week 8"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Edinburgh Postpartum Depression Scale (EPDS)",
            "description": "Measure of postpartum depression. A 10-item self-report questionnaire that assesses depression criteria and yields a total score from 0 to 30 where higher scores denote greater depression.",
            "timeFrame": "Change Baseline to Post-treatment at Week 8"
          },
          {
            "measure": "Patient Health Questionnaire (PHQ-9)",
            "description": "Measure of depression. A 9-item self-report questionnaire where total scores range from 0 to 27, with higher scores indicating greater levels of depression",
            "timeFrame": "Change Baseline to Post-treatment at Week 8"
          },
          {
            "measure": "Generalized Anxiety Disorder Questionnaire (GAD-7)",
            "description": "Measure of anxiety. A 7-item brief self-report questionnaire, where total score range is between 0-21, with higher scores indicate greater levels of anxiety.",
            "timeFrame": "Change from Baseline to Post-treatment at Week 8"
          },
          {
            "measure": "Mother-to-Infant Bonding Scale (MIBS)",
            "description": "Measure of mother-infant bond. An 8-item self-report questionnaire, where total scores range from 0 to 24, with lower scores indicating good bonding.",
            "timeFrame": "Change from Baseline to Post-treatment at Week 8"
          },
          {
            "measure": "Clinical Global Impressions Scale - Severity of Illness (CGI-S)",
            "description": "Measure of overall severity of current clinical presentation and symptomatology. A single item, 7-point Likert scale on which the investigator will rate patients' severity of illness based on clinical interviews and assessments relative to their experience with other patients with the same diagnosis. Responses include 0 (not assessed) and range from 1 (Normal, not at all ill) to 7 (Among the most extremely ill).",
            "timeFrame": "Change Baseline to Post-treatment at Week 8"
          },
          {
            "measure": "Clinical Global Impressions Scale - Global Improvement (CGI-I)",
            "description": "Measure of improvement. A single item, 7-point Likert scale that assesses the overall improvement in patients' condition at the end of treatment. The investigator will rate whether the participant's total improvement was due entirely to the intervention. Responses include 0 (not assessed) and range from 1 (very much improved) to 7 (very much worse).",
            "timeFrame": "Change from Mid-treatment at Week 4 to Post-treatment at Week 8"
          },
          {
            "measure": "Patient Global Impression Scale (PGI)",
            "description": "Measure of change in clinical status. A single item scale based on the CGI and adapted to the patient that mainly measures change in clinical status (PGI-C) but can also measure disease severity (PGI-S) or disease improvement (PGI-I). PGI-S responses for current illness severity range from \"I Feel Fine (1)\" to \"I Feel Extremely Ill (4)\". PGI-C responses range from \"Very Much Improved (1) to \"Very Much Worse (7)\" since starting the trial. For both scales, lower scores indicate better outcomes.",
            "timeFrame": "PGI-S: Change from Baseline to Post-treatment at Week 8; PGI-C: Change from Mid-treatment at Week 4 to Post-treatment at Week 8"
          },
          {
            "measure": "Client Satisfaction Questionnaire (CSQ-8)",
            "description": "An 8-item measure used to assess client's satisfaction with treatment.Total scores range from 8-32, with high scores indicating greater satisfaction with the treatment.",
            "timeFrame": "Post-treatment at Week 8"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n1. Must have primary residence in the United States\n2. Must be ≤ 92 days postpartum\n3. Must be women aged 22-45 years who had onset of a major depressive episode any time during pregnancy or within 4 weeks following delivery\n4. Must own or have regular access to a smartphone (Android or iOS smartphone with a recent, supported operating system), and has reliable Wi-Fi access or sufficient data plan to engage with assigned treatment condition for the duration of the study\n5. Participants must have current mild-moderate depression as measured by the HAMD-6 score \\>7 and \\<13 at screening\n6. Participant must have a form of TAU, defined as clinician supervised outpatient care management and includes follow-up visits, medication, psychotherapy, or some combination thereof\n7. TAU must be regularly scheduled or stable for at least 4 weeks prior to baseline (BL) visit\n\nExclusion Criteria:\n\n1. Gestation less than 28 weeks\n2. HAMD-6 score ≤7 or ≥13 (severe depression) at screening\n3. Currently pregnant or plans to become pregnant within the next 8 weeks\n4. History of drug and/or alcohol use disorder within the past 12 months\n5. Lifetime history of suicide attempt or ideation with a plan and intent to harm oneself during the current episode of PPD\n6. Current or lifetime psychosis\n7. Current or lifetime history of schizophrenia, schizoaffective disorder, bipolar disorder, and/or homicidal or infanticidal ideation\n8. History of antidepressant treatment with ketamine/esketamine, electroconvulsive therapy, vagal nerve stimulation, or a deep brain stimulation device\n9. History of treatment-resistant depression (TRD)\n10. Fetal demise within the past 18 months",
        "healthyVolunteers": false,
        "sex": "FEMALE",
        "minimumAge": "22 Years",
        "maximumAge": "45 Years",
        "stdAges": ["ADULT"]
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "facility": "Woebot Investigational Site",
            "city": "Lafayette",
            "state": "California",
            "zip": "94549",
            "country": "United States",
            "geoPoint": { "lat": 37.88576, "lon": -122.11802 }
          },
          {
            "facility": "Woebot Investigational Site",
            "city": "Santa Ana",
            "state": "California",
            "zip": "92704",
            "country": "United States",
            "geoPoint": { "lat": 33.74557, "lon": -117.86783 }
          },
          {
            "facility": "Woebot Investigational Site",
            "city": "DeLand",
            "state": "Florida",
            "zip": "32720",
            "country": "United States",
            "geoPoint": { "lat": 29.02832, "lon": -81.30312 }
          },
          {
            "facility": "Woebot Investigational Site",
            "city": "Miami Lakes",
            "state": "Florida",
            "zip": "33016",
            "country": "United States",
            "geoPoint": { "lat": 25.90871, "lon": -80.30866 }
          },
          {
            "facility": "Woebot Investigational Site",
            "city": "Seminole",
            "state": "Florida",
            "zip": "33777",
            "country": "United States",
            "geoPoint": { "lat": 27.83975, "lon": -82.79121 }
          },
          {
            "facility": "Woebot Investigational Site",
            "city": "Decatur",
            "state": "Georgia",
            "zip": "30033",
            "country": "United States",
            "geoPoint": { "lat": 33.77483, "lon": -84.29631 }
          },
          {
            "facility": "Woebot Investigational Site",
            "city": "Glen Oaks",
            "state": "New York",
            "zip": "11004",
            "country": "United States",
            "geoPoint": { "lat": 40.74705, "lon": -73.71152 }
          },
          {
            "facility": "Woebot Investigational Site",
            "city": "Cleveland",
            "state": "Ohio",
            "zip": "44122",
            "country": "United States",
            "geoPoint": { "lat": 41.4995, "lon": -81.69541 }
          }
        ]
      }
    },
    "resultsSection": {
      "participantFlowModule": {
        "groups": [
          {
            "id": "FG000",
            "title": "WB001 With Adjunctive Treatment as Usual",
            "description": "Participants randomized to the WB001 + TAU group will be asked to download and use the study application.\n\nWB001: WB001 is a digital therapeutic for postpartum depression."
          },
          {
            "id": "FG001",
            "title": "Educational Control (ED001) With Adjunctive Treatment as Usual",
            "description": "Participants randomized to the ED001 + TAU group will be asked to download and use the study application.\n\nED001: ED001 is a digital therapeutic for postpartum depression."
          }
        ],
        "periods": [
          {
            "title": "Overall Study",
            "milestones": [
              {
                "type": "STARTED",
                "achievements": [
                  { "groupId": "FG000", "numSubjects": "1" },
                  { "groupId": "FG001", "numSubjects": "6" }
                ]
              },
              {
                "type": "COMPLETED",
                "achievements": [
                  { "groupId": "FG000", "numSubjects": "1" },
                  { "groupId": "FG001", "numSubjects": "6" }
                ]
              },
              {
                "type": "NOT COMPLETED",
                "achievements": [
                  { "groupId": "FG000", "numSubjects": "0" },
                  { "groupId": "FG001", "numSubjects": "0" }
                ]
              }
            ]
          }
        ]
      },
      "baselineCharacteristicsModule": {
        "groups": [
          {
            "id": "BG000",
            "title": "WB001 With Adjunctive Treatment as Usual",
            "description": "Participants randomized to the WB001 + TAU group will be asked to download and use the study application.\n\nWB001: WB001 is a digital therapeutic for postpartum depression."
          },
          {
            "id": "BG001",
            "title": "Educational Control (ED001) With Adjunctive Treatment as Usual",
            "description": "Participants randomized to the ED001 + TAU group will be asked to download and use the study application.\n\nED001: ED001 is a digital therapeutic for postpartum depression."
          },
          {
            "id": "BG002",
            "title": "Total",
            "description": "Total of all reporting groups"
          }
        ],
        "denoms": [
          {
            "units": "Participants",
            "counts": [
              { "groupId": "BG000", "value": "1" },
              { "groupId": "BG001", "value": "6" },
              { "groupId": "BG002", "value": "7" }
            ]
          }
        ],
        "measures": [
          {
            "title": "Age, Categorical",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "<=18 years",
                    "measurements": [
                      { "groupId": "BG000", "value": "0" },
                      { "groupId": "BG001", "value": "0" },
                      { "groupId": "BG002", "value": "0" }
                    ]
                  },
                  {
                    "title": "Between 18 and 65 years",
                    "measurements": [
                      { "groupId": "BG000", "value": "1" },
                      { "groupId": "BG001", "value": "6" },
                      { "groupId": "BG002", "value": "7" }
                    ]
                  },
                  {
                    "title": ">=65 years",
                    "measurements": [
                      { "groupId": "BG000", "value": "0" },
                      { "groupId": "BG001", "value": "0" },
                      { "groupId": "BG002", "value": "0" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Sex: Female, Male",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "Female",
                    "measurements": [
                      { "groupId": "BG000", "value": "1" },
                      { "groupId": "BG001", "value": "6" },
                      { "groupId": "BG002", "value": "7" }
                    ]
                  },
                  {
                    "title": "Male",
                    "measurements": [
                      { "groupId": "BG000", "value": "0" },
                      { "groupId": "BG001", "value": "0" },
                      { "groupId": "BG002", "value": "0" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Ethnicity (NIH/OMB)",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "Hispanic or Latino",
                    "measurements": [
                      { "groupId": "BG000", "value": "0" },
                      { "groupId": "BG001", "value": "2" },
                      { "groupId": "BG002", "value": "2" }
                    ]
                  },
                  {
                    "title": "Not Hispanic or Latino",
                    "measurements": [
                      { "groupId": "BG000", "value": "1" },
                      { "groupId": "BG001", "value": "4" },
                      { "groupId": "BG002", "value": "5" }
                    ]
                  },
                  {
                    "title": "Unknown or Not Reported",
                    "measurements": [
                      { "groupId": "BG000", "value": "0" },
                      { "groupId": "BG001", "value": "0" },
                      { "groupId": "BG002", "value": "0" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Race (NIH/OMB)",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "American Indian or Alaska Native",
                    "measurements": [
                      { "groupId": "BG000", "value": "0" },
                      { "groupId": "BG001", "value": "0" },
                      { "groupId": "BG002", "value": "0" }
                    ]
                  },
                  {
                    "title": "Asian",
                    "measurements": [
                      { "groupId": "BG000", "value": "0" },
                      { "groupId": "BG001", "value": "0" },
                      { "groupId": "BG002", "value": "0" }
                    ]
                  },
                  {
                    "title": "Native Hawaiian or Other Pacific Islander",
                    "measurements": [
                      { "groupId": "BG000", "value": "0" },
                      { "groupId": "BG001", "value": "0" },
                      { "groupId": "BG002", "value": "0" }
                    ]
                  },
                  {
                    "title": "Black or African American",
                    "measurements": [
                      { "groupId": "BG000", "value": "0" },
                      { "groupId": "BG001", "value": "2" },
                      { "groupId": "BG002", "value": "2" }
                    ]
                  },
                  {
                    "title": "White",
                    "measurements": [
                      { "groupId": "BG000", "value": "1" },
                      { "groupId": "BG001", "value": "4" },
                      { "groupId": "BG002", "value": "5" }
                    ]
                  },
                  {
                    "title": "More than one race",
                    "measurements": [
                      { "groupId": "BG000", "value": "0" },
                      { "groupId": "BG001", "value": "0" },
                      { "groupId": "BG002", "value": "0" }
                    ]
                  },
                  {
                    "title": "Unknown or Not Reported",
                    "measurements": [
                      { "groupId": "BG000", "value": "0" },
                      { "groupId": "BG001", "value": "0" },
                      { "groupId": "BG002", "value": "0" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Region of Enrollment",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "title": "United States",
                "categories": [
                  {
                    "title": "New York (Northeast)",
                    "measurements": [
                      { "groupId": "BG000", "value": "1" },
                      { "groupId": "BG001", "value": "4" },
                      { "groupId": "BG002", "value": "5" }
                    ]
                  },
                  {
                    "title": "Florida (Southeast)",
                    "measurements": [
                      { "groupId": "BG000", "value": "0" },
                      { "groupId": "BG001", "value": "1" },
                      { "groupId": "BG002", "value": "1" }
                    ]
                  },
                  {
                    "title": "California (West)",
                    "measurements": [
                      { "groupId": "BG000", "value": "0" },
                      { "groupId": "BG001", "value": "1" },
                      { "groupId": "BG002", "value": "1" }
                    ]
                  }
                ]
              }
            ]
          }
        ]
      },
      "outcomeMeasuresModule": {
        "outcomeMeasures": [
          {
            "type": "PRIMARY",
            "title": "Hamilton Rating Scale for Depression (HAM-D)",
            "description": "Measure of depression. This is a 6-item questionnaire, where total scores range from 0 to 22, with higher scores indicating greater severity of depression.",
            "populationDescription": "One participant missing data at Week 8",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "Change from Baseline to Post-treatment at Week 8",
            "groups": [
              {
                "id": "OG000",
                "title": "WB001 With Adjunctive Treatment as Usual",
                "description": "Participants randomized to the WB001 + TAU group will be asked to download and use the study application.\n\nWB001: WB001 is a digital therapeutic for postpartum depression."
              },
              {
                "id": "OG001",
                "title": "Educational Control (ED001) With Adjunctive Treatment as Usual",
                "description": "Participants randomized to the ED001 + TAU group will be asked to download and use the study application.\n\nED001: ED001 is a digital therapeutic for postpartum depression."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "1" },
                  { "groupId": "OG001", "value": "5" }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "0", "spread": "0" },
                      { "groupId": "OG001", "value": "-5.4", "spread": "3.36" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Edinburgh Postpartum Depression Scale (EPDS)",
            "description": "Measure of postpartum depression. A 10-item self-report questionnaire that assesses depression criteria and yields a total score from 0 to 30 where higher scores denote greater depression.",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "Change Baseline to Post-treatment at Week 8",
            "groups": [
              {
                "id": "OG000",
                "title": "WB001 With Adjunctive Treatment as Usual",
                "description": "Participants randomized to the WB001 + TAU group will be asked to download and use the study application.\n\nWB001: WB001 is a digital therapeutic for postpartum depression."
              },
              {
                "id": "OG001",
                "title": "Educational Control (ED001) With Adjunctive Treatment as Usual",
                "description": "Participants randomized to the ED001 + TAU group will be asked to download and use the study application.\n\nED001: ED001 is a digital therapeutic for postpartum depression."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "1" },
                  { "groupId": "OG001", "value": "6" }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "0", "spread": "0" },
                      { "groupId": "OG001", "value": "-6.83", "spread": "6.37" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Patient Health Questionnaire (PHQ-9)",
            "description": "Measure of depression. A 9-item self-report questionnaire where total scores range from 0 to 27, with higher scores indicating greater levels of depression",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "Change Baseline to Post-treatment at Week 8",
            "groups": [
              {
                "id": "OG000",
                "title": "WB001 With Adjunctive Treatment as Usual",
                "description": "Participants randomized to the WB001 + TAU group will be asked to download and use the study application.\n\nWB001: WB001 is a digital therapeutic for postpartum depression."
              },
              {
                "id": "OG001",
                "title": "Educational Control (ED001) With Adjunctive Treatment as Usual",
                "description": "Participants randomized to the ED001 + TAU group will be asked to download and use the study application.\n\nED001: ED001 is a digital therapeutic for postpartum depression."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "1" },
                  { "groupId": "OG001", "value": "6" }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "-3", "spread": "0" },
                      { "groupId": "OG001", "value": "-8.17", "spread": "6.18" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Generalized Anxiety Disorder Questionnaire (GAD-7)",
            "description": "Measure of anxiety. A 7-item brief self-report questionnaire, where total score range is between 0-21, with higher scores indicate greater levels of anxiety.",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "Change from Baseline to Post-treatment at Week 8",
            "groups": [
              {
                "id": "OG000",
                "title": "WB001 With Adjunctive Treatment as Usual",
                "description": "Participants randomized to the WB001 + TAU group will be asked to download and use the study application.\n\nWB001: WB001 is a digital therapeutic for postpartum depression."
              },
              {
                "id": "OG001",
                "title": "Educational Control (ED001) With Adjunctive Treatment as Usual",
                "description": "Participants randomized to the ED001 + TAU group will be asked to download and use the study application.\n\nED001: ED001 is a digital therapeutic for postpartum depression."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "1" },
                  { "groupId": "OG001", "value": "6" }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "1", "spread": "0" },
                      { "groupId": "OG001", "value": "-6.33", "spread": "2.88" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Mother-to-Infant Bonding Scale (MIBS)",
            "description": "Measure of mother-infant bond. An 8-item self-report questionnaire, where total scores range from 0 to 24, with lower scores indicating good bonding.",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "Change from Baseline to Post-treatment at Week 8",
            "groups": [
              {
                "id": "OG000",
                "title": "WB001 With Adjunctive Treatment as Usual",
                "description": "Participants randomized to the WB001 + TAU group will be asked to download and use the study application.\n\nWB001: WB001 is a digital therapeutic for postpartum depression."
              },
              {
                "id": "OG001",
                "title": "Educational Control (ED001) With Adjunctive Treatment as Usual",
                "description": "Participants randomized to the ED001 + TAU group will be asked to download and use the study application.\n\nED001: ED001 is a digital therapeutic for postpartum depression."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "1" },
                  { "groupId": "OG001", "value": "6" }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "-2", "spread": "0" },
                      { "groupId": "OG001", "value": "0.17", "spread": "2.40" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Clinical Global Impressions Scale - Severity of Illness (CGI-S)",
            "description": "Measure of overall severity of current clinical presentation and symptomatology. A single item, 7-point Likert scale on which the investigator will rate patients' severity of illness based on clinical interviews and assessments relative to their experience with other patients with the same diagnosis. Responses include 0 (not assessed) and range from 1 (Normal, not at all ill) to 7 (Among the most extremely ill).",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "Change Baseline to Post-treatment at Week 8",
            "groups": [
              {
                "id": "OG000",
                "title": "WB001 With Adjunctive Treatment as Usual",
                "description": "Participants randomized to the WB001 + TAU group will be asked to download and use the study application.\n\nWB001: WB001 is a digital therapeutic for postpartum depression."
              },
              {
                "id": "OG001",
                "title": "Educational Control (ED001) With Adjunctive Treatment as Usual",
                "description": "Participants randomized to the ED001 + TAU group will be asked to download and use the study application.\n\nED001: ED001 is a digital therapeutic for postpartum depression."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "1" },
                  { "groupId": "OG001", "value": "6" }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "0", "spread": "0" },
                      { "groupId": "OG001", "value": "-1.50", "spread": "0.84" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Clinical Global Impressions Scale - Global Improvement (CGI-I)",
            "description": "Measure of improvement. A single item, 7-point Likert scale that assesses the overall improvement in patients' condition at the end of treatment. The investigator will rate whether the participant's total improvement was due entirely to the intervention. Responses include 0 (not assessed) and range from 1 (very much improved) to 7 (very much worse).",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "Change from Mid-treatment at Week 4 to Post-treatment at Week 8",
            "groups": [
              {
                "id": "OG000",
                "title": "WB001 With Adjunctive Treatment as Usual",
                "description": "Participants randomized to the WB001 + TAU group will be asked to download and use the study application.\n\nWB001: WB001 is a digital therapeutic for postpartum depression."
              },
              {
                "id": "OG001",
                "title": "Educational Control (ED001) With Adjunctive Treatment as Usual",
                "description": "Participants randomized to the ED001 + TAU group will be asked to download and use the study application.\n\nED001: ED001 is a digital therapeutic for postpartum depression."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "1" },
                  { "groupId": "OG001", "value": "6" }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "0", "spread": "0" },
                      { "groupId": "OG001", "value": "-1.17", "spread": "0.98" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Patient Global Impression Scale (PGI)",
            "description": "Measure of change in clinical status. A single item scale based on the CGI and adapted to the patient that mainly measures change in clinical status (PGI-C) but can also measure disease severity (PGI-S) or disease improvement (PGI-I). PGI-S responses for current illness severity range from \"I Feel Fine (1)\" to \"I Feel Extremely Ill (4)\". PGI-C responses range from \"Very Much Improved (1) to \"Very Much Worse (7)\" since starting the trial. For both scales, lower scores indicate better outcomes.",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "PGI-S: Change from Baseline to Post-treatment at Week 8; PGI-C: Change from Mid-treatment at Week 4 to Post-treatment at Week 8",
            "groups": [
              {
                "id": "OG000",
                "title": "WB001 With Adjunctive Treatment as Usual",
                "description": "Participants randomized to the WB001 + TAU group will be asked to download and use the study application.\n\nWB001: WB001 is a digital therapeutic for postpartum depression."
              },
              {
                "id": "OG001",
                "title": "Educational Control (ED001) With Adjunctive Treatment as Usual",
                "description": "Participants randomized to the ED001 + TAU group will be asked to download and use the study application.\n\nED001: ED001 is a digital therapeutic for postpartum depression."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "1" },
                  { "groupId": "OG001", "value": "6" }
                ]
              }
            ],
            "classes": [
              {
                "title": "PGI-S",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "1", "spread": "0" },
                      { "groupId": "OG001", "value": "-0.67", "spread": "1.21" }
                    ]
                  }
                ]
              },
              {
                "title": "PGI-C",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "1", "spread": "0" },
                      { "groupId": "OG001", "value": "-1", "spread": "0.63" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Client Satisfaction Questionnaire (CSQ-8)",
            "description": "An 8-item measure used to assess client's satisfaction with treatment.Total scores range from 8-32, with high scores indicating greater satisfaction with the treatment.",
            "populationDescription": "One participant did not complete the CSQ-8",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "Post-treatment at Week 8",
            "groups": [
              {
                "id": "OG000",
                "title": "WB001 With Adjunctive Treatment as Usual",
                "description": "Participants randomized to the WB001 + TAU group will be asked to download and use the study application.\n\nWB001: WB001 is a digital therapeutic for postpartum depression."
              },
              {
                "id": "OG001",
                "title": "Educational Control (ED001) With Adjunctive Treatment as Usual",
                "description": "Participants randomized to the ED001 + TAU group will be asked to download and use the study application.\n\nED001: ED001 is a digital therapeutic for postpartum depression."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "1" },
                  { "groupId": "OG001", "value": "5" }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "17", "spread": "0" },
                      { "groupId": "OG001", "value": "29", "spread": "4.64" }
                    ]
                  }
                ]
              }
            ]
          }
        ]
      },
      "adverseEventsModule": {
        "frequencyThreshold": "0",
        "timeFrame": "8 weeks",
        "description": "Systematic assessment of adverse events included Principal Investigator assessment as well as unsolicited participant reports.",
        "eventGroups": [
          {
            "id": "EG000",
            "title": "WB001 With Adjunctive Treatment as Usual",
            "description": "Participants randomized to the WB001 + TAU group will be asked to download and use the study application.\n\nWB001: WB001 is a digital therapeutic for postpartum depression.",
            "deathsNumAffected": 0,
            "deathsNumAtRisk": 1,
            "seriousNumAffected": 0,
            "seriousNumAtRisk": 1,
            "otherNumAffected": 0,
            "otherNumAtRisk": 1
          },
          {
            "id": "EG001",
            "title": "Educational Control (ED001) With Adjunctive Treatment as Usual",
            "description": "Participants randomized to the ED001 + TAU group will be asked to download and use the study application.\n\nED001: ED001 is a digital therapeutic for postpartum depression.",
            "deathsNumAffected": 0,
            "deathsNumAtRisk": 6,
            "seriousNumAffected": 0,
            "seriousNumAtRisk": 6,
            "otherNumAffected": 0,
            "otherNumAtRisk": 6
          }
        ]
      },
      "moreInfoModule": {
        "certainAgreement": {
          "piSponsorEmployee": false,
          "restrictionType": "LTE60",
          "restrictiveAgreement": true
        },
        "pointOfContact": {
          "title": "Kate Martin",
          "organization": "Woebot Health",
          "email": "kate@woebothealth.com",
          "phone": "(415) 209-5642"
        }
      }
    },
    "documentSection": {
      "largeDocumentModule": {
        "largeDocs": [
          {
            "typeAbbrev": "Prot_SAP",
            "hasProtocol": true,
            "hasSap": true,
            "hasIcf": false,
            "label": "Study Protocol and Statistical Analysis Plan",
            "date": "2022-11-03",
            "uploadDate": "2024-10-22T12:59",
            "filename": "Prot_SAP_000.pdf",
            "size": 936590
          }
        ]
      }
    },
    "derivedSection": {
      "miscInfoModule": {
        "versionHolder": "2025-05-07",
        "submissionTracking": {
          "firstMcpInfo": {
            "postDateStruct": { "date": "2024-11-12", "type": "ACTUAL" }
          }
        }
      },
      "conditionBrowseModule": {
        "meshes": [
          { "id": "D019052", "term": "Depression, Postpartum" },
          { "id": "D003863", "term": "Depression" },
          { "id": "D003866", "term": "Depressive Disorder" }
        ],
        "ancestors": [
          { "id": "D001526", "term": "Behavioral Symptoms" },
          { "id": "D019964", "term": "Mood Disorders" },
          { "id": "D001523", "term": "Mental Disorders" },
          { "id": "D011644", "term": "Puerperal Disorders" },
          { "id": "D011248", "term": "Pregnancy Complications" },
          {
            "id": "D005261",
            "term": "Female Urogenital Diseases and Pregnancy Complications"
          },
          { "id": "D000091642", "term": "Urogenital Diseases" }
        ],
        "browseLeaves": [
          {
            "id": "M7061",
            "name": "Depressive Disorder",
            "asFound": "Depression",
            "relevance": "HIGH"
          },
          {
            "id": "M7058",
            "name": "Depression",
            "asFound": "Depression",
            "relevance": "HIGH"
          },
          {
            "id": "M21076",
            "name": "Depression, Postpartum",
            "asFound": "Postpartum Depression",
            "relevance": "HIGH"
          },
          { "id": "M4818", "name": "Behavioral Symptoms", "relevance": "LOW" },
          { "id": "M21835", "name": "Mood Disorders", "relevance": "LOW" },
          { "id": "M14473", "name": "Psychotic Disorders", "relevance": "LOW" },
          { "id": "M4815", "name": "Mental Disorders", "relevance": "LOW" },
          { "id": "M14499", "name": "Puerperal Disorders", "relevance": "LOW" },
          {
            "id": "M14127",
            "name": "Pregnancy Complications",
            "relevance": "LOW"
          },
          { "id": "M2875", "name": "Urogenital Diseases", "relevance": "LOW" },
          {
            "id": "M27093",
            "name": "Female Urogenital Diseases",
            "relevance": "LOW"
          },
          {
            "id": "M8399",
            "name": "Female Urogenital Diseases and Pregnancy Complications",
            "relevance": "LOW"
          }
        ],
        "browseBranches": [
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" },
          { "abbrev": "All", "name": "All Conditions" },
          {
            "abbrev": "BXS",
            "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
          }
        ]
      }
    },
    "hasResults": true
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT03683472",
        "orgStudyIdInfo": {
          "id": "1R41MH118130-01",
          "type": "NIH",
          "link": "https://reporter.nih.gov/quickSearch/1R41MH118130-01"
        },
        "organization": {
          "fullName": "MindSciences, Inc.",
          "class": "INDUSTRY"
        },
        "briefTitle": "Developing a Novel Digital Therapeutic for the Treatment of Generalized Anxiety Disorder",
        "officialTitle": "Developing a Novel Digital Therapeutic for the Treatment of Generalized Anxiety Disorder"
      },
      "statusModule": {
        "statusVerifiedDate": "2020-05",
        "overallStatus": "COMPLETED",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2019-05-20", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2019-10-17",
          "type": "ACTUAL"
        },
        "completionDateStruct": { "date": "2019-10-17", "type": "ACTUAL" },
        "studyFirstSubmitDate": "2018-06-11",
        "studyFirstSubmitQcDate": "2018-09-21",
        "studyFirstPostDateStruct": { "date": "2018-09-25", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2020-05-14",
        "lastUpdatePostDateStruct": { "date": "2020-05-18", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": {
          "type": "PRINCIPAL_INVESTIGATOR",
          "investigatorFullName": "Judson Brewer",
          "investigatorTitle": "Director of Research & Innovation",
          "investigatorAffiliation": "Brown University"
        },
        "leadSponsor": { "name": "MindSciences, Inc.", "class": "INDUSTRY" },
        "collaborators": [{ "name": "Brown University", "class": "OTHER" }]
      },
      "oversightModule": {
        "oversightHasDmc": true,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": false
      },
      "descriptionModule": {
        "briefSummary": "The investigators propose to develop and adapt Unwinding Anxiety phone app specifically for individuals with generalized anxiety disorder.",
        "detailedDescription": "The study aims are to (1) develop and refine Unwinding Anxiety for individuals with generalized anxiety disorder, (2) determine user engagement and acceptability as well as measure effect sizes of the program vs. treatment as usual, and (3) preliminarily test mechanisms of action. The knowledge gained will set the stage for a number of future studies related to further elucidating the mechanisms of mindfulness, and the clinical efficacy and utility of this type of training delivered via digital therapeutics in general. Specifically, this study will provide necessary variances for powering larger phase 2 studies."
      },
      "conditionsModule": {
        "conditions": ["Anxiety Disorders"],
        "keywords": ["Anxiety, worry, mindfulness, meditation"]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": { "masking": "SINGLE", "whoMasked": ["PARTICIPANT"] }
        },
        "enrollmentInfo": { "count": 65, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "Treatment as usual (TAU)",
            "type": "NO_INTERVENTION",
            "description": "Individuals will receive treatment as usual"
          },
          {
            "label": "TAU and Unwinding Anxiety Phone App",
            "type": "ACTIVE_COMPARATOR",
            "description": "The Unwinding Anxiety program focuses on teaching individuals 1) to understand how anxious worry is developed and perpetuated through reinforcement learning, 2) how to recognize these worry \"habit loops\" and 3) how to bring mindful awareness to moments of worry such that they can uncouple feelings of anxiety from reactive worry thinking and \"ride out\" habitual mind states that perpetuate and reinforce anxiety. Together, these help individuals \"unlearn\"/extinguish worry at a core mechanistic level.",
            "interventionNames": ["Behavioral: Unwinding Anxiety Phone App"]
          }
        ],
        "interventions": [
          {
            "type": "BEHAVIORAL",
            "name": "Unwinding Anxiety Phone App",
            "description": "The Unwinding Anxiety program focuses on teaching individuals 1) to understand how anxious worry is developed and perpetuated through reinforcement learning, 2) how to recognize these worry \"habit loops\" and 3) how to bring mindful awareness to moments of worry such that they can uncouple feelings of anxiety from reactive worry thinking and \"ride out\" habitual mind states that perpetuate and reinforce anxiety",
            "armGroupLabels": ["TAU and Unwinding Anxiety Phone App"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "UA Program engagement",
            "description": "Number of modules completed",
            "timeFrame": "Two months"
          },
          {
            "measure": "Change in worry",
            "description": "Penn State Worry Questionnaire (PSWQ)",
            "timeFrame": "Baseline, two months"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Change in non-reactivity & awareness",
            "description": "Five Facet Mindfulness Questionnaire - Non-Reactivity subscale (FFMQ)",
            "timeFrame": "Baseline, two months"
          },
          {
            "measure": "UA Program Acceptability",
            "description": "Net Promoter Score (NPS)",
            "timeFrame": "Two months"
          }
        ],
        "otherOutcomes": [
          {
            "measure": "Change in anxiety",
            "description": "Generalized Anxiety Disorder - 7 items (GAD-7)",
            "timeFrame": "Baseline, two months"
          },
          {
            "measure": "Change in self-regulation",
            "description": "Multidimensional Assessment of Interoceptive Awareness (MAIA)",
            "timeFrame": "Baseline, two months"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* Owns a smart phone\n* GAD - 7 is equal to or greater than 10\n\nExclusion Criteria:\n\n* If using psychotropic medication - not on a stable dosage for at least 6 weeks\n* Medical disorder of the severity that would interfere with ability to participate\n* Not being fluent in English (due to instructions provided in English)\n* As needed use (i.e. prn) of benzodiazepines\n* Psychotic disorder,\n* Previous MT (e.g. MBSR, other Claritas MindSciences training programs).",
        "healthyVolunteers": true,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "Judson Brewer",
            "affiliation": "Brown University",
            "role": "PRINCIPAL_INVESTIGATOR"
          }
        ],
        "locations": [
          {
            "facility": "Brown University",
            "city": "Providence",
            "state": "Rhode Island",
            "zip": "02912",
            "country": "United States",
            "geoPoint": { "lat": 41.82399, "lon": -71.41283 }
          }
        ]
      },
      "referencesModule": {
        "references": [
          {
            "pmid": "34860673",
            "type": "DERIVED",
            "citation": "Roy A, Hoge EA, Abrante P, Druker S, Liu T, Brewer JA. Clinical Efficacy and Psychological Mechanisms of an App-Based Digital Therapeutic for Generalized Anxiety Disorder: Randomized Controlled Trial. J Med Internet Res. 2021 Dec 2;23(12):e26987. doi: 10.2196/26987."
          }
        ]
      },
      "ipdSharingStatementModule": { "ipdSharing": "NO" }
    },
    "documentSection": {
      "largeDocumentModule": {
        "largeDocs": [
          {
            "typeAbbrev": "ICF",
            "hasProtocol": false,
            "hasSap": false,
            "hasIcf": true,
            "label": "Informed Consent Form",
            "date": "2019-05-02",
            "uploadDate": "2020-03-16T12:50",
            "filename": "ICF_000.pdf",
            "size": 131119
          }
        ]
      }
    },
    "annotationSection": {
      "annotationModule": {
        "unpostedAnnotation": {
          "unpostedResponsibleParty": "Judson Brewer, Director of Research & Innovation, Brown University",
          "unpostedEvents": [
            { "type": "RELEASE", "date": "2022-02-21" },
            { "type": "RESET", "date": "2022-03-18" },
            { "type": "RELEASE", "date": "2022-06-14" },
            { "type": "RESET", "date": "2022-07-06" },
            { "type": "RELEASE", "date": "2022-09-20" },
            { "type": "RESET", "date": "2022-10-12" }
          ]
        }
      }
    },
    "derivedSection": {
      "miscInfoModule": {
        "versionHolder": "2025-05-07",
        "submissionTracking": {
          "estimatedResultsFirstSubmitDate": "2022-02-21",
          "submissionInfos": [
            { "releaseDate": "2022-02-21", "resetDate": "2022-03-18" },
            { "releaseDate": "2022-06-14", "resetDate": "2022-07-06" },
            { "releaseDate": "2022-09-20", "resetDate": "2022-10-12" },
            { "releaseDate": "2025-05-06" }
          ]
        }
      },
      "conditionBrowseModule": {
        "meshes": [{ "id": "D001008", "term": "Anxiety Disorders" }],
        "ancestors": [{ "id": "D001523", "term": "Mental Disorders" }],
        "browseLeaves": [
          {
            "id": "M4324",
            "name": "Anxiety Disorders",
            "asFound": "Anxiety Disorder",
            "relevance": "HIGH"
          },
          { "id": "M14473", "name": "Psychotic Disorders", "relevance": "LOW" },
          { "id": "M4815", "name": "Mental Disorders", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" },
          { "abbrev": "All", "name": "All Conditions" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT06130267",
        "orgStudyIdInfo": { "id": "2022-2849" },
        "organization": {
          "fullName": "Ciusss de L'Est de l'Île de Montréal",
          "class": "OTHER"
        },
        "briefTitle": "The Impact of an Immersive Digital Therapeutic Tool on Pain Perception",
        "officialTitle": "The Impact of an Immersive Digital Therapeutic Tool on Pain Perception: An Experimental Study With an Active Control Condition"
      },
      "statusModule": {
        "statusVerifiedDate": "2023-11",
        "overallStatus": "COMPLETED",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2022-06-24", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2023-04-15",
          "type": "ACTUAL"
        },
        "completionDateStruct": { "date": "2023-04-15", "type": "ACTUAL" },
        "studyFirstSubmitDate": "2023-11-05",
        "studyFirstSubmitQcDate": "2023-11-11",
        "studyFirstPostDateStruct": { "date": "2023-11-14", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2023-11-11",
        "lastUpdatePostDateStruct": { "date": "2023-11-14", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": {
          "type": "SPONSOR_INVESTIGATOR",
          "investigatorFullName": "Stéphane Potvin",
          "investigatorTitle": "Full-time professor",
          "investigatorAffiliation": "Ciusss de L'Est de l'Île de Montréal"
        },
        "leadSponsor": { "name": "Stéphane Potvin", "class": "OTHER" }
      },
      "oversightModule": {
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": false,
        "isUsExport": false
      },
      "descriptionModule": {
        "briefSummary": "The goal of this experimental study is to examine the impact of a virtual reality paradigm on heat pain perception in healthy volunteers. The main question it aims to answer is to determine if the virtual reality paradigm reduces pain intensity and unpleasantness evoked by tonic heat pain stimulation. Tonic heat pain stimulation is applied on the left forearm of participants using a Peltier thermode immediately before, during and immediately after virtual reality exposure. Using a with-subject design, participants are sequentially exposed to both the virtual reality condition and an active control condition. The order of administration of the virtual reality and control conditions is randomized.",
        "detailedDescription": "Pain is a complex and multifaced sensory and emotional experience. Virtual reality has shown promise in reducing experimental pain and chronic pain. However, many previous trials in the field lacked proper control conditions. This experimental study examines an immersive virtual environment initially designed for the treatment of endometriosis patients, which demonstrated promising analgesic effects. The current study aims to determine the impact of the virtual reality paradigm on experimental pain perception both during and after virtual reality exposure, while using an active control condition. This study involves healthy individuals with no chronic pain and uses a within-subject design, comparing a virtual reality paradigm with an active control condition. Continuous heat pain stimulation is applied to the left forearm of participants with a Peltier thermode, before, during and immediately after virtual reality exposure. For each continuous heat pain stimulation, pain intensity and unpleasantness are measured using a scale from 0 (no pain) to 100 (worst pain). Using a with-subject design, participants are sequentially exposed to both the virtual reality condition and an active control condition. The order of administration of the virtual reality and control conditions is randomized. Both conditions are administered in a single experimental session at the laboratory."
      },
      "conditionsModule": {
        "conditions": ["Pain Perception"],
        "keywords": [
          "Pain",
          "Emotions",
          "virtual reality",
          "within-subject design"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "CROSSOVER",
          "primaryPurpose": "OTHER",
          "maskingInfo": { "masking": "SINGLE", "whoMasked": ["PARTICIPANT"] }
        },
        "enrollmentInfo": { "count": 21, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "control condition",
            "type": "PLACEBO_COMPARATOR",
            "description": "same paradigm without the active agent",
            "interventionNames": ["Other: Endocare"]
          },
          {
            "label": "Virtual Reality condition",
            "type": "EXPERIMENTAL",
            "description": "calming VR environment",
            "interventionNames": ["Other: Endocare"]
          }
        ],
        "interventions": [
          {
            "type": "OTHER",
            "name": "Endocare",
            "description": "Virtual paradigm (calming environnement)",
            "armGroupLabels": ["Virtual Reality condition", "control condition"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Thermal heat pain induced with a Peltier thermode",
            "description": "Pain intensity and unpleasantness, on a COVAS scale from 0 (no pain) to 100 (worse pain)",
            "timeFrame": "Immediately before, during and immediately after VR exposure"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* healthy men and women\n* between 18 and 50 years old\n* willing to participate in the study\n* able to sign the informed consent form\n\nExclusion Criteria:\n\n* neurological disorders\n* substance use disorders\n* severe mental health disorder\n* chronic pain\n* any acute and unstable medical condition\n* taking medication that acts on the central nervous system",
        "healthyVolunteers": true,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "maximumAge": "50 Years",
        "stdAges": ["ADULT"]
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "Stéphane Potvin, PhD",
            "affiliation": "University of Montreal, Centre de recherche de l'institut universitaire en santé mentale de montréal",
            "role": "STUDY_DIRECTOR"
          }
        ],
        "locations": [
          {
            "facility": "Centre de recherche de l'institut universitaire de santé mentale de Montréal",
            "city": "Montréal",
            "state": "Quebec",
            "zip": "H1N 3V2",
            "country": "Canada",
            "geoPoint": { "lat": 45.50884, "lon": -73.58781 }
          }
        ]
      }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "browseLeaves": [
          { "id": "M13066", "name": "Pain", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "BC23", "name": "Symptoms and General Pathology" },
          { "abbrev": "All", "name": "All Conditions" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT05146765",
        "orgStudyIdInfo": { "id": "D-ST01" },
        "organization": {
          "fullName": "Ewha Womans University Seoul Hospital",
          "class": "OTHER"
        },
        "briefTitle": "Efficacy of a Digital Therapeutic for People With Dysarthria After Stroke",
        "officialTitle": "Efficacy of a Digital Therapeutic for People With Dysarthria After Stroke; Pilot Trial"
      },
      "statusModule": {
        "statusVerifiedDate": "2023-12",
        "overallStatus": "COMPLETED",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2022-01-18", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2022-08-30",
          "type": "ACTUAL"
        },
        "completionDateStruct": { "date": "2022-08-30", "type": "ACTUAL" },
        "studyFirstSubmitDate": "2021-11-14",
        "studyFirstSubmitQcDate": "2021-12-02",
        "studyFirstPostDateStruct": { "date": "2021-12-07", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2023-12-14",
        "lastUpdatePostDateStruct": { "date": "2023-12-20", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": {
          "type": "PRINCIPAL_INVESTIGATOR",
          "investigatorFullName": "Tae-Jin Song, MD, PhD",
          "investigatorTitle": "Principal investigator, Department of neurology, Seoul Hospital, Ewha Womans University College of Medicine",
          "investigatorAffiliation": "Ewha Womans University Seoul Hospital"
        },
        "leadSponsor": {
          "name": "Ewha Womans University Seoul Hospital",
          "class": "OTHER"
        }
      },
      "oversightModule": {
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": false
      },
      "descriptionModule": {
        "briefSummary": "This pilot trial will establish the feasibility of a new digitized speech rehabilitation developed for patients with post-stroke dysarthria. For this study, participants will be instructed to use the speech therapy app for 30 minutes to 1 hour per day over a 4-week period.",
        "detailedDescription": "A total of 40 patients with post-stroke dysarthria will be recruited and randomly divided into intervention and control groups.\n\nPatients in the intervention group will be instructed to receive speech treatments including oro-motor exercise, phonation, articulation, resonance, syllable repetition, and reading exercise (App on mobile devices). Daily sessions will be provided during a 4-week period. Both groups will also receive treatment as usual. The aim of the study is to investigate the efficacy of mobile-based speech therapy in patients with dysarthria in the acute phase following stroke."
      },
      "conditionsModule": {
        "conditions": ["Dysarthria as Late Effect of Stroke"],
        "keywords": [
          "Dysarthria",
          "Stroke",
          "digital therapeutics",
          "Speech Disorders",
          "Language Disorders",
          "speech rehabilitation",
          "application",
          "Post-stroke dysarthria"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "interventionModelDescription": "Pilot trial",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": {
            "masking": "SINGLE",
            "maskingDescription": "Outcome Assessor",
            "whoMasked": ["PARTICIPANT"]
          }
        },
        "enrollmentInfo": { "count": 40, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "Intervention",
            "type": "EXPERIMENTAL",
            "description": "The intervention group will receive treatment as usual along with the speech therapy app.",
            "interventionNames": [
              "Device: Mobile application",
              "Other: Treatment as usual"
            ]
          },
          {
            "label": "Control",
            "type": "NO_INTERVENTION",
            "description": "The control group will receive treatment as usual only."
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "Mobile application",
            "description": "Device: Use of mobile application Participants will be instructed to use the speech therapy app for 30 minutes to one hour per day over a 4-week period.",
            "armGroupLabels": ["Intervention"]
          },
          {
            "type": "OTHER",
            "name": "Treatment as usual",
            "description": "The patients will follow the treatment as usual, including conventional stroke therapy if needed based on the medical guidelines.",
            "armGroupLabels": ["Intervention"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Speech intelligibility",
            "description": "Speech intelligibility is evaluated with a score of 0 (normal), 1 (intelligible, some differences noticeable), 2 (intelligible, noticeably different), 3 (intelligible with careful listening, some unintelligible), 4 (difficult to understand, many words unintelligible), 5 (usually unintelligible), or 6 (unintelligible).",
            "timeFrame": "Baseline, 4weeks"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "The percent change in score on the Urimal Test of Articulation and Phonology 2 (UTAP2)",
            "description": "he UTAP2, an essential tool for determining articulatory proficiency, will be employed to evaluate the Percentage of Consonants Correct (PCC), a crucial metric for identifying irregularities in articulation. Study participants will be instructed to read all 30 words from the UTAP2 word-level test. Following this, evaluators will calculate the PCC, expressed as a percentage, using the 94 consonants included in these words. This methodology acknowledges that a PCC of 0% signifies lower articulatory accuracy, whereas a PCC of 100% reflects a higher level of precision.",
            "timeFrame": "Baseline, 4weeks"
          }
        ],
        "otherOutcomes": [
          {
            "measure": "National Institute of Health Stroke Scale (NIHSS)",
            "description": "NIHSS will be used to assess stroke-related neurologic deficits. The NIHSS scale is made up of 11 different elements that evaluate specific abilities; level of consciousness (LOC), best gaze, visual field, facial palsy, motor arm, motor leg, limb ataxia, sensory, best language, dysarthria, extinction, inattention. The score ranges from 0 to 42; higher scores indicate more severe stroke symptoms.",
            "timeFrame": "Baseline, 4weeks"
          },
          {
            "measure": "Patient Health Questionnaire-9 (PHQ-9)",
            "description": "The PHQ-9 is a nine-item self-reported questionnaire that is used to assess depressive symptoms. The score ranges from 0 to 27, with lower scores indicating less depressive severity.",
            "timeFrame": "Baseline, 4weeks"
          },
          {
            "measure": "Generalized Anxiety disorder-7",
            "description": "GAD-7(Generalized Anxiety disorder-7) will be used to assess anxiety. The GAD-7(Generalized Anxiety disorder-7) is a seven-item self-reported questionnaire that evaluates anxiety symptoms. The score ranges from 0 to 21, with lower scores indicating lower anxiety symptoms.",
            "timeFrame": "Baseline, 4weeks"
          },
          {
            "measure": "Euro Quality of Life (EQ-5D)",
            "description": "EQ-5D will be used to assess the quality of life. The EQ-5D is a self-report questionnaire that measures health-related quality of life. The questionnaire consists of five dimensions: mobility, self-care, ordinary activities, discomfort, and mood state related to anxiety or depression. The responses indicate three levels of severity (\"no problems\", \"some problems\", and \"extreme problems\") within each EQ-5D dimension.",
            "timeFrame": "Baseline, 4weeks"
          },
          {
            "measure": "Modified Computer Self-Efficacy Scale (mCSES)",
            "description": "mCSES will be used to assess participants' perceptions of self-efficacy with respect to using a computerized system. The mCSES is a 10-item self-reported questionnaire. The score ranges from 0 to 100; higher scores indicate a stronger sense of personal competence.",
            "timeFrame": "Baseline, 4weeks"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n1. Neurologically stable, as determined by the clinician.\n2. Onset of stroke within four weeks prior to randomization.\n3. Diagnosis of dysarthria caused by stroke as confirmed by a stroke specialty neurologist.\n4. Maintains enough cognitive function to use the speech therapy application without problems, as determined by a Mini-Mental State Exam score of 26 ≥ within 1 month prior to randomization.\n5. Capable of walking or moving alone or with the assistance of a walking aid (e.g., walkers, canes, or wheelchairs).\n6. Must have intact vision, hearing, communication skills, and motor skills, as well as comprehension sufficient to proceed with assessment, as judged by the clinician.\n\nExclusion Criteria:\n\n1. Unable to measure articulatory or orofacial functions due to organic causes/lesions in articulatory and cervical structure.\n2. Has comorbid neurological conditions that, in the opinion of the investigator, could impair study participation, such as dementia (Alzheimer's disease, vascular dementia, Central Nervous System Infection \\[e.g., Human Immunodeficiency Virus, syphilis\\], Creutzfeld-Jacob disease, etc.), Pick's disease, Huntington's disease, or Parkinson's disease.\n3. Has a Mini-Mental State Exam score of 26 or below at the time of screening.\n4. Has a Clinical Dementia Rating score of 1 ≥ or a Global Deterioration Scale score of 3 ≥ at the time of screening.\n5. Received dementia treatment within 3 months of screening.\n6. Takes medication that may impact cognitive function during the clinical trial period.\n7. Co-medication is prohibited during the entire trial period for the following medications: drugs for dementia treatment, Central Nervous System stimulants, anticholinergics, tricyclic antidepressants, typical antipsychotics, and sleeping pills (excluding rapid-acting sleeping pills).\n8. Co-medication is permitted if continued use of the following medications has been at a stable dose for 2 months prior to randomization: atypical antipsychotics, anxiolytics, antidepressants (excluding tricyclic antidepressants), thyroid hormone, and rapid-acting sleeping pills.\n9. Is uneducated or illiterate.\n10. Has been diagnosed with a serious mental illness such as severe depression, schizophrenia, alcohol addiction, or drug addiction.\n11. Unable to use D-ST01 due to severe speech impairment, as determined by the clinician.",
        "healthyVolunteers": false,
        "sex": "ALL",
        "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "Tae-Jin Song, MD, PhD",
            "affiliation": "Department of Neurology, Ewha University College of Medicine, Seoul, Republic of Korea",
            "role": "PRINCIPAL_INVESTIGATOR"
          }
        ],
        "locations": [
          {
            "facility": "Ewha Womans University Medical Center",
            "city": "Seoul",
            "zip": "07804",
            "country": "Korea, Republic of",
            "geoPoint": { "lat": 37.566, "lon": 126.9784 }
          }
        ]
      },
      "ipdSharingStatementModule": { "ipdSharing": "NO" }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [
          { "id": "D020521", "term": "Stroke" },
          { "id": "D004401", "term": "Dysarthria" }
        ],
        "ancestors": [
          { "id": "D002561", "term": "Cerebrovascular Disorders" },
          { "id": "D001927", "term": "Brain Diseases" },
          { "id": "D002493", "term": "Central Nervous System Diseases" },
          { "id": "D009422", "term": "Nervous System Diseases" },
          { "id": "D014652", "term": "Vascular Diseases" },
          { "id": "D002318", "term": "Cardiovascular Diseases" },
          { "id": "D001184", "term": "Articulation Disorders" },
          { "id": "D013064", "term": "Speech Disorders" },
          { "id": "D007806", "term": "Language Disorders" },
          { "id": "D003147", "term": "Communication Disorders" },
          { "id": "D019954", "term": "Neurobehavioral Manifestations" },
          { "id": "D009461", "term": "Neurologic Manifestations" }
        ],
        "browseLeaves": [
          {
            "id": "M22306",
            "name": "Stroke",
            "asFound": "Stroke",
            "relevance": "HIGH"
          },
          { "id": "M10823", "name": "Language Disorders", "relevance": "LOW" },
          { "id": "M15864", "name": "Speech Disorders", "relevance": "LOW" },
          {
            "id": "M7575",
            "name": "Dysarthria",
            "asFound": "Dysarthria",
            "relevance": "HIGH"
          },
          {
            "id": "M5810",
            "name": "Cerebrovascular Disorders",
            "relevance": "LOW"
          },
          { "id": "M5204", "name": "Brain Diseases", "relevance": "LOW" },
          {
            "id": "M5742",
            "name": "Central Nervous System Diseases",
            "relevance": "LOW"
          },
          { "id": "M17400", "name": "Vascular Diseases", "relevance": "LOW" },
          {
            "id": "M4492",
            "name": "Articulation Disorders",
            "relevance": "LOW"
          },
          {
            "id": "M6374",
            "name": "Communication Disorders",
            "relevance": "LOW"
          },
          {
            "id": "M21826",
            "name": "Neurobehavioral Manifestations",
            "relevance": "LOW"
          },
          {
            "id": "M12404",
            "name": "Neurologic Manifestations",
            "relevance": "LOW"
          }
        ],
        "browseBranches": [
          { "abbrev": "BC10", "name": "Nervous System Diseases" },
          { "abbrev": "BC14", "name": "Heart and Blood Diseases" },
          { "abbrev": "All", "name": "All Conditions" },
          { "abbrev": "BC23", "name": "Symptoms and General Pathology" },
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" }
        ]
      },
      "interventionBrowseModule": {
        "browseLeaves": [
          { "id": "M6263", "name": "Coal Tar", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "Derm", "name": "Dermatologic Agents" },
          { "abbrev": "All", "name": "All Drugs and Chemicals" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT05440721",
        "orgStudyIdInfo": { "id": "CT-101-002" },
        "organization": {
          "fullName": "Click Therapeutics, Inc.",
          "class": "INDUSTRY"
        },
        "briefTitle": "Clinical Trial of an Innovative Digital Therapeutic for Smoking Cessation With Biochemical Verification",
        "officialTitle": "Clinical Trial of an Innovative Digital Therapeutic for Smoking Cessation With Biochemical Verification"
      },
      "statusModule": {
        "statusVerifiedDate": "2022-06",
        "overallStatus": "WITHDRAWN",
        "whyStopped": "Change of company's priority; learning from a separate CT-101-CLS-001 (NCT04857515) is deemed sufficient",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2018-10-25", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2022-07",
          "type": "ESTIMATED"
        },
        "completionDateStruct": { "date": "2022-08", "type": "ESTIMATED" },
        "studyFirstSubmitDate": "2022-06-22",
        "studyFirstSubmitQcDate": "2022-06-27",
        "studyFirstPostDateStruct": { "date": "2022-07-01", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2022-06-27",
        "lastUpdatePostDateStruct": { "date": "2022-07-01", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": {
          "name": "Click Therapeutics, Inc.",
          "class": "INDUSTRY"
        }
      },
      "oversightModule": {
        "oversightHasDmc": true,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": true,
        "isUsExport": false
      },
      "descriptionModule": {
        "briefSummary": "This study is evaluating the efficacy of Treatment A for short-term smoking cessation through a blinded randomized controlled trial (RCT) vs.Treatment B.",
        "detailedDescription": "The overarching study aim is to recruit a population of current smokers who are motivated to quit with the assistance of a mobile solution, enroll them into a study testing apps to help them quit, and randomize them into one of two arms. The core study period will consist of 8 weeks of usage of Treatment A or Treatment B. At the end of this period, users will receive notifications to link them to an online survey, which will record their responses in a secure database."
      },
      "conditionsModule": {
        "conditions": [
          "Nicotine Addiction",
          "Drug Addiction",
          "Drug Dependence",
          "Substance Use Disorder",
          "Tobacco Dependence"
        ],
        "keywords": [
          "Smoking",
          "Cigarette Smoking",
          "Tobacco Smoking",
          "Nicotine",
          "Drug",
          "Addiction",
          "Tobacco"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "primaryPurpose": "BASIC_SCIENCE",
          "maskingInfo": {
            "masking": "TRIPLE",
            "whoMasked": ["PARTICIPANT", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]
          }
        },
        "enrollmentInfo": { "count": 0, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "Treatment A (device Clickotine®)",
            "type": "ACTIVE_COMPARATOR",
            "description": "User will open and use Treatment A (Clickotine® device) several times a day up to their quit date to complete a program of 21 Missions.",
            "interventionNames": [
              "Device: Treatment A with device Clickotine® (Active intervention)"
            ]
          },
          {
            "label": "Treatment B (smoking education)",
            "type": "SHAM_COMPARATOR",
            "description": "Treatment B app provides education and support to smokers seeking to quit. When a user has a craving or wants support or education, they can log into the app.",
            "interventionNames": [
              "Device: Treatment B with smoking education (control)"
            ]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "Treatment A with device Clickotine® (Active intervention)",
            "description": "The intervention regimen around Treatment A is almost entirely user-directed. When a person has a craving, a series of options are available to ease the craving and resist the urge to smoke. The user will also engage with Clickotine® leading up to their quit date to complete a program of 21 Missions, daily activities which help prepare them to quit and keep them off cigarettes. Ideally, the user will open and use Treatment A several times a day.",
            "armGroupLabels": ["Treatment A (device Clickotine®)"]
          },
          {
            "type": "DEVICE",
            "name": "Treatment B with smoking education (control)",
            "description": "The Treatment B app is operated by the National Cancer Institute to provide education and support to smokers seeking to quit. The QG regimen is entirely user-directed. When a user has a craving or wants support or education, they can log into the QG app. The QG app also provides lessons relevant for preparing to quit and beginning to quit.",
            "armGroupLabels": ["Treatment B (smoking education)"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Primary Outcome Measure:",
            "description": "The primary objective is to confirm the improved efficacy of CKT for short-term smoking cessation through a blinded randomized controlled trial (RCT) vs. QuitGuide.\n\n\\*\\*Acceptance criteria: Self-reported 30 day point prevalence quit rates will be significantly higher in the CKT arm than QuitGuide.",
            "timeFrame": "[Time Frame: 8 week core study]"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Secondary Outcome Measure",
            "description": "A secondary objective of the study is to establish the feasibility of biochemical verification of smoking cessation in a fully remote, digital clinical trial.",
            "timeFrame": "[Time Frame: 8 week core study]"
          },
          {
            "measure": "Secondary Outcome Measure",
            "description": "A secondary objective of the study is to compare cessation rates between the CKT+NRT group and the CKT-only group, to address expected med/NRT use during the trial and to confirm the initial trial result that CKT+NRT is not superior to CKT-alone.",
            "timeFrame": "[Time Frame: 8 week core study]"
          },
          {
            "measure": "Secondary Outcome Measure",
            "description": "A secondary objective of the study is to demonstrate the feasibility of evaluating CKT in a Magellan Behavioral Health (A Click Therapeutics partner) value-based care population",
            "timeFrame": "[Time Frame: 8 week core study]"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n1. Age 18 to 65\n2. Smokes at least 5 cigarettes daily\n3. Is interested in quitting in the next 30 days\n4. Owns an iPhone with iOS 9 or higher or Android with OS 4.1 or higher\n5. Willing and able to receive SMS text messages\n6. Able to comprehend the English-language and the informed consent form\n7. Lives in the United States\n8. One half of the study sample will be recruited from the general population of smokers via social media advertisements\n9. One half of the study sample will be recruited via mail from a Magellan Behavioral Health value-based care network\n\nExclusion Criteria:\n\n1. Prior use of Clickotine or QuitGuide\n2. Current use of pharmacotherapy for smoking cessation or nicotine replacement therapy (NRT)",
        "healthyVolunteers": true,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "maximumAge": "65 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "Shaheen Lakhan, MDPhD, FAAN",
            "affiliation": "Click Therapeutics",
            "role": "STUDY_CHAIR"
          }
        ],
        "locations": [
          {
            "facility": "Click Therapeutics",
            "city": "New York",
            "state": "New York",
            "zip": "10013",
            "country": "United States",
            "geoPoint": { "lat": 40.71427, "lon": -74.00597 }
          }
        ]
      },
      "ipdSharingStatementModule": { "ipdSharing": "NO" }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [
          { "id": "D019966", "term": "Substance-Related Disorders" },
          { "id": "D014029", "term": "Tobacco Use Disorder" },
          { "id": "D016739", "term": "Behavior, Addictive" }
        ],
        "ancestors": [
          { "id": "D003192", "term": "Compulsive Behavior" },
          { "id": "D007175", "term": "Impulsive Behavior" },
          { "id": "D064419", "term": "Chemically-Induced Disorders" },
          { "id": "D001523", "term": "Mental Disorders" }
        ],
        "browseLeaves": [
          {
            "id": "M19100",
            "name": "Behavior, Addictive",
            "asFound": "Addiction",
            "relevance": "HIGH"
          },
          {
            "id": "M21837",
            "name": "Substance-Related Disorders",
            "asFound": "Substance Use Disorders",
            "relevance": "HIGH"
          },
          {
            "id": "M16785",
            "name": "Tobacco Use Disorder",
            "asFound": "Nicotine Addiction",
            "relevance": "HIGH"
          },
          { "id": "M6418", "name": "Compulsive Behavior", "relevance": "LOW" },
          { "id": "M10220", "name": "Impulsive Behavior", "relevance": "LOW" },
          {
            "id": "M30302",
            "name": "Chemically-Induced Disorders",
            "relevance": "LOW"
          },
          { "id": "M14473", "name": "Psychotic Disorders", "relevance": "LOW" },
          { "id": "M4815", "name": "Mental Disorders", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" },
          { "abbrev": "All", "name": "All Conditions" },
          { "abbrev": "BC25", "name": "Substance Related Disorders" }
        ]
      },
      "interventionBrowseModule": {
        "browseLeaves": [
          { "id": "M12478", "name": "Nicotine", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "All", "name": "All Drugs and Chemicals" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT03569618",
        "orgStudyIdInfo": { "id": "16-19891" },
        "organization": {
          "fullName": "University of California, San Francisco",
          "class": "OTHER"
        },
        "briefTitle": "Digital Cognition in Multiple Sclerosis",
        "officialTitle": "Effect of a Digital Therapeutic on Processing Speed in Adults With Multiple Sclerosis",
        "acronym": "DigCog"
      },
      "statusModule": {
        "statusVerifiedDate": "2020-10",
        "overallStatus": "COMPLETED",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2018-04-01", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2018-11-01",
          "type": "ACTUAL"
        },
        "completionDateStruct": { "date": "2019-01-15", "type": "ACTUAL" },
        "studyFirstSubmitDate": "2018-03-13",
        "studyFirstSubmitQcDate": "2018-06-14",
        "studyFirstPostDateStruct": { "date": "2018-06-26", "type": "ACTUAL" },
        "resultsFirstSubmitDate": "2019-12-11",
        "resultsFirstSubmitQcDate": "2020-10-23",
        "resultsFirstPostDateStruct": {
          "date": "2020-10-26",
          "type": "ACTUAL"
        },
        "lastUpdateSubmitDate": "2020-10-23",
        "lastUpdatePostDateStruct": { "date": "2020-10-26", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": {
          "name": "University of California, San Francisco",
          "class": "OTHER"
        },
        "collaborators": [
          { "name": "Akili Interactive Labs, Inc.", "class": "INDUSTRY" }
        ]
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": true,
        "isUnapprovedDevice": true,
        "isUsExport": false
      },
      "descriptionModule": {
        "briefSummary": "A DIGITAL THERAPEUTIC TO IMPROVE THINKING IN MULTIPLE SCLEROSIS\n\nWHO: 65 participants with a confirmed diagnosis of Multiple Sclerosis (MS)\n\nWHY: Purpose of the study is to compare the effect of 2 tablet-based brain training digital tools on important components of thinking (cognition).\n\nWHAT: Complete a set of tests (physical and cognitive) at baseline, 6 weeks and 14 weeks, and use one of two brain training tools on an iPad in your home, for 25 minutes a day, 5 days a week, for 6 weeks.\n\nWHERE: UCSF WEILL INSTITUTE FOR NEUROSCIENCES (675 Nelson Rising Lane, San Francisco, CA)",
        "detailedDescription": "The purpose of this study is to begin to test a brain training video game in people with Multiple Sclerosis (MS).\n\nVisit 1. After informed consent, you will complete a series of questions about your functioning and mood. You will then complete a series of tests (vision, hand tapping, walking). Then, you will complete a set of thinking tests. The first set will be paper and pencil. The second set will be on a tablet or a computer. You will use your study code to sign into these tools and you won't provide any personal details for the digitized tests.\n\nFinally, you will complete the \"cognitive training tool\". There are two versions of this digital, iPad based tool, which takes about 25 minutes to complete and is designed to be entertaining. You will be randomized into 1 of 2 groups: each group will play a version of the brain training game. You will not be told what group/game type you were randomized into. You will be given the tablet with the game on it to take home, and to practice this game 5 times a week for 6 weeks.\n\nVisit 2. After the 6 weeks of at-home training, you will then come back to the research study unit to do a repeat of the initial visit (with physical and cognitive assessments). At this study visit, you will also be returning the iPad.\n\nVisit 3. You will then return 8 weeks after Visit 2, to do a repeat of the assessments.\n\nYou will be compensated for each study visit (visit 1: $50, visit 2: $100, visit 3: $150)."
      },
      "conditionsModule": {
        "conditions": ["Multiple Sclerosis", "Cognitive Decline"]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": {
            "masking": "TRIPLE",
            "maskingDescription": "Study assessment administrator is blinded to what digital tool the subject has been assigned.",
            "whoMasked": ["PARTICIPANT", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]
          }
        },
        "enrollmentInfo": { "count": 44, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "Game 1",
            "type": "ACTIVE_COMPARATOR",
            "description": "Tablet-based Game 1.",
            "interventionNames": ["Device: Tablet-based Game"]
          },
          {
            "label": "Game 2",
            "type": "PLACEBO_COMPARATOR",
            "description": "Tablet-based Game 2.",
            "interventionNames": ["Device: Tablet-based Game"]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "Tablet-based Game",
            "description": "Tablet-based game aimed at improving processing speed and attention.",
            "armGroupLabels": ["Game 1", "Game 2"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Change in Processing Speed After 6 Weeks of Treatment With a Digital Therapeutic 'Game 1', vs. 'Game 2'.",
            "description": "Processing speed is being measured by the Symbol Digit Modalities Test (SDMT) score. SDMT measures the time to pair abstract symbols with specific numbers. The test requires visuoperceptual processing, working memory, and psychomotor speed. The score is the number of correctly coded items in 90 seconds. (max=110, min=0). Higher scores indicate improvement. Lower scores indicate worsening.",
            "timeFrame": "Baseline and 6 weeks"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Number of Participants With at Least 4-point Increase in SDMT Above Their Baseline Value 8 Weeks After Treatment",
            "description": "Number of participants showing a clinically meaningful 4+ point increase in SDMT (symbol digit modalities test) relative to baseline SDMT score. Comparison of SDMT changes 8 weeks after end of treatment with Tool 1 vs. Tool 2.",
            "timeFrame": "14 weeks"
          }
        ],
        "otherOutcomes": [
          {
            "measure": "Change in Mood After 6 Weeks Treatment With Game 1 vs. Game 2",
            "description": "Comparison of changes in mood (depression, anxiety). Depression measured using the Center for Epidemiologic Studies Depression Scale (CES-D). Possible range of scores is zero to 60, with the higher scores indicating the presence of more symptomatology. Anxiety measured using the State-Trait Anxiety Inventory - State subtest (STAI-S) and the State-Trait Anxiety Inventory - Trait subtest (STAI-T). Both have 20 questions and a score range 20-80, with higher scores indicating greater anxiety.",
            "timeFrame": "Baseline and 6 weeks"
          },
          {
            "measure": "Change in Fatigue After 6 Weeks Treatment With Game 1 vs. Game 2.",
            "description": "Fatigue is being measured by the Modified Fatigue Impact Scale (MFIS) which has participants rank 21 items on 1 to 4 (never to always) scale. The score is the sum of these subscales. (max=84, min=0) Lower scores indicate improvement. Higher scores indicate worsening.",
            "timeFrame": "Baseline and 6 weeks"
          },
          {
            "measure": "Change in a Digital Cognitive Battery After 6 Weeks Treatment With Game 1 vs. Game 2.",
            "description": "Comparison of changes in scores on Match, a tablet-based assessment of processing speed and executive function. Performance is gauged on a continuous scale using the total number of correct responses given in 2-minutes. The minimum possible score is 0 (no correct responses) with higher scores indicating better performance (no maximum possible score).",
            "timeFrame": "Baseline and 6 weeks"
          },
          {
            "measure": "Change in Paper and Pencil Cognitive Testing After 6 Weeks Treatment With Game 1 vs. Game 2.",
            "description": "Comparison of changes in cognition, as assessed using the BICAMS battery (Brief International Cognitive Assessment for Multiple Sclerosis) and PASAT (Paced Auditory Serial Addition Test). The BICAMS battery is composed of 3 tests (for all, higher scores indicate better performance): (1) The Symbol Digit Modalities Test (SDMT), a measure of information processing speed where performance is gauged by the number of correct responses given in 90-seconds, with a minimum possible score of 0 and maximum of 110. (2) The California Verbal Learning Test-II (CVLT-II) is a 5-trial auditory/verbal learning test with a total min. score of 0 and max of 80. (3) The Brief Visuospatial Memory Test -- Revised (BVMT-R) is a visual and spatial memory test given in 3 trials with a total min score of 0 and max of 36.\n\nThe PASAT is a test of information processing and attention with a minimum score of 0 and maximum of 60. Higher scores indicate better performance.",
            "timeFrame": "Baseline and 6 weeks"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* Adult men or women diagnosed with multiple sclerosis (MS) or clinically isolated syndrome (CIS)\n* SDMT z-score range (-2 to +1)\n* Wifi available in home\n* Able to use a tablet (iPad)\n* Able to attend 3 study visits in person.\n\nExclusion Criteria:\n\n* Clinician's assessment of visual, cognitive, or motor impairment that would preclude participation.\n* A clinical relapse within the last 30 days.\n* Steroid treatment for clinical relapse within the last 30 days.",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "maximumAge": "71 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "Riley Bove, MD",
            "affiliation": "University of California, San Francisco",
            "role": "PRINCIPAL_INVESTIGATOR"
          }
        ],
        "locations": [
          {
            "facility": "University of California San Francisco",
            "city": "San Francisco",
            "state": "California",
            "zip": "94158",
            "country": "United States",
            "geoPoint": { "lat": 37.77493, "lon": -122.41942 }
          }
        ]
      },
      "referencesModule": {
        "references": [
          {
            "pmid": "32584155",
            "type": "RESULT",
            "citation": "Bove R, Rowles W, Zhao C, Anderson A, Friedman S, Langdon D, Alexander A, Sacco S, Henry R, Gazzaley A, Feinstein A, Anguera JA. A novel in-home digital treatment to improve processing speed in people with multiple sclerosis: A pilot study. Mult Scler. 2021 Apr;27(5):778-789. doi: 10.1177/1352458520930371. Epub 2020 Jun 25."
          },
          {
            "pmid": "34967751",
            "type": "DERIVED",
            "citation": "Hsu WY, Rowles W, Anguera JA, Anderson A, Younger JW, Friedman S, Gazzaley A, Bove R. Assessing Cognitive Function in Multiple Sclerosis With Digital Tools: Observational Study. J Med Internet Res. 2021 Dec 30;23(12):e25748. doi: 10.2196/25748."
          },
          {
            "pmid": "33470940",
            "type": "DERIVED",
            "citation": "Hsu WY, Rowles W, Anguera JA, Zhao C, Anderson A, Alexander A, Sacco S, Henry R, Gazzaley A, Bove R. Application of an Adaptive, Digital, Game-Based Approach for Cognitive Assessment in Multiple Sclerosis: Observational Study. J Med Internet Res. 2021 Jan 20;23(1):e24356. doi: 10.2196/24356. Erratum In: J Med Internet Res. 2021 Jan 27;23(1):e27440. doi: 10.2196/27440."
          }
        ]
      },
      "ipdSharingStatementModule": { "ipdSharing": "NO" }
    },
    "resultsSection": {
      "participantFlowModule": {
        "groups": [
          {
            "id": "FG000",
            "title": "AKL-T03",
            "description": "Tablet-based game aimed at improving processing speed and attention."
          },
          {
            "id": "FG001",
            "title": "AKL-T09",
            "description": "Control, tablet-based word-finding game"
          }
        ],
        "periods": [
          {
            "title": "Overall Study",
            "milestones": [
              {
                "type": "STARTED",
                "achievements": [
                  { "groupId": "FG000", "numSubjects": "23" },
                  { "groupId": "FG001", "numSubjects": "21" }
                ]
              },
              {
                "type": "COMPLETED",
                "achievements": [
                  { "groupId": "FG000", "numSubjects": "20" },
                  { "groupId": "FG001", "numSubjects": "20" }
                ]
              },
              {
                "type": "NOT COMPLETED",
                "achievements": [
                  { "groupId": "FG000", "numSubjects": "3" },
                  { "groupId": "FG001", "numSubjects": "1" }
                ]
              }
            ]
          }
        ]
      },
      "baselineCharacteristicsModule": {
        "groups": [
          {
            "id": "BG000",
            "title": "AKL-T03",
            "description": "Tablet-based game aimed at improving processing speed and attention."
          },
          {
            "id": "BG001",
            "title": "AKL-T09",
            "description": "Control, tablet-based word finding game"
          },
          {
            "id": "BG002",
            "title": "Total",
            "description": "Total of all reporting groups"
          }
        ],
        "denoms": [
          {
            "units": "Participants",
            "counts": [
              { "groupId": "BG000", "value": "23" },
              { "groupId": "BG001", "value": "21" },
              { "groupId": "BG002", "value": "44" }
            ]
          }
        ],
        "measures": [
          {
            "title": "Age, Categorical",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "<=18 years",
                    "measurements": [
                      { "groupId": "BG000", "value": "0" },
                      { "groupId": "BG001", "value": "0" },
                      { "groupId": "BG002", "value": "0" }
                    ]
                  },
                  {
                    "title": "Between 18 and 65 years",
                    "measurements": [
                      { "groupId": "BG000", "value": "18" },
                      { "groupId": "BG001", "value": "19" },
                      { "groupId": "BG002", "value": "37" }
                    ]
                  },
                  {
                    "title": ">=65 years",
                    "measurements": [
                      { "groupId": "BG000", "value": "5" },
                      { "groupId": "BG001", "value": "2" },
                      { "groupId": "BG002", "value": "7" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Age, Continuous",
            "paramType": "MEAN",
            "dispersionType": "STANDARD_DEVIATION",
            "unitOfMeasure": "years",
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "BG000", "value": "52.9", "spread": "14.0" },
                      { "groupId": "BG001", "value": "49.2", "spread": "10.9" },
                      { "groupId": "BG002", "value": "51.1", "spread": "12.6" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Sex: Female, Male",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "Female",
                    "measurements": [
                      { "groupId": "BG000", "value": "17" },
                      { "groupId": "BG001", "value": "18" },
                      { "groupId": "BG002", "value": "35" }
                    ]
                  },
                  {
                    "title": "Male",
                    "measurements": [
                      { "groupId": "BG000", "value": "6" },
                      { "groupId": "BG001", "value": "3" },
                      { "groupId": "BG002", "value": "9" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Race (NIH/OMB)",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "American Indian or Alaska Native",
                    "measurements": [
                      { "groupId": "BG000", "value": "1" },
                      { "groupId": "BG001", "value": "0" },
                      { "groupId": "BG002", "value": "1" }
                    ]
                  },
                  {
                    "title": "Asian",
                    "measurements": [
                      { "groupId": "BG000", "value": "1" },
                      { "groupId": "BG001", "value": "1" },
                      { "groupId": "BG002", "value": "2" }
                    ]
                  },
                  {
                    "title": "Native Hawaiian or Other Pacific Islander",
                    "measurements": [
                      { "groupId": "BG000", "value": "0" },
                      { "groupId": "BG001", "value": "0" },
                      { "groupId": "BG002", "value": "0" }
                    ]
                  },
                  {
                    "title": "Black or African American",
                    "measurements": [
                      { "groupId": "BG000", "value": "0" },
                      { "groupId": "BG001", "value": "2" },
                      { "groupId": "BG002", "value": "2" }
                    ]
                  },
                  {
                    "title": "White",
                    "measurements": [
                      { "groupId": "BG000", "value": "17" },
                      { "groupId": "BG001", "value": "18" },
                      { "groupId": "BG002", "value": "35" }
                    ]
                  },
                  {
                    "title": "More than one race",
                    "measurements": [
                      { "groupId": "BG000", "value": "1" },
                      { "groupId": "BG001", "value": "0" },
                      { "groupId": "BG002", "value": "1" }
                    ]
                  },
                  {
                    "title": "Unknown or Not Reported",
                    "measurements": [
                      { "groupId": "BG000", "value": "3" },
                      { "groupId": "BG001", "value": "0" },
                      { "groupId": "BG002", "value": "3" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Region of Enrollment",
            "paramType": "NUMBER",
            "unitOfMeasure": "participants",
            "classes": [
              {
                "title": "United States",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "BG000", "value": "23" },
                      { "groupId": "BG001", "value": "21" },
                      { "groupId": "BG002", "value": "44" }
                    ]
                  }
                ]
              }
            ]
          }
        ]
      },
      "outcomeMeasuresModule": {
        "outcomeMeasures": [
          {
            "type": "PRIMARY",
            "title": "Change in Processing Speed After 6 Weeks of Treatment With a Digital Therapeutic 'Game 1', vs. 'Game 2'.",
            "description": "Processing speed is being measured by the Symbol Digit Modalities Test (SDMT) score. SDMT measures the time to pair abstract symbols with specific numbers. The test requires visuoperceptual processing, working memory, and psychomotor speed. The score is the number of correctly coded items in 90 seconds. (max=110, min=0). Higher scores indicate improvement. Lower scores indicate worsening.",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "Baseline and 6 weeks",
            "groups": [
              {
                "id": "OG000",
                "title": "AKL-T03",
                "description": "Tablet-based game aimed at improving processing speed and attention."
              },
              {
                "id": "OG001",
                "title": "AKL-T09",
                "description": "Control, tablet-based word-finding game"
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "20" },
                  { "groupId": "OG001", "value": "20" }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "6.10", "spread": "4.62" },
                      { "groupId": "OG001", "value": "3.55", "spread": "7.51" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Number of Participants With at Least 4-point Increase in SDMT Above Their Baseline Value 8 Weeks After Treatment",
            "description": "Number of participants showing a clinically meaningful 4+ point increase in SDMT (symbol digit modalities test) relative to baseline SDMT score. Comparison of SDMT changes 8 weeks after end of treatment with Tool 1 vs. Tool 2.",
            "populationDescription": "39 participants (97.5%) returned for Visit 3",
            "reportingStatus": "POSTED",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "timeFrame": "14 weeks",
            "groups": [
              {
                "id": "OG000",
                "title": "AKL-T03",
                "description": "Tablet-based game aimed at improving processing speed and attention."
              },
              {
                "id": "OG001",
                "title": "AKL-T09",
                "description": "Control, tablet-based word-finding game"
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "20" },
                  { "groupId": "OG001", "value": "19" }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "14" },
                      { "groupId": "OG001", "value": "7" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "OTHER_PRE_SPECIFIED",
            "title": "Change in Mood After 6 Weeks Treatment With Game 1 vs. Game 2",
            "description": "Comparison of changes in mood (depression, anxiety). Depression measured using the Center for Epidemiologic Studies Depression Scale (CES-D). Possible range of scores is zero to 60, with the higher scores indicating the presence of more symptomatology. Anxiety measured using the State-Trait Anxiety Inventory - State subtest (STAI-S) and the State-Trait Anxiety Inventory - Trait subtest (STAI-T). Both have 20 questions and a score range 20-80, with higher scores indicating greater anxiety.",
            "populationDescription": "Missing data for 6 participants on trait anxiety (STAI-T), 3 per study group; as well as for 2 participants on depression (CES-D) and state anxiety (STAI-S) measures, 1 per study group.",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "Baseline and 6 weeks",
            "groups": [
              {
                "id": "OG000",
                "title": "AKL-T03",
                "description": "Tablet-based game aimed at improving processing speed and attention."
              },
              {
                "id": "OG001",
                "title": "AKL-T09",
                "description": "Control, tablet-based word-finding game"
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "19" },
                  { "groupId": "OG001", "value": "19" }
                ]
              }
            ],
            "classes": [
              {
                "title": "Depression (CES-D)",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "19" },
                      { "groupId": "OG001", "value": "19" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "1.11", "spread": "6.14" },
                      { "groupId": "OG001", "value": "-.90", "spread": "5.57" }
                    ]
                  }
                ]
              },
              {
                "title": "Anxiety - State (STAI-S)",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "19" },
                      { "groupId": "OG001", "value": "19" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": ".05", "spread": "4.64" },
                      { "groupId": "OG001", "value": ".21", "spread": "8.93" }
                    ]
                  }
                ]
              },
              {
                "title": "Anxiety - Trait (STAI-T)",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "17" },
                      { "groupId": "OG001", "value": "17" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": ".77", "spread": "4.10" },
                      { "groupId": "OG001", "value": ".35", "spread": "3.35" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "OTHER_PRE_SPECIFIED",
            "title": "Change in Fatigue After 6 Weeks Treatment With Game 1 vs. Game 2.",
            "description": "Fatigue is being measured by the Modified Fatigue Impact Scale (MFIS) which has participants rank 21 items on 1 to 4 (never to always) scale. The score is the sum of these subscales. (max=84, min=0) Lower scores indicate improvement. Higher scores indicate worsening.",
            "populationDescription": "Missing fatigue survey data (MFIS) for 2 participants, 1 per study group.",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "Baseline and 6 weeks",
            "groups": [
              {
                "id": "OG000",
                "title": "AKL-T03",
                "description": "Tablet-based game aimed at improving processing speed and attention."
              },
              {
                "id": "OG001",
                "title": "AKL-T09",
                "description": "Control, tablet-based word-finding game"
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "19" },
                  { "groupId": "OG001", "value": "19" }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-4.79",
                        "spread": "6.27"
                      },
                      { "groupId": "OG001", "value": "-2.95", "spread": "9.55" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "OTHER_PRE_SPECIFIED",
            "title": "Change in a Digital Cognitive Battery After 6 Weeks Treatment With Game 1 vs. Game 2.",
            "description": "Comparison of changes in scores on Match, a tablet-based assessment of processing speed and executive function. Performance is gauged on a continuous scale using the total number of correct responses given in 2-minutes. The minimum possible score is 0 (no correct responses) with higher scores indicating better performance (no maximum possible score).",
            "populationDescription": "Match data was unavailable for some participants (n = 6, 3 per group)",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "number of correct responses",
            "timeFrame": "Baseline and 6 weeks",
            "groups": [
              {
                "id": "OG000",
                "title": "AKL-T03",
                "description": "Tablet-based game aimed at improving processing speed and attention."
              },
              {
                "id": "OG001",
                "title": "AKL-T09",
                "description": "Control, tablet-based word finding game"
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "17" },
                  { "groupId": "OG001", "value": "17" }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "0.94", "spread": "3.54" },
                      { "groupId": "OG001", "value": "0.35", "spread": "4.66" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "OTHER_PRE_SPECIFIED",
            "title": "Change in Paper and Pencil Cognitive Testing After 6 Weeks Treatment With Game 1 vs. Game 2.",
            "description": "Comparison of changes in cognition, as assessed using the BICAMS battery (Brief International Cognitive Assessment for Multiple Sclerosis) and PASAT (Paced Auditory Serial Addition Test). The BICAMS battery is composed of 3 tests (for all, higher scores indicate better performance): (1) The Symbol Digit Modalities Test (SDMT), a measure of information processing speed where performance is gauged by the number of correct responses given in 90-seconds, with a minimum possible score of 0 and maximum of 110. (2) The California Verbal Learning Test-II (CVLT-II) is a 5-trial auditory/verbal learning test with a total min. score of 0 and max of 80. (3) The Brief Visuospatial Memory Test -- Revised (BVMT-R) is a visual and spatial memory test given in 3 trials with a total min score of 0 and max of 36.\n\nThe PASAT is a test of information processing and attention with a minimum score of 0 and maximum of 60. Higher scores indicate better performance.",
            "populationDescription": "Missing PASAT data for 3 participants, 2 in AKL-T03 and 1 in AKL-T09. Data for other measures (SDMT, BVMT-R and CVLT-II) were collected from all participants.",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "Baseline and 6 weeks",
            "groups": [
              {
                "id": "OG000",
                "title": "AKL-T03",
                "description": "Tablet-based game aimed at improving processing speed and attention."
              },
              {
                "id": "OG001",
                "title": "AKL-T09",
                "description": "Control, tablet-based word finding game"
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "20" },
                  { "groupId": "OG001", "value": "20" }
                ]
              }
            ],
            "classes": [
              {
                "title": "SDMT",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "20" },
                      { "groupId": "OG001", "value": "20" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "6.10", "spread": "4.62" },
                      { "groupId": "OG001", "value": "3.55", "spread": "7.51" }
                    ]
                  }
                ]
              },
              {
                "title": "CVLT-II",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "20" },
                      { "groupId": "OG001", "value": "20" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "2.05", "spread": "9.14" },
                      { "groupId": "OG001", "value": "5.20", "spread": "8.60" }
                    ]
                  }
                ]
              },
              {
                "title": "BVMT-R",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "20" },
                      { "groupId": "OG001", "value": "20" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "0.70", "spread": "4.47" },
                      { "groupId": "OG001", "value": "3.25", "spread": "5.23" }
                    ]
                  }
                ]
              },
              {
                "title": "PASAT",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "18" },
                      { "groupId": "OG001", "value": "19" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "2.72", "spread": "5.41" },
                      { "groupId": "OG001", "value": "2.53", "spread": "7.19" }
                    ]
                  }
                ]
              }
            ]
          }
        ]
      },
      "adverseEventsModule": {
        "frequencyThreshold": "0",
        "timeFrame": "Duration of the 6-week intervention period between Visits 1 and 2",
        "eventGroups": [
          {
            "id": "EG000",
            "title": "AKL-T03",
            "description": "Tablet-based game aimed at improving processing speed and attention.",
            "deathsNumAffected": 0,
            "deathsNumAtRisk": 20,
            "seriousNumAffected": 0,
            "seriousNumAtRisk": 20,
            "otherNumAffected": 0,
            "otherNumAtRisk": 20
          },
          {
            "id": "EG001",
            "title": "AKL-T09",
            "description": "Control, tablet-based word-finding game",
            "deathsNumAffected": 0,
            "deathsNumAtRisk": 20,
            "seriousNumAffected": 0,
            "seriousNumAtRisk": 20,
            "otherNumAffected": 0,
            "otherNumAtRisk": 20
          }
        ]
      },
      "moreInfoModule": {
        "certainAgreement": {
          "piSponsorEmployee": true,
          "restrictiveAgreement": false
        },
        "pointOfContact": {
          "title": "Riley Bove, MD MSc",
          "organization": "University of California, San Francisco",
          "email": "riley.bove@ucsf.edu",
          "phone": "415.502.7209"
        }
      }
    },
    "documentSection": {
      "largeDocumentModule": {
        "largeDocs": [
          {
            "typeAbbrev": "Prot",
            "hasProtocol": true,
            "hasSap": false,
            "hasIcf": false,
            "label": "Study Protocol",
            "date": "2018-08-01",
            "uploadDate": "2019-12-11T16:45",
            "filename": "Prot_000.pdf",
            "size": 490086
          },
          {
            "typeAbbrev": "SAP",
            "hasProtocol": false,
            "hasSap": true,
            "hasIcf": false,
            "label": "Statistical Analysis Plan",
            "date": "2018-08-01",
            "uploadDate": "2019-12-11T16:45",
            "filename": "SAP_001.pdf",
            "size": 218097
          }
        ]
      }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [
          { "id": "D009103", "term": "Multiple Sclerosis" },
          { "id": "D012598", "term": "Sclerosis" },
          { "id": "D060825", "term": "Cognitive Dysfunction" }
        ],
        "ancestors": [
          { "id": "D010335", "term": "Pathologic Processes" },
          { "id": "D020278", "term": "Demyelinating Autoimmune Diseases, CNS" },
          {
            "id": "D020274",
            "term": "Autoimmune Diseases of the Nervous System"
          },
          { "id": "D009422", "term": "Nervous System Diseases" },
          { "id": "D003711", "term": "Demyelinating Diseases" },
          { "id": "D001327", "term": "Autoimmune Diseases" },
          { "id": "D007154", "term": "Immune System Diseases" },
          { "id": "D003072", "term": "Cognition Disorders" },
          { "id": "D019965", "term": "Neurocognitive Disorders" },
          { "id": "D001523", "term": "Mental Disorders" }
        ],
        "browseLeaves": [
          {
            "id": "M12060",
            "name": "Multiple Sclerosis",
            "asFound": "Multiple Sclerosis",
            "relevance": "HIGH"
          },
          {
            "id": "M15415",
            "name": "Sclerosis",
            "asFound": "Sclerosis",
            "relevance": "HIGH"
          },
          {
            "id": "M29705",
            "name": "Cognitive Dysfunction",
            "asFound": "Cognitive Decline",
            "relevance": "HIGH"
          },
          { "id": "M4629", "name": "Autoimmune Diseases", "relevance": "LOW" },
          {
            "id": "M22098",
            "name": "Demyelinating Autoimmune Diseases, CNS",
            "relevance": "LOW"
          },
          {
            "id": "M22094",
            "name": "Autoimmune Diseases of the Nervous System",
            "relevance": "LOW"
          },
          {
            "id": "M6909",
            "name": "Demyelinating Diseases",
            "relevance": "LOW"
          },
          {
            "id": "M10200",
            "name": "Immune System Diseases",
            "relevance": "LOW"
          },
          { "id": "M6301", "name": "Cognition Disorders", "relevance": "LOW" },
          {
            "id": "M21836",
            "name": "Neurocognitive Disorders",
            "relevance": "LOW"
          },
          { "id": "M14473", "name": "Psychotic Disorders", "relevance": "LOW" },
          { "id": "M4815", "name": "Mental Disorders", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "BC10", "name": "Nervous System Diseases" },
          { "abbrev": "BC20", "name": "Immune System Diseases" },
          { "abbrev": "All", "name": "All Conditions" },
          { "abbrev": "BC23", "name": "Symptoms and General Pathology" },
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" }
        ]
      }
    },
    "hasResults": true
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT06883097",
        "orgStudyIdInfo": { "id": "IRB00112958" },
        "secondaryIdInfos": [
          {
            "id": "7R01CA285331-02",
            "type": "NIH",
            "link": "https://reporter.nih.gov/quickSearch/7R01CA285331-02"
          }
        ],
        "organization": {
          "fullName": "Wake Forest University Health Sciences",
          "class": "OTHER"
        },
        "briefTitle": "Quitting Matters Human Immunodeficiency Virus Hybrid Trial",
        "officialTitle": "Hybrid Trial of a Digital Therapeutic for Smoking Cessation Among Persons Living With HIV",
        "acronym": "QMH"
      },
      "statusModule": {
        "statusVerifiedDate": "2025-01",
        "overallStatus": "NOT_YET_RECRUITING",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2025-05", "type": "ESTIMATED" },
        "primaryCompletionDateStruct": {
          "date": "2028-12",
          "type": "ESTIMATED"
        },
        "completionDateStruct": { "date": "2028-12", "type": "ESTIMATED" },
        "studyFirstSubmitDate": "2025-03-12",
        "studyFirstSubmitQcDate": "2025-03-12",
        "studyFirstPostDateStruct": { "date": "2025-03-19", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2025-03-12",
        "lastUpdatePostDateStruct": { "date": "2025-03-19", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": {
          "name": "Wake Forest University Health Sciences",
          "class": "OTHER"
        },
        "collaborators": [
          { "name": "University at Buffalo", "class": "OTHER" },
          { "name": "National Institutes of Health (NIH)", "class": "NIH" },
          { "name": "National Cancer Institute (NCI)", "class": "NIH" }
        ]
      },
      "oversightModule": {
        "oversightHasDmc": true,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": false,
        "isUsExport": false
      },
      "descriptionModule": {
        "briefSummary": "The purpose of this study is to compare the advantages and disadvantages of two approaches for quitting smoking among people living with HIV (PWH). Participants will complete a 24- week (\\~6-month) study where the Participants will be assigned to one of two smartphone apps to help with quitting smoking. Regardless of the group participants are assigned to, they will also receive a combination of nicotine replacement therapy (patches and gums) that have been shown to help people quit smoking. The main questions this study aims to answer are:\n\nParticipants will complete 5 video call visits over about 6 months. Participants will install their assigned smoking cessation app onto their phone and will be asked to use the app for the duration of the study along with their provided Nicotine Replacement Therapy (NRT) products. During the study visits, participants will meet with study staff to complete questionnaires and interviews. Participants may be asked to provide breath and saliva samples to measure the level of carbon monoxide and nicotine.",
        "detailedDescription": "Tobacco use has alarmingly high rates among people with Human Immunodeficiency Virus (HIV) (PWH), 43% compared with 15% in the general population. Due to the development of highly effective treatments for HIV and the resulting increased longevity among PWH, this population now loses more life years to smoking than to HIV infection itself. Novel and effective models to deliver wider reaching smoking cessation interventions for PWH are highly needed and indicated as a priority for National Institute of Health. Digital therapeutics (DTx) may be a novel, scalable, and highly available approach for engaging and treating smoking in this population. However, although DTx for smoking cessation have been shown effective in the general population, no large trial to date has examined the effectiveness of a tailored DTx for smoking cessation in PWH, and no implementation science work has examined barriers and facilitators of implementation of DTx for smoking cessation in this population."
      },
      "conditionsModule": {
        "conditions": [
          "Tobacco",
          "Tobacco Abstinence",
          "Smoking Cessation",
          "Smoking Cessation; Tobacco Dependence",
          "Human Immunodeficiency Virus (HIV)",
          "Tobacco Dependence Caused by Cigarettes",
          "Cancer Prevention"
        ],
        "keywords": [
          "Tobacco",
          "Smoking Cessation",
          "Human immunodeficiency virus (HIV)",
          "Tobacco Abstinence",
          "Quit Smoking"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": { "masking": "NONE" }
        },
        "enrollmentInfo": { "count": 474, "type": "ESTIMATED" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "Learn to Quit - HIV (LTQ-H) App",
            "type": "EXPERIMENTAL",
            "description": "a smoking cessation Digital Therapeutic (DTx) for people with HIV (PWH)",
            "interventionNames": ["Behavioral: Learn to Quit-HIV (LTQ-H) App"]
          },
          {
            "label": "QuitGuide App",
            "type": "ACTIVE_COMPARATOR",
            "description": "an evidence-based DTx designed for the general population",
            "interventionNames": ["Behavioral: QuitGuide"]
          }
        ],
        "interventions": [
          {
            "type": "BEHAVIORAL",
            "name": "Learn to Quit-HIV (LTQ-H) App",
            "description": "LTQ-H consists of 319 screens divided into: (a) HIV-tailored smoking cessation ACT skills, (b) education about tobacco dependence and treatment (USCPG), and (c) NRT psychoeducation and adherence. Content is gradually presented across 28 modules (14 education and 14 skills) that can be completed in 14 days.",
            "armGroupLabels": ["Learn to Quit - HIV (LTQ-H) App"],
            "otherNames": ["a smoking cessation Digital Therapeutic (DTx)"]
          },
          {
            "type": "BEHAVIORAL",
            "name": "QuitGuide",
            "description": "This DTx, QuitGuide was adapted from the National Cancer Institute Smokefree.gov Initiative's QuitGuide's 5 modules have the following intervention components: (a) psychoeducation about the impact of smoking on health, (b) setting up a quit date and a quit plan, (c) selecting reasons for quitting, (d) tracking triggers and smoking habits, and (e) tips for quitting.",
            "armGroupLabels": ["QuitGuide App"],
            "otherNames": [
              "an evidence-based DTx designed for the general population"
            ]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Biochemically verified 7-day point prevalence abstinence at 24-weeks",
            "description": "Abstinence is determined by a self-report of not smoking any tobacco product for greater than or equal to 7 days prior to Week 24 and biochemically verified by an expired carbon monoxide breath test reading of \\< 5 ppm at Week 24. If the participant does not meet both criteria, they are not considered abstinent. As per convention, participants are assumed to be smoking if they report smoking at the time-point, cannot be reached to provide data at the time-point, fail to provide a breath sample at the time-point, or provide a breath sample at the time-point that is greater than or equal to 5 ppm.",
            "timeFrame": "24 weeks"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Self-reported 7-day point prevalence abstinence at 4 weeks - the percentage of participants who are abstinent (not using the substance) at a given point in time",
            "description": "Percent of subjects in each group self-reporting no smoking at all for greater or equal to 7 days prior to the timepoint.",
            "timeFrame": "Four weeks"
          },
          {
            "measure": "Self-reported 7-day point prevalence abstinence at 12 weeks - the percentage of participants who are abstinent (not using the substance) at a given point in time",
            "description": "Percent of subjects in each group self-reporting no smoking at all for greater or equal to 7 days prior to the timepoint.",
            "timeFrame": "12 weeks"
          },
          {
            "measure": "Self-reported 7-day point prevalence abstinence at 24 weeks - the percentage of participants who are abstinent (not using the substance) at a given point in time",
            "description": "Percent of subjects in each group self-reporting no smoking at all for greater or equal to 7 days prior to the timepoint.",
            "timeFrame": "24 weeks"
          },
          {
            "measure": "Self-reported 30-day point prevalence abstinence at 4 weeks - the percentage of participants who are abstinent (not using the substance) at a given point in time",
            "description": "Percent of subjects in each group self-reporting no smoking at all for greater or equal to 30 days but \\< 30 days prior to the timepoint.",
            "timeFrame": "4 weeks"
          },
          {
            "measure": "Self-reported 30-day point prevalence abstinence at 12 weeks - the percentage of participants who are abstinent (not using the substance) at a given point in time",
            "description": "Percent of subjects in each group self-reporting no smoking at all for greater or equal to 30 days prior to the timepoint.",
            "timeFrame": "12 weeks"
          },
          {
            "measure": "Self-reported 30-day point prevalence abstinence at 28 weeks - the percentage of participants who are abstinent (not using the substance) at a given point in time",
            "description": "Percent of subjects in each group self-reporting no smoking at all for greater or equal to 30 days prior to the timepoint.",
            "timeFrame": "28 weeks"
          },
          {
            "measure": "Change in average number of cigarettes smoked per day",
            "description": "Change in self-reported number of cigarettes smoked per day, averaged within groups.",
            "timeFrame": "4 weeks"
          },
          {
            "measure": "Change in average number of cigarettes smoked per day",
            "description": "Change in self-reported number of cigarettes smoked per day, averaged within groups.",
            "timeFrame": "12 weeks"
          },
          {
            "measure": "Change in average number of cigarettes smoked per day",
            "description": "Change in self-reported number of cigarettes smoked per day, averaged within groups.",
            "timeFrame": "24 weeks"
          },
          {
            "measure": "Average number of quit attempts",
            "description": "Average number of quit attempts self-reported per group at the specified time point. Quit attempts are defined by no smoking at all for 24 hours or more.",
            "timeFrame": "4 weeks"
          },
          {
            "measure": "Average number of quit attempts",
            "description": "Average number of quit attempts self-reported per group at the specified time point. Quit attempts are defined by no smoking at all for 24 hours or more.",
            "timeFrame": "12 weeks"
          },
          {
            "measure": "Average number of quit attempts",
            "description": "Average number of quit attempts self-reported per group at the specified time point. Quit attempts are defined by no smoking at all for 24 hours or more.",
            "timeFrame": "24 weeks"
          },
          {
            "measure": "Average acceptance of physical smoking cravings",
            "description": "Average self-reported scores of acceptance of cravings on the physical sensations subscale of the Avoidance and Inflexibility Scale. Scores range from 4-20 with lower scores indicating more acceptance of smoking cravings.",
            "timeFrame": "4 weeks"
          },
          {
            "measure": "Average acceptance of physical smoking cravings",
            "description": "Average self-reported scores of acceptance of cravings on the physical sensations subscale of the Avoidance and Inflexibility Scale. Scores range from 4-20 with lower scores indicating more acceptance of smoking cravings.",
            "timeFrame": "12 weeks"
          },
          {
            "measure": "Average acceptance of physical smoking cravings",
            "description": "Average self-reported scores of acceptance of cravings on the physical sensations subscale of the Avoidance and Inflexibility Scale. Scores range from 4-20 with lower scores indicating more acceptance of smoking cravings.",
            "timeFrame": "24 weeks"
          },
          {
            "measure": "Average frequency of app use",
            "description": "Average frequency of app use over the 24-week study period. Measured by average number of app openings.",
            "timeFrame": "Weeks 0-24"
          },
          {
            "measure": "Average duration of app use",
            "description": "Average duration of app use over the 24-week study period.",
            "timeFrame": "Weeks 0-24"
          },
          {
            "measure": "Average number of app modules completed",
            "description": "Average number of app modules completed over the 24-week study period.",
            "timeFrame": "Weeks 0-24"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n1. Self-reported daily cigarette smoking over the past 30 days\n2. Self-reported HIV status\n3. Age 18 or older\n4. Desire to quit smoking\n5. Willing and medically eligible to use NRT\n6. Currently receiving HIV care\n7. Currently owning an Android or iOS smartphone\n\nExclusion Criteria:\n\n1. Current acute psychotic episode or unsafe to participate in the study\n2. Pregnant or intending to become pregnant in the next 6 months\n3. Currently receiving any pharmacological and/or behavioral intervention or counseling for smoking cessation\n4. Any medical condition or medication that could compromise subject safety, as determined by the PIs and/or study physician\n5. Not able to fluently speak and write in English\n6. Hearing, comprehension, visual, speech, or motor limitations that preclude study participation",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "centralContacts": [
          {
            "name": "Roger Vilardaga Vierra, Ph.D.",
            "role": "CONTACT",
            "phone": "336-716-1495",
            "email": "rvilarda@wakehealth.edu"
          },
          {
            "name": "Clinical Studies Coordinator",
            "role": "CONTACT",
            "phone": "(984) 377-4306",
            "email": "cdarnold@wakehealth.edu"
          }
        ],
        "overallOfficials": [
          {
            "name": "Roger Vilardaga Viera, Ph.D.",
            "affiliation": "Wake Forest University Health Sciences",
            "role": "PRINCIPAL_INVESTIGATOR"
          }
        ]
      },
      "ipdSharingStatementModule": { "ipdSharing": "NO" }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [
          { "id": "D000163", "term": "Acquired Immunodeficiency Syndrome" },
          { "id": "D015658", "term": "HIV Infections" },
          { "id": "D007153", "term": "Immunologic Deficiency Syndromes" },
          { "id": "D014029", "term": "Tobacco Use Disorder" }
        ],
        "ancestors": [
          { "id": "D007154", "term": "Immune System Diseases" },
          { "id": "D000086982", "term": "Blood-Borne Infections" },
          { "id": "D003141", "term": "Communicable Diseases" },
          { "id": "D007239", "term": "Infections" },
          { "id": "D015229", "term": "Sexually Transmitted Diseases, Viral" },
          { "id": "D012749", "term": "Sexually Transmitted Diseases" },
          { "id": "D016180", "term": "Lentivirus Infections" },
          { "id": "D012192", "term": "Retroviridae Infections" },
          { "id": "D012327", "term": "RNA Virus Infections" },
          { "id": "D014777", "term": "Virus Diseases" },
          { "id": "D012897", "term": "Slow Virus Diseases" },
          { "id": "D000091662", "term": "Genital Diseases" },
          { "id": "D000091642", "term": "Urogenital Diseases" },
          { "id": "D019966", "term": "Substance-Related Disorders" },
          { "id": "D064419", "term": "Chemically-Induced Disorders" },
          { "id": "D001523", "term": "Mental Disorders" }
        ],
        "browseLeaves": [
          {
            "id": "M10199",
            "name": "Immunologic Deficiency Syndromes",
            "asFound": "Immunodeficiency",
            "relevance": "HIGH"
          },
          { "id": "M17522", "name": "Virus Diseases", "relevance": "LOW" },
          {
            "id": "M3522",
            "name": "Acquired Immunodeficiency Syndrome",
            "asFound": "Human Immunodeficiency Virus",
            "relevance": "HIGH"
          },
          {
            "id": "M18250",
            "name": "HIV Infections",
            "asFound": "Human Immunodeficiency Virus",
            "relevance": "HIGH"
          },
          { "id": "M16355", "name": "Syndrome", "relevance": "LOW" },
          { "id": "M10283", "name": "Infections", "relevance": "LOW" },
          {
            "id": "M6368",
            "name": "Communicable Diseases",
            "relevance": "LOW"
          },
          {
            "id": "M16785",
            "name": "Tobacco Use Disorder",
            "asFound": "Tobacco Dependence",
            "relevance": "HIGH"
          },
          {
            "id": "M10200",
            "name": "Immune System Diseases",
            "relevance": "LOW"
          },
          {
            "id": "M2593",
            "name": "Blood-Borne Infections",
            "relevance": "LOW"
          },
          {
            "id": "M15558",
            "name": "Sexually Transmitted Diseases",
            "relevance": "LOW"
          },
          {
            "id": "M17933",
            "name": "Sexually Transmitted Diseases, Viral",
            "relevance": "LOW"
          },
          {
            "id": "M18640",
            "name": "Lentivirus Infections",
            "relevance": "LOW"
          },
          {
            "id": "M15026",
            "name": "Retroviridae Infections",
            "relevance": "LOW"
          },
          {
            "id": "M15149",
            "name": "RNA Virus Infections",
            "relevance": "LOW"
          },
          { "id": "M15700", "name": "Slow Virus Diseases", "relevance": "LOW" },
          { "id": "M2876", "name": "Genital Diseases", "relevance": "LOW" },
          { "id": "M2875", "name": "Urogenital Diseases", "relevance": "LOW" },
          {
            "id": "M21837",
            "name": "Substance-Related Disorders",
            "relevance": "LOW"
          },
          {
            "id": "M30302",
            "name": "Chemically-Induced Disorders",
            "relevance": "LOW"
          },
          { "id": "M14473", "name": "Psychotic Disorders", "relevance": "LOW" },
          { "id": "M4815", "name": "Mental Disorders", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "BC20", "name": "Immune System Diseases" },
          { "abbrev": "All", "name": "All Conditions" },
          { "abbrev": "BC01", "name": "Infections" },
          {
            "abbrev": "BXS",
            "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
          },
          { "abbrev": "BC23", "name": "Symptoms and General Pathology" },
          { "abbrev": "BC25", "name": "Substance Related Disorders" },
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT06454123",
        "orgStudyIdInfo": { "id": "2023-Oui-001" },
        "secondaryIdInfos": [
          {
            "id": "1R41MH134704-01",
            "type": "NIH",
            "link": "https://reporter.nih.gov/quickSearch/1R41MH134704-01"
          }
        ],
        "organization": {
          "fullName": "Oui Therapeutics, Inc.",
          "class": "INDUSTRY"
        },
        "briefTitle": "Feasibility of a Digital Therapeutic for Adults With Binge Eating and Obesity",
        "officialTitle": "A Feasibility Study of a Digital Therapeutic for Adults With Recurrent Binge Eating and Obesity"
      },
      "statusModule": {
        "statusVerifiedDate": "2024-06",
        "overallStatus": "NOT_YET_RECRUITING",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2024-09", "type": "ESTIMATED" },
        "primaryCompletionDateStruct": {
          "date": "2025-03",
          "type": "ESTIMATED"
        },
        "completionDateStruct": { "date": "2025-06", "type": "ESTIMATED" },
        "studyFirstSubmitDate": "2024-06-06",
        "studyFirstSubmitQcDate": "2024-06-06",
        "studyFirstPostDateStruct": { "date": "2024-06-12", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2024-06-06",
        "lastUpdatePostDateStruct": { "date": "2024-06-12", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": {
          "name": "Oui Therapeutics, Inc.",
          "class": "INDUSTRY"
        },
        "collaborators": [
          {
            "name": "National Institute of Mental Health (NIMH)",
            "class": "NIH"
          }
        ]
      },
      "oversightModule": {
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": false
      },
      "descriptionModule": {
        "briefSummary": "The primary objective of this study is to test the feasibility of a digital therapeutic to address comorbid binge eating and obesity in adults.",
        "detailedDescription": "This single-arm, open-label clinical trial will test the feasibility, usability, acceptability, and preliminary efficacy of a digital therapeutic in reducing binge eating and weight in 30 adults with comorbid recurrent binge eating and obesity."
      },
      "conditionsModule": { "conditions": ["Binge Eating", "Obesity"] },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "NA",
          "interventionModel": "SINGLE_GROUP",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": { "masking": "NONE" }
        },
        "enrollmentInfo": { "count": 30, "type": "ESTIMATED" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "Treatment",
            "type": "EXPERIMENTAL",
            "interventionNames": ["Device: OTX-401"]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "OTX-401",
            "description": "Evidence-based treatments for obesity and binge eating",
            "armGroupLabels": ["Treatment"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "System Usability Sale (SUS)",
            "description": "The SUS and a semi-structured user feedback interview will be utilized to systematically capture usability and acceptability.",
            "timeFrame": "Week 12"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n1. English speaking male or female patients, 18-70 years\n2. Patients with recurrent binge eating (≥12 episodes in 3 months) and obesity (BMI ≥30)\n3. Understand written and spoken English\n4. Own an iPhone with iOS 11 or higher, or Android with OS 8.1 or higher\n5. Willing and able to complete enrollment procedures\n6. Able to understand the nature of the study and provide written informed consent\n\nExclusion Criteria:\n\n1. Patients with active psychosis\n2. Patients who are acutely intoxicated at the time of enrollment\n3. Currently enrolled in other treatment studies for the symptoms and behaviors targeted\n4. Patients who are cognitively impaired\n5. Patients who, in the judgment of the investigator, would have an unfavorable risk/benefit profile with respect to the digital therapeutic",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "maximumAge": "70 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "centralContacts": [
          {
            "name": "Brian Keenaghan",
            "role": "CONTACT",
            "phone": "2037254024",
            "email": "brian@ouitherapeutics.com"
          }
        ]
      }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [
          { "id": "D009765", "term": "Obesity" },
          { "id": "D002032", "term": "Bulimia" },
          { "id": "D056912", "term": "Binge-Eating Disorder" }
        ],
        "ancestors": [
          { "id": "D050177", "term": "Overweight" },
          { "id": "D044343", "term": "Overnutrition" },
          { "id": "D009748", "term": "Nutrition Disorders" },
          { "id": "D001835", "term": "Body Weight" },
          { "id": "D006963", "term": "Hyperphagia" },
          { "id": "D012817", "term": "Signs and Symptoms, Digestive" },
          { "id": "D001068", "term": "Feeding and Eating Disorders" },
          { "id": "D001523", "term": "Mental Disorders" }
        ],
        "browseLeaves": [
          {
            "id": "M12701",
            "name": "Obesity",
            "asFound": "Obesity",
            "relevance": "HIGH"
          },
          { "id": "M14850", "name": "Recurrence", "relevance": "LOW" },
          {
            "id": "M5304",
            "name": "Bulimia",
            "asFound": "Binge Eating",
            "relevance": "HIGH"
          },
          {
            "id": "M28641",
            "name": "Binge-Eating Disorder",
            "asFound": "Binge Eating",
            "relevance": "HIGH"
          },
          { "id": "M26956", "name": "Bulimia Nervosa", "relevance": "LOW" },
          { "id": "M26186", "name": "Overweight", "relevance": "LOW" },
          { "id": "M25307", "name": "Overnutrition", "relevance": "LOW" },
          { "id": "M12684", "name": "Nutrition Disorders", "relevance": "LOW" },
          { "id": "M5114", "name": "Body Weight", "relevance": "LOW" },
          { "id": "M10014", "name": "Hyperphagia", "relevance": "LOW" },
          {
            "id": "M15622",
            "name": "Signs and Symptoms, Digestive",
            "relevance": "LOW"
          },
          {
            "id": "M4380",
            "name": "Feeding and Eating Disorders",
            "relevance": "LOW"
          },
          { "id": "M14473", "name": "Psychotic Disorders", "relevance": "LOW" },
          { "id": "M4815", "name": "Mental Disorders", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "BC18", "name": "Nutritional and Metabolic Diseases" },
          { "abbrev": "BC23", "name": "Symptoms and General Pathology" },
          { "abbrev": "All", "name": "All Conditions" },
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT05302050",
        "orgStudyIdInfo": { "id": "DM2-07-MGB" },
        "organization": {
          "fullName": "Better Therapeutics",
          "class": "INDUSTRY"
        },
        "briefTitle": "A Cognitive Behavioral Digital Therapeutic InterventiON for Glycemic Control in Type 2 Diabetes Mellitus",
        "officialTitle": "A Cognitive Behavioral Digital Therapeutic InterventiON for Glycemic Control in Type 2 Diabetes Mellitus",
        "acronym": "ACTION-DM"
      },
      "statusModule": {
        "statusVerifiedDate": "2023-10",
        "overallStatus": "ACTIVE_NOT_RECRUITING",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2022-03-07", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2025-12-01",
          "type": "ESTIMATED"
        },
        "completionDateStruct": { "date": "2025-12-01", "type": "ESTIMATED" },
        "studyFirstSubmitDate": "2022-03-21",
        "studyFirstSubmitQcDate": "2022-03-21",
        "studyFirstPostDateStruct": { "date": "2022-03-31", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2023-10-27",
        "lastUpdatePostDateStruct": { "date": "2023-10-30", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": { "name": "Better Therapeutics", "class": "INDUSTRY" },
        "collaborators": [
          { "name": "Mass General Brigham", "class": "UNKNOWN" }
        ]
      },
      "oversightModule": {
        "oversightHasDmc": true,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": true,
        "isUnapprovedDevice": true,
        "isUsExport": false
      },
      "descriptionModule": {
        "briefSummary": "Randomized, controlled, pragmatic trial with open-label extension evaluating BT-001, an investigational digital therapeutic intended to help patients with type 2 diabetes improve their glycemic control.",
        "detailedDescription": "The study intervention, BT-001 (the App), will be dispensed at enrollment to the Immediate Intervention App Use arm of the trial. Patients randomized to the Delayed Intervention App Use arm will be provided a \"control App\" with diabetes control, and then the BT-001 App after 180 days. Each participant is assigned to one 90-day treatment cycle of BT-001. Over the 12-month intervention period, study participants will be able to opt into up to 3 additional treatment cycles of BT-001. Study schema is included at the end of this section"
      },
      "conditionsModule": { "conditions": ["Diabetes Type 2"] },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "interventionModelDescription": "The study population consists of approximately 500 total participants, ages 18 - 75 years old, inclusive, who have type 2 diabetes. They will be randomized to the treatment or control group at a 3:1 ratio",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": {
            "masking": "NONE",
            "maskingDescription": "open label"
          }
        },
        "enrollmentInfo": { "count": 500, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "Intervention BT-001 + Standard of Care",
            "type": "ACTIVE_COMPARATOR",
            "description": "Patients in this arm will receive the BT-001 treatment for up to 18 months.",
            "interventionNames": ["Device: BT-001"]
          },
          {
            "label": "Standard of Care",
            "type": "OTHER",
            "description": "Patients will have access to a control mobile application for 6 months and then will have the option to use the treatment for the remainder of the 18 month study",
            "interventionNames": ["Device: Control Mobile Application"]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "BT-001",
            "description": "BT-001is a software application that delivers treatment to participants with type 2 diabetes, using behavioral therapy. BT-001 is accessed via the participants' smartphone.\n\nThe behavioral intervention process involves:\n\nIdentifying maladaptive thoughts based on misinformed core beliefs that lead to disease-promoting behaviors; replacing maladaptive core beliefs with adaptive ways of thinking; and providing collaborative construction of behavioral exercises to test core beliefs.\n\nEach week, BT-001 asks participants to complete a new lesson, along with one skill exercise. The lessons are expected to take between 10-20 minutes to complete. In addition to completing a lesson and skill, participants will be directed to report plant-based meals consumed and minutes of exercise completed and to measure their blood sugar daily.",
            "armGroupLabels": ["Intervention BT-001 + Standard of Care"]
          },
          {
            "type": "DEVICE",
            "name": "Control Mobile Application",
            "description": "The app asks patients brief questions about their health but does not include any behavioral therapy.",
            "armGroupLabels": ["Standard of Care"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Change in HbA1c",
            "description": "Change in HbA1c from baseline (enrollment) to 6 months after enrollment between groups.",
            "timeFrame": "Baseline and Day 180"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Change in HbA1c",
            "description": "Change in HbA1c from baseline (enrollment) and from 6 months, to 12 months after enrollment between groups",
            "timeFrame": "Baseline and day 180, 365"
          },
          {
            "measure": "Significant change in HbA1c",
            "description": "Proportion of patients with a ≥ 0.4% decrease in HbA1c at 12 months within each study group",
            "timeFrame": "Baseline and Day 365"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* Current (within 3 months prior to enrollment) HbA1c \\>=7.01%\n* Possession of and ability to use Android or iPhone mobile phone\n* Speaks and reads in English\n* Willing to measure frequent fasting finger glucose measurements as part of the App utilization\n\nExclusion Criteria:\n\n* Current use of insulin other than a long-acting insulin analogue or human NPH insulin\n* HbA1c \\>=11%\n* Cognitive impairment or degenerative neuropsychiatric condition (e.g. Alzheimer's, dementia, mixed dementia, other significant memory loss, schizophrenia), or any other condition that in the Investigator's opinion may prevent patient from completing study activities\n* Any terminal medical condition with life expectancy of \\< 1 year.",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "maximumAge": "75 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "facility": "Mass General Brigham Hospital and Clinics",
            "city": "Boston",
            "state": "Massachusetts",
            "zip": "02199",
            "country": "United States",
            "geoPoint": { "lat": 42.35843, "lon": -71.05977 }
          }
        ]
      },
      "ipdSharingStatementModule": {
        "ipdSharing": "NO",
        "description": "IPD will not be shared"
      }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [
          { "id": "D003920", "term": "Diabetes Mellitus" },
          { "id": "D003924", "term": "Diabetes Mellitus, Type 2" }
        ],
        "ancestors": [
          { "id": "D044882", "term": "Glucose Metabolism Disorders" },
          { "id": "D008659", "term": "Metabolic Diseases" },
          { "id": "D004700", "term": "Endocrine System Diseases" }
        ],
        "browseLeaves": [
          {
            "id": "M7115",
            "name": "Diabetes Mellitus",
            "asFound": "Diabetes Mellitus",
            "relevance": "HIGH"
          },
          {
            "id": "M7119",
            "name": "Diabetes Mellitus, Type 2",
            "asFound": "Type 2 Diabetes Mellitus",
            "relevance": "HIGH"
          },
          { "id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW" },
          {
            "id": "M25403",
            "name": "Glucose Metabolism Disorders",
            "relevance": "LOW"
          },
          {
            "id": "M7862",
            "name": "Endocrine System Diseases",
            "relevance": "LOW"
          }
        ],
        "browseBranches": [
          { "abbrev": "BC18", "name": "Nutritional and Metabolic Diseases" },
          { "abbrev": "BC19", "name": "Gland and Hormone Related Diseases" },
          { "abbrev": "All", "name": "All Conditions" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT05584540",
        "orgStudyIdInfo": { "id": "21-421" },
        "organization": {
          "fullName": "Dana-Farber Cancer Institute",
          "class": "OTHER"
        },
        "briefTitle": "UNTIRE: Cancer-related Fatigue With Digital Treatment",
        "officialTitle": "The UNTIRE App Trial: The Feasibility of Using the Untire App for the Colorectal Cancer Patient to Manage Their Cancer Related Fatigue"
      },
      "statusModule": {
        "statusVerifiedDate": "2025-03",
        "overallStatus": "WITHDRAWN",
        "whyStopped": "loss of funding",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2025-01-30", "type": "ESTIMATED" },
        "primaryCompletionDateStruct": {
          "date": "2025-12-30",
          "type": "ESTIMATED"
        },
        "completionDateStruct": { "date": "2026-01-30", "type": "ESTIMATED" },
        "studyFirstSubmitDate": "2022-10-14",
        "studyFirstSubmitQcDate": "2022-10-14",
        "studyFirstPostDateStruct": { "date": "2022-10-18", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2025-03-10",
        "lastUpdatePostDateStruct": { "date": "2025-03-12", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": {
          "type": "PRINCIPAL_INVESTIGATOR",
          "investigatorFullName": "Nina Grenon, NP",
          "investigatorTitle": "Principal Investigator",
          "investigatorAffiliation": "Dana-Farber Cancer Institute"
        },
        "leadSponsor": {
          "name": "Dana-Farber Cancer Institute",
          "class": "OTHER"
        }
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": false
      },
      "descriptionModule": {
        "briefSummary": "This research is being done to find out if using a smartphone app as digital treatment to reduce Cancer Related Fatigue is feasible and easy to use.\n\nThis research study is evaluating a smartphone application named the \"Untire\" app. The Untire app was designed as a digital treatment plan for people experiencing Cancer Related Fatigue (CRF).",
        "detailedDescription": "This is a single arm, pilot study evaluating the feasibility, acceptability, and effectiveness of a self-managed digital therapeutic application, the Untire App, for the treatment of cancer-related fatigue in the Colorectal (CRC) cancer patient community.\n\nThe Untire app was developed by Psychology Oncologists and combines proven treatments for Cancer Related Fatigue like cognitive behavioral therapy, mindfulness exercises, physical activities, education, and positive tips. The Untire app helps a patient recognize and learn about daily behaviors, fatigue levels, and energy levels. The Untire app has been tested on all different cancer types globally and has been proven to decrease fatigue and improve overall quality of life but this is the first-time investigators are examining the strengths and weaknesses of using the Untire app as a digital treatment plan for Cancer Related Fatigue.\n\nThe research study procedures include screening for eligibility and study interventions including smartphone app use and evaluations with questionnaires and follow up visits.\n\nParticipants will be in this research study for up to 12 months.\n\nIt is expected that about 60 people will take part in this research study."
      },
      "conditionsModule": {
        "conditions": ["Colorectal Cancer", "Fatigue"],
        "keywords": ["Colorectal Cancer", "Fatigue"]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "NA",
          "interventionModel": "SINGLE_GROUP",
          "primaryPurpose": "SUPPORTIVE_CARE",
          "maskingInfo": { "masking": "NONE" }
        },
        "enrollmentInfo": { "count": 0, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "UNTIRE App",
            "type": "EXPERIMENTAL",
            "description": "At baseline meeting participants will answer questionnaires and be introduced and instructed on self-managed use of Untire app treatment program.\n\nParticipants will then have check in meetings assessing app usage and progress on weeks 4, 8 and 12 post baseline, then a final check-in 6 months post baseline.",
            "interventionNames": ["Behavioral: UNTIRE App"]
          }
        ],
        "interventions": [
          {
            "type": "BEHAVIORAL",
            "name": "UNTIRE App",
            "description": "Digital therapeutic application",
            "armGroupLabels": ["UNTIRE App"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Enrollment Rate",
            "description": "Primary outcome is feasibility. Feasibility will be described as the number and percentage of enrolled patients that used the app more than once.",
            "timeFrame": "3 months"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "CSQ-I Score",
            "description": "Acceptability will be evaluated using the number and percentage of people that scored more than 16 points on the Client Satisfaction Questionnaire - Internet (CSQ- I).",
            "timeFrame": "3 months"
          }
        ],
        "otherOutcomes": [
          {
            "measure": "The Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Ratings",
            "description": "Patient's cancer related fatigue (CRF) will be described at baseline and at 4, 8, 12 weeks, and 6 months of treatment with the Untire app measured by The Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) and its different subscale (e.g. physical, social, family, emotional, functional well-being, etc.)\\[13\\].",
            "timeFrame": "Baseline and at 4, 8, and 12 weeks."
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* \\>/= 18 years of age\n* Owns a smart phone or Ipad\n* Diagnosis of Metastatic Colorectal Cancer, adenocarcinoma\n* Actively undergoing treatment for Metastatic disease\n* Speak and read English at a 6th grade level or higher\n* A score of 1 or greater on the PRO CTACE DFCI fatigue (questions 53a or 53b)\n\nExclusion Criteria:\n\n* Patients in Surveillance\n* Patients receiving end of life care\n* Patients taking dexamethasone other than for the control of nausea\n* Patients taking methylphenidate (Ritalin) for the treatment of CRF",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "Nina N Grenon, DNP, AOCN",
            "affiliation": "Dana-Farber Cancer Institute",
            "role": "PRINCIPAL_INVESTIGATOR"
          }
        ],
        "locations": [
          {
            "facility": "Dana-Farber Cancer Institute",
            "city": "Boston",
            "state": "Massachusetts",
            "zip": "02215",
            "country": "United States",
            "geoPoint": { "lat": 42.35843, "lon": -71.05977 }
          }
        ]
      },
      "ipdSharingStatementModule": {
        "ipdSharing": "YES",
        "description": "The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: \\[contact information for Sponsor Investigator or designee\\]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.",
        "infoTypes": ["STUDY_PROTOCOL", "SAP", "ICF"],
        "timeFrame": "Data can be shared no earlier than 1 year following the date of publication",
        "accessCriteria": "Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu"
      }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [
          { "id": "D015179", "term": "Colorectal Neoplasms" },
          { "id": "D005221", "term": "Fatigue" }
        ],
        "ancestors": [
          { "id": "D007414", "term": "Intestinal Neoplasms" },
          { "id": "D005770", "term": "Gastrointestinal Neoplasms" },
          { "id": "D004067", "term": "Digestive System Neoplasms" },
          { "id": "D009371", "term": "Neoplasms by Site" },
          { "id": "D009369", "term": "Neoplasms" },
          { "id": "D004066", "term": "Digestive System Diseases" },
          { "id": "D005767", "term": "Gastrointestinal Diseases" },
          { "id": "D003108", "term": "Colonic Diseases" },
          { "id": "D007410", "term": "Intestinal Diseases" },
          { "id": "D012002", "term": "Rectal Diseases" }
        ],
        "browseLeaves": [
          {
            "id": "M8364",
            "name": "Fatigue",
            "asFound": "Fatigue",
            "relevance": "HIGH"
          },
          {
            "id": "M17890",
            "name": "Colorectal Neoplasms",
            "asFound": "Colorectal Cancer",
            "relevance": "HIGH"
          },
          {
            "id": "M10448",
            "name": "Intestinal Neoplasms",
            "relevance": "LOW"
          },
          {
            "id": "M8886",
            "name": "Gastrointestinal Neoplasms",
            "relevance": "LOW"
          },
          {
            "id": "M7256",
            "name": "Digestive System Neoplasms",
            "relevance": "LOW"
          },
          {
            "id": "M8883",
            "name": "Gastrointestinal Diseases",
            "relevance": "LOW"
          },
          {
            "id": "M7255",
            "name": "Digestive System Diseases",
            "relevance": "LOW"
          },
          { "id": "M6336", "name": "Colonic Diseases", "relevance": "LOW" },
          { "id": "M10444", "name": "Intestinal Diseases", "relevance": "LOW" },
          { "id": "M14844", "name": "Rectal Diseases", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "BC23", "name": "Symptoms and General Pathology" },
          { "abbrev": "All", "name": "All Conditions" },
          { "abbrev": "BC04", "name": "Neoplasms" },
          { "abbrev": "BC06", "name": "Digestive System Diseases" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT05351866",
        "orgStudyIdInfo": { "id": "LMX-004" },
        "organization": {
          "fullName": "Limbix Health, Inc.",
          "class": "INDUSTRY"
        },
        "briefTitle": "Digital Therapeutic for Adolescent Depressive Symptoms in Hematology, Oncology, and Weight Management",
        "officialTitle": "Feasibility and Acceptability of a Digital Therapeutic for Adolescent Depressive Symptoms in Hematology/Oncology and Weight Management"
      },
      "statusModule": {
        "statusVerifiedDate": "2023-08",
        "overallStatus": "TERMINATED",
        "whyStopped": "Low Enrollment",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2023-01-26", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2023-06-26",
          "type": "ACTUAL"
        },
        "completionDateStruct": { "date": "2023-06-26", "type": "ACTUAL" },
        "studyFirstSubmitDate": "2022-04-18",
        "studyFirstSubmitQcDate": "2022-04-22",
        "studyFirstPostDateStruct": { "date": "2022-04-28", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2023-08-02",
        "lastUpdatePostDateStruct": { "date": "2023-08-04", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": { "name": "Limbix Health, Inc.", "class": "INDUSTRY" },
        "collaborators": [{ "name": "Children's Health", "class": "OTHER" }]
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": true,
        "isUsExport": true
      },
      "descriptionModule": {
        "briefSummary": "The primary aims of the proposed research are to assess the feasibility, acceptability, and preliminary evidence of efficacy of a self-guided, cognitive behavioral therapy (CBT)-based mobile app intervention (SparkRx) for the treatment of adolescents presenting with symptoms of depression in specialty medical care settings (e.g.Hematology/Oncology, Weight Management, etc.) at Children's Health System of Texas (CHST).",
        "detailedDescription": "The primary aims of the proposed research are to assess the feasibility, acceptability, and preliminary evidence of efficacy of a self-guided, cognitive behavioral therapy (CBT)-based mobile app intervention (SparkRx) for the treatment of adolescents presenting with symptoms of depression in specialty medical care settings (e.g.Hematology/Oncology, Weight Management, etc.) at Children's Health System of Texas (CHST).\n\nThese aims will be accomplished by evaluating:\n\n* Feasibility of recruiting and enrolling adolescents with mild to severe symptoms of depression from specialty care medical programs at CHST.\n* Retention, program adherence, completion, and withdrawal rates.\n* Perceived utility, usability, and enjoyment of the program by adolescents\n* Clinically significant changes between pre- to -post treatment and persistence of such gains at 1 month follow up.\n* Preliminary evidence of efficacy defined as a statistically significant difference in the eight-item Patient Health Questionnaire (PHQ-8) scores (p \\< 0.05) between Spark and an educational control at post-treatment.\n* Safety of the intervention, including rates of reported adverse events and adverse device effects"
      },
      "conditionsModule": {
        "conditions": [
          "Depression",
          "Depressive Disorder",
          "Depressive Symptoms",
          "Depressive Episode",
          "Adolescent Behavior",
          "Adolescent - Emotional Problem",
          "Hematologic Diseases",
          "Oncology",
          "Weight, Body"
        ],
        "keywords": ["Depression", "Mental Health", "Adolescent mental health"]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": { "masking": "NONE" }
        },
        "enrollmentInfo": { "count": 7, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "SparkRx",
            "type": "EXPERIMENTAL",
            "description": "5-week CBT-based mobile intervention for adolescents with depressive symptoms",
            "interventionNames": [
              "Device: CBT-based mobile intervention for depression"
            ]
          },
          {
            "label": "Educational Control",
            "type": "ACTIVE_COMPARATOR",
            "description": "5-week mobile control with education about depression",
            "interventionNames": [
              "Device: Mobile control with education about depression"
            ]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "CBT-based mobile intervention for depression",
            "description": "SparkRx is a 5-week program divided into levels intended to be completed weekly. SparkRx is a behavioral activation program. Participants are instructed to complete a weekly Patient Health Questionnaire (PHQ)-8 assessment and participant symptom check (PSC) in the mobile app. Tasks in the mobile app progress in a linear fashion (i.e., each task must be completed to progress to the next task).",
            "armGroupLabels": ["SparkRx"],
            "otherNames": ["SparkRx"]
          },
          {
            "type": "DEVICE",
            "name": "Mobile control with education about depression",
            "description": "The control mobile application will consist of 5 weeks of educational content about depression. Participants will be instructed to complete a weekly Patient Health Questionnaire (PHQ)-8 assessment and PSC in the mobile app.",
            "armGroupLabels": ["Educational Control"],
            "otherNames": ["Educational Control"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Feasibility of intervention: Eligibility",
            "description": "Percent of potential participants eligible to participate",
            "timeFrame": "Screening"
          },
          {
            "measure": "Feasibility of intervention: Participant willingness",
            "description": "Percent of eligible participants willing to participate",
            "timeFrame": "Screening"
          },
          {
            "measure": "Feasibility of intervention: Completion adherence",
            "description": "Adherence to program determined by percent of enrolled participants completing all modules within 5 weeks and by post-treatment",
            "timeFrame": "5 weeks"
          },
          {
            "measure": "Feasibility of intervention: Module adherence",
            "description": "Adherence to program determined by average number of modules completed",
            "timeFrame": "5 weeks"
          },
          {
            "measure": "Feasibility of intervention: Time adherence",
            "description": "Adherence to program determined by engagement with program (time spent in app)",
            "timeFrame": "5 weeks"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Change in depressive symptoms",
            "description": "Measured by the Patient Health Questionnaire (PHQ-8). Score range of 0 to 24 with higher scores indicating worse outcome.\n\n* Clinically significant improvement: reduction in assessment score \\>= 5\n* Treatment response: 50% reduction in symptoms from pre to post-intervention\n* Remission is defined as a score \\< 5",
            "timeFrame": "5 weeks"
          },
          {
            "measure": "Adverse events",
            "description": "Rates of adverse events and adverse advice effects",
            "timeFrame": "11 weeks"
          },
          {
            "measure": "Usability",
            "description": "Usability measured with the System Usability Scale (SUS), which consists of 10 items, each with five response options for respondents; from Strongly agree to Strongly disagree. Scores range from 0-100, with higher scores meaning more usable.",
            "timeFrame": "5 weeks"
          },
          {
            "measure": "Engagement",
            "description": "Engagement measured with the User Engagement Scale - Short Form (UES-SF), which measures self-reported user engagement. The form has 12 items and uses a 5 point Likert scale. Scores range from 1-5, with higher scores indicating more engaging material.",
            "timeFrame": "5 weeks"
          }
        ],
        "otherOutcomes": [
          {
            "measure": "Treatment-related change in depressive symptoms",
            "description": "Difference in the change in PHQ-8 scores between the SparkRx and control arms. Score range of 0 to 24 with higher scores indicating worse outcome.",
            "timeFrame": "Change over 5 weeks"
          },
          {
            "measure": "Treatment-related change in anxiety",
            "description": "Measured by the Generalized Anxiety Disorder scale (GAD-7).The GAD-7 is a brief 7-item assessment for generalized anxiety disorder with satisfactory sensitivity and specificity. Score range of 0 to 21 with a higher score indicating worse outcome.",
            "timeFrame": "Change over 5 weeks"
          },
          {
            "measure": "Treatment-related change in global functioning",
            "description": "Measured using the Short Form-36 (SF-36), a set of generic, coherent, self-reported, and easily administered quality-of-life measures used to routinely monitor and assess the care outcomes of participants. 8 subscales with scores ranging from 0-100, higher being a more favorable health state.\n\nPhysical functioning Role limitations due to physical health Role limitations due to emotional problems Energy/fatigue Emotional well-being Social functioning Pain General health",
            "timeFrame": "Change over 5 weeks"
          },
          {
            "measure": "Caregiver proxy treatment-related change in depressive symptoms",
            "description": "Measured using caregiver proxy measures of the PHQ-8. Score range of 0 to 24 with higher scores indicating worse outcome.",
            "timeFrame": "Change over 5 weeks"
          },
          {
            "measure": "Caregiver proxy treatment-related change in global functioning",
            "description": "Measured using caregiver proxy measures of the SF-36. 8 subscales with scores ranging from 0-100, higher being a more favorable health state.",
            "timeFrame": "Change over 5 weeks"
          },
          {
            "measure": "Treatment-related change in hope",
            "description": "Measured using the Hope Scale, a 12-item self-report measure, which assesses dispositional hope in adults. Each item rated from 1-8 (definitely false - definitely true). Scores range from 8-64, with higher being more hopeful.\n\nSubscales: agency and pathway.",
            "timeFrame": "Change over 5 weeks"
          },
          {
            "measure": "Healthcare utilization",
            "description": "Descriptive understanding of healthcare utilization. Measured by the Healthcare Utilization Questionnaire. A two-item questionnaire that assesses participants' use of healthcare resources.",
            "timeFrame": "Change over 5 weeks"
          },
          {
            "measure": "Caregiver burden",
            "description": "Descriptive understanding of caregiver burden, measured by the work absenteeism questionnaire, containing questions about caregiving responsibilities and related impacts on employment. Higher scores indicate more hours missed per week of work.",
            "timeFrame": "Change over 5 weeks"
          },
          {
            "measure": "Treatment-related change in physical symptom severity",
            "description": "Measured by the Functional Disability Inventory a fifteen-item questionnaire that measures functional disability and evaluates the impact of illness on the respondents' physical and psychosocial functioning in everyday social roles. Each question is rated on a 5-point scale from 0(No Trouble) to 4 (Impossible). Score range is 0 to 60 with higher scores indicating a worse outcome.",
            "timeFrame": "Change over 5 weeks"
          },
          {
            "measure": "Treatment-related perceptions of experience with SparkRx",
            "description": "Measured by the User Experience (UXR) questionnaire. Includes questions from the Usability Metric for User Experience (UMUX)-Lite; a two-item questionnaire that assesses the usability of the mobile application. Questions have seven response options from Strongly agree to Strongly disagree. Includes questions from the Happiness Tracking Surveys (HaTs); an open-ended questionnaire that assesses respondents' experiences with the product and provides options for feedback.",
            "timeFrame": "5 weeks"
          },
          {
            "measure": "Treatment expectations",
            "description": "Identifying the relationship between treatment expectations and treatment outcomes. Expectations measured with the Stanford Expectations of Treatment Scale (SETS), an instrument for measuring positive and negative treatment expectancies. There are two subscales, the positive and negative expectancy. Scores range from 1-7, with higher scores indicating greater positive and negative expectancy.\n\nOutcomes measured with the PHQ-8. Score range of 0 to 24 with higher scores indicating worse outcome.",
            "timeFrame": "5 weeks"
          },
          {
            "measure": "Treatment expectations: Credibility/Expectancy",
            "description": "Identifying the relationship between treatment expectations and treatment outcomes. Expectations measured with the Credibility/Expectancy Questionnaire (CEQ), a questionnaire for measuring cognitively-based credibility and relatively more affectively-based expectancy of therapy outcomes. Scores range from 6-60, with higher scores indicating a greater expectation of treatment success.\n\nOutcomes measured with the PHQ-8. Score range of 0 to 24 with higher scores indicating worse outcome.",
            "timeFrame": "5 weeks"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* Between the ages of 13 and 22\n* Moderate- severe self-reported symptoms of depression at baseline (PHQ-8 \\>= 5)\n* Have a comorbid medical condition and under the care of a healthcare provider at CHST\n* English fluency and literacy of adolescent; English or Spanish fluency and literacy of consenting legal guardian if under 18\n* Access to a compatible smartphone (or other device) and operating system (i.e., capable of installing the app from the Google Play or Apple App Store; list will be provided to participants) and regular internet access\n* Willing to provide informed consent/assent and have legal guardian willing to provide informed consent (if required)\n\nExclusion Criteria:\n\n* Concurrent psychotherapy: Have met with a psychologist for intervention (not assessment) for 30 minutes or more, more than once in the 3 weeks prior to enrollment as determined by the study team\n* Change in psychotropic medication (initiation or change in dose) within the past 30 days prior to enrollment\n* Suicide attempt within the past year as determined at eligibility screening\n* Active suicidal ideation with intent as determined at eligibility screening\n* Previously participated in user testing or clinical testing of the Spark app\n* Participating in any other psychiatric or psychological treatment based clinical research at the time of enrollment and up to two months prior to enrollment or planning to participate in any other psychiatric or psychological treatment based clinical research during the study intervention period (5 weeks)\n* Any condition, comorbidity, or event that, in the opinion of the investigator, will prevent the participant from adhering to the protocol or benefiting from the treatment (e.g., unable to provide informed assent or consent) or will prevent investigators from being able to ensure safety (e.g., will be leaving the country during study time period)",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "13 Years",
        "maximumAge": "22 Years",
        "stdAges": ["CHILD", "ADULT"]
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "Julie Germann, PhD.",
            "affiliation": "Children's Health System of Texas",
            "role": "PRINCIPAL_INVESTIGATOR"
          }
        ],
        "locations": [
          {
            "facility": "Children's Hospital Texas",
            "city": "Dallas",
            "state": "Texas",
            "zip": "75235",
            "country": "United States",
            "geoPoint": { "lat": 32.78306, "lon": -96.80667 }
          }
        ]
      },
      "ipdSharingStatementModule": { "ipdSharing": "NO" }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [
          { "id": "D009369", "term": "Neoplasms" },
          { "id": "D006402", "term": "Hematologic Diseases" },
          { "id": "D001835", "term": "Body Weight" },
          { "id": "D003863", "term": "Depression" },
          { "id": "D003866", "term": "Depressive Disorder" }
        ],
        "ancestors": [
          { "id": "D001526", "term": "Behavioral Symptoms" },
          { "id": "D019964", "term": "Mood Disorders" },
          { "id": "D001523", "term": "Mental Disorders" }
        ],
        "browseLeaves": [
          {
            "id": "M7061",
            "name": "Depressive Disorder",
            "asFound": "Depressive Disorder",
            "relevance": "HIGH"
          },
          {
            "id": "M7058",
            "name": "Depression",
            "asFound": "Depressive Symptoms",
            "relevance": "HIGH"
          },
          {
            "id": "M5114",
            "name": "Body Weight",
            "asFound": "Weight, Body",
            "relevance": "HIGH"
          },
          {
            "id": "M9490",
            "name": "Hematologic Diseases",
            "asFound": "Hematologic Diseases",
            "relevance": "HIGH"
          },
          { "id": "M4818", "name": "Behavioral Symptoms", "relevance": "LOW" },
          { "id": "M21835", "name": "Mood Disorders", "relevance": "LOW" },
          { "id": "M14473", "name": "Psychotic Disorders", "relevance": "LOW" },
          { "id": "M4815", "name": "Mental Disorders", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" },
          { "abbrev": "All", "name": "All Conditions" },
          { "abbrev": "BC23", "name": "Symptoms and General Pathology" },
          { "abbrev": "BC15", "name": "Blood and Lymph Conditions" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT05144685",
        "orgStudyIdInfo": { "id": "2020-Oui-001" },
        "secondaryIdInfos": [
          {
            "id": "2R42MH123357-02",
            "type": "NIH",
            "link": "https://reporter.nih.gov/quickSearch/2R42MH123357-02"
          }
        ],
        "organization": {
          "fullName": "Oui Therapeutics, Inc.",
          "class": "INDUSTRY"
        },
        "briefTitle": "A Study to Evaluate the Safety and Effectiveness of a Digital Therapeutic",
        "officialTitle": "A Randomized, Double Blind Controlled Study to Evaluate the Safety and Effectiveness of a Digital Therapeutic for Individuals With Suicidal Ideation and/or Suicide Attempts"
      },
      "statusModule": {
        "statusVerifiedDate": "2025-01",
        "overallStatus": "TERMINATED",
        "whyStopped": "Data Safety Monitoring Board (DSMB) recommendation per Charter stopping rules. The study surpassed the pre-planned futility boundary.",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2022-04-07", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2024-06-14",
          "type": "ACTUAL"
        },
        "completionDateStruct": { "date": "2024-06-14", "type": "ACTUAL" },
        "studyFirstSubmitDate": "2021-11-11",
        "studyFirstSubmitQcDate": "2021-11-22",
        "studyFirstPostDateStruct": { "date": "2021-12-03", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2025-01-09",
        "lastUpdatePostDateStruct": { "date": "2025-01-13", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": {
          "name": "Oui Therapeutics, Inc.",
          "class": "INDUSTRY"
        },
        "collaborators": [
          {
            "name": "National Institute of Mental Health (NIMH)",
            "class": "NIH"
          }
        ]
      },
      "oversightModule": {
        "oversightHasDmc": true,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": true,
        "isUnapprovedDevice": true
      },
      "descriptionModule": {
        "briefSummary": "The primary objective of this study is to assess the effectiveness of a digital intervention in reducing suicide attempts.",
        "detailedDescription": "This double blind, randomized controlled trial will evaluate effectiveness of two digital interventions among 391 participants. Study participation will start when participants sign consent. Participants and research assessors will be blinded to treatment assignment."
      },
      "conditionsModule": {
        "conditions": ["Suicide, Attempted", "Suicidal Ideation"]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["PHASE2", "PHASE3"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "SEQUENTIAL",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": {
            "masking": "DOUBLE",
            "maskingDescription": "Participants and research assessors will be blinded to treatment assignment.",
            "whoMasked": ["PARTICIPANT", "OUTCOMES_ASSESSOR"]
          }
        },
        "enrollmentInfo": { "count": 356, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "Experimental App + Treatment as Usual",
            "type": "EXPERIMENTAL",
            "description": "This intervention will be for the treatment group",
            "interventionNames": ["Device: OTX-202"]
          },
          {
            "label": "Other App + Treatment as Usual",
            "type": "EXPERIMENTAL",
            "description": "This intervention will be for the control group",
            "interventionNames": ["Device: OTX-000"]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "OTX-202",
            "description": "Experimental Pscyhoeducation and Intervention App",
            "armGroupLabels": ["Experimental App + Treatment as Usual"]
          },
          {
            "type": "DEVICE",
            "name": "OTX-000",
            "description": "Other Pscyhoeducation App",
            "armGroupLabels": ["Other App + Treatment as Usual"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Columbia-Suicide Severity Rating Scale(C-SSRS)",
            "description": "The C-SSRS will be used to assess change in suicide behaviors at 8 separate time points from screening period to Week 104.",
            "timeFrame": "Screening, Week 4, Week 8, Week 12, Week 24, Week 52, Week 78, Week 104"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n1. Ages ≥18 years old\n2. Patients recently hospitalized.\n3. Owns a smartphone.\n4. Willing and able to complete enrollment procedures.\n5. Able to understand the nature of the study.\n6. Able and willing to provide at least two verifiable contacts.\n\nExclusion Criteria:\n\n1. Patients who have untreated psychosis or active psychosis\n2. Patients who appear to be impaired by the use of alcohol or other substance(s)\n3. Patients who sign, or have signed, an informed consent form to participate in any clinical research\n4. Patients who upon clinical examination are cognitively impaired\n5. Patients with a medical condition that may compromise, interfere, limit, effect or reduce the subject's ability to complete",
        "healthyVolunteers": true,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "facility": "UCDDenver / Denver Health",
            "city": "Denver",
            "state": "Colorado",
            "zip": "80204",
            "country": "United States",
            "geoPoint": { "lat": 39.73915, "lon": -104.9847 }
          },
          {
            "facility": "Yale",
            "city": "New Haven",
            "state": "Connecticut",
            "zip": "06511",
            "country": "United States",
            "geoPoint": { "lat": 41.30815, "lon": -72.92816 }
          },
          {
            "facility": "Common Spirit",
            "city": "Omaha",
            "state": "Nebraska",
            "zip": "68131",
            "country": "United States",
            "geoPoint": { "lat": 41.25626, "lon": -95.94043 }
          },
          {
            "facility": "Northwell Health",
            "city": "Glen Oaks",
            "state": "New York",
            "zip": "11004",
            "country": "United States",
            "geoPoint": { "lat": 40.74705, "lon": -73.71152 }
          },
          {
            "facility": "University of Cincinnati",
            "city": "Cincinnati",
            "state": "Ohio",
            "zip": "45219",
            "country": "United States",
            "geoPoint": { "lat": 39.12713, "lon": -84.51435 }
          },
          {
            "facility": "Harding Hospital",
            "city": "Columbus",
            "state": "Ohio",
            "zip": "43210",
            "country": "United States",
            "geoPoint": { "lat": 39.96118, "lon": -82.99879 }
          }
        ]
      }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [
          { "id": "D013405", "term": "Suicide" },
          { "id": "D059020", "term": "Suicidal Ideation" },
          { "id": "D013406", "term": "Suicide, Attempted" }
        ],
        "ancestors": [
          { "id": "D016728", "term": "Self-Injurious Behavior" },
          { "id": "D001526", "term": "Behavioral Symptoms" }
        ],
        "browseLeaves": [
          {
            "id": "M29364",
            "name": "Suicidal Ideation",
            "asFound": "Suicidal Ideation",
            "relevance": "HIGH"
          },
          {
            "id": "M16191",
            "name": "Suicide",
            "asFound": "Suicide",
            "relevance": "HIGH"
          },
          {
            "id": "M16192",
            "name": "Suicide, Attempted",
            "asFound": "Suicide, Attempted",
            "relevance": "HIGH"
          },
          {
            "id": "M19089",
            "name": "Self-Injurious Behavior",
            "relevance": "LOW"
          },
          { "id": "M4818", "name": "Behavioral Symptoms", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" },
          { "abbrev": "All", "name": "All Conditions" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT05094401",
        "orgStudyIdInfo": { "id": "DM2-07-CAT" },
        "organization": {
          "fullName": "Better Therapeutics",
          "class": "INDUSTRY"
        },
        "briefTitle": "Use of an Investigational Digital Therapeutic in Patients With Type 2 Diabetes",
        "officialTitle": "Long-term Effectiveness and Medication Changes After Use of an Investigational Digital Therapeutic in Patients With Type 2 Diabetes Cared for in a Community Based, Clinically Integrated Network"
      },
      "statusModule": {
        "statusVerifiedDate": "2023-09",
        "overallStatus": "TERMINATED",
        "whyStopped": "Sponsor/Investigator Decision",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2021-10-04", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2023-04-01",
          "type": "ACTUAL"
        },
        "completionDateStruct": { "date": "2023-04-01", "type": "ACTUAL" },
        "studyFirstSubmitDate": "2021-10-14",
        "studyFirstSubmitQcDate": "2021-10-14",
        "studyFirstPostDateStruct": { "date": "2021-10-26", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2023-09-26",
        "lastUpdatePostDateStruct": { "date": "2023-09-28", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": { "name": "Better Therapeutics", "class": "INDUSTRY" },
        "collaborators": [
          { "name": "Catalyst Health Network", "class": "UNKNOWN" }
        ]
      },
      "oversightModule": {
        "oversightHasDmc": true,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": false
      },
      "descriptionModule": {
        "briefSummary": "BT-001 is a software program intended to help patients with type 2 diabetes, under the guidance of their physician, improve glycemic control (i.e., levels of blood sugar). The BT-001 software delivers a type of behavioral therapy to patients via a mobile application that targets behaviors related to achieving glycemic control. The effectiveness of BT-001 will be measured by its ability to help patients reduce Hemoglobin A1c, or HbA1c (a marker in the blood that measures blood sugar) in patients with type 2 diabetes.",
        "detailedDescription": "The study will utilize an open-label, pragmatic design to confirm and characterize the safety and efficacy of BT-001 used in addition to standard of care (SOC) in patients with type 2 diabetes. The screening period will consist of review of Electronic Health Record (EHR) for participants that meet inclusion criteria and telephonic outreach.\n\nOnce confirmed consented, patients will then be given access to BT-001 for 90 days with an opportunity to continue using the product for an additional 275 days.\n\nParticipants will continue their standard of care with their provider in addition to using BT-001."
      },
      "conditionsModule": { "conditions": ["Type2 Diabetes"] },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["PHASE3"],
        "designInfo": {
          "allocation": "NA",
          "interventionModel": "SINGLE_GROUP",
          "interventionModelDescription": "Open-Label, Pragmatic",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": { "masking": "NONE" }
        },
        "enrollmentInfo": { "count": 76, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "Intervention BT-001 + Standard of Care",
            "type": "EXPERIMENTAL",
            "description": "BT-001 is a software program used with physician guidance, being investigated to improve glycemic control. Patients randomized to this arm of the study will interact with the BT-001 software program in addition to receiving Standard of Care for type 2 diabetes",
            "interventionNames": ["Device: BT-001"]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "BT-001",
            "description": "BT-001 is a software program intended to help patients with type 2 diabetes, under the guidance of their physician, improve glycemic control.",
            "armGroupLabels": ["Intervention BT-001 + Standard of Care"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Mean change in HbA1c",
            "description": "Mean change in HbA1c from baseline (enrollment) to 12 months after enrollment",
            "timeFrame": "Baseline and Day 365"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Change in Medications",
            "description": "The change in number and type of medications used to treat type 2 diabetes, hypertension and dyslipidemia from baseline to 12 months",
            "timeFrame": "Baseline and Day 365"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* Diagnosis of Type2 Diabetes\n* Possess a smart phone (iPhone or Android only) capable of running the smart phone application (App) used in the study;\n* HbA1c level ≥7% and \\<11%, as determined by the HbA1c measured within the previous 12 months;\n* Willing to use a glucometer for self-monitoring blood glucose while using the study App;\n* Capable of giving informed consent in English, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.\n\nExclusion Criteria:\n\n* Unable to understand, consent to, or comply with the study protocol for any reason, including the inability to read or comprehend English. The behavioral intervention mechanisms, including educational materials and digital tools, are only available in English at this time;\n* Currently taking prandial (mealtime) insulin;\n* Currently experiencing heart failure of New York Heart Association Class IV;\n* Currently experiencing stage 4 or 5 chronic kidney disease;\n* Currently on kidney dialysis (hemo or peritoneal);\n* Currently on the list for an organ transplant or previously received a transplant of any organ;\n* Currently receiving treatment for cancer;\n* For women only: pregnant or lactating or having the intention of becoming pregnant during the time frame of the study;\n* Presumed or confirmed COVID-19 diagnosis within 90 days prior to study enrollment",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "maximumAge": "75 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "facility": "Catalyst Health Network",
            "city": "Plano",
            "state": "Texas",
            "zip": "75024",
            "country": "United States",
            "geoPoint": { "lat": 33.01984, "lon": -96.69889 }
          }
        ]
      },
      "ipdSharingStatementModule": { "ipdSharing": "NO" }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [
          { "id": "D003920", "term": "Diabetes Mellitus" },
          { "id": "D003924", "term": "Diabetes Mellitus, Type 2" }
        ],
        "ancestors": [
          { "id": "D044882", "term": "Glucose Metabolism Disorders" },
          { "id": "D008659", "term": "Metabolic Diseases" },
          { "id": "D004700", "term": "Endocrine System Diseases" }
        ],
        "browseLeaves": [
          {
            "id": "M7115",
            "name": "Diabetes Mellitus",
            "asFound": "Diabetes",
            "relevance": "HIGH"
          },
          {
            "id": "M7119",
            "name": "Diabetes Mellitus, Type 2",
            "asFound": "Type 2 Diabetes",
            "relevance": "HIGH"
          },
          { "id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW" },
          {
            "id": "M25403",
            "name": "Glucose Metabolism Disorders",
            "relevance": "LOW"
          },
          {
            "id": "M7862",
            "name": "Endocrine System Diseases",
            "relevance": "LOW"
          }
        ],
        "browseBranches": [
          { "abbrev": "BC18", "name": "Nutritional and Metabolic Diseases" },
          { "abbrev": "BC19", "name": "Gland and Hormone Related Diseases" },
          { "abbrev": "All", "name": "All Conditions" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT04974645",
        "orgStudyIdInfo": { "id": "62053" },
        "organization": { "fullName": "Woebot Health", "class": "INDUSTRY" },
        "briefTitle": "Pilot: Digital Therapeutic vs Education for the Management of Problematic Substance Use",
        "officialTitle": "Pilot: Randomized Controlled Trial of an Digital Therapeutic Versus Education for the Management of Problematic Substance Use"
      },
      "statusModule": {
        "statusVerifiedDate": "2024-01",
        "overallStatus": "COMPLETED",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2021-11-03", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2022-05-18",
          "type": "ACTUAL"
        },
        "completionDateStruct": { "date": "2022-05-18", "type": "ACTUAL" },
        "studyFirstSubmitDate": "2021-07-13",
        "studyFirstSubmitQcDate": "2021-07-13",
        "studyFirstPostDateStruct": { "date": "2021-07-23", "type": "ACTUAL" },
        "resultsFirstSubmitDate": "2023-12-12",
        "resultsFirstSubmitQcDate": "2024-01-31",
        "resultsFirstPostDateStruct": {
          "date": "2024-02-02",
          "type": "ACTUAL"
        },
        "lastUpdateSubmitDate": "2024-01-31",
        "lastUpdatePostDateStruct": { "date": "2024-02-02", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": { "name": "Woebot Health", "class": "INDUSTRY" },
        "collaborators": [
          { "name": "Stanford University", "class": "OTHER" },
          { "name": "National Institute on Drug Abuse (NIDA)", "class": "NIH" }
        ]
      },
      "oversightModule": {
        "oversightHasDmc": true,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": false
      },
      "descriptionModule": {
        "briefSummary": "Prior to launching a randomized controlled trial, this pilot study will investigate the feasibility and acceptability of the administration of a diagnostic interview and collection of a biomarker test, as well as engagement and preliminary efficacy with W-SUDs and the education arm, among a sample of adults who screen positive for problematic substance use."
      },
      "conditionsModule": {
        "conditions": ["Alcohol Use Disorder (AUD)", "Substance Use Disorders"]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": { "masking": "NONE" }
        },
        "enrollmentInfo": { "count": 20, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "W-SUDs",
            "type": "EXPERIMENTAL",
            "description": "Woebot (W-SUDs), a Conversational Agent (CA) instantaneously available 24 hours per day, 7 days per week, 'checks in' with users. Using conversational tones, it encourages mood tracking and delivers general psychoeducation as well as tailored empathy, cognitive behavior therapy (CBT)-based behavior change tools, and behavioral pattern insight. Woebot's app-based platform and user-centered design philosophy makes it an optimal modality for Substance Use Disorders (SUD) treatment delivery. It offers immediate, evidence-based tailored support in the patient's peak moment of craving.",
            "interventionNames": ["Device: W-SUDs"]
          },
          {
            "label": "Digitally-delivered Psychoeducation",
            "type": "OTHER",
            "description": "Psychoeducation digitally delivers weekly fact sheets that include information on:\n\n1. Alcohol-specific topics;\n2. Drug-specific topics;\n3. General addiction topics;\n4. Statistics relating to alcohol and substance use.",
            "interventionNames": ["Other: Digitally-delivered Psychoeducation"]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "W-SUDs",
            "description": "Woebot (W-SUDs) is an automated conversational agent, available through a smartphone application, that delivers evidence-based psychotherapeutics, empathy, and emotional health psychoeducation.",
            "armGroupLabels": ["W-SUDs"]
          },
          {
            "type": "OTHER",
            "name": "Digitally-delivered Psychoeducation",
            "description": "A form of psychoeducation for those seeking treatment for their alcohol and/or substance use concern. Psychoeducation is commonly provided for those with substance use. Psychoeducation in substance use is intended to increase the users' knowledge of their substances of use, and effects on the body, behaviors, and consequences. The recipient of psychoeducation is expected to increase their own awareness of their substance use and ideally incorporate this newfound knowledge when making changes to their substance use. The information provided in this group are from factsheets found on NIAAA, NIDA, and CDC web pages.",
            "armGroupLabels": ["Digitally-delivered Psychoeducation"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Change in Number of Substance Use Occasions",
            "description": "Change in number of substance use occasions in the past 30 days",
            "timeFrame": "Change from Baseline to Mid-Treatment at 4 weeks; Change from Baseline to Post-treatment at 8 weeks; Change from Baseline to 1-Month Follow-up at 12 weeks"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Past Month Average Days Per Week of Drinking Alcohol",
            "description": "Assessed with the Quick Drinking Screen (QDS), a measure of alcohol consumption. The QDS is a brief self-report measure used to assess average alcohol consumption over a specified time period (in the present study it was the past 30 days). The QDS collects drinking data for three variables including number of days drinking, number of standard drinks per drinking day, and number of binge/risky drinking days. Binge/risky drinking days is defined as days when they have had 5 or more standard drinks (for men) or 4 or more standard drinks (for women).",
            "timeFrame": "Change from Baseline to Mid-Treatment at 4 weeks; Change from Baseline to Post-treatment at 8 weeks; Change from Baseline to 1-Month Follow-up at 12 weeks"
          },
          {
            "measure": "Past Month Average Standard Drinks in a Day",
            "description": "Assessed with the Quick Drinking Screen (QDS), a measure of alcohol consumption. The QDS is a brief self-report measure used to assess average alcohol consumption over a specified time period (in the present study it was the past 30 days). The QDS collects drinking data for three variables including number of days drinking, number of standard drinks per drinking day, and number of binge/risky drinking days. Binge/risky drinking days is defined as days when they have had 5 or more standard drinks (for men) or 4 or more standard drinks (for women).",
            "timeFrame": "Change from Baseline to Mid-Treatment at 4 weeks; Change from Baseline to Post-treatment at 8 weeks; Change from Baseline to 1-Month Follow-up at 12 weeks"
          },
          {
            "measure": "Past Month Number of Binge Days",
            "description": "Assessed with the Quick Drinking Screen (QDS), a measure of alcohol consumption. The QDS is a brief self-report measure used to assess average alcohol consumption over a specified time period (in the present study it was the past 30 days). The QDS collects drinking data for three variables including number of days drinking, number of standard drinks per drinking day, and number of binge/risky drinking days. Binge/risky drinking days is defined as days when they have had 5 or more standard drinks (for men) or 4 or more standard drinks (for women).",
            "timeFrame": "Change from Baseline to Mid-Treatment at 4 weeks; Change from Baseline to Post-treatment at 8 weeks; Change from Baseline to 1-Month Follow-up at 12 weeks"
          },
          {
            "measure": "Past Month Average Standard Drinks in a Week",
            "description": "Assessed with the Quick Drinking Screen (QDS), a measure of alcohol consumption. The QDS is a brief self-report measure used to assess average alcohol consumption over a specified time period (in the present study it was the past 30 days). The QDS collects drinking data for three variables including number of days drinking, number of standard drinks per drinking day, and number of binge/risky drinking days. Binge/risky drinking days is defined as days when they have had 5 or more standard drinks (for men) or 4 or more standard drinks (for women). Number of standard drinks per week is calculated by multiplying number of standard drinks per day in the past month and number of binge days per month.",
            "timeFrame": "Change from Baseline to Mid-Treatment at 4 weeks; Change from Baseline to Post-treatment at 8 weeks; Change from Baseline to 1-Month Follow-up at 12 weeks"
          },
          {
            "measure": "Short Inventory of Problems- Alcohol and Drugs (SIP-AD)",
            "description": "The SIP-AD assesses substance use problems in the past 30 days. The scored variables, total scores and 15-item mean, summarize consequences of alcohol and drug use. Scores range from 0-45, where greater scores indicate greater substance use problems.",
            "timeFrame": "Change from Baseline to Mid-Treatment at 4 weeks; Change from Baseline to Post-treatment at 8 weeks; Change from Baseline to 1-Month Follow-up at 12 weeks"
          },
          {
            "measure": "Craving Ratings",
            "description": "Self-reported ratings of craving intensity. Craving is assessed with a single question, \"In the past 7 days, how much were you bothered by cravings or urges to drink alcohol or use drugs?\". The question is rated on a scale of 0 to 4 where 0 = not at all, 1 = a little bit, 2 = moderately, 3 = quite a bit, and 4 = extremely. Greater scores indicate a more intense urge to use.",
            "timeFrame": "Change from Baseline to Mid-Treatment at 4 weeks; Change from Baseline to Post-treatment at 8 weeks; Change from Baseline to 1-Month Follow-up at 12 weeks"
          },
          {
            "measure": "Working Alliance Inventory (WAI-SR)",
            "description": "Measure of working alliance. A measure of therapeutic alliance that assesses three key aspects of the therapeutic alliance: (a) agreement on the tasks of therapy, (b) agreement on the goals of therapy and (c) development of an affective bond. Task, goal, and bond subscales scores range from 5-20, with higher scores indicating greater alliance. The present study utilized the validated 12-item Short-Revised version (WAI-SR) with minor changes to language, replacing \"therapist\" with \"Woebot\".",
            "timeFrame": "Difference between Mid-treatment at 4 weeks and Post-treatment at 8 weeks"
          },
          {
            "measure": "Stanford Presenteeism Scale (SPS-6)",
            "description": "Measure of the effects of substance use on productivity. The SPS-6 is a 6-item self-report measure used to assess perceptions of the effects of substance use on past 2-week work productivity. Response options range from strongly disagree (1) to strongly agree (5). Total scores range from 6 to 30, where higher scores indicate higher presenteeism.",
            "timeFrame": "Change from Baseline to Post-treatment at 8 weeks"
          },
          {
            "measure": "Thoughts About Abstinence (TAA)",
            "description": "Modified for alcohol and substances. 5-item questionnaire assessing desire to quit, expected success at quitting, expected difficulty of quitting, and confidence in ability to quit. Each item is rated on a scale of 1 to 10 where 1 is the lowest (desire, expectation, confidence) and 10 is the highest (desire, expectation, confidence).",
            "timeFrame": "Change from Baseline to Post-treatment at 8 weeks"
          },
          {
            "measure": "CAIR Pandemic Impact Questionnaire (C-PIQ)",
            "description": "Assesses impact of the COVID-19 pandemic in terms of exposure to stressors, mental health impact and growth. Exposure domain total scores range from 0-15, with higher scores indicating greater exposure. Impact domain total scores range from 0-23, where greater scores are related to greater impact.",
            "timeFrame": "Change from Baseline to Post-treatment at 8 weeks"
          },
          {
            "measure": "Patient Health Questionnaire (PHQ-8)",
            "description": "Measure of depression severity. An 8-item abbreviated version of the PHQ-9 used to assess mood symptoms. The PHQ-8 excludes an item assessing suicidality. Items are rated on a 4-point Likert scale (0 = \"not at all\" to 3 = \"nearly every day\"). Total score between 0-24, with higher scores indicating greater severity of depression symptoms.",
            "timeFrame": "Change from Baseline to Mid-Treatment at 4 weeks; Change from Baseline to Post-treatment at 8 weeks; Change from Baseline to 1-Month Follow-up at 12 weeks"
          },
          {
            "measure": "Generalized Anxiety Disorder (GAD-7)",
            "description": "Measure of anxiety severity. A 7-item self-report measure used to assess the frequency and severity of anxious thoughts and behaviors over the past 2 weeks. Items are rated on a 4-point Likert scale (0 = \"not at all\" to 3 = \"nearly every day\").Total scores range from 0-21, where higher scores indicate greater severity of anxiety symptoms.",
            "timeFrame": "Change from Baseline to Mid-Treatment at 4 weeks; Change from Baseline to Post-treatment at 8 weeks; Change from Baseline to 1-Month Follow-up at 12 weeks"
          },
          {
            "measure": "Brief Situational Confidence Questionnaire (BSCQ)",
            "description": "Measure of self-confidence. The 8-item BSCQ is a state dependent measure that assesses self-confidence to resist the urge to drink heavily or use drugs in a variety of situations. Each of the 8 scale situations consists of a 100-mm line, anchored by 0% (\"not at all confident\") and 100% (\"totally confident\") where clients are asked to indicate confidence on a scale from 0% to 100%. Higher scores are associated with greater confidence.",
            "timeFrame": "Change from Baseline to Mid-Treatment at 4 weeks; Change from Baseline to Post-treatment at 8 weeks; Change from Baseline to 1-Month Follow-up at 12 weeks"
          },
          {
            "measure": "Usage Rating Profile - Intervention (URPI)-Acceptability",
            "description": "Measure of acceptability. A 9-item subscale that inquires about intervention acceptability. For the purposes of this study, an adapted 6-item version of the subscale was utilized. Items are rated on a 6-point Likert scale (1 = \"strongly disagree\" to 6 = \"strongly agree\"). Total acceptability scores range from 6-36, with higher scores indicating greater intervention acceptability.",
            "timeFrame": "Post-treatment (8 weeks from baseline)"
          },
          {
            "measure": "Usage Rating Profile Intervention - Intervention (URPI)-Feasibility",
            "description": "Measure of feasibility. A 6-item subscale that inquires about factors that impact treatment usage (i.e., intervention quality). Items are rated on a 6-point Likert scale (1 = \"slightly disagree\" to 6 = \"strongly agree\"). Total feasibility scores range from 6-36, with higher scores indicating greater intervention feasibility.",
            "timeFrame": "Post-treatment (8 weeks from baseline)"
          },
          {
            "measure": "Client Satisfaction Questionnaire (CSQ)",
            "description": "Measure of satisfaction. An 8-item measure used to assess client's satisfaction with treatment on a 4-point scale. Example questions include, \"How would you rate the quality of service you received\"? and \"Did you get the kind of service you wanted?\" Total sums range from 8-32, with high scores indicating greater satisfaction with the W-SUDs mobile application.",
            "timeFrame": "Post-treatment (8 weeks from baseline)"
          },
          {
            "measure": "Number of Participants Indicating Substance Use",
            "description": "The alcohol use disorder and substance use disorder (non-alcohol) modules of the Mini-International Neuropsychiatric Interview (MINI) was used to assess a alcohol and substance use diagnosis.",
            "timeFrame": "Baseline"
          },
          {
            "measure": "Number of Participants Providing PEth Sample Phosphatidylethanol (PEth)",
            "description": "Phosphatidylethanol (PEth) is an alcohol biomarker, where a positive result is an indication of alcohol exposure during the 2-4 weeks prior to specimen collection. Participants were asked to complete PEth tests at Baseline and Post-treatment at 8 weeks.",
            "timeFrame": "Baseline and Post-treatment at 8 weeks"
          },
          {
            "measure": "Engagement With Control Condition",
            "description": "Assessment of number of emails opened duration of study",
            "timeFrame": "Baseline to Post-treatment at 8 weeks"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n1. Have a smartphone\n2. Endorse a substance use concern\n3. Be between 18 and 65 years of age\n4. Be available and committed to engage with the Woebot app\n5. Be literate in English.(This is required for inclusion because all materials will be in English).\n\nExclusion Criteria:\n\n1. Pregnancy (as W-SUDs will not be specifically developed to address the unique needs of this population)\n2. Suicide attempt within the past year (12 months)\n3. Symptoms of severe drug/alcohol history: History of delirium tremens; Experiencing hypertension, drenching sweats, seizures or confusion after stopping alcohol or drugs; Liver trouble (cirrhosis or hepatitis); Convulsions or GI bleeding due to drug/alcohol use\n4. Opioid overdose within the past year (12 months)\n5. Opioid misuse without medication-assisted treatment\n6. Not residing in the U.S.\n7. Ever used Woebot",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "maximumAge": "65 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "facility": "Stanford University",
            "city": "Palo Alto",
            "state": "California",
            "zip": "94306",
            "country": "United States",
            "geoPoint": { "lat": 37.44188, "lon": -122.14302 }
          },
          {
            "facility": "Woebot Health",
            "city": "San Francisco",
            "state": "California",
            "zip": "94103",
            "country": "United States",
            "geoPoint": { "lat": 37.77493, "lon": -122.41942 }
          }
        ]
      }
    },
    "resultsSection": {
      "participantFlowModule": {
        "groups": [
          {
            "id": "FG000",
            "title": "W-SUDs",
            "description": "Woebot (W-SUDs), a Conversational Agent (CA) instantaneously available 24 hours per day, 7 days per week, 'checks in' with users. Using conversational tones, it encourages mood tracking and delivers general psychoeducation as well as tailored empathy, cognitive behavior therapy (CBT)-based behavior change tools, and behavioral pattern insight. Woebot's app-based platform and user-centered design philosophy makes it an optimal modality for Substance Use Disorders (SUD) treatment delivery. It offers immediate, evidence-based tailored support in the patient's peak moment of craving.\n\nW-SUDs: Woebot (W-SUDs) is an automated conversational agent, available through a smartphone application, that delivers evidence-based psychotherapeutics, empathy, and emotional health psychoeducation."
          },
          {
            "id": "FG001",
            "title": "Education",
            "description": "Education digitally delivers weekly fact sheets that include information on:\n\n1. Alcohol-specific topics;\n2. Drug-specific topics;\n3. General addiction topics;\n4. Statistics relating to alcohol and substance use.\n\nEducation: The education arm will receive digitally delivered psychoeducation for those seeking treatment for their alcohol and/or substance use concern. Psychoeducation is commonly provided for those with substance use. Psychoeducation in substance use is intended to increase the users' knowledge of their substances of use, and effects on the body, behaviors, and consequences. The recipient of psychoeducation is expected to increase their own awareness of their substance use and ideally incorporate this newfound knowledge when making changes to their substance use. The information provided in this group are from factsheets found on NIAAA, NIDA, and CDC web pages."
          }
        ],
        "periods": [
          {
            "title": "Overall Study",
            "milestones": [
              {
                "type": "STARTED",
                "achievements": [
                  { "groupId": "FG000", "numSubjects": "10" },
                  { "groupId": "FG001", "numSubjects": "10" }
                ]
              },
              {
                "type": "COMPLETED",
                "achievements": [
                  { "groupId": "FG000", "numSubjects": "10" },
                  { "groupId": "FG001", "numSubjects": "10" }
                ]
              },
              {
                "type": "NOT COMPLETED",
                "achievements": [
                  { "groupId": "FG000", "numSubjects": "0" },
                  { "groupId": "FG001", "numSubjects": "0" }
                ]
              }
            ]
          }
        ]
      },
      "baselineCharacteristicsModule": {
        "groups": [
          {
            "id": "BG000",
            "title": "W-SUDs",
            "description": "Woebot (W-SUDs), a Conversational Agent (CA) instantaneously available 24 hours per day, 7 days per week, 'checks in' with users. Using conversational tones, it encourages mood tracking and delivers general psychoeducation as well as tailored empathy, cognitive behavior therapy (CBT)-based behavior change tools, and behavioral pattern insight. Woebot's app-based platform and user-centered design philosophy makes it an optimal modality for Substance Use Disorders (SUD) treatment delivery. It offers immediate, evidence-based tailored support in the patient's peak moment of craving.\n\nW-SUDs: Woebot (W-SUDs) is an automated conversational agent, available through a smartphone application, that delivers evidence-based psychotherapeutics, empathy, and emotional health psychoeducation."
          },
          {
            "id": "BG001",
            "title": "Education",
            "description": "Education digitally delivers weekly fact sheets that include information on:\n\n1. Alcohol-specific topics;\n2. Drug-specific topics;\n3. General addiction topics;\n4. Statistics relating to alcohol and substance use.\n\nEducation: The education arm will receive digitally delivered psychoeducation for those seeking treatment for their alcohol and/or substance use concern. Psychoeducation is commonly provided for those with substance use. Psychoeducation in substance use is intended to increase the users' knowledge of their substances of use, and effects on the body, behaviors, and consequences. The recipient of psychoeducation is expected to increase their own awareness of their substance use and ideally incorporate this newfound knowledge when making changes to their substance use. The information provided in this group are from factsheets found on NIAAA, NIDA, and CDC web pages."
          },
          {
            "id": "BG002",
            "title": "Total",
            "description": "Total of all reporting groups"
          }
        ],
        "denoms": [
          {
            "units": "Participants",
            "counts": [
              { "groupId": "BG000", "value": "10" },
              { "groupId": "BG001", "value": "10" },
              { "groupId": "BG002", "value": "20" }
            ]
          }
        ],
        "measures": [
          {
            "title": "Age, Continuous",
            "paramType": "MEAN",
            "dispersionType": "STANDARD_DEVIATION",
            "unitOfMeasure": "years",
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "BG000", "value": "44.2", "spread": "11.5" },
                      { "groupId": "BG001", "value": "43.3", "spread": "7.8" },
                      { "groupId": "BG002", "value": "43.8", "spread": "9.5" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Sex: Female, Male",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "Female",
                    "measurements": [
                      { "groupId": "BG000", "value": "2" },
                      { "groupId": "BG001", "value": "7" },
                      { "groupId": "BG002", "value": "9" }
                    ]
                  },
                  {
                    "title": "Male",
                    "measurements": [
                      { "groupId": "BG000", "value": "8" },
                      { "groupId": "BG001", "value": "3" },
                      { "groupId": "BG002", "value": "11" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Ethnicity (NIH/OMB)",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "Hispanic or Latino",
                    "measurements": [
                      { "groupId": "BG000", "value": "1" },
                      { "groupId": "BG001", "value": "2" },
                      { "groupId": "BG002", "value": "3" }
                    ]
                  },
                  {
                    "title": "Not Hispanic or Latino",
                    "measurements": [
                      { "groupId": "BG000", "value": "9" },
                      { "groupId": "BG001", "value": "8" },
                      { "groupId": "BG002", "value": "17" }
                    ]
                  },
                  {
                    "title": "Unknown or Not Reported",
                    "measurements": [
                      { "groupId": "BG000", "value": "0" },
                      { "groupId": "BG001", "value": "0" },
                      { "groupId": "BG002", "value": "0" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Race (NIH/OMB)",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "American Indian or Alaska Native",
                    "measurements": [
                      { "groupId": "BG000", "value": "0" },
                      { "groupId": "BG001", "value": "0" },
                      { "groupId": "BG002", "value": "0" }
                    ]
                  },
                  {
                    "title": "Asian",
                    "measurements": [
                      { "groupId": "BG000", "value": "0" },
                      { "groupId": "BG001", "value": "0" },
                      { "groupId": "BG002", "value": "0" }
                    ]
                  },
                  {
                    "title": "Native Hawaiian or Other Pacific Islander",
                    "measurements": [
                      { "groupId": "BG000", "value": "0" },
                      { "groupId": "BG001", "value": "0" },
                      { "groupId": "BG002", "value": "0" }
                    ]
                  },
                  {
                    "title": "Black or African American",
                    "measurements": [
                      { "groupId": "BG000", "value": "2" },
                      { "groupId": "BG001", "value": "2" },
                      { "groupId": "BG002", "value": "4" }
                    ]
                  },
                  {
                    "title": "White",
                    "measurements": [
                      { "groupId": "BG000", "value": "8" },
                      { "groupId": "BG001", "value": "7" },
                      { "groupId": "BG002", "value": "15" }
                    ]
                  },
                  {
                    "title": "More than one race",
                    "measurements": [
                      { "groupId": "BG000", "value": "0" },
                      { "groupId": "BG001", "value": "1" },
                      { "groupId": "BG002", "value": "1" }
                    ]
                  },
                  {
                    "title": "Unknown or Not Reported",
                    "measurements": [
                      { "groupId": "BG000", "value": "0" },
                      { "groupId": "BG001", "value": "0" },
                      { "groupId": "BG002", "value": "0" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Region of Enrollment",
            "paramType": "NUMBER",
            "unitOfMeasure": "participants",
            "classes": [
              {
                "title": "United States",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "BG000", "value": "10" },
                      { "groupId": "BG001", "value": "10" },
                      { "groupId": "BG002", "value": "20" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Gender",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "Man",
                    "measurements": [
                      { "groupId": "BG000", "value": "7" },
                      { "groupId": "BG001", "value": "3" },
                      { "groupId": "BG002", "value": "10" }
                    ]
                  },
                  {
                    "title": "Woman",
                    "measurements": [
                      { "groupId": "BG000", "value": "2" },
                      { "groupId": "BG001", "value": "7" },
                      { "groupId": "BG002", "value": "9" }
                    ]
                  },
                  {
                    "title": "Genderqueer/Gender Non-conforming",
                    "measurements": [
                      { "groupId": "BG000", "value": "1" },
                      { "groupId": "BG001", "value": "0" },
                      { "groupId": "BG002", "value": "1" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Sexual Orientation",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "Heterosexual",
                    "measurements": [
                      { "groupId": "BG000", "value": "8" },
                      { "groupId": "BG001", "value": "10" },
                      { "groupId": "BG002", "value": "18" }
                    ]
                  },
                  {
                    "title": "Gay/Lesbian",
                    "measurements": [
                      { "groupId": "BG000", "value": "2" },
                      { "groupId": "BG001", "value": "0" },
                      { "groupId": "BG002", "value": "2" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Marital Status",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "Married/Partnered/Cohabitating",
                    "measurements": [
                      { "groupId": "BG000", "value": "7" },
                      { "groupId": "BG001", "value": "2" },
                      { "groupId": "BG002", "value": "9" }
                    ]
                  },
                  {
                    "title": "Divorced/Separated",
                    "measurements": [
                      { "groupId": "BG000", "value": "1" },
                      { "groupId": "BG001", "value": "2" },
                      { "groupId": "BG002", "value": "3" }
                    ]
                  },
                  {
                    "title": "Widowed",
                    "measurements": [
                      { "groupId": "BG000", "value": "0" },
                      { "groupId": "BG001", "value": "1" },
                      { "groupId": "BG002", "value": "1" }
                    ]
                  },
                  {
                    "title": "Single",
                    "measurements": [
                      { "groupId": "BG000", "value": "2" },
                      { "groupId": "BG001", "value": "5" },
                      { "groupId": "BG002", "value": "7" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Highest Level of Education",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "Secondary/High School",
                    "measurements": [
                      { "groupId": "BG000", "value": "7" },
                      { "groupId": "BG001", "value": "4" },
                      { "groupId": "BG002", "value": "11" }
                    ]
                  },
                  {
                    "title": "College/University",
                    "measurements": [
                      { "groupId": "BG000", "value": "2" },
                      { "groupId": "BG001", "value": "4" },
                      { "groupId": "BG002", "value": "6" }
                    ]
                  },
                  {
                    "title": "Graduate/Postgraduate",
                    "measurements": [
                      { "groupId": "BG000", "value": "1" },
                      { "groupId": "BG001", "value": "2" },
                      { "groupId": "BG002", "value": "3" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Therapy Experience",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "Experience in therapy",
                    "measurements": [
                      { "groupId": "BG000", "value": "6" },
                      { "groupId": "BG001", "value": "8" },
                      { "groupId": "BG002", "value": "14" }
                    ]
                  },
                  {
                    "title": "No therapy experience",
                    "measurements": [
                      { "groupId": "BG000", "value": "4" },
                      { "groupId": "BG001", "value": "2" },
                      { "groupId": "BG002", "value": "6" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Past 30 Day Therapy",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "Outpatient Services",
                    "measurements": [
                      { "groupId": "BG000", "value": "2" },
                      { "groupId": "BG001", "value": "2" },
                      { "groupId": "BG002", "value": "4" }
                    ]
                  },
                  {
                    "title": "Multiple (self-help, outpatient, residential/inpatient/detox)",
                    "measurements": [
                      { "groupId": "BG000", "value": "0" },
                      { "groupId": "BG001", "value": "1" },
                      { "groupId": "BG002", "value": "1" }
                    ]
                  },
                  {
                    "title": "None",
                    "measurements": [
                      { "groupId": "BG000", "value": "6" },
                      { "groupId": "BG001", "value": "5" },
                      { "groupId": "BG002", "value": "11" }
                    ]
                  },
                  {
                    "title": "Unknown or Not Reported",
                    "measurements": [
                      { "groupId": "BG000", "value": "2" },
                      { "groupId": "BG001", "value": "2" },
                      { "groupId": "BG002", "value": "4" }
                    ]
                  }
                ]
              }
            ]
          }
        ]
      },
      "outcomeMeasuresModule": {
        "outcomeMeasures": [
          {
            "type": "PRIMARY",
            "title": "Change in Number of Substance Use Occasions",
            "description": "Change in number of substance use occasions in the past 30 days",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "occasions",
            "timeFrame": "Change from Baseline to Mid-Treatment at 4 weeks; Change from Baseline to Post-treatment at 8 weeks; Change from Baseline to 1-Month Follow-up at 12 weeks",
            "groups": [
              {
                "id": "OG000",
                "title": "W-SUDs",
                "description": "Woebot (W-SUDs), a Conversational Agent (CA) instantaneously available 24 hours per day, 7 days per week, 'checks in' with users. Using conversational tones, it encourages mood tracking and delivers general psychoeducation as well as tailored empathy, cognitive behavior therapy (CBT)-based behavior change tools, and behavioral pattern insight. Woebot's app-based platform and user-centered design philosophy makes it an optimal modality for Substance Use Disorders (SUD) treatment delivery. It offers immediate, evidence-based tailored support in the patient's peak moment of craving.\n\nW-SUDs: Woebot (W-SUDs) is an automated conversational agent, available through a smartphone application, that delivers evidence-based psychotherapeutics, empathy, and emotional health psychoeducation."
              },
              {
                "id": "OG001",
                "title": "Digitally-delivered Psychoeducation",
                "description": "Psychoeducation digitally delivers weekly fact sheets that include information on:\n\n1. Alcohol-specific topics;\n2. Drug-specific topics;\n3. General addiction topics;\n4. Statistics relating to alcohol and substance use.\n\nPsychoeducation: A form of psychoeducation for those seeking treatment for their alcohol and/or substance use concern. Psychoeducation is commonly provided for those with substance use. Psychoeducation in substance use is intended to increase the users' knowledge of their substances of use, and effects on the body, behaviors, and consequences. The recipient of psychoeducation is expected to increase their own awareness of their substance use and ideally incorporate this newfound knowledge when making changes to their substance use. The information provided in this group are from factsheets found on NIAAA, NIDA, and CDC web pages."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "10" },
                  { "groupId": "OG001", "value": "10" }
                ]
              }
            ],
            "classes": [
              {
                "title": "Baseline to Mid-treatment at 4 weeks",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "-0.6", "spread": "18.3" },
                      { "groupId": "OG001", "value": "-7.2", "spread": "28.3" }
                    ]
                  }
                ]
              },
              {
                "title": "Baseline to Post-treatment at 8 weeks",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "-3.9", "spread": "20.6" },
                      { "groupId": "OG001", "value": "-6.7", "spread": "27.8" }
                    ]
                  }
                ]
              },
              {
                "title": "Baseline to 1-month Follow-up at 12 weeks",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "-4.9", "spread": "21.3" },
                      { "groupId": "OG001", "value": "-6.6", "spread": "37.8" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Past Month Average Days Per Week of Drinking Alcohol",
            "description": "Assessed with the Quick Drinking Screen (QDS), a measure of alcohol consumption. The QDS is a brief self-report measure used to assess average alcohol consumption over a specified time period (in the present study it was the past 30 days). The QDS collects drinking data for three variables including number of days drinking, number of standard drinks per drinking day, and number of binge/risky drinking days. Binge/risky drinking days is defined as days when they have had 5 or more standard drinks (for men) or 4 or more standard drinks (for women).",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "days per week",
            "timeFrame": "Change from Baseline to Mid-Treatment at 4 weeks; Change from Baseline to Post-treatment at 8 weeks; Change from Baseline to 1-Month Follow-up at 12 weeks",
            "groups": [
              {
                "id": "OG000",
                "title": "W-SUDs",
                "description": "Woebot (W-SUDs), a Conversational Agent (CA) instantaneously available 24 hours per day, 7 days per week, 'checks in' with users. Using conversational tones, it encourages mood tracking and delivers general psychoeducation as well as tailored empathy, cognitive behavior therapy (CBT)-based behavior change tools, and behavioral pattern insight. Woebot's app-based platform and user-centered design philosophy makes it an optimal modality for Substance Use Disorders (SUD) treatment delivery. It offers immediate, evidence-based tailored support in the patient's peak moment of craving.\n\nW-SUDs: Woebot (W-SUDs) is an automated conversational agent, available through a smartphone application, that delivers evidence-based psychotherapeutics, empathy, and emotional health psychoeducation."
              },
              {
                "id": "OG001",
                "title": "Digitally-delivered Psychoeducation",
                "description": "Psychoeducation digitally delivers weekly fact sheets that include information on:\n\n1. Alcohol-specific topics;\n2. Drug-specific topics;\n3. General addiction topics;\n4. Statistics relating to alcohol and substance use.\n\nDigitally-delivered Psychoeducation: A form of psychoeducation for those seeking treatment for their alcohol and/or substance use concern. Psychoeducation is commonly provided for those with substance use. Psychoeducation in substance use is intended to increase the users' knowledge of their substances of use, and effects on the body, behaviors, and consequences. The recipient of psychoeducation is expected to increase their own awareness of their substance use and ideally incorporate this newfound knowledge when making changes to their substance use. The information provided in this group are from factsheets found on NIAAA, NIDA, and CDC web pages."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "10" },
                  { "groupId": "OG001", "value": "10" }
                ]
              }
            ],
            "classes": [
              {
                "title": "Baseline to Mid-treatment at 4 weeks: Past month average days per week of drinking alcohol",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "-0.4", "spread": "0.9" },
                      { "groupId": "OG001", "value": "-2.4", "spread": "2.6" }
                    ]
                  }
                ]
              },
              {
                "title": "Baseline to Post-treatment at 8 weeks: Past month average days per week of drinking alcohol",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "-0.2", "spread": "0.8" },
                      { "groupId": "OG001", "value": "-1.6", "spread": "2.7" }
                    ]
                  }
                ]
              },
              {
                "title": "Baseline to 1-month Follow-up at 12 weeks: Past month average days per week of drinking alcohol",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "-0.6", "spread": "1.7" },
                      { "groupId": "OG001", "value": "-1.4", "spread": "2.7" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Past Month Average Standard Drinks in a Day",
            "description": "Assessed with the Quick Drinking Screen (QDS), a measure of alcohol consumption. The QDS is a brief self-report measure used to assess average alcohol consumption over a specified time period (in the present study it was the past 30 days). The QDS collects drinking data for three variables including number of days drinking, number of standard drinks per drinking day, and number of binge/risky drinking days. Binge/risky drinking days is defined as days when they have had 5 or more standard drinks (for men) or 4 or more standard drinks (for women).",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "drinks per drinking day",
            "timeFrame": "Change from Baseline to Mid-Treatment at 4 weeks; Change from Baseline to Post-treatment at 8 weeks; Change from Baseline to 1-Month Follow-up at 12 weeks",
            "groups": [
              {
                "id": "OG000",
                "title": "W-SUDs",
                "description": "Woebot (W-SUDs), a Conversational Agent (CA) instantaneously available 24 hours per day, 7 days per week, 'checks in' with users. Using conversational tones, it encourages mood tracking and delivers general psychoeducation as well as tailored empathy, cognitive behavior therapy (CBT)-based behavior change tools, and behavioral pattern insight. Woebot's app-based platform and user-centered design philosophy makes it an optimal modality for Substance Use Disorders (SUD) treatment delivery. It offers immediate, evidence-based tailored support in the patient's peak moment of craving.\n\nW-SUDs: Woebot (W-SUDs) is an automated conversational agent, available through a smartphone application, that delivers evidence-based psychotherapeutics, empathy, and emotional health psychoeducation."
              },
              {
                "id": "OG001",
                "title": "Digitally-delivered Psychoeducation",
                "description": "Psychoeducation digitally delivers weekly fact sheets that include information on:\n\n1. Alcohol-specific topics;\n2. Drug-specific topics;\n3. General addiction topics;\n4. Statistics relating to alcohol and substance use.\n\nDigitally-delivered Psychoeducation: A form of psychoeducation for those seeking treatment for their alcohol and/or substance use concern. Psychoeducation is commonly provided for those with substance use. Psychoeducation in substance use is intended to increase the users' knowledge of their substances of use, and effects on the body, behaviors, and consequences. The recipient of psychoeducation is expected to increase their own awareness of their substance use and ideally incorporate this newfound knowledge when making changes to their substance use. The information provided in this group are from factsheets found on NIAAA, NIDA, and CDC web pages."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "10" },
                  { "groupId": "OG001", "value": "10" }
                ]
              }
            ],
            "classes": [
              {
                "title": "Baseline to Mid-treatment at 4 weeks: Past month average standard drinks in a day",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "1.6", "spread": "2.5" },
                      { "groupId": "OG001", "value": "-1.0", "spread": "3.0" }
                    ]
                  }
                ]
              },
              {
                "title": "Baseline to Post-treatment at 8 weeks: Past month average standard drinks in a day",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "-0.3", "spread": "0.8" },
                      { "groupId": "OG001", "value": "-1.1", "spread": "2.8" }
                    ]
                  }
                ]
              },
              {
                "title": "Baseline to 1-month Follow-up at 12 weeks: Past month average standard drinks in a day",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "-2.4", "spread": "6.0" },
                      { "groupId": "OG001", "value": "-0.8", "spread": "3.0" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Past Month Number of Binge Days",
            "description": "Assessed with the Quick Drinking Screen (QDS), a measure of alcohol consumption. The QDS is a brief self-report measure used to assess average alcohol consumption over a specified time period (in the present study it was the past 30 days). The QDS collects drinking data for three variables including number of days drinking, number of standard drinks per drinking day, and number of binge/risky drinking days. Binge/risky drinking days is defined as days when they have had 5 or more standard drinks (for men) or 4 or more standard drinks (for women).",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "days",
            "timeFrame": "Change from Baseline to Mid-Treatment at 4 weeks; Change from Baseline to Post-treatment at 8 weeks; Change from Baseline to 1-Month Follow-up at 12 weeks",
            "groups": [
              {
                "id": "OG000",
                "title": "W-SUDs",
                "description": "Woebot (W-SUDs), a Conversational Agent (CA) instantaneously available 24 hours per day, 7 days per week, 'checks in' with users. Using conversational tones, it encourages mood tracking and delivers general psychoeducation as well as tailored empathy, cognitive behavior therapy (CBT)-based behavior change tools, and behavioral pattern insight. Woebot's app-based platform and user-centered design philosophy makes it an optimal modality for Substance Use Disorders (SUD) treatment delivery. It offers immediate, evidence-based tailored support in the patient's peak moment of craving.\n\nW-SUDs: Woebot (W-SUDs) is an automated conversational agent, available through a smartphone application, that delivers evidence-based psychotherapeutics, empathy, and emotional health psychoeducation."
              },
              {
                "id": "OG001",
                "title": "Digitally-delivered Psychoeducation",
                "description": "Psychoeducation digitally delivers weekly fact sheets that include information on:\n\n1. Alcohol-specific topics;\n2. Drug-specific topics;\n3. General addiction topics;\n4. Statistics relating to alcohol and substance use.\n\nDigitally-delivered Psychoeducation: A form of psychoeducation for those seeking treatment for their alcohol and/or substance use concern. Psychoeducation is commonly provided for those with substance use. Psychoeducation in substance use is intended to increase the users' knowledge of their substances of use, and effects on the body, behaviors, and consequences. The recipient of psychoeducation is expected to increase their own awareness of their substance use and ideally incorporate this newfound knowledge when making changes to their substance use. The information provided in this group are from factsheets found on NIAAA, NIDA, and CDC web pages."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "10" },
                  { "groupId": "OG001", "value": "10" }
                ]
              }
            ],
            "classes": [
              {
                "title": "Baseline to Mid-treatment at 4 weeks: Past month number of binge days",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "4", "spread": "11.6" },
                      { "groupId": "OG001", "value": "-1.3", "spread": "9.0" }
                    ]
                  }
                ]
              },
              {
                "title": "Baseline to Post-treatment at 8 weeks: Past month number of binge days",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "2.0", "spread": "9.9" },
                      { "groupId": "OG001", "value": "-7.4", "spread": "9.6" }
                    ]
                  }
                ]
              },
              {
                "title": "Baseline to 1-month Follow-up at 12 weeks: Past month number of binge days",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "-3.7", "spread": "7.3" },
                      { "groupId": "OG001", "value": "-4.1", "spread": "11.1" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Past Month Average Standard Drinks in a Week",
            "description": "Assessed with the Quick Drinking Screen (QDS), a measure of alcohol consumption. The QDS is a brief self-report measure used to assess average alcohol consumption over a specified time period (in the present study it was the past 30 days). The QDS collects drinking data for three variables including number of days drinking, number of standard drinks per drinking day, and number of binge/risky drinking days. Binge/risky drinking days is defined as days when they have had 5 or more standard drinks (for men) or 4 or more standard drinks (for women). Number of standard drinks per week is calculated by multiplying number of standard drinks per day in the past month and number of binge days per month.",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "drinks per week",
            "timeFrame": "Change from Baseline to Mid-Treatment at 4 weeks; Change from Baseline to Post-treatment at 8 weeks; Change from Baseline to 1-Month Follow-up at 12 weeks",
            "groups": [
              {
                "id": "OG000",
                "title": "W-SUDs",
                "description": "Woebot (W-SUDs), a Conversational Agent (CA) instantaneously available 24 hours per day, 7 days per week, 'checks in' with users. Using conversational tones, it encourages mood tracking and delivers general psychoeducation as well as tailored empathy, cognitive behavior therapy (CBT)-based behavior change tools, and behavioral pattern insight. Woebot's app-based platform and user-centered design philosophy makes it an optimal modality for Substance Use Disorders (SUD) treatment delivery. It offers immediate, evidence-based tailored support in the patient's peak moment of craving.\n\nW-SUDs: Woebot (W-SUDs) is an automated conversational agent, available through a smartphone application, that delivers evidence-based psychotherapeutics, empathy, and emotional health psychoeducation."
              },
              {
                "id": "OG001",
                "title": "Digitally-delivered Psychoeducation",
                "description": "Psychoeducation digitally delivers weekly fact sheets that include information on:\n\n1. Alcohol-specific topics;\n2. Drug-specific topics;\n3. General addiction topics;\n4. Statistics relating to alcohol and substance use.\n\nDigitally-delivered Psychoeducation: A form of psychoeducation for those seeking treatment for their alcohol and/or substance use concern. Psychoeducation is commonly provided for those with substance use. Psychoeducation in substance use is intended to increase the users' knowledge of their substances of use, and effects on the body, behaviors, and consequences. The recipient of psychoeducation is expected to increase their own awareness of their substance use and ideally incorporate this newfound knowledge when making changes to their substance use. The information provided in this group are from factsheets found on NIAAA, NIDA, and CDC web pages."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "10" },
                  { "groupId": "OG001", "value": "10" }
                ]
              }
            ],
            "classes": [
              {
                "title": "Baseline to Mid-treatment at 4 weeks: Past month average standard drinks in a week",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "8.2", "spread": "19.2" },
                      { "groupId": "OG001", "value": "-8.0", "spread": "14.2" }
                    ]
                  }
                ]
              },
              {
                "title": "Baseline to Post-treatment at 8 weeks: Past month average standard drinks in a week",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "-2.3", "spread": "4.1" },
                      { "groupId": "OG001", "value": "-6.7", "spread": "13.8" }
                    ]
                  }
                ]
              },
              {
                "title": "Baseline to 1-month Follow-up at 12 weeks: Past month average standard drinks in a week",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-10.3",
                        "spread": "17.2"
                      },
                      { "groupId": "OG001", "value": "-4.6", "spread": "16.2" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Short Inventory of Problems- Alcohol and Drugs (SIP-AD)",
            "description": "The SIP-AD assesses substance use problems in the past 30 days. The scored variables, total scores and 15-item mean, summarize consequences of alcohol and drug use. Scores range from 0-45, where greater scores indicate greater substance use problems.",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "Change from Baseline to Mid-Treatment at 4 weeks; Change from Baseline to Post-treatment at 8 weeks; Change from Baseline to 1-Month Follow-up at 12 weeks",
            "groups": [
              {
                "id": "OG000",
                "title": "W-SUDs",
                "description": "Woebot (W-SUDs), a Conversational Agent (CA) instantaneously available 24 hours per day, 7 days per week, 'checks in' with users. Using conversational tones, it encourages mood tracking and delivers general psychoeducation as well as tailored empathy, cognitive behavior therapy (CBT)-based behavior change tools, and behavioral pattern insight. Woebot's app-based platform and user-centered design philosophy makes it an optimal modality for Substance Use Disorders (SUD) treatment delivery. It offers immediate, evidence-based tailored support in the patient's peak moment of craving.\n\nW-SUDs: Woebot (W-SUDs) is an automated conversational agent, available through a smartphone application, that delivers evidence-based psychotherapeutics, empathy, and emotional health psychoeducation."
              },
              {
                "id": "OG001",
                "title": "Digitally-delivered Psychoeducation",
                "description": "Psychoeducation digitally delivers weekly fact sheets that include information on:\n\n1. Alcohol-specific topics;\n2. Drug-specific topics;\n3. General addiction topics;\n4. Statistics relating to alcohol and substance use.\n\nDigitally-delivered Psychoeducation: A form of psychoeducation for those seeking treatment for their alcohol and/or substance use concern. Psychoeducation is commonly provided for those with substance use. Psychoeducation in substance use is intended to increase the users' knowledge of their substances of use, and effects on the body, behaviors, and consequences. The recipient of psychoeducation is expected to increase their own awareness of their substance use and ideally incorporate this newfound knowledge when making changes to their substance use. The information provided in this group are from factsheets found on NIAAA, NIDA, and CDC web pages."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "10" },
                  { "groupId": "OG001", "value": "10" }
                ]
              }
            ],
            "classes": [
              {
                "title": "Baseline to Mid-Treatment at 4 weeks",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "-7.6", "spread": "9.2" },
                      { "groupId": "OG001", "value": "-1.1", "spread": "10.5" }
                    ]
                  }
                ]
              },
              {
                "title": "Baseline to Post-treatment at 8 weeks",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "-7.4", "spread": "8.4" },
                      { "groupId": "OG001", "value": "-4.0", "spread": "13.3" }
                    ]
                  }
                ]
              },
              {
                "title": "Baseline to 1-Month Follow-up at 12 weeks",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "-9.6", "spread": "8.1" },
                      { "groupId": "OG001", "value": "-4.4", "spread": "12.7" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Craving Ratings",
            "description": "Self-reported ratings of craving intensity. Craving is assessed with a single question, \"In the past 7 days, how much were you bothered by cravings or urges to drink alcohol or use drugs?\". The question is rated on a scale of 0 to 4 where 0 = not at all, 1 = a little bit, 2 = moderately, 3 = quite a bit, and 4 = extremely. Greater scores indicate a more intense urge to use.",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "Change from Baseline to Mid-Treatment at 4 weeks; Change from Baseline to Post-treatment at 8 weeks; Change from Baseline to 1-Month Follow-up at 12 weeks",
            "groups": [
              {
                "id": "OG000",
                "title": "W-SUDs",
                "description": "Woebot (W-SUDs), a Conversational Agent (CA) instantaneously available 24 hours per day, 7 days per week, 'checks in' with users. Using conversational tones, it encourages mood tracking and delivers general psychoeducation as well as tailored empathy, cognitive behavior therapy (CBT)-based behavior change tools, and behavioral pattern insight. Woebot's app-based platform and user-centered design philosophy makes it an optimal modality for Substance Use Disorders (SUD) treatment delivery. It offers immediate, evidence-based tailored support in the patient's peak moment of craving.\n\nW-SUDs: Woebot (W-SUDs) is an automated conversational agent, available through a smartphone application, that delivers evidence-based psychotherapeutics, empathy, and emotional health psychoeducation."
              },
              {
                "id": "OG001",
                "title": "Digitally-delivered Psychoeducation",
                "description": "Psychoeducation digitally delivers weekly fact sheets that include information on:\n\n1. Alcohol-specific topics;\n2. Drug-specific topics;\n3. General addiction topics;\n4. Statistics relating to alcohol and substance use.\n\nDigitally-delivered Psychoeducation: A form of psychoeducation for those seeking treatment for their alcohol and/or substance use concern. Psychoeducation is commonly provided for those with substance use. Psychoeducation in substance use is intended to increase the users' knowledge of their substances of use, and effects on the body, behaviors, and consequences. The recipient of psychoeducation is expected to increase their own awareness of their substance use and ideally incorporate this newfound knowledge when making changes to their substance use. The information provided in this group are from factsheets found on NIAAA, NIDA, and CDC web pages."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "10" },
                  { "groupId": "OG001", "value": "10" }
                ]
              }
            ],
            "classes": [
              {
                "title": "Baseline to Mid-Treatment at 4 weeks",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "-0.1", "spread": "0.7" },
                      { "groupId": "OG001", "value": "0.0", "spread": "1.2" }
                    ]
                  }
                ]
              },
              {
                "title": "Baseline to Post-treatment at 8 weeks",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "-0.3", "spread": "0.7" },
                      { "groupId": "OG001", "value": "-0.1", "spread": "1.4" }
                    ]
                  }
                ]
              },
              {
                "title": "Baseline to 1-Month Follow-up at 12 weeks",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "-0.3", "spread": "0.8" },
                      { "groupId": "OG001", "value": "-0.3", "spread": "1.3" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Working Alliance Inventory (WAI-SR)",
            "description": "Measure of working alliance. A measure of therapeutic alliance that assesses three key aspects of the therapeutic alliance: (a) agreement on the tasks of therapy, (b) agreement on the goals of therapy and (c) development of an affective bond. Task, goal, and bond subscales scores range from 5-20, with higher scores indicating greater alliance. The present study utilized the validated 12-item Short-Revised version (WAI-SR) with minor changes to language, replacing \"therapist\" with \"Woebot\".",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "Difference between Mid-treatment at 4 weeks and Post-treatment at 8 weeks",
            "groups": [
              {
                "id": "OG000",
                "title": "W-SUDs",
                "description": "Woebot (W-SUDs), a Conversational Agent (CA) instantaneously available 24 hours per day, 7 days per week, 'checks in' with users. Using conversational tones, it encourages mood tracking and delivers general psychoeducation as well as tailored empathy, cognitive behavior therapy (CBT)-based behavior change tools, and behavioral pattern insight. Woebot's app-based platform and user-centered design philosophy makes it an optimal modality for Substance Use Disorders (SUD) treatment delivery. It offers immediate, evidence-based tailored support in the patient's peak moment of craving.\n\nW-SUDs: Woebot (W-SUDs) is an automated conversational agent, available through a smartphone application, that delivers evidence-based psychotherapeutics, empathy, and emotional health psychoeducation."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [{ "groupId": "OG000", "value": "8" }]
              }
            ],
            "classes": [
              {
                "title": "Goal",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "0.14", "spread": "4.56" }
                    ]
                  }
                ]
              },
              {
                "title": "Task",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "0.57", "spread": "5.03" }
                    ]
                  }
                ]
              },
              {
                "title": "Bond",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "1.57", "spread": "3.95" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Stanford Presenteeism Scale (SPS-6)",
            "description": "Measure of the effects of substance use on productivity. The SPS-6 is a 6-item self-report measure used to assess perceptions of the effects of substance use on past 2-week work productivity. Response options range from strongly disagree (1) to strongly agree (5). Total scores range from 6 to 30, where higher scores indicate higher presenteeism.",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "Change from Baseline to Post-treatment at 8 weeks",
            "groups": [
              {
                "id": "OG000",
                "title": "W-SUDs",
                "description": "Woebot (W-SUDs), a Conversational Agent (CA) instantaneously available 24 hours per day, 7 days per week, 'checks in' with users. Using conversational tones, it encourages mood tracking and delivers general psychoeducation as well as tailored empathy, cognitive behavior therapy (CBT)-based behavior change tools, and behavioral pattern insight. Woebot's app-based platform and user-centered design philosophy makes it an optimal modality for Substance Use Disorders (SUD) treatment delivery. It offers immediate, evidence-based tailored support in the patient's peak moment of craving.\n\nW-SUDs: Woebot (W-SUDs) is an automated conversational agent, available through a smartphone application, that delivers evidence-based psychotherapeutics, empathy, and emotional health psychoeducation."
              },
              {
                "id": "OG001",
                "title": "Digitally-delivered Psychoeducation",
                "description": "Psychoeducation digitally delivers weekly fact sheets that include information on:\n\n1. Alcohol-specific topics;\n2. Drug-specific topics;\n3. General addiction topics;\n4. Statistics relating to alcohol and substance use.\n\nDigitally-delivered Psychoeducation: A form of psychoeducation for those seeking treatment for their alcohol and/or substance use concern. Psychoeducation is commonly provided for those with substance use. Psychoeducation in substance use is intended to increase the users' knowledge of their substances of use, and effects on the body, behaviors, and consequences. The recipient of psychoeducation is expected to increase their own awareness of their substance use and ideally incorporate this newfound knowledge when making changes to their substance use. The information provided in this group are from factsheets found on NIAAA, NIDA, and CDC web pages."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "6" },
                  { "groupId": "OG001", "value": "6" }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "2.3", "spread": "3.7" },
                      { "groupId": "OG001", "value": "2.7", "spread": "3.4" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Thoughts About Abstinence (TAA)",
            "description": "Modified for alcohol and substances. 5-item questionnaire assessing desire to quit, expected success at quitting, expected difficulty of quitting, and confidence in ability to quit. Each item is rated on a scale of 1 to 10 where 1 is the lowest (desire, expectation, confidence) and 10 is the highest (desire, expectation, confidence).",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "Change from Baseline to Post-treatment at 8 weeks",
            "groups": [
              {
                "id": "OG000",
                "title": "W-SUDs",
                "description": "Woebot (W-SUDs), a Conversational Agent (CA) instantaneously available 24 hours per day, 7 days per week, 'checks in' with users. Using conversational tones, it encourages mood tracking and delivers general psychoeducation as well as tailored empathy, cognitive behavior therapy (CBT)-based behavior change tools, and behavioral pattern insight. Woebot's app-based platform and user-centered design philosophy makes it an optimal modality for Substance Use Disorders (SUD) treatment delivery. It offers immediate, evidence-based tailored support in the patient's peak moment of craving.\n\nW-SUDs: Woebot (W-SUDs) is an automated conversational agent, available through a smartphone application, that delivers evidence-based psychotherapeutics, empathy, and emotional health psychoeducation."
              },
              {
                "id": "OG001",
                "title": "Digitally-delivered Psychoeducation",
                "description": "Psychoeducation digitally delivers weekly fact sheets that include information on:\n\n1. Alcohol-specific topics;\n2. Drug-specific topics;\n3. General addiction topics;\n4. Statistics relating to alcohol and substance use.\n\nDigitally-delivered Psychoeducation: A form of psychoeducation for those seeking treatment for their alcohol and/or substance use concern. Psychoeducation is commonly provided for those with substance use. Psychoeducation in substance use is intended to increase the users' knowledge of their substances of use, and effects on the body, behaviors, and consequences. The recipient of psychoeducation is expected to increase their own awareness of their substance use and ideally incorporate this newfound knowledge when making changes to their substance use. The information provided in this group are from factsheets found on NIAAA, NIDA, and CDC web pages."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "8" },
                  { "groupId": "OG001", "value": "10" }
                ]
              }
            ],
            "classes": [
              {
                "title": "Desire to quit",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "-0.8", "spread": "1.4" },
                      { "groupId": "OG001", "value": "1.4", "spread": "2.0" }
                    ]
                  }
                ]
              },
              {
                "title": "Perceived success in quitting",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "0.4", "spread": "2.3" },
                      { "groupId": "OG001", "value": "-0.8", "spread": "1.9" }
                    ]
                  }
                ]
              },
              {
                "title": "Difficulty in staying quit",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "0.6", "spread": "3.7" },
                      { "groupId": "OG001", "value": "-0.6", "spread": "2.8" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "CAIR Pandemic Impact Questionnaire (C-PIQ)",
            "description": "Assesses impact of the COVID-19 pandemic in terms of exposure to stressors, mental health impact and growth. Exposure domain total scores range from 0-15, with higher scores indicating greater exposure. Impact domain total scores range from 0-23, where greater scores are related to greater impact.",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "Change from Baseline to Post-treatment at 8 weeks",
            "groups": [
              {
                "id": "OG000",
                "title": "W-SUDs",
                "description": "Woebot (W-SUDs), a Conversational Agent (CA) instantaneously available 24 hours per day, 7 days per week, 'checks in' with users. Using conversational tones, it encourages mood tracking and delivers general psychoeducation as well as tailored empathy, cognitive behavior therapy (CBT)-based behavior change tools, and behavioral pattern insight. Woebot's app-based platform and user-centered design philosophy makes it an optimal modality for Substance Use Disorders (SUD) treatment delivery. It offers immediate, evidence-based tailored support in the patient's peak moment of craving.\n\nW-SUDs: Woebot (W-SUDs) is an automated conversational agent, available through a smartphone application, that delivers evidence-based psychotherapeutics, empathy, and emotional health psychoeducation."
              },
              {
                "id": "OG001",
                "title": "Digitally-delivered Psychoeducation",
                "description": "Psychoeducation digitally delivers weekly fact sheets that include information on:\n\n1. Alcohol-specific topics;\n2. Drug-specific topics;\n3. General addiction topics;\n4. Statistics relating to alcohol and substance use.\n\nDigitally-delivered Psychoeducation: A form of psychoeducation for those seeking treatment for their alcohol and/or substance use concern. Psychoeducation is commonly provided for those with substance use. Psychoeducation in substance use is intended to increase the users' knowledge of their substances of use, and effects on the body, behaviors, and consequences. The recipient of psychoeducation is expected to increase their own awareness of their substance use and ideally incorporate this newfound knowledge when making changes to their substance use. The information provided in this group are from factsheets found on NIAAA, NIDA, and CDC web pages."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "8" },
                  { "groupId": "OG001", "value": "10" }
                ]
              }
            ],
            "classes": [
              {
                "title": "Exposure",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "-1.1", "spread": "1.7" },
                      { "groupId": "OG001", "value": "0.1", "spread": "0.6" }
                    ]
                  }
                ]
              },
              {
                "title": "Impact",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "-2.8", "spread": "2.4" },
                      { "groupId": "OG001", "value": "-1.3", "spread": "1.3" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Patient Health Questionnaire (PHQ-8)",
            "description": "Measure of depression severity. An 8-item abbreviated version of the PHQ-9 used to assess mood symptoms. The PHQ-8 excludes an item assessing suicidality. Items are rated on a 4-point Likert scale (0 = \"not at all\" to 3 = \"nearly every day\"). Total score between 0-24, with higher scores indicating greater severity of depression symptoms.",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "Change from Baseline to Mid-Treatment at 4 weeks; Change from Baseline to Post-treatment at 8 weeks; Change from Baseline to 1-Month Follow-up at 12 weeks",
            "groups": [
              {
                "id": "OG000",
                "title": "W-SUDs",
                "description": "Woebot (W-SUDs), a Conversational Agent (CA) instantaneously available 24 hours per day, 7 days per week, 'checks in' with users. Using conversational tones, it encourages mood tracking and delivers general psychoeducation as well as tailored empathy, cognitive behavior therapy (CBT)-based behavior change tools, and behavioral pattern insight. Woebot's app-based platform and user-centered design philosophy makes it an optimal modality for Substance Use Disorders (SUD) treatment delivery. It offers immediate, evidence-based tailored support in the patient's peak moment of craving.\n\nW-SUDs: Woebot (W-SUDs) is an automated conversational agent, available through a smartphone application, that delivers evidence-based psychotherapeutics, empathy, and emotional health psychoeducation."
              },
              {
                "id": "OG001",
                "title": "Digitally-delivered Psychoeducation",
                "description": "Psychoeducation digitally delivers weekly fact sheets that include information on:\n\n1. Alcohol-specific topics;\n2. Drug-specific topics;\n3. General addiction topics;\n4. Statistics relating to alcohol and substance use.\n\nDigitally-delivered Psychoeducation: A form of psychoeducation for those seeking treatment for their alcohol and/or substance use concern. Psychoeducation is commonly provided for those with substance use. Psychoeducation in substance use is intended to increase the users' knowledge of their substances of use, and effects on the body, behaviors, and consequences. The recipient of psychoeducation is expected to increase their own awareness of their substance use and ideally incorporate this newfound knowledge when making changes to their substance use. The information provided in this group are from factsheets found on NIAAA, NIDA, and CDC web pages."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "10" },
                  { "groupId": "OG001", "value": "10" }
                ]
              }
            ],
            "classes": [
              {
                "title": "Baseline to Mid-treatment at 4 weeks",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "-3.9", "spread": "6.3" },
                      { "groupId": "OG001", "value": "-2.0", "spread": "5.2" }
                    ]
                  }
                ]
              },
              {
                "title": "Baseline to Post-treatment at 8 weeks",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "-1.9", "spread": "4.4" },
                      { "groupId": "OG001", "value": "-1.2", "spread": "6.5" }
                    ]
                  }
                ]
              },
              {
                "title": "Baseline to 1-month Follow-up at 12 weeks",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "-1.4", "spread": "4.2" },
                      { "groupId": "OG001", "value": "-2.9", "spread": "5.2" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Generalized Anxiety Disorder (GAD-7)",
            "description": "Measure of anxiety severity. A 7-item self-report measure used to assess the frequency and severity of anxious thoughts and behaviors over the past 2 weeks. Items are rated on a 4-point Likert scale (0 = \"not at all\" to 3 = \"nearly every day\").Total scores range from 0-21, where higher scores indicate greater severity of anxiety symptoms.",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "Change from Baseline to Mid-Treatment at 4 weeks; Change from Baseline to Post-treatment at 8 weeks; Change from Baseline to 1-Month Follow-up at 12 weeks",
            "groups": [
              {
                "id": "OG000",
                "title": "W-SUDs",
                "description": "Woebot (W-SUDs), a Conversational Agent (CA) instantaneously available 24 hours per day, 7 days per week, 'checks in' with users. Using conversational tones, it encourages mood tracking and delivers general psychoeducation as well as tailored empathy, cognitive behavior therapy (CBT)-based behavior change tools, and behavioral pattern insight. Woebot's app-based platform and user-centered design philosophy makes it an optimal modality for Substance Use Disorders (SUD) treatment delivery. It offers immediate, evidence-based tailored support in the patient's peak moment of craving.\n\nW-SUDs: Woebot (W-SUDs) is an automated conversational agent, available through a smartphone application, that delivers evidence-based psychotherapeutics, empathy, and emotional health psychoeducation."
              },
              {
                "id": "OG001",
                "title": "Digitally-delivered Psychoeducation",
                "description": "Psychoeducation digitally delivers weekly fact sheets that include information on:\n\n1. Alcohol-specific topics;\n2. Drug-specific topics;\n3. General addiction topics;\n4. Statistics relating to alcohol and substance use.\n\nDigitally-delivered Psychoeducation: A form of psychoeducation for those seeking treatment for their alcohol and/or substance use concern. Psychoeducation is commonly provided for those with substance use. Psychoeducation in substance use is intended to increase the users' knowledge of their substances of use, and effects on the body, behaviors, and consequences. The recipient of psychoeducation is expected to increase their own awareness of their substance use and ideally incorporate this newfound knowledge when making changes to their substance use. The information provided in this group are from factsheets found on NIAAA, NIDA, and CDC web pages."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "10" },
                  { "groupId": "OG001", "value": "10" }
                ]
              }
            ],
            "classes": [
              {
                "title": "Baseline to Mid-treatment at 4 weeks",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "-3.4", "spread": "4.2" },
                      { "groupId": "OG001", "value": "0.6", "spread": "3.7" }
                    ]
                  }
                ]
              },
              {
                "title": "Baseline to Post-treatment at 8 weeks",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "-0.6", "spread": "2.2" },
                      { "groupId": "OG001", "value": "-0.2", "spread": "4.3" }
                    ]
                  }
                ]
              },
              {
                "title": "Baseline to 1-month Follow-up at 12 weeks",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "-2.7", "spread": "2.7" },
                      { "groupId": "OG001", "value": "0.6", "spread": "3.3" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Brief Situational Confidence Questionnaire (BSCQ)",
            "description": "Measure of self-confidence. The 8-item BSCQ is a state dependent measure that assesses self-confidence to resist the urge to drink heavily or use drugs in a variety of situations. Each of the 8 scale situations consists of a 100-mm line, anchored by 0% (\"not at all confident\") and 100% (\"totally confident\") where clients are asked to indicate confidence on a scale from 0% to 100%. Higher scores are associated with greater confidence.",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "Change from Baseline to Mid-Treatment at 4 weeks; Change from Baseline to Post-treatment at 8 weeks; Change from Baseline to 1-Month Follow-up at 12 weeks",
            "groups": [
              {
                "id": "OG000",
                "title": "W-SUDs",
                "description": "Woebot (W-SUDs), a Conversational Agent (CA) instantaneously available 24 hours per day, 7 days per week, 'checks in' with users. Using conversational tones, it encourages mood tracking and delivers general psychoeducation as well as tailored empathy, cognitive behavior therapy (CBT)-based behavior change tools, and behavioral pattern insight. Woebot's app-based platform and user-centered design philosophy makes it an optimal modality for Substance Use Disorders (SUD) treatment delivery. It offers immediate, evidence-based tailored support in the patient's peak moment of craving.\n\nW-SUDs: Woebot (W-SUDs) is an automated conversational agent, available through a smartphone application, that delivers evidence-based psychotherapeutics, empathy, and emotional health psychoeducation."
              },
              {
                "id": "OG001",
                "title": "Digitally-delivered Psychoeducation",
                "description": "Psychoeducation digitally delivers weekly fact sheets that include information on:\n\n1. Alcohol-specific topics;\n2. Drug-specific topics;\n3. General addiction topics;\n4. Statistics relating to alcohol and substance use.\n\nDigitally-delivered Psychoeducation: A form of psychoeducation for those seeking treatment for their alcohol and/or substance use concern. Psychoeducation is commonly provided for those with substance use. Psychoeducation in substance use is intended to increase the users' knowledge of their substances of use, and effects on the body, behaviors, and consequences. The recipient of psychoeducation is expected to increase their own awareness of their substance use and ideally incorporate this newfound knowledge when making changes to their substance use. The information provided in this group are from factsheets found on NIAAA, NIDA, and CDC web pages."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "10" },
                  { "groupId": "OG001", "value": "10" }
                ]
              }
            ],
            "classes": [
              {
                "title": "Baseline to Mid-treatment at 4 weeks",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "10.9", "spread": "9.5" },
                      { "groupId": "OG001", "value": "20.7", "spread": "21.1" }
                    ]
                  }
                ]
              },
              {
                "title": "Baseline to Post-treatment at 8 weeks",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "10.9", "spread": "12.8" },
                      { "groupId": "OG001", "value": "18.9", "spread": "21.2" }
                    ]
                  }
                ]
              },
              {
                "title": "Baseline to 1-month Follow-up at 12 weeks",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "9.2", "spread": "10.3" },
                      { "groupId": "OG001", "value": "20.7", "spread": "20.9" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Usage Rating Profile - Intervention (URPI)-Acceptability",
            "description": "Measure of acceptability. A 9-item subscale that inquires about intervention acceptability. For the purposes of this study, an adapted 6-item version of the subscale was utilized. Items are rated on a 6-point Likert scale (1 = \"strongly disagree\" to 6 = \"strongly agree\"). Total acceptability scores range from 6-36, with higher scores indicating greater intervention acceptability.",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "Post-treatment (8 weeks from baseline)",
            "groups": [
              {
                "id": "OG000",
                "title": "W-SUDs",
                "description": "Woebot (W-SUDs), a Conversational Agent (CA) instantaneously available 24 hours per day, 7 days per week, 'checks in' with users. Using conversational tones, it encourages mood tracking and delivers general psychoeducation as well as tailored empathy, cognitive behavior therapy (CBT)-based behavior change tools, and behavioral pattern insight. Woebot's app-based platform and user-centered design philosophy makes it an optimal modality for Substance Use Disorders (SUD) treatment delivery. It offers immediate, evidence-based tailored support in the patient's peak moment of craving.\n\nW-SUDs: Woebot (W-SUDs) is an automated conversational agent, available through a smartphone application, that delivers evidence-based psychotherapeutics, empathy, and emotional health psychoeducation."
              },
              {
                "id": "OG001",
                "title": "Digitally-delivered Psychoeducation",
                "description": "Psychoeducation digitally delivers weekly fact sheets that include information on:\n\n1. Alcohol-specific topics;\n2. Drug-specific topics;\n3. General addiction topics;\n4. Statistics relating to alcohol and substance use.\n\nDigitally-delivered Psychoeducation: A form of psychoeducation for those seeking treatment for their alcohol and/or substance use concern. Psychoeducation is commonly provided for those with substance use. Psychoeducation in substance use is intended to increase the users' knowledge of their substances of use, and effects on the body, behaviors, and consequences. The recipient of psychoeducation is expected to increase their own awareness of their substance use and ideally incorporate this newfound knowledge when making changes to their substance use. The information provided in this group are from factsheets found on NIAAA, NIDA, and CDC web pages."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "8" },
                  { "groupId": "OG001", "value": "10" }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "24.1", "spread": "6.2" },
                      { "groupId": "OG001", "value": "27.4", "spread": "8.4" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Usage Rating Profile Intervention - Intervention (URPI)-Feasibility",
            "description": "Measure of feasibility. A 6-item subscale that inquires about factors that impact treatment usage (i.e., intervention quality). Items are rated on a 6-point Likert scale (1 = \"slightly disagree\" to 6 = \"strongly agree\"). Total feasibility scores range from 6-36, with higher scores indicating greater intervention feasibility.",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "Post-treatment (8 weeks from baseline)",
            "groups": [
              {
                "id": "OG000",
                "title": "W-SUDs",
                "description": "Woebot (W-SUDs), a Conversational Agent (CA) instantaneously available 24 hours per day, 7 days per week, 'checks in' with users. Using conversational tones, it encourages mood tracking and delivers general psychoeducation as well as tailored empathy, cognitive behavior therapy (CBT)-based behavior change tools, and behavioral pattern insight. Woebot's app-based platform and user-centered design philosophy makes it an optimal modality for Substance Use Disorders (SUD) treatment delivery. It offers immediate, evidence-based tailored support in the patient's peak moment of craving.\n\nW-SUDs: Woebot (W-SUDs) is an automated conversational agent, available through a smartphone application, that delivers evidence-based psychotherapeutics, empathy, and emotional health psychoeducation."
              },
              {
                "id": "OG001",
                "title": "Digitally-delivered Psychoeducation",
                "description": "Psychoeducation digitally delivers weekly fact sheets that include information on:\n\n1. Alcohol-specific topics;\n2. Drug-specific topics;\n3. General addiction topics;\n4. Statistics relating to alcohol and substance use.\n\nDigitally-delivered Psychoeducation: A form of psychoeducation for those seeking treatment for their alcohol and/or substance use concern. Psychoeducation is commonly provided for those with substance use. Psychoeducation in substance use is intended to increase the users' knowledge of their substances of use, and effects on the body, behaviors, and consequences. The recipient of psychoeducation is expected to increase their own awareness of their substance use and ideally incorporate this newfound knowledge when making changes to their substance use. The information provided in this group are from factsheets found on NIAAA, NIDA, and CDC web pages."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "8" },
                  { "groupId": "OG001", "value": "10" }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "27.4", "spread": "5.3" },
                      { "groupId": "OG001", "value": "34.2", "spread": "2.7" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Client Satisfaction Questionnaire (CSQ)",
            "description": "Measure of satisfaction. An 8-item measure used to assess client's satisfaction with treatment on a 4-point scale. Example questions include, \"How would you rate the quality of service you received\"? and \"Did you get the kind of service you wanted?\" Total sums range from 8-32, with high scores indicating greater satisfaction with the W-SUDs mobile application.",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "Post-treatment (8 weeks from baseline)",
            "groups": [
              {
                "id": "OG000",
                "title": "W-SUDs",
                "description": "Woebot (W-SUDs), a Conversational Agent (CA) instantaneously available 24 hours per day, 7 days per week, 'checks in' with users. Using conversational tones, it encourages mood tracking and delivers general psychoeducation as well as tailored empathy, cognitive behavior therapy (CBT)-based behavior change tools, and behavioral pattern insight. Woebot's app-based platform and user-centered design philosophy makes it an optimal modality for Substance Use Disorders (SUD) treatment delivery. It offers immediate, evidence-based tailored support in the patient's peak moment of craving.\n\nW-SUDs: Woebot (W-SUDs) is an automated conversational agent, available through a smartphone application, that delivers evidence-based psychotherapeutics, empathy, and emotional health psychoeducation."
              },
              {
                "id": "OG001",
                "title": "Digitally-delivered Psychoeducation",
                "description": "Psychoeducation digitally delivers weekly fact sheets that include information on:\n\n1. Alcohol-specific topics;\n2. Drug-specific topics;\n3. General addiction topics;\n4. Statistics relating to alcohol and substance use.\n\nDigitally-delivered Psychoeducation: A form of psychoeducation for those seeking treatment for their alcohol and/or substance use concern. Psychoeducation is commonly provided for those with substance use. Psychoeducation in substance use is intended to increase the users' knowledge of their substances of use, and effects on the body, behaviors, and consequences. The recipient of psychoeducation is expected to increase their own awareness of their substance use and ideally incorporate this newfound knowledge when making changes to their substance use. The information provided in this group are from factsheets found on NIAAA, NIDA, and CDC web pages."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "8" },
                  { "groupId": "OG001", "value": "10" }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "23.4", "spread": "5.5" },
                      { "groupId": "OG001", "value": "26.1", "spread": "6.6" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Number of Participants Indicating Substance Use",
            "description": "The alcohol use disorder and substance use disorder (non-alcohol) modules of the Mini-International Neuropsychiatric Interview (MINI) was used to assess a alcohol and substance use diagnosis.",
            "reportingStatus": "POSTED",
            "paramType": "NUMBER",
            "unitOfMeasure": "participants",
            "timeFrame": "Baseline",
            "groups": [
              {
                "id": "OG000",
                "title": "W-SUDs",
                "description": "Woebot (W-SUDs), a Conversational Agent (CA) instantaneously available 24 hours per day, 7 days per week, 'checks in' with users. Using conversational tones, it encourages mood tracking and delivers general psychoeducation as well as tailored empathy, cognitive behavior therapy (CBT)-based behavior change tools, and behavioral pattern insight. Woebot's app-based platform and user-centered design philosophy makes it an optimal modality for Substance Use Disorders (SUD) treatment delivery. It offers immediate, evidence-based tailored support in the patient's peak moment of craving.\n\nW-SUDs: Woebot (W-SUDs) is an automated conversational agent, available through a smartphone application, that delivers evidence-based psychotherapeutics, empathy, and emotional health psychoeducation."
              },
              {
                "id": "OG001",
                "title": "Digitally-delivered Psychoeducation",
                "description": "Psychoeducation digitally delivers weekly fact sheets that include information on:\n\n1. Alcohol-specific topics;\n2. Drug-specific topics;\n3. General addiction topics;\n4. Statistics relating to alcohol and substance use.\n\nDigitally-delivered Psychoeducation: A form of psychoeducation for those seeking treatment for their alcohol and/or substance use concern. Psychoeducation is commonly provided for those with substance use. Psychoeducation in substance use is intended to increase the users' knowledge of their substances of use, and effects on the body, behaviors, and consequences. The recipient of psychoeducation is expected to increase their own awareness of their substance use and ideally incorporate this newfound knowledge when making changes to their substance use. The information provided in this group are from factsheets found on NIAAA, NIDA, and CDC web pages."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "8" },
                  { "groupId": "OG001", "value": "6" }
                ]
              }
            ],
            "classes": [
              {
                "title": "Alcohol (mild)",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "0" },
                      { "groupId": "OG001", "value": "1" }
                    ]
                  }
                ]
              },
              {
                "title": "Alcohol (moderate)",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "1" },
                      { "groupId": "OG001", "value": "2" }
                    ]
                  }
                ]
              },
              {
                "title": "Alcohol (severe)",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "4" },
                      { "groupId": "OG001", "value": "3" }
                    ]
                  }
                ]
              },
              {
                "title": "Stimulant (severe)",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "3" },
                      { "groupId": "OG001", "value": "0" }
                    ]
                  }
                ]
              },
              {
                "title": "Cocaine (moderate)",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "0" },
                      { "groupId": "OG001", "value": "1" }
                    ]
                  }
                ]
              },
              {
                "title": "Hallucinogen (mild)",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "0" },
                      { "groupId": "OG001", "value": "1" }
                    ]
                  }
                ]
              },
              {
                "title": "Inhalant (mild)",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "1" },
                      { "groupId": "OG001", "value": "0" }
                    ]
                  }
                ]
              },
              {
                "title": "Cannabis (moderate)",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "1" },
                      { "groupId": "OG001", "value": "0" }
                    ]
                  }
                ]
              },
              {
                "title": "Cannabis (severe)",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "3" },
                      { "groupId": "OG001", "value": "2" }
                    ]
                  }
                ]
              },
              {
                "title": "Sedatives (mild)",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "1" },
                      { "groupId": "OG001", "value": "0" }
                    ]
                  }
                ]
              },
              {
                "title": "Sedatives (severe)",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "1" },
                      { "groupId": "OG001", "value": "0" }
                    ]
                  }
                ]
              },
              {
                "title": "Multiple Diagnoses",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "5" },
                      { "groupId": "OG001", "value": "2" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Number of Participants Providing PEth Sample Phosphatidylethanol (PEth)",
            "description": "Phosphatidylethanol (PEth) is an alcohol biomarker, where a positive result is an indication of alcohol exposure during the 2-4 weeks prior to specimen collection. Participants were asked to complete PEth tests at Baseline and Post-treatment at 8 weeks.",
            "reportingStatus": "POSTED",
            "paramType": "NUMBER",
            "unitOfMeasure": "participants",
            "timeFrame": "Baseline and Post-treatment at 8 weeks",
            "groups": [
              {
                "id": "OG000",
                "title": "W-SUDs",
                "description": "Woebot (W-SUDs), a Conversational Agent (CA) instantaneously available 24 hours per day, 7 days per week, 'checks in' with users. Using conversational tones, it encourages mood tracking and delivers general psychoeducation as well as tailored empathy, cognitive behavior therapy (CBT)-based behavior change tools, and behavioral pattern insight. Woebot's app-based platform and user-centered design philosophy makes it an optimal modality for Substance Use Disorders (SUD) treatment delivery. It offers immediate, evidence-based tailored support in the patient's peak moment of craving.\n\nW-SUDs: Woebot (W-SUDs) is an automated conversational agent, available through a smartphone application, that delivers evidence-based psychotherapeutics, empathy, and emotional health psychoeducation."
              },
              {
                "id": "OG001",
                "title": "Digitally-delivered Psychoeducation",
                "description": "Psychoeducation digitally delivers weekly fact sheets that include information on:\n\n1. Alcohol-specific topics;\n2. Drug-specific topics;\n3. General addiction topics;\n4. Statistics relating to alcohol and substance use.\n\nDigitally-delivered Psychoeducation: A form of psychoeducation for those seeking treatment for their alcohol and/or substance use concern. Psychoeducation is commonly provided for those with substance use. Psychoeducation in substance use is intended to increase the users' knowledge of their substances of use, and effects on the body, behaviors, and consequences. The recipient of psychoeducation is expected to increase their own awareness of their substance use and ideally incorporate this newfound knowledge when making changes to their substance use. The information provided in this group are from factsheets found on NIAAA, NIDA, and CDC web pages."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "10" },
                  { "groupId": "OG001", "value": "10" }
                ]
              }
            ],
            "classes": [
              {
                "title": "PEth completed at Baseline",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "5" },
                      { "groupId": "OG001", "value": "5" }
                    ]
                  }
                ]
              },
              {
                "title": "PEth completed at Post-treatment at 8 weeks",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "3" },
                      { "groupId": "OG001", "value": "4" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Engagement With Control Condition",
            "description": "Assessment of number of emails opened duration of study",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "emails",
            "timeFrame": "Baseline to Post-treatment at 8 weeks",
            "groups": [
              {
                "id": "OG000",
                "title": "Digitally-delivered Psychoeducation",
                "description": "Psychoeducation digitally delivers weekly fact sheets that include information on:\n\n1. Alcohol-specific topics;\n2. Drug-specific topics;\n3. General addiction topics;\n4. Statistics relating to alcohol and substance use.\n\nDigitally-delivered Psychoeducation: A form of psychoeducation for those seeking treatment for their alcohol and/or substance use concern. Psychoeducation is commonly provided for those with substance use. Psychoeducation in substance use is intended to increase the users' knowledge of their substances of use, and effects on the body, behaviors, and consequences. The recipient of psychoeducation is expected to increase their own awareness of their substance use and ideally incorporate this newfound knowledge when making changes to their substance use. The information provided in this group are from factsheets found on NIAAA, NIDA, and CDC web pages."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [{ "groupId": "OG000", "value": "10" }]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "6.7", "spread": "2.4" }
                    ]
                  }
                ]
              }
            ]
          }
        ]
      },
      "adverseEventsModule": {
        "frequencyThreshold": "0",
        "timeFrame": "Serious adverse events were assessed at post-treatment and follow-up at 8-weeks and 12-weeks from baseline, respectively.",
        "description": "Serious adverse events occurring during treatment were assessed for hospitalization related to substance use, suicide attempt, alcohol or drug overdose, and severe withdrawal (e.g., delirium tremens). Positive endorsements were followed up with questions about the timing, diagnosis, and resolution. If additional details were needed to determine whether the event was study related, a team member reached out to the participant.",
        "eventGroups": [
          {
            "id": "EG000",
            "title": "W-SUDs",
            "description": "Woebot (W-SUDs), a Conversational Agent (CA) instantaneously available 24 hours per day, 7 days per week, 'checks in' with users. Using conversational tones, it encourages mood tracking and delivers general psychoeducation as well as tailored empathy, cognitive behavior therapy (CBT)-based behavior change tools, and behavioral pattern insight. Woebot's app-based platform and user-centered design philosophy makes it an optimal modality for Substance Use Disorders (SUD) treatment delivery. It offers immediate, evidence-based tailored support in the patient's peak moment of craving.\n\nW-SUDs: Woebot (W-SUDs) is an automated conversational agent, available through a smartphone application, that delivers evidence-based psychotherapeutics, empathy, and emotional health psychoeducation.",
            "deathsNumAffected": 0,
            "deathsNumAtRisk": 10,
            "seriousNumAffected": 0,
            "seriousNumAtRisk": 10,
            "otherNumAffected": 0,
            "otherNumAtRisk": 10
          },
          {
            "id": "EG001",
            "title": "Digitally-delivered Psychoeducation",
            "description": "Psychoeducation digitally delivers weekly fact sheets that include information on:\n\n1. Alcohol-specific topics;\n2. Drug-specific topics;\n3. General addiction topics;\n4. Statistics relating to alcohol and substance use.\n\nDigitally-delivered Psychoeducation: A form of psychoeducation for those seeking treatment for their alcohol and/or substance use concern. Psychoeducation is commonly provided for those with substance use. Psychoeducation in substance use is intended to increase the users' knowledge of their substances of use, and effects on the body, behaviors, and consequences. The recipient of psychoeducation is expected to increase their own awareness of their substance use and ideally incorporate this newfound knowledge when making changes to their substance use. The information provided in this group are from factsheets found on NIAAA, NIDA, and CDC web pages.",
            "deathsNumAffected": 0,
            "deathsNumAtRisk": 10,
            "seriousNumAffected": 0,
            "seriousNumAtRisk": 10,
            "otherNumAffected": 0,
            "otherNumAtRisk": 10
          }
        ]
      },
      "moreInfoModule": {
        "certainAgreement": {
          "piSponsorEmployee": false,
          "restrictiveAgreement": false
        },
        "pointOfContact": {
          "title": "Judith J. Prochaska, PhD, MPH",
          "organization": "Stanford Prevention Research Center, Department of Medicine, Stanford",
          "email": "jpro@stanford.edu",
          "phone": "650-724-3608"
        }
      }
    },
    "documentSection": {
      "largeDocumentModule": {
        "largeDocs": [
          {
            "typeAbbrev": "Prot",
            "hasProtocol": true,
            "hasSap": false,
            "hasIcf": false,
            "label": "Study Protocol",
            "date": "2022-04-13",
            "uploadDate": "2022-04-29T12:32",
            "filename": "Prot_000.pdf",
            "size": 275295
          },
          {
            "typeAbbrev": "SAP",
            "hasProtocol": false,
            "hasSap": true,
            "hasIcf": false,
            "label": "Statistical Analysis Plan",
            "date": "2023-12-12",
            "uploadDate": "2023-12-12T14:24",
            "filename": "SAP_002.pdf",
            "size": 43288
          },
          {
            "typeAbbrev": "ICF",
            "hasProtocol": false,
            "hasSap": false,
            "hasIcf": true,
            "label": "Informed Consent Form",
            "date": "2021-09-15",
            "uploadDate": "2021-11-01T15:44",
            "filename": "ICF_001.pdf",
            "size": 330212
          }
        ]
      }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [
          { "id": "D019966", "term": "Substance-Related Disorders" },
          { "id": "D000437", "term": "Alcoholism" }
        ],
        "ancestors": [
          { "id": "D064419", "term": "Chemically-Induced Disorders" },
          { "id": "D001523", "term": "Mental Disorders" },
          { "id": "D019973", "term": "Alcohol-Related Disorders" }
        ],
        "browseLeaves": [
          { "id": "M3774", "name": "Alcohol Drinking", "relevance": "LOW" },
          {
            "id": "M21837",
            "name": "Substance-Related Disorders",
            "asFound": "Substance Use",
            "relevance": "HIGH"
          },
          {
            "id": "M3783",
            "name": "Alcoholism",
            "asFound": "Alcohol Use Disorder",
            "relevance": "HIGH"
          },
          {
            "id": "M30302",
            "name": "Chemically-Induced Disorders",
            "relevance": "LOW"
          },
          { "id": "M14473", "name": "Psychotic Disorders", "relevance": "LOW" },
          { "id": "M4815", "name": "Mental Disorders", "relevance": "LOW" },
          {
            "id": "M21842",
            "name": "Alcohol-Related Disorders",
            "relevance": "LOW"
          }
        ],
        "browseBranches": [
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" },
          { "abbrev": "All", "name": "All Conditions" },
          { "abbrev": "BC25", "name": "Substance Related Disorders" }
        ]
      },
      "interventionBrowseModule": {
        "browseLeaves": [
          { "id": "M3777", "name": "Ethanol", "relevance": "LOW" },
          { "id": "M14474", "name": "Psychotropic Drugs", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "Infe", "name": "Anti-Infective Agents" },
          { "abbrev": "CNSDep", "name": "Central Nervous System Depressants" },
          { "abbrev": "All", "name": "All Drugs and Chemicals" },
          { "abbrev": "PsychDr", "name": "Psychotropic Drugs" }
        ]
      }
    },
    "hasResults": true
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT06878859",
        "orgStudyIdInfo": { "id": "2025p000583" },
        "organization": {
          "fullName": "Massachusetts General Hospital",
          "class": "OTHER"
        },
        "briefTitle": "Preliminary Efficacy Trial of a Digital Intervention for Depression and Cannabis Use",
        "officialTitle": "AMP-C: a Digital Therapeutic for Reward Dysfunction in Co-Occurring Depression and Cannabis Use"
      },
      "statusModule": {
        "statusVerifiedDate": "2025-03",
        "overallStatus": "NOT_YET_RECRUITING",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2025-10", "type": "ESTIMATED" },
        "primaryCompletionDateStruct": {
          "date": "2027-12",
          "type": "ESTIMATED"
        },
        "completionDateStruct": { "date": "2030-03", "type": "ESTIMATED" },
        "studyFirstSubmitDate": "2025-03-06",
        "studyFirstSubmitQcDate": "2025-03-10",
        "studyFirstPostDateStruct": { "date": "2025-03-17", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2025-03-10",
        "lastUpdatePostDateStruct": { "date": "2025-03-17", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": {
          "type": "PRINCIPAL_INVESTIGATOR",
          "investigatorFullName": "Amanda C. Collins",
          "investigatorTitle": "Principal Investigator",
          "investigatorAffiliation": "Massachusetts General Hospital"
        },
        "leadSponsor": {
          "name": "Massachusetts General Hospital",
          "class": "OTHER"
        }
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": false,
        "isUsExport": false
      },
      "descriptionModule": {
        "briefSummary": "The purpose of this study is to examine the feasibility, acceptability, and preliminary efficacy of a digital intervention for co-occurring cannabis use and depression. Participants will be randomized to complete Amplification of Positivity - Cannabis Use (AMP-C) or symptom tracking. The main outcomes will include participant acceptability and usability ratings, completion rates and compliance, positive affect, substance use, and depression severity."
      },
      "conditionsModule": {
        "conditions": [
          "Depression - Major Depressive Disorder",
          "Cannabis Use Disorder",
          "Mental Disorder"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": {
            "masking": "SINGLE",
            "whoMasked": ["OUTCOMES_ASSESSOR"]
          }
        },
        "enrollmentInfo": { "count": 80, "type": "ESTIMATED" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "Amplification of Positivity - Cannabis Use (AMP-C)",
            "type": "EXPERIMENTAL",
            "interventionNames": [
              "Behavioral: Amplification of Positivity - Cannabis Use (AMP-C)"
            ]
          },
          { "label": "Symptom Tracking", "type": "NO_INTERVENTION" }
        ],
        "interventions": [
          {
            "type": "BEHAVIORAL",
            "name": "Amplification of Positivity - Cannabis Use (AMP-C)",
            "description": "AMP-C is a smartphone-based digital intervention that includes activities that focus on positivity (e.g., noticing and capitalizing on positive events) to increase positive emotions, thoughts, and behaviors. The role and impact of CU on the maintenance of depression and reward dysfunction (and vice versa), is intertwined throughout the intervention.",
            "armGroupLabels": [
              "Amplification of Positivity - Cannabis Use (AMP-C)"
            ]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Usability (System Usability Scale; SUS)",
            "description": "The System Usability Scale (SUS) is a 10-item self-report measure commonly used to assess the degree to which participants endorse ease of use following task-based operation of computer systems (i.e., perceived usability). Total scores on the SUS range from 0 to 100, with greater scores indicating greater usability.",
            "timeFrame": "Post-Intervention (approximately one week after completing intervention)"
          },
          {
            "measure": "Intervention Feasibility (App Usage)",
            "description": "Feasibility will be measured through app usage time (hours).",
            "timeFrame": "Post-Intervention (approximately one week after completing intervention)"
          },
          {
            "measure": "Change in Depressive Symptoms (Patient Health Questionnaire-9; PHQ-9)",
            "description": "Depressive symptoms will be measured with the Patient Health Questionnaire-9 (PHQ-9). The PHQ-9 is a widely-used 9-item self-report measure that assesses depressive symptom severity over the previous two weeks. Scores on the PHQ-9 range from 0-27, with greater scores indicating greater depression severity.",
            "timeFrame": "Baseline, Primary Endpoint: Post-Intervention (approximately one week after completing intervention), Secondary Endpoints: 1-, 3-, 6-, and 12-months after completing intervention"
          },
          {
            "measure": "Change in Cannabis Use (Daily Sessions, Frequency, Age of Onset, and Quantity of Cannabis Use Inventory; DFAQ-CU)",
            "description": "Cannabis use will be measured with the Daily Sessions, Frequency, Age of Onset, and Quantity of Cannabis Use Inventory (DFAQ-CU). The DFAQ-CU is a 24-item self-report measure that assesses frequency, age of onset, and quantity of cannabis use. There are six factors: daily sessions, frequency, age of onset, marijuana quantity, concentrate quantity, and edible quantity. The six factors, except age of onset, are independently scored, and higher scores indicate greater cannabis use.",
            "timeFrame": "Baseline, Primary Endpoint: Post-Intervention (approximately one week after completing intervention), Secondary Endpoints: 1-, 3-, 6-, and 12-months after completing intervention"
          },
          {
            "measure": "Acceptability (Treatment Adherence and Acceptability Scale; TAAS)",
            "description": "The Treatment Adherence and Acceptability Scale (TAAS) is a 10-item self-report measure developed to assess (a) the degree to which a client finds a treatment to be acceptable, and (b) self-reported likelihood a client anticipates they will adhere to proposed treatment procedures. A total score, ranging from 7-70, is calculated by summing all items with greater scores indicating greater acceptability.",
            "timeFrame": "Pre-Intervention (Baseline)"
          },
          {
            "measure": "Changes in Daily Depressive Symptoms (Mobile Patient Health Questionnaire-9; MPHQ-9)",
            "description": "Daily depressive symptoms will be measured with the Mobile Patient Health Questionnaire-9 (MPHQ-9). The MPHQ-9 is a modified version of the paper PHQ-9, which has been used in intensive sampling studies. Participants answer questions regarding their experience with the nine symptoms of MDD over the past 24 hours on a sliding scale. Total scores range from 0-900, with greater scores representing greater depression severity.",
            "timeFrame": "Daily for 8 weeks during intervention"
          },
          {
            "measure": "Changes in Daily Cannabis Use",
            "description": "Daily cannabis use will be measured with a series of questions related to cannabis use consumption. These questions will capture frequency, quantity, product types, potencies, and administration methods of cannabis over the past 24 hours.",
            "timeFrame": "Daily for 8 weeks during intervention"
          },
          {
            "measure": "Feasibility (Engagement)",
            "description": "Feasibility will be measured through the number of modules completed.",
            "timeFrame": "Post-Intervention (approximately one week after completing intervention)"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Change in Positive Affect (Positive and Negative Affect Schedule; PANAS-PA)",
            "description": "The Positive and Negative Affect Schedule (PANAS) is a 20-item self-report measure that assesses affect for the current day. The PANAS has two subscales (10 items each) that represent overall positive affect (PA) and overall negative affect (NA). Total scores range from 20-100 (or 10-50 for each subscale), with greater scores representing greater affect.",
            "timeFrame": "Baseline, Primary Endpoint: Post-Intervention (approximately one week after completing intervention), Secondary Endpoints: 1-, 3-, 6-, and 12-months after completing intervention"
          },
          {
            "measure": "Change in Alcohol Use (Drinking Motives Questionnaire-Revised; DMQR)",
            "description": "Reasons for drinking alcohol will be measured with the Drinking Motives Questionnaire-Revised (DMQR). The DMQR is a 20-item self-report measure that assesses common reasons for why people might drink alcohol. There are four subscales: Social, Coping, Enhancement, and Conformity. Subscale scores range from 1-25, with greater scores representing greater endorsement of specific reasons for drinking alcohol.",
            "timeFrame": "Baseline, Primary Endpoint: Post-Intervention (approximately one week after completing intervention), Secondary Endpoints: 1-, 3-, 6-, and 12-months after completing intervention"
          },
          {
            "measure": "Change in Substance Use (Timeline Followback; TLFB)",
            "description": "Broader substance use will be measured with the Timeline Followback (TLFB). The TLFB is a self-report measure that assesses substance use and related behaviors over the past 30 days. Participants will be asked to identify the number of days over the 30 days in which they have consumed alcohol, tobacco/nicotine, opioids, stimulants, hallucinogens, sedatives/depressives, inhalants, and other illicit or prescription drugs. Total scores are not calculated, but the outcomes of interest include number of days per substance, with greater scores indicating a higher number of days of substance use in the past 30 days.",
            "timeFrame": "Baseline, Primary Endpoint: Post-Intervention (approximately one week after completing intervention), Secondary Endpoints: 1-, 3-, 6-, and 12-months after completing intervention"
          },
          {
            "measure": "Change in Anticipatory and Consummatory Anhedonia (Temporal Experience of Pleasure Scale; TEPS)",
            "description": "Anticipatory and consummatory anhedonia will be measured with the Temporal Experience of Pleasure Scale (TEPS). The TEPS is a 18-item self-report measure that assesses reward anticipation (e.g., motivation) and responsiveness (e.g., pleasure). There are two subscales in the TEPS: anticipatory anhedonia and consummatory anhedonia. Scores on the anticipatory subscale range from 10 to 60, and scores on the consummatory subscale range from 8 to 48. Higher scores indicate greater pleasure.",
            "timeFrame": "Baseline, Primary Endpoint: Post-Intervention (approximately one week after completing intervention), Secondary Endpoints: 1-, 3-, 6-, and 12-months after completing intervention"
          },
          {
            "measure": "Change in Anhedonia (Specific Loss of Interest and Pleasure Scale; SLIPS)",
            "description": "Recent changes in anhedonia will be measured with the Specific Loss of Interest and Pleasure Scale (SLIPS). The SLIPS is a 23-item self-report measure that assesses for changes in anhedonia over the previous two weeks. Total scores on the SLIPS range from 0-46, with greater scores indicating greater changes in anhedonia over the previous two weeks.",
            "timeFrame": "Post-Intervention (approximately one week after completing intervention)"
          },
          {
            "measure": "Change in Anxiety Symptoms (Generalized Anxiety Disorder-7; GAD-7)",
            "description": "Anxiety symptoms will be measured with the Generalized Anxiety Disorder-7 (GAD-7). The GAD-7 is a 7-item self-report measure that assesses anxiety symptom severity over the previous two weeks. Total scores range from 0-21, with higher scores representing higher anxiety severity.",
            "timeFrame": "Baseline, Primary Endpoint: Post-Intervention (approximately one week after completing intervention), Secondary Endpoints: 1-, 3-, 6-, and 12-months after completing intervention"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* Aged ≥ 18 years\n* Resides in the United States\n* Able to read and understand English and willing to provide informed consent/comply with the study protocol\n* Moderate depressive symptom severity, as indicated by the Patient Health Questionnaire-9 (PHQ-9)\n* Problematic cannabis use, as indicated by the Cannabis Use Disorder Identification Test - Revised (CUDIT-R)\n* Current elevated anhedonia, as indicated by the PHQ-9\n* Interest in receiving treatment for their cannabis use and/or depression\n* Meet criteria for current MDD and CUD per the DSM-5\n\nExclusion Criteria:\n\n* History of a psychotic disorder or bipolar disorder type I/II\n* Active suicidal ideation or intent based on the Columbia-Suicide Severity Rating Scale\n* Current psychotherapy engagement\n* Changes in psychotropic medication within six weeks of the start of study",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "centralContacts": [
          {
            "name": "Amanda C Collins, PhD",
            "role": "CONTACT",
            "phone": "617-726-4034",
            "email": "accollins@mgh.harvard.edu"
          }
        ],
        "locations": [
          {
            "facility": "Massachusetts General Hospital",
            "city": "Boston",
            "state": "Massachusetts",
            "zip": "02114",
            "country": "United States",
            "contacts": [
              {
                "name": "Amanda C Collins, PhD",
                "role": "CONTACT",
                "phone": "617-726-4034",
                "email": "accollins@mgh.harvard.edu"
              },
              { "name": "Amanda C Collins, PhD", "role": "CONTACT" }
            ],
            "geoPoint": { "lat": 42.35843, "lon": -71.05977 }
          }
        ]
      },
      "ipdSharingStatementModule": { "ipdSharing": "NO" }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [
          { "id": "D002189", "term": "Marijuana Abuse" },
          { "id": "D003863", "term": "Depression" },
          { "id": "D003866", "term": "Depressive Disorder" },
          { "id": "D003865", "term": "Depressive Disorder, Major" },
          { "id": "D001523", "term": "Mental Disorders" }
        ],
        "ancestors": [
          { "id": "D001526", "term": "Behavioral Symptoms" },
          { "id": "D019964", "term": "Mood Disorders" },
          { "id": "D019966", "term": "Substance-Related Disorders" },
          { "id": "D064419", "term": "Chemically-Induced Disorders" }
        ],
        "browseLeaves": [
          { "id": "M14473", "name": "Psychotic Disorders", "relevance": "LOW" },
          {
            "id": "M4815",
            "name": "Mental Disorders",
            "asFound": "Mental Disorders",
            "relevance": "HIGH"
          },
          {
            "id": "M7061",
            "name": "Depressive Disorder",
            "asFound": "Depression",
            "relevance": "HIGH"
          },
          {
            "id": "M7060",
            "name": "Depressive Disorder, Major",
            "asFound": "Major Depressive Disorder",
            "relevance": "HIGH"
          },
          {
            "id": "M7058",
            "name": "Depression",
            "asFound": "Depression",
            "relevance": "HIGH"
          },
          {
            "id": "M5449",
            "name": "Marijuana Abuse",
            "asFound": "Cannabis",
            "relevance": "HIGH"
          },
          { "id": "M4818", "name": "Behavioral Symptoms", "relevance": "LOW" },
          { "id": "M21835", "name": "Mood Disorders", "relevance": "LOW" },
          {
            "id": "M21837",
            "name": "Substance-Related Disorders",
            "relevance": "LOW"
          },
          {
            "id": "M30302",
            "name": "Chemically-Induced Disorders",
            "relevance": "LOW"
          }
        ],
        "browseBranches": [
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" },
          { "abbrev": "All", "name": "All Conditions" },
          { "abbrev": "BC25", "name": "Substance Related Disorders" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT03103880",
        "nctIdAliases": ["NCT05712863"],
        "orgStudyIdInfo": { "id": "2017 Observational Study 1.0" },
        "organization": { "fullName": "CoheroHealth", "class": "INDUSTRY" },
        "briefTitle": "Assessing the Use of Mobile Technology in Adult Asthma Patients",
        "officialTitle": "Assessing the Use of Digital Therapeutic in Adult Asthma Patients: A Remote Observational Study"
      },
      "statusModule": {
        "statusVerifiedDate": "2024-07",
        "overallStatus": "COMPLETED",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2017-04-21", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2018-08-29",
          "type": "ACTUAL"
        },
        "completionDateStruct": { "date": "2018-08-29", "type": "ACTUAL" },
        "studyFirstSubmitDate": "2017-03-28",
        "studyFirstSubmitQcDate": "2017-03-31",
        "studyFirstPostDateStruct": { "date": "2017-04-06", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2024-07-29",
        "lastUpdatePostDateStruct": { "date": "2024-07-30", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": { "name": "CoheroHealth", "class": "INDUSTRY" }
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": true,
        "isUsExport": false
      },
      "descriptionModule": {
        "briefSummary": "This is a prospective, remote observational study of adults with persistent asthma who are managed on inhaled corticosteroids.",
        "detailedDescription": "The study consists of one interventional group and all 104 subjects will be included in this group. All subjects will be provided with the HeroTracker package, which includes:\n\n1. HeroTracker sensor that counts dosage and monitors real-time medication adherence\n2. BreatheSmart mobile application that sends subjects real-time alerts and allows patients respond to questionnaires / surveys."
      },
      "conditionsModule": {
        "conditions": ["Asthma"],
        "keywords": [
          "Patient adherence",
          "Mobile application",
          "Mobile health",
          "Digital therapeutics",
          "Digital health"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "NA",
          "interventionModel": "SINGLE_GROUP",
          "primaryPurpose": "HEALTH_SERVICES_RESEARCH",
          "maskingInfo": { "masking": "NONE" }
        },
        "enrollmentInfo": { "count": 104, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "BreatheSmart",
            "type": "EXPERIMENTAL",
            "description": "104 subjects will be provided with the BreatheSmart platform, which consists of:\n\n1. HeroTracker sensor that monitors real-time asthma medication adherence\n2. BreatheSmart mobile application that provides patients with real-time alerts, environmental information (weather, pollution, etc.), and the ability to complete questionnaires / surveys.",
            "interventionNames": ["Device: BreatheSmart"]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "BreatheSmart",
            "description": "BreatheSmart is a comprehensive asthma monitoring system that combines a medical device and mobile application that are designed for use with Apple and Android mobile devices. The medical device connects to the mobile application using Bluetooth to facilitate the collection of controlled medication adherence, rescue medication usage, and asthma control.",
            "armGroupLabels": ["BreatheSmart"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Change in asthma control",
            "description": "Determine change in the asthma control test (ACT), a validated asthma test, in subjects using the BreatheSmart system from baseline to 3 months.",
            "timeFrame": "3 months"
          },
          {
            "measure": "Change in rescue medication usage",
            "description": "Determine change in rescue medication usage in subjects the BreatheSmart system from baseline to 3 months.",
            "timeFrame": "3 months"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Change in controller medication adherence",
            "description": "Obtain medication adherence percentage (that ranges from 0-100%) to asthma inhaled corticosteroids (ICS) at baseline to 3 months.",
            "timeFrame": "3 months"
          },
          {
            "measure": "Acceptability of BreatheSmart system",
            "description": "Acceptability questionnaire (delivered through the BreatheSmart mobile application) that includes subjects' opinion on the platform, features, usability, and usefulness.",
            "timeFrame": "3 months"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* Ability to provide written informed consent\n* Male and female adults (aged ≥ 18 years)\n* Diagnosis of asthma for at least 6 months\n* ICS (inhaled corticosteroid) use for at least 3 months\n* Use of a pressurized metered dose inhaler (pMDI) compatible with the HeroTracker\n* Possess a compatible smartphone (iOS 8.0 or higher and Android 4.3 or higher)\n\nExclusion Criteria:\n\n* Currently pregnant or planning to become pregnant during the study period\n* Primary language other than English (BreatheSmart mobile app is currently available only in English)",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "Anne Tam, MPH",
            "affiliation": "Cohero Health, Inc.",
            "role": "STUDY_DIRECTOR"
          }
        ],
        "locations": [
          {
            "facility": "Cohero Health, Inc.",
            "city": "New York",
            "state": "New York",
            "zip": "10017",
            "country": "United States",
            "geoPoint": { "lat": 40.71427, "lon": -74.00597 }
          }
        ]
      },
      "referencesModule": {
        "references": [
          {
            "pmid": "19183166",
            "type": "BACKGROUND",
            "citation": "Lasmar L, Camargos P, Champs NS, Fonseca MT, Fontes MJ, Ibiapina C, Alvim C, Moura JA. Adherence rate to inhaled corticosteroids and their impact on asthma control. Allergy. 2009 May;64(5):784-9. doi: 10.1111/j.1398-9995.2008.01877.x. Epub 2009 Jan 21."
          },
          {
            "pmid": "25840665",
            "type": "BACKGROUND",
            "citation": "Chan AH, Harrison J, Black PN, Mitchell EA, Foster JM. Using electronic monitoring devices to measure inhaler adherence: a practical guide for clinicians. J Allergy Clin Immunol Pract. 2015 May-Jun;3(3):335-49.e1-5. doi: 10.1016/j.jaip.2015.01.024. Epub 2015 Apr 1."
          },
          {
            "pmid": "19767070",
            "type": "BACKGROUND",
            "citation": "Schatz M, Kosinski M, Yarlas AS, Hanlon J, Watson ME, Jhingran P. The minimally important difference of the Asthma Control Test. J Allergy Clin Immunol. 2009 Oct;124(4):719-23.e1. doi: 10.1016/j.jaci.2009.06.053. Epub 2009 Sep 19."
          },
          {
            "pmid": "23058645",
            "type": "BACKGROUND",
            "citation": "Jia CE, Zhang HP, Lv Y, Liang R, Jiang YQ, Powell H, Fu JJ, Wang L, Gibson PG, Wang G. The Asthma Control Test and Asthma Control Questionnaire for assessing asthma control: Systematic review and meta-analysis. J Allergy Clin Immunol. 2013 Mar;131(3):695-703. doi: 10.1016/j.jaci.2012.08.023. Epub 2012 Oct 8."
          },
          {
            "pmid": "22401649",
            "type": "BACKGROUND",
            "citation": "Melosini L, Dente FL, Bacci E, Bartoli ML, Cianchetti S, Costa F, Di Franco A, Malagrino L, Novelli F, Vagaggini B, Paggiaro P. Asthma control test (ACT): comparison with clinical, functional, and biological markers of asthma control. J Asthma. 2012 Apr;49(3):317-23. doi: 10.3109/02770903.2012.661008. Epub 2012 Mar 9."
          },
          {
            "pmid": "22123375",
            "type": "BACKGROUND",
            "citation": "Korn S, Both J, Jung M, Hubner M, Taube C, Buhl R. Prospective evaluation of current asthma control using ACQ and ACT compared with GINA criteria. Ann Allergy Asthma Immunol. 2011 Dec;107(6):474-9. doi: 10.1016/j.anai.2011.09.001. Epub 2011 Oct 5."
          },
          {
            "pmid": "29071077",
            "type": "DERIVED",
            "citation": "Melvin E, Cushing A, Tam A, Kitada R, Manice M. Assessing the use of BreatheSmart(R) mobile technology in adult patients with asthma: a remote observational study. BMJ Open Respir Res. 2017 Aug 16;4(1):e000204. doi: 10.1136/bmjresp-2017-000204. eCollection 2017."
          }
        ]
      },
      "ipdSharingStatementModule": { "ipdSharing": "NO" }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [{ "id": "D001249", "term": "Asthma" }],
        "ancestors": [
          { "id": "D001982", "term": "Bronchial Diseases" },
          { "id": "D012140", "term": "Respiratory Tract Diseases" },
          { "id": "D008173", "term": "Lung Diseases, Obstructive" },
          { "id": "D008171", "term": "Lung Diseases" },
          { "id": "D012130", "term": "Respiratory Hypersensitivity" },
          { "id": "D006969", "term": "Hypersensitivity, Immediate" },
          { "id": "D006967", "term": "Hypersensitivity" },
          { "id": "D007154", "term": "Immune System Diseases" }
        ],
        "browseLeaves": [
          {
            "id": "M4556",
            "name": "Asthma",
            "asFound": "Asthma",
            "relevance": "HIGH"
          },
          { "id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW" },
          {
            "id": "M14977",
            "name": "Respiratory Tract Diseases",
            "relevance": "LOW"
          },
          { "id": "M11168", "name": "Lung Diseases", "relevance": "LOW" },
          {
            "id": "M11170",
            "name": "Lung Diseases, Obstructive",
            "relevance": "LOW"
          },
          { "id": "M10018", "name": "Hypersensitivity", "relevance": "LOW" },
          {
            "id": "M14967",
            "name": "Respiratory Hypersensitivity",
            "relevance": "LOW"
          },
          {
            "id": "M10020",
            "name": "Hypersensitivity, Immediate",
            "relevance": "LOW"
          },
          {
            "id": "M10200",
            "name": "Immune System Diseases",
            "relevance": "LOW"
          }
        ],
        "browseBranches": [
          {
            "abbrev": "BC08",
            "name": "Respiratory Tract (Lung and Bronchial) Diseases"
          },
          { "abbrev": "BC20", "name": "Immune System Diseases" },
          { "abbrev": "All", "name": "All Conditions" }
        ]
      },
      "interventionBrowseModule": {
        "browseLeaves": [
          { "id": "M6263", "name": "Coal Tar", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "Derm", "name": "Dermatologic Agents" },
          { "abbrev": "All", "name": "All Drugs and Chemicals" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT05847673",
        "orgStudyIdInfo": { "id": "RG1123270" },
        "secondaryIdInfos": [
          {
            "id": "NCI-2023-03050",
            "type": "REGISTRY",
            "domain": "CTRP (Clinical Trial Reporting Program)"
          },
          {
            "id": "RG1123270",
            "type": "OTHER",
            "domain": "Fred Hutch/University of Washington Cancer Consortium"
          }
        ],
        "organization": {
          "fullName": "Fred Hutchinson Cancer Center",
          "class": "OTHER"
        },
        "briefTitle": "Avatar-Led Digital Therapeutic for Aiding Smoking Cessation in Sexual and Gender Minority Young Adults",
        "officialTitle": "Avatar-Led Digital Therapeutic to Aid Smoking Cessation Among Sexual and Gender Minority Young Adults"
      },
      "statusModule": {
        "statusVerifiedDate": "2024-07",
        "overallStatus": "COMPLETED",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2023-08-20", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2024-06-13",
          "type": "ACTUAL"
        },
        "completionDateStruct": { "date": "2024-06-13", "type": "ACTUAL" },
        "studyFirstSubmitDate": "2023-04-27",
        "studyFirstSubmitQcDate": "2023-04-27",
        "studyFirstPostDateStruct": { "date": "2023-05-08", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2024-07-17",
        "lastUpdatePostDateStruct": { "date": "2024-07-19", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": {
          "name": "Fred Hutchinson Cancer Center",
          "class": "OTHER"
        },
        "collaborators": [
          {
            "name": "The Leonard and Norma Klorfine Foundation",
            "class": "UNKNOWN"
          }
        ]
      },
      "oversightModule": {
        "oversightHasDmc": true,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": false
      },
      "descriptionModule": {
        "briefSummary": "This trial assesses the acceptability and preliminary efficacy of Empowered, Queer, Quitting, and Living (EQQUAL) smoking-cessation intervention for sexual and gender minority young adult smokers. The prevalence of tobacco use among sexual and gender minority (SGM) young adults is more than twice as high as non-SGM young adults, suggesting that existing SGM-related disparities in tobacco use will persist well into the foreseeable future unless sustained efforts are undertaken to address them. EQQUAL is an online smoking cessation intervention designed specifically for SGM young adult smokers, and may help them quit smoking.",
        "detailedDescription": "OUTLINE: Participants are randomized to 1 of 2 arms.\n\nARM I: Participants receive self-guided, online quit smoking program, called EQQUAL Program A.\n\nARM II: Participants receive self-guided online quit smoking program, EQQUAL Program B."
      },
      "conditionsModule": {
        "conditions": ["Cigarette Smoking-Related Carcinoma"]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "primaryPurpose": "PREVENTION",
          "maskingInfo": {
            "masking": "SINGLE",
            "whoMasked": ["OUTCOMES_ASSESSOR"]
          }
        },
        "enrollmentInfo": { "count": 125, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "Arm I (EQQUAL A)",
            "type": "EXPERIMENTAL",
            "description": "Participants receive self-guided online EQQUAL A program on study. Participants also receive motivational messages and smoking cessation information via text messages.",
            "interventionNames": [
              "Behavioral: Online Smoking Cessation Intervention",
              "Other: Questionnaire Administration",
              "Other: Health Promotion and Education"
            ]
          },
          {
            "label": "Arm II (EQQUAL B)",
            "type": "ACTIVE_COMPARATOR",
            "description": "Participants receive self-guided online EQQUAL B program on study. Participants also receive motivational messages and smoking cessation information via text messages.",
            "interventionNames": [
              "Behavioral: Online Smoking Cessation Intervention",
              "Other: Questionnaire Administration",
              "Other: Health Promotion and Education"
            ]
          }
        ],
        "interventions": [
          {
            "type": "BEHAVIORAL",
            "name": "Online Smoking Cessation Intervention",
            "description": "Receive EQQUAL A intervention",
            "armGroupLabels": ["Arm I (EQQUAL A)"],
            "otherNames": ["Smoking and Tobacco Use Cessation Intervention"]
          },
          {
            "type": "BEHAVIORAL",
            "name": "Online Smoking Cessation Intervention",
            "description": "Receive EQQUAL B intervention",
            "armGroupLabels": ["Arm II (EQQUAL B)"],
            "otherNames": ["Smoking and Tobacco Use Cessation Intervention"]
          },
          {
            "type": "OTHER",
            "name": "Questionnaire Administration",
            "description": "Ancillary studies",
            "armGroupLabels": ["Arm I (EQQUAL A)", "Arm II (EQQUAL B)"]
          },
          {
            "type": "OTHER",
            "name": "Health Promotion and Education",
            "description": "Receive motivational messages and smoking cessation information via SMS text messages",
            "armGroupLabels": ["Arm I (EQQUAL A)", "Arm II (EQQUAL B)"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Overall satisfaction",
            "description": "Will be assessed with a 5-point Likert-type item on the 3-month survey. Responses will be recorded into a binary variable representing responses of \"mostly satisfied\" or \"very satisfied\" versus all other responses (i.e., \"not at all,\" \"a little,\" and \"somewhat\"). Will test for statistical differences between arms using a logistic regression, with adjustment for the stratification variables, as well as adjustment for any baseline variables that had a statistically significant difference by study arm and were associated with the outcome (i.e., potential confounders).",
            "timeFrame": "At 3-month follow-up"
          },
          {
            "measure": "Average change in Contemplation Ladder scores",
            "description": "Contemplation Ladder scores will be used to assess readiness to quit using cigarettes. Will test for statistical differences between arms using linear regression, with adjustment for the stratification variables, as well as adjustment for any baseline variables that had a statistically significant difference by study arm and were associated with the outcome (i.e., potential confounders).",
            "timeFrame": "Baseline through 3-month follow-up"
          },
          {
            "measure": "Reduction in cigarettes smoked per day",
            "description": "Change in cigarette smoked per day will be assessed as the difference between average number of cigarettes smoked per day over the past 7 days at baseline and at 3-month follow-up. Will test for statistical differences between arms using a negative binomial regression with adjustment for the stratification variables, as well as adjustment for any baseline variables that had a statistically significant difference by study arm and were associated with the outcome (i.e., potential confounders).",
            "timeFrame": "Baseline through 3-month follow-up"
          },
          {
            "measure": "7-day point prevalence abstinence (PPA) from all nicotine and tobacco use",
            "description": "Self-report of no nicotine and tobacco use over the past 7 days, biochemically confirmed via saliva cotinine. Will test for statistical differences between arms using a logistic regression, with adjustment for the stratification variables, as well as adjustment for any baseline variables that had a statistically significant difference by study arm and were associated with the outcome (i.e., potential confounders).",
            "timeFrame": "At 3-month follow-up"
          },
          {
            "measure": "Usability of the Empowered, Queer, Quitting, and Living (EQQUAL) program",
            "description": "Measured by the System Usability Scale. Will be presented descriptively as an average usability score.",
            "timeFrame": "At 3-month follow-up"
          },
          {
            "measure": "Acceptability of the EQQUAL avatar",
            "description": "Will be assessed using the Agent Persona Instrument, an adapted version of the Robotics Social Attribute Scale, and 4 open-ended, study specific questions. Will be presented descriptively as frequencies and percentages.",
            "timeFrame": "At 3-month follow-up"
          },
          {
            "measure": "Number of EQQUAL sessions completed",
            "description": "Will be presented descriptively as frequencies and percentages.",
            "timeFrame": "Up to 3 months"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Changes in the acceptance of smoking triggers",
            "description": "Assessed by the emotional and physical subscales of the Avoidance and Inflexibility Scale (AIS). Will calculate the change score as 3-month follow-up minus baseline score and use a linear regression model with adjustment for the baseline value of the measure of interest and for the stratification variables, as well as adjustment for any baseline variables that had a statistically significant difference by study arm and were associated with the outcome.",
            "timeFrame": "Baseline through 3-month follow-up"
          },
          {
            "measure": "Changes in psychological flexibility",
            "description": "Assessed by the short version of the Multidimensional Psychological Flexibility Inventory (MPFI). Will calculate the change score as 3-month follow-up minus baseline score and use a linear regression model with adjustment for the baseline value of the measure of interest and for the stratification variables, as well as adjustment for any baseline variables that had a statistically significant difference by study arm and were associated with the outcome.",
            "timeFrame": "Baseline through 3-month follow-up"
          },
          {
            "measure": "Changes in valued living",
            "description": "Assessed by the Valuing Questionnaire. Will calculate the change score as 3-month follow-up minus baseline score and use a linear regression model with adjustment for the baseline value of the measure of interest and for the stratification variables, as well as adjustment for any baseline variables that had a statistically significant difference by study arm and were associated with the outcome.",
            "timeFrame": "Baseline through 3-month follow-up"
          },
          {
            "measure": "Differences in 3-month smoking outcomes between those with high versus low baseline readiness to quit",
            "description": "Will be presented descriptively as frequencies and percentages.",
            "timeFrame": "Baseline through 3-month follow-up"
          },
          {
            "measure": "Differences in 3-month smoking outcomes between those who identify as gender minority versus those who don't",
            "description": "Will be presented descriptively as frequencies and percentages.",
            "timeFrame": "Baseline through 3-month follow-up"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* DEMOGRAPHIC CRITERIA:\n* Participants must self-identify being between 18 and 30 years of age\n* Participants must self-identify as a sexual and/or gender minority (i.e., a sexual orientation other than straight and/or gender that doesn't match sex assigned at birth)\n* Participants must currently reside in the United States, with a United States (US) mailing address, and anticipate remaining in the US for the duration of the study (3 months)\n* SMOKING CRITERIA:\n* Participants must self-report smoking at least 1 cigarette per day in the 30 days prior to screening\n* TREATMENT ACCESSIBILITY:\n* Participants must self-report having at least weekly Internet access for the next three months\n* Participants must self-report being willing and able to stream audio and video online for this study\n* Participants must self-report current use of a personal email account\n* Participants must self-report current use of text messaging\n* OTHER CRITERIA:\n* Participants must self-report that they are interested in participating in the study for themselves (versus \\[vs\\] someone else)\n* Participants must self-report that they have not participated in one of our prior smoking cessation studies\n* Participants must self-report that they are comfortable reading, writing, and speaking English\n* Participants must self-report that they understand and agree to the conditions of compensation\n* Participants must self-report that they are not currently incarcerated\n* Participants must be willing to use the assigned intervention program, complete the study assessments, and consent to participate in this study\n* Participants must be willing to upload a photo of themselves (face visible)\n\nExclusion Criteria:\n\n* Participants must not be currently using other tobacco cessation treatments at the time of screening, including pharmacotherapy or behavioral support (but initiating these treatments during the study is allowed)\n* Participants must not be a member of the same household as another research participant\n* Having a Google voice number as their sole phone number",
        "healthyVolunteers": true,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "maximumAge": "30 Years",
        "stdAges": ["ADULT"]
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "Jaimee Heffner",
            "affiliation": "Fred Hutch/University of Washington Cancer Consortium",
            "role": "PRINCIPAL_INVESTIGATOR"
          }
        ],
        "locations": [
          {
            "facility": "Fred Hutch/University of Washington Cancer Consortium",
            "city": "Seattle",
            "state": "Washington",
            "zip": "98109",
            "country": "United States",
            "geoPoint": { "lat": 47.60621, "lon": -122.33207 }
          }
        ]
      },
      "ipdSharingStatementModule": { "ipdSharing": "NO" }
    },
    "documentSection": {
      "largeDocumentModule": {
        "largeDocs": [
          {
            "typeAbbrev": "ICF",
            "hasProtocol": false,
            "hasSap": false,
            "hasIcf": true,
            "label": "Informed Consent Form",
            "date": "2023-11-22",
            "uploadDate": "2024-03-07T17:03",
            "filename": "ICF_000.pdf",
            "size": 3829260
          }
        ]
      }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "browseLeaves": [
          { "id": "M5534", "name": "Carcinoma", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "BC04", "name": "Neoplasms" },
          { "abbrev": "All", "name": "All Conditions" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT06797245",
        "orgStudyIdInfo": { "id": "APPROVE" },
        "organization": {
          "fullName": "Medstar Health Research Institute",
          "class": "OTHER"
        },
        "briefTitle": "APPROVE Trial: Evaluating a Prescription Digital Therapeutic for Treatment of OAB in Women",
        "officialTitle": "The APPROVE Trial: A Randomized Controlled Trial Evaluating the Efficacy and Safety of a Prescription Digital Therapeutic for Treatment of Overactive Bladder in Women",
        "acronym": "APPROVE"
      },
      "statusModule": {
        "statusVerifiedDate": "2025-03",
        "overallStatus": "RECRUITING",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2025-03-17", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2026-07",
          "type": "ESTIMATED"
        },
        "completionDateStruct": { "date": "2028-07", "type": "ESTIMATED" },
        "studyFirstSubmitDate": "2025-01-22",
        "studyFirstSubmitQcDate": "2025-01-22",
        "studyFirstPostDateStruct": { "date": "2025-01-28", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2025-05-04",
        "lastUpdatePostDateStruct": {
          "date": "2025-05-07",
          "type": "ESTIMATED"
        }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": {
          "name": "Medstar Health Research Institute",
          "class": "OTHER"
        },
        "collaborators": [
          {
            "name": "Foundation for Female Health Awareness (FFHA)",
            "class": "UNKNOWN"
          }
        ]
      },
      "oversightModule": {
        "oversightHasDmc": true,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": false,
        "isUsExport": false
      },
      "descriptionModule": {
        "briefSummary": "The APPROVE trial is a multi-centered, randomized controlled trial designed to assess differences in symptom improvement, quality of life, bladder symptoms, satisfaction with treatment and continued treatment efficacy in women with overactive bladder (OAB) randomized to a prescription digital therapeutic (PDTx) app called RiSolve compared to standard behavioral education (handouts).",
        "detailedDescription": "In this trial, we will employ a randomized controlled trial design to determine if women with overactive bladder (OAB) treated with the RiSolve prescription digital therapeutic (PDTx) demonstrate greater improvement in OAB-related health as compared to standard behavioral education with informational handouts. RiSolve is a digital therapeutic device intended to provide behavioral therapy and cognitive behavioral therapy (CBT) for adult women who have been diagnosed with OAB, which includes urinary urgency with or without urge urinary incontinence (UUI), urinary frequency, nocturia, and mixed incontinence with predominant OAB symptoms. RiSolve is indicated as an 8-week treatment to reduce the symptoms of OAB.\n\nFor the purposes of this trial, the primary outcome to determine improvement in OAB-related health will be defined as achieving the MID (defined as an improvement of 10 points or more) on the OAB-q SF Symptom Severity subscale after 8 weeks of treatment. Secondary outcomes will include achieving the MID on the OAB-q SF Health-Related Quality of Life subscale, meeting the patient's acceptable symptoms state (PASS) on the Patient Global Impression of Severity (PGI-S) and Patient Global Impression of Improvement (PGI-I), and improvements in frequency, nocturia and urge urinary incontinence (UUI) on a 3-day bladder diary and on the ICIQ-FLUTS. Participants will be randomized to either PDTx therapy (active) or standard treatment of behavioral education (control). Participants randomized to control will have the option to crossover to PDTx after the initial 8 weeks of the trial if desired. Participants will continue to be followed and asked about their symptoms at 6 and 12 months.\n\nThe impact of this trial has enormous potential to improve treatment of OAB. The ability to offer behavioral therapy via PDTx will reduce patient burden while simultaneously increasing quality of life for women suffering from OAB and decreasing provider burden. The high-quality data from this study will be used to support a marketing application with the FDA through the De Novo pathway for an accessible, low-burden, efficient intervention to help millions of women currently suffering from this burdensome condition."
      },
      "conditionsModule": {
        "conditions": [
          "Overactive Bladder (OAB)",
          "Urinary Urgency",
          "Urinary Urge Incontinence (UUI)",
          "Nocturia",
          "Urinary Frequency"
        ],
        "keywords": ["Overactive Bladder (OAB)"]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": { "masking": "NONE" }
        },
        "enrollmentInfo": { "count": 596, "type": "ESTIMATED" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "Intervention - RiSolve PDTx App",
            "type": "EXPERIMENTAL",
            "description": "Participants randomized to intervention will be given access to the RiSolve PDTx app for 10 weeks after initial activation.",
            "interventionNames": ["Device: RiSolve App"]
          },
          {
            "label": "Control - Standard Therapy",
            "type": "ACTIVE_COMPARATOR",
            "description": "Participants randomized to the control will receive a brief explanation of behavioral therapy with details provided in the form educational handouts including the American Urogynecologic Society (AUGS) \"Overactive Bladder\" and \"Pelvic Floor Muscles and Bladder Training\" Patient Fact Sheets.",
            "interventionNames": ["Behavioral: AUGS Patient Handouts"]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "RiSolve App",
            "description": "Participants randomized to intervention will be given access to the RiSolve PDTx app for 10 weeks after initial activation.",
            "armGroupLabels": ["Intervention - RiSolve PDTx App"]
          },
          {
            "type": "BEHAVIORAL",
            "name": "AUGS Patient Handouts",
            "description": "AUGS \"Overactive Bladder\" and \"Pelvic Floor Muscles and Bladder Training\" Patient Fact Sheets will be provided and reviewed.",
            "armGroupLabels": ["Control - Standard Therapy"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Overactive Bladder Questionnaire short-form (OAB-q SF)",
            "description": "The OAB-q SF is utilized to assess the impact of OAB symptoms on the patient's life,35 and has been shown to be responsive to reductions in urinary urgency, frequency and incontinence during anticholinergic therapy.3 The scale ranges from 0 to 100 with a higher score indicating worse symptom severity. The MID is defined as a change of 10 points",
            "timeFrame": "8 Weeks"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "OAB-q SF Health-Related Quality of Life (HRQL)",
            "description": "The OAB-q SF Health-Related Quality of Life (HRQL) subscale is a13-item health-related quality of life subscale of the OAB-q SF. The scale ranges from 0 to 100 with a higher score indicating better quality of life. The MID is defined as a change of 10 points.",
            "timeFrame": "8 Weeks"
          },
          {
            "measure": "Patient Global Impression of Severity (PGI-S)",
            "description": "Patient Global Impression of Severity (PGI-S) is a single item questionnaire to assess a person's impression of disease severity. For purposes of this trial, it will ask participants to \"Check the one number that best describes how your urinary tract condition is now\" on a 4-point Likert scale ranging from (1) \"normal\" to (4) \"severe\". The PASS threshold PGI-S score is \\< 3.",
            "timeFrame": "8 Weeks"
          },
          {
            "measure": "Patient Global Impression of Improvement (PGI-I)",
            "description": "The Patient Global Impression of Improvement (PGI-I) is a single item questionnaire to assess an individual's impression of change in urinary symptoms. For purposes of this trial the PGI-S has been adapted by removing \"taking medication\" and it will ask participants to \"Check the one number that best describes how your urinary tract condition is now, compared with how it was before you began this study\" on a 7-point Likert scale ranging from (1) \"very much better\" to (7) \"very much worse\". The PASS threshold PGI-I score is \\< 3.",
            "timeFrame": "8 Weeks"
          },
          {
            "measure": "3-Day Bladder Diary",
            "description": "A 3-day Bladder Diary will be an electronic bladder diary collected over a 3-day (72 hour) period focusing specifically on number of voids per day, number of voids per night, and number of urinary incontinence (UI) episodes and whether these events are associated with urgency.",
            "timeFrame": "8 Weeks"
          },
          {
            "measure": "Questionnaire for Urinary Incontinence Diagnosis (QUID)",
            "description": "The Questionnaire for Urinary Incontinence Diagnosis (QUID) is a 6-item UI symptom questionnaire to distinguish stress and urgency UI. The QUID serves both as a diagnostic tool to assess UI type and as a measure of SUI and UUI frequency before and after treatment. Prior research has shown that a cut off QUID stress score ≥ 4 and QUID urge score ≥ 6 identify UI type (SUI, UUI or mixed) accurately in 80% of patients as compared to provider diagnosis.",
            "timeFrame": "8 Weeks"
          },
          {
            "measure": "International Consultation on Incontinence Questionnaire Female Lower Urinary Tract Symptoms (ICIQ-FLUTS)",
            "description": "The International Consultation on Incontinence Questionnaire Female Lower Urinary Tract Symptoms (ICIQ-FLUTS) is a 12-item questionnaire to evaluate female lower urinary tract symptoms and impact on quality of life derived from the BFLUTS-SF questionnaire. The ICIQ-FLUTS asks each person to rate the frequency of a specific lower urinary tract symptom (such as urgency, frequency, nocturia, nocturnal enuresis, stress incontinence, pain, etc.) on various 5 point scales and then asks the participant to rate the level of bother from that specific symptom on a Likert scale from (0) \"not at all\" to (10) \"a great deal\".",
            "timeFrame": "8 Weeks"
          },
          {
            "measure": "Short Personal Experience Questionnaire (SPEQ)",
            "description": "The Short Personal Experience Questionnaire (SPEQ) is a 13-item questionnaire that assesses sexual enjoyment, desire, arousal, orgasm, dyspareunia, sexual activity, sexual partner, and partner limitations. To limit participant burden, the SPEQ has been modified to a shorter 8-item version to include fewer items on partner limitations.",
            "timeFrame": "8 Weeks"
          },
          {
            "measure": "Mobile Application Rating Scale: user version (uMARS)",
            "description": "The Mobile Application Rating Scale: user version (uMARS) is comprised of a 20-item objective quality rating with 4 subscales (engagement, functionality, aesthetics, and information quality), and 6-item subjective quality rating. Higher scores are more desirable. Participants randomized to or who crossover to PDTx treatment will be asked to complete the uMARS questionnaire 8 weeks after starting PDTx treatment. A uMARS score of ≥ 3 is considered acceptable.",
            "timeFrame": "8 Weeks"
          },
          {
            "measure": "Treatment Satisfaction",
            "description": "Treatment satisfaction will be assessed by asking participants to \"Rate your level of satisfaction with the study treatment\" they received on a 5-point Likert scale ranging from (1) \"very satisfied\" to (5) \"very dissatisfied\".",
            "timeFrame": "8 Weeks"
          },
          {
            "measure": "Treatment accessibility",
            "description": "Treatment accessibility will be assessed by recording the number of participants who are unable to or have difficulty accessing the App and any phone calls/tech support requests.",
            "timeFrame": "8 Weeks"
          },
          {
            "measure": "Treatment adherence",
            "description": "Treatment adherence for participants receiving PDTx treatment will be assessed via App usage data. For the control group direct questioning will be used to assess treatment adherence (Did you read the leaflet? Answer choices: Yes / No. If yes, how much of it did you read? With answer choices in % categories; If yes, did you return to the leaflet during the 8 weeks to refresh your memory? Answer choices: Yes / No). For those prescribed an anticholinergic or beta-agonist medication we will assess medication compliance through direct patient questioning to assess if the medication was obtained from the pharmacy, how long the medication was taken, any side effects, and, if applicable, the reason for stopping the medication.",
            "timeFrame": "8 Weeks"
          },
          {
            "measure": "Other Treatments",
            "description": "Other treatments will be assessed following the initial 8-week intervention period by querying participants as to whether they have any new conditions or are using or have tried using additional treatments that could affect OAB symptoms. These will include assessing for diagnosis of and treatment for stress urinary incontinence, urinary retention, pelvic organ prolapse, genitourinary syndrome of menopause, vaginal atrophy, pregnancy, sleep apnea, heart failure, and diabetes.",
            "timeFrame": "12 Months"
          },
          {
            "measure": "Adverse Events",
            "description": "Adverse events will be assessed by querying participants regarding any adverse events that may occur throughout the trial",
            "timeFrame": "12 Months"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* Women ≥ 22 years old\n* Bothersome OAB symptoms (defined as bother rating ≥ 5 on ICIQ-FLUTS question #3b or #9b)\n* English-speaking\n* Willing to forego other treatment outside of medications for the 8-week trial period\n* Use of at least one mobile App\n\nExclusion Criteria:\n\n* Stress-predominant mixed urinary incontinence (defined as QUID stress score \\> QUID urge score)\n* Voiding dysfunction defined as response ≥ 2 on ICIQ-FLUTS question #7a\n* Bladder pain defined as response ≥ 2 on ICIQ-FLUTS question #4a\n* Use of an OAB medication (anticholinergic or beta-agonist) within the past two weeks\n* Currently using intermittent or indwelling catheter\n* History of bladder/urethral, colon/anal, or cervical cancer\n* Current or prior use of sacral neuromodulation, tibial stimulation or onabotulinum toxin type A intradetrusor injection\n* Currently taking antibiotics/drugs for urinary tract infection\\^\n* Currently undergoing or unwilling to forego pelvic floor physical therapy with a physical therapist or prescription device for the 8-week intervention period\n* Planning surgery for pelvic organ prolapse within 12 months of randomization\n* Pelvic surgery within the past 6 months\n* Planning to undergo pessary fitting °\n\n  * Those on antibiotics for urinary tract infection will be eligible for enrollment 2 weeks after completing antibiotic therapy with subjective resolution of UTI symptoms °Will be eligible after completing pessary fitting\n\nhttps://researchdata.medstar.net/redcap/surveys/?s=MM7WN7EXACX4PNXJ",
        "healthyVolunteers": false,
        "sex": "FEMALE",
        "minimumAge": "22 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "centralContacts": [
          {
            "name": "Melissa G Goodwin",
            "role": "CONTACT",
            "phone": "202-877-6502",
            "email": "melissa.g.goodwin@medstar.net"
          },
          {
            "name": "Alexis Dieter, MD",
            "role": "CONTACT",
            "phone": "2027-877-6526"
          }
        ],
        "locations": [
          {
            "facility": "MedStar Health",
            "status": "RECRUITING",
            "city": "Washington",
            "state": "District of Columbia",
            "zip": "20010",
            "country": "United States",
            "contacts": [
              {
                "name": "Kendra Green",
                "role": "CONTACT",
                "phone": "(202) 997-4536",
                "email": "kendra.s.green@medstar.net"
              },
              { "name": "Robert Gutman, MD", "role": "PRINCIPAL_INVESTIGATOR" },
              { "name": "Cheryl Iglesia, MD", "role": "SUB_INVESTIGATOR" },
              { "name": "Lee Ann Richter, MD", "role": "SUB_INVESTIGATOR" },
              { "name": "Andrew Sokol, MD", "role": "SUB_INVESTIGATOR" },
              { "name": "Alexis Dieter, MD", "role": "SUB_INVESTIGATOR" }
            ],
            "geoPoint": { "lat": 38.89511, "lon": -77.03637 }
          },
          {
            "facility": "Curavit",
            "status": "RECRUITING",
            "city": "Boston",
            "state": "Massachusetts",
            "zip": "02116",
            "country": "United States",
            "contacts": [
              {
                "name": "Arsheen Ali",
                "role": "CONTACT",
                "phone": "626-483-9418",
                "email": "arsheen.ali@curavit.io"
              }
            ],
            "geoPoint": { "lat": 42.35843, "lon": -71.05977 }
          }
        ]
      },
      "referencesModule": {
        "references": [
          {
            "pmid": "20410783",
            "type": "BACKGROUND",
            "citation": "Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Obstet Gynecol. 2010 May;115(5):1063-1070. doi: 10.1097/AOG.0b013e3181d9d421. No abstract available."
          },
          {
            "pmid": "18929686",
            "type": "BACKGROUND",
            "citation": "Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009 Apr;42(2):377-81. doi: 10.1016/j.jbi.2008.08.010. Epub 2008 Sep 30."
          },
          {
            "type": "BACKGROUND",
            "citation": "Rubin D. Multiple Imputation for Nonresponse in Surveys. New York: John Wiley & Sons, Inc.; 1987."
          },
          {
            "pmid": "31078660",
            "type": "BACKGROUND",
            "citation": "Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, McLeod L, Delacqua G, Delacqua F, Kirby J, Duda SN; REDCap Consortium. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform. 2019 Jul;95:103208. doi: 10.1016/j.jbi.2019.103208. Epub 2019 May 9."
          },
          {
            "pmid": "25783168",
            "type": "BACKGROUND",
            "citation": "Coyne KS, Thompson CL, Lai JS, Sexton CC. An overactive bladder symptom and health-related quality of life short-form: validation of the OAB-q SF. Neurourol Urodyn. 2015 Mar;34(3):255-63. doi: 10.1002/nau.22559. Epub 2014 Jan 13."
          },
          {
            "pmid": "33957642",
            "type": "BACKGROUND",
            "citation": "Burkett LS, Siddique M, Zeymo A, Brunn EA, Gutman RE, Park AJ, Iglesia CB. Clobetasol Compared With Fractionated Carbon Dioxide Laser for Lichen Sclerosus: A Randomized Controlled Trial. Obstet Gynecol. 2021 Jun 1;137(6):968-978. doi: 10.1097/AOG.0000000000004332."
          },
          {
            "pmid": "27287964",
            "type": "BACKGROUND",
            "citation": "Stoyanov SR, Hides L, Kavanagh DJ, Wilson H. Development and Validation of the User Version of the Mobile Application Rating Scale (uMARS). JMIR Mhealth Uhealth. 2016 Jun 10;4(2):e72. doi: 10.2196/mhealth.5849."
          },
          {
            "pmid": "11441518",
            "type": "BACKGROUND",
            "citation": "Dennerstein L, Lehert P, Dudley E. Short scale to measure female sexuality: adapted from McCoy Female Sexuality Questionnaire. J Sex Marital Ther. 2001 Jul-Sep;27(4):339-51. doi: 10.1080/009262301317081098."
          },
          {
            "pmid": "8628042",
            "type": "BACKGROUND",
            "citation": "Ware J Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996 Mar;34(3):220-33. doi: 10.1097/00005650-199603000-00003."
          },
          {
            "pmid": "15295345",
            "type": "BACKGROUND",
            "citation": "Brookes ST, Donovan JL, Wright M, Jackson S, Abrams P. A scored form of the Bristol Female Lower Urinary Tract Symptoms questionnaire: data from a randomized controlled trial of surgery for women with stress incontinence. Am J Obstet Gynecol. 2004 Jul;191(1):73-82. doi: 10.1016/j.ajog.2003.12.027."
          },
          {
            "pmid": "15672005",
            "type": "BACKGROUND",
            "citation": "Bradley CS, Rovner ES, Morgan MA, Berlin M, Novi JM, Shea JA, Arya LA. A new questionnaire for urinary incontinence diagnosis in women: development and testing. Am J Obstet Gynecol. 2005 Jan;192(1):66-73. doi: 10.1016/j.ajog.2004.07.037."
          },
          {
            "pmid": "19787711",
            "type": "BACKGROUND",
            "citation": "Bradley CS, Rahn DD, Nygaard IE, Barber MD, Nager CW, Kenton KS, Siddiqui NY, Abel RB, Spino C, Richter HE. The questionnaire for urinary incontinence diagnosis (QUID): validity and responsiveness to change in women undergoing non-surgical therapies for treatment of stress predominant urinary incontinence. Neurourol Urodyn. 2010 Jun;29(5):727-34. doi: 10.1002/nau.20818."
          },
          {
            "pmid": "12861145",
            "type": "BACKGROUND",
            "citation": "Yalcin I, Bump RC. Validation of two global impression questionnaires for incontinence. Am J Obstet Gynecol. 2003 Jul;189(1):98-101. doi: 10.1067/mob.2003.379."
          },
          {
            "pmid": "12206577",
            "type": "BACKGROUND",
            "citation": "Coyne K, Revicki D, Hunt T, Corey R, Stewart W, Bentkover J, Kurth H, Abrams P. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res. 2002 Sep;11(6):563-74. doi: 10.1023/a:1016370925601."
          },
          {
            "pmid": "34009829",
            "type": "BACKGROUND",
            "citation": "Sanderson DJ, Zavez A, Meekins AR, Eddib A, Lee TG, Barber MD, Duecy E. The Patient Acceptable Symptom State in Female Urinary Incontinence. Female Pelvic Med Reconstr Surg. 2022 Jan 1;28(1):33-39. doi: 10.1097/SPV.0000000000001055."
          },
          {
            "pmid": "32618414",
            "type": "BACKGROUND",
            "citation": "Funada S, Watanabe N, Goto T, Negoro H, Akamatsu S, Uozumi R, Kishimoto S, Ichioka K, Segawa T, Furukawa TA, Ogawa O. Clinical feasibility and acceptability of adding cognitive behavioral therapy to pharmacotherapy for drug-resistant overactive bladder in women: A single-arm pilot study. Low Urin Tract Symptoms. 2021 Jan;13(1):69-78. doi: 10.1111/luts.12333. Epub 2020 Jul 3."
          },
          {
            "pmid": "18646067",
            "type": "BACKGROUND",
            "citation": "Price JR, Mitchell E, Tidy E, Hunot V. Cognitive behaviour therapy for chronic fatigue syndrome in adults. Cochrane Database Syst Rev. 2008 Jul 16;2008(3):CD001027. doi: 10.1002/14651858.CD001027.pub2."
          },
          {
            "pmid": "26721342",
            "type": "BACKGROUND",
            "citation": "Laird KT, Tanner-Smith EE, Russell AC, Hollon SD, Walker LS. Short-term and Long-term Efficacy of Psychological Therapies for Irritable Bowel Syndrome: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2016 Jul;14(7):937-947.e4. doi: 10.1016/j.cgh.2015.11.020. Epub 2015 Dec 22."
          },
          {
            "pmid": "20727679",
            "type": "BACKGROUND",
            "citation": "Glombiewski JA, Sawyer AT, Gutermann J, Koenig K, Rief W, Hofmann SG. Psychological treatments for fibromyalgia: a meta-analysis. Pain. 2010 Nov;151(2):280-295. doi: 10.1016/j.pain.2010.06.011. Epub 2010 Aug 19."
          },
          {
            "pmid": "32775969",
            "type": "BACKGROUND",
            "citation": "Luo C, Sanger N, Singhal N, Pattrick K, Shams I, Shahid H, Hoang P, Schmidt J, Lee J, Haber S, Puckering M, Buchanan N, Lee P, Ng K, Sun S, Kheyson S, Chung DC, Sanger S, Thabane L, Samaan Z. A comparison of electronically-delivered and face to face cognitive behavioural therapies in depressive disorders: A systematic review and meta-analysis. EClinicalMedicine. 2020 Jun 27;24:100442. doi: 10.1016/j.eclinm.2020.100442. eCollection 2020 Jul. Erratum In: EClinicalMedicine. 2021 Nov 02;41:101182. doi: 10.1016/j.eclinm.2021.101182."
          },
          {
            "pmid": "29901820",
            "type": "BACKGROUND",
            "citation": "Hanlon I, Hewitt C, Bell K, Phillips A, Mikocka-Walus A. Systematic review with meta-analysis: online psychological interventions for mental and physical health outcomes in gastrointestinal disorders including irritable bowel syndrome and inflammatory bowel disease. Aliment Pharmacol Ther. 2018 Aug;48(3):244-259. doi: 10.1111/apt.14840. Epub 2018 Jun 14."
          },
          {
            "pmid": "32865497",
            "type": "BACKGROUND",
            "citation": "Etzelmueller A, Vis C, Karyotaki E, Baumeister H, Titov N, Berking M, Cuijpers P, Riper H, Ebert DD. Effects of Internet-Based Cognitive Behavioral Therapy in Routine Care for Adults in Treatment for Depression and Anxiety: Systematic Review and Meta-Analysis. J Med Internet Res. 2020 Aug 31;22(8):e18100. doi: 10.2196/18100."
          },
          {
            "pmid": "28407347",
            "type": "BACKGROUND",
            "citation": "Melotti IGR, Juliato CRT, Tanaka M, Riccetto CLZ. Severe depression and anxiety in women with overactive bladder. Neurourol Urodyn. 2018 Jan;37(1):223-228. doi: 10.1002/nau.23277. Epub 2017 Apr 13."
          },
          {
            "pmid": "28954462",
            "type": "BACKGROUND",
            "citation": "Melotti IGR, Juliato CRT, Coelho SCA, Lima M, Riccetto CLZ. Is There Any Difference Between Depression and Anxiety in Overactive Bladder According to Sex? A Systematic Review and Meta-Analysis. Int Neurourol J. 2017 Sep;21(3):204-211. doi: 10.5213/inj.1734890.445. Epub 2017 Sep 12."
          },
          {
            "pmid": "27716241",
            "type": "BACKGROUND",
            "citation": "Lai HH, Shen B, Rawal A, Vetter J. The relationship between depression and overactive bladder/urinary incontinence symptoms in the clinical OAB population. BMC Urol. 2016 Oct 6;16(1):60. doi: 10.1186/s12894-016-0179-x."
          },
          {
            "pmid": "22642959",
            "type": "BACKGROUND",
            "citation": "Harvey J, Finney S, Stewart L, Gillespie J. The relationship between cognition and sensation in determining when and where to void: the concept of cognitive voiding. BJU Int. 2012 Dec;110(11):1756-61. doi: 10.1111/j.1464-410X.2012.11078.x. Epub 2012 May 29."
          },
          {
            "pmid": "38465995",
            "type": "BACKGROUND",
            "citation": "Sooknarine C, Farrell S, Sarma S, Salameh F, Burke N, Staunton B, Carr E, Sexton K, Agnew G, Downey A, D'Arcy F, Cundiff GW. Pilot Study of a Digital Behavioral Therapy for Overactive Bladder in Women. Urogynecology (Phila). 2024 Mar 7. doi: 10.1097/SPV.0000000000001499. Online ahead of print."
          },
          {
            "pmid": "31039103",
            "type": "BACKGROUND",
            "citation": "Lightner DJ, Gomelsky A, Souter L, Vasavada SP. Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline Amendment 2019. J Urol. 2019 Sep;202(3):558-563. doi: 10.1097/JU.0000000000000309. Epub 2019 Aug 8."
          },
          {
            "pmid": "19941278",
            "type": "BACKGROUND",
            "citation": "Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, Monga A, Petri E, Rizk DE, Sand PK, Schaer GN; International Urogynecological Association; International Continence Society. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn. 2010;29(1):4-20. doi: 10.1002/nau.20798."
          },
          {
            "pmid": "25623739",
            "type": "BACKGROUND",
            "citation": "Gormley EA, Lightner DJ, Faraday M, Vasavada SP; American Urological Association; Society of Urodynamics, Female Pelvic Medicine. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. J Urol. 2015 May;193(5):1572-80. doi: 10.1016/j.juro.2015.01.087. Epub 2015 Jan 23."
          },
          {
            "pmid": "26851599",
            "type": "BACKGROUND",
            "citation": "Olivera CK, Meriwether K, El-Nashar S, Grimes CL, Chen CC, Orejuela F, Antosh D, Gleason J, Kim-Fine S, Wheeler T, McFadden B, Balk EM, Murphy M; Systematic Review Group for the Society of Gynecological Surgeons. Nonantimuscarinic treatment for overactive bladder: a systematic review. Am J Obstet Gynecol. 2016 Jul;215(1):34-57. doi: 10.1016/j.ajog.2016.01.156. Epub 2016 Feb 4."
          },
          {
            "pmid": "15028438",
            "type": "BACKGROUND",
            "citation": "Hu TW, Wagner TH, Bentkover JD, Leblanc K, Zhou SZ, Hunt T. Costs of urinary incontinence and overactive bladder in the United States: a comparative study. Urology. 2004 Mar;63(3):461-5. doi: 10.1016/j.urology.2003.10.037."
          },
          {
            "pmid": "16985613",
            "type": "BACKGROUND",
            "citation": "Chermansky CJ, Chancellor MB. Increasing awareness and improving the care of urinary incontinence: highlights from the world health organization 2nd international consultation on incontinence july 1-4, 2001, paris, france. Rev Urol. 2003 Winter;5(1):22-5. No abstract available."
          },
          {
            "pmid": "35266189",
            "type": "BACKGROUND",
            "citation": "Wadensten T, Nystrom E, Nord A, Lindam A, Sjostrom M, Samuelsson E. App-based self-management of urgency and mixed urinary incontinence in women: One-year follow-up. Neurourol Urodyn. 2022 Apr;41(4):945-954. doi: 10.1002/nau.24898. Epub 2022 Mar 9."
          },
          {
            "pmid": "11377301",
            "type": "BACKGROUND",
            "citation": "Liberman JN, Hunt TL, Stewart WF, Wein A, Zhou Z, Herzog AR, Lipton RB, Diokno AC. Health-related quality of life among adults with symptoms of overactive bladder: results from a U.S. community-based survey. Urology. 2001 Jun;57(6):1044-50. doi: 10.1016/s0090-4295(01)00986-4."
          },
          {
            "pmid": "12811491",
            "type": "BACKGROUND",
            "citation": "Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, Hunt TL, Wein AJ. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003 May;20(6):327-36. doi: 10.1007/s00345-002-0301-4. Epub 2002 Nov 15."
          },
          {
            "pmid": "18457475",
            "type": "BACKGROUND",
            "citation": "Shamliyan T, Wyman J, Bliss DZ, Kane RL, Wilt TJ. Prevention of urinary and fecal incontinence in adults. Evid Rep Technol Assess (Full Rep). 2007 Dec;(161):1-379."
          },
          {
            "pmid": "11703207",
            "type": "BACKGROUND",
            "citation": "Hagglund D, Walker-Engstrom ML, Larsson G, Leppert J. Quality of life and seeking help in women with urinary incontinence. Acta Obstet Gynecol Scand. 2001 Nov;80(11):1051-5."
          },
          {
            "pmid": "14616456",
            "type": "BACKGROUND",
            "citation": "Coyne KS, Zhou Z, Thompson C, Versi E. The impact on health-related quality of life of stress, urge and mixed urinary incontinence. BJU Int. 2003 Nov;92(7):731-5. doi: 10.1046/j.1464-410x.2003.04463.x."
          },
          {
            "pmid": "18454794",
            "type": "BACKGROUND",
            "citation": "Coyne KS, Sexton CC, Irwin DE, Kopp ZS, Kelleher CJ, Milsom I. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int. 2008 Jun;101(11):1388-95. doi: 10.1111/j.1464-410X.2008.07601.x."
          },
          {
            "pmid": "12705999",
            "type": "BACKGROUND",
            "citation": "Chiaffarino F, Parazzini F, Lavezzari M, Giambanco V; Gruppo Interdisciplinare di Studio Incontinenza Urinaria (GISIU). Impact of urinary incontinence and overactive bladder on quality of life. Eur Urol. 2003 May;43(5):535-8. doi: 10.1016/s0302-2838(03)00097-6."
          },
          {
            "pmid": "11183901",
            "type": "BACKGROUND",
            "citation": "Abrams P, Kelleher CJ, Kerr LA, Rogers RG. Overactive bladder significantly affects quality of life. Am J Manag Care. 2000 Jul;6(11 Suppl):S580-90."
          },
          {
            "pmid": "16813906",
            "type": "BACKGROUND",
            "citation": "Coyne KS, Matza LS, Thompson CL, Kopp ZS, Khullar V. Determining the importance of change in the overactive bladder questionnaire. J Urol. 2006 Aug;176(2):627-32; discussion 632. doi: 10.1016/j.juro.2006.03.088."
          },
          {
            "pmid": "15747340",
            "type": "BACKGROUND",
            "citation": "Matza LS, Thompson CL, Krasnow J, Brewster-Jordan J, Zyczynski T, Coyne KS. Test-retest reliability of four questionnaires for patients with overactive bladder: the overactive bladder questionnaire (OAB-q), patient perception of bladder condition (PPBC), urgency questionnaire (UQ), and the primary OAB symptom questionnaire (POSQ). Neurourol Urodyn. 2005;24(3):215-25. doi: 10.1002/nau.20110."
          },
          {
            "pmid": "16022077",
            "type": "BACKGROUND",
            "citation": "Coyne KS, Matza LS, Thompson CL. The responsiveness of the Overactive Bladder Questionnaire (OAB-q). Qual Life Res. 2005 Apr;14(3):849-55. doi: 10.1007/s11136-004-0706-1."
          },
          {
            "pmid": "15891521",
            "type": "BACKGROUND",
            "citation": "Wu EQ, Birnbaum H, Marynchenko M, Mareva M, Williamson T, Mallett D. Employees with overactive bladder: work loss burden. J Occup Environ Med. 2005 May;47(5):439-46. doi: 10.1097/01.jom.0000161744.21780.c1."
          },
          {
            "pmid": "17257467",
            "type": "BACKGROUND",
            "citation": "Dmochowski RR, Newman DK. Impact of overactive bladder on women in the United States: results of a national survey. Curr Med Res Opin. 2007 Jan;23(1):65-76. doi: 10.1185/030079907X159533."
          }
        ]
      },
      "ipdSharingStatementModule": {
        "ipdSharing": "NO",
        "description": "Participant data will be collected and analyzed as an aggregate for any results."
      }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [
          { "id": "D053201", "term": "Urinary Bladder, Overactive" },
          { "id": "D053202", "term": "Urinary Incontinence, Urge" },
          { "id": "D053158", "term": "Nocturia" }
        ],
        "ancestors": [
          { "id": "D001745", "term": "Urinary Bladder Diseases" },
          { "id": "D014570", "term": "Urologic Diseases" },
          { "id": "D052776", "term": "Female Urogenital Diseases" },
          {
            "id": "D005261",
            "term": "Female Urogenital Diseases and Pregnancy Complications"
          },
          { "id": "D000091642", "term": "Urogenital Diseases" },
          { "id": "D052801", "term": "Male Urogenital Diseases" },
          { "id": "D059411", "term": "Lower Urinary Tract Symptoms" },
          { "id": "D020924", "term": "Urological Manifestations" },
          { "id": "D014549", "term": "Urinary Incontinence" },
          { "id": "D014555", "term": "Urination Disorders" }
        ],
        "browseLeaves": [
          {
            "id": "M27167",
            "name": "Urinary Bladder, Overactive",
            "asFound": "Overactive Bladder",
            "relevance": "HIGH"
          },
          {
            "id": "M27168",
            "name": "Urinary Incontinence, Urge",
            "asFound": "Urinary Urge Incontinence",
            "relevance": "HIGH"
          },
          {
            "id": "M27158",
            "name": "Nocturia",
            "asFound": "Nocturia",
            "relevance": "HIGH"
          },
          {
            "id": "M17299",
            "name": "Urinary Incontinence",
            "relevance": "LOW"
          },
          { "id": "M7936", "name": "Enuresis", "relevance": "LOW" },
          {
            "id": "M5026",
            "name": "Urinary Bladder Diseases",
            "relevance": "LOW"
          },
          { "id": "M17319", "name": "Urologic Diseases", "relevance": "LOW" },
          { "id": "M2875", "name": "Urogenital Diseases", "relevance": "LOW" },
          {
            "id": "M27093",
            "name": "Female Urogenital Diseases",
            "relevance": "LOW"
          },
          {
            "id": "M14127",
            "name": "Pregnancy Complications",
            "relevance": "LOW"
          },
          {
            "id": "M8399",
            "name": "Female Urogenital Diseases and Pregnancy Complications",
            "relevance": "LOW"
          },
          {
            "id": "M27095",
            "name": "Male Urogenital Diseases",
            "relevance": "LOW"
          },
          {
            "id": "M29464",
            "name": "Lower Urinary Tract Symptoms",
            "relevance": "LOW"
          },
          {
            "id": "M22659",
            "name": "Urological Manifestations",
            "relevance": "LOW"
          },
          { "id": "M17305", "name": "Urination Disorders", "relevance": "LOW" }
        ],
        "browseBranches": [
          {
            "abbrev": "BXS",
            "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
          },
          { "abbrev": "BC23", "name": "Symptoms and General Pathology" },
          { "abbrev": "All", "name": "All Conditions" },
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT04137081",
        "orgStudyIdInfo": { "id": "H00014985" },
        "organization": {
          "fullName": "University of Massachusetts, Worcester",
          "class": "OTHER"
        },
        "briefTitle": "Unwinding Physician Anxiety",
        "officialTitle": "Managing Risk at Its Source: Reducing Clinician Burnout Through Digital Therapeutic Delivery of Mindfulness Training"
      },
      "statusModule": {
        "statusVerifiedDate": "2019-10",
        "overallStatus": "COMPLETED",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2018-04-03", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2018-08-28",
          "type": "ACTUAL"
        },
        "completionDateStruct": { "date": "2018-08-28", "type": "ACTUAL" },
        "studyFirstSubmitDate": "2019-10-22",
        "studyFirstSubmitQcDate": "2019-10-22",
        "studyFirstPostDateStruct": { "date": "2019-10-23", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2019-10-22",
        "lastUpdatePostDateStruct": { "date": "2019-10-23", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": {
          "type": "PRINCIPAL_INVESTIGATOR",
          "investigatorFullName": "Judson Brewer",
          "investigatorTitle": "Principal Investigator",
          "investigatorAffiliation": "University of Massachusetts, Worcester"
        },
        "leadSponsor": {
          "name": "University of Massachusetts, Worcester",
          "class": "OTHER"
        }
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": false
      },
      "descriptionModule": {
        "briefSummary": "The purpose of this study is to test an app-based mindfulness training program to see if it can reduce anxiety and burnout in physicians.",
        "detailedDescription": "In this study, 50 clinicians will be provided access to the Unwinding Anxiety program. The intervention period will last 3 months and changes in anxiety and burnout along with program engagement will be assessed at baseline, 1 month, and 3 months."
      },
      "conditionsModule": {
        "conditions": ["Anxiety", "Burnout, Professional"],
        "keywords": ["Physicians"]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "NA",
          "interventionModel": "SINGLE_GROUP",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": { "masking": "NONE" }
        },
        "enrollmentInfo": { "count": 57, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "App-based mindfulness training",
            "type": "EXPERIMENTAL",
            "description": "The Unwinding Anxiety program is delivered via a smartphone-based platform, which includes a progression through 30+ daily modules of brief didactic and experience-based mindfulness training (videos and animations), app-triggered check-ins to encourage engagement, and user-initiated guided mindfulness exercises to help disrupt worry cycles in the moment.",
            "interventionNames": ["Behavioral: App-based mindfulness training"]
          }
        ],
        "interventions": [
          {
            "type": "BEHAVIORAL",
            "name": "App-based mindfulness training",
            "description": "Unwinding Anxiety is an app-based mindfulness training program which includes a progression through 30+ daily modules. Each module's training is delivered via short video tutorials and animations (\\~10 min/day). Each training builds on the previous one; modules are 'locked' so that they can only be viewed at a pace of 1/day (previous modules can be reviewed at any time). A built-in self-assessment is taken after every seven modules to ensure key concepts are learned before moving on with automated suggestions on which modules to repeat based on self-assessment results. User-initiated guided practices range from short exercises (30 seconds) to manage anxiety the moment it arises to formal guided meditations (up to 15 minutes), and can be accessed at any time.",
            "armGroupLabels": ["App-based mindfulness training"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Changes in anxiety",
            "description": "Generalized Anxiety Disorder 7-item (GAD-7) questionnaire will be used to assess anxiety. The GAD-7 uses a 4-point Likert scale where 0 is \"Not at all\" to 3 \"Nearly every day\". Scores can range from 0 to 21 and higher scores indicate increasing severity of anxiety.",
            "timeFrame": "1 month"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Changes in burnout",
            "description": "Two, single-item questions from the emotional exhaustion and cynicism domains of the Maslach Burnout Inventory will be used to assess burnout. Both questions are on a 7-point Likert scale where 0 is \"never\" and 7 is \"every day\". Scores can range from 0 to 7 for each domain and higher scores indicate increasing levels of burnout.",
            "timeFrame": "1 month"
          },
          {
            "measure": "Program engagement",
            "description": "Program engagement will be assessed based on the number of modules completed. The program has 30 modules therefore scores scan range from 0 to 30 modules.",
            "timeFrame": "1 month"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* Currently employed as a physician\n* Direct patient interaction\n* Owns a smartphone\n* Endorsed anxiety based on answering yes to following questions:\n\n  1. Do you feel nervous, anxious, or on edge?\n  2. Do you feel you worry too much about different things?\n* Endorsed willingness to use smartphone app for 10+ minutes/day for 30 days\n* Endorsed willingness to complete online surveys\n\nExclusion Criteria:\n\n* None",
        "healthyVolunteers": true,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "Principal Investigator",
            "affiliation": "UMass Worcester",
            "role": "PRINCIPAL_INVESTIGATOR"
          }
        ],
        "locations": [
          {
            "facility": "University of Massachusetts Medical School",
            "city": "Worcester",
            "state": "Massachusetts",
            "zip": "01655",
            "country": "United States",
            "geoPoint": { "lat": 42.26259, "lon": -71.80229 }
          }
        ]
      },
      "referencesModule": {
        "references": [
          {
            "pmid": "32234708",
            "type": "DERIVED",
            "citation": "Roy A, Druker S, Hoge EA, Brewer JA. Physician Anxiety and Burnout: Symptom Correlates and a Prospective Pilot Study of App-Delivered Mindfulness Training. JMIR Mhealth Uhealth. 2020 Apr 1;8(4):e15608. doi: 10.2196/15608."
          }
        ]
      },
      "ipdSharingStatementModule": { "ipdSharing": "NO" }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [
          { "id": "D002055", "term": "Burnout, Professional" },
          { "id": "D000077062", "term": "Burnout, Psychological" }
        ],
        "ancestors": [
          { "id": "D013315", "term": "Stress, Psychological" },
          { "id": "D001526", "term": "Behavioral Symptoms" },
          { "id": "D000073397", "term": "Occupational Stress" },
          { "id": "D009784", "term": "Occupational Diseases" }
        ],
        "browseLeaves": [
          { "id": "M4324", "name": "Anxiety Disorders", "relevance": "LOW" },
          {
            "id": "M1658",
            "name": "Burnout, Psychological",
            "asFound": "Burnout",
            "relevance": "HIGH"
          },
          {
            "id": "M5325",
            "name": "Burnout, Professional",
            "asFound": "Burnout, Professional",
            "relevance": "HIGH"
          },
          {
            "id": "M16105",
            "name": "Stress, Psychological",
            "relevance": "LOW"
          },
          { "id": "M4818", "name": "Behavioral Symptoms", "relevance": "LOW" },
          { "id": "M1167", "name": "Occupational Stress", "relevance": "LOW" },
          {
            "id": "M12719",
            "name": "Occupational Diseases",
            "relevance": "LOW"
          }
        ],
        "browseBranches": [
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" },
          { "abbrev": "All", "name": "All Conditions" },
          { "abbrev": "BC24", "name": "Occupational Diseases" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT06113666",
        "orgStudyIdInfo": { "id": "623308" },
        "organization": { "fullName": "St. Olavs Hospital", "class": "OTHER" },
        "briefTitle": "A Digital Therapeutic to Improve Insomnia in Multiple Sclerosis: A Randomized Controlled Trial.",
        "officialTitle": "Digital Cognitive Behavior Therapy for Insomnia Compared With Digital Patient Education About Insomnia in People With Multiple Sclerosis in Norway",
        "acronym": "NorseMS"
      },
      "statusModule": {
        "statusVerifiedDate": "2025-02",
        "overallStatus": "RECRUITING",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2023-11-16", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2025-10-30",
          "type": "ESTIMATED"
        },
        "completionDateStruct": { "date": "2029-10-30", "type": "ESTIMATED" },
        "studyFirstSubmitDate": "2023-10-27",
        "studyFirstSubmitQcDate": "2023-10-27",
        "studyFirstPostDateStruct": { "date": "2023-11-02", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2025-02-06",
        "lastUpdatePostDateStruct": { "date": "2025-02-10", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": { "name": "St. Olavs Hospital", "class": "OTHER" }
      },
      "oversightModule": {
        "oversightHasDmc": true,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": false
      },
      "descriptionModule": {
        "briefSummary": "The goal of this randomized controlled trial is to test the effectiveness of digital cognitive behavioral therapy for insomnia (dCBT-I) compared with digital patient education about insomnia for people with Multiple Sclerosis (MS). The main questions it aims to answer are whether dCBT-I is effective in reducing insomnia severity in people with MS, whether dCBT-I is effective in reducing daytime fatigue, psychological distress, cognitive problems, medication use (hypnotic, sedative/anxiolytic and antidepressant), resource utilization and if these changes are mediated by improvements in insomnia severity and whether dCBT-I is feasible for people with MS",
        "detailedDescription": "Insomnia is prevalent among individuals with Multiple Sclerosis (MS). Improving sleep is an important therapeutic goal, but there is currently a lack of effective treatment options. Cognitive Behavioral Therapy for Insomnia (CBT-I) has been widely studied in other patient groups and is currently recommended as first- line treatment for chronic insomnia.\n\nOverall, the availability of CBT-I has been limited, as the number of patients in need of treatment far exceeds the number of available therapists. Therefore, fully automated digital adaptations of CBT-I (dCBT-I) have been developed that contain both screening and intervention. Whether this treatment is effective for a clinical sample of patients diagnosed with MS, or if improved sleep can lead to improved daytime functioning in MS, is however, currently unknown.\n\nThis is a novel approach to a digital treatment of a common disorder in MS, and that may result in improved implementation of a low-threshold intervention.\n\nUpdate August 28th, 2024\n\nWe aim to increase the target sample size from 260 to 550 to increase the statistical power to detect differences between the intervention group and control group on the secondary outcomes, e.g., fatigue, cognitive functioning, mental health, and movement measures measured with actigraphy. Few treatment options have shown effects on these outcomes for people with MS but are a significant problem for this patient group. Small effects from this trial may have substantial scientific and clinical value and are important to test with adequate statistical power.\n\nBased on previous RCTs investigating the effectiveness of dCBT-I we aim to have a sample size large enough to detect small to moderate effects (Cohen's d = 0.3 til 0.5) on the secondary outcome measures fatigue, cognitive function, mental health and movement measures measured with actigraphy. As the planned RCT involves limited contact between researchers and participants, we have predicted that the study dropout rate will likely reach about 50%. Therefore, we aim to recruit 550 participants, to enable us to retain 275 participants (137 in each treatment arm) at the end of the RCT. For a two-sample t-test with alpha=0.05, this sample size gives a power of 90% of detecting a difference of Cohen's d = 0.40."
      },
      "conditionsModule": {
        "conditions": ["Multiple Sclerosis", "Insomnia"],
        "keywords": [
          "Cognitive Behavioral Therapy for Insomnia",
          "Fatigue",
          "Cognitive performance"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": {
            "masking": "NONE",
            "maskingDescription": "The participants are in theory blinded to which group they are allocated to. However, it is not possible to blind completely as it is easy for the patients to see if they are receiving active, interactive treatment or are allocated into the control group with patient education."
          }
        },
        "enrollmentInfo": { "count": 550, "type": "ESTIMATED" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "Digital cognitive behavioral therapy for insomnia",
            "type": "EXPERIMENTAL",
            "description": "Behavioral: digital cognitive behavioral therapy (dCBT-I)",
            "interventionNames": [
              "Behavioral: Digital Cognitive Behavioral Therapy for Insomnia (dCBT-I)"
            ]
          },
          {
            "label": "Patient Education about insomnia",
            "type": "ACTIVE_COMPARATOR",
            "description": "Behavioral: Digital patient education about insomnia (PE)",
            "interventionNames": [
              "Behavioral: Digital patient education about insomnia (PE)"
            ]
          }
        ],
        "interventions": [
          {
            "type": "BEHAVIORAL",
            "name": "Digital Cognitive Behavioral Therapy for Insomnia (dCBT-I)",
            "description": "dCBT-I during 9 weeks. Multicomponent intervention that includes the following: psychoeducation about sleep, sleep hygiene, sleep restriction therapy, stimulus control and challenging beliefs and perception about sleep. The digital CBT-I that will be utilized in this study is named Sleep Healthy Using The internet (SHUTi). The intervention is fully automated with no contact with health care personnel, it is interactive and adapts to input from the users. It comprises of the same elements included in face-to-face CBT-I, but the user gains access to a new educational, behavioral or cognitive module each week only after completion of digital sleep diaries. dCBT-I can be accessed on computers or hand-held devices",
            "armGroupLabels": [
              "Digital cognitive behavioral therapy for insomnia"
            ],
            "otherNames": ["Sleep Healthy Using The Internet (SHUTi)"]
          },
          {
            "type": "BEHAVIORAL",
            "name": "Digital patient education about insomnia (PE)",
            "description": "Control condition PE during 9 weeks. A digital patient education program that can be accessed on computers or hand-held devices. The information overlaps with that included in the dCBT-I intervention but it does not include any of the interactive features of the dCBT-I intervention and all the information is available from the moment the PE site is opened.",
            "armGroupLabels": ["Patient Education about insomnia"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Between-group difference in insomnia severity at week 9 after randomization",
            "description": "Assessed with the Insomnia Severity Index (ISI), a 7-item questionnaire for the severity of insomnia symptoms the last 14 days. Each item is rated on a 0 to 4 rating scale with higher scores indicating more severe symptoms. The ISI has good psychometric properties and is validated for online use. Range is 0-28 with higher values represent higher levels of insomnia symptom severity.",
            "timeFrame": "9 weeks after randomization"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Between-group difference in insomnia severity at week 33 after randomization",
            "description": "While between-group difference on the ISI on week 9 is our primary endpoint, we will also assess between group differences on the ISI at week 33 (six months after post-assessment) and week 61 (one year after post assessment). Assessed with the Insomnia Severity Index (ISI), a 7-item questionnaire for the severity of insomnia symptoms the last 14 days. Each item is rated on a 0 to 4 rating scale with higher scores indicating more severe symptoms. The ISI has good psychometric properties and is validated for online use. Range is 0-28 with higher values represent higher levels of insomnia symptom severity.",
            "timeFrame": "33 weeks after randomization"
          },
          {
            "measure": "Between-group difference in insomnia severity at week 61 after randomization",
            "description": "While between-group difference on the ISI on week 9 is our primary endpoint, we will also assess between group differences on the ISI at week 33 (six months after post-assessment) and week 61 (one year after post assessment). Assessed with the Insomnia Severity Index (ISI), a 7-item questionnaire for the severity of insomnia symptoms the last 14 days. Each item is rated on a 0 to 4 rating scale with higher scores indicating more severe symptoms. The ISI has good psychometric properties and is validated for online use. Range is 0-28 with higher values represent higher levels of insomnia symptom severity.",
            "timeFrame": "61 weeks after randomization"
          },
          {
            "measure": "Prospective daily sleep-wake pattern at week 9 after randomization",
            "description": "Assessed with the Consensus Sleep Dairy (sleep-onset latency \\[SOL\\]; wake-time after sleep onset \\[WASO\\]; sleep efficiency \\[SE\\]; total sleep time \\[TST\\]; sleep quality \\[SQ\\]), which will be completed by the participant at baseline and each follow-up point for at least 10 out of 14 consecutive days.",
            "timeFrame": "9 weeks after randomization"
          },
          {
            "measure": "Prospective daily sleep-wake pattern at week 33 after randomization",
            "description": "Assessed with the Consensus Sleep Dairy (sleep-onset latency \\[SOL\\]; wake-time after sleep onset \\[WASO\\]; sleep efficiency \\[SE\\]; total sleep time \\[TST\\]; sleep quality \\[SQ\\]), which will be completed by the participant at baseline and each follow-up point for at least 10 out of 14 consecutive days.",
            "timeFrame": "33 weeks after randomization"
          },
          {
            "measure": "Prospective daily sleep-wake pattern at week 61 after randomization",
            "description": "Assessed with the Consensus Sleep Dairy (sleep-onset latency \\[SOL\\]; wake-time after sleep onset \\[WASO\\]; sleep efficiency \\[SE\\]; total sleep time \\[TST\\]; sleep quality \\[SQ\\]), which will be completed by the participant at baseline and each follow-up point for at least 10 out of 14 consecutive days.",
            "timeFrame": "61 weeks after randomization"
          },
          {
            "measure": "Self-reported mental health status at baseline",
            "description": "Assessed with the Outcome Questionnaire - 45.2 (OQ-45.2), a 45 item self-report scale for mental health status, specifically designed for patient progress throughout therapy. It has excellent internal consistency and is highly correlated with well-known outcomes such as the Symptom Checklist 90R, Beck Depression Inventory, The State Trait Inventory, The inventory of interpersonal problems, The Social Adjustment Scale, and the SF-36.34 The scale is scored on a scale of 0 (=never) to 5 (=almost always) giving a range of 0 to 180, with higher scores indicating higher levels of psychopathology. The OQ-45.2 has three validated subscales: symptom distress, interpersonal relations, and social role functioning (perceived level of difficulties in the workplace, school or home duties). Results will be reported for the sum score, and for the three subscales. The OQ-45.2 has an established clinical cut-off value and reliable change index",
            "timeFrame": "Baseline"
          },
          {
            "measure": "Self-reported mental health status at week 9 after randomization",
            "description": "Assessed with the Outcome Questionnaire - 45.2 (OQ-45.2), a 45 item self-report scale for mental health status, specifically designed for patient progress throughout therapy. It has excellent internal consistency and is highly correlated with well-known outcomes such as the Symptom Checklist 90R, Beck Depression Inventory, The State Trait Inventory, The inventory of interpersonal problems, The Social Adjustment Scale, and the SF-36.34 The scale is scored on a scale of 0 (=never) to 5 (=almost always) giving a range of 0 to 180, with higher scores indicating higher levels of psychopathology. The OQ-45.2 has three validated subscales: symptom distress, interpersonal relations, and social role functioning (perceived level of difficulties in the workplace, school or home duties). Results will be reported for the sum score, and for the three subscales. The OQ-45.2 has an established clinical cut-off value and reliable change index",
            "timeFrame": "9 weeks after randomization"
          },
          {
            "measure": "Self-reported mental health status at week 33 after randomization",
            "description": "Assessed with the Outcome Questionnaire - 45.2 (OQ-45.2), a 45 item self-report scale for mental health status, specifically designed for patient progress throughout therapy. It has excellent internal consistency and is highly correlated with well-known outcomes such as the Symptom Checklist 90R, Beck Depression Inventory, The State Trait Inventory, The inventory of interpersonal problems, The Social Adjustment Scale, and the SF-36.34 The scale is scored on a scale of 0 (=never) to 5 (=almost always) giving a range of 0 to 180, with higher scores indicating higher levels of psychopathology. The OQ-45.2 has three validated subscales: symptom distress, interpersonal relations, and social role functioning (perceived level of difficulties in the workplace, school or home duties). Results will be reported for the sum score, and for the three subscales. The OQ-45.2 has an established clinical cut-off value and reliable change index",
            "timeFrame": "33 weeks after randomization"
          },
          {
            "measure": "Self-reported mental health status at week 61 after randomization",
            "description": "Assessed with the Outcome Questionnaire - 45.2 (OQ-45.2), a 45 item self-report scale for mental health status, specifically designed for patient progress throughout therapy. It has excellent internal consistency and is highly correlated with well-known outcomes such as the Symptom Checklist 90R, Beck Depression Inventory, The State Trait Inventory, The inventory of interpersonal problems, The Social Adjustment Scale, and the SF-36.34 The scale is scored on a scale of 0 (=never) to 5 (=almost always) giving a range of 0 to 180, with higher scores indicating higher levels of psychopathology. The OQ-45.2 has three validated subscales: symptom distress, interpersonal relations, and social role functioning (perceived level of difficulties in the workplace, school or home duties). Results will be reported for the sum score, and for the three subscales. The OQ-45.2 has an established clinical cut-off value and reliable change index",
            "timeFrame": "61 weeks after randomization"
          },
          {
            "measure": "Anxiety/depression at baseline",
            "description": "Assessed with the Hospital Anxiety and Depression Scale (HADS), a 14-item questionnaire for non-vegetative symptoms of anxiety and depression on a 0 to 3 likert scale. The sum score can be used as a measure of general psychological distress and is widely used in the community, general practice and psychiatric settings. It has a range of 0 to 42 points with higher scores indicating higher levels of psychological distress.",
            "timeFrame": "Baseline"
          },
          {
            "measure": "Anxiety/depression at week 9 after randomization",
            "description": "Assessed with the Hospital Anxiety and Depression Scale (HADS), a 14-item questionnaire for non-vegetative symptoms of anxiety and depression on a 0 to 3 likert scale. The sum score can be used as a measure of general psychological distress and is widely used in the community, general practice and psychiatric settings. It has a range of 0 to 42 points with higher scores indicating higher levels of psychological distress.",
            "timeFrame": "9 weeks after randomization"
          },
          {
            "measure": "Anxiety/depression at week 33 after randomization",
            "description": "Assessed with the Hospital Anxiety and Depression Scale (HADS), a 14-item questionnaire for non-vegetative symptoms of anxiety and depression on a 0 to 3 likert scale. The sum score can be used as a measure of general psychological distress and is widely used in the community, general practice and psychiatric settings. It has a range of 0 to 42 points with higher scores indicating higher levels of psychological distress.",
            "timeFrame": "33 weeks after randomization"
          },
          {
            "measure": "Anxiety/depression at week 61 after randomization",
            "description": "Assessed with the Hospital Anxiety and Depression Scale (HADS), a 14-item questionnaire for non-vegetative symptoms of anxiety and depression on a 0 to 3 likert scale. The sum score can be used as a measure of general psychological distress and is widely used in the community, general practice and psychiatric settings. It has a range of 0 to 42 points with higher scores indicating higher levels of psychological distress.",
            "timeFrame": "61 weeks after randomization"
          },
          {
            "measure": "Fatigue at baseline",
            "description": "Assessed with the Chalder Fatigue Questionnaire (CFQ), a 11-item questionnaire for daytime physical and psychological fatigue on a 0 to 3 likert scale (0=less than usual, 3=much more than usual). The scale has a range of 0 to 33 with higher scores indicating higher levels of fatigue. Two additional items assess duration of fatigue (0=less than a week, 4=six months or more) and how much of the time the individual experience fatigue (0=25% of the time, 3=all the time)",
            "timeFrame": "Baseline"
          },
          {
            "measure": "Fatigue at week 9 after randomization",
            "description": "Assessed with the Chalder Fatigue Questionnaire (CFQ), a 11-item questionnaire for daytime physical and psychological fatigue on a 0 to 3 likert scale (0=less than usual, 3=much more than usual). The scale has a range of 0 to 33 with higher scores indicating higher levels of fatigue. Two additional items assess duration of fatigue (0=less than a week, 4=six months or more) and how much of the time the individual experience fatigue (0=25% of the time, 3=all the time)",
            "timeFrame": "9 weeks after randomization"
          },
          {
            "measure": "Fatigue at week 33 after randomization",
            "description": "Assessed with the Chalder Fatigue Questionnaire (CFQ), a 11-item questionnaire for daytime physical and psychological fatigue on a 0 to 3 likert scale (0=less than usual, 3=much more than usual). The scale has a range of 0 to 33 with higher scores indicating higher levels of fatigue. Two additional items assess duration of fatigue (0=less than a week, 4=six months or more) and how much of the time the individual experience fatigue (0=25% of the time, 3=all the time)",
            "timeFrame": "33 weeks after randomization"
          },
          {
            "measure": "Fatigue at week 61 after randomization",
            "description": "Assessed with the Chalder Fatigue Questionnaire (CFQ), a 11-item questionnaire for daytime physical and psychological fatigue on a 0 to 3 likert scale (0=less than usual, 3=much more than usual). The scale has a range of 0 to 33 with higher scores indicating higher levels of fatigue. Two additional items assess duration of fatigue (0=less than a week, 4=six months or more) and how much of the time the individual experience fatigue (0=25% of the time, 3=all the time)",
            "timeFrame": "61 weeks after randomization"
          },
          {
            "measure": "Fatigue severity at baseline",
            "description": "Assessed with the Fatigue Severity Scale (FSS), a 9-item questionnaire with statements about physical, social and cognitive effects of fatigue on a 1 to 7 likert scale (1=strongly disagree, 7=strongly agree). Higher total scores indicate higher levels of fatigue.",
            "timeFrame": "Baseline"
          },
          {
            "measure": "Fatigue severity at week 9 after randomization",
            "description": "Assessed with the Fatigue Severity Scale (FSS), a 9-item questionnaire with statements about physical, social and cognitive effects of fatigue on a 1 to 7 likert scale (1=strongly disagree, 7=strongly agree). Higher total scores indicate higher levels of fatigue.",
            "timeFrame": "9 weeks after randomization"
          },
          {
            "measure": "Fatigue severity at week 33 after randomization",
            "description": "Assessed with the Fatigue Severity Scale (FSS), a 9-item questionnaire with statements about physical, social and cognitive effects of fatigue on a 1 to 7 likert scale (1=strongly disagree, 7=strongly agree). Higher total scores indicate higher levels of fatigue.",
            "timeFrame": "33 weeks after randomization"
          },
          {
            "measure": "Fatigue severity at week 61 after randomization",
            "description": "Assessed with the Fatigue Severity Scale (FSS), a 9-item questionnaire with statements about physical, social and cognitive effects of fatigue on a 1 to 7 likert scale (1=strongly disagree, 7=strongly agree). Higher total scores indicate higher levels of fatigue.",
            "timeFrame": "61 weeks after randomization"
          },
          {
            "measure": "Cognitive test performance at baseline",
            "description": "Assessed with the home-based cognitive test battery Memoro. At baseline the test battery includes subtests for assessing reaction time, spatial memory, working memory, processing speed, attention and abstract reasoning.",
            "timeFrame": "Baseline"
          },
          {
            "measure": "Cognitive test performance at week 9 after randomization",
            "description": "Assessed with the home-based cognitive test battery Memoro. At follow-up the test battery includes the subtests Coding (The Symbol Digit Modalities Test) assessing processing speed and a continuous performance test assessing attention and cognitive control function. Cognitive performance will be assessed with reaction time, number of errors and performance variability (standard deviations of hit reaction times).",
            "timeFrame": "9 weeks after randomization"
          },
          {
            "measure": "Cognitive test performance at week 33 after randomization",
            "description": "Assessed with the home-based cognitive test battery Memoro. At follow-up the test battery includes the subtests Coding (The Symbol Digit Modalities Test) assessing processing speed and a continuous performance test assessing attention and cognitive control function. Cognitive performance will be assessed with reaction time, number of errors and performance variability (standard deviations of hit reaction times).",
            "timeFrame": "33 weeks after randomization"
          },
          {
            "measure": "Cognitive test performance at week 61 after randomization",
            "description": "Assessed with the home-based cognitive test battery Memoro. At follow-up the test battery includes the subtests Coding (The Symbol Digit Modalities Test) assessing processing speed and a continuous performance test assessing attention and cognitive control function. Cognitive performance will be assessed with reaction time, number of errors and performance variability (standard deviations of hit reaction times).",
            "timeFrame": "61 weeks after randomization"
          },
          {
            "measure": "Continuous recordings of daytime activity and sleep from baseline to 9 weeks after randomization",
            "description": "Sleep and daytime activity will be recorded using actigraphy (GENEactiv Original, Activinsights Ltd, Kimbolton, United Kingdom). This will primarily allow collection of data to assess details of sleep-wake cycles as well as adherence to the intervention. It will also allow assessment of any intervention-related changes in daytime activity patterns and novel use of mathematical modelling.",
            "timeFrame": "From baseline to 9 weeks after randomization."
          },
          {
            "measure": "Use of health care services at baseline",
            "description": "Number of appointments at mental health care clinics, type and timing of treatment and admissions, and date of the first appointment for each patient during the study period from the Norwegian Patient Registry",
            "timeFrame": "Baseline"
          },
          {
            "measure": "Use of health care services at 61 weeks after randomization",
            "description": "Number of appointments at mental health care clinics, type and timing of treatment and admissions, and date of the first appointment for each patient during the study period from the Norwegian Patient Registry",
            "timeFrame": "61 weeks after randomization"
          },
          {
            "measure": "Use of health care services at 5 years after randomization",
            "description": "Number of appointments at mental health care clinics, type and timing of treatment and admissions, and date of the first appointment for each patient during the study period from the Norwegian Patient Registry",
            "timeFrame": "5 years after randomization"
          },
          {
            "measure": "Medication use at baseline",
            "description": "Dose, timing, and type of prescribed hypnotic, sedative/anxiolytic, antidepressant and other psychotropic medications and medications used in treatment of MS (According to the WHO Anatomical Therapeutic Chemical Classification System) and changes recorded during the RCT (data from the Norwegian Prescription Database",
            "timeFrame": "Baseline"
          },
          {
            "measure": "Medication use at 61 weeks after randomization",
            "description": "Dose, timing, and type of prescribed hypnotic, sedative/anxiolytic, antidepressant and other psychotropic medications and medications used in treatment of MS (According to the WHO Anatomical Therapeutic Chemical Classification System) and changes recorded during the RCT (data from the Norwegian Prescription Database",
            "timeFrame": "61 weeks after randomization"
          },
          {
            "measure": "Medication use at 5 years after randomization",
            "description": "Dose, timing, and type of prescribed hypnotic, sedative/anxiolytic, antidepressant and other psychotropic medications and medications used in treatment of MS (According to the WHO Anatomical Therapeutic Chemical Classification System) and changes recorded during the RCT (data from the Norwegian Prescription Database",
            "timeFrame": "5 years after randomization"
          },
          {
            "measure": "Costs of treatment offered by the public services at baseline",
            "description": "Data from the database named 'Kontroll og Utbetaling av Helserefusjon'",
            "timeFrame": "Baseline"
          },
          {
            "measure": "Costs of treatment offered by the public services 61 weeks after randomization",
            "description": "Data from the database named 'Kontroll og Utbetaling av Helserefusjon'",
            "timeFrame": "61 weeks after randomization"
          },
          {
            "measure": "Costs of treatment offered by the public services 5 years after randomization",
            "description": "Data from the database named 'Kontroll og Utbetaling av Helserefusjon'",
            "timeFrame": "5 years after randomization"
          },
          {
            "measure": "Sick leave or in receipt of disability benefits at baseline",
            "description": "Data from the administrative database called Forløpsdatabasen",
            "timeFrame": "Baseline"
          },
          {
            "measure": "Sick leave or in receipt of disability benefits 61 weeks after randomization",
            "description": "Data from the administrative database called Forløpsdatabasen",
            "timeFrame": "61 weeks after randomization"
          },
          {
            "measure": "Sick leave or in receipt of disability benefits 5 years after randomization",
            "description": "Data from the administrative database called Forløpsdatabasen",
            "timeFrame": "5 years after randomization"
          },
          {
            "measure": "Information about the MS disease at baseline",
            "description": "Disability status assessed with the Extended Disability Status Scale from the Norwegian MS registry, information about previous and current treatment for MS, previous attack phases, first diagnosis of MS from the Norwegian MS registry.",
            "timeFrame": "Baseline"
          },
          {
            "measure": "Information about the MS disease at week 61 after randomization",
            "description": "Disability status assessed with the Extended Disability Status Scale from the Norwegian MS registry, information about previous and current treatment for MS, previous attack phases, first diagnosis of MS from the Norwegian MS registry.",
            "timeFrame": "61 weeks after randomization"
          },
          {
            "measure": "Information about the MS disease at 5 years after randomization",
            "description": "Disability status assessed with the Extended Disability Status Scale from the Norwegian MS registry, information about previous and current treatment for MS, previous attack phases, first diagnosis of MS from the Norwegian MS registry.",
            "timeFrame": "5 years after randomization"
          },
          {
            "measure": "Excessive daytime sleepiness at baseline",
            "description": "Assessed with the Epworth Sleepiness Scale, a eight item questionnaire. The eight items represent real-life situations where the participants must rate their chance of dozing off using a 4-point scale from 0 to 3. Higher scores indicate higher chance of dozing off. Total score indicates the extent of self-reported sleep propensity.",
            "timeFrame": "Baseline"
          },
          {
            "measure": "Subjective cognitive disfunction at baseline",
            "description": "Assessed with the Cognitive Complaints in Bipolar Disorder Rating Assessment (COBRA), a 16-item self-reported instrument of subjective cognitive dysfunctions including executive function, processing speed, working memory, verbal learning and memory, attention/concentration and mental tracking. Items are rated using a 4-point scale. The higher the score, the more subjective complaints. Although the assessment was initially introduced for use with individuals with bipolar disorders, the rating can be used in other clinical populations",
            "timeFrame": "Baseline"
          },
          {
            "measure": "Subjective executive functions at baseline",
            "description": "Assessed with the Behavior Rating Inventory of Executive Function for Adults, a 75 item questionnaire that that captures views of an adult's executive functions or self-regulation in his or her everyday environment. Items are rated on a 3-point scale (Never a problem - sometimes a problem - often a problem).",
            "timeFrame": "Baseline"
          },
          {
            "measure": "Subjective executive functions at 9 weeks after randomization",
            "description": "Assessed with the Behavior Rating Inventory of Executive Function for Adults, a 75 item questionnaire that that captures views of an adult's executive functions or self-regulation in his or her everyday environment. Items are rated on a 3-point scale (Never a problem - sometimes a problem - often a problem).",
            "timeFrame": "9 weeks after randomization"
          },
          {
            "measure": "Subjective executive functions at 33 weeks after randomization",
            "description": "Assessed with the Behavior Rating Inventory of Executive Function for Adults, a 75 item questionnaire that that captures views of an adult's executive functions or self-regulation in his or her everyday environment. Items are rated on a 3-point scale (Never a problem - sometimes a problem - often a problem).",
            "timeFrame": "33 weeks after randomization"
          },
          {
            "measure": "Subjective executive functions at 61 weeks after randomization",
            "description": "Assessed with the Behavior Rating Inventory of Executive Function for Adults, a 75 item questionnaire that that captures views of an adult's executive functions or self-regulation in his or her everyday environment. Items are rated on a 3-point scale (Never a problem - sometimes a problem - often a problem).",
            "timeFrame": "61 weeks after randomization"
          },
          {
            "measure": "Subjective disability status at baseline",
            "description": "Assessed with the Patient-Determined Disease Steps (PDDS), a questionnaire where the participants are asked to choose one out of nine alternatives that bests describes their current disability status",
            "timeFrame": "Baseline"
          },
          {
            "measure": "Fatigue before and after cognitive testing at baseline",
            "description": "Feelings of state fatigue assessed with a single question (i.e \"How much fatigue do you feel right now\"). The participants are asked to rate their feelings of fatigue on a 4-point scale from 0=no fatigue, to 4=severe fatigue right before cognitive testing and immediately after cognitive testing.",
            "timeFrame": "Baseline"
          },
          {
            "measure": "Fatigue before and after cognitive testing at 9 weeks",
            "description": "Feelings of state fatigue assessed with a single question (i.e \"How much fatigue do you feel right now\"). The participants are asked to rate their feelings of fatigue on a 4-point scale from 0=no fatigue, to 4=severe fatigue right before cognitive testing and immediately after cognitive testing.",
            "timeFrame": "9 weeks after randomization"
          },
          {
            "measure": "Fatigue before and after cognitive testing at 33 weeks",
            "description": "Feelings of state fatigue assessed with a single question (i.e \"How much fatigue do you feel right now\"). The participants are asked to rate their feelings of fatigue on a 4-point scale from 0=no fatigue, to 4=severe fatigue right before cognitive testing and immediately after cognitive testing.",
            "timeFrame": "33 weeks after randomization"
          },
          {
            "measure": "Fatigue before and after cognitive testing at 61 weeks",
            "description": "Feelings of state fatigue assessed with a single question (i.e \"How much fatigue do you feel right now\"). The participants are asked to rate their feelings of fatigue on a 4-point scale from 0=no fatigue, to 4=severe fatigue right before cognitive testing and immediately after cognitive testing.",
            "timeFrame": "61 weeks after randomization"
          },
          {
            "measure": "Perceived performance after cognitive testing at baseline",
            "description": "Perceived performance after cognitive testing will be assessed with a single question (i.e. How did you feel like you performed on the test?) rated on a 10-point scale (1=very bad, 10=very good performance)",
            "timeFrame": "Baseline"
          },
          {
            "measure": "Perceived performance after cognitive testing at 9 weeks",
            "description": "Perceived performance after cognitive testing will be assessed with a single question (i.e. How did you feel like you performed on the test?) rated on a 10-point scale (1=very bad, 10=very good performance)",
            "timeFrame": "9 weeks after randomization"
          },
          {
            "measure": "Perceived performance after cognitive testing at 33 weeks",
            "description": "Perceived performance after cognitive testing will be assessed with a single question (i.e. How did you feel like you performed on the test?) rated on a 10-point scale (1=very bad, 10=very good performance)",
            "timeFrame": "33 weeks after randomization"
          },
          {
            "measure": "Perceived performance after cognitive testing at 61 weeks",
            "description": "Perceived performance after cognitive testing will be assessed with a single question (i.e. How did you feel like you performed on the test?) rated on a 10-point scale (1=very bad, 10=very good performance)",
            "timeFrame": "61 weeks after randomization"
          },
          {
            "measure": "Perceived exertion after cognitive testing at baseline",
            "description": "Perceived exertion after cognitive testing will be assessed with a single question (i.e. How much exertion did you feel during the test?) rated on a 10-point scale (1=no exertion at all, 10=very much exertion)",
            "timeFrame": "Baseline"
          },
          {
            "measure": "Perceived exertion after cognitive testing at 9 weeks",
            "description": "Perceived exertion after cognitive testing will be assessed with a single question (i.e. How much exertion did you feel during the test?) rated on a 10-point scale (1=no exertion at all, 10=very much exertion)",
            "timeFrame": "9 weeks after randomization"
          },
          {
            "measure": "Perceived exertion after cognitive testing at 33 weeks",
            "description": "Perceived exertion after cognitive testing will be assessed with a single question (i.e. How much exertion did you feel during the test?) rated on a 10-point scale (1=no exertion at all, 10=very much exertion)",
            "timeFrame": "33 weeks after randomization"
          },
          {
            "measure": "Perceived exertion after cognitive testing at 61 weeks",
            "description": "Perceived exertion after cognitive testing will be assessed with a single question (i.e. How much exertion did you feel during the test?) rated on a 10-point scale (1=no exertion at all, 10=very much exertion)",
            "timeFrame": "61 weeks after randomization"
          },
          {
            "measure": "Insomnia symptoms and severity at baseline",
            "description": "Assessed with the Bergen Insomnia Scale (BIS). BIS comprises six items that assesses symptoms of insomnia based on the insomnia criteria found in the Diagnostic and Statistical Manual of Mental Disorders-IVTR (American Psychiatric Association).",
            "timeFrame": "Baseline"
          },
          {
            "measure": "Insomnia symptoms and severity at 9 weeks",
            "description": "Assessed with the Bergen Insomnia Scale (BIS). BIS comprises six items that assesses symptoms of insomnia based on the insomnia criteria found in the Diagnostic and Statistical Manual of Mental Disorders-IVTR (American Psychiatric Association).",
            "timeFrame": "9 weeks after randomization"
          },
          {
            "measure": "Insomnia symptoms and severity at 33 weeks",
            "description": "Assessed with the Bergen Insomnia Scale (BIS). BIS comprises six items that assesses symptoms of insomnia based on the insomnia criteria found in the Diagnostic and Statistical Manual of Mental Disorders-IVTR (American Psychiatric Association).",
            "timeFrame": "33 weeks after randomization"
          },
          {
            "measure": "Insomnia symptoms and severity at 61 weeks",
            "description": "Assessed with the Bergen Insomnia Scale (BIS). BIS comprises six items that assesses symptoms of insomnia based on the insomnia criteria found in the Diagnostic and Statistical Manual of Mental Disorders-IVTR (American Psychiatric Association).",
            "timeFrame": "61 weeks after randomization"
          },
          {
            "measure": "Pain map with numeric rating scale at baseline",
            "description": "Presence of pain beyond everyday mundane pain, that have lasted longer than 3 months will be assessed with a single yes/no question. Location of pain will be assessed with a pain map, and levels of pain will be assessed with a 11-point numeric rating scale (0 = no pain to 10= severe pain.)",
            "timeFrame": "Baseline"
          },
          {
            "measure": "Frequency of alcohol use at baseline",
            "description": "Assessed with the Alcohol Use Disorders Identification Test - Consumption (AUDIT-C), a three-item self-report questionnaire assessing frequency of alcohol use (0=never, 4=four times each week or more), number of units typical for a drinking day (0=1-2 units, 4=10 or more units), and frequency of binge-drinking (0=never, 4=daily or almost daily). It is a short-version of the 10-item AUDIT developed by the World Health Organization",
            "timeFrame": "Baseline"
          },
          {
            "measure": "Frequency of alcohol use at 9 weeks",
            "description": "Assessed with the Alcohol Use Disorders Identification Test - Consumption (AUDIT-C), a three-item self-report questionnaire assessing frequency of alcohol use (0=never, 4=four times each week or more), number of units typical for a drinking day (0=1-2 units, 4=10 or more units), and frequency of binge-drinking (0=never, 4=daily or almost daily). It is a short-version of the 10-item AUDIT developed by the World Health Organization",
            "timeFrame": "9 weeks after randomization"
          },
          {
            "measure": "Frequency of alcohol use at 33 weeks",
            "description": "Assessed with the Alcohol Use Disorders Identification Test - Consumption (AUDIT-C), a three-item self-report questionnaire assessing frequency of alcohol use (0=never, 4=four times each week or more), number of units typical for a drinking day (0=1-2 units, 4=10 or more units), and frequency of binge-drinking (0=never, 4=daily or almost daily). It is a short-version of the 10-item AUDIT developed by the World Health Organization",
            "timeFrame": "33 weeks after randomization"
          },
          {
            "measure": "Frequency of alcohol use at 61 weeks",
            "description": "Assessed with the Alcohol Use Disorders Identification Test - Consumption (AUDIT-C), a three-item self-report questionnaire assessing frequency of alcohol use (0=never, 4=four times each week or more), number of units typical for a drinking day (0=1-2 units, 4=10 or more units), and frequency of binge-drinking (0=never, 4=daily or almost daily). It is a short-version of the 10-item AUDIT developed by the World Health Organization",
            "timeFrame": "61 weeks after randomization"
          },
          {
            "measure": "Self reported quality of life at baseline",
            "description": "Assessed with the 12-Item Short Form Survey (SF-12). SF-12 The SF-12 is a self-reported outcome measure assessing the impact of health on an individual's everyday life, and is a measure of quality of life. The SF-12 is a shortened version of the SF-36.",
            "timeFrame": "Baseline"
          },
          {
            "measure": "Self reported quality of life at 9 weeks",
            "description": "Assessed with the 12-Item Short Form Survey (SF-12). SF-12 The SF-12 is a self-reported outcome measure assessing the impact of health on an individual's everyday life, and is a measure of quality of life. The SF-12 is a shortened version of the SF-36.",
            "timeFrame": "9 weeks after randomization"
          },
          {
            "measure": "Self reported quality of life at 33 weeks",
            "description": "Assessed with the 12-Item Short Form Survey (SF-12). SF-12 The SF-12 is a self-reported outcome measure assessing the impact of health on an individual's everyday life, and is a measure of quality of life. The SF-12 is a shortened version of the SF-36.",
            "timeFrame": "33 weeks after randomization"
          },
          {
            "measure": "Self reported quality of life at 61 weeks after randomization",
            "description": "Assessed with the 12-Item Short Form Survey (SF-12). SF-12 The SF-12 is a self-reported outcome measure assessing the impact of health on an individual's everyday life, and is a measure of quality of life. The SF-12 is a shortened version of the SF-36.",
            "timeFrame": "61 weeks after randomization"
          },
          {
            "measure": "General health state at baseline",
            "description": "Assessed with Euroqol-5D, a 5-item self-report questionnaire for general health state on a 0 to 5 likert scale. It measures levels of problems with walking, performing self-care, doing usual activities, pain/discomfort, and anxiety/depression. It is widely used across Europe in assessments of health resources utilization as it allows measurement of Quality Adjusted Life Years (QALYs) in individuals presenting with a wide range of physical and mental disorders",
            "timeFrame": "Baseline"
          },
          {
            "measure": "General health state at 9 weeks",
            "description": "Assessed with Euroqol-5D, a 5-item self-report questionnaire for general health state on a 0 to 5 likert scale. It measures levels of problems with walking, performing self-care, doing usual activities, pain/discomfort, and anxiety/depression. It is widely used across Europe in assessments of health resources utilization as it allows measurement of Quality Adjusted Life Years (QALYs) in individuals presenting with a wide range of physical and mental disorders",
            "timeFrame": "9 weeks after randomization"
          },
          {
            "measure": "General health state at 33 weeks",
            "description": "Assessed with Euroqol-5D, a 5-item self-report questionnaire for general health state on a 0 to 5 likert scale. It measures levels of problems with walking, performing self-care, doing usual activities, pain/discomfort, and anxiety/depression. It is widely used across Europe in assessments of health resources utilization as it allows measurement of Quality Adjusted Life Years (QALYs) in individuals presenting with a wide range of physical and mental disorders",
            "timeFrame": "33 weeks after randomization"
          },
          {
            "measure": "General health state at 61 weeks",
            "description": "Assessed with Euroqol-5D, a 5-item self-report questionnaire for general health state on a 0 to 5 likert scale. It measures levels of problems with walking, performing self-care, doing usual activities, pain/discomfort, and anxiety/depression. It is widely used across Europe in assessments of health resources utilization as it allows measurement of Quality Adjusted Life Years (QALYs) in individuals presenting with a wide range of physical and mental disorders",
            "timeFrame": "61 weeks after randomization"
          },
          {
            "measure": "Opinion on negative effects of the intervention at 9 weeks",
            "description": "Assessed with the Negative Effects Questionnaire (NEQ), a self-report measure that contains 20 items that are scored on a five-point Likert-scale (rated 0-4) where higher scores indicate higher levels of negative effects. After each item, the individual is asked whether they consider the effect to be caused by the intervention received or caused by other circumstances (yes/no), as well as one open-ended question",
            "timeFrame": "9 weeks after randomization"
          },
          {
            "measure": "Opinion on negative effects of the intervention at 61 weeks",
            "description": "Assessed with the Negative Effects Questionnaire (NEQ), a self-report measure that contains 20 items that are scored on a five-point Likert-scale (rated 0-4) where higher scores indicate higher levels of negative effects. After each item, the individual is asked whether they consider the effect to be caused by the intervention received or caused by other circumstances (yes/no), as well as one open-ended question",
            "timeFrame": "61 weeks after randomization"
          },
          {
            "measure": "Use of therapeutic techniques at 33 weeks",
            "description": "Assessed with the Use of Sleep Strategies (USS), a six item self-report questionnaire developed to measure how often individuals use six different therapeutic techniques (keep a stable rise time, refrain from sleeping during daytime, use the bed and bedroom only for sleeping, practiced sleep restriction, practiced stimulus control) and their perception of its utility. The techniques are integral to CBT-I but are also described in sleep psychoeducation or hygiene programmes",
            "timeFrame": "33 weeks after randomization"
          },
          {
            "measure": "Use of therapeutic techniques at 61 weeks",
            "description": "Assessed with the Use of Sleep Strategies (USS), a six item self-report questionnaire developed to measure how often individuals use six different therapeutic techniques (keep a stable rise time, refrain from sleeping during daytime, use the bed and bedroom only for sleeping, practiced sleep restriction, practiced stimulus control) and their perception of its utility. The techniques are integral to CBT-I but are also described in sleep psychoeducation or hygiene programmes",
            "timeFrame": "61 weeks after randomization"
          },
          {
            "measure": "Self-reported medication usage at baseline",
            "description": "Dose, timing, and type of prescribed and unsubscribed medications",
            "timeFrame": "Baseline"
          },
          {
            "measure": "Self-reported previous and current physical and mental disorders at baseline",
            "description": "Assessed by checking of a list of 20 common medical conditions, and 9 common mental disorders",
            "timeFrame": "Baseline"
          },
          {
            "measure": "Self-reported physical activity at baseline",
            "description": "Number of physical activities per week at moderate and/or strenuous intensity, and duration of the activities",
            "timeFrame": "Baseline"
          },
          {
            "measure": "Self-reported Body Mass Index (BMI) at baseline",
            "description": "One question assessing height and one question assessing weight",
            "timeFrame": "Baseline"
          },
          {
            "measure": "Self-reported internet and media usage at baseline",
            "description": "Familiarity with use of the internet at baseline and electronic media use (five items) over time. These ratings will be used in subsidiary analyses as for example, how baseline skills in using the internet may affect engagement with internet interventions.",
            "timeFrame": "Baseline"
          },
          {
            "measure": "Self-reported previous treatments for mental disorders at baseline",
            "description": "Number of previous treatments, number of prescribed medications for mental disorders",
            "timeFrame": "Baseline"
          },
          {
            "measure": "Self-reported previous treatments for insomnia at baseline",
            "description": "Number of previous treatments, number of prescribed medications for insomnia",
            "timeFrame": "Baseline"
          },
          {
            "measure": "Self-reported duration of sleep problems at baseline",
            "description": "One item assessing for how long the current sleep problem have lasted in years and months",
            "timeFrame": "Baseline"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n1. Having an established diagnosis of Multiple Sclerosis (MS) and being included in the Norwegian MS registry\n2. Being 18 years or older\n3. Scoring at least 12 points on the Insomnia Severity Index\n4. Willing and able to provide written informed consent\n\nExclusion Criteria:\n\n1. Self-reported symptoms of sleep apnea: Positive endorsement of a screening question for sleep apnoea (the item asks if they 'usually or everyday snore and stop breathing and have difficulties staying awake during the day')\n2. Self-reported surgery for heart disease the last two months\n3. Currently in an attack phase of MS and/or on treatment with steroids,\n4. Self-reported night shifts in their work schedule,\n5. Inadequate opportunity to sleep or living in circumstances that prevent modification of sleep pattern (e.g. having an infant residing at home),\n6. Pregnant in the last two trimesters\n7. Unable to get into bed or out of bed without human assistance.\n8. Concomitant psychological treatment for sleep problems",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "centralContacts": [
          {
            "name": "Simen Saksvik, PhD",
            "role": "CONTACT",
            "phone": "+4797542252",
            "email": "simen.b.saksvik@ntnu.no"
          },
          {
            "name": "Håvard Kallestad, PhD",
            "role": "CONTACT",
            "phone": "+4793027262",
            "email": "havard.kallestad@ntnu.no"
          }
        ],
        "overallOfficials": [
          {
            "name": "Håvard Kallestad, PhD",
            "affiliation": "Senior clinical psychologist and researcher",
            "role": "PRINCIPAL_INVESTIGATOR"
          }
        ],
        "locations": [
          {
            "facility": "St.Olavs Hospital",
            "status": "RECRUITING",
            "city": "Trondheim",
            "zip": "7044",
            "country": "Norway",
            "contacts": [
              {
                "name": "Håvard Kallestad, PhD",
                "role": "CONTACT",
                "phone": "93027262",
                "email": "havard.kallestad@ntnu.no"
              }
            ],
            "geoPoint": { "lat": 63.43049, "lon": 10.39506 }
          }
        ]
      },
      "ipdSharingStatementModule": { "ipdSharing": "NO" }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [
          { "id": "D009103", "term": "Multiple Sclerosis" },
          {
            "id": "D007319",
            "term": "Sleep Initiation and Maintenance Disorders"
          },
          { "id": "D012598", "term": "Sclerosis" }
        ],
        "ancestors": [
          { "id": "D010335", "term": "Pathologic Processes" },
          { "id": "D020278", "term": "Demyelinating Autoimmune Diseases, CNS" },
          {
            "id": "D020274",
            "term": "Autoimmune Diseases of the Nervous System"
          },
          { "id": "D009422", "term": "Nervous System Diseases" },
          { "id": "D003711", "term": "Demyelinating Diseases" },
          { "id": "D001327", "term": "Autoimmune Diseases" },
          { "id": "D007154", "term": "Immune System Diseases" },
          { "id": "D020919", "term": "Sleep Disorders, Intrinsic" },
          { "id": "D020920", "term": "Dyssomnias" },
          { "id": "D012893", "term": "Sleep Wake Disorders" },
          { "id": "D001523", "term": "Mental Disorders" }
        ],
        "browseLeaves": [
          {
            "id": "M12060",
            "name": "Multiple Sclerosis",
            "asFound": "Multiple Sclerosis",
            "relevance": "HIGH"
          },
          {
            "id": "M15415",
            "name": "Sclerosis",
            "asFound": "Sclerosis",
            "relevance": "HIGH"
          },
          { "id": "M8364", "name": "Fatigue", "relevance": "LOW" },
          {
            "id": "M10356",
            "name": "Sleep Initiation and Maintenance Disorders",
            "asFound": "Insomnia",
            "relevance": "HIGH"
          },
          { "id": "M4629", "name": "Autoimmune Diseases", "relevance": "LOW" },
          {
            "id": "M22098",
            "name": "Demyelinating Autoimmune Diseases, CNS",
            "relevance": "LOW"
          },
          {
            "id": "M22094",
            "name": "Autoimmune Diseases of the Nervous System",
            "relevance": "LOW"
          },
          {
            "id": "M6909",
            "name": "Demyelinating Diseases",
            "relevance": "LOW"
          },
          {
            "id": "M10200",
            "name": "Immune System Diseases",
            "relevance": "LOW"
          },
          { "id": "M22242", "name": "Parasomnias", "relevance": "LOW" },
          {
            "id": "M22654",
            "name": "Sleep Disorders, Intrinsic",
            "relevance": "LOW"
          },
          { "id": "M22655", "name": "Dyssomnias", "relevance": "LOW" },
          {
            "id": "M15696",
            "name": "Sleep Wake Disorders",
            "relevance": "LOW"
          },
          { "id": "M14473", "name": "Psychotic Disorders", "relevance": "LOW" },
          { "id": "M4815", "name": "Mental Disorders", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "BC10", "name": "Nervous System Diseases" },
          { "abbrev": "BC20", "name": "Immune System Diseases" },
          { "abbrev": "All", "name": "All Conditions" },
          { "abbrev": "BC23", "name": "Symptoms and General Pathology" },
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT04985331",
        "orgStudyIdInfo": { "id": "W-GenZD-002" },
        "organization": { "fullName": "Woebot Health", "class": "INDUSTRY" },
        "briefTitle": "Digital Therapeutic vs Psychoeducation for Management of Mild to Moderate Depression in Adolescents",
        "officialTitle": "Randomized Controlled Trial of a Digital Therapeutic Versus Psychoeducation for the Management of Mild to Moderate Depression in Adolescents"
      },
      "statusModule": {
        "statusVerifiedDate": "2022-01",
        "overallStatus": "COMPLETED",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2021-08-02", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2021-12-16",
          "type": "ACTUAL"
        },
        "completionDateStruct": { "date": "2022-01-04", "type": "ACTUAL" },
        "studyFirstSubmitDate": "2021-07-08",
        "studyFirstSubmitQcDate": "2021-07-30",
        "studyFirstPostDateStruct": { "date": "2021-08-02", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2022-01-04",
        "lastUpdatePostDateStruct": { "date": "2022-01-05", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": { "name": "Woebot Health", "class": "INDUSTRY" }
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": false
      },
      "descriptionModule": {
        "briefSummary": "The purpose of the present randomized controlled study is to investigate if there is a difference in depression symptoms at 4-weeks among adolescents ages 16-17 years assigned to W-GenZD, a digital therapeutic, as compared to a psychoeducational control group."
      },
      "conditionsModule": { "conditions": ["Depression, Teen"] },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": {
            "masking": "TRIPLE",
            "whoMasked": ["PARTICIPANT", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]
          }
        },
        "enrollmentInfo": { "count": 246, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "W-GenZD",
            "type": "EXPERIMENTAL",
            "description": "W-GenZD is powered by natural language processing and machine learning techniques, the brief, self-guided intervention draws from cognitive behavioral therapy (CBT), interpersonal psychotherapy (IPT-A) and some elements of dialectical behavior therapy (DBT), depending on the presenting situation, to help the adolescent develop emotion regulation skills in the context of their everyday life. In this way, the mobile medical application is designed to be targeted, relevant, tailored, and integrated into the lived experience of adolescents, capable of delivering the appropriate technique for the problem at hand, at the time of need.",
            "interventionNames": ["Device: W-GenZD"]
          },
          {
            "label": "Psychoeducation Control",
            "type": "NO_INTERVENTION",
            "description": "The control for this study is the scheduled delivery of digital psychoeducational files (PDFs). The PDFs were selected to provide information on depression, anxiety and stress, as well as outline common coping skills."
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "W-GenZD",
            "description": "W-GenZD is a program that delivers evidence based therapy for the symptoms of mild-moderate depression and anxiety in adolescents in brief \"conversations\" with a fully automated relational agent.",
            "armGroupLabels": ["W-GenZD"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Patient Health Questionnaire (PHQ-8)",
            "description": "Measure of depression severity. Total score between 0-27, where higher scores indicate greater levels of depression.",
            "timeFrame": "Change from Baseline to Mid-Treatment at 2 weeks; Change from Baseline to Post-treatment at 4 weeks; Change from Baseline to 1-Month Follow-up at 8 weeks"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Generalized Anxiety Disorder (GAD-7)",
            "description": "Measure of anxiety. Total score between 0-21, where higher scores indicate greater levels of anxiety.",
            "timeFrame": "Change from Baseline to Mid-Treatment at 2 weeks; Change from Baseline to Post-treatment at 4 weeks; Change from Baseline to 1-Month Follow-up at 8 weeks"
          },
          {
            "measure": "Working Alliance Inventory (WAI-SR)",
            "description": "Therapeutic alliance that assesses three key aspects of the therapeutic alliance: (a) agreement on the tasks of therapy, (b) agreement on the goals of therapy and (c) development of an affective bond. Scores range from 5-20, with higher scores indicating greater alliance.",
            "timeFrame": "Difference between mid-treatment at 3 days weeks within treatment and post-treatment at 4 weeks"
          },
          {
            "measure": "Mental Health Self-Efficacy Scale (MHSE)",
            "description": "Assesses confidence in managing stress, depression, and anxiety. Range is 10 to 60, with higher scores indicating more self-efficacy.",
            "timeFrame": "Change from Baseline to Post-treatment at 4 weeks; Change from Baseline to 1-Month Follow-up at 8 weeks"
          },
          {
            "measure": "Client Satisfaction Questionnaire (CSQ)",
            "description": "Range from 8 to 32, with higher values indicating higher satisfaction",
            "timeFrame": "Post-treatment (8 weeks from baseline)"
          },
          {
            "measure": "Usage Rating Profile Intervention (URPI)",
            "description": "Measurement of feasibility and acceptability. Scores range from 6-36, with higher scores indicating greater feasibility and acceptability.",
            "timeFrame": "Post-treatment (8 weeks from baseline)"
          },
          {
            "measure": "Number of active application days",
            "description": "Application engagement in the total number of active days using the application will be collected during the study to provide quantitative data regarding application utilization.",
            "timeFrame": "Post-treatment (8 weeks from baseline)"
          },
          {
            "measure": "Number of application messages sent per week",
            "description": "Application engagement in the number of messages sent each week within the application will be collected during the study to provide quantitative data regarding application utilization.",
            "timeFrame": "Post-treatment (8 weeks from baseline)"
          },
          {
            "measure": "Satisfaction ratings of psychoeducational materials",
            "description": "Satisfaction metrics in the total number of 'Thumbs up' (likes) or 'Thumbs down' (dislikes) will be collected during the study to provide quantitative data regarding satisfaction with program content.",
            "timeFrame": "Post-treatment (8 weeks from baseline)"
          },
          {
            "measure": "Mood change ratings after CBT skill application",
            "description": "Satisfaction metrics in the total number of mood change ratings of 'same', 'better', or 'worse, after learning a CBT skill application will be collected during the study to provide quantitative data regarding satisfaction with content.",
            "timeFrame": "Post-treatment (8 weeks from baseline)"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* Adolescents aged 16-17 years old\n* Experiencing mild-moderate depression as indicated by a PHQ-8 score between 5-19, inclusive, assessed at screening/baseline\n* Has regular access to a smartphone (Android or iOS smartphone with a recent supported operating system) with reliable WiFi access or sufficient data to engage with assigned study arm for the duration of the study\n* Available and committed to engage with the program and complete assessments for an 8-week duration\n* Able to read and write in English\n* U.S. resident\n* Regular, stable dose of antidepressant medications for (e.g. escitalopram/Lexapro, fluoxetine/ Prozac) for at least 60 days at screening with no plans to change medication/dose throughout the study\n* If currently receiving psychotherapy, then must be in therapy for at least 4 weeks at screening with no changes planned for the duration of the study\n* Participants must be able to understand and willing to provide informed assent and to comply with all study procedures and restrictions\n\nExclusion Criteria:\n\n* Lifetime diagnosis of a psychotic disorder, including schizophrenia and schizoaffective disorder\n* Lifetime diagnosis of bipolar disorder\n* Lifetime diagnosis of autistic spectrum disorder or pervasive developmental disorder (e.g. autism, Asperger syndrome, Rett's syndrome, or pervasive developmental disorder not otherwise specified)\n* Suicidal attempt or ideation with a plan and intent to harm oneself during the last 12 months\n* History of (a) drug and/or alcohol abuse within the past 12 months (determined by self-report)\n* Current use of benzodiazepines (e.g. lorazepam, clonazepam, alprazolam, diazepam, triazolam) or certain sleep aids (zolpidem, eszopiclone, zaleplon)\n* Previous Woebot Application use",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "16 Years",
        "maximumAge": "17 Years",
        "stdAges": ["CHILD"]
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "facility": "Woebot Health",
            "city": "San Francisco",
            "state": "California",
            "zip": "94107",
            "country": "United States",
            "geoPoint": { "lat": 37.77493, "lon": -122.41942 }
          }
        ]
      }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [
          { "id": "D003863", "term": "Depression" },
          { "id": "D003866", "term": "Depressive Disorder" }
        ],
        "ancestors": [
          { "id": "D001526", "term": "Behavioral Symptoms" },
          { "id": "D019964", "term": "Mood Disorders" },
          { "id": "D001523", "term": "Mental Disorders" }
        ],
        "browseLeaves": [
          {
            "id": "M7061",
            "name": "Depressive Disorder",
            "asFound": "Depression",
            "relevance": "HIGH"
          },
          {
            "id": "M7058",
            "name": "Depression",
            "asFound": "Depression",
            "relevance": "HIGH"
          },
          { "id": "M4818", "name": "Behavioral Symptoms", "relevance": "LOW" },
          { "id": "M21835", "name": "Mood Disorders", "relevance": "LOW" },
          { "id": "M14473", "name": "Psychotic Disorders", "relevance": "LOW" },
          { "id": "M4815", "name": "Mental Disorders", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" },
          { "abbrev": "All", "name": "All Conditions" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT04886388",
        "orgStudyIdInfo": { "id": "DM2-06" },
        "organization": {
          "fullName": "Better Therapeutics",
          "class": "INDUSTRY"
        },
        "briefTitle": "Pivotal Trial of a Digital Therapeutic for the Treatment of Type 2 Diabetes",
        "officialTitle": "Open-Label, Randomized, Controlled, Parallel-Group Trial of a Digital Therapeutic for the Treatment of Type 2 Diabetes"
      },
      "statusModule": {
        "statusVerifiedDate": "2022-01",
        "overallStatus": "COMPLETED",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2021-04-22", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2022-03-09",
          "type": "ACTUAL"
        },
        "completionDateStruct": { "date": "2022-09-27", "type": "ACTUAL" },
        "studyFirstSubmitDate": "2021-05-07",
        "studyFirstSubmitQcDate": "2021-05-10",
        "studyFirstPostDateStruct": { "date": "2021-05-14", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2023-09-26",
        "lastUpdatePostDateStruct": { "date": "2023-09-28", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": { "name": "Better Therapeutics", "class": "INDUSTRY" }
      },
      "oversightModule": {
        "oversightHasDmc": true,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": false
      },
      "descriptionModule": {
        "briefSummary": "BT-001 is a software program intended to help patients with type 2 diabetes, under the guidance of their physician, improve glycemic control (i.e., levels of blood sugar). The BT-001 software delivers a type of behavioral therapy to patients via a mobile application that targets behaviors related to achieving glycemic control. The effectiveness of BT-001 will be measured by its ability to help patients reduce Hemoglobin A1c, or HbA1c (a marker in the blood that measures blood sugar) compared to standard medical care in patients with type 2 diabetes.",
        "detailedDescription": "The study will utilize an open-label, randomized, parallel-group design to confirm and characterize the safety and efficacy of BT-001 used in addition to standard of care (SOC) when compared to SOC alone in patients with type 2 diabetes. The screening period will consist of a run-in during which time HbA1c will be assessed for confirmation of eligibility.\n\nOnce confirmed to be eligible, patients will then be randomized 1:1 to the following groups:\n\nInvestigational: One half of the participants will be treated with BT-001 plus SOC for 180 days;\n\nControl: One half of the participants will be treated with SOC alone for 180 days."
      },
      "conditionsModule": { "conditions": ["Type 2 Diabetes"] },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["PHASE3"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "interventionModelDescription": "Open-Label, Randomized, Controlled",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": { "masking": "NONE" }
        },
        "enrollmentInfo": { "count": 668, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "BT-001 + Standard of Care",
            "type": "EXPERIMENTAL",
            "description": "BT-001 is a software program used with physician guidance, being investigated to improve glycemic control. Patients randomized to this arm of the study will interact with the BT-001 software program in addition to receiving Standard of Care for type 2 diabetes",
            "interventionNames": [
              "Device: BT-001",
              "Other: Physician-guided Standard of Care for type 2 diabetes"
            ]
          },
          {
            "label": "Standard of Care",
            "type": "ACTIVE_COMPARATOR",
            "description": "Patients randomized to the Standard of Care arm will receive Standard of Care treatment for type 2 diabetes under the guidance of a physician",
            "interventionNames": [
              "Other: Physician-guided Standard of Care for type 2 diabetes"
            ]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "BT-001",
            "description": "BT-001 is a software program intended to help patients with type 2 diabetes, under the guidance of their physician, improve glycemic control.",
            "armGroupLabels": ["BT-001 + Standard of Care"]
          },
          {
            "type": "OTHER",
            "name": "Physician-guided Standard of Care for type 2 diabetes",
            "description": "Current ADA Standard of Care Guidelines for type 2 diabetes",
            "armGroupLabels": ["BT-001 + Standard of Care", "Standard of Care"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "The difference in the mean change from baseline in HbA1c at Day 90 between Intervention and Standard of Care groups",
            "description": "Hemoglobin A1c (HbA1c) test measures the amount of blood sugar (glucose) attached to hemoglobin.",
            "timeFrame": "Baseline and Day 90"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "The difference in the mean change from baseline in HbA1c at Day 180 between Intervention and Standard of Care groups",
            "description": "Hemoglobin A1c (HbA1c) test measures the amount of blood sugar (glucose) attached to hemoglobin.",
            "timeFrame": "Baseline and Day 180"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n1. Between 18 and 75 years old, inclusive at the time of signing the informed consent;\n2. Diagnosis of type 2 diabetes, according to the criteria of the American Diabetes Association (ADA), and confirmed at the initial eligibility screening;\n3. Body Mass Index ≥25 kg/m2;\n4. Possesses a smartphone (iPhone or Android only) capable of running the smartphone applications (Apps) used in the study;\n5. Has had no change in the last 4 months prior to randomization (3 months prior to initial screening plus 30-day run-in screening period) in antihyperglycemic medications;\n6. Has a current HbA1c level \\>7%, as determined by both screening assessments;\n7. Willing to use an FDA approved glucometer for self-monitoring blood glucose throughout the study;\n8. Is capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF).\n\nExclusion Criteria\n\n1. Are unable to understand, consent to, or comply with the study protocol for any reason;\n2. Currently taking prandial (mealtime) insulin;\n3. Have self-reported measures, collected during screening interview, that reveal:\n\n   1. An active eating disorder\n   2. The taking of or planning to take (within the next 6 months):\n\n   i. Oral steroids (planned, or within the past 3 months) ii. Chemotherapy (planned, or within the past 6 months) iii. Weight loss medications or iv. Atypical antipsychotic medications\n\n   c. A change in antidepressant or anti-anxiety medication within the past 3 months;\n\n   d. A history of bariatric surgery or planned bariatric surgery during the study;\n\n   e. The current use of marijuana, cocaine, opioid painkillers, or other addictive substances;\n\n   f. The current use of tobacco products or use of tobacco products within the past 6 months;\n\n   g. The consumption of alcohol above defined thresholds:\n\n   i. For women: more than 3 drinks in a single day, or more than 7 drinks per week and ii. For men: more than 4 drinks in a single day, or more than 14 drinks per week\n\n   h. An unstable or life-threatening medical illness;\n\n   i. Non-resolved, presumed or confirmed COVID-19 diagnosis prior to randomization or during primary study period;\n\n   j. For women only: pregnant (or lactating) or having the intention of becoming pregnant during the time frame of the study.\n4. Has a current HbA1c level ≥11%, at the screening assessment;\n5. Concurrent enrollment in any other clinical trial;\n6. Is considered unreliable by the investigator, or having any condition which, in the opinion of the investigator, would not allow safe participation in the study.",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "maximumAge": "75 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "Mark Berman, MD",
            "affiliation": "Better Therapeutics",
            "role": "STUDY_DIRECTOR"
          }
        ],
        "locations": [
          {
            "facility": "Study Site",
            "city": "San Francisco",
            "state": "California",
            "zip": "94110",
            "country": "United States",
            "geoPoint": { "lat": 37.77493, "lon": -122.41942 }
          },
          {
            "facility": "Study Site",
            "city": "Miami",
            "state": "Florida",
            "zip": "33101",
            "country": "United States",
            "geoPoint": { "lat": 25.77427, "lon": -80.19366 }
          },
          {
            "facility": "Study Site",
            "city": "Atlanta",
            "state": "Georgia",
            "zip": "30301",
            "country": "United States",
            "geoPoint": { "lat": 33.749, "lon": -84.38798 }
          },
          {
            "facility": "Study Site",
            "city": "Chicago",
            "state": "Illinois",
            "zip": "60007",
            "country": "United States",
            "geoPoint": { "lat": 41.85003, "lon": -87.65005 }
          },
          {
            "facility": "Study Site",
            "city": "New York",
            "state": "New York",
            "zip": "10001",
            "country": "United States",
            "geoPoint": { "lat": 40.71427, "lon": -74.00597 }
          },
          {
            "facility": "Study Site",
            "city": "Houston",
            "state": "Texas",
            "zip": "77001",
            "country": "United States",
            "geoPoint": { "lat": 29.76328, "lon": -95.36327 }
          }
        ]
      },
      "ipdSharingStatementModule": { "ipdSharing": "NO" }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [
          { "id": "D003920", "term": "Diabetes Mellitus" },
          { "id": "D003924", "term": "Diabetes Mellitus, Type 2" }
        ],
        "ancestors": [
          { "id": "D044882", "term": "Glucose Metabolism Disorders" },
          { "id": "D008659", "term": "Metabolic Diseases" },
          { "id": "D004700", "term": "Endocrine System Diseases" }
        ],
        "browseLeaves": [
          {
            "id": "M7115",
            "name": "Diabetes Mellitus",
            "asFound": "Diabetes",
            "relevance": "HIGH"
          },
          {
            "id": "M7119",
            "name": "Diabetes Mellitus, Type 2",
            "asFound": "Type 2 Diabetes",
            "relevance": "HIGH"
          },
          { "id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW" },
          {
            "id": "M25403",
            "name": "Glucose Metabolism Disorders",
            "relevance": "LOW"
          },
          {
            "id": "M7862",
            "name": "Endocrine System Diseases",
            "relevance": "LOW"
          }
        ],
        "browseBranches": [
          { "abbrev": "BC18", "name": "Nutritional and Metabolic Diseases" },
          { "abbrev": "BC19", "name": "Gland and Hormone Related Diseases" },
          { "abbrev": "All", "name": "All Conditions" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT05421624",
        "orgStudyIdInfo": { "id": "6518" },
        "secondaryIdInfos": [
          {
            "id": "P30AG048785",
            "type": "NIH",
            "link": "https://reporter.nih.gov/quickSearch/P30AG048785"
          }
        ],
        "organization": {
          "fullName": "Boston University Charles River Campus",
          "class": "OTHER"
        },
        "briefTitle": "Amped-PD: Amplifying Physical Activity Through Music in Parkinson Disease",
        "officialTitle": "Amped-PD: Amplifying Physical Activity Through a Novel Digital Music Therapeutic in Parkinson Disease",
        "acronym": "Amped-PD"
      },
      "statusModule": {
        "statusVerifiedDate": "2024-07",
        "overallStatus": "COMPLETED",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2022-08-01", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2023-11-01",
          "type": "ACTUAL"
        },
        "completionDateStruct": { "date": "2023-11-01", "type": "ACTUAL" },
        "studyFirstSubmitDate": "2022-06-09",
        "studyFirstSubmitQcDate": "2022-06-13",
        "studyFirstPostDateStruct": { "date": "2022-06-16", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2024-07-31",
        "lastUpdatePostDateStruct": { "date": "2024-08-01", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": {
          "name": "Boston University Charles River Campus",
          "class": "OTHER"
        },
        "collaborators": [
          { "name": "University of New England", "class": "OTHER" },
          { "name": "National Institute on Aging (NIA)", "class": "NIH" }
        ]
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": true,
        "isUnapprovedDevice": true,
        "isUsExport": true
      },
      "descriptionModule": {
        "briefSummary": "Regular, habitual exercise is a critical component of the long-term management of Parkinson disease (PD). However, PD-specific motor (e.g. slow and diminished movements, variable step timing) and non-motor (e.g. depression, apathy) problems collectively hinder physical activity. Rhythmic auditory stimulation (RAS) is a rehabilitation technique that employs coupling of auditory cues with movement. Walking with RAS has been shown to benefit walking rhythmicity, quality, and speed. These walking benefits make RAS advantageous in promoting moderate intensity walking activity -- an important health-objective in the management of PD. However, the therapeutic potential of RAS in self-directed walking programs has not been examined. In this pilot, we will utilize a breakthrough digital therapeutic that delivers music-adaptive RAS to alleviate PD-specific problems by regulating stepping patterns. Using music as a substrate for cue delivery, this digital therapeutic leverages gait benefits from RAS along with enjoyment of music listening, thus making it a viable and engaging modality that will yield habits of regular walking. Habits are automatically recurring psychological dispositions that emerge from repeated behaviors. The investigators posit that music cues provide recurring contextual cues that automatically evoke habitual response of exercise, thus has the potential to prompt regular physical activity. This study will enroll 61individuals with mild-to-moderate PD (Run-in: 17; Main Trial: 44). The experimental intervention, \"Amped-PD\", is a 6-week, user-managed community-based walking program that utilizes music-adaptive RAS that progressively increases walking intensities. This study will examine if Amped-PD (Experimental Intervention) is more effective than a standard-of-care walking program (Active-Control Intervention) in improving physical activity based on moderate intensity walking, and in improving motor deficits related to quality of walking in individuals with mild-to-moderate PD. This study will also examine whether the resultant habits formed from each intervention matter in relation to training-related changes in physical activity.",
        "detailedDescription": "Parkinson disease (PD) is the fastest growing source of disability among neurological disorders. Diminished physical activity is highly prevalent in PD and often lead to the onset of disability. Regular, habitual exercise is a critical component of the long-term PD management. However, PD-specific motor (e.g. slow and diminished movements, variable step timing) and non-motor (e.g. depression, apathy) problems collectively hinder physical activity. Rhythmic auditory stimulation (RAS) is a rehabilitation technique that employs the coupling of auditory cues with movement. When used during walking, RAS has been shown to benefit walking rhythmicity, quality, and speed. Therefore this rehabilitation technique can be advantageous in promoting moderate intensity walking activity. While clinical studies support RAS-based intervention, its translation to real-world, community-based environments and for long-term exercise for the promotion of physical activity is limited. The difference that determines viability of RAS for out-of-lab applications lie in the distinction between external entrainment (open-loop) versus autonomous entrainment (closed-loop). Open-loop RAS requires high levels of vigilance and is prone to error accumulation, which is problematic with gait dysfunction in PD. On the other hand, closed-loop RAS allows for natural and stable entrainment. A closed-loop approach in this case is a necessity of the task and a technological challenge to translate RAS to community-based settings. In this pilot, the investigators will utilize a breakthrough digital therapeutic that employs closed-loop RAS to alleviate PD-specific problems by regulating stepping patterns. Using music as a substrate for cue delivery, this digital therapeutic leverages gait benefits from RAS along with enjoyment of music listening, thus making it a viable and engaging modality that will yield habits of regular walking. The investigators posit that music that is linked to enjoyment serves as context cues that define the pre-condition to engaging in habitual walking exercise and increased physical activity. With repetition, these recurring contextual triggers (i.e. music) automatically evoke a habitual response of exercise, and thus has the potential to amplify physical activity.\n\nThe main aims of the study seek to examine if Amped-PD (Experimental Intervention) is more effective than a standard-of-care walking program (Active-Control Intervention) in improving physical activity based on moderate intensity walking (Aim 1), and in improving motor deficits related to quality of walking (Aim 2) in individuals with mild-to-moderate PD. Additionally, this study will examine whether habit formation mediates the relationship between the intervention (Amped-PD or Active-Control) and physical activity (Aim 3). The investigators hypothesize that Amped-PD will have greater improvements in amounts of moderate intensity walking and stride-to-stride variability based on stride length and swing time. Further, habit formation will be one mechanism that will explain the link between the intervention and physical activity. Secondary research aims will examine whether Amped-PD is more effective than Active-Control in improving motor and non-motor features based on short- and long-distance walking function, spatiotemporal measures of walking, step activity based on daily step counts, disease severity scores, quality of life, self-efficacy on walking, and depression.\n\nThis study will utilize the breakthrough digital music therapeutic developed and manufactured by MedRhythms (Portland, ME). To examine the effects of the intervention, the investigators will use clinical measures of motor and gait function, participant self-reports on habit formation, and quantified movement data on walking and physical activity using wearable sensors. This study will be implemented by carrying out the following study visits: (1) Primary screen over the phone, (2) Clinical Screening and Baseline Assessment, (3) Community-based, self-directed walking program (6 weeks), (3) Post-training Assessment; (4) Follow-up training (2 weeks), and (5) Final Follow-Up Assessment. Altogether, these procedures may take up to 10 weeks."
      },
      "conditionsModule": {
        "conditions": ["Parkinson Disease"],
        "keywords": [
          "Parkinson disease",
          "rhythmic auditory stimulation",
          "digital therapeutics",
          "behavior change",
          "habits",
          "physical activity"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "interventionModelDescription": "Participants are randomly assigned to either intervention of (1) Amped-PD, or (2) Active-Control.",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": {
            "masking": "SINGLE",
            "whoMasked": ["OUTCOMES_ASSESSOR"]
          }
        },
        "enrollmentInfo": { "count": 61, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "Amped-PD",
            "type": "EXPERIMENTAL",
            "description": "6-week community-based, self-directed walking program that uses a novel digital therapeutic that delivers music-adaptive rhythmic auditory stimulation.",
            "interventionNames": ["Device: Digital music therapeutic"]
          },
          {
            "label": "Active-Control",
            "type": "ACTIVE_COMPARATOR",
            "description": "6-week community-based, self-directed walking program without using a novel digital therapeutic or any form of rhythmic auditory stimulation.",
            "interventionNames": ["Behavioral: Active-Control"]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "Digital music therapeutic",
            "description": "The digital music therapeutic is comprised of foot sensors, a smart phone with pre-installed proprietary software application, and headphones. The device obtains real-time walking data through movement sensors that communicate wirelessly with the smartphone application software. Music cues are tailored to the person's walking pattern, and are transmitted wirelessly to the headphones. Music cues are time-shifted to the user's baseline cadence and adjusted in real-time based on the user's walking performance metrics.",
            "armGroupLabels": ["Amped-PD"],
            "otherNames": ["MedRhythms device"]
          },
          {
            "type": "BEHAVIORAL",
            "name": "Active-Control",
            "description": "The Active-Control intervention will implement a similarly structured community-based walking program as Amped-PD, with the only exception the digital music therapeutic.",
            "armGroupLabels": ["Active-Control"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Physical activity based on the amount of moderate intensity walking",
            "description": "The amount of moderate intensity walking, defined as mean number of minutes per day with \\>100 steps/min. This will be measured using research-grade activity monitors (StepWatch Activity Monitor, Modus Health, Edmonds, WA) validated for use in PD.",
            "timeFrame": "Baseline"
          },
          {
            "measure": "Physical activity based on the amount of moderate intensity walking",
            "description": "The amount of moderate intensity walking, defined as mean number of minutes per day with \\>100 steps/min. This will be measured using research-grade activity monitors (StepWatch Activity Monitor, Modus Health, Edmonds, WA) validated for use in PD.",
            "timeFrame": "During training up to 4 days from start of training"
          },
          {
            "measure": "Physical activity based on the amount of moderate intensity walking",
            "description": "The amount of moderate intensity walking, defined as mean number of minutes per day with \\>100 steps/min. This will be measured using research-grade activity monitors (StepWatch Activity Monitor, Modus Health, Edmonds, WA) validated for use in PD.",
            "timeFrame": "Immediately after the intervention (up to 6 weeks)"
          },
          {
            "measure": "Physical activity based on the amount of moderate intensity walking",
            "description": "The amount of moderate intensity walking, defined as mean number of minutes per day with \\>100 steps/min. This will be measured using research-grade activity monitors (StepWatch Activity Monitor, Modus Health, Edmonds, WA) validated for use in PD.",
            "timeFrame": "Follow-up (up to 2 weeks post-intervention)"
          },
          {
            "measure": "Step activity based on daily step counts",
            "description": "Daily step counts refer to the total number of steps taken on the leg with the monitor. This will be measured using research-grade activity monitors (StepWatch Activity Monitor, Modus Health, Edmonds, WA) validated for use in PD.",
            "timeFrame": "Baseline"
          },
          {
            "measure": "Step activity based on daily step counts",
            "description": "Daily step counts refer to the total number of steps taken on the leg with the monitor. This will be measured using research-grade activity monitors (StepWatch Activity Monitor, Modus Health, Edmonds, WA) validated for use in PD.",
            "timeFrame": "During training up to 4 days from start of training"
          },
          {
            "measure": "Step activity based on daily step counts",
            "description": "Daily step counts refer to the total number of steps taken on the leg with the monitor. This will be measured using research-grade activity monitors (StepWatch Activity Monitor, Modus Health, Edmonds, WA) validated for use in PD.",
            "timeFrame": "Immediately after the intervention (up to 6 weeks)"
          },
          {
            "measure": "Step activity based on daily step counts",
            "description": "Daily step counts refer to the total number of steps taken on the leg with the monitor. This will be measured using research-grade activity monitors (StepWatch Activity Monitor, Modus Health, Edmonds, WA) validated for use in PD.",
            "timeFrame": "Follow-up (up to 2 weeks post-intervention)"
          },
          {
            "measure": "Gait quality based on variability of stride time",
            "description": "Stride-to-stride variability of stride time of the gait cycle will be measured using wearable sensors.",
            "timeFrame": "Baseline"
          },
          {
            "measure": "Gait quality based on variability of stride time",
            "description": "Stride-to-stride variability of stride time of the gait cycle will be measured using wearable sensors.",
            "timeFrame": "Immediately after the intervention (up to 6 weeks)"
          },
          {
            "measure": "Gait quality based on variability of stride time",
            "description": "Stride-to-stride variability of stride time of the gait cycle will be measured using wearable sensors.",
            "timeFrame": "Follow-up (up to 2 weeks post-intervention)"
          },
          {
            "measure": "Self-Report Habit Index (SRHI)",
            "description": "The Self-Report Habit Index (SRHI) will be used to assess habit formation. This index is a patient-reported outcome that examines habit strength. This self-report index comprises of 12 statements with constructs spanning behavior repetition, automaticity, and identity, with responses made on 11-point Likert scales (0 = strongly disagree; 10 = strongly agree). Higher scores indicate stronger habit formation (min = 0, max = 100).",
            "timeFrame": "Baseline"
          },
          {
            "measure": "Self-Report Habit Index (SRHI)",
            "description": "The Self-Report Habit Index (SRHI) will be used to assess habit formation. This index is a patient-reported outcome that examines habit strength. This self-report index comprises of 12 statements with constructs spanning behavior repetition, automaticity, and identity, with responses made on 11-point Likert scales (0 = strongly disagree; 10 = strongly agree). Higher scores indicate stronger habit formation (min = 0, max = 100).",
            "timeFrame": "Follow-up (up to 2 weeks post-intervention)"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "10-Meter Walk Test (10MWT)",
            "description": "This is a test of short-distance walking function. The participant will be asked to walk at comfortable walking speed (CWS) and maximum walking speed (MWS) on a ten-meter straight walkway.",
            "timeFrame": "Baseline"
          },
          {
            "measure": "10-Meter Walk Test (10MWT)",
            "description": "This is a test of short-distance walking function. The participant will be asked to walk at comfortable walking speed (CWS) and maximum walking speed (MWS) on a ten-meter straight walkway.",
            "timeFrame": "Immediately after the intervention (up to 6 weeks)"
          },
          {
            "measure": "10-Meter Walk Test (10MWT)",
            "description": "This is a test of short-distance walking function. The participant will be asked to walk at comfortable walking speed (CWS) and maximum walking speed (MWS) on a ten-meter straight walkway.",
            "timeFrame": "Follow-up (up to 2 weeks post-intervention)"
          },
          {
            "measure": "6-Minute Walk Test (6MWT)",
            "description": "This is test of long-distance walking function. The participant will be asked to \"cover as much distance as they safely can\" for 6 minutes, and total distance is the main metric from this test.",
            "timeFrame": "Baseline"
          },
          {
            "measure": "6-Minute Walk Test (6MWT)",
            "description": "This is test of long-distance walking function. The participant will be asked to \"cover as much distance as they safely can\" for 6 minutes, and total distance is the main metric from this test.",
            "timeFrame": "Immediately after the intervention (up to 6 weeks)"
          },
          {
            "measure": "6-Minute Walk Test (6MWT)",
            "description": "This is test of long-distance walking function. The participant will be asked to \"cover as much distance as they safely can\" for 6 minutes, and total distance is the main metric from this test.",
            "timeFrame": "Follow-up (up to 2 weeks post-intervention)"
          },
          {
            "measure": "Gait velocity during in-clinic walking",
            "description": "Quantified metrics of walking velocity (m/s) will be collected using wearable sensors.",
            "timeFrame": "Baseline"
          },
          {
            "measure": "Gait velocity during in-clinic walking",
            "description": "Quantified metrics of walking velocity (m/s) will be collected using wearable sensors.",
            "timeFrame": "Immediately after the intervention (up to 6 weeks)"
          },
          {
            "measure": "Gait velocity during in-clinic walking",
            "description": "Quantified metrics of walking velocity (m/s) will be collected using wearable sensors.",
            "timeFrame": "Follow-up (up to 2 weeks post-intervention)"
          },
          {
            "measure": "Stride length during in-clinic walking",
            "description": "Quantified metrics of stride length (m) will be collected using wearable sensors.",
            "timeFrame": "Baseline"
          },
          {
            "measure": "Stride length during in-clinic walking",
            "description": "Quantified metrics of stride length (m) will be collected using wearable sensors.",
            "timeFrame": "Immediately after the intervention (up to 6 weeks)"
          },
          {
            "measure": "Stride length during in-clinic walking",
            "description": "Quantified metrics of stride length (m) will be collected using wearable sensors.",
            "timeFrame": "Follow-up (up to 2 weeks post-intervention)"
          },
          {
            "measure": "Movement Disorder Society Unified Parkinson Disease Rating Scale motor subsection (MDS-UPDRS III)",
            "description": "The MDS UPDRS is the most widely used clinical rating scale for Parkinson disease. Part III is a motor examination (33 scores summed from 18 questions) conducted by the rater. Total scores can range from 0 to 141, with higher scores indicating worse disease severity.",
            "timeFrame": "Baseline"
          },
          {
            "measure": "Movement Disorder Society Unified Parkinson Disease Rating Scale motor subsection (MDS-UPDRS III)",
            "description": "The MDS UPDRS is the most widely used clinical rating scale for Parkinson disease. Part III is a motor examination (33 scores summed from 18 questions) conducted by the rater. Total scores can range from 0 to 141, with higher scores indicating worse disease severity.",
            "timeFrame": "Immediately after the intervention (up to 6 weeks)"
          },
          {
            "measure": "Movement Disorder Society Unified Parkinson Disease Rating Scale motor subsection (MDS-UPDRS III)",
            "description": "The MDS UPDRS is the most widely used clinical rating scale for Parkinson disease. Part III is a motor examination (33 scores summed from 18 questions) conducted by the rater. Total scores can range from 0 to 141, with higher scores indicating worse disease severity.",
            "timeFrame": "Follow-up (up to 2 weeks post-intervention)"
          },
          {
            "measure": "Self-Efficacy of Walking - Duration (SEW-D)",
            "description": "The SEW-D is a 10-item self-report that will be administered to determine participants' beliefs of their physical capabilities to successfully complete incremental 5-minute intervals (5 to 40 minutes) of walking at a moderately fast pace, with responses made on 11-point Likert scale (0% = not at all confident; 100% = highly confident).",
            "timeFrame": "Baseline"
          },
          {
            "measure": "Self-Efficacy of Walking - Duration (SEW-D)",
            "description": "The SEW-D is a 10-item self-report that will be administered to determine participants' beliefs of their physical capabilities to successfully complete incremental 5-minute intervals (5 to 40 minutes) of walking at a moderately fast pace, with responses made on 11-point Likert scale (0% = not at all confident; 100% = highly confident).",
            "timeFrame": "Immediately after the intervention (up to 6 weeks)"
          },
          {
            "measure": "Self-Efficacy of Walking - Duration (SEW-D)",
            "description": "The SEW-D is a 10-item self-report that will be administered to determine participants' beliefs of their physical capabilities to successfully complete incremental 5-minute intervals (5 to 40 minutes) of walking at a moderately fast pace, with responses made on 11-point Likert scale (0% = not at all confident; 100% = highly confident).",
            "timeFrame": "Follow-up (up to 2 weeks post-intervention)"
          },
          {
            "measure": "Geriatric Depression Scale (GDS)",
            "description": "The GDS is a brief, self-report involving yes/no questions instrument on psychological aspects and social consequences of depression in the elderly. The short form of GDS of 15-items will be used in this study. Higher scores indicate greater depression (min = 0, max = 15).",
            "timeFrame": "Baseline"
          },
          {
            "measure": "Geriatric Depression Scale (GDS)",
            "description": "The GDS is a brief, self-report involving yes/no questions instrument on psychological aspects and social consequences of depression in the elderly. The short form of GDS of 15-items will be used in this study. Higher scores indicate greater depression (min = 0, max = 15).",
            "timeFrame": "Immediately after the intervention (up to 6 weeks)"
          },
          {
            "measure": "Geriatric Depression Scale (GDS)",
            "description": "The GDS is a brief, self-report involving yes/no questions instrument on psychological aspects and social consequences of depression in the elderly. The short form of GDS of 15-items will be used in this study. Higher scores indicate greater depression (min = 0, max = 15).",
            "timeFrame": "Follow-up (up to 2 weeks post-intervention)"
          },
          {
            "measure": "Parkinson's Disease Questionnaire - 39 (PDQ-39)",
            "description": "The PDQ- 39 is a self-report questionnaire that assesses quality of life over the past month across 8 different dimensions. Items are scored based on a 5-point ordinal system with lower scores reflecting better quality of life. Lower scores reflect better quality of life (min = 0, max = 100).",
            "timeFrame": "Baseline"
          },
          {
            "measure": "Parkinson's Disease Questionnaire - 39 (PDQ-39)",
            "description": "The PDQ- 39 is a self-report questionnaire that assesses quality of life over the past month across 8 different dimensions. Items are scored based on a 5-point ordinal system with lower scores reflecting better quality of life. Lower scores reflect better quality of life (min = 0, max = 100).",
            "timeFrame": "Immediately after the intervention (up to 6 weeks)"
          },
          {
            "measure": "Parkinson's Disease Questionnaire - 39 (PDQ-39)",
            "description": "The PDQ- 39 is a self-report questionnaire that assesses quality of life over the past month across 8 different dimensions. Items are scored based on a 5-point ordinal system with lower scores reflecting better quality of life. Lower scores reflect better quality of life (min = 0, max = 100).",
            "timeFrame": "Follow-up (up to 2 weeks post-intervention)"
          },
          {
            "measure": "Mini Balance Evaluation Systems Test (Mini BESTest)",
            "description": "This test comprises of 14 items that span anticipatory postural adjustments, reactive postural control, sensory orientation, and dynamic gait. The test has a maximum score of 28, with each item is scored from 0-2 (0 = lowest level of function, 2 = highest level of function).",
            "timeFrame": "Baseline"
          },
          {
            "measure": "Mini Balance Evaluation Systems Test (Mini BESTest)",
            "description": "This test comprises of 14 items that span anticipatory postural adjustments, reactive postural control, sensory orientation, and dynamic gait. The test has a maximum score of 28, with each item is scored from 0-2 (0 = lowest level of function, 2 = highest level of function).",
            "timeFrame": "Immediately after the intervention (up to 6 weeks)"
          },
          {
            "measure": "Mini Balance Evaluation Systems Test (Mini BESTest)",
            "description": "This test comprises of 14 items that span anticipatory postural adjustments, reactive postural control, sensory orientation, and dynamic gait. The test has a maximum score of 28, with each item is scored from 0-2 (0 = lowest level of function, 2 = highest level of function).",
            "timeFrame": "Follow-up (up to 2 weeks post-intervention)"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* Diagnosis of idiopathic, typical Parkinson disease (based on the UK PD Society Brain Bank Criteria7) by a physician\n* Modified Hoehn and Yahr stages 1-3 per physical exam by a licensed physical therapist\n* 40 - 85 years of age\n* Community-dwelling\n* Able to walk independently without physical assistance or an assistive device for at least 10 minutes.\n* Have stable PD medications for at least two weeks prior to enrollment.\n* Willing and able to provide informed consent.\n* Provide HIPAA Authorization to allow communication with the primary healthcare provider for communication (as needed) during the study period.\n\nExclusion Criteria:\n\n* \\< 40 years of age\n* Diagnosis of atypical Parkinsonism\n* Modified Hoehn and Yahr stages 4-5\n* Moderately or significantly disturbing freezing episodes during daily walking based on the New Freezing of Gait Questionnaire\n* History of \\>1 fall over the past 3 months\n* Cognitive impairment (i.e., Mini-Mental State Exam Score (MMSE) \\< 24)\n* Unable to walk independently (i.e. without physical assistance or assistive device) at a comfortable speed of 0.4m/s or greater (i.e., 10-meter Walk Test (10mWT))\n* Unable to independently use the music-based digital therapeutic during training\n* Significant hearing impairment\n* Currently participating in physical therapy\n* Currently performing regular walking exercise \\> 3x/week for 30 minutes per session.\n* Cardiac conditions that may limit safe participation in exercise\n* Orthopedic conditions that may limit safe participation in exercise\n* Any other medical conditions that would preclude successful participation as determined by a physical therapist",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "40 Years",
        "maximumAge": "85 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "Franchino Porciuncula, PT, EdD",
            "affiliation": "Boston University",
            "role": "PRINCIPAL_INVESTIGATOR"
          },
          {
            "name": "Terry D. Ellis, PT, PhD",
            "affiliation": "Boston University",
            "role": "PRINCIPAL_INVESTIGATOR"
          }
        ],
        "locations": [
          {
            "facility": "Center for Neurorehabilitation at Boston University",
            "city": "Boston",
            "state": "Massachusetts",
            "zip": "02215",
            "country": "United States",
            "geoPoint": { "lat": 42.35843, "lon": -71.05977 }
          }
        ]
      },
      "referencesModule": {
        "references": [
          {
            "pmid": "25858971",
            "type": "BACKGROUND",
            "citation": "Cavanaugh JT, Ellis TD, Earhart GM, Ford MP, Foreman KB, Dibble LE. Toward Understanding Ambulatory Activity Decline in Parkinson Disease. Phys Ther. 2015 Aug;95(8):1142-50. doi: 10.2522/ptj.20140498. Epub 2015 Apr 9."
          },
          {
            "pmid": "26876037",
            "type": "BACKGROUND",
            "citation": "Ellis TD, Cavanaugh JT, Earhart GM, Ford MP, Foreman KB, Thackeray A, Thiese MS, Dibble LE. Identifying clinical measures that most accurately reflect the progression of disability in Parkinson disease. Parkinsonism Relat Disord. 2016 Apr;25:65-71. doi: 10.1016/j.parkreldis.2016.02.006. Epub 2016 Feb 2."
          },
          {
            "pmid": "24012774",
            "type": "BACKGROUND",
            "citation": "Nombela C, Hughes LE, Owen AM, Grahn JA. Into the groove: can rhythm influence Parkinson's disease? Neurosci Biobehav Rev. 2013 Dec;37(10 Pt 2):2564-70. doi: 10.1016/j.neubiorev.2013.08.003. Epub 2013 Sep 3."
          },
          {
            "pmid": "8684391",
            "type": "BACKGROUND",
            "citation": "Thaut MH, McIntosh GC, Rice RR, Miller RA, Rathbun J, Brault JM. Rhythmic auditory stimulation in gait training for Parkinson's disease patients. Mov Disord. 1996 Mar;11(2):193-200. doi: 10.1002/mds.870110213."
          },
          {
            "pmid": "33040685",
            "type": "BACKGROUND",
            "citation": "Hutchinson K, Sloutsky R, Collimore A, Adams B, Harris B, Ellis TD, Awad LN. A Music-Based Digital Therapeutic: Proof-of-Concept Automation of a Progressive and Individualized Rhythm-Based Walking Training Program After Stroke. Neurorehabil Neural Repair. 2020 Nov;34(11):986-996. doi: 10.1177/1545968320961114. Epub 2020 Oct 10."
          },
          {
            "pmid": "25207647",
            "type": "BACKGROUND",
            "citation": "Gardner B. A review and analysis of the use of 'habit' in understanding, predicting and influencing health-related behaviour. Health Psychol Rev. 2015;9(3):277-95. doi: 10.1080/17437199.2013.876238. Epub 2014 Jan 21."
          },
          {
            "pmid": "25643222",
            "type": "BACKGROUND",
            "citation": "Galla BM, Duckworth AL. More than resisting temptation: Beneficial habits mediate the relationship between self-control and positive life outcomes. J Pers Soc Psychol. 2015 Sep;109(3):508-25. doi: 10.1037/pspp0000026. Epub 2015 Feb 2."
          },
          {
            "pmid": "32083083",
            "type": "BACKGROUND",
            "citation": "Wittwer JE, Winbolt M, Morris ME. Home-Based Gait Training Using Rhythmic Auditory Cues in Alzheimer's Disease: Feasibility and Outcomes. Front Med (Lausanne). 2020 Jan 31;6:335. doi: 10.3389/fmed.2019.00335. eCollection 2019."
          },
          {
            "pmid": "32255504",
            "type": "BACKGROUND",
            "citation": "Jeng B, Cederberg KL, Lai B, Sasaki JE, Bamman MM, Motl RW. Step-rate threshold for physical activity intensity in Parkinson's disease. Acta Neurol Scand. 2020 Aug;142(2):145-150. doi: 10.1111/ane.13250. Epub 2020 Apr 22."
          },
          {
            "pmid": "21798044",
            "type": "BACKGROUND",
            "citation": "Tudor-Locke C, Craig CL, Aoyagi Y, Bell RC, Croteau KA, De Bourdeaudhuij I, Ewald B, Gardner AW, Hatano Y, Lutes LD, Matsudo SM, Ramirez-Marrero FA, Rogers LQ, Rowe DA, Schmidt MD, Tully MA, Blair SN. How many steps/day are enough? For older adults and special populations. Int J Behav Nutr Phys Act. 2011 Jul 28;8:80. doi: 10.1186/1479-5868-8-80."
          }
        ]
      },
      "ipdSharingStatementModule": { "ipdSharing": "NO" }
    },
    "derivedSection": {
      "miscInfoModule": {
        "versionHolder": "2025-05-07",
        "submissionTracking": {
          "estimatedResultsFirstSubmitDate": "2025-01-07",
          "submissionInfos": [
            {
              "releaseDate": "2025-01-07",
              "resetDate": "2025-01-28",
              "mcpReleaseN": 10
            },
            {
              "releaseDate": "2025-02-25",
              "resetDate": "2025-03-13",
              "mcpReleaseN": 11
            }
          ]
        }
      },
      "conditionBrowseModule": {
        "meshes": [{ "id": "D010300", "term": "Parkinson Disease" }],
        "ancestors": [
          { "id": "D020734", "term": "Parkinsonian Disorders" },
          { "id": "D001480", "term": "Basal Ganglia Diseases" },
          { "id": "D001927", "term": "Brain Diseases" },
          { "id": "D002493", "term": "Central Nervous System Diseases" },
          { "id": "D009422", "term": "Nervous System Diseases" },
          { "id": "D009069", "term": "Movement Disorders" },
          { "id": "D000080874", "term": "Synucleinopathies" },
          { "id": "D019636", "term": "Neurodegenerative Diseases" }
        ],
        "browseLeaves": [
          {
            "id": "M13213",
            "name": "Parkinson Disease",
            "asFound": "Parkinson's Disease",
            "relevance": "HIGH"
          },
          {
            "id": "M22494",
            "name": "Parkinsonian Disorders",
            "relevance": "LOW"
          },
          { "id": "M25603", "name": "Ganglion Cysts", "relevance": "LOW" },
          { "id": "M16358", "name": "Synovial Cyst", "relevance": "LOW" },
          {
            "id": "M4774",
            "name": "Basal Ganglia Diseases",
            "relevance": "LOW"
          },
          { "id": "M5204", "name": "Brain Diseases", "relevance": "LOW" },
          {
            "id": "M5742",
            "name": "Central Nervous System Diseases",
            "relevance": "LOW"
          },
          { "id": "M12029", "name": "Movement Disorders", "relevance": "LOW" },
          { "id": "M2217", "name": "Synucleinopathies", "relevance": "LOW" },
          {
            "id": "M21558",
            "name": "Neurodegenerative Diseases",
            "relevance": "LOW"
          }
        ],
        "browseBranches": [
          { "abbrev": "BC10", "name": "Nervous System Diseases" },
          { "abbrev": "All", "name": "All Conditions" },
          { "abbrev": "BC04", "name": "Neoplasms" },
          { "abbrev": "BC17", "name": "Skin and Connective Tissue Diseases" },
          { "abbrev": "BC18", "name": "Nutritional and Metabolic Diseases" }
        ]
      },
      "interventionBrowseModule": {
        "browseLeaves": [
          { "id": "M11767", "name": "Metronidazole", "relevance": "LOW" },
          { "id": "M6263", "name": "Coal Tar", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "Infe", "name": "Anti-Infective Agents" },
          { "abbrev": "All", "name": "All Drugs and Chemicals" },
          { "abbrev": "Derm", "name": "Dermatologic Agents" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT05266716",
        "orgStudyIdInfo": { "id": "Methamphetamine Field Study" },
        "organization": {
          "fullName": "Affect Therapeutics, Inc.",
          "class": "INDUSTRY"
        },
        "briefTitle": "Field Study of a Digital Therapeutic Platform to Facilitate Treatment for Methamphetamine-Primary Stimulant Use Disorder",
        "officialTitle": "Field Study of a Digital Therapeutic Platform to Facilitate Treatment for Methamphetamine-Primary Stimulant Use Disorder"
      },
      "statusModule": {
        "statusVerifiedDate": "2022-02",
        "overallStatus": "COMPLETED",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2021-02-18", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2021-06-30",
          "type": "ACTUAL"
        },
        "completionDateStruct": { "date": "2022-01-07", "type": "ACTUAL" },
        "studyFirstSubmitDate": "2022-01-07",
        "studyFirstSubmitQcDate": "2022-02-23",
        "studyFirstPostDateStruct": { "date": "2022-03-04", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2022-02-23",
        "lastUpdatePostDateStruct": { "date": "2022-03-04", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": {
          "name": "Affect Therapeutics, Inc.",
          "class": "INDUSTRY"
        }
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": false
      },
      "descriptionModule": {
        "briefSummary": "The overall purpose of the observational, investigational pilot study is to assess the clinical utility of the Affect digital health platform (the Affect® \"app\") as part of the Affect program of treatment for methamphetamine-primary stimulant use disorder. The study also will identify elements of the Affect app that enhance engagement of participants in the study toward the goal of improving patient outcomes, including reduction/cessation of stimulant use.",
        "detailedDescription": "The research project is a single-group observational demonstration study to assess the clinical utility of a digital therapeutic technology (the Affect app) in terms of participant acceptance and the app's ability to enhance retention in the Affect program of services for the treatment of individuals with meth-primary stimulant use disorder (MUD). Measures of reduction and/or cessation of methamphetamine use will be assessed by saliva drug tests at least twice weekly during each participant's 8-week involvement in the program, at end of treatment, and via self-report at follow-up points at 1, 3, and 6 months after completion of the program. The app-based program will involve the same services for study participants as would occur regardless of the research, being a standard of care for MUD. The intervention phase of the study will be completed within approximately four months, with follow-ups of the final participants occurring approximately six months after the end of the intervention phase."
      },
      "conditionsModule": { "conditions": ["Methamphetamine Abuse"] },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "NA",
          "interventionModel": "SINGLE_GROUP",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": { "masking": "NONE" }
        },
        "enrollmentInfo": { "count": 79, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "Primary Arm",
            "type": "EXPERIMENTAL",
            "description": "The study will involve a total of approximately 48 individuals enrolled during a six-week period as participants in the field test of the Affect digital therapeutic platform",
            "interventionNames": [
              "Behavioral: Affect Methamphetamine Treatment Program"
            ]
          }
        ],
        "interventions": [
          {
            "type": "BEHAVIORAL",
            "name": "Affect Methamphetamine Treatment Program",
            "description": "Components of the treatment services include: contingency management (CM; monetary incentives for drug tests negative for stimulants), the digital behavioral therapy curriculum (based on CBT) delivered via the Affect app on smartphones, weekly one-on-one telemedicine (TM) with clinical personnel and group therapy, and referral to psychiatrist for medication support, as needed. The program incrementally builds skills and beliefs to develop personally meaningful strategies to combat cravings, using such techniques as regular app-promoted deep breathing exercises, daily exercise, and help in making and sticking to a relapse prevention plan. Counseling sessions are arranged via text sent by the Team Care advocate and also presented to the participant via the app as a reminder. Individual and group therapy sessions occur over Zoom, which is integrated into the app.\n\nContingency Management (CM). CM utilizes monetary incentives and rewards to promote behavior change.",
            "armGroupLabels": ["Primary Arm"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Participant retention in treatment",
            "description": "Consistent with general approaches to measure retention (Hser et al., 2004, McLellan et al., 2006), the outcome will be based on completion as a binary measure at the end of the planned 8-week intervention for each participant. At the end-of-program telephone interview, participants will be deemed to be either treatment completers (i.e., retained) or dropouts (not retained if out of program before the end of week 4). Termination, expulsion, or unexplained non-response to or no contact with Affect personnel for more than seven consecutive days in any period of the 8-week study period equates to \"drop-out\" for the purpose of determining retention.",
            "timeFrame": "Up to 8 weeks through the duration of treatment"
          },
          {
            "measure": "Participant participation in program",
            "description": "The nature/degree of participation in this study is a construct composed of the number of successfully \"attended\" therapeutic tasks/events/activities per the Affect app relative to not-attended events such as: scheduled/planned digital/virtual interactions for program activities (e.g., counseling, group meetings), completed biological assessments (remote drug saliva tests), and kept appointments with referred service providers (e.g., psychiatrists, physicians).",
            "timeFrame": "Up to 8 weeks through the duration of treatment"
          },
          {
            "measure": "Participant engagement with the Affect app",
            "description": "Engagement with the Affect app components will be assessed via app-derived data on activity (i.e., duration, frequency, and consistency of involvement with app-directed tasks).",
            "timeFrame": "Up to 8 weeks through the duration of treatment"
          },
          {
            "measure": "Participant satisfaction with the Affect app",
            "description": "The investigators will assess the results of surveys/questionnaires/focus groups to characterize participant satisfaction with the app and importance of its features in the overall treatment program.",
            "timeFrame": "Up to 8 weeks through the duration of treatment"
          },
          {
            "measure": "Effectiveness in reducing meth use",
            "description": "The effectiveness measure is a composite of self-reported meth use (daily Yes/No) and meth-negative saliva test results (conducted remotely) over the course of each participant's 8-week duration in the program. A participant who provides at least 6 of 8 meth-negative saliva tests during the final 4 weeks of the 8-week program meets criteria for reduction/cessation of meth and thus demonstrates within-participant effectiveness of the program. Characteristics of the participants will be explored for possible associated factors that correlate with variations in outcomes across the sample.",
            "timeFrame": "Up to 8 weeks through the duration of treatment"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "To be eligible to participate in the study, prospective participants must:\n\n1. Be 18 years of age or older;\n2. Have methamphetamine use disorder (MUD) or documented high-risk methamphetamine use history, confirmed by DSM-5 criteria for stimulant use disorder, methamphetamine type;\n3. Have stated interest in reducing and/or stopping methamphetamine use;\n4. Have and be able to use a smartphone and agree to download and use the Affect app as part of treatment and study-related procedures;\n5. Have a health insurance plan (or Medicaid) to ensure that participants have access to medical care if needed;\n6. Be English speaking and have reading capacity sufficient to understand explanations of study procedures and the informed consent to participate;\n7. Be a California resident with a mailing address or P.O. Box\n8. Be able to freely give informed consent and be willing to electronically sign the digital informed consent to participate in the study;\n9. Be willing to comply with study procedures, including use of the Affect app consistent with the study protocol and therapeutic activities.\n\nIII.6 EXCLUSION CRITERIA\n\nIndividuals will be precluded from enrolling in the study if they endorse (or if there is documentation of) any of following conditions. Already enrolled participants will be withdrawn from study participation upon emergence of any excluded condition (except pregnancy):\n\n1. Serious medical diagnoses (e.g., seizure, stroke, heart disease);\n2. Serious mental illness (e.g., schizophrenia, bipolar, active suicidality);\n3. Moderate- to severe-level opioid use disorder or alcohol use disorder;\n4. Pregnancy;\n5. Have been in a prior study of pharmacological or behavioral treatment for MUD within 6 months of study consent;\n6. Be concurrently receiving other behavioral or pharmacological services for treatment of MUD;\n7. Have pending legal action or other situation that could inhibit consistent participation in the study or in study activities.",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "Michael Zito, MD",
            "affiliation": "University of California, Los Angeles",
            "role": "PRINCIPAL_INVESTIGATOR"
          }
        ],
        "locations": [
          {
            "facility": "Affect Therapeutics",
            "city": "New York",
            "state": "New York",
            "zip": "10012",
            "country": "United States",
            "geoPoint": { "lat": 40.71427, "lon": -74.00597 }
          }
        ]
      },
      "ipdSharingStatementModule": {
        "ipdSharing": "NO",
        "description": "No participant data will be shared."
      }
    },
    "documentSection": {
      "largeDocumentModule": {
        "largeDocs": [
          {
            "typeAbbrev": "ICF",
            "hasProtocol": false,
            "hasSap": false,
            "hasIcf": true,
            "label": "Informed Consent Form",
            "date": "2021-02-18",
            "uploadDate": "2022-02-15T15:51",
            "filename": "ICF_000.pdf",
            "size": 303124
          }
        ]
      }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "interventionBrowseModule": {
        "meshes": [{ "id": "D008694", "term": "Methamphetamine" }],
        "ancestors": [
          { "id": "D000697", "term": "Central Nervous System Stimulants" },
          { "id": "D045505", "term": "Physiological Effects of Drugs" },
          { "id": "D013566", "term": "Sympathomimetics" },
          { "id": "D001337", "term": "Autonomic Agents" },
          { "id": "D018373", "term": "Peripheral Nervous System Agents" },
          { "id": "D015259", "term": "Dopamine Agents" },
          { "id": "D018377", "term": "Neurotransmitter Agents" },
          {
            "id": "D045504",
            "term": "Molecular Mechanisms of Pharmacological Action"
          },
          { "id": "D018663", "term": "Adrenergic Agents" },
          { "id": "D018759", "term": "Adrenergic Uptake Inhibitors" },
          { "id": "D014179", "term": "Neurotransmitter Uptake Inhibitors" },
          { "id": "D049990", "term": "Membrane Transport Modulators" },
          { "id": "D018765", "term": "Dopamine Uptake Inhibitors" }
        ],
        "browseLeaves": [
          {
            "id": "M11674",
            "name": "Methamphetamine",
            "asFound": "Relapsing Multiple Sclerosis",
            "relevance": "HIGH"
          },
          {
            "id": "M4029",
            "name": "Central Nervous System Stimulants",
            "relevance": "LOW"
          },
          { "id": "M16345", "name": "Sympathomimetics", "relevance": "LOW" },
          { "id": "M7473", "name": "Dopamine", "relevance": "LOW" },
          { "id": "M17962", "name": "Dopamine Agents", "relevance": "LOW" },
          {
            "id": "M20504",
            "name": "Neurotransmitter Agents",
            "relevance": "LOW"
          },
          { "id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW" },
          {
            "id": "M20832",
            "name": "Dopamine Uptake Inhibitors",
            "relevance": "LOW"
          }
        ],
        "browseBranches": [
          { "abbrev": "CNSSti", "name": "Central Nervous System Stimulants" },
          { "abbrev": "All", "name": "All Drugs and Chemicals" },
          { "abbrev": "CaAg", "name": "Cardiotonic Agents" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT05031416",
        "orgStudyIdInfo": { "id": "IRB00273925" },
        "secondaryIdInfos": [
          {
            "id": "P50MH115842",
            "type": "NIH",
            "link": "https://reporter.nih.gov/quickSearch/P50MH115842"
          }
        ],
        "organization": {
          "fullName": "Johns Hopkins University",
          "class": "OTHER"
        },
        "briefTitle": "Developing and Pilot Testing a Remote Smoking Cessation Digital Therapeutic for Individuals With Serious Mental Illness",
        "officialTitle": "Developing and Pilot Testing a Remote Smoking Cessation Digital Therapeutic for Individuals With Serious Mental Illness"
      },
      "statusModule": {
        "statusVerifiedDate": "2025-04",
        "overallStatus": "WITHDRAWN",
        "whyStopped": "Decided not to proceed with the study at this time.",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2025-06", "type": "ESTIMATED" },
        "primaryCompletionDateStruct": {
          "date": "2025-12",
          "type": "ESTIMATED"
        },
        "completionDateStruct": { "date": "2025-12", "type": "ESTIMATED" },
        "studyFirstSubmitDate": "2021-08-12",
        "studyFirstSubmitQcDate": "2021-08-26",
        "studyFirstPostDateStruct": { "date": "2021-09-01", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2025-04-01",
        "lastUpdatePostDateStruct": { "date": "2025-04-04", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": { "name": "Johns Hopkins University", "class": "OTHER" },
        "collaborators": [
          {
            "name": "National Institute of Mental Health (NIMH)",
            "class": "NIH"
          }
        ]
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": false,
        "isUsExport": false
      },
      "descriptionModule": {
        "briefSummary": "This is a pilot randomized clinical trial testing an implementation intervention to support delivery of a smoking cessation app tailored to the needs of those individuals with SMI who at community mental health programs.",
        "detailedDescription": "Learn to Quit (LTQ), an evidence-based smoking cessation app tailored to the needs of individuals with serious mental illness (SMI) that demonstrated promising smoking cessation outcomes in a recent pilot randomized controlled trial (R00 DA037276). In parallel, several trials demonstrated that widely available social media platforms can be effectively utilized to enhance the effects of standard of care evidence-based smoking cessation treatments. Both approaches capitalize on highly scalable digital technologies, and are therefore likely to have population level impact. Drawing from these two separate programs of research, the central premise of this proposal is that LTQ, a stand-alone smoking cessation app tailored to patients with SMI, can be enhanced with peer-support delivered on social media. Therefore, this proposal seeks to develop and asses the acceptability and feasibility of LTQ-Connect -- the integration of the evidence-based smoking cessation app, LTQ, with social support delivered via social media -- to boost the efficacy and community reach of digital therapeutics tailored for patients with SMI. To achieve this goal, we will:\n\n(1) determine the ideal design requirements of an LTQ-Connect integration among smokers with SMI, and (2) investigate the feasibility of LTQ-Connect in a single group pilot trial. Both interventions will be combined with nicotine replacement therapy, a safe and widely available medication."
      },
      "conditionsModule": { "conditions": ["Smoking Cessation"] },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "NA",
          "interventionModel": "SINGLE_GROUP",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": { "masking": "NONE" }
        },
        "enrollmentInfo": { "count": 0, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "Consumers who smoke at outpatient community mental health clinic",
            "type": "EXPERIMENTAL",
            "description": "Consumers with serious mental illness who attend outpatient community mental health clinic will participate in a smoking cessation with the LTQ application and nicotine replacement therapy",
            "interventionNames": ["Combination Product: LTQ"]
          }
        ],
        "interventions": [
          {
            "type": "COMBINATION_PRODUCT",
            "name": "LTQ",
            "description": "The investigators will test the LTQ-Connect application and a standard 10-week course of nicotine replacement therapy (NRT) nicotine patches, and Facebook groups, which will run for a total of 3 months with research study participants",
            "armGroupLabels": [
              "Consumers who smoke at outpatient community mental health clinic"
            ]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Change in Self reported social support",
            "description": "An adapted version of Online Social Support (OSS) scale for smokers will be used to evaluate self-reported social support from online smoking cessation treatment (LTQapp + Facebook group) The OSS scale is a 14 item scale with choices - 1 disagree a lot, to 4 agree a lot. Scale range 14- 56 with higher score indicating better outcome.",
            "timeFrame": "13 weeks"
          },
          {
            "measure": "App Usability",
            "description": "The System Usability Scale (SUS) is a 10-item scale used to evaluate usability of the LTQ-Connect app. Choices range from 1 strongly disagree, to 5 Strongly agree. Scale range 10-50 with higher score indicating more agreement.",
            "timeFrame": "13 weeks"
          },
          {
            "measure": "Number of user Interactions with the Learn to Quit (LTQ) app",
            "description": "Google Analytics will be used to extract number of daily app interactions and duration of engagement with LTQ app.",
            "timeFrame": "13 weeks"
          },
          {
            "measure": "Duration of user Interactions with the Learn to Quit (LTQ) app",
            "description": "Google Analytics will be used to extract daily duration of interactions with LTQ app in minutes.",
            "timeFrame": "13 weeks"
          },
          {
            "measure": "User Engagement with Facebook groups - Posts",
            "description": "The Facebook API will be used to extract number of Facebook posts.",
            "timeFrame": "13 weeks"
          },
          {
            "measure": "User Engagement with Facebook groups - Comments",
            "description": "The Facebook application programming interface (API) will be used to extract number of Facebook comments.",
            "timeFrame": "13 weeks"
          },
          {
            "measure": "User Engagement with Facebook groups - Likes",
            "description": "The Facebook API will be used to extract number of Facebook likes.",
            "timeFrame": "13 weeks"
          },
          {
            "measure": "User Engagement with Facebook groups - Content",
            "description": "The Facebook API will be used to extract engagement content of Facebook posts, comments, and 'likes.'",
            "timeFrame": "13 weeks"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Change in number of cigarettes smoked per day",
            "description": "The Smoking timeline follow-back (TLFB) will be used to estimate the number of cigarettes per day",
            "timeFrame": "Week 5, Week 9, and Week 13"
          },
          {
            "measure": "Psychiatric Functioning",
            "description": "The Brief Symptom Inventory (BSI) assesses distress participants are experiencing. The BSI is a 13 item scale with choices 0=not at all, to 4= Extremely. A higher score indicates more distress. Score range 0-52.",
            "timeFrame": "Week 5, Week 9, and Week 13"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* Must be a mental health consumer at Johns Hopkins Bayview Adult Psychiatry Program\n* A regular smoker who is willing to quit\n* Own a smart cell phone\n* Willing to participate\n\nExclusion Criteria:\n\n* Women who report being pregnant or have the intention to become pregnant in the 3 months",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "Gail Daumit",
            "affiliation": "Johns Hopkins University",
            "role": "PRINCIPAL_INVESTIGATOR"
          }
        ],
        "locations": [
          {
            "facility": "Johns Hopkins University School of Medicine",
            "city": "Baltimore",
            "state": "Maryland",
            "zip": "21287",
            "country": "United States",
            "geoPoint": { "lat": 39.29038, "lon": -76.61219 }
          }
        ]
      },
      "ipdSharingStatementModule": { "ipdSharing": "NO" }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [{ "id": "D001523", "term": "Mental Disorders" }],
        "browseLeaves": [
          {
            "id": "M4815",
            "name": "Mental Disorders",
            "asFound": "Mental Illness",
            "relevance": "HIGH"
          },
          { "id": "M14473", "name": "Psychotic Disorders", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" },
          { "abbrev": "All", "name": "All Conditions" }
        ]
      },
      "interventionBrowseModule": {
        "browseLeaves": [
          { "id": "M12478", "name": "Nicotine", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "All", "name": "All Drugs and Chemicals" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT06653829",
        "orgStudyIdInfo": { "id": "NST-SPARK-1b" },
        "organization": {
          "fullName": "North Shore Therapeutics, Inc.",
          "class": "INDUSTRY"
        },
        "briefTitle": "NST-SPARK: Preliminary Study of an Augmented Reality (AR) App Delivering Recovery-Oriented Cognitive Therapy for Negative Symptoms in Schizophrenia",
        "officialTitle": "NST-SPARK: Preliminary Study of an Augmented Reality (AR) App Delivering Recovery-Oriented Cognitive Therapy for Negative Symptoms in Schizophrenia",
        "acronym": "NST-SPARK-1b"
      },
      "statusModule": {
        "statusVerifiedDate": "2024-10",
        "overallStatus": "COMPLETED",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2023-11-06", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2024-08-31",
          "type": "ACTUAL"
        },
        "completionDateStruct": { "date": "2024-08-31", "type": "ACTUAL" },
        "studyFirstSubmitDate": "2024-01-26",
        "studyFirstSubmitQcDate": "2024-10-21",
        "studyFirstPostDateStruct": { "date": "2024-10-22", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2024-10-21",
        "lastUpdatePostDateStruct": { "date": "2024-10-22", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": {
          "name": "North Shore Therapeutics, Inc.",
          "class": "INDUSTRY"
        }
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": true,
        "isUsExport": false
      },
      "descriptionModule": {
        "briefSummary": "This study evaluates the feasibility and acceptability of a prototype for NST-SPARK (version 1.5). This is an augmented reality (AR) mobile phone application that uses Recovery-oriented Cognitive Therapy (CT-R) to target negative symptoms of schizophrenia.\n\nNST-SPARK uses a game AR activity to recapitulate the beginning activation and engagement phase of each CT-R session as per standardized practices for this therapeutic modality.",
        "detailedDescription": "The specific beliefs targeted during each module are queried before engaging in the AR activity to obtain participant buy in. A self-assessment is taken before and then subsequent prompts challenge these beliefs over the course of the activity. After completion of the AR activity the self-assessment is performed again and the results are compared against the pre-activity responses.\n\nThe responses received pre- and then post- activity determine the responses SPARK provides to the participant.\n\nExample: Question: How ambitious or motivated do you feel now?\n\nIf the post activity response shows a higher level of motivation compared to the pre-activity assessment the participant will receive the following: So you felt more motivated and more energized! And you did more work not less! Like the more you do the better you feel.\n\nThe prototype NST-SPARK v.1.5 has 2 modules: 1) SPARK ENERGY and 2) SPARK MOTIVATION, and is an abbreviated experience following the general framework for NST-SPARK."
      },
      "conditionsModule": {
        "conditions": [
          "Negative Symptoms in Schizophrenia",
          "Schizophrenia",
          "Schizoaffective Disorder"
        ],
        "keywords": [
          "Schizophrenia",
          "Digital Therapeutic",
          "Schizoaffective disorder",
          "Negative Symptoms"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "NA",
          "interventionModel": "SINGLE_GROUP",
          "interventionModelDescription": "A group of participants will be introduced to the device and preliminary feasibility, acceptability, and initial target engagement will be assessed.",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": { "masking": "NONE" }
        },
        "enrollmentInfo": { "count": 20, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "SSD",
            "type": "EXPERIMENTAL",
            "description": "The study design for participants with SSD is a single-arm open-label intervention study. We will collect descriptive information on feasibility and acceptability. Changes in defeatist beliefs and attitudes toward behavioral changes will be evaluated by comparing self-reported ratings before the app intervention vs. immediately afterward and at the 1-week follow-up. All visits will be conducted over video conference with a trained research coordinator.",
            "interventionNames": ["Device: SPARK"]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "SPARK",
            "description": "A gamified augmented reality activity to recapitulate the beginning activation and engagement phase of each recovery-oriented cognitive therapy (CT-R) session",
            "armGroupLabels": ["SSD"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Acceptability of NST-SPARK",
            "description": "Measured by average ratings from the self-reported questionnaire (Acceptability of Intervention Measure, scored from 1-5 with 5 representing the highest level of acceptability).",
            "timeFrame": "This measure will be collected twice: 1) at the first study visit, immediately after using the intervention, and 2) at the 1 week follow-up."
          },
          {
            "measure": "Feasibility of NST-SPARK",
            "description": "Measured by average ratings from self-reported questionnaire (Feasibility of Intervention Measure - FIM), scored from 1-5 with 5 representing the highest level of feasibility)",
            "timeFrame": "This measure will be collected twice: 1) at the first study visit, immediately after using the intervention, and 2) at the 1 week follow-up."
          },
          {
            "measure": "Open-ended feedback about the NST-SPARK user experience",
            "description": "Qualitative summary of responses to semi-structured open-ended interview to be conducted with participants, eliciting responses to questions like the following:\n\nWhat are your first impressions? What do you like most about the app? What do you like least about the app or what are some areas that need to be improved? Did you experience any negative effects from using the app? For example, dizziness, vertigo, or changes in your symptoms? Do you think you'd be able to use this app from a technical perspective? Does it seem simple enough to operate? If no, which parts seemed confusing or difficult? (Imagine that we added similar but more elaborate experiences for a 12-week long experience, and also provided guides for reaching your goals in the real world.) Would you use this app if your doctor prescribed it for you? What makes you say that?",
            "timeFrame": "This measure will be collected twice: 1) at the first study visit, immediately after using the intervention, and 2) at the 1 week follow-up."
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Changes in defeatist beliefs",
            "description": "Measured by a self-reported scale (Defeatist Beliefs Scale - 5 items scored from 1-7 with 7 being the lowest level of defeatist beliefs).",
            "timeFrame": "This measure will be collected three times: 1) at the first study visit, before using the intervention, 2) at the first study visit, immediately after using the intervention, and 3) at the 1 week follow-up."
          },
          {
            "measure": "Attitude toward goal-oriented activities",
            "description": "Customized likert scale and semi-structured questions about participant attitudes toward goals they have identified. Results to be reported quantitatively as degree of agreement with statements regarding intention and confidence in making progress toward the goals (scale from 1-5, 5 being the highest level of agreement). Also reporting yes/no and descriptive responses regarding progress toward goals which will be summarized as a percentage of participants who made progress (or not) and as qualitative responses.",
            "timeFrame": "This measure will be collected three times: 1) at the first study visit, before using the intervention, 2) at the first study visit, immediately after using the intervention, and 3) at the 1 week follow-up."
          },
          {
            "measure": "Changes in Self Esteem",
            "description": "Beck Self Esteem Scale with 18 items rated from 1-10 with 10 representing the lowest level of self esteem.",
            "timeFrame": "This measure will be collected three times: 1) at the first study visit, before using the intervention, 2) at the first study visit, immediately after using the intervention, and 3) at the 1 week follow-up."
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* Meets DSM-5 criteria for schizophrenia, schizoaffective disorder, schizophreniform disorder, or unspecified psychotic disorder.\n* Presence of negative symptoms - SANS rating of 2 or higher on either Avolition/Apathy or Anhedonia/Asociality subscale.\n* Capacity to understand the study procedures and provide informed consent.\n* Has dependable access to a device with videoconferencing capability and stable wifi connection which can be accessed by the study iPhone.\n* Proficient in English.\n\nExclusion Criteria:\n\n* Recent change in level of care: antipsychotic medication changes in the last 4 weeks OR hospitalization or emergency room/crisis visits in the last 12 weeks.\n* Acute safety risk - any indication of ongoing risk to themselves or others.\n* Substance induced psychotic disorder or primary mood disorder with psychosis.\n* Severe cognitive or physical limitations preventing the participant from being able to independently use NST-SPARK.",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "maximumAge": "65 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "Sunny X Tang, M.D.",
            "affiliation": "North Shore Therapeutics",
            "role": "PRINCIPAL_INVESTIGATOR"
          }
        ],
        "locations": [
          {
            "facility": "North Shore Therapeutics, Inc.",
            "city": "Rochester",
            "state": "Minnesota",
            "zip": "55902",
            "country": "United States",
            "geoPoint": { "lat": 44.02163, "lon": -92.4699 }
          }
        ]
      },
      "referencesModule": {
        "references": [
          {
            "pmid": "2695141",
            "type": "BACKGROUND",
            "citation": "Andreasen NC. The Scale for the Assessment of Negative Symptoms (SANS): conceptual and theoretical foundations. Br J Psychiatry Suppl. 1989 Nov;(7):49-58. No abstract available."
          },
          {
            "pmid": "20059765",
            "type": "BACKGROUND",
            "citation": "Ascher-Svanum H, Zhu B, Faries DE, Salkever D, Slade EP, Peng X, Conley RR. The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC Psychiatry. 2010 Jan 7;10:2. doi: 10.1186/1471-244X-10-2."
          },
          {
            "pmid": "25403863",
            "type": "BACKGROUND",
            "citation": "Carbon M, Correll CU. Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia. CNS Spectr. 2014 Dec;19 Suppl 1:38-52; quiz 35-7, 53. doi: 10.1017/S1092852914000601. Epub 2014 Nov 18."
          },
          {
            "pmid": "29800949",
            "type": "BACKGROUND",
            "citation": "Correll CU, Galling B, Pawar A, Krivko A, Bonetto C, Ruggeri M, Craig TJ, Nordentoft M, Srihari VH, Guloksuz S, Hui CLM, Chen EYH, Valencia M, Juarez F, Robinson DG, Schooler NR, Brunette MF, Mueser KT, Rosenheck RA, Marcy P, Addington J, Estroff SE, Robinson J, Penn D, Severe JB, Kane JM. Comparison of Early Intervention Services vs Treatment as Usual for Early-Phase Psychosis: A Systematic Review, Meta-analysis, and Meta-regression. JAMA Psychiatry. 2018 Jun 1;75(6):555-565. doi: 10.1001/jamapsychiatry.2018.0623."
          },
          {
            "pmid": "37035477",
            "type": "BACKGROUND",
            "citation": "Ford TJ, Buchanan DM, Azeez A, Benrimoh DA, Kaloiani I, Bandeira ID, Hunegnaw S, Lan L, Gholmieh M, Buch V, Williams NR. Taking modern psychiatry into the metaverse: Integrating augmented, virtual, and mixed reality technologies into psychiatric care. Front Digit Health. 2023 Mar 24;5:1146806. doi: 10.3389/fdgth.2023.1146806. eCollection 2023."
          },
          {
            "pmid": "37145841",
            "type": "BACKGROUND",
            "citation": "Lundin RM, Yeap Y, Menkes DB. Adverse Effects of Virtual and Augmented Reality Interventions in Psychiatry: Systematic Review. JMIR Ment Health. 2023 May 5;10:e43240. doi: 10.2196/43240."
          },
          {
            "pmid": "28851459",
            "type": "BACKGROUND",
            "citation": "Weiner BJ, Lewis CC, Stanick C, Powell BJ, Dorsey CN, Clary AS, Boynton MH, Halko H. Psychometric assessment of three newly developed implementation outcome measures. Implement Sci. 2017 Aug 29;12(1):108. doi: 10.1186/s13012-017-0635-3."
          }
        ]
      },
      "ipdSharingStatementModule": {
        "ipdSharing": "YES",
        "description": "Deidentified individual responses and metadata will be shared for peer review purposes",
        "infoTypes": ["STUDY_PROTOCOL", "SAP"],
        "timeFrame": "metadata will become available after study termination for an indefinite period.",
        "accessCriteria": "Eligible researchers"
      }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [
          { "id": "D012559", "term": "Schizophrenia" },
          { "id": "D011618", "term": "Psychotic Disorders" }
        ],
        "ancestors": [
          {
            "id": "D019967",
            "term": "Schizophrenia Spectrum and Other Psychotic Disorders"
          },
          { "id": "D001523", "term": "Mental Disorders" }
        ],
        "browseLeaves": [
          {
            "id": "M15376",
            "name": "Schizophrenia",
            "asFound": "Schizophrenia",
            "relevance": "HIGH"
          },
          {
            "id": "M14473",
            "name": "Psychotic Disorders",
            "asFound": "Schizoaffective Disorder",
            "relevance": "HIGH"
          },
          { "id": "M4815", "name": "Mental Disorders", "relevance": "LOW" },
          {
            "id": "M21838",
            "name": "Schizophrenia Spectrum and Other Psychotic Disorders",
            "relevance": "LOW"
          }
        ],
        "browseBranches": [
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" },
          { "abbrev": "All", "name": "All Conditions" }
        ]
      },
      "interventionBrowseModule": {
        "browseLeaves": [
          { "id": "M15642", "name": "Silver Sulfadiazine", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "Infe", "name": "Anti-Infective Agents" },
          { "abbrev": "All", "name": "All Drugs and Chemicals" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT06295185",
        "orgStudyIdInfo": { "id": "AJOUIRB-IV-2024-097" },
        "organization": {
          "fullName": "Ajou University School of Medicine",
          "class": "OTHER"
        },
        "briefTitle": "Digital Therapeutic Workplace Technology as a Employee Management Tool and Employee's Mental Health Care",
        "officialTitle": "How Social Ventures Boost Performance and Sustain Businesses With Digital Therapeutic Workplace Technology (Smartphone App 'Maro') Designed to Support Individual Employee's Mental Health"
      },
      "statusModule": {
        "statusVerifiedDate": "2024-09",
        "overallStatus": "COMPLETED",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2024-05-20", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2024-07-31",
          "type": "ACTUAL"
        },
        "completionDateStruct": { "date": "2024-07-31", "type": "ACTUAL" },
        "studyFirstSubmitDate": "2024-02-16",
        "studyFirstSubmitQcDate": "2024-03-03",
        "studyFirstPostDateStruct": { "date": "2024-03-06", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2024-09-09",
        "lastUpdatePostDateStruct": { "date": "2024-09-19", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": {
          "type": "PRINCIPAL_INVESTIGATOR",
          "investigatorFullName": "Chang Hyung Hong",
          "investigatorTitle": "Principal Investigator",
          "investigatorAffiliation": "Ajou University School of Medicine"
        },
        "leadSponsor": {
          "name": "Ajou University School of Medicine",
          "class": "OTHER"
        }
      },
      "oversightModule": {
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": false
      },
      "descriptionModule": {
        "briefSummary": "The purpose of the study is to determine whether a digital healthcare app for employee's mental health can effectively improve the mental health of Hisbeans's employees and the managerial performance of Hisbeans, which is represented as a 'social enterprise'.",
        "detailedDescription": "Hisbeans is a social enterprise where employees are consist of individual with mental disabilities.\n\n'Hisbeans' employees(N = 150 subjects) will be randomly assigned to Group 1 (maro intervention), or Group 2 (control app intervention) by cluster randomization depending on the branch of the company.\n\n* MARO intervention group: MARO (mental health digital application) use\n* Control group: sham app use\n\nThe intervention period will be 8weeks."
      },
      "conditionsModule": {
        "conditions": ["Depression", "Mental Health Issue"]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": { "masking": "SINGLE", "whoMasked": ["PARTICIPANT"] }
        },
        "enrollmentInfo": { "count": 165, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "mental health treated with digital intervention app 'Maro'",
            "type": "EXPERIMENTAL",
            "description": "Intervention group will use 'Maro app' which was developed to improve mental health for 8weeks.\n\nThrough 8weeks intervention group will record their status more than once a day and utilize specific functions in the app.\n\nThey will also have meetings once a week in the online chat in order to share their own experience about Maro application use with other employees in the same branch.",
            "interventionNames": ["Other: application MARO"]
          },
          {
            "label": "Digital Sham App",
            "type": "SHAM_COMPARATOR",
            "description": "Control group will use Sham app for 8weeks.",
            "interventionNames": ["Other: Sham application"]
          }
        ],
        "interventions": [
          {
            "type": "OTHER",
            "name": "application MARO",
            "description": "It is a mental healthcare application aim to improve mental health.",
            "armGroupLabels": [
              "mental health treated with digital intervention app 'Maro'"
            ]
          },
          {
            "type": "OTHER",
            "name": "Sham application",
            "description": "It is a sham application in order to control spill over bias.",
            "armGroupLabels": ["Digital Sham App"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Change in network on the Standard Name Generator Approach scale",
            "description": "* Description: A validated self-reported list of names assessing the subject's network scores\n* minimum and maximum values: from no name to the maximum available subject employees in the focal company that subject employees work for\n* score meaning: an individual subject generating more names means he or she has more connected people in the company",
            "timeFrame": "4weeks, 8weeks after starting treatment"
          },
          {
            "measure": "Change in depression symptoms severity on the Patient Health Questionnaire-9",
            "description": "* Description: Validated self-reported questionnaire assessing the severity of depression symptom\n* minimum and maximum values: 9-item scale with total scores between 0 and 27\n* score meaning: higher scores indicate greater symptoms severity",
            "timeFrame": "4weeks, 8weeks after starting treatment"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Change in social capital on the Social Capital Scale",
            "description": "* Description: Based on the validated self-reported name assessing the person's network scores, researchers calculate the inverse degree to which individuals hold less constraints in the network landscape\n* minimum and maximum values: a scale between 0 and 1 multiplied by the number of subjects individuals\n* score meaning: higher scores indicate greater social capital",
            "timeFrame": "4weeks, 8weeks after starting treatment"
          },
          {
            "measure": "Change in perceived workload on the Perceived Workload Scale",
            "description": "* Description: Validated self-reported questionnaire assessing the complexity of jobs and the work-related stress\n* minimum and maximum values: a 4-item scale with total scores between 0 and 28\n* score meaning: higher scores indicate greater perceived workload",
            "timeFrame": "4weeks, 8weeks after starting treatment"
          },
          {
            "measure": "Change in job self-efficacy on the Job Self-Efficacy Scale",
            "description": "* Description: Validated self-reported questionnaire assessing the efficacy of one's job and tasks\n* minimum and maximum values: a 11-item scale with total scores between 0 and 77\n* score meaning: higher scores indicate greater job self-efficacy",
            "timeFrame": "4weeks, 8weeks after starting treatment"
          },
          {
            "measure": "Change in sense of meaningfulness for job on the Sense of Meaningfulness for Job Scale",
            "description": "* Description: Validated self-reported questionnaire assessing the sense of meaningfulness toward one's job\n* minimum and maximum values: a 6-item scale with total scores between 0 and 42\n* score meaning: higher scores indicate greater sense of meaningfulness for job",
            "timeFrame": "4weeks, 8weeks after starting treatment"
          },
          {
            "measure": "Change in work orientation toward his or her job on the Work Orientation Scale",
            "description": "* Description: Validated self-reported questionnaire assessing one's work orientation toward his or her job\n* minimum and maximum values: categorical values among 'economic-value group', 'achievement group', and 'calling group'\n* score meaning: one sorting into a certain categorical value means one such",
            "timeFrame": "4weeks, 8weeks after starting treatment"
          },
          {
            "measure": "Change in sense of psychological safety on the Perception of Psychological Safety Scale of Company Employees",
            "description": "* Description: Validated self-reported questionnaire assessing one's perception of psychological safety within the company\n* minimum and maximum values: a 7-item scale with average scores between 0 and 7\n* score meaning: higher scores indicate greater sense of psychological safety",
            "timeFrame": "4weeks, 8weeks after starting treatment"
          },
          {
            "measure": "Change in firm performance on the Company weekly sales records",
            "description": "* Description: Validated objective measure of firm's performance assessing the department's weekly revenue\n* minimum and maximum values: a monetary scale between 0 and possibly generatable revenue during firm's operation time\n* score meaning: higher sales indicate greater firm performance",
            "timeFrame": "4weeks, 8weeks after starting treatment"
          },
          {
            "measure": "Change in amsenteeism/leaves on the absenteeism/leave scales for employees with severe mental disabilities",
            "description": "* Description: Validated numeric, objective measure assessing the individual employees' absenteeism or turnover cases, among which we also measure the employees with severe mental disabilities.\n* minimum and maximum values: the number of individuals scale between 0 and the maximum possible employees working for the firm.\n* score meaning: higher number indicates greater amsenteeism/leaves",
            "timeFrame": "4weeks, 8weeks after starting treatment"
          },
          {
            "measure": "Change in stress regulation skill on the Emotional/Cognitive/Behavioral State Questionnaire",
            "description": "* Description: self-reported questionnaire assessing stress regulation skill\n* minimum and maximum values: 3-item scale with total scores between 3 and 30\n* score meaning: higher scores indicate greater stress regulation skill",
            "timeFrame": "4weeks, 8weeks after starting treatment"
          },
          {
            "measure": "Change in anxiety symptoms severity on the General Anxiety Disorder-7items scale",
            "description": "* Description: Validated self-reported questionnaire assessing the severity of anxiety symptom\n* minimum and maximum values: 7-item scale with total scores between 0 and 21\n* score meaning: higher scores indicate greater symptoms severity",
            "timeFrame": "4weeks, 8weeks after starting treatment"
          },
          {
            "measure": "Change in perceived stress level on the Perceived Stress Scale",
            "description": "* Description: Validated self-reported questionnaire assessing perceived stress\n* minimum and maximum values: 10 scale with total scores between 0 and 40\n* score meaning: higher scores indicate greater perceived stress",
            "timeFrame": "4weeks, 8weeks after starting treatment"
          },
          {
            "measure": "Change in social functioning on Social Adaptation Self Rating Scale",
            "description": "* Description: Validated self-reported questionnaire assessing social motivation and behavior\n* minimum and maximum values: 21-item scale with total scores between 21 and 84\n* score meaning: higher scores indicate greater social functioning",
            "timeFrame": "4weeks, 8weeks after starting treatment"
          },
          {
            "measure": "Change in positive psychological capital on Korean version of Positive Psychological Capital Scale",
            "description": "* Description: Validated self-reported questionnaire assessing positive psychological capital, which consist of self-efficacy, hope, optimism, and resilience\n* minimum and maximum values: 18-item scale with total scores between 18 and 90\n* score meaning: higher scores indicate greater Positive Psychological Capital",
            "timeFrame": "4weeks, 8weeks after starting treatment"
          },
          {
            "measure": "Change in Organizational Companionship on Organizational Culture Inventory",
            "description": "* Description: Validated self-reported questionnaire assessing Organizational Companionship\n* minimum and maximum values: 28-item scale with total scores between 28 and 196\n* score meaning: higher scores indicate a higher degress of organizational companionship",
            "timeFrame": "4weeks, 8weeks after starting treatment"
          },
          {
            "measure": "Change in individual's social network on Lubben Social Network Scale-18",
            "description": "* Description: Validated self-reported questionnaire assessing an individual's social network of relatives, friends, and neighbors.\n* minimum and maximum values: 18-item scale with total scores between 0 and 90\n* score meaning: higher scores indicate a larger social network",
            "timeFrame": "4weeks, 8weeks after starting treatment"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n1. HISBEANS store employees\n2. Age: 18 years old or older\n3. possessing a smartphone with internet connection\n4. subjects agree to participate in the study\n\nExclusion Criteria:\n\n1. Those who have symptoms of psychotic disorder are acutely active or advanced, making clinical intervention difficult\n2. Those who has been started or changed their antidepressant medication within the last 1 month or cannot be maintained stably during the intervention period\n3. Those who are non-literate\n4. Those who have used the Maro app previously\n5. Those who couldn't use Maro app in their own smartphone\n6. Those who participate in another intervention study\n7. Those who have a serious medical condition that prevents them from participating in the intervention and efficacy evaluation\n8. Those who is unable to participate fully and cooperatively by the judgment of the researcher",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "Chang Hyung Hong, Ph.D",
            "affiliation": "Ajou Medical Center",
            "role": "PRINCIPAL_INVESTIGATOR"
          }
        ],
        "locations": [
          {
            "facility": "Ajou Medical University",
            "city": "Suwon",
            "zip": "16499",
            "country": "Korea, Republic of",
            "geoPoint": { "lat": 37.29111, "lon": 127.00889 }
          }
        ]
      },
      "ipdSharingStatementModule": { "ipdSharing": "NO" }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [{ "id": "D003863", "term": "Depression" }],
        "ancestors": [{ "id": "D001526", "term": "Behavioral Symptoms" }],
        "browseLeaves": [
          { "id": "M7061", "name": "Depressive Disorder", "relevance": "LOW" },
          {
            "id": "M7058",
            "name": "Depression",
            "asFound": "Depression",
            "relevance": "HIGH"
          },
          { "id": "M4818", "name": "Behavioral Symptoms", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" },
          { "abbrev": "All", "name": "All Conditions" }
        ]
      },
      "interventionBrowseModule": {
        "browseLeaves": [
          { "id": "M16204", "name": "Sulfamethazine", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "Infe", "name": "Anti-Infective Agents" },
          { "abbrev": "All", "name": "All Drugs and Chemicals" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT05998161",
        "orgStudyIdInfo": { "id": "reviga RCT 2023" },
        "organization": { "fullName": "Gaia AG", "class": "INDUSTRY" },
        "briefTitle": "Evaluating the Effectiveness of a Digital Therapeutic (Reviga) for People With Stress or Burnout",
        "officialTitle": "Evaluating the Effectiveness of a Digital Therapeutic (Reviga) for People With Stress or Burnout - a Randomized Controlled Trial",
        "acronym": "LAVENDER"
      },
      "statusModule": {
        "statusVerifiedDate": "2025-04",
        "overallStatus": "COMPLETED",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2023-09-04", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2024-06-22",
          "type": "ACTUAL"
        },
        "completionDateStruct": { "date": "2024-06-22", "type": "ACTUAL" },
        "studyFirstSubmitDate": "2023-08-09",
        "studyFirstSubmitQcDate": "2023-08-09",
        "studyFirstPostDateStruct": { "date": "2023-08-18", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2025-04-03",
        "lastUpdatePostDateStruct": { "date": "2025-04-04", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": { "name": "Gaia AG", "class": "INDUSTRY" },
        "collaborators": [
          {
            "name": "University Hospital Schleswig-Holstein",
            "class": "OTHER"
          },
          { "name": "Hannover Medical School", "class": "OTHER" }
        ]
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": false
      },
      "descriptionModule": {
        "briefSummary": "In this single-blinded randomized controlled clinical trial 290 patients with stress or burnout will be investigated regarding the effectiveness of a digital therapeutic for improvement of stress level, the unguided online intervention reviga.\n\nInclusion criteria are: age 18-65 years, ICD-10 diagnosis Z73, operationalized as above average general stress level (PSS score \\> 21) and increased levels of work-related stress / burnout (OLBI score ≥ 2.18), living in Germany, working a minimum of 20h per week, having a stable treatment for at least 30 days at the time of inclusion, and consent to participation. Exclusion criterion is having plans to change the treatment in the upcoming three months at the time of inclusion.\n\nPatients will be randomized and allocated to either an intervention group, receiving reviga in addition to treatment as usual (TAU), or a control group, receiving only TAU. The control group will be granted access to the program at the end of the study. Primary endpoint will be the perceived stress measured by the PSS score, with three months post-allocation being the primary time point for assessment of effectiveness. Six months post allocation will be used as a timepoint for follow-up assessment of endpoints. Secondary endpoints will be anxiety symptoms, level of functioning, burnout symptoms, health-related quality of life, and sick days."
      },
      "conditionsModule": { "conditions": ["Stress", "Burnout"] },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": {
            "masking": "NONE",
            "maskingDescription": "All endpoints are patient-reported outcome measures (PROMs). Given that participants are aware of their study group (receiving reviga in addition to treatment as usual or only receiving treatment as usual), this trial is not blinded."
          }
        },
        "enrollmentInfo": { "count": 290, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "reviga + TAU",
            "type": "EXPERIMENTAL",
            "description": "Participants allocated to the intervention group will receive access to reviga in addition to treatment as usual (TAU).\n\nreviga is a digital health application designed for individuals with stress and burnout, accessible through a web browser. The application focuses on treatment methods derived from cognitive behavioral therapy (CBT). Topics addressed by reviga are relaxation, psychoeducation and exercises regarding relevant cognitions and behavior, acceptance, relationships, problem solving strategies, and positive psychology.\n\nThe program operates through interactive \"dialogues\", which are accompanied by illustrations, audio recordings, motivating text messages, worksheets, and summaries. Users are also encouraged to regularly complete short questionnaires to monitor their complaints. Once registered, the program remains accessible for 180 days.",
            "interventionNames": ["Behavioral: reviga"]
          },
          {
            "label": "TAU",
            "type": "NO_INTERVENTION",
            "description": "Participants allocated to the control group will receive access to treatment as usual (TAU)."
          }
        ],
        "interventions": [
          {
            "type": "BEHAVIORAL",
            "name": "reviga",
            "description": "Participants will receive access to the digital health intervention reviga in addition to TAU.",
            "armGroupLabels": ["reviga + TAU"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Stress symptoms",
            "description": "Perceived Stress Scale (PSS-10). Total score ranging from 0-40; higher scores mean more stress symptoms (worse outcome).",
            "timeFrame": "3 months"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Anxiety symptoms",
            "description": "Generalized Anxiety Assessment (GAD-7). Total score ranging from 0-21; higher scores mean higher anxiety (worse outcome).",
            "timeFrame": "3 months, 6 months"
          },
          {
            "measure": "Functioning",
            "description": "Work and Social Adjustment Scale (WSAS). Total score ranging from 0-40; higher scores mean higher impairment (worse outcome).",
            "timeFrame": "3 months, 6 months"
          },
          {
            "measure": "Burnout symptoms",
            "description": "Oldenburg Burnout Inventory (OLBI). Two subscales (exhaustion and disengagement), each ranging from 8-32; higher scores mean higher burnout symptoms (worse outcome).",
            "timeFrame": "3 months, 6 months"
          },
          {
            "measure": "Health-related quality of life",
            "description": "Assessment of Quality of Life - 8D (AQoL-8D). AQoL-8D score ranging from 0-100; higher scores mean higher quality of life (better outcome).",
            "timeFrame": "3 months, 6 months"
          },
          {
            "measure": "Sick days",
            "description": "Number of sick days in the past 3 months",
            "timeFrame": "3 months, 6 months"
          },
          {
            "measure": "Stress symptoms",
            "description": "Perceived Stress Scale (PSS-10). Total score ranging from 0-40; higher scores mean more stress symptoms (worse outcome).",
            "timeFrame": "6 months"
          }
        ],
        "otherOutcomes": [
          {
            "measure": "Depressive symptoms",
            "description": "Patient Health Questionnaire - 9 item version (PHQ-9). Total score ranging from 0-27; higher scores mean higher depressive symptoms (worse outcome).",
            "timeFrame": "3 months, 6 months"
          },
          {
            "measure": "Effort and reward imbalance",
            "description": "Effort-reward-imbalance (ERI). Three subscales: effort, ranging from 3-12, higher scores mean higher effort; reward, ranging from 7=28, higher scores mean higher reward; over-commitment, ranging from 6-24, higher scores mean higher over-commitment. Ratio effort/reward: scores \\>1 mean more efforts for each reward (worse outcome).",
            "timeFrame": "3 months, 6 months"
          },
          {
            "measure": "hospital stays",
            "description": "Number of hospital stays in the past 3 months",
            "timeFrame": "3 months, 6 months"
          },
          {
            "measure": "curative stays",
            "description": "Number of curative stays in the past 3 months",
            "timeFrame": "3 months, 6 months"
          },
          {
            "measure": "doctor visits",
            "description": "Number of doctor visits in the past 3 months",
            "timeFrame": "3 months, 6 months"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* age 18-65 years\n* living in Germany\n* employed (minimum of 20h/week)\n* ICD-10 diagnosis Z73, operationalized as above average general stress level (PSS score \\> 21) and increased levels of work-related stress / burnout (OLBI score ≥ 2.18)\n* stable treatment (psychotherapy, medication, no treatment) for at least 30 days at the time of inclusion\n* consent to participation\n\nExclusion Criteria:\n\n* plans to change treatment (psychotherapy, medication, ...) in the upcoming three months at the time of inclusion",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "maximumAge": "65 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "Kamila Jauch-Chara, MD",
            "affiliation": "Universitätsklinikum Schleswig-Holstein, Campus Kiel, Klinik für Psychosomatik und Psychotherapie, Zentrum für Integrative Psychiatrie, Michaelistraße 1, 24105 Kiel",
            "role": "PRINCIPAL_INVESTIGATOR"
          }
        ],
        "locations": [
          {
            "facility": "GAIA AG",
            "city": "Hamburg",
            "zip": "22085",
            "country": "Germany",
            "geoPoint": { "lat": 53.57532, "lon": 10.01534 }
          }
        ]
      },
      "ipdSharingStatementModule": { "ipdSharing": "NO" }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [{ "id": "D000077062", "term": "Burnout, Psychological" }],
        "ancestors": [
          { "id": "D013315", "term": "Stress, Psychological" },
          { "id": "D001526", "term": "Behavioral Symptoms" }
        ],
        "browseLeaves": [
          {
            "id": "M1658",
            "name": "Burnout, Psychological",
            "asFound": "Burnout",
            "relevance": "HIGH"
          },
          {
            "id": "M16105",
            "name": "Stress, Psychological",
            "relevance": "LOW"
          },
          { "id": "M4818", "name": "Behavioral Symptoms", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" },
          { "abbrev": "All", "name": "All Conditions" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT06028984",
        "orgStudyIdInfo": { "id": "BH-SP-01" },
        "organization": { "fullName": "Big Health Inc.", "class": "INDUSTRY" },
        "briefTitle": "Self-guided Treatment for Depression",
        "officialTitle": "Self-guided Treatment for Adolescents/Adults Navigating Depression (STAND-MDD): A Randomized Controlled Trial"
      },
      "statusModule": {
        "statusVerifiedDate": "2024-04",
        "overallStatus": "ACTIVE_NOT_RECRUITING",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2023-10-12", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2025-03",
          "type": "ESTIMATED"
        },
        "completionDateStruct": { "date": "2025-09", "type": "ESTIMATED" },
        "studyFirstSubmitDate": "2023-08-29",
        "studyFirstSubmitQcDate": "2023-08-29",
        "studyFirstPostDateStruct": { "date": "2023-09-08", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2024-04-04",
        "lastUpdatePostDateStruct": { "date": "2024-04-05", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": { "name": "Big Health Inc.", "class": "INDUSTRY" },
        "collaborators": [
          { "name": "Duke University", "class": "OTHER" },
          {
            "name": "National Institute of Mental Health (NIMH)",
            "class": "NIH"
          }
        ]
      },
      "oversightModule": {
        "oversightHasDmc": true,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": true,
        "isUnapprovedDevice": true
      },
      "descriptionModule": {
        "briefSummary": "This study will examine the efficacy and safety of a self-guided digital therapeutic app for the adjunct treatment of Major Depressive Disorder compared to a control app in adolescents and adults.",
        "detailedDescription": "This study aims to examine the efficacy of a self-guided digital therapeutic app for depression compared to a control app in individuals aged 13 and older with a diagnosis of Major Depressive Disorder. The primary outcomes are patient- and clinician-reported depression symptom severity after 5 weeks."
      },
      "conditionsModule": {
        "conditions": ["Major Depressive Disorder"],
        "keywords": [
          "Major Depressive Disorder",
          "MDD",
          "depression",
          "digital therapeutic"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": {
            "masking": "TRIPLE",
            "whoMasked": ["PARTICIPANT", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]
          }
        },
        "enrollmentInfo": { "count": 248, "type": "ESTIMATED" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "Intervention app",
            "type": "EXPERIMENTAL",
            "description": "Digitally-delivered self-guided intervention for depression accessed via mobile app",
            "interventionNames": ["Device: Intervention app"]
          },
          {
            "label": "Control app",
            "type": "ACTIVE_COMPARATOR",
            "description": "An app based control condition",
            "interventionNames": ["Other: Control app"]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "Intervention app",
            "description": "An app-based intervention for depression",
            "armGroupLabels": ["Intervention app"]
          },
          {
            "type": "OTHER",
            "name": "Control app",
            "description": "An app with non-therapeutic content",
            "armGroupLabels": ["Control app"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Patient Health Questionnaire (PHQ-8)",
            "description": "Validated questionnaire; an 8-item scale with total scores between 0 and 24 where higher scores indicate greater severity",
            "timeFrame": "5 weeks post-randomization"
          },
          {
            "measure": "Montgomery-Åsberg Depression Rating Scale (MADRS)",
            "description": "Validated assessment: a 10-item scale based on clinical interview with total scores between 0 and 60 where higher scores indicate greater severity",
            "timeFrame": "5 weeks post-randomization"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Clinically important improvement based on the Patient Health Questionnaire (PHQ-8)",
            "description": "5 point or greater reduction in PHQ-8 score from baseline",
            "timeFrame": "5 weeks post-randomization, 1-month followup"
          },
          {
            "measure": "Response based on the Patient Health Questionnaire (PHQ-8)",
            "description": "50% or greater reduction in PHQ-8 score from baseline",
            "timeFrame": "5 weeks post-randomization, 1-month followup"
          },
          {
            "measure": "Remission based on the Patient Health Questionnaire (PHQ-8)",
            "description": "PHQ-8 less than 5",
            "timeFrame": "5 weeks post-randomization, 1-month followup"
          },
          {
            "measure": "Global improvement assessed using the clinician-rated Clinical Global Impression Scale - Improvement (CGI-I)",
            "description": "A single-item measure scored between 1 and 7 where lower scores indicate greater improvement in global functioning",
            "timeFrame": "5 weeks post-randomization, 1-month followup"
          },
          {
            "measure": "Clinical Global Impression - Severity (CGI-S)",
            "description": "A single-item measure scored between 1 and 7 where higher scores indicate greater severity of Major Depressive Disorder Symptoms",
            "timeFrame": "5-weeks post-randomization, 1-month followup"
          },
          {
            "measure": "Clinically important improvement based on the Montgomery-Åsberg Depression Scale (MADRS)",
            "description": "10 point or greater reduction in MADRS score from baseline",
            "timeFrame": "5 weeks post-randomization, 1-month followup"
          },
          {
            "measure": "Depression severity assessed with the Patient Health Questionnaire (PHQ-8) at followup",
            "description": "Validated questionnaire; an 8-item scale with total scores between 0 and 24 where higher scores indicate greater severity",
            "timeFrame": "1-, 3- and 6-month followup"
          },
          {
            "measure": "Clinician-rated depression severity as measured by the Montgomery-Åsberg Depression Scale (MADRS) at followup",
            "description": "Validated assessment: a 10-item scale based on clinical interview with total scores between 0 and 60 where higher scores indicate greater severity",
            "timeFrame": "1 month follow up"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* Positive self report screen for depression\n* Participant is at least 13 years of age\n* Willing and able to provide informed consent; if under 18 years of age, willing and able to provide assent, and has a legal guardian willing and able to provide consent\n* Primary diagnosis of Major Depressive Disorder (MDD)\n* Under the care of a United States (U.S.)-based licensed healthcare provider and willing and able to provide contact information for the provider and sign a HIPAA release that allows investigator to contact provider\n* Fluent and literate in English\n* Has access to a compatible device and operating system (i.e., capable of installing the app from the Google Play or Apple App Store) and regular internet access\n* Located in the continental U.S., Hawaii, or Alaska, and not planning to leave the U.S. during the primary study period\n\nExclusion Criteria:\n\n* Has changed or initiated psychotherapy with a mental health professional within 30 days prior to eligibility screening\n* Has received certain types of psychotherapy within the last 6 months\n* Has changed prescribed psychotropic medication (initiation or change in dose) within the past 30 days\n* Plans to initiate or change treatment (e.g., psychotherapy, psychotropic medication, and/or other psychosocial treatment) for a mental health disorder during study intervention period\n* Suicidal behavior within the past year\n* Active suicide ideation with intent within the past 3 months\n* Previously participated in user testing or a clinical study at Limbix Health Inc. or Big Health Inc. (such as the STAND study or Rise study), or have used a Limbix app\n* Participated in any other clinical research involving an intervention or treatment within the past 60 days\n* Plans to participate in any other clinical research involving an intervention or treatment during the study intervention period\n* Living in the same household as another participant in the study (e.g., a sibling)\n* Has a diagnosis of MDD with psychotic features or comorbid Psychotic Disorder\n* Has a concurrent diagnosis of (or has been treated for) bipolar disorder I and II or severe substance use disorder within the past year\n* Has treatment resistant depression\n* Is employed by Big Health Inc., or is a collaborator, associate, or relation of Big Health Inc. staff\n* Any condition, comorbidity, or event (other than the above) that, in the opinion of the investigator, will prevent the participant from adhering to the protocol or benefitting from the intervention, or will prevent investigators from being able to ensure safety",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "13 Years",
        "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "facility": "Big Health, Inc.",
            "city": "San Francisco",
            "state": "California",
            "zip": "94108",
            "country": "United States",
            "geoPoint": { "lat": 37.77493, "lon": -122.41942 }
          }
        ]
      },
      "ipdSharingStatementModule": { "ipdSharing": "NO" }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [
          { "id": "D003863", "term": "Depression" },
          { "id": "D003866", "term": "Depressive Disorder" },
          { "id": "D003865", "term": "Depressive Disorder, Major" }
        ],
        "ancestors": [
          { "id": "D001526", "term": "Behavioral Symptoms" },
          { "id": "D019964", "term": "Mood Disorders" },
          { "id": "D001523", "term": "Mental Disorders" }
        ],
        "browseLeaves": [
          {
            "id": "M7061",
            "name": "Depressive Disorder",
            "asFound": "Depressive Disorder",
            "relevance": "HIGH"
          },
          {
            "id": "M7060",
            "name": "Depressive Disorder, Major",
            "asFound": "Major Depressive Disorder",
            "relevance": "HIGH"
          },
          {
            "id": "M7058",
            "name": "Depression",
            "asFound": "Depression",
            "relevance": "HIGH"
          },
          { "id": "M4818", "name": "Behavioral Symptoms", "relevance": "LOW" },
          { "id": "M21835", "name": "Mood Disorders", "relevance": "LOW" },
          { "id": "M14473", "name": "Psychotic Disorders", "relevance": "LOW" },
          { "id": "M4815", "name": "Mental Disorders", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" },
          { "abbrev": "All", "name": "All Conditions" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT05558865",
        "orgStudyIdInfo": { "id": "somnovia-RCT" },
        "organization": { "fullName": "Gaia AG", "class": "INDUSTRY" },
        "briefTitle": "Effectiveness of a Digital Health Application for People With Insomnia Disorder (Somnovia)",
        "officialTitle": "Evaluating the Effectiveness of a Digital Therapeutic (Somnovia) for People With Insomnia Disorder - a Randomized Controlled Trial"
      },
      "statusModule": {
        "statusVerifiedDate": "2023-06",
        "overallStatus": "COMPLETED",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2022-11-08", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2023-05-22",
          "type": "ACTUAL"
        },
        "completionDateStruct": { "date": "2023-09-18", "type": "ACTUAL" },
        "studyFirstSubmitDate": "2022-09-26",
        "studyFirstSubmitQcDate": "2022-09-26",
        "studyFirstPostDateStruct": { "date": "2022-09-28", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2023-09-22",
        "lastUpdatePostDateStruct": { "date": "2023-09-25", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": { "name": "Gaia AG", "class": "INDUSTRY" },
        "collaborators": [
          {
            "name": "University Hospital Schleswig-Holstein",
            "class": "OTHER"
          },
          { "name": "University Hospital Freiburg", "class": "OTHER" }
        ]
      },
      "oversightModule": {
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": false
      },
      "descriptionModule": {
        "briefSummary": "The trial aims to evaluate the effectiveness of a novel digital health application (somnovia), which was designed to increase sleep quality in persons with insomnia disorder. Therefore, 290 people with insomnia disorder will be recruited and randomized to two groups: (1) a control group, in which they may engage with any treatment for insomnia disorder and are offered access to somnovia after a delay of 6 months (i.e., Care-as-Usual \\[CAU\\]), or (2) to a treatment group that immediately receives 6-month access to somnovia and may also use CAU. The primary outcome measure is the score of the Insomnia Severity Index (ISI), collected at three months post-baseline."
      },
      "conditionsModule": { "conditions": ["Insomnia Disorder"] },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": {
            "masking": "SINGLE",
            "whoMasked": ["OUTCOMES_ASSESSOR"]
          }
        },
        "enrollmentInfo": { "count": 290, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "somnovia",
            "type": "EXPERIMENTAL",
            "description": "somnovia is a digital health application for people with Insomnia Disorder. Content is continuously adapted to patients' concerns and needs. somnovia is a comprehensive program, which is conceptually and substantially based on the Cognitive Behavioral Therapy for Insomnia (CBT-I) used in patients with Insomnia Disorder. It contains interactive dialogues that can be accessed via computer or smartphone, illustrations, audio recordings and motivating text messages. Techniques to cope with insomnia symptoms (e.g., psychoeducation about causes and basic emotional needs in addition to relevant strategies to improve sleep quality) are conveyed in interactive sequences that are accompanied by audio recordings, illustrations, and worksheets. Patients are also prompted to regularly complete brief symptom severity self-monitoring questionnaires. Optional daily text messages with motivational content accompany the program. The program can be accessed for 365 days after registration.",
            "interventionNames": ["Behavioral: somnovia"]
          },
          {
            "label": "Care as Usual",
            "type": "NO_INTERVENTION",
            "description": "Care as Usual: In the CAU control group, participants are free to continue to engage with any treatment they require. However, they will be offered access to somnovia after 6 months post-baseline."
          }
        ],
        "interventions": [
          {
            "type": "BEHAVIORAL",
            "name": "somnovia",
            "description": "Participants receive access to the digital health application somnovia",
            "armGroupLabels": ["somnovia"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Insomnia Severity Index (ISI)",
            "description": "The ISI is a 7-item patient-reported outcome measure (PROM) assessing the nature, severity, and impact of insomnia on a 5-point Likert scale to rate each item from 0 (no problem) to 4 (very severe problem).",
            "timeFrame": "3 months after randomization"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Insomnia Severity Index (ISI)",
            "description": "The ISI is a 7-item patient-reported outcome measure (PROM) assessing the nature, severity, and impact of insomnia on a 5-point Likert scale to rate each item from 0 (no problem) to 4 (very severe problem).",
            "timeFrame": "6 months after randomization"
          },
          {
            "measure": "Patient Health Questionnaire (PHQ-9)",
            "description": "The PHQ-9 is a well-validated nine-item self-report questionnaire developed to score each of the nine DSM-IV criteria for major depressive disorder on a 4-point Likert scale, from \"0\" (not at all) to \"3\" (nearly every day).",
            "timeFrame": "3 months and 6 months after randomization"
          },
          {
            "measure": "Generalized Anxiety Disorder Assessment (GAD-7)",
            "description": "The GAD-7 is a self-administered patient questionnaire used as a screening tool and severity measure for generalized anxiety disorder (GAD)",
            "timeFrame": "3 months and 6 months after randomization"
          },
          {
            "measure": "Work and Social Assessment Scale (WSAS)",
            "description": "WSAS is a 5-item self-report scale to measure the ability to work in regard to physical, mental and social health as well as age group referenced competence for performance. Each item is rated on a 9-point Likert scale from 0 = \"not at all impaired\" to 8 = \"very severely impaired\".",
            "timeFrame": "3 months and 6 months after randomization"
          },
          {
            "measure": "Responder Rate on Insomnia Severity Index",
            "description": "A Responder is defined as a patient with an improvement of \\> 6 points on the total score of the Insomnia Severity Index from T0 to T1",
            "timeFrame": "3 months after randomization"
          },
          {
            "measure": "Remission Rate on Insomnia Severity Index",
            "description": "Remission is defined as patients with a total score on the Insomnia Severity Index of \\< 8",
            "timeFrame": "3 months after randomization"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* diagnosis of chronic insomnia\n* impaired quality of sleep (Insomnia Severity Index Score ≥ 10)\n\nExclusion Criteria:\n\n* none",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "Robert Göder, Prof. Dr.",
            "affiliation": "Christian-Albrechts-Universität zu Kiel, Clinic for Psychiatry and Psychotherapy",
            "role": "PRINCIPAL_INVESTIGATOR"
          }
        ],
        "locations": [
          {
            "facility": "GAIA AG",
            "city": "Hamburg",
            "zip": "20144",
            "country": "Germany",
            "geoPoint": { "lat": 53.57532, "lon": 10.01534 }
          }
        ]
      }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [
          {
            "id": "D007319",
            "term": "Sleep Initiation and Maintenance Disorders"
          }
        ],
        "ancestors": [
          { "id": "D020919", "term": "Sleep Disorders, Intrinsic" },
          { "id": "D020920", "term": "Dyssomnias" },
          { "id": "D012893", "term": "Sleep Wake Disorders" },
          { "id": "D009422", "term": "Nervous System Diseases" },
          { "id": "D001523", "term": "Mental Disorders" }
        ],
        "browseLeaves": [
          {
            "id": "M10356",
            "name": "Sleep Initiation and Maintenance Disorders",
            "asFound": "Insomnia Disorder",
            "relevance": "HIGH"
          },
          { "id": "M22242", "name": "Parasomnias", "relevance": "LOW" },
          {
            "id": "M22654",
            "name": "Sleep Disorders, Intrinsic",
            "relevance": "LOW"
          },
          { "id": "M22655", "name": "Dyssomnias", "relevance": "LOW" },
          {
            "id": "M15696",
            "name": "Sleep Wake Disorders",
            "relevance": "LOW"
          },
          { "id": "M14473", "name": "Psychotic Disorders", "relevance": "LOW" },
          { "id": "M4815", "name": "Mental Disorders", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "BC10", "name": "Nervous System Diseases" },
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" },
          { "abbrev": "All", "name": "All Conditions" },
          { "abbrev": "BC23", "name": "Symptoms and General Pathology" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT05634291",
        "orgStudyIdInfo": { "id": "H210106" },
        "organization": { "fullName": "VRx Medical Inc", "class": "INDUSTRY" },
        "briefTitle": "Effects of the Nottingham Augmented Reality (AR) App for Arthritis Hand Joint Pain",
        "officialTitle": "Effects of the Nottingham Arthritis App for Arthritis Pain"
      },
      "statusModule": {
        "statusVerifiedDate": "2023-02",
        "overallStatus": "COMPLETED",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2022-06-13", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2023-06-16",
          "type": "ACTUAL"
        },
        "completionDateStruct": { "date": "2023-07-21", "type": "ACTUAL" },
        "studyFirstSubmitDate": "2022-11-21",
        "studyFirstSubmitQcDate": "2022-11-21",
        "studyFirstPostDateStruct": { "date": "2022-12-02", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2023-07-22",
        "lastUpdatePostDateStruct": { "date": "2023-07-25", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": { "name": "VRx Medical Inc", "class": "INDUSTRY" },
        "collaborators": [
          { "name": "National Institute on Drug Abuse (NIDA)", "class": "NIH" },
          { "name": "San Diego Veterans Healthcare System", "class": "FED" }
        ]
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": false
      },
      "descriptionModule": {
        "briefSummary": "The aim of this run-in design, feasibility study is to assess outcomes (including opioid-use, pain intensity, emotional function, and general physical function) for an augmented reality illusion therapy in participants with chronic hand joint pain due to arthritis.",
        "detailedDescription": "This is a run-in design, feasibility study that uses the enrolled participants as their own control. After consenting to join the study, for the first 30 days, participants will be on their current Standard of Care (SoC). Then, for the next 30 days, the same group of participants will use the Nottingham digital treatment daily. Pre- and Post-SoC and Treatment period measures of opioid use and pain, quality of life measures will be administered and measured. Additionally, for qualifying participants, Pre- and Post-treatment functional Magnetic Resonance Imaging (fMRI) scans will be performed to assess how Nottingham AR therapy affects neuroplastic changes in the supraspinal pain network associated with the therapy sessions."
      },
      "conditionsModule": {
        "conditions": ["Chronic Pain", "Arthritis Hand", "Opioid Use"],
        "keywords": [
          "Augmented Reality",
          "Smartphone application",
          "Digital Therapeutic"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "NA",
          "interventionModel": "SINGLE_GROUP",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": { "masking": "NONE" }
        },
        "enrollmentInfo": { "count": 36, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "Standard of Care followed by AR digital treatment",
            "type": "EXPERIMENTAL",
            "description": "Standard of care period without active intervention followed by Digital treatment with active intervention",
            "interventionNames": [
              "Other: Standard of care",
              "Device: Nottingham AR smartphone app with active intervention"
            ]
          }
        ],
        "interventions": [
          {
            "type": "OTHER",
            "name": "Standard of care",
            "description": "Standard of care as prescribed by healthcare provider.",
            "armGroupLabels": [
              "Standard of Care followed by AR digital treatment"
            ]
          },
          {
            "type": "DEVICE",
            "name": "Nottingham AR smartphone app with active intervention",
            "description": "AR software treatment delivered by smartphone app and developed by VRx Medical (VRx) using established principles of illusion therapies (e.g. mirror therapy) for pain management.",
            "armGroupLabels": [
              "Standard of Care followed by AR digital treatment"
            ]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "The Pain, Enjoyment of Life and General Activity scale (PEG)",
            "description": "PEG is a three-Item scale assessing pain intensity and interference. Scale is from 0 (no pain) to 10 (pain as bad as you can imagine).",
            "timeFrame": "Change from baseline to day 30"
          },
          {
            "measure": "Milligrams of Morphine Equivalent (MME)",
            "description": "MME is a standard measure of opioid use",
            "timeFrame": "Change from baseline to day 30"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Resting State brain imaging data",
            "description": "fMRI compare pre- to post treatment - imaging data to show hyperactivities and enhanced functional connectivity in supraspinal regions associated with the affective aspect of pain perception.",
            "timeFrame": "Change from baseline to day 30"
          },
          {
            "measure": "Non-opioid pain medicine usage",
            "description": "Pain medicine usage will be tracked for dose and frequency.",
            "timeFrame": "Change from baseline to day 30"
          },
          {
            "measure": "Pain Disability Index (PDI)",
            "description": "PDI is a standard questionnaire designed to help patients measure the degree their daily lives are disrupted by chronic pain.",
            "timeFrame": "Change from baseline to day 30"
          },
          {
            "measure": "Patient Health Questionnaire (PHQ-9)",
            "description": "PHQ-9, a Quick Depression Assessment, is a reliable and valid measure of depression. severity",
            "timeFrame": "Change from baseline to day 30"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n1. Male and female adults ages 21-80\n2. Clinical diagnosis of chronic hand pain from arthritis or as determined by study physician 3) Hand joint pain at a severity of 4 and above (on a 0 to 10 scale) daily\n\n4) Use of prescribed opioids 5) English-speaking, literate, with stable residence 5) Able to operate a smartphone as evidenced by direct observation.\n\nExclusion Criteria:\n\n1. Major medical illness that might confound effects of pain on function (e.g., advanced cardiac or pulmonary disease)\n2. Current active alcohol or substance use disorder as evidenced from medical record\n3. Currently active unstable psychiatric status in previous three months as measured by direct observation, patient self-report, or medical record\n4. Moderate or severe cognitive impairment as demonstrated by medical diagnosis or clinical observation\n5. fMRI exclusion only: Any factors that would prevent participation in fMRI",
        "healthyVolunteers": true,
        "sex": "ALL",
        "minimumAge": "21 Years",
        "maximumAge": "80 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "Thomas Rutledge, PhD",
            "affiliation": "San Diego Veterans Healthcare System",
            "role": "PRINCIPAL_INVESTIGATOR"
          }
        ],
        "locations": [
          {
            "facility": "VA San Diego Healthcare System",
            "city": "San Diego",
            "state": "California",
            "zip": "92161",
            "country": "United States",
            "geoPoint": { "lat": 32.71533, "lon": -117.15726 }
          }
        ]
      },
      "ipdSharingStatementModule": { "ipdSharing": "NO" }
    },
    "annotationSection": {
      "annotationModule": {
        "unpostedAnnotation": {
          "unpostedResponsibleParty": "VRx Medical Inc",
          "unpostedEvents": [
            { "type": "RELEASE", "date": "2024-08-22" },
            { "type": "RESET", "date": "2024-09-16" }
          ]
        }
      }
    },
    "derivedSection": {
      "miscInfoModule": {
        "versionHolder": "2025-05-07",
        "submissionTracking": {
          "estimatedResultsFirstSubmitDate": "2024-08-22",
          "submissionInfos": [
            { "releaseDate": "2024-08-22", "resetDate": "2024-09-16" }
          ]
        }
      },
      "conditionBrowseModule": {
        "meshes": [
          { "id": "D001168", "term": "Arthritis" },
          { "id": "D059350", "term": "Chronic Pain" }
        ],
        "ancestors": [
          { "id": "D007592", "term": "Joint Diseases" },
          { "id": "D009140", "term": "Musculoskeletal Diseases" },
          { "id": "D010146", "term": "Pain" },
          { "id": "D009461", "term": "Neurologic Manifestations" }
        ],
        "browseLeaves": [
          { "id": "M13066", "name": "Pain", "relevance": "LOW" },
          {
            "id": "M4476",
            "name": "Arthritis",
            "asFound": "Arthritis",
            "relevance": "HIGH"
          },
          {
            "id": "M29442",
            "name": "Chronic Pain",
            "asFound": "Chronic Pain",
            "relevance": "HIGH"
          },
          { "id": "M20833", "name": "Arthralgia", "relevance": "LOW" },
          { "id": "M10621", "name": "Joint Diseases", "relevance": "LOW" },
          {
            "id": "M12097",
            "name": "Musculoskeletal Diseases",
            "relevance": "LOW"
          },
          {
            "id": "M12404",
            "name": "Neurologic Manifestations",
            "relevance": "LOW"
          },
          {
            "id": "T1303",
            "name": "Chronic Graft Versus Host Disease",
            "relevance": "LOW"
          }
        ],
        "browseBranches": [
          { "abbrev": "BC23", "name": "Symptoms and General Pathology" },
          { "abbrev": "All", "name": "All Conditions" },
          { "abbrev": "BC05", "name": "Musculoskeletal Diseases" },
          { "abbrev": "BC10", "name": "Nervous System Diseases" },
          { "abbrev": "Rare", "name": "Rare Diseases" }
        ]
      },
      "interventionBrowseModule": {
        "browseLeaves": [
          { "id": "M4548", "name": "Aspirin", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "Antipy", "name": "Antipyretics" },
          { "abbrev": "Infl", "name": "Anti-Inflammatory Agents" },
          { "abbrev": "ARhu", "name": "Antirheumatic Agents" },
          { "abbrev": "FiAg", "name": "Fibrinolytic Agents" },
          { "abbrev": "Analg", "name": "Analgesics" },
          { "abbrev": "PlAggInh", "name": "Platelet Aggregation Inhibitors" },
          { "abbrev": "All", "name": "All Drugs and Chemicals" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT05147506",
        "orgStudyIdInfo": { "id": "CNRM-92-10531" },
        "organization": {
          "fullName": "Henry M. Jackson Foundation for the Advancement of Military Medicine",
          "class": "OTHER"
        },
        "briefTitle": "Digital Therapeutic for Depression After Head Injury in Current and Former US Military Personnel",
        "officialTitle": "A Single-Blind, Randomized, Controlled Trial of a Cognitive-Behavioral Therapy Digital Therapeutic to Combat Symptoms of Depression in Service Members and Adults With a History of MildTraumatic Brain Injury"
      },
      "statusModule": {
        "statusVerifiedDate": "2024-06",
        "overallStatus": "ACTIVE_NOT_RECRUITING",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2022-06-22", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2024-10-30",
          "type": "ESTIMATED"
        },
        "completionDateStruct": { "date": "2025-01-01", "type": "ESTIMATED" },
        "studyFirstSubmitDate": "2021-07-20",
        "studyFirstSubmitQcDate": "2021-11-24",
        "studyFirstPostDateStruct": { "date": "2021-12-07", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2024-06-12",
        "lastUpdatePostDateStruct": { "date": "2024-06-13", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": {
          "name": "Henry M. Jackson Foundation for the Advancement of Military Medicine",
          "class": "OTHER"
        }
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": true
      },
      "descriptionModule": {
        "briefSummary": "The Center for Neuroscience and Regenerative Medicine (CNRM) Clinical Trials Unit has developed the first cognitive-behavioral therapy (CBT) digital therapeutic (DTx) mobile application to counteract depressive symptoms in military service members and veterans with a history of mild traumatic brain injury (mTBI). This trial will assess the efficacy of the novel CBT-DTx for depression following mTBI compared to an educational comparison DTx.",
        "detailedDescription": "This trial is a single-blind, randomized, controlled interventional trial of current and former military personnel with symptoms of depression and a history of mTBI. The study will be conducted remotely."
      },
      "conditionsModule": {
        "conditions": ["Depressive Symptoms", "Mild Traumatic Brain Injury"]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": { "masking": "SINGLE", "whoMasked": ["PARTICIPANT"] }
        },
        "enrollmentInfo": { "count": 113, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "CBT DTx",
            "type": "EXPERIMENTAL",
            "description": "Participants randomized to active intervention will access a structured, cognitive behavioral therapy (CBT) intervention.",
            "interventionNames": ["Device: CNRM DTx"]
          },
          {
            "label": "Psychoeducations DTx",
            "type": "ACTIVE_COMPARATOR",
            "description": "Participants randomized to the comparison group will access an unstructured educational DTx.",
            "interventionNames": ["Other: Psychoeducation Comparison"]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "CNRM DTx",
            "description": "A mobile application intervention adapted from the CBT for Depression and CBT for TBI manuals.",
            "armGroupLabels": ["CBT DTx"]
          },
          {
            "type": "OTHER",
            "name": "Psychoeducation Comparison",
            "description": "A mobile application that consists of psychoeducational material regarding depression and brain injury.",
            "armGroupLabels": ["Psychoeducations DTx"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Change of the mean difference in Patient Health Questionnaire (PHQ-9) total score",
            "description": "Self-report measure of depression symptom severity; range 0-27; higher score indicates greater severity",
            "timeFrame": "Week 12 and Week 16 compared to Baseline"
          },
          {
            "measure": "Change of the mean difference in Patient Health Questionnaire (PHQ-9) total scores of participants who complete all treatment modules compared to those who do not",
            "description": "Self-report measure of depression symptom severity; range 0-27; higher score indicates greater severity",
            "timeFrame": "Week 12 compared to Baseline"
          },
          {
            "measure": "Change of the mean difference in Patient Health Questionnaire (PHQ-9) total scores of participants who report history of depression prior to mTBI compared to those who do not",
            "description": "Self-report measure of depression symptom severity; range 0-27; higher score indicates greater severity",
            "timeFrame": "Week 12 compared to Baseline"
          },
          {
            "measure": "Change of the mean difference in Patient Health Questionnaire (PHQ-9) total scores of participants who report family history of depression compared to those who do no",
            "description": "Self-report measure of depression symptom severity; range 0-27; higher score indicates greater severity",
            "timeFrame": "Week 12 compared to Baseline"
          },
          {
            "measure": "Change of the mean difference in Patient Health Questionnaire (PHQ-9) total scores, comparison between depression severity group",
            "description": "Self-report measure of depression symptom severity; range 0-27; higher score indicates greater severity",
            "timeFrame": "Week 12 compared to Baseline"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Change of the mean difference in Traumatic Brain Injury-Quality of Life (TBI-QOL) total score",
            "description": "Computerized adaptive test that measures post-concussive symptoms and quality of life across multiple domains",
            "timeFrame": "Week 12 and Week 16, compared to Baseline"
          },
          {
            "measure": "Change of the mean difference in Posttraumatic Stress Disorder Checklist (PCL-5) total score",
            "description": "Self-report measure of PTSD severity; range 0-80; higher score indicates greater severity",
            "timeFrame": "Week 12 and Week 16, compared to Baseline"
          },
          {
            "measure": "Change of the mean difference in Insomnia Severity Index (ISI) total score",
            "description": "Self-report measure of insomnia severity; range 0-28; higher score indicates greater severity",
            "timeFrame": "Week 12 and Week 16, compared to Baseline"
          },
          {
            "measure": "Change in Credibility and Expectancy Questionnaire (CEQ)",
            "description": "Self-report measure of participation expectation of benefit",
            "timeFrame": "Week 12 and Week 16, compared to Baseline"
          },
          {
            "measure": "Blinding Efficacy",
            "description": "Participant blinding questionnaire",
            "timeFrame": "Week 12 and Week 16, compared to Baseline"
          }
        ],
        "otherOutcomes": [
          {
            "measure": "User Version of the Mobile Application Rating Scale (uMARS)",
            "description": "Self-report measure that assess user opinion in 4 objective quality subscales: engagement, functionality, aesthetics, information quality; 1 subjective quality subscale; and 1 scale that measures the perceived impact of the app being evaluated",
            "timeFrame": "Week 12"
          },
          {
            "measure": "Mobile Agnew Relationship Measure (mARM) Questionnaire",
            "description": "Self-report measure of therapeutic alliance with mobile health intervention",
            "timeFrame": "Week 12"
          },
          {
            "measure": "HEXACO Personality Inventory-Revised (HEXACO-PI-R)",
            "description": "Self-report personality inventory that measures 6 dimensions of personality: honesty-humility, emotionality, eXtraversion, agreeableness (versus anger), conscientiousness, openness to experience",
            "timeFrame": "Baseline"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* Be aged ≥ 18 to ≤ 65 years\n* Be able to provide informed consent\n* Diagnosed with mild TBI as defined by the Department of Veteran's Affairs and Department of Defense Clinical Practice\n* Have a PHQ-9 score of ≥ 5 to 27, indicative of mild or greater depressive symptoms\n* Have ownership of or reliable access to a smartphone with a data plan or internet connecting capabilities\n* While participating in this study, be able to ensure that you have access to regular care for mental health and to speak with your provider as necessary\n\nExclusion Criteria:\n\n* Report of starting pharmacological or non-pharmacological treatment for depression within the 3 months prior to trial enrollment\n* Report a recent change in type or dose of antidepressant medications within 12 weeks prior to trial enrollment\n* Report active psychotic or bipolar symptoms\n* Active plan and/or intent of suicide or homicide\n* In the opinion of the investigator, they have other considerations that may adversely affect patient safety, participation, or scientific validity of the data being collected",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "maximumAge": "65 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "David Brody, MD",
            "affiliation": "Uniformed Services University of the Health Sciences",
            "role": "PRINCIPAL_INVESTIGATOR"
          }
        ],
        "locations": [
          {
            "facility": "Remote Recruitment: Center for Neuroscience and Regenerative Medicine",
            "city": "Bethesda",
            "state": "Maryland",
            "zip": "20851",
            "country": "United States",
            "geoPoint": { "lat": 38.98067, "lon": -77.10026 }
          }
        ]
      },
      "ipdSharingStatementModule": {
        "ipdSharing": "YES",
        "description": "Identifier-free participant data sets will be shared with the Uniformed Services University Center for Neuroscience and Regenerative Medicine Data Repository. Identifier-free data sets may also be shared with the Federal Interagency Traumatic Brain Injury Research (FITBIR) Data Repository.",
        "timeFrame": "After study completion, data sets will be de-identified and shared with the repositories. De-identified data sets will be stored in the repositories indefinitely.",
        "accessCriteria": "Access to the CNRM Data Repository will be determined b the CNRM Data Quality, Access, and Publication Committee. Investigators requesting access to the data will provide a list of investigators and collaborators who will have access to the data, documentation of Ethical Conduct of Research and Human Participants Protection Training, and documentation of Institutional Review Board Approval of the research project.\n\nAccess to FITBIR will follow FITBIR Access Criteria",
        "url": "http://fitbir.nih.gov/content/access-data"
      }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [
          { "id": "D001930", "term": "Brain Injuries" },
          { "id": "D000070642", "term": "Brain Injuries, Traumatic" },
          { "id": "D001924", "term": "Brain Concussion" },
          { "id": "D014947", "term": "Wounds and Injuries" },
          { "id": "D003863", "term": "Depression" }
        ],
        "ancestors": [
          { "id": "D001526", "term": "Behavioral Symptoms" },
          { "id": "D001927", "term": "Brain Diseases" },
          { "id": "D002493", "term": "Central Nervous System Diseases" },
          { "id": "D009422", "term": "Nervous System Diseases" },
          { "id": "D006259", "term": "Craniocerebral Trauma" },
          { "id": "D020196", "term": "Trauma, Nervous System" },
          { "id": "D016489", "term": "Head Injuries, Closed" },
          { "id": "D014949", "term": "Wounds, Nonpenetrating" }
        ],
        "browseLeaves": [
          { "id": "M7061", "name": "Depressive Disorder", "relevance": "LOW" },
          {
            "id": "M7058",
            "name": "Depression",
            "asFound": "Depressive Symptoms",
            "relevance": "HIGH"
          },
          {
            "id": "M5207",
            "name": "Brain Injuries",
            "asFound": "Brain Injury",
            "relevance": "HIGH"
          },
          {
            "id": "M628",
            "name": "Brain Injuries, Traumatic",
            "asFound": "Traumatic Brain Injury",
            "relevance": "HIGH"
          },
          {
            "id": "M5201",
            "name": "Brain Concussion",
            "asFound": "Mild Traumatic Brain Injury",
            "relevance": "HIGH"
          },
          {
            "id": "M9349",
            "name": "Craniocerebral Trauma",
            "relevance": "LOW"
          },
          {
            "id": "M17685",
            "name": "Wounds and Injuries",
            "asFound": "Injury",
            "relevance": "HIGH"
          },
          { "id": "M4818", "name": "Behavioral Symptoms", "relevance": "LOW" },
          { "id": "M5204", "name": "Brain Diseases", "relevance": "LOW" },
          {
            "id": "M5742",
            "name": "Central Nervous System Diseases",
            "relevance": "LOW"
          },
          {
            "id": "M22023",
            "name": "Trauma, Nervous System",
            "relevance": "LOW"
          },
          {
            "id": "M18892",
            "name": "Head Injuries, Closed",
            "relevance": "LOW"
          },
          {
            "id": "M17687",
            "name": "Wounds, Nonpenetrating",
            "relevance": "LOW"
          }
        ],
        "browseBranches": [
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" },
          { "abbrev": "All", "name": "All Conditions" },
          { "abbrev": "BC10", "name": "Nervous System Diseases" },
          { "abbrev": "BC26", "name": "Wounds and Injuries" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT04652622",
        "orgStudyIdInfo": { "id": "FHREB 2020-091" },
        "organization": { "fullName": "Fraser Health", "class": "OTHER" },
        "briefTitle": "Use of a Novel Digital Therapeutic Intervention for the Management of Delirium in the Acute Care Environment",
        "officialTitle": "Use of a Novel Digital Therapeutic Intervention for the Management of Delirium in the Acute Care Environment"
      },
      "statusModule": {
        "statusVerifiedDate": "2023-01",
        "overallStatus": "COMPLETED",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2021-03-16", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2022-01-05",
          "type": "ACTUAL"
        },
        "completionDateStruct": { "date": "2022-12-05", "type": "ACTUAL" },
        "studyFirstSubmitDate": "2020-11-17",
        "studyFirstSubmitQcDate": "2020-12-02",
        "studyFirstPostDateStruct": { "date": "2020-12-03", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2023-01-04",
        "lastUpdatePostDateStruct": { "date": "2023-01-06", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": { "name": "Fraser Health", "class": "OTHER" },
        "collaborators": [
          { "name": "BC Support Unit", "class": "OTHER" },
          { "name": "Royal Columbian Hospital Foundation", "class": "UNKNOWN" },
          { "name": "Mitacs", "class": "INDUSTRY" }
        ]
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": false
      },
      "descriptionModule": {
        "briefSummary": "Delirium is a condition of fluctuating confusion and agitation that affects as many as 80% of patients in critical care. Hyperactive delirium consumes a significant amount of clinical attention and resources due to the associated psychomotor agitation. Patients can become aggressive or combative putting both themselves and healthcare workers at risk of harm. Delirium has been linked to an increased risk of death and poor overall outcomes. Management largely relies on the use of potentially toxic medications and physical restraints despite limited proof of success of these interventions. Our research group will study the use of a novel interactive digital therapeutic behavior modification platform aimed at reducing anxiety and agitation associated with hyperactive delirium. We hypothesize that Use of the Mindful Garden behavioral modification platform will result in normalization of agitation and delirium scores when used for the management of delirium associated agitation in the adult delirious acute care population compared to standard care alone.",
        "detailedDescription": "Mindful Garden is a digital behavior modification platform that utilizes screen based delivery systems and sensor technologies. Mindful Garden delivers real 2-dimensional nature video layered with hyper-real 3-dimensional animations of growing and receding flowers and butterflies in flight which aims to reduce anxiety and agitation in the delirious critical care population. In doing so, normalization of agitation and delirium scores may be achieved as well as a reduction in reliance on pharmacological interventions and the use of physical restraints, which have been linked to adverse outcomes and significant side effects.\n\nParticipants with a diagnosis of hyperactive delirium in acute care inpatient units will be randomized to receive 4 hours of exposure to the MG platform in addition to standard care or to the control arm of monitoring with standard care only for the same time period."
      },
      "conditionsModule": {
        "conditions": ["Delirium"],
        "keywords": [
          "digital therapeutic",
          "behavioral",
          "critical care",
          "behavior modification"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "interventionModelDescription": "participants will be randomized to either exposure to the intervention arm in conjunction with standard care or the control arm and will receive standard care alone",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": {
            "masking": "SINGLE",
            "maskingDescription": "data will be blinded for analysis but the study is open label due to the nature of the intervention",
            "whoMasked": ["OUTCOMES_ASSESSOR"]
          }
        },
        "enrollmentInfo": { "count": 70, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "Intervention arm",
            "type": "EXPERIMENTAL",
            "description": "Participants will receive 4 hours of exposure to the Mindful Garden digital therapeutic platform in addition to standard care",
            "interventionNames": ["Device: Mindful Garden"]
          },
          {
            "label": "Control Arm",
            "type": "NO_INTERVENTION",
            "description": "Participants will be monitored over a 4 hour period of standard care interventions"
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "Mindful Garden",
            "description": "Mindful Garden is an interactive digital behavior modification platform utilizing inbuilt sensors and screen based delivery system. The platform delivers calming visual output of real nature video layered with hyper-real animations of growing and receding flowers and butterflies in flight in a volume directly responsive to measured patient activity. Patient movement and vocalization are the surrogate markers for agitation and using proprietary algorithms drive onscreen content.",
            "armGroupLabels": ["Intervention arm"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Agitation scores",
            "description": "Richmond Agitation Sedation Score is a validated and standardized scoring system ranging from -5 (deeply sedated) to 0 (awake and calm) to +4 (combative). Scores are measured hourly from study start, one hour post intervention and at the start of the following nursing shift.",
            "timeFrame": "5 hours"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Use of unscheduled medications for the management of delirium associated agitation",
            "description": "Incidence of unscheduled or \"PRN\" medication use for the management of delirium associated agitation throughout the 4 hour study period",
            "timeFrame": "4 hours"
          },
          {
            "measure": "Delirium Scores",
            "description": "Delirium scores will be measured using the Intensive Care Delirium Screening Checklist. Delirium score is a range of zero to 8 with scores above or equal to 4 being diagnostic for the presence of delirium and higher scores being indicative of added severity of symptoms. Intensive Care Delirium Screening Checklist will be measured at study initiation, after 2 hours, at study completion (4 hours) and the start of the following nursing shift",
            "timeFrame": "4 hours"
          },
          {
            "measure": "Richmond Agitation Sedation Scale of zero",
            "description": "Proportion of patients achieving a Richmond Agitation Sedation Scale score of zero throughout the study period. Score range is -5 to +4 with a score of zero indicating the patient is awake and calm. Negative scores indicate deeper sedation, positive scores reflect agitation",
            "timeFrame": "4 hours"
          },
          {
            "measure": "Physical Restraint Use",
            "description": "Proportion of participants with physical restraints in use throughout the study period and the length of time of restraints in use",
            "timeFrame": "4 hours"
          },
          {
            "measure": "Incidence of Unplanned Line removal",
            "description": "Incidence of unplanned removal of lines or tubes by the study participant (endotracheal tubes, nasogastric tubes, oral-gastric tubes, central venous lines, peripheral intravenous lines, urinary catheters, arterial lines) throughout the study period.",
            "timeFrame": "4 hours"
          },
          {
            "measure": "PRN medication use in the 2 hours post study",
            "description": "Incidence of unscheduled medication administration for the management of delirium behaviors in the 2 hours following the study or intervention period.",
            "timeFrame": "2 hours"
          },
          {
            "measure": "Movement Count Average",
            "description": "Those in the intervention arm will have generated activity logs stored within the device units. The movement count average is calculated by comparing the difference in pixel density from the previous frame to the current one. The resulting value is then averaged over the collected frames and returned as a decimal percentage of change. Values are between 0 and 1 with 0 showing the lowest amount of activity and one the highest",
            "timeFrame": "4 Hours"
          },
          {
            "measure": "Physiological data",
            "description": "Basic physiological data will be collected and analyzed from nursing records and for a smaller proportion directly from telemetry monitors where available to compare between arms as well as to evaluate trends over the course of the study period. Parameters include heart rate, mean arterial blood pressure, respiratory rate, oxygen saturation and use of vasopressors",
            "timeFrame": "4 hours"
          },
          {
            "measure": "heart rate variability",
            "description": "For a small subset of the overall population ECG data will be collected to assess differences in heart rate variability between study arms measured as pNN50 and RMMSD. Five minute ECG recordings will be taken hourly starting one hour before the study period until one hour post timed to match agitation and delirium scores",
            "timeFrame": "6 hours"
          }
        ],
        "otherOutcomes": [
          {
            "measure": "Survey of caregivers",
            "description": "a 5 question survey of caregivers will be conducted using a 9 point Likert scale evaluating the ease of use of the intervention and acceptability of the intervention. On the scale 1 indicates strongly disagree to 9 indicating strongly agree, 5 being neutral. The questionnaire will be conducted at the end of the study period where possible",
            "timeFrame": "4 hours"
          },
          {
            "measure": "Survey of family members",
            "description": "a 5 question survey of family members if present during exposure to the intervention will be conducted using a 9 point Likert scale evaluating acceptability of the intervention. On the scale 1 indicates strongly disagree to 9 indicating strongly agree, 5 being neutral",
            "timeFrame": "4 hours"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* Adult (age \\>18yrs)\n* Admitted to the Royal Columbian Hospital\n* RASS +1 or greater for 2 assessments 1 hour apart within the 24-hour period directly prior to study enrollment and persisting at the time of enrollment\n* Demonstrated incidence of at least 2 PRN medication events for the management of delirium-associated agitation in the preceding 24 hours and/or infusion of psycho- active medication for the management of delirium (eg: dexmeditomodine)\n* ICDSC greater than or equal to 4 at time of enrollment or CAM positive\n\nExclusion Criteria:\n\n* Planned procedure or test that precludes participation in the full 4-hour study session\n* Unable to see (visual impairment such as documented blindness, ongoing inability to keep eyes open or documented or assessed inability to focus, track or maintain visual contact for extended periods as determined by recruitment personnel)\n* Significant uncontrolled pain with a Verbal Pain scale of 5/10 or greater or a Clinical Pain Observation Tool \\>4 despite intervention at the time of enrollment.\n* RASS of 0 to -5 at study enrollment indicating patient is awake and calm or sedated\n* Refusal for participation by the participant's responsible physician or request to not retain data by participants substitute decision maker\n* Currently enrolled in any other research study involving drugs or devices which could impact on the outcomes of interest, as evaluated by the Principal Investigator",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "Steven Reynolds",
            "affiliation": "Fraser Health Authority",
            "role": "PRINCIPAL_INVESTIGATOR"
          }
        ],
        "locations": [
          {
            "facility": "Royal Columbian Hospital",
            "city": "New Westminster",
            "state": "British Columbia",
            "zip": "V3L 3W7",
            "country": "Canada",
            "geoPoint": { "lat": 49.20678, "lon": -122.91092 }
          }
        ]
      },
      "ipdSharingStatementModule": { "ipdSharing": "NO" }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [{ "id": "D003693", "term": "Delirium" }],
        "ancestors": [
          { "id": "D003221", "term": "Confusion" },
          { "id": "D019954", "term": "Neurobehavioral Manifestations" },
          { "id": "D009461", "term": "Neurologic Manifestations" },
          { "id": "D009422", "term": "Nervous System Diseases" },
          { "id": "D019965", "term": "Neurocognitive Disorders" },
          { "id": "D001523", "term": "Mental Disorders" }
        ],
        "browseLeaves": [
          {
            "id": "M6894",
            "name": "Delirium",
            "asFound": "Delirium",
            "relevance": "HIGH"
          },
          { "id": "M6446", "name": "Confusion", "relevance": "LOW" },
          {
            "id": "M21826",
            "name": "Neurobehavioral Manifestations",
            "relevance": "LOW"
          },
          {
            "id": "M12404",
            "name": "Neurologic Manifestations",
            "relevance": "LOW"
          },
          {
            "id": "M21836",
            "name": "Neurocognitive Disorders",
            "relevance": "LOW"
          },
          { "id": "M14473", "name": "Psychotic Disorders", "relevance": "LOW" },
          { "id": "M4815", "name": "Mental Disorders", "relevance": "LOW" },
          {
            "id": "T170",
            "name": "Acute Graft Versus Host Disease",
            "relevance": "LOW"
          }
        ],
        "browseBranches": [
          { "abbrev": "BC10", "name": "Nervous System Diseases" },
          { "abbrev": "BC23", "name": "Symptoms and General Pathology" },
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" },
          { "abbrev": "All", "name": "All Conditions" },
          { "abbrev": "Rare", "name": "Rare Diseases" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT06021431",
        "orgStudyIdInfo": { "id": "00157860" },
        "secondaryIdInfos": [
          {
            "id": "5R44DA053848",
            "type": "NIH",
            "link": "https://reporter.nih.gov/quickSearch/5R44DA053848"
          }
        ],
        "organization": { "fullName": "BehaVR LLC", "class": "INDUSTRY" },
        "briefTitle": "Virtual Reality Cognitive-Affective Training for Opioid Use Disorder- A Phase 2 RCT",
        "officialTitle": "Digital Therapeutic Development of Virtual Cognitive-Affective Training for Opioid Use Disorder: A Phase 2 Randomized Controlled Trial"
      },
      "statusModule": {
        "statusVerifiedDate": "2024-03",
        "overallStatus": "RECRUITING",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2023-09-07", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2026-03",
          "type": "ESTIMATED"
        },
        "completionDateStruct": { "date": "2026-05", "type": "ESTIMATED" },
        "studyFirstSubmitDate": "2023-08-28",
        "studyFirstSubmitQcDate": "2023-08-28",
        "studyFirstPostDateStruct": { "date": "2023-09-01", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2024-03-27",
        "lastUpdatePostDateStruct": { "date": "2024-03-28", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": { "name": "BehaVR LLC", "class": "INDUSTRY" },
        "collaborators": [
          { "name": "University of Utah", "class": "OTHER" },
          { "name": "National Institute on Drug Abuse (NIDA)", "class": "NIH" }
        ]
      },
      "oversightModule": {
        "oversightHasDmc": true,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": true,
        "isUnapprovedDevice": true,
        "isUsExport": false
      },
      "descriptionModule": {
        "briefSummary": "The goal of this clinical trial is to examine the usefulness of a virtual reality-delivered intervention for individuals with opioid use disorder who are taking medication. The main question it aims to answer is will people with opioid use disorder who receive the study intervention, Mindfulness-Oriented Recovery Enhancement in Virtual Reality (MORE-VR), have fewer days in which they use opioids than will people who just receive their usual treatment. Participants will be randomly assigned to either receive 8 weekly sessions of MORE-VR in addition to their usual treatment, or treatment as usual only. Researchers will compare these groups at the end of treatment and three months after treatment is over on number of days of opioid use and time until first opioid use lapse, as well as drug craving and mood.",
        "detailedDescription": "This project is a Phase II, two-arm, parallel randomized controlled trial (RCT) of a virtual reality form of Mindfulness-Oriented Recovery Enhancement (MORE-VR) versus treatment as usual (TAU) for patients receiving medications for opioid use disorder (MOUD) to assess the efficacy of the MORE-VR system. Participants will be randomized (1:1) to either 8 weekly sessions of MORE-VR or TAU. Participants will be assessed at intake, post-treatment, and a 3 month post-treatment follow-up. The primary outcome assessed will be days of opioid use."
      },
      "conditionsModule": {
        "conditions": ["Opioid Use Disorder"],
        "keywords": ["Mindfulness", "Virtual Reality", "Opioid Use Disorder"]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": {
            "masking": "SINGLE",
            "whoMasked": ["OUTCOMES_ASSESSOR"]
          }
        },
        "enrollmentInfo": { "count": 128, "type": "ESTIMATED" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "MORE-VR",
            "type": "EXPERIMENTAL",
            "description": "An 8-session version of Mindfulness-Oriented Recovery Enhancement (MORE) delivered by virtual reality. The treatment involves training in mindfulness, reappraisal, and savoring techniques to address OUD.\n\nParticipants in this arm will also receive Treatment as usual (TAU) with medications for opioid use disorder (MOUD) such as buprenorphine, methadone, or naltrexone plus any psychological counseling they are already receiving in their standard care.",
            "interventionNames": [
              "Device: MORE-VR",
              "Other: Treatment as Usual"
            ]
          },
          {
            "label": "Treatment as Usual (TAU)",
            "type": "ACTIVE_COMPARATOR",
            "description": "Treatment as usual (TAU) with medications for opioid use disorder (MOUD) such as buprenorphine, methadone, or naltrexone plus any psychological counseling they are already receiving in their standard care.",
            "interventionNames": ["Other: Treatment as Usual"]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "MORE-VR",
            "description": "An 8-session version of Mindfulness-Oriented Recovery Enhancement (MORE) delivered by virtual reality. The treatment involves training in mindfulness,reappraisal, and savoring techniques to address OUD.\n\nCombination Product: Participants in this arm will also receive Treatment as usual (TAU) with medications for opioid use disorder (MOUD). Usual addictions treatment with medications such as buprenorphine or methadone plus psychological counseling.",
            "armGroupLabels": ["MORE-VR"],
            "otherNames": [
              "Mindfulness-Oriented Recovery Enhancement in Virtual Reality"
            ]
          },
          {
            "type": "OTHER",
            "name": "Treatment as Usual",
            "description": "Participants will receive their usual treatment for OUD, including medications such as buprenorphine or methadone and any counseling they might already be receiving",
            "armGroupLabels": ["MORE-VR", "Treatment as Usual (TAU)"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Days of opioid use",
            "description": "Days of opioid use assessed with the Timeline Followback method, ecological momentary assessments, and/or drug toxicology screen",
            "timeFrame": "Baseline to post-treatment assessment (8 weeks)"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Days of opioid use at follow-up",
            "description": "Days of opioid use assessed with the Timeline Followback method, ecological momentary assessments, and/or drug toxicology screen",
            "timeFrame": "Baseline to 3 months post treatment (20 weeks from baseline)"
          },
          {
            "measure": "Time until opioid lapse",
            "description": "Number of days until opioid lapse assessed with the Timeline Followback method, ecological momentary assessments, and/or drug toxicology screen",
            "timeFrame": "Baseline through 3 month post-treatment follow-up"
          },
          {
            "measure": "Time until dropout from opioid use disorder treatment",
            "description": "Number of days unti dropout from treatment, assessed by Timeline Followback and chart review",
            "timeFrame": "Baseline through 3 month post-treatment follow-up"
          },
          {
            "measure": "Desire for drugs",
            "description": "Desires for Drug Questionnaire, range from 14 to 98, higher scores indicating more intense desires for drugs",
            "timeFrame": "Baseline, post-treatment, 3 month post-treatment follow-up, and weekly during intervention period"
          },
          {
            "measure": "Opioid craving",
            "description": "0-10 numeric rating scale via ecological momentary assessment (0=no craving, 10=extreme craving).",
            "timeFrame": "Baseline, post-treatment, 3 month post-treatment follow-up, and weekly during intervention period"
          },
          {
            "measure": "Positive Affect",
            "description": "0-10 numeric rating scale via ecological momentary assessment (0=no positive affect, 10=extremely strong positive affect).",
            "timeFrame": "Baseline, post-treatment, 3 month post-treatment follow-up, and weekly during intervention period"
          },
          {
            "measure": "Negative Affect",
            "description": "0-10 numeric rating scale via ecological momentary assessment (0=no negative affect, 10=extremely strong negative affect).",
            "timeFrame": "Baseline, post-treatment, 3 month post-treatment follow-up, and weekly during intervention period"
          },
          {
            "measure": "Positive and Negative Affect Schedule",
            "description": "A 20-item scale measuring both positive and negative affect, where each affective term is rated on a scale of 1 (not at all) to 5 (very much)",
            "timeFrame": "Baseline, post-treatment, 3 month post-treatment follow-up, and weekly during intervention period"
          },
          {
            "measure": "Distress",
            "description": "Emotional distress measured by the Depression Anxiety Stress Scale, range from 0 to 63, higher scores indicating worse distress.",
            "timeFrame": "Baseline through 3 month post-treatment follow-up"
          },
          {
            "measure": "Health-related Quality of Life",
            "description": "World Health Organization Quality of Life Scale Quality of life measured by the World Health Organization Quality of Life Scale (WHO-5), scores ranging from 0 to 25, with higher scores indicating better quality of life.",
            "timeFrame": "Baseline through 3 month post-treatment follow-up"
          }
        ],
        "otherOutcomes": [
          {
            "measure": "Drug cue reactivity",
            "description": "For a subset of participants, we will asses change from baseline in neurophysiological response during lab-based task involving presentation of drug cues designed to measure cue-reactivity.",
            "timeFrame": "Baseline to immediately after the intervention"
          },
          {
            "measure": "Emotion regulation",
            "description": "For a subset of participants, we will assess change from baseline in neurophysiological response during lab-based task involving presentation of emotional stimuli.",
            "timeFrame": "Baseline to immediately after the intervention"
          },
          {
            "measure": "Theta oscillations",
            "description": "For a subset of participants, we will assess theta oscillations as measured by EEG during meditation",
            "timeFrame": "Baseline to immediately after the intervention"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* 18 years of age or older\n* current DSM-5 OUD diagnosis\n* prescribed medications for opioid use disorder (e.g., buprenorphine, methadone)\n\nExclusion Criteria:\n\n* completion of a standardized mindfulness intervention (e.g., MORE, MBRP, MBSR)\n* active psychosis or suicidality\n* reports, or is noted by clinical or study staff as showing cognitive impairment\n* condition which might be contraindicated for VR use including seizure disorder, vertigo, severe motion sickness, recent concussion",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "centralContacts": [
          {
            "name": "Risa Weisberg, PhD",
            "role": "CONTACT",
            "phone": "502-777-1593",
            "email": "risaweisberg@behavr.com"
          },
          {
            "name": "Eric Garland, PhD",
            "role": "CONTACT",
            "phone": "801-581-3826",
            "email": "eric.garland@socwk.utah.edu"
          }
        ],
        "overallOfficials": [
          {
            "name": "Risa Weisberg, PhD",
            "affiliation": "BehaVR LLC",
            "role": "PRINCIPAL_INVESTIGATOR"
          }
        ],
        "locations": [
          {
            "facility": "University of Utah",
            "status": "RECRUITING",
            "city": "Salt Lake City",
            "state": "Utah",
            "zip": "84112",
            "country": "United States",
            "contacts": [
              {
                "name": "Eric Garland, PhD",
                "role": "CONTACT",
                "phone": "801-581-3826",
                "email": "eric.garland@socwk.utah.edu"
              }
            ],
            "geoPoint": { "lat": 40.76078, "lon": -111.89105 }
          }
        ]
      },
      "ipdSharingStatementModule": {
        "ipdSharing": "YES",
        "infoTypes": ["STUDY_PROTOCOL", "SAP"],
        "timeFrame": "Data will be available after publication of the primary, secondary, and mechanistic outcomes of the trial.",
        "accessCriteria": "Data will be available with a signed data access agreement"
      }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [
          { "id": "D009293", "term": "Opioid-Related Disorders" },
          { "id": "D019966", "term": "Substance-Related Disorders" }
        ],
        "ancestors": [
          { "id": "D000079524", "term": "Narcotic-Related Disorders" },
          { "id": "D064419", "term": "Chemically-Induced Disorders" },
          { "id": "D001523", "term": "Mental Disorders" }
        ],
        "browseLeaves": [
          {
            "id": "M12244",
            "name": "Opioid-Related Disorders",
            "asFound": "Opioid Use Disorder",
            "relevance": "HIGH"
          },
          {
            "id": "M21837",
            "name": "Substance-Related Disorders",
            "asFound": "Opioid Use Disorder",
            "relevance": "HIGH"
          },
          {
            "id": "M2057",
            "name": "Narcotic-Related Disorders",
            "relevance": "LOW"
          },
          {
            "id": "M30302",
            "name": "Chemically-Induced Disorders",
            "relevance": "LOW"
          },
          { "id": "M14473", "name": "Psychotic Disorders", "relevance": "LOW" },
          { "id": "M4815", "name": "Mental Disorders", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "BC25", "name": "Substance Related Disorders" },
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" },
          { "abbrev": "All", "name": "All Conditions" }
        ]
      },
      "interventionBrowseModule": {
        "browseLeaves": [
          { "id": "M5317", "name": "Buprenorphine", "relevance": "LOW" },
          { "id": "M11671", "name": "Methadone", "relevance": "LOW" },
          { "id": "M4033", "name": "Analgesics, Opioid", "relevance": "LOW" },
          { "id": "M12222", "name": "Naltrexone", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "Analg", "name": "Analgesics" },
          { "abbrev": "CNSDep", "name": "Central Nervous System Depressants" },
          { "abbrev": "NarcAntag", "name": "Narcotic Antagonists" },
          { "abbrev": "All", "name": "All Drugs and Chemicals" },
          { "abbrev": "AnTuAg", "name": "Antitussive Agents" },
          { "abbrev": "Resp", "name": "Respiratory System Agents" },
          { "abbrev": "AlcDet", "name": "Alcohol Deterrents" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT06615167",
        "orgStudyIdInfo": { "id": "G00020" },
        "organization": { "fullName": "HAII corp.ltd", "class": "INDUSTRY" },
        "briefTitle": "Confirmatory Clinical Trial for Verifying the Efficacy and Safety of 'ALZGUARD' as a Digital Dementia Diagnostic Aid-Tool for the Diagnosis of the Major Neurocognitive Disorders",
        "officialTitle": "A Single-blind (Data Analyst 1), Single-arm Design, Prospective, Multi-center Confirmatory Clinical Trial for Verifying the Efficacy and Safety of 'ALZGUARD' as a Digital Dementia Diagnostic Aid-Tool for the Diagnosis of the Major Neurocognitive Disorders According to DSM-5"
      },
      "statusModule": {
        "statusVerifiedDate": "2024-09",
        "overallStatus": "RECRUITING",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2024-09-12", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2025-04-30",
          "type": "ESTIMATED"
        },
        "completionDateStruct": { "date": "2025-04-30", "type": "ESTIMATED" },
        "studyFirstSubmitDate": "2024-09-20",
        "studyFirstSubmitQcDate": "2024-09-25",
        "studyFirstPostDateStruct": { "date": "2024-09-26", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2024-09-25",
        "lastUpdatePostDateStruct": { "date": "2024-09-26", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": { "name": "HAII corp.ltd", "class": "INDUSTRY" }
      },
      "oversightModule": {
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": false
      },
      "descriptionModule": {
        "briefSummary": "The goal of this clinical trial is to evalute the efficacy of ALZGUARD, a smartphone-based digital therapeutic(DTx), in comparison to diagnosis by medical doctors, as weel as to assess the safety of the application.",
        "detailedDescription": "The study will be conducted across multiple sites, enrolling participants aged 55 to 85 years olds.\n\nThe primary objective of the study is to compare the diagnositic accuracy of ALZGAURD against traditional diagnostic evaluactions conducted by medical professionals. The primary endpoint for efficacy will be the Area Under the Curve(AUC), which will measure the diagnostic performance of the application. This statistical metric will help determine how well ALZGUARD can identify dementia compared to standard diagnostic methods."
      },
      "conditionsModule": {
        "conditions": ["Dementia", "Major Neurocognitive Disorder"]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "NA",
          "interventionModel": "SINGLE_GROUP",
          "interventionModelDescription": "This is a single-arm, interventional clinical trial designed to evlauate the efficacy and safety of ALZGAURD, a smartphone-based digital therapeutic, in detecting dementia.\n\nStudy type: interentional (clinical trial) Masking: Single-blind (Outcomes assessor) Intervention description: The ALZGUARD application will be used by participants to assess cognitive function. Results will be compared to clinical diagnoses made by neurologists.\n\nPrimary Outcome: the accuracy of the ALZGUARD diagnosis, measured by Area Under the Curve.",
          "primaryPurpose": "DIAGNOSTIC",
          "maskingInfo": {
            "masking": "NONE",
            "maskingDescription": "In this study, there will be two data analysts involved. Analyst 1 will be responsible for analyzing the results generated by the ALZGUARD application, which are based on the ALZGUARD AI model. This analyst will assess whether each subject has dementia and the likelihood or probability of the diagnosis. Analyst 1 will be blinded to any clinical assessments or dianoses made by the neurologists."
          }
        },
        "enrollmentInfo": { "count": 122, "type": "ESTIMATED" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "ALZGUARD Intervention Group",
            "type": "EXPERIMENTAL",
            "description": "All participants wil use the ALZGAURD smartphone-based digital therapeutic(DTx) to assess cognitive function for detecting dementia.",
            "interventionNames": ["Device: ALZGUARD"]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "ALZGUARD",
            "description": "A digital therapeutic(DTx) application that uses artifical intelligence to analyze cognitive function and provide a diagnosis of dementia.",
            "armGroupLabels": ["ALZGUARD Intervention Group"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Area Under the Curve (AUC)",
            "description": "The primary outcome will be the Area Under the Curve (AUC), which will assess the diagnostic accuracy of ALZGUARD by comparing its results with the clinical diagnosis made by neurologists. AUC will be calculated to determine the performance of ALZGUARD in detecting dementia.",
            "timeFrame": "up to 8 months"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Sensitivity",
            "description": "The one of the secondary outcome will measure the sensitivity of ALZGUARD in detecting dementia. Sensitivity refers to the proportion of true positive cases accurately identified by ALZGUARD, compared to clinical diagnosis made by neurologists. This measure will assess the ability of ALZGUARD to correctly identiry patients who have dementia.",
            "timeFrame": "up to 8 months"
          },
          {
            "measure": "Specificity",
            "description": "Specificity refers to the proportion of true negative cases accurately identified by ALZGUARD, compared to the clinical diagnosis made by neurologists. This outcome will assess the ability of ALZGUARD to correctly identify patient who do not have dementia.",
            "timeFrame": "up to 8 months"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* Participants must be between 55 and 85 years old (both men and women).\n* Participants must be able to understand and voluntarily agree to the purpose, content, and procedures of the clinical trial.\n\nExclusion Criteria:\n\n* Participants with no literacy or illiteracy.\n* Participants with an intellectual disability.\n* Participants with presenting active psychiatric symptoms.\n* Participants who have difficulty ALZGUARD application\n* Participants who are unable to use a smartphone, unless they can use it with assistant.\n* Participants with a history of suicidal ideation or suicidal complusion in the last 6 months.\n* Other conditions as deemed inappropriate for study participant by the Principal Investigator(PI).",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "55 Years",
        "maximumAge": "85 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "centralContacts": [
          {
            "name": "Rachel Lee",
            "role": "CONTACT",
            "phone": "+82 10-7390-5023",
            "email": "rachel.lee@haii.io"
          }
        ],
        "locations": [
          {
            "facility": "Kangwon National University Hospital",
            "status": "RECRUITING",
            "city": "Chuncheon",
            "state": "Kangwon",
            "country": "Korea, Republic of",
            "contacts": [
              {
                "name": "YeShin Kim",
                "role": "CONTACT",
                "email": "yeshins@gmail.com"
              },
              {
                "name": "KungHee Bae",
                "role": "CONTACT",
                "email": "khjy2@naver.com"
              },
              { "name": "YeShin Kim", "role": "PRINCIPAL_INVESTIGATOR" }
            ],
            "geoPoint": { "lat": 37.87472, "lon": 127.73417 }
          },
          {
            "facility": "Ewha Womans University Mokdong Medical Center",
            "status": "RECRUITING",
            "city": "Seoul",
            "country": "Korea, Republic of",
            "contacts": [
              {
                "name": "GeonHa Kim",
                "role": "CONTACT",
                "email": "geonha@ewha.ac.kr"
              },
              {
                "name": "JiSook Lim",
                "role": "CONTACT",
                "email": "jsskin@naver.com"
              },
              { "name": "GeonHa Kim", "role": "PRINCIPAL_INVESTIGATOR" }
            ],
            "geoPoint": { "lat": 37.566, "lon": 126.9784 }
          },
          {
            "facility": "Yongin Severance Hospital",
            "status": "RECRUITING",
            "city": "Seoul",
            "country": "Korea, Republic of",
            "contacts": [
              {
                "name": "MinYoung Jeon",
                "role": "CONTACT",
                "email": "myc5198@gmail.com"
              },
              {
                "name": "JiSu Jeong",
                "role": "CONTACT",
                "email": "xodud1234@yuhs.ac"
              },
              { "name": "MinYoung Jeon", "role": "PRINCIPAL_INVESTIGATOR" }
            ],
            "geoPoint": { "lat": 37.566, "lon": 126.9784 }
          }
        ]
      }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [
          { "id": "D003704", "term": "Dementia" },
          { "id": "D019965", "term": "Neurocognitive Disorders" }
        ],
        "ancestors": [
          { "id": "D001927", "term": "Brain Diseases" },
          { "id": "D002493", "term": "Central Nervous System Diseases" },
          { "id": "D009422", "term": "Nervous System Diseases" },
          { "id": "D001523", "term": "Mental Disorders" }
        ],
        "browseLeaves": [
          {
            "id": "M6904",
            "name": "Dementia",
            "asFound": "Dementia",
            "relevance": "HIGH"
          },
          {
            "id": "M21836",
            "name": "Neurocognitive Disorders",
            "asFound": "Neurocognitive Disorders",
            "relevance": "HIGH"
          },
          { "id": "M5204", "name": "Brain Diseases", "relevance": "LOW" },
          {
            "id": "M5742",
            "name": "Central Nervous System Diseases",
            "relevance": "LOW"
          },
          { "id": "M14473", "name": "Psychotic Disorders", "relevance": "LOW" },
          { "id": "M4815", "name": "Mental Disorders", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "BC10", "name": "Nervous System Diseases" },
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" },
          { "abbrev": "All", "name": "All Conditions" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT00710099",
        "orgStudyIdInfo": { "id": "DCIC/08/08" },
        "organization": {
          "fullName": "University Hospital, Grenoble",
          "class": "OTHER"
        },
        "briefTitle": "Effect of Oral Sildenafil With Digital Therapeutic Iontophoresis of Sodium Nitroprussiate in Healthy Volunteers",
        "officialTitle": "Effect of Oral Sildenafil With Digital Therapeutic Iontophoresis of Sodium Nitroprussiate on Cutaneous Blood Flow in Healthy Volunteers",
        "acronym": "INFLUX-VS"
      },
      "statusModule": {
        "statusVerifiedDate": "2011-10",
        "overallStatus": "COMPLETED",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2008-07" },
        "primaryCompletionDateStruct": { "date": "2011-06", "type": "ACTUAL" },
        "completionDateStruct": { "date": "2011-06", "type": "ACTUAL" },
        "studyFirstSubmitDate": "2008-07-02",
        "studyFirstSubmitQcDate": "2008-07-03",
        "studyFirstPostDateStruct": {
          "date": "2008-07-04",
          "type": "ESTIMATED"
        },
        "lastUpdateSubmitDate": "2011-10-05",
        "lastUpdatePostDateStruct": {
          "date": "2011-10-06",
          "type": "ESTIMATED"
        }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": {
          "name": "University Hospital, Grenoble",
          "class": "OTHER"
        }
      },
      "oversightModule": { "oversightHasDmc": false },
      "descriptionModule": {
        "briefSummary": "Iontophoresis is a employed to facilitate drug absorption without systemic effect. This study investigates cutaneous microcirculation when we associate sildenafil per os with SNP via iontophoresis.",
        "detailedDescription": "The main outcome is the proof of concept of effect of systemic absorption sildenafil on cutaneous microcirculation associated with SNP iontophoresis."
      },
      "conditionsModule": {
        "conditions": ["Healthy"],
        "keywords": [
          "iontophoresis",
          "cutaneous microcirculation",
          "sildenafil",
          "Healthy volunteers"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "NON_RANDOMIZED",
          "interventionModel": "SINGLE_GROUP",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": { "masking": "NONE" }
        },
        "enrollmentInfo": { "count": 40, "type": "ESTIMATED" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "1",
            "type": "EXPERIMENTAL",
            "interventionNames": ["Drug: sildenafil"]
          },
          {
            "label": "2",
            "type": "ACTIVE_COMPARATOR",
            "description": "SNP iontophoresis",
            "interventionNames": ["Drug: nitroprussiate iontophoresis"]
          }
        ],
        "interventions": [
          {
            "type": "DRUG",
            "name": "sildenafil",
            "description": "systemic absorption of sildenafil",
            "armGroupLabels": ["1"]
          },
          {
            "type": "DRUG",
            "name": "nitroprussiate iontophoresis",
            "description": "nitroprussiate iontophoresis",
            "armGroupLabels": ["2"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "variation of conductance of nitroprussiate iontophoresis associated with oral sildenafil",
            "timeFrame": "one hour"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "To assess the effect of oral sildenafil (50 mg and 100 mg) on skin microvascular reactivity to local cooling, on the forearm and the finger",
            "timeFrame": "one hour"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* Age over 18\n* No significant medical history\n\nExclusion Criteria:\n\n* Age under 18\n* Period of exclusion for an other study\n* Pregnancy\n* Breast feeding\n* Severe disease\n* Cigarette smoking",
        "healthyVolunteers": true,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "Jean-Luc CRACOWSKI, MD",
            "affiliation": "Institut National de la Santé Et de la Recherche Médicale, France",
            "role": "PRINCIPAL_INVESTIGATOR"
          }
        ],
        "locations": [
          {
            "facility": "Clinical Researsh Centre",
            "city": "Grenoble",
            "state": "Isere",
            "zip": "38043",
            "country": "France",
            "geoPoint": { "lat": 45.16667, "lon": 5.71667 }
          }
        ]
      },
      "referencesModule": {
        "references": [
          {
            "pmid": "16876881",
            "type": "BACKGROUND",
            "citation": "Cracowski JL, Minson CT, Salvat-Melis M, Halliwill JR. Methodological issues in the assessment of skin microvascular endothelial function in humans. Trends Pharmacol Sci. 2006 Sep;27(9):503-8. doi: 10.1016/j.tips.2006.07.008. Epub 2006 Jul 31."
          }
        ]
      }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "interventionBrowseModule": {
        "meshes": [{ "id": "D000068677", "term": "Sildenafil Citrate" }],
        "ancestors": [
          { "id": "D014665", "term": "Vasodilator Agents" },
          { "id": "D058986", "term": "Phosphodiesterase 5 Inhibitors" },
          { "id": "D010726", "term": "Phosphodiesterase Inhibitors" },
          { "id": "D004791", "term": "Enzyme Inhibitors" },
          {
            "id": "D045504",
            "term": "Molecular Mechanisms of Pharmacological Action"
          },
          { "id": "D064804", "term": "Urological Agents" }
        ],
        "browseLeaves": [
          {
            "id": "M292",
            "name": "Sildenafil Citrate",
            "asFound": "rTMS",
            "relevance": "HIGH"
          },
          { "id": "M21320", "name": "Citric Acid", "relevance": "LOW" },
          { "id": "M1837", "name": "Sodium Citrate", "relevance": "LOW" },
          { "id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW" },
          {
            "id": "M29332",
            "name": "Phosphodiesterase 5 Inhibitors",
            "relevance": "LOW"
          },
          {
            "id": "M13629",
            "name": "Phosphodiesterase Inhibitors",
            "relevance": "LOW"
          },
          { "id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW" },
          { "id": "T382", "name": "Citrate", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "VaDiAg", "name": "Vasodilator Agents" },
          { "abbrev": "Urol", "name": "Urological Agents" },
          { "abbrev": "All", "name": "All Drugs and Chemicals" },
          { "abbrev": "AnCoag", "name": "Anticoagulants" },
          { "abbrev": "Ot", "name": "Other Dietary Supplements" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT05989841",
        "orgStudyIdInfo": { "id": "UNLV-2023-649" },
        "organization": {
          "fullName": "University of Nevada, Las Vegas",
          "class": "OTHER"
        },
        "briefTitle": "Mitigating PTSD-CUD After Sexual Assault",
        "officialTitle": "Mitigating PTSD-CUD Among Women Presenting to Emergency Care After Sexual Assault: Testing a Digital Therapeutic Targeting Anxiety Sensitivity",
        "acronym": "RISE-C"
      },
      "statusModule": {
        "statusVerifiedDate": "2025-01",
        "overallStatus": "RECRUITING",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2023-12-15", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2027-02-28",
          "type": "ESTIMATED"
        },
        "completionDateStruct": { "date": "2028-02-29", "type": "ESTIMATED" },
        "studyFirstSubmitDate": "2023-05-10",
        "studyFirstSubmitQcDate": "2023-08-10",
        "studyFirstPostDateStruct": { "date": "2023-08-14", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2025-01-21",
        "lastUpdatePostDateStruct": { "date": "2025-01-24", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": {
          "name": "University of Nevada, Las Vegas",
          "class": "OTHER"
        },
        "collaborators": [
          {
            "name": "University of North Carolina, Chapel Hill",
            "class": "OTHER"
          }
        ]
      },
      "oversightModule": {
        "oversightHasDmc": true,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": false,
        "isUsExport": false
      },
      "descriptionModule": {
        "briefSummary": "683,000 women are sexually assaulted annually in the United States, half of whom develop chronic posttraumatic stress disorder (PTSD) and thus have markedly increased risk for cannabis use disorder (CUD). The current proposal will test the acceptability, initial efficacy, and mechanisms underlying a novel digital therapeutic targeting risk for PTSD-CUD, which could address the critical need for PTSD-CUD prevention for the 100,000 women who annually present for emergency care after sexual assault. In this research context, the applicant will receive key training in multisite, emergency-care based randomized clinical trials (RCTs), advanced statistical analyses for RCTs and ecological momentary assessment data, biobehavioral mechanisms underlying PTSD-CUD prevention, and professional development, launching her independent research career focused on reducing the public health burden of PTSD-CUD among sexual assault survivors by leveraging digital therapeutics."
      },
      "conditionsModule": {
        "conditions": ["Posttraumatic Stress Disorder", "Cannabis Use Disorder"]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "primaryPurpose": "PREVENTION",
          "maskingInfo": {
            "masking": "TRIPLE",
            "whoMasked": ["PARTICIPANT", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]
          }
        },
        "enrollmentInfo": { "count": 100, "type": "ESTIMATED" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "RISE Guide",
            "type": "EXPERIMENTAL",
            "description": "Brief cognitive behavioral intervention completed in the 3 weeks post-assault delivered via Internet on participants' smartphones targeting anxiety sensitivity, or fear of anxious arousal. Patients learn psychoeducation regarding the nature of stress, cognitive retraining to reduce negative interpretations of stress, and how to complete interoceptive exposures to reduce anxiety sensitivity. These skills are supported by 6 concurrent then subsequent weeks of ecological momentary intervention to deliver personalized intervention reminders based on symptoms.",
            "interventionNames": ["Behavioral: RISE Guide"]
          },
          {
            "label": "Relaxation",
            "type": "ACTIVE_COMPARATOR",
            "description": "Patients will download the \"Breathe2Relax\" app, which delivers information about how to use diaphragm breathing (taking slow, deep breaths through the diaphragm) to manage stress. Participants will receive reminders to engage with the intervention. Participants will also receive ecological momentary intervention reminders to engage with the relaxation intervention.",
            "interventionNames": ["Behavioral: Relaxation Control"]
          }
        ],
        "interventions": [
          {
            "type": "BEHAVIORAL",
            "name": "RISE Guide",
            "description": "Brief cognitive behavioral intervention completed in the 3 weeks post-assault delivered via Internet on participants' smartphones targeting anxiety sensitivity, or fear of anxious arousal. Patients learn psychoeducation regarding the nature of stress, cognitive retraining to reduce negative interpretations of stress, and how to complete interoceptive exposures to reduce anxiety sensitivity. These skills are supported by 6 concurrent then subsequent weeks of ecological momentary intervention to deliver personalized intervention reminders based on symptoms.",
            "armGroupLabels": ["RISE Guide"]
          },
          {
            "type": "BEHAVIORAL",
            "name": "Relaxation Control",
            "description": "Patients will download the \"Breathe2Relax\" app, which delivers information about how to use diaphragm breathing (taking slow, deep breaths through the diaphragm) to manage stress. Participants will receive reminders to engage with the intervention. Participants will also receive ecological momentary intervention reminders to engage with the relaxation intervention.",
            "armGroupLabels": ["Relaxation"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Anxiety Sensitivity Index-3 (ASI-3)",
            "description": "18-item self-report measure of anxiety sensitivity assessing all three subdomains of anxiety sensitivity (physical, cognitive, social). Participants respond to 18 items (e.g., It scares me when my heart beats rapidly) on a 4-point Likert scale. Scores range from 0-72, with higher scores indicating higher levels of anxiety sensitivity.",
            "timeFrame": "6 weeks"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Marijuana Problems Scale (MPS)",
            "description": "19-item self-report measure of problems related to cannabis use (e.g., problems with work, school, social functioning). Participants rate 19 items on a 3- point Likert scale. Scores range from 0 to 38, with higher scores indicating more problems related to cannabis use.",
            "timeFrame": "6 months"
          },
          {
            "measure": "Marijuana Motives Measure - Coping",
            "description": "The MMM is a 25-item self-report measure of cannabis motives, including coping-oriented motives for cannabis use. Participants respond to a list of motives (e.g., to forget my worries, to get high) on a 5-point Likert scale. Scores range from 25 to 125 for the entire measure, with higher scores indicating higher levels of various types of marijuana motives. The primary motive that will be used as an outcome is coping motives (scores range from 4 to 20 on this subscale).",
            "timeFrame": "6 months"
          },
          {
            "measure": "Patient Reported Outcome Measurement Information System - Anxiety Measurement Information System (PROMIS) Anxiety and Depression",
            "description": "7-items assessing self-reported symptoms of anxiety (e.g., anxious, worried, nervous) rated on a 5-point scale. Scores range from 7 to 35, with higher scores indicating higher levels of anxiety. T-scores are used for final scoring.",
            "timeFrame": "6 months"
          },
          {
            "measure": "Patient Reported Outcome Measurement Information System - Depression Measurement Information System (PROMIS) Anxiety and Depression",
            "description": "8 items assessing self-reported symptoms of depression (e.g., worthlessness, helplessness, sadness) rated on a 5-point scale. Scores range from 8 to 40, with higher scores indicating higher levels of depression. T-scores are used for final scoring.",
            "timeFrame": "6 months"
          },
          {
            "measure": "Cannabis Use Frequency",
            "description": "Ecological momentary assessment will include self-report measures of whether or not cannabis was used that day (yes/no). The item will be scored as 0 (no) vs. 1 (yes), with higher scores indicating higher levels of cannabis use frequency.",
            "timeFrame": "6 weeks"
          },
          {
            "measure": "Cannabis Use Quantity",
            "description": "Ecological momentary assessment will assess quantity of cannabis used on an 8-point scale, assessed 1x/day over 6 weeks. Scores will range from 1-8, with higher scores indicating a higher quantity of cannabis consumed.",
            "timeFrame": "6 weeks"
          },
          {
            "measure": "Marijuana Cravings - Emotionality Questionnaire",
            "description": "Ecological momentary assessment will include a state version of the emotionality subscale of the Marijuana Cravings Questionnaire. This consists of 4 items rated on a 7-point Likert scale, assessed 4x/day over 6 weeks. Scores range from 4 to 28, with higher scores indicating higher levels of cravings.",
            "timeFrame": "6 weeks"
          },
          {
            "measure": "PTSD Checklist for Diagnostic and Statistical Manual -5 (DSM-5) (PCL-5)",
            "description": "20-item self-report measure of DSM-5 PTSD symptoms, including 4 symptom clusters of PTSD (re-experiencing, avoidance, negative alterations in cognition and mood, alterations in arousal and reactivity). Participants respond to items corresponding to each DSM-5 symptom of PTSD on a 5-point Likert scale (0 to 4). Scores range from 0 to 80, with higher scores indicating higher levels of PTSD symptoms.",
            "timeFrame": "6 months"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n1. Women sexual assault survivors presenting for emergency care \\<72 hours post-assault at 1 of our 4 emergency care sites\n2. English speakers\n3. 18+ years of age\n4. Able to provide informed consent\n5. Have a smartphone with continuous service \\>1 year\n6. Report \\>1x/weekly cannabis use on a substance use screener\n7. Report elevated AS (\\>17 on the Anxiety Sensitivity Index-3)\n\nExclusion Criteria:\n\n1. Inability to provide informed consent (e.g., serious injury preventing the ability to hear, speak, or see to consent and participate, or other causes (e.g., diagnosed cognitive deficits, diagnosed dementia, asleep at time of screening)).\n2. Prisoner\n3. Currently pregnant\n4. Lives with assailant and plans to continue to do so\n5. Admitted patient\n6. No mailing address\n7. Previously enrolled\n8. No sexual assault nurse examiner (SANE) examination\n9. Reporting current plan and intent for suicide or homicide\n10. Does not understand written and spoken English",
        "healthyVolunteers": false,
        "sex": "FEMALE",
        "genderBased": true,
        "genderDescription": "Assigned female at birth and currently identifying as female",
        "minimumAge": "18 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "centralContacts": [
          {
            "name": "Nicole A Short, PhD",
            "role": "CONTACT",
            "phone": "7028950606",
            "email": "nicole.short@unlv.edu"
          }
        ],
        "locations": [
          {
            "facility": "Hennepin Assault Response Team",
            "status": "NOT_YET_RECRUITING",
            "city": "Minneapolis",
            "state": "Minnesota",
            "zip": "55415",
            "country": "United States",
            "contacts": [
              {
                "name": "Jeffrey Ho, MD",
                "role": "CONTACT",
                "phone": "(612) 873-5832",
                "phoneExt": "2",
                "email": "jeffrey.ho@hcmed.org"
              }
            ],
            "geoPoint": { "lat": 44.97997, "lon": -93.26384 }
          },
          {
            "facility": "University Medical Center",
            "status": "NOT_YET_RECRUITING",
            "city": "Las Vegas",
            "state": "Nevada",
            "zip": "89102",
            "country": "United States",
            "contacts": [
              {
                "name": "Jordana Haber, MD",
                "role": "CONTACT",
                "phone": "(702) 383-2000",
                "email": "jordana.haber@unlv.edu"
              },
              { "name": "Jordana Haber, MD", "role": "CONTACT" }
            ],
            "geoPoint": { "lat": 36.17497, "lon": -115.13722 }
          },
          {
            "facility": "UNC Chapel Hill",
            "status": "NOT_YET_RECRUITING",
            "city": "Chapel Hill",
            "state": "North Carolina",
            "zip": "27599",
            "country": "United States",
            "contacts": [
              {
                "name": "Karen Serrano, MD",
                "role": "CONTACT",
                "phone": "(919) 966-6442",
                "email": "kserrano@email.unc.edu"
              },
              { "name": "Karen Serrano, MD", "role": "CONTACT" }
            ],
            "geoPoint": { "lat": 35.9132, "lon": -79.05584 }
          },
          {
            "facility": "Harbor Shelter",
            "status": "RECRUITING",
            "city": "Smithfield",
            "state": "North Carolina",
            "zip": "27577",
            "country": "United States",
            "contacts": [
              {
                "name": "Laurie Mayenschein",
                "role": "CONTACT",
                "phone": "919-628-3380",
                "email": "lmayenschein@harborshelter.org"
              }
            ],
            "geoPoint": { "lat": 35.50849, "lon": -78.33945 }
          },
          {
            "facility": "Tulsa Forensic Nursing",
            "status": "NOT_YET_RECRUITING",
            "city": "Tulsa",
            "state": "Oklahoma",
            "zip": "74103",
            "country": "United States",
            "contacts": [
              {
                "name": "Kasey Magness, BSN",
                "role": "CONTACT",
                "phone": "9187435763",
                "email": "kmagness@cityoftulsa.org"
              },
              { "name": "Kasey Magness, BSN", "role": "CONTACT" }
            ],
            "geoPoint": { "lat": 36.15398, "lon": -95.99277 }
          },
          {
            "facility": "SAFE Austin",
            "status": "RECRUITING",
            "city": "Austin",
            "state": "Texas",
            "zip": "74103",
            "country": "United States",
            "contacts": [
              {
                "name": "Jenny Black, BSN",
                "role": "CONTACT",
                "phone": "512.267.7233",
                "email": "jblack@safeaustin.org"
              },
              { "name": "Jenny Black, BSN", "role": "CONTACT" }
            ],
            "geoPoint": { "lat": 30.26715, "lon": -97.74306 }
          }
        ]
      }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [
          { "id": "D013313", "term": "Stress Disorders, Post-Traumatic" }
        ],
        "ancestors": [
          { "id": "D040921", "term": "Stress Disorders, Traumatic" },
          {
            "id": "D000068099",
            "term": "Trauma and Stressor Related Disorders"
          },
          { "id": "D001523", "term": "Mental Disorders" }
        ],
        "browseLeaves": [
          { "id": "M7796", "name": "Emergencies", "relevance": "LOW" },
          { "id": "M10018", "name": "Hypersensitivity", "relevance": "LOW" },
          {
            "id": "M16103",
            "name": "Stress Disorders, Post-Traumatic",
            "asFound": "Posttraumatic Stress Disorder",
            "relevance": "HIGH"
          },
          { "id": "M4324", "name": "Anxiety Disorders", "relevance": "LOW" },
          {
            "id": "M24916",
            "name": "Stress Disorders, Traumatic",
            "relevance": "LOW"
          },
          { "id": "M5449", "name": "Marijuana Abuse", "relevance": "LOW" },
          { "id": "M17685", "name": "Wounds and Injuries", "relevance": "LOW" },
          {
            "id": "M222",
            "name": "Trauma and Stressor Related Disorders",
            "relevance": "LOW"
          },
          { "id": "M14473", "name": "Psychotic Disorders", "relevance": "LOW" },
          { "id": "M4815", "name": "Mental Disorders", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "BC23", "name": "Symptoms and General Pathology" },
          { "abbrev": "All", "name": "All Conditions" },
          { "abbrev": "BC20", "name": "Immune System Diseases" },
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" },
          { "abbrev": "BC25", "name": "Substance Related Disorders" },
          { "abbrev": "BC26", "name": "Wounds and Injuries" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT06067984",
        "orgStudyIdInfo": { "id": "CT-155-E-001" },
        "organization": {
          "fullName": "Click Therapeutics, Inc.",
          "class": "INDUSTRY"
        },
        "briefTitle": "An Extension Study of a Second Course of a Digital Therapeutic for the Treatment of Experiential Negative Symptoms of Schizophrenia",
        "officialTitle": "A Single-Arm, Open Label, 16-week Extension Study to Evaluate the Efficacy and Safety of a Second Course of a Digital Therapeutic As an Adjunct to Standard of Care Antipsychotic Therapy in Adult and Late Adolescent Participants with Experiential Negative Symptoms of Schizophrenia"
      },
      "statusModule": {
        "statusVerifiedDate": "2025-01",
        "overallStatus": "ACTIVE_NOT_RECRUITING",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2023-09-12", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2025-04-22",
          "type": "ESTIMATED"
        },
        "completionDateStruct": { "date": "2025-05-20", "type": "ESTIMATED" },
        "studyFirstSubmitDate": "2023-09-28",
        "studyFirstSubmitQcDate": "2023-09-28",
        "studyFirstPostDateStruct": { "date": "2023-10-05", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2025-01-23",
        "lastUpdatePostDateStruct": { "date": "2025-01-27", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": {
          "name": "Click Therapeutics, Inc.",
          "class": "INDUSTRY"
        },
        "collaborators": [
          { "name": "Boehringer Ingelheim", "class": "INDUSTRY" }
        ]
      },
      "oversightModule": {
        "oversightHasDmc": true,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": true,
        "isUnapprovedDevice": true,
        "isUsExport": false
      },
      "descriptionModule": {
        "briefSummary": "The purpose of the proposed an open label extension (OLE) study is to evaluate the maintained efficacy and safety of a second consecutive course of Click Therapeutics Study App as an adjunct treatment to standard of care (SOC) in participants who were on the Study App and have recently completed the Click Therapeutics Randomized Clinical Trial NCT05838625.",
        "detailedDescription": "Click Therapeutics Study App is an interactive, software-based intervention for experiential negative symptoms of schizophrenia.\n\nThe purpose of the proposed OLE study is to evaluate the maintained efficacy and safety of a second consecutive course of Click Therapeutics Study App as an adjunct treatment to standard of care (SOC) in participants who were on the Study App and have recently completed the Click Therapeutics Randomized Clinical Trial."
      },
      "conditionsModule": {
        "conditions": ["Schizophrenia", "Negative Symptoms in Schizophrenia"],
        "keywords": [
          "Prescription digital therapeutic (PDT)",
          "Software as a Medical Device (SaMD)",
          "Smartphone app",
          "Schizophrenia",
          "Negative Symptoms"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["PHASE3"],
        "designInfo": {
          "allocation": "NA",
          "interventionModel": "SINGLE_GROUP",
          "interventionModelDescription": "This study evaluates the efficacy of a prescription digital therapeutic (PDT) in addition to standard of care (SOC) therapy for the treatment of experiential negative symptoms of schizophrenia in late adolescents and adults.",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": { "masking": "NONE" }
        },
        "enrollmentInfo": { "count": 75, "type": "ESTIMATED" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "Arm A",
            "type": "EXPERIMENTAL",
            "description": "Evaluate the efficacy and safety of a digital therapeutic as an adjunct treatment to SOC in participants with experiential negative symptoms of schizophrenia.",
            "interventionNames": ["Device: Study App"]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "Study App",
            "description": "An investigational prescription digital therapeutic in the form of a smartphone app.",
            "armGroupLabels": ["Arm A"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Change in Experiential Negative Symptoms",
            "description": "Change from baseline to Week 16 in the Clinical Assessment Interview for Negative Symptoms, Motivation and Pleasure Scale (CAINS-MAP)",
            "timeFrame": "Baseline to Week 16"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Change in Experiential Negative Symptoms",
            "description": "Change from baseline to Week 8 in the CAINS-MAP",
            "timeFrame": "Baseline to Week 8"
          },
          {
            "measure": "Change in Expressive Negative Symptoms",
            "description": "Change from baseline to Week 8 and to Week 16 in expressive negative symptoms, as assessed by the CAINS-EXP",
            "timeFrame": "Baseline to Weeks 8 and 16"
          },
          {
            "measure": "Change in Positive Symptoms",
            "description": "Change from baseline to Week 16 in positive symptoms, as assessed by the Positive and Negative Syndrome Scale (PANSS)",
            "timeFrame": "Baseline to Week 16"
          },
          {
            "measure": "Change in Social Functioning",
            "description": "Change from baseline to Week 16 in social functioning, as assessed by the Personal and Social Performance Scale (PSP)",
            "timeFrame": "Baseline to Week 16"
          },
          {
            "measure": "Change in Defeatist Beliefs",
            "description": "Change from baseline to Week 16 in self-reported defeatist beliefs, as assessed by the Defeatist Beliefs Subscale of the Dysfunctional Attitude Scale (DAS)",
            "timeFrame": "Baseline to Week 16"
          },
          {
            "measure": "Impression of Improvement",
            "description": "Patient Global Impression of Improvement Scale (PGI-I) at Week 16",
            "timeFrame": "Week 16"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\nA participant will be eligible for entry into the study if all the following criteria are met:\n\n* Completed participation in NCT05838625 study within 7 days of the extension study Baseline Visit (Day 1).\n* Is the sole user of an iPhone with an iPhone operating system (iOS) 14 or greater or a smartphone with an Android operating system (OS) 10 or greater and is willing to download and use the specified Study App required by the protocol.\n* Is willing and able to receive SMS text messages and push messages on their smartphone.\n* It is the owner of, and has regular access to, an email address.\n* Has regular access to the Internet via cellular data plan and/or wi-fi.\n* Had stable housing during NCT05838625, with no anticipated housing changes during the duration of this study.\n\nExclusion Criteria:\n\nA participant will not be eligible for study entry if any of the following criteria are met:\n\n* Has not completed the Week 16 Visit (Day 112) in the NCT05838625 study.\n* Has a positive urine drug screening or participant self-reports use of synthetic cathinones (bath salts), synthetic cannabinoids (K2, Spice), inhalants, amphetamines (including MDMA/ecstasy), phencyclidine (PCP), cocaine, opiates, benzodiazepines, barbiturates, hallucinogens, or parenteral drugs. Participants with a positive urine drug test and/or recreational use of THC will not be excluded from the study at the discretion of the investigator. Participants with a positive urine drug screen (UDS) or self-report who have a valid prescription for barbiturates, benzodiazepines, or opiates will not be excluded from the study at the discretion of the investigator.\n* Has suicidal ideation or behavior, as assessed by the C-SSRS:\n\n  1. Participants with a \"yes\" response to either Items 4 or 5 on the C-SSRS Suicidal Ideation Item during the NCT05838625 study.\n  2. Participants with a \"yes\" response on the C-SSRS Suicidal Behavior Items within the last 6 months (26 weeks) prior to or at the Baseline Visit\n* Participants who, in the opinion of the investigator, present a serious risk of suicide.",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "Shaheen Lakhan, MD, PhD, FAAN",
            "affiliation": "Click Therapeutics",
            "role": "STUDY_DIRECTOR"
          }
        ],
        "locations": [
          {
            "facility": "Click Therapeutics",
            "city": "New York City",
            "state": "New York",
            "zip": "10013",
            "country": "United States",
            "geoPoint": { "lat": 40.71427, "lon": -74.00597 }
          }
        ]
      },
      "ipdSharingStatementModule": { "ipdSharing": "NO" }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [{ "id": "D012559", "term": "Schizophrenia" }],
        "ancestors": [
          {
            "id": "D019967",
            "term": "Schizophrenia Spectrum and Other Psychotic Disorders"
          },
          { "id": "D001523", "term": "Mental Disorders" }
        ],
        "browseLeaves": [
          {
            "id": "M15376",
            "name": "Schizophrenia",
            "asFound": "Schizophrenia",
            "relevance": "HIGH"
          },
          { "id": "M14473", "name": "Psychotic Disorders", "relevance": "LOW" },
          { "id": "M4815", "name": "Mental Disorders", "relevance": "LOW" },
          {
            "id": "M21838",
            "name": "Schizophrenia Spectrum and Other Psychotic Disorders",
            "relevance": "LOW"
          }
        ],
        "browseBranches": [
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" },
          { "abbrev": "All", "name": "All Conditions" }
        ]
      },
      "interventionBrowseModule": {
        "browseLeaves": [
          { "id": "M16904", "name": "Antipsychotic Agents", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "CNSDep", "name": "Central Nervous System Depressants" },
          { "abbrev": "PsychDr", "name": "Psychotropic Drugs" },
          { "abbrev": "All", "name": "All Drugs and Chemicals" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT03751280",
        "orgStudyIdInfo": { "id": "CPEA001A12201" },
        "organization": { "fullName": "Novartis", "class": "INDUSTRY" },
        "briefTitle": "Study of Efficacy of PEAR-004 in Schizophrenia",
        "officialTitle": "A Randomized, Sham-Controlled Study of PEAR-004 as an Adjunct to Standard-of-care Treatment for Schizophrenia"
      },
      "statusModule": {
        "statusVerifiedDate": "2020-10",
        "overallStatus": "COMPLETED",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2018-12-10", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2019-09-26",
          "type": "ACTUAL"
        },
        "completionDateStruct": { "date": "2019-09-26", "type": "ACTUAL" },
        "studyFirstSubmitDate": "2018-11-08",
        "studyFirstSubmitQcDate": "2018-11-20",
        "studyFirstPostDateStruct": { "date": "2018-11-23", "type": "ACTUAL" },
        "resultsFirstSubmitDate": "2020-09-11",
        "resultsFirstSubmitQcDate": "2020-10-30",
        "resultsFirstPostDateStruct": {
          "date": "2020-11-23",
          "type": "ACTUAL"
        },
        "lastUpdateSubmitDate": "2020-12-09",
        "lastUpdatePostDateStruct": { "date": "2021-01-05", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": {
          "name": "Novartis Pharmaceuticals",
          "class": "INDUSTRY"
        }
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": true,
        "isUnapprovedDevice": true
      },
      "descriptionModule": {
        "briefSummary": "The purpose of the study was to determine in patients currently being administered antipsychotic pharmacotherapy whether PEAR-004 could further reduce symptoms of schizophrenia as measured by the Positive and Negative Syndrome Scale (PANSS).\n\nThe overall rationale for the study was to assess the first prescription digital therapeutic (PDT) in schizophrenia using a form of proven psychosocial intervention, cognitive behavioral therapy (CBT), to supplement standard of care with antipsychotic medications.",
        "detailedDescription": "This was a randomized, sham-controlled, rater-blinded, parallel group trial. Overall, 112 subjects were randomized 1:1 in to the following groups:\n\n* Group A: Clinician-directed pharmacotherapy + PEAR-004\n* Group B: Clinician-directed pharmacotherapy + sham app An up to 28-day screening period included standard screening assessments as defined in the assessment schedule. Eligible subjects were randomized on Day 1 into one of the treatment groups.\n\nSubjects in both groups continued to receive their clinician-directed standard-of-care treatment for schizophrenia, including pharmacotherapy. Subjects in Group A used PEAR 004 and subjects in Group B used a sham for a period of 12 weeks. Subjects returned to the clinic for outpatient visits at Week 4 (day 29), Week 8 (day 57), and Week 12 (day 85). At each visit, standard assessments were performed according to the assessment schedule, including PANSS, ISST-Plus, CGI, BMQ, MAP-SR, WHOQOL-BREF, BDI-II, ISI, and adverse events (AEs). A final follow-up visit was performed at Week 16 (day 115),"
      },
      "conditionsModule": {
        "conditions": ["Schizophrenia"],
        "keywords": [
          "Schizophrenia",
          "Digital Therapeutic",
          "CBT",
          "smartphone app",
          "mental disorder",
          "psychosis",
          "acute psychotic reaction",
          "chronic psychosis",
          "failure to recognize what is real",
          "false beliefs",
          "unclear thinking,",
          "confused thinking",
          "auditory hallucinations",
          "paranoia",
          "reduced social engagement",
          "reduced emotional expression"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["PHASE2"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": {
            "masking": "SINGLE",
            "whoMasked": ["OUTCOMES_ASSESSOR"]
          }
        },
        "enrollmentInfo": { "count": 112, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "PEAR-004",
            "type": "EXPERIMENTAL",
            "description": "Eligible participants were able to access PEAR-004 (an investigational digital therapeutic) on a mobile device (iOS and Android based) as needed to receive suggestions about coping strategies to overcome difficulties in daily life.",
            "interventionNames": ["Device: PEAR-004"]
          },
          {
            "label": "Sham",
            "type": "SHAM_COMPARATOR",
            "description": "Eligible participants were able to access a sham control downloaded on a mobile device (iOS and Android based) as needed to receive notifications prompting the participant to open the sham app, which displayed a prescription timer for the remaining duration of app availability.",
            "interventionNames": ["Device: Sham"]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "PEAR-004",
            "description": "PEAR-004 (an investigational digital therapeutic) or sham (control) was downloaded to the subject's phone and then the assigned application was unlocked using a prescription code provided by Pear Therapeutics. As this was a digital therapeutic device study, dose or mode of administration is not applicable.",
            "armGroupLabels": ["PEAR-004"]
          },
          {
            "type": "DEVICE",
            "name": "Sham",
            "description": "PEAR-004 (an investigational digital therapeutic) or sham (control) was downloaded to the subject's phone and then the assigned application was unlocked using a prescription code provided by Pear Therapeutics. As this was a digital therapeutic device study, dose or mode of administration is not applicable.",
            "armGroupLabels": ["Sham"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Change From Baseline in Total Positive and Negative Syndrome Scale (PANSS) Score",
            "description": "The Positive and Negative Syndrome Scale (PANSS) is a well validated, standardized method of evaluating and monitoring psychotic symptoms. The PANSS assesses: positive (hallucinations, delusions, thought disorder), negative (blunted affect, abstract thinking and general symptomatology. The positive and negative subscale each consist of 7 items rated from 1(absent) - 7(extreme) with a minimum score = 7, maximum score = 49. The general subscale consists of 16 items with a minimum score = 16, maximum score = 112. A Total PANSS score (positive+ negative + general scores) has a minimum of 30 and maximum of 210. Higher scores represent more severity in symptoms.",
            "timeFrame": "Baseline, Day 29, Day 57, Day 85"
          },
          {
            "measure": "Percent of Dropout",
            "description": "Dropout rate to evaluate retention to assigned study treatment",
            "timeFrame": "Day 115"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Change From Baseline in the Positive PANSS Score",
            "description": "The PANSS includes 3 scales and 30 items: 7 items that make up the Positive Scale (eg, delusions, conceptual disorganization, hallucinatory behavior); 7 items that make up the Negative Scale (eg, blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal); and 16 items that make up the General Psychopathology Scale (eg, somatic concern, anxiety, guilt feelings, mannerisms and posturing, motor retardation, uncooperativeness, disorientation, poor impulse control, preoccupation). Individual items are scored with values ranging from 1 to 7. Total Negative and Positive Subscale scores each range from 7 to 49; higher score indicates greater severity.",
            "timeFrame": "Baseline, Day 29, Day 57, Day 85"
          },
          {
            "measure": "Change From Baseline in the General Psychopathology PANSS Score",
            "description": "The PANSS includes 3 scales and 30 items: 7 items that make up the Positive Scale (eg, delusions, conceptual disorganization, hallucinatory behavior); 7 items that make up the Negative Scale (eg, blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal); and 16 items that make up the General Psychopathology Scale (eg, somatic concern, anxiety, guilt feelings, mannerisms and posturing, motor retardation, uncooperativeness, disorientation, poor impulse control, preoccupation). Individual items are scored with values ranging from 1 to 7. Total General Psychopathology Subscale score range from 16 to 112; higher score indicates greater severity.",
            "timeFrame": "Baseline, Day 29, Day 57, Day 85"
          },
          {
            "measure": "Change From Baseline in the Negative PANSS Score",
            "description": "The PANSS includes 3 scales and 30 items: 7 items that make up the Positive Scale (eg, delusions, conceptual disorganization, hallucinatory behavior); 7 items that make up the Negative Scale (eg, blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal); and 16 items that make up the General Psychopathology Scale (eg, somatic concern, anxiety, guilt feelings, mannerisms and posturing, motor retardation, uncooperativeness, disorientation, poor impulse control, preoccupation). Individual items are scored with values ranging from 1 to 7. Total Negative and Positive Subscale scores each range from 7 to 49; higher score indicates greater severity.",
            "timeFrame": "Baseline, Day 29, Day 57, Day 85"
          },
          {
            "measure": "Change From Baseline in the Motivation and Pleasure Self-report (MAP-SR) Score",
            "description": "The MAP-SR is a 15-item self-report measure that provides a total score index of current motivation/pleasure negative symptoms. Responses are given on a 5-point scale where 0 = no pleasure or motivation and 4 = extreme pleasure or motivation. Total scores range from 0 to 60 and higher scores indicate greater motivation and pleasure during everyday activities.",
            "timeFrame": "Baseline, Day 29, Day 57, Day 85"
          },
          {
            "measure": "Change From Baseline in the World Health Organization Quality of Life (WHOQOL-BREF) Scale",
            "description": "The WHOQOL-BREF is a 26-item, self-report questionnaire and short version of WHOQOL-100, consisting of 4 domains: physical health (7 items) (Domain 1), psychological health (6 items) (Domian 2), social relationships (3 items) (Domain 3), and environmental health (8 items) (Domain 4); it also contains QOL and general health items. Domain scores are scaled in a positive direction (i.e. higher scores denote higher quality of life). The mean score of items within each domain is used to calculate the domain score. Each individual item of the WHOQOL-BREF is scored from 1=not at all to 5=completely on a response scale, which is stipulated as a 5-point ordinal scale. The scores are then transformed linearly to a scale of 0 (the worse quality of life) to 100 (the worse quality of life).",
            "timeFrame": "Baseline, Day 29, Day 57, Day 85"
          },
          {
            "measure": "Change From Baseline in the Beck Depression Inventory, Second Ed. (BDI-II) Total Score",
            "description": "Beck Depression Inventory (BDI) is a 21-items self reported inventory with a scale evaluating depressive symptoms and the changes in BDI after treatment compared to baseline. The range of scores is 0 to 63, with higher scores indicating greater severity of depression.",
            "timeFrame": "Baseline, Day 29, Day 57, Day 85"
          },
          {
            "measure": "Percentage Change From Baseline in Total PANSS Score (Within Assigned Treatment Group)",
            "description": "The Positive and Negative Syndrome Scale (PANSS) is a well validated, standardized method of evaluating and monitoring psychotic symptoms. The PANSS assesses: positive (hallucinations, delusions, thought disorder), negative (blunted affect, abstract thinking and general symptomatology. The positive and negative subscale each consist of 7 items rated from 1(absent) - 7(extreme) with a minimum score = 7, maximum score = 49. The general subscale consists of 16 items with a minimum score = 16, maximum score = 112. A Total PANSS score (positive+ negative + general scores) has a minimum of 30 and maximum of 210. Higher scores represent more severity in symptoms.",
            "timeFrame": "Baseline, Day 29, Day 57, Day 85"
          },
          {
            "measure": "Percentage of Responders as Assessed by the Brief Medication Questionnaire (BMQ)",
            "description": "The Brief Medication Questionnaire (BMQ) collects information about current schizophrenia medication use.",
            "timeFrame": "Day 29, Day 57, and Day 85"
          },
          {
            "measure": "Percentage of Responders as Assessed by the Total PANSS Score",
            "description": "A Response is defined as a reduction of at least 20% at day 85 or last visit in total PANSS score relative to Baseline.",
            "timeFrame": "Day 85"
          },
          {
            "measure": "Number of Patients With Adverse Events",
            "description": "Adverse events, serious adverse events, and adverse events leading to discontinuation throughout the study",
            "timeFrame": "Day 115"
          },
          {
            "measure": "Number of Patients With Vital Sign Measurements",
            "description": "Vital signs at baseline, day 85 or last visit",
            "timeFrame": "Day 85"
          },
          {
            "measure": "InterSePT Scale for Suicidal Thinking-Plus (ISST-Plus) Score",
            "description": "InterSePT Scale for Suicidal Thinking-Plus (ISST-Plus) score. Semi-structured interview to assess severity of suicidal ideation and behavior Part I: collects information on 7 days prior to visit; 13 items scored 0 (min) to 2 (max) for suicidality, with a higher score representing a worse outcome Part II: collects information on suicidal behavior since last visit, with nominal categories Yes / No / Unknown (NA) Part III: global rating of status at time of interview; scored 0 (min) to 5 (max) for suicidality, with a higher score representing a worse outcome.\n\nPlease note that only part III score (severity of suicidal risk) was summarized and reported.",
            "timeFrame": "Baseline, Day 29, 57, 85, and 115"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Key Inclusion Criteria:\n\n* Signed informed consent must be obtained prior to participation in the study.\n* Healthy male and female subjects 18 to 65 years of age, inclusive, and in good health as determined by medical history, physical examination, and vital signs at screening\n* SCID-based DSM-5 diagnosis of schizophrenia and a total PANSS score \\> 60\n* Proficient in English at 5th grade reading level or higher, in the judgement of the investigator\n* Capable of using a mobile device (compatible with PEAR-004) and using common applications, in the judgement of the investigator\n\nKey Exclusion Criteria:\n\n* Major change in primary antipsychotic medication in the prior 4 weeks before screening (e.g., switching to a new agent or a dose adjustment within two weeks of randomization)\n* Planning to move out of the geographic area within 3 months\n* Unable to use English to participate in the consent process, the interventions or assessments\n* Inability to comply with study procedures, due to severe medical conditions or otherwise\n* Meet DSM-5 diagnosis for a current episode of major depression, mania, or hypomania in the past month\n* Meet DSM-5 diagnosis for a current moderate or severe alcohol or cannabis use disorder in the past 2 months\n* Meet DSM-5 diagnosis for a current substance use disorder (other than alcohol or cannabis) in the past 2 months\n* Considered high risk for suicidal behavior based on ISST-Plus score at screening, or in the judgement of the investigator\n* Previously participated in a clinical study involving PEAR-004",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "maximumAge": "65 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "Novartis Pharmaceuticals",
            "affiliation": "Novartis Pharmaceuticals",
            "role": "STUDY_DIRECTOR"
          }
        ],
        "locations": [
          {
            "facility": "Novartis Investigative Site",
            "city": "Garden Grove",
            "state": "California",
            "zip": "92845",
            "country": "United States",
            "geoPoint": { "lat": 33.77391, "lon": -117.94145 }
          },
          {
            "facility": "Novartis Investigative Site",
            "city": "Oakland",
            "state": "California",
            "zip": "94607",
            "country": "United States",
            "geoPoint": { "lat": 37.80437, "lon": -122.2708 }
          },
          {
            "facility": "Novartis Investigative Site",
            "city": "Torrance",
            "state": "California",
            "zip": "90502",
            "country": "United States",
            "geoPoint": { "lat": 33.83585, "lon": -118.34063 }
          },
          {
            "facility": "Novartis Investigative Site",
            "city": "Maitland",
            "state": "Florida",
            "zip": "32751",
            "country": "United States",
            "geoPoint": { "lat": 28.62778, "lon": -81.36312 }
          },
          {
            "facility": "Novartis Investigative Site",
            "city": "Grand Rapids",
            "state": "Michigan",
            "zip": "49548",
            "country": "United States",
            "geoPoint": { "lat": 42.96336, "lon": -85.66809 }
          },
          {
            "facility": "Novartis Investigative Site",
            "city": "Albuquerque",
            "state": "New Mexico",
            "zip": "87102",
            "country": "United States",
            "geoPoint": { "lat": 35.08449, "lon": -106.65114 }
          }
        ]
      },
      "referencesModule": {
        "references": [
          {
            "pmid": "35343910",
            "type": "DERIVED",
            "citation": "Ghaemi SN, Sverdlov O, van Dam J, Campellone T, Gerwien R. A Smartphone-Based Intervention as an Adjunct to Standard-of-Care Treatment for Schizophrenia: Randomized Controlled Trial. JMIR Form Res. 2022 Mar 28;6(3):e29154. doi: 10.2196/29154."
          }
        ],
        "seeAlsoLinks": [
          {
            "label": "A Plain Language Trial Summary is available on novartisclinicatrials.com",
            "url": "https://www.novctrd.com/ctrdweb/patientsummary/patientsummaries?patientSummaryId=554"
          }
        ]
      },
      "ipdSharingStatementModule": {
        "ipdSharing": "YES",
        "description": "Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.\n\nThis trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com",
        "url": "https://www.clinicalstudydatarequest.com/"
      }
    },
    "resultsSection": {
      "participantFlowModule": {
        "preAssignmentDetails": "The eligible subjects were randomized in 1:1 ratio to receive either PEAR-004 or sham.",
        "recruitmentDetails": "This study was conducted at 6 centers in the USA.",
        "groups": [
          {
            "id": "FG000",
            "title": "PEAR-004",
            "description": "Eligible participants were to access PEAR-004 (an investigational digital therapeutic) on a mobile device (iOS and Android based) as needed to receive suggestions about coping strategies to overcome difficulties in daily life."
          },
          {
            "id": "FG001",
            "title": "Sham",
            "description": "Eligible participants were to access a sham control downloaded on a mobile device (iOS and Android based) as needed to delivering notifications prompting the participant to open the sham app, and then display a prescription timer for the remaining duration of app availability."
          }
        ],
        "periods": [
          {
            "title": "Overall Study",
            "milestones": [
              {
                "type": "STARTED",
                "comment": "All enrolled participants were in Randomized Set",
                "achievements": [
                  { "groupId": "FG000", "numSubjects": "56" },
                  { "groupId": "FG001", "numSubjects": "56" }
                ]
              },
              {
                "type": "Full Analysis Set (FAS)",
                "achievements": [
                  { "groupId": "FG000", "numSubjects": "54" },
                  { "groupId": "FG001", "numSubjects": "55" }
                ]
              },
              {
                "type": "Safety Set (SAF)",
                "achievements": [
                  { "groupId": "FG000", "numSubjects": "55" },
                  { "groupId": "FG001", "numSubjects": "55" }
                ]
              },
              {
                "type": "COMPLETED",
                "achievements": [
                  { "groupId": "FG000", "numSubjects": "48" },
                  { "groupId": "FG001", "numSubjects": "44" }
                ]
              },
              {
                "type": "NOT COMPLETED",
                "achievements": [
                  { "groupId": "FG000", "numSubjects": "8" },
                  { "groupId": "FG001", "numSubjects": "12" }
                ]
              }
            ],
            "dropWithdraws": [
              {
                "type": "Adverse Event",
                "reasons": [
                  { "groupId": "FG000", "numSubjects": "0" },
                  { "groupId": "FG001", "numSubjects": "1" }
                ]
              },
              {
                "type": "Lost to Follow-up",
                "reasons": [
                  { "groupId": "FG000", "numSubjects": "3" },
                  { "groupId": "FG001", "numSubjects": "5" }
                ]
              },
              {
                "type": "Physician Decision",
                "reasons": [
                  { "groupId": "FG000", "numSubjects": "0" },
                  { "groupId": "FG001", "numSubjects": "2" }
                ]
              },
              {
                "type": "Protocol Violation",
                "reasons": [
                  { "groupId": "FG000", "numSubjects": "0" },
                  { "groupId": "FG001", "numSubjects": "2" }
                ]
              },
              {
                "type": "Withdrawal by Subject",
                "reasons": [
                  { "groupId": "FG000", "numSubjects": "5" },
                  { "groupId": "FG001", "numSubjects": "2" }
                ]
              }
            ]
          }
        ]
      },
      "baselineCharacteristicsModule": {
        "populationDescription": "Safety Analysis Set = all randomized participants who received the study treatment.",
        "groups": [
          {
            "id": "BG000",
            "title": "PEAR-004",
            "description": "Eligible participants were to access PEAR-004 (an investigational digital therapeutic) on a mobile device (iOS and Android based) as needed to receive suggestions about coping strategies to overcome difficulties in daily life."
          },
          {
            "id": "BG001",
            "title": "Sham",
            "description": "Eligible participants were to access a sham control downloaded on a mobile device (iOS and Android based) as needed to delivering notifications prompting the participant to open the sham app, and then display a prescription timer for the remaining duration of app availability."
          },
          {
            "id": "BG002",
            "title": "Total",
            "description": "Total of all reporting groups"
          }
        ],
        "denoms": [
          {
            "units": "Participants",
            "counts": [
              { "groupId": "BG000", "value": "55" },
              { "groupId": "BG001", "value": "55" },
              { "groupId": "BG002", "value": "110" }
            ]
          }
        ],
        "measures": [
          {
            "title": "Age, Continuous",
            "paramType": "MEAN",
            "dispersionType": "STANDARD_DEVIATION",
            "unitOfMeasure": "Years",
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "43.7",
                        "spread": "10.99"
                      },
                      {
                        "groupId": "BG001",
                        "value": "45.7",
                        "spread": "11.60"
                      },
                      { "groupId": "BG002", "value": "44.7", "spread": "11.29" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Sex: Female, Male",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "Female",
                    "measurements": [
                      { "groupId": "BG000", "value": "19" },
                      { "groupId": "BG001", "value": "19" },
                      { "groupId": "BG002", "value": "38" }
                    ]
                  },
                  {
                    "title": "Male",
                    "measurements": [
                      { "groupId": "BG000", "value": "36" },
                      { "groupId": "BG001", "value": "36" },
                      { "groupId": "BG002", "value": "72" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Race/Ethnicity, Customized",
            "paramType": "NUMBER",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "title": "American Indian or Alaska Native",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "BG000", "value": "3" },
                      { "groupId": "BG001", "value": "0" },
                      { "groupId": "BG002", "value": "3" }
                    ]
                  }
                ]
              },
              {
                "title": "Asian",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "BG000", "value": "3" },
                      { "groupId": "BG001", "value": "4" },
                      { "groupId": "BG002", "value": "7" }
                    ]
                  }
                ]
              },
              {
                "title": "Black or African American",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "BG000", "value": "28" },
                      { "groupId": "BG001", "value": "25" },
                      { "groupId": "BG002", "value": "53" }
                    ]
                  }
                ]
              },
              {
                "title": "Native Hawaiian or other Pacific Islander",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "BG000", "value": "0" },
                      { "groupId": "BG001", "value": "1" },
                      { "groupId": "BG002", "value": "1" }
                    ]
                  }
                ]
              },
              {
                "title": "White",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "BG000", "value": "18" },
                      { "groupId": "BG001", "value": "25" },
                      { "groupId": "BG002", "value": "43" }
                    ]
                  }
                ]
              },
              {
                "title": "Other",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "BG000", "value": "3" },
                      { "groupId": "BG001", "value": "0" },
                      { "groupId": "BG002", "value": "3" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Disease duration at baseline",
            "description": "Disease Duration at baseline: Duration (in Years) from informed consent to date of diagnosis. Date of diagnosis corresponds to date where subjects reported schizophrenia diagnosis in medical history at screening visit.",
            "paramType": "MEAN",
            "dispersionType": "STANDARD_DEVIATION",
            "unitOfMeasure": "Years",
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "16.2",
                        "spread": "11.40"
                      },
                      {
                        "groupId": "BG001",
                        "value": "18.2",
                        "spread": "11.56"
                      },
                      { "groupId": "BG002", "value": "17.2", "spread": "11.47" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Total Positive and Negative Syndrome Scale (PANSS) score at baseline",
            "description": "The Positive and Negative Syndrome Scale (PANSS) assesses: positive (hallucinations, delusions, thought disorder), negative (blunted affect, abstract thinking and general symptomatology. The positive and negative subscale each consist of 7 items rated from 1(absent) - 7(extreme) with a minimum score = 7, maximum score = 49. The general subscale consists of 16 items with a minimum score = 16, maximum score = 112. A Total PANSS score (positive+ negative + general scores) has a minimum of 30 and maximum of 210. Higher scores represent more severity in symptoms.",
            "paramType": "MEAN",
            "dispersionType": "STANDARD_DEVIATION",
            "unitOfMeasure": "Score",
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "73.5",
                        "spread": "10.25"
                      },
                      {
                        "groupId": "BG001",
                        "value": "72.7",
                        "spread": "10.10"
                      },
                      { "groupId": "BG002", "value": "73.1", "spread": "10.14" }
                    ]
                  }
                ]
              }
            ]
          }
        ]
      },
      "outcomeMeasuresModule": {
        "outcomeMeasures": [
          {
            "type": "PRIMARY",
            "title": "Change From Baseline in Total Positive and Negative Syndrome Scale (PANSS) Score",
            "description": "The Positive and Negative Syndrome Scale (PANSS) is a well validated, standardized method of evaluating and monitoring psychotic symptoms. The PANSS assesses: positive (hallucinations, delusions, thought disorder), negative (blunted affect, abstract thinking and general symptomatology. The positive and negative subscale each consist of 7 items rated from 1(absent) - 7(extreme) with a minimum score = 7, maximum score = 49. The general subscale consists of 16 items with a minimum score = 16, maximum score = 112. A Total PANSS score (positive+ negative + general scores) has a minimum of 30 and maximum of 210. Higher scores represent more severity in symptoms.",
            "populationDescription": "Full Analysis Set (FAS)",
            "reportingStatus": "POSTED",
            "paramType": "LEAST_SQUARES_MEAN",
            "dispersionType": "Standard Error",
            "unitOfMeasure": "Score",
            "timeFrame": "Baseline, Day 29, Day 57, Day 85",
            "groups": [
              {
                "id": "OG000",
                "title": "PEAR-004",
                "description": "Eligible participants were to access PEAR-004 (an investigational digital therapeutic) on a mobile device (iOS and Android based) as needed to receive suggestions about coping strategies to overcome difficulties in daily life."
              },
              {
                "id": "OG001",
                "title": "Sham",
                "description": "Eligible participants were to access a sham control downloaded on a mobile device (iOS and Android based) as needed to delivering notifications prompting the participant to open the sham app, and then display a prescription timer for the remaining duration of app availability."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "54" },
                  { "groupId": "OG001", "value": "55" }
                ]
              }
            ],
            "classes": [
              {
                "title": "Day 29",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "52" },
                      { "groupId": "OG001", "value": "54" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "-1.6", "spread": "0.86" },
                      { "groupId": "OG001", "value": "-2.2", "spread": "0.84" }
                    ]
                  }
                ]
              },
              {
                "title": "Day 57",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "49" },
                      { "groupId": "OG001", "value": "47" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "-2.5", "spread": "0.9" },
                      { "groupId": "OG001", "value": "-3.3", "spread": "0.9" }
                    ]
                  }
                ]
              },
              {
                "title": "Day 85",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "48" },
                      { "groupId": "OG001", "value": "49" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "-2.6", "spread": "1.14" },
                      { "groupId": "OG001", "value": "-5.3", "spread": "1.13" }
                    ]
                  }
                ]
              }
            ],
            "analyses": [
              {
                "groupIds": ["OG000", "OG001"],
                "groupDescription": "Day 29",
                "nonInferiorityType": "OTHER",
                "paramType": "Comparison of adjusted least square mean",
                "paramValue": "0.61",
                "ciPctValue": "90",
                "ciNumSides": "TWO_SIDED",
                "ciLowerLimit": "-1.4",
                "ciUpperLimit": "2.6",
                "dispersionType": "STANDARD_ERROR_OF_MEAN",
                "dispersionValue": "1.200",
                "estimateComment": "mixed effects model with treatment, visit as fixed effects, baseline and disease duration at baseline as continuous covariates, treatment \\* visit and baseline \\* visit interaction effects."
              },
              {
                "groupIds": ["OG000", "OG001"],
                "groupDescription": "Day 57",
                "nonInferiorityType": "OTHER",
                "paramType": "Comparison of adjusted least square mean",
                "paramValue": "0.80",
                "ciPctValue": "90",
                "ciNumSides": "TWO_SIDED",
                "ciLowerLimit": "-1.3",
                "ciUpperLimit": "2.9",
                "dispersionType": "STANDARD_ERROR_OF_MEAN",
                "dispersionValue": "1.279",
                "estimateComment": "mixed effects model with treatment, visit as fixed effects, baseline and disease duration at baseline as continuous covariates, treatment \\* visit and baseline \\* visit interaction effects."
              },
              {
                "groupIds": ["OG000", "OG001"],
                "groupDescription": "Day 85",
                "nonInferiorityType": "OTHER",
                "pValue": "0.0931",
                "statisticalMethod": "t-test, 2 sided",
                "paramType": "Comparison of adjusted least square mean",
                "paramValue": "2.73",
                "ciPctValue": "90",
                "ciNumSides": "TWO_SIDED",
                "ciLowerLimit": "0.1",
                "ciUpperLimit": "5.4",
                "dispersionType": "STANDARD_ERROR_OF_MEAN",
                "dispersionValue": "1.611",
                "estimateComment": "mixed effects model with treatment, visit as fixed effects, baseline and disease duration at baseline as continuous covariates, treatment \\* visit and baseline \\* visit interaction effects."
              }
            ]
          },
          {
            "type": "PRIMARY",
            "title": "Percent of Dropout",
            "description": "Dropout rate to evaluate retention to assigned study treatment",
            "populationDescription": "Randomized Set",
            "reportingStatus": "POSTED",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "timeFrame": "Day 115",
            "groups": [
              {
                "id": "OG000",
                "title": "PEAR-004",
                "description": "Eligible participants were to access PEAR-004 (an investigational digital therapeutic) on a mobile device (iOS and Android based) as needed to receive suggestions about coping strategies to overcome difficulties in daily life."
              },
              {
                "id": "OG001",
                "title": "Sham",
                "description": "Eligible participants were to access a sham control downloaded on a mobile device (iOS and Android based) as needed to delivering notifications prompting the participant to open the sham app, and then display a prescription timer for the remaining duration of app availability."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "56" },
                  { "groupId": "OG001", "value": "56" }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "8" },
                      { "groupId": "OG001", "value": "12" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Change From Baseline in the Positive PANSS Score",
            "description": "The PANSS includes 3 scales and 30 items: 7 items that make up the Positive Scale (eg, delusions, conceptual disorganization, hallucinatory behavior); 7 items that make up the Negative Scale (eg, blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal); and 16 items that make up the General Psychopathology Scale (eg, somatic concern, anxiety, guilt feelings, mannerisms and posturing, motor retardation, uncooperativeness, disorientation, poor impulse control, preoccupation). Individual items are scored with values ranging from 1 to 7. Total Negative and Positive Subscale scores each range from 7 to 49; higher score indicates greater severity.",
            "populationDescription": "Full Analysis Set (FAS)",
            "reportingStatus": "POSTED",
            "paramType": "LEAST_SQUARES_MEAN",
            "dispersionType": "Standard Error",
            "unitOfMeasure": "Score",
            "timeFrame": "Baseline, Day 29, Day 57, Day 85",
            "groups": [
              {
                "id": "OG000",
                "title": "PEAR-004",
                "description": "Eligible participants were to access PEAR-004 (an investigational digital therapeutic) on a mobile device (iOS and Android based) as needed to receive suggestions about coping strategies to overcome difficulties in daily life."
              },
              {
                "id": "OG001",
                "title": "Sham",
                "description": "Eligible participants were to access a sham control downloaded on a mobile device (iOS and Android based) as needed to delivering notifications prompting the participant to open the sham app, and then display a prescription timer for the remaining duration of app availability."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "54" },
                  { "groupId": "OG001", "value": "55" }
                ]
              }
            ],
            "classes": [
              {
                "title": "Day 29",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "52" },
                      { "groupId": "OG001", "value": "54" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "-0.2", "spread": "0.36" },
                      { "groupId": "OG001", "value": "-0.4", "spread": "0.35" }
                    ]
                  }
                ]
              },
              {
                "title": "Day 57",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "49" },
                      { "groupId": "OG001", "value": "47" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "-0.8", "spread": "0.38" },
                      { "groupId": "OG001", "value": "-1.4", "spread": "0.38" }
                    ]
                  }
                ]
              },
              {
                "title": "Day 85",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "48" },
                      { "groupId": "OG001", "value": "49" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "-1.0", "spread": "0.46" },
                      { "groupId": "OG001", "value": "-1.8", "spread": "0.45" }
                    ]
                  }
                ]
              }
            ],
            "analyses": [
              {
                "groupIds": ["OG000", "OG001"],
                "groupDescription": "Day 29",
                "nonInferiorityType": "OTHER",
                "paramType": "Comparison of adjusted least square mean",
                "paramValue": "0.21",
                "ciPctValue": "90",
                "ciNumSides": "TWO_SIDED",
                "ciLowerLimit": "-0.6",
                "ciUpperLimit": "1",
                "dispersionType": "STANDARD_ERROR_OF_MEAN",
                "dispersionValue": "0.501",
                "estimateComment": "mixed effects model with treatment, visit as fixed effects, baseline and disease duration at baseline as continuous covariates, treatment \\* visit and baseline \\* visit interaction effects."
              },
              {
                "groupIds": ["OG000", "OG001"],
                "groupDescription": "Day 57",
                "nonInferiorityType": "OTHER",
                "paramType": "Comparison of adjusted least square mean",
                "paramValue": "0.61",
                "ciPctValue": "90",
                "ciNumSides": "TWO_SIDED",
                "ciLowerLimit": "-0.3",
                "ciUpperLimit": "1.5",
                "dispersionType": "STANDARD_ERROR_OF_MEAN",
                "dispersionValue": "0.538",
                "estimateComment": "mixed effects model with treatment, visit as fixed effects, baseline and disease duration at baseline as continuous covariates, treatment \\* visit and baseline \\* visit interaction effects."
              },
              {
                "groupIds": ["OG000", "OG001"],
                "groupDescription": "Day 85",
                "nonInferiorityType": "OTHER",
                "pValue": "0.2069",
                "statisticalMethod": "t-test, 2 sided",
                "paramType": "Comparison of adjusted least square mean",
                "paramValue": "0.82",
                "ciPctValue": "90",
                "ciNumSides": "TWO_SIDED",
                "ciLowerLimit": "-0.3",
                "ciUpperLimit": "1.9",
                "dispersionType": "STANDARD_ERROR_OF_MEAN",
                "dispersionValue": "0.648",
                "estimateComment": "mixed effects model with treatment, visit as fixed effects, baseline and disease duration at baseline as continuous covariates, treatment \\* visit and baseline \\* visit interaction effects."
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Change From Baseline in the General Psychopathology PANSS Score",
            "description": "The PANSS includes 3 scales and 30 items: 7 items that make up the Positive Scale (eg, delusions, conceptual disorganization, hallucinatory behavior); 7 items that make up the Negative Scale (eg, blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal); and 16 items that make up the General Psychopathology Scale (eg, somatic concern, anxiety, guilt feelings, mannerisms and posturing, motor retardation, uncooperativeness, disorientation, poor impulse control, preoccupation). Individual items are scored with values ranging from 1 to 7. Total General Psychopathology Subscale score range from 16 to 112; higher score indicates greater severity.",
            "populationDescription": "Full Analysis Set (FAS)",
            "reportingStatus": "POSTED",
            "paramType": "LEAST_SQUARES_MEAN",
            "dispersionType": "Standard Error",
            "unitOfMeasure": "Score",
            "timeFrame": "Baseline, Day 29, Day 57, Day 85",
            "groups": [
              {
                "id": "OG000",
                "title": "PEAR-004",
                "description": "Eligible participants were to access PEAR-004 (an investigational digital therapeutic) on a mobile device (iOS and Android based) as needed to receive suggestions about coping strategies to overcome difficulties in daily life."
              },
              {
                "id": "OG001",
                "title": "Sham",
                "description": "Eligible participants were to access a sham control downloaded on a mobile device (iOS and Android based) as needed to delivering notifications prompting the participant to open the sham app, and then display a prescription timer for the remaining duration of app availability."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "54" },
                  { "groupId": "OG001", "value": "55" }
                ]
              }
            ],
            "classes": [
              {
                "title": "Day 29",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "52" },
                      { "groupId": "OG001", "value": "54" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "-0.8", "spread": "0.61" },
                      { "groupId": "OG001", "value": "-1.4", "spread": "0.59" }
                    ]
                  }
                ]
              },
              {
                "title": "Day 57",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "49" },
                      { "groupId": "OG001", "value": "47" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "-1.4", "spread": "0.63" },
                      { "groupId": "OG001", "value": "-1.5", "spread": "0.63" }
                    ]
                  }
                ]
              },
              {
                "title": "Day 85",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "48" },
                      { "groupId": "OG001", "value": "49" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "-1.2", "spread": "0.76" },
                      { "groupId": "OG001", "value": "-2.8", "spread": "0.75" }
                    ]
                  }
                ]
              }
            ],
            "analyses": [
              {
                "groupIds": ["OG000", "OG001"],
                "groupDescription": "Day 29",
                "nonInferiorityType": "OTHER",
                "paramType": "Comparison of adjusted least square mean",
                "paramValue": "0.51",
                "ciPctValue": "90",
                "ciNumSides": "TWO_SIDED",
                "ciLowerLimit": "-0.9",
                "ciUpperLimit": "1.9",
                "dispersionType": "STANDARD_ERROR_OF_MEAN",
                "dispersionValue": "0.849",
                "estimateComment": "mixed effects model with treatment, visit as fixed effects, baseline and disease duration at baseline as continuous covariates, treatment \\* visit and baseline \\* visit interaction effects."
              },
              {
                "groupIds": ["OG000", "OG001"],
                "groupDescription": "Day 57",
                "nonInferiorityType": "OTHER",
                "paramType": "Comparison of adjusted least square mean",
                "paramValue": "0.12",
                "ciPctValue": "90",
                "ciNumSides": "TWO_SIDED",
                "ciLowerLimit": "-1.4",
                "ciUpperLimit": "1.6",
                "dispersionType": "STANDARD_ERROR_OF_MEAN",
                "dispersionValue": "0.890",
                "estimateComment": "mixed effects model with treatment, visit as fixed effects, baseline and disease duration at baseline as continuous covariates, treatment \\* visit and baseline \\* visit interaction effects."
              },
              {
                "groupIds": ["OG000", "OG001"],
                "groupDescription": "Day 85",
                "nonInferiorityType": "OTHER",
                "pValue": "0.1368",
                "statisticalMethod": "t-test, 2 sided",
                "paramType": "Comparison of adjusted least square mean",
                "paramValue": "1.61",
                "ciPctValue": "90",
                "ciNumSides": "TWO_SIDED",
                "ciLowerLimit": "-0.2",
                "ciUpperLimit": "3.4",
                "dispersionType": "STANDARD_ERROR_OF_MEAN",
                "dispersionValue": "1.071"
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Change From Baseline in the Negative PANSS Score",
            "description": "The PANSS includes 3 scales and 30 items: 7 items that make up the Positive Scale (eg, delusions, conceptual disorganization, hallucinatory behavior); 7 items that make up the Negative Scale (eg, blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal); and 16 items that make up the General Psychopathology Scale (eg, somatic concern, anxiety, guilt feelings, mannerisms and posturing, motor retardation, uncooperativeness, disorientation, poor impulse control, preoccupation). Individual items are scored with values ranging from 1 to 7. Total Negative and Positive Subscale scores each range from 7 to 49; higher score indicates greater severity.",
            "populationDescription": "Full Analysis Set (FAS)",
            "reportingStatus": "POSTED",
            "paramType": "LEAST_SQUARES_MEAN",
            "dispersionType": "Standard Error",
            "unitOfMeasure": "Score",
            "timeFrame": "Baseline, Day 29, Day 57, Day 85",
            "groups": [
              {
                "id": "OG000",
                "title": "PEAR-004",
                "description": "Eligible participants were to access PEAR-004 (an investigational digital therapeutic) on a mobile device (iOS and Android based) as needed to receive suggestions about coping strategies to overcome difficulties in daily life."
              },
              {
                "id": "OG001",
                "title": "Sham",
                "description": "Eligible participants were to access a sham control downloaded on a mobile device (iOS and Android based) as needed to delivering notifications prompting the participant to open the sham app, and then display a prescription timer for the remaining duration of app availability."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "54" },
                  { "groupId": "OG001", "value": "55" }
                ]
              }
            ],
            "classes": [
              {
                "title": "Day 29",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "52" },
                      { "groupId": "OG001", "value": "54" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "-0.5", "spread": "0.31" },
                      { "groupId": "OG001", "value": "-0.4", "spread": "0.3" }
                    ]
                  }
                ]
              },
              {
                "title": "Day 57",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "49" },
                      { "groupId": "OG001", "value": "47" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "-0.3", "spread": "0.32" },
                      { "groupId": "OG001", "value": "-0.5", "spread": "0.32" }
                    ]
                  }
                ]
              },
              {
                "title": "Day 85",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "48" },
                      { "groupId": "OG001", "value": "49" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "-0.4", "spread": "0.41" },
                      { "groupId": "OG001", "value": "-0.9", "spread": "0.41" }
                    ]
                  }
                ]
              }
            ],
            "analyses": [
              {
                "groupIds": ["OG000", "OG001"],
                "groupDescription": "Day 29",
                "nonInferiorityType": "OTHER",
                "paramType": "Comparison of adjusted least square mean",
                "paramValue": "-0.13",
                "ciPctValue": "90",
                "ciNumSides": "TWO_SIDED",
                "ciLowerLimit": "-0.8",
                "ciUpperLimit": "0.6",
                "dispersionType": "STANDARD_ERROR_OF_MEAN",
                "dispersionValue": "0.430",
                "estimateComment": "mixed effects model with treatment, visit as fixed effects, baseline and disease duration at baseline as continuous covariates, treatment \\* visit and baseline \\* visit interaction effects."
              },
              {
                "groupIds": ["OG000", "OG001"],
                "groupDescription": "Day 57",
                "nonInferiorityType": "OTHER",
                "paramType": "Comparison of adjusted least square mean",
                "paramValue": "0.15",
                "ciPctValue": "90",
                "ciNumSides": "TWO_SIDED",
                "ciLowerLimit": "-0.6",
                "ciUpperLimit": "0.9",
                "dispersionType": "STANDARD_ERROR_OF_MEAN",
                "dispersionValue": "0.453",
                "estimateComment": "mixed effects model with treatment, visit as fixed effects, baseline and disease duration at baseline as continuous covariates, treatment \\* visit and baseline \\* visit interaction effects."
              },
              {
                "groupIds": ["OG000", "OG001"],
                "nonInferiorityType": "OTHER",
                "pValue": "0.3798",
                "statisticalMethod": "t-test, 2 sided",
                "paramType": "Comparison of adjusted least square mean",
                "paramValue": "0.51",
                "ciPctValue": "90",
                "ciNumSides": "TWO_SIDED",
                "ciLowerLimit": "-0.5",
                "ciUpperLimit": "1.5",
                "dispersionType": "STANDARD_ERROR_OF_MEAN",
                "dispersionValue": "0.581",
                "estimateComment": "mixed effects model with treatment, visit as fixed effects, baseline and disease duration at baseline as continuous covariates, treatment \\* visit and baseline \\* visit interaction effects."
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Change From Baseline in the Motivation and Pleasure Self-report (MAP-SR) Score",
            "description": "The MAP-SR is a 15-item self-report measure that provides a total score index of current motivation/pleasure negative symptoms. Responses are given on a 5-point scale where 0 = no pleasure or motivation and 4 = extreme pleasure or motivation. Total scores range from 0 to 60 and higher scores indicate greater motivation and pleasure during everyday activities.",
            "populationDescription": "Full Analysis Set (FAS)",
            "reportingStatus": "POSTED",
            "paramType": "LEAST_SQUARES_MEAN",
            "dispersionType": "Standard Error",
            "unitOfMeasure": "Score",
            "timeFrame": "Baseline, Day 29, Day 57, Day 85",
            "groups": [
              {
                "id": "OG000",
                "title": "PEAR-004",
                "description": "Eligible participants were to access PEAR-004 (an investigational digital therapeutic) on a mobile device (iOS and Android based) as needed to receive suggestions about coping strategies to overcome difficulties in daily life."
              },
              {
                "id": "OG001",
                "title": "Sham",
                "description": "Eligible participants were to access a sham control downloaded on a mobile device (iOS and Android based) as needed to delivering notifications prompting the participant to open the sham app, and then display a prescription timer for the remaining duration of app availability."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "54" },
                  { "groupId": "OG001", "value": "55" }
                ]
              }
            ],
            "classes": [
              {
                "title": "Day 29",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "51" },
                      { "groupId": "OG001", "value": "54" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "0.8", "spread": "1.05" },
                      { "groupId": "OG001", "value": "1.6", "spread": "1.02" }
                    ]
                  }
                ]
              },
              {
                "title": "Day 57",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "49" },
                      { "groupId": "OG001", "value": "47" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "-0.5", "spread": "1.41" },
                      { "groupId": "OG001", "value": "1.1", "spread": "1.43" }
                    ]
                  }
                ]
              },
              {
                "title": "Day 851.43",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "48" },
                      { "groupId": "OG001", "value": "49" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "-1.2", "spread": "1.26" },
                      { "groupId": "OG001", "value": "2.8", "spread": "1.25" }
                    ]
                  }
                ]
              }
            ],
            "analyses": [
              {
                "groupIds": ["OG000", "OG001"],
                "groupDescription": "Day 29",
                "nonInferiorityType": "OTHER",
                "paramType": "Comparison of adjusted least square mean",
                "paramValue": "-0.79",
                "ciPctValue": "90",
                "ciNumSides": "TWO_SIDED",
                "ciLowerLimit": "-3.2",
                "ciUpperLimit": "1.6",
                "dispersionType": "STANDARD_ERROR_OF_MEAN",
                "dispersionValue": "-0.79",
                "estimateComment": "mixed effects model with treatment, visit as fixed effects, baseline and disease duration at baseline as continuous covariates, treatment \\* visit and baseline \\* visit interaction effects."
              },
              {
                "groupIds": ["OG000", "OG001"],
                "groupDescription": "Day 57",
                "nonInferiorityType": "OTHER",
                "paramType": "Comparison of adjusted least square mean",
                "paramValue": "-1.60",
                "ciPctValue": "90",
                "ciNumSides": "TWO_SIDED",
                "ciLowerLimit": "-4.9",
                "ciUpperLimit": "1.7",
                "dispersionType": "STANDARD_ERROR_OF_MEAN",
                "dispersionValue": "2.006",
                "estimateComment": "mixed effects model with treatment, visit as fixed effects, baseline and disease duration at baseline as continuous covariates, treatment \\* visit and baseline \\* visit interaction effects."
              },
              {
                "groupIds": ["OG000", "OG001"],
                "groupDescription": "Day 85",
                "nonInferiorityType": "OTHER",
                "pValue": "0.0245",
                "statisticalMethod": "t-test, 2 sided",
                "paramType": "Comparison of adjusted least square mean",
                "paramValue": "-4.07",
                "ciPctValue": "90",
                "ciNumSides": "TWO_SIDED",
                "ciLowerLimit": "-7.0",
                "ciUpperLimit": "-1.1",
                "dispersionType": "STANDARD_ERROR_OF_MEAN",
                "dispersionValue": "1.780",
                "estimateComment": "mixed effects model with treatment, visit as fixed effects, baseline and disease duration at baseline as continuous covariates, treatment \\* visit and baseline \\* visit interaction effects."
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Change From Baseline in the World Health Organization Quality of Life (WHOQOL-BREF) Scale",
            "description": "The WHOQOL-BREF is a 26-item, self-report questionnaire and short version of WHOQOL-100, consisting of 4 domains: physical health (7 items) (Domain 1), psychological health (6 items) (Domian 2), social relationships (3 items) (Domain 3), and environmental health (8 items) (Domain 4); it also contains QOL and general health items. Domain scores are scaled in a positive direction (i.e. higher scores denote higher quality of life). The mean score of items within each domain is used to calculate the domain score. Each individual item of the WHOQOL-BREF is scored from 1=not at all to 5=completely on a response scale, which is stipulated as a 5-point ordinal scale. The scores are then transformed linearly to a scale of 0 (the worse quality of life) to 100 (the worse quality of life).",
            "populationDescription": "Full Analysis Set (FAS)",
            "reportingStatus": "POSTED",
            "paramType": "LEAST_SQUARES_MEAN",
            "dispersionType": "Standard Error",
            "unitOfMeasure": "Score",
            "timeFrame": "Baseline, Day 29, Day 57, Day 85",
            "groups": [
              {
                "id": "OG000",
                "title": "PEAR-004",
                "description": "Eligible participants were to access PEAR-004 (an investigational digital therapeutic) on a mobile device (iOS and Android based) as needed to receive suggestions about coping strategies to overcome difficulties in daily life."
              },
              {
                "id": "OG001",
                "title": "Sham",
                "description": "Eligible participants were to access a sham control downloaded on a mobile device (iOS and Android based) as needed to delivering notifications prompting the participant to open the sham app, and then display a prescription timer for the remaining duration of app availability."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "54" },
                  { "groupId": "OG001", "value": "55" }
                ]
              }
            ],
            "classes": [
              {
                "title": "Day 29-Domain 1",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "52" },
                      { "groupId": "OG001", "value": "54" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "-0.1", "spread": "0.37" },
                      { "groupId": "OG001", "value": "0.1", "spread": "0.36" }
                    ]
                  }
                ]
              },
              {
                "title": "Day 57-Domain 1",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "49" },
                      { "groupId": "OG001", "value": "47" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "-0.3", "spread": "0.44" },
                      { "groupId": "OG001", "value": "-0.3", "spread": "0.45" }
                    ]
                  }
                ]
              },
              {
                "title": "Day 85-Domain 1",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "48" },
                      { "groupId": "OG001", "value": "49" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "0.2", "spread": "0.45" },
                      { "groupId": "OG001", "value": "0.1", "spread": "0.45" }
                    ]
                  }
                ]
              },
              {
                "title": "Day 29-Domain 2",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "52" },
                      { "groupId": "OG001", "value": "54" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "-0.6", "spread": "0.4" },
                      { "groupId": "OG001", "value": "-0.1", "spread": "0.39" }
                    ]
                  }
                ]
              },
              {
                "title": "Day 57-Domain 2",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "49" },
                      { "groupId": "OG001", "value": "47" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "-0.7", "spread": "0.37" },
                      { "groupId": "OG001", "value": "-0.6", "spread": "0.38" }
                    ]
                  }
                ]
              },
              {
                "title": "Day 85-Domain 2",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "48" },
                      { "groupId": "OG001", "value": "49" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "-0.5", "spread": "0.43" },
                      { "groupId": "OG001", "value": "0.1", "spread": "0.42" }
                    ]
                  }
                ]
              },
              {
                "title": "Day 29-Domain 3",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "52" },
                      { "groupId": "OG001", "value": "54" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "-0.3", "spread": "0.28" },
                      { "groupId": "OG001", "value": "0.1", "spread": "0.27" }
                    ]
                  }
                ]
              },
              {
                "title": "Day 57-Domain 3",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "49" },
                      { "groupId": "OG001", "value": "47" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "-0.3", "spread": "0.33" },
                      { "groupId": "OG001", "value": "0.1", "spread": "0.33" }
                    ]
                  }
                ]
              },
              {
                "title": "Day 85-Domain 3",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "54" },
                      { "groupId": "OG001", "value": "55" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "0.5", "spread": "0.33" },
                      { "groupId": "OG001", "value": "0.3", "spread": "0.33" }
                    ]
                  }
                ]
              },
              {
                "title": "Day 29-Domain 4",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "52" },
                      { "groupId": "OG001", "value": "54" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "-0.2", "spread": "0.61" },
                      { "groupId": "OG001", "value": "-0.9", "spread": "0.6" }
                    ]
                  }
                ]
              },
              {
                "title": "Day 57-Domain 4",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "49" },
                      { "groupId": "OG001", "value": "47" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "-0.5", "spread": "0.61" },
                      { "groupId": "OG001", "value": "-0.7", "spread": "0.61" }
                    ]
                  }
                ]
              },
              {
                "title": "Day 85-Domain 4",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "54" },
                      { "groupId": "OG001", "value": "55" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "-0.1", "spread": "0.69" },
                      { "groupId": "OG001", "value": "1.1", "spread": "0.68" }
                    ]
                  }
                ]
              }
            ],
            "analyses": [
              {
                "groupIds": ["OG000", "OG001"],
                "groupDescription": "Day 29-Domain 1",
                "nonInferiorityType": "OTHER",
                "paramType": "Comparison of adjusted least square mean",
                "paramValue": "-0.18",
                "ciPctValue": "90",
                "ciNumSides": "TWO_SIDED",
                "ciLowerLimit": "-1.0",
                "ciUpperLimit": "0.7",
                "dispersionType": "STANDARD_ERROR_OF_MEAN",
                "dispersionValue": "0.516",
                "estimateComment": "mixed effects model with treatment, visit as fixed effects, baseline and disease duration at baseline as continuous covariates, treatment \\* visit and baseline \\* visit interaction effects."
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Change From Baseline in the Beck Depression Inventory, Second Ed. (BDI-II) Total Score",
            "description": "Beck Depression Inventory (BDI) is a 21-items self reported inventory with a scale evaluating depressive symptoms and the changes in BDI after treatment compared to baseline. The range of scores is 0 to 63, with higher scores indicating greater severity of depression.",
            "populationDescription": "Full Analysis Set (FAS)",
            "reportingStatus": "POSTED",
            "paramType": "LEAST_SQUARES_MEAN",
            "dispersionType": "Standard Error",
            "unitOfMeasure": "Score",
            "timeFrame": "Baseline, Day 29, Day 57, Day 85",
            "groups": [
              {
                "id": "OG000",
                "title": "PEAR-004",
                "description": "Eligible participants were to access PEAR-004 (an investigational digital therapeutic) on a mobile device (iOS and Android based) as needed to receive suggestions about coping strategies to overcome difficulties in daily life."
              },
              {
                "id": "OG001",
                "title": "Sham",
                "description": "Eligible participants were to access a sham control downloaded on a mobile device (iOS and Android based) as needed to delivering notifications prompting the participant to open the sham app, and then display a prescription timer for the remaining duration of app availability."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "54" },
                  { "groupId": "OG001", "value": "55" }
                ]
              }
            ],
            "classes": [
              {
                "title": "Day 29",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "52" },
                      { "groupId": "OG001", "value": "54" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "-1.0", "spread": "1.13" },
                      { "groupId": "OG001", "value": "-0.1", "spread": "1.11" }
                    ]
                  }
                ]
              },
              {
                "title": "Day 57",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "49" },
                      { "groupId": "OG001", "value": "47" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "-4.8", "spread": "1.14" },
                      { "groupId": "OG001", "value": "-1.5", "spread": "1.15" }
                    ]
                  }
                ]
              },
              {
                "title": "Day 85",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "48" },
                      { "groupId": "OG001", "value": "49" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "-3.4", "spread": "1.32" },
                      { "groupId": "OG001", "value": "-3.2", "spread": "1.3" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Percentage Change From Baseline in Total PANSS Score (Within Assigned Treatment Group)",
            "description": "The Positive and Negative Syndrome Scale (PANSS) is a well validated, standardized method of evaluating and monitoring psychotic symptoms. The PANSS assesses: positive (hallucinations, delusions, thought disorder), negative (blunted affect, abstract thinking and general symptomatology. The positive and negative subscale each consist of 7 items rated from 1(absent) - 7(extreme) with a minimum score = 7, maximum score = 49. The general subscale consists of 16 items with a minimum score = 16, maximum score = 112. A Total PANSS score (positive+ negative + general scores) has a minimum of 30 and maximum of 210. Higher scores represent more severity in symptoms.",
            "populationDescription": "Full Analysis Set (FAS)",
            "reportingStatus": "POSTED",
            "paramType": "LEAST_SQUARES_MEAN",
            "dispersionType": "Standard Error",
            "unitOfMeasure": "Score",
            "timeFrame": "Baseline, Day 29, Day 57, Day 85",
            "groups": [
              {
                "id": "OG000",
                "title": "PEAR-004",
                "description": "Eligible participants were to access PEAR-004 (an investigational digital therapeutic) on a mobile device (iOS and Android based) as needed to receive suggestions about coping strategies to overcome difficulties in daily life."
              },
              {
                "id": "OG001",
                "title": "Sham",
                "description": "Eligible participants were to access a sham control downloaded on a mobile device (iOS and Android based) as needed to delivering notifications prompting the participant to open the sham app, and then display a prescription timer for the remaining duration of app availability."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "54" },
                  { "groupId": "OG001", "value": "55" }
                ]
              }
            ],
            "classes": [
              {
                "title": "Day 29",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "52" },
                      { "groupId": "OG001", "value": "54" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "-2.0", "spread": "1.21" },
                      { "groupId": "OG001", "value": "-3.0", "spread": "1.18" }
                    ]
                  }
                ]
              },
              {
                "title": "Day 57",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "49" },
                      { "groupId": "OG001", "value": "47" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "-3.6", "spread": "1.28" },
                      { "groupId": "OG001", "value": "-4.4", "spread": "1.29" }
                    ]
                  }
                ]
              },
              {
                "title": "Day 85",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "48" },
                      { "groupId": "OG001", "value": "49" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "-3.7", "spread": "1.57" },
                      { "groupId": "OG001", "value": "-7.1", "spread": "1.55" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Percentage of Responders as Assessed by the Brief Medication Questionnaire (BMQ)",
            "description": "The Brief Medication Questionnaire (BMQ) collects information about current schizophrenia medication use.",
            "populationDescription": "Full Analysis Set (FAS)",
            "reportingStatus": "POSTED",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "timeFrame": "Day 29, Day 57, and Day 85",
            "groups": [
              {
                "id": "OG000",
                "title": "PEAR-004",
                "description": "Eligible participants were to access PEAR-004 (an investigational digital therapeutic) on a mobile device (iOS and Android based) as needed to receive suggestions about coping strategies to overcome difficulties in daily life."
              },
              {
                "id": "OG001",
                "title": "Sham",
                "description": "Eligible participants were to access a sham control downloaded on a mobile device (iOS and Android based) as needed to delivering notifications prompting the participant to open the sham app, and then display a prescription timer for the remaining duration of app availability."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "54" },
                  { "groupId": "OG001", "value": "55" }
                ]
              }
            ],
            "classes": [
              {
                "title": "Day 1",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "53" },
                      { "groupId": "OG001", "value": "54" }
                    ]
                  }
                ]
              },
              {
                "title": "Day 29",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "52" },
                      { "groupId": "OG001", "value": "53" }
                    ]
                  }
                ]
              },
              {
                "title": "Day 57",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "49" },
                      { "groupId": "OG001", "value": "46" }
                    ]
                  }
                ]
              },
              {
                "title": "Day 85",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "48" },
                      { "groupId": "OG001", "value": "48" }
                    ]
                  }
                ]
              },
              {
                "title": "Day 115 / End of Study",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "54" },
                      { "groupId": "OG001", "value": "52" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Percentage of Responders as Assessed by the Total PANSS Score",
            "description": "A Response is defined as a reduction of at least 20% at day 85 or last visit in total PANSS score relative to Baseline.",
            "populationDescription": "Full Analysis Set (FAS)",
            "reportingStatus": "POSTED",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "timeFrame": "Day 85",
            "groups": [
              {
                "id": "OG000",
                "title": "PEAR-004",
                "description": "Eligible participants were to access PEAR-004 (an investigational digital therapeutic) on a mobile device (iOS and Android based) as needed to receive suggestions about coping strategies to overcome difficulties in daily life."
              },
              {
                "id": "OG001",
                "title": "Sham",
                "description": "Eligible participants were to access a sham control downloaded on a mobile device (iOS and Android based) as needed to delivering notifications prompting the participant to open the sham app, and then display a prescription timer for the remaining duration of app availability."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "54" },
                  { "groupId": "OG001", "value": "55" }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "2" },
                      { "groupId": "OG001", "value": "9" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Number of Patients With Adverse Events",
            "description": "Adverse events, serious adverse events, and adverse events leading to discontinuation throughout the study",
            "populationDescription": "Safety Set (SAF)",
            "reportingStatus": "POSTED",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "timeFrame": "Day 115",
            "groups": [
              {
                "id": "OG000",
                "title": "PEAR-004",
                "description": "Eligible participants were to access PEAR-004 (an investigational digital therapeutic) on a mobile device (iOS and Android based) as needed to receive suggestions about coping strategies to overcome difficulties in daily life."
              },
              {
                "id": "OG001",
                "title": "Sham",
                "description": "Eligible participants were to access a sham control downloaded on a mobile device (iOS and Android based) as needed to delivering notifications prompting the participant to open the sham app, and then display a prescription timer for the remaining duration of app availability."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "55" },
                  { "groupId": "OG001", "value": "55" }
                ]
              }
            ],
            "classes": [
              {
                "title": "Participants with at least one AE",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "12" },
                      { "groupId": "OG001", "value": "10" }
                    ]
                  }
                ]
              },
              {
                "title": "Study drug-related AEs",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "1" },
                      { "groupId": "OG001", "value": "0" }
                    ]
                  }
                ]
              },
              {
                "title": "Participants with at least one SAE",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "0" },
                      { "groupId": "OG001", "value": "1" }
                    ]
                  }
                ]
              },
              {
                "title": "AEs leading to discontinuation of study treatment",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "0" },
                      { "groupId": "OG001", "value": "0" }
                    ]
                  }
                ]
              },
              {
                "title": "Study-drug related AEs leading to treatment disc.",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "0" },
                      { "groupId": "OG001", "value": "0" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Number of Patients With Vital Sign Measurements",
            "description": "Vital signs at baseline, day 85 or last visit",
            "reportingStatus": "POSTED",
            "paramType": "NUMBER",
            "unitOfMeasure": "Number of participants",
            "timeFrame": "Day 85",
            "groups": [
              {
                "id": "OG000",
                "title": "PEAR-004",
                "description": "Eligible participants were to access PEAR-004 (an investigational digital therapeutic) on a mobile device (iOS and Android based) as needed to receive suggestions about coping strategies to overcome difficulties in daily life."
              },
              {
                "id": "OG001",
                "title": "Sham",
                "description": "Eligible participants were to access a sham control downloaded on a mobile device (iOS and Android based) as needed to delivering notifications prompting the participant to open the sham app, and then display a prescription timer for the remaining duration of app availability."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "55" },
                  { "groupId": "OG001", "value": "55" }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "55" },
                      { "groupId": "OG001", "value": "55" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "InterSePT Scale for Suicidal Thinking-Plus (ISST-Plus) Score",
            "description": "InterSePT Scale for Suicidal Thinking-Plus (ISST-Plus) score. Semi-structured interview to assess severity of suicidal ideation and behavior Part I: collects information on 7 days prior to visit; 13 items scored 0 (min) to 2 (max) for suicidality, with a higher score representing a worse outcome Part II: collects information on suicidal behavior since last visit, with nominal categories Yes / No / Unknown (NA) Part III: global rating of status at time of interview; scored 0 (min) to 5 (max) for suicidality, with a higher score representing a worse outcome.\n\nPlease note that only part III score (severity of suicidal risk) was summarized and reported.",
            "populationDescription": "The number of subjects analyzed at different visits may differ from the overall number analyzed within a treatment group because some patients missed some visits.",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "scores on a scale",
            "timeFrame": "Baseline, Day 29, 57, 85, and 115",
            "groups": [
              {
                "id": "OG000",
                "title": "PEAR-004",
                "description": "Eligible participants were to access PEAR-004 (an investigational digital therapeutic) on a mobile device (iOS and Android based) as needed to receive suggestions about coping strategies to overcome difficulties in daily life."
              },
              {
                "id": "OG001",
                "title": "Sham",
                "description": "Eligible participants were to access a sham control downloaded on a mobile device (iOS and Android based) as needed to delivering notifications prompting the participant to open the sham app, and then display a prescription timer for the remaining duration of app availability."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "54" },
                  { "groupId": "OG001", "value": "53" }
                ]
              }
            ],
            "classes": [
              {
                "title": "Baseline",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "52" },
                      { "groupId": "OG001", "value": "50" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "0.0", "spread": "0.00" },
                      { "groupId": "OG001", "value": "0.1", "spread": "0.24" }
                    ]
                  }
                ]
              },
              {
                "title": "Day 1",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "50" },
                      { "groupId": "OG001", "value": "52" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "0.1", "spread": "0.31" },
                      { "groupId": "OG001", "value": "0.0", "spread": "0.14" }
                    ]
                  }
                ]
              },
              {
                "title": "Day 29",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "51" },
                      { "groupId": "OG001", "value": "53" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "0.0", "spread": "0.28" },
                      { "groupId": "OG001", "value": "0.1", "spread": "0.41" }
                    ]
                  }
                ]
              },
              {
                "title": "Day 57",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "47" },
                      { "groupId": "OG001", "value": "46" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "0.1", "spread": "0.44" },
                      { "groupId": "OG001", "value": "0.0", "spread": "0.00" }
                    ]
                  }
                ]
              },
              {
                "title": "Day 85",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "48" },
                      { "groupId": "OG001", "value": "49" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "0.1", "spread": "0.45" },
                      { "groupId": "OG001", "value": "0.1", "spread": "0.32" }
                    ]
                  }
                ]
              },
              {
                "title": "Day 115 / End Of Study",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "54" },
                      { "groupId": "OG001", "value": "53" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "0.1", "spread": "0.43" },
                      { "groupId": "OG001", "value": "0.1", "spread": "0.45" }
                    ]
                  }
                ]
              }
            ]
          }
        ]
      },
      "adverseEventsModule": {
        "frequencyThreshold": "5",
        "timeFrame": "Adverse events were collected from first dose of study treatment until end of study treatment plus 30 days post treatment, up to maximum duration of 119 days.",
        "eventGroups": [
          {
            "id": "EG000",
            "title": "PEAR-004",
            "description": "Eligible participants were to access PEAR-004 (an investigational digital therapeutic) on a mobile device (iOS and Android based) as needed to receive suggestions about coping strategies to overcome difficulties in daily life.",
            "deathsNumAffected": 0,
            "deathsNumAtRisk": 55,
            "seriousNumAffected": 0,
            "seriousNumAtRisk": 55,
            "otherNumAffected": 0,
            "otherNumAtRisk": 55
          },
          {
            "id": "EG001",
            "title": "Sham",
            "description": "Eligible participants were to access a sham control downloaded on a mobile device (iOS and Android based) as needed to delivering notifications prompting the participant to open the sham app, and then display a prescription timer for the remaining duration of app availability.",
            "deathsNumAffected": 0,
            "deathsNumAtRisk": 55,
            "seriousNumAffected": 1,
            "seriousNumAtRisk": 55,
            "otherNumAffected": 0,
            "otherNumAtRisk": 55
          },
          {
            "id": "EG002",
            "title": "Total",
            "description": "Total",
            "deathsNumAffected": 0,
            "deathsNumAtRisk": 110,
            "seriousNumAffected": 1,
            "seriousNumAtRisk": 110,
            "otherNumAffected": 0,
            "otherNumAtRisk": 110
          }
        ],
        "seriousEvents": [
          {
            "term": "Suicidal ideation",
            "organSystem": "Psychiatric disorders",
            "sourceVocabulary": "MedDRA (22.0)",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              { "groupId": "EG000", "numAffected": 0, "numAtRisk": 55 },
              { "groupId": "EG001", "numAffected": 1, "numAtRisk": 55 },
              { "groupId": "EG002", "numAffected": 1, "numAtRisk": 110 }
            ]
          }
        ]
      },
      "moreInfoModule": {
        "certainAgreement": {
          "piSponsorEmployee": false,
          "restrictionType": "OTHER",
          "restrictiveAgreement": true,
          "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial."
        },
        "pointOfContact": {
          "title": "Study Director",
          "organization": "Novartis Pharmaceuticals",
          "email": "Novartis.email@novartis.com",
          "phone": "862-778-8300"
        }
      }
    },
    "documentSection": {
      "largeDocumentModule": {
        "largeDocs": [
          {
            "typeAbbrev": "SAP",
            "hasProtocol": false,
            "hasSap": true,
            "hasIcf": false,
            "label": "Statistical Analysis Plan",
            "date": "2019-05-15",
            "uploadDate": "2020-09-11T09:32",
            "filename": "SAP_000.pdf",
            "size": 327498
          },
          {
            "typeAbbrev": "Prot",
            "hasProtocol": true,
            "hasSap": false,
            "hasIcf": false,
            "label": "Study Protocol",
            "date": "2018-10-12",
            "uploadDate": "2020-09-11T09:32",
            "filename": "Prot_001.pdf",
            "size": 404274
          }
        ]
      }
    },
    "derivedSection": {
      "miscInfoModule": {
        "versionHolder": "2025-05-07",
        "submissionTracking": {
          "firstMcpInfo": {
            "postDateStruct": { "date": "2020-10-08", "type": "ACTUAL" }
          }
        }
      },
      "conditionBrowseModule": {
        "meshes": [{ "id": "D012559", "term": "Schizophrenia" }],
        "ancestors": [
          {
            "id": "D019967",
            "term": "Schizophrenia Spectrum and Other Psychotic Disorders"
          },
          { "id": "D001523", "term": "Mental Disorders" }
        ],
        "browseLeaves": [
          { "id": "M14473", "name": "Psychotic Disorders", "relevance": "LOW" },
          { "id": "M4815", "name": "Mental Disorders", "relevance": "LOW" },
          {
            "id": "M15376",
            "name": "Schizophrenia",
            "asFound": "Schizophrenia",
            "relevance": "HIGH"
          },
          { "id": "M9304", "name": "Hallucinations", "relevance": "LOW" },
          { "id": "M13172", "name": "Paranoid Disorders", "relevance": "LOW" },
          { "id": "M6446", "name": "Confusion", "relevance": "LOW" },
          {
            "id": "M21838",
            "name": "Schizophrenia Spectrum and Other Psychotic Disorders",
            "relevance": "LOW"
          },
          {
            "id": "T1303",
            "name": "Chronic Graft Versus Host Disease",
            "relevance": "LOW"
          },
          {
            "id": "T170",
            "name": "Acute Graft Versus Host Disease",
            "relevance": "LOW"
          }
        ],
        "browseBranches": [
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" },
          { "abbrev": "All", "name": "All Conditions" },
          { "abbrev": "BC10", "name": "Nervous System Diseases" },
          { "abbrev": "BC23", "name": "Symptoms and General Pathology" },
          { "abbrev": "Rare", "name": "Rare Diseases" }
        ]
      },
      "interventionBrowseModule": {
        "browseLeaves": [
          { "id": "M6263", "name": "Coal Tar", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "Derm", "name": "Dermatologic Agents" },
          { "abbrev": "All", "name": "All Drugs and Chemicals" }
        ]
      }
    },
    "hasResults": true
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT04723056",
        "orgStudyIdInfo": { "id": "59209" },
        "organization": { "fullName": "Stanford University", "class": "OTHER" },
        "briefTitle": "Zemedy Application for Irritable Bowel Syndrome",
        "officialTitle": "Zemedy - Evaluation of Zemedy, a Cognitive Behavioral Therapy-based Digital Therapeutic Application for the Treatment of Irritable Bowel Syndrome"
      },
      "statusModule": {
        "statusVerifiedDate": "2023-12",
        "overallStatus": "ACTIVE_NOT_RECRUITING",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2021-10-15", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2024-03",
          "type": "ESTIMATED"
        },
        "completionDateStruct": { "date": "2024-03", "type": "ESTIMATED" },
        "studyFirstSubmitDate": "2021-01-20",
        "studyFirstSubmitQcDate": "2021-01-22",
        "studyFirstPostDateStruct": { "date": "2021-01-25", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2023-12-15",
        "lastUpdatePostDateStruct": { "date": "2023-12-19", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": {
          "type": "PRINCIPAL_INVESTIGATOR",
          "investigatorFullName": "Linda Nguyen",
          "investigatorTitle": "Clinical Professor",
          "investigatorAffiliation": "Stanford University"
        },
        "leadSponsor": { "name": "Stanford University", "class": "OTHER" },
        "collaborators": [{ "name": "Bold Health Inc.", "class": "INDUSTRY" }]
      },
      "oversightModule": {
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": true,
        "isUnapprovedDevice": true,
        "isUsExport": false
      },
      "descriptionModule": {
        "briefSummary": "The purpose of the study is investigate the effectiveness of Zemedy, a mobile application that enables the digital delivery of a CBT program to people with IBS.",
        "detailedDescription": "Irritable bowel syndrome (IBS) is defined as having recurrent abdominal pain associated with defecation or a change of bowel habits. The pathophysiology of IBS can be looked through the biopsychosocial model of disease which is defined by the complex interplay between genetic, cultural, environmental, and psychosocial factors.\n\nTreatment of IBS is multifaceted and ranges from exercise to dietary restrictions, however, psychological treatments to target the gut-brain axis such as cognitive-behavior therapy (CBT) have also been shown to be an effective therapy, and aims to address the psychological and environmental stressors that contribute to the symptoms. Therefore the purpose of the study is investigate the effectiveness of Zemedy, a mobile application that enables the digital delivery of a CBT program to people with IBS.\n\nCBT has been shown to reduce the severity of intractable IBS symptoms by as much as 70%. The investigators hope to learn whether the Zemedy mobile application is effective in the reduction of IBS. This will be measured based on their IBS Symptom Severity Scores (SSS) at week 8 compared to baseline."
      },
      "conditionsModule": {
        "conditions": ["IBS - Irritable Bowel Syndrome"],
        "keywords": [
          "Irritable Bowel Syndrome",
          "Cognitive Behavioral Therapy",
          "Self Help"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "interventionModelDescription": "Randomized trial comparing Zemedy CBT app vs. Treatment as usual",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": { "masking": "NONE" }
        },
        "enrollmentInfo": { "count": 22, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "Control Group (TAU only)",
            "type": "NO_INTERVENTION",
            "description": "Treatment as Usual (TAU) for IBS patients are tailored to each individual's needs and may involve treatment such as: dietary modification, exercise, medication, and anti-diarrheal therapy."
          },
          {
            "label": "Experimental (TAU plus CBT)",
            "type": "EXPERIMENTAL",
            "description": "Subjects who are in the Experimental Group will receive 8 weeks of CBT from the Zemedy mobile application in addition to their treatment as usual (TAU).",
            "interventionNames": ["Device: Use of Zemedy Application"]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "Use of Zemedy Application",
            "description": "8 weeks of CBT via the Zemedy Application.",
            "armGroupLabels": ["Experimental (TAU plus CBT)"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "IBS-SSS at 8 Weeks",
            "description": "Change in IBS symptoms based on the change in IBS symptom severity score (IBS-SSS) score at week 8 compared to baseline. Score range: 0-500",
            "timeFrame": "Baseline and at Week 8."
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "IBS-SSS at 24 Weeks",
            "description": "Change in IBS symptoms based on the change in IBS symptom severity score (IBS-SSS) score at week 24 compared to baseline. Score range: 0-500",
            "timeFrame": "Baseline and at Week 24."
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n1. Male and female patients \\>=18 years old.\n2. Meet Rome IV criteria for IBS for at least 6 months. No restrictions on type of IBS.\n3. English proficiency (in order to understand use of the application.\n4. Patient must be on a stable regimen for IBS for at least 30 days.\n5. Patients must own a smartphone (iOS or Android) in order to participate in the CBT application.\n\nExclusion Criteria:\n\n1. Laboratory or imaging evidence of an alternative explanation of patient's symptoms.\n2. Active gastrointestinal disease such as Crohn's disease, ulcerative colitis, history of complete colon resection, acute infection, or any disease that precludes participation in CBT application.\n3. Patient already undergoing cognitive behavioral therapy.\n4. Psychiatric hospitalization within 10 years.\n5. Current or past diagnosis of a major mental illness such as schizophrenia, bipolar disorder, personality disorder or substance abuse.\n6. Active (within the past 3 months) suicidal ideation.\n7. Prisoners or other detained individuals.\n8. Adults unable to consent.\n9. Pregnant people.",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "Linda Nguyen, MD",
            "affiliation": "Stanford University",
            "role": "PRINCIPAL_INVESTIGATOR"
          }
        ],
        "locations": [
          {
            "facility": "Stanford University School of Medicine",
            "city": "Redwood City",
            "state": "California",
            "zip": "94063",
            "country": "United States",
            "geoPoint": { "lat": 37.48522, "lon": -122.23635 }
          }
        ]
      },
      "ipdSharingStatementModule": { "ipdSharing": "NO" }
    },
    "derivedSection": {
      "miscInfoModule": {
        "versionHolder": "2025-05-07",
        "submissionTracking": {
          "estimatedResultsFirstSubmitDate": "2025-03-27",
          "submissionInfos": [
            {
              "releaseDate": "2025-03-27",
              "resetDate": "2025-04-15",
              "mcpReleaseN": 4
            }
          ]
        }
      },
      "conditionBrowseModule": {
        "meshes": [
          { "id": "D043183", "term": "Irritable Bowel Syndrome" },
          { "id": "D013577", "term": "Syndrome" }
        ],
        "ancestors": [
          { "id": "D004194", "term": "Disease" },
          { "id": "D010335", "term": "Pathologic Processes" },
          { "id": "D003109", "term": "Colonic Diseases, Functional" },
          { "id": "D003108", "term": "Colonic Diseases" },
          { "id": "D007410", "term": "Intestinal Diseases" },
          { "id": "D005767", "term": "Gastrointestinal Diseases" },
          { "id": "D004066", "term": "Digestive System Diseases" }
        ],
        "browseLeaves": [
          {
            "id": "M25118",
            "name": "Irritable Bowel Syndrome",
            "asFound": "Irritable Bowel Syndrome",
            "relevance": "HIGH"
          },
          {
            "id": "M16355",
            "name": "Syndrome",
            "asFound": "Syndrome",
            "relevance": "HIGH"
          },
          { "id": "M6336", "name": "Colonic Diseases", "relevance": "LOW" },
          {
            "id": "M6337",
            "name": "Colonic Diseases, Functional",
            "relevance": "LOW"
          },
          { "id": "M10444", "name": "Intestinal Diseases", "relevance": "LOW" },
          {
            "id": "M8883",
            "name": "Gastrointestinal Diseases",
            "relevance": "LOW"
          },
          {
            "id": "M7255",
            "name": "Digestive System Diseases",
            "relevance": "LOW"
          }
        ],
        "browseBranches": [
          { "abbrev": "BC06", "name": "Digestive System Diseases" },
          { "abbrev": "All", "name": "All Conditions" },
          { "abbrev": "BC23", "name": "Symptoms and General Pathology" }
        ]
      },
      "interventionBrowseModule": {
        "browseLeaves": [
          { "id": "M11139", "name": "Loperamide", "relevance": "LOW" },
          { "id": "M4249", "name": "Antidiarrheals", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "Gast", "name": "Gastrointestinal Agents" },
          { "abbrev": "All", "name": "All Drugs and Chemicals" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT04508153",
        "orgStudyIdInfo": { "id": "OBVIO-REN-001" },
        "organization": { "fullName": "Renovia, Inc.", "class": "INDUSTRY" },
        "briefTitle": "Pelvic Floor Muscle Training With a Digital Therapeutic Device to Standard Exercises for Stress Urinary Incontinence",
        "officialTitle": "A Prospective Randomized Trial Comparing Efficacy of Pelvic Floor Muscle Training With a Digital Therapeutic Device to Standard Exercises for the Treatment of Stress Urinary Incontinence: A Remote Digital Trial"
      },
      "statusModule": {
        "statusVerifiedDate": "2021-01",
        "overallStatus": "COMPLETED",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2020-10-01", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2021-04-23",
          "type": "ACTUAL"
        },
        "completionDateStruct": { "date": "2021-09-01", "type": "ACTUAL" },
        "studyFirstSubmitDate": "2020-08-05",
        "studyFirstSubmitQcDate": "2020-08-07",
        "studyFirstPostDateStruct": { "date": "2020-08-11", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2021-12-08",
        "lastUpdatePostDateStruct": { "date": "2021-12-09", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": { "name": "Renovia, Inc.", "class": "INDUSTRY" },
        "collaborators": [
          { "name": "OBVIO HEALTH USA, Inc.", "class": "UNKNOWN" },
          { "name": "University of Alabama at Birmingham", "class": "OTHER" }
        ]
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": true,
        "isUsExport": false
      },
      "descriptionModule": {
        "briefSummary": "A virtual prospective randomized controlled study to evaluate the efficacy of using the leva® Pelvic Digital Health System (PDHS) to perform PFMT compared to a standard home exercise home program for the treatment of SUI/SMUI. The treatment part of the study lasts eight weeks and has two arms. One group will receive routine care consisting of at-home Kegel exercises, and the other will be provided with a leva® device and instructions for use. Subjects in both groups will be assessed at baseline, then at 4 and 8 weeks for change and improvement of their symptoms. They will also be assessed at 6 and12 months after study completion.",
        "detailedDescription": "This trial is entirely virtual. No office visits, specific locations, or physical examination will be required. Enrollment may occur from any location in the United States\n\n* A virtual prospective randomized controlled study to evaluate the efficacy of using the leva® PDHS to perform PFMT (leva arm) compared to standard care of a PFM exercise home program (Kegel arm) for the treatment of SUI or SMUI.\n* Following completion of e-consent and screening, including an initial bladder diary and introductory phone call to review the study requirements, subjects are considered officially enrolled.\n* A series of baseline assessments will be administered to all subjects to evaluate symptom severity, frequency and impact.\n* Subjects will then be randomized to either the leva® arm or Kegel arm on a 1 to 1 ratio using block randomization. Prior to initiation of the trial, a randomization sequence will be generated by the ObvioHealth system. Participants will be automatically allocated the next available slot in the sequence at the time of their randomization and assigned to the leva® or Kegel group accordingly.\n* Prior to beginning the program, subjects in the Kegel arm will receive printed instructions for PFMT with Kegel exercises. Subjects in the leva® arm will be shipped the leva® digital device, along with instructions for use and how to download the corresponding digital app. Day 1 of the study begins the day following receipt of materials.\n* Study population: women with SUI or SMUI.\n* The study requires no office visits. All participant data will be entered in the subject's smartphone using a custom designed mobile application. Participants will be able to interact with the app throughout the study period and will be presented with surveys and a voiding diary on a specified schedule during an 8-week treatment period. There will also be expected post-intervention follow up surveys at 6- and 12-months\n* Using virtual recruiting, a total of up to 350 subjects will be enrolled in the trial.\n* Subjects in both arms will have three scheduled phone calls with study staff during the first two weeks of treatment.\n* Subjects can speak to the study staff at any time via an in-app chat function, the phone, or videoconference."
      },
      "conditionsModule": { "conditions": ["Stress Urinary Incontinence"] },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "interventionModelDescription": "A virtual prospective randomized controlled study to evaluate the efficacy of using the leva® PDHS to perform PFMT (leva arm) compared to standard care of a PFM exercise home program (Kegel arm) for the treatment of SUI or SMUI.",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": {
            "masking": "DOUBLE",
            "maskingDescription": "Subjects will be randomized to either the leva® arm or Kegel arm on a 1 to 1 ratio using block randomization. Prior to initiation of the trial, a randomization sequence will be generated by the ObvioHealth system. Participants will be automatically allocated the next available slot in the sequence at the time of their randomization and assigned to the leva® or Kegel group accordingly",
            "whoMasked": ["INVESTIGATOR", "OUTCOMES_ASSESSOR"]
          }
        },
        "enrollmentInfo": { "count": 369, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "Leva PDHS arm",
            "type": "OTHER",
            "description": "Upon randomization, subjects randomized to the leva® arm will receive the leva® PDHS, and instructions for how to download the smartphone app to facilitate use of the device. They will be instructed to use leva® based on the in-app training provided.\n\nWithin the app, subjects will be instructed to use the leva® device to perform PFMT according to the training program provided through the smartphone app associated with the device. This entails 2 ½ minute training sessions, three times daily, 7 days per week for a total of 8 weeks.",
            "interventionNames": ["Device: Leva Pelvic Digital Health System"]
          },
          {
            "label": "Kegel arm",
            "type": "OTHER",
            "description": "Subjects randomized to the Kegel arm will be provided links to view instructions on how to perform PFMT (written instructions per the handout adapted from Voices for PFD, the patient advocacy arm of the American Urogynecologic Society), as well as an audio/visual didactic instructing them to perform Pelvic Floor Muscle Exercises (PFME) three times daily, seven days per week throughout the 8-week study period.",
            "interventionNames": ["Other: Kegel exercises"]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "Leva Pelvic Digital Health System",
            "description": "Pelvic floor muscle training using the pelvic digital health system to treat pelvic floor disorders, specifically stress urinary incontinence.",
            "armGroupLabels": ["Leva PDHS arm"]
          },
          {
            "type": "OTHER",
            "name": "Kegel exercises",
            "description": "Pelvic floor muscle training (PFMT), commonly referred to as \"Kegel\" exercises, is a first line conservative treatment for pelvic floor disorders, specifically stress urinary incontinence (SUI) or stress-predominant mixed urinary incontinence (SMUI).",
            "armGroupLabels": ["Kegel arm"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Efficacy - Urogenital Distress Inventory (UDI-6)",
            "description": "UDI-6 is a validated questionnaire assessing symptom presence and degree of bother. It will be used to compare the degree of symptom change in the leva arm vs the Kegel arm within and between groups.",
            "timeFrame": "Baseline, 4 weeks, 8 weeks, 6 months and 12 months"
          },
          {
            "measure": "Efficacy - Bladder diaries",
            "description": "Bladder diaries evaluating the average number of stress-incontinence episodes in 3 days will be compared within and between groups",
            "timeFrame": "Baseline and 8 weeks"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Survey evaluations of incontinence Pelvic Organ Prolapse Distress Inventory (POPDI-6)",
            "description": "POPDI-6 to assess the impact that pelvic floor disorders have on the health related quality of life in women",
            "timeFrame": "Baseline, 4 weeks, 8 weeks, 6 months and 12 months"
          },
          {
            "measure": "Patient Reported perception of general health Short Form-20 (SF-20)",
            "description": "SF-20 survey on the participants perception of their general health.",
            "timeFrame": "Baseline, 4 weeks, 8 weeks, 6 months and 12 months"
          },
          {
            "measure": "Self-reported adherence",
            "description": "Visual Analog Score for self-reported adherence to the prescribed therapy, 0% = did not adhere to the prescribed treatment regimen/did not perform any Pelvic Floor exercises to 100% = adhered to the prescribed treatment regimen",
            "timeFrame": "4 weeks, 8 weeks"
          },
          {
            "measure": "Correlations between self-reported adherence and device reported adherence in the leva group",
            "description": "Self-reported adherence and Device-reported adherence in the Leva group will be correlated",
            "timeFrame": "4 weeks, 8 weeks"
          },
          {
            "measure": "Incidence of Treatment-Emergent Adverse Events (Safety and tolerability)",
            "description": "Monitored for adverse events and serious adverse events",
            "timeFrame": "Through study completion, an average of 1 year"
          },
          {
            "measure": "Feedback on perception of treatment - likelihood of recommending to a friend",
            "description": "Visual Analog Score of likelihood of recommending to a friend Scale from 0-100%. 0%= Will not recommend to a friend to 100%=Will definitely recommend to a friend.",
            "timeFrame": "4 weeks, 8 weeks"
          },
          {
            "measure": "Feedback on perception of treatment - interest in surgical treatment",
            "description": "Visual Analog Score of interest in surgical treatment for urinary incontinence. Scale from 0-100%. 0%= Not interested at all in surgical treatment to 100%=Extremely interested in surgical treatment.",
            "timeFrame": "4 weeks, 8 weeks"
          },
          {
            "measure": "Survey evaluations of incontinence Colorectal-Anal Distress Inventory-8 (CRADI-8)",
            "description": "CRADI-8 to assess the impact that pelvic floor disorders have on the health related quality of life in women",
            "timeFrame": "Baseline, 4 weeks, 8 weeks, 6 months and 12 months"
          },
          {
            "measure": "Survey evaluations of incontinence Pelvic Floor Distress Inventory (PFDI-20)",
            "description": "PFDI-20 to assess the impact that pelvic floor disorders have on the health related quality of life in women",
            "timeFrame": "Baseline, 4 weeks, 8 weeks, 6 months and 12 months"
          },
          {
            "measure": "Survey evaluations of incontinence Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-IR)",
            "description": "PISQ-IR to assess the impact that pelvic floor disorders have on the health related quality of life in women",
            "timeFrame": "Baseline, 4 weeks, 8 weeks, 6 months and 12 months"
          },
          {
            "measure": "Survey evaluations of incontinence Patient Global Impression of Severity (PGI-S)",
            "description": "PGI-S is the participants description of how their urinary tract condition is currently.",
            "timeFrame": "Baseline, 4 weeks, 8 weeks, 6 months and 12 months"
          },
          {
            "measure": "Survey evaluations of incontinence Patient Global Impression of Improvement (PGI-I)",
            "description": "PGI-I is the participants description on how their urinary symptoms are now, compared with how they were before they began the study.",
            "timeFrame": "4 weeks, 8 weeks, 6 months and 12 months"
          },
          {
            "measure": "Survey evaluations of incontinence Pelvic Floor Impact Questionnaire (PFIQ)",
            "description": "PFIQ to assess the impact that pelvic floor disorders have on the health related quality of life in women",
            "timeFrame": "Baseline, 4 weeks, 8 weeks, 6 months and 12 months"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* ≥18 years of age\n* Capable of giving informed consent\n* Possess a smartphone capable of interacting with the ObvioHealth and Renovia apps\n* Self-reported SUI/SMUI symptoms of ≥ three months duration\n* Diagnosis SMUI based on Medical, Epidemiologic and Social Aspects of Aging (MESA) stress symptom score (Percent of total possible stress score) greater than MESA urge symptom score (percent of total possible urge score)\n* English speaking\n* Postmenopausal, post hysterectomy, or willing to use an acceptable method of birth control for the duration of the study\n* Able to complete a bladder diary using the ObvioHealth app\n* Able to complete electronic surveys and upload data\n* Willing to provide contact information and respond to remote contact: phone calls, text messages, email\n* Willing to participate in the 8-week study with follow up at 6-and 12-months, refraining from the pursuit of treatment for Stress UI using other modalities (i.e. will not wear a pessary, participate in pelvic floor Physical Therapy or surgery) during the first 8 weeks\n\nExclusion Criteria:\n\n* Absence of a vagina, per patient report\n* Reports seeing or feeling a vaginal bulge or sensation of vaginal bulge\n* Diagnosis of any neuromuscular disease that may contribute to UI (i.e., multiple sclerosis, spinal cord injury, Parkinson's Disease, etc.)\n* Non-ambulatory, per patient report\n* Currently pregnant or \\<6 months post-partum per patient report\n* Currently (or within the last 1 month) breast feeding\n* Prior surgery for stress UI\n* Previous PFMT: 2 visits within the last 3 months under a supervised therapeutic plan of care\n* Currently taking, or has taken within the last 2 months, medication to treat UI\n* Prior augmentation cystoplasty or artificial sphincter\n* Implanted nerve stimulator for urinary symptoms, active within the past 60 days\n* Participation in another clinical study within 30 days of screening\n* Impaired cognitive function per patient report and evaluation of medication list\n* Contraindication to the use of a vaginal probe\n* Unable to understand instructions on the use of the leva® PDHS\n* Unable to operate a smartphone app with use of Bluetooth and Wi-Fi connectivity",
        "healthyVolunteers": false,
        "sex": "FEMALE",
        "minimumAge": "18 Years",
        "maximumAge": "100 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "Holly Richter, MD PhD",
            "affiliation": "University of Alabama at Birmingham",
            "role": "PRINCIPAL_INVESTIGATOR"
          },
          {
            "name": "Milena Weinstein, MD",
            "affiliation": "Massachusetts General Hospital",
            "role": "PRINCIPAL_INVESTIGATOR"
          },
          {
            "name": "Gena Dunnivan, MD",
            "affiliation": "University of New Mexico",
            "role": "PRINCIPAL_INVESTIGATOR"
          },
          {
            "name": "Noelani M Guaderrama, MD",
            "affiliation": "Southern California Permanentae",
            "role": "PRINCIPAL_INVESTIGATOR"
          }
        ],
        "locations": [
          {
            "facility": "University of Alabama *** Virtual Trial May be enrolled from any US Location",
            "city": "Birmingham",
            "state": "Alabama",
            "zip": "35233",
            "country": "United States",
            "geoPoint": { "lat": 33.52066, "lon": -86.80249 }
          },
          {
            "facility": "Southern California Permanente Medical Group*** Virtual Trial May be enrolled from any US Location",
            "city": "Irvine",
            "state": "California",
            "zip": "92618",
            "country": "United States",
            "geoPoint": { "lat": 33.66946, "lon": -117.82311 }
          },
          {
            "facility": "University of New Mexico *** Virtual Trial May be enrolled from any US Location",
            "city": "Albuquerque",
            "state": "New Mexico",
            "zip": "87112",
            "country": "United States",
            "geoPoint": { "lat": 35.08449, "lon": -106.65114 }
          }
        ]
      },
      "referencesModule": {
        "references": [
          {
            "pmid": "35271539",
            "type": "DERIVED",
            "citation": "Weinstein MM, Dunivan G, Guaderrama NM, Richter HE. Digital Therapeutic Device for Urinary Incontinence: A Randomized Controlled Trial. Obstet Gynecol. 2022 Apr 1;139(4):606-615. doi: 10.1097/AOG.0000000000004725. Epub 2022 Mar 10."
          },
          {
            "pmid": "33866003",
            "type": "DERIVED",
            "citation": "Weinstein MM, Pulliam SJ, Richter HE. Randomized trial comparing efficacy of pelvic floor muscle training with a digital therapeutic motion-based device to standard pelvic floor exercises for treatment of stress urinary incontinence (SUV trial): An all-virtual trial design. Contemp Clin Trials. 2021 Jun;105:106406. doi: 10.1016/j.cct.2021.106406. Epub 2021 Apr 16."
          }
        ]
      },
      "ipdSharingStatementModule": { "ipdSharing": "NO" }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [
          { "id": "D014549", "term": "Urinary Incontinence" },
          { "id": "D004775", "term": "Enuresis" },
          { "id": "D014550", "term": "Urinary Incontinence, Stress" }
        ],
        "ancestors": [
          { "id": "D014555", "term": "Urination Disorders" },
          { "id": "D014570", "term": "Urologic Diseases" },
          { "id": "D052776", "term": "Female Urogenital Diseases" },
          {
            "id": "D005261",
            "term": "Female Urogenital Diseases and Pregnancy Complications"
          },
          { "id": "D000091642", "term": "Urogenital Diseases" },
          { "id": "D052801", "term": "Male Urogenital Diseases" },
          { "id": "D059411", "term": "Lower Urinary Tract Symptoms" },
          { "id": "D020924", "term": "Urological Manifestations" },
          { "id": "D001526", "term": "Behavioral Symptoms" },
          { "id": "D019960", "term": "Elimination Disorders" },
          { "id": "D001523", "term": "Mental Disorders" }
        ],
        "browseLeaves": [
          {
            "id": "M17299",
            "name": "Urinary Incontinence",
            "asFound": "Urinary Incontinence",
            "relevance": "HIGH"
          },
          {
            "id": "M7936",
            "name": "Enuresis",
            "asFound": "Urinary Incontinence",
            "relevance": "HIGH"
          },
          {
            "id": "M17300",
            "name": "Urinary Incontinence, Stress",
            "asFound": "Stress Urinary Incontinence",
            "relevance": "HIGH"
          },
          { "id": "M27171", "name": "Nocturnal Enuresis", "relevance": "LOW" },
          { "id": "M17305", "name": "Urination Disorders", "relevance": "LOW" },
          { "id": "M17319", "name": "Urologic Diseases", "relevance": "LOW" },
          { "id": "M2875", "name": "Urogenital Diseases", "relevance": "LOW" },
          {
            "id": "M27093",
            "name": "Female Urogenital Diseases",
            "relevance": "LOW"
          },
          {
            "id": "M14127",
            "name": "Pregnancy Complications",
            "relevance": "LOW"
          },
          {
            "id": "M8399",
            "name": "Female Urogenital Diseases and Pregnancy Complications",
            "relevance": "LOW"
          },
          {
            "id": "M27095",
            "name": "Male Urogenital Diseases",
            "relevance": "LOW"
          },
          {
            "id": "M29464",
            "name": "Lower Urinary Tract Symptoms",
            "relevance": "LOW"
          },
          {
            "id": "M22659",
            "name": "Urological Manifestations",
            "relevance": "LOW"
          },
          { "id": "M4818", "name": "Behavioral Symptoms", "relevance": "LOW" },
          {
            "id": "M21832",
            "name": "Elimination Disorders",
            "relevance": "LOW"
          },
          { "id": "M14473", "name": "Psychotic Disorders", "relevance": "LOW" },
          { "id": "M4815", "name": "Mental Disorders", "relevance": "LOW" }
        ],
        "browseBranches": [
          {
            "abbrev": "BXS",
            "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
          },
          { "abbrev": "BC23", "name": "Symptoms and General Pathology" },
          { "abbrev": "All", "name": "All Conditions" },
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT04571398",
        "orgStudyIdInfo": { "id": "AH0001" },
        "organization": {
          "fullName": "Apricity Health, Inc",
          "class": "INDUSTRY"
        },
        "briefTitle": "A Study of ApricityRx™ for Management of IR-AEs in Patients on Immuno-Oncology Therapy",
        "officialTitle": "A Study of ApricityRx™ Digital Therapeutic for Management of Immune-Related Adverse Events in Patients on Immuno-Oncology Therapy"
      },
      "statusModule": {
        "statusVerifiedDate": "2020-09",
        "overallStatus": "UNKNOWN",
        "lastKnownStatus": "RECRUITING",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2019-11-19", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2022-10-15",
          "type": "ESTIMATED"
        },
        "completionDateStruct": { "date": "2023-10-15", "type": "ESTIMATED" },
        "studyFirstSubmitDate": "2020-09-25",
        "studyFirstSubmitQcDate": "2020-09-25",
        "studyFirstPostDateStruct": { "date": "2020-10-01", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2020-09-25",
        "lastUpdatePostDateStruct": { "date": "2020-10-01", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": { "name": "Apricity Health, Inc", "class": "INDUSTRY" }
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": false
      },
      "descriptionModule": {
        "briefSummary": "Study of ApricityRx™ for Management of IR-AEs for patients on I-O therapy. Patients currently receiving immunotherapy will be asked to consent to participate in ApricityRx software platform mobile telephone application to report symptoms, view educational content in video form about IO and irAEs and communicate with site study team."
      },
      "conditionsModule": {
        "conditions": ["Cancer"],
        "keywords": [
          "cancer",
          "immunotherapy",
          "checkpoint inhibitors",
          "immune-related adverse events"
        ]
      },
      "designModule": {
        "studyType": "OBSERVATIONAL",
        "patientRegistry": false,
        "designInfo": {
          "observationalModel": "COHORT",
          "timePerspective": "PROSPECTIVE"
        },
        "enrollmentInfo": { "count": 100, "type": "ESTIMATED" }
      },
      "armsInterventionsModule": {
        "interventions": [
          {
            "type": "OTHER",
            "name": "ApricityRx mobile application",
            "description": "AE detection and monitoring software"
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Evaluate digital therapeutic mobile app to capture and transmit to care team patient-generated health data and access education content on IO and irAEs",
            "description": "Number of times and percentage of study participants who use the app to report patient reported health data during a 12 week period and access education videos.",
            "timeFrame": "12 weeks"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* Confirmed cancer diagnosis\n* Prescribed treatment with immune-checkpoint inhibitor\n* Age ≥ 18 years\n* Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Uncomfortable with or unwilling to use digital or mobile technology\n* Lack of a smart phone with compatible operating systems: iOS version 10 and above, or Android 6.0 Marshmallow\n* Presence of any medical, psychological or social condition that, in the opinion of the investigator, would preclude participation in this study.",
        "sex": "ALL",
        "minimumAge": "18 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"],
        "studyPopulation": "Subject with a confirmed cancer diagnosis and prescribed checkpoint inhibitor therapy.",
        "samplingMethod": "NON_PROBABILITY_SAMPLE"
      },
      "contactsLocationsModule": {
        "centralContacts": [
          {
            "name": "Research Nurse Navigator",
            "role": "CONTACT",
            "phone": "212-342-5162",
            "email": "cancerclinicaltrials@cumc.columbia.edu"
          }
        ],
        "overallOfficials": [
          {
            "name": "Brian Henick, MD",
            "affiliation": "Columbia University",
            "role": "PRINCIPAL_INVESTIGATOR"
          }
        ],
        "locations": [
          {
            "facility": "Columbia University Irving Medical Center",
            "status": "RECRUITING",
            "city": "New York",
            "state": "New York",
            "zip": "10032",
            "country": "United States",
            "geoPoint": { "lat": 40.71427, "lon": -74.00597 }
          }
        ]
      },
      "ipdSharingStatementModule": { "ipdSharing": "NO" }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "interventionBrowseModule": {
        "browseLeaves": [
          {
            "id": "M2853",
            "name": "Immunomodulating Agents",
            "relevance": "LOW"
          }
        ],
        "browseBranches": [
          { "abbrev": "All", "name": "All Drugs and Chemicals" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT05305235",
        "orgStudyIdInfo": { "id": "20-3494" },
        "organization": {
          "fullName": "University of North Carolina, Chapel Hill",
          "class": "OTHER"
        },
        "briefTitle": "RCT for Innovating Stress-related eHealth",
        "officialTitle": "Development of a Digital Therapeutic Targeting Anxiety Sensitivity to Reduce Posttraumatic Stress in Women Presenting for Emergency Care After Sexual Assault",
        "acronym": "RISE"
      },
      "statusModule": {
        "statusVerifiedDate": "2025-02",
        "overallStatus": "COMPLETED",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2021-12-01", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2024-02-24",
          "type": "ACTUAL"
        },
        "completionDateStruct": { "date": "2024-02-24", "type": "ACTUAL" },
        "studyFirstSubmitDate": "2022-03-22",
        "studyFirstSubmitQcDate": "2022-03-30",
        "studyFirstPostDateStruct": { "date": "2022-03-31", "type": "ACTUAL" },
        "resultsFirstSubmitDate": "2024-12-12",
        "resultsFirstSubmitQcDate": "2025-02-27",
        "resultsFirstPostDateStruct": {
          "date": "2025-03-05",
          "type": "ACTUAL"
        },
        "lastUpdateSubmitDate": "2025-02-27",
        "lastUpdatePostDateStruct": { "date": "2025-03-05", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": {
          "name": "University of North Carolina, Chapel Hill",
          "class": "OTHER"
        },
        "collaborators": [{ "name": "Mayday Fund", "class": "OTHER" }]
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": true,
        "isUnapprovedDevice": true,
        "isUsExport": false
      },
      "descriptionModule": {
        "briefSummary": "The Randomized Control Trial for Innovating Stress-related eHealth (RISE) Study tests the hypotheses that a highly promising digital therapeutic (RISE Guide) targeting anxiety sensitivity (AS) will be acceptable to women sexual assault survivors; reduce survivors' anxiety sensitivity, and, in turn, posttraumatic stress.\n\nIf successful, RISE Guide could be provided at no cost to all women who present to US emergency departments for emergency care after sexual assault.",
        "detailedDescription": "The RISE Study plans to recruit up to 60 women (natal and self-identifying) who present for Sexual Assault Nurse Examiner (SANE) care within 72 hours of experiencing sexual assault. Willing participants will complete enrollment procedures (i.e., consent forms and initial survey) during this same, initial SANE care visit.\n\nAll enrolled participants will complete 4/day ecological momentary assessments (EMAs; day 1 through day 49) and complete a follow-up assessment at week 1. More information on EMA and week 1 assessment content is available in the \"Outcome Measurements\" section of this listing.\n\nFollowing their week 1 survey, all participants will be randomized into either the active (RISE Guide) or control (Breathe2Relax app) condition. Participants will receive a link to their assigned intervention. Participants in the active condition will additionally begin receiving ecological momentary interventions (EMIs) at the end of their ecological momentary assessments, which consist of personalized feedback based on symptoms reported during EMAs.\n\nAll participants will receive an Empatica wristband in the mail. Participants will wear the wristband week 1 through week 7 and press a button on the wristband's interface whenever they experience internal (e.g. thought) or external (e.g. seeing the assailant in public) trauma reminders. The wristband will collect continuous data on participants' heart rate, temperature, and perspiration, which will be used as measurements of stress reactivity.\n\nAll participants will complete further follow-up assessments at week 7, month 6, and month 12.\\* More information on each follow-up assessment's content is available in the \"Outcome Measurements\" section of this listing.\n\n\\*The month 12 follow-up assessment was removed via an IRB modification approved on December 14, 2022. Participants enrolled after December 14, 2022 will not complete this timepoint."
      },
      "conditionsModule": {
        "conditions": [
          "Posttraumatic Stress Disorder",
          "Sexual Assault",
          "Pain"
        ],
        "keywords": [
          "Clinical Trials, Randomized",
          "Prevention",
          "eHealth",
          "Anxiety Sensitivity"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "interventionModelDescription": "Randomization tables will be generated by the study Biostatistician and uploaded into the study REDCap database by a UNC Research Coordinator prior to launching data collection. Participants are randomized (1:1) to receive either the RISE Guide (experimental) condition or Breathe2Relax (control) condition after completing their 1-week survey. The list of assignments will be stored securely in REDCap.",
          "primaryPurpose": "PREVENTION",
          "maskingInfo": {
            "masking": "TRIPLE",
            "maskingDescription": "Participants will not be masked to their study conditions, as branding is visible in both RISE Guide and Breathe2Relax. Moreover, the UNC Research Coordinators will not be masked to condition, as they will be responsible for tracking RISE Guide progress and managing participant payments. The Principal Investigator, Biostatistician, Site Principal Investigators, Site Research Associates, and anyone involved in data analysis will remain masked to condition until data analysis is complete; masking will be maintained through reduced data viewing privileges in REDCap.",
            "whoMasked": ["CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]
          }
        },
        "enrollmentInfo": { "count": 75, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "RISE Guide",
            "type": "EXPERIMENTAL",
            "description": "The RISE (RCT for Innovating Stress-related eHealth) Guide is based on Cognitive Anxiety Sensitivity Treatment (CAST), an anxiety sensitivity intervention effective in reducing anxiety sensitivity, posttraumatic stress, depression, and anxiety. RISE Guide delivers psychoeducation and cognitive-behavioral therapy principles in an interactive, audio-visual format discussing the stress response, myth-busting cognitive distortions related to stress, and facilitating safe exposure to feared sensations. Participants then complete a validated cognitive bias modification (CBM-I) for interpretation biases related to anxiety sensitivity. Finally, intervention principles are reinforced using ecological momentary intervention (EMI), in which surveys and personalized reminders are delivered based on symptoms reported during ecological momentary assessments (EMAs)\n\nRISE Guide delivered by smartphone via Qualtrics and is completed in \\~45 minutes over 2 weeks, with EMI weeks 1-7 post-assault.",
            "interventionNames": ["Device: RISE Guide"]
          },
          {
            "label": "Relaxation Control",
            "type": "ACTIVE_COMPARATOR",
            "description": "Breathe2Relax is a mobile application that instructs users on diaphragmatic breathing, a coping tool in which slow breathing through the diaphragm reduces anxiety. Participants in the control condition will download Breathe2Relax to their smartphones and receive short message service (SMS) reminders to engage with the app. The control intervention is expected to reduce symptoms, but not as much as the cognitive-behavioral therapy strategies taught in RISE Guide.",
            "interventionNames": ["Device: Relaxation Control"]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "RISE Guide",
            "description": "Smartphone-based intervention that uses Cognitive Bias Modification to change perceptions of stress.",
            "armGroupLabels": ["RISE Guide"],
            "otherNames": ["RCT for Innovating Stress-related eHealth"]
          },
          {
            "type": "DEVICE",
            "name": "Relaxation Control",
            "description": "Guides users through relaxation techniques.",
            "armGroupLabels": ["Relaxation Control"],
            "otherNames": ["Breathe2Relax"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Treatment Adherence/Acceptability Scale",
            "description": "The Treatment Adherence/Acceptability Scale (TAAS) is a 10-item measure of treatment acceptability (e.g., I would recommend this treatment to a friend) and adherence (e.g., I would be able to finish \\[this treatment\\]) that participants rate on a 7-point Likert scale with scores ranging from 10-70. Higher scores indicate higher acceptability.",
            "timeFrame": "1 Week"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Credibility/Expectancy Questionnaire",
            "description": "Credibility/Expectancy Questionnaire (CEQ; 1 week) 6-item measure of treatment credibility and expectancy of treatment to improve symptoms. Items are rated on 9-to-11-point Likert scales. 11-point scales (0-100% in 10% intervals are recoded to align with the 1-9 scales). Higher scores indicate higher credibility/expectancy. Scores can range from 4 to 56.",
            "timeFrame": "7 Week"
          },
          {
            "measure": "Treatment Utilization and Acceptability",
            "description": "6 items self-report survey created for the current study on a 5-point Likert scale, such as How often did you log in? How interested were you? and 4 open-ended questions; e.g., What did you like about RISE Guide?; What did you not like? Lower scores indicate higher treatment utilization and acceptability. Scores range from 6-30.",
            "timeFrame": "7 Week"
          },
          {
            "measure": "Average Number of Participants Successfully Randomized Per Month Over the Entirety of the Study",
            "description": "The purpose of this outcome is to measure feasibility across the entirety of successful recruitment and randomization.",
            "timeFrame": "From first to last participant approached (up to 20 months)"
          },
          {
            "measure": "Final Proportion of Participants Who Completed Follow-ups",
            "description": "The proportion of participants who complete follow-ups (i.e., 7-week, 6 months) will be used to evaluate feasibility of retaining the target sample (goal retention=75% or higher).",
            "timeFrame": "7 Weeks Follow Up, 6 Month Follow Up (up to 7 months)"
          },
          {
            "measure": "Unexpected Adverse Events by Event",
            "description": "Investigators will examine whether unexpected adverse events occur throughout each participant's participation in the study.",
            "timeFrame": "up to approximately 7 months"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* Women sexual assault survivors presenting for emergency care \\<72 hours post-assault at one of our study locations.\n* English speakers\n* 18+ years of age\n* Able to provide informed consent\n* Have a smartphone with continuous service \\>1 year\n\nExclusion Criteria:\n\n* Inability to provide informed consent (e.g., serious injury preventing the ability to hear, speak, or see to consent and participate, or other causes (e.g., diagnosed cognitive deficits, diagnosed dementia, asleep at time of screening).\n* Prisoner\n* Currently pregnant\n* Lives with assailant and plans to continue to do so\n* Admitted patient\n* No mailing address\n* Previously enrolled\n* No SANE examination",
        "healthyVolunteers": true,
        "sex": "FEMALE",
        "genderBased": true,
        "genderDescription": "Identifies as woman.",
        "minimumAge": "18 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "Samuel A. McLean, MD, MPH",
            "affiliation": "University of North Carolina, Chapel Hill",
            "role": "PRINCIPAL_INVESTIGATOR"
          },
          {
            "name": "Nicole A. Short, PhD",
            "affiliation": "University of Nevada, Las Vegas",
            "role": "PRINCIPAL_INVESTIGATOR"
          }
        ],
        "locations": [
          {
            "facility": "University of North Carolina at Chapel Hill, SANE Program",
            "city": "Chapel Hill",
            "state": "North Carolina",
            "zip": "27599",
            "country": "United States",
            "geoPoint": { "lat": 35.9132, "lon": -79.05584 }
          },
          {
            "facility": "Austin Stop Abuse for Everyone (SAFE)",
            "city": "Austin",
            "state": "Texas",
            "zip": "78760",
            "country": "United States",
            "geoPoint": { "lat": 30.26715, "lon": -97.74306 }
          }
        ]
      },
      "referencesModule": {
        "references": [
          {
            "pmid": "25848562",
            "type": "BACKGROUND",
            "citation": "Broderick JE, DeWitt EM, Rothrock N, Crane PK, Forrest CB. Advances in Patient-Reported Outcomes: The NIH PROMIS((R)) Measures. EGEMS (Wash DC). 2013 Aug 2;1(1):1015. doi: 10.13063/2327-9214.1015. eCollection 2013."
          }
        ]
      },
      "ipdSharingStatementModule": {
        "ipdSharing": "YES",
        "description": "Deidentified individual data that supports the results will be shared by reasonable request beginning 9 to 36 months following publication provided the investigator who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and executes a data use/sharing agreement with UNC.",
        "infoTypes": ["STUDY_PROTOCOL", "SAP", "ICF", "ANALYTIC_CODE"],
        "timeFrame": "Data will become available 9 to 36 months following publication and will remain available for five years.",
        "accessCriteria": "The investigator who proposes to use the data has IRB, IEC, or REB approval, as applicable, and an executed data use/sharing agreement with UNC."
      }
    },
    "resultsSection": {
      "participantFlowModule": {
        "preAssignmentDetails": "Of the 75 participants who signed informed consent, only 60 completed the required one-week follow up and were randomly assigned to a treatment intervention.",
        "groups": [
          {
            "id": "FG000",
            "title": "RISE Guide",
            "description": "The RISE (RCT for Innovating Stress-related eHealth) Guide is based on Cognitive Anxiety Sensitivity Treatment (CAST), an anxiety sensitivity intervention effective in reducing anxiety sensitivity, posttraumatic stress, depression, and anxiety. RISE Guide delivers psychoeducation and cognitive-behavioral therapy principles in an interactive, audio-visual format discussing the stress response, myth-busting cognitive distortions related to stress, and facilitating safe exposure to feared sensations. Participants then complete a validated cognitive bias modification (CBM-I) for interpretation biases related to anxiety sensitivity. Finally, intervention principles are reinforced using ecological momentary intervention (EMI), in which surveys and personalized reminders are delivered based on symptoms reported during ecological momentary assessments (EMAs)\n\nRISE Guide delivered by smartphone via Qualtrics and is completed in \\~45 minutes over 2 weeks, with EMI weeks 1-7 post-assault.\n\nRISE Guide: Smartphone-based intervention that uses Cognitive Bias Modification to change perceptions of stress."
          },
          {
            "id": "FG001",
            "title": "Relaxation Control",
            "description": "Breathe2Relax is a mobile application that instructs users on diaphragmatic breathing, a coping tool in which slow breathing through the diaphragm reduces anxiety. Participants in the control condition will download Breathe2Relax to their smartphones and receive short message service (SMS) reminders to engage with the app. The control intervention is expected to reduce symptoms, but not as much as the cognitive-behavioral therapy strategies taught in RISE Guide.\n\nRelaxation Control: Guides users through relaxation techniques."
          }
        ],
        "periods": [
          {
            "title": "Overall Study",
            "milestones": [
              {
                "type": "STARTED",
                "achievements": [
                  { "groupId": "FG000", "numSubjects": "27" },
                  { "groupId": "FG001", "numSubjects": "33" }
                ]
              },
              {
                "type": "COMPLETED",
                "achievements": [
                  { "groupId": "FG000", "numSubjects": "19" },
                  { "groupId": "FG001", "numSubjects": "17" }
                ]
              },
              {
                "type": "NOT COMPLETED",
                "achievements": [
                  { "groupId": "FG000", "numSubjects": "8" },
                  { "groupId": "FG001", "numSubjects": "16" }
                ]
              }
            ]
          }
        ]
      },
      "baselineCharacteristicsModule": {
        "groups": [
          {
            "id": "BG000",
            "title": "RISE Guide",
            "description": "The RISE (RCT for Innovating Stress-related eHealth) Guide is based on CAST, an anxiety sensitivity intervention effective in reducing anxiety sensitivity, posttraumatic stress, depression, and anxiety. RISE Guide delivers psychoeducation and cognitive-behavioral therapy principles in an interactive, audio-visual format discussing the stress response, myth-busting cognitive distortions related to stress, and facilitating safe exposure to feared sensations. Participants then complete a validated cognitive bias modification (CBM-I) for interpretation biases related to anxiety sensitivity. Finally, intervention principles are reinforced using ecological momentary intervention (EMI), in which surveys and personalized reminders are delivered based on symptoms reported during ecological momentary assessments (EMAs)\n\nRISE Guide delivered by smartphone via Qualtrics and is completed in \\~45 minutes over 2 weeks, with EMI weeks 1-7 post-assault.\n\nRISE Guide: Smartphone-based intervention that uses Cognitive Bias Modification to change perceptions of stress."
          },
          {
            "id": "BG001",
            "title": "Relaxation Control",
            "description": "Breathe2Relax is a mobile application that instructs users on diaphragmatic breathing, a coping tool in which slow breathing through the diaphragm reduces anxiety. Participants in the control condition will download Breathe2Relax to their smartphones and receive short message service (SMS) reminders to engage with the app. The control intervention is expected to reduce symptoms, but not as much as the cognitive-behavioral therapy strategies taught in RISE Guide.\n\nRelaxation Control: Guides users through relaxation techniques."
          },
          {
            "id": "BG002",
            "title": "Total",
            "description": "Total of all reporting groups"
          }
        ],
        "denoms": [
          {
            "units": "Participants",
            "counts": [
              { "groupId": "BG000", "value": "27" },
              { "groupId": "BG001", "value": "33" },
              { "groupId": "BG002", "value": "60" }
            ]
          }
        ],
        "measures": [
          {
            "title": "Age, Continuous",
            "paramType": "MEAN",
            "dispersionType": "STANDARD_DEVIATION",
            "unitOfMeasure": "years",
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "25.80",
                        "spread": "6.90"
                      },
                      {
                        "groupId": "BG001",
                        "value": "25.38",
                        "spread": "6.64"
                      },
                      { "groupId": "BG002", "value": "25.56", "spread": "6.70" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Sex: Female, Male",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "Female",
                    "measurements": [
                      { "groupId": "BG000", "value": "27" },
                      { "groupId": "BG001", "value": "33" },
                      { "groupId": "BG002", "value": "60" }
                    ]
                  },
                  {
                    "title": "Male",
                    "measurements": [
                      { "groupId": "BG000", "value": "0" },
                      { "groupId": "BG001", "value": "0" },
                      { "groupId": "BG002", "value": "0" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Ethnicity (NIH/OMB)",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "Hispanic or Latino",
                    "measurements": [
                      { "groupId": "BG000", "value": "8" },
                      { "groupId": "BG001", "value": "11" },
                      { "groupId": "BG002", "value": "19" }
                    ]
                  },
                  {
                    "title": "Not Hispanic or Latino",
                    "measurements": [
                      { "groupId": "BG000", "value": "17" },
                      { "groupId": "BG001", "value": "22" },
                      { "groupId": "BG002", "value": "39" }
                    ]
                  },
                  {
                    "title": "Unknown or Not Reported",
                    "measurements": [
                      { "groupId": "BG000", "value": "2" },
                      { "groupId": "BG001", "value": "0" },
                      { "groupId": "BG002", "value": "2" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Race (NIH/OMB)",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "American Indian or Alaska Native",
                    "measurements": [
                      { "groupId": "BG000", "value": "0" },
                      { "groupId": "BG001", "value": "1" },
                      { "groupId": "BG002", "value": "1" }
                    ]
                  },
                  {
                    "title": "Asian",
                    "measurements": [
                      { "groupId": "BG000", "value": "0" },
                      { "groupId": "BG001", "value": "3" },
                      { "groupId": "BG002", "value": "3" }
                    ]
                  },
                  {
                    "title": "Native Hawaiian or Other Pacific Islander",
                    "measurements": [
                      { "groupId": "BG000", "value": "0" },
                      { "groupId": "BG001", "value": "1" },
                      { "groupId": "BG002", "value": "1" }
                    ]
                  },
                  {
                    "title": "Black or African American",
                    "measurements": [
                      { "groupId": "BG000", "value": "5" },
                      { "groupId": "BG001", "value": "3" },
                      { "groupId": "BG002", "value": "8" }
                    ]
                  },
                  {
                    "title": "White",
                    "measurements": [
                      { "groupId": "BG000", "value": "17" },
                      { "groupId": "BG001", "value": "21" },
                      { "groupId": "BG002", "value": "38" }
                    ]
                  },
                  {
                    "title": "More than one race",
                    "measurements": [
                      { "groupId": "BG000", "value": "2" },
                      { "groupId": "BG001", "value": "1" },
                      { "groupId": "BG002", "value": "3" }
                    ]
                  },
                  {
                    "title": "Unknown or Not Reported",
                    "measurements": [
                      { "groupId": "BG000", "value": "3" },
                      { "groupId": "BG001", "value": "3" },
                      { "groupId": "BG002", "value": "6" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Region of Enrollment",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "title": "United States",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "BG000", "value": "27" },
                      { "groupId": "BG001", "value": "33" },
                      { "groupId": "BG002", "value": "60" }
                    ]
                  }
                ]
              }
            ]
          }
        ]
      },
      "outcomeMeasuresModule": {
        "outcomeMeasures": [
          {
            "type": "PRIMARY",
            "title": "Treatment Adherence/Acceptability Scale",
            "description": "The Treatment Adherence/Acceptability Scale (TAAS) is a 10-item measure of treatment acceptability (e.g., I would recommend this treatment to a friend) and adherence (e.g., I would be able to finish \\[this treatment\\]) that participants rate on a 7-point Likert scale with scores ranging from 10-70. Higher scores indicate higher acceptability.",
            "populationDescription": "This measure was only provided to participants in the active (RISE Guide) condition. Data are reported for all RISE Guide participants who opted to complete the TAAS.",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "1 Week",
            "groups": [
              {
                "id": "OG000",
                "title": "RISE Guide",
                "description": "The RISE (RCT for Innovating Stress-related eHealth) Guide is based on CAST, an anxiety sensitivity intervention effective in reducing anxiety sensitivity, posttraumatic stress, depression, and anxiety. RISE Guide delivers psychoeducation and cognitive-behavioral therapy principles in an interactive, audio-visual format discussing the stress response, myth-busting cognitive distortions related to stress, and facilitating safe exposure to feared sensations. Participants then complete a validated cognitive bias modification (CBM-I) for interpretation biases related to anxiety sensitivity. Finally, intervention principles are reinforced using ecological momentary intervention (EMI), in which surveys and personalized reminders are delivered based on symptoms reported during ecological momentary assessments (EMAs)\n\nRISE Guide delivered by smartphone via Qualtrics and is completed in \\~45 minutes over 2 weeks, with EMI weeks 1-7 post-assault.\n\nRISE Guide: Smartphone-based intervention that uses Cognitive Bias Modification to change perceptions of stress."
              },
              {
                "id": "OG001",
                "title": "Relaxation Control",
                "description": "Breathe2Relax is a mobile application that instructs users on diaphragmatic breathing, a coping tool in which slow breathing through the diaphragm reduces anxiety. Participants in the control condition will download Breathe2Relax to their smartphones and receive short message service (SMS) reminders to engage with the app. The control intervention is expected to reduce symptoms, but not as much as the cognitive-behavioral therapy strategies taught in RISE Guide.\n\nRelaxation Control: Guides users through relaxation techniques."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "17" },
                  { "groupId": "OG001", "value": "0" }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "57.53", "spread": "7.70" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Credibility/Expectancy Questionnaire",
            "description": "Credibility/Expectancy Questionnaire (CEQ; 1 week) 6-item measure of treatment credibility and expectancy of treatment to improve symptoms. Items are rated on 9-to-11-point Likert scales. 11-point scales (0-100% in 10% intervals are recoded to align with the 1-9 scales). Higher scores indicate higher credibility/expectancy. Scores can range from 4 to 56.",
            "populationDescription": "All data collected are reported, some were missing due to attrition. Some participants chose to opt out of certain questionnaires.",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "7 Week",
            "groups": [
              {
                "id": "OG000",
                "title": "RISE Guide",
                "description": "The RISE (RCT for Innovating Stress-related eHealth) Guide is based on CAST, an anxiety sensitivity intervention effective in reducing anxiety sensitivity, posttraumatic stress, depression, and anxiety. RISE Guide delivers psychoeducation and cognitive-behavioral therapy principles in an interactive, audio-visual format discussing the stress response, myth-busting cognitive distortions related to stress, and facilitating safe exposure to feared sensations. Participants then complete a validated cognitive bias modification (CBM-I) for interpretation biases related to anxiety sensitivity. Finally, intervention principles are reinforced using ecological momentary intervention (EMI), in which surveys and personalized reminders are delivered based on symptoms reported during ecological momentary assessments (EMAs)\n\nRISE Guide delivered by smartphone via Qualtrics and is completed in \\~45 minutes over 2 weeks, with EMI weeks 1-7 post-assault.\n\nRISE Guide: Smartphone-based intervention that uses Cognitive Bias Modification to change perceptions of stress."
              },
              {
                "id": "OG001",
                "title": "Relaxation Control",
                "description": "Breathe2Relax is a mobile application that instructs users on diaphragmatic breathing, a coping tool in which slow breathing through the diaphragm reduces anxiety. Participants in the control condition will download Breathe2Relax to their smartphones and receive short message service (SMS) reminders to engage with the app. The control intervention is expected to reduce symptoms, but not as much as the cognitive-behavioral therapy strategies taught in RISE Guide.\n\nRelaxation Control: Guides users through relaxation techniques."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "21" },
                  { "groupId": "OG001", "value": "22" }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "22.85",
                        "spread": "10.98"
                      },
                      {
                        "groupId": "OG001",
                        "value": "18.61",
                        "spread": "13.37"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Treatment Utilization and Acceptability",
            "description": "6 items self-report survey created for the current study on a 5-point Likert scale, such as How often did you log in? How interested were you? and 4 open-ended questions; e.g., What did you like about RISE Guide?; What did you not like? Lower scores indicate higher treatment utilization and acceptability. Scores range from 6-30.",
            "populationDescription": "All data collected are reported, some were missing due to attrition. Some participants chose to opt out of certain questionnaires.",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "7 Week",
            "groups": [
              {
                "id": "OG000",
                "title": "RISE Guide",
                "description": "The RISE (RCT for Innovating Stress-related eHealth) Guide is based on CAST, an anxiety sensitivity intervention effective in reducing anxiety sensitivity, posttraumatic stress, depression, and anxiety. RISE Guide delivers psychoeducation and cognitive-behavioral therapy principles in an interactive, audio-visual format discussing the stress response, myth-busting cognitive distortions related to stress, and facilitating safe exposure to feared sensations. Participants then complete a validated cognitive bias modification (CBM-I) for interpretation biases related to anxiety sensitivity. Finally, intervention principles are reinforced using ecological momentary intervention (EMI), in which surveys and personalized reminders are delivered based on symptoms reported during ecological momentary assessments (EMAs)\n\nRISE Guide delivered by smartphone via Qualtrics and is completed in \\~45 minutes over 2 weeks, with EMI weeks 1-7 post-assault.\n\nRISE Guide: Smartphone-based intervention that uses Cognitive Bias Modification to change perceptions of stress."
              },
              {
                "id": "OG001",
                "title": "Relaxation Control",
                "description": "Breathe2Relax is a mobile application that instructs users on diaphragmatic breathing, a coping tool in which slow breathing through the diaphragm reduces anxiety. Participants in the control condition will download Breathe2Relax to their smartphones and receive short message service (SMS) reminders to engage with the app. The control intervention is expected to reduce symptoms, but not as much as the cognitive-behavioral therapy strategies taught in RISE Guide.\n\nRelaxation Control: Guides users through relaxation techniques."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "22" },
                  { "groupId": "OG001", "value": "19" }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "12.45",
                        "spread": "4.51"
                      },
                      { "groupId": "OG001", "value": "10.89", "spread": "6.58" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Average Number of Participants Successfully Randomized Per Month Over the Entirety of the Study",
            "description": "The purpose of this outcome is to measure feasibility across the entirety of successful recruitment and randomization.",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "Participants recruited and randomized",
            "timeFrame": "From first to last participant approached (up to 20 months)",
            "groups": [
              {
                "id": "OG000",
                "title": "All Participants Enrolled and Randomized",
                "description": "Participants who were enrolled and randomized regardless of treatment condition."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [{ "groupId": "OG000", "value": "60" }]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "2", "spread": "2.52" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Final Proportion of Participants Who Completed Follow-ups",
            "description": "The proportion of participants who complete follow-ups (i.e., 7-week, 6 months) will be used to evaluate feasibility of retaining the target sample (goal retention=75% or higher).",
            "reportingStatus": "POSTED",
            "paramType": "NUMBER",
            "unitOfMeasure": "proportion of participants",
            "timeFrame": "7 Weeks Follow Up, 6 Month Follow Up (up to 7 months)",
            "groups": [
              {
                "id": "OG000",
                "title": "RISE Guide",
                "description": "The RISE (RCT for Innovating Stress-related eHealth) Guide is based on CAST, an anxiety sensitivity intervention effective in reducing anxiety sensitivity, posttraumatic stress, depression, and anxiety. RISE Guide delivers psychoeducation and cognitive-behavioral therapy principles in an interactive, audio-visual format discussing the stress response, myth-busting cognitive distortions related to stress, and facilitating safe exposure to feared sensations. Participants then complete a validated cognitive bias modification (CBM-I) for interpretation biases related to anxiety sensitivity. Finally, intervention principles are reinforced using ecological momentary intervention (EMI), in which surveys and personalized reminders are delivered based on symptoms reported during ecological momentary assessments (EMAs)\n\nRISE Guide delivered by smartphone via Qualtrics and is completed in \\~45 minutes over 2 weeks, with EMI weeks 1-7 post-assault.\n\nRISE Guide: Smartphone-based intervention that uses Cognitive Bias Modification to change perceptions of stress."
              },
              {
                "id": "OG001",
                "title": "Relaxation Control",
                "description": "Breathe2Relax is a mobile application that instructs users on diaphragmatic breathing, a coping tool in which slow breathing through the diaphragm reduces anxiety. Participants in the control condition will download Breathe2Relax to their smartphones and receive short message service (SMS) reminders to engage with the app. The control intervention is expected to reduce symptoms, but not as much as the cognitive-behavioral therapy strategies taught in RISE Guide.\n\nRelaxation Control: Guides users through relaxation techniques."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "27" },
                  { "groupId": "OG001", "value": "33" }
                ]
              }
            ],
            "classes": [
              {
                "title": "7 Weeks",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "0.85" },
                      { "groupId": "OG001", "value": "0.67" }
                    ]
                  }
                ]
              },
              {
                "title": "6 Months",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "0.70" },
                      { "groupId": "OG001", "value": "0.52" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Unexpected Adverse Events by Event",
            "description": "Investigators will examine whether unexpected adverse events occur throughout each participant's participation in the study.",
            "reportingStatus": "POSTED",
            "paramType": "NUMBER",
            "unitOfMeasure": "adverse events",
            "timeFrame": "up to approximately 7 months",
            "groups": [
              {
                "id": "OG000",
                "title": "RISE Guide",
                "description": "The RISE (RCT for Innovating Stress-related eHealth) Guide is based on CAST, an anxiety sensitivity intervention effective in reducing anxiety sensitivity, posttraumatic stress, depression, and anxiety. RISE Guide delivers psychoeducation and cognitive-behavioral therapy principles in an interactive, audio-visual format discussing the stress response, myth-busting cognitive distortions related to stress, and facilitating safe exposure to feared sensations. Participants then complete a validated cognitive bias modification (CBM-I) for interpretation biases related to anxiety sensitivity. Finally, intervention principles are reinforced using ecological momentary intervention (EMI), in which surveys and personalized reminders are delivered based on symptoms reported during ecological momentary assessments (EMAs)\n\nRISE Guide delivered by smartphone via Qualtrics and is completed in \\~45 minutes over 2 weeks, with EMI weeks 1-7 post-assault.\n\nRISE Guide: Smartphone-based intervention that uses Cognitive Bias Modification to change perceptions of stress."
              },
              {
                "id": "OG001",
                "title": "Relaxation Control",
                "description": "Breathe2Relax is a mobile application that instructs users on diaphragmatic breathing, a coping tool in which slow breathing through the diaphragm reduces anxiety. Participants in the control condition will download Breathe2Relax to their smartphones and receive short message service (SMS) reminders to engage with the app. The control intervention is expected to reduce symptoms, but not as much as the cognitive-behavioral therapy strategies taught in RISE Guide.\n\nRelaxation Control: Guides users through relaxation techniques."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "27" },
                  { "groupId": "OG001", "value": "33" }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "0" },
                      { "groupId": "OG001", "value": "0" }
                    ]
                  }
                ]
              }
            ]
          }
        ]
      },
      "adverseEventsModule": {
        "frequencyThreshold": "0",
        "timeFrame": "From the time of signing informed consent through 6-month follow-up, up to 7 months total.",
        "eventGroups": [
          {
            "id": "EG000",
            "title": "RISE Guide",
            "description": "The RISE (RCT for Innovating Stress-related eHealth) Guide is based on CAST, an anxiety sensitivity intervention effective in reducing anxiety sensitivity, posttraumatic stress, depression, and anxiety. RISE Guide delivers psychoeducation and cognitive-behavioral therapy principles in an interactive, audio-visual format discussing the stress response, myth-busting cognitive distortions related to stress, and facilitating safe exposure to feared sensations. Participants then complete a validated cognitive bias modification (CBM-I) for interpretation biases related to anxiety sensitivity. Finally, intervention principles are reinforced using ecological momentary intervention (EMI), in which surveys and personalized reminders are delivered based on symptoms reported during ecological momentary assessments (EMAs)\n\nRISE Guide delivered by smartphone via Qualtrics and is completed in \\~45 minutes over 2 weeks, with EMI weeks 1-7 post-assault.\n\nRISE Guide: Smartphone-based intervention that uses Cognitive Bias Modification to change perceptions of stress.",
            "deathsNumAffected": 0,
            "deathsNumAtRisk": 27,
            "seriousNumAffected": 0,
            "seriousNumAtRisk": 27,
            "otherNumAffected": 0,
            "otherNumAtRisk": 27
          },
          {
            "id": "EG001",
            "title": "Relaxation Control",
            "description": "Breathe2Relax is a mobile application that instructs users on diaphragmatic breathing, a coping tool in which slow breathing through the diaphragm reduces anxiety. Participants in the control condition will download Breathe2Relax to their smartphones and receive short message service (SMS) reminders to engage with the app. The control intervention is expected to reduce symptoms, but not as much as the cognitive-behavioral therapy strategies taught in RISE Guide.\n\nRelaxation Control: Guides users through relaxation techniques.",
            "deathsNumAffected": 0,
            "deathsNumAtRisk": 33,
            "seriousNumAffected": 0,
            "seriousNumAtRisk": 33,
            "otherNumAffected": 0,
            "otherNumAtRisk": 33
          }
        ]
      },
      "moreInfoModule": {
        "certainAgreement": { "piSponsorEmployee": true },
        "pointOfContact": {
          "title": "Nicole Short, PhD",
          "organization": "University of North Carolina at Chapel Hill",
          "email": "nicole.short@unlv.edu",
          "phone": "702-895-3305"
        }
      }
    },
    "documentSection": {
      "largeDocumentModule": {
        "largeDocs": [
          {
            "typeAbbrev": "Prot_SAP",
            "hasProtocol": true,
            "hasSap": true,
            "hasIcf": false,
            "label": "Study Protocol and Statistical Analysis Plan",
            "date": "2024-11-27",
            "uploadDate": "2024-12-12T15:54",
            "filename": "Prot_SAP_000.pdf",
            "size": 1617418
          }
        ]
      }
    },
    "derivedSection": {
      "miscInfoModule": {
        "versionHolder": "2025-05-07",
        "submissionTracking": {
          "firstMcpInfo": {
            "postDateStruct": { "date": "2025-01-08", "type": "ACTUAL" }
          }
        }
      },
      "conditionBrowseModule": {
        "meshes": [
          { "id": "D013313", "term": "Stress Disorders, Post-Traumatic" }
        ],
        "ancestors": [
          { "id": "D040921", "term": "Stress Disorders, Traumatic" },
          {
            "id": "D000068099",
            "term": "Trauma and Stressor Related Disorders"
          },
          { "id": "D001523", "term": "Mental Disorders" }
        ],
        "browseLeaves": [
          { "id": "M13066", "name": "Pain", "relevance": "LOW" },
          { "id": "M7796", "name": "Emergencies", "relevance": "LOW" },
          { "id": "M10018", "name": "Hypersensitivity", "relevance": "LOW" },
          {
            "id": "M16103",
            "name": "Stress Disorders, Post-Traumatic",
            "asFound": "Posttraumatic Stress Disorder",
            "relevance": "HIGH"
          },
          { "id": "M4324", "name": "Anxiety Disorders", "relevance": "LOW" },
          {
            "id": "M24916",
            "name": "Stress Disorders, Traumatic",
            "relevance": "LOW"
          },
          { "id": "M17685", "name": "Wounds and Injuries", "relevance": "LOW" },
          {
            "id": "M222",
            "name": "Trauma and Stressor Related Disorders",
            "relevance": "LOW"
          },
          { "id": "M14473", "name": "Psychotic Disorders", "relevance": "LOW" },
          { "id": "M4815", "name": "Mental Disorders", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "BC23", "name": "Symptoms and General Pathology" },
          { "abbrev": "All", "name": "All Conditions" },
          { "abbrev": "BC20", "name": "Immune System Diseases" },
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" },
          { "abbrev": "BC26", "name": "Wounds and Injuries" }
        ]
      }
    },
    "hasResults": true
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT04524598",
        "orgStudyIdInfo": { "id": "Limbix Spark 02" },
        "organization": {
          "fullName": "Limbix Health, Inc.",
          "class": "INDUSTRY"
        },
        "briefTitle": "A CBT-based Mobile Intervention as First Line Treatment for Adolescent Depression During COVID-19",
        "officialTitle": "Limbix Spark: A CBT-based Mobile Intervention as First Line Treatment for Adolescent Depression During COVID-19"
      },
      "statusModule": {
        "statusVerifiedDate": "2023-04",
        "overallStatus": "COMPLETED",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2020-07-20", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2021-09-03",
          "type": "ACTUAL"
        },
        "completionDateStruct": { "date": "2022-01-16", "type": "ACTUAL" },
        "studyFirstSubmitDate": "2020-08-20",
        "studyFirstSubmitQcDate": "2020-08-20",
        "studyFirstPostDateStruct": { "date": "2020-08-24", "type": "ACTUAL" },
        "resultsFirstSubmitDate": "2021-09-30",
        "resultsFirstSubmitQcDate": "2021-12-09",
        "resultsFirstPostDateStruct": {
          "date": "2021-12-13",
          "type": "ACTUAL"
        },
        "lastUpdateSubmitDate": "2023-04-25",
        "lastUpdatePostDateStruct": { "date": "2023-05-18", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": { "name": "Limbix Health, Inc.", "class": "INDUSTRY" }
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": true,
        "isUnapprovedDevice": true,
        "isUsExport": true
      },
      "descriptionModule": {
        "briefSummary": "Over 3 million teenagers in the USA have depression, and rates of depression and suicide are sharply increasing. Teenage depression has far-reaching consequences including impairments in academic and work performance and social and family relationships, substance abuse, and worsening of other health conditions, which can persist into adulthood. Access to mental health care for teenagers is limited due to a shortage of mental health providers and many teenagers and parents are reluctant to take antidepressants. COVID-19 and mandated physical and social distancing is expected to increase rates of teenage depression, and further limit access to traditional methods of care (e.g. psychotherapy). This highlights an urgent need to develop accessible, digital treatments for teenage depression to address the serious mental health impacts of the COVID-19 pandemic. This fully virtual study (https://www.limbix.com/spark) will compare the relative safety, effectiveness, and engagement of a mobile application based on cognitive behavioral therapy and behavioral activation (Limbix Spark), focusing on the idea that engaging in behaviors that are rewarding or provide a sense of mastery can be effective in reducing symptoms of depression. Limbix Spark will be compared to a mobile app containing educational material about depression (Psychoeducation).",
        "detailedDescription": "Depression in adolescence is a public health crisis, with incidence and suicide rates rising sharply over the past decade. The COVID-19 global pandemic, along with mandated social and physical distancing, is expected to have substantial repercussions on public mental health and exacerbate the mental health crisis among teens. Adolescents, a group with significant unmet mental health needs, are at risk during this time, as they are especially vulnerable to depression and suicidality following environmental stressors, trauma, and social isolation that are endemic to this global pandemic. With difficulties in receiving in person care magnified during social distancing, now more than ever, there is an immediate need for safe, accessible, and effective digital treatments for mental health disorders.\n\nThe proposed intervention is intended to increase access to mental health care during the COVID-19 pandemic. This study aims to evaluate the clinical effectiveness and safety of a cognitive behavioral therapy (CBT)- based digital treatment for adolescent depression (Limbix Spark) relative to psychoeducation. Limbix Spark implements behavioral activation (BA), a key CBT skill that provides a sense of pleasure or mastery through self-monitored activities to reduce depressive symptoms and improve functional outcomes.\n\nAdolescents with depression (13-21 years old) across the country will be recruited to participate in a fully remote, clinical trial via https://www.limbix.com/spark. At an initial virtual visit, following informed consent, adolescents and parents (for those under 18) will fill out standardized questionnaires designed to measure symptoms of depression, anxiety, and general health. Participants will then download an app onto their mobile phone and be randomly assigned to one of two groups. One group will receive the Limbix Spark program and the other will receive the Psychoeducation program for 5 weeks. The Limbix Spark program is divided into 5 levels. Each level provides educational information about cognitive behavioral therapy and behavioral activation, and interactive activities including mood tracking and activity scheduling. The Psychoeducation program is divided into 5 lessons. Each lesson covers a different topic about depression. During both 5 week programs, patients will also complete a weekly Patient Health Questionnaire, which is designed to measure depressive symptoms and also will report any negative side effects they may be experiencing. After 5 weeks, participants and legal guardians (for those under 18) will complete another set of standardized questionnaires designed to measure symptoms of depression, anxiety, and general health. Patients will also complete questionnaires asking them about their thoughts and experiences with the program they just completed. Lastly, a subset of patients and parents will be invited to complete a virtual interview to provide feedback on using the program.\n\nThe trial will be divided into two phases. The first phase will enroll 60 participants and participants will be randomized to either Spark and Control groups as described above. The second phase will enroll 175 participants and those randomized into the control group will be given access to the 5-week Spark intervention after completing the 5 weeks of control condition (control extension arm). Once completing the control extension arm, participants will complete a second set of post study questionnaires after 5 weeks.\n\nAll study participants that complete the 5-week Limbix Spark program and the post study questionnaires will be contacted and asked to consent to participation in the follow-up study. Only participants who did not opt-out to being contacted for future research will be contacted. This study will collect questionnaires from participants at any or all of the following time frames as indicated: 1-month, 3-month, and 6-month following completion of the Spark arm."
      },
      "conditionsModule": {
        "conditions": ["Depression"],
        "keywords": [
          "Adolescence",
          "Digital Therapeutic",
          "Cognitive Behavioral Therapy",
          "Behavioral Activation"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": { "masking": "NONE" }
        },
        "enrollmentInfo": { "count": 227, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "Limbix Spark",
            "type": "EXPERIMENTAL",
            "description": "A 5 week CBT-based intervention",
            "interventionNames": ["Device: Limbix Spark"]
          },
          {
            "label": "Psychoeducation",
            "type": "ACTIVE_COMPARATOR",
            "description": "5 weeks of psychoeducation about depression. Upon completion, participants will be automatically enrolled into the Limbix Spark CBT-based intervention",
            "interventionNames": ["Other: Psychoeducation"]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "Limbix Spark",
            "description": "The Limbix Spark program is divided into 5 levels. Each level provides educational information about cognitive behavioral therapy and interactive activities.",
            "armGroupLabels": ["Limbix Spark"]
          },
          {
            "type": "OTHER",
            "name": "Psychoeducation",
            "description": "The Psychoeducation program is divided into 5 lessons. Each lesson covers a different topic about depression.",
            "armGroupLabels": ["Psychoeducation"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Phase I - Feasibility (Eligibility)",
            "description": "Descriptive report of participant eligibility. Percentage of people who enrolled in each arm after expressing interest in participating in the study. Phase I participant arms are reported for this outcome.",
            "timeFrame": "Pre-enrollment"
          },
          {
            "measure": "Number of Participants With Willingness to Participate and Program Adherence",
            "description": "Descriptive report of willingness to participate and program adherence. Phase I participant arms are reported for this outcome.",
            "timeFrame": "From Baseline to Post Treatment (Week 5)"
          },
          {
            "measure": "Phase I - Feasibility (Satisfaction)",
            "description": "Descriptive report of participant satisfaction (mood improvement and enjoyment) on a scale of 0-10, with 0 meaning lower satisfaction and 10 meaning higher satisfaction. Phase I participant arms are reported for this outcome.",
            "timeFrame": "Post-Treatment -\"Week 5\""
          },
          {
            "measure": "Phase I - Feasibility (Safety)",
            "description": "Descriptive report of participant safety. Phase I participant arms are reported for this outcome.",
            "timeFrame": "From Baseline to Post Treatment (Week 5)"
          },
          {
            "measure": "Phase II - Change in Depressive Symptoms",
            "description": "Between-subjects treatment-related change in depressive symptoms from baseline to 5-weeks as measured by Personal Health Questionnaire (PHQ-8) (min: 0; max: 24, with higher score indicating more severe depression) for those with baseline PHQ-8 ≥10.",
            "timeFrame": "Change from Baseline to Post treatment (5 weeks)"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Phase I - Change in Depression Symptoms",
            "description": "Between-subjects treatment-related change in depressive symptoms from baseline to 5-weeks as measured by Personal Health Questionnaire (PHQ-8) (min: 0; max: 24, with higher score indicating more severe depression) for those with baseline PHQ-8 ≥5. Only Phase I participants were included in this Outcome measure.",
            "timeFrame": "From Baseline to Post Treatment (Week 5)"
          },
          {
            "measure": "Number of Participants in Remission",
            "description": "Remission rates based on PHQ-8 \\< 10 (sub-analysis for those with baseline PHQ-8 ≥ 10). Phase I and Phase II participant arms are reported for this outcome.",
            "timeFrame": "From Baseline to Post Treatment (Week 5)"
          },
          {
            "measure": "Change in Participant-rated Anxiety Symptoms and Global Functioning",
            "description": "Between-subjects treatment-related change in participant-rated anxiety symptoms and global functioning as measured by GAD-7 Anxiety and PROMIS Pediatric Global Health Scale.\n\nThe GAD-7 Anxiety is a brief 7-item assessment for generalized anxiety disorder. Values range from 0-21, with higher scores representing more severe anxiety.\n\nThe PROMIS Pediatric Global Health Scale is a 7-item assessment for perceived physical, mental, and social health. Values range from 7-35, with higher scores representing better health.\n\nPhase I and Phase II participant arms are reported for this Outcome. Statistical Analyses are presented for Phase II results only because Phase I was intentionally not powered for analysis.",
            "timeFrame": "From Baseline to Post Treatment (Week 5)"
          },
          {
            "measure": "Change in Parent-reported Depressive Symptoms and Global Functioning.",
            "description": "Between-subjects treatment-related change in parent-reported depressive symptoms and global functioning as measured by Mood and Feelings Questionnaire (MFQ-PS), and PROMIS Parent Proxy Global Health Scale.\n\nThe MFQ-PS consists of a series of 13 descriptive phrases regarding how the subject has been feeling or acting in the past two weeks and is a screening tool for depression in children and young people. Values range from 0-26, with higher scores representing more severe symptoms.\n\nThe PROMIS Parent Proxy Global Health Scale is a 7-item assessment for perceived physical, mental, and social health. Values range from 7-35, with higher scores representing better health.\n\nPhase I and Phase II participant arms are reported for this Outcome. Statistical Analyses are presented for Phase II results only because Phase I was intentionally not powered for analysis.",
            "timeFrame": "From Baseline to Post Treatment (Week 5)"
          },
          {
            "measure": "Average Treatment-related Usability and Engagement Ratings",
            "description": "Average treatment-related usability (System Usability Scale; SUS) and engagement (User Engagement Scale-Short Form; UES-SF) ratings. Phase I and Phase II participant arms are reported for this outcome.\n\nThe SUS is a 10-item questionnaire measuring the usability of systems. Responses range from Strongly Agree to Strongly Disagree. Scores are percentile rankings and range from 0-100. Higher scores represent higher usability.\n\nThe UES-SF is a 12-item questionnaire measuring self-reported user-engagement. The form uses a 5-point Likert scale. Overall engagement scores range from 1-5. Higher scores represent more engagement.",
            "timeFrame": "Post-Treatment"
          },
          {
            "measure": "Phase II - Safety",
            "description": "Between-group treatment-related differences in clinical concern rates and serious clinical concerns. Phase II participant arms are reported for this outcome.",
            "timeFrame": "From Baseline to Post Treatment (Week 5)"
          },
          {
            "measure": "App Engagement and Adherence",
            "description": "Between-group treatment-related differences in program adherence and engagement based on behavioral and mobile app analytics. Phase I and Phase II Spark participant arms are reported for this outcome. We are reporting the average number of app modules completed (out of 5 total modules).",
            "timeFrame": "From Baseline to Post Treatment (Week 5)"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* Between the ages of 13 and 21\n* Self-reported symptoms of depression\n* Will be residing in the USA for the duration of the 5-week study\n* Under the care of a US-based primary care and/or licensed mental healthcare provider and willing and able to provide the name and contact information of the provider during consent appointment.\n* English fluency and literacy of adolescent and consenting legal guardian if under 18\n* Access to a smartphone (iPhone 5s or later or running Android 4.4 KitKat or later) and regular internet access\n* Willing to provide informed e-consent/assent and have legal guardian willing to provide informed e-consent if under 18.\n\nExclusion Criteria:\n\n* Self-reported lifetime suicide attempt or active self-harm or active suicidal ideation with intent\n* Have a diagnosis by a clinician of bipolar disorder, substance use disorder, or any psychotic disorder including schizophrenia\n* Incapable of understanding or completing study procedures and digital intervention as determined by participant, patient/legal guardian, healthcare provider, or clinical research team",
        "healthyVolunteers": true,
        "sex": "ALL",
        "minimumAge": "13 Years",
        "maximumAge": "21 Years",
        "stdAges": ["CHILD", "ADULT"]
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "Jessica Lake, PhD",
            "affiliation": "Director of Research",
            "role": "PRINCIPAL_INVESTIGATOR"
          },
          {
            "name": "Aarthi Padmanabhan, Phd",
            "affiliation": "Research Director",
            "role": "PRINCIPAL_INVESTIGATOR"
          }
        ],
        "locations": [
          {
            "facility": "Limbix Health, Inc.",
            "city": "San Francisco",
            "state": "California",
            "zip": "94104",
            "country": "United States",
            "geoPoint": { "lat": 37.77493, "lon": -122.41942 }
          }
        ]
      },
      "ipdSharingStatementModule": { "ipdSharing": "NO" }
    },
    "resultsSection": {
      "participantFlowModule": {
        "groups": [
          {
            "id": "FG000",
            "title": "Limbix Spark - Phase I",
            "description": "A 5 week CBT-based intervention\n\nLimbix Spark: The Limbix Spark program is divided into 5 levels. Each level provides educational information about cognitive behavioral therapy and interactive activities."
          },
          {
            "id": "FG001",
            "title": "Psychoeducation - Phase I",
            "description": "5 weeks of psychoeducation about depression. Upon completion, participants will be automatically enrolled into the Limbix Spark CBT-based intervention\n\nPsychoeducation: The Psychoeducation program is divided into 5 lessons. Each lesson covers a different topic about depression."
          },
          {
            "id": "FG002",
            "title": "Limbix Spark - Phase II",
            "description": "A 5 week CBT-based intervention\n\nLimbix Spark: The Limbix Spark program is divided into 5 levels. Each level provides educational information about cognitive behavioral therapy and interactive activities."
          },
          {
            "id": "FG003",
            "title": "Psychoeducation - Phase II",
            "description": "5 weeks of psychoeducation about depression. Upon completion, participants will be automatically enrolled into the Limbix Spark CBT-based intervention\n\nPsychoeducation: The Psychoeducation program is divided into 5 lessons. Each lesson covers a different topic about depression."
          },
          {
            "id": "FG004",
            "title": "Control Extension - Phase II",
            "description": "Participants who were initially assigned to the Psychoeducation control arm were given the opportunity to then complete the 5 week CBT-based intervention, Limbix Spark.\n\nLimbix Spark: The Limbix Spark program is divided into 5 levels. Each level provides educational information about cognitive behavioral therapy and interactive activities."
          }
        ],
        "periods": [
          {
            "title": "Phase I - Feasibility",
            "milestones": [
              {
                "type": "STARTED",
                "achievements": [
                  { "groupId": "FG000", "numSubjects": "35" },
                  { "groupId": "FG001", "numSubjects": "25" },
                  { "groupId": "FG002", "numSubjects": "0" },
                  { "groupId": "FG003", "numSubjects": "0" },
                  { "groupId": "FG004", "numSubjects": "0" }
                ]
              },
              {
                "type": "COMPLETED",
                "achievements": [
                  { "groupId": "FG000", "numSubjects": "31" },
                  { "groupId": "FG001", "numSubjects": "20" },
                  { "groupId": "FG002", "numSubjects": "0" },
                  { "groupId": "FG003", "numSubjects": "0" },
                  { "groupId": "FG004", "numSubjects": "0" }
                ]
              },
              {
                "type": "NOT COMPLETED",
                "achievements": [
                  { "groupId": "FG000", "numSubjects": "4" },
                  { "groupId": "FG001", "numSubjects": "5" },
                  { "groupId": "FG002", "numSubjects": "0" },
                  { "groupId": "FG003", "numSubjects": "0" },
                  { "groupId": "FG004", "numSubjects": "0" }
                ]
              }
            ],
            "dropWithdraws": [
              {
                "type": "Lost to Follow-up",
                "reasons": [
                  { "groupId": "FG000", "numSubjects": "2" },
                  { "groupId": "FG001", "numSubjects": "4" },
                  { "groupId": "FG002", "numSubjects": "0" },
                  { "groupId": "FG003", "numSubjects": "0" },
                  { "groupId": "FG004", "numSubjects": "0" }
                ]
              },
              {
                "type": "Dropped for missing two consecutive weekly safety check-ins.",
                "reasons": [
                  { "groupId": "FG000", "numSubjects": "2" },
                  { "groupId": "FG001", "numSubjects": "1" },
                  { "groupId": "FG002", "numSubjects": "0" },
                  { "groupId": "FG003", "numSubjects": "0" },
                  { "groupId": "FG004", "numSubjects": "0" }
                ]
              }
            ]
          },
          {
            "title": "Phase II - Outcomes",
            "milestones": [
              {
                "type": "STARTED",
                "achievements": [
                  { "groupId": "FG000", "numSubjects": "0" },
                  { "groupId": "FG001", "numSubjects": "0" },
                  { "groupId": "FG002", "numSubjects": "80" },
                  { "groupId": "FG003", "numSubjects": "80" },
                  { "groupId": "FG004", "numSubjects": "0" }
                ]
              },
              {
                "type": "Met PHQ-8 Threshold (Baseline >/= 10)",
                "comment": "Participants who met this threshold were included in the intention-to-treat analysis and the per protocol analyses.",
                "achievements": [
                  { "groupId": "FG000", "numSubjects": "0" },
                  { "groupId": "FG001", "numSubjects": "0" },
                  { "groupId": "FG002", "numSubjects": "63" },
                  { "groupId": "FG003", "numSubjects": "58" },
                  { "groupId": "FG004", "numSubjects": "0" }
                ]
              },
              {
                "type": "COMPLETED",
                "achievements": [
                  { "groupId": "FG000", "numSubjects": "0" },
                  { "groupId": "FG001", "numSubjects": "0" },
                  { "groupId": "FG002", "numSubjects": "54" },
                  { "groupId": "FG003", "numSubjects": "67" },
                  { "groupId": "FG004", "numSubjects": "0" }
                ]
              },
              {
                "type": "NOT COMPLETED",
                "achievements": [
                  { "groupId": "FG000", "numSubjects": "0" },
                  { "groupId": "FG001", "numSubjects": "0" },
                  { "groupId": "FG002", "numSubjects": "26" },
                  { "groupId": "FG003", "numSubjects": "13" },
                  { "groupId": "FG004", "numSubjects": "0" }
                ]
              }
            ],
            "dropWithdraws": [
              {
                "type": "Lost to Follow-up",
                "reasons": [
                  { "groupId": "FG000", "numSubjects": "0" },
                  { "groupId": "FG001", "numSubjects": "0" },
                  { "groupId": "FG002", "numSubjects": "16" },
                  { "groupId": "FG003", "numSubjects": "8" },
                  { "groupId": "FG004", "numSubjects": "0" }
                ]
              },
              {
                "type": "Withdrawal by Subject",
                "reasons": [
                  { "groupId": "FG000", "numSubjects": "0" },
                  { "groupId": "FG001", "numSubjects": "0" },
                  { "groupId": "FG002", "numSubjects": "2" },
                  { "groupId": "FG003", "numSubjects": "0" },
                  { "groupId": "FG004", "numSubjects": "0" }
                ]
              },
              {
                "type": "Dropped for missing two consecutive weekly safety check-ins.",
                "reasons": [
                  { "groupId": "FG000", "numSubjects": "0" },
                  { "groupId": "FG001", "numSubjects": "0" },
                  { "groupId": "FG002", "numSubjects": "8" },
                  { "groupId": "FG003", "numSubjects": "5" },
                  { "groupId": "FG004", "numSubjects": "0" }
                ]
              }
            ]
          },
          {
            "title": "Phase II - Control Extension",
            "milestones": [
              {
                "type": "STARTED",
                "achievements": [
                  { "groupId": "FG000", "numSubjects": "0" },
                  { "groupId": "FG001", "numSubjects": "0" },
                  { "groupId": "FG002", "numSubjects": "0" },
                  { "groupId": "FG003", "numSubjects": "0" },
                  { "groupId": "FG004", "numSubjects": "66" }
                ]
              },
              {
                "type": "COMPLETED",
                "achievements": [
                  { "groupId": "FG000", "numSubjects": "0" },
                  { "groupId": "FG001", "numSubjects": "0" },
                  { "groupId": "FG002", "numSubjects": "0" },
                  { "groupId": "FG003", "numSubjects": "0" },
                  { "groupId": "FG004", "numSubjects": "54" }
                ]
              },
              {
                "type": "NOT COMPLETED",
                "achievements": [
                  { "groupId": "FG000", "numSubjects": "0" },
                  { "groupId": "FG001", "numSubjects": "0" },
                  { "groupId": "FG002", "numSubjects": "0" },
                  { "groupId": "FG003", "numSubjects": "0" },
                  { "groupId": "FG004", "numSubjects": "12" }
                ]
              }
            ],
            "dropWithdraws": [
              {
                "type": "Lost to Follow-up",
                "reasons": [
                  { "groupId": "FG000", "numSubjects": "0" },
                  { "groupId": "FG001", "numSubjects": "0" },
                  { "groupId": "FG002", "numSubjects": "0" },
                  { "groupId": "FG003", "numSubjects": "0" },
                  { "groupId": "FG004", "numSubjects": "6" }
                ]
              },
              {
                "type": "Dropped for missing two consecutive weekly safety check-ins.",
                "reasons": [
                  { "groupId": "FG000", "numSubjects": "0" },
                  { "groupId": "FG001", "numSubjects": "0" },
                  { "groupId": "FG002", "numSubjects": "0" },
                  { "groupId": "FG003", "numSubjects": "0" },
                  { "groupId": "FG004", "numSubjects": "6" }
                ]
              }
            ]
          }
        ]
      },
      "baselineCharacteristicsModule": {
        "groups": [
          {
            "id": "BG000",
            "title": "Limbix Spark - Phase I",
            "description": "A 5 week CBT-based intervention\n\nLimbix Spark: The Limbix Spark program is divided into 5 levels. Each level provides educational information about cognitive behavioral therapy and interactive activities."
          },
          {
            "id": "BG001",
            "title": "Psychoeducation - Phase I",
            "description": "5 weeks of psychoeducation about depression. Upon completion, participants will be automatically enrolled into the Limbix Spark CBT-based intervention\n\nPsychoeducation: The Psychoeducation program is divided into 5 lessons. Each lesson covers a different topic about depression."
          },
          {
            "id": "BG002",
            "title": "Limbix Spark - Phase II",
            "description": "A 5 week CBT-based intervention\n\nLimbix Spark: The Limbix Spark program is divided into 5 levels. Each level provides educational information about cognitive behavioral therapy and interactive activities."
          },
          {
            "id": "BG003",
            "title": "Psychoeducation/Control Extension - Phase II",
            "description": "5 weeks of psychoeducation about depression. Upon completion, participants will be automatically enrolled into the Limbix Spark CBT-based intervention\n\nPsychoeducation: The Psychoeducation program is divided into 5 lessons. Each lesson covers a different topic about depression.\n\nParticipants who were initially assigned to the Psychoeducation control arm were given the opportunity to then complete the 5 week CBT-based intervention, Limbix Spark.\n\nLimbix Spark: The Limbix Spark program is divided into 5 levels. Each level provides educational information about cognitive behavioral therapy and interactive activities."
          },
          {
            "id": "BG004",
            "title": "Total",
            "description": "Total of all reporting groups"
          }
        ],
        "denoms": [
          {
            "units": "Participants",
            "counts": [
              { "groupId": "BG000", "value": "35" },
              { "groupId": "BG001", "value": "25" },
              { "groupId": "BG002", "value": "63" },
              { "groupId": "BG003", "value": "58" },
              { "groupId": "BG004", "value": "181" }
            ]
          }
        ],
        "measures": [
          {
            "title": "Age, Categorical",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "<=18 years",
                    "measurements": [
                      { "groupId": "BG000", "value": "18" },
                      { "groupId": "BG001", "value": "17" },
                      { "groupId": "BG002", "value": "33" },
                      { "groupId": "BG003", "value": "35" },
                      { "groupId": "BG004", "value": "103" }
                    ]
                  },
                  {
                    "title": "Between 18 and 65 years",
                    "measurements": [
                      { "groupId": "BG000", "value": "17" },
                      { "groupId": "BG001", "value": "8" },
                      { "groupId": "BG002", "value": "30" },
                      { "groupId": "BG003", "value": "23" },
                      { "groupId": "BG004", "value": "78" }
                    ]
                  },
                  {
                    "title": ">=65 years",
                    "measurements": [
                      { "groupId": "BG000", "value": "0" },
                      { "groupId": "BG001", "value": "0" },
                      { "groupId": "BG002", "value": "0" },
                      { "groupId": "BG003", "value": "0" },
                      { "groupId": "BG004", "value": "0" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Age, Continuous",
            "paramType": "MEAN",
            "dispersionType": "STANDARD_DEVIATION",
            "unitOfMeasure": "years",
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "BG000", "value": "18", "spread": "2.36" },
                      { "groupId": "BG001", "value": "17", "spread": "2.57" },
                      {
                        "groupId": "BG002",
                        "value": "17.06",
                        "spread": "2.49"
                      },
                      {
                        "groupId": "BG003",
                        "value": "16.46",
                        "spread": "2.43"
                      },
                      { "groupId": "BG004", "value": "16.78", "spread": "2.47" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Sex/Gender, Customized",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "title": "Participant Reported Gender",
                "categories": [
                  {
                    "title": "Female",
                    "measurements": [
                      { "groupId": "BG000", "value": "28" },
                      { "groupId": "BG001", "value": "19" },
                      { "groupId": "BG002", "value": "42" },
                      { "groupId": "BG003", "value": "39" },
                      { "groupId": "BG004", "value": "128" }
                    ]
                  },
                  {
                    "title": "Male",
                    "measurements": [
                      { "groupId": "BG000", "value": "6" },
                      { "groupId": "BG001", "value": "5" },
                      { "groupId": "BG002", "value": "16" },
                      { "groupId": "BG003", "value": "10" },
                      { "groupId": "BG004", "value": "37" }
                    ]
                  },
                  {
                    "title": "Non-Binary",
                    "measurements": [
                      { "groupId": "BG000", "value": "1" },
                      { "groupId": "BG001", "value": "1" },
                      { "groupId": "BG002", "value": "5" },
                      { "groupId": "BG003", "value": "9" },
                      { "groupId": "BG004", "value": "16" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Ethnicity (NIH/OMB)",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "Hispanic or Latino",
                    "measurements": [
                      { "groupId": "BG000", "value": "6" },
                      { "groupId": "BG001", "value": "4" },
                      { "groupId": "BG002", "value": "11" },
                      { "groupId": "BG003", "value": "8" },
                      { "groupId": "BG004", "value": "29" }
                    ]
                  },
                  {
                    "title": "Not Hispanic or Latino",
                    "measurements": [
                      { "groupId": "BG000", "value": "29" },
                      { "groupId": "BG001", "value": "21" },
                      { "groupId": "BG002", "value": "46" },
                      { "groupId": "BG003", "value": "47" },
                      { "groupId": "BG004", "value": "143" }
                    ]
                  },
                  {
                    "title": "Unknown or Not Reported",
                    "measurements": [
                      { "groupId": "BG000", "value": "0" },
                      { "groupId": "BG001", "value": "0" },
                      { "groupId": "BG002", "value": "6" },
                      { "groupId": "BG003", "value": "3" },
                      { "groupId": "BG004", "value": "9" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Race (NIH/OMB)",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "American Indian or Alaska Native",
                    "measurements": [
                      { "groupId": "BG000", "value": "1" },
                      { "groupId": "BG001", "value": "0" },
                      { "groupId": "BG002", "value": "1" },
                      { "groupId": "BG003", "value": "2" },
                      { "groupId": "BG004", "value": "4" }
                    ]
                  },
                  {
                    "title": "Asian",
                    "measurements": [
                      { "groupId": "BG000", "value": "7" },
                      { "groupId": "BG001", "value": "4" },
                      { "groupId": "BG002", "value": "4" },
                      { "groupId": "BG003", "value": "0" },
                      { "groupId": "BG004", "value": "15" }
                    ]
                  },
                  {
                    "title": "Native Hawaiian or Other Pacific Islander",
                    "measurements": [
                      { "groupId": "BG000", "value": "0" },
                      { "groupId": "BG001", "value": "0" },
                      { "groupId": "BG002", "value": "0" },
                      { "groupId": "BG003", "value": "0" },
                      { "groupId": "BG004", "value": "0" }
                    ]
                  },
                  {
                    "title": "Black or African American",
                    "measurements": [
                      { "groupId": "BG000", "value": "2" },
                      { "groupId": "BG001", "value": "3" },
                      { "groupId": "BG002", "value": "3" },
                      { "groupId": "BG003", "value": "2" },
                      { "groupId": "BG004", "value": "10" }
                    ]
                  },
                  {
                    "title": "White",
                    "measurements": [
                      { "groupId": "BG000", "value": "20" },
                      { "groupId": "BG001", "value": "17" },
                      { "groupId": "BG002", "value": "47" },
                      { "groupId": "BG003", "value": "45" },
                      { "groupId": "BG004", "value": "129" }
                    ]
                  },
                  {
                    "title": "More than one race",
                    "measurements": [
                      { "groupId": "BG000", "value": "3" },
                      { "groupId": "BG001", "value": "1" },
                      { "groupId": "BG002", "value": "8" },
                      { "groupId": "BG003", "value": "8" },
                      { "groupId": "BG004", "value": "20" }
                    ]
                  },
                  {
                    "title": "Unknown or Not Reported",
                    "measurements": [
                      { "groupId": "BG000", "value": "2" },
                      { "groupId": "BG001", "value": "0" },
                      { "groupId": "BG002", "value": "0" },
                      { "groupId": "BG003", "value": "1" },
                      { "groupId": "BG004", "value": "3" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Region of Enrollment",
            "paramType": "NUMBER",
            "unitOfMeasure": "participants",
            "classes": [
              {
                "title": "United States",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "BG000", "value": "35" },
                      { "groupId": "BG001", "value": "25" },
                      { "groupId": "BG002", "value": "63" },
                      { "groupId": "BG003", "value": "58" },
                      { "groupId": "BG004", "value": "121" }
                    ]
                  }
                ]
              }
            ]
          }
        ]
      },
      "outcomeMeasuresModule": {
        "outcomeMeasures": [
          {
            "type": "PRIMARY",
            "title": "Phase I - Feasibility (Eligibility)",
            "description": "Descriptive report of participant eligibility. Percentage of people who enrolled in each arm after expressing interest in participating in the study. Phase I participant arms are reported for this outcome.",
            "populationDescription": "People who expressed interest in participating in the study.",
            "reportingStatus": "POSTED",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "timeFrame": "Pre-enrollment",
            "groups": [
              {
                "id": "OG000",
                "title": "Number of Potentially Eligible Participants",
                "description": "The number of participants who expressed interest in participating in the study"
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [{ "groupId": "OG000", "value": "150" }]
              }
            ],
            "classes": [
              {
                "title": "Limbix Spark - Phase I",
                "categories": [
                  { "measurements": [{ "groupId": "OG000", "value": "35" }] }
                ]
              },
              {
                "title": "Psychoeducation - Phase I",
                "categories": [
                  { "measurements": [{ "groupId": "OG000", "value": "25" }] }
                ]
              }
            ]
          },
          {
            "type": "PRIMARY",
            "title": "Number of Participants With Willingness to Participate and Program Adherence",
            "description": "Descriptive report of willingness to participate and program adherence. Phase I participant arms are reported for this outcome.",
            "populationDescription": "Phase I participant arms are reported for this outcome because this was an a priori primary outcome for Phase I. Due to programming of the app, module completion was not tracked in the psychoeducation arm of the study.",
            "reportingStatus": "POSTED",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "timeFrame": "From Baseline to Post Treatment (Week 5)",
            "groups": [
              {
                "id": "OG000",
                "title": "Limbix Spark - Phase I",
                "description": "A 5 week CBT-based intervention\n\nLimbix Spark: The Limbix Spark program is divided into 5 levels. Each level provides educational information about cognitive behavioral therapy and interactive activities."
              },
              {
                "id": "OG001",
                "title": "Psychoeducation - Phase I",
                "description": "5 weeks of psychoeducation about depression. Upon completion, participants will be automatically enrolled into the Limbix Spark CBT-based intervention\n\nPsychoeducation: The Psychoeducation program is divided into 5 lessons. Each lesson covers a different topic about depression."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "35" },
                  { "groupId": "OG001", "value": "25" }
                ]
              }
            ],
            "classes": [
              {
                "title": "% of eligible participants willing to participate",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "35" },
                      { "groupId": "OG001", "value": "25" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "35" },
                      { "groupId": "OG001", "value": "25" }
                    ]
                  }
                ]
              },
              {
                "title": "% of enrolled participants completing all sessions by post-treatment",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "35" },
                      { "groupId": "OG001", "value": "0" }
                    ]
                  }
                ],
                "categories": [
                  { "measurements": [{ "groupId": "OG000", "value": "8" }] }
                ]
              }
            ]
          },
          {
            "type": "PRIMARY",
            "title": "Phase I - Feasibility (Satisfaction)",
            "description": "Descriptive report of participant satisfaction (mood improvement and enjoyment) on a scale of 0-10, with 0 meaning lower satisfaction and 10 meaning higher satisfaction. Phase I participant arms are reported for this outcome.",
            "populationDescription": "Participants who completed the post-treatment questionnaires.",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "units on a scale",
            "timeFrame": "Post-Treatment -\"Week 5\"",
            "groups": [
              {
                "id": "OG000",
                "title": "Limbix Spark - Phase I",
                "description": "A 5 week CBT-based intervention\n\nLimbix Spark: The Limbix Spark program is divided into 5 levels. Each level provides educational information about cognitive behavioral therapy and interactive activities."
              },
              {
                "id": "OG001",
                "title": "Psychoeducation - Phase I",
                "description": "5 weeks of psychoeducation about depression. Upon completion, participants will be automatically enrolled into the Limbix Spark CBT-based intervention\n\nPsychoeducation: The Psychoeducation program is divided into 5 lessons. Each lesson covers a different topic about depression."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "24" },
                  { "groupId": "OG001", "value": "18" }
                ]
              }
            ],
            "classes": [
              {
                "title": "Participant Reported Mood Improvement",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "5.08", "spread": "2.54" },
                      { "groupId": "OG001", "value": "1.78", "spread": "2.21" }
                    ]
                  }
                ]
              },
              {
                "title": "Participant Reported Enjoyment",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "6.79", "spread": "2.11" },
                      { "groupId": "OG001", "value": "3.94", "spread": "2.51" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "PRIMARY",
            "title": "Phase I - Feasibility (Safety)",
            "description": "Descriptive report of participant safety. Phase I participant arms are reported for this outcome.",
            "reportingStatus": "POSTED",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "timeFrame": "From Baseline to Post Treatment (Week 5)",
            "groups": [
              {
                "id": "OG000",
                "title": "Limbix Spark - Phase I",
                "description": "A 5 week CBT-based intervention\n\nLimbix Spark: The Limbix Spark program is divided into 5 levels. Each level provides educational information about cognitive behavioral therapy and interactive activities."
              },
              {
                "id": "OG001",
                "title": "Psychoeducation - Phase I",
                "description": "5 weeks of psychoeducation about depression. Upon completion, participants will be automatically enrolled into the Limbix Spark CBT-based intervention\n\nPsychoeducation: The Psychoeducation program is divided into 5 lessons. Each lesson covers a different topic about depression."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "35" },
                  { "groupId": "OG001", "value": "25" }
                ]
              }
            ],
            "classes": [
              {
                "title": "Adverse Events",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "0" },
                      { "groupId": "OG001", "value": "0" }
                    ]
                  }
                ]
              },
              {
                "title": "Serious Adverse Events",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "0" },
                      { "groupId": "OG001", "value": "2" }
                    ]
                  }
                ]
              },
              {
                "title": "Adverse Device Effects",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "0" },
                      { "groupId": "OG001", "value": "0" }
                    ]
                  }
                ]
              },
              {
                "title": "Unanticipated Adverse Device Effects",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "0" },
                      { "groupId": "OG001", "value": "0" }
                    ]
                  }
                ]
              },
              {
                "title": "None",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "35" },
                      { "groupId": "OG001", "value": "23" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "PRIMARY",
            "title": "Phase II - Change in Depressive Symptoms",
            "description": "Between-subjects treatment-related change in depressive symptoms from baseline to 5-weeks as measured by Personal Health Questionnaire (PHQ-8) (min: 0; max: 24, with higher score indicating more severe depression) for those with baseline PHQ-8 ≥10.",
            "populationDescription": "Participants who had a PHQ-8 score of ≥10 at Baseline. This was a Phase II Primary Outcome measure, so only Phase II arms are reported.",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "95% Confidence Interval",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "Change from Baseline to Post treatment (5 weeks)",
            "groups": [
              {
                "id": "OG000",
                "title": "Limbix Spark - Phase II",
                "description": "A 5 week CBT-based intervention\n\nLimbix Spark: The Limbix Spark program is divided into 5 levels. Each level provides educational information about cognitive behavioral therapy and interactive activities."
              },
              {
                "id": "OG001",
                "title": "Psychoeducation - Phase II",
                "description": "5 weeks of psychoeducation about depression. Upon completion, participants will be automatically enrolled into the Limbix Spark CBT-based intervention\n\nPsychoeducation: The Psychoeducation program is divided into 5 lessons. Each lesson covers a different topic about depression."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "63" },
                  { "groupId": "OG001", "value": "58" }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-5.08",
                        "lowerLimit": "-6.72",
                        "upperLimit": "-3.42"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-3.51",
                        "lowerLimit": "-5.09",
                        "upperLimit": "-1.93"
                      }
                    ]
                  }
                ]
              }
            ],
            "analyses": [
              {
                "groupIds": ["OG000", "OG001"],
                "groupDescription": "A linear mixed-effects model (LMM) analysis was implemented on an averaged imputed dataset to evaluate main effects of Group (Spark, Control) and Week (0-5), and the Group x Week interaction. Group and Week were entered as fixed factors. Spark version, and assessment completion days since baseline were included as fixed factors to control for effects of app version and differences in time between completion of successive weekly assessments.",
                "nonInferiorityType": "SUPERIORITY",
                "pValue": "0.06",
                "statisticalMethod": "Mixed Models Analysis",
                "paramType": "t",
                "paramValue": "-1.911",
                "ciNumSides": "TWO_SIDED"
              },
              {
                "groupIds": ["OG000", "OG001"],
                "groupDescription": "We used a Per Protocol approach that included participants who completed the PHQ at baseline and each week. A linear mixed-effects model (LMM) analysis was implemented on an averaged imputed dataset to evaluate main effects of Group (Spark, Control) and Week (0-5), and the Group x Week interaction.",
                "nonInferiorityType": "SUPERIORITY",
                "pValue": "0.01",
                "statisticalMethod": "Mixed Models Analysis",
                "paramType": "t",
                "paramValue": "-2.546",
                "ciNumSides": "TWO_SIDED"
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Phase I - Change in Depression Symptoms",
            "description": "Between-subjects treatment-related change in depressive symptoms from baseline to 5-weeks as measured by Personal Health Questionnaire (PHQ-8) (min: 0; max: 24, with higher score indicating more severe depression) for those with baseline PHQ-8 ≥5. Only Phase I participants were included in this Outcome measure.",
            "populationDescription": "Only Phase I participants were included in this Outcome measure.",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "From Baseline to Post Treatment (Week 5)",
            "groups": [
              {
                "id": "OG000",
                "title": "Limbix Spark - Phase I",
                "description": "A 5 week CBT-based intervention\n\nLimbix Spark: The Limbix Spark program is divided into 5 levels. Each level provides educational information about cognitive behavioral therapy and interactive activities."
              },
              {
                "id": "OG001",
                "title": "Psychoeducation - Phase I",
                "description": "5 weeks of psychoeducation about depression. Upon completion, participants will be automatically enrolled into the Limbix Spark CBT-based intervention\n\nPsychoeducation: The Psychoeducation program is divided into 5 lessons. Each lesson covers a different topic about depression."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "34" },
                  { "groupId": "OG001", "value": "23" }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-3.89",
                        "spread": "5.29"
                      },
                      { "groupId": "OG001", "value": "-3.34", "spread": "5.14" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Number of Participants in Remission",
            "description": "Remission rates based on PHQ-8 \\< 10 (sub-analysis for those with baseline PHQ-8 ≥ 10). Phase I and Phase II participant arms are reported for this outcome.",
            "populationDescription": "Participants with baseline PHQ-8 ≥ 10.",
            "reportingStatus": "POSTED",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "timeFrame": "From Baseline to Post Treatment (Week 5)",
            "groups": [
              {
                "id": "OG000",
                "title": "Limbix Spark - Phase I",
                "description": "A 5 week CBT-based intervention\n\nLimbix Spark: The Limbix Spark program is divided into 5 levels. Each level provides educational information about cognitive behavioral therapy and interactive activities."
              },
              {
                "id": "OG001",
                "title": "Psychoeducation - Phase I",
                "description": "5 weeks of psychoeducation about depression. Upon completion, participants will be automatically enrolled into the Limbix Spark CBT-based intervention\n\nPsychoeducation: The Psychoeducation program is divided into 5 lessons. Each lesson covers a different topic about depression."
              },
              {
                "id": "OG002",
                "title": "Limbix Spark - Phase II",
                "description": "A 5 week CBT-based intervention\n\nLimbix Spark: The Limbix Spark program is divided into 5 levels. Each level provides educational information about cognitive behavioral therapy and interactive activities."
              },
              {
                "id": "OG003",
                "title": "Psychoeducation/Control Extension - Phase II",
                "description": "5 weeks of psychoeducation about depression. Upon completion, participants will be automatically enrolled into the Limbix Spark CBT-based intervention\n\nPsychoeducation: The Psychoeducation program is divided into 5 lessons. Each lesson covers a different topic about depression.\n\nParticipants who were initially assigned to the Psychoeducation control arm were given the opportunity to then complete the 5 week CBT-based intervention, Limbix Spark.\n\nLimbix Spark: The Limbix Spark program is divided into 5 levels. Each level provides educational information about cognitive behavioral therapy and interactive activities."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "27" },
                  { "groupId": "OG001", "value": "21" },
                  { "groupId": "OG002", "value": "63" },
                  { "groupId": "OG003", "value": "58" }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "13" },
                      { "groupId": "OG001", "value": "7" },
                      { "groupId": "OG002", "value": "11" },
                      { "groupId": "OG003", "value": "2" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Change in Participant-rated Anxiety Symptoms and Global Functioning",
            "description": "Between-subjects treatment-related change in participant-rated anxiety symptoms and global functioning as measured by GAD-7 Anxiety and PROMIS Pediatric Global Health Scale.\n\nThe GAD-7 Anxiety is a brief 7-item assessment for generalized anxiety disorder. Values range from 0-21, with higher scores representing more severe anxiety.\n\nThe PROMIS Pediatric Global Health Scale is a 7-item assessment for perceived physical, mental, and social health. Values range from 7-35, with higher scores representing better health.\n\nPhase I and Phase II participant arms are reported for this Outcome. Statistical Analyses are presented for Phase II results only because Phase I was intentionally not powered for analysis.",
            "populationDescription": "Participants who completed post-program questionnaires. Phase II participants were included if they had a baseline PHQ-8 score ≥ 10.",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "From Baseline to Post Treatment (Week 5)",
            "groups": [
              {
                "id": "OG000",
                "title": "Limbix Spark - Phase I",
                "description": "A 5 week CBT-based intervention\n\nLimbix Spark: The Limbix Spark program is divided into 5 levels. Each level provides educational information about cognitive behavioral therapy and interactive activities."
              },
              {
                "id": "OG001",
                "title": "Psychoeducation - Phase I",
                "description": "5 weeks of psychoeducation about depression. Upon completion, participants will be automatically enrolled into the Limbix Spark CBT-based intervention\n\nPsychoeducation: The Psychoeducation program is divided into 5 lessons. Each lesson covers a different topic about depression."
              },
              {
                "id": "OG002",
                "title": "Limbix Spark - Phase II",
                "description": "A 5 week CBT-based intervention\n\nLimbix Spark: The Limbix Spark program is divided into 5 levels. Each level provides educational information about cognitive behavioral therapy and interactive activities."
              },
              {
                "id": "OG003",
                "title": "Psychoeducation/Control Extension - Phase II",
                "description": "5 weeks of psychoeducation about depression. Upon completion, participants will be automatically enrolled into the Limbix Spark CBT-based intervention\n\nPsychoeducation: The Psychoeducation program is divided into 5 lessons. Each lesson covers a different topic about depression.\n\nParticipants who were initially assigned to the Psychoeducation control arm were given the opportunity to then complete the 5 week CBT-based intervention, Limbix Spark.\n\nLimbix Spark: The Limbix Spark program is divided into 5 levels. Each level provides educational information about cognitive behavioral therapy and interactive activities."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "30" },
                  { "groupId": "OG001", "value": "21" },
                  { "groupId": "OG002", "value": "43" },
                  { "groupId": "OG003", "value": "49" }
                ]
              }
            ],
            "classes": [
              {
                "title": "GAD-7",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-2.87",
                        "spread": "4.67"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-2.29",
                        "spread": "3.94"
                      },
                      {
                        "groupId": "OG002",
                        "value": "-3.21",
                        "spread": "4.54"
                      },
                      { "groupId": "OG003", "value": "-1.45", "spread": "3.33" }
                    ]
                  }
                ]
              },
              {
                "title": "PROMIS - General Health",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "1.13", "spread": "3.64" },
                      {
                        "groupId": "OG001",
                        "value": "-0.14",
                        "spread": "2.69"
                      },
                      { "groupId": "OG002", "value": "1.35", "spread": "3.41" },
                      { "groupId": "OG003", "value": "-0.35", "spread": "1.85" }
                    ]
                  }
                ]
              }
            ],
            "analyses": [
              {
                "groupIds": ["OG002", "OG003"],
                "groupDescription": "We conducted a repeated measures ANOVA (Group x Time) on GAD-7 scores to compare the change in anxiety symptoms from Baseline to Post treatment for Phase II participants who had a baseline PHQ-8 score \\>= 10. The interaction term is presented.",
                "nonInferiorityType": "SUPERIORITY",
                "pValue": "0.23",
                "statisticalMethod": "ANOVA",
                "paramType": "F",
                "paramValue": "1.46",
                "ciNumSides": "TWO_SIDED"
              },
              {
                "groupIds": ["OG002", "OG003"],
                "groupDescription": "We conducted a repeated measures ANOVA (Group x Time) on the PROMIS - General Health Score to compare the change in general health from Baseline to Post treatment for Phase II participants who had a baseline PHQ-8 score \\>= 10. The interaction term is reported.",
                "nonInferiorityType": "SUPERIORITY",
                "pValue": "0.11",
                "statisticalMethod": "ANOVA",
                "paramType": "F",
                "paramValue": "2.59",
                "ciNumSides": "TWO_SIDED"
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Change in Parent-reported Depressive Symptoms and Global Functioning.",
            "description": "Between-subjects treatment-related change in parent-reported depressive symptoms and global functioning as measured by Mood and Feelings Questionnaire (MFQ-PS), and PROMIS Parent Proxy Global Health Scale.\n\nThe MFQ-PS consists of a series of 13 descriptive phrases regarding how the subject has been feeling or acting in the past two weeks and is a screening tool for depression in children and young people. Values range from 0-26, with higher scores representing more severe symptoms.\n\nThe PROMIS Parent Proxy Global Health Scale is a 7-item assessment for perceived physical, mental, and social health. Values range from 7-35, with higher scores representing better health.\n\nPhase I and Phase II participant arms are reported for this Outcome. Statistical Analyses are presented for Phase II results only because Phase I was intentionally not powered for analysis.",
            "populationDescription": "Parent/Legal Guardians of participants \\<18 years old who completed both baseline and post-treatment questionnaires. Phase II participants were included if they had a baseline PHQ-8 score ≥ 10.",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "From Baseline to Post Treatment (Week 5)",
            "groups": [
              {
                "id": "OG000",
                "title": "Limbix Spark - Phase I",
                "description": "A 5 week CBT-based intervention\n\nLimbix Spark: The Limbix Spark program is divided into 5 levels. Each level provides educational information about cognitive behavioral therapy and interactive activities."
              },
              {
                "id": "OG001",
                "title": "Psychoeducation - Phase I",
                "description": "5 weeks of psychoeducation about depression. Upon completion, participants will be automatically enrolled into the Limbix Spark CBT-based intervention\n\nPsychoeducation: The Psychoeducation program is divided into 5 lessons. Each lesson covers a different topic about depression."
              },
              {
                "id": "OG002",
                "title": "Limbix Spark - Phase II",
                "description": "A 5 week CBT-based intervention\n\nLimbix Spark: The Limbix Spark program is divided into 5 levels. Each level provides educational information about cognitive behavioral therapy and interactive activities."
              },
              {
                "id": "OG003",
                "title": "Psychoeducation/Control Extension - Phase II",
                "description": "5 weeks of psychoeducation about depression. Upon completion, participants will be automatically enrolled into the Limbix Spark CBT-based intervention\n\nPsychoeducation: The Psychoeducation program is divided into 5 lessons. Each lesson covers a different topic about depression.\n\nParticipants who were initially assigned to the Psychoeducation control arm were given the opportunity to then complete the 5 week CBT-based intervention, Limbix Spark.\n\nLimbix Spark: The Limbix Spark program is divided into 5 levels. Each level provides educational information about cognitive behavioral therapy and interactive activities."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "10" },
                  { "groupId": "OG001", "value": "8" },
                  { "groupId": "OG002", "value": "23" },
                  { "groupId": "OG003", "value": "27" }
                ]
              }
            ],
            "classes": [
              {
                "title": "MFQ-SF",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-4.20",
                        "spread": "5.49"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-4.88",
                        "spread": "3.60"
                      },
                      {
                        "groupId": "OG002",
                        "value": "-4.83",
                        "spread": "4.31"
                      },
                      { "groupId": "OG003", "value": "-2.85", "spread": "4.14" }
                    ]
                  }
                ]
              },
              {
                "title": "PROMIS Parent Proxy - General Health",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "0.70", "spread": "2.54" },
                      { "groupId": "OG001", "value": "0.88", "spread": "2.59" },
                      { "groupId": "OG002", "value": "1.21", "spread": "3.23" },
                      { "groupId": "OG003", "value": "1.04", "spread": "2.47" }
                    ]
                  }
                ]
              }
            ],
            "analyses": [
              {
                "groupIds": ["OG002", "OG003"],
                "groupDescription": "We conducted a repeated measures ANOVA (Time x Group) on the MFQ to compare the change in parent report of depressive symptoms from Baseline to Post treatment for Phase II participants who had a baseline PHQ-8 score \\>= 10. The interaction term is presented.",
                "nonInferiorityType": "SUPERIORITY",
                "pValue": "0.33",
                "statisticalMethod": "ANOVA",
                "paramType": "F",
                "paramValue": "0.94",
                "ciNumSides": "TWO_SIDED"
              },
              {
                "groupIds": ["OG002", "OG003"],
                "groupDescription": "We conducted a repeated measures ANOVA (Group x Time) on the PROMIS Parent Proxy - General Health Score to compare the change in parent reported general health from Baseline to Post treatment for Phase II participants who had a baseline PHQ-8 score \\>= 10. The interaction term is reported.",
                "nonInferiorityType": "SUPERIORITY",
                "pValue": "0.90",
                "statisticalMethod": "ANOVA",
                "paramType": "F",
                "paramValue": "0.02",
                "ciNumSides": "TWO_SIDED"
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Average Treatment-related Usability and Engagement Ratings",
            "description": "Average treatment-related usability (System Usability Scale; SUS) and engagement (User Engagement Scale-Short Form; UES-SF) ratings. Phase I and Phase II participant arms are reported for this outcome.\n\nThe SUS is a 10-item questionnaire measuring the usability of systems. Responses range from Strongly Agree to Strongly Disagree. Scores are percentile rankings and range from 0-100. Higher scores represent higher usability.\n\nThe UES-SF is a 12-item questionnaire measuring self-reported user-engagement. The form uses a 5-point Likert scale. Overall engagement scores range from 1-5. Higher scores represent more engagement.",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Error",
            "unitOfMeasure": "units on a scale",
            "timeFrame": "Post-Treatment",
            "groups": [
              {
                "id": "OG000",
                "title": "Limbix Spark - Phase I",
                "description": "A 5 week CBT-based intervention\n\nLimbix Spark: The Limbix Spark program is divided into 5 levels. Each level provides educational information about cognitive behavioral therapy and interactive activities."
              },
              {
                "id": "OG001",
                "title": "Psychoeducation - Phase I",
                "description": "5 weeks of psychoeducation about depression. Upon completion, participants will be automatically enrolled into the Limbix Spark CBT-based intervention\n\nPsychoeducation: The Psychoeducation program is divided into 5 lessons. Each lesson covers a different topic about depression."
              },
              {
                "id": "OG002",
                "title": "Limbix Spark - Phase II",
                "description": "A 5 week CBT-based intervention\n\nLimbix Spark: The Limbix Spark program is divided into 5 levels. Each level provides educational information about cognitive behavioral therapy and interactive activities."
              },
              {
                "id": "OG003",
                "title": "Psychoeducation/Control Extension - Phase II",
                "description": "5 weeks of psychoeducation about depression. Upon completion, participants will be automatically enrolled into the Limbix Spark CBT-based intervention\n\nPsychoeducation: The Psychoeducation program is divided into 5 lessons. Each lesson covers a different topic about depression.\n\nParticipants who were initially assigned to the Psychoeducation control arm were given the opportunity to then complete the 5 week CBT-based intervention, Limbix Spark.\n\nLimbix Spark: The Limbix Spark program is divided into 5 levels. Each level provides educational information about cognitive behavioral therapy and interactive activities."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "30" },
                  { "groupId": "OG001", "value": "21" },
                  { "groupId": "OG002", "value": "43" },
                  { "groupId": "OG003", "value": "49" }
                ]
              }
            ],
            "classes": [
              {
                "title": "SUS",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "80.67",
                        "spread": "2.17"
                      },
                      {
                        "groupId": "OG001",
                        "value": "75.83",
                        "spread": "2.29"
                      },
                      {
                        "groupId": "OG002",
                        "value": "82.85",
                        "spread": "1.89"
                      },
                      { "groupId": "OG003", "value": "76.12", "spread": "1.92" }
                    ]
                  }
                ]
              },
              {
                "title": "UES-SF",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "3.62", "spread": "0.10" },
                      { "groupId": "OG001", "value": "3.10", "spread": "0.12" },
                      { "groupId": "OG002", "value": "3.80", "spread": "0.08" },
                      { "groupId": "OG003", "value": "3.22", "spread": "0.09" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Phase II - Safety",
            "description": "Between-group treatment-related differences in clinical concern rates and serious clinical concerns. Phase II participant arms are reported for this outcome.",
            "reportingStatus": "POSTED",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "timeFrame": "From Baseline to Post Treatment (Week 5)",
            "groups": [
              {
                "id": "OG000",
                "title": "Limbix Spark - Phase II",
                "description": "A 5 week CBT-based intervention\n\nLimbix Spark: The Limbix Spark program is divided into 5 levels. Each level provides educational information about cognitive behavioral therapy and interactive activities."
              },
              {
                "id": "OG001",
                "title": "Psychoeducation - Phase II",
                "description": "5 weeks of psychoeducation about depression. Upon completion, participants will be automatically enrolled into the Limbix Spark CBT-based intervention\n\nPsychoeducation: The Psychoeducation program is divided into 5 lessons. Each lesson covers a different topic about depression."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "80" },
                  { "groupId": "OG001", "value": "80" }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "title": "Adverse Events",
                    "measurements": [
                      { "groupId": "OG000", "value": "4" },
                      { "groupId": "OG001", "value": "2" }
                    ]
                  },
                  {
                    "title": "Serious Adverse Events",
                    "measurements": [
                      { "groupId": "OG000", "value": "0" },
                      { "groupId": "OG001", "value": "0" }
                    ]
                  },
                  {
                    "title": "Adverse Device Effects",
                    "measurements": [
                      { "groupId": "OG000", "value": "0" },
                      { "groupId": "OG001", "value": "0" }
                    ]
                  },
                  {
                    "title": "Unanticipated Adverse Device Effects",
                    "measurements": [
                      { "groupId": "OG000", "value": "0" },
                      { "groupId": "OG001", "value": "0" }
                    ]
                  },
                  {
                    "title": "None",
                    "measurements": [
                      { "groupId": "OG000", "value": "76" },
                      { "groupId": "OG001", "value": "78" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "App Engagement and Adherence",
            "description": "Between-group treatment-related differences in program adherence and engagement based on behavioral and mobile app analytics. Phase I and Phase II Spark participant arms are reported for this outcome. We are reporting the average number of app modules completed (out of 5 total modules).",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "app modules completed",
            "timeFrame": "From Baseline to Post Treatment (Week 5)",
            "groups": [
              {
                "id": "OG000",
                "title": "Limbix Spark - Phase I",
                "description": "A 5 week CBT-based intervention\n\nLimbix Spark: The Limbix Spark program is divided into 5 levels. Each level provides educational information about cognitive behavioral therapy and interactive activities."
              },
              {
                "id": "OG001",
                "title": "Limbix Spark - Phase II",
                "description": "A 5 week CBT-based intervention\n\nLimbix Spark: The Limbix Spark program is divided into 5 levels. Each level provides educational information about cognitive behavioral therapy and interactive activities."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "35" },
                  { "groupId": "OG001", "value": "63" }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "2.74", "spread": "1.69" },
                      { "groupId": "OG001", "value": "3.17", "spread": "1.82" }
                    ]
                  }
                ]
              }
            ]
          }
        ]
      },
      "adverseEventsModule": {
        "frequencyThreshold": "0",
        "timeFrame": "Adverse events were collected per patient during their 7-week (5 weeks of treatment program plus a 2 week post program questionnaire) duration of study participation. The entire duration of the study was from 30NOV2020 thru 03SEP2021.",
        "description": "Adverse events were monitored on a daily basis via the review of free form text that could be entered by participants throughout the study and from specific questions in the weekly symptom check and weekly PHQ-8 assessments.",
        "eventGroups": [
          {
            "id": "EG000",
            "title": "Limbix Spark - Phase I",
            "description": "A 5 week CBT-based intervention\n\nLimbix Spark: The Limbix Spark program is divided into 5 levels. Each level provides educational information about cognitive behavioral therapy and interactive activities.",
            "deathsNumAffected": 0,
            "deathsNumAtRisk": 35,
            "seriousNumAffected": 0,
            "seriousNumAtRisk": 35,
            "otherNumAffected": 0,
            "otherNumAtRisk": 35
          },
          {
            "id": "EG001",
            "title": "Psychoeducation - Phase I",
            "description": "5 weeks of psychoeducation about depression. Upon completion, participants will be automatically enrolled into the Limbix Spark CBT-based intervention\n\nPsychoeducation: The Psychoeducation program is divided into 5 lessons. Each lesson covers a different topic about depression.",
            "deathsNumAffected": 0,
            "deathsNumAtRisk": 25,
            "seriousNumAffected": 2,
            "seriousNumAtRisk": 25,
            "otherNumAffected": 0,
            "otherNumAtRisk": 25
          },
          {
            "id": "EG002",
            "title": "Limbix Spark - Phase II",
            "description": "A 5 week CBT-based intervention\n\nLimbix Spark: The Limbix Spark program is divided into 5 levels. Each level provides educational information about cognitive behavioral therapy and interactive activities.",
            "deathsNumAffected": 0,
            "deathsNumAtRisk": 80,
            "seriousNumAffected": 0,
            "seriousNumAtRisk": 80,
            "otherNumAffected": 4,
            "otherNumAtRisk": 80
          },
          {
            "id": "EG003",
            "title": "Psychoeducation - Phase II",
            "description": "5 weeks of psychoeducation about depression. Upon completion, participants will be automatically enrolled into the Limbix Spark CBT-based intervention\n\nPsychoeducation: The Psychoeducation program is divided into 5 lessons. Each lesson covers a different topic about depression.",
            "deathsNumAffected": 0,
            "deathsNumAtRisk": 80,
            "seriousNumAffected": 0,
            "seriousNumAtRisk": 80,
            "otherNumAffected": 2,
            "otherNumAtRisk": 80
          }
        ],
        "seriousEvents": [
          {
            "term": "Hospitalized for a suicide attempt",
            "organSystem": "Psychiatric disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "notes": "Parent reported participant hospitalization because of suicide attempt",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 35
              },
              {
                "groupId": "EG001",
                "numEvents": 1,
                "numAffected": 1,
                "numAtRisk": 25
              },
              {
                "groupId": "EG002",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 80
              },
              {
                "groupId": "EG003",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 80
              }
            ]
          },
          {
            "term": "Hospitalized for \"low mood\"",
            "organSystem": "Psychiatric disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "notes": "Parent reported participant hospitalization for \"low mood\"",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 35
              },
              {
                "groupId": "EG001",
                "numEvents": 1,
                "numAffected": 1,
                "numAtRisk": 25
              },
              {
                "groupId": "EG002",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 80
              },
              {
                "groupId": "EG003",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 80
              }
            ]
          }
        ],
        "otherEvents": [
          {
            "term": "Clinical Deterioration",
            "organSystem": "Psychiatric disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "notes": "Clinical deterioration in PHQ for 2 consecutive weeks",
            "stats": [
              { "groupId": "EG000", "numAffected": 0, "numAtRisk": 35 },
              { "groupId": "EG001", "numAffected": 0, "numAtRisk": 25 },
              { "groupId": "EG002", "numAffected": 1, "numAtRisk": 80 },
              { "groupId": "EG003", "numAffected": 2, "numAtRisk": 80 }
            ]
          },
          {
            "term": "Suicidal Ideation",
            "organSystem": "Psychiatric disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "notes": "Participant reported suicidal ideation",
            "stats": [
              { "groupId": "EG000", "numAffected": 0, "numAtRisk": 35 },
              { "groupId": "EG001", "numAffected": 0, "numAtRisk": 25 },
              { "groupId": "EG002", "numAffected": 2, "numAtRisk": 80 },
              { "groupId": "EG003", "numAffected": 0, "numAtRisk": 80 }
            ]
          },
          {
            "term": "Non-Suicidal Self-Injury Ideation",
            "organSystem": "Psychiatric disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "notes": "Parent reported that participant was experiencing Non-Suicidal Self-Injury ideation",
            "stats": [
              { "groupId": "EG000", "numAffected": 0, "numAtRisk": 35 },
              { "groupId": "EG001", "numAffected": 0, "numAtRisk": 25 },
              { "groupId": "EG002", "numAffected": 1, "numAtRisk": 80 },
              { "groupId": "EG003", "numAffected": 0, "numAtRisk": 80 }
            ]
          }
        ]
      },
      "moreInfoModule": {
        "certainAgreement": { "piSponsorEmployee": true },
        "pointOfContact": {
          "title": "Janel Shelton-DeMagnus, Research Operations Manager",
          "organization": "Limbix Health",
          "email": "janel@limbix.com",
          "phone": "8885462495",
          "phoneExt": "709"
        }
      }
    },
    "documentSection": {
      "largeDocumentModule": {
        "largeDocs": [
          {
            "typeAbbrev": "Prot_SAP",
            "hasProtocol": true,
            "hasSap": true,
            "hasIcf": false,
            "label": "Study Protocol and Statistical Analysis Plan",
            "date": "2021-04-21",
            "uploadDate": "2021-09-29T14:00",
            "filename": "Prot_SAP_000.pdf",
            "size": 254466
          }
        ]
      }
    },
    "derivedSection": {
      "miscInfoModule": {
        "versionHolder": "2025-05-07",
        "submissionTracking": {
          "firstMcpInfo": {
            "postDateStruct": { "date": "2021-10-11", "type": "ACTUAL" }
          }
        }
      },
      "conditionBrowseModule": {
        "meshes": [
          { "id": "D003863", "term": "Depression" },
          { "id": "D003866", "term": "Depressive Disorder" }
        ],
        "ancestors": [
          { "id": "D001526", "term": "Behavioral Symptoms" },
          { "id": "D019964", "term": "Mood Disorders" },
          { "id": "D001523", "term": "Mental Disorders" }
        ],
        "browseLeaves": [
          { "id": "M2561", "name": "COVID-19", "relevance": "LOW" },
          {
            "id": "M7061",
            "name": "Depressive Disorder",
            "asFound": "Depression",
            "relevance": "HIGH"
          },
          {
            "id": "M7058",
            "name": "Depression",
            "asFound": "Depression",
            "relevance": "HIGH"
          },
          { "id": "M4818", "name": "Behavioral Symptoms", "relevance": "LOW" },
          { "id": "M21835", "name": "Mood Disorders", "relevance": "LOW" },
          { "id": "M14473", "name": "Psychotic Disorders", "relevance": "LOW" },
          { "id": "M4815", "name": "Mental Disorders", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "BC01", "name": "Infections" },
          {
            "abbrev": "BC08",
            "name": "Respiratory Tract (Lung and Bronchial) Diseases"
          },
          { "abbrev": "All", "name": "All Conditions" },
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" }
        ]
      }
    },
    "hasResults": true
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT03968276",
        "orgStudyIdInfo": { "id": "APPLIAC" },
        "organization": {
          "fullName": "Fondation Hôpital Saint-Joseph",
          "class": "OTHER"
        },
        "briefTitle": "Study of the Interest of Patients Undergoing Anti-thrombotic Treatment in a Digital Application of Therapeutic Assistance",
        "officialTitle": "Study of the Interest of Patients Undergoing Anti-thrombotic Treatment in a Digital Application of Therapeutic Assistance",
        "acronym": "APPLIAC"
      },
      "statusModule": {
        "statusVerifiedDate": "2022-10",
        "overallStatus": "TERMINATED",
        "whyStopped": "The PI decided to stop the study.",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2019-11-21", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2022-10-10",
          "type": "ACTUAL"
        },
        "completionDateStruct": { "date": "2022-10-10", "type": "ACTUAL" },
        "studyFirstSubmitDate": "2019-05-27",
        "studyFirstSubmitQcDate": "2019-05-29",
        "studyFirstPostDateStruct": { "date": "2019-05-30", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2022-10-31",
        "lastUpdatePostDateStruct": { "date": "2022-11-02", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": {
          "name": "Fondation Hôpital Saint-Joseph",
          "class": "OTHER"
        }
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": false
      },
      "descriptionModule": {
        "briefSummary": "Medical ethics encourages medical personal to actively care for patients, however old they may be, if they have maintained their physical autonomy and mental integrity to travel the path of medical care together. Many of the patients are in this situation today and their age does not seem to be a limiting factor in the care required.\n\nFor more than 60 years, antithrombotics have played a major role in the management of thromboembolic and arterioatheromatous diseases. the doctors have therefore seen the advent of low molecular weight heparins, new platelet antiaggregants and then direct oral anticoagulants.\n\nIf their contribution is no longer discussed today, it is necessary to take into consideration the risks they cause, particularly in terms of haemorrhage. Indeed, antithrombotics are the leading cause of serious adverse reactions in France with anti-vitamins K (AVK) which are the leading cause of hospitalization for severe iatrogeny in France. This risk is increased by the coexistence of haemorrhagic risk factors: drug interaction, misuse, failure to comply with contraindications and precautions for use, especially as exposure to these drugs increases with age.",
        "detailedDescription": "The risk of bleeding varies in different populations and according to the treatment used. Severe bleeding under AVK has an incidence of 0.6 to 10% per year. Fatal hemorrhage is in the order of 1%. The risk factors for bleeding are controversial: history of bleeding in the patient, instability of the International Normalized Ratio (INR) at the time of introduction of KVAs and during the first few months, poor patient compliance, drug combinations (antiplatelet, non-steroidal anti-inflammatory drugs: NSAIDs, paracetamol, etc.) or association with alcohol. National pharmacovigilance data indicate that serious accidents are not uncommon due to frequent misuse of antithrombotics in common practice.\n\nThere are risk factors related to the patient and his or her comorbidities: history of bleeding, stroke, comorbidities such as age \\> 65 years, diabetes, cancer, chronic renal failure.\n\nDespite the various aids to therapeutic patient education (surveillance logbook, computerised INR monitoring), there has been no decrease in the frequency of iatrogenic accidents, either in hospitals or in urban medicine.\n\nThe use of smartphone applications in the medical field is increasingly evolving among healthcare professionals and patients. They allow for more personalized care, and can also promote interaction with health professionals.\n\nStrengthening the link between specialist doctors and the general practitioner for joint patient management will improve their follow-up and reduce the risk of iatrogeny.\n\nIn 2016, a survey was conducted in the vascular medicine department of the Groupe Hospitalier Paris Saint-Joseph (GHPSJ) to assess access to smartphones among patients on anti-thrombotic medication. Of the 100 patients enrolled, 74 were on anticoagulant or platelet aggregation therapy. Of these, 50 had a mobile phone and 24% used the Internet and made downloads to their phones.\n\nThis raises the question of the interest that patients might have in a mobile application on the use of anti-thrombotics. As the profile of patients seen in hospital is different from those consulting in general medicine, it seems interesting to study these two populations in order to know if there is a difference in their attitude towards the smartphone.\n\nIn order to find a new way to limit the iatrogeny of antithrombotic drugs, the investigators wanted to set up a medical application (educational tablet) for patients to provide them with support to better manage their treatment."
      },
      "conditionsModule": {
        "conditions": ["Vascular Diseases"],
        "keywords": [
          "antithrombotic treatment",
          "digital therapeutic application assistance"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "NA",
          "interventionModel": "SINGLE_GROUP",
          "primaryPurpose": "OTHER",
          "maskingInfo": { "masking": "NONE" }
        },
        "enrollmentInfo": { "count": 25, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "use of digital tablet",
            "type": "EXPERIMENTAL",
            "description": "if the patient is included in the study, an educational tablet (digital tablet) is given to the patient.\n\nThe first connection to the tablet and then to the \"My medication protects my vessels\" application is made by the investigator in the presence of the patient. The application is configured by the investigator with the choice of the vascular pathology(s) corresponding to the patient included and the prescribed anti-thrombotic treatments. Thus, for each patient, the content of the tablet is adapted and personalized according to his vascular profile.\n\nAfter discharge from hospital, the patient has the educational tablet at his disposal for 1 month at home. The application offers patients various information supports (tools, questionnaires and pill box). Throughout its use, it may contact the investigating physician via a telephone number available within the application if it encounters a problem related to the study.",
            "interventionNames": ["Other: use of digital tablet"]
          }
        ],
        "interventions": [
          {
            "type": "OTHER",
            "name": "use of digital tablet",
            "description": "At the end of hospitalization, the patient has an educational tablet at his disposal for 1 month at home. Throughout its use, the patient may contact the investigating physician via a telephone number available within the application if he/she encounters a problem related to the study. At the end of this month, the patient must complete two questionnaires through the application to assess his or her knowledge of his or her condition and treatment, as well as his or her satisfaction with the use of the tablet.\n\nIn this research, 1 month after inclusion, the patient will have an additional follow-up visit corresponding to a dedicated consultation in the vascular medicine department. It will allow the patient to review the use of the tablet and his or her satisfaction with the use of such a tool.",
            "armGroupLabels": ["use of digital tablet"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Return of the tablet in working order and to its use",
            "description": "return (yes/no) and use",
            "timeFrame": "1 month"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Number of pages consulted on the educational tablet",
            "timeFrame": "1 month"
          },
          {
            "measure": "Analyses of patient treatment knowledge assessment questionnaires",
            "description": "The two questionnaires contain 12 and 11 questions respectively. the possible answers are yes or no",
            "timeFrame": "Day 0 - 1 month"
          },
          {
            "measure": "Analogical visual scale of patient satisfaction",
            "description": "Analogical visual scale of patient satisfaction from minimum 0 (very satisfied) to maximum 10 (not satisfied)",
            "timeFrame": "1 month"
          },
          {
            "measure": "Questionnaire on compliance with antithrombotic treatments on application",
            "description": "taking antithrombotic treatments (yes/no)",
            "timeFrame": "1 month"
          },
          {
            "measure": "Reporting of adverse events via the dedicated field on the educational tablet",
            "timeFrame": "1 month"
          },
          {
            "measure": "Number of calls from city physicians and pharmacists received by the investigator",
            "timeFrame": "1 month"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* Patient ≥ 18 years old\n* Patient hospitalized in the vascular medicine department of the GHPSJ or attending a general medical consultation at the CMT\n* Patient with at least one vascular pathology: pulmonary embolism, venous thrombosis or phlebitis, cardiac arrhythmia by atrial fibrillation, obliterating arteriopathy of the lower limbs or myocardial infarction\n* Patient on antithrombotic treatment\\[anticoagulants : AVK or Anticoagulants Oraux Directs (AOD), or antiplatelet agents\\]\n* Patient affiliated to a health insurance plan\n* Patient able to read and understand the French language\n* Patient capable of giving free, informed and express consent\n\nExclusion Criteria:\n\n* Patient not residing in Ile de France\n* Patient whose investigator considers that he/she is not able to use a digital tablet\n* Patient deprived of liberty\n* Patient under guardianship or curatorship\n* Refusal to participate in the study\n* Patient judged not to be included by the investigator on the basis of the inclusion questionnaire",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "Parinaz GHAFFARI, MD",
            "affiliation": "Fondation Hôpital Saint-Joseph",
            "role": "STUDY_DIRECTOR"
          }
        ],
        "locations": [
          {
            "facility": "Groupe Hospitalier Paris Saint-Joseph",
            "city": "Paris",
            "zip": "75014",
            "country": "France",
            "geoPoint": { "lat": 48.85341, "lon": 2.3488 }
          }
        ]
      },
      "referencesModule": {
        "references": [
          {
            "pmid": "14644891",
            "type": "RESULT",
            "citation": "Linkins LA, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med. 2003 Dec 2;139(11):893-900. doi: 10.7326/0003-4819-139-11-200312020-00007."
          },
          {
            "pmid": "18000602",
            "type": "RESULT",
            "citation": "Dahri K, Loewen P. The risk of bleeding with warfarin: a systematic review and performance analysis of clinical prediction rules. Thromb Haemost. 2007 Nov;98(5):980-7."
          }
        ]
      }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [{ "id": "D014652", "term": "Vascular Diseases" }],
        "ancestors": [{ "id": "D002318", "term": "Cardiovascular Diseases" }],
        "browseLeaves": [
          {
            "id": "M17400",
            "name": "Vascular Diseases",
            "asFound": "Vascular Disease",
            "relevance": "HIGH"
          }
        ],
        "browseBranches": [
          { "abbrev": "BC14", "name": "Heart and Blood Diseases" },
          { "abbrev": "All", "name": "All Conditions" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT02782117",
        "orgStudyIdInfo": { "id": "C-AM-1C AND C-AM-1D" },
        "organization": { "fullName": "Luminopia", "class": "INDUSTRY" },
        "briefTitle": "Luminopia One Pilot Study",
        "officialTitle": "Luminopia One Pilot Study"
      },
      "statusModule": {
        "statusVerifiedDate": "2020-07",
        "overallStatus": "COMPLETED",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2017-08-01", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2019-02-06",
          "type": "ACTUAL"
        },
        "completionDateStruct": { "date": "2019-02-06", "type": "ACTUAL" },
        "studyFirstSubmitDate": "2016-05-19",
        "studyFirstSubmitQcDate": "2016-05-20",
        "studyFirstPostDateStruct": {
          "date": "2016-05-25",
          "type": "ESTIMATED"
        },
        "dispFirstSubmitDate": "2020-02-20",
        "dispFirstSubmitQcDate": "2020-02-20",
        "dispFirstPostDateStruct": { "date": "2020-02-25", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2020-07-07",
        "lastUpdatePostDateStruct": { "date": "2020-07-09", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": { "name": "Luminopia", "class": "INDUSTRY" },
        "collaborators": [
          { "name": "Boston Children's Hospital", "class": "OTHER" }
        ]
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": true,
        "isUnapprovedDevice": true
      },
      "descriptionModule": {
        "briefSummary": "A single-arm, multi-center, open-label pilot study to evaluate the feasibility, safety, and efficacy of the Luminopia One digital therapeutic in improving visual acuity in a pediatric amblyopia population."
      },
      "conditionsModule": { "conditions": ["Amblyopia"] },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "NA",
          "interventionModel": "SINGLE_GROUP",
          "interventionModelDescription": "A single-arm, multi-center, open-label pilot study conducted in two phases. Phase 1 enrolled 10 participants at 1 site and phase 2 enrolled 74 participants at 9 sites.",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": { "masking": "NONE" }
        },
        "enrollmentInfo": { "count": 84, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "Treatment Regimen A",
            "type": "EXPERIMENTAL",
            "description": "Treatment Regimen A will use the Luminopia device for an hour per day for 12 weeks.",
            "interventionNames": ["Device: Luminopia One"]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "Luminopia One",
            "description": "Luminopia One is a digital therapeutic that allows patients to watch videos with therapeutic modifications applied.",
            "armGroupLabels": ["Treatment Regimen A"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Amblyopic eye best-corrected visual acuity",
            "description": "Electronic ATS-HOTV protocol for participants \\< 7 years of age and electronic ETDRS protocol for participants ≥ 7 years of age",
            "timeFrame": "12 weeks"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Amblyopic eye best-corrected visual acuity",
            "description": "Electronic ATS-HOTV protocol for participants \\< 7 years of age and electronic ETDRS protocol for participants ≥ 7 years of age",
            "timeFrame": "8 weeks"
          },
          {
            "measure": "Amblyopic eye best-corrected visual acuity",
            "description": "Electronic ATS-HOTV protocol for participants \\< 7 years of age and electronic ETDRS protocol for participants ≥ 7 years of age",
            "timeFrame": "4 weeks"
          },
          {
            "measure": "Adherence",
            "description": "Duration spent using the device divided by duration of treatment prescribed (objectively monitored)",
            "timeFrame": "12 weeks"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Major Eligibility Criteria:\n\n* Age 4 to \\<8 years (phase 1) or age 4 to \\<13 years (phase 2)\n* Monocular amblyopia associated with anisometropia, strabismus or both combined\n* Amblyopic eye best-corrected visual acuity (BCVA) 20/40 to 20/200 inclusive (0.3-1.0 logMAR)\n* Fellow eye BCVA 20/25 or better (phase 1) or 20/32 or better (phase 2)\n* Interocular BCVA difference ≥3 lines (≥0.3 logMAR)\n* Visual acuity stability in current refractive correction (phase 2)\n* Corrected distance heterotropia ≤5 prism diopters on simultaneous prism and cover test (SPCT)",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "4 Years",
        "maximumAge": "12 Years",
        "stdAges": ["CHILD"]
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "David Hunter, MD PhD",
            "affiliation": "Boston Children's Hospital",
            "role": "STUDY_DIRECTOR"
          }
        ],
        "locations": [
          {
            "facility": "Eye Physicians of Central Florida",
            "city": "Maitland",
            "state": "Florida",
            "zip": "32751",
            "country": "United States",
            "geoPoint": { "lat": 28.62778, "lon": -81.36312 }
          },
          {
            "facility": "Wheaton Eye Clinic",
            "city": "Chicago",
            "state": "Illinois",
            "zip": "60187",
            "country": "United States",
            "geoPoint": { "lat": 41.85003, "lon": -87.65005 }
          },
          {
            "facility": "Indiana University",
            "city": "Bloomington",
            "state": "Indiana",
            "zip": "47405",
            "country": "United States",
            "geoPoint": { "lat": 39.16533, "lon": -86.52639 }
          },
          {
            "facility": "Kids Eye Care of Maryland",
            "city": "Frederick",
            "state": "Maryland",
            "zip": "21703",
            "country": "United States",
            "geoPoint": { "lat": 39.41427, "lon": -77.41054 }
          },
          {
            "facility": "Children's Eye Care of Michigan",
            "city": "Dearborn",
            "state": "Michigan",
            "zip": "48124",
            "country": "United States",
            "geoPoint": { "lat": 42.32226, "lon": -83.17631 }
          },
          {
            "facility": "Concord Eye Center",
            "city": "Concord",
            "state": "New Hampshire",
            "zip": "03301",
            "country": "United States",
            "geoPoint": { "lat": 43.20814, "lon": -71.53757 }
          },
          {
            "facility": "Conestoga Eye",
            "city": "Lancaster",
            "state": "Pennsylvania",
            "zip": "17601",
            "country": "United States",
            "geoPoint": { "lat": 40.03788, "lon": -76.30551 }
          },
          {
            "facility": "Houston Eye Associates",
            "city": "Houston",
            "state": "Texas",
            "zip": "77025",
            "country": "United States",
            "geoPoint": { "lat": 29.76328, "lon": -95.36327 }
          },
          {
            "facility": "Virginia Pediatric Eye Center",
            "city": "Virginia Beach",
            "state": "Virginia",
            "zip": "23452",
            "country": "United States",
            "geoPoint": { "lat": 36.85293, "lon": -75.97799 }
          }
        ]
      },
      "ipdSharingStatementModule": { "ipdSharing": "NO" }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [{ "id": "D000550", "term": "Amblyopia" }],
        "ancestors": [
          { "id": "D001927", "term": "Brain Diseases" },
          { "id": "D002493", "term": "Central Nervous System Diseases" },
          { "id": "D009422", "term": "Nervous System Diseases" },
          { "id": "D014786", "term": "Vision Disorders" },
          { "id": "D012678", "term": "Sensation Disorders" },
          { "id": "D009461", "term": "Neurologic Manifestations" },
          { "id": "D005128", "term": "Eye Diseases" }
        ],
        "browseLeaves": [
          {
            "id": "M3891",
            "name": "Amblyopia",
            "asFound": "Amblyopia",
            "relevance": "HIGH"
          },
          { "id": "M5204", "name": "Brain Diseases", "relevance": "LOW" },
          {
            "id": "M5742",
            "name": "Central Nervous System Diseases",
            "relevance": "LOW"
          },
          { "id": "M17530", "name": "Vision Disorders", "relevance": "LOW" },
          { "id": "M15490", "name": "Sensation Disorders", "relevance": "LOW" },
          {
            "id": "M12404",
            "name": "Neurologic Manifestations",
            "relevance": "LOW"
          },
          { "id": "M8271", "name": "Eye Diseases", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "BC10", "name": "Nervous System Diseases" },
          { "abbrev": "BC11", "name": "Eye Diseases" },
          { "abbrev": "BC23", "name": "Symptoms and General Pathology" },
          { "abbrev": "All", "name": "All Conditions" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT05601362",
        "orgStudyIdInfo": { "id": "STUDY00003315" },
        "organization": {
          "fullName": "University of Texas at Austin",
          "class": "OTHER"
        },
        "briefTitle": "Evaluation of a Therapeutic Mobile App for Depression",
        "officialTitle": "Evaluation of a Therapeutic Mobile App for Depression"
      },
      "statusModule": {
        "statusVerifiedDate": "2024-12",
        "overallStatus": "COMPLETED",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2023-03-30", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2023-08-30",
          "type": "ACTUAL"
        },
        "completionDateStruct": { "date": "2023-08-30", "type": "ACTUAL" },
        "studyFirstSubmitDate": "2022-10-26",
        "studyFirstSubmitQcDate": "2022-10-26",
        "studyFirstPostDateStruct": { "date": "2022-11-01", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2024-12-03",
        "lastUpdatePostDateStruct": { "date": "2024-12-06", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": {
          "name": "University of Texas at Austin",
          "class": "OTHER"
        }
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": true,
        "isUnapprovedDevice": true
      },
      "descriptionModule": {
        "briefSummary": "The purpose of this study is a preliminary evaluation of a gamified attention bias modification training (GAMBT) for reducing symptoms of depression and rumination. Individuals with elevated symptoms of depression will use the digital intervention over the course of 4 weeks. They will complete a brief (\\~5 question) survey daily, as well as weekly assessments.",
        "detailedDescription": "This study aims to assess the feasibility and efficacy of the digital therapeutic attention bias modification (ABM) intervention that targets and reduces negative attention bias among adults with elevated symptoms of depression. Consistent with the experimental therapeutics approach ABM has been shown to both reduce negative attention bias and improve symptoms of depression. However, engagement with these tasks have been mixed, with some participants describing traditional ABM tasks as boring. This had led to the development of gamified versions of ABM with the intent to improve participant engagement. Nevertheless, there have been very few rigorous trials of ABM for depression, and no one to our knowledge has used ecological momentary assessment to tease apart the mechanisms by which ABM can lead to improvements in depression symptoms.\n\nParticipants will access the intervention on their mobile smart phone and complete treatment over a period of 4 weeks. Enrolled participants will be randomly assigned to one of two groups: Gamified attention bias modification training, or gamified placebo training. They will complete brief (\\~5 questions) daily surveys, as well as weekly remote assessments of attention bias and depression symptoms."
      },
      "conditionsModule": { "conditions": ["Depression"] },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": {
            "masking": "DOUBLE",
            "whoMasked": ["PARTICIPANT", "OUTCOMES_ASSESSOR"]
          }
        },
        "enrollmentInfo": { "count": 110, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "Gamified Attention Bias Modification",
            "type": "ACTIVE_COMPARATOR",
            "description": "Digital therapeutic intervention based on Attention Bias Modification Training (ABMT) designed to decrease negative attention bias.",
            "interventionNames": [
              "Device: Gamified Attention Bias Modification"
            ]
          },
          {
            "label": "Gamified Placebo Training",
            "type": "SHAM_COMPARATOR",
            "description": "Identical version of the gamified behavioral intervention without manipulation designed to decrease negative attention bias",
            "interventionNames": ["Device: Gamified Placebo Training"]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "Gamified Attention Bias Modification",
            "description": "Gamified computerized behavioral therapy with therapeutic intervention based on Attention Bias Modification Training (ABMT).",
            "armGroupLabels": ["Gamified Attention Bias Modification"]
          },
          {
            "type": "DEVICE",
            "name": "Gamified Placebo Training",
            "description": "Placebo version of Gamified Attention Bias Modification. (Identical version of the gamified behavioral intervention without manipulation designed to decrease negative attention bias).",
            "armGroupLabels": ["Gamified Placebo Training"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Patient Health Questionnaire - 8 (PHQ-8)",
            "description": "8-item self-report measure of depression symptom severity (Range: 0-24, higher scores indicate greater depression severity)",
            "timeFrame": "Baseline to Treatment End (4 weeks)"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Ruminative Response Scale - Brooding subscale (RRS-B)",
            "description": "5-item self-report measure of rumination frequency (Range: 1-20, higher scores indicate more rumination)",
            "timeFrame": "Baseline to Treatment End (4 weeks)"
          },
          {
            "measure": "Perseverative Thinking Questionnaire (PTQ) -\"Difficult to Disengage from\" subscale",
            "description": "3-item self-report measure of rumination frequency (Range: 0-12, higher scores indicate more rumination)",
            "timeFrame": "Baseline to Treatment End (4 weeks)"
          },
          {
            "measure": "Inventory of Depression and Anxiety Symptoms (IDAS) Dysphoria subscale",
            "description": "10-item measure of dysphoria and depression symptoms (Range: 10-50, higher scores indicate greater dysphoria)",
            "timeFrame": "Baseline to Treatment End (4 weeks)"
          }
        ],
        "otherOutcomes": [
          {
            "measure": "Attention bias (mousetracking)",
            "description": "Change in scan time for viewing sad stimuli assessed via mousetracking",
            "timeFrame": "Weekly assessment over 4 weeks"
          },
          {
            "measure": "General Rumination",
            "description": "Change in rumination (assessed via smartphone-delivered ecological momentary assessment items used in prior EMA research (Smith et al., 2021)). (Range: 4-20, higher scores indicate more rumination)",
            "timeFrame": "daily over 4 weeks"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* able and willing to provide informed consent;\n* fluent in English;\n* normal or corrected-to-normal vision\n* moderate or greater depression symptoms (defined as greater than or equal to 10 on the PHQ-8);\n* attention bias for negative stimuli (operationalized as greater than an average of 6500 ms of dwell time on sad faces in an attention bias task);\n* stable psychiatric and neurological medication usage.\n* access to a smartphone for downloading the app and a laptop or desktop computer to complete the weekly assessments\n\nExclusion Criteria:\n\n* recent heavy alcohol use defined as a score of 2 or higher on the PDSQ\n* past or present comorbidity of other serious mental illness (e.g., schizophrenia, substance use disorder, bipolar disorder, etc.)\n* previous experience with gamified attention bias modification app",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "maximumAge": "45 Years",
        "stdAges": ["ADULT"]
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "facility": "Mary Eileen McNamara",
            "city": "Austin",
            "state": "Texas",
            "zip": "78712",
            "country": "United States",
            "geoPoint": { "lat": 30.26715, "lon": -97.74306 }
          }
        ]
      },
      "ipdSharingStatementModule": {
        "ipdSharing": "YES",
        "description": "De-identified data will be made available upon study completion."
      }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [
          { "id": "D003863", "term": "Depression" },
          { "id": "D003866", "term": "Depressive Disorder" }
        ],
        "ancestors": [
          { "id": "D001526", "term": "Behavioral Symptoms" },
          { "id": "D019964", "term": "Mood Disorders" },
          { "id": "D001523", "term": "Mental Disorders" }
        ],
        "browseLeaves": [
          {
            "id": "M7061",
            "name": "Depressive Disorder",
            "asFound": "Depression",
            "relevance": "HIGH"
          },
          {
            "id": "M7058",
            "name": "Depression",
            "asFound": "Depression",
            "relevance": "HIGH"
          },
          { "id": "M4818", "name": "Behavioral Symptoms", "relevance": "LOW" },
          { "id": "M21835", "name": "Mood Disorders", "relevance": "LOW" },
          { "id": "M14473", "name": "Psychotic Disorders", "relevance": "LOW" },
          { "id": "M4815", "name": "Mental Disorders", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" },
          { "abbrev": "All", "name": "All Conditions" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT03934658",
        "orgStudyIdInfo": { "id": "NW101004" },
        "organization": { "fullName": "NightWare", "class": "INDUSTRY" },
        "briefTitle": "Remote Study of NightWare for PTSD With Nightmares",
        "officialTitle": "A Remote Randomized Double-Blind Sham-Controlled Clinical Trial of NightWare in Adults With Post-Traumatic Stress Disorder and Co-Morbid Nightmare Disorder",
        "acronym": "NWVRCT"
      },
      "statusModule": {
        "statusVerifiedDate": "2022-01",
        "overallStatus": "COMPLETED",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2019-05-21", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2021-12-15",
          "type": "ACTUAL"
        },
        "completionDateStruct": { "date": "2021-12-15", "type": "ACTUAL" },
        "studyFirstSubmitDate": "2019-04-29",
        "studyFirstSubmitQcDate": "2019-04-30",
        "studyFirstPostDateStruct": { "date": "2019-05-02", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2022-01-27",
        "lastUpdatePostDateStruct": { "date": "2022-01-28", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": { "name": "NightWare", "class": "INDUSTRY" },
        "collaborators": [
          { "name": "RationalPsych", "class": "UNKNOWN" },
          {
            "name": "Center for International Emergency Medical Services",
            "class": "OTHER"
          }
        ]
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": true,
        "isUnapprovedDevice": true,
        "isUsExport": false
      },
      "descriptionModule": {
        "briefSummary": "This study will provide measures of safety and efficacy of the NightWare digital therapeutic system (iPhone + Apple watch + proprietary application) for the treatment of nightmare disorder associated with post-traumatic stress disorder (PTSD)-related sleep disturbance and the impact of improved sleep with the NightWare digital therapeutic system. The investigators hypothesize that the NightWare digital therapeutic system will significantly improve sleep quality in participants with PTSD-Related nightmares and poor sleep quality.",
        "detailedDescription": "Nightmares are a common problem affecting 2-8% of the general population and a higher proportion of clinical populations. The negative consequences of untreated nightmares are significant and include impaired quality of life, sleep deprivation (often resulting in an increased intensity of nightmares), insomnia, daytime sleepiness, and fatigue. Untreated nightmares can also exacerbate the symptoms of underlying psychological dysfunction in people with depression and anxiety, leading to poor occupational and or social functioning. Nightmares can be idiopathic or associated with the use (or withdrawal) of certain medications or substances or associated with disorders including PTSD.\n\nNightWare (Minneapolis, MN) has developed a novel approach to the treatment of nightmares. Through the use of a smartwatch-based application that senses physiologic parameters, the participant is aroused from sleep (without awakening the participant) so that the nightmare is interrupted prior to reaching a threshold of severity in which the participant would awaken in distress. Seconds later the participant returns to sleep without having experienced a nightmare. This approach avoids risk from pharmacological treatment, avoids exacerbation of symptoms from image rehearsal therapy and allows for a simple method with easily achieved adherence compared to existing treatments.\n\nThe NightWare digital therapeutic system consists of a proprietary software application installed on a smartwatch. The application has been effective in focus groups when used on both Apple smartwatches and Motorola smartwatches. For the purposes of this study, the investigators will be using only the Apple (Cupertino, CA) 3rd generation smartwatch and the Apple iPhone. The NightWare application uses physiological markers obtained via the smartwatch to determine by proprietary algorithm whether a participant is in the early stages of a nightmare, but has not yet awoken in distress. As directed by the algorithm, the smartwatch then applies varying degrees of vibratory stimulation to the wrist over variable lengths of time with the intention of arousing the participant from sleep without eliciting an awakening."
      },
      "conditionsModule": {
        "conditions": [
          "PostTraumatic Stress Disorder",
          "Sleep Disorder",
          "Stress Disorder",
          "Sleep Initiation and Maintenance Disorders",
          "Combat Disorders",
          "Nightmares Associated With Chronic Post-Traumatic Stress Disorder",
          "Nightmare",
          "Nightmares, REM-Sleep Type"
        ],
        "keywords": [
          "PTSD",
          "Nightmare Disorder",
          "Post-traumatic stress disorder",
          "Veteran",
          "Digital therapeutic",
          "Digital medicine",
          "Nightmares"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": {
            "masking": "QUADRUPLE",
            "whoMasked": [
              "PARTICIPANT",
              "CARE_PROVIDER",
              "INVESTIGATOR",
              "OUTCOMES_ASSESSOR"
            ]
          }
        },
        "enrollmentInfo": { "count": 81, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "Active Treatment Arm",
            "type": "EXPERIMENTAL",
            "description": "Intervention with the NightWare Therapeutic System every night.",
            "interventionNames": ["Device: NightWare Therapeutic System"]
          },
          {
            "label": "Sham Arm",
            "type": "SHAM_COMPARATOR",
            "description": "NightWare Therapeutic System every night with interventions not-enabled.",
            "interventionNames": [
              "Device: NightWare Therapeutic System in Sham Mode"
            ]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "NightWare Therapeutic System",
            "description": "A wearable digital therapeutic system that will measure physiologic data when worn during sleep to deliver a mild vibration via the watch to elicit arousal thereby disrupting nightmares. This detection and stimulation sequence will be performed according to NightWare's proprietary algorithm.",
            "armGroupLabels": ["Active Treatment Arm"]
          },
          {
            "type": "DEVICE",
            "name": "NightWare Therapeutic System in Sham Mode",
            "description": "A wearable digital therapeutic system that will measure physiologic data when worn during sleep that does not deliver interventions.",
            "armGroupLabels": ["Sham Arm"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Change in global score on the Pittsburgh Sleep Quality Index (PSQI) from Day 0 to each subsequent 28 day evaluation period",
            "description": "The Pittsburgh Sleep Quality Index (PSQI) is a self-rated questionnaire which assesses sleep quality and disturbances over a 1-month time interval. Nineteen individual items generate seven \"component\" scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. The sum of scores for these seven components yields one global score. In scoring the PSQI, seven component scores are derived, each scored 0 (no difficulty) to 3 (severe difficulty). The component scores are summed to produce a global score (range 0 to 21). Higher scores indicate worse sleep quality. This outcome is the difference between the global score on the Pittsburgh Sleep Quality Index (PSQI) score at baseline (Day 0) and average global PSQI score across the post-treatment initiation assessments (Days 14, 28 and every 28 days after that).",
            "timeFrame": "0-730 days"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria\n\n* Self report of diagnosis with PTSD\n* Self-report of PTSD-related repetitive nightmares contributing to disrupted sleep.\n* Equal to or older than 18 years of age.\n* Proficient in both reading and writing in the English language.\n* Pittsburgh Sleep Quality Index (PSQI) score equal to or greater than 10.\n* ESS: On question #8 any score above \"0\" will prompt an additional question:\n* Do you drive (\"get behind the wheel\") when you are drowsy? Answer must be \"No\" to be enrolled in the study for safety.\n* Participant owns or has access to devices appropriate for participation in the study including compatible Apple Watch and Apple iPhone.\n* Wireless Internet and two power outlets where they sleep.\n* Willingness not to use any other application which collects heart rate data on the phone and watch that is used for NightWare.\n\nExclusion Criteria\n\n* Circadian rhythm disruption on a regular basis (shift-work)\n* Concurrent presence of prohibited medications\n* Current use of varenicline\n* Current use of beta-blockers (unless ophthalmic solutions)\n* Current use of non-dihydropyridines\n* Current use of Prazosin for the treatment of nightmares (can include subjects 2 weeks post-taper and discontinuation)\n* Concurrent presence of prohibited diagnoses\n* Known diagnosis of OSA\n* Diagnosis of an active disorder of arousal from non-rapid eye movement sleep\n* Diagnosis of rapid eye movement sleep behavior disorder\n* Diagnosis of narcolepsy\n* Diagnosis of dementia\n* Uncontrolled atrial fibrillation\n* Use of Alcohol or Drugs as specified:\n* Alcohol Use Disorders Inventory Test (AUDIT) (score of 8 or higher)\n* Drug Abuse Screening Test-10 (DAST-10) (score greater than 2)\n* Suspicion of nightmares being secondary to substance abuse or withdrawal\n* Previous or foreseeable legal proceedings involving nightmares or trauma\n* Nocturia that causes awakening from sleep\n* Known sleep walking\n* Acting out of dreams PRIOR to PTSD trauma\n* Self reported pregnancy or intent to become pregnant during the course of the study",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "Daniel R Karlin, MD MA",
            "affiliation": "RationalPsych",
            "role": "PRINCIPAL_INVESTIGATOR"
          }
        ],
        "locations": [
          {
            "facility": "RationalPsych",
            "city": "Bronx",
            "state": "New York",
            "zip": "10461",
            "country": "United States",
            "geoPoint": { "lat": 40.84985, "lon": -73.86641 }
          }
        ]
      },
      "ipdSharingStatementModule": { "ipdSharing": "YES" }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [
          { "id": "D012893", "term": "Sleep Wake Disorders" },
          {
            "id": "D007319",
            "term": "Sleep Initiation and Maintenance Disorders"
          },
          { "id": "D040921", "term": "Stress Disorders, Traumatic" },
          { "id": "D013313", "term": "Stress Disorders, Post-Traumatic" },
          { "id": "D003130", "term": "Combat Disorders" }
        ],
        "ancestors": [
          {
            "id": "D000068099",
            "term": "Trauma and Stressor Related Disorders"
          },
          { "id": "D001523", "term": "Mental Disorders" },
          { "id": "D009422", "term": "Nervous System Diseases" },
          { "id": "D009461", "term": "Neurologic Manifestations" },
          { "id": "D020919", "term": "Sleep Disorders, Intrinsic" },
          { "id": "D020920", "term": "Dyssomnias" }
        ],
        "browseLeaves": [
          {
            "id": "M16103",
            "name": "Stress Disorders, Post-Traumatic",
            "asFound": "Post Traumatic Stress Disorder",
            "relevance": "HIGH"
          },
          {
            "id": "M24916",
            "name": "Stress Disorders, Traumatic",
            "asFound": "Stress Disorder",
            "relevance": "HIGH"
          },
          {
            "id": "M10356",
            "name": "Sleep Initiation and Maintenance Disorders",
            "asFound": "Sleep Initiation and Maintenance Disorders",
            "relevance": "HIGH"
          },
          { "id": "M22242", "name": "Parasomnias", "relevance": "LOW" },
          {
            "id": "M6358",
            "name": "Combat Disorders",
            "asFound": "Combat Disorders",
            "relevance": "HIGH"
          },
          {
            "id": "M15696",
            "name": "Sleep Wake Disorders",
            "asFound": "Sleep Disorders",
            "relevance": "HIGH"
          },
          { "id": "M17685", "name": "Wounds and Injuries", "relevance": "LOW" },
          {
            "id": "M222",
            "name": "Trauma and Stressor Related Disorders",
            "relevance": "LOW"
          },
          { "id": "M14473", "name": "Psychotic Disorders", "relevance": "LOW" },
          { "id": "M4815", "name": "Mental Disorders", "relevance": "LOW" },
          {
            "id": "M12404",
            "name": "Neurologic Manifestations",
            "relevance": "LOW"
          },
          {
            "id": "M22654",
            "name": "Sleep Disorders, Intrinsic",
            "relevance": "LOW"
          },
          { "id": "M22655", "name": "Dyssomnias", "relevance": "LOW" },
          {
            "id": "T1303",
            "name": "Chronic Graft Versus Host Disease",
            "relevance": "LOW"
          }
        ],
        "browseBranches": [
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" },
          { "abbrev": "All", "name": "All Conditions" },
          { "abbrev": "BC10", "name": "Nervous System Diseases" },
          { "abbrev": "BC23", "name": "Symptoms and General Pathology" },
          { "abbrev": "BC26", "name": "Wounds and Injuries" },
          { "abbrev": "Rare", "name": "Rare Diseases" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT04853849",
        "orgStudyIdInfo": { "id": "CECE2021" },
        "organization": { "fullName": "Renalis", "class": "INDUSTRY" },
        "briefTitle": "Treatment of Overactive Bladder With a Digital Conversational Agent: the MOTIVATION Study",
        "officialTitle": "Treatment of Overactive Bladder With a Digital Conversational Agent: the MOTIVATION Study",
        "acronym": "MOTIVATION"
      },
      "statusModule": {
        "statusVerifiedDate": "2021-11",
        "overallStatus": "UNKNOWN",
        "lastKnownStatus": "RECRUITING",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2021-08-26", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2022-04-30",
          "type": "ESTIMATED"
        },
        "completionDateStruct": { "date": "2024-04-30", "type": "ESTIMATED" },
        "studyFirstSubmitDate": "2021-03-26",
        "studyFirstSubmitQcDate": "2021-04-17",
        "studyFirstPostDateStruct": { "date": "2021-04-21", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2021-11-27",
        "lastUpdatePostDateStruct": { "date": "2021-12-10", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": { "name": "Renalis", "class": "INDUSTRY" },
        "collaborators": [
          {
            "name": "University Hospitals Cleveland Medical Center",
            "class": "OTHER"
          }
        ]
      },
      "oversightModule": {
        "oversightHasDmc": true,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": false
      },
      "descriptionModule": {
        "briefSummary": "This is a proof of concept study for a digital therapeutic designed to provide first-line behavioral modification therapy for overactive bladder.",
        "detailedDescription": "The investigators seek to evaluate a commercial digital therapeutic, called CeCe, designed to provide first-line behavioral modification therapy for overactive bladder (OAB). This digital platform provides daily contact with the user to maximize compliance. It allows a provider to administer behavioral modification treatment while minimizing in-office visits.\n\nThe investigators expect that a proportion of participants using Cece will experience significant and satisfactory improvement in their voiding symptoms, to the point where no further treatment is necessary. Others will require additional treatment with the usual therapies such physical therapy and medications, per clinical standards.\n\nParticipants will download CeCe to their smart phones and interact with the program for 8 weeks. Participant consent and specific instructions will be provided during study enrollment and through the app. Study outcomes are collected through the program via in-app questionnaires and voiding diaries.\n\nA total of 50 participants will be recruited. They will be compensated a total sum of $175; $50 at completion of an initial set of questionnaires, $50 at completion of 4 week follow-up questionnaires, and $75 at completion of 8 week follow-up."
      },
      "conditionsModule": {
        "conditions": [
          "Overactive Bladder",
          "Urge Incontinence",
          "Pelvic Floor Disorders"
        ],
        "keywords": [
          "Digital therapeutic",
          "Overactive bladder",
          "Urge incontinence",
          "Pelvic floor disorders"
        ]
      },
      "designModule": {
        "studyType": "OBSERVATIONAL",
        "patientRegistry": false,
        "designInfo": {
          "observationalModel": "COHORT",
          "timePerspective": "PROSPECTIVE"
        },
        "enrollmentInfo": { "count": 50, "type": "ESTIMATED" }
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Change of overactive bladder quality of life measure",
            "description": "International Consultation on Incontinence Questionnaire Overactive Bladder Quality of Life questionnaire (ICIQ-OAB-QoL) is a 26 item questionnaire evaluating quality of life (QoL) in patients with overactive bladder. Scores range from 25-160, with greater values indicating increased impact on quality of life.",
            "timeFrame": "Baseline, 4 weeks, and 8 weeks"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Change in symptoms of Overactive bladder",
            "description": "OAB-SS is a symptom assessment questionnaire designed to quantify OAB symptoms. The questionnaire consists of 4 questions. The score ranges from 0-15 with higher score indicating more severe OAB symptoms",
            "timeFrame": "Baseline, 4 weeks, and 8 weeks"
          },
          {
            "measure": "Change in general health state",
            "description": "SF-36 is a 36 item questionnaire measuring general health. Scores range from 0-100 with higher scores indicating more favorable health state.",
            "timeFrame": "Baseline, 4 weeks, and 8 weeks"
          },
          {
            "measure": "Global impression of improvement",
            "description": "The Patient Global Impression of Improvement (PGI-I) is a global index used to rate the response of a condition to a therapy. Scores range from 1-7, with higher values (5-7) indicating higher degree is improvement and lower values (1-3) indicating worse outcomes.",
            "timeFrame": "At 4 weeks"
          },
          {
            "measure": "Global impression of improvement",
            "description": "The Patient Global Impression of Improvement (PGI-I) is a global index used to rate the response of a condition to a therapy. Scores range from 1-7, with higher values (5-7) indicating higher degree is improvement and lower values (1-3) indicating worse outcomes.",
            "timeFrame": "At 8 weeks"
          },
          {
            "measure": "Change in anxiety",
            "description": "General Anxiety Disorder 7 item (GAD-7) questionnaire is a measure for assessing generalized anxiety disorder. Score ranges from 0-21 with high scores representing more severe depression.",
            "timeFrame": "Baseline, 4 weeks, and 8 weeks"
          },
          {
            "measure": "Usability",
            "description": "System Usability Scale (SUS) is a 10 item questionnaire for measuring the usability. Scores range from 0-100, with higher scores indicating better usability.",
            "timeFrame": "8 weeks"
          },
          {
            "measure": "Usability",
            "description": "Nelson's Attributes of Usability (NAU) is a 19 item questionnaire measuring usability. Scores range from 0-50, with higher scores indicating better usability",
            "timeFrame": "8 weeks"
          },
          {
            "measure": "Usability",
            "description": "The Chatbot Usability Questionnaire (CUQ) is a 16 item questionnaire measuring usability of a chatbot. Scores range from 0-100, with higher scores indicating better usability",
            "timeFrame": "8 weeks"
          },
          {
            "measure": "Mobile device proficiency",
            "description": "The Mobile Device Proficiency Questionnaire (MDPQ-16) is a 16 item survey. Scores range from 8.5 - 40, with higher values indicating greater proficiency with mobile devices.",
            "timeFrame": "Baseline"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* Symptoms of overactive bladder with urgency urinary incontinence, with or without nocturia/nocturnal enuresis\n* Symptoms of mixed urinary incontinence if urgency incontinence is the predominant complaint\n* Post-void residual \\<100ml\n* English speaking\n* Access to a smartphone\n* Normal urinalysis without evidence of UTI, gross or microscopic hematuria\n* Greater than 6 months since receiving intradetrusor injection of botulinum toxin\n* Not currently undergoing sacral neuromodulation therapy\n* Not currently receiving pharmacotherapy for overactive bladder\n\nExclusion Criteria:\n\n* Less than 40 years of age\n* Mixed incontinence with predominant stress urinary incontinence symptoms\n* Diagnosis of chronic pelvic pain\n* symptomatic pelvic organ prolapse\n* symptoms of dysuria\n* Diagnosis of interstitial cystitis/painful bladder syndrome\n* Reported \\>2 UTI in 6 months or \\>3 in 12 months\n* Do not have access to a smartphone\n* Non-English speaking\n* Diagnosis of neurogenic bladder\n* Gross or microscopic hematuria\n* Has diagnosis of dementia, cognitive impairment or other neurologic condition which impairs decision making\n* Current Pharmacotherapy or neuromodulation therapy\n* Less than 6 months since intradetrusor botulinum toxin injection\n* Has decreased mobility or ambulation\n* Has post-void residual \\>100 mL\n* Has BMI \\> 40 kg/m\\^2\n* Inability to voluntarily contract the pelvic floor muscles (a 0/5 in strength).\n* Has \\>4/10 pain with palpation of levator ani, coccygeus, pyriformis, obturator internus or perineal body",
        "sex": "FEMALE",
        "minimumAge": "40 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"],
        "studyPopulation": "Research will be conducted at all University Hospital sites that have a member of the Female Pelvic Medicine and Reconstructive Surgery division seeing patients. This includes UH Richmond, UH Bedford, St. Johns Westshore Medical Center, Landerbook Medical Center, UH Portage Urology, UH Geauga Urology, UHCMC, and UH Westlake. Women 40 years or older with overactive bladder will be screened for and offered study enrollment by the study investigators at each of the above sites.",
        "samplingMethod": "NON_PROBABILITY_SAMPLE"
      },
      "contactsLocationsModule": {
        "centralContacts": [
          {
            "name": "Yufan Chen, MD",
            "role": "CONTACT",
            "phone": "510-364-2122",
            "email": "brandon@renalis.health"
          },
          {
            "name": "Missy Lavender",
            "role": "CONTACT",
            "email": "Missy@renalis.health"
          }
        ],
        "overallOfficials": [
          {
            "name": "David Sheyn, MD",
            "affiliation": "University Hospitals Cleveland Medical Center",
            "role": "PRINCIPAL_INVESTIGATOR"
          }
        ],
        "locations": [
          {
            "facility": "University Hospitals Cleveland Medical Center",
            "status": "RECRUITING",
            "city": "Cleveland",
            "state": "Ohio",
            "zip": "44106",
            "country": "United States",
            "contacts": [{ "name": "David Sheyn, MD", "role": "CONTACT" }],
            "geoPoint": { "lat": 41.4995, "lon": -81.69541 }
          }
        ]
      },
      "referencesModule": {
        "references": [
          {
            "pmid": "10571620",
            "type": "BACKGROUND",
            "citation": "Brown K, Hilton P. The incidence of detrusor instability before and after colposuspension: a study using conventional and ambulatory urodynamic monitoring. BJU Int. 1999 Dec;84(9):961-5. doi: 10.1046/j.1464-410x.1999.00390.x."
          },
          {
            "pmid": "26000514",
            "type": "BACKGROUND",
            "citation": "Reynolds WS, McPheeters M, Blume J, Surawicz T, Worley K, Wang L, Hartmann K. Comparative Effectiveness of Anticholinergic Therapy for Overactive Bladder in Women: A Systematic Review and Meta-analysis. Obstet Gynecol. 2015 Jun;125(6):1423-1432. doi: 10.1097/AOG.0000000000000851."
          },
          {
            "pmid": "14973993",
            "type": "BACKGROUND",
            "citation": "Ostaszkiewicz J, Johnston L, Roe B. Timed voiding for the management of urinary incontinence in adults. Cochrane Database Syst Rev. 2004;2004(1):CD002802. doi: 10.1002/14651858.CD002802.pub2."
          },
          {
            "pmid": "15106179",
            "type": "BACKGROUND",
            "citation": "Ostaszkiewicz J, Johnston L, Roe B. Habit retraining for the management of urinary incontinence in adults. Cochrane Database Syst Rev. 2004;2004(2):CD002801. doi: 10.1002/14651858.CD002801.pub2."
          },
          {
            "pmid": "17184371",
            "type": "BACKGROUND",
            "citation": "Roe B, Ostaszkiewicz J, Milne J, Wallace S. Systematic reviews of bladder training and voiding programmes in adults: a synopsis of findings from data analysis and outcomes using metastudy techniques. J Adv Nurs. 2007 Jan;57(1):15-31. doi: 10.1111/j.1365-2648.2006.04097.x."
          },
          {
            "pmid": "25349943",
            "type": "BACKGROUND",
            "citation": "Kandadai P, O'Dell K, Saini J. Correct performance of pelvic muscle exercises in women reporting prior knowledge. Female Pelvic Med Reconstr Surg. 2015 May-Jun;21(3):135-40. doi: 10.1097/SPV.0000000000000145."
          },
          {
            "pmid": "30527941",
            "type": "BACKGROUND",
            "citation": "Meister MR, Sutcliffe S, Ghetti C, Chu CM, Spitznagle T, Warren DK, Lowder JL. Development of a standardized, reproducible screening examination for assessment of pelvic floor myofascial pain. Am J Obstet Gynecol. 2019 Mar;220(3):255.e1-255.e9. doi: 10.1016/j.ajog.2018.11.1106. Epub 2018 Dec 7."
          },
          {
            "type": "BACKGROUND",
            "citation": "Stewart WF, Corey R, Herzog AR, et al. Prevalence of overactive bladder in women: results from the NOBLE program. International Urogynecology Journal 2001; 12: pp. S66"
          }
        ]
      },
      "ipdSharingStatementModule": { "ipdSharing": "NO" }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [
          { "id": "D053201", "term": "Urinary Bladder, Overactive" },
          { "id": "D059952", "term": "Pelvic Floor Disorders" },
          { "id": "D053202", "term": "Urinary Incontinence, Urge" }
        ],
        "ancestors": [
          { "id": "D001745", "term": "Urinary Bladder Diseases" },
          { "id": "D014570", "term": "Urologic Diseases" },
          { "id": "D052776", "term": "Female Urogenital Diseases" },
          {
            "id": "D005261",
            "term": "Female Urogenital Diseases and Pregnancy Complications"
          },
          { "id": "D000091642", "term": "Urogenital Diseases" },
          { "id": "D052801", "term": "Male Urogenital Diseases" },
          { "id": "D059411", "term": "Lower Urinary Tract Symptoms" },
          { "id": "D020924", "term": "Urological Manifestations" },
          { "id": "D011248", "term": "Pregnancy Complications" },
          { "id": "D014549", "term": "Urinary Incontinence" },
          { "id": "D014555", "term": "Urination Disorders" }
        ],
        "browseLeaves": [
          {
            "id": "M27167",
            "name": "Urinary Bladder, Overactive",
            "asFound": "Overactive Bladder",
            "relevance": "HIGH"
          },
          {
            "id": "M27168",
            "name": "Urinary Incontinence, Urge",
            "asFound": "Urge Incontinence",
            "relevance": "HIGH"
          },
          {
            "id": "M29565",
            "name": "Pelvic Floor Disorders",
            "asFound": "Pelvic Floor Disorders",
            "relevance": "HIGH"
          },
          {
            "id": "M17299",
            "name": "Urinary Incontinence",
            "relevance": "LOW"
          },
          { "id": "M7936", "name": "Enuresis", "relevance": "LOW" },
          {
            "id": "M5026",
            "name": "Urinary Bladder Diseases",
            "relevance": "LOW"
          },
          { "id": "M17319", "name": "Urologic Diseases", "relevance": "LOW" },
          { "id": "M2875", "name": "Urogenital Diseases", "relevance": "LOW" },
          {
            "id": "M27093",
            "name": "Female Urogenital Diseases",
            "relevance": "LOW"
          },
          {
            "id": "M14127",
            "name": "Pregnancy Complications",
            "relevance": "LOW"
          },
          {
            "id": "M8399",
            "name": "Female Urogenital Diseases and Pregnancy Complications",
            "relevance": "LOW"
          },
          {
            "id": "M27095",
            "name": "Male Urogenital Diseases",
            "relevance": "LOW"
          },
          {
            "id": "M29464",
            "name": "Lower Urinary Tract Symptoms",
            "relevance": "LOW"
          },
          {
            "id": "M22659",
            "name": "Urological Manifestations",
            "relevance": "LOW"
          },
          { "id": "M17305", "name": "Urination Disorders", "relevance": "LOW" }
        ],
        "browseBranches": [
          {
            "abbrev": "BXS",
            "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
          },
          { "abbrev": "BC23", "name": "Symptoms and General Pathology" },
          { "abbrev": "All", "name": "All Conditions" },
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT05266625",
        "orgStudyIdInfo": { "id": "DM2-07-CPC" },
        "organization": {
          "fullName": "Better Therapeutics",
          "class": "INDUSTRY"
        },
        "briefTitle": "Digital Therapeutic Based Investigation to Improve Glycemic Control in Patients With Type 2 Diabetes and Residual Hyperglycemia on Stable Medical Therapy",
        "officialTitle": "Randomized, Controlled, Multicenter, Pragmatic, Trial With Open-label Extension of BT-001 to Improve Glycemic Control in Adults With Type 2 Diabetes in a Real-world Setting",
        "acronym": "BRIGHT"
      },
      "statusModule": {
        "statusVerifiedDate": "2023-10",
        "overallStatus": "ACTIVE_NOT_RECRUITING",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2022-02-14", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2025-11",
          "type": "ESTIMATED"
        },
        "completionDateStruct": { "date": "2025-11", "type": "ESTIMATED" },
        "studyFirstSubmitDate": "2022-02-23",
        "studyFirstSubmitQcDate": "2022-02-23",
        "studyFirstPostDateStruct": { "date": "2022-03-04", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2023-10-26",
        "lastUpdatePostDateStruct": { "date": "2023-10-30", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": { "name": "Better Therapeutics", "class": "INDUSTRY" },
        "collaborators": [
          { "name": "CPC Clinical Research", "class": "UNKNOWN" },
          { "name": "University of Colorado, Denver", "class": "OTHER" },
          { "name": "Ascension Health", "class": "INDUSTRY" },
          {
            "name": "Department of Veterans Affairs Hospital Durham, NC",
            "class": "UNKNOWN"
          },
          {
            "name": "University of Colorado Health Clinics",
            "class": "UNKNOWN"
          }
        ]
      },
      "oversightModule": {
        "oversightHasDmc": true,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": true,
        "isUnapprovedDevice": true,
        "isUsExport": false
      },
      "descriptionModule": {
        "briefSummary": "Randomized, controlled, multicenter, pragmatic, pivotal trial with open-label extension evaluating the hypothesis that BT-001 an investigational digital therapeutic intended to help patients with type 2 diabetes improve their glycemic control, will lower hemoglobin A1c (HbA1c) compared to a control application added to usual care and across a broad range of patients in a real-world setting",
        "detailedDescription": "This randomized, controlled, multicenter, parallel-arm, pragmatic pivotal trial with extension will evaluate the hypothesis that BT-001 compared to a control application, both on top of usual care, will lower HbA1c in real world clinical practice. Approximately five-hundred (500) adults with type 2 diabetes will be randomized (1:1) to BT-001 or the control application. Most clinical data will be collected via the electronic medical records (EMR) system with limited additional contacts to ascertain adverse device effects (ADEs), adverse events (AEs) and clinical events which may have occurred outside the health system and were not recorded in the EMR. For primary efficacy endpoint assessment, a requisition form for HbA1c at a local laboratory will be provided if HbA1c is not available from the EMR within the 90- and 180-day time windows. During the extension phase, biomarker endpoint data will only be collected from the EMR. For all participants, clinical and healthcare utilization data will be extracted from their EMR for the period from 180 days prior to enrollment to 720 days after enrollment."
      },
      "conditionsModule": { "conditions": ["Diabetes Mellitus, Type 2"] },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "interventionModelDescription": "Patients will be randomized to an intervention arm or control arm. After 6 months, patients in the control arm will be able to cross over to using the intervention.",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": {
            "masking": "NONE",
            "maskingDescription": "While patients and providers will not be told which arm they are in, it will be obvious when they complete the installation of the mobile application which arm they are in."
          }
        },
        "enrollmentInfo": { "count": 500, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "Intervention BT-001 + Standard of Care",
            "type": "EXPERIMENTAL",
            "description": "Patients in this arm will receive the BT-001 treatment for up to 720 days.",
            "interventionNames": ["Behavioral: BT-001"]
          },
          {
            "label": "Standard of Care",
            "type": "OTHER",
            "description": "Patients will have access to a control mobile application for 180 days and then will have the option to use the treatment for the remainder of the 720 day study",
            "interventionNames": ["Other: Control App"]
          }
        ],
        "interventions": [
          {
            "type": "BEHAVIORAL",
            "name": "BT-001",
            "description": "Bt-001 is a software application that delivers treatment to participants with type 2 diabetes, using behavioral therapy. BT-001 is accessed via the participants' smartphone.\n\nThe behavioral intervention process involves:\n\nIdentifying maladaptive thoughts based on misinformed core beliefs that lead to disease-promoting behaviors; replacing maladaptive core beliefs with adaptive ways of thinking; and providing collaborative construction of behavioral exercises to test core beliefs.\n\nEach week, Bt-001 asks participants to complete a new lesson, along with one skill exercise. The lessons are expected to take between 10-20 minutes to complete. In addition to completing a lesson and skill, participants will be directed to report plant-based meals consumed and minutes of exercise completed and to measure their blood sugar daily.",
            "armGroupLabels": ["Intervention BT-001 + Standard of Care"]
          },
          {
            "type": "OTHER",
            "name": "Control App",
            "description": "The app asks patients brief questions about their health but does not include any behavioral therapy.",
            "armGroupLabels": ["Standard of Care"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Change in HbA1c",
            "description": "Difference in the mean change from baseline in HbA1c between treatment groups.",
            "timeFrame": "90 days"
          },
          {
            "measure": "Adverse Events",
            "description": "Occurrence, relatedness and severity of adverse device effects and adverse events between treatment groups",
            "timeFrame": "90 days"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Difference in HbA1c",
            "description": "Difference in mean change from baseline in HbA1c between treatment groups.",
            "timeFrame": "180 days"
          },
          {
            "measure": "Adverse Events",
            "description": "Occurrence, relatedness and severity of adverse device effects and adverse events between treatment groups",
            "timeFrame": "180 days"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* Age 18-75 years, inclusive at the time of signing the informed consent\n* Type 2 diabetes on stable anti-diabetic regimen for at least three (3) months\n* HbA1c 7.0% to 10.9% (within thirty \\[30\\] days of signing the informed consent form \\[ICF\\])\n* Able to use BT-001 e.g., English fluent, smartphone is capable of running the study intervention.\n\nExclusion Criteria:\n\n* Current use of outpatient prandial insulin\n* In the opinion of the investigator, life expectancy \\< one (1) year\n* COVID-19 diagnosis within thirty (30) days prior to randomization.",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "maximumAge": "75 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "facility": "University of Colorado Hospital",
            "city": "Aurora",
            "state": "Colorado",
            "zip": "80045",
            "country": "United States",
            "geoPoint": { "lat": 39.72943, "lon": -104.83192 }
          },
          {
            "facility": "Ascension DePaul Community Health",
            "city": "New Orleans",
            "state": "Louisiana",
            "zip": "70118",
            "country": "United States",
            "geoPoint": { "lat": 29.95465, "lon": -90.07507 }
          },
          {
            "facility": "VA Medical Center-Durham",
            "city": "Durham",
            "state": "North Carolina",
            "zip": "27705",
            "country": "United States",
            "geoPoint": { "lat": 35.99403, "lon": -78.89862 }
          }
        ]
      },
      "ipdSharingStatementModule": {
        "ipdSharing": "NO",
        "description": "no plan to share IPD"
      }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [
          { "id": "D003920", "term": "Diabetes Mellitus" },
          { "id": "D003924", "term": "Diabetes Mellitus, Type 2" }
        ],
        "ancestors": [
          { "id": "D044882", "term": "Glucose Metabolism Disorders" },
          { "id": "D008659", "term": "Metabolic Diseases" },
          { "id": "D004700", "term": "Endocrine System Diseases" }
        ],
        "browseLeaves": [
          {
            "id": "M7115",
            "name": "Diabetes Mellitus",
            "asFound": "Diabetes",
            "relevance": "HIGH"
          },
          {
            "id": "M7119",
            "name": "Diabetes Mellitus, Type 2",
            "asFound": "Diabetes Mellitus, Type 2",
            "relevance": "HIGH"
          },
          { "id": "M9994", "name": "Hyperglycemia", "relevance": "LOW" },
          { "id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW" },
          {
            "id": "M25403",
            "name": "Glucose Metabolism Disorders",
            "relevance": "LOW"
          },
          {
            "id": "M7862",
            "name": "Endocrine System Diseases",
            "relevance": "LOW"
          }
        ],
        "browseBranches": [
          { "abbrev": "BC18", "name": "Nutritional and Metabolic Diseases" },
          { "abbrev": "BC19", "name": "Gland and Hormone Related Diseases" },
          { "abbrev": "All", "name": "All Conditions" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT06669780",
        "orgStudyIdInfo": { "id": "AMMO-TBI-2023" },
        "organization": {
          "fullName": "Henry M. Jackson Foundation for the Advancement of Military Medicine",
          "class": "OTHER"
        },
        "briefTitle": "E-CBT DTx for Post Traumatic Headaches in Adults with History of TBI",
        "officialTitle": "Single-Blind, Randomized, Controlled Pilot Trial of a Cognitive-Behavioral Therapy Digital Therapeutic Delivered Online for Post-Traumatic Headaches in Adults with History of Concussive Traumatic Brain Injury",
        "acronym": "AMMO"
      },
      "statusModule": {
        "statusVerifiedDate": "2025-01",
        "overallStatus": "RECRUITING",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2024-01-03", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2025-12-31",
          "type": "ESTIMATED"
        },
        "completionDateStruct": { "date": "2026-06-30", "type": "ESTIMATED" },
        "studyFirstSubmitDate": "2024-06-24",
        "studyFirstSubmitQcDate": "2024-10-31",
        "studyFirstPostDateStruct": { "date": "2024-11-01", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2025-01-06",
        "lastUpdatePostDateStruct": { "date": "2025-01-07", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": {
          "name": "Henry M. Jackson Foundation for the Advancement of Military Medicine",
          "class": "OTHER"
        },
        "collaborators": [
          {
            "name": "Uniformed Services University of the Health Sciences",
            "class": "FED"
          },
          {
            "name": "Military Traumatic Brain Injury Initiative",
            "class": "UNKNOWN"
          }
        ]
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": true,
        "isUsExport": true
      },
      "descriptionModule": {
        "briefSummary": "The AMMO digital therapeutic (DTx) study will provide an online based program for participants with migraines after head injury to follow for 12 weeks. This study aims to see if using cognitive behavioral therapy aimed at military service members in an online self administered platform is effective therapy in the relief of migraines compared. The study will use a single blind online comparative program to test the effect.",
        "detailedDescription": "The AMMO digital therapeutic (DTx) will be a novel intervention for PTH following concussive TBI, therefore this project is a pilot trial designed to test this new treatment. This pilot is a single-blind, randomized, controlled, interventional trial of current and former military personnel along with civilians with a history of concussive TBI and current PTH. The pilot trial will be conducted via online portal accessible by smartphone, tablet, or computer with remote interaction between participants and study staff. The pilot trial will include up to 100 participants randomized to either the active intervention or a comparison condition at a 1:1 ratio, and will provide preliminary data to determine the sample size of a future full clinical trial. Participants will complete a 12 week intervention period followed by a follow-up assessment 4 weeks after intervention is complete. Participants randomized to the comparison group will be provided access to the open label after end of 16 week follow-up.\n\nIn addition, updates to the DTx to improve usability and acceptability will be made if necessary based on feedback from the pilot trial, then applied to the final DTx used in a future, larger, clinical trial."
      },
      "conditionsModule": { "conditions": ["Post-Traumatic Headache"] },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": { "masking": "SINGLE", "whoMasked": ["PARTICIPANT"] }
        },
        "enrollmentInfo": { "count": 100, "type": "ESTIMATED" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "Active",
            "type": "EXPERIMENTAL",
            "description": "This arm will receive access to an online program that will guide them through cognitive behavioral therapy program.",
            "interventionNames": ["Device: AMMO PTH DTx"]
          },
          {
            "label": "Sham comparator",
            "type": "SHAM_COMPARATOR",
            "description": "Participants will obtain access to an online program with activities not including the cognitive behavioral therapy",
            "interventionNames": ["Device: AMMO SHAM"]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "AMMO PTH DTx",
            "description": "An online cognitive behavioral therapy program accessed through a online program.",
            "armGroupLabels": ["Active"]
          },
          {
            "type": "DEVICE",
            "name": "AMMO SHAM",
            "description": "Online activities not including CBT in the AMMO online program.",
            "armGroupLabels": ["Sham comparator"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "6-Item Headache Impact Test™ (HIT-6™)",
            "description": "The HIT-6™ is a brief standardized headache screening tool and questionnaire, derived from the original 54-item Headache Impact Test. It has been found to have good psychometric properties in assessing headache impact among patients in clinical practice and research (Bjorner, Kosinski, \\& Ware, 2003; Kosinski et al., 2003).",
            "timeFrame": "16 weeks"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Determine the appropriate sample size for a future full clinical trial based on preliminary estimates of effect size for outcome measures",
            "description": "Use of Headache Impact Test and number of headache days per month to compare arms. This data will identify any changes to sample size in future studies.",
            "timeFrame": "12 weeks"
          },
          {
            "measure": "Post Traumatic Stress Disorder Checklist (DSM-5)",
            "description": "The PCL-5 is a self-report questionnaire designed to assess symptoms of PTSD (Blevins, Weathers, Davis, Witte, \\& Domino, 2015). The PCL-5 takes approximately 5-10 minutes to complete.",
            "timeFrame": "16 weeks"
          },
          {
            "measure": "Traumatic Brain Injury Quality of Life Scale (TBI-QOL)",
            "description": "The TBI-QOL is a self-report questionnaire composed of 22 item banks (Tulsky et al., 2016). It was developed to measure multiple domains of life for patients living with TBI, including physical, mental, cognitive, and social. The TBI-QOL takes approximately 30 minutes to complete.",
            "timeFrame": "16 weeks"
          },
          {
            "measure": "Patient Health Questionnaire-9",
            "description": "The PHQ-9 is a self-report assessment for depressive symptoms (Kroenke, Spitzer, \\& Williams, 2001). Each item is scored on a scale of 0 to 3 providing a summary score that ranges from 0 to 27, with higher scores representing more severe depression. On the PHQ-9 a total score \\<5 is considered minimal depression, and scores of 5 to 9, 10 to 14, 15 to 19, and 20 to 27 are considered mild, moderate, moderately severe, and severe depression, respectively.",
            "timeFrame": "16 weeks"
          },
          {
            "measure": "Insomnia Severity Index (ISI)",
            "description": "The ISI is a self-report questionnaire designed to assess the presence and severity of primary insomnia sleep disorder and is empirically-validated in general and military populations (Bastien et al., 2001; Jenkins et al., 2015; Morin, Belleville, Belanger, \\& Ivers, 2011).",
            "timeFrame": "16 weeks"
          },
          {
            "measure": "User Version of the Mobile Application Rating Scale",
            "description": "Adapted from the Mobile Application Rating Scale (MARS), the uMARS is a 26-item self-report questionnaire designed to assess the quality, functionality, and aesthetics of a mobile application and its information (Stoyanov, Hides, Kavanagh, \\& Wilson, 2016). There is an additional open-text question for further comments on the users' opinions of the application. The uMARS takes approximately 15 minutes to complete. This measure will be optional for participants to complete.",
            "timeFrame": "12 weeks"
          },
          {
            "measure": "Mobile Agnew Relationship Measure",
            "description": "The mARM is an adaptation of a valid and reliable assessment of therapeutic alliance in face-to-face therapy (Berry, Salter, Morris, James, \\& Bucci, 2018). The 25-item questionnaire has been adjusted for use with digital health interventions, specifically for mental health. The mARM takes approximately 5 minutes to complete.",
            "timeFrame": "12 weeks"
          },
          {
            "measure": "User Program Feedback Questionnaire",
            "description": "Brief questionnaire utilizing Likert Scales related to gathering user feedback on personal experience with ease and accessibility of app utilization.",
            "timeFrame": "12 weeks"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* Be aged ≥ 18 to ≤ 70 years\n* Have a history of concussive TBI ≥ 3 months prior to enrollment:\n* A concussive TBI is defined by having at least one of the following after a head trauma (ACRM, 1993) oAny period of loss of consciousness; oAny loss of memory for events immediately before or after the accident; oAny alteration in mental state at the time of the accident (e.g., feeling dazed, disoriented, or confused); and oFocal neurological deficit(s) that may or may not be transient oThe injury must not exceed any of the following (ACRM, 1993):\n* Loss of consciousness of approximately 30 minutes or less;\n* After 30 minutes an initial GCS score of 13-15; and\n* PTA not greater than 24 hours\n\n  * Head trauma resulting in concussive TBI can be due to blast or non-blast mechanisms\n  * Head trauma resulting in concussive TBI can have occurred any time in the participant's life: prior to military service, during deployment, in garrison, or after leaving military service\n* Have a history of chronic PTH defined as:\n\n  o Headache is reported to have developed (or worsened) after one of the following\\*:\n* The injury to the head;\n* Regaining of consciousness following the injury to the head; or\n* Discontinuation of medication(s) impairing ability to sense or report headache following the injury to the head\n* Not better accounted for by another ICHD-3 diagnosis\\*\\*\n\n  o The headache persists for \\>3 months after its onset (ICHD, 2013)\n* Have a HIT-6™ score of ≥ 56 to 78 indicative of substantial impact (56-59) or severe impact (60-78) on functioning (Yang, Rendas-Baum, Varon, \\& Kosinski, 2011)\n* Be able to provide written, informed consent in English and follow study-related instructions\n* Have ownership of or reliable access to a smartphone with a data plan or internet connecting capabilities\n* Be aged ≥ 18 to ≤ 70 years\n* Have a history of concussive TBI ≥ 3 months prior to enrollment:\n* A concussive TBI is defined by having at least one of the following after a head trauma (ACRM, 1993):\n\n  * Any period of loss of consciousness;\n  * Any loss of memory for events immediately before or after the accident;\n  * Any alteration in mental state at the time of the accident (e.g., feeling dazed, disoriented, or confused); and\n  * Focal neurological deficit(s) that may or may not be transient\n  * The injury must not exceed any of the following (ACRM, 1993):\n* Loss of consciousness of approximately 30 minutes or less;\n* After 30 minutes an initial GCS score of 13-15; and\n* PTA not greater than 24 hours\n\n  * Head trauma resulting in concussive TBI can be due to blast or non-blast mechanisms\n  * Head trauma resulting in concussive TBI can have occurred any time in the participant's life: prior to military service, during deployment, in garrison, or after leaving military service\n* Have a history of chronic PTH defined as:\n\n  o Headache is reported to have developed (or worsened) after one of the following\\*:\n* The injury to the head;\n* Regaining of consciousness following the injury to the head; or\n* Discontinuation of medication(s) impairing ability to sense or report headache following the injury to the head\n* Not better accounted for by another ICHD-3 diagnosis\\*\\*\n\n  o The headache persists for \\>3 months after its onset (ICHD, 2013)\n* Have a HIT-6™ score of ≥ 56 to 78 indicative of substantial impact (56-59) or severe impact (60-78) on functioning (Yang, Rendas-Baum, Varon, \\& Kosinski, 2011)\n* Be able to provide written, informed consent in English and follow study-related instructions\n* Have ownership of or reliable access to a smartphone with a data plan or internet connecting capabilities\n\nExclusion Criteria:\n\n* They experienced a moderate or severe TBI\n* Their secondary headache is better accounted for by the ICHD-3 diagnosis of 8.2 medication-overuse headache; must meet diagnostic criteria for at least 1 medication-overuse headache diagnosis (8.2.1-8.2.8)\n* They are currently engaged in psychotherapeutic treatment or have engaged in psychotherapeutic treatment within 8 weeks prior to trial enrollment (for more information regarding recent treatment in potential participants, see section '3.2 Study Procedures,' sub-section 'Baseline Evaluation')\n* They report change or discontinuation of headache prophylaxis in the past 4 weeks\n* They report active psychotic or bipolar symptoms\n* In the opinion of the investigator, they have other considerations that may adversely affect patient safety, participation, or scientific validity of the data being collected (including, but not limited to, active plan or intent for suicide, visual impairment, hand dysfunction or amputation, substantial cognitive impairment, life expectancy of less than 6 months)",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "maximumAge": "70 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "centralContacts": [
          {
            "name": "Noushin Mannan",
            "role": "CONTACT",
            "phone": "301-456-5474",
            "email": "AMMO@usuhs.edu"
          }
        ],
        "locations": [
          {
            "facility": "100% Remote Recruitment: Center for Neurscience and Regenerative Medicine",
            "status": "RECRUITING",
            "city": "Bethesda",
            "state": "Maryland",
            "zip": "20817",
            "country": "United States",
            "contacts": [
              {
                "name": "Noushin Mannan",
                "role": "CONTACT",
                "phone": "301-456-5474",
                "email": "AMMO@usuhs.edu"
              },
              {
                "name": "Olivia Shaw",
                "role": "CONTACT",
                "phone": "301-461-4322",
                "email": "AMMO@usuhs.edu"
              },
              { "name": "David Brody, MD", "role": "CONTACT" }
            ],
            "geoPoint": { "lat": 38.98067, "lon": -77.10026 }
          }
        ]
      },
      "referencesModule": {
        "references": [
          {
            "pmid": "29674307",
            "type": "BACKGROUND",
            "citation": "Berry K, Salter A, Morris R, James S, Bucci S. Assessing Therapeutic Alliance in the Context of mHealth Interventions for Mental Health Problems: Development of the Mobile Agnew Relationship Measure (mARM) Questionnaire. J Med Internet Res. 2018 Apr 19;20(4):e90. doi: 10.2196/jmir.8252."
          },
          {
            "pmid": "27287964",
            "type": "BACKGROUND",
            "citation": "Stoyanov SR, Hides L, Kavanagh DJ, Wilson H. Development and Validation of the User Version of the Mobile Application Rating Scale (uMARS). JMIR Mhealth Uhealth. 2016 Jun 10;4(2):e72. doi: 10.2196/mhealth.5849."
          },
          {
            "pmid": "21532953",
            "type": "BACKGROUND",
            "citation": "Morin CM, Belleville G, Belanger L, Ivers H. The Insomnia Severity Index: psychometric indicators to detect insomnia cases and evaluate treatment response. Sleep. 2011 May 1;34(5):601-8. doi: 10.1093/sleep/34.5.601."
          },
          {
            "pmid": "26085301",
            "type": "BACKGROUND",
            "citation": "Jenkins MM, Colvonen PJ, Norman SB, Afari N, Allard CB, Drummond SP. Prevalence and Mental Health Correlates of Insomnia in First-Encounter Veterans with and without Military Sexual Trauma. Sleep. 2015 Oct 1;38(10):1547-54. doi: 10.5665/sleep.5044."
          },
          {
            "pmid": "11438246",
            "type": "BACKGROUND",
            "citation": "Bastien CH, Vallieres A, Morin CM. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med. 2001 Jul;2(4):297-307. doi: 10.1016/s1389-9457(00)00065-4."
          },
          {
            "pmid": "25931184",
            "type": "BACKGROUND",
            "citation": "Tulsky DS, Kisala PA, Victorson D, Carlozzi N, Bushnik T, Sherer M, Choi SW, Heinemann AW, Chiaravalloti N, Sander AM, Englander J, Hanks R, Kolakowsky-Hayner S, Roth E, Gershon R, Rosenthal M, Cella D. TBI-QOL: Development and Calibration of Item Banks to Measure Patient Reported Outcomes Following Traumatic Brain Injury. J Head Trauma Rehabil. 2016 Jan-Feb;31(1):40-51. doi: 10.1097/HTR.0000000000000131."
          },
          {
            "pmid": "11556941",
            "type": "BACKGROUND",
            "citation": "Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001 Sep;16(9):606-13. doi: 10.1046/j.1525-1497.2001.016009606.x."
          },
          {
            "pmid": "26606250",
            "type": "BACKGROUND",
            "citation": "Blevins CA, Weathers FW, Davis MT, Witte TK, Domino JL. The Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5): Development and Initial Psychometric Evaluation. J Trauma Stress. 2015 Dec;28(6):489-98. doi: 10.1002/jts.22059. Epub 2015 Nov 25."
          },
          {
            "pmid": "14651411",
            "type": "BACKGROUND",
            "citation": "Kosinski M, Bjorner JB, Ware JE Jr, Batenhorst A, Cady RK. The responsiveness of headache impact scales scored using 'classical' and 'modern' psychometric methods: a re-analysis of three clinical trials. Qual Life Res. 2003 Dec;12(8):903-12. doi: 10.1023/a:1026111029376."
          },
          {
            "pmid": "14651417",
            "type": "BACKGROUND",
            "citation": "Bjorner JB, Kosinski M, Ware JE Jr. Using item response theory to calibrate the Headache Impact Test (HIT) to the metric of traditional headache scales. Qual Life Res. 2003 Dec;12(8):981-1002. doi: 10.1023/a:1026123400242."
          }
        ]
      },
      "ipdSharingStatementModule": { "ipdSharing": "NO" }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [
          { "id": "D051298", "term": "Post-Traumatic Headache" },
          { "id": "D006261", "term": "Headache" }
        ],
        "ancestors": [
          { "id": "D010146", "term": "Pain" },
          { "id": "D009461", "term": "Neurologic Manifestations" },
          { "id": "D051271", "term": "Headache Disorders, Secondary" },
          { "id": "D020773", "term": "Headache Disorders" },
          { "id": "D001927", "term": "Brain Diseases" },
          { "id": "D002493", "term": "Central Nervous System Diseases" },
          { "id": "D009422", "term": "Nervous System Diseases" }
        ],
        "browseLeaves": [
          { "id": "M5207", "name": "Brain Injuries", "relevance": "LOW" },
          {
            "id": "M628",
            "name": "Brain Injuries, Traumatic",
            "relevance": "LOW"
          },
          {
            "id": "M9351",
            "name": "Headache",
            "asFound": "Headache",
            "relevance": "HIGH"
          },
          {
            "id": "M26669",
            "name": "Post-Traumatic Headache",
            "asFound": "Post-Traumatic Headache",
            "relevance": "HIGH"
          },
          { "id": "M13066", "name": "Pain", "relevance": "LOW" },
          {
            "id": "M12404",
            "name": "Neurologic Manifestations",
            "relevance": "LOW"
          },
          { "id": "M12307", "name": "Neoplasm Metastasis", "relevance": "LOW" },
          { "id": "M22529", "name": "Headache Disorders", "relevance": "LOW" },
          {
            "id": "M26658",
            "name": "Headache Disorders, Secondary",
            "relevance": "LOW"
          },
          { "id": "M5204", "name": "Brain Diseases", "relevance": "LOW" },
          {
            "id": "M5742",
            "name": "Central Nervous System Diseases",
            "relevance": "LOW"
          }
        ],
        "browseBranches": [
          { "abbrev": "BC10", "name": "Nervous System Diseases" },
          { "abbrev": "BC26", "name": "Wounds and Injuries" },
          { "abbrev": "All", "name": "All Conditions" },
          { "abbrev": "BC23", "name": "Symptoms and General Pathology" },
          { "abbrev": "BC04", "name": "Neoplasms" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT05032404",
        "orgStudyIdInfo": { "id": "PROT002 - Test Plan 01 Rev A" },
        "organization": {
          "fullName": "Blue Note Therapeutics",
          "class": "INDUSTRY"
        },
        "briefTitle": "Blue Note Therapeutics Product BNT 103 Usability and User Engagement",
        "officialTitle": "BNT 103 Usability and User Engagement"
      },
      "statusModule": {
        "statusVerifiedDate": "2022-10",
        "overallStatus": "COMPLETED",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2021-09-01", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2021-10-26",
          "type": "ACTUAL"
        },
        "completionDateStruct": { "date": "2021-12-31", "type": "ACTUAL" },
        "studyFirstSubmitDate": "2021-08-31",
        "studyFirstSubmitQcDate": "2021-08-31",
        "studyFirstPostDateStruct": { "date": "2021-09-02", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2022-10-18",
        "lastUpdatePostDateStruct": { "date": "2022-10-19", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": {
          "name": "Blue Note Therapeutics",
          "class": "INDUSTRY"
        },
        "collaborators": [
          {
            "name": "Healthcare Innovation Technology Lab",
            "class": "INDUSTRY"
          }
        ]
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": true,
        "isUnapprovedDevice": true,
        "isUsExport": false
      },
      "descriptionModule": {
        "briefSummary": "This test aims to explore product development-focused usability and user engagement.",
        "detailedDescription": "Sponsor is testing an innovative peer-to-peer communication tool during this trial."
      },
      "conditionsModule": { "conditions": ["Breast Cancer Female"] },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "NA",
          "interventionModel": "SINGLE_GROUP",
          "primaryPurpose": "DEVICE_FEASIBILITY",
          "maskingInfo": { "masking": "NONE" }
        },
        "enrollmentInfo": { "count": 15, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "BNT103",
            "type": "EXPERIMENTAL",
            "description": "All participants receive BNT103. BNT103 provides 10 sessions over approximately 10 weeks.",
            "interventionNames": ["Device: BNT103"]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "BNT103",
            "description": "BNT-103™ is a prescription digital therapeutic specifically designed to treat the symptoms of anxiety and depression related to cancer. There are 10 sessions provided over approximately 10 weeks.",
            "armGroupLabels": ["BNT103"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Mean mHealth App Usability Questionnaire (MAUQ) for Standalone mHealth Apps Used by Patients",
            "description": "Higher scores indicate higher ease of use / easier to use applications",
            "timeFrame": "Baseline up to Week 7"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Measure of Current Status - Anxiety (MOCS-A)",
            "description": "The MOCS-A is a 13-item self-report measure developed to assess participants' current self-perceived status on: the ability to relax at will, recognize stress-inducing situations, restructure maladaptive thoughts, be assertive about needs, and choose appropriate coping responses as needed, higher scores indicate greater self-perceived proficiency with these skills.",
            "timeFrame": "Baseline up to Week 7"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* Patient can read, write, and speak in English\n* Patient is between the ages of 35-55\n* Diagnosed with Stage I-III breast cancer\n* In active treatment or within 3 months of ending active treatment and under the care of a clinician at time of study\n* Apple mobile phone or tablet user\n* Willing to participate in study protocol\n\nExclusion Criteria:\n\n* Any participant not meeting inclusion criteria",
        "healthyVolunteers": false,
        "sex": "FEMALE",
        "genderBased": true,
        "genderDescription": "Diagnosed with breast cancer",
        "minimumAge": "35 Years",
        "maximumAge": "55 Years",
        "stdAges": ["ADULT"]
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "Dianne Shumay, PhD",
            "affiliation": "Blue Note Therapeutics, Inc",
            "role": "PRINCIPAL_INVESTIGATOR"
          }
        ],
        "locations": [
          {
            "facility": "Blue Note Therapeutics",
            "city": "San Francisco",
            "state": "California",
            "zip": "93065",
            "country": "United States",
            "geoPoint": { "lat": 37.77493, "lon": -122.41942 }
          }
        ]
      },
      "referencesModule": {
        "references": [
          {
            "pmid": "18835434",
            "type": "BACKGROUND",
            "citation": "Antoni MH, Lechner S, Diaz A, Vargas S, Holley H, Phillips K, McGregor B, Carver CS, Blomberg B. Cognitive behavioral stress management effects on psychosocial and physiological adaptation in women undergoing treatment for breast cancer. Brain Behav Immun. 2009 Jul;23(5):580-91. doi: 10.1016/j.bbi.2008.09.005. Epub 2008 Sep 20."
          }
        ]
      },
      "ipdSharingStatementModule": { "ipdSharing": "NO" }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "browseLeaves": [
          { "id": "M5220", "name": "Breast Neoplasms", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "BC04", "name": "Neoplasms" },
          { "abbrev": "BC17", "name": "Skin and Connective Tissue Diseases" },
          { "abbrev": "All", "name": "All Conditions" }
        ]
      },
      "interventionBrowseModule": {
        "browseLeaves": [
          { "id": "M6263", "name": "Coal Tar", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "Derm", "name": "Dermatologic Agents" },
          { "abbrev": "All", "name": "All Drugs and Chemicals" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT05372913",
        "orgStudyIdInfo": { "id": "W-GenZD-003" },
        "organization": { "fullName": "Woebot Health", "class": "INDUSTRY" },
        "briefTitle": "Feasibility and Acceptability of W-GenZD vs CBT-light Teletherapy for Adolescents Seeking Mental Health Services",
        "officialTitle": "A Randomized Controlled Trial of the Feasibility and Acceptability of W-GenZD Versus CBT-light Teletherapy for Adolescents Seeking Mental Health Services"
      },
      "statusModule": {
        "statusVerifiedDate": "2024-07",
        "overallStatus": "COMPLETED",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2022-05-11", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2023-01-19",
          "type": "ACTUAL"
        },
        "completionDateStruct": { "date": "2023-02-16", "type": "ACTUAL" },
        "studyFirstSubmitDate": "2022-04-29",
        "studyFirstSubmitQcDate": "2022-05-12",
        "studyFirstPostDateStruct": { "date": "2022-05-13", "type": "ACTUAL" },
        "resultsFirstSubmitDate": "2024-01-10",
        "resultsFirstSubmitQcDate": "2024-07-26",
        "resultsFirstPostDateStruct": {
          "date": "2024-10-17",
          "type": "ACTUAL"
        },
        "lastUpdateSubmitDate": "2024-07-26",
        "lastUpdatePostDateStruct": { "date": "2024-10-17", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": { "name": "Woebot Health", "class": "INDUSTRY" },
        "collaborators": [
          {
            "name": "Children's Hospital of The King's Daughters",
            "class": "OTHER"
          }
        ]
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": false
      },
      "descriptionModule": {
        "briefSummary": "The primary aim of this study is to determine the feasibility and acceptability of the W-GenZD mobile application among a group of adolescents and who have screened and triaged into low-intensity treatment within the Children's Hospital of the King's Daughters. The secondary aim of this study is to determine the preliminary comparative efficacy of W-GenZD and CBT-light teletherapy zoom groups to manage mood concerns at 4-weeks end of treatment relative to baseline. The third aim of this study is to investigate potential differences between group differences on working alliance. An exploratory aim of this study is to observe and describe the utilization and outcomes of the safety procedures utilized within this study."
      },
      "conditionsModule": {
        "conditions": ["Depression", "Anxiety"],
        "keywords": [
          "Mental Health",
          "Adolescence",
          "Digital Therapeutic",
          "Cognitive Behavioral Therapy",
          "Chatbot",
          "Mental Health App"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": { "masking": "NONE" }
        },
        "enrollmentInfo": { "count": 141, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "W-GenZD Mobile Application Group",
            "type": "EXPERIMENTAL",
            "description": "Participants assigned to the W-GenZD mobile application group will be asked to download and use the W-GenZD mobile application that will provide information and tools through a chatbot (a computer program designed to communicate with users). Participants will be invited to use the mobile application as often as they like during the 4-week treatment period - we will encourage 5 to 10 minutes of daily use.",
            "interventionNames": [
              "Device: Woebot for Adolescents (W-GenZD) Mobile Application"
            ]
          },
          {
            "label": "CBT-Lite Teletherapy Group",
            "type": "ACTIVE_COMPARATOR",
            "description": "Participants assigned to the CBT-lite teletherapy group will be asked to attend 1-hour teletherapy group sessions over Zoom once a week for 4 weeks. In this group, a study clinician will cover topics such as building a coping tool box, accepting your feelings, challenging negative thoughts, and problem solving.",
            "interventionNames": ["Behavioral: CBT-Lite Teletherapy Group"]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "Woebot for Adolescents (W-GenZD) Mobile Application",
            "description": "Woebot for Adolescents (W-GenZD) is a mobile application program that delivers evidence-based therapy for the symptoms of mild-moderate depression and anxiety in adolescents in brief \"conversations\" with a fully automated relational agent called Woebot. It is a brief, self-guided 4 week-intervention that draws from cognitive behavioral therapy (CBT), interpersonal psychotherapy for adolescents (IPT-A), and elements of dialectical behavior therapy (DBT), depending on the presenting situation, to help the adolescent develop emotion regulation skills in the context of their everyday life. In this way, the mobile application is designed to be targeted, relevant, and integrated into the lived experience of adolescents, capable of delivering the appropriate technique for the problem at hand, at the time of need.",
            "armGroupLabels": ["W-GenZD Mobile Application Group"]
          },
          {
            "type": "BEHAVIORAL",
            "name": "CBT-Lite Teletherapy Group",
            "description": "The CBT-Lite teletherapy group is a brief, 4-week intervention held once weekly for an hour, and limited to those triaged into the Children's Hospital of the King's Daughters low-intensity track and participating in this protocol. An assigned study clinician will facilitate each teletherapy group with approximately 10 adolescents in each session. Each group begins with orientation and reviewing group rules, individual check-ins with each participant (rating stress level and hopefulness), followed by a guided mindfulness moment. Sessions are designed to draw from elements of cognitive behavioral therapy (CBT) and the 4 topics include: building a coping tool box, accepting your feelings, challenging negative thoughts, and problem solving.",
            "armGroupLabels": ["CBT-Lite Teletherapy Group"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Usage Rating Profile-Intervention Revised (URP-IR), Feasibility Subscale",
            "description": "Measure of feasibility. A 6-item subscale that inquires about factors that impact treatment usage (i.e., intervention quality). Items (e.g., \"The total time required to do the treatment procedures was manageable\") are rated on a 6-point Likert scale (1 = \"strongly disagree\" to 6 = \"strongly agree\"). Total feasibility scores range from 6-36, with higher scores indicating greater intervention feasibility with the W-GenZD mobile application or the CBT-Lite teletherapy groups.",
            "timeFrame": "End-of-treatment (4 weeks from baseline)"
          },
          {
            "measure": "Usage Rating Profile-Intervention Revised (URP-IR), Acceptability Subscale",
            "description": "Measure of acceptability. A 9-item subscale that inquires about intervention acceptability. For the purposes of this study, an adapted 6-item version of the subscale was utilized. Items (e.g., \"This treatment is an effective choice for addressing a variety of depression concerns) are rated on a 6-point Likert scale (1 = \"strongly disagree\" to 6 = \"strongly agree\"). Total acceptability scores range from 6-36, with higher scores indicating greater intervention acceptability with the W-GenZD mobile application or the CBT-Lite teletherapy groups.",
            "timeFrame": "End-of-treatment (4 weeks from baseline)"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Patient Health Questionnaire, 8 Items (PHQ-8)",
            "description": "Measure of depression severity. An 8-item abbreviated version of the PHQ-9 used to assess depressive symptomatology over the past 2 weeks. The PHQ-8 excludes an item assessing suicidality. Items (e.g., \"Over the last 2 weeks, how often have you been bothered by ... feeling down, depressed or hopeless?\") are rated on a 4-point Likert scale (0 = \"not at all\" to 3 = \"nearly every day\"). Total scores range from 0-24, with higher scores indicating increased severity of depressive symptoms.",
            "timeFrame": "Baseline; end-of-treatment (4 weeks from baseline); change from baseline to end-of-treatment at 4 weeks"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n1. Have completed triage at the Children's Hospital of the King's Daughters (CHKD) and have been deemed appropriate for the low-intensity intervention track, given presenting problem(s) of depressive or anxiety symptoms\n2. Adolescent 13-17 years of age, inclusive\n3. U.S. resident\n4. Both adolescent participant and parent/guardian are able to read and write in English\n5. Own or have regular access to a smartphone (Android or iOS smartphone with a recent, supported operating system), that can receive SMS messages, and reliable Wi-Fi access or sufficient data to engage with assigned treatment condition for the duration of the study\n6. If currently prescribed antidepressant medications (e.g. escitalopram/Lexapro, fluoxetine/ Prozac), antipsychotic medications (e.g. aripiprazole, asenapine, olanzapine, paliperidone, quetiapine, risperidone), or stimulants (e.g. amphetamine/Adderall, Methylphenidate/Ritalin) and alpha agonists (e.g. atomoxetine/Strattera, Guanfacine/Intuniv) they are at a regular, stable dose for at least 60 days at screening\n7. Not currently actively engaged is psychotherapy\n8. Available and committed to engage with the program and complete assessments for a 8-week duration\n9. Family is willing and able to engage in discussion of safety planning in the event of suicidal symptoms\n\nExclusion Criteria:\n\n1. Lifetime diagnosis of a psychotic disorder (including schizophrenia or schizoaffective disorder)\n2. Lifetime diagnosis of bipolar disorder\n3. Lifetime diagnosis of autism spectrum disorder or pervasive developmental disorder (e.g. autism, Asperger syndrome, Rett's syndrome)\n4. Current diagnosis of developmental delay or intellectual disability\n5. Suicidal ideation with a plan or intent or a suicidal attempt within the past 12 months\n6. History of (a) drug and/or alcohol abuse within the past 12 months\n7. Current use of benzodiazepines (e.g. lorazepam, clonazepam, alprazolam, diazepam, triazolam) or certain sleep aids (zolpidem, eszopiclone, zaleplon)\n8. Previous Woebot application use\n9. Enrollment of more than one member of the same household",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "13 Years",
        "maximumAge": "17 Years",
        "stdAges": ["CHILD"]
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "Mary Margaret Gleason, MD",
            "affiliation": "Children's Hospital of The King's Daughters",
            "role": "PRINCIPAL_INVESTIGATOR"
          }
        ],
        "locations": [
          {
            "facility": "Children's Hospital of The King's Daughters",
            "city": "Norfolk",
            "state": "Virginia",
            "zip": "23507",
            "country": "United States",
            "geoPoint": { "lat": 36.84681, "lon": -76.28522 }
          }
        ]
      }
    },
    "resultsSection": {
      "participantFlowModule": {
        "groups": [
          {
            "id": "FG000",
            "title": "W-GenZD Mobile Application Group",
            "description": "Participants assigned to the W-GenZD mobile application group will be asked to download and use the W-GenZD mobile application that will provide information and tools through a chatbot (a computer program designed to communicate with users). Participants will be invited to use the mobile application as often as they like during the 4-week treatment period - we will encourage 5 to 10 minutes of daily use.\n\nW-GenZD Mobile Application: Woebot for Adolescents (W-GenZD) is a mobile application program that delivers evidence-based therapy for the symptoms of mild-moderate depression and anxiety in adolescents in brief \"conversations\" with a fully automated relational agent called Woebot. It is a brief, self-guided 4 week-intervention that draws from cognitive behavioral therapy (CBT), interpersonal psychotherapy for adolescents (IPT-A), and elements of dialectical behavior therapy (DBT), depending on the presenting situation, to help the adolescent develop emotion regulation skills in the context of their everyday life. In this way, the mobile application is designed to be targeted, relevant, and integrated into the lived experience of adolescents, capable of delivering the appropriate technique for the problem at hand, at the time of need."
          },
          {
            "id": "FG001",
            "title": "CBT-Lite Teletherapy Group",
            "description": "Participants assigned to the CBT-Lite teletherapy group will be asked to attend 1-hour teletherapy group sessions over Zoom once a week for 4 weeks. In this group, a study clinician will cover topics such as building a coping tool box, accepting your feelings, challenging negative thoughts, and problem solving.\n\nCBT-Lite Teletherapy Group: The CBT-Lite teletherapy group is a brief, 4-week intervention held once weekly for an hour, and limited to those triaged into the Children's Hospital of the King's Daughters low-intensity track and participating in this protocol. An assigned study clinician will facilitate each teletherapy group with approximately 10 adolescents in each session. Each group begins with orientation and reviewing group rules, individual check-ins with each participant (rating stress level and hopefulness), followed by a guided mindfulness moment. Sessions are designed to draw from elements of cognitive behavioral therapy (CBT) and the 4 topics include: building a coping tool box, accepting your feelings, challenging negative thoughts, and problem solving."
          }
        ],
        "periods": [
          {
            "title": "Overall Study",
            "milestones": [
              {
                "type": "STARTED",
                "achievements": [
                  { "groupId": "FG000", "numSubjects": "71" },
                  { "groupId": "FG001", "numSubjects": "70" }
                ]
              },
              {
                "type": "COMPLETED",
                "achievements": [
                  { "groupId": "FG000", "numSubjects": "69" },
                  { "groupId": "FG001", "numSubjects": "65" }
                ]
              },
              {
                "type": "NOT COMPLETED",
                "achievements": [
                  { "groupId": "FG000", "numSubjects": "2" },
                  { "groupId": "FG001", "numSubjects": "5" }
                ]
              }
            ],
            "dropWithdraws": [
              {
                "type": "Withdrawal by Subject",
                "reasons": [
                  { "groupId": "FG000", "numSubjects": "0" },
                  { "groupId": "FG001", "numSubjects": "2" }
                ]
              },
              {
                "type": "Protocol Violation",
                "reasons": [
                  { "groupId": "FG000", "numSubjects": "2" },
                  { "groupId": "FG001", "numSubjects": "2" }
                ]
              },
              {
                "type": "Adverse Event",
                "reasons": [
                  { "groupId": "FG000", "numSubjects": "0" },
                  { "groupId": "FG001", "numSubjects": "1" }
                ]
              }
            ]
          }
        ]
      },
      "baselineCharacteristicsModule": {
        "groups": [
          {
            "id": "BG000",
            "title": "W-GenZD Mobile Application Group",
            "description": "Participants assigned to the W-GenZD mobile application group will be asked to download and use the W-GenZD mobile application that will provide information and tools through a chatbot (a computer program designed to communicate with users). Participants will be invited to use the mobile application as often as they like during the 4-week treatment period - we will encourage 5 to 10 minutes of daily use.\n\nW-GenZD Mobile Application: Woebot for Adolescents (W-GenZD) is a mobile application program that delivers evidence-based therapy for the symptoms of mild-moderate depression and anxiety in adolescents in brief \"conversations\" with a fully automated relational agent called Woebot. It is a brief, self-guided 4 week-intervention that draws from cognitive behavioral therapy (CBT), interpersonal psychotherapy for adolescents (IPT-A), and elements of dialectical behavior therapy (DBT), depending on the presenting situation, to help the adolescent develop emotion regulation skills in the context of their everyday life. In this way, the mobile application is designed to be targeted, relevant, and integrated into the lived experience of adolescents, capable of delivering the appropriate technique for the problem at hand, at the time of need."
          },
          {
            "id": "BG001",
            "title": "CBT-Lite Teletherapy Group",
            "description": "Participants assigned to the CBT-Lite teletherapy group will be asked to attend 1-hour teletherapy group sessions over Zoom once a week for 4 weeks. In this group, a study clinician will cover topics such as building a coping tool box, accepting your feelings, challenging negative thoughts, and problem solving.\n\nCBT-Lite Teletherapy: The CBT-Lite teletherapy group is a brief, 4-week intervention held once weekly for an hour, and limited to those triaged into the Children's Hospital of the King's Daughters low-intensity track and participating in this protocol. An assigned study clinician will facilitate each teletherapy group with approximately 10 adolescents in each session. Each group begins with orientation and reviewing group rules, individual check-ins with each participant (rating stress level and hopefulness), followed by a guided mindfulness moment. Sessions are designed to draw from elements of cognitive behavioral therapy (CBT) and the 4 topics include: building a coping tool box, accepting your feelings, challenging negative thoughts, and problem solving."
          },
          {
            "id": "BG002",
            "title": "Total",
            "description": "Total of all reporting groups"
          }
        ],
        "denoms": [
          {
            "units": "Participants",
            "counts": [
              { "groupId": "BG000", "value": "71" },
              { "groupId": "BG001", "value": "70" },
              { "groupId": "BG002", "value": "141" }
            ]
          }
        ],
        "measures": [
          {
            "title": "Age, Customized",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "title": "Age, Categorical",
                "categories": [
                  {
                    "title": "13 years",
                    "measurements": [
                      { "groupId": "BG000", "value": "14" },
                      { "groupId": "BG001", "value": "14" },
                      { "groupId": "BG002", "value": "28" }
                    ]
                  },
                  {
                    "title": "14 years",
                    "measurements": [
                      { "groupId": "BG000", "value": "25" },
                      { "groupId": "BG001", "value": "19" },
                      { "groupId": "BG002", "value": "44" }
                    ]
                  },
                  {
                    "title": "15 years",
                    "measurements": [
                      { "groupId": "BG000", "value": "17" },
                      { "groupId": "BG001", "value": "14" },
                      { "groupId": "BG002", "value": "31" }
                    ]
                  },
                  {
                    "title": "16 years",
                    "measurements": [
                      { "groupId": "BG000", "value": "9" },
                      { "groupId": "BG001", "value": "19" },
                      { "groupId": "BG002", "value": "28" }
                    ]
                  },
                  {
                    "title": "17 years",
                    "measurements": [
                      { "groupId": "BG000", "value": "6" },
                      { "groupId": "BG001", "value": "4" },
                      { "groupId": "BG002", "value": "10" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Sex: Female, Male",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "Female",
                    "measurements": [
                      { "groupId": "BG000", "value": "56" },
                      { "groupId": "BG001", "value": "54" },
                      { "groupId": "BG002", "value": "110" }
                    ]
                  },
                  {
                    "title": "Male",
                    "measurements": [
                      { "groupId": "BG000", "value": "15" },
                      { "groupId": "BG001", "value": "16" },
                      { "groupId": "BG002", "value": "31" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Race/Ethnicity, Customized",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "African American",
                    "measurements": [
                      { "groupId": "BG000", "value": "24" },
                      { "groupId": "BG001", "value": "24" },
                      { "groupId": "BG002", "value": "48" }
                    ]
                  },
                  {
                    "title": "American Indian or Alaskan Native",
                    "measurements": [
                      { "groupId": "BG000", "value": "0" },
                      { "groupId": "BG001", "value": "1" },
                      { "groupId": "BG002", "value": "1" }
                    ]
                  },
                  {
                    "title": "Asian",
                    "measurements": [
                      { "groupId": "BG000", "value": "3" },
                      { "groupId": "BG001", "value": "1" },
                      { "groupId": "BG002", "value": "4" }
                    ]
                  },
                  {
                    "title": "Hispanic",
                    "measurements": [
                      { "groupId": "BG000", "value": "9" },
                      { "groupId": "BG001", "value": "2" },
                      { "groupId": "BG002", "value": "11" }
                    ]
                  },
                  {
                    "title": "Mixed Race",
                    "measurements": [
                      { "groupId": "BG000", "value": "4" },
                      { "groupId": "BG001", "value": "2" },
                      { "groupId": "BG002", "value": "6" }
                    ]
                  },
                  {
                    "title": "Native Hawaiian or other Pacific Islander",
                    "measurements": [
                      { "groupId": "BG000", "value": "1" },
                      { "groupId": "BG001", "value": "0" },
                      { "groupId": "BG002", "value": "1" }
                    ]
                  },
                  {
                    "title": "Other",
                    "measurements": [
                      { "groupId": "BG000", "value": "1" },
                      { "groupId": "BG001", "value": "0" },
                      { "groupId": "BG002", "value": "1" }
                    ]
                  },
                  {
                    "title": "White",
                    "measurements": [
                      { "groupId": "BG000", "value": "29" },
                      { "groupId": "BG001", "value": "40" },
                      { "groupId": "BG002", "value": "69" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Gender Identity",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "Agender",
                    "measurements": [
                      { "groupId": "BG000", "value": "0" },
                      { "groupId": "BG001", "value": "2" },
                      { "groupId": "BG002", "value": "2" }
                    ]
                  },
                  {
                    "title": "Different identity",
                    "measurements": [
                      { "groupId": "BG000", "value": "1" },
                      { "groupId": "BG001", "value": "2" },
                      { "groupId": "BG002", "value": "3" }
                    ]
                  },
                  {
                    "title": "Genderqueer",
                    "measurements": [
                      { "groupId": "BG000", "value": "1" },
                      { "groupId": "BG001", "value": "0" },
                      { "groupId": "BG002", "value": "1" }
                    ]
                  },
                  {
                    "title": "Man/boy",
                    "measurements": [
                      { "groupId": "BG000", "value": "22" },
                      { "groupId": "BG001", "value": "17" },
                      { "groupId": "BG002", "value": "39" }
                    ]
                  },
                  {
                    "title": "Non-binary",
                    "measurements": [
                      { "groupId": "BG000", "value": "1" },
                      { "groupId": "BG001", "value": "4" },
                      { "groupId": "BG002", "value": "5" }
                    ]
                  },
                  {
                    "title": "Prefer not to answer",
                    "measurements": [
                      { "groupId": "BG000", "value": "2" },
                      { "groupId": "BG001", "value": "3" },
                      { "groupId": "BG002", "value": "5" }
                    ]
                  },
                  {
                    "title": "Woman/girl",
                    "measurements": [
                      { "groupId": "BG000", "value": "44" },
                      { "groupId": "BG001", "value": "42" },
                      { "groupId": "BG002", "value": "86" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Sexual Orientation",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "Asexual",
                    "measurements": [
                      { "groupId": "BG000", "value": "2" },
                      { "groupId": "BG001", "value": "0" },
                      { "groupId": "BG002", "value": "2" }
                    ]
                  },
                  {
                    "title": "Bisexual",
                    "measurements": [
                      { "groupId": "BG000", "value": "9" },
                      { "groupId": "BG001", "value": "11" },
                      { "groupId": "BG002", "value": "20" }
                    ]
                  },
                  {
                    "title": "Don't know",
                    "measurements": [
                      { "groupId": "BG000", "value": "5" },
                      { "groupId": "BG001", "value": "1" },
                      { "groupId": "BG002", "value": "6" }
                    ]
                  },
                  {
                    "title": "Lesbian or gay",
                    "measurements": [
                      { "groupId": "BG000", "value": "2" },
                      { "groupId": "BG001", "value": "5" },
                      { "groupId": "BG002", "value": "7" }
                    ]
                  },
                  {
                    "title": "Pansexual",
                    "measurements": [
                      { "groupId": "BG000", "value": "8" },
                      { "groupId": "BG001", "value": "5" },
                      { "groupId": "BG002", "value": "13" }
                    ]
                  },
                  {
                    "title": "Pansexual; Asexual",
                    "measurements": [
                      { "groupId": "BG000", "value": "2" },
                      { "groupId": "BG001", "value": "0" },
                      { "groupId": "BG002", "value": "2" }
                    ]
                  },
                  {
                    "title": "Prefer not to answer",
                    "measurements": [
                      { "groupId": "BG000", "value": "2" },
                      { "groupId": "BG001", "value": "2" },
                      { "groupId": "BG002", "value": "4" }
                    ]
                  },
                  {
                    "title": "Queer",
                    "measurements": [
                      { "groupId": "BG000", "value": "1" },
                      { "groupId": "BG001", "value": "1" },
                      { "groupId": "BG002", "value": "2" }
                    ]
                  },
                  {
                    "title": "Straight or heterosexual",
                    "measurements": [
                      { "groupId": "BG000", "value": "40" },
                      { "groupId": "BG001", "value": "45" },
                      { "groupId": "BG002", "value": "85" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Highest Education Level",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "Elementary or middle school (grades 1-8)",
                    "measurements": [
                      { "groupId": "BG000", "value": "26" },
                      { "groupId": "BG001", "value": "24" },
                      { "groupId": "BG002", "value": "50" }
                    ]
                  },
                  {
                    "title": "High school graduate or GED (grade 12)",
                    "measurements": [
                      { "groupId": "BG000", "value": "1" },
                      { "groupId": "BG001", "value": "3" },
                      { "groupId": "BG002", "value": "4" }
                    ]
                  },
                  {
                    "title": "Some high school (grades 9-11)",
                    "measurements": [
                      { "groupId": "BG000", "value": "44" },
                      { "groupId": "BG001", "value": "43" },
                      { "groupId": "BG002", "value": "87" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Primary Presenting Problem at Intake",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "Anxiety",
                    "measurements": [
                      { "groupId": "BG000", "value": "37" },
                      { "groupId": "BG001", "value": "39" },
                      { "groupId": "BG002", "value": "76" }
                    ]
                  },
                  {
                    "title": "Depression",
                    "measurements": [
                      { "groupId": "BG000", "value": "34" },
                      { "groupId": "BG001", "value": "31" },
                      { "groupId": "BG002", "value": "65" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Concomitant Medications",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "title": "Currently Taking Antidepressants",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "BG000", "value": "10" },
                      { "groupId": "BG001", "value": "11" },
                      { "groupId": "BG002", "value": "21" }
                    ]
                  }
                ]
              },
              {
                "title": "Currently Taking Antipsychotics",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "BG000", "value": "0" },
                      { "groupId": "BG001", "value": "0" },
                      { "groupId": "BG002", "value": "0" }
                    ]
                  }
                ]
              },
              {
                "title": "Currently Taking Stimulants",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "BG000", "value": "8" },
                      { "groupId": "BG001", "value": "8" },
                      { "groupId": "BG002", "value": "16" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Caregiver Relationship to Participant",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "Legal guardian",
                    "measurements": [
                      { "groupId": "BG000", "value": "3" },
                      { "groupId": "BG001", "value": "5" },
                      { "groupId": "BG002", "value": "8" }
                    ]
                  },
                  {
                    "title": "Parent",
                    "measurements": [
                      { "groupId": "BG000", "value": "68" },
                      { "groupId": "BG001", "value": "65" },
                      { "groupId": "BG002", "value": "133" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Caregiver Employment Status",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "Employed, full time",
                    "measurements": [
                      { "groupId": "BG000", "value": "41" },
                      { "groupId": "BG001", "value": "44" },
                      { "groupId": "BG002", "value": "85" }
                    ]
                  },
                  {
                    "title": "Employed, part time",
                    "measurements": [
                      { "groupId": "BG000", "value": "8" },
                      { "groupId": "BG001", "value": "4" },
                      { "groupId": "BG002", "value": "12" }
                    ]
                  },
                  {
                    "title": "Not employed, looking for work",
                    "measurements": [
                      { "groupId": "BG000", "value": "4" },
                      { "groupId": "BG001", "value": "2" },
                      { "groupId": "BG002", "value": "6" }
                    ]
                  },
                  {
                    "title": "Not employed, not looking for work",
                    "measurements": [
                      { "groupId": "BG000", "value": "0" },
                      { "groupId": "BG001", "value": "3" },
                      { "groupId": "BG002", "value": "3" }
                    ]
                  },
                  {
                    "title": "On disability, not able to work",
                    "measurements": [
                      { "groupId": "BG000", "value": "2" },
                      { "groupId": "BG001", "value": "2" },
                      { "groupId": "BG002", "value": "4" }
                    ]
                  },
                  {
                    "title": "Prefer not to answer",
                    "measurements": [
                      { "groupId": "BG000", "value": "4" },
                      { "groupId": "BG001", "value": "4" },
                      { "groupId": "BG002", "value": "8" }
                    ]
                  },
                  {
                    "title": "Primary care-taker at home, not employed outside of the home",
                    "measurements": [
                      { "groupId": "BG000", "value": "11" },
                      { "groupId": "BG001", "value": "8" },
                      { "groupId": "BG002", "value": "19" }
                    ]
                  },
                  {
                    "title": "Retired",
                    "measurements": [
                      { "groupId": "BG000", "value": "1" },
                      { "groupId": "BG001", "value": "3" },
                      { "groupId": "BG002", "value": "4" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Caregiver Marital Status",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "Divorced / Separated",
                    "measurements": [
                      { "groupId": "BG000", "value": "18" },
                      { "groupId": "BG001", "value": "11" },
                      { "groupId": "BG002", "value": "29" }
                    ]
                  },
                  {
                    "title": "Married / Partnered / Cohabiting",
                    "measurements": [
                      { "groupId": "BG000", "value": "36" },
                      { "groupId": "BG001", "value": "43" },
                      { "groupId": "BG002", "value": "79" }
                    ]
                  },
                  {
                    "title": "Prefer not to answer",
                    "measurements": [
                      { "groupId": "BG000", "value": "0" },
                      { "groupId": "BG001", "value": "4" },
                      { "groupId": "BG002", "value": "4" }
                    ]
                  },
                  {
                    "title": "Single",
                    "measurements": [
                      { "groupId": "BG000", "value": "14" },
                      { "groupId": "BG001", "value": "11" },
                      { "groupId": "BG002", "value": "25" }
                    ]
                  },
                  {
                    "title": "Widowed",
                    "measurements": [
                      { "groupId": "BG000", "value": "3" },
                      { "groupId": "BG001", "value": "1" },
                      { "groupId": "BG002", "value": "4" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Caregiver Insurance Type",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "Medicaid and similar insurance",
                    "measurements": [
                      { "groupId": "BG000", "value": "26" },
                      { "groupId": "BG001", "value": "13" },
                      { "groupId": "BG002", "value": "39" }
                    ]
                  },
                  {
                    "title": "Medicare",
                    "measurements": [
                      { "groupId": "BG000", "value": "1" },
                      { "groupId": "BG001", "value": "2" },
                      { "groupId": "BG002", "value": "3" }
                    ]
                  },
                  {
                    "title": "Multiple sources",
                    "measurements": [
                      { "groupId": "BG000", "value": "4" },
                      { "groupId": "BG001", "value": "3" },
                      { "groupId": "BG002", "value": "7" }
                    ]
                  },
                  {
                    "title": "No insurance",
                    "measurements": [
                      { "groupId": "BG000", "value": "1" },
                      { "groupId": "BG001", "value": "0" },
                      { "groupId": "BG002", "value": "1" }
                    ]
                  },
                  {
                    "title": "Prefer not to answer",
                    "measurements": [
                      { "groupId": "BG000", "value": "0" },
                      { "groupId": "BG001", "value": "2" },
                      { "groupId": "BG002", "value": "2" }
                    ]
                  },
                  {
                    "title": "Private insurance",
                    "measurements": [
                      { "groupId": "BG000", "value": "30" },
                      { "groupId": "BG001", "value": "36" },
                      { "groupId": "BG002", "value": "66" }
                    ]
                  },
                  {
                    "title": "TRICARE or other military health care",
                    "measurements": [
                      { "groupId": "BG000", "value": "6" },
                      { "groupId": "BG001", "value": "14" },
                      { "groupId": "BG002", "value": "20" }
                    ]
                  },
                  {
                    "title": "VA: Past and present",
                    "measurements": [
                      { "groupId": "BG000", "value": "3" },
                      { "groupId": "BG001", "value": "0" },
                      { "groupId": "BG002", "value": "3" }
                    ]
                  }
                ]
              }
            ]
          }
        ]
      },
      "outcomeMeasuresModule": {
        "outcomeMeasures": [
          {
            "type": "PRIMARY",
            "title": "Usage Rating Profile-Intervention Revised (URP-IR), Feasibility Subscale",
            "description": "Measure of feasibility. A 6-item subscale that inquires about factors that impact treatment usage (i.e., intervention quality). Items (e.g., \"The total time required to do the treatment procedures was manageable\") are rated on a 6-point Likert scale (1 = \"strongly disagree\" to 6 = \"strongly agree\"). Total feasibility scores range from 6-36, with higher scores indicating greater intervention feasibility with the W-GenZD mobile application or the CBT-Lite teletherapy groups.",
            "reportingStatus": "POSTED",
            "paramType": "MEDIAN",
            "dispersionType": "Inter-Quartile Range",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "End-of-treatment (4 weeks from baseline)",
            "groups": [
              {
                "id": "OG000",
                "title": "W-GenZD Mobile Application Group",
                "description": "Participants assigned to the W-GenZD mobile application group will be asked to download and use the W-GenZD mobile application that will provide information and tools through a chatbot (a computer program designed to communicate with users). Participants will be invited to use the mobile application as often as they like during the 4-week treatment period - we will encourage 5 to 10 minutes of daily use.\n\nW-GenZD Mobile Application: Woebot for Adolescents (W-GenZD) is a mobile application program that delivers evidence-based therapy for the symptoms of mild-moderate depression and anxiety in adolescents in brief \"conversations\" with a fully automated relational agent called Woebot. It is a brief, self-guided 4 week-intervention that draws from cognitive behavioral therapy (CBT), interpersonal psychotherapy for adolescents (IPT-A), and elements of dialectical behavior therapy (DBT), depending on the presenting situation, to help the adolescent develop emotion regulation skills in the context of their everyday life. In this way, the mobile application is designed to be targeted, relevant, and integrated into the lived experience of adolescents, capable of delivering the appropriate technique for the problem at hand, at the time of need."
              },
              {
                "id": "OG001",
                "title": "CBT-Lite Teletherapy Group",
                "description": "Participants assigned to the CBT-Lite teletherapy group will be asked to attend 1-hour teletherapy group sessions over Zoom once a week for 4 weeks. In this group, a study clinician will cover topics such as building a coping tool box, accepting your feelings, challenging negative thoughts, and problem solving.\n\nCBT-Lite Teletherapy: The CBT-Lite teletherapy group is a brief, 4-week intervention held once weekly for an hour, and limited to those triaged into the Children's Hospital of the King's Daughters low-intensity track and participating in this protocol. An assigned study clinician will facilitate each teletherapy group with approximately 10 adolescents in each session. Each group begins with orientation and reviewing group rules, individual check-ins with each participant (rating stress level and hopefulness), followed by a guided mindfulness moment. Sessions are designed to draw from elements of cognitive behavioral therapy (CBT) and the 4 topics include: building a coping tool box, accepting your feelings, challenging negative thoughts, and problem solving."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "71" },
                  { "groupId": "OG001", "value": "70" }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "30.00",
                        "lowerLimit": "28.50",
                        "upperLimit": "31.50"
                      },
                      {
                        "groupId": "OG001",
                        "value": "30.00",
                        "lowerLimit": "28.20",
                        "upperLimit": "31.80"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "PRIMARY",
            "title": "Usage Rating Profile-Intervention Revised (URP-IR), Acceptability Subscale",
            "description": "Measure of acceptability. A 9-item subscale that inquires about intervention acceptability. For the purposes of this study, an adapted 6-item version of the subscale was utilized. Items (e.g., \"This treatment is an effective choice for addressing a variety of depression concerns) are rated on a 6-point Likert scale (1 = \"strongly disagree\" to 6 = \"strongly agree\"). Total acceptability scores range from 6-36, with higher scores indicating greater intervention acceptability with the W-GenZD mobile application or the CBT-Lite teletherapy groups.",
            "reportingStatus": "POSTED",
            "paramType": "MEDIAN",
            "dispersionType": "Inter-Quartile Range",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "End-of-treatment (4 weeks from baseline)",
            "groups": [
              {
                "id": "OG000",
                "title": "W-GenZD Mobile Application Group",
                "description": "Participants assigned to the W-GenZD mobile application group will be asked to download and use the W-GenZD mobile application that will provide information and tools through a chatbot (a computer program designed to communicate with users). Participants will be invited to use the mobile application as often as they like during the 4-week treatment period - we will encourage 5 to 10 minutes of daily use.\n\nW-GenZD Mobile Application: Woebot for Adolescents (W-GenZD) is a mobile application program that delivers evidence-based therapy for the symptoms of mild-moderate depression and anxiety in adolescents in brief \"conversations\" with a fully automated relational agent called Woebot. It is a brief, self-guided 4 week-intervention that draws from cognitive behavioral therapy (CBT), interpersonal psychotherapy for adolescents (IPT-A), and elements of dialectical behavior therapy (DBT), depending on the presenting situation, to help the adolescent develop emotion regulation skills in the context of their everyday life. In this way, the mobile application is designed to be targeted, relevant, and integrated into the lived experience of adolescents, capable of delivering the appropriate technique for the problem at hand, at the time of need."
              },
              {
                "id": "OG001",
                "title": "CBT-Lite Teletherapy Group",
                "description": "Participants assigned to the CBT-Lite teletherapy group will be asked to attend 1-hour teletherapy group sessions over Zoom once a week for 4 weeks. In this group, a study clinician will cover topics such as building a coping tool box, accepting your feelings, challenging negative thoughts, and problem solving.\n\nCBT-Lite Teletherapy: The CBT-Lite teletherapy group is a brief, 4-week intervention held once weekly for an hour, and limited to those triaged into the Children's Hospital of the King's Daughters low-intensity track and participating in this protocol. An assigned study clinician will facilitate each teletherapy group with approximately 10 adolescents in each session. Each group begins with orientation and reviewing group rules, individual check-ins with each participant (rating stress level and hopefulness), followed by a guided mindfulness moment. Sessions are designed to draw from elements of cognitive behavioral therapy (CBT) and the 4 topics include: building a coping tool box, accepting your feelings, challenging negative thoughts, and problem solving."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "71" },
                  { "groupId": "OG001", "value": "70" }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "28.00",
                        "lowerLimit": "26.05",
                        "upperLimit": "29.95"
                      },
                      {
                        "groupId": "OG001",
                        "value": "29.10",
                        "lowerLimit": "26.70",
                        "upperLimit": "31.51"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Patient Health Questionnaire, 8 Items (PHQ-8)",
            "description": "Measure of depression severity. An 8-item abbreviated version of the PHQ-9 used to assess depressive symptomatology over the past 2 weeks. The PHQ-8 excludes an item assessing suicidality. Items (e.g., \"Over the last 2 weeks, how often have you been bothered by ... feeling down, depressed or hopeless?\") are rated on a 4-point Likert scale (0 = \"not at all\" to 3 = \"nearly every day\"). Total scores range from 0-24, with higher scores indicating increased severity of depressive symptoms.",
            "populationDescription": "Multiple imputation used for missing scores at end-of-treatment at 4 weeks",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "Baseline; end-of-treatment (4 weeks from baseline); change from baseline to end-of-treatment at 4 weeks",
            "groups": [
              {
                "id": "OG000",
                "title": "W-GenZD Mobile Application Group",
                "description": "Participants assigned to the W-GenZD mobile application group will be asked to download and use the W-GenZD mobile application that will provide information and tools through a chatbot (a computer program designed to communicate with users). Participants will be invited to use the mobile application as often as they like during the 4-week treatment period - we will encourage 5 to 10 minutes of daily use.\n\nW-GenZD Mobile Application: W-GenZD is a mobile application program that delivers evidence-based therapy for the symptoms of mild-moderate depression and anxiety in adolescents in brief \"conversations\" with a fully automated relational agent called Woebot. It is a brief, self-guided 4 week-intervention that draws from cognitive behavioral therapy (CBT), interpersonal psychotherapy for adolescents (IPT-A), and elements of dialectical behavior therapy (DBT), depending on the presenting situation, to help the adolescent develop emotion regulation skills in the context of their everyday life. In this way, the mobile application is designed to be targeted, relevant, and integrated into the lived experience of adolescents, capable of delivering the appropriate technique for the problem at hand, at the time of need."
              },
              {
                "id": "OG001",
                "title": "CBT-Lite Teletherapy Group",
                "description": "Participants assigned to the CBT-lite teletherapy group will be asked to attend 1-hour teletherapy group sessions over Zoom once a week for 4 weeks. In this group, a study clinician will cover topics such as building a coping tool box, accepting your feelings, challenging negative thoughts, and problem solving.\n\nCBT-Lite Teletherapy: The CBT-Lite teletherapy group is a brief, 4-week intervention held once weekly for an hour, and limited to those triaged into the Children's Hospital of the King's Daughters low-intensity track and participating in this protocol. An assigned study clinician will facilitate each teletherapy group with approximately 10 adolescents in each session. Each group begins with orientation and reviewing group rules, individual check-ins with each participant (rating stress level and hopefulness), followed by a guided mindfulness moment. Sessions are designed to draw from elements of cognitive behavioral therapy (CBT) and the 4 topics include: building a coping tool box, accepting your feelings, challenging negative thoughts, and problem solving."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "71" },
                  { "groupId": "OG001", "value": "70" }
                ]
              }
            ],
            "classes": [
              {
                "title": "PHQ-8 at Baseline",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "10.65",
                        "spread": "6.31"
                      },
                      { "groupId": "OG001", "value": "11.16", "spread": "5.20" }
                    ]
                  }
                ]
              },
              {
                "title": "PHQ-8 at Week 4 (EOT)",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "8.75", "spread": "4.91" },
                      { "groupId": "OG001", "value": "9.42", "spread": "4.88" }
                    ]
                  }
                ]
              },
              {
                "title": "PHQ-8 Change from Baseline to Week 4 (EOT)",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-1.89",
                        "spread": "4.83"
                      },
                      { "groupId": "OG001", "value": "-1.74", "spread": "4.33" }
                    ]
                  }
                ]
              }
            ],
            "analyses": [
              {
                "groupIds": ["OG000", "OG001"],
                "nonInferiorityType": "NON_INFERIORITY",
                "nonInferiorityComment": "The non-inferiority (NI) test for the secondary outcome (i.e., PHQ-8 Week 4 EOT score) was assessed using the pre-specified NI margin of 2.0. NI of W-GenZD to CBT-Lite was declared if the upper bound of the one-sided 97.5% confidence interval (CI) was less than 2.",
                "paramType": "Mean Difference (Net)",
                "paramValue": "-0.67",
                "ciPctValue": "95",
                "ciNumSides": "TWO_SIDED",
                "ciLowerLimit": "-2.30",
                "ciUpperLimit": "0.96"
              }
            ]
          }
        ]
      },
      "adverseEventsModule": {
        "frequencyThreshold": "0",
        "timeFrame": "Throughout study (from baseline through 8 weeks)",
        "description": "Safety was monitored via: 1) concerning language detection within each intervention; 2) biweekly phone check-ins by the research coordinator with the caregiver; 3) spontaneous report to study personnel. Upon learning of a potential safety concern, on-call licensed study personnel contacted the caregiver to assess the adolescent's safety, identify the level of intervention needed, and provide resources as needed. Participants were withdrawn if they were deemed to require a higher level of care.",
        "eventGroups": [
          {
            "id": "EG000",
            "title": "W-GenZD Mobile Application Group",
            "description": "Participants assigned to the W-GenZD mobile application group will be asked to download and use the W-GenZD mobile application that will provide information and tools through a chatbot (a computer program designed to communicate with users). Participants will be invited to use the mobile application as often as they like during the 4-week treatment period - we will encourage 5 to 10 minutes of daily use.\n\nW-GenZD Mobile Application: Woebot for Adolescents (W-GenZD) is a mobile application program that delivers evidence-based therapy for the symptoms of mild-moderate depression and anxiety in adolescents in brief \"conversations\" with a fully automated relational agent called Woebot. It is a brief, self-guided 4 week-intervention that draws from cognitive behavioral therapy (CBT), interpersonal psychotherapy for adolescents (IPT-A), and elements of dialectical behavior therapy (DBT), depending on the presenting situation, to help the adolescent develop emotion regulation skills in the context of their everyday life. In this way, the mobile application is designed to be targeted, relevant, and integrated into the lived experience of adolescents, capable of delivering the appropriate technique for the problem at hand, at the time of need.",
            "deathsNumAffected": 0,
            "deathsNumAtRisk": 71,
            "seriousNumAffected": 0,
            "seriousNumAtRisk": 71,
            "otherNumAffected": 2,
            "otherNumAtRisk": 71
          },
          {
            "id": "EG001",
            "title": "CBT-Lite Teletherapy Group",
            "description": "Participants assigned to the CBT-Lite teletherapy group will be asked to attend 1-hour teletherapy group sessions over Zoom once a week for 4 weeks. In this group, a study clinician will cover topics such as building a coping tool box, accepting your feelings, challenging negative thoughts, and problem solving.\n\nCBT-Lite Teletherapy: The CBT-Lite teletherapy group is a brief, 4-week intervention held once weekly for an hour, and limited to those triaged into the Children's Hospital of the King's Daughters low-intensity track and participating in this protocol. An assigned study clinician will facilitate each teletherapy group with approximately 10 adolescents in each session. Each group begins with orientation and reviewing group rules, individual check-ins with each participant (rating stress level and hopefulness), followed by a guided mindfulness moment. Sessions are designed to draw from elements of cognitive behavioral therapy (CBT) and the 4 topics include: building a coping tool box, accepting your feelings, challenging negative thoughts, and problem solving.",
            "deathsNumAffected": 0,
            "deathsNumAtRisk": 70,
            "seriousNumAffected": 0,
            "seriousNumAtRisk": 70,
            "otherNumAffected": 2,
            "otherNumAtRisk": 70
          }
        ],
        "otherEvents": [
          {
            "term": "Adverse Event, Mild Severity",
            "organSystem": "Psychiatric disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 1,
                "numAffected": 1,
                "numAtRisk": 71
              },
              {
                "groupId": "EG001",
                "numEvents": 1,
                "numAffected": 1,
                "numAtRisk": 70
              }
            ]
          },
          {
            "term": "Adverse Event, Moderate Severity",
            "organSystem": "Psychiatric disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 1,
                "numAffected": 1,
                "numAtRisk": 71
              },
              {
                "groupId": "EG001",
                "numEvents": 1,
                "numAffected": 1,
                "numAtRisk": 70
              }
            ]
          }
        ]
      },
      "moreInfoModule": {
        "certainAgreement": {
          "piSponsorEmployee": false,
          "restrictiveAgreement": false
        },
        "pointOfContact": {
          "title": "Dr. Athena Robinson",
          "organization": "Woebot Health",
          "email": "athena@woebothealth.com",
          "phone": "(415) 209-5642"
        }
      }
    },
    "documentSection": {
      "largeDocumentModule": {
        "largeDocs": [
          {
            "typeAbbrev": "Prot_SAP",
            "hasProtocol": true,
            "hasSap": true,
            "hasIcf": false,
            "label": "Study Protocol and Statistical Analysis Plan",
            "date": "2023-05-31",
            "uploadDate": "2023-10-25T14:47",
            "filename": "Prot_SAP_000.pdf",
            "size": 453360
          }
        ]
      }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [{ "id": "D003863", "term": "Depression" }],
        "ancestors": [{ "id": "D001526", "term": "Behavioral Symptoms" }],
        "browseLeaves": [
          { "id": "M4324", "name": "Anxiety Disorders", "relevance": "LOW" },
          { "id": "M7061", "name": "Depressive Disorder", "relevance": "LOW" },
          {
            "id": "M7058",
            "name": "Depression",
            "asFound": "Depression",
            "relevance": "HIGH"
          },
          { "id": "M4818", "name": "Behavioral Symptoms", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" },
          { "abbrev": "All", "name": "All Conditions" }
        ]
      }
    },
    "hasResults": true
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT05120609",
        "orgStudyIdInfo": { "id": "1001" },
        "organization": { "fullName": "Beats Medical", "class": "INDUSTRY" },
        "briefTitle": "Pilot Study to Evaluate the Self-Management of Gait, Speech, and Dexterity Symptoms in Parkinson's Disease Using a Smartphone Application",
        "officialTitle": "A Randomized, Cross-Over, Placebo-Controlled Pilot Study to Evaluate the Self-Management of Gait, Speech and Dexterity in Patients With Parkinson's Disease Using a Novel Digital Therapeutic Approach"
      },
      "statusModule": {
        "statusVerifiedDate": "2021-10",
        "overallStatus": "UNKNOWN",
        "lastKnownStatus": "NOT_YET_RECRUITING",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2021-12", "type": "ESTIMATED" },
        "primaryCompletionDateStruct": {
          "date": "2022-07",
          "type": "ESTIMATED"
        },
        "completionDateStruct": { "date": "2022-12", "type": "ESTIMATED" },
        "studyFirstSubmitDate": "2021-11-04",
        "studyFirstSubmitQcDate": "2021-11-04",
        "studyFirstPostDateStruct": { "date": "2021-11-15", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2021-11-04",
        "lastUpdatePostDateStruct": { "date": "2021-11-15", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": { "name": "Beats Medical", "class": "INDUSTRY" }
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": false
      },
      "descriptionModule": {
        "briefSummary": "The purpose of this study is to evaluate the impact of a smartphone application that delivers at-home therapy exercises on patients' self-management of gait, speech, and dexterity symptoms."
      },
      "conditionsModule": {
        "conditions": ["Parkinson Disease"],
        "keywords": [
          "Nervous System Diseases",
          "Movement Disorders",
          "Neurodegenerative Diseases",
          "Brain Diseases",
          "Central Nervous System Diseases"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "CROSSOVER",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": { "masking": "NONE" }
        },
        "enrollmentInfo": { "count": 40, "type": "ESTIMATED" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "Parkinson's Application",
            "type": "EXPERIMENTAL",
            "description": "Subjects will complete at-home allied health therapy exercises delivered through a smartphone application. Subjects will use the application daily for 4 weeks, each daily session takes up to 30 minutes to complete.",
            "interventionNames": ["Device: Parkinson's Application"]
          },
          {
            "label": "Digital Placebo",
            "type": "PLACEBO_COMPARATOR",
            "description": "Subjects will have access to a digital placebo application and continue usual care.",
            "interventionNames": ["Device: Digital Placebo Application"]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "Parkinson's Application",
            "description": "The application delivers at-home, tailored allied health exercises (physiotherapy, speech and language therapy, and occupational therapy) for the gait, speech, and manual dexterity symptoms associated with Parkinson's disease.",
            "armGroupLabels": ["Parkinson's Application"]
          },
          {
            "type": "DEVICE",
            "name": "Digital Placebo Application",
            "description": "The application is designed to provide a method of capturing outcome measures without providing access to the therapy exercises.",
            "armGroupLabels": ["Digital Placebo"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Change in Gait Velocity (m/s)",
            "description": "Gait velocity on a 10-Meter Walk Test (10MWT) conducted in-clinic.",
            "timeFrame": "Baseline, Week 4, Week 8, Week 12"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Step Length (m)",
            "description": "Change in Step length on a 10-Meter Walk Test (10MWT) conducted in-clinic.",
            "timeFrame": "Baseline, Week 4, Week 8, Week 12"
          },
          {
            "measure": "Step Frequency (steps/min)",
            "description": "Change in Step frequency on a 10-Meter Walk Test (10MWT) conducted in-clinic.",
            "timeFrame": "Baseline, Week 4, Week 8, Week 12"
          },
          {
            "measure": "MDS-UPDRS Total Score for Part II Item 2.1 + Part III Item 3.1",
            "description": "Movement Disorders Society Sponsored Unified Parkinson's Disease Rating Scale (MDS-UPDRS) is designed to monitor the burden and extent of Parkinson's disease. The MDS-UPDRS is divided into 4 parts: (Part I; 13 items) non-motor experiences of daily living, (Part II; 13) motor experiences of daily living, (Part III; 34) motor examination, and (Part IV; 6) motor complications. In each part, all items are rated on a scale from 0-4, with higher scores reflecting greater severity.\n\nThe sum of items 2.1 (Speech) and Part III 3.1 (Speech) will be used to calculate a total score to assess speech abilities.",
            "timeFrame": "Baseline, Week 4, Week 8, Week 12"
          },
          {
            "measure": "MDS-UPDRS Total Score for Part II Item 2.7 + Part III Item 3.4 + Part III 3.5",
            "description": "The sum of items 2.7 (handwriting), 3.4 (finger tapping), and 3.5 (hand movements) will be used to calculate a total score to assess manual dexterity. All items are rated on a scale from 0-4, with higher scores reflecting greater severity.",
            "timeFrame": "Baseline, Week 4, Week 8, Week 12"
          },
          {
            "measure": "MDS-UPDRS Part II Total Score",
            "description": "For MDS-UPDRS Part II (motor experiences of daily living) scores, the scale range for Part II Total Score is 0-52, with higher scores reflecting greater severity.",
            "timeFrame": "Baseline, Week 4, Week 8, Week 12"
          },
          {
            "measure": "Daily steps",
            "description": "Physical activity will be assessed by the relative change in daily steps recorded by the in-device sensors in the smartphone.",
            "timeFrame": "Week 1,2,3,4,5,6,7,8"
          }
        ],
        "otherOutcomes": [
          {
            "measure": "Average duration (seconds) of sustained vowel phonation",
            "description": "Change in the average duration of sustained vowel phonation on a smartphone-based speech assessment conducted in-clinic.",
            "timeFrame": "Baseline, Week 4, Week 8, Week 12"
          },
          {
            "measure": "Time taken to complete a smartphone-based 9-Hole Peg Test (seconds)",
            "description": "Change in time taken to complete a smartphone-based 9-Hole Peg Test conducted in-clinic.",
            "timeFrame": "Baseline, Week 4, Week 8, Week 12"
          },
          {
            "measure": "Total Distance (m) walked on a smartphone-based 2-minute walk test (2MWT)",
            "description": "Change in total distance walked on a smartphone-based at-home 2-minute walk test (2MWT).",
            "timeFrame": "Baseline, Week 4, Week 8, Week 12"
          },
          {
            "measure": "Gait velocity (m/s) on a smartphone based 2-minute walk test (2MWT)",
            "description": "Chance in gait velocity on a smartphone-based at-home 2-minute walk test (2MWT).",
            "timeFrame": "Baseline, Week 4, Week 8, Week 12"
          },
          {
            "measure": "Step frequency (steps/min) on a smartphone-based 2-minute walk test (2MWT)",
            "description": "Change in step frequency on a smartphone-based at-home 2-minute walk test (2MWT).",
            "timeFrame": "Baseline, Week 4, Week 8, Week 12"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* Male and female subjects at least 30 years of age or older,\n* History of idiopathic Parkinson's Disease (Hoehn and Yahr stage of II-IV),\n* Normal joint range of motion in both legs,\n* Able to walk independently for 10 feet with or without an assistive device,\n* Parkinson's gait and mild to moderate speech impairment,\n* No history of vestibular disease,\n* No evidence of dementia (MMSE ≥24),\n* Clear benefit from Levodopa,\n* Agrees to Beats Medical Application Privacy Policy and Terms of Use,\n* Access to an iPhone 7 or higher to use the Beats Medical applications.\n\nExclusion Criteria:\n\n* Medical condition for which exercise is contraindicated,\n* History or evidence of neurological deficit other than Parkinson's Disease that could interfere, such as previous stroke or muscle disease,\n* History or evidence of orthopaedic or muscular problems,\n* Subject is currently enrolled in a study to evaluate an investigational drug or device,\n* Subject unable or unwilling to provide informed consent,\n* Vulnerable populations as deemed inappropriate for the study by site Principal Investigator,\n* History of falls in the past 6 months,\n* Pregnancy,\n* Current or previous use of the Beats Medical Parkinson's application.",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "30 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "centralContacts": [
          {
            "name": "Armistead Williams, MD",
            "role": "CONTACT",
            "phone": "757-226-0655",
            "email": "awilliams@mcrmed.com"
          }
        ],
        "locations": [
          {
            "facility": "Meridian Clinical Research",
            "city": "Norfolk",
            "state": "Virginia",
            "zip": "23502",
            "country": "United States",
            "contacts": [
              { "name": "Armistead Williams, MD", "role": "CONTACT" },
              {
                "name": "Armistead Williams, MD",
                "role": "PRINCIPAL_INVESTIGATOR"
              }
            ],
            "geoPoint": { "lat": 36.84681, "lon": -76.28522 }
          }
        ]
      },
      "ipdSharingStatementModule": { "ipdSharing": "NO" }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [{ "id": "D010300", "term": "Parkinson Disease" }],
        "ancestors": [
          { "id": "D020734", "term": "Parkinsonian Disorders" },
          { "id": "D001480", "term": "Basal Ganglia Diseases" },
          { "id": "D001927", "term": "Brain Diseases" },
          { "id": "D002493", "term": "Central Nervous System Diseases" },
          { "id": "D009422", "term": "Nervous System Diseases" },
          { "id": "D009069", "term": "Movement Disorders" },
          { "id": "D000080874", "term": "Synucleinopathies" },
          { "id": "D019636", "term": "Neurodegenerative Diseases" }
        ],
        "browseLeaves": [
          { "id": "M5204", "name": "Brain Diseases", "relevance": "LOW" },
          {
            "id": "M13213",
            "name": "Parkinson Disease",
            "asFound": "Parkinson's Disease",
            "relevance": "HIGH"
          },
          { "id": "M12029", "name": "Movement Disorders", "relevance": "LOW" },
          {
            "id": "M5742",
            "name": "Central Nervous System Diseases",
            "relevance": "LOW"
          },
          {
            "id": "M21558",
            "name": "Neurodegenerative Diseases",
            "relevance": "LOW"
          },
          {
            "id": "M22494",
            "name": "Parkinsonian Disorders",
            "relevance": "LOW"
          },
          { "id": "M25603", "name": "Ganglion Cysts", "relevance": "LOW" },
          { "id": "M16358", "name": "Synovial Cyst", "relevance": "LOW" },
          {
            "id": "M4774",
            "name": "Basal Ganglia Diseases",
            "relevance": "LOW"
          },
          { "id": "M2217", "name": "Synucleinopathies", "relevance": "LOW" },
          {
            "id": "T4202",
            "name": "Oculocerebral Syndrome With Hypopigmentation",
            "relevance": "LOW"
          }
        ],
        "browseBranches": [
          { "abbrev": "BC10", "name": "Nervous System Diseases" },
          { "abbrev": "All", "name": "All Conditions" },
          { "abbrev": "BC04", "name": "Neoplasms" },
          { "abbrev": "BC17", "name": "Skin and Connective Tissue Diseases" },
          { "abbrev": "BC18", "name": "Nutritional and Metabolic Diseases" },
          { "abbrev": "Rare", "name": "Rare Diseases" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT04040387",
        "orgStudyIdInfo": { "id": "NW101002" },
        "organization": { "fullName": "NightWare", "class": "INDUSTRY" },
        "briefTitle": "Traumatic Nightmares Treated by NightWare (To Arouse Not Awaken)",
        "officialTitle": "TNT/NW: Traumatic Nightmares Treated by NightWare (To Arouse Not Awaken)",
        "acronym": "TNT/NW"
      },
      "statusModule": {
        "statusVerifiedDate": "2023-11",
        "overallStatus": "ENROLLING_BY_INVITATION",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2019-07-24", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2024-08-24",
          "type": "ESTIMATED"
        },
        "completionDateStruct": { "date": "2024-08-24", "type": "ESTIMATED" },
        "studyFirstSubmitDate": "2019-07-29",
        "studyFirstSubmitQcDate": "2019-07-29",
        "studyFirstPostDateStruct": { "date": "2019-07-31", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2023-11-07",
        "lastUpdatePostDateStruct": { "date": "2023-11-08", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": { "name": "NightWare", "class": "INDUSTRY" },
        "collaborators": [
          {
            "name": "Minneapolis Veterans Affairs Medical Center",
            "class": "FED"
          },
          { "name": "Louis Stokes VA Medical Center", "class": "FED" },
          {
            "name": "Walter Reed National Military Medical Center",
            "class": "FED"
          },
          { "name": "Fort Belvoir Community Hospital", "class": "FED" }
        ]
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": true,
        "isUsExport": false
      },
      "descriptionModule": {
        "briefSummary": "This study will provide preliminary estimates of safety and efficacy of the NightWare digital therapeutic system (iPhone + Apple watch + proprietary application) for the treatment of nightmare disorder associated with post-traumatic stress disorder (PTSD)-related sleep disturbance and the impact of improved sleep with the NightWare digital therapeutic system. The investigators hypothesize that the NightWare digital therapeutic system will significantly improve sleep quality in participants with PTSD-Related nightmares and poor sleep quality.",
        "detailedDescription": "Nightmares are a common problem affecting 2-8% of the general population and a higher proportion of clinical populations. The negative consequences of untreated nightmares are significant and include impaired quality of life, sleep deprivation (often resulting in an increased intensity of nightmares), insomnia, daytime sleepiness, and fatigue. Untreated nightmares can also exacerbate the symptoms of underlying psychological dysfunction in people with depression and anxiety, leading to poor occupational and or social functioning. Nightmares can be idiopathic or associated with the use (or withdrawal) of certain medications or substances, or associated with disorders including PTSD.\n\nNightWare (Minneapolis, MN) has developed a novel approach to the treatment of nightmares. Through the use of a smartwatch-based application that senses physiologic parameters, the participant is aroused from sleep (without awakening the participant) so that the nightmare is interrupted prior to reaching a threshold of severity in which the participant would awaken in distress. Seconds later the participant returns to sleep without having experienced a nightmare. This approach avoids risk from pharmacological treatment, avoids exacerbation of symptoms from image rehearsal therapy and allows for a simple method with easily achieved adherence compared to existing treatments.\n\nThe NightWare digital therapeutic system consists of a proprietary software application installed on a smartwatch. The application has been effective in focus groups when used on both Apple smartwatches and Motorola smartwatches. For the purposes of this study, the investigators will be using only the Apple (Cupertino, CA) 3rd generation smartwatch and the Apple iPhone. The NightWare application uses physiological markers obtained via the smartwatch to determine by proprietary algorithm whether a participant is in the early stages of a nightmare, but has not yet awoken in distress. As directed by the algorithm, the smartwatch then applies varying degrees of vibratory stimulation to the wrist over variable lengths of time with the intention of arousing the participant from sleep without eliciting an awakening."
      },
      "conditionsModule": {
        "conditions": [
          "Stress Disorders, Post-Traumatic",
          "Combat Disorders",
          "Ptsd",
          "Nightmare",
          "Nightmares, REM-Sleep Type",
          "Nightmare Disorder With Associated Non-Sleep Disorder"
        ],
        "keywords": [
          "PTSD",
          "Nightmare",
          "Nightmare Disorder",
          "Post-traumatic stress disorder",
          "Veteran",
          "Digital therapeutic",
          "Digital medicine"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": {
            "masking": "QUADRUPLE",
            "whoMasked": [
              "PARTICIPANT",
              "CARE_PROVIDER",
              "INVESTIGATOR",
              "OUTCOMES_ASSESSOR"
            ]
          }
        },
        "enrollmentInfo": { "count": 270, "type": "ESTIMATED" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "Treatment Arm",
            "type": "EXPERIMENTAL",
            "description": "Intervention with NightWare Therapeutic System",
            "interventionNames": ["Device: NightWare Therapeutic System"]
          },
          {
            "label": "Sham Arm",
            "type": "SHAM_COMPARATOR",
            "description": "NightWare system set to not provide any interventions",
            "interventionNames": ["Device: Sham NightWare"]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "NightWare Therapeutic System",
            "description": "A wearable digital therapeutic system that will measure physiologic data when worn during sleep to deliver a mild vibration via the watch to elicit arousal thereby disrupting nightmares. This detection and stimulation sequence will be performed according to NightWare's proprietary algorithm.",
            "armGroupLabels": ["Treatment Arm"]
          },
          {
            "type": "DEVICE",
            "name": "Sham NightWare",
            "description": "NightWare device not providing interventions",
            "armGroupLabels": ["Sham Arm"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Change in global score on the Pittsburgh Sleep Quality Index (PSQI) from Day 0 to Day 60",
            "description": "The Pittsburgh Sleep Quality Index (PSQI) is a self-rated questionnaire which assesses sleep quality and disturbances over a 1-month time interval. Nineteen individual items generate seven \"component\" scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. The sum of scores for these seven components yields one global score. In scoring the PSQI, seven component scores are derived, each scored 0 (no difficulty) to 3 (severe difficulty). The component scores are summed to produce a global score (range 0 to 21). Higher scores indicate worse sleep quality. This outcome is the difference between the global score on the Pittsburgh Sleep Quality Index (PSQI) score at baseline (Day 0) and average global PSQI score across the four post-treatment initiation assessments (Days 14, 30, 44 and 60).",
            "timeFrame": "0-60 days"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* Veterans and Active-Duty Service Member Enrolled in the Minneapolis/St. Cloud VAHCS, Louis Stokes VAHCS in Cleveland, Walter Reed National Military Medical Center, or Fort Belvoir Community Hospital\n* Diagnosis of PTSD via American Psychiatric Association PTSD diagnostic criteria in the fifth edition of its Diagnostic and Statistical Manual of Mental Disorders (DSM-5).\n* Equal to or older than 22 years of age.\n* Proficient in both reading and writing in the English language.\n* Pittsburgh Sleep Quality Index (PSQI) score 10 or higher.\n* Epworth Sleepiness Scale (ESS): On question #8 any score above \"0\" will prompt an additional question: Do you drive (\"get behind the wheel\") when you are drowsy? The answer must be \"No\" to be enrolled in the study due to safety concerns.\n* Have repetitive nightmares contributing to disrupted sleep as reported by the patient\n* Wireless Internet and two power outlets where they sleep\n* Prazosin use; if yes, the patient may be included if tapered by prescribing provider. Taper must be completed and subject must be off prazosin for 2 days prior to enrollment.\n\nExclusion Criteria:\n\n* Patient Health Questionnaire-9 (PHQ-9) score greater than or equal to 20. A score of 1 or more on the suicide ideation item of the PHQ-9 will trigger a risk assessment.\n* Uncontrolled atrial fibrillation\n* Current use of varenicline\n* Current use of beta-blockers (unless ophthalmic solutions)\n* Current use of non-dihydropyridines\n* Current use of Prazosin for the treatment of nightmares (can include patients 2 days following taper and discontinuation) This would be coordinated with the prescribing provider\n* Circadian rhythm disruption on a regular basis (shift-work)\n* Known diagnosis of Obstructive Sleep Apnea\n* Diagnosis of an active disorder of arousal from non-rapid eye movement sleep\n* Diagnosis of rapid eye movement sleep behavior disorder\n* Diagnosis of narcolepsy\n* Alcohol Use Disorders Inventory Test (AUDIT) (score of 8 or higher)\n* Drug Abuse Screening Test-10 (DAST-10) (score greater than 2)\n* Suspicion of nightmares being secondary to substance abuse or withdrawal\n* Diagnosis or suspicion of dementia\n* Previous or foreseeable legal proceedings involving nightmares or trauma\n* Nocturia that causes awakening from sleep\n* Known sleepwalking\n* Acting out of dreams prior to PTSD trauma",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "22 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "Daniel R Karlin, MD MA",
            "affiliation": "NightWare",
            "role": "STUDY_CHAIR"
          }
        ],
        "locations": [
          {
            "facility": "Walter Reed National Military Medical Center",
            "city": "Bethesda",
            "state": "Maryland",
            "zip": "20814",
            "country": "United States",
            "geoPoint": { "lat": 38.98067, "lon": -77.10026 }
          },
          {
            "facility": "Minneapolis VA Healthcare System",
            "city": "Minneapolis",
            "state": "Minnesota",
            "zip": "55417",
            "country": "United States",
            "geoPoint": { "lat": 44.97997, "lon": -93.26384 }
          },
          {
            "facility": "Louis Stokes Cleveland VA Medical Center",
            "city": "Cleveland",
            "state": "Ohio",
            "zip": "44106",
            "country": "United States",
            "geoPoint": { "lat": 41.4995, "lon": -81.69541 }
          },
          {
            "facility": "Fort Belvoir Community Hospital",
            "city": "Fort Belvoir",
            "state": "Virginia",
            "zip": "22060",
            "country": "United States",
            "geoPoint": { "lat": 38.7119, "lon": -77.14589 }
          }
        ]
      },
      "referencesModule": {
        "references": [
          {
            "pmid": "36305584",
            "type": "DERIVED",
            "citation": "Davenport ND, Werner JK. A randomized sham-controlled clinical trial of a novel wearable intervention for trauma-related nightmares in military veterans. J Clin Sleep Med. 2023 Feb 1;19(2):361-369. doi: 10.5664/jcsm.10338."
          }
        ]
      },
      "ipdSharingStatementModule": { "ipdSharing": "NO" }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [
          { "id": "D040921", "term": "Stress Disorders, Traumatic" },
          { "id": "D013313", "term": "Stress Disorders, Post-Traumatic" },
          { "id": "D003130", "term": "Combat Disorders" }
        ],
        "ancestors": [
          {
            "id": "D000068099",
            "term": "Trauma and Stressor Related Disorders"
          },
          { "id": "D001523", "term": "Mental Disorders" }
        ],
        "browseLeaves": [
          {
            "id": "M16103",
            "name": "Stress Disorders, Post-Traumatic",
            "asFound": "Stress Disorders, Post-Traumatic",
            "relevance": "HIGH"
          },
          {
            "id": "M24916",
            "name": "Stress Disorders, Traumatic",
            "asFound": "Stress Disorder",
            "relevance": "HIGH"
          },
          {
            "id": "M6358",
            "name": "Combat Disorders",
            "asFound": "Combat Disorders",
            "relevance": "HIGH"
          },
          { "id": "M17685", "name": "Wounds and Injuries", "relevance": "LOW" },
          {
            "id": "M222",
            "name": "Trauma and Stressor Related Disorders",
            "relevance": "LOW"
          },
          { "id": "M14473", "name": "Psychotic Disorders", "relevance": "LOW" },
          { "id": "M4815", "name": "Mental Disorders", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" },
          { "abbrev": "All", "name": "All Conditions" },
          { "abbrev": "BC26", "name": "Wounds and Injuries" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT03828656",
        "orgStudyIdInfo": { "id": "NW101003" },
        "organization": { "fullName": "NightWare", "class": "INDUSTRY" },
        "briefTitle": "NightWare Open Enrollment Study",
        "officialTitle": "NightWare Open Enrollment Study",
        "acronym": "NWOES"
      },
      "statusModule": {
        "statusVerifiedDate": "2021-03",
        "overallStatus": "UNKNOWN",
        "lastKnownStatus": "ENROLLING_BY_INVITATION",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2019-02-01", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2022-02-01",
          "type": "ESTIMATED"
        },
        "completionDateStruct": { "date": "2022-02-01", "type": "ESTIMATED" },
        "studyFirstSubmitDate": "2019-01-31",
        "studyFirstSubmitQcDate": "2019-01-31",
        "studyFirstPostDateStruct": { "date": "2019-02-04", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2021-03-03",
        "lastUpdatePostDateStruct": { "date": "2021-03-04", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": { "name": "NightWare", "class": "INDUSTRY" },
        "collaborators": [
          { "name": "RationalPsych", "class": "UNKNOWN" },
          {
            "name": "Center for International Emergency Medical Services",
            "class": "OTHER"
          }
        ]
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": true,
        "isUnapprovedDevice": true,
        "isUsExport": false
      },
      "descriptionModule": {
        "briefSummary": "This study will provide measures of safety and efficacy of the NightWare digital therapeutic system (iPhone + Apple watch + proprietary application) for the treatment of nightmare disorder associated with post-traumatic stress disorder (PTSD)-related sleep disturbance and the impact of improved sleep with the NightWare digital therapeutic system. The investigators hypothesize that the NightWare digital therapeutic system will significantly improve sleep quality in participants with PTSD-Related nightmares and poor sleep quality.",
        "detailedDescription": "Nightmares are a common problem affecting 2-8% of the general population and a higher proportion of clinical populations. The negative consequences of untreated nightmares are significant and include impaired quality of life, sleep deprivation (often resulting in an increased intensity of nightmares), insomnia, daytime sleepiness, and fatigue. Untreated nightmares can also exacerbate the symptoms of underlying psychological dysfunction in people with depression and anxiety, leading to poor occupational and or social functioning. Nightmares can be idiopathic or associated with the use (or withdrawal) of certain medications or substances or associated with disorders including PTSD.\n\nNightWare (Minneapolis, MN) has developed a novel approach to the treatment of nightmares. Through the use of a smartwatch-based application that senses physiologic parameters, the participant is aroused from sleep (without awakening the participant) so that the nightmare is interrupted prior to reaching a threshold of severity in which the participant would awaken in distress. Seconds later the participant returns to sleep without having experienced a nightmare. This approach avoids risk from pharmacological treatment, avoids exacerbation of symptoms from image rehearsal therapy and allows for a simple method with easily achieved adherence compared to existing treatments.\n\nThe NightWare digital therapeutic system consists of a proprietary software application installed on a smartwatch. The application has been effective in focus groups when used on both Apple smartwatches and Motorola smartwatches. For the purposes of this study, the investigators will be using only the Apple (Cupertino, CA) 3rd generation smartwatch and the Apple iPhone. The NightWare application uses physiological markers obtained via the smartwatch to determine by proprietary algorithm whether a participant is in the early stages of a nightmare, but has not yet awoken in distress. As directed by the algorithm, the smartwatch then applies varying degrees of vibratory stimulation to the wrist over variable lengths of time with the intention of arousing the participant from sleep without eliciting an awakening."
      },
      "conditionsModule": {
        "conditions": [
          "PostTraumatic Stress Disorder",
          "Sleep Disorder",
          "Stress Disorder",
          "Sleep Initiation and Maintenance Disorders",
          "Combat Disorders",
          "Nightmares Associated With Chronic Post-Traumatic Stress Disorder",
          "Nightmare",
          "Nightmares, REM-Sleep Type"
        ],
        "keywords": [
          "PTSD",
          "Nightmare Disorder",
          "Post-traumatic stress disorder",
          "Veteran",
          "Digital therapeutic",
          "Digital medicine",
          "Nightmares"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "NA",
          "interventionModel": "SINGLE_GROUP",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": { "masking": "NONE" }
        },
        "enrollmentInfo": { "count": 400, "type": "ESTIMATED" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "Open Label Treatment Arm",
            "type": "EXPERIMENTAL",
            "description": "Open-label Intervention with the NightWare Therapeutic System every night.",
            "interventionNames": ["Device: NightWare Therapeutic System"]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "NightWare Therapeutic System",
            "description": "A wearable digital therapeutic system that will measure physiologic data when worn during sleep to deliver a mild vibration via the watch to elicit arousal thereby disrupting nightmares. This detection and stimulation sequence will be performed according to NightWare's proprietary algorithm.",
            "armGroupLabels": ["Open Label Treatment Arm"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Change in global score on the Pittsburgh Sleep Quality Index (PSQI) from Day 0 to each subsequent 28 day evaluation period",
            "description": "The Pittsburgh Sleep Quality Index (PSQI) is a self-rated questionnaire which assesses sleep quality and disturbances over a 1-month time interval. Nineteen individual items generate seven \"component\" scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. The sum of scores for these seven components yields one global score. In scoring the PSQI, seven component scores are derived, each scored 0 (no difficulty) to 3 (severe difficulty). The component scores are summed to produce a global score (range 0 to 21). Higher scores indicate worse sleep quality. This outcome is the difference between the global score on the Pittsburgh Sleep Quality Index (PSQI) score at baseline (Day 0) and average global PSQI score across the post-treatment initiation assessments (Days 14, 28 and every 28 days after that).",
            "timeFrame": "0-730 days"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\nNew to NightWare\n\n* Self report of diagnosis with PTSD\n* Self-report of PTSD-related repetitive nightmares contributing to disrupted sleep.\n* Equal to or older than 18 years of age.\n* Proficient in both reading and writing in the English language.\n* Pittsburgh Sleep Quality Index (PSQI) score equal to or greater than 10.\n* ESS: On question #8 any score above \"0\" will prompt an additional question:\n* Do you drive (\"get behind the wheel\") when you are drowsy?\n* Answer must be \"No\" to be enrolled in the study for safety.\n* Participant owns or has access to devices appropriate for participation in the study including compatible Apple Watch and Apple iPhone.\n* Wireless Internet and two power outlets where they sleep.\n\nOR\n\nCurrent NightWare user - Is a participant in current NightWare consumer preference study or has successfully completed any NightWare study protocol.\n\nExclusion Criteria:\n\nNew to NightWare\n\n* Circadian rhythm disruption on a regular basis (shift-work)\n* Concurrent presence of prohibited diagnoses\n* Known diagnosis of OSA\n* Diagnosis of an active disorder of arousal from non-rapid eye movement sleep\n* Diagnosis of rapid eye movement sleep behavior disorder\n* Diagnosis of narcolepsy\n* Diagnosis of dementia\n* Uncontrolled atrial fibrillation\n* Use of Alcohol or Drugs as specified:\n* Alcohol Use Disorders Inventory Test (AUDIT) (score of 8 or higher)\n* Drug Abuse Screening Test-10 (DAST-10) (score greater than 2)\n* Suspicion of nightmares being secondary to substance abuse or withdrawal\n* Previous or foreseeable legal proceedings involving nightmares or trauma\n* Nocturia that causes awakening from sleep\n* Known sleep walking\n* Acting out of dreams PRIOR to PTSD trauma\n* Willingness not to use any other application which collects heart rate data on the phone and watch that is used for NightWare.\n\nOR\n\nCurrent NightWare User\n\n- No known adverse reaction to the use of the NightWare system.",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "Daniel R Karlin, MD MA",
            "affiliation": "RationalPsych",
            "role": "PRINCIPAL_INVESTIGATOR"
          }
        ],
        "locations": [
          {
            "facility": "RationalPsych",
            "city": "Bronx",
            "state": "New York",
            "zip": "10461",
            "country": "United States",
            "geoPoint": { "lat": 40.84985, "lon": -73.86641 }
          }
        ]
      },
      "ipdSharingStatementModule": { "ipdSharing": "YES" }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [
          { "id": "D012893", "term": "Sleep Wake Disorders" },
          {
            "id": "D007319",
            "term": "Sleep Initiation and Maintenance Disorders"
          },
          { "id": "D040921", "term": "Stress Disorders, Traumatic" },
          { "id": "D013313", "term": "Stress Disorders, Post-Traumatic" },
          { "id": "D003130", "term": "Combat Disorders" }
        ],
        "ancestors": [
          {
            "id": "D000068099",
            "term": "Trauma and Stressor Related Disorders"
          },
          { "id": "D001523", "term": "Mental Disorders" },
          { "id": "D009422", "term": "Nervous System Diseases" },
          { "id": "D009461", "term": "Neurologic Manifestations" },
          { "id": "D020919", "term": "Sleep Disorders, Intrinsic" },
          { "id": "D020920", "term": "Dyssomnias" }
        ],
        "browseLeaves": [
          {
            "id": "M16103",
            "name": "Stress Disorders, Post-Traumatic",
            "asFound": "Chronic Post-Traumatic Stress Disorder",
            "relevance": "HIGH"
          },
          {
            "id": "M24916",
            "name": "Stress Disorders, Traumatic",
            "asFound": "Stress Disorder",
            "relevance": "HIGH"
          },
          {
            "id": "M10356",
            "name": "Sleep Initiation and Maintenance Disorders",
            "asFound": "Sleep Initiation and Maintenance Disorders",
            "relevance": "HIGH"
          },
          { "id": "M22242", "name": "Parasomnias", "relevance": "LOW" },
          {
            "id": "M6358",
            "name": "Combat Disorders",
            "asFound": "Combat Disorders",
            "relevance": "HIGH"
          },
          {
            "id": "M15696",
            "name": "Sleep Wake Disorders",
            "asFound": "Sleep Disorders",
            "relevance": "HIGH"
          },
          { "id": "M17685", "name": "Wounds and Injuries", "relevance": "LOW" },
          {
            "id": "M222",
            "name": "Trauma and Stressor Related Disorders",
            "relevance": "LOW"
          },
          { "id": "M14473", "name": "Psychotic Disorders", "relevance": "LOW" },
          { "id": "M4815", "name": "Mental Disorders", "relevance": "LOW" },
          {
            "id": "M12404",
            "name": "Neurologic Manifestations",
            "relevance": "LOW"
          },
          {
            "id": "M22654",
            "name": "Sleep Disorders, Intrinsic",
            "relevance": "LOW"
          },
          { "id": "M22655", "name": "Dyssomnias", "relevance": "LOW" },
          {
            "id": "T1303",
            "name": "Chronic Graft Versus Host Disease",
            "relevance": "LOW"
          }
        ],
        "browseBranches": [
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" },
          { "abbrev": "All", "name": "All Conditions" },
          { "abbrev": "BC10", "name": "Nervous System Diseases" },
          { "abbrev": "BC23", "name": "Symptoms and General Pathology" },
          { "abbrev": "BC26", "name": "Wounds and Injuries" },
          { "abbrev": "Rare", "name": "Rare Diseases" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT03795987",
        "orgStudyIdInfo": { "id": "NW101001" },
        "organization": { "fullName": "NightWare", "class": "INDUSTRY" },
        "briefTitle": "Traumatic Nightmares Treated by NightWare (To Arouse Not Awaken)",
        "officialTitle": "TNT/NW: Traumatic Nightmares Treated by NightWare (To Arouse Not Awaken)",
        "acronym": "TNT/NW"
      },
      "statusModule": {
        "statusVerifiedDate": "2020-02",
        "overallStatus": "COMPLETED",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2019-02-07", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2019-08-14",
          "type": "ACTUAL"
        },
        "completionDateStruct": { "date": "2019-08-14", "type": "ACTUAL" },
        "studyFirstSubmitDate": "2019-01-04",
        "studyFirstSubmitQcDate": "2019-01-04",
        "studyFirstPostDateStruct": { "date": "2019-01-08", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2020-02-25",
        "lastUpdatePostDateStruct": { "date": "2020-02-26", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": { "name": "NightWare", "class": "INDUSTRY" },
        "collaborators": [
          {
            "name": "Minneapolis Veterans Affairs Medical Center",
            "class": "FED"
          }
        ]
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": true,
        "isUnapprovedDevice": true,
        "isUsExport": false
      },
      "descriptionModule": {
        "briefSummary": "This study will provide preliminary estimates of safety and efficacy of the NightWare digital therapeutic system (iPhone + Apple watch + proprietary application) for the treatment of nightmare disorder associated with post-traumatic stress disorder (PTSD)-related sleep disturbance and the impact of improved sleep with the NightWare digital therapeutic system. The investigators hypothesize that the NightWare digital therapeutic system will significantly improve sleep quality in participants with PTSD-Related nightmares and poor sleep quality.",
        "detailedDescription": "Nightmares are a common problem affecting 2-8% of the general population and a higher proportion of clinical populations. The negative consequences of untreated nightmares are significant and include impaired quality of life, sleep deprivation (often resulting in an increased intensity of nightmares), insomnia, daytime sleepiness, and fatigue. Untreated nightmares can also exacerbate the symptoms of underlying psychological dysfunction in people with depression and anxiety, leading to poor occupational and or social functioning. Nightmares can be idiopathic or associated with the use (or withdrawal) of certain medications or substances, or associated with disorders including PTSD.\n\nNightWare (Minneapolis, MN) has developed a novel approach to the treatment of nightmares. Through the use of a smartwatch-based application that senses physiologic parameters, the participant is aroused from sleep (without awakening the participant) so that the nightmare is interrupted prior to reaching a threshold of severity in which the participant would awaken in distress. Seconds later the participant returns to sleep without having experienced a nightmare. This approach avoids risk from pharmacological treatment, avoids exacerbation of symptoms from image rehearsal therapy and allows for a simple method with easily achieved adherence compared to existing treatments.\n\nThe NightWare digital therapeutic system consists of a proprietary software application installed on a smartwatch. The application has been effective in focus groups when used on both Apple smartwatches and Motorola smartwatches. For the purposes of this study, the investigators will be using only the Apple (Cupertino, CA) 3rd generation smartwatch and the Apple iPhone. The NightWare application uses physiological markers obtained via the smartwatch to determine by proprietary algorithm whether a participant is in the early stages of a nightmare, but has not yet awoken in distress. As directed by the algorithm, the smartwatch then applies varying degrees of vibratory stimulation to the wrist over variable lengths of time with the intention of arousing the participant from sleep without eliciting an awakening."
      },
      "conditionsModule": {
        "conditions": [
          "Stress Disorders, Post-Traumatic",
          "Combat Disorders",
          "Ptsd",
          "Nightmare",
          "Nightmares, REM-Sleep Type",
          "Nightmare Disorder With Associated Non-Sleep Disorder"
        ],
        "keywords": [
          "PTSD",
          "Nightmare",
          "Nightmare Disorder",
          "Post-traumatic stress disorder",
          "Veteran",
          "Digital therapeutic",
          "Digital medicine"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "NA",
          "interventionModel": "SINGLE_GROUP",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": { "masking": "NONE" }
        },
        "enrollmentInfo": { "count": 15, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "Open Label Treatment Arm",
            "type": "EXPERIMENTAL",
            "description": "Intervention with NightWare Therapeutic System",
            "interventionNames": ["Device: NightWare Therapeutic System"]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "NightWare Therapeutic System",
            "description": "A wearable digital therapeutic system that will measure physiologic data when worn during sleep to deliver a mild vibration via the watch to elicit arousal thereby disrupting nightmares. This detection and stimulation sequence will be performed according to NightWare's proprietary algorithm.",
            "armGroupLabels": ["Open Label Treatment Arm"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Change in global score on the Pittsburgh Sleep Quality Index (PSQI) from Day 0 to Day 60",
            "description": "The Pittsburgh Sleep Quality Index (PSQI) is a self-rated questionnaire which assesses sleep quality and disturbances over a 1-month time interval. Nineteen individual items generate seven \"component\" scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. The sum of scores for these seven components yields one global score. In scoring the PSQI, seven component scores are derived, each scored 0 (no difficulty) to 3 (severe difficulty). The component scores are summed to produce a global score (range 0 to 21). Higher scores indicate worse sleep quality. This outcome is the difference between the global score on the Pittsburgh Sleep Quality Index (PSQI) score at baseline (Day 0) and average global PSQI score across the four post-treatment initiation assessments (Days 14, 30, 44 and 60).",
            "timeFrame": "0-60 days"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* Veteran Enrolled in the Minneapolis/St. Cloud VAHCS.\n* Diagnosis of PTSD via American Psychiatric Association PTSD diagnostic criteria in the fifth edition of its Diagnostic and Statistical Manual of Mental Disorders (DSM-5).\n* Equal to or older than 22 years of age.\n* Proficient in both reading and writing in the English language.\n* Pittsburgh Sleep Quality Index (PSQI) score 10 or higher.\n* Epworth Sleepiness Scale (ESS): On question #8 any score above \"0\" will prompt an additional question: Do you drive (\"get behind the wheel\") when you are drowsy? The answer must be \"No\" to be enrolled in the study due to safety concerns.\n* Have repetitive nightmares contributing to disrupted sleep as reported by the patient\n* Wireless Internet and two power outlets where they sleep\n* Prazosin use; if yes, the patient may be included if tapered by prescribing provider. Taper must be completed and subject must be off prazosin for 2 days prior to enrollment.\n\nExclusion Criteria:\n\n* Patient Health Questionnaire-9 (PHQ-9) score greater than or equal to 20. A score of 1 or more on the suicide ideation item of the PHQ-9 will trigger a risk assessment.\n* Uncontrolled atrial fibrillation\n* Current use of varenicline\n* Current use of beta-blockers (unless ophthalmic solutions)\n* Current use of non-dihydropyridines\n* Current use of Prazosin for the treatment of nightmares (can include patients 2 days following taper and discontinuation) This would be coordinated with the prescribing provider\n* Circadian rhythm disruption on a regular basis (shift-work)\n* Known diagnosis of Obstructive Sleep Apnea\n* Diagnosis of an active disorder of arousal from non-rapid eye movement sleep\n* Diagnosis of rapid eye movement sleep behavior disorder\n* Diagnosis of narcolepsy\n* Alcohol Use Disorders Inventory Test (AUDIT) (score of 8 or higher)\n* Drug Abuse Screening Test-10 (DAST-10) (score greater than 2)\n* Suspicion of nightmares being secondary to substance abuse or withdrawal\n* Diagnosis or suspicion of dementia\n* Previous or foreseeable legal proceedings involving nightmares or trauma\n* Nocturia that causes awakening from sleep\n* Known sleepwalking\n* Acting out of dreams prior to PTSD trauma",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "22 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "Daniel R Karlin, MD MA",
            "affiliation": "NightWare",
            "role": "STUDY_CHAIR"
          }
        ],
        "locations": [
          {
            "facility": "Minneapolis VA Healthcare System",
            "city": "Minneapolis",
            "state": "Minnesota",
            "zip": "55417",
            "country": "United States",
            "geoPoint": { "lat": 44.97997, "lon": -93.26384 }
          }
        ]
      },
      "ipdSharingStatementModule": { "ipdSharing": "NO" }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [
          { "id": "D040921", "term": "Stress Disorders, Traumatic" },
          { "id": "D013313", "term": "Stress Disorders, Post-Traumatic" },
          { "id": "D003130", "term": "Combat Disorders" }
        ],
        "ancestors": [
          {
            "id": "D000068099",
            "term": "Trauma and Stressor Related Disorders"
          },
          { "id": "D001523", "term": "Mental Disorders" }
        ],
        "browseLeaves": [
          {
            "id": "M16103",
            "name": "Stress Disorders, Post-Traumatic",
            "asFound": "Stress Disorders, Post-Traumatic",
            "relevance": "HIGH"
          },
          {
            "id": "M24916",
            "name": "Stress Disorders, Traumatic",
            "asFound": "Stress Disorder",
            "relevance": "HIGH"
          },
          {
            "id": "M6358",
            "name": "Combat Disorders",
            "asFound": "Combat Disorders",
            "relevance": "HIGH"
          },
          { "id": "M17685", "name": "Wounds and Injuries", "relevance": "LOW" },
          {
            "id": "M222",
            "name": "Trauma and Stressor Related Disorders",
            "relevance": "LOW"
          },
          { "id": "M14473", "name": "Psychotic Disorders", "relevance": "LOW" },
          { "id": "M4815", "name": "Mental Disorders", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" },
          { "abbrev": "All", "name": "All Conditions" },
          { "abbrev": "BC26", "name": "Wounds and Injuries" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT04817267",
        "orgStudyIdInfo": { "id": "IRB00282938" },
        "organization": {
          "fullName": "Johns Hopkins University",
          "class": "OTHER"
        },
        "briefTitle": "Pilot Study of reSET-O to Treatment-as-usual in Acute Care Settings",
        "officialTitle": "Pilot Study of reSET-O to Treatment-as-usual in Acute Care Settings"
      },
      "statusModule": {
        "statusVerifiedDate": "2024-05",
        "overallStatus": "TERMINATED",
        "whyStopped": "ReSET-O product no longer available, Pear Therapeutics, Inc. filed for bankruptsy",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2022-03-11", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2023-01-01",
          "type": "ACTUAL"
        },
        "completionDateStruct": { "date": "2024-05-01", "type": "ACTUAL" },
        "studyFirstSubmitDate": "2021-03-23",
        "studyFirstSubmitQcDate": "2021-03-23",
        "studyFirstPostDateStruct": { "date": "2021-03-26", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2024-05-21",
        "lastUpdatePostDateStruct": { "date": "2024-05-23", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": { "name": "Johns Hopkins University", "class": "OTHER" },
        "collaborators": [
          { "name": "Pear Therapeutics, Inc.", "class": "INDUSTRY" }
        ]
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": false
      },
      "descriptionModule": {
        "briefSummary": "This randomized controlled pilot study will evaluate feasibility, acceptability, and potential efficacy of an app, reSET-O, for patients being started on buprenorphine in acute care settings.",
        "detailedDescription": "This randomized controlled pilot study will enroll 60 participants, who will be randomly assigned to a treatment as usual (TAU) group or a reSET-O+TAU group after being started on buprenorphine in acute care settings (e.g., emergency department) and referred to community treatment. Study enrollment will last for 3 months after discharge from the acute care setting. Participants in the reSET-O+TAU group will be provided with the reSET-O app and will be encouraged to engage with the app for the 3 months following discharge from the acute care unit. The app works as an extension of cognitive behavioral therapy, providing psychoeducation related to opioid use disorder. All participants will be assessed at study intake and every month during the 3-month intervention."
      },
      "conditionsModule": { "conditions": ["Opioid-use Disorder"] },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": { "masking": "NONE" }
        },
        "enrollmentInfo": { "count": 8, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "reSET-O + Treatment-As-Usual (TAU)",
            "type": "EXPERIMENTAL",
            "description": "Participants randomly assigned to this group will receive the TAU plus the reSET-O app.",
            "interventionNames": ["Device: reSET-O app"]
          },
          {
            "label": "Treatment-As-Usual (TAU)",
            "type": "NO_INTERVENTION",
            "description": "Participants randomly assigned to this group will receive the TAU only (no use of the reSET-O app)."
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "reSET-O app",
            "description": "The reSET-O app, a prescription digital therapeutic, provides cognitive behavioral therapy for opioid use disorder. The app provides psychoeducation related to opioid use, coping skills, and skills to avoid relapse.",
            "armGroupLabels": ["reSET-O + Treatment-As-Usual (TAU)"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Percentage of approached patients who are eligible for and interested in participation",
            "description": "Percentage of approached patients who are eligible for and interested in participation will be used to assess feasibility.",
            "timeFrame": "3 months"
          },
          {
            "measure": "Acceptability as assessed by the Treatment Acceptability Questionnaire",
            "description": "Participant responses to the Treatment Acceptability Questionnaire.",
            "timeFrame": "3 months"
          },
          {
            "measure": "Acceptability as assessed by the System Usability Scale",
            "description": "Participant responses to the System Usability Scale.",
            "timeFrame": "3 months"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Attendance at follow-up appointment for on-going buprenorphine treatment within 30 days of discharge",
            "description": "Attendance at follow-up appointment for on-going buprenorphine treatment within 30 days of discharge will be used to assess Treatment Engagement.",
            "timeFrame": "30 days"
          },
          {
            "measure": "Percentage of drug-negative urine samples during the 3-month intervention",
            "description": "Percentage of drug-negative urine samples during the 3-month intervention will be used to assess Illicit opioid/other drug use.",
            "timeFrame": "3 months"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* 18-65 years old\n* Opioid use disorder\n* Eligible for buprenorphine treatment\n* Has reSET-O compatible mobile device\n\nExclusion Criteria:\n\n* Pregnancy\n* Significant psychiatric comorbidity",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "maximumAge": "65 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "August Holtyn",
            "affiliation": "Johns Hopkins University",
            "role": "PRINCIPAL_INVESTIGATOR"
          }
        ],
        "locations": [
          {
            "facility": "Johns Hopkins Bayivew Emergency Department",
            "city": "Baltimore",
            "state": "Maryland",
            "zip": "21224",
            "country": "United States",
            "geoPoint": { "lat": 39.29038, "lon": -76.61219 }
          }
        ]
      },
      "ipdSharingStatementModule": { "ipdSharing": "NO" }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [{ "id": "D009293", "term": "Opioid-Related Disorders" }],
        "ancestors": [
          { "id": "D000079524", "term": "Narcotic-Related Disorders" },
          { "id": "D019966", "term": "Substance-Related Disorders" },
          { "id": "D064419", "term": "Chemically-Induced Disorders" },
          { "id": "D001523", "term": "Mental Disorders" }
        ],
        "browseLeaves": [
          {
            "id": "M12244",
            "name": "Opioid-Related Disorders",
            "asFound": "Opioid Use Disorder",
            "relevance": "HIGH"
          },
          {
            "id": "M2057",
            "name": "Narcotic-Related Disorders",
            "relevance": "LOW"
          },
          {
            "id": "M21837",
            "name": "Substance-Related Disorders",
            "relevance": "LOW"
          },
          {
            "id": "M30302",
            "name": "Chemically-Induced Disorders",
            "relevance": "LOW"
          },
          { "id": "M14473", "name": "Psychotic Disorders", "relevance": "LOW" },
          { "id": "M4815", "name": "Mental Disorders", "relevance": "LOW" },
          {
            "id": "T170",
            "name": "Acute Graft Versus Host Disease",
            "relevance": "LOW"
          }
        ],
        "browseBranches": [
          { "abbrev": "BC25", "name": "Substance Related Disorders" },
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" },
          { "abbrev": "All", "name": "All Conditions" },
          { "abbrev": "Rare", "name": "Rare Diseases" }
        ]
      },
      "interventionBrowseModule": {
        "browseLeaves": [
          { "id": "M4033", "name": "Analgesics, Opioid", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "Analg", "name": "Analgesics" },
          { "abbrev": "CNSDep", "name": "Central Nervous System Depressants" },
          { "abbrev": "All", "name": "All Drugs and Chemicals" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT06648538",
        "orgStudyIdInfo": { "id": "38RC22.0299" },
        "secondaryIdInfos": [
          { "id": "2022-A02645-38", "type": "REGISTRY", "domain": "ID-RCB" },
          {
            "id": "22.04601.000170",
            "type": "OTHER",
            "domain": "SI Number (research ethics committees Number)"
          }
        ],
        "organization": {
          "fullName": "University Hospital, Grenoble",
          "class": "OTHER"
        },
        "briefTitle": "Evaluation of a Therapeutic Education Application in the Treatment of Young People with Moderate or Problematic Screen Use",
        "officialTitle": "Evaluation D'une Application D'éducation Thérapeutique Dans La Prise En Charge De Jeunes Ayant Un Usage Modéré Ou Problématique Des Écrans",
        "acronym": "PHONIX CARE"
      },
      "statusModule": {
        "statusVerifiedDate": "2024-04",
        "overallStatus": "COMPLETED",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2023-03-03", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2024-01-16",
          "type": "ACTUAL"
        },
        "completionDateStruct": { "date": "2024-01-16", "type": "ACTUAL" },
        "studyFirstSubmitDate": "2024-10-16",
        "studyFirstSubmitQcDate": "2024-10-16",
        "studyFirstPostDateStruct": { "date": "2024-10-18", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2024-10-16",
        "lastUpdatePostDateStruct": { "date": "2024-10-18", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": {
          "name": "University Hospital, Grenoble",
          "class": "OTHER"
        },
        "collaborators": [
          {
            "name": "Laboratoire Autonomie, Gérontologie, E-santé, Imagerie et Société (AGEIS)",
            "class": "UNKNOWN"
          },
          {
            "name": "Laboratoire de Psychologie et NeuroCognition",
            "class": "OTHER"
          },
          { "name": "University Grenoble Alps", "class": "OTHER" },
          {
            "name": "Centre National de la Recherche Scientifique, France",
            "class": "OTHER"
          },
          { "name": "Université Savoie Mont Blanc", "class": "OTHER" },
          {
            "name": "Institut National de la Santé Et de la Recherche Médicale, France",
            "class": "OTHER_GOV"
          }
        ]
      },
      "oversightModule": {
        "oversightHasDmc": true,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": false,
        "isUsExport": false
      },
      "descriptionModule": {
        "briefSummary": "This single-center, controlled, and randomized study evaluates the effectiveness of the Phonix Care app in regulating screen use among young people aged 11 to 25. Faced with high and often concerning levels of screen consumption among youth, this research aims to provide an innovative intervention method beyond current psychotherapeutic and pharmacological approaches, which are often limited by the risk of relapse and the difficulty in delaying the short-term rewards offered by screen activities \\[1, 2, 3\\]. Phonix Care is designed to encourage awareness and self-regulation of screen use, thus promoting more responsible and autonomous behavior.\n\nThe primary outcome measure is based on a problematic screen use score derived from the Digital Addiction Scale. Secondary objectives include examining the effects of the app on screen consumption, physical health, mental health, and motivation towards studies, measured through a series of questionnaires and objective evaluations.\n\nThe study is conducted on 138 subjects, divided into two groups: an experimental group and a control group, over a participation period of six months. Statistical analyses will include descriptive analyses, multiple linear regression, and mediation models to assess the impact of Phonix Care.\n\nThe expected outcomes of this research include significant contributions to the scientific literature regarding screen use among youth, as well as advances in adolescent and young adult health and psychology. In practice, the evaluation of Phonix Care could lead to the development of an effective medical device to quantify and treat problematic screen use, offering a complementary therapy to existing methods to prevent or remedy this issue.\n\n1. Winkler A, Dörsing B, Rief W, Shen Y, Glombiewski JA. Treatment of Internet addiction: A meta-analysis. Clinical Psychology Review. 2013;33(2):317-29. https://doi.org/10.1016/j.cpr.2012.12.005\n2. Xu LX, Wu LL, Geng XM, Wang ZL, Guo XY, Song KR, Liu GQ, Deng LY, Zhang JT, Potenza MN. A review of psychological interventions for Internet addiction. Psychiatry Research. 2021;302: 114016. https://doi.org/10.1016/j.psychres.2021.114016\n3. Zajac K, Ginley MK, Chang R, Petry NM. Treatments for Internet gaming disorder and Internet addiction: A systematic review. Psychology of Addictive Behaviors. 2017;31(8):979-94. https://doi.org/10.1037/adb0000315",
        "detailedDescription": "Quality assurance: A risk analysis of our application was conducted by an external organization, Surgiqual Institute. Their audit validated that our cybersecurity systems and risk management procedures were state-of-the-art in compliance with medical legislation applicable to our application. They produced a document to state that, based on their audit, they affirm the responsibility for ensuring the technical and legislative compliance of our application.\n\n------------------------------------------------------------------------------------------------------------------------------------\n\nData checks: each data type had to match with a user profile template (JSON FORMAT) :\n\n* unique_encrypted_code_name (characters AND number)\n* usage_data (characters)\n* date (characters : DD-MM-YY)\n* screen_type (characters)\n* app_name : (characters)\n* usage_data_per_app : usage_value (number)\n* questionnaire_data (characters)\n* date (characters : DD-MM-YY)\n* questionnaire_name (characters)\n* questionnaire_item : questionnaire_response (number)\n* additional_personal_data (characters)\n\nSource data verification: a preliminary technical study (with 15 participants) was conducted to:\n\n* Validate that the self-reported hourly screen usage in the technical study corresponded to the data passively collected by our telemetric measurement applications over one month.\n* Confirm that the self-reported responses to online questionnaires matched the actual answers provided by the participants.\n* Ensure that each participant's key could be used only once.\n* Verify that participants assigned to the experimental group couldn't bypass the application's restrictions.\n\nData dictionary:\n\n* Daily application usage data (Source : application Phonix Care) :\n\n  * First opening schedule\n  * Last opening schedule\n  * Opening Frequency\n  * Usage duration\n* Questionnaires responses (Source : the participant through the application Phonix Care)\n\n  o Digital Addiction Scale\n  * Regulation of Screen Time Consumption\n  * International Physical Activity Questionnaire\n  * Sleep Schedules diary\n  * Revised Screen for Child Anxiety Related Emotional Disorders (SCARED-R)\n  * University of Laval Loneliness Scale (ULS)\n  * Rosenberg Self-Esteem Scale\n  * Education Motivation Scale (EMS)\n* Experimental arm only : specific screen rules during the 5-months intervention period and the number of challenges that were completed\n\nStandard Operating Procedures (SOPs) were split into 10 steps :\n\n1. Patient Recruitment:\n\n   * Patient recruitment procedures will be conducted in accordance with the study protocol.\n   * Recruitment efforts will be documented and tracked using electronic records maintained within the clinical trial management system (CTMS).\n2. Data Collection:\n\n   • Data collection will be performed using the Phonix Care application for daily application usage data.\n   * Participants will input responses to questionnaires directly into the Phonix Care application.\n   * For participants in the experimental arm, specific screen rules adherence and challenge completion will be recorded within the Phonix Care application.\n3. Data Management:\n\n   * Data collected from the Phonix Care application will be securely transmitted and stored on a dedicated health server hosted by a certified data management provider (AZNETWORK).\n   * Access to the data will be restricted to authorized personnel only, with appropriate user permissions assigned based on roles and responsibilities.\n   * Pseudo-anonymization procedures will be implemented to protect participant confidentiality.\n   * Regular data backups will be performed to ensure data integrity and availability.\n4. Data Analysis:\n\n   • Data analysis will be conducted using statistical software approved by the study investigators (notably R, SPSS and Python).\n\n   • Analysis will include aggregating daily application usage data, questionnaire responses, and experimental arm-specific data to assess intervention efficacy and participant outcomes.\n5. Reporting for Adverse Events:\n\n   * Any adverse events reported by participants will be documented in a dedicated electronic data capture system.\n   * Adverse events will be promptly reviewed by the study investigators and reported to the appropriate regulatory authorities as per regulatory requirements.\n6. Change Management:\n\n   * Any modifications to the study protocol or data management procedures will be documented and approved by the study sponsor and ethics committee.\n   * Changes will be communicated to relevant study personnel, and updated procedures will be implemented accordingly.\n7. Quality Assurance:\n\n   * Regular quality checks will be conducted to ensure data accuracy and consistency.\n   * Data validation checks will be performed to identify any discrepancies or anomalies in the collected data.\n   * Internal audits will be conducted periodically to review data management procedures and compliance with SOPs.\n8. Training and Compliance:\n\n   * Study personnel involved in data collection and management will receive training on SOPs and data handling procedures.\n   * Compliance with SOPs will be monitored and enforced throughout the duration of the study.\n9. Record Keeping:\n\n   • All study-related documentation, including SOPs, data management logs, and training records, will be maintained in a secure electronic repository and duplicated to a secured space into a specific room of the AGEIS laboratory.\n\n   • Records will be retained in accordance with regulatory requirements and study protocol specifications.\n10. Documentation and Archiving:\n\n    * Upon study completion, all study documentation will be archived for future reference and audit purposes.\n    * Archiving procedures will adhere to regulatory guidelines and institutional policies.\n\nSample size assessment: To evaluate the effectiveness of Phonix Care using the overall score from the Digital Addiction Scale by Hawi et al. (2019), with an average Cohen's effect size d= 0.30 to 0.40 and a standard deviation of 19.25 (mean= 56.3), here are the necessary sample sizes for different statistical powers (1-β), with a significance level of α= 0.05:\n\n80% power: from 96 to 174 participants required. 85% power: from 110 to 200 participants required. 90% power: from 129 to 233 participants required.\n\n------------------------------------------------------------------------------------------------------------------------------------\n\nPlan for missing data: We conduct an analysis of the missing data mechanism according to the rules set by Little and Rubin. Although it is very rare, if we validate the hypothesis that the missing data are completely random (Missing Completely At Random), we conduct the analyses using the incomplete data set. This data set will not bias the estimates. The most likely case is the validation of the Missing At Random hypothesis, which suggests that the missing data are due to one or more factors in our possession (e.g., experimental condition, threshold of problematic use), we proceed with multiple imputations before conducting our analyses. To determine if certain factors can explain whether the data are missing or not, we use logistic regression analyses via the GLM package on R Studio version 4.0.2. In the case of multiple imputations, we use the MICE package on R Studio version 4.0.2.\n\n------------------------------------------------------------------------------------------------------------------------------------\n\nStatistical analysis plan: We first proceed with the descriptive analysis of screen usage profiles and the number of profiles observed in our sample. We expect to observe at least three usage profiles: moderate, intensive, and problematic. To do this, we use the K-means clustering method. Next, the variables measured by questionnaire undergo longitudinal confirmatory factor analyses to ensure that, despite experimentation, we observe some longitudinal invariance of the measurement constructs (i.e., weak invariance). For our primary research objective, we conduct analyses using multiple linear regression. By controlling for certain factors that may have an effect on problematic screen usage (e.g., gender, age), we evaluate the simple effects of digital addiction scores before the study and the assignment group, and then the interaction effect between this addiction score and the assignment group on digital addiction scores at the end of the study. To address our secondary objectives, we conduct multiple linear regression and mediation analyses for each of the secondary objective variables as dependent variables in linear regressions and as mediation variables."
      },
      "conditionsModule": {
        "conditions": ["Internet Addiction Disorder"],
        "keywords": [
          "Problematic Screen Use",
          "Digital Therapeutics",
          "Therapeutic Education Application",
          "Young People",
          "Mental Health",
          "Physical Health"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "interventionModelDescription": "For each participant:\n\n15 days of pre-intervention monitoring for Control group and Experimental Group\n\nAffectation in each group:\n\nControl group: 5 months of monitoring Experimental group: 5 months of therapeutic educational app (Phonix Care) 15 days of post-intervention monitoring for Control group and Experimental Group",
          "primaryPurpose": "PREVENTION",
          "maskingInfo": {
            "masking": "SINGLE",
            "maskingDescription": "In this study, it is impossible for participants to be blinded, as they know whether or not the Phonix Care tool is configured on their screens. However, we measure our primary and secondary judgment criteria at the first measurement time, before assigning subjects to one of the two groups. At the first stage, measurements are therefore collected blind to the conditions. In addition, the data analyses are carried out blind to the groups.",
            "whoMasked": ["INVESTIGATOR"]
          }
        },
        "enrollmentInfo": { "count": 139, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "Phonix Care experimental group",
            "type": "EXPERIMENTAL",
            "description": "The experimental arm involves modifying the functionalities of the user's digital devices (e.g., computer, smartphone, tablet, gaming console). The objective is to allow individuals access only to essential digital functionalities such as calls, alarms, work tools, camera, and unlock recreational digital functionalities only if the user engages in non-digital leisure activities (e.g., cultural, sports, family, artistic activities). The smartphone sensors validate the activities performed to earn digital time that can be spent by the user. Gradually, the user progresses a virtual animal until reaching the third stage of therapeutic education.\n\nA phoenix will evolve simultaneously with the user when they engage in non-digital recreational activities.\n\nFor 5 months, all participants' cross-platform screen-usage data are monitored with fine granularity, including the frequency of app openings, schedules of opening, and names of app openings.",
            "interventionNames": ["Device: Phonix Care"]
          },
          {
            "label": "Observational group",
            "type": "NO_INTERVENTION",
            "description": "For 5 months, all participants' cross-platform screen-usage data are monitored with fine granularity, including the frequency of app openings, schedules of opening, and names of app openings."
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "Phonix Care",
            "description": "Phonix Care consists of a 5-month digital therapeutic program that encourages the user to engage in non-digital activities through pre-defined screen rules and off-screen challenges validated by smartphone sensors.",
            "armGroupLabels": ["Phonix Care experimental group"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Digital Addiction Scale",
            "description": "The primary outcome measure is a problematic screen usage score ranging from 25 to 125 points, calculated from an online assessment questionnaire translated into French from the Digital Addiction Scale (Hawi et al., 2019). Participants respond to 25 statements in which they are asked to select the option that best reflects their thoughts on their screen usage, with the following response options: 1 \"never\"; 2 \"rarely\"; 3 \"sometimes\"; 4 \"often\"; and 5 \"always\". The statements describe nine criteria related to problematic screen usage: preoccupation; tolerance; deprivation; conflicts; associated problems; deception; attraction to other activities; relapse; and mood modification. The higher the participants' total score, the more problematic their screen usage is reported. This information is collected at two measurement times: before and after the experiment. We control for the pre-experiment level, and our primary outcome measure refers to the measurement taken after the experiment.",
            "timeFrame": "pre-intervention (T0), post-intervention (T0 + 5 months), with an estimated completion duration of 15 minutes."
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Regulation of Screen Time Consumption",
            "description": "The regulation of screen consumption is measured using a global score based on objective data through the Phonix Care tool (connection time on each screen and disconnection time on each screen; names of applications/software; number of times applications/software are accessed each day; duration of use for each application/software; time of first use for each application/software; time of last use for each application/software). This score will be defined after processing the data from the exploratory study to aid in diagnosis.",
            "timeFrame": "pre-intervention (T0), post-intervention (T0 + 5 months), with a completion duration of 0 minutes (data is collected passively)."
          },
          {
            "measure": "International Physical Activity Questionnaire",
            "description": "Physical activity and sedentary behavior: we assess the number of physical activities conducted over 7 days and sedentary behavior using a French translation of Craig et al.'s (2003) IPAQ. Three types of physical activities are targeted by the questionnaire: vigorous physical activities, moderate activities, and walking (i.e., number of days, number of hours, and minutes). Additionally, to measure subjects' sedentary behavior, the number of days, hours, and minutes spent sitting over the past 7 days is also requested.",
            "timeFrame": "pre-intervention (T0), post-intervention (T0 + 5 months), with an estimated completion duration of 15 minutes."
          },
          {
            "measure": "Sleep Schedules diary",
            "description": "Quality and quantity of sleep: We assess sleep daily for 7 days using an online diary to be filled out each morning by the subject. This is a subjective but scientifically reliable method, used for 30 years to evaluate vigilance disorders (Bastuji \\& Jouvet, 1985).",
            "timeFrame": "pre-intervention (T0), post-intervention (T0 + 5 months), with an estimated completion duration of 15 minutes."
          },
          {
            "measure": "Revised Screen for Child Anxiety Related Emotional Disorders (SCARED-R)",
            "description": "To measure depression (10 statements), general anxiety (10 statements), and social phobia (5 statements), we use the Revisited Child Anxiety and Depression Scale (RCADS) translated into French by Bouvard et al. (2012). Subjects are required to indicate, for the 25 statements of the questionnaire, how often each thing happens to them. For each category, we calculate an average score from the responses to items ranging from 0 to 3, where 0 corresponds to \"never,\" 1 to \"sometimes,\" 2 to \"often,\" and 3 to \"always.\" The higher the subjects report that situations always happen to them, the more they report psychological distress.",
            "timeFrame": "pre-intervention (T0), post-intervention (T0 + 5 months), with an estimated completion duration of 15 minutes."
          },
          {
            "measure": "University of Laval Loneliness Scale (ULS)",
            "description": "The University of Laval Loneliness Scale (ESUL), consisting of 20 statements, is a French translation of the UCLA-R Loneliness Scale (de Grâce et al., 1993). For each statement, subjects indicate the frequency with which each statement describes well what they feel (e.g., \"My interests and ideas are not shared by those around me\"). The response scale ranges from 1 \"never\" to 4 \"always.\" The more subjects report that situations always happen to them, the more they report social isolation.",
            "timeFrame": "pre-intervention (T0), post-intervention (T0 + 5 months), with an estimated completion duration of 15 minutes."
          },
          {
            "measure": "Rosenberg Self-Esteem Scale",
            "description": "It is measured by a questionnaire (EES-10 by Rosenberg, 2008) and consists of 10 statements. Subjects will need to indicate their agreement with each statement, knowing that 1 corresponds to \"not at all agree\", 2 to \"rather disagree\", 3 to \"rather agree\", and 4 to \"completely agree\".",
            "timeFrame": "pre-intervention (T0), post-intervention (T0 + 5 months), with an estimated completion duration of 15 minutes."
          },
          {
            "measure": "Education Motivation Scale (EMS)",
            "description": "We assess motivation in studies using the EME-C28 questionnaire by Vallerand et al. (1989). This questionnaire consists of 28 statements distributed across 7 subscales. These subscales measure three types of intrinsic motivation (to know, to accomplish, and to stimulate), three types of extrinsic motivation (identified, introjected, external), and amotivation. Participants are required to indicate the extent to which each statement currently corresponds to one of the reasons why they pursue their studies, with a response of 1 indicating that the reason does not correspond to them at all, and 7 indicating that it corresponds to them completely.",
            "timeFrame": "pre-intervention (T0), post-intervention (T0 + 5 months), with an estimated completion duration of 15 minutes."
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* To have an Android-compatible smartphone.\n* To be enrolled in middle school, high school, or university.\n* To be between 11 and 25 years old.\n\nExclusion Criteria:\n\n* To have a poor understanding of the French language.\n* To have participated in another interventional study in the same field within the last six months.\n* To undergo psychological and/or medical follow-up related to screen addiction.\n* To undergo pharmacological treatment for screen addiction disorder.\n* To exceed the VRB threshold of 4500 euros.",
        "healthyVolunteers": true,
        "sex": "ALL",
        "minimumAge": "11 Years",
        "maximumAge": "25 Years",
        "stdAges": ["CHILD", "ADULT"]
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "Alexandre BELLIER, MD, PhD",
            "affiliation": "Centre d'Investigation Clinique - CHU Grenoble Alpes / Département d'Anatomie (LADAF) - Université Grenoble Alpes / Laboratoire AGEIS - Université Grenoble Alpes",
            "role": "PRINCIPAL_INVESTIGATOR"
          }
        ],
        "locations": [
          {
            "facility": "PupilLab",
            "city": "Saint-Martin-d'Hères",
            "zip": "38400",
            "country": "France",
            "geoPoint": { "lat": 45.16528, "lon": 5.76337 }
          }
        ]
      },
      "referencesModule": {
        "references": [
          {
            "pmid": "31545344",
            "type": "BACKGROUND",
            "citation": "Adelantado-Renau M, Moliner-Urdiales D, Cavero-Redondo I, Beltran-Valls MR, Martinez-Vizcaino V, Alvarez-Bueno C. Association Between Screen Media Use and Academic Performance Among Children and Adolescents: A Systematic Review and Meta-analysis. JAMA Pediatr. 2019 Nov 1;173(11):1058-1067. doi: 10.1001/jamapediatrics.2019.3176."
          },
          {
            "pmid": "25291882",
            "type": "BACKGROUND",
            "citation": "Kapp C, Perlini T, Baggio S, Stephan P, Urrego AR, Rengade CE, Macias M, Hainard N, Halfon O. [Psychometric properties of the Consumer Satisfaction Questionnaire (CSQ-8) and the Helping Alliance Questionnaire (HAQ)]. Sante Publique. 2014 May-Jun;26(3):337-44. French."
          },
          {
            "pmid": "17485625",
            "type": "BACKGROUND",
            "citation": "Johnson JG, Cohen P, Kasen S, Brook JS. Extensive television viewing and the development of attention and learning difficulties during adolescence. Arch Pediatr Adolesc Med. 2007 May;161(5):480-6. doi: 10.1001/archpedi.161.5.480."
          },
          {
            "pmid": "34938847",
            "type": "BACKGROUND",
            "citation": "Pilatti A, Bravo AJ, Michelini Y, Aguirre P, Pautassi RM. Self-control and problematic use of social networking sites: Examining distress tolerance as a mediator among Argentinian college students. Addict Behav Rep. 2021 Oct 21;14:100389. doi: 10.1016/j.abrep.2021.100389. eCollection 2021 Dec."
          },
          {
            "pmid": "32237970",
            "type": "BACKGROUND",
            "citation": "Wartberg L, Zieglmeier M, Kammerl R. An Empirical Exploration of Longitudinal Predictors for Problematic Internet Use and Problematic Gaming Behavior. Psychol Rep. 2021 Apr;124(2):543-554. doi: 10.1177/0033294120913488. Epub 2020 Apr 1."
          },
          {
            "pmid": "26854132",
            "type": "BACKGROUND",
            "citation": "Chen YL, Gau SS. Sleep problems and internet addiction among children and adolescents: a longitudinal study. J Sleep Res. 2016 Aug;25(4):458-65. doi: 10.1111/jsr.12388. Epub 2016 Feb 8."
          },
          {
            "pmid": "34832011",
            "type": "BACKGROUND",
            "citation": "Ratan ZA, Parrish AM, Zaman SB, Alotaibi MS, Hosseinzadeh H. Smartphone Addiction and Associated Health Outcomes in Adult Populations: A Systematic Review. Int J Environ Res Public Health. 2021 Nov 22;18(22):12257. doi: 10.3390/ijerph182212257."
          },
          {
            "pmid": "28602529",
            "type": "BACKGROUND",
            "citation": "Royant-Parola S, Londe V, Trehout S, Hartley S. [The use of social media modifies teenagers' sleep-related behavior]. Encephale. 2018 Sep;44(4):321-328. doi: 10.1016/j.encep.2017.03.009. Epub 2017 Jun 8. French."
          },
          {
            "pmid": "31244720",
            "type": "BACKGROUND",
            "citation": "Zagalaz-Sanchez ML, Cachon-Zagalaz J, Sanchez-Zafra M, Lara-Sanchez A. Mini Review of the Use of the Mobile Phone and Its Repercussion in the Deficit of Physical Activity. Front Psychol. 2019 Jun 6;10:1307. doi: 10.3389/fpsyg.2019.01307. eCollection 2019."
          },
          {
            "type": "BACKGROUND",
            "citation": "Prizant-Passal S, Shechner T, Aderka IM. Social anxiety and Internet use A meta-analysis: What do we know? What are we missing? Computers in Human Behavior. 2016;62 :221-9. https://doi.org/10.1016/j.chb.2016.04.003"
          },
          {
            "type": "BACKGROUND",
            "citation": "Twenge JM. More Time on Technology, Less Happiness Associations Between Digital-Media Use and Psychological Well-Being. Current Directions in Psychological Science. 2019;28(4):372-9.https://doi.org/10.1177/0963721419838244"
          },
          {
            "pmid": "30406005",
            "type": "BACKGROUND",
            "citation": "Twenge JM, Campbell WK. Associations between screen time and lower psychological well-being among children and adolescents: Evidence from a population-based study. Prev Med Rep. 2018 Oct 18;12:271-283. doi: 10.1016/j.pmedr.2018.10.003. eCollection 2018 Dec."
          },
          {
            "type": "BACKGROUND",
            "citation": "Deci EL, Ryan RM. Intrinsic Motivation and Self-Determination in Human Behavior. Boston, MA: Springer US; 1985. https://doi.org/10.1007/978-1-4899-2271-7"
          },
          {
            "type": "BACKGROUND",
            "citation": "Deci EL, Ryan RM. Favoriser la motivation optimale et la santé mentale dans les divers milieux de vie. Canadian Psychology/Psychologie canadienne. 2008 ; 49(1) : 24-34. https://doi.org/10.1037/0708-5591.49.1.24"
          },
          {
            "type": "BACKGROUND",
            "citation": "Mills DJ, Milyavskaya M, Mettler J, Heath NL. Exploring the pull and push underlying problem video game use: A Self-Determination Theory approach. Personality and Individual Differences. 2018;135: 176-81. https://doi.org/10.1016/j.paid.2018.07.007"
          },
          {
            "pmid": "35150965",
            "type": "BACKGROUND",
            "citation": "Meng SQ, Cheng JL, Li YY, Yang XQ, Zheng JW, Chang XW, Shi Y, Chen Y, Lu L, Sun Y, Bao YP, Shi J. Global prevalence of digital addiction in general population: A systematic review and meta-analysis. Clin Psychol Rev. 2022 Mar;92:102128. doi: 10.1016/j.cpr.2022.102128. Epub 2022 Jan 25."
          },
          {
            "pmid": "32431636",
            "type": "BACKGROUND",
            "citation": "Harris B, Regan T, Schueler J, Fields SA. Problematic Mobile Phone and Smartphone Use Scales: A Systematic Review. Front Psychol. 2020 May 5;11:672. doi: 10.3389/fpsyg.2020.00672. eCollection 2020."
          },
          {
            "pmid": "34703533",
            "type": "BACKGROUND",
            "citation": "Notara V, Vagka E, Gnardellis C, Lagiou A. The Emerging Phenomenon of Nomophobia in Young Adults: A Systematic Review Study. Addict Health. 2021 Apr;13(2):120-136. doi: 10.22122/ahj.v13i2.309."
          },
          {
            "pmid": "32467846",
            "type": "BACKGROUND",
            "citation": "Ryding FC, Kuss DJ. Passive objective measures in the assessment of problematic smartphone use: A systematic review. Addict Behav Rep. 2020 Jan 27;11:100257. doi: 10.1016/j.abrep.2020.100257. eCollection 2020 Jun."
          },
          {
            "type": "BACKGROUND",
            "citation": "King D, Delfabbro P. Internet Gaming Disorder: Theory, Assessment, Treatment, and Prevention. Academic Press; 2018. 294 p."
          },
          {
            "type": "BACKGROUND",
            "citation": "Radtke T, Apel T, Schenkel K, Keller J, von Lindern E. Digital detox: An effective solution in the smartphone era? A systematic literature review. Mobile Media & Communication. 2021:205015792110286. https://doi.org/10.1177/20501579211028647"
          },
          {
            "pmid": "23354007",
            "type": "BACKGROUND",
            "citation": "Winkler A, Dorsing B, Rief W, Shen Y, Glombiewski JA. Treatment of internet addiction: a meta-analysis. Clin Psychol Rev. 2013 Mar;33(2):317-29. doi: 10.1016/j.cpr.2012.12.005. Epub 2013 Jan 5."
          },
          {
            "pmid": "34087672",
            "type": "BACKGROUND",
            "citation": "Xu LX, Wu LL, Geng XM, Wang ZL, Guo XY, Song KR, Liu GQ, Deng LY, Zhang JT, Potenza MN. A review of psychological interventions for internet addiction. Psychiatry Res. 2021 Aug;302:114016. doi: 10.1016/j.psychres.2021.114016. Epub 2021 May 21."
          },
          {
            "pmid": "28921996",
            "type": "BACKGROUND",
            "citation": "Zajac K, Ginley MK, Chang R, Petry NM. Treatments for Internet gaming disorder and Internet addiction: A systematic review. Psychol Addict Behav. 2017 Dec;31(8):979-994. doi: 10.1037/adb0000315. Epub 2017 Sep 18."
          },
          {
            "pmid": "24911068",
            "type": "BACKGROUND",
            "citation": "Przepiorka AM, Blachnio A, Miziak B, Czuczwar SJ. Clinical approaches to treatment of Internet addiction. Pharmacol Rep. 2014 Apr;66(2):187-91. doi: 10.1016/j.pharep.2013.10.001. Epub 2014 Mar 2."
          },
          {
            "pmid": "17927535",
            "type": "BACKGROUND",
            "citation": "Young KS. Cognitive behavior therapy with Internet addicts: treatment outcomes and implications. Cyberpsychol Behav. 2007 Oct;10(5):671-9. doi: 10.1089/cpb.2007.9971."
          },
          {
            "pmid": "25270173",
            "type": "BACKGROUND",
            "citation": "Clark NM, Zimmerman BJ. A social cognitive view of self-regulated learning about health. Health Educ Behav. 2014 Oct;41(5):485-91. doi: 10.1177/1090198114547512."
          },
          {
            "pmid": "31755742",
            "type": "BACKGROUND",
            "citation": "Hawi NS, Samaha M, Griffiths MD. The Digital Addiction Scale for Children: Development and Validation. Cyberpsychol Behav Soc Netw. 2019 Dec;22(12):771-778. doi: 10.1089/cyber.2019.0132. Epub 2019 Nov 22."
          },
          {
            "type": "BACKGROUND",
            "citation": "Bouvard M, Dacquin F, Denis A. Étude de la validité de l'échelle d'anxiété et de dépression révisée (RCADS) et de la grille d'évaluation des troubles anxieux forme révisée (SCARED-R). Journal de Thérapie Comportementale et Cognitive. 2012 ; 22 (4) : 175-81. https://doi.org/10.1016/j.jtcc.2012.09.003"
          },
          {
            "type": "BACKGROUND",
            "citation": "de Grâce GR, Joshi P, Pelletier R. L'Échelle de solitude de l'Université Laval (ÉSUL) : validation canadienne-française du UCLA Loneliness Scale. Canadian Journal of Behavioural Science/Revue canadienne des sciences du comportement. 1993 ; 25 (1) : 12-27. https://doi.org/10.1037/h0078812"
          },
          {
            "type": "BACKGROUND",
            "citation": "Crépin N, Delerue F. Echelle d'Estime de Soi de Rosenberg. Institut Régional du Bien-être, de la Médecine et du Sport Santé. 2008."
          },
          {
            "pmid": "12900694",
            "type": "BACKGROUND",
            "citation": "Craig CL, Marshall AL, Sjostrom M, Bauman AE, Booth ML, Ainsworth BE, Pratt M, Ekelund U, Yngve A, Sallis JF, Oja P. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc. 2003 Aug;35(8):1381-95. doi: 10.1249/01.MSS.0000078924.61453.FB."
          },
          {
            "type": "BACKGROUND",
            "citation": "Vallerand RJ, Blais MR, Brière NM, Pelletier LG. Construction et validation de l'échelle de motivation en éducation (EME). Canadian Journal of Behavioural Science / Revue canadienne des sciences du comportement. 1989 ; 21(3) : 323-49. https://doi.org/10.1037/h0079855"
          },
          {
            "pmid": "2579796",
            "type": "BACKGROUND",
            "citation": "Bastuji H, Jouvet M. [Value of the sleep diary in the study of vigilance dis]. Electroencephalogr Clin Neurophysiol. 1985 Apr;60(4):299-305. doi: 10.1016/0013-4694(85)90003-3. French."
          },
          {
            "type": "BACKGROUND",
            "citation": "Little RJ, Rubin DB. Statistical Analysis with Missing Data. Wiley & Sons, Incorporated, John; 2019. 464 p."
          },
          {
            "type": "BACKGROUND",
            "citation": "Brown TA. Confirmatory Factor Analysis for Applied Research, Second Edition. Guilford Publications; 2015. 462 p."
          },
          {
            "type": "BACKGROUND",
            "citation": "Hayes AF. Introduction to Mediation, Moderation, and Conditional Process Analysis, Second Edition: A Regression-Based Approach. The Guilford Press; 2022. 692 p"
          }
        ],
        "seeAlsoLinks": [
          {
            "label": "Website where participants could register to the study, get additional informations, download the digital therapeutic program and fill questionnaires.",
            "url": "https://www.phonixhealth.com/"
          },
          {
            "label": "Mildeca \\[En ligne\\]. Les français \" addicts \" à leurs écrans ? Publication des résultats du premier Baromètre MILDECA/Harris Interactive sur les usages d'écrans et les problématiques associées ; 2021",
            "url": "https://www.drogues.gouv.fr"
          },
          {
            "label": "Rapport du Haut Conseil de la santé publique \\[En ligne\\]. Effets de l'exposition des enfants et des jeunes aux écrans ; 2019.",
            "url": "https://www.hcsp.fr/explore.cgi/avisrapportsdomaine?clefr=759"
          },
          {
            "label": "Rapport du Haut Conseil de la santé publique \\[En ligne\\]. Effets de l'exposition des enfants et des jeunes aux écrans (seconde partie) : de l'usage excessif à la dépendance ; 2021.",
            "url": "https://www.hcsp.fr/Explore.cgi/AvisRapportsDomaine?clefr=1074"
          },
          {
            "label": "Médiamétrie \\[En ligne\\]. La parentalité à l'épreuve du numérique. Observatoire de la Parentalité \\& de l'Education Numérique et UNAF ; 2020.",
            "url": "https://www.open-asso.org/wp-content/uploads/2020/02/Livret-Unaf-Open-version-VF.pdf"
          }
        ]
      },
      "ipdSharingStatementModule": {
        "ipdSharing": "NO",
        "description": "There is no IPD sharing plan."
      }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [
          { "id": "D000082424", "term": "Internet Addiction Disorder" }
        ],
        "ancestors": [
          { "id": "D016739", "term": "Behavior, Addictive" },
          { "id": "D003192", "term": "Compulsive Behavior" },
          { "id": "D007175", "term": "Impulsive Behavior" },
          { "id": "D000088942", "term": "Technology Addiction" }
        ],
        "browseLeaves": [
          {
            "id": "M2355",
            "name": "Internet Addiction Disorder",
            "asFound": "Internet Addiction Disorder",
            "relevance": "HIGH"
          },
          { "id": "M19100", "name": "Behavior, Addictive", "relevance": "LOW" },
          { "id": "M6418", "name": "Compulsive Behavior", "relevance": "LOW" },
          { "id": "M10220", "name": "Impulsive Behavior", "relevance": "LOW" },
          { "id": "M2684", "name": "Technology Addiction", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" },
          { "abbrev": "All", "name": "All Conditions" }
        ]
      },
      "interventionBrowseModule": {
        "browseLeaves": [
          { "id": "M6263", "name": "Coal Tar", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "Derm", "name": "Dermatologic Agents" },
          { "abbrev": "All", "name": "All Drugs and Chemicals" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT03608150",
        "orgStudyIdInfo": { "id": "C-AM-2" },
        "organization": { "fullName": "Luminopia", "class": "INDUSTRY" },
        "briefTitle": "Luminopia One Amblyopia Vision Improvement Study",
        "officialTitle": "Luminopia One Amblyopia Vision Improvement Study"
      },
      "statusModule": {
        "statusVerifiedDate": "2024-02",
        "overallStatus": "COMPLETED",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2019-01-16", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2020-07-31",
          "type": "ACTUAL"
        },
        "completionDateStruct": { "date": "2020-07-31", "type": "ACTUAL" },
        "studyFirstSubmitDate": "2018-07-12",
        "studyFirstSubmitQcDate": "2018-07-30",
        "studyFirstPostDateStruct": { "date": "2018-07-31", "type": "ACTUAL" },
        "resultsFirstSubmitDate": "2022-04-04",
        "resultsFirstSubmitQcDate": "2024-02-24",
        "resultsFirstPostDateStruct": {
          "date": "2024-03-20",
          "type": "ACTUAL"
        },
        "lastUpdateSubmitDate": "2024-02-24",
        "lastUpdatePostDateStruct": { "date": "2024-03-20", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": { "name": "Luminopia", "class": "INDUSTRY" }
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": true,
        "isUnapprovedDevice": true,
        "isUsExport": false
      },
      "descriptionModule": {
        "briefSummary": "The objective of the study is to demonstrate the safety and efficacy of Luminopia One in amblyopia patients with amblyopia associated with anisometropia and/or with mild strabismus.",
        "detailedDescription": "The proposed study is a multi-center randomized controlled clinical trial which compares the mean change in amblyopic eye Best Corrected Visual Acuity from baseline with Luminopia One (\"therapeutic\") to refractive correction (\"control\"). One-hundred and forty participants (n = 140) aged 4-7 years will be enrolled. Participants will be randomized 1:1 to the \"therapeutic group \", to use Luminopia One, or the \"control group\", to undergo continued refractive correction, for 12 weeks of treatment."
      },
      "conditionsModule": { "conditions": ["Amblyopia"] },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": {
            "masking": "SINGLE",
            "whoMasked": ["OUTCOMES_ASSESSOR"]
          }
        },
        "enrollmentInfo": { "count": 117, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "Therapeutic Group",
            "type": "EXPERIMENTAL",
            "description": "Participants assigned to the therapeutic group will be prescribed Luminopia One for 1 hour per day, 6 days per week for 12 weeks.",
            "interventionNames": ["Device: Luminopia One"]
          },
          {
            "label": "Control Group",
            "type": "ACTIVE_COMPARATOR",
            "description": "Participants assigned to the control group will wear their current refractive correction full-time for 12 weeks.",
            "interventionNames": ["Device: Refractive Correction"]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "Luminopia One",
            "description": "Luminopia One is a virtual-reality based digital therapeutic that applies therapeutic modifications in real-time to cinematic content to rebalance visual input and treat amblyopia.",
            "armGroupLabels": ["Therapeutic Group"]
          },
          {
            "type": "DEVICE",
            "name": "Refractive Correction",
            "description": "Standard of care refractive correction (ex. spectacles)",
            "armGroupLabels": ["Control Group"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Best-Corrected Visual Acuity of Amblyopic Eye",
            "description": "Mean improvement in best-corrected visual acuity of amblyopic eye from baseline after 12 weeks of treatment using electronic ATS-HOTV protocol.",
            "timeFrame": "12 weeks"
          },
          {
            "measure": "Best-Corrected Visual Acuity of Fellow Eye",
            "description": "Mean improvement in best-corrected visual acuity of fellow eye from baseline after 12 weeks of treatment using electronic ATS-HOTV protocol.",
            "timeFrame": "12 weeks"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Adherence",
            "description": "Mean adherence with the therapeutic in treatment group.",
            "timeFrame": "12 weeks"
          },
          {
            "measure": "Best-Corrected Visual Acuity of Amblyopic Eye",
            "description": "Mean improvement in best-corrected visual acuity of amblyopic eye from baseline after 4 weeks using electronic ATS-HOTV protocol.",
            "timeFrame": "4 weeks"
          },
          {
            "measure": "Best-Corrected Visual Acuity of Amblyopic Eye",
            "description": "Mean improvement in best-corrected visual acuity of amblyopic eye from baseline after 8 weeks using electronic ATS-HOTV protocol.",
            "timeFrame": "8 weeks"
          },
          {
            "measure": "Stereoacuity",
            "description": "Mean stereoacuity improvement from baseline after 12 weeks.",
            "timeFrame": "12 weeks"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* Age 4 to 7 years at the time of consent.\n* Amblyopia associated with anisometropia and/or mild strabismus.\n* Current refractive correction worn for at least 16 weeks or until 2 consecutive visual acuity measurements at least 8 weeks apart do not change by more than 1 logMAR lines.\n* Amblyopic eye best-corrected visual acuity (BCVA) 20/40 to 20/200 inclusive.\n* Fellow eye BCVA 20/32 or better.\n* Interocular difference ≥ 3 logMAR lines.\n* Heterotropia ≤ 5 prism diopters in current refractive correction at distance measured by SPCT.\n\nExclusion Criteria:\n\n* Atropine treatment in the past 2 weeks.\n* Prior amblyopia treatment (other than refractive correction) for \\> 12 months in total.\n* High myopia, previous intraocular / refractive surgery, severe ocular co-morbidities or development / cognitive delay.\n* History of low adherence with amblyopia treatment or light-induced seizures.",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "4 Years",
        "maximumAge": "7 Years",
        "stdAges": ["CHILD"]
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "Scott Xiao",
            "affiliation": "Luminopia",
            "role": "STUDY_DIRECTOR"
          }
        ],
        "locations": [
          {
            "facility": "UCLA Jules Stein Eye Institute",
            "city": "Los Angeles",
            "state": "California",
            "zip": "90095",
            "country": "United States",
            "geoPoint": { "lat": 34.05223, "lon": -118.24368 }
          },
          {
            "facility": "Family Focus Eye Care",
            "city": "Gainesville",
            "state": "Florida",
            "zip": "32605",
            "country": "United States",
            "geoPoint": { "lat": 29.65163, "lon": -82.32483 }
          },
          {
            "facility": "Eye Physicians of Central Florida",
            "city": "Maitland",
            "state": "Florida",
            "zip": "32751",
            "country": "United States",
            "geoPoint": { "lat": 28.62778, "lon": -81.36312 }
          },
          {
            "facility": "Lurie Children's Hospital",
            "city": "Chicago",
            "state": "Illinois",
            "zip": "60611",
            "country": "United States",
            "geoPoint": { "lat": 41.85003, "lon": -87.65005 }
          },
          {
            "facility": "IU School of Optometry",
            "city": "Bloomington",
            "state": "Indiana",
            "zip": "47405",
            "country": "United States",
            "geoPoint": { "lat": 39.16533, "lon": -86.52639 }
          },
          {
            "facility": "Kids Eye Care of Maryland",
            "city": "Frederick",
            "state": "Maryland",
            "zip": "21703",
            "country": "United States",
            "geoPoint": { "lat": 39.41427, "lon": -77.41054 }
          },
          {
            "facility": "Specialized Pediatric Eye Care",
            "city": "Beverly",
            "state": "Massachusetts",
            "zip": "01915",
            "country": "United States",
            "geoPoint": { "lat": 42.55843, "lon": -70.88005 }
          },
          {
            "facility": "Children's Eye Care of Michigan",
            "city": "Dearborn",
            "state": "Michigan",
            "zip": "48124",
            "country": "United States",
            "geoPoint": { "lat": 42.32226, "lon": -83.17631 }
          },
          {
            "facility": "Saint Louis University",
            "city": "Saint Louis",
            "state": "Missouri",
            "zip": "63104",
            "country": "United States",
            "geoPoint": { "lat": 38.62727, "lon": -90.19789 }
          },
          {
            "facility": "University of Nebraska Medical Center",
            "city": "Omaha",
            "state": "Nebraska",
            "zip": "68198",
            "country": "United States",
            "geoPoint": { "lat": 41.25626, "lon": -95.94043 }
          },
          {
            "facility": "Duke University",
            "city": "Durham",
            "state": "North Carolina",
            "zip": "27708",
            "country": "United States",
            "geoPoint": { "lat": 35.99403, "lon": -78.89862 }
          },
          {
            "facility": "Cleveland Clinic",
            "city": "Cleveland",
            "state": "Ohio",
            "zip": "44195",
            "country": "United States",
            "geoPoint": { "lat": 41.4995, "lon": -81.69541 }
          },
          {
            "facility": "OSU College of Optometry",
            "city": "Columbus",
            "state": "Ohio",
            "zip": "43210",
            "country": "United States",
            "geoPoint": { "lat": 39.96118, "lon": -82.99879 }
          },
          {
            "facility": "Pediatric Ophthalmology of Erie",
            "city": "Erie",
            "state": "Pennsylvania",
            "zip": "16501",
            "country": "United States",
            "geoPoint": { "lat": 42.12922, "lon": -80.08506 }
          },
          {
            "facility": "Conestoga Eye",
            "city": "Lancaster",
            "state": "Pennsylvania",
            "zip": "17601",
            "country": "United States",
            "geoPoint": { "lat": 40.03788, "lon": -76.30551 }
          },
          {
            "facility": "Children's Hospital Of Philadelphia",
            "city": "Philadelphia",
            "state": "Pennsylvania",
            "zip": "19104",
            "country": "United States",
            "geoPoint": { "lat": 39.95233, "lon": -75.16379 }
          },
          {
            "facility": "Tri-County Eye Physicians",
            "city": "Southampton",
            "state": "Pennsylvania",
            "zip": "18966",
            "country": "United States",
            "geoPoint": { "lat": 40.17428, "lon": -75.04378 }
          },
          {
            "facility": "Houston Eye Associates",
            "city": "Houston",
            "state": "Texas",
            "zip": "77025",
            "country": "United States",
            "geoPoint": { "lat": 29.76328, "lon": -95.36327 }
          },
          {
            "facility": "Texas Children's Hospital (BCM)",
            "city": "Houston",
            "state": "Texas",
            "zip": "77030",
            "country": "United States",
            "geoPoint": { "lat": 29.76328, "lon": -95.36327 }
          },
          {
            "facility": "Houston Eye Associates",
            "city": "Houston",
            "state": "Texas",
            "zip": "77381",
            "country": "United States",
            "geoPoint": { "lat": 29.76328, "lon": -95.36327 }
          },
          {
            "facility": "Rocky Mountain Eye Care",
            "city": "Salt Lake City",
            "state": "Utah",
            "zip": "84107",
            "country": "United States",
            "geoPoint": { "lat": 40.76078, "lon": -111.89105 }
          },
          {
            "facility": "Virginia Pediatric Eye Center",
            "city": "Virginia Beach",
            "state": "Virginia",
            "zip": "23452",
            "country": "United States",
            "geoPoint": { "lat": 36.85293, "lon": -75.97799 }
          }
        ]
      },
      "ipdSharingStatementModule": { "ipdSharing": "NO" }
    },
    "resultsSection": {
      "participantFlowModule": {
        "groups": [
          {
            "id": "FG000",
            "title": "Therapeutic Group",
            "description": "Participants assigned to the therapeutic group will be prescribed Luminopia One for 1 hour per day, 6 days per week for 12 weeks.\n\nLuminopia One: Luminopia One is a virtual-reality based digital therapeutic that applies therapeutic modifications in real-time to cinematic content to rebalance visual input and treat amblyopia."
          },
          {
            "id": "FG001",
            "title": "Control Group",
            "description": "Participants assigned to the control group will wear their current refractive correction full-time for 12 weeks.\n\nRefractive Correction: Standard of care refractive correction (ex. spectacles)"
          }
        ],
        "periods": [
          {
            "title": "Overall Study",
            "milestones": [
              {
                "type": "STARTED",
                "achievements": [
                  { "groupId": "FG000", "numSubjects": "58" },
                  { "groupId": "FG001", "numSubjects": "59" }
                ]
              },
              {
                "type": "COMPLETED",
                "achievements": [
                  { "groupId": "FG000", "numSubjects": "47" },
                  { "groupId": "FG001", "numSubjects": "48" }
                ]
              },
              {
                "type": "NOT COMPLETED",
                "achievements": [
                  { "groupId": "FG000", "numSubjects": "11" },
                  { "groupId": "FG001", "numSubjects": "11" }
                ]
              }
            ]
          }
        ]
      },
      "baselineCharacteristicsModule": {
        "groups": [
          {
            "id": "BG000",
            "title": "Therapeutic Group",
            "description": "Participants assigned to the therapeutic group will be prescribed Luminopia One for 1 hour per day, 6 days per week for 12 weeks.\n\nLuminopia One: Luminopia One is a virtual-reality based digital therapeutic that applies therapeutic modifications in real-time to cinematic content to rebalance visual input and treat amblyopia."
          },
          {
            "id": "BG001",
            "title": "Control Group",
            "description": "Participants assigned to the control group will wear their current refractive correction full-time for 12 weeks.\n\nRefractive Correction: Standard of care refractive correction (ex. spectacles)"
          },
          {
            "id": "BG002",
            "title": "Total",
            "description": "Total of all reporting groups"
          }
        ],
        "denoms": [
          {
            "units": "Participants",
            "counts": [
              { "groupId": "BG000", "value": "58" },
              { "groupId": "BG001", "value": "59" },
              { "groupId": "BG002", "value": "117" }
            ]
          }
        ],
        "measures": [
          {
            "title": "Age, Continuous",
            "paramType": "MEAN",
            "dispersionType": "STANDARD_DEVIATION",
            "unitOfMeasure": "years",
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "BG000", "value": "6.2", "spread": "0.9" },
                      { "groupId": "BG001", "value": "5.9", "spread": "1.1" },
                      { "groupId": "BG002", "value": "6.0", "spread": "1.0" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Sex: Female, Male",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "Female",
                    "measurements": [
                      { "groupId": "BG000", "value": "23" },
                      { "groupId": "BG001", "value": "28" },
                      { "groupId": "BG002", "value": "51" }
                    ]
                  },
                  {
                    "title": "Male",
                    "measurements": [
                      { "groupId": "BG000", "value": "35" },
                      { "groupId": "BG001", "value": "31" },
                      { "groupId": "BG002", "value": "66" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Ethnicity (NIH/OMB)",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "Hispanic or Latino",
                    "measurements": [
                      { "groupId": "BG000", "value": "13" },
                      { "groupId": "BG001", "value": "6" },
                      { "groupId": "BG002", "value": "19" }
                    ]
                  },
                  {
                    "title": "Not Hispanic or Latino",
                    "measurements": [
                      { "groupId": "BG000", "value": "45" },
                      { "groupId": "BG001", "value": "53" },
                      { "groupId": "BG002", "value": "98" }
                    ]
                  },
                  {
                    "title": "Unknown or Not Reported",
                    "measurements": [
                      { "groupId": "BG000", "value": "0" },
                      { "groupId": "BG001", "value": "0" },
                      { "groupId": "BG002", "value": "0" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Race (NIH/OMB)",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "American Indian or Alaska Native",
                    "measurements": [
                      { "groupId": "BG000", "value": "1" },
                      { "groupId": "BG001", "value": "0" },
                      { "groupId": "BG002", "value": "1" }
                    ]
                  },
                  {
                    "title": "Asian",
                    "measurements": [
                      { "groupId": "BG000", "value": "0" },
                      { "groupId": "BG001", "value": "6" },
                      { "groupId": "BG002", "value": "6" }
                    ]
                  },
                  {
                    "title": "Native Hawaiian or Other Pacific Islander",
                    "measurements": [
                      { "groupId": "BG000", "value": "1" },
                      { "groupId": "BG001", "value": "0" },
                      { "groupId": "BG002", "value": "1" }
                    ]
                  },
                  {
                    "title": "Black or African American",
                    "measurements": [
                      { "groupId": "BG000", "value": "4" },
                      { "groupId": "BG001", "value": "7" },
                      { "groupId": "BG002", "value": "11" }
                    ]
                  },
                  {
                    "title": "White",
                    "measurements": [
                      { "groupId": "BG000", "value": "50" },
                      { "groupId": "BG001", "value": "46" },
                      { "groupId": "BG002", "value": "96" }
                    ]
                  },
                  {
                    "title": "More than one race",
                    "measurements": [
                      { "groupId": "BG000", "value": "2" },
                      { "groupId": "BG001", "value": "0" },
                      { "groupId": "BG002", "value": "2" }
                    ]
                  },
                  {
                    "title": "Unknown or Not Reported",
                    "measurements": [
                      { "groupId": "BG000", "value": "0" },
                      { "groupId": "BG001", "value": "0" },
                      { "groupId": "BG002", "value": "0" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Region of Enrollment",
            "paramType": "NUMBER",
            "unitOfMeasure": "participants",
            "classes": [
              {
                "title": "United States",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "BG000", "value": "58" },
                      { "groupId": "BG001", "value": "59" },
                      { "groupId": "BG002", "value": "117" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Prior Amblyopia Treatment",
            "paramType": "NUMBER",
            "unitOfMeasure": "participants",
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "BG000", "value": "48" },
                      { "groupId": "BG001", "value": "43" },
                      { "groupId": "BG002", "value": "91" }
                    ]
                  }
                ]
              }
            ]
          }
        ]
      },
      "outcomeMeasuresModule": {
        "outcomeMeasures": [
          {
            "type": "PRIMARY",
            "title": "Best-Corrected Visual Acuity of Amblyopic Eye",
            "description": "Mean improvement in best-corrected visual acuity of amblyopic eye from baseline after 12 weeks of treatment using electronic ATS-HOTV protocol.",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "Lines of visual acuity improvement",
            "timeFrame": "12 weeks",
            "groups": [
              {
                "id": "OG000",
                "title": "Therapeutic Group",
                "description": "Participants assigned to the therapeutic group will be prescribed Luminopia One for 1 hour per day, 6 days per week for 12 weeks.\n\nLuminopia One: Luminopia One is a virtual-reality based digital therapeutic that applies therapeutic modifications in real-time to cinematic content to rebalance visual input and treat amblyopia."
              },
              {
                "id": "OG001",
                "title": "Control Group",
                "description": "Participants assigned to the control group will wear their current refractive correction full-time for 12 weeks.\n\nRefractive Correction: Standard of care refractive correction (ex. spectacles)"
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "47" },
                  { "groupId": "OG001", "value": "48" }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "1.77", "spread": "1.56" },
                      { "groupId": "OG001", "value": "0.85", "spread": "1.34" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "PRIMARY",
            "title": "Best-Corrected Visual Acuity of Fellow Eye",
            "description": "Mean improvement in best-corrected visual acuity of fellow eye from baseline after 12 weeks of treatment using electronic ATS-HOTV protocol.",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "Lines of visual acuity improvement",
            "timeFrame": "12 weeks",
            "groups": [
              {
                "id": "OG000",
                "title": "Therapeutic Group",
                "description": "Participants assigned to the therapeutic group will be prescribed Luminopia One for 1 hour per day, 6 days per week for 12 weeks.\n\nLuminopia One: Luminopia One is a virtual-reality based digital therapeutic that applies therapeutic modifications in real-time to cinematic content to rebalance visual input and treat amblyopia."
              },
              {
                "id": "OG001",
                "title": "Control Group",
                "description": "Participants assigned to the control group will wear their current refractive correction full-time for 12 weeks.\n\nRefractive Correction: Standard of care refractive correction (ex. spectacles)"
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "47" },
                  { "groupId": "OG001", "value": "48" }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "0.30", "spread": "0.78" },
                      { "groupId": "OG001", "value": "0.17", "spread": "0.56" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Adherence",
            "description": "Mean adherence with the therapeutic in treatment group.",
            "reportingStatus": "POSTED",
            "paramType": "MEDIAN",
            "dispersionType": "Inter-Quartile Range",
            "unitOfMeasure": "percentage of prescribed therapy",
            "timeFrame": "12 weeks",
            "groups": [
              {
                "id": "OG000",
                "title": "Therapeutic Group",
                "description": "Participants assigned to the therapeutic group will be prescribed Luminopia One for 1 hour per day, 6 days per week for 12 weeks.\n\nLuminopia One: Luminopia One is a virtual-reality based digital therapeutic that applies therapeutic modifications in real-time to cinematic content to rebalance visual input and treat amblyopia."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [{ "groupId": "OG000", "value": "56" }]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "85",
                        "lowerLimit": "48",
                        "upperLimit": "99"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Best-Corrected Visual Acuity of Amblyopic Eye",
            "description": "Mean improvement in best-corrected visual acuity of amblyopic eye from baseline after 4 weeks using electronic ATS-HOTV protocol.",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "Lines of visual acuity improvement",
            "timeFrame": "4 weeks",
            "groups": [
              {
                "id": "OG000",
                "title": "Therapeutic Group",
                "description": "Participants assigned to the therapeutic group will be prescribed Luminopia One for 1 hour per day, 6 days per week for 12 weeks.\n\nLuminopia One: Luminopia One is a virtual-reality based digital therapeutic that applies therapeutic modifications in real-time to cinematic content to rebalance visual input and treat amblyopia."
              },
              {
                "id": "OG001",
                "title": "Control Group",
                "description": "Participants assigned to the control group will wear their current refractive correction full-time for 12 weeks.\n\nRefractive Correction: Standard of care refractive correction (ex. spectacles)"
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "50" },
                  { "groupId": "OG001", "value": "49" }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "1.06", "spread": "1.32" },
                      { "groupId": "OG001", "value": "0.37", "spread": "1.75" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Best-Corrected Visual Acuity of Amblyopic Eye",
            "description": "Mean improvement in best-corrected visual acuity of amblyopic eye from baseline after 8 weeks using electronic ATS-HOTV protocol.",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "Lines of visual acuity improvement",
            "timeFrame": "8 weeks",
            "groups": [
              {
                "id": "OG000",
                "title": "Therapeutic Group",
                "description": "Participants assigned to the therapeutic group will be prescribed Luminopia One for 1 hour per day, 6 days per week for 12 weeks.\n\nLuminopia One: Luminopia One is a virtual-reality based digital therapeutic that applies therapeutic modifications in real-time to cinematic content to rebalance visual input and treat amblyopia."
              },
              {
                "id": "OG001",
                "title": "Control Group",
                "description": "Participants assigned to the control group will wear their current refractive correction full-time for 12 weeks.\n\nRefractive Correction: Standard of care refractive correction (ex. spectacles)"
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "48" },
                  { "groupId": "OG001", "value": "44" }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "1.48", "spread": "1.25" },
                      { "groupId": "OG001", "value": "0.95", "spread": "1.63" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Stereoacuity",
            "description": "Mean stereoacuity improvement from baseline after 12 weeks.",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "Change in log arc seconds",
            "timeFrame": "12 weeks",
            "groups": [
              {
                "id": "OG000",
                "title": "Therapeutic Group",
                "description": "Participants assigned to the therapeutic group will be prescribed Luminopia One for 1 hour per day, 6 days per week for 12 weeks.\n\nLuminopia One: Luminopia One is a virtual-reality based digital therapeutic that applies therapeutic modifications in real-time to cinematic content to rebalance visual input and treat amblyopia."
              },
              {
                "id": "OG001",
                "title": "Control Group",
                "description": "Participants assigned to the control group will wear their current refractive correction full-time for 12 weeks.\n\nRefractive Correction: Standard of care refractive correction (ex. spectacles)"
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "42" },
                  { "groupId": "OG001", "value": "46" }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "1.0", "spread": "5.8" },
                      { "groupId": "OG001", "value": "0.8", "spread": "2.9" }
                    ]
                  }
                ]
              }
            ]
          }
        ]
      },
      "adverseEventsModule": {
        "frequencyThreshold": "5",
        "timeFrame": "Adverse event data were collected throughout the study at each follow-up phone call or visit.",
        "description": "Serious and Mortality adverse events are reported for all consented individuals. Non-serious adverse events are reported for all participants in the study according to the As Treated Population. i.e. participants actually using the investigational product or the control group product.",
        "eventGroups": [
          {
            "id": "EG000",
            "title": "Therapeutic Group",
            "description": "Participants assigned to the therapeutic group will be prescribed Luminopia One for 1 hour per day, 6 days per week for 12 weeks.\n\nLuminopia One: Luminopia One is a virtual-reality based digital therapeutic that applies therapeutic modifications in real-time to cinematic content to rebalance visual input and treat amblyopia.",
            "deathsNumAffected": 0,
            "deathsNumAtRisk": 58,
            "seriousNumAffected": 0,
            "seriousNumAtRisk": 58,
            "otherNumAffected": 13,
            "otherNumAtRisk": 51
          },
          {
            "id": "EG001",
            "title": "Control Group",
            "description": "Participants assigned to the control group will wear their current refractive correction full-time for 12 weeks.\n\nRefractive Correction: Standard of care refractive correction (ex. spectacles)",
            "deathsNumAffected": 0,
            "deathsNumAtRisk": 59,
            "seriousNumAffected": 0,
            "seriousNumAtRisk": 59,
            "otherNumAffected": 9,
            "otherNumAtRisk": 59
          }
        ],
        "otherEvents": [
          {
            "term": "New heterotropia",
            "organSystem": "Eye disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 4,
                "numAffected": 4,
                "numAtRisk": 51
              },
              {
                "groupId": "EG001",
                "numEvents": 4,
                "numAffected": 4,
                "numAtRisk": 59
              }
            ]
          },
          {
            "term": "Headache",
            "organSystem": "General disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 9,
                "numAffected": 8,
                "numAtRisk": 51
              },
              {
                "groupId": "EG001",
                "numEvents": 1,
                "numAffected": 1,
                "numAtRisk": 59
              }
            ]
          },
          {
            "term": "Worsening best-corrected visual acuity",
            "organSystem": "Eye disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 2,
                "numAffected": 2,
                "numAtRisk": 51
              },
              {
                "groupId": "EG001",
                "numEvents": 6,
                "numAffected": 5,
                "numAtRisk": 59
              }
            ]
          }
        ]
      },
      "moreInfoModule": {
        "limitationsAndCaveats": {
          "description": "We evaluated the therapeutic alongside continued refractive correction alone over 12 weeks and we did not compare with patching or atropine penalization, so we do not know the relative safety and efficacy of the therapeutic versus patching or atropine, nor the durability of benefit from the therapeutic. The duration of our study was limited to 12 weeks, which may have biased the results toward superiority of one treatment over the other depending on the time course of responses."
        },
        "certainAgreement": {
          "piSponsorEmployee": false,
          "restrictionType": "LTE60",
          "restrictiveAgreement": true
        },
        "pointOfContact": {
          "title": "VP of Clinical Development",
          "organization": "Luminopia, Inc.",
          "email": "endri@luminopia.com",
          "phone": "9788067080"
        }
      }
    },
    "documentSection": {
      "largeDocumentModule": {
        "largeDocs": [
          {
            "typeAbbrev": "Prot",
            "hasProtocol": true,
            "hasSap": false,
            "hasIcf": false,
            "label": "Study Protocol",
            "date": "2018-10-08",
            "uploadDate": "2020-05-12T19:52",
            "filename": "Prot_000.pdf",
            "size": 537545
          },
          {
            "typeAbbrev": "SAP",
            "hasProtocol": false,
            "hasSap": true,
            "hasIcf": false,
            "label": "Statistical Analysis Plan",
            "date": "2020-04-09",
            "uploadDate": "2022-09-02T12:46",
            "filename": "SAP_001.pdf",
            "size": 10143591
          }
        ]
      }
    },
    "derivedSection": {
      "miscInfoModule": {
        "versionHolder": "2025-05-07",
        "submissionTracking": {
          "firstMcpInfo": {
            "postDateStruct": { "date": "2022-04-29", "type": "ACTUAL" }
          }
        }
      },
      "conditionBrowseModule": {
        "meshes": [{ "id": "D000550", "term": "Amblyopia" }],
        "ancestors": [
          { "id": "D001927", "term": "Brain Diseases" },
          { "id": "D002493", "term": "Central Nervous System Diseases" },
          { "id": "D009422", "term": "Nervous System Diseases" },
          { "id": "D014786", "term": "Vision Disorders" },
          { "id": "D012678", "term": "Sensation Disorders" },
          { "id": "D009461", "term": "Neurologic Manifestations" },
          { "id": "D005128", "term": "Eye Diseases" }
        ],
        "browseLeaves": [
          {
            "id": "M3891",
            "name": "Amblyopia",
            "asFound": "Amblyopia",
            "relevance": "HIGH"
          },
          { "id": "M5204", "name": "Brain Diseases", "relevance": "LOW" },
          {
            "id": "M5742",
            "name": "Central Nervous System Diseases",
            "relevance": "LOW"
          },
          { "id": "M17530", "name": "Vision Disorders", "relevance": "LOW" },
          { "id": "M15490", "name": "Sensation Disorders", "relevance": "LOW" },
          {
            "id": "M12404",
            "name": "Neurologic Manifestations",
            "relevance": "LOW"
          },
          { "id": "M8271", "name": "Eye Diseases", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "BC10", "name": "Nervous System Diseases" },
          { "abbrev": "BC11", "name": "Eye Diseases" },
          { "abbrev": "BC23", "name": "Symptoms and General Pathology" },
          { "abbrev": "All", "name": "All Conditions" }
        ]
      }
    },
    "hasResults": true
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT04948307",
        "orgStudyIdInfo": { "id": "OXD01-001" },
        "organization": { "fullName": "Orexo AB", "class": "INDUSTRY" },
        "briefTitle": "OXD01 in Combination With Sublingual Buprenorphine/Naloxone for Treatment of Opioid Use Disorder",
        "officialTitle": "A Randomized, Open-label, Parallel-group Study to Evaluate the Efficacy of the Digital Therapeutic OXD01 (MODIA™) in Combination With Sublingual Buprenorphine/Naloxone for the Treatment of Opioid Use Disorder"
      },
      "statusModule": {
        "statusVerifiedDate": "2023-08",
        "overallStatus": "COMPLETED",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2021-06-30", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2023-04-12",
          "type": "ACTUAL"
        },
        "completionDateStruct": { "date": "2023-05-10", "type": "ACTUAL" },
        "studyFirstSubmitDate": "2021-06-22",
        "studyFirstSubmitQcDate": "2021-06-22",
        "studyFirstPostDateStruct": { "date": "2021-07-01", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2023-08-04",
        "lastUpdatePostDateStruct": { "date": "2023-08-07", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": { "name": "Orexo AB", "class": "INDUSTRY" }
      },
      "oversightModule": {
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": true,
        "isUnapprovedDevice": true,
        "isUsExport": false
      },
      "descriptionModule": {
        "briefSummary": "This is an open-label, randomized, parallel-group multicenter study designed to evaluate the efficacy of the digital therapeutic OXD01 (MODIA) combined with sublingual buprenorphine/naloxone standard of care (SL BUP/NAL SOC) background therapy compared to SL BUP/NAL alone to change opioid use patterns in subjects with OUD.\n\nApproximately 400 subjects will be randomized. The study will include a screening visit and a randomization visit, followed by 24 weeks of study treatment. Subjects will be scheduled for evaluation visits, which will include a UDS and a self report of drug use, weekly during the first four weeks of treatment, then every other week from weeks 5 through 12, then monthly through week 25. Subjects will also return to the site for only a urine drug screen (UDS) and a self-report of drug use each week between the evaluation visits.\n\nThe primary objective of the study is to determine whether the combination of sublingual (SL) buprenorphine/naloxone (BUP/NAL) standard of care (SOC) background therapy and the digital therapeutic OXD01 is superior to SL BUP/NAL alone to reduce opioid use.",
        "detailedDescription": "Medication-assisted treatment, the current standard for opioid addiction, is the use of medications in combination with counseling and behavioral therapies to provide a \"whole-patient\" approach to the treatment of opioid use disorder (OUD). However, patients may not have optimal access to faceto-face clinical behavioral health services. Digital therapeutics can help bridge the gap between accessible services and optimal treatment of OUD, the primary goal of which is to reduce the use of opioids. OXD01 is a device-based digital therapeutic, designed to offer individuals diagnosed with OUD quality psychotherapy intervention based on cognitive behavioral therapy and motivational interviewing. This study is being conducted to determine the value of OXD01 when combined with medication to change opioid use patterns in subjects with OUD.\n\nNote: No investigational product will be administered as part of this study."
      },
      "conditionsModule": {
        "conditions": ["Opioid-use Disorder"],
        "keywords": ["digital therapy", "cognitive behavioral therapy", "CBT"]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": { "masking": "NONE" }
        },
        "enrollmentInfo": { "count": 437, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "SL BUP/NAL SOC background therapy",
            "type": "OTHER",
            "description": "standard of care. Subjects in both groups will receive the assigned treatment for 24 weeks. Subjects in both groups may also be encouraged to participate in behavioral health therapies in accordance with the Investigator's standard of practice.",
            "interventionNames": ["Other: Standard of Care"]
          },
          {
            "label": "SL BUP/NAL + OXD01",
            "type": "EXPERIMENTAL",
            "description": "standard of care + OXD01 (digital therapy). Subjects in both groups will receive the assigned treatment for 24 weeks. Subjects in both groups may also be encouraged to participate in behavioral health therapies in accordance with the Investigator's standard of practice.",
            "interventionNames": [
              "Device: OXD01 digital therapy",
              "Other: Standard of Care"
            ]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "OXD01 digital therapy",
            "description": "OXD01 digital therapy, 1-2 times per week 15-30 minutes each time.",
            "armGroupLabels": ["SL BUP/NAL + OXD01"]
          },
          {
            "type": "OTHER",
            "name": "Standard of Care",
            "description": "sublingual buprenorphine/naloxone Medication-assisted treatment, the current standard for opioid addiction; the use of medications in combination with counseling",
            "armGroupLabels": [
              "SL BUP/NAL + OXD01",
              "SL BUP/NAL SOC background therapy"
            ]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "change of Opioid use",
            "description": "The primary objective of the study is to determine whether the combination of sublingual (SL) buprenorphine/naloxone (BUP/NAL) standard of care (SOC) background therapy and the digital therapeutic OXD01 is superior to SL BUP/NAL alone for the change of opioid use.",
            "timeFrame": "from week 6 to week 25"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n1. Male or female 18 - 65 years of age at the screening visit, fluent in English and able to read, comprehend, and willingly sign the informed consent form (ICF).\n2. Voluntarily seeking treatment for OUD.\n3. In the judgment of the Investigator has the appropriate hearing, vision, manual dexterity, ability to understand instructions, and ability to use and understand internet-based applications.\n4. Currently meets the criteria for moderate or severe opioid use disorder according to Diagnostic and Statistical Manual of Mental Disorders (DSM)-V (Appendix B).\n5. Has a positive UDS for opioids at screening that is consistent with their drug use history.\n6. In good health as determined by lack of clinically significant abnormalities in health assessments performed at screening.\n7. Agrees not to take any buprenorphine products other than those prescribed by the Investigator during participation in the study, and agrees to use OXD01 as directed if randomized to that treatment group.\n8. Completed SL BUP/NAL induction, with physical withdrawal symptoms reduced so the subject is able to fulling participate in OXD01 training, if randomized to that treatment group, and is no greater than 14 days from the first dose of SL BUP/NAL induction.\n\nExclusion Criteria:\n\n* 1. Unwilling or unable to comply with the requirements of the protocol or are in a situation or condition that, in the opinion of an Investigator, may interfere with participation in the study (e.g., does not have reliable internet access).\n\n  2. History of allergy or sensitivity to naloxone, buprenorphine or other opioids, or history of any drug hypersensitivity or intolerance which, in the opinion of an Investigator, would compromise the safety of the subject.\n\n  3. Used an investigational drug within 30 days or 5 half-lives (whichever is greater) prior to randomization.\n\n  4. Received prescribed medication-assisted treatment with buprenorphine, methadone, or naltrexone for opioid use disorder within 14 days prior to screening.\n\n  5. Past or present diseases that, judged by an Investigator and based on available medical history/records, may jeopardize the safety of the subject or impact the validity of the study results.\n\n  6. Tongue piercing, or piercings in the mouth or oral deformities that may affect sublingual absorption, in the opinion of an Investigator.\n\n  7. Hospitalization for a psychiatric disorder in the past 30 days, not including inpatient treatment for drug rehabilitation.\n\n  8. Schizophrenia, or other serious mental illness defined as a mental, behavioral, or emotional disorder resulting in serious functional impairment which substantially interferes with or limits participation in the study.\n\n  9. A Quick Inventory of Depression Symptoms - Self-Report (QIDS-SR, Appendix C) score ≥ 16 (severe depression) or a rating of 2 or 3 for question 12 (Thoughts of Death or Suicide) at screening.\n\n  10. A current diagnosis, other than opioid use disorder, requiring chronic opioid treatment.\n\n  11. Chronic pain that is unremitting or unstable. 12. Current DSM-V diagnosis of moderate to severe substance use disorder for psychoactive substances other than opioids, caffeine, marijuana, or nicotine.\n\n  13. Requires current use of medications that are strong inhibitors or inducers of cytochrome P450 (CYP) 3A4 (Section 4.3.1).\n\n  14. Any pending legal action that could affect participation or compliance in the trial.\n\n  15. Is an employee of the Investigator or the trial site, with direct involvement in the proposed trial or other trials under the direction of the Investigator or trial site, or is a family member of the Investigator or an employee.",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "maximumAge": "65 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "facility": "Parkway Medical Center",
            "city": "Birmingham",
            "state": "Alabama",
            "zip": "35215",
            "country": "United States",
            "geoPoint": { "lat": 33.52066, "lon": -86.80249 }
          },
          {
            "facility": "North County Clinical Research",
            "city": "Oceanside",
            "state": "California",
            "zip": "92054",
            "country": "United States",
            "geoPoint": { "lat": 33.19587, "lon": -117.37948 }
          },
          {
            "facility": "Artemis Institute for Clinical Research",
            "city": "San Diego",
            "state": "California",
            "zip": "92103",
            "country": "United States",
            "geoPoint": { "lat": 32.71533, "lon": -117.15726 }
          },
          {
            "facility": "Wetlin Research Associates, Inc",
            "city": "San Diego",
            "state": "California",
            "zip": "92120",
            "country": "United States",
            "geoPoint": { "lat": 32.71533, "lon": -117.15726 }
          },
          {
            "facility": "Humanity Clinical Research",
            "city": "Pembroke Pines",
            "state": "Florida",
            "zip": "33024",
            "country": "United States",
            "geoPoint": { "lat": 26.00315, "lon": -80.22394 }
          },
          {
            "facility": "Southern Illinois Associates LLC",
            "city": "Glen Carbon",
            "state": "Illinois",
            "zip": "62034",
            "country": "United States",
            "geoPoint": { "lat": 38.74838, "lon": -89.98316 }
          },
          {
            "facility": "Otrimed Clinical Research",
            "city": "Edgewood",
            "state": "Kentucky",
            "zip": "41017",
            "country": "United States",
            "geoPoint": { "lat": 39.01867, "lon": -84.58189 }
          },
          {
            "facility": "Patient First Medical Clinic",
            "city": "Dearborn",
            "state": "Michigan",
            "zip": "48126",
            "country": "United States",
            "geoPoint": { "lat": 42.32226, "lon": -83.17631 }
          },
          {
            "facility": "Precise Research Centers",
            "city": "Flowood",
            "state": "Mississippi",
            "zip": "39232",
            "country": "United States",
            "geoPoint": { "lat": 32.30959, "lon": -90.13898 }
          },
          {
            "facility": "PsychCare Consultants Research",
            "city": "Saint Louis",
            "state": "Missouri",
            "zip": "63128",
            "country": "United States",
            "geoPoint": { "lat": 38.62727, "lon": -90.19789 }
          },
          {
            "facility": "Dr. Vando Medical Services PC",
            "city": "Bronx",
            "state": "New York",
            "zip": "10466",
            "country": "United States",
            "geoPoint": { "lat": 40.84985, "lon": -73.86641 }
          },
          {
            "facility": "Midwest Clinical Research Center",
            "city": "Dayton",
            "state": "Ohio",
            "zip": "45417",
            "country": "United States",
            "geoPoint": { "lat": 39.75895, "lon": -84.19161 }
          },
          {
            "facility": "North Star Medical Research",
            "city": "Middleburg Heights",
            "state": "Ohio",
            "zip": "44130",
            "country": "United States",
            "geoPoint": { "lat": 41.36144, "lon": -81.81291 }
          },
          {
            "facility": "Neuro-Behavioral Clinical Research Center",
            "city": "North Canton",
            "state": "Ohio",
            "zip": "44720",
            "country": "United States",
            "geoPoint": { "lat": 40.87589, "lon": -81.40234 }
          },
          {
            "facility": "CincyScience",
            "city": "West Chester",
            "state": "Ohio",
            "zip": "45069",
            "country": "United States",
            "geoPoint": { "lat": 40.23368, "lon": -81.34428 }
          },
          {
            "facility": "Pahl Pharmaceuticals Professions",
            "city": "Oklahoma City",
            "state": "Oklahoma",
            "zip": "73112",
            "country": "United States",
            "geoPoint": { "lat": 35.46756, "lon": -97.51643 }
          },
          {
            "facility": "Thalia Medical Center",
            "city": "Haverford",
            "state": "Pennsylvania",
            "zip": "19041",
            "country": "United States",
            "geoPoint": { "lat": 40.01317, "lon": -75.29435 }
          },
          {
            "facility": "MD Medical Management",
            "city": "Kingston",
            "state": "Pennsylvania",
            "zip": "18704",
            "country": "United States",
            "geoPoint": { "lat": 41.26175, "lon": -75.89686 }
          },
          {
            "facility": "Medically Assisted Recovery Service",
            "city": "Philadelphia",
            "state": "Pennsylvania",
            "zip": "19116",
            "country": "United States",
            "geoPoint": { "lat": 39.95233, "lon": -75.16379 }
          },
          {
            "facility": "Institute of Addiction Medicine",
            "city": "Plymouth Meeting",
            "state": "Pennsylvania",
            "zip": "19462",
            "country": "United States",
            "geoPoint": { "lat": 40.10233, "lon": -75.27435 }
          },
          {
            "facility": "Aspen Clinical Research",
            "city": "Orem",
            "state": "Utah",
            "zip": "84058",
            "country": "United States",
            "geoPoint": { "lat": 40.2969, "lon": -111.69465 }
          }
        ]
      },
      "ipdSharingStatementModule": { "ipdSharing": "NO" }
    },
    "derivedSection": {
      "miscInfoModule": {
        "versionHolder": "2025-05-07",
        "submissionTracking": {
          "estimatedResultsFirstSubmitDate": "2024-05-06",
          "submissionInfos": [
            {
              "releaseDate": "2024-05-06",
              "resetDate": "2024-06-05",
              "mcpReleaseN": 8
            },
            {
              "releaseDate": "2024-06-20",
              "resetDate": "2024-07-16",
              "mcpReleaseN": 9
            },
            {
              "releaseDate": "2024-07-31",
              "resetDate": "2024-08-23",
              "mcpReleaseN": 10
            }
          ]
        }
      },
      "conditionBrowseModule": {
        "meshes": [
          { "id": "D009293", "term": "Opioid-Related Disorders" },
          { "id": "D019966", "term": "Substance-Related Disorders" }
        ],
        "ancestors": [
          { "id": "D000079524", "term": "Narcotic-Related Disorders" },
          { "id": "D064419", "term": "Chemically-Induced Disorders" },
          { "id": "D001523", "term": "Mental Disorders" }
        ],
        "browseLeaves": [
          {
            "id": "M12244",
            "name": "Opioid-Related Disorders",
            "asFound": "Opioid Use Disorder",
            "relevance": "HIGH"
          },
          {
            "id": "M21837",
            "name": "Substance-Related Disorders",
            "asFound": "Opioid Use Disorder",
            "relevance": "HIGH"
          },
          {
            "id": "M2057",
            "name": "Narcotic-Related Disorders",
            "relevance": "LOW"
          },
          {
            "id": "M30302",
            "name": "Chemically-Induced Disorders",
            "relevance": "LOW"
          },
          { "id": "M14473", "name": "Psychotic Disorders", "relevance": "LOW" },
          { "id": "M4815", "name": "Mental Disorders", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "BC25", "name": "Substance Related Disorders" },
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" },
          { "abbrev": "All", "name": "All Conditions" }
        ]
      },
      "interventionBrowseModule": {
        "browseLeaves": [
          { "id": "M5317", "name": "Buprenorphine", "relevance": "LOW" },
          { "id": "M4033", "name": "Analgesics, Opioid", "relevance": "LOW" },
          { "id": "M12221", "name": "Naloxone", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "Analg", "name": "Analgesics" },
          { "abbrev": "CNSDep", "name": "Central Nervous System Depressants" },
          { "abbrev": "NarcAntag", "name": "Narcotic Antagonists" },
          { "abbrev": "All", "name": "All Drugs and Chemicals" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT06376032",
        "orgStudyIdInfo": { "id": "Akili-068" },
        "organization": {
          "fullName": "Akili Interactive Labs, Inc.",
          "class": "INDUSTRY"
        },
        "briefTitle": "EndeavorOTC® Research Study in College Students",
        "officialTitle": "EndeavorOTC® Research Study in College Students"
      },
      "statusModule": {
        "statusVerifiedDate": "2024-06",
        "overallStatus": "ACTIVE_NOT_RECRUITING",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2024-01-10", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2025-12-31",
          "type": "ESTIMATED"
        },
        "completionDateStruct": { "date": "2025-12-31", "type": "ESTIMATED" },
        "studyFirstSubmitDate": "2024-04-17",
        "studyFirstSubmitQcDate": "2024-04-17",
        "studyFirstPostDateStruct": { "date": "2024-04-19", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2024-06-25",
        "lastUpdatePostDateStruct": { "date": "2024-06-27", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": {
          "name": "Akili Interactive Labs, Inc.",
          "class": "INDUSTRY"
        },
        "collaborators": [
          { "name": "Landmark College", "class": "UNKNOWN" },
          { "name": "Villa Maria College", "class": "UNKNOWN" }
        ]
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": true,
        "isUnapprovedDevice": true
      },
      "descriptionModule": {
        "briefSummary": "The objective of this study is to evaluate the impact of a digital therapeutic (EndeavorOTC®, also known as AKL-T01A) on clinical symptoms of executive and cognitive functioning in a real-world sample of university students. This study aims to answer whether EndeavorOTC represents a useful intervention for targeting broad cognitive and emotional health among university students.",
        "detailedDescription": "University students face an increased risk of mental health challenges, as well as elevated stress due to the demands of managing coursework and social stress during a formative developmental period with increased independence. Consequently, there is a need for scalable, evidence-based interventions that can help university students manage their cognitive and emotional health. Through a partnership between Akili Interactive Labs and participating colleges, free 12-week access to AKL-T01 will be provided to any student interested in treatment for the duration of an academic semester, up to an N of 500 per site. This study will evaluate changes in participants across a range of clinical and functional outcomes, including cognitive functioning, academic outcomes, social functioning, attention and associated symptoms, and quality of life. The study will also evaluate user feedback and information on the usability of AKL-T01 through both quantitative and qualitative methods."
      },
      "conditionsModule": {
        "conditions": ["Attention", "Cognition", "University Students"]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "CROSSOVER",
          "interventionModelDescription": "Eligible students will be randomized\\* to two cohorts: the first will receive immediate access to AKL-T01, and the second will complete weekly online surveys and receive access to AKL-T01 after the first group has completed the recommended 6 weeks of use. Regardless of group assignment, all participants will receive full 12-weeks of access to AKL-T01 during the course of the study.\n\n\\*Depending on enrollment numbers for a given semester (e.g., if \\<100 students are enrolled and the study is underpowered to conduct between-group comparisons), all participants may be assigned to receive treatment immediately (i.e., single-arm design) and primary study hypotheses may be evaluated according to within-person changes in outcomes.",
          "primaryPurpose": "OTHER",
          "maskingInfo": { "masking": "NONE" }
        },
        "enrollmentInfo": { "count": 69, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "Group 1",
            "type": "EXPERIMENTAL",
            "description": "Participants receive immediate 12-week access to EndeavorOTC.",
            "interventionNames": ["Device: EndeavorOTC®"]
          },
          {
            "label": "Group 2",
            "type": "EXPERIMENTAL",
            "description": "Participants receive 12-week access to EndeavorOTC 6-weeks after Group 1.",
            "interventionNames": ["Device: EndeavorOTC®"]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "EndeavorOTC®",
            "description": "EndeavorOTC is an over the counter digital therapeutic designed to improve attention function as measured by computer-based testing in patients 18 and older with primarily inattentive or combined type ADHD, who have a demonstrated attention issue. EndeavorOTC utilizes the same proprietary technology underlying EndeavorRx®, an FDA-authorized prescription digital therapeutic indicated to improve attention function in children ages 8-17. EndeavorOTC is deployed on mobile devices and incorporates adaptive, simultaneous cognitive tasks in a consumer-grade action videogame-based platform with high-quality graphics and reward mechanisms.",
            "armGroupLabels": ["Group 1", "Group 2"],
            "otherNames": ["AKL-T01A"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Computerized Adaptive Test, Mental Health (CAT-MH®)",
            "description": "Computerized Adaptive Test, Mental Health (CAT-MH®) is a distinct suite of computer adaptive tests that is based on multidimensional item response theory. The adult ADHD module is a dimensional severity measure of attention-deficit/hyperactivity disorder symptomatology for adults 18 and over. The number and selection of questions within the assessment varies as individuals' initial item responses are used to determine a provisional estimate of their standing on the measured trait to be used for subsequent item selection. Items are scored on a Likert scale of 1 (Not at all), 2 (Just a little), 3 (Somewhat), 4 (Quite a bit), and 5 (Very much).\n\nNegative change in score indicates improvement in ADHD severity.",
            "timeFrame": "Baseline, Exit (Day 84)"
          },
          {
            "measure": "PROMIS Cognitive Function v2.0 - Short Form",
            "description": "The PROMIS Cognitive Function v2.0 short form consists of six questions about the respondent's cognitive function in the past 7 days rated on a Likert scale of 1-5, where 1=Very often (Several times a day) and 5=Never.\n\nHigher score indicates higher levels of cognition. Positive change in score indicates improvement.",
            "timeFrame": "Baseline, Day 42, Day 84"
          },
          {
            "measure": "PROMIS Satisfaction with Participation in Discretionary Social Activities (v1.0)",
            "description": "The PROMIS Satisfaction with Participation in Discretionary Social Activities scale consists of 7 questions about the respondent's satisfaction in the past 7 days rated on a Likert scale of 1-5 where 1=Not at all and 5=Very much.\n\nHigher score indicates more satisfaction. Positive change in score indicates improvement.",
            "timeFrame": "Baseline, Day 42, Day 84"
          },
          {
            "measure": "General Academic Self-Efficacy scale (GASE)",
            "description": "The GASE is a short and concise five-item measure of the longer form Academic self-efficacy (ASE) scale. The scale assesses a student's global belief in his or her ability to master the various academic challenges in an academic setting and is considered an essential antecedent of wellbeing and performance.\n\nHigher score indicates more self-efficacy. Positive change in score indicates improvement.",
            "timeFrame": "Baseline, Day 42, Day 84"
          },
          {
            "measure": "Mental Health Quality of Life Scale (MHQoL)",
            "description": "The MHQoL is a standardized, validated self-report measure of quality of life that has been developed for use in people with mental health problems.18 It consists of 7-items covering self-image, independence, mood, relationships, daily activities, physical health, and future measured on a 4-point Likert scale ranging from \"Very satisfied\" to \"Very dissatisfied,\" and an analogue scale from regarding psychological well-being where 0 = \"worst imaginable psychological well-being\" and 10 = \"best imaginable psychological well-being.\"\n\nHigher score indicates a better quality of life. Positive change in score indicates improvement.",
            "timeFrame": "Baseline, Day 42, Day 84"
          },
          {
            "measure": "Adult ADHD Self-Report Scale (ASRS)",
            "description": "The ASRS v1.1 is an 18-item self-report validated questionnaire designed to assess ADHD symptoms in adults. No total score or diagnostic likelihood is utilized for the twelve questions. Frequency scores are used to determine if the patient has symptoms highly consistent with ADHD in adults. The frequency-based response is more sensitive with certain questions.\n\nGreater frequency indicates higher symptom consistency with ADHD in adults. Negative change indicates improvement.",
            "timeFrame": "Baseline, Day 42, Day 84"
          },
          {
            "measure": "Patient Health Questionnaire-4 (PHQ-4)",
            "description": "PHQ-4 is an ultra-brief, validated screening assessment for anxiety and depression, consisting of four-items that are scored on a Likert scale of 0 (not at all), 1 (several days), 2 (more than half the days), and 3 (nearly every day).\n\nA higher score indicates greater levels of depression and anxiety. Negative change indicates improvement.",
            "timeFrame": "Baseline, Day 42, Day 84"
          }
        ],
        "otherOutcomes": [
          {
            "measure": "System Usability Scale (SUS)",
            "description": "The SUS is a brief, validated 10-item questionnaire that is designed to evaluate a wide variety of products and services, including hardware, software, mobile devices, websites and applications.22 The SUS consists of 10 items rated on a 5-point Likert scale that range from \"strongly agree\" to \"strongly disagree.\" Results interpretation typically requires normalizing the scores to produce a percentile ranking; however, a SUS score above 68 can generally be considered above average, and a score below 68, generally considered below average.",
            "timeFrame": "Day 84"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* Owns a personal Android or iOS device to access AKL-T01 treatment\n* Provides informed consent to participate in this study\n* Is 18 years of age or older\n\nExclusion Criteria:\n\n* Known photosensitive epilepsy, color blindness, and any physical limitation that would make engagement with an app-based digital intervention difficult\n* Has participated in the same study in previous semesters\n\nPregnant and nursing people are eligible to participate.",
        "healthyVolunteers": true,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "Caitlin Stamatis, PhD",
            "affiliation": "Akili Interactive Labs, Inc.",
            "role": "PRINCIPAL_INVESTIGATOR"
          }
        ],
        "locations": [
          {
            "facility": "Villa Maria College",
            "city": "Cheektowaga",
            "state": "New York",
            "zip": "14225",
            "country": "United States",
            "geoPoint": { "lat": 42.90339, "lon": -78.75475 }
          },
          {
            "facility": "Landmark College",
            "city": "Putney",
            "state": "Vermont",
            "zip": "05346",
            "country": "United States",
            "geoPoint": { "lat": 42.9748, "lon": -72.52176 }
          }
        ]
      },
      "ipdSharingStatementModule": {
        "ipdSharing": "NO",
        "description": "IPD will not be shared with other researchers."
      }
    },
    "derivedSection": { "miscInfoModule": { "versionHolder": "2025-05-07" } },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT05822999",
        "orgStudyIdInfo": { "id": "WCTP-I-B-01" },
        "organization": { "fullName": "WELT corp", "class": "INDUSTRY" },
        "briefTitle": "Study of Efficacy of WELT-IP in Insomnia (WCTP-I-B-01)",
        "officialTitle": "A Multicenter, Randomized, Double-blinded, Sham-controlled Clinical Trial to Evaluate the Safety and Efficacy of Digital Cognitive Behavioral Therapy for Insomnia"
      },
      "statusModule": {
        "statusVerifiedDate": "2023-03",
        "overallStatus": "COMPLETED",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2021-12-15", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2022-04-26",
          "type": "ACTUAL"
        },
        "completionDateStruct": { "date": "2022-06-08", "type": "ACTUAL" },
        "studyFirstSubmitDate": "2023-03-14",
        "studyFirstSubmitQcDate": "2023-04-09",
        "studyFirstPostDateStruct": { "date": "2023-04-21", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2023-04-09",
        "lastUpdatePostDateStruct": { "date": "2023-04-21", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": { "name": "WELT corp", "class": "INDUSTRY" }
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": false
      },
      "descriptionModule": {
        "briefSummary": "The purpose of the study was to determine safety and efficacy of WELT-IP in adult insomnia patients. WELT-IP is a cognitive behavioral therapy for insomnia (CBT-I) based digital therapeutics.",
        "detailedDescription": "This was a randomized, double-blinded, sham-controlled trial. Overall, 52 subjects were randomized into the following groups:\n\n* WELT-IP group: WELT-IP (insomnia digital therapeutics) use\n* Control group: sham app use Subjects in both groups continued to receive their clinician-directed standard-of-care treatment for insomnia, if applicable, including pharmacotherapy. Subjects were randomized and in WELT-IP group used WELT-IP and subjects in control group used a sham for a period of 6 weeks."
      },
      "conditionsModule": {
        "conditions": ["Insomnia"],
        "keywords": ["digital therapeutics"]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "interventionModelDescription": "This is a randomized, double-blinded design, with seven points of measurement. The subjects will receive either the WELT-IP app or sham app.",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": {
            "masking": "DOUBLE",
            "maskingDescription": "double-blinded",
            "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]
          }
        },
        "enrollmentInfo": { "count": 52, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "WELT-IP",
            "type": "EXPERIMENTAL",
            "description": "Eligible subjects were able to access WELT-IP (an investigational digital therapeutic) on a mobile device (iOS and Android) as scheduled to receive CBT-I.",
            "interventionNames": ["Device: WELT-IP"]
          },
          {
            "label": "Sham",
            "type": "SHAM_COMPARATOR",
            "description": "Eligible subjects were able to access a sham app downloaded on a mobile device (iOS and Android) which included sleep diary and general content regarding sleep.",
            "interventionNames": ["Device: Sham"]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "WELT-IP",
            "description": "WELT-IP (an investigational digital therapeutic) is an CBT-I based intervention designed to treat insomnia, conducted in 6 sessions. It is a comprehensive program delivering sleep restriction, stimulation control, muscle relaxation, cognitive treatment, and sleep hygiene education. Main features are sleep diary, sleep reports, daily lessons of CBT-I, muscle relaxation techniques, and cognitive intervention through chatbot.",
            "armGroupLabels": ["WELT-IP"]
          },
          {
            "type": "DEVICE",
            "name": "Sham",
            "description": "Sham was downloaded to the subject's phone and was subject was instructed to complete sleep diary and sleep educational contents as needed.",
            "armGroupLabels": ["Sham"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Change from baseline (before using) to week 8 (after 6 weeks of using) of Insomnia severity index (ISI)",
            "description": "Insomnia severity index has seven questions. Total score ranges from 0 to 28, where higher scores indicate more acute symptoms of insomnia.",
            "timeFrame": "8 weeks"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Change from week 1 (before using) to week 8 (after 6 weeks of using) of Sleep efficiency (SE)",
            "description": "Sleep efficiency is calculated as percentage of Total sleep time/time in bed.",
            "timeFrame": "8 weeks"
          },
          {
            "measure": "Change from week 1 (before using) to week 8 (after 6 weeks of using) of Sleep quality (SQ)",
            "description": "Sleep quality ranges from 1 to 5, where higher score indicates better quality of sleep.",
            "timeFrame": "8 weeks"
          },
          {
            "measure": "Change from week 1 (before using) to week 8 (after 6 weeks of using) of Sleep onset latency (SOL)",
            "description": "Sleep onset latency is evaluated as the time it takes a person to fall asleep after going to bed.",
            "timeFrame": "8 weeks"
          },
          {
            "measure": "Change from week 1 (before using) to week 8 (after 6 weeks of using) of Wake after sleep onset (WASO)",
            "description": "Wake after sleep onset is calculated as the total number of minutes that a person is awake after initially falling asleep.",
            "timeFrame": "8 weeks"
          },
          {
            "measure": "Change from week 1 (before using) to week 8 (after 6 weeks of using) of Total sleep time (TST)",
            "description": "Total sleep time is calculated as the total number of minutes that a person actually sleep.",
            "timeFrame": "8 weeks"
          },
          {
            "measure": "Change from week 1 (before using) to week 8 (after 6 weeks of using) of Number of awakening (NOA)",
            "description": "Number of awakening is evaluated as the number of times a person wakes up after falling asleep.",
            "timeFrame": "8 weeks"
          },
          {
            "measure": "Change from baseline (before using) to week 8 (after 6 weeks of using) of Pittsburgh sleep quality index (PSQI)",
            "description": "Pittsburgh sleep quality index has ten questions. Total score ranges from 0 to 21, where higher scores indicate lower quality of sleep.",
            "timeFrame": "8 weeks"
          },
          {
            "measure": "Change from baseline (before using) to week 8 (after 6 weeks of using) of Dysfunctional beliefs and attitudes about sleep-16 (DBAS-16)",
            "description": "Dysfunctional beliefs and attitudes about sleep-16 has sixteen questions. Responses can range from 0 to 10, where higher scores indicate more irrational belief and attitude toward sleep.",
            "timeFrame": "8 weeks"
          },
          {
            "measure": "Change from baseline (before using) to week 8 (after 6 weeks of using) of Patient health questionnaire-9 (PHQ-9)",
            "description": "Patient health questionnaire-9 has nine questions. Total score ranges from 0 to 27, where higher scores indicate more acute symptoms of depression.",
            "timeFrame": "8 weeks"
          },
          {
            "measure": "Change from baseline (before using) to week 8 (after 6 weeks of using) of Generalized anxiety disorder-7 item scale (GAD-7)",
            "description": "Generalized anxiety disorder-7 item scale has seven questions. Total score ranges from 0 to 21, where higher scores indicate more acute symptoms of anxiety.",
            "timeFrame": "8 weeks"
          },
          {
            "measure": "Change from baseline (before using) to week 8 (after 6 weeks of using) of Epworth sleepiness scale (ESS)",
            "description": "Epworth sleepiness scale has eight questions. Total score ranges from 0 to 24. A total score of 10 or less is evaluated as normal. A total score of 11 to 15 is evaluated as significant sleepiness. A total score of 16 or more is evaluated as pathological sleepiness.",
            "timeFrame": "8 weeks"
          },
          {
            "measure": "Change from baseline (before using) to week 14 (after 6 weeks from close out visit) of Insomnia severity index (ISI) for WELT-IP group",
            "description": "Insomnia severity index has seven questions. Total score ranges from 0 to 28, where higher scores indicate more acute symptoms of insomnia.",
            "timeFrame": "14 weeks"
          },
          {
            "measure": "Percentage of subjects achieving SE ≥ 85%",
            "timeFrame": "8 weeks"
          },
          {
            "measure": "Compliance (completion rate of lessons, for WELT-IP group only)",
            "description": "Compliance is evaluated as completion rate of lessons.",
            "timeFrame": "8 weeks"
          }
        ],
        "otherOutcomes": [
          {
            "measure": "App Satisfaction Survey (for WELT-IP group only)",
            "timeFrame": "8 weeks"
          },
          { "measure": "Sleep Environment Survey", "timeFrame": "8 weeks" },
          {
            "measure": "Activity data from mobile device",
            "description": "Activity data is evaluated as change of number of steps from baseline to week 8.",
            "timeFrame": "8 weeks"
          },
          {
            "measure": "EuroQol 5 dimensions 5 level (EQ-5D-5L) Survey",
            "description": "EuroQol 5 dimensions 5 level comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression.",
            "timeFrame": "8 weeks"
          },
          {
            "measure": "EuroQol-visual analogue scales (EQ-VAS) Survey",
            "description": "EuroQol-visual analogue scales records the self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'.",
            "timeFrame": "8 weeks"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* DSM-5 insomnia patient\n* ISI of 8 or above\n* for 7 days before baseline visit (Visit 2), completing sleep diary for more than 4 days in the guidelines\n* capable of using mobile device and application\n\nExclusion Criteria:\n\n* currently on non-pharmacological treatment for insomnia (ex. CBT-I, light therapy, oriental therapy for insomnia)\n* sleep disorders diagnosis other than insomnia (ex. Obstructive sleep apnea, sleep behavior problem, restless leg syndrome)\n* progressive and active medical conditions\n* received continuous psychotherapy such as CBT, motivational enhancement therapy, psychotherapy, and psychoanalysis in the past 3 months\n* major psychiatric illness as assessed through MINI\n* suicide risk as assessed through C-SSRS\n* having occupational risk due to sleep restriction\n* shift workers",
        "healthyVolunteers": true,
        "sex": "ALL",
        "minimumAge": "19 Years",
        "maximumAge": "65 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "facility": "Severance Hospital",
            "city": "Seoul",
            "zip": "03722",
            "country": "Korea, Republic of",
            "geoPoint": { "lat": 37.566, "lon": 126.9784 }
          }
        ]
      },
      "ipdSharingStatementModule": { "ipdSharing": "NO" }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [
          {
            "id": "D007319",
            "term": "Sleep Initiation and Maintenance Disorders"
          }
        ],
        "ancestors": [
          { "id": "D020919", "term": "Sleep Disorders, Intrinsic" },
          { "id": "D020920", "term": "Dyssomnias" },
          { "id": "D012893", "term": "Sleep Wake Disorders" },
          { "id": "D009422", "term": "Nervous System Diseases" },
          { "id": "D001523", "term": "Mental Disorders" }
        ],
        "browseLeaves": [
          { "id": "M17330", "name": "Urticaria", "relevance": "LOW" },
          {
            "id": "M10356",
            "name": "Sleep Initiation and Maintenance Disorders",
            "asFound": "Insomnia",
            "relevance": "HIGH"
          },
          { "id": "M22242", "name": "Parasomnias", "relevance": "LOW" },
          {
            "id": "M22654",
            "name": "Sleep Disorders, Intrinsic",
            "relevance": "LOW"
          },
          { "id": "M22655", "name": "Dyssomnias", "relevance": "LOW" },
          {
            "id": "M15696",
            "name": "Sleep Wake Disorders",
            "relevance": "LOW"
          },
          { "id": "M14473", "name": "Psychotic Disorders", "relevance": "LOW" },
          { "id": "M4815", "name": "Mental Disorders", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "BC17", "name": "Skin and Connective Tissue Diseases" },
          { "abbrev": "BC20", "name": "Immune System Diseases" },
          { "abbrev": "All", "name": "All Conditions" },
          { "abbrev": "BC10", "name": "Nervous System Diseases" },
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" },
          { "abbrev": "BC23", "name": "Symptoms and General Pathology" }
        ]
      },
      "interventionBrowseModule": {
        "browseLeaves": [
          { "id": "M6263", "name": "Coal Tar", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "Derm", "name": "Dermatologic Agents" },
          { "abbrev": "All", "name": "All Drugs and Chemicals" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT05809544",
        "orgStudyIdInfo": { "id": "WCTP-I-B-02" },
        "organization": { "fullName": "WELT corp", "class": "INDUSTRY" },
        "briefTitle": "Study of Efficacy of WELT-IP in Insomnia (WCTP-I-B-02)",
        "officialTitle": "A Randomized, Double-blinded, Sham-controlled Clinical Trial to Evaluate the Safety and Efficacy of Digital Cognitive Behavioral Therapy for Insomnia"
      },
      "statusModule": {
        "statusVerifiedDate": "2023-03",
        "overallStatus": "COMPLETED",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2022-10-14", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2023-02-20",
          "type": "ACTUAL"
        },
        "completionDateStruct": { "date": "2023-02-20", "type": "ACTUAL" },
        "studyFirstSubmitDate": "2023-03-13",
        "studyFirstSubmitQcDate": "2023-04-09",
        "studyFirstPostDateStruct": { "date": "2023-04-12", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2023-04-09",
        "lastUpdatePostDateStruct": { "date": "2023-04-12", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": { "name": "WELT corp", "class": "INDUSTRY" }
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": false
      },
      "descriptionModule": {
        "briefSummary": "The purpose of the study was to determine safety and efficacy of WELT-IP in adult insomnia patients. WELT-IP is a cognitive behavioral therapy for insomnia (CBT-I) based digital therapeutics.",
        "detailedDescription": "This was a randomized, double-blinded, sham-controlled trial. Overall, 68 subjects were randomized into the following groups:\n\n* WELT-IP group: WELT-IP (insomnia digital therapeutics) use\n* Control group: sham app use Subjects in both groups continued to receive their clinician-directed standard-of-care treatment for insomnia, if applicable, including pharmacotherapy. After screening of sleep diary, subjects were randomized and in WELT-IP group used WELT-IP and subjects in control group used a sham for a period of 6 weeks."
      },
      "conditionsModule": {
        "conditions": ["Insomnia"],
        "keywords": ["digital therapeutics"]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "interventionModelDescription": "This is a randomized, double-blinded design, with three points of measurement. The subjects will receive either the WELT-IP app or sham app.",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": {
            "masking": "DOUBLE",
            "maskingDescription": "double-blinded",
            "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]
          }
        },
        "enrollmentInfo": { "count": 68, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "WELT-IP",
            "type": "EXPERIMENTAL",
            "description": "Eligible subjects were able to access WELT-IP (an investigational digital therapeutic) on a mobile device (iOS and Android) as scheduled to receive CBT-I.",
            "interventionNames": ["Device: WELT-IP"]
          },
          {
            "label": "Sham",
            "type": "SHAM_COMPARATOR",
            "description": "Eligible subjects were able to access a sham app downloaded on a mobile device (iOS and Android) which included sleep diary and general content regarding sleep.",
            "interventionNames": ["Device: Sham"]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "WELT-IP",
            "description": "WELT-IP (an investigational digital therapeutic) is an CBT-I based intervention designed to treat insomnia, conducted in 6 sessions. It is a comprehensive program delivering sleep restriction, stimulation control, muscle relaxation, cognitive treatment, and sleep hygiene education. Main features are sleep diary, sleep reports, daily lessons of CBT-I, muscle relaxation techniques, and cognitive intervention through chatbot.",
            "armGroupLabels": ["WELT-IP"]
          },
          {
            "type": "DEVICE",
            "name": "Sham",
            "description": "Sham was downloaded to the subject's phone and was subject was instructed to complete sleep diary and sleep educational contents as needed.",
            "armGroupLabels": ["Sham"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Change from baseline to week 7 (post-treatment) of Sleep efficiency(SE)",
            "description": "Sleep efficiency is calculated as percentage of Total sleep time/Time in bed.",
            "timeFrame": "7 weeks"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Change from baseline to week 7 (post-treatment) of Sleep quality (SQ)",
            "description": "Sleep quality ranges from 1 to 5, where higher score indicates better quality of sleep.",
            "timeFrame": "7 weeks"
          },
          {
            "measure": "Change from baseline to week 7 (post-treatment) of Sleep onset latency (SOL)",
            "description": "Sleep onset latency is evaluated as the time it takes a person to fall asleep after going to bed.",
            "timeFrame": "7 weeks"
          },
          {
            "measure": "Change from baseline to week 7 (post-treatment) of Wake after sleep onset (WASO)",
            "description": "Wake after sleep onset is calculated as the total number of minutes that a person is awake after initially falling asleep.",
            "timeFrame": "7 weeks"
          },
          {
            "measure": "Change from baseline to week 7 (post-treatment) of Total sleep time (TST)",
            "description": "Total sleep time is calculated as the total number of minutes that a person actually sleep.",
            "timeFrame": "7 weeks"
          },
          {
            "measure": "Change from baseline to week 7 (post-treatment) of Number of awakening (NOA)",
            "description": "Number of awakening is evaluated as the number of times a person wakes up after falling asleep.",
            "timeFrame": "7 weeks"
          },
          {
            "measure": "Change from baseline to week 7 (post-treatment) of Insomnia severity index (ISI)",
            "description": "Insomnia severity index has seven questions. Total score ranges from 0 to 28, where higher scores indicate more acute symptoms of insomnia.",
            "timeFrame": "7 weeks"
          },
          {
            "measure": "Change from baseline to week 7 (post-treatment) of Dysfunctional beliefs and attitudes about sleep-16 (DBAS-16)",
            "description": "Dysfunctional beliefs and attitudes about sleep-16 has sixteen questions. Responses can range from 0 to 10, where higher scores indicate more irrational beliefs and attitudes toward sleep.",
            "timeFrame": "7 weeks"
          },
          {
            "measure": "Change from baseline to week 7 (post-treatment) of Patient health questionnaire-9 (PHQ-9)",
            "description": "Patient health questionnaire-9 has nine questions. Total score ranges from 0 to 27, where higher scores indicate more acute symptoms of depression.",
            "timeFrame": "7 weeks"
          },
          {
            "measure": "Change from baseline to week 7 (post-treatment) of Generalized anxiety disorder-7 item scale (GAD-7)",
            "description": "Generalized anxiety disorder-7 item scale has seven questions. Total score ranges from 0 to 21, where higher scores indicate more acute symptoms of anxiety.",
            "timeFrame": "7 weeks"
          },
          {
            "measure": "Percentage of subjects achieving SE ≥ 85%",
            "timeFrame": "7 weeks"
          },
          {
            "measure": "Compliance (completion rate of lessons, for WELT-IP group only)",
            "description": "Compliance is evaluated as completion rate of lessons.",
            "timeFrame": "7 weeks"
          }
        ],
        "otherOutcomes": [
          { "measure": "App Satisfaction Survey", "timeFrame": "7 weeks" },
          { "measure": "Sleep Environment Survey", "timeFrame": "7 weeks" },
          {
            "measure": "Activity data from mobile device",
            "description": "Activity data is evaluated as change of number of steps from baseline to week 7.",
            "timeFrame": "7 weeks"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* DSM-5 insomnia patient\n* SE (sleep efficiency) \\<80%\n* completing screening sleep diary of 7 consecutive days\n* ISI of 8 or above\n* capable of using mobile device and application\n\nExclusion Criteria:\n\n* currently on non-pharmacological treatment for insomnia (ex. CBT-I, light therapy, oriental therapy for insomnia)\n* sleep disorders diagnosis other than insomnia (ex. Obstructive sleep apnea, sleep behavior problem, restless leg syndrome)\n* progressive and active medical conditions\n* received continuous psychotherapy such as CBT, motivational enhancement therapy, psychotherapy, and psychoanalysis in the past 3 months\n* major psychiatric illness as assessed through MINI\n* suicide risk as assessed through C-SSRS\n* having occupational risk due to sleep restriction\n* shift workers",
        "healthyVolunteers": true,
        "sex": "ALL",
        "minimumAge": "19 Years",
        "maximumAge": "65 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "facility": "Severance Hospital",
            "city": "Seoul",
            "zip": "03722",
            "country": "Korea, Republic of",
            "geoPoint": { "lat": 37.566, "lon": 126.9784 }
          }
        ]
      },
      "ipdSharingStatementModule": { "ipdSharing": "NO" }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [
          {
            "id": "D007319",
            "term": "Sleep Initiation and Maintenance Disorders"
          }
        ],
        "ancestors": [
          { "id": "D020919", "term": "Sleep Disorders, Intrinsic" },
          { "id": "D020920", "term": "Dyssomnias" },
          { "id": "D012893", "term": "Sleep Wake Disorders" },
          { "id": "D009422", "term": "Nervous System Diseases" },
          { "id": "D001523", "term": "Mental Disorders" }
        ],
        "browseLeaves": [
          { "id": "M17330", "name": "Urticaria", "relevance": "LOW" },
          {
            "id": "M10356",
            "name": "Sleep Initiation and Maintenance Disorders",
            "asFound": "Insomnia",
            "relevance": "HIGH"
          },
          { "id": "M22242", "name": "Parasomnias", "relevance": "LOW" },
          {
            "id": "M22654",
            "name": "Sleep Disorders, Intrinsic",
            "relevance": "LOW"
          },
          { "id": "M22655", "name": "Dyssomnias", "relevance": "LOW" },
          {
            "id": "M15696",
            "name": "Sleep Wake Disorders",
            "relevance": "LOW"
          },
          { "id": "M14473", "name": "Psychotic Disorders", "relevance": "LOW" },
          { "id": "M4815", "name": "Mental Disorders", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "BC17", "name": "Skin and Connective Tissue Diseases" },
          { "abbrev": "BC20", "name": "Immune System Diseases" },
          { "abbrev": "All", "name": "All Conditions" },
          { "abbrev": "BC10", "name": "Nervous System Diseases" },
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" },
          { "abbrev": "BC23", "name": "Symptoms and General Pathology" }
        ]
      },
      "interventionBrowseModule": {
        "browseLeaves": [
          { "id": "M6263", "name": "Coal Tar", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "Derm", "name": "Dermatologic Agents" },
          { "abbrev": "All", "name": "All Drugs and Chemicals" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT05697627",
        "orgStudyIdInfo": { "id": "HUM00227345" },
        "organization": {
          "fullName": "University of Michigan",
          "class": "OTHER"
        },
        "briefTitle": "Cognitive Training Video Game to Target Subclinical Depressive Symptoms in Youth",
        "officialTitle": "Cognitive Training Video Game to Target Subclinical Depressive Symptoms in Youth"
      },
      "statusModule": {
        "statusVerifiedDate": "2024-09",
        "overallStatus": "COMPLETED",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2023-05-03", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2024-07-01",
          "type": "ACTUAL"
        },
        "completionDateStruct": { "date": "2024-08-05", "type": "ACTUAL" },
        "studyFirstSubmitDate": "2023-01-07",
        "studyFirstSubmitQcDate": "2023-01-21",
        "studyFirstPostDateStruct": { "date": "2023-01-26", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2024-09-10",
        "lastUpdatePostDateStruct": { "date": "2024-09-19", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": {
          "type": "PRINCIPAL_INVESTIGATOR",
          "investigatorFullName": "Hannah Becker, MS",
          "investigatorTitle": "Doctoral Candidate in Clinical Science",
          "investigatorAffiliation": "University of Michigan"
        },
        "leadSponsor": { "name": "University of Michigan", "class": "OTHER" }
      },
      "oversightModule": {
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": true
      },
      "descriptionModule": {
        "briefSummary": "The purpose of the study is to determine how cognitive control training (CCT) changes behavior in youth with subclinical depressive symptoms. This research will show what types of behavior changes are important for CCT to help reduce depressive symptoms. In the future, we will use this information to try to improve how we prevent the development of depression, so that it can help more patients.",
        "detailedDescription": "The primary study investigator acknowledges contributions from Kate Fitzgerald, Emily Bilek, Christopher Monk, and Adriene Beltz."
      },
      "conditionsModule": {
        "conditions": ["Depression", "Subclinical Depressive Symptoms"],
        "keywords": ["Cognitive Training Video Game"]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "NA",
          "interventionModel": "SINGLE_GROUP",
          "primaryPurpose": "SUPPORTIVE_CARE",
          "maskingInfo": { "masking": "NONE" }
        },
        "enrollmentInfo": { "count": 20, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "Computerized cognitive training (CCT) using EndeavorRx",
            "type": "EXPERIMENTAL",
            "description": "Exciting, youth-friendly computer game, EndeavorRx engages and trains cognitive control across component processes of attention, response inhibition, shifting and working memory.",
            "interventionNames": [
              "Device: Computerized cognitive training (CCT) using EndeavorRx"
            ]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "Computerized cognitive training (CCT) using EndeavorRx",
            "description": "The EndeavorRx video game is a digital therapeutic designed to improve attention and related cognitive control processes by training interference management.\n\n\\~25 minutes of EndeavorRx video game play per day, for 5 days/week, for up to 4 weeks",
            "armGroupLabels": [
              "Computerized cognitive training (CCT) using EndeavorRx"
            ]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Change in depressive symptoms as measured by Children's Depression Inventory (CDI)",
            "description": "Self-report, 27 item scale on depressive symptoms. Total scores on this measure range from 0 to 54. Higher scores indicate worse depressive symptoms.",
            "timeFrame": "Baseline, following intervention (approximately 5 weeks)"
          },
          {
            "measure": "Change in cognitive control scores on several cognitive tasks administered through Inquisit Millisecond. These individual tasks are not part of a composite battery with standard scoring.",
            "description": "There are six different tasks in the non-standardized battery that assess different aspects of cognitive control and emotion regulation. Several tasks (2-3) with the least missingness and/or outliers will be selected to analyze, and task selection will be completed prior to analysis. For measures of reaction time, lower scores indicate better performance. For scores of accuracy, higher scores indicate better performance.",
            "timeFrame": "Baseline, following intervention (approximately 5 weeks)"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Depressive symptoms as measured by CDI",
            "description": "Self-report, 27 item scale on depressive symptoms. Total scores on this measure range from 0 to 54. Higher scores indicate worse depressive symptoms.",
            "timeFrame": "Up to 4 months"
          },
          {
            "measure": "Change in cognitive control scores on several cognitive tasks administered through Inquisit Millisecond. These individual tasks are not part of a composite battery with standard scoring.",
            "description": "There are six different tasks in the non-standardized battery that assess different aspects of cognitive control and emotion regulation. Several tasks (2-3) with the least missingness and/or outliers will be selected to analyze, and task selection will be completed prior to analysis. For measures of reaction time, lower scores indicate better performance. For scores of accuracy, higher scores indicate better performance.",
            "timeFrame": "Up to 4 months"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion criteria:\n\n1. Parent or guardian willing to give informed consent, and children willing to give informed assent to participate in the study.\n2. Males and females (age 9 - 17.99)\n3. Participant is willing to engage in a technology-based intervention (technology will be provided to participants who live in the state of Michigan, if not already accessible to participant).\n4. Self-reported depressive symptoms\n5. Participants will be required to maintain a stable dose of medications\n\nEXCLUSION CRITERIA\n\n1. Color blindness\n2. Unable to play the video game for any reason\n3. Current K-SADS diagnosis of clinical depression, psychosis, or Autism Spectrum Disorder\n4. Has enrolled in new psychotherapy (for the treatment of a mood or anxiety disorder) or had changes to their psychotherapy in the 4-weeks prior to study enrollment\n5. Endorses items #1, #2, #3, #4, #5. #6 on the C-SSRS Screener (Past-Month); i.e., has present suicidal intention/behavior.\n6. Has had any changes to their medication in the 4-weeks prior to study enrollment",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "9 Years",
        "maximumAge": "17 Years",
        "stdAges": ["CHILD"]
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "Hannah Becker, M.S.",
            "affiliation": "University of Michigan",
            "role": "PRINCIPAL_INVESTIGATOR"
          }
        ],
        "locations": [
          {
            "facility": "University of Michigan",
            "city": "Ann Arbor",
            "state": "Michigan",
            "zip": "48109",
            "country": "United States",
            "geoPoint": { "lat": 42.27756, "lon": -83.74088 }
          }
        ]
      },
      "ipdSharingStatementModule": {
        "ipdSharing": "NO",
        "description": "contact"
      }
    },
    "derivedSection": {
      "miscInfoModule": {
        "versionHolder": "2025-05-07",
        "submissionTracking": {
          "estimatedResultsFirstSubmitDate": "2025-05-03",
          "submissionInfos": [{ "releaseDate": "2025-05-03" }]
        }
      },
      "conditionBrowseModule": {
        "meshes": [{ "id": "D003863", "term": "Depression" }],
        "ancestors": [{ "id": "D001526", "term": "Behavioral Symptoms" }],
        "browseLeaves": [
          { "id": "M7061", "name": "Depressive Disorder", "relevance": "LOW" },
          {
            "id": "M7058",
            "name": "Depression",
            "asFound": "Depressive Symptoms",
            "relevance": "HIGH"
          },
          { "id": "M4818", "name": "Behavioral Symptoms", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" },
          { "abbrev": "All", "name": "All Conditions" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT06486948",
        "orgStudyIdInfo": { "id": "CT-156-C-002" },
        "organization": {
          "fullName": "Click Therapeutics, Inc.",
          "class": "INDUSTRY"
        },
        "briefTitle": "An Exploratory, Double-arm, 8-week Study to Explore the Feasibility and Acceptability of Abbreviated Treatment with CT-156 in People with Schizophrenia.",
        "officialTitle": "A Multicenter, Exploratory, Randomized, Double-Arm, 8-week Study to Evaluate the Feasibility and Acceptability of an Abbreviated Treatment with CT-156 in People with Schizophrenia"
      },
      "statusModule": {
        "statusVerifiedDate": "2025-01",
        "overallStatus": "COMPLETED",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2024-05-06", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2024-08-09",
          "type": "ACTUAL"
        },
        "completionDateStruct": { "date": "2024-08-09", "type": "ACTUAL" },
        "studyFirstSubmitDate": "2024-06-27",
        "studyFirstSubmitQcDate": "2024-07-02",
        "studyFirstPostDateStruct": { "date": "2024-07-05", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2025-01-08",
        "lastUpdatePostDateStruct": { "date": "2025-01-09", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": {
          "name": "Click Therapeutics, Inc.",
          "class": "INDUSTRY"
        },
        "collaborators": [
          { "name": "Boehringer Ingelheim", "class": "INDUSTRY" }
        ]
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": true,
        "isUnapprovedDevice": true,
        "isUsExport": false
      },
      "descriptionModule": {
        "briefSummary": "An exploratory, double-arm, 8-week study to explore the feasibility and acceptability of abbreviated treatment with CT-156 for people with Schizophrenia."
      },
      "conditionsModule": {
        "conditions": ["Schizophrenia"],
        "keywords": [
          "Schizophrenia",
          "Software as a Medical Device (SaMD)",
          "Smartphone app"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "primaryPurpose": "BASIC_SCIENCE",
          "maskingInfo": { "masking": "NONE" }
        },
        "enrollmentInfo": { "count": 58, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "CT-156",
            "type": "ACTIVE_COMPARATOR",
            "description": "Study App investigational treatment for adult patients diagnosed with Schizophrenia.",
            "interventionNames": ["Device: CT-156"]
          },
          {
            "label": "CT-156 + UXR",
            "type": "EXPERIMENTAL",
            "description": "Study app investigational treatment for adult patients diagnosed with schizophrenia with up to five in-patient visits with three interviews for UXR (user experience research) arm.",
            "interventionNames": ["Device: CT-156"]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "CT-156",
            "description": "CT-156 is a digital therapeutic (DTx) under development to treat patients 18 years of age and older with a diagnosis of schizophrenia under standard of care therapy who are on antipsychotic medication and not currently experiencing acute hallucinations or delusions.",
            "armGroupLabels": ["CT-156", "CT-156 + UXR"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Number of Days Used",
            "description": "Number of days the Study App is opened out of total days of treatment",
            "timeFrame": "Day 0 to Week 8"
          },
          {
            "measure": "Number of Times Study App is Opened",
            "description": "Number of times the Study App is opened during the treatment period",
            "timeFrame": "Day 0 to Week 8"
          },
          {
            "measure": "Number of Medication Check-ins Completed",
            "description": "Number of medication check-ins completed during the treatment period out of total assigned",
            "timeFrame": "Day 0 to Week 8"
          },
          {
            "measure": "Number of Assigned Tasks Completed",
            "description": "Number of assigned tasks completed during the treatment period",
            "timeFrame": "Day 0 to Week 8"
          },
          {
            "measure": "Average Duration of Use",
            "description": "Average duration of each App-use session",
            "timeFrame": "Day 0 to Week 8"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* Willing and able to provide written informed consent to participate in the study, attend study visits, and comply with study-related requirements and assessments.\n* Is at least 18 years of age at the time of informed consent.\n* Fluent in written and spoken English, confirmed by ability to read and understand the informed consent form.\n* Lives in the United States.\n* Meets diagnostic criteria for a primary diagnosis of schizophrenia as defined in the ICD-11 or DSM-5 for at least 6 months prior to screening.\n* Has outpatient treatment status at the time of screening, with no psychiatric inpatient hospitalization within 13 weeks (3 months) prior to screening.\n* Is currently prescribed at least one typical and/or atypical antipsychotic medication and has been on the same antipsychotic medication(s) for at least 13 weeks (3 months) prior to enrollment (Day 1). Dose adjustments are permitted during the study as outlined in the respective package insert(s).\n* Has an average domain score ≥2 in at least 2 domains of Understanding and Communicating, Getting Along with People, Life Activities - Household, or Participation in Society on the WHO-DAS 2.0.\n* Participant is the only user of an iPhone with iPhone operating system (iOS) version 15 or later or a smartphone with an Android operating system (OS) version 12 or later and agrees to download and use the digital mobile application as required by the protocol.\n* Is willing and able to receive short message service (SMS) text messages and push messages on their smartphone.\n* Is the owner of or has regular access to an email address.\n* Has regular access to the internet via cellular data plan and/or WiFi.\n* Has stable housing and has remained at the same residence for at least 13 weeks (3 months) prior to screening and does not anticipate any housing changes for the duration of the study.\n* Understands the use of Study App during the Screening Period and at the Baseline Visit, per investigator judgment.\n\nExclusion Criteria:\n\n* Has positive symptoms of schizophrenia that, in the opinion of the investigator, would preclude effective engagement in the treatment to improve functional impairment.\n* Is currently receiving or has received concomitant therapy, defined as individual or group-based structured treatment (e.g., Cognitive Behavioral Therapy, Social Skills Training, Motivational Interviewing, or Vocational/Occupational Therapy), within 3 months (13 weeks) prior to screening per investigator assessment.\n* Is currently treated with more than 2 antipsychotic medications (including more than 2 dosage forms).\n* Meets ICD-11 or DSM-5 criteria for diagnoses not under investigation that will impact compliance to the protocol, including schizophreniform, schizoaffective, or psychosis non-specific disorders (post-traumatic stress disorder \\[PTSD\\], bipolar disorder, major depressive disorder, developmental disorders).\n* Meets ICD-11 or DSM-5 criteria for a current episode of depression, mania or hypomania.\n* Meets ICD-11 or DSM-5 criteria for a current substance or alcohol use disorder (excluding caffeine and nicotine) that would interfere with compliance to the protocol, per investigator judgment. Diagnoses classified as in sustained remission are permitted.\n* In the investigator's opinion, currently needs or will likely require prohibited concomitant medications and/or therapy during the study.\n* Is at moderate to high risk for suicide, defined by any of the following:\n\n  1. A \"yes\" response to either item 4 or 5 on the Columbia-Suicide Severity Rating Scale (C-SSRS) Suicidal Ideation Items within the last 13 weeks (3 months) prior to screening or at Baseline (Day 1)\n  2. A \"yes\" response on the C-SSRS Suicidal Behavior Items within the last 26 weeks (6 months) prior to screening or at Baseline (Day 1)\n  3. In the opinion of the investigator, presents a serious risk of suicide\n* Has participated in another clinical study (interventional or observational) in the last 13 weeks (3 months).\n* Has previously participated in any of the following studies: CT-155-C-001, CT-155-C-002, CT-155-C-003, CT-155-P-00x, CT-155-A-001, CT-155-R- 001, CT-156-D-001, CT-156-C-001, CT-156-P-00x.",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "Shaheen Lakhan",
            "affiliation": "Click Therapeutics",
            "role": "STUDY_DIRECTOR"
          }
        ],
        "locations": [
          {
            "facility": "Click Therapeutics",
            "city": "New York",
            "state": "New York",
            "zip": "10013",
            "country": "United States",
            "geoPoint": { "lat": 40.71427, "lon": -74.00597 }
          }
        ]
      },
      "ipdSharingStatementModule": { "ipdSharing": "NO" }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [{ "id": "D012559", "term": "Schizophrenia" }],
        "ancestors": [
          {
            "id": "D019967",
            "term": "Schizophrenia Spectrum and Other Psychotic Disorders"
          },
          { "id": "D001523", "term": "Mental Disorders" }
        ],
        "browseLeaves": [
          {
            "id": "M15376",
            "name": "Schizophrenia",
            "asFound": "Schizophrenia",
            "relevance": "HIGH"
          },
          { "id": "M14473", "name": "Psychotic Disorders", "relevance": "LOW" },
          { "id": "M4815", "name": "Mental Disorders", "relevance": "LOW" },
          {
            "id": "M21838",
            "name": "Schizophrenia Spectrum and Other Psychotic Disorders",
            "relevance": "LOW"
          }
        ],
        "browseBranches": [
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" },
          { "abbrev": "All", "name": "All Conditions" }
        ]
      },
      "interventionBrowseModule": {
        "browseLeaves": [
          { "id": "M16904", "name": "Antipsychotic Agents", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "CNSDep", "name": "Central Nervous System Depressants" },
          { "abbrev": "PsychDr", "name": "Psychotropic Drugs" },
          { "abbrev": "All", "name": "All Drugs and Chemicals" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT06136936",
        "orgStudyIdInfo": { "id": "CT-156-C-001" },
        "organization": {
          "fullName": "Click Therapeutics, Inc.",
          "class": "INDUSTRY"
        },
        "briefTitle": "A Study to Evaluate the Overall Effects of Treatment With Abbreviated CT-156 in People With Schizophrenia",
        "officialTitle": "A Multicenter, Exploratory, Randomized, Double-Arm, 4-week Study to Evaluate the Overall Effects of Treatment With Abbreviated CT-156 in People With Schizophrenia"
      },
      "statusModule": {
        "statusVerifiedDate": "2025-04",
        "overallStatus": "COMPLETED",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2023-09-20", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2024-01-18",
          "type": "ACTUAL"
        },
        "completionDateStruct": { "date": "2024-02-22", "type": "ACTUAL" },
        "studyFirstSubmitDate": "2023-11-03",
        "studyFirstSubmitQcDate": "2023-11-13",
        "studyFirstPostDateStruct": { "date": "2023-11-18", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2025-04-28",
        "lastUpdatePostDateStruct": { "date": "2025-05-01", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": {
          "name": "Click Therapeutics, Inc.",
          "class": "INDUSTRY"
        },
        "collaborators": [
          { "name": "Boehringer Ingelheim", "class": "INDUSTRY" }
        ]
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": true,
        "isUnapprovedDevice": true,
        "isUsExport": false
      },
      "descriptionModule": {
        "briefSummary": "An exploratory, double-arm, 4-week study to explore the feasibility and acceptability of abbreviated treatment with CT-156 for people with Schizophrenia.",
        "detailedDescription": "The purpose of the proposed study is to evaluate the overall effects of use of an abbreviated version of CT-156 (the Study App) in participants aged 18 years or older with schizophrenia."
      },
      "conditionsModule": {
        "conditions": ["Schizophrenia"],
        "keywords": [
          "Schizophrenia",
          "Software as a Medical Device (SaMD)",
          "Smartphone app"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "primaryPurpose": "DEVICE_FEASIBILITY",
          "maskingInfo": { "masking": "SINGLE", "whoMasked": ["PARTICIPANT"] }
        },
        "enrollmentInfo": { "count": 53, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "CT-156",
            "type": "ACTIVE_COMPARATOR",
            "description": "Study app investigational treatment for adult patients diagnosed with schizophrenia.",
            "interventionNames": ["Device: CT-156-C-001"]
          },
          {
            "label": "CT-156 + UXR",
            "type": "EXPERIMENTAL",
            "description": "Study app investigational treatment for adult patients diagnosed with schizophrenia with up to five in-patient visits with three interviews for UXR (user experience research) arm.",
            "interventionNames": ["Device: CT-156-C-001"]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "CT-156-C-001",
            "description": "CT-156 is a digital therapeutic (DTx) under development to treat patients 18 years of age and older with a diagnosis of schizophrenia under standard of care therapy who are on antipsychotic medication and not currently experiencing acute hallucinations or delusions.",
            "armGroupLabels": ["CT-156", "CT-156 + UXR"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Number of days used",
            "description": "Number of days the Study App is opened out of total days of treatment",
            "timeFrame": "Day 0 to Week 4"
          },
          {
            "measure": "Number of times Study App is opened",
            "description": "Number of times the Study App is opened during the treatment period",
            "timeFrame": "Day 0 to Week 4"
          },
          {
            "measure": "Number of tasks completed",
            "description": "Number of assigned tasks completed during the treatment period",
            "timeFrame": "Day 0 to Week 4"
          },
          {
            "measure": "Length of time in App",
            "description": "Length of each App-use session",
            "timeFrame": "Day 0 to Week 4"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* A participant will be eligible for entry into the study if all of the following criteria are met:\n\n  1. Willing and able to provide written informed consent to participate in the study, attend study visits, and comply with study-related requirements and assessments.\n  2. Is an adult at least 18 years of age at the time of informed consent.\n  3. Fluent in written and spoken English, confirmed by ability to read and understand the informed consent form.\n  4. Lives in the United States.\n  5. Meets diagnostic criteria for a primary diagnosis of schizophrenia as defined in the International Classification of Diseases, Eleventh Edition (ICD-11) or Diagnostic Statistical Manual, Fifth Edition (DSM-5) for at least 6 months prior to screening.\n  6. Has outpatient treatment status at the time of screening, with no psychiatric inpatient hospitalization within 13 weeks (3 months) prior to screening.\n  7. Is currently prescribed at least one typical and/or atypical antipsychotic medication, and has been on the same antipsychotic medication(s) for at least 13 weeks (3 months) prior to randomization (Day 1). Dose adjustments are permitted during the study as outlined in the respective package insert(s).\n  8. Has an average score of \\>2 in at least 2 domains of Understanding and communicating, Getting Along with People, Life Activities - Household, or Participation in Society on the World Health Organization Disability Assessment Schedule 2.0 (WHO-DAS 2.0).\n  9. Participant is the only user of an iPhone with iPhone operating system (iOS) version 14 or later or a smartphone with an Android operating system (OS) version 11 or later and agrees to download and use the digital mobile application as required by the protocol.\n  10. Is willing and able to receive SMS text messages and push messages on their smartphone.\n  11. Is the owner of and has regular access to an email address.\n  12. Has regular access to the internet via cellular data plan and/or wi-fi.\n  13. Has stable housing and has remained at the same residence for at least 13 weeks (3 months) prior to screening, and does not anticipate housing changes for the duration of the study.\n  14. Understands the use of the Study App during the screening period and at the Baseline Visit, per investigator judgment.\n\nExclusion Criteria:\n\n* A participant will not be eligible for study entry if any of the following criteria are met:\n\n  1. Has acute prominent positive symptoms that, in the opinion of the investigator, would preclude effective engagement with the app\n  2. Is currently receiving or has received concomitant therapy, defined as individual or group-based structured treatment (e.g., Cognitive Behavioral Therapy, Social Skills Training, Motivational Interviewing, or Vocational/Occupational Therapy), within 6 months (26 weeks) prior to screening per investigator assessment.\n  3. Is currently treated with more than two antipsychotic medications (including more than 2 dosage forms).\n  4. Is currently treated with clozapine, or was treated with clozapine within 5 years of the Screening Visit.\n  5. Meets ICD-11 or DSM-5 criteria for diagnoses not under investigation that will impact compliance to the protocol, including schizophreniform, schizoaffective, or psychosis non-specific disorders (post-traumatic stress disorder \\[PTSD\\], bipolar disorder, major depressive disorder, developmental disorders).\n  6. Meets ICD-11 or DSM-5 criteria for a current episode of depression, mania or hypomania.\n  7. Meets ICD-11 or DSM-5 criteria for a current substance or alcohol use disorder (excluding caffeine and nicotine) within 26 weeks (6 months) of the Screening Visit. Diagnoses classified as in sustained remission are permitted.\n  8. In the investigator's opinion, currently needs or will likely require prohibited concomitant medications and/or therapy during the study.\n  9. Is at risk for suicide, as defined by any of the following:\n\n     1. A \"yes\" response to either item 4 or 5 on the C-SSRS Suicidal Ideation Items within the last 13 weeks (3 months) prior to screening or at the Baseline Visit.\n     2. A \"yes\" response on the C-SSRS Suicidal Behavior Items within the last 26 weeks (6 months) prior to screening or at the Baseline Visit.\n     3. In the opinion of the investigator, presents a serious risk of suicide.\n  10. Has participated in another clinical study (interventional or observational) in the last 26 weeks (6 months).\n  11. Has previously participated in study CT-155-C-001, CT-155-C-002, CT-155-C-003, CT-155-P-00x, or CT-155-A-001.",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "Shaheen Lakhan",
            "affiliation": "Click Therapeutics",
            "role": "STUDY_DIRECTOR"
          }
        ],
        "locations": [
          {
            "facility": "Click Therapeutics",
            "city": "New York",
            "state": "New York",
            "zip": "10013",
            "country": "United States",
            "geoPoint": { "lat": 40.71427, "lon": -74.00597 }
          }
        ]
      },
      "ipdSharingStatementModule": { "ipdSharing": "NO" }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [{ "id": "D012559", "term": "Schizophrenia" }],
        "ancestors": [
          {
            "id": "D019967",
            "term": "Schizophrenia Spectrum and Other Psychotic Disorders"
          },
          { "id": "D001523", "term": "Mental Disorders" }
        ],
        "browseLeaves": [
          {
            "id": "M15376",
            "name": "Schizophrenia",
            "asFound": "Schizophrenia",
            "relevance": "HIGH"
          },
          { "id": "M14473", "name": "Psychotic Disorders", "relevance": "LOW" },
          { "id": "M4815", "name": "Mental Disorders", "relevance": "LOW" },
          {
            "id": "M21838",
            "name": "Schizophrenia Spectrum and Other Psychotic Disorders",
            "relevance": "LOW"
          }
        ],
        "browseBranches": [
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" },
          { "abbrev": "All", "name": "All Conditions" }
        ]
      },
      "interventionBrowseModule": {
        "browseLeaves": [
          { "id": "M16904", "name": "Antipsychotic Agents", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "CNSDep", "name": "Central Nervous System Depressants" },
          { "abbrev": "PsychDr", "name": "Psychotropic Drugs" },
          { "abbrev": "All", "name": "All Drugs and Chemicals" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT06109051",
        "orgStudyIdInfo": { "id": "Akili-065" },
        "organization": {
          "fullName": "Akili Interactive Labs, Inc.",
          "class": "INDUSTRY"
        },
        "briefTitle": "EndeavorOTC™ Prospective Product Registry",
        "officialTitle": "EndeavorOTC™ Prospective Product Registry"
      },
      "statusModule": {
        "statusVerifiedDate": "2024-06",
        "overallStatus": "ACTIVE_NOT_RECRUITING",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2023-10-03", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2026-12-31",
          "type": "ESTIMATED"
        },
        "completionDateStruct": { "date": "2026-12-31", "type": "ESTIMATED" },
        "studyFirstSubmitDate": "2023-10-23",
        "studyFirstSubmitQcDate": "2023-10-27",
        "studyFirstPostDateStruct": { "date": "2023-10-31", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2024-06-25",
        "lastUpdatePostDateStruct": { "date": "2024-06-27", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": {
          "name": "Akili Interactive Labs, Inc.",
          "class": "INDUSTRY"
        }
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": true,
        "isUnapprovedDevice": true,
        "isUsExport": false
      },
      "descriptionModule": {
        "briefSummary": "The EndeavorOTC product registry aims to collect real world data from EndeavorOTC users. The objectives of this registry are to describe clinical and demographic characteristics, treatment patterns, clinical and quality of life outcomes, and healthcare utilization in EndeavorOTC users in a real-world setting.",
        "detailedDescription": "All EndeavorOTC users who subscribe to EndeavorOTC are invited to participate in this product registry. Users must provide their informed consent and have an active subscription to the product at time of enrollment to participate. Study activities are emailed to participants at baseline, 1, 2, 3, 6, 9, and 12-months after enrollment. Study activities consist of an online survey and online ADHD assessment. All data are captured electronically and securely through commercial data capture platforms."
      },
      "conditionsModule": { "conditions": ["ADHD"] },
      "designModule": {
        "studyType": "OBSERVATIONAL",
        "patientRegistry": true,
        "targetDuration": "1 Year",
        "designInfo": {
          "observationalModel": "COHORT",
          "timePerspective": "PROSPECTIVE"
        },
        "enrollmentInfo": { "count": 198, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "EndeavorOTC Users",
            "description": "All users who subscribe to EndeavorOTC for any duration",
            "interventionNames": ["Device: EndeavorOTC"]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "EndeavorOTC",
            "description": "EndeavorOTC™ is an over-the-counter digital therapeutic designed to improve attention function, ADHD symptoms, and quality of life in users 18 years of age and older with primarily inattentive or combined-type ADHD, who have been identified as having a significant attentional impairment. EndeavorOTC utilizes the same proprietary technology underlying EndeavorRx, a prescription digital therapeutic indicated to improve attention function in children ages 8-12. EndeavorOTC is not intended to be a replacement for any form of ongoing treatment. EndeavorOTC is deployed on mobile devices and incorporates adaptive, simultaneous cognitive tasks in a consumer-grade action videogame-based platform with high-quality graphics and reward mechanisms.",
            "armGroupLabels": ["EndeavorOTC Users"],
            "otherNames": ["AKL-T01A"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Computerized Adaptive Test, Mental Health (CAT-MH®)",
            "description": "Computerized Adaptive Test, Mental Health (CAT-MH®) is a distinct suite of computer adaptive tests that is based on multidimensional item response theory. The adult ADHD module is a dimensional severity measure of attention-deficit/hyperactivity disorder symptomatology for adults 18 and over. The number and selection of questions within the assessment varies as individuals' initial item responses are used to determine a provisional estimate of their standing on the measured trait to be used for subsequent item selection. Items are scored on a Likert scale of 1 (Not at all), 2 (Just a little), 3 (Somewhat), 4 (Quite a bit), and 5 (Very much).\n\nNegative change in score indicates improvement in ADHD severity.",
            "timeFrame": "Baseline, Months 1, 2, 3, 6, 9, 12"
          },
          {
            "measure": "Conners' Adult ADHD Rating Scales-Self Report: Short Version (CAARS-S:S)",
            "description": "Conners' Adult ADHD Rating Scales-Self Report: Short Version (CAARS-S:S) provides an assessment of symptoms and behaviors associated with ADHD in adults ages 18 and older. The short versions of the self-report form (CAARS-S:S) contain 26 items that are scored on a scale of 0 (Not at all, never), 1 (Just a little, once in a while), 2 (Pretty much, often), and 3 (Very much, very frequently).\n\nNegative change in score indicates improvement in ADHD symptoms and behaviors.",
            "timeFrame": "Baseline, Months 1, 2, 3, 6, 9, 12"
          },
          {
            "measure": "Adult ADHD Quality of Life (AAQoL)",
            "description": "Adult ADHD Quality of Life (AAQoL) is a 29-item, self-report measure of functioning in a variety of life domains and adult roles. Items are rated on a 5-point scale that are transformed into a 0-100 scale, with higher scores reflecting higher quality of life. Scores are calculated for life productivity, psychological health, life outlook, and relationships, in addition to total score.\n\nPositive change in score indicates improvement in quality of life.",
            "timeFrame": "Baseline, Months 1, 2, 3, 6, 9, 12"
          },
          {
            "measure": "Patient Health Questionnaire - 4 items (PHQ-4)",
            "description": "Patient Health Questionnaire - 4 items (PHQ-4) is an ultra-brief, validated screening assessment for anxiety and depression, consisting of four-items that are scored on a Likert scale of 0 (not at all), 1 (several days), 2 (more than half the days), and 3 (nearly every day). A higher score indicates greater levels of depression and anxiety.\n\nNegative change in score indicates improvement in anxiety and depression.",
            "timeFrame": "Baseline, Months 1, 2, 3, 6, 9, 12"
          },
          {
            "measure": "Treatment Inventory of Costs in Patients with psychiatric disorders (TIC-P)",
            "description": "Treatment Inventory of Costs in Patients with psychiatric disorders (TIC-P) is a questionnaire that assesses the utilization of medical care and productivity loss. Select questions from the TIC-P questionnaire will be used to estimate costs of healthcare utilization. This assessment will be administered once every 3 months. Participants are asked to provide the number of appointments they have had with a specific healthcare provider or service in the past three months. The sum of total number of appointments utilized within a three month period will be compared between study time points.\n\nNegative change in total number of appointments indicates improvement.",
            "timeFrame": "Baseline, Months 3, 6, 9, 12"
          },
          {
            "measure": "Percent work time missed due to ADHD, as measured by Work Productivity and Activity Impairment Questionnaire plus Classroom Impairment Questions: Specific Health Problem (WPAI+CIQ:SHP), Version 2.0",
            "description": "Work Productivity and Activity Impairment Questionnaire plus Classroom Impairment Questions: Specific Health Problem (WPAI+CIQ:SHP), Version 2.0 is a 10-item, validated self-report questionnaire which is based on an individual's absenteeism, presenteeism, work or classroom productivity loss, and activity impairment due to a specific disease/condition. This questionnaire has been adapted to the specific health problem of ADHD. Outcomes are expressed as impairment percentages (0-100), with higher numbers indicating greater impairment and less productivity.\n\nNegative change indicates improvement.",
            "timeFrame": "Baseline, Months 1, 2, 3, 6, 9, 12"
          },
          {
            "measure": "Percent impairment while working due to ADHD, as measured by WPAI+CIQ:ADHD",
            "description": "Work Productivity and Activity Impairment Questionnaire plus Classroom Impairment Questions: Specific Health Problem (WPAI+CIQ:SHP), Version 2.0 is a 10-item, validated self-report questionnaire which is based on an individual's absenteeism, presenteeism, work or classroom productivity loss, and activity impairment due to a specific disease/condition. This questionnaire has been adapted to the specific health problem of ADHD. Outcomes are expressed as impairment percentages (0-100), with higher numbers indicating greater impairment and less productivity.\n\nNegative change indicates improvement.",
            "timeFrame": "Baseline, Months 1, 2, 3, 6, 9, 12"
          },
          {
            "measure": "Percent overall work impairment due to ADHD, as measured by WPAI+CIQ:ADHD",
            "description": "Work Productivity and Activity Impairment Questionnaire plus Classroom Impairment Questions: Specific Health Problem (WPAI+CIQ:SHP), Version 2.0 is a 10-item, validated self-report questionnaire which is based on an individual's absenteeism, presenteeism, work or classroom productivity loss, and activity impairment due to a specific disease/condition. This questionnaire has been adapted to the specific health problem of ADHD. Outcomes are expressed as impairment percentages (0-100), with higher numbers indicating greater impairment and less productivity.\n\nNegative change indicates improvement.",
            "timeFrame": "Baseline, Months 1, 2, 3, 6, 9, 12"
          },
          {
            "measure": "Percent class time missed due to ADHD, as measured by WPAI+CIQ:ADHD",
            "description": "Work Productivity and Activity Impairment Questionnaire plus Classroom Impairment Questions: Specific Health Problem (WPAI+CIQ:SHP), Version 2.0 is a 10-item, validated self-report questionnaire which is based on an individual's absenteeism, presenteeism, work or classroom productivity loss, and activity impairment due to a specific disease/condition. This questionnaire has been adapted to the specific health problem of ADHD. Outcomes are expressed as impairment percentages (0-100), with higher numbers indicating greater impairment and less productivity.\n\nNegative change indicates improvement.",
            "timeFrame": "Baseline, Months 1, 2, 3, 6, 9, 12"
          },
          {
            "measure": "Percent overall classroom impairment due to ADHD, as measured by WPAI+CIQ:ADHD",
            "description": "Work Productivity and Activity Impairment Questionnaire plus Classroom Impairment Questions: Specific Health Problem (WPAI+CIQ:SHP), Version 2.0 is a 10-item, validated self-report questionnaire which is based on an individual's absenteeism, presenteeism, work or classroom productivity loss, and activity impairment due to a specific disease/condition. This questionnaire has been adapted to the specific health problem of ADHD. Outcomes are expressed as impairment percentages (0-100), with higher numbers indicating greater impairment and less productivity.\n\nNegative change indicates improvement.",
            "timeFrame": "Baseline, Months 1, 2, 3, 6, 9, 12"
          },
          {
            "measure": "Percent activity impairment due to ADHD, as measured by WPAI+CIQ:ADHD",
            "description": "Work Productivity and Activity Impairment Questionnaire plus Classroom Impairment Questions: Specific Health Problem (WPAI+CIQ:SHP), Version 2.0 is a 10-item, validated self-report questionnaire which is based on an individual's absenteeism, presenteeism, work or classroom productivity loss, and activity impairment due to a specific disease/condition. This questionnaire has been adapted to the specific health problem of ADHD. Outcomes are expressed as impairment percentages (0-100), with higher numbers indicating greater impairment and less productivity.\n\nNegative change indicates improvement.",
            "timeFrame": "Baseline, Months 1, 2, 3, 6, 9, 12"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* Has an active EndeavorOTC™subscription\n* Provide informed consent to participate in the registry\n\nExclusion Criteria:\n\n* N/A",
        "sex": "ALL",
        "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"],
        "studyPopulation": "EndeavorOTC users may enroll and participate in the product registry for the full year regardless of the length of their EndeavorOTC subscription.",
        "samplingMethod": "NON_PROBABILITY_SAMPLE"
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "Scott H Kollins, PhD",
            "affiliation": "Akili Interactive Labs, Inc.",
            "role": "PRINCIPAL_INVESTIGATOR"
          }
        ],
        "locations": [
          {
            "facility": "Akili Interactive Labs, Inc.",
            "city": "Boston",
            "state": "Massachusetts",
            "zip": "02110",
            "country": "United States",
            "geoPoint": { "lat": 42.35843, "lon": -71.05977 }
          }
        ]
      }
    },
    "derivedSection": { "miscInfoModule": { "versionHolder": "2025-05-07" } },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT05486312",
        "orgStudyIdInfo": { "id": "CT-155-C-002" },
        "organization": {
          "fullName": "Click Therapeutics, Inc.",
          "class": "INDUSTRY"
        },
        "briefTitle": "7-week Study With CT-155 in People With Schizophrenia",
        "officialTitle": "A Multi-center, Exploratory, Single-Arm, 7-week Study to Evaluate the Feasibility and Acceptability of Treatment With CT-155 in People With Schizophrenia"
      },
      "statusModule": {
        "statusVerifiedDate": "2023-09",
        "overallStatus": "COMPLETED",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2022-07-05", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2022-09-22",
          "type": "ACTUAL"
        },
        "completionDateStruct": { "date": "2022-12-12", "type": "ACTUAL" },
        "studyFirstSubmitDate": "2022-08-01",
        "studyFirstSubmitQcDate": "2022-08-01",
        "studyFirstPostDateStruct": { "date": "2022-08-03", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2023-09-28",
        "lastUpdatePostDateStruct": { "date": "2023-10-02", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": {
          "name": "Click Therapeutics, Inc.",
          "class": "INDUSTRY"
        }
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": true,
        "isUnapprovedDevice": true,
        "isUsExport": false
      },
      "descriptionModule": {
        "briefSummary": "CT-155 is a novel prescription digital therapeutic (PDT) to treat schizophrenia",
        "detailedDescription": "CT-155 is a novel prescription digital therapeutic (PDT) being developed by Click Therapeutics, Inc. (Click) and Boehringer Ingelheim (BI) using an interactive, software-based intervention to treat schizophrenia.\n\nThis is a multi-center, exploratory, single-arm study to evaluate the feasibility and acceptability of treatment with an abbreviated version of CT-155 in adults diagnosed with schizophrenia. Eligible participants must have a diagnosis of schizophrenia per the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5).\n\nParticipants that meet eligibility criteria will be enrolled in the study on Day 1. The study consists of an up to 7-day screening period, a 49-day engagement period, and an up to 7-day follow-up period."
      },
      "conditionsModule": {
        "conditions": ["Schizophrenia"],
        "keywords": [
          "Prescription digital therapeutic (PDT)",
          "Software-as-a Medical Device (SaMD)",
          "Smartphone app",
          "Schizophrenia"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "NA",
          "interventionModel": "SINGLE_GROUP",
          "interventionModelDescription": "This is a multi-center, exploratory, single-arm study to evaluate the overall effects of use of an abbreviated version of CT-155 in adults diagnosed with schizophrenia",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": { "masking": "NONE" }
        },
        "enrollmentInfo": { "count": 50, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "Single arm",
            "type": "EXPERIMENTAL",
            "description": "Single arm acceptability and feasibility of CT-155.",
            "interventionNames": ["Device: CT-155 smartphone app"]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "CT-155 smartphone app",
            "description": "The CT-155 study app is designed to provide treatment monitoring and educational components of a full treatment cycle with CT-155. This design allows inferences to be made about the usability and acceptability of CT-155. Eligible participants will be enrolled during an in-person clinic visit on Day 1. Participants will then be directed to access the study app and perform tasks each day for the 49-day engagement period.",
            "armGroupLabels": ["Single arm"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Feasibility and acceptability with the study app as measured by Mobile App Rating Scale (MARS) at week 7",
            "description": "Participants ratings of Study App quality and satisfaction as measured by the Mobile App Rating Scale (MARS) at Week 7\n\nThe MARS is a validated 23-items rated on a 5-point anchored scale 1 being the lowest and 5 the highest",
            "timeFrame": "MARS scale on Week 7 at the end of the treatment period"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Change in strength of digital working alliance from Week 3 to Week 7 as assessed by the Mobile Agnew Relationships Measure (mARM)",
            "description": "To explore the establishment of a digital working alliance as assessed by the change from Week 3 to Week 7 of the Mobile Agnew Relationships Measure. The Mobile Agnew Relationships Measures is on a 7-item scale that ranges from \"Strongly Disagree\" as scale 1 to \"Strongly Agree\" as scale 7.",
            "timeFrame": "Change from Week 3 to Week 7 of the Mobile Agnew Relationships Measure"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n1. Has outpatient treatment status of schizophrenia.\n2. Is on a stable dose of antipsychotic medication(s)\n3. Is the solo user of an iPhone with iPhone operating system (iOS)13 or greater capabilities or a smart phone with an Android operating system (OS) 9 or greater capabilities.\n4. Is the owner of, and has regular access to, an email address.\n5. Has regular access to the internet via cellular data plan and/or wifi.\n6. Willing and able to receive SMS text messages on their smartphone and email messages, and understand how to use the downloaded Study App.\n7. Has stable housing and has remained at the same residence for at least 12 weeks prior to screening, with no anticipated housing changes during the duration of the study\n\nExclusion Criteria:\n\n1. Is currently treated with more than two antipsychotic medications.\n2. Is currently treated with clozapine or haloperidol.\n3. Has active prominent positive symptoms to preclude effective engagement in treatment for negative symptoms.\n4. Is currently receiving or has received psychotherapy within 12 weeks prior to screening.\n5. Meets either the International Classification of Diseases (ICD-10) or DSM-5 criteria for diagnoses not under investigation.\n6. Has post-traumatic stress disorder (PTSD), bipolar disorder, major depressive disorder, developmental disorders, or any prominent disorder.\n7. Has substance or alcohol use disorder.\n8. Currently needs or will likely require prohibited concomitant medications.\n9. Is currently participating in another clinical study.\n10. Prior participation in the CT-155-C-001 clinical study.\n11. Has suicidal ideation or behavior.",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "maximumAge": "64 Years",
        "stdAges": ["ADULT"]
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "Shaheen Lakhan, MDPhD, FAAN",
            "affiliation": "Click Therapeutics",
            "role": "STUDY_CHAIR"
          }
        ],
        "locations": [
          {
            "facility": "CT-155 Study Center",
            "city": "Culver City",
            "state": "California",
            "zip": "90230",
            "country": "United States",
            "geoPoint": { "lat": 34.02112, "lon": -118.39647 }
          },
          {
            "facility": "CT-155 Study Center",
            "city": "Garden Grove",
            "state": "California",
            "zip": "92845",
            "country": "United States",
            "geoPoint": { "lat": 33.77391, "lon": -117.94145 }
          },
          {
            "facility": "CT-155 Study Center",
            "city": "La Habra",
            "state": "California",
            "zip": "90631",
            "country": "United States",
            "geoPoint": { "lat": 33.93196, "lon": -117.94617 }
          },
          {
            "facility": "CT-155 Study Center",
            "city": "San Bernardino",
            "state": "California",
            "zip": "92408",
            "country": "United States",
            "geoPoint": { "lat": 34.10834, "lon": -117.28977 }
          },
          {
            "facility": "CT-155 Study Center",
            "city": "Santa Ana",
            "state": "California",
            "zip": "92704",
            "country": "United States",
            "geoPoint": { "lat": 33.74557, "lon": -117.86783 }
          },
          {
            "facility": "CT-155 Study Center",
            "city": "Chicago",
            "state": "Illinois",
            "zip": "60611",
            "country": "United States",
            "geoPoint": { "lat": 41.85003, "lon": -87.65005 }
          },
          {
            "facility": "CT-155 Study Center",
            "city": "New York",
            "state": "New York",
            "zip": "10032",
            "country": "United States",
            "geoPoint": { "lat": 40.71427, "lon": -74.00597 }
          },
          {
            "facility": "CT-155 study Center",
            "city": "Staten Island",
            "state": "New York",
            "zip": "10314",
            "country": "United States",
            "geoPoint": { "lat": 40.56233, "lon": -74.13986 }
          },
          {
            "facility": "CT-155 Study Center",
            "city": "Beachwood",
            "state": "Ohio",
            "zip": "44122",
            "country": "United States",
            "geoPoint": { "lat": 41.4645, "lon": -81.50873 }
          },
          {
            "facility": "CT-155 Study Center",
            "city": "Oklahoma City",
            "state": "Oklahoma",
            "zip": "73112",
            "country": "United States",
            "geoPoint": { "lat": 35.46756, "lon": -97.51643 }
          }
        ]
      },
      "ipdSharingStatementModule": { "ipdSharing": "NO" }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [{ "id": "D012559", "term": "Schizophrenia" }],
        "ancestors": [
          {
            "id": "D019967",
            "term": "Schizophrenia Spectrum and Other Psychotic Disorders"
          },
          { "id": "D001523", "term": "Mental Disorders" }
        ],
        "browseLeaves": [
          {
            "id": "M15376",
            "name": "Schizophrenia",
            "asFound": "Schizophrenia",
            "relevance": "HIGH"
          },
          { "id": "M14473", "name": "Psychotic Disorders", "relevance": "LOW" },
          { "id": "M4815", "name": "Mental Disorders", "relevance": "LOW" },
          {
            "id": "M21838",
            "name": "Schizophrenia Spectrum and Other Psychotic Disorders",
            "relevance": "LOW"
          }
        ],
        "browseBranches": [
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" },
          { "abbrev": "All", "name": "All Conditions" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT06685900",
        "orgStudyIdInfo": { "id": "1-2024-0028" },
        "organization": { "fullName": "Yonsei University", "class": "OTHER" },
        "briefTitle": "Efficacy and Safety of Symptom Improvement by Digital Therapeutics to Manage Hypotension Symptoms",
        "officialTitle": "A Single-center, Randomized Controlled Pilot Trial to Evaluate Efficacy and Safety of Symptom Improvement by Digital Therapeutics to Manage Hypotension Symptoms"
      },
      "statusModule": {
        "statusVerifiedDate": "2024-11",
        "overallStatus": "NOT_YET_RECRUITING",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2024-11", "type": "ESTIMATED" },
        "primaryCompletionDateStruct": {
          "date": "2025-03-01",
          "type": "ESTIMATED"
        },
        "completionDateStruct": { "date": "2025-04-01", "type": "ESTIMATED" },
        "studyFirstSubmitDate": "2024-10-06",
        "studyFirstSubmitQcDate": "2024-11-11",
        "studyFirstPostDateStruct": { "date": "2024-11-13", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2024-11-11",
        "lastUpdatePostDateStruct": { "date": "2024-11-13", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": { "name": "Yonsei University", "class": "OTHER" }
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": false
      },
      "descriptionModule": {
        "briefSummary": "This clinical trial is an exploratory study aimed at assessing the efficacy and safety of a digital therapeutic for managing symptoms of hypotension, with the goal of providing evidence for the design of future confirmatory clinical research."
      },
      "conditionsModule": { "conditions": ["Hypotension"] },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "primaryPurpose": "DIAGNOSTIC",
          "maskingInfo": {
            "masking": "DOUBLE",
            "maskingDescription": "Participant and Sub-investigator",
            "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]
          }
        },
        "enrollmentInfo": { "count": 44, "type": "ESTIMATED" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "Early intervention group (EIG)",
            "type": "EXPERIMENTAL",
            "description": "the trial group that begins treatment in the 3-week of the total 15-week study period",
            "interventionNames": ["Device: digital therapeutics"]
          },
          {
            "label": "Late intervention group (LIG)",
            "type": "EXPERIMENTAL",
            "description": "the comparator group that begins treament in the 9-week of the total 15-week study period",
            "interventionNames": ["Device: digital therapeutics"]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "digital therapeutics",
            "description": "Early intervention group will undergo app usage training, disease education, blood pressure measurements, orthostatic blood pressure measurements, and postprandial blood pressure measurements up to the third week of participation. From the fourth week onward, for a duration of 12 weeks, non-pharmacological treatment education will be provided through a digital therapeutic, and blood pressure will be measured according to a specified schedule.",
            "armGroupLabels": ["Early intervention group (EIG)"]
          },
          {
            "type": "DEVICE",
            "name": "digital therapeutics",
            "description": "Late intervention group will undergo app usage training, disease education, blood pressure measurements, orthostatic blood pressure measurements, and postprandial blood pressure measurements up to the ninth week of participation. From the tenth week onward, for a duration of 6 weeks, non-pharmacological treatment education will be provided through a digital therapeutic, and blood pressure will be measured according to a specified schedule.",
            "armGroupLabels": ["Late intervention group (LIG)"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "The number of hypotension symptom events",
            "description": "The effectiveness of symptom improvement for hypotension was evaluated in the trial and control groups based on the frequency of hypotension symptoms over a 6-week period.",
            "timeFrame": "within the first 6weeks after intervention"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Number of symptoms related to hypotension",
            "description": "Comparison of the frequency of symptoms suspected to be caused by hypotension before and after the intervention",
            "timeFrame": "over 15weeks"
          },
          {
            "measure": "Number of falling accident",
            "description": "To investigate whether regularly measuring blood pressure can help prevent falls.",
            "timeFrame": "over 15weeks"
          },
          {
            "measure": "Details for disease diagnosis and concomitant medications",
            "description": "To idenfity the correlation between hypotension and other causes and symptoms",
            "timeFrame": "over 15weeks"
          },
          {
            "measure": "The frequency of use of digital therapeutics",
            "description": "To identify how many times participants use digital therapeutics to measure blood pressure.\n\nDisplay the frequency of data input through digital therapeutics as the mean or median.",
            "timeFrame": "at 15weeks"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n1. Adults aged 19 and older with symptoms suspected to be related to dizziness due to hypotension within the past year.\n2. Individuals who are able to walk and can participate in the study using a smartphone, or for whom cooperation from a guardian is available.\n\nExclusion Criteria:\n\n1. Individuals diagnosed with causes of dizziness other than hypotension, such as benign paroxysmal positional vertigo or stroke, within the past year.\n2. Severe anemia (history of Hb \\< 8.0 g/dL within the last 3 months).\n3. Individuals unable to use a smartphone (Android phone) or smartwatch.\n4. Individuals with a life expectancy of less than 1 year due to diseases such as malignant tumors.\n5. Individuals diagnosed with severe heart valve disease or severe heart failure with LVEF \\< 35% (based on the most recent examination).\n6. Recent rapid and unintended weight loss (5% or more, or 5 kg or more, within the last 6 months).",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "19 Years",
        "maximumAge": "99 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "centralContacts": [
          {
            "name": "Dong-Ho Shin",
            "role": "CONTACT",
            "phone": "+82222281979",
            "email": "dhshin@yuhs.ac"
          }
        ],
        "locations": [
          {
            "facility": "Yonsei university college of medicine",
            "city": "Seoul",
            "zip": "03722",
            "country": "Korea, Republic of",
            "contacts": [
              {
                "name": "Dong-Ho Shin",
                "role": "CONTACT",
                "phone": "+82222281979",
                "email": "dhshin@yuhs.ac"
              }
            ],
            "geoPoint": { "lat": 37.566, "lon": 126.9784 }
          }
        ]
      }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [{ "id": "D007022", "term": "Hypotension" }],
        "ancestors": [
          { "id": "D014652", "term": "Vascular Diseases" },
          { "id": "D002318", "term": "Cardiovascular Diseases" }
        ],
        "browseLeaves": [
          {
            "id": "M10072",
            "name": "Hypotension",
            "asFound": "Hypotension",
            "relevance": "HIGH"
          },
          { "id": "M17400", "name": "Vascular Diseases", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "BC14", "name": "Heart and Blood Diseases" },
          { "abbrev": "All", "name": "All Conditions" }
        ]
      },
      "interventionBrowseModule": {
        "meshes": [{ "id": "D003033", "term": "Coal Tar" }],
        "ancestors": [
          { "id": "D007641", "term": "Keratolytic Agents" },
          { "id": "D003879", "term": "Dermatologic Agents" }
        ],
        "browseLeaves": [
          {
            "id": "M6263",
            "name": "Coal Tar",
            "asFound": "Milligrams per kilogram",
            "relevance": "HIGH"
          },
          { "id": "M10667", "name": "Keratolytic Agents", "relevance": "LOW" },
          { "id": "M7074", "name": "Dermatologic Agents", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "Derm", "name": "Dermatologic Agents" },
          { "abbrev": "All", "name": "All Drugs and Chemicals" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT06339853",
        "orgStudyIdInfo": { "id": "1-2023-0023" },
        "organization": { "fullName": "Yonsei University", "class": "OTHER" },
        "briefTitle": "Study of Efficacy of Digital Cognitive Behavioral Therapy With Wearable Device for Insomnia",
        "officialTitle": "A Single-arm Clinical Trial to Evaluate the Safety and Efficacy of Digital Cognitive Behavioral Therapy With Wearable Device for Insomnia"
      },
      "statusModule": {
        "statusVerifiedDate": "2024-03",
        "overallStatus": "COMPLETED",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2023-09-07", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2024-02-29",
          "type": "ACTUAL"
        },
        "completionDateStruct": { "date": "2024-02-29", "type": "ACTUAL" },
        "studyFirstSubmitDate": "2024-03-17",
        "studyFirstSubmitQcDate": "2024-03-24",
        "studyFirstPostDateStruct": { "date": "2024-04-01", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2024-03-24",
        "lastUpdatePostDateStruct": { "date": "2024-04-01", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": { "name": "Yonsei University", "class": "OTHER" }
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": false
      },
      "descriptionModule": {
        "briefSummary": "The purpose of the study was to examine safety and efficacy of cognitive behavioral therapy (CBT)-based wearable integrated digital therapeutics for insomnia patients",
        "detailedDescription": "The investigators intend to conduct a single-arm clinical trial. Following voluntary consent during the screening visit, participants will undergo screening procedures. The screening process will proceed step by step, evaluating selection/exclusion criteria through assessments such as the Mini International Neuropsychiatric Interview (MINI), Columbia Suicide Severity Rating Scale (C-SSRS), etc. Participants who meet the selection criteria and do not meet the exclusion criteria will use the DTx app for 8 weeks. Surveys conducted after app installation (Insomnia Severity Index (ISI), Patient Health Questionnaire-9 (PHQ-9), Generalized Anxiety Disorder 7-item Scale (GAD-7), and a sleep environment questionnaire) will serve as the baseline.\n\nDuring the clinical trial period, sleep diaries and compliance (lesson completion rate) (applicable only to the experimental group) will be collected through the app. Sleep diaries will be used to evaluate sleep metrics such as sleep efficiency (SE), sleep onset latency (SOL), wake after sleep onset (WASO), etc.\n\nFor the experimental group, assessments as per the protocol will be conducted at baseline (Visit 1), and safety (adverse events) evaluation and termination of app usage will occur at 9 weeks (Visit 2)."
      },
      "conditionsModule": { "conditions": ["Insomnia"] },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "NA",
          "interventionModel": "SINGLE_GROUP",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": { "masking": "NONE" }
        },
        "enrollmentInfo": { "count": 30, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "WELT-IP",
            "type": "EXPERIMENTAL",
            "description": "Eligible subjects were able to access WELT-IP (an investigational digital therapeutic) on a mobile device (iOS and Android) as scheduled to receive cognitive behavioral therapy for insomnia (CBT-I). To collect sleep and environmental data, participants will wear the wearable devices, either (1) Apple Watch (Apple Watch Series 8 41mm (GPS)) or Galaxy Watch 5 40mm (Model: SM-R900NZAAKOO), and (2) Oura Ring (Model: Heritage), during the WELT-IP treatment period.",
            "interventionNames": [
              "Device: WELT-IP with wearable devices (Apple/galaxy watch. Oura ring)"
            ]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "WELT-IP with wearable devices (Apple/galaxy watch. Oura ring)",
            "description": "WELT-IP (an investigational digital therapeutic) is an CBT-I based intervention designed to treat insomnia, conducted in 6 sessions. It is a comprehensive program delivering sleep restriction, stimulation control, muscle relaxation, cognitive treatment, and sleep hygiene education. Main features are sleep diary, sleep reports, daily lessons of CBT-I, muscle relaxation techniques, and cognitive intervention through chatbot. By using WELT-IP simultaneously with wearing an Apple Watch/Galaxy Watch and Oura Ring, sleep and environmental data can be collected.",
            "armGroupLabels": ["WELT-IP"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Change from baseline to week 9 (post-treatment) of ISI",
            "description": "Change from baseline to week 9 (post-treatment) of ISI. ISI has 7 questions. Total score ranges from 0 to 28, where higher scores indicate more acute symptoms of insomnia.",
            "timeFrame": "9 weeks"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Secondary Outcome - Changes from baseline to week 9 of SE",
            "description": "Change from baseline to week 9 (post-treatment) of SE. Sleep efficiency is calculated as percentage of total sleep time/time in bed.",
            "timeFrame": "9 weeks"
          },
          {
            "measure": "Changes from baseline to week 9 of SOL.",
            "description": "Change from baseline to week 9 (post-treatment) of SOL. Sleep onset latency is evaluated as the time it takes a person to fall asleep after going to bed.",
            "timeFrame": "9 weeks"
          },
          {
            "measure": "Changes from baseline to week 9 of WASO.",
            "description": "Change from baseline to week 9 (post-treatment) of WASO. WASO is calculated as the total number of minutes that a person is awake after initially falling asleep.",
            "timeFrame": "9 weeks"
          },
          {
            "measure": "Changes from baseline to week 9 of PHQ-9.",
            "description": "Change from baseline to week 9 (post-treatment) of PHQ-9. PHQ-9 has nine questions. Total score ranges from 0 to 27, where higher scores indicate more acute symptoms of depression.",
            "timeFrame": "9 weeks"
          },
          {
            "measure": "Changes from baseline to week 9 of GAD-7.",
            "description": "Change from baseline to week 9 (post-treatment) of GAD-7. GAD-7 has seven questions. Total score ranges from 0 to 21, where higher scores indicate more acute symptoms of anxiety.",
            "timeFrame": "9 weeks"
          },
          {
            "measure": "Changes from baseline to week 9 of compliance.",
            "description": "Compliance (completion rate or lessons) Compliance is evaluated as completion rate of lessons.",
            "timeFrame": "9 weeks"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n1. Individuals aged 19 to 65 years old\n2. DSM-5 insomnia disorder patient\n3. ISI ≥11\n4. Capable of using mobile device and application\n\nExclusion Criteria:\n\n1. currently on non-pharmacological treatment for insomnia (ex. CBT-I, light therapy, oriental therapy for insomnia)\n2. sleep disorders diagnosis other than insomnia (ex. Obstructive sleep apnea, sleep behavior problem, restless leg syndrome)\n3. progressive and active medical conditions\n4. received continuous psychotherapy such as CBT, motivational enhancement therapy, psychotherapy, and psychoanalysis in the past 3 months\n5. major psychiatric illness as assessed through MINI\n6. suicide risk as assessed through C-SSRS\n7. having occupational risk due to sleep restriction\n8. shift workers\n9. PHQ-9 of 20 or above\n10. Individuals who have actually slept less than an average of 5 hours per night over the past month\n11. Pregnant women or individuals planning pregnancy during the clinical trial period",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "19 Years",
        "maximumAge": "65 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "facility": "Department of Psychiatry, Severance Hospital",
            "city": "Seoul,",
            "zip": "120-752",
            "country": "Korea, Republic of",
            "geoPoint": { "lat": 37.566, "lon": 126.9784 }
          }
        ]
      },
      "ipdSharingStatementModule": { "ipdSharing": "NO" }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [
          {
            "id": "D007319",
            "term": "Sleep Initiation and Maintenance Disorders"
          }
        ],
        "ancestors": [
          { "id": "D020919", "term": "Sleep Disorders, Intrinsic" },
          { "id": "D020920", "term": "Dyssomnias" },
          { "id": "D012893", "term": "Sleep Wake Disorders" },
          { "id": "D009422", "term": "Nervous System Diseases" },
          { "id": "D001523", "term": "Mental Disorders" }
        ],
        "browseLeaves": [
          {
            "id": "M10356",
            "name": "Sleep Initiation and Maintenance Disorders",
            "asFound": "Insomnia",
            "relevance": "HIGH"
          },
          { "id": "M22242", "name": "Parasomnias", "relevance": "LOW" },
          {
            "id": "M22654",
            "name": "Sleep Disorders, Intrinsic",
            "relevance": "LOW"
          },
          { "id": "M22655", "name": "Dyssomnias", "relevance": "LOW" },
          {
            "id": "M15696",
            "name": "Sleep Wake Disorders",
            "relevance": "LOW"
          },
          { "id": "M14473", "name": "Psychotic Disorders", "relevance": "LOW" },
          { "id": "M4815", "name": "Mental Disorders", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "BC10", "name": "Nervous System Diseases" },
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" },
          { "abbrev": "All", "name": "All Conditions" },
          { "abbrev": "BC23", "name": "Symptoms and General Pathology" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT05365607",
        "orgStudyIdInfo": { "id": "21-5027" },
        "secondaryIdInfos": [
          {
            "id": "R21AG075544",
            "type": "NIH",
            "link": "https://reporter.nih.gov/quickSearch/R21AG075544"
          }
        ],
        "organization": {
          "fullName": "University of Colorado, Denver",
          "class": "OTHER"
        },
        "briefTitle": "NightWare and Cardiovascular Health in Adults With PTSD",
        "officialTitle": "NightWare Therapeutic Platform for Improving Cardiovascular Health in Adults With Nightmares Associated With PTSD"
      },
      "statusModule": {
        "statusVerifiedDate": "2024-10",
        "overallStatus": "COMPLETED",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2022-06-24", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2024-08-15",
          "type": "ACTUAL"
        },
        "completionDateStruct": { "date": "2024-08-18", "type": "ACTUAL" },
        "studyFirstSubmitDate": "2022-05-02",
        "studyFirstSubmitQcDate": "2022-05-04",
        "studyFirstPostDateStruct": { "date": "2022-05-09", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2024-10-07",
        "lastUpdatePostDateStruct": { "date": "2024-10-08", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": {
          "name": "University of Colorado, Denver",
          "class": "OTHER"
        },
        "collaborators": [
          { "name": "National Institute on Aging (NIA)", "class": "NIH" }
        ]
      },
      "oversightModule": {
        "oversightHasDmc": true,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": true,
        "isUsExport": false
      },
      "descriptionModule": {
        "briefSummary": "The purpose of this study is to determine whether NightWare therapeutic intervention improves biomarkers of vascular aging and autonomic function in adults with nightmares related to PTSD.",
        "detailedDescription": "Posttraumatic stress disorder (PTSD) is linked to accelerated aging and is associated with increased risk of early-onset cardiovascular disease (CVD) in both men and women. The pathophysiological link between PTSD and CVD is complex and multi-factorial that likely involves premature vascular aging (i.e., large elastic arterial stiffening and vascular endothelial dysfunction) and autonomic dysfunction (e.g., reduced cardiovagal baroreflex sensitivity \\[cBRS\\] and heart rate variability \\[HRV\\]), along with other mechanisms. Vascular aging and autonomic dysfunction are key antecedents in the development of CVD and individuals with PTSD have greater arterial stiffening, endothelial dysfunction and reductions in cBRS and HRV compared to those without PTSD. The mechanisms by which PTSD contributes to greater vascular and autonomic dysfunction are not completely understood. Sleep is important for cellular and tissue repair, free radical detoxification and reducing oxidative stress and inflammation. Sleep disturbance is a hallmark symptom of PTSD and is associated with biomarkers of vascular aging, autonomic dysfunction and increased risk of CVD. Nightmares, a central feature of PTSD associated-sleep disturbance, are a debilitating symptom that can lead to insomnia or sleep deprivation, daytime sleepiness or fatigue, mood disturbances, cognitive impairments, behavioral problems, or other sequela, that ultimately causes clinically significant distress and impairment in social, occupational and physiological function, as well as increased CVD risk. As such, therapeutic strategies and interventions aimed at reducing nightmare-associated sleep disturbances in individuals with PTSD are clinically important for improving sleep quality, cardiovascular health and risk for future age-associated CVD.\n\nVarious psychotherapeutic (e.g., imagery rehearsal therapy \\[IRT\\]) and pharmacological (e.g., prazosin) interventions are available for treatment of nightmares associated with PTSD. However, the evidence for their efficacy for addressing sleep disturbances is inconsistent, particularly with pharmaceuticals, and implementation barriers and poor adherence exist with psychotherapy. As such, novel alternative approaches, including the use of digital medicine such as app-based and digital platforms are being developed to improve treatment delivery. NightWare™ digital therapeutic system is one such novel platform that was recently granted Breakthrough Device designation by the FDA for the treatment of nightmares in adults with PTSD. NightWare uses a proprietary application on the Apple Watch® to collect biometric data (i.e., heart rate \\[HR\\] and body movement) to learn sleep patterns to create a stress Index. When an individual exceeds this index due to entering a nightmare, NightWare intervenes by sending vibrotactile feedback to the Apple Watch, arousing the individual and interrupting the nightmare without waking or disrupting sleep. Through machine learning, NightWare continually refines its model and knowledge of the person's response, consequently leading to fewer nightmare associated awakenings. In unpublished preliminary studies, NightWare was shown to be safe (no change in suicide risk or daytime sleepiness) and a tendency to have greater improvement in objective measures of sleep quality (i.e., Pittsburgh Sleep Quality Index \\[PSQI\\] and amendment for PTSD \\[PSQI-A\\]) compared to sham (NightWare but intervention disabled, i.e., no vibration). Whether NightWare improves cardiovascular health in adults with PTSD-related nightmares has yet to be studied.\n\nAccordingly, the investigators are proposing a randomized, double-blind, placebo (i.e., sham intervention) controlled parallel pilot study that will provide the first clinical evidence for the efficacy of the NightWare digital therapeutic system to improve cardiovascular health outcomes in adults with PTSD-related nightmares."
      },
      "conditionsModule": {
        "conditions": [
          "Posttraumatic Stress Disorder",
          "Cardiovascular Diseases",
          "Autonomic Dysfunction",
          "Vascular Stiffness",
          "Nightmare",
          "Endothelial Dysfunction"
        ],
        "keywords": [
          "sleep",
          "oxidative stress",
          "aging",
          "inflammation",
          "sex/gender"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "interventionModelDescription": "Randomized, double-blind, placebo (i.e., sham intervention) controlled parallel pilot study",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": {
            "masking": "QUADRUPLE",
            "whoMasked": [
              "PARTICIPANT",
              "CARE_PROVIDER",
              "INVESTIGATOR",
              "OUTCOMES_ASSESSOR"
            ]
          }
        },
        "enrollmentInfo": { "count": 40, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "NightWare",
            "type": "EXPERIMENTAL",
            "description": "In individuals randomized to the active condition, when the stress index is reached during sleep, NightWare will intervene with varying degrees of vibratory stimulation to the watch over a variable length of time to arouse the person out of the nightmare without awaking.",
            "interventionNames": ["Device: NightWare"]
          },
          {
            "label": "Sham NightWare",
            "type": "SHAM_COMPARATOR",
            "description": "In individuals randomized to the sham condition, the NightWare intervention will not be enabled.",
            "interventionNames": ["Device: Sham NightWare"]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "NightWare",
            "description": "A wearable digital therapeutic platform consisting of an Apple Watch and iPhone pre-provisioned with Nightware intervention app that will deliver a mild vibration to the watch after detecting individual having a nightmare based on Nightware proprietary algorithm, arousing the individual and disrupting nightmare without awakening.",
            "armGroupLabels": ["NightWare"]
          },
          {
            "type": "DEVICE",
            "name": "Sham NightWare",
            "description": "NightWare device will not deliver an intervention (i.e., no vibration)",
            "armGroupLabels": ["Sham NightWare"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Change in large elastic artery stiffness -carotid artery",
            "description": "Carotid artery compliance using carotid artery ultrasound",
            "timeFrame": "Measured before and after 6 weeks of NightWare and sham conditions"
          },
          {
            "measure": "Change in endothelial function",
            "description": "Brachial artery flow-mediated dilation (FMD) using ultrasound",
            "timeFrame": "Measured before and after 6 weeks of NightWare and sham conditions"
          },
          {
            "measure": "Change in 1utonomic function - BRS",
            "description": "Cardiovagal baroreflex sensitivity (cBRS)",
            "timeFrame": "Measured before and after 6 weeks of NightWare and sham conditions"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Change in large elastic artery stiffness",
            "description": "Carotid-femoral pulse wave velocity (PWV)",
            "timeFrame": "Measured before and after 6 weeks of NightWare and sham conditions"
          },
          {
            "measure": "Change in autonomic function - HRV",
            "description": "Heart rate variability",
            "timeFrame": "Measured before and after 6 weeks of NightWare and sham conditions"
          }
        ],
        "otherOutcomes": [
          {
            "measure": "Change in PSQI",
            "description": "sleep questionnaire",
            "timeFrame": "Measured before and after 6 weeks of NightWare and sham conditions"
          },
          {
            "measure": "Change in PSQI-A",
            "description": "sleep questionnaire",
            "timeFrame": "Measured before and after 6 weeks of NightWare and sham conditions"
          },
          {
            "measure": "Change in Epworth sleepiness scale (ESS)",
            "description": "sleep questionnaire",
            "timeFrame": "Measured before and after 6 weeks of NightWare and sham conditions"
          },
          {
            "measure": "Change in CESD",
            "description": "Depression questionnaire",
            "timeFrame": "Measured before and after 6 weeks of NightWare and sham conditions"
          },
          {
            "measure": "Change in SF-36",
            "description": "Perceived psychosocial and health functioning questionnaire",
            "timeFrame": "Measured before and after 6 weeks of NightWare and sham conditions"
          },
          {
            "measure": "Change in PCL-5",
            "description": "Presence and severity of PTSD symptoms questionnaire",
            "timeFrame": "Measured before and after 6 weeks of NightWare and sham conditions"
          },
          {
            "measure": "Change in Nightmare disorder index",
            "description": "NDI questionnaire",
            "timeFrame": "Measured before and after 6 weeks of NightWare and sham conditions"
          },
          {
            "measure": "Change in CSSR-S",
            "description": "Suicide risk assessment",
            "timeFrame": "Measured before and after 6 weeks of NightWare and sham conditions"
          },
          {
            "measure": "Change in Norepinephrine",
            "description": "Marker of sympathetic activity",
            "timeFrame": "Measured before and after 6 weeks of NightWare and sham conditions"
          },
          {
            "measure": "Change in Oxidized LDL",
            "description": "Marker of oxidative stress",
            "timeFrame": "Measured before and after 6 weeks of NightWare and sham conditions"
          },
          {
            "measure": "Change in Total antioxidant status",
            "description": "Marker of oxidative stress",
            "timeFrame": "Measured before and after 6 weeks of NightWare and sham conditions"
          },
          {
            "measure": "Change in Interleukin-6",
            "description": "Marker of inflammation",
            "timeFrame": "Measured before and after 6 weeks of NightWare and sham conditions"
          },
          {
            "measure": "Change in C-Reactive Protein",
            "description": "Marker of inflammation",
            "timeFrame": "Measured before and after 6 weeks of NightWare and sham conditions"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n1. Diagnosis of PTSD via American Psychiatric Association PTSD diagnostic criteria in the fifth edition of its Diagnostic and Statistical Manual of Mental Disorders (DSM-5).\n2. Self-report having repetitive nightmares contributing to disrupted sleep\n3. age \\>22 years (rationale is because the device has only been used in adults in 22 years and older);\n4. resting blood pressure (BP, \\<160/100 mmHg);\n5. fasted glucose \\<126 mg/d;\n6. non-smokers;\n7. no use of vitamin supplements or anti-inflammatory medications, or willing to stop 1 month prior to the vascular visit;\n8. Pittsburgh Sleep Quality Index (PSQI) score 6 or higher;\n9. Epworth Sleepiness Scale (ESS): Question #8 score above \"0\" will prompt an additional question: Does individual drive (\"get behind the wheel\") when they are drowsy? The answer must be \"No\" to be enrolled in the study due to safety concerns;\n10. Wireless Internet and two power outlets where they sleep;\n11. Willingness not to use any other application which collects heart rate data on the phone and watch that is used for NightWare.\n\nExclusion Criteria:\n\n1. uncontrolled hypertension;\n2. current or preexisting CVD or cancers (with the exception of past skin cancers) or active infection;\n3. diabetes;\n4. thyroid dysfunction, defined as an ultrasensitive TSH \\<0.5 or \\>5.0 mU/L; volunteers with abnormal TSH values will be re-considered for participation in the study after follow-up evaluation by the PCP with initiation or adjustment of thyroid hormone replacement; or other problems that would interfere with participation in the study;\n5. pregnancy or currently breast feeding;\n6. current use (or within previous 6 months) of hormone therapy in postmenopausal women;\n7. current substance (including marijuana) or alcohol use disorder (past 12 months) per the SCID-5 (see methods of Research Strategy). Adults with past substance or alcohol use disorders will be allowed to participate.\n8. Prazosin use; however, participant may be included if tapered by prescribing provider. Taper must be completed and individual must be off prazosin for 2 days prior to enrollment;\n9. Participants will be excluded if they report elevated acute risk for suicidal self-directed violence warranting immediate intervention (e.g., suicidal ideation with intent, evaluated by the Columbia-Suicide Severity Rating Scale \\[C-SSRS\\]).\n10. Current use of varenicline, beta-blockers (unless ophthalmic solutions), or non-dihydropyridines;\n11. Shift workers (due to circadian rhythm disruption);\n12. Moderate or Severe obstructive sleep apnea (either diagnosed or determined during screening with the WatchPat \\[AHI≥15\\];\n13. Diagnosis of narcolepsy;\n14. Known sleepwalking;\n\n16) Acting out of dreams prior to PTSD trauma; 17) Diagnosis or suspicion of dementia",
        "healthyVolunteers": true,
        "sex": "ALL",
        "minimumAge": "22 Years",
        "maximumAge": "99 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "Kerrie Moreau, PhD",
            "affiliation": "University of Colorado, Denver",
            "role": "PRINCIPAL_INVESTIGATOR"
          }
        ],
        "locations": [
          {
            "facility": "University of Colorado Anschutz Medical Campus",
            "city": "Aurora",
            "state": "Colorado",
            "zip": "80045",
            "country": "United States",
            "geoPoint": { "lat": 39.72943, "lon": -104.83192 }
          },
          {
            "facility": "University of Colorado CCTSI CTRC",
            "city": "Denver",
            "state": "Colorado",
            "zip": "80045",
            "country": "United States",
            "geoPoint": { "lat": 39.73915, "lon": -104.9847 }
          }
        ]
      },
      "ipdSharingStatementModule": { "ipdSharing": "NO" }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [
          { "id": "D001342", "term": "Autonomic Nervous System Diseases" },
          { "id": "D054969", "term": "Primary Dysautonomias" },
          { "id": "D002318", "term": "Cardiovascular Diseases" },
          { "id": "D013313", "term": "Stress Disorders, Post-Traumatic" }
        ],
        "ancestors": [
          { "id": "D040921", "term": "Stress Disorders, Traumatic" },
          {
            "id": "D000068099",
            "term": "Trauma and Stressor Related Disorders"
          },
          { "id": "D001523", "term": "Mental Disorders" },
          { "id": "D009422", "term": "Nervous System Diseases" }
        ],
        "browseLeaves": [
          { "id": "M10293", "name": "Inflammation", "relevance": "LOW" },
          {
            "id": "M16103",
            "name": "Stress Disorders, Post-Traumatic",
            "asFound": "Posttraumatic Stress Disorder",
            "relevance": "HIGH"
          },
          {
            "id": "M24916",
            "name": "Stress Disorders, Traumatic",
            "relevance": "LOW"
          },
          {
            "id": "M4643",
            "name": "Autonomic Nervous System Diseases",
            "asFound": "Autonomic Dysfunction",
            "relevance": "HIGH"
          },
          {
            "id": "M27979",
            "name": "Primary Dysautonomias",
            "asFound": "Autonomic Dysfunction",
            "relevance": "HIGH"
          },
          { "id": "M17685", "name": "Wounds and Injuries", "relevance": "LOW" },
          {
            "id": "M222",
            "name": "Trauma and Stressor Related Disorders",
            "relevance": "LOW"
          },
          { "id": "M14473", "name": "Psychotic Disorders", "relevance": "LOW" },
          { "id": "M4815", "name": "Mental Disorders", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "BC23", "name": "Symptoms and General Pathology" },
          { "abbrev": "All", "name": "All Conditions" },
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" },
          { "abbrev": "BC10", "name": "Nervous System Diseases" },
          { "abbrev": "BC26", "name": "Wounds and Injuries" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT06889259",
        "orgStudyIdInfo": { "id": "2023GR0400" },
        "organization": {
          "fullName": "Korea University Guro Hospital",
          "class": "OTHER"
        },
        "briefTitle": "Efficacy and Safety of CBT on Tinnitus",
        "officialTitle": "Efficacy and Safety of Cognitive Behavioral Therapy, Tones Stimulator in Patients With Subjective Tinnitus: Prospective, Multi-center, Randomized, Single Blind (Subject), Parallel, Superiority, Confirmatory Trial"
      },
      "statusModule": {
        "statusVerifiedDate": "2025-03",
        "overallStatus": "COMPLETED",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2024-01-01", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2024-10-31",
          "type": "ACTUAL"
        },
        "completionDateStruct": { "date": "2024-12-31", "type": "ACTUAL" },
        "studyFirstSubmitDate": "2025-03-03",
        "studyFirstSubmitQcDate": "2025-03-16",
        "studyFirstPostDateStruct": { "date": "2025-03-21", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2025-03-16",
        "lastUpdatePostDateStruct": { "date": "2025-03-21", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": {
          "name": "Korea University Guro Hospital",
          "class": "OTHER"
        }
      },
      "oversightModule": {
        "oversightHasDmc": true,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": false
      },
      "descriptionModule": {
        "briefSummary": "Tinnitus, the perception of sound without external stimuli, affects 14% of the global population, posing a significant public health concern. This predominantly subjective condition often leads to psychological and physical distress, including anxiety, depression, and insomnia. As tinnitus prevalence rises due to aging populations and increased noise exposure, the need for effective treatments grows urgent.\n\nCurrent approaches include pharmacological interventions, sound therapy, and cognitive behavioral therapy (CBT), with CBT recognized as most effective for addressing psychological distress. However, traditional therapies face accessibility barriers such as frequent in-person sessions and high costs.\n\nDigital therapeutics, particularly mobile applications, offer promising solutions by providing scalable, accessible interventions. These allow patients to engage in therapy conveniently, accessing real-time, personalized content. Despite advancements, research on digital therapeutics combining CBT and sound therapy for tinnitus remains limited.\n\nThis study aims to address this gap by evaluating the clinical efficacy of a mobile application delivering personalized CBT and sound stimulation compared to conventional CBT, potentially contributing to more accessible and effective tinnitus treatment options.",
        "detailedDescription": "Tinnitus, characterized by the perception of sound without external stimuli, affects approximately 14% of the global population, posing a significant public health concern. This predominantly subjective condition often leads to psychological and physical distress, including anxiety, depression, and insomnia. Current approaches to managing tinnitus include pharmacological interventions, sound therapy, and cognitive behavioral therapy (CBT). Among these, CBT is recognized as one of the most effective methods for addressing the psychological distress associated with tinnitus. However, traditional CBT often faces accessibility barriers, such as the need for frequent in-person sessions and high costs. This limits its reach and effectiveness for many patients.Digital therapeutics, particularly mobile applications, offer promising solutions by providing scalable and accessible interventions. These platforms allow patients to engage in therapy conveniently, accessing real-time, personalized content. Despite advancements in digital therapeutics, research on combining CBT and sound therapy for tinnitus remains limited. This gap in research highlights the need for innovative, accessible treatments that can be tailored to individual patient needs.\n\nThis study aims to address this gap by evaluating the clinical efficacy of a mobile application that delivers personalized CBT and sound stimulation. The application, designed to provide tailored interventions, will be compared to conventional CBT methods. By leveraging the strengths of both CBT and sound therapy, this study seeks to contribute to the development of more accessible and effective tinnitus treatment options.\n\nThe study will employ a prospective, multicenter, randomized, single-blind (participant), parallel-design, superiority, confirmatory trial to assess the efficacy and safety of the mobile application. Participants will be randomly assigned to either the intervention group using the mobile application or the control group receiving conventional CBT educational materials. The primary outcome will be the change in Tinnitus Handicap Inventory (THI) scores from baseline to 6 weeks, with secondary outcomes including changes in THI subscales, Tinnitus Functional Index (TFI), Visual Analog Scale (VAS) for negative emotions and tinnitus discomfort, Beck Depression Inventory (BDI), and Beck Anxiety Inventory (BAI).\n\nThe study's design and methodology are crucial for evaluating the effectiveness of the mobile application. By using a randomized controlled trial design, the study ensures that any observed effects can be attributed to the intervention rather than external factors. The use of standardized assessment tools like THI and TFI will provide a comprehensive understanding of the application's impact on tinnitus-related distress.\n\nFurthermore, the study will assess the safety and tolerability of the mobile application, monitoring for any adverse events or side effects. This is essential for ensuring that the treatment is not only effective but also safe for widespread use."
      },
      "conditionsModule": { "conditions": ["Tinnitus"] },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "interventionModelDescription": "Prospective, Multi-center, Randomized, single blind (subject), Parallel, Superiority, Confirmatory Trial",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": {
            "masking": "DOUBLE",
            "whoMasked": ["INVESTIGATOR", "OUTCOMES_ASSESSOR"]
          }
        },
        "enrollmentInfo": { "count": 100, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "CBT based digital therapeutics",
            "type": "ACTIVE_COMPARATOR",
            "description": "CBT using digital therapeutics",
            "interventionNames": ["Behavioral: CBT based digital therapeutics"]
          },
          {
            "label": "Conventional CBT",
            "type": "SHAM_COMPARATOR",
            "description": "Conventional CBT",
            "interventionNames": ["Behavioral: Conventional CBT"]
          }
        ],
        "interventions": [
          {
            "type": "BEHAVIORAL",
            "name": "CBT based digital therapeutics",
            "description": "The mobile-based digital therapeutic intervention integrated video education, thought record sheets, and sound therapy. This comprehensive treatment was administered five times weekly. The program consisted of a total of 30 sessions.",
            "armGroupLabels": ["CBT based digital therapeutics"]
          },
          {
            "type": "BEHAVIORAL",
            "name": "Conventional CBT",
            "description": "The cognitive behavioral therapy program for tinnitus, based on a paper manual, was administered five times per week. The treatment regimen consisted of a total of 30 sessions,.",
            "armGroupLabels": ["Conventional CBT"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Tinnitus handicap inventory",
            "description": "The Tinnitus Handicap Inventory is a widely used 25-item self-report questionnaire designed to assess the impact of tinnitus on an individual's daily life. It evaluates functional, emotional, and catastrophic effects of tinnitus, with scores ranging from 0 to 100. Higher score means worse outcome。",
            "timeFrame": "Baseline, 4weeks, 5weeks 6weeks"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* Subjective tinnitus more than 3mo\n* age over 19\n* Pure tone audiometry \\< 60 decibel\n* Tinnitus handicap inventory score \\> 18\n\nExclusion Criteria:\n\n* Objective tinnitus\n* Otitis, labyrinthitis\n* Depression, Anxiety, Insomnia or other psychiatric disorder\n* Pregnancy",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "19 Years",
        "maximumAge": "75 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "Jae-Jun Song",
            "affiliation": "Korea University Guro Hospital",
            "role": "STUDY_DIRECTOR"
          }
        ],
        "locations": [
          {
            "facility": "Korea University Guro Hospital",
            "city": "Seoul",
            "zip": "08308",
            "country": "Korea, Republic of",
            "geoPoint": { "lat": 37.566, "lon": 126.9784 }
          }
        ]
      },
      "ipdSharingStatementModule": { "ipdSharing": "NO" }
    },
    "documentSection": {
      "largeDocumentModule": {
        "largeDocs": [
          {
            "typeAbbrev": "Prot_SAP",
            "hasProtocol": true,
            "hasSap": true,
            "hasIcf": false,
            "label": "Study Protocol and Statistical Analysis Plan",
            "date": "2023-07-20",
            "uploadDate": "2025-03-16T04:49",
            "filename": "Prot_SAP_000.pdf",
            "size": 64005
          },
          {
            "typeAbbrev": "ICF",
            "hasProtocol": false,
            "hasSap": false,
            "hasIcf": true,
            "label": "Informed Consent Form",
            "date": "2023-07-20",
            "uploadDate": "2025-03-16T04:28",
            "filename": "ICF_001.pdf",
            "size": 144057
          }
        ]
      }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [{ "id": "D014012", "term": "Tinnitus" }],
        "ancestors": [
          { "id": "D006311", "term": "Hearing Disorders" },
          { "id": "D004427", "term": "Ear Diseases" },
          { "id": "D010038", "term": "Otorhinolaryngologic Diseases" },
          { "id": "D012678", "term": "Sensation Disorders" },
          { "id": "D009461", "term": "Neurologic Manifestations" },
          { "id": "D009422", "term": "Nervous System Diseases" }
        ],
        "browseLeaves": [
          {
            "id": "M16769",
            "name": "Tinnitus",
            "asFound": "Tinnitus",
            "relevance": "HIGH"
          },
          { "id": "M9400", "name": "Hearing Disorders", "relevance": "LOW" },
          { "id": "M7601", "name": "Ear Diseases", "relevance": "LOW" },
          {
            "id": "M12961",
            "name": "Otorhinolaryngologic Diseases",
            "relevance": "LOW"
          },
          { "id": "M15490", "name": "Sensation Disorders", "relevance": "LOW" },
          {
            "id": "M12404",
            "name": "Neurologic Manifestations",
            "relevance": "LOW"
          }
        ],
        "browseBranches": [
          { "abbrev": "BC09", "name": "Ear, Nose, and Throat Diseases" },
          { "abbrev": "BC10", "name": "Nervous System Diseases" },
          { "abbrev": "BC23", "name": "Symptoms and General Pathology" },
          { "abbrev": "All", "name": "All Conditions" }
        ]
      },
      "interventionBrowseModule": {
        "meshes": [{ "id": "D003033", "term": "Coal Tar" }],
        "ancestors": [
          { "id": "D007641", "term": "Keratolytic Agents" },
          { "id": "D003879", "term": "Dermatologic Agents" }
        ],
        "browseLeaves": [
          {
            "id": "M6263",
            "name": "Coal Tar",
            "asFound": "Milligrams per kilogram",
            "relevance": "HIGH"
          },
          { "id": "M10667", "name": "Keratolytic Agents", "relevance": "LOW" },
          { "id": "M7074", "name": "Dermatologic Agents", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "Derm", "name": "Dermatologic Agents" },
          { "abbrev": "All", "name": "All Drugs and Chemicals" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT04581499",
        "orgStudyIdInfo": { "id": "DCH002" },
        "secondaryIdInfos": [
          {
            "id": "2R44AA026234-02",
            "type": "NIH",
            "link": "https://reporter.nih.gov/quickSearch/2R44AA026234-02"
          },
          {
            "id": "5R44AA026234-03",
            "type": "NIH",
            "link": "https://reporter.nih.gov/quickSearch/5R44AA026234-03"
          }
        ],
        "organization": {
          "fullName": "DynamiCare Health",
          "class": "INDUSTRY"
        },
        "briefTitle": "Tech-Enabled CM for AUD at Scale",
        "officialTitle": "Applying Technology-Enabled Contingency Management for Alcohol Use Disorder at Scale"
      },
      "statusModule": {
        "statusVerifiedDate": "2023-06",
        "overallStatus": "ACTIVE_NOT_RECRUITING",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2021-01-01", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2024-04",
          "type": "ESTIMATED"
        },
        "completionDateStruct": { "date": "2024-04", "type": "ESTIMATED" },
        "studyFirstSubmitDate": "2020-09-15",
        "studyFirstSubmitQcDate": "2020-10-05",
        "studyFirstPostDateStruct": { "date": "2020-10-09", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2023-06-26",
        "lastUpdatePostDateStruct": { "date": "2023-06-28", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": { "name": "DynamiCare Health", "class": "INDUSTRY" },
        "collaborators": [
          { "name": "RAND", "class": "OTHER" },
          {
            "name": "National Institute on Alcohol Abuse and Alcoholism (NIAAA)",
            "class": "NIH"
          }
        ]
      },
      "oversightModule": {
        "oversightHasDmc": true,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": false
      },
      "descriptionModule": {
        "briefSummary": "This Phase II Small Business Innovative Research (SBIR) project is a clinical effectiveness and cost-effectiveness random controlled trial (RCT) of DynamiCare Health's innovative smartphone/smart debit card remote digital coaching program, which integrates Contingency Management, Recovery Coaching, and cognitive behavioral therapy (CBT), to address alcohol use disorder (AUD) in 300 adults.",
        "detailedDescription": "This application proposes to continue clinical effectiveness and cost-effectiveness testing of the DynamiCare Health platform. This is an innovative smartphone-based digital coaching program that offers remotely-delivered contingency management (CM), Recovery Coaching, and cognitive behavioral therapy (CBT) content to address alcohol use disorder (AUD). CM, which uses financial incentives to reward abstinence and treatment attendance, is one of the most effective, evidence-based, and overlooked intervention for substance use disorders (SUD). DynamiCare, through its remote delivery system, has addressed the logistical barriers to adoption, and now seeks, through this proposal, to drive payer adoption. Our Phase 1 preliminary data shows that the intervention is acceptable and can be highly effective when delivered as a supplemental therapy to persons with AUD enrolled in treatment. Phase 2 proposes to partner with Medicaid to deploy and test the fully developed intervention in an RCT among individuals with AUD (n=300). Our goals are to: 1) Deploy the DynamiCare CM and digital coaching program at scale among Medicaid members with AUD; 2) determine clinical effectiveness; and 3) evaluate the cost-effectiveness and return-on-investment from the payer perspective. This study design addresses a lack in the CM literature of empirical evidence on the cost-savings for payers from CM. If CM can be shown to create cost-savings for payers, the final barrier to widespread adoption would fall. Overall, this Phase 2 project, which follows a highly successful Phase 1, will provide critical data to advance the utility of this innovative digital platform as it is deployed in the real world to help the millions of people with AUD."
      },
      "conditionsModule": {
        "conditions": [
          "Alcohol Use Disorder",
          "Alcohol Dependence",
          "Drug Dependence"
        ],
        "keywords": [
          "contingency management",
          "motivational incentives",
          "cognitive behavioral therapy",
          "CBT",
          "recovery",
          "recovery coach",
          "recovery coaching",
          "telehealth",
          "digital therapeutic",
          "remote monitoring",
          "drug testing",
          "breathalyzer",
          "Medicaid",
          "alcoholism",
          "alcohol abuse",
          "addiction"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "interventionModelDescription": "Random-controlled trial",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": { "masking": "NONE" }
        },
        "enrollmentInfo": { "count": 236, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "DynamiCare Motivation Support Program",
            "type": "EXPERIMENTAL",
            "description": "Intervention Group members will receive 32 weeks of remote Contingency Management (CM; financial motivational incentives), Recovery Coaching, substance testing, appointment reminding/tracking, and in-app Cognitive Behavioral Therapy (CBT). After 32 weeks, coaching, testing, appointment tracking and CBT will continue until an overall 12 months in the project is completed.",
            "interventionNames": [
              "Combination Product: DynamiCare Motivation Support Program"
            ]
          },
          {
            "label": "Untreated or Routine Care Control Group",
            "type": "OTHER",
            "description": "Control participants will receive substance tests at the same frequency as Intervention participants, and the same incentive amounts for tests as treatment participants. Controls' payments, however, will not be contingent on positive/negative results, but rather only on valid, on-time submission. Controls will not receive coaching, CBT or rewards for appointments.",
            "interventionNames": [
              "Other: Untreated or Routine Care Control Group"
            ]
          }
        ],
        "interventions": [
          {
            "type": "COMBINATION_PRODUCT",
            "name": "DynamiCare Motivation Support Program",
            "description": "DynamiCare is an evidence-based, multi-service platform that combines software, smartphone and pocket-sized alcohol and drug testing hardware, and recovery services, designed to remotely deliver evidence-based methodologies to facilitate people's motivation and accountability to overcome alcohol, nicotine and other drug use disorders, whether in formal treatment or not.",
            "armGroupLabels": ["DynamiCare Motivation Support Program"]
          },
          {
            "type": "OTHER",
            "name": "Untreated or Routine Care Control Group",
            "description": "No specific intervention, i.e., research participation plus any community-based treatment the individual seeks to obtain.",
            "armGroupLabels": ["Untreated or Routine Care Control Group"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Alcohol Use",
            "description": "The primary outcome measure is alcohol use, in terms of the number of weeks of abstinence confirmed by DynamiCare Breathalyzer tests and self-report.",
            "timeFrame": "32 weeks"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Engagement",
            "description": "Percent of available funds earned as a composite measure.",
            "timeFrame": "32 weeks"
          },
          {
            "measure": "Retention",
            "description": "Monthly rates of retention in the program.",
            "timeFrame": "32 weeks"
          },
          {
            "measure": "Drug Use Clinical Effectiveness",
            "description": "Measured by DynamiCare saliva drug test results and weekly self-report.",
            "timeFrame": "32 weeks"
          },
          {
            "measure": "Cost-effectiveness",
            "description": "Medicaid healthcare utilization claims costs vs. prior 12 months.",
            "timeFrame": "12 months"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\nParticipants in the study must have Alcohol Use Disorder (AUD) and:\n\n1. Be \\>18 years old\n2. Meet the DSM-5 criteria for current (past year) AUD, or be recommended for care in the ASAM CO-Triage assessment\n3. Have consumed at least one alcoholic beverage within the last 10 days, according to self-report\n4. Speak English\n5. Have an Android or iOS smartphone.\n\nExclusion Criteria:\n\n1. Participants with current suicidal intent will be excluded as they require a higher level of care that cannot be provided by DynamiCare and our Recovery Coaches (hence, these individuals will be directly referred for clinical evaluation).\n2. Participants with ASAM CO-Triage level needs higher than Level 3.1 (e.g., greater than community-based, working halfway house) and not receiving addiction treatment will be excluded because they require inpatient treatment. Once the participant has received treatment, Recovery Coaches will reach out again to re-enroll the participant in the study if the participant wishes",
        "healthyVolunteers": false,
        "sex": "ALL",
        "genderBased": true,
        "genderDescription": "All genders are eligible",
        "minimumAge": "18 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "Eric E Gastfriend, MBA",
            "affiliation": "DynamiCare Health Inc.",
            "role": "PRINCIPAL_INVESTIGATOR"
          }
        ],
        "locations": [
          {
            "facility": "DynamiCare Health",
            "city": "Boston",
            "state": "Massachusetts",
            "zip": "02109",
            "country": "United States",
            "geoPoint": { "lat": 42.35843, "lon": -71.05977 }
          }
        ]
      },
      "referencesModule": {
        "seeAlsoLinks": [
          {
            "label": "Press release describing study launch and Vermont Medicaid's Chief Medical Officer's rationale.",
            "url": "https://www.prnewswire.com/news-releases/vt-medicaid-gets-creative-on-addiction-during-covid-19-301108477.html"
          }
        ]
      },
      "ipdSharingStatementModule": { "ipdSharing": "NO" }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [
          { "id": "D000437", "term": "Alcoholism" },
          { "id": "D019966", "term": "Substance-Related Disorders" },
          { "id": "D000428", "term": "Alcohol Drinking" }
        ],
        "ancestors": [
          { "id": "D004327", "term": "Drinking Behavior" },
          { "id": "D019973", "term": "Alcohol-Related Disorders" },
          { "id": "D064419", "term": "Chemically-Induced Disorders" },
          { "id": "D001523", "term": "Mental Disorders" }
        ],
        "browseLeaves": [
          {
            "id": "M3783",
            "name": "Alcoholism",
            "asFound": "Alcohol Use Disorder",
            "relevance": "HIGH"
          },
          { "id": "M19100", "name": "Behavior, Addictive", "relevance": "LOW" },
          {
            "id": "M3774",
            "name": "Alcohol Drinking",
            "asFound": "Alcohol Use",
            "relevance": "HIGH"
          },
          {
            "id": "M21837",
            "name": "Substance-Related Disorders",
            "asFound": "Drug Dependence",
            "relevance": "HIGH"
          },
          { "id": "M7502", "name": "Drinking Behavior", "relevance": "LOW" },
          {
            "id": "M21842",
            "name": "Alcohol-Related Disorders",
            "relevance": "LOW"
          },
          {
            "id": "M30302",
            "name": "Chemically-Induced Disorders",
            "relevance": "LOW"
          },
          { "id": "M14473", "name": "Psychotic Disorders", "relevance": "LOW" },
          { "id": "M4815", "name": "Mental Disorders", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "BC25", "name": "Substance Related Disorders" },
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" },
          { "abbrev": "All", "name": "All Conditions" }
        ]
      },
      "interventionBrowseModule": {
        "browseLeaves": [
          { "id": "M12478", "name": "Nicotine", "relevance": "LOW" },
          { "id": "M3777", "name": "Ethanol", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "All", "name": "All Drugs and Chemicals" },
          { "abbrev": "Infe", "name": "Anti-Infective Agents" },
          { "abbrev": "CNSDep", "name": "Central Nervous System Depressants" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT05991167",
        "orgStudyIdInfo": { "id": "Akili-060" },
        "organization": {
          "fullName": "Akili Interactive Labs, Inc.",
          "class": "INDUSTRY"
        },
        "briefTitle": "EndeavorRx® Prospective Product Registry (\"Expedition EndeavorRx\")",
        "officialTitle": "EndeavorRx® Prospective Product Registry"
      },
      "statusModule": {
        "statusVerifiedDate": "2024-06",
        "overallStatus": "ACTIVE_NOT_RECRUITING",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2022-06-01", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2025-12-31",
          "type": "ESTIMATED"
        },
        "completionDateStruct": { "date": "2025-12-31", "type": "ESTIMATED" },
        "studyFirstSubmitDate": "2023-08-04",
        "studyFirstSubmitQcDate": "2023-08-04",
        "studyFirstPostDateStruct": { "date": "2023-08-14", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2024-06-25",
        "lastUpdatePostDateStruct": { "date": "2024-06-27", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": {
          "name": "Akili Interactive Labs, Inc.",
          "class": "INDUSTRY"
        }
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": true,
        "isUsExport": false
      },
      "descriptionModule": {
        "briefSummary": "The EndeavorRx Prospective Product Registry aims to collect real world data from participants receiving the digital therapeutic, EndeavorRx, under conditions of routine clinical practice.",
        "detailedDescription": "The objectives of this registry are to describe clinical and demographic characteristics, prescribing patterns, treatment patterns, and outcomes in participants treated with EndeavorRx in a real-world setting.\n\nPatients and their caregivers will be informed about the registry as part of a series of product welcome emails following product activation. Patients/caregivers enroll into the study by providing their electronic informed consent (eConsent) and assent (eAssent). All data are captured electronically and securely through a commercial data capture platform. Participants can also invite their child's teacher to submit surveys of their observations of the child's ADHD symptoms for the study. Study activities are emailed to caregivers at baseline, 1, 2, 3, and 6-months after enrollment.\n\nA valid and active EndeavorRx prescription is required to enroll. However, an active prescription throughout the entire 6 months of study participation is not required."
      },
      "conditionsModule": {
        "conditions": ["ADHD"],
        "keywords": ["ADHD", "AKL-T01", "EndeavorRx", "Akili", "Registry"]
      },
      "designModule": {
        "studyType": "OBSERVATIONAL",
        "patientRegistry": true,
        "targetDuration": "1 Year",
        "designInfo": {
          "observationalModel": "COHORT",
          "timePerspective": "PROSPECTIVE"
        },
        "enrollmentInfo": { "count": 150, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "EndeavorRx Users",
            "description": "All participants with an active EndeavorRx prescription. Treatment regimen is as directed by their prescribing healthcare provider.",
            "interventionNames": ["Device: EndeavorRx"]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "EndeavorRx",
            "description": "EndeavorRx® is an FDA cleared digital therapeutic indicated to improve attention function as measured by computer-based testing in children ages 8-12 years old with primarily inattentive or combined-type attention-deficit/hyperactivity disorder (ADHD), who have a demonstrated attention issue. EndeavorRx is deployed on mobile devices and incorporates adaptive, simultaneous cognitive tasks in a consumer-grade action videogame-based platform with high-quality graphics and reward mechanisms.",
            "armGroupLabels": ["EndeavorRx Users"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Clinical and demographic characteristics",
            "description": "Socio-demographic and clinical characteristics of the registry population will be described using mean and standard deviation as well as median, minimum, maximum, and interquartile range, as appropriate for continuous variables, and counts with percentages for categorical variables. To explore changes in the profile of participants entering the registry over time, results may be stratified by enrollment date grouped by, for example, calendar month or quarter and year.",
            "timeFrame": "Baseline"
          },
          {
            "measure": "Prescribing patterns",
            "description": "Prescribing patterns will be summarized using count and percent of EndeavorRx prescriber types reported by registry participants. Analysis of treatment patterns will be repeated stratified by prescriber type to explore any potential differences in treatment approaches and/or adherence by prescribing healthcare provider specialty. To explore changes in prescribers over time, results may be stratified by enrollment date (e.g., calendar month or quarter and year).",
            "timeFrame": "Months 1, 2, 3, and 6"
          },
          {
            "measure": "Treatment patterns",
            "description": "Past and current treatments for ADHD will be summarized for registry participants using counts and percentages. Adherence to EndeavorRx treatment will be assessed using gameplay data and may be defined based on number of missions and/or days played, duration of gameplay, and/or patterns of gameplay (e.g., level of effort) in relation to the values that would be expected per product instructions for use. Measures will be described using mean, standard deviation, median, minimum, maximum, and interquartile range for continuous variables, and counts with percentages for categorical variables. Adherence will be summarized overall and for time intervals after commencing treatment (e.g., weekly, monthly).",
            "timeFrame": "Baseline, Months 1, 2, 3, and 6"
          },
          {
            "measure": "Conners 3 ADHD Index - Parent Form",
            "description": "Descriptive statistics for each continuous outcome at baseline and each follow-up timepoint, as well as change from baseline at each follow-up timepoint, will be calculated. Changes in continuous outcome measures may also be assessed using linear mixed model repeated measures analyses (MMRM) to assess the effect of EndeavorRx treatment over time and adjust for potential confounding factors as necessary. Stratified analyses by treatment characteristics (e.g., concomitant ADHD medications, treatment adherence) may be conducted to examine whether changes in assessments vary with different treatment patterns.",
            "timeFrame": "Baseline, Months 1, 2, 3, and 6"
          },
          {
            "measure": "Conners 3 ADHD Index - Teacher Form",
            "description": "Descriptive statistics for each continuous outcome at baseline and each follow-up timepoint, as well as change from baseline at each follow-up timepoint, will be calculated. Changes in continuous outcome measures may also be assessed using linear mixed model repeated measures analyses (MMRM) to assess the effect of EndeavorRx treatment over time and adjust for potential confounding factors as necessary. Stratified analyses by treatment characteristics (e.g., concomitant ADHD medications, treatment adherence) may be conducted to examine whether changes in assessments vary with different treatment patterns.",
            "timeFrame": "Baseline, Months 1 and 3"
          },
          {
            "measure": "Global Impression of Perceived Difficulties (GIPD) assessment",
            "description": "Descriptive statistics for each continuous outcome at baseline and each follow-up timepoint, as well as change from baseline at each follow-up timepoint, will be calculated. Changes in continuous outcome measures may also be assessed using linear mixed model repeated measures analyses (MMRM) to assess the effect of EndeavorRx treatment over time and adjust for potential confounding factors as necessary. Stratified analyses by treatment characteristics (e.g., concomitant ADHD medications, treatment adherence) may be conducted to examine whether changes in assessments vary with different treatment patterns.",
            "timeFrame": "Baseline, Months 1, 2, 3, and 6"
          },
          {
            "measure": "CAT-MH® ADHD module",
            "description": "Descriptive statistics for each continuous outcome at baseline and each follow-up timepoint, as well as change from baseline at each follow-up timepoint, will be calculated. Changes in continuous outcome measures may also be assessed using linear mixed model repeated measures analyses (MMRM) to assess the effect of EndeavorRx treatment over time and adjust for potential confounding factors as necessary. Stratified analyses by treatment characteristics (e.g., concomitant ADHD medications, treatment adherence) may be conducted to examine whether changes in assessments vary with different treatment patterns.",
            "timeFrame": "Baseline, Months 1, 2, 3, and 6"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* Are prescribed EndeavorRx by their healthcare provider as part of routine clinical practice\n* Provide informed consent/assent to participate in the registry\n\nExclusion Criteria:\n\n* N/A",
        "sex": "ALL",
        "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"],
        "studyPopulation": "All patients who are prescribed EndeavorRx and activates their prescription are eligible to participate in this study.",
        "samplingMethod": "NON_PROBABILITY_SAMPLE"
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "Scott H Kollins, PhD",
            "affiliation": "Akili Interactive Labs, Inc.",
            "role": "PRINCIPAL_INVESTIGATOR"
          }
        ],
        "locations": [
          {
            "facility": "Akili Interactive Labs, Inc.",
            "city": "Boston",
            "state": "Massachusetts",
            "zip": "02110",
            "country": "United States",
            "geoPoint": { "lat": 42.35843, "lon": -71.05977 }
          }
        ]
      }
    },
    "derivedSection": { "miscInfoModule": { "versionHolder": "2025-05-07" } },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT06568081",
        "orgStudyIdInfo": { "id": "338439" },
        "organization": {
          "fullName": "King's College London",
          "class": "OTHER"
        },
        "briefTitle": "SloMo2: Implementation, Effectiveness, and Cost-effectiveness Study",
        "officialTitle": "SloMo2: a Process Evaluation, Effectiveness, and Cost-effectiveness Study of a Digitally Supported Therapy for Psychosis in Routine Care"
      },
      "statusModule": {
        "statusVerifiedDate": "2024-08",
        "overallStatus": "RECRUITING",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2024-10-16", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2025-12-31",
          "type": "ESTIMATED"
        },
        "completionDateStruct": { "date": "2026-09-01", "type": "ESTIMATED" },
        "studyFirstSubmitDate": "2024-08-13",
        "studyFirstSubmitQcDate": "2024-08-20",
        "studyFirstPostDateStruct": { "date": "2024-08-23", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2024-12-17",
        "lastUpdatePostDateStruct": { "date": "2024-12-20", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": { "name": "King's College London", "class": "OTHER" },
        "collaborators": [
          {
            "name": "South London and Maudsley NHS Foundation Trust",
            "class": "OTHER"
          },
          {
            "name": "Sussex Partnership NHS Foundation Trust",
            "class": "OTHER"
          },
          {
            "name": "Northumberland, Tyne and Wear NHS Foundation Trust",
            "class": "OTHER"
          }
        ]
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": false,
        "isUsExport": false
      },
      "descriptionModule": {
        "briefSummary": "Worries about harm from others (also known as paranoia) are common. Thinking fast or going on gut feelings is natural but can fuel these worries. For some, fast thinking and worries start to get in the way of life. Cognitive behaviour therapy for psychosis (CBTp) is the recommended talking therapy. However, only a minority of people can access CBTp due to limited resources, and even when available, therapy can be difficult to do and use in daily life.\n\nSloMo is a digitally supported therapy that aims to overcome these barriers, and was developed by people with psychosis, designers, and psychologists. It supports people to notice worries and fast thinking habits. During therapy sessions, people learn to slow down and feel safer. Personalised spinning thought bubbles are slowed down using SloMo tips. An app provides access to helpful messages.\n\nSloMo was previously tested in a randomised trial of 361 people attending mental health services. SloMo was found to be safe to use, with no adverse events linked to the software. People in the SloMo group had lower paranoia, and better confidence and wellbeing, over 6 months compared to people who just received their usual care. People found SloMo enjoyable and easy to use.\n\nThe next step is to evaluate if SloMo can be safely and effectively delivered by therapists working in NHS services. If SloMo works in routine care, the therapy will be made more widely available in the NHS.\n\nAn improved version of SloMo has been co-produced based on feedback. Sixty therapists will be trained and supervised in 3 trusts to deliver SloMo to 150 people who fear harm from others. Safety, technical performance, uptake, engagement and acceptability data, alongside interviews with patients, therapists, and managers, will investigate how SloMo is used. Paranoia severity and wellbeing will be measured pre and post therapy to find out if SloMo helps. Service use data will evaluate costs and savings.",
        "detailedDescription": "DESIGN AND AIMS The study is a repeated measures design, with clinical outcome assessments pre- and post-delivery of SloMoR2, and a 6-month follow-up for health economics data collection. The aim is to evaluate if SloMo is implementable and effective when delivered in routine care by therapists working in NHS routine services. Delivery with high and low intensity therapists will be evaluated, with the former holding doctorate or diploma therapy qualifications, and the latter representing graduate psychologists or the NHS's expanding workforce of psychological practitioners. Outcomes will be evaluated using questionnaires, software analytics, and medical record data (for demographics, adverse events, and service use). Interviews will be conducted with a subgroup of relevant stakeholders to understand their experiences of SloMo.\n\nThe project will be conducted in 3 NHS trusts. Each trust will have a local study team, funded by the research grant and directly employed by local services, to support training, supervision, and implementation. Design research has already been conducted in preparation for the study to support the co-production of an improved version of SloMo tailored for implementation (SloMoR2). The study will run for 24 months and consists of four stages:\n\n1. Site set-up (month 1-3) Site set-up will be conducted to pilot the training, supervision, and technical support procedures that will ensure SloMoR2's performance, data protection and clinical safety.\n\n2a. Process evaluation: Implementation (month 4 - 21) A mixed-method process evaluation will be co-produced to understand how SloMoR2 is experienced, including safety, engagement, adherence, acceptability, fidelity \\& usability, and to identify barriers and enablers to implementation.\n\n2ba. Effectiveness and cost-effectiveness (month 4 - 21) An evaluation will be conducted to establish the effectiveness and cost-effectiveness of SloMoR2 when delivered in routine care.\n\n3. Analysis, resource development and dissemination (month 22 - 24) Findings will be summarised in consultation with our LEAP group. They will be written up in a plain English summary and as articles for submission to peer-review publications. Experiences of therapy delivery will inform any further refinements to the SloMoR2 software. Findings will also be used to support the co-design of an automated e-learning programme for therapists and develop a commercialisation strategy to assist being scaled up in the NHS.\n\nSAMPLE AND RECRUITMENT Service user recruitment: The recruitment target is to deliver SloMo to 150 service user participants (across Stage 1 and 2) who are: Aged ≥18 years, meet criteria for ICD-10 psychosis diagnoses (F20-29, F30-39), seeking therapy for paranoia, in contact with secondary care mental health services, and capable of providing informed consent to engage in therapy. People will be excluded if they: are at acute risk of harm to self or others, are unable to engage in therapy due to language barriers, and have a primary diagnosis of alcohol/substance dependence, learning disability, or organic brain injury or illness implicated in psychosis.\n\nTherapist recruitment, training, and supervision: In Stage 1, an initial cohort of therapists ('high intensity'; n = 5 per trust) will be selected from senior clinicians experienced in delivery and supervision of CBT for psychosis. Therapists will be required to complete a 1-day training. They will subsequently be able to access on-demand clinical and technical supervision from their local study team as required to support SloMoR2 delivery. In Stage 2, a further 45 'high' and 'low' intensity therapists will be trained across the 3 sites. This will be based on a 'training the trainers' model. The initial cohort of five trained high intensity therapists from Stage 1 will support training and supervision of an additional 15 therapists per site. Training will be extended to 3 days for low intensity therapists. The local study team will liaise with local services to promote SloMo2 and support trainers to roll out training to other high and low intensity therapists.\n\nStakeholder recruitment: The experience of SloMo's delivery will be evaluated using subgroups of the therapist and participant samples recruited in Stages 1 and 2 (N = 60, and N = 150, respectively). This will involve interviewing subgroups of service users (n = 20) and therapists (n = 6) involved in SloMo's delivery, as well as senior managers (n = 5) and payers (stakeholders involved in the commissioning of mental health services; n = 5), about their experience of SloMo. The service users will be recruited by the local study team. They will approach participants who consented to be contacted about further SloMo studies, once the participant has disengaged (therapist defined) or completed therapy. The four samples will be recruited to ensure a diverse range with respect to age, ethnicity, gender, site, and professional background (for staff interviews). All potential participants will be provided with a participant information sheet and given the opportunity to ask questions before signing the consent form.\n\nPROCEDURE The local study team will initially conduct PPI consultation with their trust therapy workforce to scope readiness for adoption of SloMoR2. This work will identify implementation barriers and facilitators, to enable tailoring of implementation resources and strategies to site needs.\n\nTrained therapists will identify potential participants and offer them SloMo, based on their clinical judgement. Following an initial introduction, participants will provide informed consent to receive SloMo and for their data to be collected for research purposes, with an optional opt-in for contact about further SloMo research. The burden of the informed consent process will be minimised where possible. This has been done by embedding the participant information sheet and consent form at the beginning of the SloMo webapp ('therapy platform'). Therapists will review this with potential participants and address any questions they have. Data storage and strategies for data protection will be emphasised, based on PPI feedback that this is a key area of concern. It will also be emphasised that service users will be free to withdraw their consent to engage in therapy at any time or to request that their data be deleted from the SloMo software or omitted from the research analysis.\n\nIf willing to proceed, participants' consent will be provided by indicating consent on the form. Participants will not sign the consent form with their name, to minimise the personally identifiable information stored in the software. Therapists will countersign and date the consent form. A copy of the countersigned consent form will be posted or sent electronically to the participant by the local SloMo team.\n\nPre and post therapy measures will be collected through the SloMo therapy platform at the first (R-GPTS (part B), short WEMWBS), second (GBO) and last therapy session (all). Sessional measures will be taken at each session. The local study team will extract demographic, adverse event, and service use data from participants' medical record.\n\nINTERVENTION SloMoR2 consists of up to 11 digitally supported therapy platform modules targeting paranoia and a mobile app for use outside of sessions. Therapy will be delivered according to the SloMo manual instructions for use. The therapy helps people learn to slow down for a moment to find ways of feeling safer and living well. Animated stories and interactive tasks support participants to learn how to apply SloMo tips to manage their worries, with in-session content synchronised to the mobile app which provides out of session support.\n\nOUTCOMES\n\n1a) Implementation To address the primary research question, is SloMoR2 implementable in routine care, quantitative data will be gathered for the following primary outcomes: i) safety, measured by frequency of any unanticipated serious therapy and/or device-related adverse events, and ii) service user engagement, measured by the proportion of participants who are delivered 5 or more SloMo sessions ('minimum therapeutic dose'). In addition, data will be gathered for the following secondary outcomes: i) service user engagement, measured by the number of individuals who begin (1 or more sessions) and complete therapy (8 or more sessions, 'full course' as three modules are optional), ii) therapist uptake, measured by the percentage of therapists that receive SloMo R2 training who commence therapy with at least one participant, iii) adherence, measured by percentage completion of sessions started, iv) usage, service user usage of mobile app, v) acceptability, measured by the percentage of positive responses on the NHS Family and Friends Test, vi) fidelity, competence of therapy delivery (with a random selection of 10 sessions per site assessed by the local study lead), vii) stakeholder experience of implementation, based on qualitative interviews with service users, therapists, senior managers, and payers, and viii) usability, measured by the User Experience Survey (UES; Service user and therapist). The qualitative interviews exploring user experience in participants who have been offered SloMo will be lived experience researcher-led. The qualitative interviews with therapists will explore experiences of training and delivery of SloMoR2 in more detail. Finally, senior managers and payers, who have and have not been involved in implementing SloMo, will be interviewed to understand their perspective on SloMo and its scale-up. All interviews will be audio recorded and transcribed for analysis. Participants will be reimbursed for their time according to INVOLVE guidelines.\n\n1b) Effectiveness To address the primary research question, is SloMoR2 effective for paranoia and wellbeing when delivered in routine care, participants will complete (via the SloMo therapy platform) three brief questionnaires at the beginning and end of therapy. The primary effectiveness outcome measure is the persecution subscale (part B) of the Revised Green Paranoid Thoughts Scale (RGPTS-B). Secondary effectiveness outcome measures are the short Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS) and the Goal Based Outcome. Sessional measures will be collected during therapy sessions to monitor progress, using four scales (rated from 0 - 100) of paranoia distress, fast and slow thinking, safety beliefs and confidence.\n\n1b) Cost-effectiveness To address the primary research question, is SloMoR2 cost-effective when delivered in routine care, costs and savings will be evaluated by the local study team extracting mental health service use data from participant medical records using the Client Service Receipt Inventory (CSRI), and QALYs derived from an algorithm applied to the Revised Green Paranoid Thoughts Scale, persecution subscale (part B) (RGPTS-B). Mental health service use data will cover the 6-month period prior to the intervention, the period during the intervention, and the 6-month period following its end. This analysis will also incorporate the service use data collected for the SlowMoR1 trial as this will provide additional data to enhance the health economic modelling."
      },
      "conditionsModule": {
        "conditions": [
          "Schizophrenia Spectrum and Other Psychotic Disorders",
          "Affective Psychoses"
        ],
        "keywords": ["Digital health", "User-centred design"]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "NA",
          "interventionModel": "SINGLE_GROUP",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": { "masking": "NONE" }
        },
        "enrollmentInfo": { "count": 150, "type": "ESTIMATED" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "SloMo",
            "type": "EXPERIMENTAL",
            "interventionNames": ["Other: SloMo"]
          }
        ],
        "interventions": [
          {
            "type": "OTHER",
            "name": "SloMo",
            "description": "SloMo, is a blended digital therapeutic for people who fear harm from others. It is based on cognitive-behavioural therapy for psychosis. An online therapy platform supports the delivery of 11 face-to-face sessions, which are synchronised to a native mobile app for use in daily life. SloMo works by helping people to notice their worries and fast thinking habits, and encourages them to slow down for a moment to find ways of feeling safer.",
            "armGroupLabels": ["SloMo"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Implementation: Safety (adverse event incidence)",
            "description": "Frequency of any unanticipated serious therapy and/or device-related adverse events",
            "timeFrame": "Pre-therapy to 6 months post therapy discharge."
          },
          {
            "measure": "Implementation: Service user engagement",
            "description": "Proportion of participants who are delivered 5 or more SloMo sessions ('minimum therapeutic dose')",
            "timeFrame": "Duration of therapy (up to 6 months)"
          },
          {
            "measure": "Effectiveness: Paranoid thoughts",
            "description": "Revised Green Paranoid Thoughts Scale, persecution subscale (part B) (RGPTS-B, Freeman et al, 2021). Range 0-40, higher scores indicate worse outcome.",
            "timeFrame": "Pre- to post-therapy."
          },
          {
            "measure": "Cost-effectiveness: Service use",
            "description": "Unit costs calculated from the Client Service Receipt Inventory (CSRI, Beecham and Knapp, 2001)",
            "timeFrame": "Pre-therapy to 6 months post therapy discharge."
          },
          {
            "measure": "Cost-effectiveness: Paranoid thoughts",
            "description": "QALYs derived from an algorithm applied to the Revised Green Paranoid Thoughts Scale, persecution subscale (part B) (RGPTS-B, Freeman et al, 2021)",
            "timeFrame": "Pre-therapy to 6 months post therapy discharge."
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Implementation: Service user engagement",
            "description": "Number of individuals who begin (1 or more sessions) and complete therapy (8 or more sessions, 'full course' as three modules are optional)",
            "timeFrame": "Duration of therapy (up to 6 months)"
          },
          {
            "measure": "Implementation: Therapist uptake",
            "description": "Percentage of therapists that receive SloMo R2 training who commence therapy with at least one participant",
            "timeFrame": "Duration of study (24 months)"
          },
          {
            "measure": "Implementation: Adherence",
            "description": "Percentage completion of sessions started.",
            "timeFrame": "Duration of therapy (up to 6 months)"
          },
          {
            "measure": "Implementation: Usage",
            "description": "Percentage of service users meeting mobile app adherence criteria (at least 1 home screen interaction after a minimum of 3 therapy sessions).",
            "timeFrame": "Pre- to post-therapy (up to 6 months)"
          },
          {
            "measure": "Implementation: Acceptability",
            "description": "Percentage of positive responses on the NHS Family and Friends Test",
            "timeFrame": "Post-therapy (at up to 6 months)"
          },
          {
            "measure": "Implementation: Fidelity",
            "description": "Proportion of therapists meeting competence on the Revised Cognitive Therapy Scale (CTS-R) (of a random selection of 10 sessions scored per site, assessed by the local study lead).",
            "timeFrame": "Duration of study (24 months)"
          },
          {
            "measure": "Implementation: Stakeholder experience of implementation",
            "description": "Qualitative interviews with i) service users, ii) therapists, iii) senior managers, iv) payers",
            "timeFrame": "Duration of study (24 months)"
          },
          {
            "measure": "Implementation: Usability",
            "description": "User Experience Survey (UES, Hardy et al, 2022; Service user and therapist)",
            "timeFrame": "Post-therapy (at up to 6 months)"
          },
          {
            "measure": "Effectiveness: Wellbeing",
            "description": "Short-Warwick-Edinburgh Mental Wellbeing Scale (SWEMWBS, Stewart-Brown et al, 2009). Range 7-35, higher scores indicate better outcome.",
            "timeFrame": "Pre- to post-therapy (up to 6 months)"
          },
          {
            "measure": "Effectiveness: Sessional measures",
            "description": "Collected using visual analogue scales (rated from 0 - 100) of paranoia distress, fast and slow thinking, safety beliefs and confidence",
            "timeFrame": "Duration of therapy (up to 6 months)"
          },
          {
            "measure": "Effectiveness: Goal attainment",
            "description": "Goal Based Outcome (GBO, Law et al, 2015). Range 0 (no progress) to 10 (goal has been reached), higher scores indicate better outcome.",
            "timeFrame": "Pre- to post-therapy (up to 6 months)"
          },
          {
            "measure": "Cost-effectiveness: Wellbeing",
            "description": "QALYs derived from an algorithm applied to the Short-Warwick-Edinburgh Mental Wellbeing Scale (SWEMWBS, Stewart-Brown et al, 2009)",
            "timeFrame": "Pre- to 6 months post-therapy."
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* Meet criteria for ICD-10 psychosis diagnoses (F20-29, F30-39)\n* Seeking therapy for paranoia\n* In contact with secondary care mental health services\n* Capacity to provide informed consent to engage in therapy\n\nExclusion Criteria:\n\n* Acute risk of harm to self or others\n* Unable to engage in therapy due to language barriers\n* Primary diagnosis of alcohol/substance dependence, learning disability, or organic brain injury or illness implicated in psychosis",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "centralContacts": [
          {
            "name": "Kathryn M Taylor",
            "role": "CONTACT",
            "phone": "07876876164",
            "email": "kathryn.taylor@kcl.ac.uk"
          }
        ],
        "overallOfficials": [
          {
            "name": "Amy Hardy",
            "affiliation": "King's College London",
            "role": "PRINCIPAL_INVESTIGATOR"
          }
        ],
        "locations": [
          {
            "facility": "South London and Maudsley NHS Foundation Trust",
            "status": "RECRUITING",
            "city": "London",
            "country": "United Kingdom",
            "contacts": [
              {
                "name": "Amy Hardy",
                "role": "CONTACT",
                "email": "amy.hardy@slam.nhs.uk"
              },
              { "name": "Amy Hardy", "role": "CONTACT" }
            ],
            "geoPoint": { "lat": 51.50853, "lon": -0.12574 }
          }
        ]
      },
      "ipdSharingStatementModule": {
        "ipdSharing": "YES",
        "description": "A fully anonymised, aggregate dataset will be shared with the wider research community. We will upload the data resulting from the study to ClinicalStudyDataRequest.com (CSDR), a consortium of clinical study sponsors/funders which is endorsed by Wellcome. In addition, other researchers may request access to IPD by contacting the study team, and will be shared in line with access criteria below.",
        "infoTypes": ["STUDY_PROTOCOL", "SAP", "ICF", "CSR"],
        "timeFrame": "Data will be made available after completion of data collection and analysis, and publication of the main outcome papers, and will be available indefinitely via CSDR.",
        "accessCriteria": "CSDR provides an ongoing forum where research proposals are checked and reviewed in 3 stages: 1) by the Wellcome Trust, which is the secretariat for the Independent Review Panel (IRP), 2) study funders sponsors and 3) the IRP.\n\nDirect requests for access must be accompanied by a protocol setting out the aims of the study for which the data are requested, very brief details of the credentials of team conducting the study (institutional affiliation, degrees or qualifications), methods outlined and appropriate ethical approval in place."
      }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [
          { "id": "D012559", "term": "Schizophrenia" },
          { "id": "D011618", "term": "Psychotic Disorders" },
          { "id": "D001523", "term": "Mental Disorders" },
          {
            "id": "D019967",
            "term": "Schizophrenia Spectrum and Other Psychotic Disorders"
          },
          { "id": "D000341", "term": "Affective Disorders, Psychotic" }
        ],
        "browseLeaves": [
          {
            "id": "M14473",
            "name": "Psychotic Disorders",
            "asFound": "Psychotic Disorders",
            "relevance": "HIGH"
          },
          {
            "id": "M4815",
            "name": "Mental Disorders",
            "asFound": "Psychosis",
            "relevance": "HIGH"
          },
          {
            "id": "M15376",
            "name": "Schizophrenia",
            "asFound": "Schizophrenia",
            "relevance": "HIGH"
          },
          {
            "id": "M21838",
            "name": "Schizophrenia Spectrum and Other Psychotic Disorders",
            "asFound": "Schizophrenia Spectrum and Other Psychotic Disorders",
            "relevance": "HIGH"
          },
          {
            "id": "M3691",
            "name": "Affective Disorders, Psychotic",
            "asFound": "Affective Psychosis",
            "relevance": "HIGH"
          },
          { "id": "M21835", "name": "Mood Disorders", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" },
          { "abbrev": "All", "name": "All Conditions" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT05184725",
        "orgStudyIdInfo": { "id": "CAR-0320" },
        "organization": {
          "fullName": "Adhera Health, Inc.",
          "class": "INDUSTRY"
        },
        "briefTitle": "CARINAE for Stress Relief in Perioperative Care",
        "officialTitle": "CARINAE: A Digital Health Intervention for Stress Relief in Perioperative Care: Clinical Study",
        "acronym": "CARINAE"
      },
      "statusModule": {
        "statusVerifiedDate": "2022-07",
        "overallStatus": "COMPLETED",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2022-01-10", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2022-04-30",
          "type": "ACTUAL"
        },
        "completionDateStruct": { "date": "2022-05-31", "type": "ACTUAL" },
        "studyFirstSubmitDate": "2021-11-29",
        "studyFirstSubmitQcDate": "2022-01-10",
        "studyFirstPostDateStruct": { "date": "2022-01-11", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2022-07-29",
        "lastUpdatePostDateStruct": { "date": "2022-08-01", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": { "name": "Adhera Health, Inc.", "class": "INDUSTRY" },
        "collaborators": [
          { "name": "Maastricht University Medical Center", "class": "OTHER" },
          { "name": "Hospital Sant Joan de Deu", "class": "OTHER" },
          { "name": "Parc Taulí Hospital Universitari", "class": "OTHER" },
          {
            "name": "Hospital Universitario Reina Sofia de Cordoba",
            "class": "OTHER_GOV"
          },
          {
            "name": "Istituto Nazionale di Ricovero e Cura per Anziani",
            "class": "OTHER"
          }
        ]
      },
      "oversightModule": {
        "oversightHasDmc": true,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": false
      },
      "descriptionModule": {
        "briefSummary": "Preventing pre-surgical stress can help patients achieve positive outcomes on health and well-being. However, very few patients receive adequate stress relief support prior to a surgical procedure. Provision of education and information about the surgery can be a crucial component of the preoperative experience and is inversely related to levels of preoperative anxiety. However, resource constraints make face-to-face education sessions untenable, given cost considerations and time investment by trained health personnel. Interventions based on mobile health (mHealth) technologies, geared towards increasing familiarity with surgical procedures and hospital environments have been shown to help patients feel informed about possible benefits and risks of available treatment options. mHealth apps and Virtual Reality (VR) can offer patients experience in the perioperative environment that can be helpful in empowering patients and enhancing a more positive experience, while reducing stress. However, available applications focus only on providing informative content, neglecting the importance of patient empowerment with a more robust educational curriculum.\n\nAccording to this, the Software as a Medical Device (SaMD) CARINAE, aims to support patients and caregivers during the whole perioperative process. SaMD CARINAE consists of an mHealth mobile application for patients and caregivers, a Virtual Reality headset for patients, and a web application for healthcare professionals.",
        "detailedDescription": "Patients will be randomly assigned to intervention group or the control group. Intervention group will be exposed to the use of SaMD CARINAE for 2 months approximately. The intervention trial will include a total of 4 visits: 1. Recruitment; 2. Hospital admission; 3. Hospital discharge; 4. Post-operative follow-up in 14 days.\n\nSaMD CARINAE delivers the following interventions to the patients:\n\n* Personalised patient-centred health education program to improve patient's condition and recovery self-management skills.\n* Artificial Intelligence-based behaviour change program to promote healthier lifestyle habits.\n* Personalised mental well-being coaching program to improve patient's ability to cope with emotional disturbances such as stress and anxiety.\n* A collaborative digital support platform to enable information exchange between patients, caregivers, and healthcare professionals.\n\nThe program is delivered to patients and caregivers as a SaMD mHealth application (smartphone app) and an immersive environment with a VR device. Healthcare professionals will be able to access the collaborative digital support platform through a web application.\n\nFinally, the control group will not be exposed to SaMD CARINAE solution, following the traditional routine visits, and after each traditional visit patients will answer to questionnaires specified in the secondary outcome measures section."
      },
      "conditionsModule": {
        "conditions": [
          "Psychological Stress",
          "Cardiopulmonary Bypass Surgery",
          "Coronary Artery Bypass Surgery",
          "Cardiac Valve Replacement",
          "Hip Replacement",
          "Orthognathic Surgery",
          "Scoliosis",
          "Knee Replacement",
          "Prostate Cancer",
          "Kidney Cancer",
          "Bladder Cancer"
        ],
        "keywords": [
          "Pre-operative Stress",
          "mHealth Device",
          "Virtual Reality (VR)",
          "Health Recommender System",
          "I-Change Behavioral Change Model",
          "Artificial Intelligence (AI)",
          "Software as a Medical Device (SaMD)"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "interventionModelDescription": "The SaMD CARINAE embeds the I-Change Model, which claims that behavioral changes depend on the inner motivation to perform a specific behavior and the self-perception of personal abilities, or self-efficacy perception, to carry out the behavioral change.",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": { "masking": "NONE" }
        },
        "enrollmentInfo": { "count": 50, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "Control Group",
            "type": "NO_INTERVENTION",
            "description": "Patients will follow the usual care procedures and after each procedure they answer questionnaires related to pain and stress levels (VAS), Anxiety and depression levels (HADS), health-related quality of life (HRQoL), mental wellbeing (SWEMWBS), self-efficacy (GSE) and Patient Activation status (PAM-13)."
          },
          {
            "label": "SaMD CARINAE",
            "type": "EXPERIMENTAL",
            "description": "Intervention group will be exposed to the use of SaMD CARINAE for 2 months approximately, a patientcentred digital health support program. The intervention trial will include a total of 4 visits: 1. Baseline (2-4 weeks before surgery); 2. Hospital admission (1-3 days before surgery); 3. Hospital discharge (1 week after the surgery approx.); 4. Post-operative day 14 (2 weeks after the surgery approx). After each visit and intervention trial with SaMD CARINAE the experimental group answer the same questionnaires of the control group, above mentioned Participants allocated to the intervention group will also be asked to complete questionnaires about usability, satisfaction and subjective experience.",
            "interventionNames": ["Device: SaMD CARINAE"]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "SaMD CARINAE",
            "description": "SaMD CARINAE delivers the following digital therapeutic intervention to the patients: 1) Personalised patient-centred health education program to improve patient's disease and recovery self-management skills. 2) AI-based behaviour change program to promote healthier lifestyle habits. 3) Personalised mental well-being coaching program to improve patient's ability to cope with emotional disturbances such as stress and anxiety. 4) A collaborative digital support platform to enable information exchange between patients, caregivers, and healthcare professionals.",
            "armGroupLabels": ["SaMD CARINAE"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Visual Analog Scale for Stress",
            "description": "Patient and caregiver-reported visual analog scale question to assess subjective stress.\n\nAlong a 100 mm horizontal line, patient and caregiver indicate their perceived stress intensity. Rating varies from 0 (minimum values) to 100 (maximum value). Ratings of 0 to 4 mm can be considered no stress; 5 to 44 mm, mild stress; 45 to 74 mm, moderate stress; and 75 to 100 mm, severe stress.",
            "timeFrame": "2 months: from baseline to 14 days after the surgery"
          },
          {
            "measure": "Visual Analog Scale for Pain",
            "description": "Patient-reported visual analog scale question to assess subjective pain. Along a 100 mm horizontal line, patient and caregiver indicate their perceived pain intensity. Rating varies from 0 (minimum values) to 100 (maximum value). Ratings of 0 to 4 mm can be considered no pain; 5 to 44 mm, mild pain; 45 to 74 mm, moderate pain; and 75 to 100 mm, severe pain.",
            "timeFrame": "2 months: from baseline to 14 days after the surgery"
          },
          {
            "measure": "Hospital Anxiety and Depression Scale",
            "description": "Patient-reported questionnaire on anxiety and depression levels during the hospital stay. Hospital Anxiety and Depression Scale is a fourteen-item scale with seven items each for anxiety and depression subscales evaluated on a 0-3 Likert Scale. Rating varies from 0 to 21 and a subscale score \\>8 denotes anxiety or depression.",
            "timeFrame": "45 days: From hospital admission to 14 days after the surgery"
          },
          {
            "measure": "Health-related Quality of Life - EQ-5D-3L/-Y",
            "description": "Patient-reported questionnaire on quality of life. The questionnaire consists of five items related each to one dimension: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems (1), some problems (2), and extreme problems (3). The maximum score of 1 indicates the best health state, by contrast with the scores of individual questions, where higher scores indicate more severe or frequent problems. In addition, there is a visual analogue scale (VAS) to indicate the general health status with 100 indicating the best health status.",
            "timeFrame": "45 days: From hospital admission to 14 days after the surgery"
          },
          {
            "measure": "The Positive and Negative Affect Schedule",
            "description": "Patient-reported questionnaire on emotional status. It consists of 20 items that describe n emotions of a positive or negative nature, 10 of them positive and 10 negative. Each item is answered using an Likert-tscale with 5 response options (not at all, very little, somewhat, quite a lot, very much).\n\nScores can range from 10 - 50, with higher scores representing higher levels of positive or negative affect.",
            "timeFrame": "45 days: From hospital admission to 14 days after the surgery"
          },
          {
            "measure": "The Short Warwick-Edinburgh Mental Well-Being Scale",
            "description": "Patient- and caregiver-reported questionnaire on mental well-being. It consists of 7 items and each item is answered using a 1-5 Likert scale. Scores range from 7 to 35 and higher scores indicate higher positive mental wellbeing.",
            "timeFrame": "2 months: from baseline to 14 days after the surgery"
          },
          {
            "measure": "General Self-Efficacy Scale",
            "description": "Patient- and caregiver-reported questionnaire on self-efficacy perception. It consists of 10 items evaluated on a 1-4 Likert scale. Scores range from 10 to 40 amd higher scores indicate higher self-efficacy.",
            "timeFrame": "2 months: from baseline to 14 days after the surgery"
          },
          {
            "measure": "Patient Activation Measure",
            "description": "Patient-reported questionnaire on the level of activation. It consists of 13 items that have four possible response options ranging from (1) strongly disagree to (4) strongly agree, and an additional \"not applicable\" option. To calculate the total score, the raw score is divided by the number of items answered (excepting non-applicable items) and multiplied by 13. Then, this score is transformed to a scale with a theoretical range 0-100, based on calibration tables, with higher scores indicating higher patient activation. The raw scores can be converted into four activation levels: 1 (≤47.0) not believing activation important, 2 (47.1-55.1) a lack of knowledge and confidence to take action, 3 (55.2-67.0) beginning to take action and 4 (≥67.1) taking action.",
            "timeFrame": "45 days: From baseline to hospital discharge"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "System Usability Scale",
            "description": "Questionnaire on SaMD CARINAE usability by patients, caregivers and healthcare professionals",
            "timeFrame": "30 days: from hospital admission to 14 days after surgery"
          },
          {
            "measure": "Usability questionnaire",
            "description": "Ad-hoc questionnaire for patients and healthcare professional on the digital solution usability",
            "timeFrame": "30 days: from hospital admission to 14 days after surgery"
          },
          {
            "measure": "Net Promoter Score",
            "description": "Net Promoter Score (NPS) is a questionnaire that measures patient and healthcare professionals experience and provides the core measurement for customer experience management programs.",
            "timeFrame": "30 days: from hospital admission to 14 days after surgery"
          },
          {
            "measure": "Reliability",
            "description": "Ad-Hoc questionnaire for the healthcare professional on the digital solution",
            "timeFrame": "Day 60"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients planned for one of the selected surgery types:\n* Cardiopulmonary bypass (CPB) surgery (Maastricht UMC+)\n* Coronary artery bypass surgery (Maastricht UMC+)\n* Cardiac valve replacement (SAS, Maastricht UMC+)\n* Prostate, kidney, and bladder cancer surgery (INRCA)\n* Hip and knee replacement (HSJD; Parc Tauli)\n* Maxillofacial surgery (HSJD)\n* Orthognathic surgery (HSJD)\n* Scoliosis (HSJD)\n* Signed informed consent (by patient or legal guardian in paediatric cases).\n* Patients ≥ 18 years old, except for paediatric Hospital San Joan de Deu (HSJD) ≥ 8 years old.\n* Patient owns a smartphone with Android version 4.4 or above.\n* Patient (or legal guardian/caregiver in paediatric cases) is able to demonstrate basic digital literacy (e.g. knows how to communicate through instant messaging apps or similar).\n\nExclusion Criteria:\n\n* Dementia.\n* Pregnant women.\n* Inability to understand the local language.\n* Allergic to dedicated wearable material (stainless steel and silicone).\n* Currently enrolled in a different clinical trial.",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "8 Years",
        "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "Clara Hernández Cera",
            "affiliation": "Hospital San Joan de Deu",
            "role": "PRINCIPAL_INVESTIGATOR"
          },
          {
            "name": "Ignacio Muñoz Carvajal",
            "affiliation": "Hospital Universitario Reina Sofía",
            "role": "STUDY_DIRECTOR"
          },
          {
            "name": "Juan José Lázaro Alcay",
            "affiliation": "Hospital San Joan de Deu",
            "role": "STUDY_CHAIR"
          },
          {
            "name": "Andrea Vallejo Tarrat",
            "affiliation": "Parc Taulí Hospital Universitari",
            "role": "STUDY_CHAIR"
          },
          {
            "name": "JG Maessen, Prof. dr.",
            "affiliation": "Maastricht University Medical Center",
            "role": "STUDY_CHAIR"
          },
          {
            "name": "Marco Dellabella",
            "affiliation": "Istituto di Ricovero e Cura per Anziani",
            "role": "STUDY_CHAIR"
          }
        ],
        "locations": [
          {
            "facility": "Istituto di Ricovero e Cura per Anziani",
            "city": "Ancona",
            "country": "Italy",
            "geoPoint": { "lat": 43.5942, "lon": 13.50337 }
          },
          {
            "facility": "Maastricht University Medical Center",
            "city": "Maastricht",
            "country": "Netherlands",
            "geoPoint": { "lat": 50.84833, "lon": 5.68889 }
          },
          {
            "facility": "Hospital Reina Sofía",
            "city": "Córdoba",
            "state": "Andalucía",
            "zip": "14004",
            "country": "Spain",
            "geoPoint": { "lat": 37.89155, "lon": -4.77275 }
          },
          {
            "facility": "Hospital San Joan de Deu",
            "city": "Esplugues De Llobregat",
            "state": "Catalunya",
            "zip": "08950",
            "country": "Spain",
            "geoPoint": { "lat": 41.37732, "lon": 2.08809 }
          },
          {
            "facility": "Hospital Parc Taulí",
            "city": "Sabadell",
            "state": "Catalunya",
            "zip": "08208",
            "country": "Spain",
            "geoPoint": { "lat": 41.54329, "lon": 2.10942 }
          }
        ]
      },
      "referencesModule": {
        "references": [
          {
            "type": "BACKGROUND",
            "citation": "Crichton, N. Visual analogue scale (VAS). J Clin Nurs. 2001; 10(5): 706-6."
          },
          {
            "pmid": "6880820",
            "type": "BACKGROUND",
            "citation": "Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983 Jun;67(6):361-70. doi: 10.1111/j.1600-0447.1983.tb09716.x."
          },
          {
            "pmid": "3397865",
            "type": "BACKGROUND",
            "citation": "Watson D, Clark LA, Tellegen A. Development and validation of brief measures of positive and negative affect: the PANAS scales. J Pers Soc Psychol. 1988 Jun;54(6):1063-70. doi: 10.1037//0022-3514.54.6.1063."
          },
          {
            "pmid": "19228398",
            "type": "BACKGROUND",
            "citation": "Stewart-Brown S, Tennant A, Tennant R, Platt S, Parkinson J, Weich S. Internal construct validity of the Warwick-Edinburgh Mental Well-being Scale (WEMWBS): a Rasch analysis using data from the Scottish Health Education Population Survey. Health Qual Life Outcomes. 2009 Feb 19;7:15. doi: 10.1186/1477-7525-7-15."
          },
          {
            "type": "BACKGROUND",
            "citation": "Schwarzer, R., & Jerusalem, M. Generalized Self-Efficacy scale. In J. Weinman, S. Wright, & M. Johnston, Measures in health psychology: A user's portfolio. Causal and control beliefs. Windsor, UK: NFER-NELSON. 1995; 35-37."
          },
          {
            "pmid": "15230939",
            "type": "BACKGROUND",
            "citation": "Hibbard JH, Stockard J, Mahoney ER, Tusler M. Development of the Patient Activation Measure (PAM): conceptualizing and measuring activation in patients and consumers. Health Serv Res. 2004 Aug;39(4 Pt 1):1005-26. doi: 10.1111/j.1475-6773.2004.00269.x."
          },
          {
            "type": "BACKGROUND",
            "citation": "Brooke, J. SUS-A quick and dirty usability scale. Usability evaluation in industry. 1996; 189(194): 4-7."
          },
          {
            "pmid": "14712543",
            "type": "BACKGROUND",
            "citation": "Reichheld FF. The one number you need to grow. Harv Bus Rev. 2003 Dec;81(12):46-54, 124."
          }
        ]
      },
      "ipdSharingStatementModule": { "ipdSharing": "NO" }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [
          { "id": "D007680", "term": "Kidney Neoplasms" },
          { "id": "D012600", "term": "Scoliosis" },
          { "id": "D013315", "term": "Stress, Psychological" }
        ],
        "ancestors": [
          { "id": "D014565", "term": "Urogenital Neoplasms" },
          { "id": "D009371", "term": "Neoplasms by Site" },
          { "id": "D009369", "term": "Neoplasms" },
          { "id": "D000091642", "term": "Urogenital Diseases" },
          { "id": "D052801", "term": "Male Urogenital Diseases" },
          { "id": "D014571", "term": "Urologic Neoplasms" },
          { "id": "D052776", "term": "Female Urogenital Diseases" },
          {
            "id": "D005261",
            "term": "Female Urogenital Diseases and Pregnancy Complications"
          },
          { "id": "D014570", "term": "Urologic Diseases" },
          { "id": "D013121", "term": "Spinal Curvatures" },
          { "id": "D013122", "term": "Spinal Diseases" },
          { "id": "D001847", "term": "Bone Diseases" },
          { "id": "D009140", "term": "Musculoskeletal Diseases" },
          { "id": "D007674", "term": "Kidney Diseases" },
          { "id": "D001526", "term": "Behavioral Symptoms" }
        ],
        "browseLeaves": [
          { "id": "M14335", "name": "Prostatic Neoplasms", "relevance": "LOW" },
          {
            "id": "M5030",
            "name": "Urinary Bladder Neoplasms",
            "relevance": "LOW"
          },
          {
            "id": "M5548",
            "name": "Carcinoma, Renal Cell",
            "relevance": "LOW"
          },
          {
            "id": "M10703",
            "name": "Kidney Neoplasms",
            "asFound": "Kidney Cancer",
            "relevance": "HIGH"
          },
          {
            "id": "M15417",
            "name": "Scoliosis",
            "asFound": "Scoliosis",
            "relevance": "HIGH"
          },
          {
            "id": "M16105",
            "name": "Stress, Psychological",
            "asFound": "Psychological Stress",
            "relevance": "HIGH"
          },
          {
            "id": "M17315",
            "name": "Urogenital Neoplasms",
            "relevance": "LOW"
          },
          { "id": "M2875", "name": "Urogenital Diseases", "relevance": "LOW" },
          {
            "id": "M27095",
            "name": "Male Urogenital Diseases",
            "relevance": "LOW"
          },
          { "id": "M17320", "name": "Urologic Neoplasms", "relevance": "LOW" },
          {
            "id": "M27093",
            "name": "Female Urogenital Diseases",
            "relevance": "LOW"
          },
          {
            "id": "M14127",
            "name": "Pregnancy Complications",
            "relevance": "LOW"
          },
          {
            "id": "M8399",
            "name": "Female Urogenital Diseases and Pregnancy Complications",
            "relevance": "LOW"
          },
          { "id": "M17319", "name": "Urologic Diseases", "relevance": "LOW" },
          { "id": "M15918", "name": "Spinal Curvatures", "relevance": "LOW" },
          { "id": "M15919", "name": "Spinal Diseases", "relevance": "LOW" },
          { "id": "M5126", "name": "Bone Diseases", "relevance": "LOW" },
          {
            "id": "M12097",
            "name": "Musculoskeletal Diseases",
            "relevance": "LOW"
          },
          { "id": "M10698", "name": "Kidney Diseases", "relevance": "LOW" },
          { "id": "M4818", "name": "Behavioral Symptoms", "relevance": "LOW" },
          { "id": "T4906", "name": "Renal Cell Carcinoma", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "BC04", "name": "Neoplasms" },
          {
            "abbrev": "BXS",
            "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
          },
          { "abbrev": "All", "name": "All Conditions" },
          { "abbrev": "BC05", "name": "Musculoskeletal Diseases" },
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" },
          { "abbrev": "Rare", "name": "Rare Diseases" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT04855630",
        "orgStudyIdInfo": { "id": "20220931" },
        "secondaryIdInfos": [
          { "id": "20-01023", "type": "OTHER", "domain": "NYU" }
        ],
        "organization": { "fullName": "University of Miami", "class": "OTHER" },
        "briefTitle": "Combating Alzheimer's Through Sleep and Exercise",
        "officialTitle": "Combating Alzheimer's Through Sleep and Exercise (CASE)",
        "acronym": "CASE"
      },
      "statusModule": {
        "statusVerifiedDate": "2025-02",
        "overallStatus": "RECRUITING",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2023-03-01", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2026-03-01",
          "type": "ESTIMATED"
        },
        "completionDateStruct": { "date": "2026-03-01", "type": "ESTIMATED" },
        "studyFirstSubmitDate": "2021-04-19",
        "studyFirstSubmitQcDate": "2021-04-19",
        "studyFirstPostDateStruct": { "date": "2021-04-22", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2025-02-21",
        "lastUpdatePostDateStruct": { "date": "2025-02-24", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": {
          "type": "PRINCIPAL_INVESTIGATOR",
          "investigatorFullName": "Azizi Seixas",
          "investigatorTitle": "Associate Professor",
          "investigatorAffiliation": "University of Miami"
        },
        "leadSponsor": { "name": "University of Miami", "class": "OTHER" },
        "collaborators": [
          { "name": "Shipley Foundation", "class": "UNKNOWN" },
          { "name": "Dreem", "class": "INDUSTRY" }
        ]
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": true,
        "isUsExport": false
      },
      "descriptionModule": {
        "briefSummary": "The purpose of this research is to see how sleep and exercise affects dementia risk over time."
      },
      "conditionsModule": { "conditions": ["Alzheimer Disease", "Dementia"] },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "primaryPurpose": "PREVENTION",
          "maskingInfo": { "masking": "NONE" }
        },
        "enrollmentInfo": { "count": 30, "type": "ESTIMATED" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "Sleep Only Group",
            "type": "EXPERIMENTAL",
            "description": "Participants in this group will wear the DREEM 2 headband for 12 weeks.",
            "interventionNames": ["Device: DREEM 2 Headband"]
          },
          {
            "label": "Exercise Only Group",
            "type": "ACTIVE_COMPARATOR",
            "description": "Participants in this group will workout twice a week for 12 weeks.",
            "interventionNames": ["Other: Exercise Routine"]
          },
          {
            "label": "Exercise and Sleep Group",
            "type": "ACTIVE_COMPARATOR",
            "description": "Participants in this group will take part in a guided exercise program in additional to wearing the DREEM 2 headband for 12 weeks.",
            "interventionNames": [
              "Device: DREEM 2 Headband",
              "Other: Exercise Routine"
            ]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "DREEM 2 Headband",
            "description": "Participants will wear the DREEM 2 headband for 3 months for a minimum of 4 out of 7 nights per week and will participate in its digital therapeutic Cognitive Behavioral Therapy - Insomnia (CBT-I) intervention (entails brain stimulation to improve slow wave sleep and sleep hygiene counseling tips to improve sleep behaviors).",
            "armGroupLabels": ["Exercise and Sleep Group", "Sleep Only Group"]
          },
          {
            "type": "OTHER",
            "name": "Exercise Routine",
            "description": "Participants will partake in a guided exercise routine. Each routine consists of 30-minute mild circuit training session twice per week for 3 months.",
            "armGroupLabels": [
              "Exercise Only Group",
              "Exercise and Sleep Group"
            ]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Total Cholesterol Levels",
            "description": "Measured from blood sample",
            "timeFrame": "Up to Week 12"
          },
          {
            "measure": "High-Density Lipoprotein (HDL) Levels",
            "description": "Measured from blood sample",
            "timeFrame": "Up to Week 12"
          },
          {
            "measure": "Low-Density Lipoprotein (LDL) Levels",
            "description": "Measured from blood sample",
            "timeFrame": "Up to Week 12"
          },
          {
            "measure": "Triglycerides Levels",
            "description": "Measured from blood sample",
            "timeFrame": "Up to Week 12"
          },
          {
            "measure": "High-sensitivity C-reactive protein (hs-CRP) Levels",
            "description": "Measured from blood sample",
            "timeFrame": "Up to Week 12"
          },
          {
            "measure": "HbA1c Levels",
            "description": "Measured from blood sample",
            "timeFrame": "Up to Week 12"
          },
          {
            "measure": "Heart Rate",
            "description": "Measured from Fitbit",
            "timeFrame": "Up to Week 12"
          },
          {
            "measure": "Blood Pressure",
            "description": "Measured from Fitbit",
            "timeFrame": "Up to Week 12"
          },
          {
            "measure": "Total Sleep Duration",
            "description": "Measured from DREEM 2",
            "timeFrame": "Up to Week 12"
          },
          {
            "measure": "Slow Wave Sleep Duration",
            "description": "Measured from DREEM 2",
            "timeFrame": "Up to Week 12"
          },
          {
            "measure": "Cortisol Levels",
            "description": "Measured from Urine Sample",
            "timeFrame": "Up to Week 12"
          },
          {
            "measure": "Cortisone Levels",
            "description": "Measured from Urine Sample",
            "timeFrame": "Up to Week 12"
          },
          {
            "measure": "Melatonin Levels",
            "description": "Measured from Urine Sample",
            "timeFrame": "Up to Week 12"
          },
          {
            "measure": "Creatinine Levels",
            "description": "Measured from Urine Sample",
            "timeFrame": "Up to Week 12"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n1. Able to perform mild exercise\n2. Able to wear DREEM 2 Headband\n3. Able to wear a Fitbit wrist watch\n4. Able to perform the Everlywell biomarker procedure\n5. Able to Understand and Speak English\n6. Able to operate a digital device like mobile phone, iPad, or computer\n7. Self-reported history of problems with cognitive impairment: memory, concentration, and processing information\n8. Only participants cognitively able and willing to provide consent will be included.\n\nExclusion Criteria:\n\n1. Prohibited from or unable to perform mild exercise\n2. Unable to wear wrist watch or headband devices, or unable to supply pinprick blood sample for any reason\n3. Unable to speak or understand English\n4. Unable to use mobile device/smartphone technology\n5. Unable or unwilling to consent for any reason.",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "45 Years",
        "maximumAge": "80 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "centralContacts": [
          {
            "name": "Azizi A Seixas, PhD",
            "role": "CONTACT",
            "phone": "3052431301",
            "email": "Azizi.seixas@med.miami.edu"
          },
          {
            "name": "Debbie Chung, PhD",
            "role": "CONTACT",
            "phone": "3052431301",
            "email": "dxc1729@miami.edu"
          }
        ],
        "overallOfficials": [
          {
            "name": "Azizi A Seixas, PhD",
            "affiliation": "University of Miami",
            "role": "PRINCIPAL_INVESTIGATOR"
          }
        ],
        "locations": [
          {
            "facility": "University of Miami Hospitals",
            "status": "RECRUITING",
            "city": "Miami",
            "state": "Florida",
            "zip": "33136",
            "country": "United States",
            "contacts": [
              {
                "name": "Debbie Chung, PhD",
                "role": "CONTACT",
                "phone": "3052431301",
                "email": "dxc1729@miami.edu"
              },
              {
                "name": "Azizi A Seixas, PhD",
                "role": "CONTACT",
                "phone": "3052431301",
                "email": "Azizi.seixas@med.miami.edu"
              },
              { "name": "Azizi A Seixas, PhD", "role": "CONTACT" },
              { "name": "Debbie Chung, PhD", "role": "CONTACT" },
              { "name": "Alberto Ramos, MD", "role": "CONTACT" }
            ],
            "geoPoint": { "lat": 25.77427, "lon": -80.19366 }
          }
        ]
      },
      "ipdSharingStatementModule": { "ipdSharing": "NO" }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [{ "id": "D000544", "term": "Alzheimer Disease" }],
        "ancestors": [
          { "id": "D003704", "term": "Dementia" },
          { "id": "D001927", "term": "Brain Diseases" },
          { "id": "D002493", "term": "Central Nervous System Diseases" },
          { "id": "D009422", "term": "Nervous System Diseases" },
          { "id": "D024801", "term": "Tauopathies" },
          { "id": "D019636", "term": "Neurodegenerative Diseases" },
          { "id": "D019965", "term": "Neurocognitive Disorders" },
          { "id": "D001523", "term": "Mental Disorders" }
        ],
        "browseLeaves": [
          {
            "id": "M3885",
            "name": "Alzheimer Disease",
            "asFound": "Alzheimer's Disease",
            "relevance": "HIGH"
          },
          { "id": "M6904", "name": "Dementia", "relevance": "LOW" },
          { "id": "M5204", "name": "Brain Diseases", "relevance": "LOW" },
          {
            "id": "M5742",
            "name": "Central Nervous System Diseases",
            "relevance": "LOW"
          },
          { "id": "M23002", "name": "Tauopathies", "relevance": "LOW" },
          {
            "id": "M21558",
            "name": "Neurodegenerative Diseases",
            "relevance": "LOW"
          },
          {
            "id": "M21836",
            "name": "Neurocognitive Disorders",
            "relevance": "LOW"
          },
          { "id": "M14473", "name": "Psychotic Disorders", "relevance": "LOW" },
          { "id": "M4815", "name": "Mental Disorders", "relevance": "LOW" },
          {
            "id": "T2192",
            "name": "Familial Alzheimer Disease",
            "relevance": "LOW"
          }
        ],
        "browseBranches": [
          { "abbrev": "BC10", "name": "Nervous System Diseases" },
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" },
          { "abbrev": "All", "name": "All Conditions" },
          { "abbrev": "Rare", "name": "Rare Diseases" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT05921747",
        "orgStudyIdInfo": { "id": "SSAHS 2023/01" },
        "organization": {
          "fullName": "Shalamar Institute of Health Sciences",
          "class": "OTHER"
        },
        "briefTitle": "The Impact of Innovative Technology Strategies on Implementing Exercise Programs Using Fully Immersive Virtual Reality for Postpartum Women",
        "officialTitle": "The Impact of Innovative Technology Strategies on Implementing Exercise Programs Using Fully Immersive Virtual Reality for Postpartum Women"
      },
      "statusModule": {
        "statusVerifiedDate": "2025-02",
        "overallStatus": "RECRUITING",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2023-10-02", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2025-06-03",
          "type": "ESTIMATED"
        },
        "completionDateStruct": { "date": "2025-10-01", "type": "ESTIMATED" },
        "studyFirstSubmitDate": "2023-04-17",
        "studyFirstSubmitQcDate": "2023-06-19",
        "studyFirstPostDateStruct": { "date": "2023-06-27", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2025-02-11",
        "lastUpdatePostDateStruct": { "date": "2025-02-13", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": {
          "name": "Shalamar Institute of Health Sciences",
          "class": "OTHER"
        }
      },
      "oversightModule": {
        "oversightHasDmc": true,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": false,
        "isUsExport": false
      },
      "descriptionModule": {
        "briefSummary": "The study aims to determine the effect of core stability exercise through using fully immersive virtual reality in postpartum female with lumbopelvic pain.\n\nThis study will be randomized clinical -trial and will be conducted at Shalamar Institute of health sciences in 1 year after the approval by institutional review board. Sixty female participants with a history of lumbopelvic pain will be recruited on the basis of inclusion and exclusion criteria. Data will be collected after taking written Informed Consent from each patient. The included participants will be randomized by gold fish randomization method and allocated to two groups (A \\& B) each with 30 participants.",
        "detailedDescription": "Lumbopelvic pain refers to self-reported pain in the lower back, sacroiliac joints, or a combination of these locations, among pregnant and postnatal women. Approximately 50% of pregnant women report lumbopelvic pain to some degree. Recent studies indicate the importance of hip extensors, pelvic floor muscle (PFM) and transverse abdominal muscle (TrAM) in the development of lumbopelvic pain.Moreover, pelvic instability, asymmetry and insufficient compression of the sacroiliac joints contribute to continuous lumbopelvic pain after delivery. In Europe every tenth women shortly postpartum and every sixth has reported similar symptoms 6 weeks later. Age, PGP during pregnancy and abdominal midline doming were associated with experiencing PGP shortly postpartum.\n\nStudies have demonstrated the importance of choosing an optimal treatment strategy in clinical practice, and 5 subgroups of self-rated pain locations have been identified in the pelvic area. The study focused on pelvic girdle pain (PGP), or PGP in combination with lumbar pain, since these groups have been shown to have the highest impact on activity levels and health-related quality of life.\n\nStabilization exercises that include dynamically controlling the lumbar segments and pelvic joints have been shown to result in functional improvement in patients with lumbopelvic pain. The term \"core stability\" is commonly used to refer to the ability of these \"core\" muscles to stabilize the lumbar spine and pelvic girdle during static postures and dynamic movements. A host of theories and \"stabilization exercise\" programs have been developed to train these muscles as a means of treating and/or preventing lower back pain (LBP). However, there is still much inconsistency and debate both in the clinical and research communities with regards to what constitutes \"core stability\" and a \"stabilization exercise\". Chronic pain is a global healthcare burden with as much as of 11% of the US population suffering from pain lasting six months or longer, and upwards of 20% in Europe. Chronic pain can lead to depression, anxiety, sleep disturbances, and impairment in cognitive tasks.\n\nEstablished research supports VR(virtual relaity) as a treatment strategy for burn pain, acute pain, and experimentally induced pain. Two primary approaches afford analgesic benefits of VR: distraction therapy and immersive-ness. Distraction therapy temporarily takes attention away from pain while patients are engaged in the VR experience. In immersive VR, the user can interact with an artificial environment to treat chronic pain. In immersive VR, the user can interact with an artificial environment to treat chronic pain. One form of immersive VR is virtual embodiment. Virtual embodiment refers to the sense of owning a virtual body, from a first-person perspective, feeling the agent of the sensory feedback related to the actions of the virtual body. Through activation of somatosensory and premotor circuitry associated with the body parts that are embodied, the use of virtual embodiment as an immersive VR technique has been shown to influence pain-free range of motion in patients with unilateral chronic shoulder pain.\n\nA case series was conducted in 2020, in which they describe two case studies that use embodiment in virtual reality as a treatment for chronic low back pain. The purpose of this case series was to determine the feasibility of a novel virtual reality-based digital therapeutic for the treatment of chronic pain. Two patients with chronic low back pain received seven sessions, two sessions per week, of a novel digital therapeutic that combines virtual embodiment with graded motor imagery to deliver functional rehabilitation exercises using an off-the-shelf virtual reality system. Pain catastrophizing scale was assessed before the first session and after the seventh session to determine the extent to which virtual embodiment training can improve psychological symptoms of chronic low back pain. In both patients, pain intensity was improved after individual sessions of virtual embodiment training. They concluded that embodiment in virtual reality improves symptoms of persistent chronic low back pain.\n\nA study (RCT) was conducted in 2022 and their study have measured the Effects of a motor control exercise program on lumbopelvic pain recurrences and intensity in pregnant women with a history of lumbopelvic pain. Forty pregnant women with a history of lower back pelvic pain (LBPP) were recruited and randomly allocated to a control (20 participants) or intervention (20 participants) group. The control group have received standard prenatal care, including basic information on what to do when suffering from LBPP. The intervention group have participated in three 40-min exercise sessions per week from \\< 20 weeks until 34-36 weeks of gestation: one supervised group session via the Zoom platform (once a month) and two unsupervised sessions at home. A motor control exercise program was developed to target strengthening of the lumbo-pelvic-hip core muscles and to improve spinal and pelvic stabilization. Participants of this group have also received standard prenatal care. They concluded that motor control exercise program have allowed pregnant women to progress at their own pace through different levels of exercises. In addition, the use of technology in the follow-up of the women will make the approach flexible and adapted to their daily routines.\n\nThe purpose of the study is to reduce the potential abuse, dependency of painkillers and manual therapy intervention for treating chronic lumbopelvic pain. In order to promote an advance and noninvasive method for treating lumbopelvic pain in postpartum female this study will help to design better rehabilitative program including core stability exercise using the analgesic and distracting effects of Immersive Virtual reality. This study will help physiotherapist as well as other health care professionals to treat other factors contributing to lumbopelvic pain other than weak muscles and posture alignment in postpartum female through virtual reality."
      },
      "conditionsModule": { "conditions": ["Post Partum Lumbopelvic Pain"] },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "interventionModelDescription": "After selecting the desired sample size (tentative 17) the subjects will be randomly allocated to the both treatment groups",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": {
            "masking": "DOUBLE",
            "maskingDescription": "The participants consented to participate will be assigned a unique number. The detailed list will be kept confidentially under the custody of the Principal Investigator. Unique numbered envelop will be provided to the participant. The participant will tell his number to the receptionist. The receptionist will send the participant to treatment room according to randomly allocation list. An outcome assessor will fill the form after treatment.",
            "whoMasked": ["PARTICIPANT", "OUTCOMES_ASSESSOR"]
          }
        },
        "enrollmentInfo": { "count": 34, "type": "ESTIMATED" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "Core stability exercise by Physiotherapist",
            "type": "ACTIVE_COMPARATOR",
            "description": "Postpartum women in this group will receive standard core stability exercise program (Bridging, Pelvic rotation, Abdominal Tuck in, Knee to chest and Squatting) under the supervision of physiotherapist.",
            "interventionNames": [
              "Other: Standard core stability exercise program"
            ]
          },
          {
            "label": "Core stability exercise by Virtual Reality",
            "type": "EXPERIMENTAL",
            "description": "Postpartum patients with lumbopelvic pain will receive two sessions per week for a period of 4 weeks of a novel digital therapeutic that combines virtual embodiment with graded motor imagery to deliver functional rehabilitation exercises using an off-the-shelf virtual reality system. The core stability exercises included Bridging, Pelvic rotation, Abdominal Tuck in, Knee to chest and Squatting. Pre and post measurement will be taken before and after the session.",
            "interventionNames": [
              "Other: Standard core stability exercise program",
              "Device: Off-the-shelf virtual reality system"
            ]
          }
        ],
        "interventions": [
          {
            "type": "OTHER",
            "name": "Standard core stability exercise program",
            "description": "The core stability exercises included Bridging, Pelvic rotation, Abdominal Tuck in, Knee to chest and Squatting. Pre and post measurement will be taken before and after the session.",
            "armGroupLabels": [
              "Core stability exercise by Physiotherapist",
              "Core stability exercise by Virtual Reality"
            ]
          },
          {
            "type": "DEVICE",
            "name": "Off-the-shelf virtual reality system",
            "description": "HTC Vive (HTC Corporation, Bellevue, WA) VR Head-Mounted Display (110º field of view, 1080 × 1200 pixels/eye, 90 Hz refresh) along with the Vive hand controllers and trackers to provide an immersive VR experience. The Vive Tracker can be used to track limb and trunk position and motion while in a VR experience. This setup will be paired with a gaming computer with the power to run a VR experience at a high frame rate to mitigate the risk of motion sickness. KVET™( Karuna Virtual Embodiment Training) consists of 10-30 minute sessions of exercises in an embodied VR experience.",
            "armGroupLabels": ["Core stability exercise by Virtual Reality"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Effect on lumbopelvic pain",
            "description": "During pregnancy, women go through several hormonal and biomechanical changes as well as neuromuscular adaptations which could explain the development of lumbopelvic pain. Pregnancy-related hormonal changes, characterized by an increase in relaxin, estrogen and progesterone levels, are potentially linked to hyperlaxity of ligament and joint instability, thus contributing to lumbopelvic pain. In addition, biomechanical changes induced by the growing fetus, can modify posture, load sharing and mechanical stress in the lumbar and pelvic structures. Finally, neuromuscular adaptations during pregnancy include an increase in the activation of lumbopelvic muscles and a decrease in endurance of the pelvic floor muscles. Short Form McGill Pain Questionnaire(SF-MPQ) will be used to determine the intensity of pain.\n\nThe main component of the SF-MPQ consists of 15 descriptors (11 sensory; 4 affective) which are rated on an intensity scale as 0 = none, 1 = mild, 2 = moderate or 3 = severe.",
            "timeFrame": "Baseline (Day 0) and Follow up 1 (Day 30) after 8 sessions of treatment."
          },
          {
            "measure": "Effect on disability due to lumbopelvic pain",
            "description": "Due to physiological changes the pregnant female experience lumber pain. to determine lumber pain Oswestry Disability Index (ODI) will be used.\n\nODI scale will include following levels for assessment 0 - 4 No disability 5 - 14 Mild disability 15 - 24 Moderate disability 25 - 34 Severe disability 35 - 50 Completely disabled",
            "timeFrame": "Baseline (Day 0) and Follow up 1 (Day 30) after 8 sessions of treatment."
          },
          {
            "measure": "Effect on disability due to pelvic pain",
            "description": "Pelvic Floor Disability Index ( PFDI) will be used to assesses the distress of pelvic organ prolapse (POP), anorectal and urinary symptoms in three subscales, respectively, Pelvic Organ Prolapse Distress Inventory (POPDI-6), Colorectal-Anal Distress Inventory (CRADI-8) and Urinary Distress Inventory (UDI-6) .The PFDI-20 has 20 items and 3 scales of your symptoms. All items use the following format with a response scale from 0 to 4. Scale Scores",
            "timeFrame": "Baseline (Day 0) and Follow up 1 (Day 30) after 8 sessions of treatment."
          },
          {
            "measure": "Effect on functioning",
            "description": "Patient Specific Functional Scale(PSFS) will be used. This scale will nominate 3 to 5 activities that they are unable to do or having difficulty doing because of their injury or problem. These activities are rated on an 11-point scale, where 0 is unable to perform the activity and 10 is able to perform the activity at preinjury level.",
            "timeFrame": "Baseline (Day 0) and Follow up 1 (Day 30) after 8 sessions of treatment."
          },
          {
            "measure": "Level of Depression, anxiety & stress",
            "description": "DASS (Depression anxiety stress scale)questionnaire will be used for assessment. The total score represents overall distress (0 to 30), with higher scores indicating more severe distress or a greater number of symptoms. Two subscales are presented: Anxiety-Stress: Items 1, 4, 6, 7, 8, 9 (raw score range = 0 to 18) Depression: Items 2, 3, 5, 10 (raw score range = 0 to 12)",
            "timeFrame": "Baseline (Day 0) and Follow up 1 (Day 30) after 8 sessions of treatment."
          },
          {
            "measure": "To access intensity of Pain",
            "description": "Visual analog scale (VAS) will be used to determine the intensity of pain. The Visual Analogue Scale (VAS) measures pain intensity. The VAS consists of a 10cm line, with two end points representing 0 ('no pain') and 10 ('pain as bad as it could possibly be')",
            "timeFrame": "Baseline (Day 0) and Follow up 1 (Day 30) after 8 sessions of treatment."
          },
          {
            "measure": "condition-specific measure for women with pelvic girdle pain",
            "description": "Pelvic Girdle Questionnaire (PGQ) will be used .To calculate the total PGQ score, all scores are summarized and divided by the total possible score of 75 (maximum possible scores of 60 for activity and 15 for symptoms), subsequently recalculated to a percentage, resulting in percentage scores ranging from 0 (no disability) to 100 (severe disability).",
            "timeFrame": "Baseline (Day 0) and Follow up 1 (Day 30) after 8 sessions of treatment."
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Level of Urinary incontinence",
            "description": "Urinary Distress Index will be used to access distress caused by urinary incontinence.UDI-6 scores more than 33.33 indicate higher distress caused by urinary incontinence symptoms.",
            "timeFrame": "Baseline (Day 0) and Follow up 1 (Day 30) after 8 sessions of treatment."
          },
          {
            "measure": "To access fear of movement",
            "description": "Tampa scale of kinesiophobia (TSK). TSK total scores range from 17 to 68 where the lowest 17 means no or negligible kinesiophobia, and the higher scores indicate an increasing degree of kinesiophobia",
            "timeFrame": "Baseline (Day 0) and Follow up 1 (Day 1), Follow Up 2, (Day 8)"
          },
          {
            "measure": "Psychological assessment (Rumination, Magnification &Helplessness)",
            "description": "Pain Catastrophizing Scale will be used for measurement. Patients are asked to rate the degree to which they have any of the thoughts described in the questionnaire using a 5-point Likert scale ranging from 0 (never) to 4 (always). The total score is the sum of the scores for the individual items, and ranges from 0 to 52.",
            "timeFrame": "Baseline (Day 0) and Follow up 1 (Day 1), Follow Up 2, (Day 8)"
          }
        ],
        "otherOutcomes": [
          {
            "measure": "Presence of Vestibular basilar artery insufficiency (VBI)",
            "description": "VBI test will be performed for assessment. Test is considered positive if there is dropping of the arms, loss of balance, or pronation of the hands; a positive result indicates decreased blood supply to the brain.\n\nIf it turns out positive then patient wont be included in the research due to use of Virtual reality.",
            "timeFrame": "Pre Treatment one time (Day 0)"
          },
          {
            "measure": "Presence of Simulator Sickness",
            "description": "Simulator Sickness Questionnaire (SSQ) will be used for assessment .The overall support score (SSQN) is calculated by taking an average of the individual scores across the 27 items. A high score on the SSQ indicates more optimism about life than a low score. Respondents with low SSQ scores have a higher prevalence of negative life events and illness.",
            "timeFrame": "Baseline (Day 0) and Follow up 1 (Day 1), Follow Up 2, (Day 8)"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* Postpartum women with acute and chronic lumbopelvic pain.\n* Primary parous \\& multiparous women.\n\nExclusion Criteria:\n\n* Postpartum women with nausea, dizziness and blurred vision, high risk pregnancies.\n* Structural disorder of spinal alignment (Scoliosis, kyphosis, lordosis)\n* Traumatic/ Inflammatory / Infectious Conditions\n* Diagnosed stress / depression\n* History of spinal, pelvic, or femur surgery or previous fracture, neoplasm\n* Any Previous history of backache",
        "healthyVolunteers": false,
        "sex": "FEMALE",
        "genderBased": true,
        "genderDescription": "Post partum Female",
        "minimumAge": "20 Years",
        "maximumAge": "40 Years",
        "stdAges": ["ADULT"]
      },
      "contactsLocationsModule": {
        "centralContacts": [
          {
            "name": "Javeria Dr Associate Professor (OMPT), Ph. D",
            "role": "CONTACT",
            "phone": "03119353656",
            "email": "jayaslam27@gmail.com"
          },
          {
            "name": "Arslan Mr Senior Lecturer (Biostatistics), M.Phil",
            "role": "CONTACT",
            "phone": "03334585339",
            "email": "arslan.saleem@sihs.org.pk"
          }
        ],
        "overallOfficials": [
          {
            "name": "Javeria Dr Aslam, Ph.D",
            "affiliation": "Shalamar Institute of Health Sciences",
            "role": "PRINCIPAL_INVESTIGATOR"
          },
          {
            "name": "Carlos R. Morales, Ph.D",
            "affiliation": "Universided Europea Madrid, Spain",
            "role": "STUDY_DIRECTOR"
          },
          {
            "name": "RAQUEL DIAZ-MECO, Ph.D",
            "affiliation": "Universided Europea Madrid, Spain",
            "role": "STUDY_DIRECTOR"
          },
          {
            "name": "Alba P. Alemany, Ph.D",
            "affiliation": "Department of Radiology & Physical Medicine, Complutense University of Madrid, Spain",
            "role": "PRINCIPAL_INVESTIGATOR"
          }
        ],
        "locations": [
          {
            "facility": "Shalamar School of Allied Health Sciences",
            "status": "RECRUITING",
            "city": "Lahore",
            "state": "Punjab",
            "zip": "54840",
            "country": "Pakistan",
            "contacts": [
              {
                "name": "Javeria Aslam, MS",
                "role": "CONTACT",
                "phone": "009242111205205",
                "phoneExt": "527",
                "email": "javeria.aslam@sihs.org.pk"
              },
              {
                "name": "Nadia Anwer, MS",
                "role": "CONTACT",
                "phone": "009242111205205",
                "phoneExt": "527",
                "email": "nadia.anwer@sihs.org.pk"
              }
            ],
            "geoPoint": { "lat": 31.558, "lon": 74.35071 }
          }
        ]
      },
      "referencesModule": {
        "references": [
          {
            "pmid": "32735717",
            "type": "BACKGROUND",
            "citation": "Vesentini G, Prior J, Ferreira PH, Hodges PW, Rudge M, Ferreira ML. Pelvic floor muscle training for women with lumbopelvic pain: A systematic review and meta-analysis. Eur J Pain. 2020 Nov;24(10):1865-1879. doi: 10.1002/ejp.1636. Epub 2020 Sep 6."
          },
          {
            "pmid": "35295430",
            "type": "BACKGROUND",
            "citation": "Daneau C, Abboud J, Marchand AA, Houle M, Pasquier M, Ruchat SM, Descarreaux M. Mechanisms Underlying Lumbopelvic Pain During Pregnancy: A Proposed Model. Front Pain Res (Lausanne). 2021 Dec 2;2:773988. doi: 10.3389/fpain.2021.773988. eCollection 2021."
          },
          {
            "pmid": "34217002",
            "type": "BACKGROUND",
            "citation": "Catena RD, Wolcott WC. Self-selection of gestational lumbopelvic posture and bipedal evolution. Gait Posture. 2021 Sep;89:7-13. doi: 10.1016/j.gaitpost.2021.06.022. Epub 2021 Jun 26."
          },
          {
            "pmid": "36266709",
            "type": "BACKGROUND",
            "citation": "Starzec-Proserpio M, Wegrzynowska M, Sys D, Kajdy A, Rongies W, Baranowska B. Prevalence and factors associated with postpartum pelvic girdle pain among women in Poland: a prospective, observational study. BMC Musculoskelet Disord. 2022 Oct 20;23(1):928. doi: 10.1186/s12891-022-05864-y."
          },
          {
            "pmid": "30282349",
            "type": "BACKGROUND",
            "citation": "Saleh MSM, Botla AMM, Elbehary NAM. Effect of core stability exercises on postpartum lumbopelvic pain: A randomized controlled trial. J Back Musculoskelet Rehabil. 2019;32(2):205-213. doi: 10.3233/BMR-181259."
          },
          {
            "pmid": "31016337",
            "type": "BACKGROUND",
            "citation": "Ehsani F, Sahebi N, Shanbehzadeh S, Arab AM, ShahAli S. Stabilization exercise affects function of transverse abdominis and pelvic floor muscles in women with postpartum lumbo-pelvic pain: a double-blinded randomized clinical trial study. Int Urogynecol J. 2020 Jan;31(1):197-204. doi: 10.1007/s00192-019-03877-1. Epub 2019 Apr 23."
          },
          {
            "pmid": "32986655",
            "type": "BACKGROUND",
            "citation": "Sonmezer E, Ozkoslu MA, Yosmaoglu HB. The effects of clinical pilates exercises on functional disability, pain, quality of life and lumbopelvic stabilization in pregnant women with low back pain: A randomized controlled study. J Back Musculoskelet Rehabil. 2021;34(1):69-76. doi: 10.3233/BMR-191810."
          },
          {
            "pmid": "33269003",
            "type": "BACKGROUND",
            "citation": "Trujillo MS, Alvarez AF, Nguyen L, Petros J. Embodiment in Virtual Reality for the Treatment of Chronic Low Back Pain: A Case Series. J Pain Res. 2020 Nov 25;13:3131-3137. doi: 10.2147/JPR.S275312. eCollection 2020."
          },
          {
            "pmid": "36064584",
            "type": "BACKGROUND",
            "citation": "Luo Y, He L, Li Y, Xie J, Gong S, Zhang Q, Yin E, Gu M, Yi C. Sacral osteotomy combined with triangular osteosynthesis in the treatment of malunion and nonunion of vertically displaced pelvic fractures. J Orthop Surg Res. 2022 Sep 5;17(1):409. doi: 10.1186/s13018-022-03296-x."
          },
          {
            "pmid": "35322080",
            "type": "BACKGROUND",
            "citation": "Matamala-Gomez M, Slater M, Sanchez-Vives MV. Impact of virtual embodiment and exercises on functional ability and range of motion in orthopedic rehabilitation. Sci Rep. 2022 Mar 23;12(1):5046. doi: 10.1038/s41598-022-08917-3."
          },
          {
            "pmid": "35313988",
            "type": "BACKGROUND",
            "citation": "Daneau C, Marchand AA, Bussieres A, O'Shaughnessy J, Ruchat SM, Descarreaux M. Effects of a motor control exercise program on lumbopelvic pain recurrences and intensity in pregnant women with a history of lumbopelvic pain: a study protocol for a randomized controlled feasibility trial. Pilot Feasibility Stud. 2022 Mar 21;8(1):65. doi: 10.1186/s40814-022-01024-0."
          },
          {
            "pmid": "25997987",
            "type": "BACKGROUND",
            "citation": "Beales D, Lutz A, Thompson J, Wand BM, O'Sullivan P. Disturbed body perception, reduced sleep, and kinesiophobia in subjects with pregnancy-related persistent lumbopelvic pain and moderate levels of disability: An exploratory study. Man Ther. 2016 Feb;21:69-75. doi: 10.1016/j.math.2015.04.016. Epub 2015 May 1."
          },
          {
            "type": "BACKGROUND",
            "citation": "Kale, A.A. and Pathan, N.M., 2019. Effect of Core Stabilisation Exercises in Postnatal Women with Lumbo-Pelvic Instability. Indian Journal of Physiotherapy and Occupational Therapy, 13(2), p.19."
          }
        ]
      },
      "ipdSharingStatementModule": { "ipdSharing": "NO" }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "browseLeaves": [
          { "id": "M13066", "name": "Pain", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "BC23", "name": "Symptoms and General Pathology" },
          { "abbrev": "All", "name": "All Conditions" }
        ]
      },
      "interventionBrowseModule": {
        "browseLeaves": [
          { "id": "T326", "name": "Witch Hazel", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "HB", "name": "Herbal and Botanical" },
          { "abbrev": "All", "name": "All Drugs and Chemicals" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT05958095",
        "orgStudyIdInfo": { "id": "CU-T-003" },
        "organization": {
          "fullName": "Healthcare Innovation Technology Lab",
          "class": "INDUSTRY"
        },
        "briefTitle": "Curio Digital Therapy for the Treatment of Post-partum Depression",
        "officialTitle": "Supporting Maternal Mental Health and Emotional Regulation (SuMMER): Assessment of the Clinical Effectiveness of a Mobile Application for Patients With Postpartum Depression",
        "acronym": "SuMMER"
      },
      "statusModule": {
        "statusVerifiedDate": "2023-07",
        "overallStatus": "ACTIVE_NOT_RECRUITING",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2023-04-01", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2023-05-24",
          "type": "ACTUAL"
        },
        "completionDateStruct": { "date": "2023-08-15", "type": "ESTIMATED" },
        "studyFirstSubmitDate": "2023-07-14",
        "studyFirstSubmitQcDate": "2023-07-14",
        "studyFirstPostDateStruct": { "date": "2023-07-24", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2023-07-14",
        "lastUpdatePostDateStruct": { "date": "2023-07-24", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": {
          "type": "PRINCIPAL_INVESTIGATOR",
          "investigatorFullName": "Stan Kachnowski",
          "investigatorTitle": "Chair",
          "investigatorAffiliation": "Healthcare Innovation Technology Lab"
        },
        "leadSponsor": {
          "name": "Healthcare Innovation Technology Lab",
          "class": "INDUSTRY"
        },
        "collaborators": [
          { "name": "Curio Digital Therapeutics, Inc.", "class": "INDUSTRY" }
        ]
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": true,
        "isUnapprovedDevice": true
      },
      "descriptionModule": {
        "briefSummary": "Primary Objective: Evaluate the clinical effectiveness of the MamaLift Plus app compared to control (digital sham plus treatment as usual) for the management of PPD in the observed population for a period of 9 calendar weeks. It is hypothesized that women who use the MamaLift Plus APP will experience less severe symptoms of depression in post-partum period than comparable women who do not and receive their usual care from health providers.",
        "detailedDescription": "Women between 18 and 50 years of age who have had a live birth within 3 months prior to study start date and have a diagnosis of mild to moderate PPD. A total of 200 women will be recruited to volunteer in the study with 166 assigned to the intervention arm and 37 assigned to the control group."
      },
      "conditionsModule": {
        "conditions": ["PostPartum Depression"],
        "keywords": [
          "PostPartum depression (PPD), symptoms of PPD, Anxiety, Peri-natal depression, mild-to-moderate depression"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "interventionModelDescription": "The data of 200 participants will be collected and analyzed for this study. Participants will be selected from a pool of patients who have given birth in the last three months prior to the study start date and been diagnosed with postpartum depression or have experienced depressive symptoms. The study aims to recruit a diverse study cohort across age, race, and SES to reflect the intended user population in the United States.",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": {
            "masking": "SINGLE",
            "maskingDescription": "Participants are not aware of whether they are receiving the MamaLift Plus interventional device or the digital placebo device. The applications have the same user interface and require a similar amount of time to complete activities. Participants in both arms will receive treatment as usual in addition.",
            "whoMasked": ["PARTICIPANT"]
          }
        },
        "enrollmentInfo": { "count": 142, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "MamaLift Plus",
            "type": "EXPERIMENTAL",
            "description": "Principles of Cognitive Behavioral Therapy used to treat PPD with App",
            "interventionNames": ["Device: MamaLift Plus"]
          },
          {
            "label": "Digital Sham App",
            "type": "SHAM_COMPARATOR",
            "description": "Content on general mental health and wellbeing topics delivered with sham App",
            "interventionNames": ["Device: Digital Sham App"]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "MamaLift Plus",
            "description": "MamaLift Plus is a digital therapeutic designed to augment usual care and support the treatment of mild-to-moderate postpartum depression (PPD). This mobile-based intervention is grounded on principles of Cognitive Behavioral Therapy (CBT) and Interpersonal Therapy (IPT) and includes key content areas for the treatment management of PPD. It also includes recent developments in acceptance and commitment-based therapies, specifically for the perinatal context.",
            "armGroupLabels": ["MamaLift Plus"]
          },
          {
            "type": "DEVICE",
            "name": "Digital Sham App",
            "description": "The digital sham app delivers content, tips, and suggestion for general wellbeing support.",
            "armGroupLabels": ["Digital Sham App"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "EPDS Score",
            "description": "Proportion of women that improve EPDS by \\>= 4 points at their end of study assessment.",
            "timeFrame": "9 week period"
          },
          {
            "measure": "EPDS Score improvement",
            "description": "Proportion of women that improve EPDS to \\< 13 points at their end of study assessment",
            "timeFrame": "9 week period"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* Participants must be able to read, write and speak English; 3. Participants must provide written informed consent prior to enrollment; 4. Participants must be 18 to 50 years of age at the time of enrollment; 5. Participants must have had a live childbirth \\<=3 months prior to their enrollment into the study; 6. Participants who have a score of greater than or equal to 13 but not exceeding 19 on the Edinburgh Postnatal Depression Scale (EPDS) during initial screening visit/call; 7. Depression diagnosis needs to be confirmed by licensed behavioral health therapist or medical professional; 8. Participants must answer \"0/Never\" or \"1/Hardly Ever\" to the self-harm question on EPDS (Question #10); 9. Participants must be willing to use a mobile app and own an iOS or android enabled mobile phone or device; 10. Participants must have wireless internet connectivity in their home (or have access to internet connectivity) and be willing to connect devices via a Wi-Fi network\n\nExclusion Criteria:\n\n-",
        "healthyVolunteers": true,
        "sex": "FEMALE",
        "genderBased": true,
        "genderDescription": "Adult females who delivered live births in the 3 months prior to study start",
        "minimumAge": "18 Years",
        "maximumAge": "50 Years",
        "stdAges": ["ADULT"]
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "Stan Kachnowski, PhD",
            "affiliation": "Healthcare Innovation Technology Lab",
            "role": "PRINCIPAL_INVESTIGATOR"
          }
        ],
        "locations": [
          {
            "facility": "Healthcare Innovation and Technology Lab",
            "city": "New York",
            "state": "New York",
            "zip": "10032",
            "country": "United States",
            "geoPoint": { "lat": 40.71427, "lon": -74.00597 }
          }
        ]
      },
      "ipdSharingStatementModule": { "ipdSharing": "NO" }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [
          { "id": "D019052", "term": "Depression, Postpartum" },
          { "id": "D003863", "term": "Depression" },
          { "id": "D003866", "term": "Depressive Disorder" }
        ],
        "ancestors": [
          { "id": "D001526", "term": "Behavioral Symptoms" },
          { "id": "D019964", "term": "Mood Disorders" },
          { "id": "D001523", "term": "Mental Disorders" },
          { "id": "D011644", "term": "Puerperal Disorders" },
          { "id": "D011248", "term": "Pregnancy Complications" },
          {
            "id": "D005261",
            "term": "Female Urogenital Diseases and Pregnancy Complications"
          },
          { "id": "D000091642", "term": "Urogenital Diseases" }
        ],
        "browseLeaves": [
          { "id": "M4324", "name": "Anxiety Disorders", "relevance": "LOW" },
          {
            "id": "M7061",
            "name": "Depressive Disorder",
            "asFound": "Depression",
            "relevance": "HIGH"
          },
          {
            "id": "M7058",
            "name": "Depression",
            "asFound": "Depression",
            "relevance": "HIGH"
          },
          {
            "id": "M21076",
            "name": "Depression, Postpartum",
            "asFound": "Postpartum Depression",
            "relevance": "HIGH"
          },
          { "id": "M4818", "name": "Behavioral Symptoms", "relevance": "LOW" },
          { "id": "M21835", "name": "Mood Disorders", "relevance": "LOW" },
          { "id": "M14473", "name": "Psychotic Disorders", "relevance": "LOW" },
          { "id": "M4815", "name": "Mental Disorders", "relevance": "LOW" },
          { "id": "M14499", "name": "Puerperal Disorders", "relevance": "LOW" },
          {
            "id": "M14127",
            "name": "Pregnancy Complications",
            "relevance": "LOW"
          },
          { "id": "M2875", "name": "Urogenital Diseases", "relevance": "LOW" },
          {
            "id": "M27093",
            "name": "Female Urogenital Diseases",
            "relevance": "LOW"
          },
          {
            "id": "M8399",
            "name": "Female Urogenital Diseases and Pregnancy Complications",
            "relevance": "LOW"
          }
        ],
        "browseBranches": [
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" },
          { "abbrev": "All", "name": "All Conditions" },
          {
            "abbrev": "BXS",
            "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
          }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT06136923",
        "orgStudyIdInfo": { "id": "CT-100-D-004" },
        "organization": {
          "fullName": "Click Therapeutics, Inc.",
          "class": "INDUSTRY"
        },
        "briefTitle": "An Exploratory Study to Evaluate Attention Biases in Adults With Multiple Sclerosis, Breast Cancer, and Lung Cancer",
        "officialTitle": "An Exploratory Study to Evaluate Attention Biases in Adults With Multiple Sclerosis, Breast Cancer, and Lung Cancer"
      },
      "statusModule": {
        "statusVerifiedDate": "2024-05",
        "overallStatus": "COMPLETED",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2023-10-19", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2024-04-18",
          "type": "ACTUAL"
        },
        "completionDateStruct": { "date": "2024-05-06", "type": "ACTUAL" },
        "studyFirstSubmitDate": "2023-11-01",
        "studyFirstSubmitQcDate": "2023-11-13",
        "studyFirstPostDateStruct": { "date": "2023-11-18", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2024-05-09",
        "lastUpdatePostDateStruct": { "date": "2024-05-13", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": {
          "name": "Click Therapeutics, Inc.",
          "class": "INDUSTRY"
        }
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": false,
        "isUsExport": false
      },
      "descriptionModule": {
        "briefSummary": "CT-100 is a platform that provides interactive, software based therapeutic components that may be used as part of a treatment in future software-based prescription digital therapeutics. One class of CT-100 components are Digital Neuro-activation and Modulation (DiNaMo) components. DiNaMo components target key neural systems (including but not limited to systems related to sensory-, perceptual-, affective-, pain-, attention-, cognitive control, social- and self-processing) to optimally improve a participant's health.",
        "detailedDescription": "CT-100 is a platform that provides interactive, software based therapeutic components that may be used as part of a treatment in future software-based prescription digital therapeutics. One class of CT-100 components are Digital Neuro-activation and Modulation (DiNaMo) components. DiNaMo components target key neural systems (including but not limited to systems related to sensory-, perceptual-, affective-, pain-, attention-, cognitive control, social- and self-processing) to optimally improve a participant's health.\n\nTargeted cognitive training is used to reduce symptoms relevant to multiple sclerosis (MS) and cancer. Biases to direct attention towards or away from certain stimuli can exacerbate a variety of symptoms in many different indications. For example, in chronic pain conditions, patients are more attentive to pain-related stimuli, which can lead to hypersensitization. Similarly, hypersensitivity to threat-related stimuli can exacerbate anxiety.\n\nIn this treatment, users are trained to re-orient attention away from negative stimuli, such as pain- or threat-related stimuli."
      },
      "conditionsModule": {
        "conditions": ["Multiple Sclerosis", "Lung Cancer", "Breast Cancer"],
        "keywords": [
          "Prescription digital therapeutic (PDT)",
          "Software as a Medical Device (SaMD)",
          "Smartphone app",
          "Attention Biases",
          "Cognition",
          "Multiple Sclerosis",
          "Lung Cancer",
          "Breast Cancer"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "primaryPurpose": "BASIC_SCIENCE",
          "maskingInfo": { "masking": "SINGLE", "whoMasked": ["PARTICIPANT"] }
        },
        "enrollmentInfo": { "count": 194, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "Multiple Sclerosis with Mobility Limitations Study App A",
            "type": "EXPERIMENTAL",
            "description": "Cognitive Training App CT-100-D-004-A uses implicit training with audiovisual stimuli to potentially redirect and modulate attention processes. This intervention is designed to help improve cognitive capabilities as well as redirect attentional biases to make participants less sensitive to distressing stimuli for multiple sclerosis with mobility limitations.",
            "interventionNames": ["Device: CT-100-D-004-A"]
          },
          {
            "label": "Multiple Sclerosis with Mobility Limitations Study App B",
            "type": "OTHER",
            "description": "Cognitive Training App CT-100-D-004-B uses implicit training with verbal processing exercises to potentially redirect and modulate attention processes. This intervention is designed to help improve cognitive capabilities as well as redirect attentional biases to make participants less sensitive to distressing stimuli for multiple sclerosis with mobility limitations.",
            "interventionNames": ["Device: CT-100-D-004-B"]
          },
          {
            "label": "Multiple Sclerosis without Mobility Limitations Study App A",
            "type": "EXPERIMENTAL",
            "description": "Cognitive Training App CT-100-D-004-A uses implicit training with audiovisual stimuli to potentially redirect and modulate attention processes. This intervention is designed to help improve cognitive capabilities as well as redirect attentional biases to make participants less sensitive to distressing stimuli for multiple sclerosis without mobility limitations.",
            "interventionNames": ["Device: CT-100-D-004-A"]
          },
          {
            "label": "Multiple Sclerosis without Mobility Limitations Study App B",
            "type": "OTHER",
            "description": "Cognitive Training App CT-100-D-004-B uses implicit training with verbal processing exercises to potentially redirect and modulate attention processes. This intervention is designed to help improve cognitive capabilities as well as redirect attentional biases to make participants less sensitive to distressing stimuli for multiple sclerosis without mobility limitations.",
            "interventionNames": ["Device: CT-100-D-004-B"]
          },
          {
            "label": "Oncology Breast Cancer Study App A",
            "type": "EXPERIMENTAL",
            "description": "Cognitive Training App CT-100-D-004-A uses implicit training with audiovisual stimuli to potentially redirect and modulate attention processes. This intervention is designed to help improve cognitive capabilities as well as redirect attentional biases to make participants less sensitive to distressing stimuli for breast cancer.",
            "interventionNames": ["Device: CT-100-D-004-A"]
          },
          {
            "label": "Oncology Breast Cancer Study App B",
            "type": "OTHER",
            "description": "Cognitive Training App CT-100-D-004-B uses implicit training with verbal processing exercises to potentially redirect and modulate attention processes. This intervention is designed to help improve cognitive capabilities as well as redirect attentional biases to make participants less sensitive to distressing stimuli for breast cancer.",
            "interventionNames": ["Device: CT-100-D-004-B"]
          },
          {
            "label": "Oncology Lung Cancer Study App A",
            "type": "EXPERIMENTAL",
            "description": "Cognitive Training App CT-100-D-004-A uses implicit training with audiovisual stimuli to potentially redirect and modulate attention processes. This intervention is designed to help improve cognitive capabilities as well as redirect attentional biases to make participants less sensitive to distressing stimuli for lung cancer.",
            "interventionNames": ["Device: CT-100-D-004-A"]
          },
          {
            "label": "Oncology Lung Cancer Study App B",
            "type": "OTHER",
            "description": "Cognitive Training App CT-100-D-004-B uses implicit training with verbal processing exercises to potentially redirect and modulate attention processes. This intervention is designed to help improve cognitive capabilities as well as redirect attentional biases to make participants less sensitive to distressing stimuli for lung cancer.",
            "interventionNames": ["Device: CT-100-D-004-B"]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "CT-100-D-004-A",
            "description": "Attention Biases App CT-100-D-004-A Digital Neuro-activation and Modulation (DiNaMo) component uses implicit training to redirect and strengthen attention processes. This intervention can help improve cognitive capabilities as well as redirect attentional biases to make participants less sensitive to distressing stimuli.",
            "armGroupLabels": [
              "Multiple Sclerosis with Mobility Limitations Study App A",
              "Multiple Sclerosis without Mobility Limitations Study App A",
              "Oncology Breast Cancer Study App A",
              "Oncology Lung Cancer Study App A"
            ]
          },
          {
            "type": "DEVICE",
            "name": "CT-100-D-004-B",
            "description": "Attention Biases App CT-100-D-004-B Digital Neuro-activation and Modulation (DiNaMo) component uses implicit training to redirect and strengthen attention processes. This intervention can help improve cognitive capabilities as well as redirect attentional biases to make participants less sensitive to distressing stimuli.",
            "armGroupLabels": [
              "Multiple Sclerosis with Mobility Limitations Study App B",
              "Multiple Sclerosis without Mobility Limitations Study App B",
              "Oncology Breast Cancer Study App B",
              "Oncology Lung Cancer Study App B"
            ]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Change in Patient Reported Outcomes",
            "description": "Change from baseline to Week 4 in quality of life as measured by PROMIS-29+2 (Patient Reported Outcomes Measurement Information System)",
            "timeFrame": "Baseline to Week 4"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Change in Pain Severity and Pain Interference",
            "description": "Change from baseline to Week 4 in pain severity and pain interference as measured by the Brief Pain Inventory (BPI)",
            "timeFrame": "Baseline to Week 4"
          },
          {
            "measure": "Change in Pain Catastrophizing Scale",
            "description": "Change from baseline to Week 4 Pain Catastrophizing Scale (PCS) from 0-30+",
            "timeFrame": "Baseline to Week 4"
          },
          {
            "measure": "Change in indication-specific measures MS",
            "description": "Change from baseline to Week 4 in indication-specific measures: Symbol Digit Modalities Test (SDMT) for MS",
            "timeFrame": "Baseline to Week 4"
          },
          {
            "measure": "Change in indication-specific measures Cancer",
            "description": "Change from baseline to Week 4 in indication-specific measures: Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog) for cancer",
            "timeFrame": "Baseline to Week 4"
          },
          {
            "measure": "Proportion of participants with an improvement",
            "description": "Proportion of participants with an improvement as measured by the Global Rating of Change (GRC) score from -5 to 5 at Week 4",
            "timeFrame": "Baseline to Week 4"
          },
          {
            "measure": "Engagement with Study App",
            "description": "Engagement with the Study App as measured by daily time in the Study App",
            "timeFrame": "Baseline to Week 4"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* A participant will be eligible for entry into the study if all of the following criteria are met:\n\n  1. Fluent in written and spoken English, confirmed by ability to read, understand, and sign the informed consent form\n  2. Lives in the United States\n  3. Adult between 22 and 65 years old\n  4. Meets indication-specific including criteria, as reported by the study participant with adequate clinical documentation (to be provided to the study team upon request)\n  5. Has an active email address and is willing and able to receive and respond to email messages\n  6. Has access to an internet connection during the study duration\n  7. Has an active PayPal account to receive study compensation, or is willing to create one\n  8. Willing and able to comply with study protocol and assessments\n  9. Is the sole user of an iPhone with an iPhone operating system (iOS) version 14 or later or a smartphone with an Android operating system (OS) version 10 or later for the duration of the study\n  10. Is willing and able to receive Short Message Service (SMS) text messages and notifications on their smartphone\n  11. Has access to operating headphones\n\nExclusion Criteria:\n\n* A participant will not be eligible for study entry if any of the following criteria are met:\n\n  1. Visual, dexterity or cognitive deficit so severe that it precludes the use of an App-based reaction time-based activity per investigator judgment\n  2. Severe psychiatric disorder involving a history of psychosis (e.g., schizophrenia, bipolar disorder, severe personality disorders)\n  3. Psychiatric hospitalization in the past 6 months\n  4. Participation in any research study (including studies on psychotherapy, mindfulness, cognitive training or pharmacological treatment) during the past 3 months\n  5. Initiation or change in primary disease-specific medication within 30 days prior to entering the study\n  6. Planning the introduction of new therapies (including studies on psychotherapy, mindfulness, cognitive training or pharmacological treatment) during the study duration (6 weeks)\n  7. Anticipating a change in current pharmacological or psychotherapy treatment regimen during the study period (6 weeks)\n  8. Self-reported substance use disorder within the past 1 year\n  9. Severe neurological disorders impairing brain function (e.g., previous stroke, dementia, primary brain function, brain metastases, Alzheimer's disease, Parkinson's disease, history of significant head trauma followed by persistent neurologic deficits or known structural brain abnormalities)\n  10. Mild, moderate, severe or profound unilateral or bilateral hearing loss",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "22 Years",
        "maximumAge": "65 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "Shaheen Lakhan",
            "affiliation": "Click Therapeutics",
            "role": "STUDY_DIRECTOR"
          }
        ],
        "locations": [
          {
            "facility": "Click Therapeutics",
            "city": "New York",
            "state": "New York",
            "zip": "10013",
            "country": "United States",
            "geoPoint": { "lat": 40.71427, "lon": -74.00597 }
          }
        ]
      }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [
          { "id": "D001943", "term": "Breast Neoplasms" },
          { "id": "D008175", "term": "Lung Neoplasms" },
          { "id": "D009103", "term": "Multiple Sclerosis" },
          { "id": "D012598", "term": "Sclerosis" }
        ],
        "ancestors": [
          { "id": "D009371", "term": "Neoplasms by Site" },
          { "id": "D009369", "term": "Neoplasms" },
          { "id": "D001941", "term": "Breast Diseases" },
          { "id": "D012871", "term": "Skin Diseases" },
          { "id": "D012142", "term": "Respiratory Tract Neoplasms" },
          { "id": "D013899", "term": "Thoracic Neoplasms" },
          { "id": "D008171", "term": "Lung Diseases" },
          { "id": "D012140", "term": "Respiratory Tract Diseases" },
          { "id": "D010335", "term": "Pathologic Processes" },
          { "id": "D020278", "term": "Demyelinating Autoimmune Diseases, CNS" },
          {
            "id": "D020274",
            "term": "Autoimmune Diseases of the Nervous System"
          },
          { "id": "D009422", "term": "Nervous System Diseases" },
          { "id": "D003711", "term": "Demyelinating Diseases" },
          { "id": "D001327", "term": "Autoimmune Diseases" },
          { "id": "D007154", "term": "Immune System Diseases" }
        ],
        "browseLeaves": [
          {
            "id": "M12060",
            "name": "Multiple Sclerosis",
            "asFound": "Multiple Sclerosis",
            "relevance": "HIGH"
          },
          {
            "id": "M15415",
            "name": "Sclerosis",
            "asFound": "Sclerosis",
            "relevance": "HIGH"
          },
          {
            "id": "M5220",
            "name": "Breast Neoplasms",
            "asFound": "Breast Cancer",
            "relevance": "HIGH"
          },
          {
            "id": "M11172",
            "name": "Lung Neoplasms",
            "asFound": "Lung Cancer",
            "relevance": "HIGH"
          },
          { "id": "M5218", "name": "Breast Diseases", "relevance": "LOW" },
          { "id": "M15674", "name": "Skin Diseases", "relevance": "LOW" },
          {
            "id": "M14979",
            "name": "Respiratory Tract Neoplasms",
            "relevance": "LOW"
          },
          { "id": "M16658", "name": "Thoracic Neoplasms", "relevance": "LOW" },
          { "id": "M11168", "name": "Lung Diseases", "relevance": "LOW" },
          {
            "id": "M14977",
            "name": "Respiratory Tract Diseases",
            "relevance": "LOW"
          },
          { "id": "M4629", "name": "Autoimmune Diseases", "relevance": "LOW" },
          {
            "id": "M22098",
            "name": "Demyelinating Autoimmune Diseases, CNS",
            "relevance": "LOW"
          },
          {
            "id": "M22094",
            "name": "Autoimmune Diseases of the Nervous System",
            "relevance": "LOW"
          },
          {
            "id": "M6909",
            "name": "Demyelinating Diseases",
            "relevance": "LOW"
          },
          {
            "id": "M10200",
            "name": "Immune System Diseases",
            "relevance": "LOW"
          }
        ],
        "browseBranches": [
          { "abbrev": "BC10", "name": "Nervous System Diseases" },
          { "abbrev": "BC20", "name": "Immune System Diseases" },
          { "abbrev": "All", "name": "All Conditions" },
          { "abbrev": "BC23", "name": "Symptoms and General Pathology" },
          { "abbrev": "BC04", "name": "Neoplasms" },
          { "abbrev": "BC17", "name": "Skin and Connective Tissue Diseases" },
          {
            "abbrev": "BC08",
            "name": "Respiratory Tract (Lung and Bronchial) Diseases"
          }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT05160233",
        "orgStudyIdInfo": { "id": "1794767" },
        "secondaryIdInfos": [
          {
            "id": "R01DA047954",
            "type": "NIH",
            "link": "https://reporter.nih.gov/quickSearch/R01DA047954"
          }
        ],
        "organization": { "fullName": "Kaiser Permanente", "class": "OTHER" },
        "briefTitle": "Digital Treatments for Opioids and Other Substance Use Disorders in Primary Care",
        "officialTitle": "Digital Treatments for Opioids and Other Substance Use Disorders (DIGITS) in Primary Care: A Hybrid Type-III Implementation Trial",
        "acronym": "DIGITS"
      },
      "statusModule": {
        "statusVerifiedDate": "2024-07",
        "overallStatus": "ACTIVE_NOT_RECRUITING",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2021-12-09", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2024-09-09",
          "type": "ESTIMATED"
        },
        "completionDateStruct": { "date": "2024-09-09", "type": "ESTIMATED" },
        "studyFirstSubmitDate": "2021-12-03",
        "studyFirstSubmitQcDate": "2021-12-03",
        "studyFirstPostDateStruct": { "date": "2021-12-16", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2024-07-01",
        "lastUpdatePostDateStruct": { "date": "2024-07-03", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": { "name": "Kaiser Permanente", "class": "OTHER" },
        "collaborators": [
          { "name": "National Institute on Drug Abuse (NIDA)", "class": "NIH" }
        ]
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": false
      },
      "descriptionModule": {
        "briefSummary": "The DIGITS Trial addresses a critical knowledge gap: How to best implement digital treatments for opioids and other substance use disorders in primary care. The DIGITS Trial is a partnership between Kaiser Permanente Washington Health Research Institute (KPWHRI) in Seattle, and Kaiser Permanente Washington, a healthcare delivery system in Washington State.\n\nIn this study, the FDA-authorized reSET and reSET-O digital therapeutics will be implemented in Kaiser Permanente Washington primary care clinics. The study will evaluate the extent to which two implementation strategy interventions, health coaching and practice coaching, improve the implementation. Primary care clinics are randomized to receive these implementation strategy interventions. Each clinic will have a 12-month active implementation period beginning on its date of randomization. To study the continued use of reSET and reSET-O after the active implementation period is completed, a sustainment period of up 12 months will follow the active implementation period.",
        "detailedDescription": "Specific Aims of the DIGITS Trial are to:\n\n1. Estimate the effect of practice facilitation and health coaching implementation strategies in increasing the reach and fidelity of a digital therapeutic for substance use disorders in primary care clinics.\n2. Compare the population-level cost-effectiveness of each implementation strategy in increasing reach, fidelity, and abstinence."
      },
      "conditionsModule": {
        "conditions": [
          "Drug Use Disorders",
          "Illicit Drug Use",
          "Alcohol-Related Disorders",
          "Opioid Use Disorder"
        ],
        "keywords": [
          "substance use disorders",
          "mHealth",
          "digital therapeutics",
          "primary care",
          "implementation science",
          "randomized controlled trial",
          "factorial trial",
          "opioid use disorders"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "FACTORIAL",
          "interventionModelDescription": "Cluster-randomized trial with 2x2 factorial randomization of two experimental strategies resulting in four arms: 2x2 factorial design to four approaches: (1) \"standard implementation\"; (2) \"standard implementation plus practice facilitation\"; (3) \"standard implementation plus health coach\"; and (4) \"standard implementation plus both.",
          "primaryPurpose": "HEALTH_SERVICES_RESEARCH",
          "maskingInfo": {
            "masking": "SINGLE",
            "maskingDescription": "All outcomes are derived from secondary administrative data.",
            "whoMasked": ["OUTCOMES_ASSESSOR"]
          }
        },
        "enrollmentInfo": { "count": 13000, "type": "ESTIMATED" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "Standard Implementation",
            "type": "ACTIVE_COMPARATOR",
            "description": "All primary care clinics will implement reSET and reSET-O using standard implementation approach.",
            "interventionNames": ["Behavioral: Standard implementation"]
          },
          {
            "label": "Standard Implementation Plus Health Coaching",
            "type": "EXPERIMENTAL",
            "description": "The clinics in this arm will implement reSET and reSET-O with a standard implementation strategy and patients at the clinic will receive support from a health coach to help them engage with reSET and reSET-O.",
            "interventionNames": [
              "Behavioral: Standard implementation",
              "Behavioral: Health Coaching"
            ]
          },
          {
            "label": "Standard Implementation Plus Practice Facilitation",
            "type": "EXPERIMENTAL",
            "description": "The clinics in this arm will implement reSET and reSET-O with a standard implementation strategy and a practice facilitator will provide the clinic with support for implementation.",
            "interventionNames": [
              "Behavioral: Standard implementation",
              "Behavioral: Practice Facilitation"
            ]
          },
          {
            "label": "Standard Implementation Plus Health Coaching and Practice Facilitation",
            "type": "EXPERIMENTAL",
            "description": "The clinics in this arm will implement reSET and reSET-O with a standard implementation strategy and patients at the clinic will receive support from a health coach to help them engage with reSET and reSET-O. Additionally, a practice facilitator will provide the clinic with support for implementation.",
            "interventionNames": [
              "Behavioral: Standard implementation",
              "Behavioral: Health Coaching",
              "Behavioral: Practice Facilitation"
            ]
          }
        ],
        "interventions": [
          {
            "type": "BEHAVIORAL",
            "name": "Standard implementation",
            "description": "Brief clinician training and an implementation toolkit consisting of job aids, patient educational materials, scripted conversations, electronic health record tools, and a population management workbench.",
            "armGroupLabels": [
              "Standard Implementation",
              "Standard Implementation Plus Health Coaching",
              "Standard Implementation Plus Health Coaching and Practice Facilitation",
              "Standard Implementation Plus Practice Facilitation"
            ]
          },
          {
            "type": "BEHAVIORAL",
            "name": "Health Coaching",
            "description": "The clinic is provided access to a health coach who conducts outreach with patients. The health coach facilitates engagement with the digital therapeutic and encourages contact with the care team.",
            "armGroupLabels": [
              "Standard Implementation Plus Health Coaching",
              "Standard Implementation Plus Health Coaching and Practice Facilitation"
            ]
          },
          {
            "type": "BEHAVIORAL",
            "name": "Practice Facilitation",
            "description": "A trained facilitator provides support for implementation by delivering the following interventions to clinic staff: Bolster Education, Audit and Provide Feedback, Support Plan-Do-Study-Act Cycles, Engage Others in Change.",
            "armGroupLabels": [
              "Standard Implementation Plus Health Coaching and Practice Facilitation",
              "Standard Implementation Plus Practice Facilitation"
            ]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Reach of the digital therapeutic to patients in the primary care clinic",
            "description": "The proportion of patients who initiate the digital therapeutic, defined by instances in which patients open the app, enter the prescription code, and use a treatment module.",
            "timeFrame": "12 months"
          },
          {
            "measure": "Fidelity of patients' use of the digital therapeutic to clinical recommendations",
            "description": "Mean number of weeks during patients' 12-week prescription in which patients use 4 app modules/week and have visited a clinician in the past 30 days",
            "timeFrame": "15 months"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Engagement",
            "description": "Mean number of months in which patients make ≥1 visit for substance use disorder",
            "timeFrame": "15 months"
          },
          {
            "measure": "Economic costs",
            "description": "Costs from the perspective of a health system and payer including implementation, direct intervention, operating, and other indirect health care costs. This measure will be used to calculate the population-level cost effectiveness of increasing reach, fidelity, and engagement.",
            "timeFrame": "12 months"
          }
        ],
        "otherOutcomes": [
          {
            "measure": "Reach-2",
            "description": "The proportion of patients prescribed reSET or reSET-O",
            "timeFrame": "12 months"
          },
          {
            "measure": "Fidelity-2",
            "description": "Mean number of weeks in which patients use at least 1 module/week",
            "timeFrame": "15 months"
          },
          {
            "measure": "Sustainment",
            "description": "The proportion of patients who are reached during the sustainment period",
            "timeFrame": "12 months"
          },
          {
            "measure": "Substance use",
            "description": "The proportion of patients who are reached and reduce their substance use",
            "timeFrame": "Up to 18 months from the patients index visit date"
          },
          {
            "measure": "Abstinence",
            "description": "The proportion of patients who are reached and are abstinent from substances",
            "timeFrame": "Up to 18 months from the patients index visit date"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Patient Inclusion Criteria:\n\n* Had a primary care visit in a participating clinic during the active implementation period or sustainment period\n* Screened positive for substance use on the day of the visit or in the prior year\n* Adult aged 18 years or older at time of visit\n\nClinic Inclusion Criteria:\n\n- At least 1 clinician trained in the use of reSET/reSET-O\n\nPatient Exclusion Criteria:\n\n- Patients who have requested through their health system to opt out of research\n\nClinic Exclusion Criteria:\n\n- Previously participated in a pilot implementation of reSET/reSET-O",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "Joseph E Glass, PhD, MSW",
            "affiliation": "Kaiser Permanente",
            "role": "PRINCIPAL_INVESTIGATOR"
          }
        ],
        "locations": [
          {
            "facility": "Kaiser Permanente Washington",
            "city": "Seattle",
            "state": "Washington",
            "zip": "98101",
            "country": "United States",
            "geoPoint": { "lat": 47.60621, "lon": -122.33207 }
          }
        ]
      },
      "ipdSharingStatementModule": { "ipdSharing": "NO" }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [
          { "id": "D019966", "term": "Substance-Related Disorders" },
          { "id": "D009293", "term": "Opioid-Related Disorders" },
          { "id": "D019973", "term": "Alcohol-Related Disorders" }
        ],
        "ancestors": [
          { "id": "D064419", "term": "Chemically-Induced Disorders" },
          { "id": "D001523", "term": "Mental Disorders" },
          { "id": "D000079524", "term": "Narcotic-Related Disorders" }
        ],
        "browseLeaves": [
          {
            "id": "M21842",
            "name": "Alcohol-Related Disorders",
            "asFound": "Alcohol-Related Disorders",
            "relevance": "HIGH"
          },
          {
            "id": "M21837",
            "name": "Substance-Related Disorders",
            "asFound": "Substance Use Disorders",
            "relevance": "HIGH"
          },
          {
            "id": "M12244",
            "name": "Opioid-Related Disorders",
            "asFound": "Opioid Use Disorder",
            "relevance": "HIGH"
          },
          {
            "id": "M30302",
            "name": "Chemically-Induced Disorders",
            "relevance": "LOW"
          },
          { "id": "M14473", "name": "Psychotic Disorders", "relevance": "LOW" },
          { "id": "M4815", "name": "Mental Disorders", "relevance": "LOW" },
          {
            "id": "M2057",
            "name": "Narcotic-Related Disorders",
            "relevance": "LOW"
          }
        ],
        "browseBranches": [
          { "abbrev": "BC25", "name": "Substance Related Disorders" },
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" },
          { "abbrev": "All", "name": "All Conditions" }
        ]
      },
      "interventionBrowseModule": {
        "browseLeaves": [
          { "id": "M4033", "name": "Analgesics, Opioid", "relevance": "LOW" },
          { "id": "M6263", "name": "Coal Tar", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "Analg", "name": "Analgesics" },
          { "abbrev": "CNSDep", "name": "Central Nervous System Depressants" },
          { "abbrev": "All", "name": "All Drugs and Chemicals" },
          { "abbrev": "Derm", "name": "Dermatologic Agents" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT04907045",
        "orgStudyIdInfo": { "id": "218046" },
        "secondaryIdInfos": [
          {
            "id": "R01DA047954",
            "type": "NIH",
            "link": "https://reporter.nih.gov/quickSearch/R01DA047954"
          }
        ],
        "organization": { "fullName": "Kaiser Permanente", "class": "OTHER" },
        "briefTitle": "An Initial Study of the Implementation of Digital Therapeutics for Substance Use Disorders in Primary Care",
        "officialTitle": "Digital Therapeutics for Opioids and Other Substance Use Disorders in Primary Care Pilot (DIGITS Trial Pilot)",
        "acronym": "DIGITS Pilot"
      },
      "statusModule": {
        "statusVerifiedDate": "2024-05",
        "overallStatus": "COMPLETED",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2021-05-06", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2023-12-04",
          "type": "ACTUAL"
        },
        "completionDateStruct": { "date": "2023-12-04", "type": "ACTUAL" },
        "studyFirstSubmitDate": "2021-05-25",
        "studyFirstSubmitQcDate": "2021-05-25",
        "studyFirstPostDateStruct": { "date": "2021-05-28", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2024-05-14",
        "lastUpdatePostDateStruct": { "date": "2024-05-16", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": { "name": "Kaiser Permanente", "class": "OTHER" },
        "collaborators": [
          { "name": "National Institute on Drug Abuse (NIDA)", "class": "NIH" }
        ]
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": false
      },
      "descriptionModule": {
        "briefSummary": "The DIGITS Trial addresses a critical knowledge gap: How to best implement digital treatments for opioids and other substance use disorders in primary care. In this pilot study, the FDA-authorized reSET and reSET-O digital therapeutics will be implemented in 2 primary care clinics as part of quality improvement. The pilot is comprised of a 3-month period in which a standard approach to implementing reSET and reSET-O is applied in the two primary care clinics \"standard implementation\", followed by a second 3-month period in which the study will test and refine the two experimental implementation strategy interventions, health coaching (patient-facing) and practice coaching (clinician-facing) in the same clinics. This study will also pilot economic data collection tools and collect qualitative data for a formative evaluation. The analytic goals are to inform the statistical design and data collection processes for the subsequent cluster-randomized DIGITS Trial."
      },
      "conditionsModule": {
        "conditions": [
          "Drug Use Disorders",
          "Illicit Drug Use",
          "Alcohol-Related Disorders"
        ],
        "keywords": [
          "Implementation Science",
          "Mobile Applications",
          "Drug Use Disorders",
          "Quality Improvement",
          "Primary Health Care"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "NON_RANDOMIZED",
          "interventionModel": "PARALLEL",
          "interventionModelDescription": "Non-randomized parallel groups pilot study to evaluate intervention delivery, data collection, and analysis procedures. Two primary care clinics will implement the reSET and reSET-O digital therapeutics for substance use disorders. There will be one clinic per arm in this pilot study. Implementation strategies will be varied across arms.",
          "primaryPurpose": "HEALTH_SERVICES_RESEARCH",
          "maskingInfo": { "masking": "NONE" }
        },
        "enrollmentInfo": { "count": 1552, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "Standard Implementation Plus Health Coaching",
            "type": "EXPERIMENTAL",
            "description": "The clinic in this arm will implement reSET and reSET-O with a standard implementation strategy and patients at the clinic will receive support from a health coach to help them engage with reSET and reSET-O.",
            "interventionNames": [
              "Behavioral: Health Coaching",
              "Behavioral: Standard Implementation"
            ]
          },
          {
            "label": "Standard Implementation Plus Health Coaching and Practice Facilitation",
            "type": "EXPERIMENTAL",
            "description": "The clinic in this arm will implement reSET and reSET-O with a standard implementation strategy and patients at the clinic will receive support from a health coach to help them engage with reSET and reSET-O. Additionally, a practice facilitator will provide the clinic with support for implementation.",
            "interventionNames": [
              "Behavioral: Health Coaching",
              "Behavioral: Practice Facilitation",
              "Behavioral: Standard Implementation"
            ]
          }
        ],
        "interventions": [
          {
            "type": "BEHAVIORAL",
            "name": "Health Coaching",
            "description": "The clinic is provided access to a health coach who conducts outreach with patients. The health coach facilitates engagement with the digital therapeutic and encourages contact with the care team.",
            "armGroupLabels": [
              "Standard Implementation Plus Health Coaching",
              "Standard Implementation Plus Health Coaching and Practice Facilitation"
            ]
          },
          {
            "type": "BEHAVIORAL",
            "name": "Practice Facilitation",
            "description": "In the context of a supportive relationship, a trained facilitator delivers the following interventions to clinic staff: Bolster Education, Audit and Provide Feedback, Support Plan-Do-Study-Act Cycles, Engage Others in Change.",
            "armGroupLabels": [
              "Standard Implementation Plus Health Coaching and Practice Facilitation"
            ]
          },
          {
            "type": "BEHAVIORAL",
            "name": "Standard Implementation",
            "description": "Brief clinician training and an implementation toolkit consisting of job aids, patient educational materials, scripted conversations, electronic health record tools, and a population management workbench.",
            "armGroupLabels": [
              "Standard Implementation Plus Health Coaching",
              "Standard Implementation Plus Health Coaching and Practice Facilitation"
            ]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Reach of the digital therapeutic to patients in the primary care clinic",
            "description": "The proportion of patients who initiate the digital therapeutic, defined by instances in which patients open the app, enter the prescription code, and use a treatment module",
            "timeFrame": "6 months"
          },
          {
            "measure": "Fidelity of patients use of the digital therapeutic to clinical recommendations",
            "description": "Mean number of weeks in which patients use 4 app modules/week and have visited a clinician in the past month",
            "timeFrame": "9 months"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Effectiveness",
            "description": "Mean number of months in which patients make monthly visits for substance use disorder",
            "timeFrame": "9 months"
          }
        ],
        "otherOutcomes": [
          {
            "measure": "Reach-2",
            "description": "The proportion of patients prescribed reSET or reSET-O",
            "timeFrame": "6 months"
          },
          {
            "measure": "Reach-3",
            "description": "The proportion of patients who download and unlock reSET or reSET-O",
            "timeFrame": "6 months"
          },
          {
            "measure": "Fidelity-2",
            "description": "Mean number of weeks in which patients use at least 1 module/week",
            "timeFrame": "9 months"
          },
          {
            "measure": "Fidelity-3",
            "description": "Mean number of weeks in which patients use at least 4 modules/week",
            "timeFrame": "9 months"
          },
          {
            "measure": "Adoption",
            "description": "The proportion of other healthcare providers initiating a patient on reSET or reSET-O, overall and by provider type",
            "timeFrame": "6 months"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* Had a primary care visit in a participating clinic during the pilot\n* Screened positive for substance use\n* Adult aged 18 years or older at time of visit\n\nExclusion Criteria:\n\n* None",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "Joseph E Glass, PhD, MSW",
            "affiliation": "Kaiser Permanente",
            "role": "PRINCIPAL_INVESTIGATOR"
          }
        ],
        "locations": [
          {
            "facility": "Kaiser Permanente Washington",
            "city": "Seattle",
            "state": "Washington",
            "zip": "98101",
            "country": "United States",
            "geoPoint": { "lat": 47.60621, "lon": -122.33207 }
          }
        ]
      },
      "ipdSharingStatementModule": { "ipdSharing": "NO" }
    },
    "derivedSection": {
      "miscInfoModule": {
        "versionHolder": "2025-05-07",
        "submissionTracking": {
          "estimatedResultsFirstSubmitDate": "2025-04-28",
          "submissionInfos": [{ "releaseDate": "2025-04-28" }]
        }
      },
      "conditionBrowseModule": {
        "meshes": [
          { "id": "D019966", "term": "Substance-Related Disorders" },
          { "id": "D019973", "term": "Alcohol-Related Disorders" }
        ],
        "ancestors": [
          { "id": "D064419", "term": "Chemically-Induced Disorders" },
          { "id": "D001523", "term": "Mental Disorders" }
        ],
        "browseLeaves": [
          {
            "id": "M21842",
            "name": "Alcohol-Related Disorders",
            "asFound": "Alcohol-Related Disorders",
            "relevance": "HIGH"
          },
          {
            "id": "M21837",
            "name": "Substance-Related Disorders",
            "asFound": "Drug Use Disorders",
            "relevance": "HIGH"
          },
          {
            "id": "M30302",
            "name": "Chemically-Induced Disorders",
            "relevance": "LOW"
          },
          { "id": "M14473", "name": "Psychotic Disorders", "relevance": "LOW" },
          { "id": "M4815", "name": "Mental Disorders", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "BC25", "name": "Substance Related Disorders" },
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" },
          { "abbrev": "All", "name": "All Conditions" }
        ]
      },
      "interventionBrowseModule": {
        "browseLeaves": [
          { "id": "M4033", "name": "Analgesics, Opioid", "relevance": "LOW" },
          { "id": "M6263", "name": "Coal Tar", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "Analg", "name": "Analgesics" },
          { "abbrev": "CNSDep", "name": "Central Nervous System Depressants" },
          { "abbrev": "All", "name": "All Drugs and Chemicals" },
          { "abbrev": "Derm", "name": "Dermatologic Agents" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT04925570",
        "orgStudyIdInfo": { "id": "58725" },
        "organization": { "fullName": "Woebot Health", "class": "INDUSTRY" },
        "briefTitle": "The Anchor Study: Digitally Delivered Intervention for Reducing Problematic Substance Use",
        "officialTitle": "Woebot for Substance Use Disorders Phase 2 RCT: Digitally Delivered Intervention for Reducing Problematic Substance Use"
      },
      "statusModule": {
        "statusVerifiedDate": "2024-10",
        "overallStatus": "COMPLETED",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2022-11-14", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2023-08-17",
          "type": "ACTUAL"
        },
        "completionDateStruct": { "date": "2023-08-17", "type": "ACTUAL" },
        "studyFirstSubmitDate": "2021-05-25",
        "studyFirstSubmitQcDate": "2021-06-11",
        "studyFirstPostDateStruct": { "date": "2021-06-14", "type": "ACTUAL" },
        "resultsFirstSubmitDate": "2024-02-20",
        "resultsFirstSubmitQcDate": "2024-10-21",
        "resultsFirstPostDateStruct": {
          "date": "2024-10-24",
          "type": "ACTUAL"
        },
        "lastUpdateSubmitDate": "2024-10-21",
        "lastUpdatePostDateStruct": { "date": "2024-10-24", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": { "name": "Woebot Health", "class": "INDUSTRY" },
        "collaborators": [{ "name": "Stanford University", "class": "OTHER" }]
      },
      "oversightModule": {
        "oversightHasDmc": true,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": false
      },
      "descriptionModule": {
        "briefSummary": "This study aims to validate W-SUDs as a digitally-delivered substance use disorder program through a fully-powered randomized control trial that will test the comparative efficacy of the mobile-app based substance use disorder program (W-SUDs) to reduce substance use relative to a psychoeducation control condition, which has no cognitive behavioral therapy and the content is not delivered through a conversational user interface.",
        "detailedDescription": "Phase II will evaluate the efficacy of W-SUDs in a large scale RCT relative to a psychoeducation control condition. Primary outcomes will be measures of the quantity and frequency of substance use including number of substance use occasions, heavy drinking days (if applicable) and percent reduction in substance use occasions. Additionally, Phase II will evaluate whether W-SUDs results in a greater reduction in substance-related problems compared to a psychoeducation control group and explore if engagement with W-SUDs, relative to psychoeducation control,\n\n1. improves symptoms of depression and anxiety;\n2. improves work productivity (i.e. reduce presenteeism/absenteeism);\n3. reduces cravings;\n4. improves situational confidence to resist substance use."
      },
      "conditionsModule": {
        "conditions": ["Alcohol Use Disorder (AUD)", "Substance Use Disorders"],
        "keywords": [
          "Alcohol Use Disorder",
          "Substance Use Disorder",
          "AUD",
          "SUD",
          "AUD Treatment",
          "SUD Treatment",
          "Smartphone Application",
          "Digital Therapeutic",
          "Alcohol Use Disorder Treatment",
          "Substance Use Disorder Treatment"
        ]
      },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["PHASE2"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": { "masking": "SINGLE", "whoMasked": ["PARTICIPANT"] }
        },
        "enrollmentInfo": { "count": 258, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "W-SUDs",
            "type": "EXPERIMENTAL",
            "description": "Woebot (W-SUDs), a Conversational Agent (CA) instantaneously available 24 hours per day, 7 days per week, 'checks in' with users. Using conversational tones, it encourages mood tracking and delivers general psychoeducation as well as tailored empathy, cognitive behavior therapy (CBT)-based behavior change tools, and behavioral pattern insight. Woebot's app-based platform and user-centered design philosophy makes it an optimal modality for Substance Use Disorders (SUD) treatment delivery. It offers immediate, evidence-based tailored support in the patient's peak moment of craving.",
            "interventionNames": ["Device: W-SUDs"]
          },
          {
            "label": "Digitally-delivered Psychoeducation",
            "type": "OTHER",
            "description": "Psychoeducation delivers weekly fact sheets that include information on:\n\n1. Alcohol-specific topics;\n2. Drug-specific topics;\n3. General addiction topics;\n4. Statistics relating to alcohol and substance use.",
            "interventionNames": ["Other: Digitally-delivered Psychoeducation"]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "W-SUDs",
            "description": "Woebot (W-SUDs) is an automated conversational agent, available through a smartphone application, that delivers evidence-based psychotherapeutics, empathy, and emotional health psychoeducation.",
            "armGroupLabels": ["W-SUDs"]
          },
          {
            "type": "OTHER",
            "name": "Digitally-delivered Psychoeducation",
            "description": "A form of psychoeducation for those seeking treatment for their alcohol and/or substance use concern. Psychoeducation is commonly provided for those with substance use. Psychoeducation in substance use is intended to increase the users' knowledge of their substances of use, and effects on the body, behaviors, and consequences. The recipient of psychoeducation is expected to increase their own awareness of their substance use and ideally incorporate this newfound knowledge when making changes to their substance use. The information provided in this group are from factsheets found on NIAAA, NIDA, and CDC web pages.",
            "armGroupLabels": ["Digitally-delivered Psychoeducation"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Change in Number of Substance Use Occasions",
            "description": "Change in number of substance use occasions in the past 30 days",
            "timeFrame": "Change from Baseline to Mid-treatment at 4 weeks; Change from Baseline to Post-treatment at 8 weeks; Change from Baseline to Follow-up at 12 weeks"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Drug Abuse Screening Test (DAST-10)",
            "description": "Measure of drug abuse related consequences. The DAST-10 is a brief, 10-item self-report measure that assesses consequences related to drug abuse, excluding alcohol and tobacco. The range is 0-10, where higher scores indicate greater severity. Adapted from past 12 months to past 30 days.",
            "timeFrame": "Change from Baseline to Post-treatment at 8 weeks"
          },
          {
            "measure": "Working Alliance Inventory (WAI-SR)",
            "description": "Measure of working alliance. A measure of therapeutic alliance that assesses three key aspects of the therapeutic alliance: (a) agreement on the tasks of therapy, (b) agreement on the goals of therapy and (c) development of an affective bond. Task, goal, and bond subscales scores range from 5-20, with higher scores indicating greater alliance. The present study utilized the validated 12-item Short-Revised version (WAI-SR) with minor changes to language, replacing \"therapist\" with \"Woebot\".",
            "timeFrame": "Post-treatment at 8 weeks"
          },
          {
            "measure": "Stanford Presenteeism Scale (SPS-6)",
            "description": "Measure of the effects of substance use on productivity. The SPS-6 is a 6-item self-report measure used to assess perceptions of the effects of substance use on past 2-week work productivity. Response options range from strongly disagree (1) to strongly agree (5). Total scores range from 6 to 30, where higher scores indicate higher presenteeism.",
            "timeFrame": "Change from Baseline to Post-treatment at 8 weeks"
          },
          {
            "measure": "Thoughts About Abstinence (TAA): Desire to Quit, Expected Success at Quitting, Expected Difficulty of Quitting Items",
            "description": "Modified for alcohol and substances. 4-item questionnaire assessing desire to quit, expected success at quitting, expected difficulty of quitting, and goal. Each of the first three items is rated on a scale of 1 to 10 where 1 is the lowest (desire, expectation, confidence) and 10 is the highest (desire, expectation, confidence). The scores are not combined. Goal for use is a single response selection item, with the option to provide a text explanation if none of the goals align. Goal data are reported as a separate outcome measure.",
            "timeFrame": "Change from Baseline to Post-treatment at 8 weeks"
          },
          {
            "measure": "Thoughts About Abstinence (TAA): Goal Item",
            "description": "Modified for alcohol and substances. 4-item questionnaire assessing desire to quit, expected success at quitting, expected difficulty of quitting, confidence in ability to quit, and goal. Each of the first three items is rated on a scale of 1 to 10 where 1 is the lowest (desire, expectation, confidence) and 10 is the highest (desire, expectation, confidence). The scores are not combined. Goal for use is a single response selection item, with the option to provide a text explanation if none of the goals align. Desire to Quit, Expected Success at Quitting, Expected Difficulty of Quitting item data are reported as a separate outcome measure.",
            "timeFrame": "Baseline and Post-treatment at 8 weeks"
          },
          {
            "measure": "Usage Rating Profile - Intervention (URPI)-Acceptability",
            "description": "Measure of acceptability. A 9-item subscale that inquires about intervention acceptability. For the purposes of this study, an adapted 6-item version of the subscale was utilized. Items are rated on a 6-point Likert scale (1 = \"strongly disagree\" to 6 = \"strongly agree\"). Total acceptability scores range from 6-36, with higher scores indicating greater intervention acceptability.",
            "timeFrame": "Post-treatment at 8 weeks"
          },
          {
            "measure": "Usage Rating Profile - Intervention (URPI)-Feasibility",
            "description": "Measure of feasibility. A 6-item subscale that inquires about factors that impact treatment usage (i.e., intervention quality). Items are rated on a 6-point Likert scale (1 = \"slightly disagree\" to 6 = \"strongly agree\"). Total feasibility scores range from 6-36, with higher scores indicating greater intervention feasibility.",
            "timeFrame": "Post-treatment at 8 weeks"
          },
          {
            "measure": "Client Satisfaction Questionnaire (CSQ-8)",
            "description": "Measure of satisfaction. An 8-item measure used to assess client's satisfaction with treatment on a 4-point scale. Example questions include, \"How would you rate the quality of service you received\"? and \"Did you get the kind of service you wanted?\" Total sums range from 8-32, with high scores indicating greater satisfaction with the W-SUDs mobile application.",
            "timeFrame": "Post-treatment at 8 weeks"
          },
          {
            "measure": "Short Inventory of Problems- Alcohol and Drugs (SIP-AD)",
            "description": "The SIP-AD assesses substance use problems in the past 30 days. The scored variables, total scores and 15-item mean, summarize consequences of alcohol and drug use. Scores range from 0-45, where greater scores indicate greater substance use problems.",
            "timeFrame": "Change from Baseline to Mid-Treatment at 4 weeks; Change from Baseline to Post-treatment at 8 weeks; Change from Baseline to Follow-up at 12 weeks"
          },
          {
            "measure": "Patient Health Questionnaire (PHQ-8)",
            "description": "Measure of depression severity. An 8-item abbreviated version of the PHQ-9 used to assess mood symptoms. The PHQ-8 excludes an item assessing suicidality. Items are rated on a 4-point Likert scale (0 = \"not at all\" to 3 = \"nearly every day\"). Total score between 0-24, with higher scores indicating greater severity of depression symptoms.",
            "timeFrame": "Change from Baseline to Mid-treatment at 4 weeks; Change from Baseline to Post-treatment at 8 weeks; Change from Baseline to Follow-up at 12 weeks"
          },
          {
            "measure": "Generalized Anxiety Disorder (GAD-7)",
            "description": "Measure of anxiety severity. A 7-item self-report measure used to assess the frequency and severity of anxious thoughts and behaviors over the past 2 weeks. Items are rated on a 4-point Likert scale (0 = \"not at all\" to 3 = \"nearly every day\").Total scores range from 0-21, where higher scores indicate greater severity of anxiety symptoms.",
            "timeFrame": "Change from Baseline to Mid-treatment at 4 weeks; Change from Baseline to Post-treatment at 8 weeks; Change from Baseline to Follow-up at 12 weeks"
          },
          {
            "measure": "Brief Situational Confidence Questionnaire (BSCQ)",
            "description": "Measure of self-confidence. The 8-item BSCQ is a state dependent measure that assesses self-confidence to resist the urge to drink heavily or use drugs in a variety of situations. Each of the 8 scale situations consists of a 100-mm line, anchored by 0% (\"not at all confident\") and 100% (\"totally confident\") where clients are asked to indicate confidence on a scale from 0% to 100%. Higher scores are associated with greater confidence.",
            "timeFrame": "Change from Baseline to Mid-treatment at 4 weeks; Change from Baseline to Post-treatment at 8 weeks; Change from Baseline to Follow-up at 12 weeks"
          },
          {
            "measure": "Craving Ratings",
            "description": "Self-reported ratings of craving intensity. Craving is assessed with a single question, \"In the past 7 days, how much were you bothered by cravings or urges to drink alcohol or use drugs?\". The question is rated on a scale of 0 to 4 where 0 = not at all, 1 = a little bit, 2 = moderately, 3 = quite a bit, and 4 = extremely. Greater scores indicate a more intense urge to use.",
            "timeFrame": "Change from Baseline to Mid-treatment at 4 weeks; Change from Baseline to Post-treatment at 8 weeks; Change from Baseline to Follow-up at 12 weeks"
          },
          {
            "measure": "Past Month Number of Binge Days",
            "description": "Assessed with the Quick Drinking Screen (QDS), a measure of alcohol consumption. The QDS is a brief self-report measure used to assess average alcohol consumption over a specified time period (in the present study it was the past 30 days). The QDS collects drinking data for three variables including number of days drinking, number of standard drinks per drinking day, and number of binge/risky drinking days. Binge/risky drinking days is defined as days when they have had 5 or more standard drinks (for men) or 4 or more standard drinks (for women).",
            "timeFrame": "Change from Baseline to Mid-treatment at 4 weeks; Change from Baseline to Post-treatment at 8 weeks; Change from Baseline to Follow-up at 12 weeks"
          },
          {
            "measure": "Past Month Average Standard Drinks in a Week",
            "description": "Assessed with the Quick Drinking Screen (QDS), a measure of alcohol consumption. The QDS is a brief self-report measure used to assess average alcohol consumption over a specified time period (in the present study it was the past 30 days). The QDS collects drinking data for three variables including number of days drinking, number of standard drinks per drinking day, and number of binge/risky drinking days. Binge/risky drinking days is defined as days when they have had 5 or more standard drinks (for men) or 4 or more standard drinks (for women). Number of standard drinks per week is calculated by multiplying number of standard drinks per day in the past month and number of binge days per month.",
            "timeFrame": "Change from Baseline to Mid-treatment at 4 weeks; Change from Baseline to Post-treatment at 8 weeks; Change from Baseline to Follow-up at 12 weeks"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n1. Have a smartphone\n2. Endorse a substance use concern\n3. Be between 18 and 65 years of age\n4. Be available and committed to engage with the Woebot app\n5. Be literate in English. (This is required for inclusion because all materials will be in English).\n\nExclusion Criteria:\n\n1. Pregnancy (as W-SUDs will not be specifically developed to address the unique needs of this population)\n2. Suicide attempt within the past year (12 months)\n3. Symptoms of severe drug/alcohol history: History of delirium tremens; Experiencing hypertension, drenching sweats, seizures or confusion after stopping alcohol or drugs; Liver trouble (cirrhosis or hepatitis); Convulsions or GI bleeding due to drug/alcohol use\n4. Opioid overdose within the past year (12 months)\n5. Opioid misuse without medication-assisted treatment\n6. Not residing in the U.S.\n7. Previous Woebot use",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "maximumAge": "65 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "overallOfficials": [
          {
            "name": "Judith Prochaska, PhD",
            "affiliation": "Stanford University",
            "role": "PRINCIPAL_INVESTIGATOR"
          }
        ],
        "locations": [
          {
            "facility": "Stanford University",
            "city": "Palo Alto",
            "state": "California",
            "zip": "94304",
            "country": "United States",
            "geoPoint": { "lat": 37.44188, "lon": -122.14302 }
          }
        ]
      }
    },
    "resultsSection": {
      "participantFlowModule": {
        "groups": [
          {
            "id": "FG000",
            "title": "W-SUDs",
            "description": "Woebot (W-SUDs), a Conversational Agent (CA) instantaneously available 24 hours per day, 7 days per week, 'checks in' with users. Using conversational tones, it encourages mood tracking and delivers general psychoeducation as well as tailored empathy, cognitive behavior therapy (CBT)-based behavior change tools, and behavioral pattern insight. Woebot's app-based platform and user-centered design philosophy makes it an optimal modality for Substance Use Disorders (SUD) treatment delivery. It offers immediate, evidence-based tailored support in the patient's peak moment of craving.\n\nW-SUDs: Woebot (W-SUDs) is an automated conversational agent, available through a smartphone application, that delivers evidence-based psychotherapeutics, empathy, and emotional health psychoeducation."
          },
          {
            "id": "FG001",
            "title": "Digitally-delivered Psychoeducation",
            "description": "Psychoeducation delivers weekly fact sheets that include information on:\n\n1. Alcohol-specific topics;\n2. Drug-specific topics;\n3. General addiction topics;\n4. Statistics relating to alcohol and substance use.\n\nDigitally-delivered Psychoeducation: A form of psychoeducation for those seeking treatment for their alcohol and/or substance use concern. Psychoeducation is commonly provided for those with substance use. Psychoeducation in substance use is intended to increase the users' knowledge of their substances of use, and effects on the body, behaviors, and consequences. The recipient of psychoeducation is expected to increase their own awareness of their substance use and ideally incorporate this newfound knowledge when making changes to their substance use. The information provided in this group are from factsheets found on NIAAA, NIDA, and CDC web pages."
          }
        ],
        "periods": [
          {
            "title": "Overall Study",
            "milestones": [
              {
                "type": "STARTED",
                "achievements": [
                  { "groupId": "FG000", "numSubjects": "131" },
                  { "groupId": "FG001", "numSubjects": "127" }
                ]
              },
              {
                "type": "COMPLETED",
                "achievements": [
                  { "groupId": "FG000", "numSubjects": "107" },
                  { "groupId": "FG001", "numSubjects": "95" }
                ]
              },
              {
                "type": "NOT COMPLETED",
                "achievements": [
                  { "groupId": "FG000", "numSubjects": "24" },
                  { "groupId": "FG001", "numSubjects": "32" }
                ]
              }
            ],
            "dropWithdraws": [
              {
                "type": "Protocol Violation",
                "reasons": [
                  { "groupId": "FG000", "numSubjects": "24" },
                  { "groupId": "FG001", "numSubjects": "30" }
                ]
              },
              {
                "type": "Withdrawal by Subject",
                "reasons": [
                  { "groupId": "FG000", "numSubjects": "0" },
                  { "groupId": "FG001", "numSubjects": "2" }
                ]
              }
            ]
          }
        ]
      },
      "baselineCharacteristicsModule": {
        "groups": [
          {
            "id": "BG000",
            "title": "W-SUDs",
            "description": "Woebot (W-SUDs), a Conversational Agent (CA) instantaneously available 24 hours per day, 7 days per week, 'checks in' with users. Using conversational tones, it encourages mood tracking and delivers general psychoeducation as well as tailored empathy, cognitive behavior therapy (CBT)-based behavior change tools, and behavioral pattern insight. Woebot's app-based platform and user-centered design philosophy makes it an optimal modality for Substance Use Disorders (SUD) treatment delivery. It offers immediate, evidence-based tailored support in the patient's peak moment of craving.\n\nW-SUDs: Woebot (W-SUDs) is an automated conversational agent, available through a smartphone application, that delivers evidence-based psychotherapeutics, empathy, and emotional health psychoeducation."
          },
          {
            "id": "BG001",
            "title": "Digitally-delivered Psychoeducation",
            "description": "Psychoeducation delivers weekly fact sheets that include information on:\n\n1. Alcohol-specific topics;\n2. Drug-specific topics;\n3. General addiction topics;\n4. Statistics relating to alcohol and substance use.\n\nDigitally-delivered Psychoeducation: A form of psychoeducation for those seeking treatment for their alcohol and/or substance use concern. Psychoeducation is commonly provided for those with substance use. Psychoeducation in substance use is intended to increase the users' knowledge of their substances of use, and effects on the body, behaviors, and consequences. The recipient of psychoeducation is expected to increase their own awareness of their substance use and ideally incorporate this newfound knowledge when making changes to their substance use. The information provided in this group are from factsheets found on NIAAA, NIDA, and CDC web pages."
          },
          {
            "id": "BG002",
            "title": "Total",
            "description": "Total of all reporting groups"
          }
        ],
        "denoms": [
          {
            "units": "Participants",
            "counts": [
              { "groupId": "BG000", "value": "107" },
              { "groupId": "BG001", "value": "95" },
              { "groupId": "BG002", "value": "202" }
            ]
          }
        ],
        "measures": [
          {
            "title": "Age, Continuous",
            "paramType": "MEAN",
            "dispersionType": "STANDARD_DEVIATION",
            "unitOfMeasure": "years",
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "BG000", "value": "38.2", "spread": "11.4" },
                      { "groupId": "BG001", "value": "38.6", "spread": "9.2" },
                      { "groupId": "BG002", "value": "38.3", "spread": "10.4" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Sex: Female, Male",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "Female",
                    "measurements": [
                      { "groupId": "BG000", "value": "50" },
                      { "groupId": "BG001", "value": "58" },
                      { "groupId": "BG002", "value": "108" }
                    ]
                  },
                  {
                    "title": "Male",
                    "measurements": [
                      { "groupId": "BG000", "value": "57" },
                      { "groupId": "BG001", "value": "37" },
                      { "groupId": "BG002", "value": "94" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Ethnicity (NIH/OMB)",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "Hispanic or Latino",
                    "measurements": [
                      { "groupId": "BG000", "value": "12" },
                      { "groupId": "BG001", "value": "11" },
                      { "groupId": "BG002", "value": "23" }
                    ]
                  },
                  {
                    "title": "Not Hispanic or Latino",
                    "measurements": [
                      { "groupId": "BG000", "value": "94" },
                      { "groupId": "BG001", "value": "84" },
                      { "groupId": "BG002", "value": "178" }
                    ]
                  },
                  {
                    "title": "Unknown or Not Reported",
                    "measurements": [
                      { "groupId": "BG000", "value": "1" },
                      { "groupId": "BG001", "value": "0" },
                      { "groupId": "BG002", "value": "1" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Race (NIH/OMB)",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "American Indian or Alaska Native",
                    "measurements": [
                      { "groupId": "BG000", "value": "2" },
                      { "groupId": "BG001", "value": "1" },
                      { "groupId": "BG002", "value": "3" }
                    ]
                  },
                  {
                    "title": "Asian",
                    "measurements": [
                      { "groupId": "BG000", "value": "1" },
                      { "groupId": "BG001", "value": "3" },
                      { "groupId": "BG002", "value": "4" }
                    ]
                  },
                  {
                    "title": "Native Hawaiian or Other Pacific Islander",
                    "measurements": [
                      { "groupId": "BG000", "value": "0" },
                      { "groupId": "BG001", "value": "0" },
                      { "groupId": "BG002", "value": "0" }
                    ]
                  },
                  {
                    "title": "Black or African American",
                    "measurements": [
                      { "groupId": "BG000", "value": "17" },
                      { "groupId": "BG001", "value": "28" },
                      { "groupId": "BG002", "value": "45" }
                    ]
                  },
                  {
                    "title": "White",
                    "measurements": [
                      { "groupId": "BG000", "value": "86" },
                      { "groupId": "BG001", "value": "58" },
                      { "groupId": "BG002", "value": "144" }
                    ]
                  },
                  {
                    "title": "More than one race",
                    "measurements": [
                      { "groupId": "BG000", "value": "0" },
                      { "groupId": "BG001", "value": "3" },
                      { "groupId": "BG002", "value": "3" }
                    ]
                  },
                  {
                    "title": "Unknown or Not Reported",
                    "measurements": [
                      { "groupId": "BG000", "value": "1" },
                      { "groupId": "BG001", "value": "2" },
                      { "groupId": "BG002", "value": "3" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Region of Enrollment",
            "paramType": "NUMBER",
            "unitOfMeasure": "participants",
            "classes": [
              {
                "title": "United States",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "BG000", "value": "107" },
                      { "groupId": "BG001", "value": "95" },
                      { "groupId": "BG002", "value": "202" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Gender",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "Woman",
                    "measurements": [
                      { "groupId": "BG000", "value": "50" },
                      { "groupId": "BG001", "value": "56" },
                      { "groupId": "BG002", "value": "106" }
                    ]
                  },
                  {
                    "title": "Man",
                    "measurements": [
                      { "groupId": "BG000", "value": "56" },
                      { "groupId": "BG001", "value": "37" },
                      { "groupId": "BG002", "value": "93" }
                    ]
                  },
                  {
                    "title": "Non-binary",
                    "measurements": [
                      { "groupId": "BG000", "value": "1" },
                      { "groupId": "BG001", "value": "2" },
                      { "groupId": "BG002", "value": "3" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Sexual Orientation",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "Heterosexual",
                    "measurements": [
                      { "groupId": "BG000", "value": "90" },
                      { "groupId": "BG001", "value": "84" },
                      { "groupId": "BG002", "value": "174" }
                    ]
                  },
                  {
                    "title": "Gay or Lesbian",
                    "measurements": [
                      { "groupId": "BG000", "value": "8" },
                      { "groupId": "BG001", "value": "2" },
                      { "groupId": "BG002", "value": "10" }
                    ]
                  },
                  {
                    "title": "Bisexual",
                    "measurements": [
                      { "groupId": "BG000", "value": "5" },
                      { "groupId": "BG001", "value": "5" },
                      { "groupId": "BG002", "value": "10" }
                    ]
                  },
                  {
                    "title": "Queer",
                    "measurements": [
                      { "groupId": "BG000", "value": "0" },
                      { "groupId": "BG001", "value": "1" },
                      { "groupId": "BG002", "value": "1" }
                    ]
                  },
                  {
                    "title": "Pansexual",
                    "measurements": [
                      { "groupId": "BG000", "value": "2" },
                      { "groupId": "BG001", "value": "3" },
                      { "groupId": "BG002", "value": "5" }
                    ]
                  },
                  {
                    "title": "Don't know",
                    "measurements": [
                      { "groupId": "BG000", "value": "2" },
                      { "groupId": "BG001", "value": "0" },
                      { "groupId": "BG002", "value": "2" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Marital Status",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "Married/Cohabitating/Partnered",
                    "measurements": [
                      { "groupId": "BG000", "value": "53" },
                      { "groupId": "BG001", "value": "52" },
                      { "groupId": "BG002", "value": "105" }
                    ]
                  },
                  {
                    "title": "Divorced/Separated/Widowed",
                    "measurements": [
                      { "groupId": "BG000", "value": "13" },
                      { "groupId": "BG001", "value": "9" },
                      { "groupId": "BG002", "value": "22" }
                    ]
                  },
                  {
                    "title": "Never married/Single",
                    "measurements": [
                      { "groupId": "BG000", "value": "41" },
                      { "groupId": "BG001", "value": "34" },
                      { "groupId": "BG002", "value": "75" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Educational Degree",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "High School Degree or Less",
                    "measurements": [
                      { "groupId": "BG000", "value": "17" },
                      { "groupId": "BG001", "value": "13" },
                      { "groupId": "BG002", "value": "30" }
                    ]
                  },
                  {
                    "title": "Some College/Technical School",
                    "measurements": [
                      { "groupId": "BG000", "value": "37" },
                      { "groupId": "BG001", "value": "36" },
                      { "groupId": "BG002", "value": "73" }
                    ]
                  },
                  {
                    "title": "College Degree",
                    "measurements": [
                      { "groupId": "BG000", "value": "30" },
                      { "groupId": "BG001", "value": "27" },
                      { "groupId": "BG002", "value": "57" }
                    ]
                  },
                  {
                    "title": "Graduate or Post-graduate Degree",
                    "measurements": [
                      { "groupId": "BG000", "value": "23" },
                      { "groupId": "BG001", "value": "19" },
                      { "groupId": "BG002", "value": "42" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Employment Status",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "Employed Part or Full-Time",
                    "measurements": [
                      { "groupId": "BG000", "value": "74" },
                      { "groupId": "BG001", "value": "61" },
                      { "groupId": "BG002", "value": "135" }
                    ]
                  },
                  {
                    "title": "Unemployed (homemaker, student, retired)",
                    "measurements": [
                      { "groupId": "BG000", "value": "33" },
                      { "groupId": "BG001", "value": "34" },
                      { "groupId": "BG002", "value": "67" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Disability Status",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "Yes (has a disability)",
                    "measurements": [
                      { "groupId": "BG000", "value": "8" },
                      { "groupId": "BG001", "value": "10" },
                      { "groupId": "BG002", "value": "18" }
                    ]
                  },
                  {
                    "title": "No (does not have a disability)",
                    "measurements": [
                      { "groupId": "BG000", "value": "98" },
                      { "groupId": "BG001", "value": "85" },
                      { "groupId": "BG002", "value": "183" }
                    ]
                  },
                  {
                    "title": "Prefer not to answer",
                    "measurements": [
                      { "groupId": "BG000", "value": "1" },
                      { "groupId": "BG001", "value": "0" },
                      { "groupId": "BG002", "value": "1" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Insurance Status",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "Private",
                    "measurements": [
                      { "groupId": "BG000", "value": "56" },
                      { "groupId": "BG001", "value": "47" },
                      { "groupId": "BG002", "value": "103" }
                    ]
                  },
                  {
                    "title": "Medicaid or Medicare",
                    "measurements": [
                      { "groupId": "BG000", "value": "32" },
                      { "groupId": "BG001", "value": "33" },
                      { "groupId": "BG002", "value": "65" }
                    ]
                  },
                  {
                    "title": "TRICARE",
                    "measurements": [
                      { "groupId": "BG000", "value": "0" },
                      { "groupId": "BG001", "value": "2" },
                      { "groupId": "BG002", "value": "2" }
                    ]
                  },
                  {
                    "title": "VA",
                    "measurements": [
                      { "groupId": "BG000", "value": "1" },
                      { "groupId": "BG001", "value": "1" },
                      { "groupId": "BG002", "value": "2" }
                    ]
                  },
                  {
                    "title": "Doesn't have insurance",
                    "measurements": [
                      { "groupId": "BG000", "value": "18" },
                      { "groupId": "BG001", "value": "10" },
                      { "groupId": "BG002", "value": "28" }
                    ]
                  },
                  {
                    "title": "Prefer not to answer",
                    "measurements": [
                      { "groupId": "BG000", "value": "0" },
                      { "groupId": "BG001", "value": "2" },
                      { "groupId": "BG002", "value": "2" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Lifetime Mental Health Condition",
            "paramType": "NUMBER",
            "unitOfMeasure": "participants",
            "classes": [
              {
                "title": "Unipolar Depression",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "BG000", "value": "20" },
                      { "groupId": "BG001", "value": "26" },
                      { "groupId": "BG002", "value": "48" }
                    ]
                  }
                ]
              },
              {
                "title": "Bipolar/Manic Depression",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "BG000", "value": "9" },
                      { "groupId": "BG001", "value": "5" },
                      { "groupId": "BG002", "value": "14" }
                    ]
                  }
                ]
              },
              {
                "title": "Anxiety Disorder",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "BG000", "value": "34" },
                      { "groupId": "BG001", "value": "32" },
                      { "groupId": "BG002", "value": "66" }
                    ]
                  }
                ]
              },
              {
                "title": "Substance Use Disorder",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "BG000", "value": "8" },
                      { "groupId": "BG001", "value": "7" },
                      { "groupId": "BG002", "value": "15" }
                    ]
                  }
                ]
              },
              {
                "title": "Other Mental Health Disorder",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "BG000", "value": "23" },
                      { "groupId": "BG001", "value": "24" },
                      { "groupId": "BG002", "value": "47" }
                    ]
                  }
                ]
              },
              {
                "title": "Multiple Diagnoses",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "BG000", "value": "29" },
                      { "groupId": "BG001", "value": "26" },
                      { "groupId": "BG002", "value": "55" }
                    ]
                  }
                ]
              },
              {
                "title": "No History of Mental Illness",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "BG000", "value": "62" },
                      { "groupId": "BG001", "value": "48" },
                      { "groupId": "BG002", "value": "111" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Prior Therapy Experience",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "Never in Therapy",
                    "measurements": [
                      { "groupId": "BG000", "value": "66" },
                      { "groupId": "BG001", "value": "52" },
                      { "groupId": "BG002", "value": "118" }
                    ]
                  },
                  {
                    "title": "Formerly in Therapy",
                    "measurements": [
                      { "groupId": "BG000", "value": "28" },
                      { "groupId": "BG001", "value": "25" },
                      { "groupId": "BG002", "value": "53" }
                    ]
                  },
                  {
                    "title": "Currently in Therapy",
                    "measurements": [
                      { "groupId": "BG000", "value": "13" },
                      { "groupId": "BG001", "value": "18" },
                      { "groupId": "BG002", "value": "31" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Psychiatric Medications",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "Currently Taking Psychiatric Medications",
                    "measurements": [
                      { "groupId": "BG000", "value": "25" },
                      { "groupId": "BG001", "value": "17" },
                      { "groupId": "BG002", "value": "42" }
                    ]
                  },
                  {
                    "title": "Not Currently Taking Psychiatric Medications",
                    "measurements": [
                      { "groupId": "BG000", "value": "82" },
                      { "groupId": "BG001", "value": "78" },
                      { "groupId": "BG002", "value": "160" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Past 30 Day SUD Treatment",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "Self-help Groups",
                    "measurements": [
                      { "groupId": "BG000", "value": "2" },
                      { "groupId": "BG001", "value": "5" },
                      { "groupId": "BG002", "value": "7" }
                    ]
                  },
                  {
                    "title": "Outpatient Services",
                    "measurements": [
                      { "groupId": "BG000", "value": "5" },
                      { "groupId": "BG001", "value": "5" },
                      { "groupId": "BG002", "value": "10" }
                    ]
                  },
                  {
                    "title": "Intensive Outpatient/Residential",
                    "measurements": [
                      { "groupId": "BG000", "value": "2" },
                      { "groupId": "BG001", "value": "2" },
                      { "groupId": "BG002", "value": "4" }
                    ]
                  },
                  {
                    "title": "No Treatment",
                    "measurements": [
                      { "groupId": "BG000", "value": "98" },
                      { "groupId": "BG001", "value": "83" },
                      { "groupId": "BG002", "value": "181" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Past 30 Day Medication Use for SUD Treatment",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "Yes (Used medication)",
                    "measurements": [
                      { "groupId": "BG000", "value": "2" },
                      { "groupId": "BG001", "value": "1" },
                      { "groupId": "BG002", "value": "3" }
                    ]
                  },
                  {
                    "title": "No (Did not use medication)",
                    "measurements": [
                      { "groupId": "BG000", "value": "105" },
                      { "groupId": "BG001", "value": "94" },
                      { "groupId": "BG002", "value": "199" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Primary, Secondary, or Tertiary Problematic Substance",
            "paramType": "NUMBER",
            "unitOfMeasure": "participants",
            "classes": [
              {
                "title": "Alcohol",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "BG000", "value": "76" },
                      { "groupId": "BG001", "value": "72" },
                      { "groupId": "BG002", "value": "148" }
                    ]
                  }
                ]
              },
              {
                "title": "Cannabis",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "BG000", "value": "27" },
                      { "groupId": "BG001", "value": "35" },
                      { "groupId": "BG002", "value": "62" }
                    ]
                  }
                ]
              },
              {
                "title": "Stimulants",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "BG000", "value": "20" },
                      { "groupId": "BG001", "value": "15" },
                      { "groupId": "BG002", "value": "35" }
                    ]
                  }
                ]
              },
              {
                "title": "Cocaine",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "BG000", "value": "16" },
                      { "groupId": "BG001", "value": "9" },
                      { "groupId": "BG002", "value": "25" }
                    ]
                  }
                ]
              },
              {
                "title": "Tobacco",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "BG000", "value": "36" },
                      { "groupId": "BG001", "value": "34" },
                      { "groupId": "BG002", "value": "70" }
                    ]
                  }
                ]
              },
              {
                "title": "Other (e.g., Heroin, Hallucinogens, Inhalants)",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "BG000", "value": "22" },
                      { "groupId": "BG001", "value": "15" },
                      { "groupId": "BG002", "value": "37" }
                    ]
                  }
                ]
              }
            ]
          }
        ]
      },
      "outcomeMeasuresModule": {
        "outcomeMeasures": [
          {
            "type": "PRIMARY",
            "title": "Change in Number of Substance Use Occasions",
            "description": "Change in number of substance use occasions in the past 30 days",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "occasions",
            "timeFrame": "Change from Baseline to Mid-treatment at 4 weeks; Change from Baseline to Post-treatment at 8 weeks; Change from Baseline to Follow-up at 12 weeks",
            "groups": [
              {
                "id": "OG000",
                "title": "W-SUDs",
                "description": "Woebot (W-SUDs), a Conversational Agent (CA) instantaneously available 24 hours per day, 7 days per week, 'checks in' with users. Using conversational tones, it encourages mood tracking and delivers general psychoeducation as well as tailored empathy, cognitive behavior therapy (CBT)-based behavior change tools, and behavioral pattern insight. Woebot's app-based platform and user-centered design philosophy makes it an optimal modality for Substance Use Disorders (SUD) treatment delivery. It offers immediate, evidence-based tailored support in the patient's peak moment of craving.\n\nW-SUDs: Woebot (W-SUDs) is an automated conversational agent, available through a smartphone application, that delivers evidence-based psychotherapeutics, empathy, and emotional health psychoeducation."
              },
              {
                "id": "OG001",
                "title": "Digitally-delivered Psychoeducation",
                "description": "Psychoeducation delivers weekly fact sheets that include information on:\n\n1. Alcohol-specific topics;\n2. Drug-specific topics;\n3. General addiction topics;\n4. Statistics relating to alcohol and substance use.\n\nDigitally-delivered Psychoeducation: A form of psychoeducation for those seeking treatment for their alcohol and/or substance use concern. Psychoeducation is commonly provided for those with substance use. Psychoeducation in substance use is intended to increase the users' knowledge of their substances of use, and effects on the body, behaviors, and consequences. The recipient of psychoeducation is expected to increase their own awareness of their substance use and ideally incorporate this newfound knowledge when making changes to their substance use. The information provided in this group are from factsheets found on NIAAA, NIDA, and CDC web pages."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "107" },
                  { "groupId": "OG001", "value": "95" }
                ]
              }
            ],
            "classes": [
              {
                "title": "Week 4",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-11.3",
                        "spread": "15.9"
                      },
                      { "groupId": "OG001", "value": "-11.2", "spread": "12.9" }
                    ]
                  }
                ]
              },
              {
                "title": "Week 8",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-13.6",
                        "spread": "15.4"
                      },
                      { "groupId": "OG001", "value": "-12.9", "spread": "15.3" }
                    ]
                  }
                ]
              },
              {
                "title": "Week 12",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "-15.7", "spread": "18" },
                      { "groupId": "OG001", "value": "-15.4", "spread": "16.6" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Drug Abuse Screening Test (DAST-10)",
            "description": "Measure of drug abuse related consequences. The DAST-10 is a brief, 10-item self-report measure that assesses consequences related to drug abuse, excluding alcohol and tobacco. The range is 0-10, where higher scores indicate greater severity. Adapted from past 12 months to past 30 days.",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "Change from Baseline to Post-treatment at 8 weeks",
            "groups": [
              {
                "id": "OG000",
                "title": "W-SUDs",
                "description": "Woebot (W-SUDs), a Conversational Agent (CA) instantaneously available 24 hours per day, 7 days per week, 'checks in' with users. Using conversational tones, it encourages mood tracking and delivers general psychoeducation as well as tailored empathy, cognitive behavior therapy (CBT)-based behavior change tools, and behavioral pattern insight. Woebot's app-based platform and user-centered design philosophy makes it an optimal modality for Substance Use Disorders (SUD) treatment delivery. It offers immediate, evidence-based tailored support in the patient's peak moment of craving.\n\nW-SUDs: Woebot (W-SUDs) is an automated conversational agent, available through a smartphone application, that delivers evidence-based psychotherapeutics, empathy, and emotional health psychoeducation."
              },
              {
                "id": "OG001",
                "title": "Digitally-delivered Psychoeducation",
                "description": "Psychoeducation delivers weekly fact sheets that include information on:\n\n1. Alcohol-specific topics;\n2. Drug-specific topics;\n3. General addiction topics;\n4. Statistics relating to alcohol and substance use.\n\nDigitally-delivered Psychoeducation: A form of psychoeducation for those seeking treatment for their alcohol and/or substance use concern. Psychoeducation is commonly provided for those with substance use. Psychoeducation in substance use is intended to increase the users' knowledge of their substances of use, and effects on the body, behaviors, and consequences. The recipient of psychoeducation is expected to increase their own awareness of their substance use and ideally incorporate this newfound knowledge when making changes to their substance use. The information provided in this group are from factsheets found on NIAAA, NIDA, and CDC web pages."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "65" },
                  { "groupId": "OG001", "value": "54" }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-1.21",
                        "spread": "2.33"
                      },
                      { "groupId": "OG001", "value": "-1.95", "spread": "1.99" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Working Alliance Inventory (WAI-SR)",
            "description": "Measure of working alliance. A measure of therapeutic alliance that assesses three key aspects of the therapeutic alliance: (a) agreement on the tasks of therapy, (b) agreement on the goals of therapy and (c) development of an affective bond. Task, goal, and bond subscales scores range from 5-20, with higher scores indicating greater alliance. The present study utilized the validated 12-item Short-Revised version (WAI-SR) with minor changes to language, replacing \"therapist\" with \"Woebot\".",
            "populationDescription": "Number analyzed for each subscale differs from the overall number analyzed due to missingness.",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "Post-treatment at 8 weeks",
            "groups": [
              {
                "id": "OG000",
                "title": "W-SUDs",
                "description": "Woebot (W-SUDs), a Conversational Agent (CA) instantaneously available 24 hours per day, 7 days per week, 'checks in' with users. Using conversational tones, it encourages mood tracking and delivers general psychoeducation as well as tailored empathy, cognitive behavior therapy (CBT)-based behavior change tools, and behavioral pattern insight. Woebot's app-based platform and user-centered design philosophy makes it an optimal modality for Substance Use Disorders (SUD) treatment delivery. It offers immediate, evidence-based tailored support in the patient's peak moment of craving.\n\nW-SUDs: Woebot (W-SUDs) is an automated conversational agent, available through a smartphone application, that delivers evidence-based psychotherapeutics, empathy, and emotional health psychoeducation."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [{ "groupId": "OG000", "value": "98" }]
              }
            ],
            "classes": [
              {
                "title": "Goal",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [{ "groupId": "OG000", "value": "97" }]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "14.8", "spread": "4.4" }
                    ]
                  }
                ]
              },
              {
                "title": "Task",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [{ "groupId": "OG000", "value": "98" }]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "14.4", "spread": "4.5" }
                    ]
                  }
                ]
              },
              {
                "title": "Bond",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [{ "groupId": "OG000", "value": "97" }]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "15.2", "spread": "4.5" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Stanford Presenteeism Scale (SPS-6)",
            "description": "Measure of the effects of substance use on productivity. The SPS-6 is a 6-item self-report measure used to assess perceptions of the effects of substance use on past 2-week work productivity. Response options range from strongly disagree (1) to strongly agree (5). Total scores range from 6 to 30, where higher scores indicate higher presenteeism.",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "Change from Baseline to Post-treatment at 8 weeks",
            "groups": [
              {
                "id": "OG000",
                "title": "W-SUDs",
                "description": "Woebot (W-SUDs), a Conversational Agent (CA) instantaneously available 24 hours per day, 7 days per week, 'checks in' with users. Using conversational tones, it encourages mood tracking and delivers general psychoeducation as well as tailored empathy, cognitive behavior therapy (CBT)-based behavior change tools, and behavioral pattern insight. Woebot's app-based platform and user-centered design philosophy makes it an optimal modality for Substance Use Disorders (SUD) treatment delivery. It offers immediate, evidence-based tailored support in the patient's peak moment of craving.\n\nW-SUDs: Woebot (W-SUDs) is an automated conversational agent, available through a smartphone application, that delivers evidence-based psychotherapeutics, empathy, and emotional health psychoeducation."
              },
              {
                "id": "OG001",
                "title": "Digitally-delivered Psychoeducation",
                "description": "Psychoeducation delivers weekly fact sheets that include information on:\n\n1. Alcohol-specific topics;\n2. Drug-specific topics;\n3. General addiction topics;\n4. Statistics relating to alcohol and substance use.\n\nDigitally-delivered Psychoeducation: A form of psychoeducation for those seeking treatment for their alcohol and/or substance use concern. Psychoeducation is commonly provided for those with substance use. Psychoeducation in substance use is intended to increase the users' knowledge of their substances of use, and effects on the body, behaviors, and consequences. The recipient of psychoeducation is expected to increase their own awareness of their substance use and ideally incorporate this newfound knowledge when making changes to their substance use. The information provided in this group are from factsheets found on NIAAA, NIDA, and CDC web pages."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "72" },
                  { "groupId": "OG001", "value": "61" }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "-5.42", "spread": "7.2" },
                      { "groupId": "OG001", "value": "-4.12", "spread": "6.97" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Thoughts About Abstinence (TAA): Desire to Quit, Expected Success at Quitting, Expected Difficulty of Quitting Items",
            "description": "Modified for alcohol and substances. 4-item questionnaire assessing desire to quit, expected success at quitting, expected difficulty of quitting, and goal. Each of the first three items is rated on a scale of 1 to 10 where 1 is the lowest (desire, expectation, confidence) and 10 is the highest (desire, expectation, confidence). The scores are not combined. Goal for use is a single response selection item, with the option to provide a text explanation if none of the goals align. Goal data are reported as a separate outcome measure.",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "Change from Baseline to Post-treatment at 8 weeks",
            "groups": [
              {
                "id": "OG000",
                "title": "W-SUDs",
                "description": "Woebot (W-SUDs), a Conversational Agent (CA) instantaneously available 24 hours per day, 7 days per week, 'checks in' with users. Using conversational tones, it encourages mood tracking and delivers general psychoeducation as well as tailored empathy, cognitive behavior therapy (CBT)-based behavior change tools, and behavioral pattern insight. Woebot's app-based platform and user-centered design philosophy makes it an optimal modality for Substance Use Disorders (SUD) treatment delivery. It offers immediate, evidence-based tailored support in the patient's peak moment of craving.\n\nW-SUDs: Woebot (W-SUDs) is an automated conversational agent, available through a smartphone application, that delivers evidence-based psychotherapeutics, empathy, and emotional health psychoeducation."
              },
              {
                "id": "OG001",
                "title": "Digitally-delivered Psychoeducation",
                "description": "Psychoeducation delivers weekly fact sheets that include information on:\n\n1. Alcohol-specific topics;\n2. Drug-specific topics;\n3. General addiction topics;\n4. Statistics relating to alcohol and substance use.\n\nDigitally-delivered Psychoeducation: A form of psychoeducation for those seeking treatment for their alcohol and/or substance use concern. Psychoeducation is commonly provided for those with substance use. Psychoeducation in substance use is intended to increase the users' knowledge of their substances of use, and effects on the body, behaviors, and consequences. The recipient of psychoeducation is expected to increase their own awareness of their substance use and ideally incorporate this newfound knowledge when making changes to their substance use. The information provided in this group are from factsheets found on NIAAA, NIDA, and CDC web pages."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "107" },
                  { "groupId": "OG001", "value": "95" }
                ]
              }
            ],
            "classes": [
              {
                "title": "Desire to quit",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "0.21", "spread": "2.33" },
                      { "groupId": "OG001", "value": "0.12", "spread": "2.71" }
                    ]
                  }
                ]
              },
              {
                "title": "Expected success at quitting",
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "0.42", "spread": "2.37" },
                      { "groupId": "OG001", "value": "0.53", "spread": "2.72" }
                    ]
                  }
                ]
              },
              {
                "title": "Expected difficulty of quitting",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-0.64",
                        "spread": "2.44"
                      },
                      { "groupId": "OG001", "value": "-0.28", "spread": "2.91" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Thoughts About Abstinence (TAA): Goal Item",
            "description": "Modified for alcohol and substances. 4-item questionnaire assessing desire to quit, expected success at quitting, expected difficulty of quitting, confidence in ability to quit, and goal. Each of the first three items is rated on a scale of 1 to 10 where 1 is the lowest (desire, expectation, confidence) and 10 is the highest (desire, expectation, confidence). The scores are not combined. Goal for use is a single response selection item, with the option to provide a text explanation if none of the goals align. Desire to Quit, Expected Success at Quitting, Expected Difficulty of Quitting item data are reported as a separate outcome measure.",
            "populationDescription": "Number analyzed in categories reported at 8 weeks differs from overall number analyzed due to data missingness.",
            "reportingStatus": "POSTED",
            "paramType": "NUMBER",
            "unitOfMeasure": "participants",
            "timeFrame": "Baseline and Post-treatment at 8 weeks",
            "groups": [
              {
                "id": "OG000",
                "title": "W-SUDs",
                "description": "Woebot (W-SUDs), a Conversational Agent (CA) instantaneously available 24 hours per day, 7 days per week, 'checks in' with users. Using conversational tones, it encourages mood tracking and delivers general psychoeducation as well as tailored empathy, cognitive behavior therapy (CBT)-based behavior change tools, and behavioral pattern insight. Woebot's app-based platform and user-centered design philosophy makes it an optimal modality for Substance Use Disorders (SUD) treatment delivery. It offers immediate, evidence-based tailored support in the patient's peak moment of craving.\n\nW-SUDs: Woebot (W-SUDs) is an automated conversational agent, available through a smartphone application, that delivers evidence-based psychotherapeutics, empathy, and emotional health psychoeducation."
              },
              {
                "id": "OG001",
                "title": "Digitally-delivered Psychoeducation",
                "description": "Psychoeducation delivers weekly fact sheets that include information on:\n\n1. Alcohol-specific topics;\n2. Drug-specific topics;\n3. General addiction topics;\n4. Statistics relating to alcohol and substance use.\n\nDigitally-delivered Psychoeducation: A form of psychoeducation for those seeking treatment for their alcohol and/or substance use concern. Psychoeducation is commonly provided for those with substance use. Psychoeducation in substance use is intended to increase the users' knowledge of their substances of use, and effects on the body, behaviors, and consequences. The recipient of psychoeducation is expected to increase their own awareness of their substance use and ideally incorporate this newfound knowledge when making changes to their substance use. The information provided in this group are from factsheets found on NIAAA, NIDA, and CDC web pages."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "107" },
                  { "groupId": "OG001", "value": "95" }
                ]
              }
            ],
            "classes": [
              {
                "title": "No goal (Baseline)",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "107" },
                      { "groupId": "OG001", "value": "95" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "10" },
                      { "groupId": "OG001", "value": "12" }
                    ]
                  }
                ]
              },
              {
                "title": "Controlled use (Baseline)",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "107" },
                      { "groupId": "OG001", "value": "95" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "25" },
                      { "groupId": "OG001", "value": "22" }
                    ]
                  }
                ]
              },
              {
                "title": "Short-term abstinence (Baseline)",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "107" },
                      { "groupId": "OG001", "value": "95" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "14" },
                      { "groupId": "OG001", "value": "9" }
                    ]
                  }
                ]
              },
              {
                "title": "Occasional use when there is urge (Baseline)",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "107" },
                      { "groupId": "OG001", "value": "95" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "17" },
                      { "groupId": "OG001", "value": "19" }
                    ]
                  }
                ]
              },
              {
                "title": "Quit, but might slip (Baseline)",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "107" },
                      { "groupId": "OG001", "value": "95" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "13" },
                      { "groupId": "OG001", "value": "11" }
                    ]
                  }
                ]
              },
              {
                "title": "Quit forever (Baseline)",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "107" },
                      { "groupId": "OG001", "value": "95" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "25" },
                      { "groupId": "OG001", "value": "18" }
                    ]
                  }
                ]
              },
              {
                "title": "Other (Baseline)",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "107" },
                      { "groupId": "OG001", "value": "95" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "3" },
                      { "groupId": "OG001", "value": "4" }
                    ]
                  }
                ]
              },
              {
                "title": "No goal (8 weeks)",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "100" },
                      { "groupId": "OG001", "value": "90" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "16" },
                      { "groupId": "OG001", "value": "12" }
                    ]
                  }
                ]
              },
              {
                "title": "Controlled use (8 weeks)",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "100" },
                      { "groupId": "OG001", "value": "90" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "19" },
                      { "groupId": "OG001", "value": "28" }
                    ]
                  }
                ]
              },
              {
                "title": "Short-term abstinence, then decide about continued use (8 weeks)",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "100" },
                      { "groupId": "OG001", "value": "90" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "15" },
                      { "groupId": "OG001", "value": "6" }
                    ]
                  }
                ]
              },
              {
                "title": "Occasional use when there is urge (8 weeks)",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "100" },
                      { "groupId": "OG001", "value": "90" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "8" },
                      { "groupId": "OG001", "value": "6" }
                    ]
                  }
                ]
              },
              {
                "title": "Quit, but might slip (8 weeks)",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "100" },
                      { "groupId": "OG001", "value": "90" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "14" },
                      { "groupId": "OG001", "value": "11" }
                    ]
                  }
                ]
              },
              {
                "title": "Quit forever (8 weeks)",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "100" },
                      { "groupId": "OG001", "value": "90" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "25" },
                      { "groupId": "OG001", "value": "21" }
                    ]
                  }
                ]
              },
              {
                "title": "Other (8 weeks)",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "100" },
                      { "groupId": "OG001", "value": "90" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "3" },
                      { "groupId": "OG001", "value": "5" }
                    ]
                  }
                ]
              },
              {
                "title": "Prefer not to answer (8 weeks)",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "100" },
                      { "groupId": "OG001", "value": "90" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "0" },
                      { "groupId": "OG001", "value": "1" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Usage Rating Profile - Intervention (URPI)-Acceptability",
            "description": "Measure of acceptability. A 9-item subscale that inquires about intervention acceptability. For the purposes of this study, an adapted 6-item version of the subscale was utilized. Items are rated on a 6-point Likert scale (1 = \"strongly disagree\" to 6 = \"strongly agree\"). Total acceptability scores range from 6-36, with higher scores indicating greater intervention acceptability.",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "Post-treatment at 8 weeks",
            "groups": [
              {
                "id": "OG000",
                "title": "W-SUDs",
                "description": "Woebot (W-SUDs), a Conversational Agent (CA) instantaneously available 24 hours per day, 7 days per week, 'checks in' with users. Using conversational tones, it encourages mood tracking and delivers general psychoeducation as well as tailored empathy, cognitive behavior therapy (CBT)-based behavior change tools, and behavioral pattern insight. Woebot's app-based platform and user-centered design philosophy makes it an optimal modality for Substance Use Disorders (SUD) treatment delivery. It offers immediate, evidence-based tailored support in the patient's peak moment of craving.\n\nW-SUDs: Woebot (W-SUDs) is an automated conversational agent, available through a smartphone application, that delivers evidence-based psychotherapeutics, empathy, and emotional health psychoeducation."
              },
              {
                "id": "OG001",
                "title": "Digitally-delivered Psychoeducation",
                "description": "Psychoeducation delivers weekly fact sheets that include information on:\n\n1. Alcohol-specific topics;\n2. Drug-specific topics;\n3. General addiction topics;\n4. Statistics relating to alcohol and substance use.\n\nDigitally-delivered Psychoeducation: A form of psychoeducation for those seeking treatment for their alcohol and/or substance use concern. Psychoeducation is commonly provided for those with substance use. Psychoeducation in substance use is intended to increase the users' knowledge of their substances of use, and effects on the body, behaviors, and consequences. The recipient of psychoeducation is expected to increase their own awareness of their substance use and ideally incorporate this newfound knowledge when making changes to their substance use. The information provided in this group are from factsheets found on NIAAA, NIDA, and CDC web pages."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "99" },
                  { "groupId": "OG001", "value": "89" }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "30.1", "spread": "5.6" },
                      { "groupId": "OG001", "value": "30.3", "spread": "5.8" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Usage Rating Profile - Intervention (URPI)-Feasibility",
            "description": "Measure of feasibility. A 6-item subscale that inquires about factors that impact treatment usage (i.e., intervention quality). Items are rated on a 6-point Likert scale (1 = \"slightly disagree\" to 6 = \"strongly agree\"). Total feasibility scores range from 6-36, with higher scores indicating greater intervention feasibility.",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "Post-treatment at 8 weeks",
            "groups": [
              {
                "id": "OG000",
                "title": "W-SUDs",
                "description": "Woebot (W-SUDs), a Conversational Agent (CA) instantaneously available 24 hours per day, 7 days per week, 'checks in' with users. Using conversational tones, it encourages mood tracking and delivers general psychoeducation as well as tailored empathy, cognitive behavior therapy (CBT)-based behavior change tools, and behavioral pattern insight. Woebot's app-based platform and user-centered design philosophy makes it an optimal modality for Substance Use Disorders (SUD) treatment delivery. It offers immediate, evidence-based tailored support in the patient's peak moment of craving.\n\nW-SUDs: Woebot (W-SUDs) is an automated conversational agent, available through a smartphone application, that delivers evidence-based psychotherapeutics, empathy, and emotional health psychoeducation."
              },
              {
                "id": "OG001",
                "title": "Digitally-delivered Psychoeducation",
                "description": "Psychoeducation delivers weekly fact sheets that include information on:\n\n1. Alcohol-specific topics;\n2. Drug-specific topics;\n3. General addiction topics;\n4. Statistics relating to alcohol and substance use.\n\nDigitally-delivered Psychoeducation: A form of psychoeducation for those seeking treatment for their alcohol and/or substance use concern. Psychoeducation is commonly provided for those with substance use. Psychoeducation in substance use is intended to increase the users' knowledge of their substances of use, and effects on the body, behaviors, and consequences. The recipient of psychoeducation is expected to increase their own awareness of their substance use and ideally incorporate this newfound knowledge when making changes to their substance use. The information provided in this group are from factsheets found on NIAAA, NIDA, and CDC web pages."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "99" },
                  { "groupId": "OG001", "value": "89" }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "28.0", "spread": "3.5" },
                      { "groupId": "OG001", "value": "29.8", "spread": "2.6" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Client Satisfaction Questionnaire (CSQ-8)",
            "description": "Measure of satisfaction. An 8-item measure used to assess client's satisfaction with treatment on a 4-point scale. Example questions include, \"How would you rate the quality of service you received\"? and \"Did you get the kind of service you wanted?\" Total sums range from 8-32, with high scores indicating greater satisfaction with the W-SUDs mobile application.",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "Post-treatment at 8 weeks",
            "groups": [
              {
                "id": "OG000",
                "title": "W-SUDs",
                "description": "Woebot (W-SUDs), a Conversational Agent (CA) instantaneously available 24 hours per day, 7 days per week, 'checks in' with users. Using conversational tones, it encourages mood tracking and delivers general psychoeducation as well as tailored empathy, cognitive behavior therapy (CBT)-based behavior change tools, and behavioral pattern insight. Woebot's app-based platform and user-centered design philosophy makes it an optimal modality for Substance Use Disorders (SUD) treatment delivery. It offers immediate, evidence-based tailored support in the patient's peak moment of craving.\n\nW-SUDs: Woebot (W-SUDs) is an automated conversational agent, available through a smartphone application, that delivers evidence-based psychotherapeutics, empathy, and emotional health psychoeducation."
              },
              {
                "id": "OG001",
                "title": "Digitally-delivered Psychoeducation",
                "description": "Psychoeducation delivers weekly fact sheets that include information on:\n\n1. Alcohol-specific topics;\n2. Drug-specific topics;\n3. General addiction topics;\n4. Statistics relating to alcohol and substance use.\n\nDigitally-delivered Psychoeducation: A form of psychoeducation for those seeking treatment for their alcohol and/or substance use concern. Psychoeducation is commonly provided for those with substance use. Psychoeducation in substance use is intended to increase the users' knowledge of their substances of use, and effects on the body, behaviors, and consequences. The recipient of psychoeducation is expected to increase their own awareness of their substance use and ideally incorporate this newfound knowledge when making changes to their substance use. The information provided in this group are from factsheets found on NIAAA, NIDA, and CDC web pages."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "99" },
                  { "groupId": "OG001", "value": "87" }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "26.9", "spread": "5.2" },
                      { "groupId": "OG001", "value": "28.1", "spread": "4.5" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Short Inventory of Problems- Alcohol and Drugs (SIP-AD)",
            "description": "The SIP-AD assesses substance use problems in the past 30 days. The scored variables, total scores and 15-item mean, summarize consequences of alcohol and drug use. Scores range from 0-45, where greater scores indicate greater substance use problems.",
            "populationDescription": "Number analyzed for each timepoint differs from the overall number analyzed due to missingness.",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "Change from Baseline to Mid-Treatment at 4 weeks; Change from Baseline to Post-treatment at 8 weeks; Change from Baseline to Follow-up at 12 weeks",
            "groups": [
              {
                "id": "OG000",
                "title": "W-SUDs",
                "description": "Woebot (W-SUDs), a Conversational Agent (CA) instantaneously available 24 hours per day, 7 days per week, 'checks in' with users. Using conversational tones, it encourages mood tracking and delivers general psychoeducation as well as tailored empathy, cognitive behavior therapy (CBT)-based behavior change tools, and behavioral pattern insight. Woebot's app-based platform and user-centered design philosophy makes it an optimal modality for Substance Use Disorders (SUD) treatment delivery. It offers immediate, evidence-based tailored support in the patient's peak moment of craving.\n\nW-SUDs: Woebot (W-SUDs) is an automated conversational agent, available through a smartphone application, that delivers evidence-based psychotherapeutics, empathy, and emotional health psychoeducation."
              },
              {
                "id": "OG001",
                "title": "Digitally-delivered Psychoeducation",
                "description": "Psychoeducation delivers weekly fact sheets that include information on:\n\n1. Alcohol-specific topics;\n2. Drug-specific topics;\n3. General addiction topics;\n4. Statistics relating to alcohol and substance use.\n\nDigitally-delivered Psychoeducation: A form of psychoeducation for those seeking treatment for their alcohol and/or substance use concern. Psychoeducation is commonly provided for those with substance use. Psychoeducation in substance use is intended to increase the users' knowledge of their substances of use, and effects on the body, behaviors, and consequences. The recipient of psychoeducation is expected to increase their own awareness of their substance use and ideally incorporate this newfound knowledge when making changes to their substance use. The information provided in this group are from factsheets found on NIAAA, NIDA, and CDC web pages."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "100" },
                  { "groupId": "OG001", "value": "93" }
                ]
              }
            ],
            "classes": [
              {
                "title": "Mid-treatment at 4 weeks",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "98" },
                      { "groupId": "OG001", "value": "91" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-8.02",
                        "spread": "9.35"
                      },
                      { "groupId": "OG001", "value": "-7.39", "spread": "9.95" }
                    ]
                  }
                ]
              },
              {
                "title": "Post-treatment at 8 weeks",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "100" },
                      { "groupId": "OG001", "value": "90" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-9.02",
                        "spread": "11.6"
                      },
                      { "groupId": "OG001", "value": "-9.24", "spread": "10.2" }
                    ]
                  }
                ]
              },
              {
                "title": "Follow-up at 12 weeks",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "98" },
                      { "groupId": "OG001", "value": "93" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-11.5",
                        "spread": "11.5"
                      },
                      { "groupId": "OG001", "value": "-10.9", "spread": "11.5" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Patient Health Questionnaire (PHQ-8)",
            "description": "Measure of depression severity. An 8-item abbreviated version of the PHQ-9 used to assess mood symptoms. The PHQ-8 excludes an item assessing suicidality. Items are rated on a 4-point Likert scale (0 = \"not at all\" to 3 = \"nearly every day\"). Total score between 0-24, with higher scores indicating greater severity of depression symptoms.",
            "populationDescription": "Number analyzed for each timepoint differs from the overall number analyzed due to missingness.",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "Change from Baseline to Mid-treatment at 4 weeks; Change from Baseline to Post-treatment at 8 weeks; Change from Baseline to Follow-up at 12 weeks",
            "groups": [
              {
                "id": "OG000",
                "title": "W-SUDs",
                "description": "Woebot (W-SUDs), a Conversational Agent (CA) instantaneously available 24 hours per day, 7 days per week, 'checks in' with users. Using conversational tones, it encourages mood tracking and delivers general psychoeducation as well as tailored empathy, cognitive behavior therapy (CBT)-based behavior change tools, and behavioral pattern insight. Woebot's app-based platform and user-centered design philosophy makes it an optimal modality for Substance Use Disorders (SUD) treatment delivery. It offers immediate, evidence-based tailored support in the patient's peak moment of craving.\n\nW-SUDs: Woebot (W-SUDs) is an automated conversational agent, available through a smartphone application, that delivers evidence-based psychotherapeutics, empathy, and emotional health psychoeducation."
              },
              {
                "id": "OG001",
                "title": "Digitally-delivered Psychoeducation",
                "description": "Psychoeducation delivers weekly fact sheets that include information on:\n\n1. Alcohol-specific topics;\n2. Drug-specific topics;\n3. General addiction topics;\n4. Statistics relating to alcohol and substance use.\n\nDigitally-delivered Psychoeducation: A form of psychoeducation for those seeking treatment for their alcohol and/or substance use concern. Psychoeducation is commonly provided for those with substance use. Psychoeducation in substance use is intended to increase the users' knowledge of their substances of use, and effects on the body, behaviors, and consequences. The recipient of psychoeducation is expected to increase their own awareness of their substance use and ideally incorporate this newfound knowledge when making changes to their substance use. The information provided in this group are from factsheets found on NIAAA, NIDA, and CDC web pages."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "100" },
                  { "groupId": "OG001", "value": "93" }
                ]
              }
            ],
            "classes": [
              {
                "title": "Mid-treatment at 4 weeks",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "98" },
                      { "groupId": "OG001", "value": "91" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-1.84",
                        "spread": "4.24"
                      },
                      { "groupId": "OG001", "value": "-1.44", "spread": "4.45" }
                    ]
                  }
                ]
              },
              {
                "title": "Post-treatment at 8 weeks",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "100" },
                      { "groupId": "OG001", "value": "90" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-2.82",
                        "spread": "4.65"
                      },
                      { "groupId": "OG001", "value": "-2.05", "spread": "5.95" }
                    ]
                  }
                ]
              },
              {
                "title": "Follow-up at 12 weeks",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "98" },
                      { "groupId": "OG001", "value": "93" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-2.83",
                        "spread": "4.79"
                      },
                      { "groupId": "OG001", "value": "-2.87", "spread": "6.3" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Generalized Anxiety Disorder (GAD-7)",
            "description": "Measure of anxiety severity. A 7-item self-report measure used to assess the frequency and severity of anxious thoughts and behaviors over the past 2 weeks. Items are rated on a 4-point Likert scale (0 = \"not at all\" to 3 = \"nearly every day\").Total scores range from 0-21, where higher scores indicate greater severity of anxiety symptoms.",
            "populationDescription": "Number analyzed for each timepoint differs from the overall number analyzed due to missingness.",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "Change from Baseline to Mid-treatment at 4 weeks; Change from Baseline to Post-treatment at 8 weeks; Change from Baseline to Follow-up at 12 weeks",
            "groups": [
              {
                "id": "OG000",
                "title": "W-SUDs",
                "description": "Woebot (W-SUDs), a Conversational Agent (CA) instantaneously available 24 hours per day, 7 days per week, 'checks in' with users. Using conversational tones, it encourages mood tracking and delivers general psychoeducation as well as tailored empathy, cognitive behavior therapy (CBT)-based behavior change tools, and behavioral pattern insight. Woebot's app-based platform and user-centered design philosophy makes it an optimal modality for Substance Use Disorders (SUD) treatment delivery. It offers immediate, evidence-based tailored support in the patient's peak moment of craving.\n\nW-SUDs: Woebot (W-SUDs) is an automated conversational agent, available through a smartphone application, that delivers evidence-based psychotherapeutics, empathy, and emotional health psychoeducation."
              },
              {
                "id": "OG001",
                "title": "Digitally-delivered Psychoeducation",
                "description": "Psychoeducation delivers weekly fact sheets that include information on:\n\n1. Alcohol-specific topics;\n2. Drug-specific topics;\n3. General addiction topics;\n4. Statistics relating to alcohol and substance use.\n\nDigitally-delivered Psychoeducation: A form of psychoeducation for those seeking treatment for their alcohol and/or substance use concern. Psychoeducation is commonly provided for those with substance use. Psychoeducation in substance use is intended to increase the users' knowledge of their substances of use, and effects on the body, behaviors, and consequences. The recipient of psychoeducation is expected to increase their own awareness of their substance use and ideally incorporate this newfound knowledge when making changes to their substance use. The information provided in this group are from factsheets found on NIAAA, NIDA, and CDC web pages."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "100" },
                  { "groupId": "OG001", "value": "93" }
                ]
              }
            ],
            "classes": [
              {
                "title": "Mid-treatment at 4 weeks",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "98" },
                      { "groupId": "OG001", "value": "91" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-1.31",
                        "spread": "4.05"
                      },
                      { "groupId": "OG001", "value": "-1.56", "spread": "3.97" }
                    ]
                  }
                ]
              },
              {
                "title": "Post-treatment at 8 weeks",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "100" },
                      { "groupId": "OG001", "value": "90" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-1.88",
                        "spread": "4.77"
                      },
                      { "groupId": "OG001", "value": "-1.72", "spread": "4.91" }
                    ]
                  }
                ]
              },
              {
                "title": "Follow-up at 12 weeks",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "98" },
                      { "groupId": "OG001", "value": "93" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-2.09",
                        "spread": "4.67"
                      },
                      { "groupId": "OG001", "value": "-2.57", "spread": "5.08" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Brief Situational Confidence Questionnaire (BSCQ)",
            "description": "Measure of self-confidence. The 8-item BSCQ is a state dependent measure that assesses self-confidence to resist the urge to drink heavily or use drugs in a variety of situations. Each of the 8 scale situations consists of a 100-mm line, anchored by 0% (\"not at all confident\") and 100% (\"totally confident\") where clients are asked to indicate confidence on a scale from 0% to 100%. Higher scores are associated with greater confidence.",
            "populationDescription": "Number analyzed for each timepoint differs from the overall number analyzed due to missingness.",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "Change from Baseline to Mid-treatment at 4 weeks; Change from Baseline to Post-treatment at 8 weeks; Change from Baseline to Follow-up at 12 weeks",
            "groups": [
              {
                "id": "OG000",
                "title": "W-SUDs",
                "description": "Woebot (W-SUDs), a Conversational Agent (CA) instantaneously available 24 hours per day, 7 days per week, 'checks in' with users. Using conversational tones, it encourages mood tracking and delivers general psychoeducation as well as tailored empathy, cognitive behavior therapy (CBT)-based behavior change tools, and behavioral pattern insight. Woebot's app-based platform and user-centered design philosophy makes it an optimal modality for Substance Use Disorders (SUD) treatment delivery. It offers immediate, evidence-based tailored support in the patient's peak moment of craving.\n\nW-SUDs: Woebot (W-SUDs) is an automated conversational agent, available through a smartphone application, that delivers evidence-based psychotherapeutics, empathy, and emotional health psychoeducation."
              },
              {
                "id": "OG001",
                "title": "Digitally-delivered Psychoeducation",
                "description": "Psychoeducation delivers weekly fact sheets that include information on:\n\n1. Alcohol-specific topics;\n2. Drug-specific topics;\n3. General addiction topics;\n4. Statistics relating to alcohol and substance use.\n\nDigitally-delivered Psychoeducation: A form of psychoeducation for those seeking treatment for their alcohol and/or substance use concern. Psychoeducation is commonly provided for those with substance use. Psychoeducation in substance use is intended to increase the users' knowledge of their substances of use, and effects on the body, behaviors, and consequences. The recipient of psychoeducation is expected to increase their own awareness of their substance use and ideally incorporate this newfound knowledge when making changes to their substance use. The information provided in this group are from factsheets found on NIAAA, NIDA, and CDC web pages."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "96" },
                  { "groupId": "OG001", "value": "90" }
                ]
              }
            ],
            "classes": [
              {
                "title": "Mid-treatment at 4 weeks",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "95" },
                      { "groupId": "OG001", "value": "88" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "7.3", "spread": "21.4" },
                      { "groupId": "OG001", "value": "10.4", "spread": "23.2" }
                    ]
                  }
                ]
              },
              {
                "title": "Post-treatment at 8 weeks",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "96" },
                      { "groupId": "OG001", "value": "86" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "6.77", "spread": "20.4" },
                      { "groupId": "OG001", "value": "11.6", "spread": "20.3" }
                    ]
                  }
                ]
              },
              {
                "title": "Follow-up at 12 weeks",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "94" },
                      { "groupId": "OG001", "value": "90" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      { "groupId": "OG000", "value": "11.6", "spread": "21.8" },
                      { "groupId": "OG001", "value": "15.6", "spread": "26.1" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Craving Ratings",
            "description": "Self-reported ratings of craving intensity. Craving is assessed with a single question, \"In the past 7 days, how much were you bothered by cravings or urges to drink alcohol or use drugs?\". The question is rated on a scale of 0 to 4 where 0 = not at all, 1 = a little bit, 2 = moderately, 3 = quite a bit, and 4 = extremely. Greater scores indicate a more intense urge to use.",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "score on a scale",
            "timeFrame": "Change from Baseline to Mid-treatment at 4 weeks; Change from Baseline to Post-treatment at 8 weeks; Change from Baseline to Follow-up at 12 weeks",
            "groups": [
              {
                "id": "OG000",
                "title": "W-SUDs",
                "description": "Woebot (W-SUDs), a Conversational Agent (CA) instantaneously available 24 hours per day, 7 days per week, 'checks in' with users. Using conversational tones, it encourages mood tracking and delivers general psychoeducation as well as tailored empathy, cognitive behavior therapy (CBT)-based behavior change tools, and behavioral pattern insight. Woebot's app-based platform and user-centered design philosophy makes it an optimal modality for Substance Use Disorders (SUD) treatment delivery. It offers immediate, evidence-based tailored support in the patient's peak moment of craving.\n\nW-SUDs: Woebot (W-SUDs) is an automated conversational agent, available through a smartphone application, that delivers evidence-based psychotherapeutics, empathy, and emotional health psychoeducation."
              },
              {
                "id": "OG001",
                "title": "Digitally-delivered Psychoeducation",
                "description": "Psychoeducation delivers weekly fact sheets that include information on:\n\n1. Alcohol-specific topics;\n2. Drug-specific topics;\n3. General addiction topics;\n4. Statistics relating to alcohol and substance use.\n\nDigitally-delivered Psychoeducation: A form of psychoeducation for those seeking treatment for their alcohol and/or substance use concern. Psychoeducation is commonly provided for those with substance use. Psychoeducation in substance use is intended to increase the users' knowledge of their substances of use, and effects on the body, behaviors, and consequences. The recipient of psychoeducation is expected to increase their own awareness of their substance use and ideally incorporate this newfound knowledge when making changes to their substance use. The information provided in this group are from factsheets found on NIAAA, NIDA, and CDC web pages."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "107" },
                  { "groupId": "OG001", "value": "95" }
                ]
              }
            ],
            "classes": [
              {
                "title": "Mid-treatment at 4 weeks",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-0.418",
                        "spread": "0.994"
                      },
                      { "groupId": "OG001", "value": "-0.56", "spread": "1.14" }
                    ]
                  }
                ]
              },
              {
                "title": "Post-treatment at 8 weeks",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-0.66",
                        "spread": "1.18"
                      },
                      { "groupId": "OG001", "value": "-0.722", "spread": "1.2" }
                    ]
                  }
                ]
              },
              {
                "title": "Follow-up at 12 weeks",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-0.816",
                        "spread": "1.15"
                      },
                      { "groupId": "OG001", "value": "-0.892", "spread": "1.4" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Past Month Number of Binge Days",
            "description": "Assessed with the Quick Drinking Screen (QDS), a measure of alcohol consumption. The QDS is a brief self-report measure used to assess average alcohol consumption over a specified time period (in the present study it was the past 30 days). The QDS collects drinking data for three variables including number of days drinking, number of standard drinks per drinking day, and number of binge/risky drinking days. Binge/risky drinking days is defined as days when they have had 5 or more standard drinks (for men) or 4 or more standard drinks (for women).",
            "populationDescription": "Number analyzed for each timepoint differs from the overall number analyzed due to missingness.",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "days",
            "timeFrame": "Change from Baseline to Mid-treatment at 4 weeks; Change from Baseline to Post-treatment at 8 weeks; Change from Baseline to Follow-up at 12 weeks",
            "groups": [
              {
                "id": "OG000",
                "title": "W-SUDs",
                "description": "Woebot (W-SUDs), a Conversational Agent (CA) instantaneously available 24 hours per day, 7 days per week, 'checks in' with users. Using conversational tones, it encourages mood tracking and delivers general psychoeducation as well as tailored empathy, cognitive behavior therapy (CBT)-based behavior change tools, and behavioral pattern insight. Woebot's app-based platform and user-centered design philosophy makes it an optimal modality for Substance Use Disorders (SUD) treatment delivery. It offers immediate, evidence-based tailored support in the patient's peak moment of craving.\n\nW-SUDs: Woebot (W-SUDs) is an automated conversational agent, available through a smartphone application, that delivers evidence-based psychotherapeutics, empathy, and emotional health psychoeducation."
              },
              {
                "id": "OG001",
                "title": "Digitally-delivered Psychoeducation",
                "description": "Psychoeducation delivers weekly fact sheets that include information on:\n\n1. Alcohol-specific topics;\n2. Drug-specific topics;\n3. General addiction topics;\n4. Statistics relating to alcohol and substance use.\n\nDigitally-delivered Psychoeducation: A form of psychoeducation for those seeking treatment for their alcohol and/or substance use concern. Psychoeducation is commonly provided for those with substance use. Psychoeducation in substance use is intended to increase the users' knowledge of their substances of use, and effects on the body, behaviors, and consequences. The recipient of psychoeducation is expected to increase their own awareness of their substance use and ideally incorporate this newfound knowledge when making changes to their substance use. The information provided in this group are from factsheets found on NIAAA, NIDA, and CDC web pages."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "78" },
                  { "groupId": "OG001", "value": "67" }
                ]
              }
            ],
            "classes": [
              {
                "title": "Mid-treatment at 4 weeks",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "78" },
                      { "groupId": "OG001", "value": "64" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-4.26",
                        "spread": "6.88"
                      },
                      { "groupId": "OG001", "value": "-2.45", "spread": "5.66" }
                    ]
                  }
                ]
              },
              {
                "title": "Post-treatment at 8 weeks",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "75" },
                      { "groupId": "OG001", "value": "67" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-4.09",
                        "spread": "6.35"
                      },
                      { "groupId": "OG001", "value": "-2.51", "spread": "6.02" }
                    ]
                  }
                ]
              },
              {
                "title": "Follow-up at 12 weeks",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "70" },
                      { "groupId": "OG001", "value": "63" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-5.43",
                        "spread": "7.21"
                      },
                      { "groupId": "OG001", "value": "-3.14", "spread": "7.75" }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Past Month Average Standard Drinks in a Week",
            "description": "Assessed with the Quick Drinking Screen (QDS), a measure of alcohol consumption. The QDS is a brief self-report measure used to assess average alcohol consumption over a specified time period (in the present study it was the past 30 days). The QDS collects drinking data for three variables including number of days drinking, number of standard drinks per drinking day, and number of binge/risky drinking days. Binge/risky drinking days is defined as days when they have had 5 or more standard drinks (for men) or 4 or more standard drinks (for women). Number of standard drinks per week is calculated by multiplying number of standard drinks per day in the past month and number of binge days per month.",
            "populationDescription": "Number analyzed for each timepoint differs from the overall number analyzed due to missingness.",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "Drinks per week",
            "timeFrame": "Change from Baseline to Mid-treatment at 4 weeks; Change from Baseline to Post-treatment at 8 weeks; Change from Baseline to Follow-up at 12 weeks",
            "groups": [
              {
                "id": "OG000",
                "title": "W-SUDs",
                "description": "Woebot (W-SUDs), a Conversational Agent (CA) instantaneously available 24 hours per day, 7 days per week, 'checks in' with users. Using conversational tones, it encourages mood tracking and delivers general psychoeducation as well as tailored empathy, cognitive behavior therapy (CBT)-based behavior change tools, and behavioral pattern insight. Woebot's app-based platform and user-centered design philosophy makes it an optimal modality for Substance Use Disorders (SUD) treatment delivery. It offers immediate, evidence-based tailored support in the patient's peak moment of craving.\n\nW-SUDs: Woebot (W-SUDs) is an automated conversational agent, available through a smartphone application, that delivers evidence-based psychotherapeutics, empathy, and emotional health psychoeducation."
              },
              {
                "id": "OG001",
                "title": "Digitally-delivered Psychoeducation",
                "description": "Psychoeducation delivers weekly fact sheets that include information on:\n\n1. Alcohol-specific topics;\n2. Drug-specific topics;\n3. General addiction topics;\n4. Statistics relating to alcohol and substance use.\n\nDigitally-delivered Psychoeducation: A form of psychoeducation for those seeking treatment for their alcohol and/or substance use concern. Psychoeducation is commonly provided for those with substance use. Psychoeducation in substance use is intended to increase the users' knowledge of their substances of use, and effects on the body, behaviors, and consequences. The recipient of psychoeducation is expected to increase their own awareness of their substance use and ideally incorporate this newfound knowledge when making changes to their substance use. The information provided in this group are from factsheets found on NIAAA, NIDA, and CDC web pages."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  { "groupId": "OG000", "value": "78" },
                  { "groupId": "OG001", "value": "67" }
                ]
              }
            ],
            "classes": [
              {
                "title": "Mid-treatment at 4 weeks",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "78" },
                      { "groupId": "OG001", "value": "64" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-7.62",
                        "spread": "14.9"
                      },
                      { "groupId": "OG001", "value": "-6.92", "spread": "12.4" }
                    ]
                  }
                ]
              },
              {
                "title": "Post-treatment at 8 weeks",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "75" },
                      { "groupId": "OG001", "value": "67" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-8.67",
                        "spread": "14.7"
                      },
                      { "groupId": "OG001", "value": "-8.18", "spread": "11.5" }
                    ]
                  }
                ]
              },
              {
                "title": "Follow-up at 12 weeks",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      { "groupId": "OG000", "value": "70" },
                      { "groupId": "OG001", "value": "63" }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-11.1",
                        "spread": "15.7"
                      },
                      { "groupId": "OG001", "value": "-9.43", "spread": "13.9" }
                    ]
                  }
                ]
              }
            ]
          }
        ]
      },
      "adverseEventsModule": {
        "frequencyThreshold": "0",
        "timeFrame": "Serious adverse events were assessed at post-treatment and follow-up at 8-weeks and 12-weeks from baseline, respectively.",
        "description": "Serious adverse events occurring during treatment were assessed for hospitalization related to substance use, suicide attempt, alcohol or drug overdose, and severe withdrawal (e.g., delirium tremens). Positive endorsements were followed up with questions about the timing, diagnosis, and resolution. If additional details were needed to determine whether the event was study related, a team member reached out to the participant.",
        "eventGroups": [
          {
            "id": "EG000",
            "title": "W-SUDs",
            "description": "Woebot (W-SUDs), a Conversational Agent (CA) instantaneously available 24 hours per day, 7 days per week, 'checks in' with users. Using conversational tones, it encourages mood tracking and delivers general psychoeducation as well as tailored empathy, cognitive behavior therapy (CBT)-based behavior change tools, and behavioral pattern insight. Woebot's app-based platform and user-centered design philosophy makes it an optimal modality for Substance Use Disorders (SUD) treatment delivery. It offers immediate, evidence-based tailored support in the patient's peak moment of craving.\n\nW-SUDs: Woebot (W-SUDs) is an automated conversational agent, available through a smartphone application, that delivers evidence-based psychotherapeutics, empathy, and emotional health psychoeducation.",
            "deathsNumAffected": 0,
            "deathsNumAtRisk": 107,
            "seriousNumAffected": 0,
            "seriousNumAtRisk": 107,
            "otherNumAffected": 0,
            "otherNumAtRisk": 107
          },
          {
            "id": "EG001",
            "title": "Digitally-delivered Psychoeducation",
            "description": "Psychoeducation delivers weekly fact sheets that include information on:\n\n1. Alcohol-specific topics;\n2. Drug-specific topics;\n3. General addiction topics;\n4. Statistics relating to alcohol and substance use.\n\nDigitally-delivered Psychoeducation: A form of psychoeducation for those seeking treatment for their alcohol and/or substance use concern. Psychoeducation is commonly provided for those with substance use. Psychoeducation in substance use is intended to increase the users' knowledge of their substances of use, and effects on the body, behaviors, and consequences. The recipient of psychoeducation is expected to increase their own awareness of their substance use and ideally incorporate this newfound knowledge when making changes to their substance use. The information provided in this group are from factsheets found on NIAAA, NIDA, and CDC web pages.",
            "deathsNumAffected": 0,
            "deathsNumAtRisk": 95,
            "seriousNumAffected": 0,
            "seriousNumAtRisk": 95,
            "otherNumAffected": 0,
            "otherNumAtRisk": 95
          }
        ]
      },
      "moreInfoModule": {
        "certainAgreement": {
          "piSponsorEmployee": false,
          "restrictiveAgreement": false
        },
        "pointOfContact": {
          "title": "Judith J. Prochaska, PhD, MPH",
          "organization": "Stanford Prevention Research Center, Department of Medicine, Stanford",
          "email": "jpro@stanford.edu",
          "phone": "650-724-3608"
        }
      }
    },
    "documentSection": {
      "largeDocumentModule": {
        "largeDocs": [
          {
            "typeAbbrev": "Prot",
            "hasProtocol": true,
            "hasSap": false,
            "hasIcf": false,
            "label": "Study Protocol",
            "date": "2023-03-17",
            "uploadDate": "2024-08-27T17:04",
            "filename": "Prot_008.pdf",
            "size": 258579
          },
          {
            "typeAbbrev": "SAP",
            "hasProtocol": false,
            "hasSap": true,
            "hasIcf": false,
            "label": "Statistical Analysis Plan",
            "date": "2023-03-17",
            "uploadDate": "2023-11-28T11:33",
            "filename": "SAP_009.pdf",
            "size": 48224
          },
          {
            "typeAbbrev": "ICF",
            "hasProtocol": false,
            "hasSap": false,
            "hasIcf": true,
            "label": "Informed Consent Form",
            "date": "2023-03-17",
            "uploadDate": "2023-03-28T08:39",
            "filename": "ICF_007.pdf",
            "size": 332891
          }
        ]
      }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [
          { "id": "D019966", "term": "Substance-Related Disorders" },
          { "id": "D000437", "term": "Alcoholism" },
          { "id": "D000428", "term": "Alcohol Drinking" }
        ],
        "ancestors": [
          { "id": "D004327", "term": "Drinking Behavior" },
          { "id": "D064419", "term": "Chemically-Induced Disorders" },
          { "id": "D001523", "term": "Mental Disorders" },
          { "id": "D019973", "term": "Alcohol-Related Disorders" }
        ],
        "browseLeaves": [
          {
            "id": "M3774",
            "name": "Alcohol Drinking",
            "asFound": "Alcohol Use",
            "relevance": "HIGH"
          },
          {
            "id": "M21837",
            "name": "Substance-Related Disorders",
            "asFound": "Substance Use",
            "relevance": "HIGH"
          },
          {
            "id": "M3783",
            "name": "Alcoholism",
            "asFound": "Alcohol Use Disorder",
            "relevance": "HIGH"
          },
          { "id": "M7502", "name": "Drinking Behavior", "relevance": "LOW" },
          {
            "id": "M30302",
            "name": "Chemically-Induced Disorders",
            "relevance": "LOW"
          },
          { "id": "M14473", "name": "Psychotic Disorders", "relevance": "LOW" },
          { "id": "M4815", "name": "Mental Disorders", "relevance": "LOW" },
          {
            "id": "M21842",
            "name": "Alcohol-Related Disorders",
            "relevance": "LOW"
          }
        ],
        "browseBranches": [
          { "abbrev": "BXM", "name": "Behaviors and Mental Disorders" },
          { "abbrev": "All", "name": "All Conditions" },
          { "abbrev": "BC25", "name": "Substance Related Disorders" }
        ]
      },
      "interventionBrowseModule": {
        "browseLeaves": [
          { "id": "M3777", "name": "Ethanol", "relevance": "LOW" },
          { "id": "M14474", "name": "Psychotropic Drugs", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "Infe", "name": "Anti-Infective Agents" },
          { "abbrev": "CNSDep", "name": "Central Nervous System Depressants" },
          { "abbrev": "All", "name": "All Drugs and Chemicals" },
          { "abbrev": "PsychDr", "name": "Psychotropic Drugs" }
        ]
      }
    },
    "hasResults": true
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT06715774",
        "orgStudyIdInfo": { "id": "RG-2024-ortho" },
        "organization": {
          "fullName": "University of Salamanca",
          "class": "OTHER"
        },
        "briefTitle": "Impact of Twin Block and Motion Class II Appliances on Hyoid Bone Position - A Retrospective Clinical Study",
        "officialTitle": "Impact of Twin Block and Motion Class II Appliances on Hyoid Bone Position - A Retrospective Clinical Study",
        "acronym": "Hyoid bone"
      },
      "statusModule": {
        "statusVerifiedDate": "2024-11",
        "overallStatus": "COMPLETED",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2023-02-07", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2023-02-09",
          "type": "ACTUAL"
        },
        "completionDateStruct": { "date": "2024-06-25", "type": "ACTUAL" },
        "studyFirstSubmitDate": "2024-11-28",
        "studyFirstSubmitQcDate": "2024-11-28",
        "studyFirstPostDateStruct": { "date": "2024-12-04", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2024-11-28",
        "lastUpdatePostDateStruct": { "date": "2024-12-04", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": {
          "type": "PRINCIPAL_INVESTIGATOR",
          "investigatorFullName": "JAVIER MONTERO",
          "investigatorTitle": "Romane Gilbert",
          "investigatorAffiliation": "University of Salamanca"
        },
        "leadSponsor": { "name": "University of Salamanca", "class": "OTHER" }
      },
      "oversightModule": {
        "oversightHasDmc": true,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": false
      },
      "descriptionModule": {
        "briefSummary": "Analyse the impact Twin block appliance and Motion on Hyoid Bone",
        "detailedDescription": "Patients were selected, divided en two homogenous groups and underwent preoperative and postoperative lateral teleradiograph scans. The datasets were subsequently uploaded into a digital treatment planning software to record the position changes of the hyoid bone at horizontal, vertical, angular, and airway complex level; additionally, the effect of gender, age at onset, treatment time, biotype, and their interactions with the group, have been also statistically evaluated."
      },
      "conditionsModule": {
        "conditions": ["Hyoid Bone"],
        "keywords": ["Hyoid bone, twin block, motion,"]
      },
      "designModule": {
        "studyType": "OBSERVATIONAL",
        "patientRegistry": false,
        "designInfo": {
          "observationalModel": "OTHER",
          "timePerspective": "RETROSPECTIVE"
        },
        "enrollmentInfo": { "count": 82, "type": "ACTUAL" }
      },
      "armsInterventionsModule": {
        "interventions": [
          {
            "type": "DEVICE",
            "name": "Impact of Twin Block and Motion above Hyoid bone",
            "description": "All patients were submitted to preoperative and postoperative lateral teleradiography (Vatech D052SB, Puteaux, France), with the following exposure parameters: 75KV, Intensity10mA, exposition times 11s28, 112,8 mAs, using the Frankfort plane as reference parallel to the floor; moreover, patients were required to avoid moving and swallowing. Afterwards, digital datasets were uploaded and aligned into a digital therapeutic planning software (Orthalis®, Orqualceph®,group orqual) to accurately record the position changes of the hyoid bone at horizontal, vertical, and angular level, according the gender, facial biotype and airway complex, by measuring the following anatomical references:"
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Impact of Twin Block and Motion Class II Appliances on Hyoid Bone Position - A Retrospective Clinical Study",
            "description": "See the impact of twin block and motion on the hyoid bone",
            "timeFrame": "2023-2024"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* 10 and 16 years old, with sketelal class II, a ANB angle ≥4° according to the Steiner cephalometric analysis, with Twin block or Motion appliance\n\nExclusion Criteria:\n\n* without previous orthodontic treatment, without systemic disesases and adenotonsillar hypertrophy.",
        "healthyVolunteers": true,
        "sex": "ALL",
        "minimumAge": "10 Years",
        "maximumAge": "16 Years",
        "stdAges": ["CHILD"],
        "studyPopulation": "Children bewten 10-16 years old",
        "samplingMethod": "NON_PROBABILITY_SAMPLE"
      },
      "contactsLocationsModule": {
        "locations": [
          {
            "facility": "University of Salamanca",
            "city": "Salamanca",
            "zip": "37008",
            "country": "Spain",
            "geoPoint": { "lat": 40.96882, "lon": -5.66388 }
          }
        ]
      },
      "ipdSharingStatementModule": { "ipdSharing": "UNDECIDED" }
    },
    "derivedSection": { "miscInfoModule": { "versionHolder": "2025-05-07" } },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT06223893",
        "orgStudyIdInfo": { "id": "151197" },
        "organization": {
          "fullName": "University College, London",
          "class": "OTHER"
        },
        "briefTitle": "CirrhoCare- Using Smart-phone Technology to Enhance Care and Access to Treatment for Cirrhosis",
        "officialTitle": "CirrhoCare, A Real-world, Randomised Controlled Study, to Determine the Clinical and Cost-effectiveness of CirrhoCare Digital Home Monitoring and Management in Patients With Decompensated Cirrhosis",
        "acronym": "CirrhoCare"
      },
      "statusModule": {
        "statusVerifiedDate": "2025-05",
        "overallStatus": "RECRUITING",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2023-11-24", "type": "ACTUAL" },
        "primaryCompletionDateStruct": {
          "date": "2025-11",
          "type": "ESTIMATED"
        },
        "completionDateStruct": { "date": "2025-11", "type": "ESTIMATED" },
        "studyFirstSubmitDate": "2023-10-31",
        "studyFirstSubmitQcDate": "2024-01-16",
        "studyFirstPostDateStruct": { "date": "2024-01-25", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2025-05-01",
        "lastUpdatePostDateStruct": { "date": "2025-05-06", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": {
          "name": "University College, London",
          "class": "OTHER"
        },
        "collaborators": [
          { "name": "CyberLiver Ltd", "class": "UNKNOWN" },
          {
            "name": "London School of Hygiene and Tropical Medicine",
            "class": "OTHER"
          }
        ]
      },
      "oversightModule": {
        "oversightHasDmc": true,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": false,
        "isUsExport": false
      },
      "descriptionModule": {
        "briefSummary": "The CirrhoCare trial is a multi-centre, open label randomised controlled trial in patients with decompensated cirrhosis. The trial aims to investigate the clinical and cost-effectiveness of CirrhoCare digital home monitoring and management with current standard of care in these patients.",
        "detailedDescription": "Cirrhosis, progressive scaring of the liver- has many causes, principally, excessive alcohol intake, fatty-liver and viral infections. Unlike many chronic diseases, cirrhosis deaths are increasing rapidly year-on-year. It is the third commonest cause of premature, UK working-age deaths, with 62,000 years of working-life lost each year and NHS care costs of £4.53bn annually. One quarter of all UK cirrhosis patients are at-risk of acute decompensation, whereby complications such as fluid-overload, confusion and infections arise, requiring hospital-emergency treatment.\n\nCurrently, decompensated cirrhosis patients require regular hospital clinical assessments to detect these new complications. Even following hospital discharge, readmission with new decompensating complications approaches 37% in 4 weeks. This disease burden, compounded by increasing alcohol and obesity-driven liver disease, means demand for specialist liver services outweighs current capacity in a resource-stretched healthcare system. Moreover, regional variation of specialist liver services also impacts on illness and deaths, leading to a postcode lottery of care access and geographical inequity.\n\nThe CirrhoCare trial, addresses this urgent clinical-need through an innovative cirrhosis management system, including home-monitoring of decompensated cirrhosis patients, measuring vital signs such as heart rate and blood pressure (using low cost, sensing technology), assessing weight (smart-scale) and mental ability (smartphone app), all of which are impacted as cirrhosis progresses. By efficiently and securely collecting data on CyberLiver's management-system (platform), CirrhoCare provides a decision-facilitating tool, incorporating individual-patient data, helping liver-physicians to optimise and personalise treatment in the community.\n\nThe CirrhoCare trial investigators also plan to assess clinical and cost effectiveness of CirrhoCare management and seek regulatory approvals. This innovative aspect of cirrhosis management will be more acceptable and convenient for patients. It will also deliver community care with environmental, sustainable benefits, through reduced hospital visits, despite increasing service demands. The cost- effectiveness analysis will generate value-for-money evidence of CirrhoCare management, and the clinical evidence needed to inform future adoption into the NHS."
      },
      "conditionsModule": { "conditions": ["Decompensated Cirrhosis"] },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "interventionModelDescription": "Participants will be randomised 1:1 to receive either the standard of care or the CirrhoCare management system.",
          "primaryPurpose": "PREVENTION",
          "maskingInfo": { "masking": "NONE" }
        },
        "enrollmentInfo": { "count": 214, "type": "ESTIMATED" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "CirrhoCare management system",
            "type": "OTHER",
            "interventionNames": ["Device: CirrhoCare management system"]
          },
          { "label": "Standard of Care", "type": "NO_INTERVENTION" }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "CirrhoCare management system",
            "description": "This is a UKCA-marked, digital-therapeutic system consisting of:\n\n* clinical-grade, cirrhosis monitoring sensors and a smartphone app,\n* a clinical team-facing, decision-facilitating dashboard, and\n* CyberLiver's platform incorporating hepatic algorithms.\n\nThe CirrhoCare kit consists of: - Apple watch - iPhone with an in-built CirrhoCare app - a digital Bluetooth-linked system comprised of: \\~Wellue BP monitor, \\~Wellue weighing scale \\~Bluetooth thermometer.\n\nThe CirrhoCare management system also includes:\n\n* The clinician dashboard: All participant data collected through the app will be reviewed by the clinical team via the clinician dashboard.\n* The CirrhoCare algorithm: This algorithm will advise the clinical team if the participant is at high, medium, or low risk of developing a particular outcome event, based on monitoring data collected each day from the participant which is compared to the baseline values and average values collected over the first week of monitoring.",
            "armGroupLabels": ["CirrhoCare management system"]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Number of hospital interventions from new-liver related complications",
            "description": "The CirrhoCare trial will investigate whether the CirrhoCare management system leads to a reduction in the requirement for unplanned medical intervention from new-liver related complications over 90 days from hospital discharge.",
            "timeFrame": "90 days from randomisation"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "Effects on CLIF-C AD score",
            "description": "To determine the effects of the CirrhoCare management system on the Chronic Liver Failure Consortium Acute Decompensation (CLIF-C AD) score. \\[Minimum score is 0 and there is no upper limit. The higher the score the worse the outcome)",
            "timeFrame": "90 days from randomisation"
          },
          {
            "measure": "Effects on MELD score",
            "description": "To determine the effects of the CirrhoCare management system on the Model for End-Stage Liver Disease score ( MELD). \\[Score ranges from 6-40. The higher the score the worse the outcome\\]",
            "timeFrame": "90 days from randomisation"
          },
          {
            "measure": "To determine the effects of the CirrhoCare management system on the number of liver-related deaths at 90 days",
            "description": "To determine the effects of the CirrhoCare management system on the number of liver-related deaths at 90 days.",
            "timeFrame": "90 days from randomisation"
          },
          {
            "measure": "Healthcare resource use analysis",
            "description": "To assess healthcare resource use through analysis of the number of healthcare appointments during the study period",
            "timeFrame": "90 days from randomisation"
          },
          {
            "measure": "Healthcare cost analysis",
            "description": "To assess the financial costs associated with healthcare interventions during the study period (measured in British Pound Sterling).",
            "timeFrame": "90 days from randomisation"
          },
          {
            "measure": "User experience and engagement",
            "description": "To assess user experience and engagement through questionnaires and interviews : The questionnaires will be graded from 1-10 for each question, with 0 is extremely negative as a response, and 10 very highly positive response.",
            "timeFrame": "90 days from randomisation"
          },
          {
            "measure": "Quality of Life (EQ-5D-5L) assessment",
            "description": "To assess health-related quality of Life through the EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire. The score ranges from -0.59 to 1, with a score of 1 representing the best possible health status.",
            "timeFrame": "90 days from randomisation"
          },
          {
            "measure": "Frailty assessment",
            "description": "To assess frailty using the Liver Frailty Index. The score ranges from 1.0 to 7.0 with higher scores representing increased levels of frailty.",
            "timeFrame": "90 days from randomisation"
          },
          {
            "measure": "Mortality",
            "description": "To assess mortality (overall survival)",
            "timeFrame": "90 days from randomisation"
          },
          {
            "measure": "Number of hospital readmissions",
            "description": "To assess the overall number of readmissions to hospital",
            "timeFrame": "90 days from randomisation"
          },
          {
            "measure": "Effects of the individual components making up the primary outcome",
            "description": "Assessment of the effects of the individual components making up the primary outcome. Each complication of cirrhosis will be individually assessed between CirrhoCare and standard of care groups. \\[Ascites based on Gr 1-3 and HE based on West Haven criteria 1-4; Infection Positive or Negative culture\\]",
            "timeFrame": "90 days from randomisation"
          },
          {
            "measure": "Longitudinal effects of all secondary outcomes",
            "description": "The longitudinal effects of all secondary outcomes will be investigated by using an appropriate model that incorporates the Day 28 and Day 56 visits in addition to the Day 90 visit",
            "timeFrame": "Day 28, Day 56, Day 90"
          },
          {
            "measure": "Length of hospital readmissions",
            "description": "Assessment of the length of stay for each hospital readmission for a given participant recorded in days.",
            "timeFrame": "90 days from randomisation"
          }
        ],
        "otherOutcomes": [
          {
            "measure": "Nutritional impact analysis",
            "description": "To assess whether there is a change in nutritional status using the Royal Free Hospital Nutrition Prioritizing Tool (RFH-NPT). The score ranges from 0-7, with higher scores being associated with an increased risk of malnutrition.",
            "timeFrame": "90 days from randomisation"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion criteria:\n\n1. Adults ≥ 18 years and diagnosed with cirrhosis of any aetiology.\n2. Cirrhosis defined by standard clinical criteria, ultrasonographic findings and/or histology. Cirrhosis of any aetiology may be included. However, participants with cirrhosis due to autoimmune hepatitis must be on a stable corticosteroid dose for ≥3-month period before study inclusion (to be recorded on concomitant log).\n3. Cirrhosis severity-risk defined by European-Foundation Consortium Liver Failure - Acute Decompensation score (CLIF-C AD score) ≥42 points but ≤65 points at the time of screening.\n4. Hospitalisation for acute decompensation \\[determined as one or more of the following: increasing ascites, variceal haemorrhage, overt hepatic encephalopathy, spontaneous bacterial peritonitis (SBP) or hepatorenal syndrome - acute kidney injury (HRS-AKI)\\].\n5. Participants able to give informed consent.\n\nExclusion criteria:\n\n1. Participants with ACLF grade 2 and above according to the criteria published by Moreau\n2. Participants with CLIF-C AD score ≥ 66, who have a high mortality similar to ACLF ≥2 participants.\n3. Current overt hepatic encephalopathy, defined as grade II-IV hepatic encephalopathy according to the West-Haven classification, unable to give consent.\n4. Participants with active hepatocellular carcinoma (HCC) or history of HCC that is in remission for less than six months for uninodular HCC or for less than 12 months for multinodular HCC within Milan criteria.\n5. Participants with a history of significant extra hepatic disease with impaired short-term prognosis, including congestive heart failure New York Heart Association Grade III/IV, COPD GOLD \\>2, chronic kidney disease with serum creatinine \\>2mg/dL or under renal replacement therapy.\n6. Participants with documented refractory ascites\n7. Participants who are active on the transplant waiting list.\n8. Participants with current extra hepatic malignancies including solid tumours and hematologic disorders.\n9. Participants with mental incapacity, significant language barriers, or any other reason considered by the investigator precluding adequate understanding, cooperation or compliance in the study.\n10. Participants with active viral infections, or yet to achieve clear response to anti-viral therapy.\n11. Any disorders likely to impact on study engagement, including severe frailty, severe addiction history (including opioids) with evidence of multiple recent relapses.\n12. Any other reason that the PI considers would make the participant unsuitable to enter CirrhoCare (e.g., participants on an end-of-life palliative care pathway).\n13. Participants enrolled in other interventional trials.",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "centralContacts": [
          {
            "name": "Jenny Philip",
            "role": "CONTACT",
            "phone": "0203 108 4175",
            "phoneExt": "54175",
            "email": "cctu.cirrhocare@ucl.ac.uk"
          }
        ],
        "overallOfficials": [
          {
            "name": "Rajeshwar Mookerjee",
            "affiliation": "UCL",
            "role": "STUDY_CHAIR"
          }
        ],
        "locations": [
          {
            "facility": "Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust",
            "status": "RECRUITING",
            "city": "Birmingham",
            "zip": "B15 2GW",
            "country": "United Kingdom",
            "contacts": [
              {
                "name": "Neil Rajoriya",
                "role": "CONTACT",
                "email": "Neil.Rajoriya@uhb.nhs.uk"
              },
              { "name": "Neil Rajoriya", "role": "PRINCIPAL_INVESTIGATOR" }
            ],
            "geoPoint": { "lat": 52.48142, "lon": -1.89983 }
          },
          {
            "facility": "Royal Sussex County Hospital, University Hospitals Sussex NHS Foundation Trust",
            "status": "RECRUITING",
            "city": "Brighton",
            "zip": "BN2 5BE",
            "country": "United Kingdom",
            "contacts": [
              {
                "name": "Lucia Macken",
                "role": "CONTACT",
                "email": "lucia.macken@nhs.net"
              },
              { "name": "Lucia Macken", "role": "PRINCIPAL_INVESTIGATOR" }
            ],
            "geoPoint": { "lat": 50.82838, "lon": -0.13947 }
          },
          {
            "facility": "Walsgrave General Hospital, University Hospital Coventry & Warwickshire NHS Trust",
            "status": "RECRUITING",
            "city": "Coventry",
            "zip": "CV2 2DX",
            "country": "United Kingdom",
            "contacts": [
              {
                "name": "Sophia Than",
                "role": "CONTACT",
                "email": "sophia.than@uhcw.nhs.uk"
              },
              { "name": "Sophia Than", "role": "PRINCIPAL_INVESTIGATOR" }
            ],
            "geoPoint": { "lat": 52.40656, "lon": -1.51217 }
          },
          {
            "facility": "Royal Liverpool University Hospital, Liverpool University Hospitals NHS Foundation Trust",
            "status": "RECRUITING",
            "city": "Liverpool",
            "zip": "L7 8YE",
            "country": "United Kingdom",
            "contacts": [
              {
                "name": "Omar Elshaarawy",
                "role": "CONTACT",
                "email": "Omar.Elshaarawy@liverpoolft.nhs.uk"
              },
              { "name": "Omar Elshaarawy", "role": "PRINCIPAL_INVESTIGATOR" }
            ],
            "geoPoint": { "lat": 53.41058, "lon": -2.97794 }
          },
          {
            "facility": "The Royal London Hospital, Barts Health NHS Trust",
            "status": "RECRUITING",
            "city": "London",
            "zip": "E1 1FR",
            "country": "United Kingdom",
            "contacts": [
              {
                "name": "Vikram Sharma",
                "role": "CONTACT",
                "email": "vikram.sharma1@nhs.net"
              },
              { "name": "Vikram Sharma", "role": "PRINCIPAL_INVESTIGATOR" }
            ],
            "geoPoint": { "lat": 51.50853, "lon": -0.12574 }
          },
          {
            "facility": "Whittington Hospital, Whittington Health NHS Trust",
            "status": "RECRUITING",
            "city": "London",
            "zip": "N19 5NF",
            "country": "United Kingdom",
            "contacts": [
              {
                "name": "Evangelia Fatourou",
                "role": "CONTACT",
                "email": "evangelia.fatourou@nhs.net"
              },
              { "name": "Evangelia Fatourou", "role": "PRINCIPAL_INVESTIGATOR" }
            ],
            "geoPoint": { "lat": 51.50853, "lon": -0.12574 }
          },
          {
            "facility": "Royal Free Hospital, Royal Free London NHS Foundation Trust",
            "status": "RECRUITING",
            "city": "London",
            "zip": "NW3 2QG",
            "country": "United Kingdom",
            "contacts": [
              {
                "name": "Rajeshwar Mookerjee",
                "role": "CONTACT",
                "email": "r.mookerjee@ucl.ac.uk"
              },
              {
                "name": "Rajeshwar Mookerjee",
                "role": "PRINCIPAL_INVESTIGATOR"
              }
            ],
            "geoPoint": { "lat": 51.50853, "lon": -0.12574 }
          },
          {
            "facility": "St Thomas Hospital, Liverpool University Hospitals NHS Foundation Trust",
            "status": "NOT_YET_RECRUITING",
            "city": "London",
            "zip": "SE1 7EH",
            "country": "United Kingdom",
            "contacts": [
              {
                "name": "Giovanni Tritto",
                "role": "CONTACT",
                "email": "Giovanni.Tritto@gstt.nhs.uk"
              },
              { "name": "Giovanni Tritto", "role": "PRINCIPAL_INVESTIGATOR" }
            ],
            "geoPoint": { "lat": 51.50853, "lon": -0.12574 }
          },
          {
            "facility": "King's College Hospital, King's College Hospital NHS Foundation Trust",
            "status": "RECRUITING",
            "city": "London",
            "zip": "SE5 9RS",
            "country": "United Kingdom",
            "contacts": [
              {
                "name": "Vishal Patel",
                "role": "CONTACT",
                "email": "vishal.patel@researchinliver.org.uk"
              },
              { "name": "Vishal Patel", "role": "PRINCIPAL_INVESTIGATOR" }
            ],
            "geoPoint": { "lat": 51.50853, "lon": -0.12574 }
          },
          {
            "facility": "St George's Hospital, St George's university Hospital NHS Foundation Trust",
            "status": "RECRUITING",
            "city": "London",
            "zip": "SW17 0QT",
            "country": "United Kingdom",
            "contacts": [
              {
                "name": "Daniel Fortan",
                "role": "CONTACT",
                "email": "daniel.forton@nhs.net"
              },
              {
                "name": "Daniel Fortan, Prof",
                "role": "PRINCIPAL_INVESTIGATOR"
              }
            ],
            "geoPoint": { "lat": 51.50853, "lon": -0.12574 }
          },
          {
            "facility": "Queen's Medical Centre, Nottingham University Hospitals NHS Trust",
            "status": "RECRUITING",
            "city": "Nottingham",
            "zip": "NG7 2UH",
            "country": "United Kingdom",
            "contacts": [
              {
                "name": "Naaventhan Palaniyappan",
                "role": "CONTACT",
                "email": "Naaventhan.Palaniyappan@nottingham.ac.uk"
              },
              {
                "name": "Naaventhan Palaniyappan",
                "role": "PRINCIPAL_INVESTIGATOR"
              }
            ],
            "geoPoint": { "lat": 52.9536, "lon": -1.15047 }
          },
          {
            "facility": "John Radcliff Hospital, Oxford University Hospitals NHS Foundation Trust",
            "status": "RECRUITING",
            "city": "Oxford",
            "zip": "OX3 9DU",
            "country": "United Kingdom",
            "contacts": [
              {
                "name": "Jeremy Cobbold",
                "role": "CONTACT",
                "email": "Jeremy.Cobbold@ouh.nhs.uk"
              },
              { "name": "Jeremy Cobbold", "role": "PRINCIPAL_INVESTIGATOR" }
            ],
            "geoPoint": { "lat": 51.75222, "lon": -1.25596 }
          },
          {
            "facility": "Derriford Hospital, University Hospitals Plymouth NHS Trust",
            "status": "RECRUITING",
            "city": "Plymouth",
            "zip": "PL6 8DH",
            "country": "United Kingdom",
            "contacts": [
              {
                "name": "Ashwin Dhanda",
                "role": "CONTACT",
                "email": "ashwin.dhanda@nhs.net"
              },
              { "name": "Ashwin Dhanda", "role": "PRINCIPAL_INVESTIGATOR" }
            ],
            "geoPoint": { "lat": 50.37153, "lon": -4.14305 }
          },
          {
            "facility": "Southampton General Hospital, University Hospital Southampton NHS Foundation Trust",
            "status": "RECRUITING",
            "city": "Southampton",
            "zip": "SO16 6YD",
            "country": "United Kingdom",
            "contacts": [
              {
                "name": "Mark Wright",
                "role": "CONTACT",
                "email": "mark.wright@uhs.nhs.uk"
              },
              { "name": "Mark Wright", "role": "PRINCIPAL_INVESTIGATOR" }
            ],
            "geoPoint": { "lat": 50.90395, "lon": -1.40428 }
          },
          {
            "facility": "Torbay Hospital, Torbay and South Devon NHS Foundation Trust",
            "status": "RECRUITING",
            "city": "Torquay",
            "zip": "TQ2 7AA",
            "country": "United Kingdom",
            "contacts": [
              {
                "name": "James Neale",
                "role": "CONTACT",
                "email": "jamesneale@nhs.net"
              },
              { "name": "James Neale", "role": "PRINCIPAL_INVESTIGATOR" }
            ],
            "geoPoint": { "lat": 50.46198, "lon": -3.5252 }
          }
        ]
      }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [
          { "id": "D008103", "term": "Liver Cirrhosis" },
          { "id": "D005355", "term": "Fibrosis" }
        ],
        "ancestors": [
          { "id": "D010335", "term": "Pathologic Processes" },
          { "id": "D008107", "term": "Liver Diseases" },
          { "id": "D004066", "term": "Digestive System Diseases" }
        ],
        "browseLeaves": [
          {
            "id": "M11103",
            "name": "Liver Cirrhosis",
            "asFound": "Cirrhosis",
            "relevance": "HIGH"
          },
          {
            "id": "M8485",
            "name": "Fibrosis",
            "asFound": "Cirrhosis",
            "relevance": "HIGH"
          },
          { "id": "M11107", "name": "Liver Diseases", "relevance": "LOW" },
          {
            "id": "M8883",
            "name": "Gastrointestinal Diseases",
            "relevance": "LOW"
          },
          {
            "id": "M7255",
            "name": "Digestive System Diseases",
            "relevance": "LOW"
          }
        ],
        "browseBranches": [
          { "abbrev": "BC06", "name": "Digestive System Diseases" },
          { "abbrev": "BC23", "name": "Symptoms and General Pathology" },
          { "abbrev": "All", "name": "All Conditions" }
        ]
      }
    },
    "hasResults": false
  },
  {
    "protocolSection": {
      "identificationModule": {
        "nctId": "NCT05962437",
        "orgStudyIdInfo": { "id": "PI22/00829" },
        "organization": {
          "fullName": "Fundació Sant Joan de Déu",
          "class": "OTHER"
        },
        "briefTitle": "Self-guided Acceptance and Commitment Therapy-based Digital Smartphone Application for Management of Fibromyalgia",
        "officialTitle": "Three-arm Randomized Controlled Trial Investigating the Effectiveness, Cost-utility, and Physiological Effects of the Spanish Version of STANZA®: A Self-guided Digital Acceptance and Commitment Therapy (ACT) for Fibromyalgia",
        "acronym": "SMART-FM-SP"
      },
      "statusModule": {
        "statusVerifiedDate": "2023-07",
        "overallStatus": "NOT_YET_RECRUITING",
        "expandedAccessInfo": { "hasExpandedAccess": false },
        "startDateStruct": { "date": "2024-01-01", "type": "ESTIMATED" },
        "primaryCompletionDateStruct": {
          "date": "2025-06-30",
          "type": "ESTIMATED"
        },
        "completionDateStruct": { "date": "2025-12-31", "type": "ESTIMATED" },
        "studyFirstSubmitDate": "2023-07-18",
        "studyFirstSubmitQcDate": "2023-07-18",
        "studyFirstPostDateStruct": { "date": "2023-07-27", "type": "ACTUAL" },
        "lastUpdateSubmitDate": "2023-07-18",
        "lastUpdatePostDateStruct": { "date": "2023-07-27", "type": "ACTUAL" }
      },
      "sponsorCollaboratorsModule": {
        "responsibleParty": { "type": "SPONSOR" },
        "leadSponsor": {
          "name": "Fundació Sant Joan de Déu",
          "class": "OTHER"
        },
        "collaborators": [
          { "name": "Swing Therapeutics, Inc.", "class": "OTHER" }
        ]
      },
      "oversightModule": {
        "oversightHasDmc": false,
        "isFdaRegulatedDrug": false,
        "isFdaRegulatedDevice": false
      },
      "descriptionModule": {
        "briefSummary": "Introduction: Fibromyalgia (FM) is a prevalent syndrome that lacks curative treatment, imposing high healthcare and societal costs. The SMART-FM-Spain study investigates the effectiveness, physiological effects, and cost-utility of a self-guided digital intervention (STANZA-Spain) based on Acceptance and Commitment Therapy (ACT) for patients with FM.\n\nMethodology: Six-month, 3-arm randomized controlled trial (RCT) A total of 360 adult individuals meeting the 2016 American College of Rheumatology (ACR) criteria for FM will be recruited mainly at Vall d'Hebron University Hospital (Barcelona, Spain), and will be randomly allocated to one of the three study arms: Treatment as usual (TAU) plus STANZA-Spain, TAU plus digital symptom tracking (FibroST), or TAU. Participants will be assessed at baseline, post-treatment, and 6 month-follow-up. The primary outcome will be functional impairment and secondary outcomes will include patient impression of change, depression-anxiety-stress, and pain catastrophizing, among others constructs relevant to FM. Effectiveness and cost-utility analysis from a societal perspective will be computed, whereas ACT-related constructs, such as psychological flexibility, will be assessed to identify processes of change that will be analyzed with path analyses. Biomarkers will be assessed at baseline and post-treatment including hair cortisol, cortisone, corticosteroid binding globulin (CBG), adrenocorticotropic hormone (ACTH), cortisol in plasma, genotyping of FKBP5 gene polymorphisms, immune-inflammatory markers, and vitamin D levels.\n\nDiscussion: This study might represent a significant advancement in the management of FM in Spanish-speaking patients with FM, by examining the effectiveness, physiological effects, and cost-utility of a smartphone-based digital therapeutic with demonstrated empirical support in the United States of America.",
        "detailedDescription": "Main goals of the SMART-FM-SP study The main objectives of this RCT are: To analyze the effectiveness of adding Acceptance and Commitment Therapy via app (STANZA) compared to an active control arm (Fibro Symptom Tracker app -FibroST-) to the treatment as usual (TAU) for patients diagnosed of fibromyalgia; To examine the cost-utility of STANZA from healthcare and societal perspectives; To measure a set of biomarkers alongide the RCT in order to know the physiological underpinnings of the digital intervention STANZA and to identify potential predictors of treatment response.\n\nSmart-FM-SP is a 6-months RCT with three arms: TAU, TAU+STANZA and TAU+FibroST. Therefore, patients in three arms will receive TAU, and FibroACT and FibroST will be complementary treatments to the standard one provided in the public Catalan Health System."
      },
      "conditionsModule": { "conditions": ["Fibromyalgia"] },
      "designModule": {
        "studyType": "INTERVENTIONAL",
        "phases": ["NA"],
        "designInfo": {
          "allocation": "RANDOMIZED",
          "interventionModel": "PARALLEL",
          "primaryPurpose": "TREATMENT",
          "maskingInfo": {
            "masking": "TRIPLE",
            "whoMasked": ["CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]
          }
        },
        "enrollmentInfo": { "count": 360, "type": "ESTIMATED" }
      },
      "armsInterventionsModule": {
        "armGroups": [
          {
            "label": "STANZA-Spain",
            "type": "EXPERIMENTAL",
            "description": "Digital Acceptance and Commitment Terapy (ACT). It consists of 41 structured ACT lessons, incorporating mindfulness practices and daily activities to facilitate behavior change and promote gradual pacing of daily activities and exercise. The core content was designed to be completed within 8 weeks, with a 4-week maintenance period thereafter to strengthen skills.",
            "interventionNames": [
              "Device: Self-guided digital Acceptance and Commitment Therapy",
              "Behavioral: Treatment as Usual (TAU)"
            ]
          },
          {
            "label": "FibroST-Spain",
            "type": "ACTIVE_COMPARATOR",
            "description": "A digital active control intervention is implemented to control for study engagement, expectations, and healthcare provider interaction biases. Components of this active comparator include daily symptom and function tracking (Daily Symptom Tracker), symptom and function monitoring, and access to health education articles about fibromyalgia.",
            "interventionNames": [
              "Device: FM symptom tracking app (FM-ST)",
              "Behavioral: Treatment as Usual (TAU)"
            ]
          },
          {
            "label": "Treatment as Usual (TAU)",
            "type": "ACTIVE_COMPARATOR",
            "description": "Usual care is mainly carried out by general practitioners and rheumatologists through regular consultations. Clinicians prescribe medications and provide some counselling.",
            "interventionNames": ["Behavioral: Treatment as Usual (TAU)"]
          }
        ],
        "interventions": [
          {
            "type": "DEVICE",
            "name": "Self-guided digital Acceptance and Commitment Therapy",
            "description": "Smartphone-based mobile health application (app) that delivers a self-guided, evidence-based ACT program tailored to the management of FM. This investigational digital therapeutic, referred to herein as STANZA, was inspired by a web-based ACT program for FM validated by University of Manitoba and was recently granted De Novo clearance by the U.S. FDA. The app delivers ACT in 15- to 20-minute daily doses over the course of 12 weeks without the involvement of healthcare providers. The program consists of interactive educational materials that teach ACT skills which are reinforced experientially via values exploration and identification, mindfulness, and relaxation exercises. Values-based assignments follow each lesson to assist patients in incorporating ACT skills into their daily lives. Uniquely, STANZA teaches additional skills, including self-guided physical exercise and pacing daily activities via a personally customized stepwise, gradual approach.",
            "armGroupLabels": ["STANZA-Spain"]
          },
          {
            "type": "DEVICE",
            "name": "FM symptom tracking app (FM-ST)",
            "description": "Based on the same platform as STANZA, FM-ST enables self-guided daily tracking of patient-reported symptoms and functioning. Symptom tracking is commonly used in chronic pain management. FM-ST also provides access to educational materials relevant to FM and general health but does not provide any psychotherapy or healthcare professional involvement. This app mitigates potential expectation, treatment time and attention, and healthcare provider interaction biases that often occur in chronic pain studies that utilize passive comparison conditions.",
            "armGroupLabels": ["FibroST-Spain"]
          },
          {
            "type": "BEHAVIORAL",
            "name": "Treatment as Usual (TAU)",
            "description": "Usual care is mainly carried out by general practitioners and specialists in regular consultations, commonly consisting of face-to-face visits to monitor the physical and emotional status of the patient. Clinicians usually provide advice about physical exercise, diet, etc., and prescribe pharmacotherapy (pain medications, hypnotics and antidepressants)",
            "armGroupLabels": [
              "FibroST-Spain",
              "STANZA-Spain",
              "Treatment as Usual (TAU)"
            ]
          }
        ]
      },
      "outcomesModule": {
        "primaryOutcomes": [
          {
            "measure": "Fibromyalgia Impact Questionnaire Revised (FIQR)",
            "description": "The FIQR includes 21 items that are answered on a 0-10 numerical scale in which higher scores indicate greater functional impairment. The FIQR assesses the impact of FM symptoms over the past 7 days. The questionnaire consists of items that cover three domains: physical impairment, overall impact, and symptom severity. These items inquire about various aspects such as pain, energy levels, stiffness, sleep quality, depression, memory problems, anxiety, sensitivity to touch, balance issues, and heightened sensitivity to noises, lights, smells, or temperatures. The total FIQR score is calculated by summing the scores of the three subscales, resulting in a range of 0 to 100. Higher scores indicate a greater level of impairment. The Spanish version of the FIQR has an excellent internal consistency (α = 0.91-0.95)",
            "timeFrame": "Through study completion, an average of 6 months"
          }
        ],
        "secondaryOutcomes": [
          {
            "measure": "The Patient Global Impression of Change (PGIC) and the Pain Specific Impression of Change (PSIC)",
            "description": "This instrument is an indicator of meaningful clinical change in treatments for chronic pain. The PGIC is one item (on a 7-point numerical scale, from 1 = 'Much better' to 7 = 'Much worse') referred to the participants' perception of global improvement due to treatment. It has undergone validation in the context of psychologically-based treatments for chronic pain. Additionally, the PSIC evaluates (also on a 7-point Likert scale) changes in specific domains, including physical and social functioning, work-related activities, mood, and pain. Both the PGIC \\& PSIC scales will be completed by participants assigned to STANZA and FM-ST treatments.",
            "timeFrame": "At 3-months follow-up"
          },
          {
            "measure": "The Depression Anxiety Stress Scales-21 (DASS-21)",
            "description": "It discriminates between features of depression, anxiety and stress in clinical and non-clinical samples. Responders are required to indicate the presence of several symptoms over the previous week. Each item is scored from 0 (´Did not apply to me at all over the last week') to 3 ('applied to me very much or most of the time over the past week'). There are 7 items on each of the three subscales: depression, anxiety and stress. Therefore, total scores in each scale can range from 0 to 21, with higher scores indicating more severe levels of depression, anxiety and stress. The Spanish version has excellent psychometric properties.",
            "timeFrame": "Through study completion, an average of 6 months"
          },
          {
            "measure": "The Multidimensional Inventory of Subjective Cognitive Impairment (MISCI)",
            "description": "It is a 10-item self-report measure of subjective cognitive dysfunction in FM during the last week. Each item is scored from 1 ('Not at all/Never') to 5 ('Very much/Always') and the total score ranges from 10 to 50. Lower scores indicate higher cognitive dysfunction. The MISCI was developed through classical test theory and item response theory from cognitive functioning item banks developed within the Patient Reported Outcomes Measurement Information System (PROMIS). The Spanish version of the MISCI has excellent internal reliability (α = 0.91)",
            "timeFrame": "Through study completion, an average of 6 months"
          },
          {
            "measure": "The Pain Catastrophising Scale (PCS)",
            "description": "Scale of 13 items comprising three dimensions: rumination over pain, magnification of pain and helplessness in the face of pain symptoms. The PCS total score and subscale scores are computed as the sum of ratings for each item.\n\nThis study uses the total score, which can vary from 0 to 52 with higher scores indicating greater pain catastrophising.",
            "timeFrame": "Through study completion, an average of 6 months"
          }
        ],
        "otherOutcomes": [
          {
            "measure": "Psychological Inflexibility in Pain Scale (PIPS)",
            "description": "12-item scale that assesses psychological inflexibility in patients with pain and includes two factors: avoidance and cognitive fusion with pain. For this study, only the total score is used; it ranges from 12 to 84, with higher scores indicating higher level of psychological inflexibility.",
            "timeFrame": "Through study completion, an average of 6 months."
          },
          {
            "measure": "EuroQoL (EQ-5D-5L)",
            "description": "Instrument for evaluating health-related quality of life. The EQ-5D-5L scores will be used to calculate the Quality-Adjusted Life Years (QALYs) for the cost-utility analysis",
            "timeFrame": "Through study completion, an average of 6 months"
          },
          {
            "measure": "Credibility/Expectancy questionnaire (CEQ)",
            "description": "6-item questionnaire for measuring treatment expectancy and credibility for use in clinical outcome studies. Each item is rated from 0 to 10, with higher scores indicating better expectancy.",
            "timeFrame": "Baseline"
          },
          {
            "measure": "Client Service Receipt Inventory (CSRI)",
            "description": "The version used in this study is designed to retrospectively collect information on the use of health and social services during the previous six months. This instrument does not provide total or sub-scale scores, only collects information about use of services and medication consumption.",
            "timeFrame": "Through study completion, an average of 6 months"
          },
          {
            "measure": "Adverse effects of therapies",
            "description": "Qualitative ad hoc measure to check the presence of negative effects of the therapies",
            "timeFrame": "Through study completion, an average of 6 months"
          },
          {
            "measure": "Socio-demographic and clinical questionnaire",
            "description": "Gender, date of birth, marital status, living arrangements, educational level, employment status, and years lived with fibromyalgia",
            "timeFrame": "Baseline"
          },
          {
            "measure": "Immune biomarkers",
            "description": "Serum levels of IL-4, IL-6, CXCL8, IL-10, IL-17A, brain-derived neurotrophic factor (BDNF), and high sensitivity C-reactive protein (hs-CRP)",
            "timeFrame": "Baseline and 3-months follow-up"
          },
          {
            "measure": "Hair cortisol and cortisone, serum cortisol, corticosteroid-binding globulin (CBG) and vitamin D.",
            "description": "Biomarkers associated with HPA-axis functioning",
            "timeFrame": "Baseline and 3-months follow-up"
          },
          {
            "measure": "Polymorphisms in the FKBP5 gene",
            "description": "Genetic variants of the FKBP5 gene. Five proposed SNP polymorphisms in the FKBP5 gene \\[rs3800373 (SNP1), rs9296158 (SNP2), rs1360780 (SNP3), rs9470080 (SNP4) and rs4713916 (SNP5)\\].",
            "timeFrame": "Baseline"
          }
        ]
      },
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* Fibromyalgia diagnosis according to the 2016 ACR criteria\n* Fibromyalgia Impact Questionnaire Revised (FIQR) total score within the range of 35-80 at baseline.\n* Willing to maintain their current pain treatment throughout the study.\n* Having a smartphone (iOS 12 or higher or Android OS 8 or higher).\n* Proficient understanding of Spanish.\n\nExclusion Criteria:\n\n* Presence of cognitive impairment according to clinical records.\n* Diagnosis of severe medical or mental disorders such as cancer, psychotic disorder, and drug abuse according to medical records.\n* Patients at risk of suicide.\n* Being pregnant or planning a pregnancy during the study period, or currently breastfeeding.\n* Participation in other clinical trials during the study or within the previous 90 days.\n* Unable to use a smartphone.\n\nExclusion criteria for biomarkers substudy (50% of patients in each study arm):\n\n* Comorbid rheumatologic disorders such as lupus.\n* History of fever (\\> 38ºC), or infection within the last 2 weeks.\n* Recent vaccination within the last 4 weeks.\n* Needle phobia.\n* Consumption of more than 8 units of caffeine per day.\n* Smoking more than 5 cigarettes per day.\n* Having hair length less than 3 cm.",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "maximumAge": "70 Years",
        "stdAges": ["ADULT", "OLDER_ADULT"]
      },
      "contactsLocationsModule": {
        "centralContacts": [
          {
            "name": "Jaime Navarrete, PhD",
            "role": "CONTACT",
            "phone": "+34936406350",
            "phoneExt": "2543",
            "email": "jaime.navarrete@sjd.es"
          },
          {
            "name": "Mayte Serrat, PhD",
            "role": "CONTACT",
            "phone": "+34934863000",
            "phoneExt": "3361",
            "email": "mayte.serrat@vallhebron.cat"
          }
        ],
        "overallOfficials": [
          {
            "name": "Juan V Luciano, PhD",
            "affiliation": "Universitat Autònoma de Barcelona (UAB) & FSJD",
            "role": "PRINCIPAL_INVESTIGATOR"
          }
        ],
        "locations": [
          {
            "facility": "Parc Sanitari Sant Joan de Déu (PSSJD)",
            "city": "Sant Boi De Llobregat",
            "state": "Barcelona",
            "zip": "08830",
            "country": "Spain",
            "contacts": [
              {
                "name": "Juan V Luciano, PhD",
                "role": "CONTACT",
                "phone": "+34936406350",
                "phoneExt": "2540",
                "email": "juanvicente.luciano@sjd.es"
              },
              {
                "name": "Antoni Rozadilla-Sacanell, MD, PhD",
                "role": "CONTACT",
                "phone": "+34936615208",
                "email": "antoni.rozadilla@sjd.es"
              },
              {
                "name": "Juan V Luciano, PhD",
                "role": "PRINCIPAL_INVESTIGATOR"
              },
              {
                "name": "Antoni Rozadilla-Sacanell, MD, PhD",
                "role": "SUB_INVESTIGATOR"
              },
              {
                "name": "Jaime Navarrete-Hidalgo, PhD",
                "role": "SUB_INVESTIGATOR"
              },
              {
                "name": "Juan P Sanabria-Mazo, MSc",
                "role": "SUB_INVESTIGATOR"
              },
              {
                "name": "Ariadna Colomer-Carbonell, MSc",
                "role": "SUB_INVESTIGATOR"
              }
            ],
            "geoPoint": { "lat": 41.34357, "lon": 2.03659 }
          },
          {
            "facility": "Hospital Vall d'Hebrón",
            "city": "Barcelona",
            "zip": "08035",
            "country": "Spain",
            "contacts": [
              {
                "name": "Mayte Serrat, PhD",
                "role": "CONTACT",
                "phone": "+34934863000",
                "phoneExt": "3361",
                "email": "mayte.serrat@vallhebron.cat"
              },
              { "name": "Mayte Serrat, PhD", "role": "PRINCIPAL_INVESTIGATOR" },
              { "name": "Miriam Almirall, MD, PhD", "role": "SUB_INVESTIGATOR" }
            ],
            "geoPoint": { "lat": 41.38879, "lon": 2.15899 }
          }
        ]
      },
      "referencesModule": {
        "references": [
          {
            "pmid": "37382794",
            "type": "BACKGROUND",
            "citation": "Catella S, Gendreau RM, Kraus AC, Vega N, Rosenbluth MJ, Soefje S, Malhotra S, Luciano JV, McCracken LM, Williams DA, Arnold LM. Self-guided digital acceptance and commitment therapy for fibromyalgia management: results of a randomized, active-controlled, phase II pilot clinical trial. J Behav Med. 2024 Feb;47(1):27-42. doi: 10.1007/s10865-023-00429-3. Epub 2023 Jun 29."
          }
        ]
      },
      "ipdSharingStatementModule": { "ipdSharing": "NO" }
    },
    "derivedSection": {
      "miscInfoModule": { "versionHolder": "2025-05-07" },
      "conditionBrowseModule": {
        "meshes": [
          { "id": "D005356", "term": "Fibromyalgia" },
          { "id": "D009209", "term": "Myofascial Pain Syndromes" }
        ],
        "ancestors": [
          { "id": "D009135", "term": "Muscular Diseases" },
          { "id": "D009140", "term": "Musculoskeletal Diseases" },
          { "id": "D012216", "term": "Rheumatic Diseases" },
          { "id": "D009468", "term": "Neuromuscular Diseases" },
          { "id": "D009422", "term": "Nervous System Diseases" }
        ],
        "browseLeaves": [
          {
            "id": "M8486",
            "name": "Fibromyalgia",
            "asFound": "Fibromyalgia",
            "relevance": "HIGH"
          },
          {
            "id": "M12161",
            "name": "Myofascial Pain Syndromes",
            "asFound": "Fibromyalgia",
            "relevance": "HIGH"
          },
          { "id": "M13066", "name": "Pain", "relevance": "LOW" },
          { "id": "M16355", "name": "Syndrome", "relevance": "LOW" },
          { "id": "M12092", "name": "Muscular Diseases", "relevance": "LOW" },
          {
            "id": "M12097",
            "name": "Musculoskeletal Diseases",
            "relevance": "LOW"
          },
          { "id": "M15045", "name": "Rheumatic Diseases", "relevance": "LOW" },
          { "id": "M6323", "name": "Collagen Diseases", "relevance": "LOW" },
          {
            "id": "M12411",
            "name": "Neuromuscular Diseases",
            "relevance": "LOW"
          }
        ],
        "browseBranches": [
          { "abbrev": "BC05", "name": "Musculoskeletal Diseases" },
          { "abbrev": "BC10", "name": "Nervous System Diseases" },
          { "abbrev": "All", "name": "All Conditions" },
          { "abbrev": "BC23", "name": "Symptoms and General Pathology" },
          { "abbrev": "BC17", "name": "Skin and Connective Tissue Diseases" }
        ]
      },
      "interventionBrowseModule": {
        "browseLeaves": [
          { "id": "M4032", "name": "Analgesics", "relevance": "LOW" },
          { "id": "M4247", "name": "Antidepressive Agents", "relevance": "LOW" }
        ],
        "browseBranches": [
          { "abbrev": "Analg", "name": "Analgesics" },
          { "abbrev": "All", "name": "All Drugs and Chemicals" },
          { "abbrev": "PsychDr", "name": "Psychotropic Drugs" }
        ]
      }
    },
    "hasResults": false
  }
]
